<SEC-DOCUMENT>0000950170-23-005168.txt : 20230228
<SEC-HEADER>0000950170-23-005168.hdr.sgml : 20230228
<ACCEPTANCE-DATETIME>20230228164459
ACCESSION NUMBER:		0000950170-23-005168
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		120
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230228
DATE AS OF CHANGE:		20230228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innoviva, Inc.
		CENTRAL INDEX KEY:			0001080014
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943265960
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30319
		FILM NUMBER:		23686429

	BUSINESS ADDRESS:	
		STREET 1:		1350 OLD BAYSHORE HIGHWAY
		STREET 2:		SUITE 400
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
		BUSINESS PHONE:		6502389600

	MAIL ADDRESS:	
		STREET 1:		1350 OLD BAYSHORE HIGHWAY
		STREET 2:		SUITE 400
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	THERAVANCE INC
		DATE OF NAME CHANGE:	20020207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED MEDICINE INC
		DATE OF NAME CHANGE:	20000302
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>inva-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-02-28T16:25:37.5137+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:inva="http://www.inva.com/20221231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_c9380da1-1d8c-4aed-8026-f9776db8418d" name="dei:EntityCentralIndexKey" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27">0001080014</ix:nonNumeric><ix:nonFraction id="F_2e85503a-2fc3-4106-aa45-a099021141e5" name="us-gaap:CommitmentsAndContingencies" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_d6ac2f39-dcb6-4aaf-82a3-69ebb7891582" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_79aa90dd-9d5c-4099-932c-8e69511d4d22">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric id="F_41a23557-411b-40b9-88d7-b7d2076397f5" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5">http://fasb.org/us-gaap/2022#LiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric id="F_cf0494fe-35c5-4e21-a54e-9b2134b96a37" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_f52e619c-c936-46d8-b929-f6e8db146294">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric id="F_890207b9-615b-4ab9-910d-0ca859f06d2a" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530">http://fasb.org/us-gaap/2022#LiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric id="F_bd486c7a-19c1-4a3e-8db9-a057cc3e8d34" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_b5fa8ada-d91d-4d2c-8821-dc19094a35f7">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric id="F_490b67c1-915e-4461-9105-5bfc1a0f9c4a" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_e6a0ce61-2e09-425f-a9c6-2a0984724e44">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric id="F_49451cf0-b5b9-4245-8fca-d0d88b0b3246" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric id="F_1ff8c176-e5d5-4586-9991-756042d36424" name="dei:DocumentFiscalPeriodFocus" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27">FY</ix:nonNumeric><ix:nonNumeric id="F_53358c08-6ab6-4a25-9b5c-5457a5063101" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_6c19dc5a-41dc-4631-b9f8-3af4b5d09eaa">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonFraction id="F_8a7a89c9-1023-44e8-a6a6-bd7e14049025" name="us-gaap:CommitmentsAndContingencies" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_55538cac-7c93-47fb-820f-c1af2a09b9f9" name="dei:AmendmentFlag" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27">false</ix:nonNumeric><ix:nonNumeric id="F_547a2096-ca1f-487c-b0b5-45f04c844618" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric id="F_464685a2-4b4f-4d9b-b1f5-911c9d18b2b2" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_b35cf83c-d2ac-4656-ba86-ef13b30bffd3">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric id="F_73893738-ee85-428b-aa7d-acd3031222eb" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_d984fd86-fecd-403b-b06f-fd6cf9bdd507">P36M</ix:nonNumeric><ix:nonNumeric id="F_fa641eff-3195-4693-8182-1d9e0f743f4c" name="dei:CurrentFiscalYearEndDate" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" format="ixt:datemonthday">12-31</ix:nonNumeric><ix:nonNumeric id="F_48b0a504-5b75-4f2b-826e-46f825b25523" name="dei:DocumentFiscalYearFocus" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27">2022</ix:nonNumeric><ix:nonNumeric id="F_9f0bad49-93fa-4614-803a-31125d7d8918" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_a0e9d271-5df5-456e-9adc-2159553bd716">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonFraction id="F_2214fc13-a135-4176-9e10-3d32422ab21f" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" unitRef="U_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">13.8</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="inva-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_fd54577e-ca59-4227-b618-f18cb6ef69e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12567e61-7617-4c87-b922-068faca8ecd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e262e47d-f2f5-4208-90c1-3bcda7144a65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f8a395a-d382-4590-8d7a-2cc22d27ec5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c728d113-afc3-4116-a5d3-755dcf10b52b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aceba262-3c48-4f1a-bb24-393e5d13eb1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbcbd115-0d6a-4e3b-8ad7-7e5315f18708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de6c7395-9939-4c9f-99ac-cc5059cad3dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1759049-001a-42bc-8f15-3224ecf2b407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e7db92f-80b2-4ff0-a803-9c8f7437c5ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aea68a38-c031-44ae-8b1c-3569bc07a0e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80058a16-9c51-485f-8884-e6849191bd21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e61918a2-0f31-4d42-984d-dedda7b852ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3476905e-b09a-418b-a03e-4f699aa88fc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_acc278fb-4048-4edf-b4c0-fffa88f0aada"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XeravaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-22</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d3e731d-77ad-41c9-8fb2-80c5c772794f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ba64f62-a97d-4706-a41e-89bb10ec307f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4722bfe5-dfa7-4d44-bbd1-d47edc793461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d36b2a4f-1056-4575-a198-9dd2e9d0fa87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb7f1b9c-c794-42e0-872f-0ba49fe65cad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_494cf265-665e-4bbf-b3fc-fe7700a6a612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f698f68-0c0f-4134-b100-4f1a9c7c7c0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3eb9313e-795c-4ac2-b142-a5922e05f973"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf93a6aa-8431-42fa-b295-0929da337285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5fa27cc-5d17-4a15-b456-34db9e1c8687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ResearchAndDevelopmentSupportMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed938f8f-9dc7-47dc-b811-6331bcb70bcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11135088-2eb4-4727-a68e-256cf6c9a775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb4a498e-2f50-4c71-a55e-558ce1139356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c9aad10-5990-4d65-89ff-a00df760aa5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0c14dc4-3f99-40d8-a419-fb1d3a855ff6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39cf12a7-a194-4f3f-a151-0889b4253c28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f716eb1-7bc2-436b-be0b-e1913992c7a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24fc258b-a785-47f6-b359-705130868321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dba05bba-de09-4343-af7e-9fb38e51a065"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5312202a-22d7-4d9a-824b-4d80ac1dd701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fdff83b-7c27-43e0-9faa-0d7971a875c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e690336-d9c4-4186-8f97-2aa319621487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">inva:NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94397c13-ded5-4700-8d54-52976b909049"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d5aeb89-6a39-4e78-aae5-e1088841d223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71a8eb9a-e948-4bab-961c-28016a550572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b21c6819-077d-4af6-bc82-465ef43a2339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_592136c4-250e-4250-b700-73aee7f30946"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7bb172e8-abbc-4585-873a-e59b32f846e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsAcquiredInThirdQuarterOf2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_392be0e2-bd01-417a-94b2-2ef2c1b381d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a88168cf-1d99-4dfc-90ff-08a54f07f704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6adac0f-99fa-4f60-8e56-74a08935e56a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f935b07f-6611-49a5-95c9-c3a28c0fd4ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82199548-5f77-4397-8b16-459c147af958"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37b32554-8570-46f1-ad40-8f1d76b0a567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2075bc58-bfcf-44dd-85f6-c2f80538247e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93e0e07a-b332-46ca-be2f-706ee21b9d8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d4db9d3-f0ac-411c-b4be-66a68e66086e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7e84609-a139-4ee7-8f30-bd52dd4de851"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c144de1c-726a-4b34-8527-25bd42031613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93969c86-aa8a-4cdb-96b4-ca743740fab3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3014405b-7e86-4ca8-9b06-d944fd32e11a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-22</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_936c37a5-d79d-48ab-8b0a-483fe51759c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a92f3b2-2579-4b68-b675-6468f004fa64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_529cdd05-9d97-48df-bfe5-ae228fa9889c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_225556d0-78ae-4d3f-a563-0e5f56e17bdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1a5f0dc-847a-45a8-ad9c-42c8df5a3705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1AndD2PreferredStockAndCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41da565b-a64a-4074-a703-94289af0897b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-07-01</xbrli:startDate><xbrli:endDate>2014-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4367a010-1302-41f0-9af4-c6068dec7a67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba934ce3-7b7f-485e-9ba2-cec7f54bb480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsAcquiredInThirdQuarterOf2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ade68fe-6e7d-408e-8079-b75ae0d3ebb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_611351f3-6fef-4e71-8874-413587b99402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8200e2df-4805-452f-bcfe-d016a4e29503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6fe683b-fcbf-4fcd-a6b7-3a89c78e4ee9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e87648d-cc31-4ce1-9ec1-efcc2c23941b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_470cc2e5-a00e-4451-811a-42f58ffbce14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-20</xbrli:startDate><xbrli:endDate>2022-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ce8be5c-e87f-4f02-aa59-8b21ebff6e2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4440fd71-0092-4f2b-a8d0-66d0304e4b87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7c08163-5751-4218-b1ca-b2546c9f4635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71ef9fc1-7268-4619-8fc8-2922d4e683a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:StrategicAllianceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76ed3040-752a-4fbc-b4b9-e70787083404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:OneOfImaginabsCommonStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8021ae84-5f41-4763-9cbd-85aedc0bb507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62138785-e6ec-474a-9927-12031239b970"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a386f2f5-a2d5-44d9-be1d-92de778d3a08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2abf6f42-38e2-40d9-a0d2-9871c5194249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8020a62f-296d-4e43-981f-bbe959befede"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33ced285-7a79-4d44-9fd4-1c555534d19d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d570bc58-8501-4a6e-9371-fe8bdd84afc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea59fe25-23ca-4e88-abc7-36f9a00934f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50fc44f2-33ae-4838-8017-374904e41b9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b379ab38-d0be-476e-a799-edfb4d18808f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ConvertibleNoteAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-09</xbrli:startDate><xbrli:endDate>2022-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cee61bd9-edd6-431b-94c0-5db6bc13f016"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d42290f-ab32-4e25-95da-79728346288a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70bef282-aa1e-40ca-bbc9-61204a5b14c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_938323ae-b1cf-434a-be7f-895d09c3f4f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_834647f0-edd8-451a-9b07-12ae7db8308b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_940c56ba-ea2f-4556-9041-85af949e6f93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86d0f3a8-8fec-4fc2-be60-22b8b5cff09c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3aac9f2-453c-4c3b-bd1b-f1503e5f3a1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5a2a364-b173-4ae1-ab6f-e2302488dee0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc1deebf-6f63-4335-bca2-8ee328f41791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4cba0f99-f007-421e-b754-c13fe2c48144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c4ddbeb-ee5a-4ac2-80c1-fb1faed19718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b203b0f4-9fcb-40af-9c5b-8e2482e2f95a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_375a042d-32ca-4692-acf8-8877c36d21ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db24b4c5-31a5-4774-89a4-c8ee79bc160f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eddd93e6-6ae6-44b1-8b18-2af265b00535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31d13e09-7b0b-45f3-8c0c-c5750ed2e05f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49c795a8-613b-4bce-862e-f82adaa95de1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be6598b9-e8cb-47df-9144-93cf81d26295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbe9c478-819e-42cc-915c-04157a313403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-24</xbrli:startDate><xbrli:endDate>2021-11-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15fd9d26-7d1b-4c32-bc1c-d97f9e0dd0c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87e97c41-b41b-4af2-ab13-cf95548ea435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5be2f762-e576-4a23-bf25-e027f2186039"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e26b8922-044d-455a-825e-2cbd6970866c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-07-31</xbrli:startDate><xbrli:endDate>2014-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5713e251-00d3-4344-8351-32137ba92c7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_429f62d7-eb47-4068-90e0-c5530e1e1a8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c0f3b4a-32d1-4930-9562-67d67a9ae07c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9600166d-2800-4110-aac1-2f841a170cbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_892e4f08-128a-4e39-b8ba-c31860bb66fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a0c9ff2-8643-499c-bef2-5ff0feb5293d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44d06045-6a65-4a7d-ad2c-0c393e7cddf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64c565f8-b8c8-4b5e-8680-bd30e909b71f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0f2d71d-8e5b-4880-912e-cb4bc6a346e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c906192d-d614-4f00-bca0-46d8da21845f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:Incarda2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c88e8766-779e-489b-97e4-b86fcdc4511b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33e742dc-e3d7-4460-84e9-9ec66d586b4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:OneDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_238e19e1-e3b1-4349-834a-98123138313f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eeedca61-ff8b-43cf-9322-e4e591891f4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f672909-6502-4136-b275-680e838ad815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2b80c7a-b827-400e-b441-ce92d2d12b34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1aa07de-fcc2-48ae-85fd-403ac523f2e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3df3cdfa-bdca-4ba3-afb8-18a6a9c0e333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50f48cec-18c8-457e-b20c-0910ae62e850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4c99a87-e213-4345-a8ee-cea346b72126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a428dc65-c5ce-4719-a4dc-1d99f661076d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d061c9e4-9a0b-4b25-b83f-bf29e8dbc3c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b24b3e3-6e06-4dcd-8419-f71edb3c36c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_760e546c-c33b-4240-91c4-bc5ba9131a71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d3c3fb3-98ab-4ad6-a151-b473b325e723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f7d116a-6a4c-4c15-ba57-35c3c1ecdd1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f52e619c-c936-46d8-b929-f6e8db146294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d0145a4-6b73-42eb-8fa3-e5ad7079aeb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8df9d62f-9d01-41f9-9bda-746317ef7f2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98afe62c-821a-4537-b552-da050d3c5568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a492117-f656-4dab-adc6-be5db6e4dc3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_67669f2c-13f6-4732-9377-f8c04349b09d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9fa8159-64b4-4582-868c-ef082d816dac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f25f9085-e7bd-462a-8c86-23de80c89333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e529e8a-034a-4095-b62a-b22926e66498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_432870a0-b84a-44de-a37b-e2b21c245d8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad8f45f5-b03e-455b-875b-da3585e6e901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd16336a-4a72-4552-8d5c-b8332029c781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-22</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85dfe886-0475-4835-8057-5fdac892ef0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39efe5a8-fdf1-4e75-a1c6-ce190c067d56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55981a3b-c27e-47a6-bec2-2df69c4457cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c8ba09c-4a2f-49c9-b6ed-a569b29e1d50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e575930-339e-44e7-8b69-11dba2c9c328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9367326d-93f1-4347-bc8c-ea4df5b4b7d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b106910-d499-49e8-b2c4-ca13347b8e1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1aa9bc6a-6c60-4a2b-9e33-2d8d6bc2de04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GeorgeWashingtonUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2496c994-d13e-4a41-b18c-1c9ff1040e5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e288046-0f09-4c78-b427-4c133f35ca3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37ba5274-8715-4011-ab28-b8eda0d172d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5440a9c2-207c-4fb3-b81e-e1b717693af2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e9dfcc6-abf8-428e-99c1-2f4e7d75a1e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2889d5e4-431b-4019-8db7-26884c76cb7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0bc981e7-59dd-45eb-91b4-c1399903b025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:StrategicAllianceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75ae1480-904e-4b6a-9936-f2f684cc1cce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_931f2e1a-1b03-4282-9cfd-4d87cffcdb25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-07-01</xbrli:startDate><xbrli:endDate>2014-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be87ba60-82c5-4092-a52b-166288166d4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4225ffae-2b85-4646-9d44-6752e738321b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a97f4d78-4d9f-4a85-ba1d-e3c8a7909bfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesCWarrantsAndSeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7b3b46b-f87a-4221-a2f4-8bb306339707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4cc2b7aa-5de5-44f3-bfb9-3a6bc72ba7cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97660a37-a4d7-4e93-aa09-8f8b998393d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-22</xbrli:startDate><xbrli:endDate>2022-08-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_922cb55e-d579-4403-bdee-2933b4cbd111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-18</xbrli:startDate><xbrli:endDate>2022-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b234623-662e-464a-ac46-f26ea16b01cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04636ba8-4bff-4dfa-bb5d-8f341cc9b324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b4d9d60-6153-4fc7-8983-cb3d99a8f061"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9cae3f5-7d7b-44a5-96e4-e89f716538d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f4721dc-8199-4105-9ec9-a169e1f0086c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c518252b-f9c2-461f-b418-d8ec329b7c60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">inva:OtherAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30ae7ed9-ac4b-45ec-bc1f-029433db9949"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LoanRestructuringModificationAxis">inva:NewPrincipalAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NoteAmendmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b80a067-6f7f-440f-919a-9b96d0afd716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7cb7feed-1acc-460a-b96e-c4eeb94c9ae0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_439a2891-953d-43ed-8e7a-3e4c09d85e29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">inva:OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28a088e4-0dee-445b-90da-54cb1133ddc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0e9d271-5df5-456e-9adc-2159553bd716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e21d4ed9-45f2-4010-8231-c9ee66700c0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9efe7ef9-0fdb-45f7-9960-db3353139806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afbd1fdf-91b2-49f5-a71e-24558788a9c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66c13dac-92c4-4ae1-b13e-27c3b81b27cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b372f4b9-70bb-4a82-8853-c638fa566549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesA1PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2fd0a10-b4dd-4ad0-a2ee-0219d554486f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_faceb50e-f20b-4852-8586-ecbbd210fdd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e03c9a47-30dc-46ba-ba0f-c21cd67ac704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6464796-f61e-480a-9439-0d5437aeff80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef07e831-a84d-46db-aeb8-00314c87ec4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="inva:NameOfEventAxis">inva:QualifiedFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-09</xbrli:startDate><xbrli:endDate>2022-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a01857da-29eb-401d-8a40-ba6e666521ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5977bcd8-fc31-490c-827a-9db6ad3d5078"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-13</xbrli:startDate><xbrli:endDate>2022-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2137129a-9873-421f-b2c8-dd60cf04b4e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:SarissaCapitalManagementLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a9f3a87-35e9-4510-9ef5-42186f58a55d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09f7a472-62b7-4efe-90de-d979015c8cfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_faf804e2-dcb7-4016-8d35-d20f9d798b45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2438911-cddb-444f-87c4-9270c2e0d009"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-11</xbrli:startDate><xbrli:endDate>2022-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7908317-48f4-4013-9edd-7fd23e773791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2bb91c3f-a494-494f-95f3-8e82d7a8ba80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b3a5f9b-38bc-43b9-a48b-838362ad8efb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b35cf83c-d2ac-4656-ba86-ef13b30bffd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_077c554a-e6a5-43dd-991a-36356231105e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd7cfa80-9759-4df0-9de9-4910b0bcbdbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ResearchAndDevelopmentSupportMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3251587b-f79c-4e54-ba80-2c3e2d36881d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29f0ba10-c2ca-4f06-b767-8af5d73dfda3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab967707-220b-4a3c-b5c1-3b1d1f192c17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_507fe221-0e42-48ef-9715-fb7f62c2affb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53339bec-ba31-4b54-aa6a-0f92f4e9a13e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b484229-9ff6-4262-be39-4c53a0370b53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5766cee-a03e-4c21-8d34-5eef3d851a41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06e9721c-182a-4413-aa61-bad3afc7b434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16264887-a1ec-4e23-98dd-1206cc8034cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ef35e49-a54c-4f19-af9c-bb154b983308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35170e33-91df-4d33-a732-d1197ad1bca9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5fa8ada-d91d-4d2c-8821-dc19094a35f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ec4a281-c777-436a-bc57-5fae20c64ea6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4c52322-2f44-4631-88a7-a410b93eca72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0420bbef-96b0-4a85-a0f8-18bc3bd3a1fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0690f27e-7810-4f26-b005-086fd5e63db8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:WalthamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df021323-12d6-4b65-922a-6ba6dda7e339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a12f3c2b-1e4a-41a5-98c5-e299cd3ff20e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-07</xbrli:startDate><xbrli:endDate>2017-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_335d8004-849d-4d3c-98bc-66869944d3b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d412530e-32f1-46d9-9ba9-881230cd54e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4cfe9be-7f2a-4e82-81ce-72548c7e28d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc5624db-df9d-4192-9bd1-604ef2b78e37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f0ef079-42c1-4987-9230-951829c1a9cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95e0527f-161f-4b7c-9dae-e5bbe64ee040"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_148b7599-6dc0-4526-80ae-e58d4cb847c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b00c2afd-3ef2-4717-a264-dd840bff9783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4982d06-6abd-4b3b-a27d-5ce207408578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:Incarda2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f25bc928-3562-4b6b-b70a-81d5cabd17d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5fa7258b-a8a4-4978-9f93-639f24732e53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:PrivatePlacementPositionsAndConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c19dc5a-41dc-4631-b9f8-3af4b5d09eaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9355643f-3d44-439f-a87f-deec9514dc9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">inva:OptionPricingModelBacksolveValuationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9729f5e-1b98-42eb-9368-262a78500403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b335fc75-9e6c-4232-9459-e0730898b34c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsAcquiredInSecondQuarterOf2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf38e94a-771f-41f7-b87c-9a8cf1a2bfaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bd4526f-35d6-4207-93b9-c8a7c2cbe092"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ae54ce1-89e0-4a29-9584-2ca3a58b8d7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2989da91-3f0d-4f40-9d12-9977d248744f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32a14238-9913-4ca5-a7cb-512e18bd93f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a637d38-c05d-4d65-9849-9fabc00c0938"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9bfb09dd-8121-4c62-a617-c890849a7575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d59a34b7-1a2d-4e81-b069-63e808ef44cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3542ed0a-f698-456b-b13d-df3808be4d52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca10358b-8c3c-4daf-beb4-bf93df5c5577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d577f45e-f619-4e15-880c-f1fd5f863799"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b353aac4-69f8-4721-bb91-b64e5c3524b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fa03dd5-7a6f-44af-9267-849f7de0b04b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8dd6f727-6b68-40d1-9cf3-bc4664dc52cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ba508af-5e54-40ad-899c-3cb351c9a5ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4693a06-73d0-43e9-970e-27d36a30e4b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50f6e318-ebf2-4aff-955a-5ec178352190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77c4d3bf-3c11-40c8-aa43-61402306a12b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99cd87c6-e3ec-4551-aa1e-6daadd1c00f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df1e5c6b-3532-43eb-bfbb-32de7d69dfa7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1816159f-f867-4167-b36c-2cc22460814e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b36371f8-68e7-4572-9b2d-995236afdd29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_192456a0-bad3-4bac-8b5f-fc4b793611f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:OneOfImaginabsCommonStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b40705b-aebd-47f7-baf6-3520cd3218b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0aeb2ace-977a-42ee-96fb-3b9b90a42f4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2bc5e510-4f44-48df-99c8-e241a16a04b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:SoftwareAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f30142e1-26a2-4c83-99ca-64d73afa243d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0cc6f7b-c585-47f1-8084-1c731c93f71e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a053a42-fce9-401c-8cfb-e85edab1757f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_974a2f30-5728-48a5-ab31-4e0b26a6014c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd8c3695-a759-4ca6-9be7-64a5775cc175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01ddf3ce-393e-4a0e-9c61-5439a63de921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_353f3f99-bbf5-4207-bc66-407db6f33a5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87d07c35-75b2-4cc6-9d24-9604a851da8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0e7a33a-815b-42a2-be04-e2cbe14d7628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e02457d0-db2e-4c20-9634-fdad76ee8508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NoteAmendmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07d0dcab-49d7-4bf5-b5eb-1625e2fe2a1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93c757ad-d7f6-4687-bcce-bed6a5cfc531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a4c2cad-c447-47db-88d7-dca325de6712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8336f2e-614a-4763-8c0e-216cd28cb786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffc2073e-976b-4b32-9c37-71e4c30ee0f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:Incarda2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afaf4531-656e-4b03-aaf3-eae9277b1b15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a796252-a67b-414a-b751-63b9b85b975a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b56a4e8a-6960-4138-a57e-8ccc853dd6b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6063f5cf-dd80-437b-b1b3-9141091e7037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9f855c6-99ff-45d5-bdf0-1bbca9152b56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c2a82e7-af19-4a3f-9713-a56397f35d56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_873e7b0b-00b1-48d4-b5e4-b4a6e7d0eff2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EquityIncentivePlan2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_331a70dd-7cba-4846-8cf2-0dcd886d6087"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9ec2c09-fd7a-47dc-bc8d-518a4c5588a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66038b3d-4a2d-4124-9988-d7ed75e02d5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12bcde56-3f0c-4b2f-8eca-3b4cd31cef94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00652450-632d-460a-ac6b-98ad2aecada7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7955fc6-6a0b-47e2-b852-f7b1e5cc5350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8422a9e-f163-4920-b53e-2d0b99405fc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f74dd91-9ab3-47f8-86b1-ab0b359a7b86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a6e7bd4-d8ef-4aaa-8381-bf457ccf3981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_546bf034-6546-4012-bb5a-e1fa071bebc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bce10091-26f4-4aa8-ad2d-b5ecfe6c2aa9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3209a07a-0aa1-4b9b-907d-d83100cde8c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:TwoDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_508ec2d0-8cb9-4e9c-9ae3-821ebe4d8f78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_716be5cd-91a6-46f4-a203-c3c353f3575d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cd517a3-e6ab-4830-97d8-59d7687a4f18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dda65400-d844-4684-b486-4ce48278b7bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-24</xbrli:startDate><xbrli:endDate>2021-11-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dadd5411-7bb4-4843-b9b2-3fddc474ba05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:CommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ec07c39-1f00-4f12-9dfe-a75a6a1075ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20d483d2-f9e7-4620-9d3b-694ecd5af926"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5917fe5-11ac-449e-b814-c92fd58e4ce4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49055080-48eb-4604-9031-96d7f9cda5c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8bfe4f9-1bc3-43e2-b056-965fbab72a8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6a0ce61-2e09-425f-a9c6-2a0984724e44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_443136d7-7ad0-44e7-a11c-023a948f7f76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92728848-49b6-4fe1-8f74-6dcb6ee6a998"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94003f87-2752-45fd-9a31-20cecedf555d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3da5364e-c3cc-4073-9770-65a8da75a030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a09a0970-3cec-406a-9c07-37e23fc89e0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61f224cf-c012-4c9e-a814-7844fb193f6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c69e13b2-db45-4b02-9138-80f02fcf96a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2dcd6e7e-1bb4-4f65-ae76-a45c841c8639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e7a9b82-3d75-4c07-8fd4-3439f3f270c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b78012d3-6ecc-432d-b96a-e66ef1252516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-10</xbrli:startDate><xbrli:endDate>2023-01-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de713b03-f9a9-4480-b3f1-0fc2adfaf825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f59c417-5760-4636-8972-e9f5a4490a93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c21adc5-4d90-4234-8636-2bd75a4b4f4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9aeccb9a-f0c1-46ac-b1b4-641f1442275d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91dd5dfc-a8fa-4797-a5f1-1cbcfbb0101d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0741d536-3cd1-4bb3-a3d8-4a8b9e768e1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bfd9e7de-9f9b-458b-8962-ee3a5d4c660f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eee47a4c-1fd8-4bc9-916a-4c43bdc117fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-17</xbrli:startDate><xbrli:endDate>2022-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1331927b-9f86-4b7d-81d5-27a5846306f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1735a85-987d-4b96-a5cd-b22f73816924"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_975e5da7-351c-4671-96f0-b5f31daa46d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae9baafd-ad15-49ea-bd45-fcc80a92f494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d7d202f-bfb9-44a0-8281-04c234b04110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-22</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3fdbdd6-df91-4856-b880-a7ace484739f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96b9f402-f543-4b27-a705-44de9fb1db9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_283916fc-d81b-4ecf-99aa-3b90c5c75493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:StrategicAllianceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c85a10d8-967e-4263-82f9-7532cc5b50dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1503c149-1764-496d-a943-a3df60f05cd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b1298b5-e265-402c-a375-7a6c3874e7ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d895e55-890d-4019-93ff-8bf714b8997b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsAcquiredInSecondQuarterOf2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec493f0e-c275-474e-89f4-31047349c878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09f49082-679c-4f54-a8ef-7379e98314ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32dbf528-70de-47c3-9e65-d8c113adb297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_875d8b01-4f11-410a-9178-6e2dadcb8eea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_547286c7-fffc-4b6d-aa24-854799abba90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d895b864-cb0d-4144-94d3-dd388365edb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e7f2983-a46f-475a-ac66-4031d4994ae7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5afc9e88-7462-4e21-81dd-9bb66b6d8fd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5ee6d05-e981-4946-800e-de9d31604888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef336b9b-40a1-496c-9596-1c6f52048c42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5344bb21-de35-4c37-a9d5-00a950034cac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b62fd465-f5dd-40eb-aa36-8c18ef36ea86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9005816e-b3a5-4468-8183-9e0fc2383e1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90bb4c16-e20f-46dc-b959-d3bb3d63c67d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d984fd86-fecd-403b-b06f-fd6cf9bdd507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:BurlingameCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e611e3bf-95e5-47ba-b2ae-1c43a06561de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb6b6c9e-02d0-4be8-b0ad-089e8436ed15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsAcquiredInSecondQuarterOf2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8534932-ac9d-4cc5-9b1b-d50687f54e10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77fb24cf-b9f6-407a-ba9c-858247b06623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_421fbd90-baa7-4fc2-a696-1d4532ffc1a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:Incarda2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c748875-71fe-4003-b725-ef74b25e3855"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86b3b196-2603-41a6-85b5-4466e0d2b8da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3eed0352-afa7-4942-b39b-760e5fbff0cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f39c54bb-13a8-4982-a1a5-05cf42acdcd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-30</xbrli:startDate><xbrli:endDate>2022-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a2877be-4f3b-4a25-870f-05069f62cb38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_973bdb10-2dc0-4260-8de9-4c602b8d6d62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac5e1f2a-cef7-4391-8f23-5ab0d707cb92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47e6ee25-6bf5-41cf-80de-9652c932b3be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesCPreferredStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_676e4e88-33ae-4484-8dfc-e0acec87e7a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e64b6004-f679-415f-b389-067903b29e9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8114345-dec6-4194-93e9-3a1b415dbb83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsAcquiredInSecondQuarterOf2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce65868a-35fd-4e2c-8c9d-86e62db676f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eec2ed38-0112-4b50-a764-67406d54c678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f726f21-debb-4664-8555-842fbb037578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6111456-3ab3-4369-86bb-70377a24aea5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5825419d-fd73-4fa4-a6ed-aa1e87d36fa0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02211f41-81dd-4ee9-8d76-5d38e227447b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f8b66a1-3a27-4782-83da-ba9f7e42a440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc3e2576-1b0b-4887-9679-84a1bff0d7ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2276852d-99f8-449f-9f8f-9a1d7ddf7c39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20021136-8c2b-48e8-bb1e-b92302a7d43e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16a2d28f-c3aa-4dc0-a79e-e3f051ba1c79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d2ad42a-8c00-45ec-8588-2ffd6e64e9db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ff0d1ff-97a5-44b9-b6c1-09183a2ca1b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14af044e-180c-4ba7-afe8-2099db903530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74da3b8a-5055-48ca-bb11-71f8c49ad956"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ccb9cff0-df82-484b-91d7-3221007e9ea4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_435ca12f-523f-4739-86cf-686a945e5797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80443d0e-d8f2-4471-a9e1-605e05202133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79aa90dd-9d5c-4099-932c-8e69511d4d22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89b41b07-63fa-44a6-be15-5461c1916d4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a82881ba-2b0c-4f06-bda8-ddec8bb16fb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c321cb39-f5e8-42ab-b6ee-7480dacfaf27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc90f4aa-923b-4d08-8914-8e2e4b24dcfd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-22</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_006d6f8d-3460-4b4e-a5bd-62c377110a66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77f70987-1a99-49d7-a124-ec8a7e4706b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3984c86-3600-4ad8-878a-2b917b585a43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38a0f685-2b21-4d8e-aa54-1e3d3d0df2e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:OneDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_412716b4-7218-40f6-adc0-a9a7b2226300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f794c11-9aa6-4337-8539-a68ea7a89d87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b619186-bedd-4f77-a50f-71d5615f05fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa2052dc-83db-4d14-bb22-476be0ffb9e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7e11212-8609-4fda-a248-41d5348f3383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a6afb3d-ff23-4bc0-870f-2ba1de52231b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cb7b433-593e-4c62-95c5-c68106abd3d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e25220e7-99ed-4348-b545-ac306b1dcf61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69d1b8aa-4af1-4156-8bdb-c7f20d548e88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-15</xbrli:startDate><xbrli:endDate>2022-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8932c51-4ee5-4ba0-82b7-47753c1c9a9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:CommercialSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83077a73-bb79-4182-b3f3-f8a33937add7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46102164-0773-400f-906c-f458fc8d0c96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b92b149a-66d4-4743-8737-7ac6c96eb78c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13412d83-cfbd-464c-9c34-a973a9caf860"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32d6e1d8-d581-4a23-a3d6-067540daf4c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d25498d0-9e4d-4ee3-9937-2ee1a353b204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13f5a4a8-8af1-45cd-bfa0-3c008efc367c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16124fa1-bc15-44d0-adf6-79a805b582fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3016f145-17f8-4f1a-82c7-f26a7aa8c466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c844f75a-7bd8-4650-befd-f25662e94508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c50e19a1-f680-4297-ba13-d0cc4e167f05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inva:InnovivaCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-17</xbrli:startDate><xbrli:endDate>2022-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5469324-8168-4017-8117-1393b1043fb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a50f2f58-78df-4b27-976a-27d61652adb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcd3daed-e03d-43b3-995a-2376fd31c571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_836c70a9-4623-4b63-8ab6-169221b585c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8af701ba-469b-4d82-804b-8716aa0537d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d320509-4249-4817-85c1-0897de8b2875"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40d9b41f-8564-4e43-91f2-98018ace4541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_776c1f34-bbdc-44d5-80e8-a6cccdaa9570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5dd1e719-80fe-4711-a19b-c407c3e1587a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d234c0c-f63c-4792-acb9-96224e1a9014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_161e223f-b687-4431-bc47-286346549fa0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2c072bc-c407-4f39-8c36-301e061f1ca8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ParatekPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86245344-c6d4-4840-98eb-541f5a63c983"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d306884-7dee-45a2-9203-d77e41d65ae4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5874bedc-4e02-4a10-b901-1e4be59451b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cccb0641-aa44-4b1c-a0d0-fd6d4158c2b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:StrategicAllianceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe02af8a-5018-4690-9673-9a7063d85b4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce4ecb89-132b-48b5-b413-d18d79b1b130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Director"><xbrli:measure>inva:Director</xbrli:measure></xbrli:unit><xbrli:unit id="U_UsdItem"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>inva:Item</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Item"><xbrli:measure>inva:Item</xbrli:measure></xbrli:unit><xbrli:unit id="U_Customer"><xbrli:measure>inva:Customer</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_CHF"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:unit id="U_Tranche"><xbrli:measure>inva:Tranche</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Installment"><xbrli:measure>inva:Installment</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71" fromRefs="F_86dc67a7-1dc7-4bb6-ae4c-31c620a7a8c0 F_acb2f52d-086e-48bc-98c6-39e21bc6a54e F_1fa0aea7-9d32-43e0-8b99-2f28dfa45057 F_8d9bf4a0-4bf1-43e0-b158-8e543323249a F_58a6e17d-816a-4800-b40a-497386e20e19 F_521f41f8-3102-4803-8dd3-d66c56b3ac30 F_e86b34eb-a400-4de8-a6d1-bda0467868f1 F_a60f2bef-ef0a-446d-8d7c-bfb962574365 F_6c392004-41b0-4c06-b69e-3c3989f1da72 F_498794db-f6ff-4500-b278-62cc95d92aa2"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_30a29ac4-a358-403f-922e-b22439018a34" fromRefs="F_46f2d473-be14-45e0-bd3f-88d1ffb40cc2 F_13064dda-8ed2-4197-9462-3233b6e646b6 F_d4974520-3462-491d-ba7f-e59c61419650 F_92d64aad-a8aa-4799-a07a-ce78039e04c4 F_5bf8e1c8-f663-4fd3-a775-9c0173609862 F_afe13dec-76d8-453c-8941-b3e094fe42de F_065f3d03-454a-409c-b707-3411450de866 F_e2769ce1-6e57-4189-82bf-0320009c398c"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_575e1359-ac7d-4d28-a8d2-44d2392097f1" fromRefs="F_e20c2f4f-cc35-4c06-b838-d820cfd05871 F_e1fa47be-e26f-49c6-9689-9c7c455a418b F_3fdd078f-51c8-441a-bc63-74e8c5af4fba"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_4def478b-9e06-438e-961a-d2a1b65d4c32" fromRefs="F_dbecb97d-2479-4c89-ac9e-9028c435f74c F_5206e769-270f-4857-aebd-f5a635bf2283 F_148f5b6e-664c-4651-a517-7669a8556d7c"></ix:relationship></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="border-top:3pt solid;padding-top:1.0pt;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dcddda3d-1ad3-4635-9cff-16a0d0d34511" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.417%;"></td>
    <td style="width:86.583%;"></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Mark One)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_340059d9-bc11-4383-ab1d-9898d7f40844" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:DocumentAnnualReport" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_046e47cd-e27e-4b1b-96bc-bfdfbd84974d" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4e63a6f6-ab62-4d4d-b214-66a5780910e9" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_40461f0e-70ff-48de-8736-3795d61e23c0" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the transition period from              to</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File No. </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_08c5ead1-75c3-4543-9d98-6ede24d1d4ac" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">000-30319</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a6468257-5059-4262-b3df-375311a0c278" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:25.2pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bfc1595a-5821-4ae0-abb9-c8228f30d383" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />(State or other jurisdiction of<br />incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bbddd764-b195-4e08-b44c-3e872fa3a957" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94-3265960</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />(I.R.S. Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_28c78492-1cdd-4539-b492-c6ee303e546d" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1350 Old Bayshore Highway, Suite 400</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a67fe044-03c0-4a42-86d7-1efe0e6ce50b" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Burlingame</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5e9e63e0-2b33-44a3-afab-9c26cebfda2b" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CA</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f9449fcd-1fe2-493a-9e41-fa0f33a50716" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94010</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_655df631-b48c-4b0e-b279-aff0a1be2c4e" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f8c32672-5e0f-44f4-986b-a350667b9f17" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">238-9600</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.167%;"></td>
    <td style="width:1.667%;"></td>
    <td style="width:25.343%;"></td>
    <td style="width:1.481%;"></td>
    <td style="width:37.343%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of Each Class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of Each Exchange On Which Registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6b36d678-bafa-49bf-9b5f-1cfbd0bb7273" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock $0.01 Par Value</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1d2ce033-9201-4a4b-aa09-dd01bd5ba181" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INVA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9e15b5c2-7961-4ff9-94b3-6e05096283a2" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Stock Market LLC</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NONE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is a well&#x2011;known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_89242ff0-8be2-47a5-9a02-2ead34fec8f8" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;   No &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744;   </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0d59e38f-127e-4840-9502-686c097066f0" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1b67b0a6-b90a-4179-bebd-b03c7576d308" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;   No &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2e59e8d4-7b10-4a15-a7fd-be0cbbb0e4ad" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;  No &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See definition of &#x201c;accelerated filer and large accelerated filer&#x201d; in Rule 12b-2 of the Exchange Act (Check One):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.25%;"></td>
    <td style="width:17.944%;"></td>
    <td style="width:27.583%;"></td>
    <td style="width:23.222%;"></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8c6d7867-e52c-4fb2-9001-1c632f8b8a42" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer &#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non&#x2011;accelerated filer &#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_306588a6-164a-4173-b477-27fc575cbf64" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c6c0d60-cb1b-4ff5-8f6e-64f13980671f" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b90c5fa5-0f3c-42c2-89ff-9ced8b297006" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b&#x2011;2 of the Exchange Act). Yes </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e3903336-673e-49d7-9b6e-54b03680829b" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   No &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant based upon the closing price of the registrant&#x2019;s Common Stock on The Nasdaq Global Select Market on June 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd2f195a-9d3e-43e4-aa4e-62380e34a6df" contextRef="C_d570bc58-8501-4a6e-9371-fe8bdd84afc4" name="dei:EntityPublicFloat" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">923,930,805</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This calculation does not reflect a determination that persons are affiliates for any other purpose.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 14, 2023,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> there were </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57d3d938-e448-47b4-b50a-ec9fa84eedc0" contextRef="C_b8336f2e-614a-4763-8c0e-216cd28cb786" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">68,126,089</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the registrant&#x2019;s Common Stock outstanding.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9452a3f5-7ab5-4913-9a5e-a8e5cbe3e193" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specified portions of the registrant&#x2019;s definitive Proxy Statement to be issued in conjunction with the registrant&#x2019;s 2023 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant&#x2019;s fiscal year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, are incorporated by reference into Part III of this Annual Report. Except as expressly incorporated by reference, the registrant&#x2019;s Proxy Statement shall not be deemed to be a part of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.5pt solid;padding-top:1.0pt;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:3pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 Form 10&#x2011;K Annual Report</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.0%;"></td>
    <td style="width:88.0%;"></td>
    <td style="width:5.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrant_s_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for the Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_management_s_discussion_and"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_and"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_and_disagreements_with"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign_jur"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_officers_and"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_of_certain"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_and"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_and"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_and_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10_k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10&#x2011;K Summary</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#exhibits"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">143</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;" id="special_note_regarding_forward_looking"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Special Note Regarding Forward&#x2011;Looking Statements</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">This Annual Report on Form 10&#x2011;K contains forward&#x2011;looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#x201c;Securities Act&#x201d;). Such forward&#x2011;looking statements involve substantial risks, uncertainties and assumptions. All statements in this Annual Report on Form 10&#x2011;K, other than statements of historical fact, including, without limitation, statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, intentions, expectations, goals and objectives may be forward&#x2011;looking statements. The words &#x201c;anticipates,&#x201d; &#x201c;believes,&#x201d; &#x201c;could,&#x201d; &#x201c;designed,&#x201d; &#x201c;estimates,&#x201d; &#x201c;expects,&#x201d; &#x201c;goal,&#x201d; &#x201c;intends,&#x201d; &#x201c;may,&#x201d; &#x201c;objective,&#x201d; &#x201c;plans,&#x201d; &#x201c;projects,&#x201d; &#x201c;pursuing,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and similar expressions (including the negatives thereof) are intended to identify forward&#x2011;looking statements, although not all forward&#x2011;looking statements contain these identifying words. We may not actually achieve the plans, intentions, expectations or objectives disclosed in our forward&#x2011;looking statements and the assumptions underlying our forward&#x2011;looking statements may prove incorrect. Therefore, you should not place undue reliance on our forward&#x2011;looking statements. Actual results or events could differ materially from the plans, intentions, expectations and objectives disclosed in the forward&#x2011;looking statements that we make. All written and verbal forward&#x2011;looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Important factors that we believe could cause actual results or events to differ materially from our forward&#x2011;looking statements include, but are not limited to, risks related to: lower than expected future royalty revenue from respiratory products partnered with GSK, the commercialization of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">, ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">, GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in the jurisdictions in which these products have been approved; the strategies, plans and objectives of the Company (including the Company's growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus (&#x201c;COVID-19&#x201d;); the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company&#x2019;s growth strategy and risks discussed in &#x201c;Risk Factors&#x201d; in Item 1A of Part I, &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; in Item 7 of Part II and elsewhere in this Annual Report on Form 10&#x2011;K. Our forward&#x2011;looking statements in this Annual Report on Form 10&#x2011;K are based on current expectations as of the date hereof and we do not assume any obligation to update any forward&#x2011;looking statements on account of new information, future events or otherwise, except as required by law.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We encourage you to read Management&#x2019;s Discussion and Analysis of our Financial Condition and Results of Operations and our consolidated financial statements contained in this Annual Report on Form 10&#x2011;K. We also encourage you to read Item 1A of Part I of this Annual Report on Form 10&#x2011;K, entitled &#x201c;Risk Factors,&#x201d; which contains a more complete discussion of the risks and uncertainties associated with our business. In addition to the risks described above and in Item 1A of this report, other unknown or unpredictable factors also could affect our results. Therefore, the information in this report should be read together with other reports and documents that we file with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) from time to time, including on Form 10&#x2011;Q and Form 8&#x2011;K, which may supplement, modify, supersede or update those risk factors. As a result of these factors, we cannot assure you that the forward&#x2011;looking statements in this report will prove to be accurate. Furthermore, if our forward&#x2011;looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward&#x2011;looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 1.   BUSINESS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Innoviva, Inc. (&#x201c;Innoviva&#x201d;, the &#x201c;Company&#x201d;, the &#x201c;Registrant&#x201d; or &#x201c;we&#x201d; and other similar pronouns) is a diversified holding company with a portfolio of royalties and other healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#x201c;GSK&#x201d;), including RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (fluticasone furoate/vilanterol, &#x201c;FF/VI&#x201d;) and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (umeclidinium bromide/vilanterol, &#x201c;UMEC/VI&#x201d;). Under the Long-Acting Beta2 Agonist (&#x201c;LABA&#x201d;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion; and royalties from the sales of ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which tier upward at a range from 6.5% to 10%. Innoviva was also entitled to 15% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to Theravance Respiratory Company, LLC (&#x201c;TRC&#x201d;), including TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and any other product or combination of products that may be discovered or developed in the future under the LABA Collaboration Agreement and the Strategic Alliance Agreement with GSK (referred to herein as the &#x201c;GSK Agreements&#x201d;), which were assigned to TRC other than RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  We sold our 15% ownership interest in TRC on July 20, 2022, and are no longer entitled to receive royalties on sales of TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expanded our portfolio of royalties and innovative healthcare assets through the acquisition of Entasis Therapeutics Holdings Inc. (&#x201c;Entasis&#x201d;) on July 11, 2022 and the acquisition of La Jolla Pharmaceutical Company (&#x201c;La Jolla&#x201d;) on August 22, 2022. Our commercial and marketed products include GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (angiotensin II), approved in the United States (&#x201c;U.S.&#x201d;) to increase blood pressure in adults with septic or other distributive shock, and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (eravacycline) approved in the U.S. for the treatment of complicated intra-abdominal infections in adults. Our development pipeline includes medicines for the treatment of bacterial infections, such as our lead asset sulbactam-durlobactam (&#x201c;SUL-DUR&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our headquarters are located at 1350 Old Bayshore Highway, Suite 400, Burlingame, CA 94010. The Company was incorporated in Delaware in November 1996 under the name Advanced Medicine, Inc., and began operations in May 1997. It later changed its name to Theravance, Inc. in April 2002. In June 2014, we spun-off our research and development operations. In January 2016, we rebranded and changed our name to Innoviva, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our corporate strategy is currently focused on increasing stockholder value by, among other things, maximizing the potential value of our respiratory assets partnered with GSK, optimizing our operations and augmenting capital allocation. We continue to diversify our royalty management business through actively pursuing opportunistic acquisitions of promising companies and assets in the healthcare industry and enhancing the returns on our capital. In particular, our recent acquisitions of Entasis and La Jolla created a robust hospital and infectious disease platform.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Royalty Product Portfolio</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Relationship with GSK</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">LABA Collaboration</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2002, we entered into our LABA Collaboration Agreement with GSK to develop and commercialize once&#x2011;daily products for the treatment of chronic obstructive pulmonary disease (&#x201c;COPD&#x201d;) and asthma. The collaboration has developed three combination products, two of which we still retain rights in. Those two are as follows:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;FF/VI&#x201d;) (BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is the proprietary name in the U.S. and Canada and RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is the proprietary name outside the U.S. and Canada), a once-daily combination medicine consisting of a LABA, vilanterol (&#x201c;VI&#x201d;), and an inhaled corticosteroid (&#x201c;ICS&#x201d;), fluticasone furoate (&#x201c;FF&#x201d;), and,</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;UMEC/VI&#x201d;), a once-daily medicine combining a long-acting muscarinic antagonist (&#x201c;LAMA&#x201d;), umeclidinium bromide (&#x201c;UMEC&#x201d;), with a LABA, VI.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the launch and approval of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the U.S., Japan and Europe, in accordance with the LABA Collaboration Agreement, we paid milestone fees to GSK totaling $220.0 million during the year ended December 31, 2014. The milestone fees paid to GSK were recognized as capitalized fees paid, which are being amortized over their estimated useful lives commencing upon the commercial launch of the products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate that RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (FF/VI) and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (UMEC/VI) will compete with a number of approved bronchodilator drugs alone or in combination, including each other and drug candidates under development that are designed to treat asthma and COPD. These include but are not limited to:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/Seretide&#153; Diskus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/HFA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (salmeterol and fluticasone propionate as a combination) marketed by GSK</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbicort</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (formoterol and budesonide as a combination) marketed by AstraZeneca</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AirDuo Respiclick</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (salmeterol and fluticasone propionate), a non-substitutable generic version of Advair, marketed by TEVA</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Spiriva</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Handihaler</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Spiriva</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Respimat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (tiotropium) marketed by Boehringer Ingelheim</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dulera</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (formoterol and mometasone as a combination) marketed by Merck</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tudorza</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Pressair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (aclidinium) marketed by AstraZeneca and Seebri</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Breezehaler</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (glycopyrronium) marketed by Novartis outside the U.S. and Sunovion in the U.S.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incruse</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Ellipta</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (umeclidinium) and Arnuity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Ellipta</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (fluticasone furoate) (Innoviva is not entitled to any royalties from either product)</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foradil</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Aerolizer</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/Oxis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Turbuhaler</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (formoterol) marketed by a number of companies</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Striverdi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Respimat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (olodaterol) marketed by Boehringer Ingelheim</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Onbrez</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Breezehaler</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (E.U.)/Arcapta</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Neohaler</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (U.S.) (indacaterol) marketed by Novartis</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ultibro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Breezehaler</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (E.U.)/Utibron</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Neohaler</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (U.S.) (indacaterol combined with glycopyrronium bromide) developed by Novartis and approved and launched in Europe and Japan in the year ended December 31, 2013 as a once-daily treatment for COPD. In the U.S., the product was approved in October 2015 at a lower strength as a twice-daily COPD treatment, and was licensed to Sunovion in December 2016, and launched in May 2017</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stiolto (U.S.)/Spiolto (E.U.) Respimat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (tiotropium combined with olodaterol) marketed by Boehringer Ingelheim for the treatment of COPD</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bevespi Aerosphere</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (glycopyrronium bromide in combination with formoterol fumarate) marketed by AstraZeneca</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Duaklir</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Genuair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (aclidinium bromide in combination with formoterol fumarate) developed by AstraZeneca as a maintenance bronchodilator treatment for COPD and approved in November 2014 in the EU and March 2019 in the U.S.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">QMF149 (indacaterol in combination with mometasone) developed by Novartis for markets outside the U.S. and under regulatory review in the E.U. for asthma. In Phase 3 development for COPD</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trimbow (a fixed-dose, twice daily combination of formoterol, beclomethasone and glycopyrronium) manufactured by Chiesi and indicated for use in COPD in the E.U.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foster (beclomethasone dipropionate in combination with formoterol fumarate) manufactured by Chiesi and indicated for use in asthma and COPD outside the U.S.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enerzair Breezehaler (QVM149) (a fixed-dose combination of indacaterol, mometasone and glycopyrronium) developed by Novartis as a triple therapy/single inhaler for the treatment of asthma and approved in the E.U., Canada, and Japan</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Breztri Aerosphere (fixed dose combination of formoterol, glycopyrronium and budesonide) developed by AstraZeneca as a triple therapy single inhaler twice-daily medication for COPD and approved in the U.S. in July 2020</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nucala (mepolizumab; an interleukin-5 antagonist monoclonal antibody) developed by GSK for add on maintenance treatment of severe asthma in patients 12 years and older and approved in the U.S. in June 2019</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Xolair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (omalizumab, an anti-IgE antibody) developed by Genentech for patients 6 years of age and older with moderate to severe persistent asthma uncontrolled by inhaled corticosteroids and approved in 2003. Single-dose pre-filled syringes were approved by the FDA in September 2018</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cinqair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (anti-interleukin-5 monoclonal antibody for the add-on maintenance treatment of adults with severe asthma and an eosinophilic phenotype) marketed by TEVA Pharmaceutical Industries Ltd.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dupixent</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (dupilamab, an injectable IL-4 and IL-13 inhibitor) developed by Sanofi Genzyme and approved by the FDA in October 2018 as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fasenra</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (benralizumab, an injectable anti-IL-5 monoclonal antibody) for the treatment of severe asthma in patients 12 years of age and older marketed by AstraZeneca. Fasenra Pen pre-filled auto-injector was approved by the FDA for self-administration in November 2019</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Singulair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (monteleukast), an orally active leukotriene receptor antagonist for the prophylaxis and treatment of asthma in patients 12 months of age and older marketed by Merck</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tezspire</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (tezepelumab-ekko), an injectable monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP), an epithelial cytokine thought to be critical in the initiation and persistence of airway inflammation. Co-developed by Astra Zeneca and Amgen for the treatment of severe asthma. The FDA approved the Tezspire solution for subcutaneous injection in December 2021; it is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, several firms have been developing new formulations of Advair/Seretide (salmeterol /fluticasone propionate) and Symbicort (formoterol fumerate/budesonide) which may be marketed as generics or branded generics relative to the existing products from GSK and AstraZeneca, respectively. All of these efforts represent potential competition for any of our partnered products. Efforts have intensified following the publication of FDA draft guidance for the approval of fully substitutable versions of Advair and Symbicort in late 2013 and mid-2015, respectively. Current examples of these products include the marketed products Duoresp/Biresp from Teva (generic Symbicort), AirFluSal Forspiro by Sandoz, Rolenium by Elpen and Sirdupla by Mylan (all generic versions of Seretide) which are all available in a wide number of countries in the E.U. Numerous companies have brought to market generic forms of the ICS/LABA drug Advair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> since certain patents covering the Advair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> delivery device expired in 2016. In March 2017, Mylan N.V. received a complete response letter from the FDA relating to its Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder. In May 2017, Hikma announced that it received a complete response letter from the FDA relating to its ANDA for fluticasone propionate and salmeterol inhalation powder, and in February 2018, Novartis announced that its generic division Sandoz had received a complete response letter from the FDA in response to its ANDA for a third fluticasone propionate and salmeterol product. In January 2019, Mylan announced that the FDA approved Wixela&#153; Inhu&#153; (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of Advair Diskus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Sandoz terminated development of generic Advair. Teva announced that the FDA approved two of its products for adolescent and adult patients with asthma, one of which is AirDuo&#153; RespiClick</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (fluticasone propionate and salmeterol inhalation powder), a non-AB substitutable generic version of Advair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In May 2020, Cipla filed for FDA approval of a generic version of Advair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In April 2021, Hikma launched a generic version of Advair Diskus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the U.S. In January 2020, Astra Zeneca launched an authorized generic version of Symbicort. In August 2021, Lupin launched Luforbec</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a branded generic alternative to Foster, in select European markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In general, these manufacturers are required to conduct a number of clinical efficacy, pharmacokinetic and device studies to demonstrate equivalence to Advair, per the FDA&#x2019;s September 2013 Draft Guidance Document. These studies are designed to demonstrate that the generic product has the same active ingredient(s), dosage form, strength, exposure and clinical efficacy as the branded product. These generic equivalents, which must meet the same exacting quality standards as branded products, may be significantly less costly to bring to market, and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a generic competitor, a significant percentage of the sales of any branded product and products that may compete with such branded product is typically lost to the generic product. In addition, in April 2016, the FDA issued a draft guidance document covering Fluticasone Furoate/Vilanterol Trifenatate (FF/VI), the active ingredients used in RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Integrated Hospital / Infectious Disease Business</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial and Marketed Products</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our commercial and marketed products:</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img11029722_0.jpg" alt="img11029722_0.jpg" style="width:720px;height:219px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For U.S. and European approval</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S.: GIAPREZA is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">European Union: GIAPREZA is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S.: XERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (&#x201c;cIAI&#x201d;) in patients 18 years of age and older</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(5)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">European Union: XERAVA is indicated for the treatment of cIAI in adults</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (angiotensin II)</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (angiotensin II) injection is approved by the U.S. FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA is approved by the European Commission (&#x201c;EC&#x201d;) and by the Great Britain Medicines and Health Care Products Regulatory Agency (&#x201c;MHRA&#x201d;) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body&#x2019;s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system (&#x201c;RAAS&#x201d;), which in turn regulates blood pressure. GIAPREZA is marketed in the U.S. by La Jolla and is marketed in Europe and Great Britain by PAION Deutschland GmbH (&#x201c;PAION&#x201d;) on behalf of La Jolla.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Angiotensin II for the Treatment of High-Output Shock (&#x201c;ATHOS-3&#x201d;)</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GIAPREZA was approved by the U.S. FDA, EC and MHRA based on the results of ATHOS-3, which were published in the New England Journal of Medicine in August 2017. ATHOS-3 was a multinational, randomized, double-blind, placebo-controlled study in which 321 adults with septic or other distributive shock who remained hypotensive despite fluid and vasopressor therapy received either GIAPREZA or placebo, both in addition to background vasopressor therapy. The primary endpoint was mean arterial pressure</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;MAP&#x201d;) response, defined as a MAP of 75 mm Hg or higher or an increase in MAP from baseline of at least 10 mm Hg without an increase in the dose of background vasopressors at Hour 3 (Khanna et al, New England Journal of Medicine 2017; 377:419&#x2013;430).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATHOS-3 Study Design</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img11029722_1.jpg" alt="img11029722_1.jpg" style="width:565px;height:281px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAP=mean arterial pressure</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Khanna et al, New England Journal of Medicine 2017; 377:419&#x2013;430</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Standard-of-care vasopressors included norepinephrine, epinephrine, dopamine and vasopressin</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GIAPREZA significantly improved blood pressure response. Specifically, the primary endpoint was achieved by 70% of GIAPREZA-treated patients compared to 23% of placebo-treated patients (p &lt;0.0001).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Primary Endpoint: Mean Arterial Pressure Response</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1),(2)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img11029722_2.jpg" alt="img11029722_2.jpg" style="width:534px;height:327px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GIAPREZA FDA prescribing information</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAP response of 75 mm Hg or higher or an increase from baseline of at least 10 mm Hg at Hour 3 without an increase in the dose of background vasopressors</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GIAPREZA provides the ability to rapidly achieve and adjust therapeutic response. GIAPREZA rapidly increased MAP with a median time to MAP response of approximately 5 minutes. The plasma half-life of GIAPREZA is less than 1 minute.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, a positive survival trend was observed. Mortality through Day 28 was 46% on GIAPREZA and 54% on placebo (hazard ratio 0.78; 95% confidence interval 0.57&#x2013;1.07).</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Positive Survival Trend Observed (N=321)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1),(2)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img11029722_3.jpg" alt="img11029722_3.jpg" style="width:527px;height:301px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GIAPREZA FDA prescribing information</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MAP response of 75 mm Hg or higher or an increase from baseline of at least 10 mm Hg at Hour 3 without an increase in the dose of background vasopressors</span></div></div>
  <p style="margin-left:4.267%;text-indent:3.482%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adverse Reactions Occurring in &#x2265;4% of Patients Treated with GIAPREZA and &#x2265;1.5% More Often than in Placebo-treated Patients</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img11029722_4.jpg" alt="img11029722_4.jpg" style="width:544px;height:201px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GIAPREZA FDA prescribing information</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Including arterial and venous thrombotic events</span></div></div>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Percentage of Patients Experiencing &#x2265;1 Adverse Event, &#x2265;1 Serious Adverse Event and Discontinuing Treatment Due to an Adverse Event</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img11029722_5.jpg" alt="img11029722_5.jpg" style="width:481px;height:193px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Khanna et al, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">New England Journal of Medicine</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 2017; 377:419&#x2013;43</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (eravacycline)</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (eravacycline) for injection is approved by the U.S. FDA and Singapore Health Sciences Authority (&#x201c;HSA&#x201d;) as a tetracycline class antibacterial indicated for the treatment of cIAI due to susceptible microorganisms in patients 18 years of age and older. XERAVA is approved by the EC, MHRA, and the Hong Kong Department of Health (&#x201c;DoH&#x201d;) for the treatment of cIAI in adults. XERAVA is marketed in the U.S. by our wholly owned subsidiary, Tetraphase Pharmaceuticals, Inc. (&#x201c;Tetraphase&#x201d;), and is marketed in Europe and Great Britain by PAION on behalf of Tetraphase and is marketed in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines by Everest Medicines Limited (&#x201c;Everest&#x201d;). Everest submitted an NDA in China, which was accepted by the China National Medical Products Administration (&#x201c;NMPA&#x201d;) in March 2021.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cIAIs are the second most common source of severe sepsis in the ICU (Brun-Buisson et al, JAMA 1995; 274(12):968&#x2013;974). cIAIs are defined as consequences of perforations of the gastrointestinal tract that result in contamination of the peritoneal space (Solomkin et al, Clinical Infectious Diseases 2018; 69(6):921&#x2013;929).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investigating Gram-negative Infections Treated with Eravacycline (&#x201c;IGNITE&#x201d;)</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">XERAVA was approved by the U.S. FDA, HSA, EC, MHRA, and DoH based on the results of IGNITE1 and IGNITE4, which were published in JAMA Surgery in March 2017 and Clinical Infectious Diseases in December 2018, respectively.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IGNITE1 was a multinational, randomized, double-blind, active-controlled study in 538 patients with clinical evidence of cIAIs requiring urgent surgical or percutaneous intervention who received either XERAVA or ertapenem. The primary endpoint was clinical cure, defined as complete resolution or significant improvement of signs or symptoms of the index infection, at the test of cure (&#x201c;TOC&#x201d;) visit. The TOC visit was conducted 25 to 31 calendar days after the first dose of the study drug was administered.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IGNITE4 was a multinational, randomized, double-blind, active controlled study in 499 patients with clinical evidence of cIAIs requiring urgent surgical or percutaneous intervention who received either XERAVA or meropenem. The primary endpoint was clinical cure, defined as complete resolution or significant improvement of signs or symptoms of the index infection, at the TOC visit. The TOC visit was conducted 25 to 31 calendar days after the first dose of the study drug was administered.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IGNITE1 and IGNITE4 Study Design</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img11029722_6.jpg" alt="img11029722_6.jpg" style="width:538px;height:277px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Solomkin et al, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">JAMA Surgery</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 2017; 152(3):224-232</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Solomkin et al, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Infectious Diseases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 2018; 69(6):921-9</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TOC visit was conducted 25 to 31 calendar days after the first dose of the study drug was administered</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">XERAVA demonstrated statistical noninferiority in clinical cure rate in the micro-ITT population, which included all randomized subjects who had baseline bacterial pathogens that caused cIAIs and against at least one of which the investigational drug has in vitro (in a test tube) antibacterial activity (N=846).</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Primary Endpoint: Clinical Cure Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img11029722_7.jpg" alt="img11029722_7.jpg" style="width:559px;height:295px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">XERAVA FDA prescribing information</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noninferiority margins of 10% and 12.5% were used for IGNITE1 and IGNITE4, respectively</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical cure rates across patients with gram-negative, gram-positive and anaerobic pathogens, including those with resistant strains, are shown in the following tables.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical Cure Rates at TOC by Selected Baseline Pathogens in the Micro-ITT Population</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img11029722_8.jpg" alt="img11029722_8.jpg" style="width:555px;height:289px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">N=Number of subjects in the micro-ITT Population; N1=Number of subjects with a specific pathogen; n=Number of subjects with a clinical cure at the TOC visit</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">XERAVA FDA prescribing information</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comparators included ertapenem and meropenem for IGNITE1 and IGNITE4, respectively</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Streptococcus anginosus, Streptococcus constellatus, and Streptococcus intermedius</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Parabacteroides distasonis</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">XERAVA Demonstrated High Clinical Cure Rates Against Resistant Pathogens</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img11029722_9.jpg" alt="img11029722_9.jpg" style="width:521px;height:253px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CEPH-R=cephalosporin-resistant; ESBL=extended-spectrum &#x3b2;-lactamases; MDR=multidrug resistance;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">N=Number of subjects in the micro-ITT Population; N1=Number of subjects with a specific pathogen; n=Number of subjects with a clinical cure at the TOC visit</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ditch et al, 2018 ASM Microbe Annual Meeting</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comparators included ertapenem and meropenem for IGNITE1 and IGNITE4, respectively</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Data on file from IGNITE1 and IGNITE4 micro-ITT population</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The most common adverse reactions that were reported in XERAVA-treated patients in IGNITE1 and IGNITE4 were infusion site reactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selected Adverse Reactions Reported in &#x2265;1% of Patients Receiving XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img11029722_10.jpg" alt="img11029722_10.jpg" style="width:515px;height:173px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">XERAVA FDA prescribing information</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comparators included ertapenem and meropenem for IGNITE1 and IGNITE4, respectively</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Infusion site reactions include: catheter/vessel puncture site pain, infusion site extravasation, infusion site hypoaesthesia, infusion/injection site phlebitis, infusion site thrombosis, injection site/vessel puncture site erythema, phlebitis, phlebitis superficial, thrombophlebitis, and vessel puncture site swelling</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales and Marketing Organization</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We employ an experienced sales and marketing team dedicated to the commercialization of GIAPREZA and XERAVA. As of December 31, 2022, this team consisted of 35 professionals, including 27 critical care specialists.</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Customers</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, 503 hospitals in the U.S. purchased GIAPREZA, and 874 hospitals and other healthcare organizations in the U.S. purchased XERAVA. Hospitals and other healthcare organizations generally purchase our products through a network of specialty and wholesale distributors. These specialty and wholesale distributors are considered our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">customers for accounting purposes. We do not believe that the loss of one of these distributors would significantly impact the ability to distribute our products, as we expect that sales volume would be absorbed by the remaining distributors. Due to the relatively short lead-time required to fill orders for GIAPREZA and XERAVA, backlog is not material to our business.</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Catecholamines (primarily norepinephrine), which are available as generics and inexpensive, are typically used first line to treat distributive shock, while vasopressin, including Vasostrict</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Endo International plc) and vasopressin generic drugs, is typically used second line. In the randomized, Phase 3 study ATHOS-3, GIAPREZA demonstrated clinical benefit in patients who were not adequately responding to available vasopressors, including catecholamines and vasopressin. GIAPREZA&#x2019;s principal competition as a treatment in patients not adequately responding to available vasopressors is the use of these same vasopressors at increased doses. If we are unable to successfully change treatment practices, the commercial prospects for GIAPREZA will be limited, and our business may suffer.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">XERAVA competes with a number of antibiotics that are currently marketed for the treatment of cIAI and other multidrug resistant infections, including: AVYCAZ (ceftazidime and avibactam, marketed by AbbVie Inc.); MERREM IV</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (meropenem, marketed by AstraZeneca PLC); PRIMAXIN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (imipenem and cilastatin, marketed by Merck &amp; Co., Inc.); RECARBRIO&#153; (imipenem, cilastatin, and relebactam, marketed by Merck &amp; Co., Inc.); TYGACIL</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (tigecycline, marketed by Pfizer Inc.); VABOMERE&#153; (meropenem and vaborbactam, marketed by Melinta Therapeutics, Inc.); ZERBAXA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (ceftolozane and tazobactam, marketed by Merck &amp; Co., Inc.); ZOSYN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (piperacillin and tazobactam, marketed by Pfizer Inc.); and current and future generic versions of marketed antibiotics. If we are unable to successfully change treatment practices, the commercial prospects for XERAVA will be limited, and our business may suffer.</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory Exclusivity</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GIAPREZA and XERAVA are New Chemical Entities (&#x201c;NCEs&#x201d;) approved by the U.S. FDA. In the U.S., NCEs approved by the FDA are eligible for market exclusivity under the U.S. Federal Food, Drug, and Cosmetic Act (&#x201c;FDCA&#x201d;), which can prevent the approval of generic versions of the NCE for 5 to 7.5 years from the date of the initial approval of the NCE. Specifically, the FDCA provides a 5-year period of marketing exclusivity within the U.S. to the applicant that gains approval of an NDA for an NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all of the data required for approval. However, an application may be submitted 4 years after the NDA approval of the NCE if it contains a certification of patent invalidity or non-infringement. Should the NDA holder commence litigation against the ANDA filer within 45 days of receipt of the certification notice, an automatic stay of the approval of any generic competition goes into effect until the earlier of: (i) 30 months from the receipt of the certification; or (ii) a court ruling of patent invalidity or non-infringement for the relevant patents. In the absence of a court ruling, the 30-month stay will be extended by such amount of time (if any) that is required for 7.5 years to have elapsed from the date of NDA approval of the NCE.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 15, 2022, La Jolla received a paragraph IV notice of certification (the &#x201c;Notice Letter&#x201d;) from Gland Pharma Limited (&#x201c;Gland&#x201d;) advising that Gland had submitted an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA in the U.S. prior to the expiration of U.S. Patent Nos.: 9,220,745; 9,572,856; 9,867,863; 10,028,995; 10,335,451; 10,493,124; 10,500,247; 10,548,943; 11,096,983; and 11,219,662 (the &#x201c;GIAPREZA Patents&#x201d;), which are listed in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#x201c;Orange Book&#x201d;). The Notice Letter alleges that the GIAPREZA Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Gland&#x2019;s ANDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 29, 2022, La Jolla filed a complaint for patent infringement of the GIAPREZA Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland&#x2019;s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA is a new chemical entity and La Jolla filed a complaint for patent infringement within 45 days of receipt of the Notice Letter, the FDA cannot approve Gland&#x2019;s ANDA any earlier than 7.5 years from the approval of the GIAPREZA NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed. We intend to vigorously enforce our intellectual property rights relating to GIAPREZA.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Generating Antibiotic Incentives Now (&#x201c;GAIN&#x201d;) provisions of the FDA Safety and Innovation Act (&#x201c;FDASIA&#x201d;), the FDA may designate a product as a qualified infectious disease product (&#x201c;QIDP&#x201d;). In order to receive this designation, a drug must qualify as an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections. We obtained a QIDP designation for the IV formulation of XERAVA for cIAI in July 2013. Upon approving an application for a QIDP, the FDA will extend by an additional 5 years any non-patent marketing exclusivity period awarded, such as a 5-year exclusivity period awarded for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an NCE. This extension is in addition to any pediatric exclusivity extension awarded. XERAVA has been awarded this 5-year exclusivity under FDASIA.</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Product Candidates</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the status of our primary product candidates:</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img11029722_11.jpg" alt="img11029722_11.jpg" style="width:720px;height:145px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Zai Lab (Shanghai) Co., Ltd. (&#x201c;Zai Lab&#x201d;) has licensed exclusive rights to SUL-DUR in the Asia-Pacific region.</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Global Antibiotic Research and Development Partnership (&#x201c;GARDP&#x201d;) will fully fund the Phase&#x202f;3 clinical trial and pharmaceutical development activities and has commercial rights in WHO defined low-income and specified middle-income countries. We have retained commercial rights in all major markets in North America, Europe and Asia-Pacific</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUL-DUR</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead product candidate, SUL-DUR, is a novel IV antibiotic. The product is a combination of sulbactam, a &#x3b2;-lactam antibiotic, and durlobactam, our novel &#x3b2;-lactamase inhibitor (&#x201c;BLI&#x201d;) with broad spectrum &#x3b2;-lactamase coverage including Classes A, C and D, that we are developing for the treatment of a variety of serious infections caused by carbapenem-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We have completed three separate Phase&#x202f;1 clinical trials, including one evaluating the penetration of SUL-DUR into the lung and one in renally impaired patients. Subsequently, we completed a Phase&#x202f;2 clinical trial in patients with cUTIs. We initiated ATTACK, our single Phase&#x202f;3 registration trial in 2019, that evaluated SUL-DUR in patients with confirmed carbapenem-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> pneumonia and/or bloodstream infections. We believe SUL-DUR has the ability to improve outcomes of patients with multidrug-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">infections, reducing their overall mortality. We announced positive top-line Phase 3 data in October 2021 and based on our positive top-line Phase 3 data and the totality of our preclinical and clinical data, we filed a new drug application (&#x201c;NDA&#x201d;) with the FDA in September 2022. The NDA was accepted for filing by the U.S. FDA. We believe SUL-DUR has the ability to improve outcomes of patients with multidrug-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">infections, reducing their overall mortality.</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is a Gram-negative, opportunistic human pathogen that predominantly infects critically ill patients often resulting in severe pneumonia and bloodstream infections but can also infect other body sites as well. Once thought to be mostly benign, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is now considered a global threat in the healthcare setting due in part to its ability to acquire multidrug resistance at rates not previously seen in other bacteria. In addition, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has the ability to remain viable for up to 100 days in dry conditions and easily spreads via air or water droplets, which explains why the pathogen can often be found in many locations in the intensive care unit, or ICU, including bedrails, bedside tables, monitors of mechanical ventilators, intravenous pumps, door handles, stethoscopes and many other locations. Of significant concern, one study reported greater than 98% of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> isolates in an ICU from non-clinical sources such as bedrails and door handles, were determined to be multidrug resistant.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pneumonia and bloodstream infections caused by drug-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> can have mortality rates approaching 50%. Antibiotic-resistance rates of Acinetobacter to current standard-of-care treatments are some of the highest reported, between 30% and 50% in the United States and greater than 90% in parts of Europe and Asia. Acinetobacter resistance to &#x3b2;-lactams is primarily driven by the expression of Class&#x202f;D &#x3b2;-lactamases, often in combination with Class&#x202f;A and/or Class&#x202f;C &#x3b2;-lactamases. There are currently no effective antibiotics indicated for the treatment of multidrug-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections. Durlobactam is the first clinical-stage BLI with sufficient broad-spectrum activity against class A, C, and D &#x3b2;-lactamases to potentially restore the efficacy of &#x3b2;-lactam antibiotics against multidrug-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sulbactam, the &#x3b2;-lactam antibiotic used in SUL-DUR has superior microbiological potency against </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> compared to other &#x3b2;-lactam antibiotics based on </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> analyses. Historically, physicians used sulbactam to successfully treat </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections before development of broad &#x3b2;-lactamase mediated resistance rendered sulbactam on its own largely</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ineffective. We believe our data demonstrates that combining durlobactam with sulbactam can effectively restore the activity of sulbactam against multidrug-resistant strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Market Opportunity</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We estimate that there are up to 200,000 hospital-treated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections annually in the United States and Europe, of which up to 100,000 are carbapenem-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections, which we regard as our initial target markets for SUL-DUR. We also believe there could be a significant market opportunity in Asia-Pacific, Central and South America, Russia and the Middle East given resistance rates exceeding 80% in some countries. If approved, we believe SUL-DUR has the potential to address the issues of resistance facing existing regimens, which is currently limiting the utility of the carbapenems, and tolerability, which is a concern with regimens containing colistin. There are currently no antibiotics indicated for the treatment of carbapenem-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections.</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Development Plan</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Completed Clinical Trials</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 3 registration trial:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We completed ATTACK, a Phase 3 registration trial of SUL-DUR for the treatment of patients with carbapenem-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections, with positive top-line data announced in October 2021. ATTACK enrolled 207 patients at 95 clinical sites in 16 countries. This was a two-part trial with Part A being the randomized, comparative portion (SUL-DUR vs colistin) in patients with documented </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VAPB), ventilated pneumonia (VP), or bacteremia, and Part B being an open-labeled portion including </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections resistant to, or having previously failed colistin or polymyxin B treatment. Baseline </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> isolates tested were greater than 95% carbapenem resistant.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUL-DUR met the primary efficacy endpoint of 28-day all-cause mortality compared to colistin in the CRABC m-MITT population of Part A. SUL-DUR mortality was 19.0% (12/63) compared to 32.3% (20/62) in the colistin arm (treatment difference of -13.2%; 95% CI: -30.0, 3.5). Similar trends were demonstrated in 28-day and 14-day all-cause mortality favoring SUL-DUR across all study populations evaluated to date. A statistically significant difference in clinical cure at Test of Cure (TOC) was observed with 61.9% in SUL-DUR arm compared to 40.3% in the colistin arm (95% CI 2.9-40.3). In Part B, the 28-day all-cause mortality was 17.9% (5/28) and consistent with that observed in Part A.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Safety analyses from a total of 177 patients treated with SUL-DUR suggested that SUL-DUR was generally well-tolerated with a favorable safety profile compared to colistin. SUL-DUR met the primary safety objective with a statistically significant lower incidence of nephrotoxicity as measured by the RIFLE classification for acute kidney injury. SUL-DUR nephrotoxicity was 13.2% (12/91) versus 37.6% (32/85) in the colistin arm (p = 0. 0002). Overall adverse events (AEs) in the safety population were comparable between treatment groups with 87.9% (80/91) in the SUL-DUR arm vs. 94.2% (81/86) in the colistin arm in Part A, 89.3% (25/28) in Part B. Drug related AEs were 12.1% (10.7% in Part B) with SUL-DUR compared to 30.2% with colistin. The most common non-infectious AEs (&#x2265;10%) in the SUL-DUR arm were diarrhea (16.5%), allergic and hypersensitivity reactions (16.5%), anemia (13.2%) and hypokalemia (12.1%) in Part A. These AEs were also &gt;10% in the colistin arm as was acute kidney injury.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 30, 2022, we announced that the U.S. FDA accepted for Priority Review the new drug application (NDA) for SUL-DUR. The FDA is currently planning to hold an advisory committee meeting to discuss this application. The target PDUFA date (or action date) is May 29, 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2 clinical trial in cUTI patients:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We completed a Phase 2 clinical trial in cUTI patients to provide additional safety and pharmacokinetic, or PK, data as well as efficacy data against carbapenem-resistant pathogens. Eighty patients were randomized to receive either a dose of SUL-DUR or placebo every six hours for seven days. Patients in both arms also received background therapy, which is current standard-of-care, with 500 mg of imipenem, or IMI, administered through IV every six hours. There were no serious adverse events reported and the adverse event profile of SUL-DUR plus IMI was similar to that of the IMI comparator arm. PK data observed in the Phase 2 trial was consistent with the PK data observed in the Phase 1 clinical trial in healthy volunteers.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have completed three Phase&#x202f;1 clinical trials, highlighted below, in addition to a Phase 2 clinical trial in patients with cUTIs. In all of these clinical trials, SUL-DUR was observed to be generally well tolerated.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Four-part Phase 1 first-in-human trial:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our four-part Phase&#x202f;1 first-in-human clinical trial was conducted in Australia in 124 healthy volunteers. SUL-DUR was generally well tolerated, with no dose-related systemic adverse events or drug-related serious adverse events reported. SUL-DUR also exhibited linear dose-dependent increases in exposure and PK parameters across the dose range studied.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1 lung trial:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our Phase 1 lung trial assessed the concentration of SUL-DUR in lung fluid, an important metric to understand, because ATTACK includes patients with pneumonia and lack of appropriate lung tissue penetration has been found to contribute to reduced efficacy. We believe that the levels of SUL-DUR in the lung fluid achieved in this trial support its continued development as a potential treatment for pneumonia caused by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1 renal trial:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our Phase 1 renal trial analyzed serum levels in renally impaired patients and provided data to enable the development of a dose adjustment protocol for the type of patient targeted in our ongoing Phase&#x202f;3 registration trial.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We submitted an IND for SUL-DUR to the U.S. FDA in June 2017, and the FDA notified us in July 2017 that we could proceed with this program. The FDA granted Fast Track and QIDP designation for SUL-DUR in September 2017 for the treatment of hospital-acquired and ventilator-acquired bacterial pneumonia and bloodstream infections due to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Global Acinetobacter Surveillance Data</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Durlobactam has broad activity against a wide range of &#x3b2;-lactamases, including Classes A, C and D, unlike currently marketed BLIs that primarily cover only Class A and Class C &#x3b2;-lactamases. Durlobactam is the first BLI in clinical development with such a broad spectrum of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> activity.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUL-DUR has also exhibited potent microbiological activity against </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> strains </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Over a series of studies summarized in the figure below, we have compared the effectiveness of SUL-DUR, sulbactam alone and comparators in inhibiting 7,221 strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> that were collected from patients around the world between 2011 and 2020. Amikacin and colistin were tested against 6,418 of the 7,221 strains. The plot in the figure below presents the cumulative percentage of these strains inhibited by increasing concentrations of each of the tested compounds. Sulbactam alone, as well as most of the other marketed antibiotics, had a very high MIC90 value of 64 mg/L, meaning that concentrations of 64 mg/L or greater were required to inhibit growth of 90% of the strains. The corresponding breakpoints, which are established by the Clinical &amp; Lab Standards Institute, or CLSI, as the specified concentrations for each antibiotic that define whether a strain is considered resistant, are significantly lower than their MIC90 values. If the MIC90 of a drug is lower than its CLSI breakpoint, then that drug would be expected to be effective against more than 90% of the strains. If a drug&#x2019;s MIC90 is higher than its breakpoint, the drug would not be expected to have broad efficacy against those strains. This cumulative analysis suggests that recent global strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> are resistant to all the comparator antibiotics other than colistin, consistent with their significantly diminished clinical utility against </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections. In contrast, SUL-DUR had very potent activity, with a much lower MIC90 of 2 mg/L. This is lower than the CLSI breakpoint for sulbactam, which is 4 mg/L (in Unasyn</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a combination of sulbactam and ampicillin), suggesting that our chosen target exposure levels of SUL-DUR may be effective against more than 90% of global, multidrug resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">strains. A subset of 926 isolates out of the 7,221 strains tested were from Chinese hospitals collected in 2016-2018. 831 of the 926 (84.6%) Chinese isolates were carbapenem-resistant. In contrast, SUL-DUR showed potent activity against this subset, with an MIC90 of 2 mg/L and 97.9% of isolates susceptible to &#x2264; 4 mg/L of SUL-DUR.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img11029722_12.jpg" alt="img11029722_12.jpg" style="width:576px;height:332px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are initially developing SUL-DUR for the treatment of multidrug-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections. Due to rising resistance rates, standard-of-care treatment for multidrug-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections often includes a combination of several last-line treatment options, including carbapenems, tetracyclines, polymyxins, and other generically available agents. Despite using best available therapy, mortality rates of patients with multidrug-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections are reported as high as 50%. As of the date of this report, we are not aware of any marketed antibiotic that is indicated for the treatment of multidrug-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections; however, we are aware of other potentially competitive products that have shown </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> activity against some strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Melinta Therapeutics Inc. currently markets minocycline. Although recently approved for treating cUTIs, Fetroja</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, from Shionogi&#x202f;&amp;&#x202f;Co.,&#x202f;Ltd., includes in its label a specific warning of an observed increase in all-cause mortality in patients with carbapenem-resistant Gram-negative bacterial infections that were treated with the drug. BioVersys AG reported in May 2022 that their lead program BV100, being developed specifically for multidrug-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections, completed three Phase 1 clinical trials.</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Commercial Approach</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, our commercial strategy is driven by our understanding of where </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections are known to exist. Given that </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections more commonly occur in immunocompromised patients, treatment settings for these patients are frequently large intensive care units (ICUs), specialized centers like transplant, cancer, and burn, outpatient long-term acute centers (LTACs) and home infusion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUL-DUR has been developed specifically for multi-drug resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections and we believe the unmet need and value proposition of SUL-DUR will support its use for treating infections caused by this serious Gram-negative pathogen. This value proposition includes:</span></p>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections currently cost lives. There is an urgent, global unmet medical need due to the limitations of currently available treatment options. Published mortality rates of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections treated with best available therapy are reported to exceed 50%.</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections currently cost time. These serious infections directly lead to time in a hospital where hospital length of stay is often measured in months or weeks instead of days.</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">infections currently cost money. Given the limitations described above, carbapenem-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections are reported to be one of the costliest to treat, exceeding $75,000 per case based upon published literature.</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">4.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe the data from ATTACK, combined with our overall preclinical and clinical data package, clearly demonstrate an efficacy and safety benefit of SUL-DUR over colistin in treating carbapenem resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">infections.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> treatment protocols allow for clear positioning of SUL-DUR. Patients with suspected </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections are frequently treated with a broad-spectrum antibiotic, commonly a carbapenem, as first-line therapy. If susceptibility testing identifies that the causative bacterial pathogen is carbapenem-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the patient is then frequently switched to a colistin-based antibiotic regimen in an attempt to successfully treat the infection. Published literature, however, reports greater than 50% mortality rates using colistin-based regimens.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that the data from the ATTACK Phase 3 registration trial demonstrate improved efficacy and safety profiles, that could result in SUL-DUR, if approved, being preferred to a colistin-based regimen for the treatment of multidrug-resistant, including carbapenem-resistant, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">infections.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Multidrug-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acinetobacter</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infections also present a significant unmet medical need in China and across the broader Asia/Pacific territory. Our collaboration and license agreement with Zai Lab, which included their participation in the ATTACK Phase 3 registration clinical trial, provides a potentially accelerated path for regulatory approval and commercialization in China and Asia-Pacific territories. Zai Lab supported the enrollment of approximately 25% of the evaluable patients in ATTACK from China, which we believe will support a regulatory submission in China. Under our agreement with Zai Lab, we receive upfront, milestone and royalty payments in addition to payment of certain Phase 3 registration clinical trial costs. We maintain 100% of the rights and associated economics in North America and Europe. Outside of the United States, we intend to work with multi-national pharmaceutical companies to leverage their commercialization capabilities in territories not covered by our agreement with Zai Lab. In January 2023, Zai Lab announced that the Center for Drug Evaluation of China&#x2019;s National Medical Products Administration has granted priority review status to the NDA for SUL-DUR for the treatment of infections caused by Acinetobacter baumannii, including multidrug-resistant and carbapenem-resistant (CRAB) strains.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Zoliflodacin</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our second late-stage product candidate is zoliflodacin, a potential single oral dose cure for the treatment of uncomplicated gonorrhea caused by the bacterial pathogen </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Gonorrhea is an area of significant medical need and zoliflodacin is the only novel single dose treatment in development that provides a potential monotherapy oral alternative to intramuscular injections of ceftriaxone for the treatment of gonorrhea, including infections caused by drug-resistant strains. Zoliflodacin targets the validated mechanism of action of the fluoroquinolone class of antibiotics but does so in a novel manner to avoid existing fluoroquinolone resistance. We have completed several Phase&#x202f;1 clinical trials and a Phase&#x202f;2 clinical trial of zoliflodacin in patients with uncomplicated gonorrhea. In collaboration with GARDP, in 2019 we initiated a single Phase 3 registration trial of zoliflodacin in patients with uncomplicated gonorrhea. GARDP will fund all the Phase&#x202f;3 clinical trial and pharmaceutical development costs and in return will receive commercial rights for zoliflodacin in WHO-defined low-income and select middle-income countries. We have retained commercial rights in all other countries, including the major markets in North America, Europe and Asia-Pacific.</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Gonorrhea</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Uncomplicated gonorrhea is an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">N.&#x202f;gonorrhoeae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infection of the urethra, cervix, pharynx or rectum, and is more common than complicated gonorrhea, which includes spread of the infection to other tissues and potentially the bloodstream. Gonorrhea can be associated with serious complications, including pelvic inflammatory disease, ectopic pregnancy and infertility, as well as an increased risk of human immunodeficiency virus, or HIV. Despite the continued use of effective antibiotics, it remains one of the most common sexually transmitted bacterial infections in the world with an estimated 82.4&#x202f;million people worldwide infected each year. The occasional absence of symptoms, more frequent in women, is thought to be one reason for sustained levels of infection. Antibiotics remain the mainstay for treating uncomplicated gonorrhea</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">caused by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">N. gonorrhoeae.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is the bacterial pathogen responsible for gonorrhea and has a strong propensity for uptake of chromosomal DNA from other genera of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Neisseria</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which allows the bacteria to accumulate many mutations in chromosomal genes leading to frequent resistance of antibiotics. For example, penicillin was introduced for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">N. gonorrhoeae </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">infections in 1943, and initial resistance was reported in 1945. Fluoroquinolone antibiotics were first used to treat gonorrhea in 1949 and have been one of the most successful classes of antibiotics against </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, but even so resistance was identified in 1969. One member of this class, ciprofloxacin, was introduced in 1980 and resistance was identified in 1990. More recently cephalosporin antibiotics, notably cefixime, had been widely used for the treatment of gonorrhea due to their oral administration along with a favorable efficacy and safety profile, although resistance by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">N. gonorrhoeae </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">has been reported since 2007. As widespread use of these antibiotics drove the emergence of drug-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> strains, treatment guidelines have subsequently been amended. Ceftriaxone is currently the only CDC-recommended option for the treatment of gonorrhea and, until recently, was administered with azithromycin, a broad-spectrum antibiotic, to provide coverage against other sexually transmitted diseases that tend to occur concurrently with gonorrhea. However, rising resistance of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to azithromycin recently prompted the CDC to now recommend 500mg ceftriaxone monotherapy. Ceftriaxone is administered by intramuscular injection, which can be painful and may require patient monitoring by a healthcare administrator. Although ceftriaxone remains effective in most of the U.S., in Hawaii and Massachusetts as well as in several countries, including China, Japan, Vietnam, South Korea, France and Spain, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> strains with resistance to azithromycin and ceftriaxone have been reported, prompting concerns that multidrug-resistant gonorrhea may become a major community health issue.</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Market Opportunity</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is an immediate global public health threat with 82.4 million cases worldwide in 2020 (WHO estimate). Cases of gonorrhea in the United States have reached an estimated 1.6 million per year. The WHO worldwide estimate of approximately 82.4 million new cases includes infected adolescents and adults aged 15&#x2013;49 years. The CDC estimates that the cases of gonorrhea in the United States have been increasing at least 10% per year since 2009. In April 2021, the CDC announced that sexually transmitted diseases in the U.S. reached all-time high for 6th consecutive year, with approximately 2.6 million cases of chlamydia, gonorrhea &amp; syphilis reported in 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results of a 2017-2018 survey of countries reporting decreased susceptibility, DS, or resistance, R, of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to current antibiotics are reflected in the table below.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><img src="img11029722_13.jpg" alt="img11029722_13.jpg" style="width:466px;height:162px;" />&#160;</p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Historically, to reduce the risk of spreading drug-resistant </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">N. gonorrhoeae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the CDC has changed treatment guidelines when resistance rates to recommended first-line treatments reach 5%. Since 2015, there has only been one recommended treatment on CDC guidelines for gonorrhea: 250mg intramuscular injection of ceftriaxone plus 1g of oral azithromycin. In 2020 the CDC once again updated its treatment guideline, now recommending a 500mg intramuscular injection of ceftriaxone for treatment of uncomplicated gonorrhea. This follows a 2019 update in the United Kingdom where recommended empirical treatment of gonorrhea is now 1 g intramuscular ceftriaxone monotherapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Development Plan</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Ongoing Registration Trial</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 3 registration trial:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In 2019, we announced the initiation of a global, multi-center Phase 3 registration trial in collaboration with GARDP who is conducting and funding all Phase&#x202f;3 clinical trial and pharmaceutical development costs. Up to 18 clinical trial sites are planned across the U.S., Thailand, South Africa, the Netherlands and Belgium. Our Phase&#x202f;3 registration trial is a multi-center, open-label, noninferiority trial in approximately 1,000 enrolled patients with uncomplicated gonorrhea who will be randomized on a 2:1 basis to receive either a single 3.0g oral dose of zoliflodacin or a regimen of 500mg intramuscular ceftriaxone plus 1g oral azithromycin. The primary endpoint will be the proportion of patients with microbiological cure at urethral or cervical sites, approximately six days after treatment. The Data Safety Monitoring Board, or DSMB, in May 2021 recommended to continue the study without modification. Despite the ongoing challenges with the COVID-19 pandemic, we have observed an increase in the enrollment rate recently and based on current enrollment rates we anticipate completion of trial enrollment in 2023. Based on our discussions with the U.S. FDA, we believe that the efficacy data from this single Phase&#x202f;3 registration trial, if positive, along with the data from our other clinical trials of zoliflodacin, will be sufficient to support the submission of an NDA to the U.S. FDA.</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Completed Clinical Trials</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase&#x202f;2 clinical proof-of-concept trial: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have completed a multi-center, randomized, open-label Phase&#x202f;2 clinical trial comparing a single oral dose of 2.0g or 3.0g of zoliflodacin to 500mg intramuscular ceftriaxone for the treatment of uncomplicated gonorrhea. In this trial, 179 randomized patients received treatment and zoliflodacin was generally well tolerated, with efficacy outcomes comparable to ceftriaxone. Microbiological eradication and clinical cure in urogenital infections with a single dose of zoliflodacin, the primary endpoint of the trial, was comparable to ceftriaxone, with 100% cure rate in both the 3.0g zoliflodacin and ceftriaxone groups in the per-protocol population. The results of this clinical trial were published in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The New England Journal of Medicine</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in 2018.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1 clinical trial: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We evaluated zoliflodacin in two Phase&#x202f;1 clinical trials studying 72 healthy volunteers in total. In one trial, we evaluated PKs and tolerability in 48 subjects and food effects in 18 subjects, and in the second trial, we evaluated absorption, distribution, metabolism and excretion in six subjects. Zoliflodacin was generally well tolerated in these trials at doses we would expect to be clinically active for treating uncomplicated gonorrhea. Administration of a high-fat meal was associated with an increase in zoliflodacin plasma concentration, suggesting that zoliflodacin could be administered with or without food.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Data</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have generated biochemical, microbiological and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> data on zoliflodacin. The data suggest that zoliflodacin retains potent activity against contemporary clinical isolates in the U.S., Europe, China, Thailand and South Africa that are resistant to other antibiotic classes including fluroquinolones, which was expected given its novel mechanism of action. In addition, the data show</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant resistance against two of the four standard antibiotics indicated for gonorrhea, ciprofloxacin, a fluoroquinolone, and azithromycin, a macrolide.</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are initially developing zoliflodacin as a single oral dose treatment for uncomplicated gonorrhea. Gonorrhea is commonly treated with 500mg intramuscular ceftriaxone, a generically available agent. Additional generic cephalosporins and fluoroquinolones are also prescribed, but not recommended as primary treatment options given current resistance rates. Gepotidacin, currently under development for a variety of infections by GlaxoSmithKline&#x202f;plc, is the only potentially competitive product candidate in late-stage clinical development that we are aware of that is being developed for the treatment of uncomplicated urogenital gonorrhea. A Phase 3 clinical trial (EAGLE-1) was initiated by GlaxoSmithKline in October 2019. A prior Phase 2 clinical trial revealed the emergence of resistance to gepotidacin in 2 urogenital microbiological failures following administration of a single oral dose. In an attempt to overcome this resistance, gepotidacin will be given in two oral doses in the EAGLE-1 clinical trial; a 4-tablet 3000 milligram (mg) oral dose at the study site followed by another 4-tablet 3000mg oral dose as an outpatient.</span></p>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Commercial Approach</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Antibiotics to treat uncomplicated gonorrhea will typically be available through primary care physicians, outpatient clinics and emergency rooms, and numerous community sites. In addition, placement on CDC guidelines has historically driven awareness and uptake in the U.S. We have partnered with GARDP who will lead the commercialization of zoliflodacin in certain WHO-defined low-income and specified middle-income countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Zoliflodacin is a potential single dose cure (sachet in water) that can facilitate &#x201c;expedited partner therapy&#x201d; at home, which may lower the chance for a repeat infection from a partner. Expedited partner therapy, or EPT, is the clinical practice of treating the sex partners of patients diagnosed with chlamydia or gonorrhea by providing prescriptions or medications to the patient to take to his/her partner without the health care provider first examining the partner. Within the United States, EPT is permissible in 45 states, potentially allowable in 4 states and is only prohibited in one state.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO&#174;ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (FF/VI) and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (UMEC/VI) is performed by GSK.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third-party manufacturers to produce GIAPREZA and XERAVA and expect to continue to do so in the foreseeable future to meet our development and commercial needs. In all of our manufacturing agreements, we require that contract manufacturers produce active pharmaceutical ingredients (&#x201c;APIs&#x201d;) and drug products in accordance with the FDA&#x2019;s current Good Manufacturing Practices (&#x201c;cGMPs&#x201d;) and all other applicable laws and regulations. We maintain confidentiality agreements with potential and existing manufacturers in order to protect our proprietary rights related to GIAPREZA and XERAVA. The long-term commercial success of GIAPREZA and XERAVA will depend in part on the ability of our contract manufacturers to supply cGMP-compliant API and drug product without interruption.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to our product candidates, we currently rely on third-party contract manufacturers for our required raw materials, drug substance, and finished drug product for our preclinical research and clinical trials. Although we have contracts with these third parties to meet our current clinical supply needs, we do not have any current contractual relationships with these third parties for the manufacture of commercial supply of our product candidates after they are approved. As our product candidates approach potential approval by any regulatory agency, we intend to enter into agreements with third-party contract manufacturers for the commercial production of those products. We currently employ internal resources to manage our manufacturing vendor relationships and processes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, import and export of our products and reimbursement. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulation require the expenditure of substantial time and financial resources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Government Regulation</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local statutes and regulations requires the expenditure of substantial time and financial resources. The failure to comply with the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">applicable requirements at any time during the product development process, approval process or after approval may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#x2019;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and untitled letters, product recalls, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil or criminal penalties.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Approval Processes</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, or the FDCA, the Public Health Service Act, or PHSA, and implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulation require the expenditure of substantial time and financial resources. Failure to comply with the FDCA and other applicable U.S. requirements at any time during the product development process, approval process or after approval may subject us to a variety of administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include:</span></p>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal to approve pending applications;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of an approval;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">imposition of a clinical hold;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">warning letters, untitled letters and similar communications;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizures or recalls; or</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">total or partial suspension of production or distribution, or injunctions, fines, restitution, disgorgement of profits or civil or criminal investigations and penalties brought by the FDA and the Department of Justice, or DOJ, or other </span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></p>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of preclinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practices or other applicable regulations;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an IND application, which must become effective before human clinical trials may begin;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use, conducted in accordance with current good clinical practices, or cGCP, which are ethical and scientific quality standards and FDA requirements for conducting, recording and reporting clinical trials to assure that the rights, safety and well-being of trial participants are protected;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation and submission to the FDA of an NDA;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practices, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#x2019;s safety, identity, strength, quality and purity; and</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of the NDA.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once a pharmaceutical candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some preclinical or nonclinical testing may continue even after the IND is submitted. In addition to including the results of the preclinical studies, the IND will also include one or more protocols detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy determination. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the IND on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical hold may occur at any time during the life of an IND and may affect one or more specific studies or all studies conducted u1nder the IND.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with cGCP. They must be conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol and any amendments must be submitted to the FDA as part of the IND, and progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently in other situations, including the occurrence of serious adverse events. An IRB at each institution participating in the clinical trial must review and approve the protocol and any amendments before a clinical trial commences or continues at that institution, approve the information regarding the clinical trial and the informed consent form that must be provided to each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1. The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, distribution, metabolism and elimination. In the case of some products for severe or life-threatening diseases, such as multidrug-resistant infections, especially when the product may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients with the target disease or condition.</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2. Clinical trials are initiated in a limited patient population intended to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for regulatory approval and product labeling.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1, Phase 2 and Phase 3 testing may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug has been associated with unexpected serious harm to patients.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points, including prior to submission of an IND, at the end of Phase 2 and before an NDA is submitted. Meetings at other times may also be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end-of-Phase 2 meeting to discuss their Phase 2 clinical results and present their plans for the pivotal Phase 3 clinical trial or trials that they believe will support approval of the new drug.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric studies for certain drugs and biologics. Specifically, PREA requires original NDAs, biologic license applications, or BLAs, and supplements thereto for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration to contain a pediatric assessment unless the sponsor has received a deferral or waiver.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal safety studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and the manufacturer must develop methods for testing the quality, purity and potency of the final drugs. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf-life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. The submission of an NDA is subject to the payment of user fees, but a waiver of such fees may be obtained under specified circumstances. The FDA reviews all NDAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. It may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to completeness review before the FDA accepts it for filing.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once the submission is accepted for filing, the FDA begins an in-depth review. NDAs receive either standard or priority review. A drug that, if approved, would represent a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious disease or condition may receive priority review. Requests for priority review generally must be submitted at the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">time of NDA submission. The FDA has agreed to specified performance goals in the review process of NDAs. Under that agreement, 90% of applications seeking approval of new molecular entities, or NMEs, are meant to be reviewed within ten months from the date on which FDA accepts the NDA for filing, and 90% of applications for NMEs that have been designated for &#x201c;priority review&#x201d; are meant to be reviewed within six months of the filing date. For applications seeking approval of drugs that are not NMEs, the ten-month and six-month review periods run from the date that FDA receives the application. The review process may be extended by the FDA for three additional months to consider a major amendment to the application following the original submission.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing complies with cGMP requirements to assure and preserve the product&#x2019;s safety, identity, strength, quality and purity. The FDA may refer the NDA to an advisory committee for review and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendation.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured and tested. These pre-approval inspections may cover all facilities associated with NDA submission, including drug component manufacturing (such as active pharmaceutical ingredients), finished drug product manufacturing, and control testing laboratories. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP. In addition, the FDA may require, as a condition of approval, risk evaluation and mitigation strategies, or REMS (which may include requirements for, restricted distribution and use), enhanced labeling, special packaging or labeling, expedited reporting of certain adverse events, pre-approval of promotional materials, restrictions on direct-to-consumer advertising or commitments to conduct additional research post-approval.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On the basis of the FDA&#x2019;s evaluation of the NDA and accompanying information, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. If the FDA ultimately decides that the NDA does not satisfy the criteria for approval, the FDA will issue a complete response letter to indicate that the agency will not approve the NDA in its present form. The complete response letter usually describes all of the specific deficiencies in the NDA identified by the FDA. If a complete response letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Review and Approval</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has various programs, including Fast Track and priority review, which are intended to expedite or simplify the process for developing and/or reviewing drugs. Even if a drug qualifies for one or more of these programs, the FDA may later decide that the drug no longer meets the conditions for qualification or that the time period for FDA review or approval will not be shortened. Generally, drugs that may be eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. For example, Fast Track is a process designed to facilitate the clinical development and expedite the review of drugs to treat serious diseases with the potential, based on nonclinical or clinical data, to fill an unmet medical need. Priority review is designed to give drugs that offer a significant improvement in safety or effectiveness of treatment for a serious condition an expedited review within eight months from the completed submission (six months from filing) as compared to a standard review time of twelve months from the completed submission (10 months from filing) for a standard new molecular entity NDA. Although Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track designated drug and expedite review of the application for a drug designated for priority review.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Generating Antibiotic Incentives Now Act, or GAIN Act, is intended to provide incentives for the development of new QIDPs. A new drug that is designated as a QIDP after a request by the sponsor that is made before an NDA is submitted will be eligible, if approved, for an additional five years of exclusivity beyond any period of exclusivity to which it would have previously been eligible. In addition, a QIDP will receive priority review and qualify for a Fast Track designation. QIDPs are defined as antibacterial or antifungal drugs intended to treat serious or life-threatening infections, including those caused by an antibacterial or antifungal resistant pathogen or qualifying pathogens identified by the FDA. XERAVA and SUL-DUR have been designated by the FDA as a QIDP. Zoliflodacin has also been designated as a QIDP by the FDA for the treatment of uncomplicated gonorrhea.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent Term Restoration and Data Exclusivity</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA approval of the use of our drugs, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. As noted above, the Hatch-Waxman Amendments permit a patent restoration term of up to five years for a single patent for an approved product as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years from the product&#x2019;s approval date and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. We have applied for restoration of patent term for one U.S. Patent covering XERAVA and, in the future, we may apply for restoration of patent term for other currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Data exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company using the drug entitled to data exclusivity as the reference listed drug, or RLD. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of data exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the use or conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent for other uses or conditions of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct its own preclinical and clinical studies in support of its application or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as described above, under the GAIN Act a new drug that is designated as a QIDP is eligible for an additional five years of exclusivity to be added to certain other exclusivity periods that the application may qualify for upon approval, specifically five-year exclusivity, three-year exclusivity, and orphan exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pediatric Exclusivity</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Best Pharmaceuticals for Children Act provides for an additional six months of exclusivity, which is added on to patent and exclusivity periods in effect at the time the pediatric exclusivity award is granted, if a sponsor conducts clinical trials in children in response to a written request from the FDA, or a Written Request. The FDA may request studies on approved indications in separate Written Requests. The issuance of a Written Request does not require the sponsor to undertake the described studies. To date, we have not received any Written Requests.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-approval Requirements</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems, including safety issues, with a product may result in restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and approval. In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs. The FDA and other authorities also strictly regulate the promotional claims that may be made about prescription products. Under the FDCA the sponsor of an approved drug in the United States may not promote that drug for unapproved, or off-label, uses, although a physician may prescribe a drug for an off-label use in accordance with the practice of medicine. If we are found to have promoted off-label uses, we may be subject to significant liability, including sanctions, civil and criminal fines and penalties, and injunctions prohibiting us from engaging in specified promotional conduct.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, any drug products manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things:</span></p>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">record-keeping requirements;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reporting of adverse experiences with the drug;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">providing the FDA with updated safety and efficacy information;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">drug sampling and distribution requirements;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">notifying the FDA and gaining its approval of specified manufacturing or labeling changes;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">complying with certain electronic records and signature requirements; and</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">complying with FDA promotion and advertising requirements.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMP requirements and other laws.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to comply with the FDCA and other applicable U.S. requirements at any time during the product development process, approval process or after approval may subject us to a variety of administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include:</span></p>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal to approve pending applications;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of an approval;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">imposition of a clinical hold;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">warning letters, untitled letters and similar communications;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizures or recalls;</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">total or partial suspension of production or distribution; or</span></div></div>
  <div style="margin-left:4.269%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.481630819692681%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions, fines, restitution, disgorgement of profits or civil or criminal investigations and penalties brought by the FDA and DOJ, or other governmental entities.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Regulation</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the EU, before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under EU regulatory systems, a company may submit marketing authorization applications under the centralized, decentralized or mutual recognition procedures, or under the purely national route of approval. The centralized procedure is compulsory for medicinal products produced by biotechnology or those medicinal products containing new active substances for specific indications such as the treatment of acquired immune deficiency syndrome, or AIDS, cancer, neurodegenerative disorders, diabetes, viral diseases, and designated orphan medicines, and is optional for other medicines that are highly innovative. Under the centralized procedure, a marketing application is submitted to the European Medicines Agency, or EMA, where it will be evaluated by the relevant scientific committee, in most cases the Committee for Medicinal Products for Human Use, and a favorable opinion typically results in the grant by the European Commission of a single marketing authorization that is valid for all EU member states and, by extension (after national implementing measures), in Norway, Iceland and Liechtenstein. In general, an initial marketing authorization is valid for five years, but once renewed is usually valid for an unlimited period. The decentralized procedure allows marketing authorization applications to be submitted simultaneously in two or more EU member states, whereas the mutual recognition procedure must be used if the product has already been authorized in at least one other EU member state. Both the decentralized and mutual recognition procedures provide for approval by one or more &#x201c;concerned&#x201d; member states based on an assessment of an application performed by one-member state, known as the &#x201c;reference&#x201d; member state.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the decentralized approval procedure, an applicant submits an application, or dossier, and related materials to the reference member state and concerned member states. The reference member state prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. Within 90 days of receiving the reference member state&#x2019;s assessment report, each</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">concerned member state must approve the assessment report and related materials, unless they identify a serious risk to public health. Under the mutual recognition procedure, the concerned member states have the same 90-day period to recognize the marketing authorization in the reference member state. In either case, concerns about serious risks to public health escalate through the relevant EMA scientific committees, and the disputed points may eventually result in a consensus opinion from the Committee for Medicinal Products for Human Use that is referred to the European Commission, whose decision is binding on all member states. The purely national procedure results in a marketing authorization in a single EU member state.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following the result of a referendum in 2016, the United Kingdom left the EU on January 31, 2020, and as of January 1, 2021, the United Kingdom and EU operate separate regulatory regimes. The UK and EU announced on December 24, 2020, that they had agreed a Trade and Cooperation Agreement, or TCA, to govern their future relationship. The TCA remains provisional until formally ratified by the EU. The TCA sets out the new arrangements for trade of goods, including medicines and medical devices, which aims to ensure goods continue to flow between the EU and the UK and also has implications for product regulation and mutual recognition.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the United Kingdom&#x2019;s departure from the EU, if a company wishes to sell its products in the United Kingdom, it will need to seek and maintain appropriate national marketing authorizations. The TCA does not provide for wholesale mutual recognition of the regulatory regimes and so products exported from the UK to the EU must comply with the EU&#x2019;s regulatory requirements. In the pharmaceutical context, this has had a number of implications. From January 31, 2020, the UK no longer participated in EU institutions and their decision-making, including approval decisions under the centralized procedure. Moreover, the movement of finished pharmaceutical products into the EU from the UK is treated as an import from a third country. Since the TCA does not provide for mutual recognition of batch testing and release, products must be quality control tested and released in the EU. However, the UK will unilaterally waive batch testing requirements for UK imports from the EU for products placed on the market before January 2023. It remains to be seen how these developments will impact regulatory requirements for product candidates and products in the United Kingdom.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reimbursement</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such products. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all the approved products for a particular indication. For example, in the U.S. and most major foreign markets, drugs like GIAPREZA and XERAVA that are administered in the hospital must be purchased by the hospital and generally are not reimbursed by third-party payors. Hospitals instead are reimbursed for patient cases based on patients&#x2019; diagnosed conditions under the U.S. Medicare diagnosis-related group (&#x201c;DRG&#x201d;) system or other like systems for non-Medicare patients in the U.S. and in most major foreign markets. Adoption of new drugs that are administered in the hospital generally occurs more slowly than adoption of new drugs that are taken on an outpatient basis, which generally are paid for by third-party payors.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. Additionally, a payor&#x2019;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#x2019;s determination to provide coverage for a drug product does not ensure that other payors will also provide coverage for the drug product. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Health Care Laws Governing Interactions with Healthcare Providers</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws restrict our business activities, including certain marketing practices. These laws include, without limitation, anti-kickback laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item, good, facility or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#x201c;remuneration&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">has been broadly interpreted to include anything of value. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers, among others, on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration that are alleged to be intended to induce prescriptions, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#x2019;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the federal Anti-Kickback Statute has been violated. Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the Affordable Care Act, or ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim for payment for items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal false claims laws, including the civil False Claims Act, and civil monetary penalties laws prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a claim paid. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, have also been alleged to violate false claims laws.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal and civil statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. As with the federal Anti-Kickback Statute, the ACA amended the intent standard for certain healthcare fraud under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it to have committed a violation.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may be subject to data privacy and security regulations promulgated by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, impose certain requirements on covered entities (i.e., certain healthcare providers, health plans and healthcare clearinghouses) relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#x2019;s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">What is more, the federal Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, require certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the children&#x2019;s health insurance program (with certain exceptions) to annually report information related to certain payments or other transfers of value provided to covered recipients, including physicians, as defined by such law, and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals&#x2019; covered recipients and information related to certain ownership and investment interests held by physicians and their immediate family members.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The majority of states also have statutes or regulations similar to the aforementioned federal laws, some of which are broader in scope and apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government. In addition, some state laws require drug manufacturers to report information related to payments to clinicians and other healthcare providers or marketing expenditures and drug pricing. Further, some state and local laws require the licensure of pharmaceutical sales representatives. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finally, in Europe, the European Union General Data Protection Regulation (2016/679) (&#x201c;GDPR&#x201d;) contains provisions specifically directed at the processing of health information. The GDPR provides for potentially significant sanctions and contains extraterritoriality measures intended to bring non-EU companies under the regulation. In addition to the GDPR, individual countries in Europe and elsewhere in the world have enacted similar data privacy legislation. This legislation imposes increased compliance obligations and regulatory risk, including the potential for significant fines for noncompliance.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare and Other Reform</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, there have been and continue to be a number of significant legislative initiatives to contain healthcare costs. Federal and state governments continue to propose and pass legislation designed to reform delivery of, or payment for, healthcare, which include initiatives to reduce the cost of healthcare. For example, in March 2010, the United States Congress enacted the ACA, which expanded health care coverage through Medicaid expansion and the implementation of the individual mandate for health insurance coverage and which included changes to the coverage and reimbursement of drug products under government healthcare programs. Under the Trump administration, there were ongoing efforts to modify or repeal all or certain provisions of the ACA. For example, tax reform legislation was enacted at the end of 2017 that eliminated the tax penalty established under the ACA for individuals who do not maintain mandated health insurance coverage beginning in 2019. The ACA has also been subject to judicial challenge. In December 2018, a federal district court, in a challenge brought by a number of state attorneys general, found the ACA unconstitutional in its entirety because, once Congress repealed the individual mandate provision, there was no longer a basis to rely on Congressional taxing authority to support enactment of the law. In December 2019, the federal appellate court upheld the district court ruling that the individual mandate was unconstitutional and remanded the case back to the district court to determine whether the remaining provisions of the ACA are invalid as well. The case has been appealed to the U.S. Supreme Court where a ruling remains pending.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were other reform initiatives under the former Trump Administration, including initiatives focused on drug pricing. For example, the Bipartisan Budget Act of 2018 contained various provisions that affect coverage and reimbursement of drugs, including an increase in the discount that manufacturers of Medicare Part D brand name drugs must provide to Medicare Part D beneficiaries during the coverage gap from 50% to 70% starting in 2019. As another example, in 2018, President Trump and the Secretary of the HHS, released a &#x201c;blueprint&#x201d; to lower prescription drug prices and out-of-pocket costs. Certain proposals in the blueprint, and related drug pricing measures proposed since the blueprint, could cause significant operational and reimbursement changes for the pharmaceutical industry. HHS has solicited feedback on some of these measures and, at the same, has implemented others under its existing authority. On November 20, 2020, CMS issued an interim final rule through the CMS Innovation Center whereby Medicare Part B reimbursement for &#x201c;certain high-cost prescriptions drugs&#x201d; would be no more than most-favored-nation price (i.e., the lowest price) after adjustments, for a pharmaceutical product that the drug manufacturer sells in a member country of the Organization for Economic Cooperation and Development that has a comparable per-capita gross domestic product. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. While some of these and other measures may require additional authorization to become effective, members of Congress and the new Biden administration have indicated that lowering prescription drug prices is a priority, but it is not yet clear what steps the Biden Administration will take or whether such steps will be successful.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have also been recent state legislative efforts to address drug costs, which generally have focused on increasing transparency around drug costs or limiting drug prices and address price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2019, the DISARM Act of 2019 was introduced in Congress as new legislation to provide financial incentives for pharmaceutical companies to develop new antibiotics. This new legislation was guided by input from the IDSA and will help to ensure that patients can access new antibiotics when they are clinically appropriate, require hospitals to establish antibiotic stewardship programs, and spur improved reporting of antibiotic use and resistance to more rapidly identify challenges and inform best practices. More recently, this legislation was reintroduced in the U.S. House of Representatives in June 2021 which aims to amend title XVIII of the Social Security Act to encourage the development and use of DISARM antimicrobial drugs, and for other purposes.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General legislative cost control measures may also affect reimbursement for our product candidates. The Budget Control Act, as amended, resulted in the imposition of 2% reductions in Medicare, but not Medicaid, payments to providers in 2013 and will remain in effect through 2029 unless additional Congressional action is taken. There was a temporary suspension of the 2% reduction during the pandemic; that temporary suspension is scheduled to expire on March 31, 2021. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented and/or any significant taxes or fees that may be imposed on us could have an adverse impact on our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legislation was introduced to the U.S. Senate in September 2020 which aims to reinvigorate innovation for the development of new antibiotics through a subscription contract program managed by HHS. The PASTEUR Act was introduced to provide a mechanism for funding designated &#x2018;critical need antimicrobial&#x2019; drugs post FDA approval. In return, patients covered by federal insurance programs will receive these drugs at no cost. These Contracts under the PASTEUR Act could range from $750 million to $3 billion in value. It is unclear when or if the PASTEUR Act or similar incentive programs will become law. In October 2021, the PACCARB authored a letter to the Honorable Xavier Becerra, Secretary, Department of Health and Human Services recommending the passage of both DISARM and PASTEUR and the antimicrobial stewardship provisions contained within each act.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adoption of new legislation at the federal or state level could affect demand for, or pricing of, our current or future products if approved for sale. We cannot, however, predict the ultimate content, timing or effect of any changes to the ACA or other federal and state reform efforts. There is no assurance that federal or state health care reform will not adversely affect our future business and financial results.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Laws and Regulations</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to a variety of financial disclosure and securities trading regulations as a public company in the U.S., including laws relating to the oversight activities of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) and the regulations of the Nasdaq Capital Market, on which our shares of common stock are traded. We are also subject to various laws and regulations relating to safe working conditions, laboratory practices and the experimental use of animals.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection for our product candidates, our core technologies, and other know-how. To accomplish this we rely on the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary know-how that is not patentable, we rely on trade secret protection and confidentiality agreements to protect our interests. We require our employees, consultants and advisors to enter into confidentiality agreements prohibiting the disclosure of confidential information and requiring disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. We file patent applications directed to our key product candidates to establish intellectual property positions. These patent applications are intended to protect new chemical entities relating to these product candidates as well as their manufacturing processes, intermediates and uses in the treatment of diseases.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The intellectual property portfolios for our commercial products, advanced product candidates, and various compounds are summarized below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GIAPREZA</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 15, 2023 , the licensed intellectual property portfolio relating to GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> included 12 issued U.S. patents, 2 pending U.S. patent applications, 8 issued foreign patents and 15 pending foreign patent applications. The issued U.S. patents, and patents that may issue from the pending U.S. patent applications, will expire between 2029 and 2034, absent any disclaimers, extensions, or adjustments of patent term. The foreign patents, and patents that may issue from the pending foreign patent applications, will expire in 2034, absent any disclaimers, extensions, or adjustments of patent term.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 15, 2023, the intellectual property portfolio relating to GIAPREZA included 3 issued U.S. patents, 8 pending U.S. patent applications, 7 issued foreign patents and 10 pending foreign patent applications. The issued U.S. patents, and patents that may issue from the pending U.S. patent applications, will expire between 2034 and 2044, absent any disclaimers, extensions, or adjustments of patent term. The foreign patents, and patents that may issue from the pending foreign patent applications, will expire between 2034 and 2044, absent any disclaimers, extensions, or adjustments of patent term.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">XERAVA</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 15, 2023, we owned 2 issued U.S. patents, 1 pending U.S. patent application, 17 issued foreign patents and 4 pending foreign patent applications relating to XERAVA. The issued U.S. patents, and the patent that may issue from the pending U.S. patent application, will have an expiration date of August 7, 2029, absent any disclaimers, extensions, or adjustments of patent term. The term of 1 of the U.S. patents has received 508 days of patent term adjustment. The foreign patents, and patents that may issue from the pending foreign applications, will likewise have an expiration date of August 7, 2029, absent any disclaimers, extensions, or adjustments of patent term.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 15, 2023, we also filed applications for Supplementary Protection Certificates based on European Patent No. 2323972 covering the composition of matter and use of XERAVA. Some applications have been granted and others are pending.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as of February 15, 2023, we also owned 2 issued U.S. patent, 1 pending U.S. patent application and 11 pending foreign patent applications that relate to crystalline forms of eravacycline, any U.S. patent that may issue from the pending patent application will expire in 2037 absent any disclaimers, extensions, or adjustments of patent term. Likewise, any foreign patents that may issue from the pending foreign patent applications will expire in 2037. We also owned 5 issued U.S. patents, 1 pending U.S. patent application, 32 issued foreign patents and 17 pending foreign patent applications relating to other tetracycline-related intellectual property.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:16.472%;"></td>
    <td style="width:1.435%;"></td>
    <td style="width:11.454%;"></td>
    <td style="width:1.435%;"></td>
    <td style="width:11.463%;"></td>
    <td style="width:1.444%;"></td>
    <td style="width:14.519%;"></td>
    <td style="width:1.444%;"></td>
    <td style="width:11.463%;"></td>
    <td style="width:1.444%;"></td>
    <td style="width:11.463%;"></td>
    <td style="width:1.444%;"></td>
    <td style="width:14.519%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pending</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expiration</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pending</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expiration</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GIAPREZA</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2029 - 2044</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2034 - 2044</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">XERAVA</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2029 - 2037</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2029 - 2037</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2030 - 2037</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2033 - 2037</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Durlobactam</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our intellectual property portfolio for our durlobactam program contains patent applications directed to compositions of matter for durlobactam and other chemical analogs, as well as methods of making, referred to as synthetic methods, and methods of use and modes of treatment using durlobactam in combination with one or more antibiotic compounds. As of February 15, 2023, we owned four issued U.S. patents, one pending provisional application, one pending PCT application, 107 issued foreign patents as well as six pending foreign patent applications, of which two are allowed. The issued foreign patents are in several jurisdictions including Australia, the European Union, Canada, China, Hong Kong, Israel, India, Japan, Macau, Mexico, New Zealand, the Philippines, the Russian Federation, Singapore, South Africa, South Korea, Taiwan and the United Kingdom. Issued U.S. and foreign patents and patents issuing from pending U.S. and foreign applications will have expiration dates of April 2033 and April 2043.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Zoliflodacin</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our intellectual property portfolio for zoliflodacin contains patent applications directed to compositions of matter for zoliflodacin and other chemical analogs, as well as synthetic methods and methods of use and modes of treatment. As of February 15, 2023, we owned seven issued U.S. patents, 74 issued foreign patents as well as two pending foreign patent applications. The issued foreign patents are in several jurisdictions, including Australia, Brazil, Canada, China, Eurasia, the European Union, Hong Kong, India, Israel, Japan, Mexico, New Zealand, Philippines, Singapore, South Africa, South Korea, Taiwan and the United Kingdom. Issued U.S. and foreign patents and patents issuing from pending U.S. and foreign applications have expiration dates of October 2029, January 2034 and May 2035.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Trademarks, Trade Secrets and Know-How</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our trademark portfolio currently consists of various registered trademark and service mark rights in several jurisdictions, including the United States, the European Union, Japan, Argentina, Australia, Brazil, Canada, India, Mexico, Norway, the Russian Federation, South Korea, Switzerland, Taiwan, Turkey and the United Kingdom, and pending applications in other jurisdictions. In connection with the ongoing development and advancement of our products and services in the United States and various international jurisdictions, we routinely seek to create protection for our marks and enhance their value by pursuing trademarks and service marks where available and when appropriate. In addition to patents and trademark protection, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees, and consultants, and invention assignment agreements with our employees. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategic Partnership with Sarissa Capital</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Strategic Advisory Agreement</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 11, 2020, we entered into a Strategic Advisory Agreement (the &#x201c;Services Agreement&#x201d;) with Sarissa Capital Management LP (&#x201c;Sarissa Capital&#x201d;), pursuant to which Sarissa Capital provides a variety of strategic services to us in order to assist</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">us in the development and execution of our acquisition strategy intended to diversify our assets and the potential sources of revenue. Sarissa Capital is considered to be a related party due to its investment in Innoviva and its representation on our board of directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Partnership Agreement</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 11, 2020, Innoviva Strategic Partners LLC, our wholly owned subsidiary (&#x201c;Strategic Partners&#x201d;), entered into a subscription agreement and an Amended and Restated Limited Partnership Agreement (the &#x201c;Partnership Agreement&#x201d;) pursuant to which Strategic Partners became a limited partner of ISP Fund LP (the &#x201c;Partnership&#x201d;). The general partner of the Partnership is an affiliate of Sarissa Capital and, pursuant to an investment management agreement, Sarissa Capital acts as the investment adviser to the Partnership. Strategic Partners made a $300 million initial contribution to the Partnership. The Partnership was formed for the purposes of investing in equity securities in the healthcare, pharmaceutical and biotechnology industries.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, Strategic Partners received a distribution of $110.0 million from the Partnership to provide funding to us for a strategic repurchase of shares held by GSK. Pursuant to the letter agreement entered into between Strategic Partners, the Partnership, and Sarissa Capital Fund GP LP on May 20, 2021, Strategic Partners agreed to make additional capital contributions to the Partnership in an aggregate amount equal to the amount of the May 2021 distribution prior to March 31, 2022. A $110.0 million contribution was made during the first quarter of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human Capital</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had 101 employees, all of whom were full-time employees. None of our employees are represented by a labor union or covered by a collective bargaining agreement, and we consider our relations with our employees to be good. We also hire consultants and contract with third parties, as needed, to provide additional resources to support our business activities.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our key human capital management objectives are to identify, recruit, integrate, retain and motivate our new and existing employees. We believe that our compensation and benefit programs are appropriately designed to attract and retain qualified talent. Employees receive an annual base salary and are eligible to earn performance-based cash bonuses. To create and maintain a successful work environment, we offer a comprehensive package of additional benefits that support the physical and mental health and wellness of all of our employees and their families and flexible working arrangements. Additionally, we grant equity awards in order to allow employees to share in the performance of the Company. The Chief Executive Officer regularly updates our board of directors and our committees on the operation and status of these human capital trends and activities.</span></p>
  <p style="margin-left:4.267%;text-indent:-3.608%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Diversity, Equity and Inclusion</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have created an environment that fosters individual development while maintaining consistency in our corporate values and code of conduct. We offer seminars from external resources on diversity, equity and inclusion, or DEI, best practices and promote the fair treatment and full participation of all people in our workplace.</span></p>
  <p style="margin-left:4.267%;text-indent:-3.608%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Health, Safety and Wellness</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We strive to provide pay, benefits and other employee services that are competitive to market in the life sciences industry and create incentives to attract and retain employees. Our compensation package includes market-competitive pay, stock options and restrictive stock units, bonuses, employee spot awards, health care and retirement benefits, paid time off and family leave. We utilize third party consultants to review and update our compensation practices annually. We are also committed to the continued development of our people, providing opportunities for employees to further their career development through internal training and education programs and third party online training programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information about our Executive Officers</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the name, age, and position of each of our executive officers as of February 28, 2023:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.201%;"></td>
    <td style="width:1.84%;"></td>
    <td style="width:9.317%;"></td>
    <td style="width:1.84%;"></td>
    <td style="width:32.801%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Age</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Positions Held</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pavel Raifeld</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marianne Zhen</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Accounting Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pavel Raifeld</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, CFA, was appointed Chief Executive Officer in May 2020. Prior to his appointment, Mr. Raifeld, served on the investment team at Sarissa Capital Management LP. Earlier, he was a senior member of the healthcare investment banking team at Credit Suisse Securities (USA) LLC. Previously, Mr. Raifeld worked as a consultant, primarily specializing in advising biopharmaceutical companies, at McKinsey &amp; Company, Inc. and The Boston Consulting Group Ltd. Mr. Raifeld earned an AB degree from Harvard University and an MBA degree from Columbia University.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marianne Zhen</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, CPA, was appointed Chief Accounting Officer in July 2018. Prior to joining Innoviva in October 2014, Ms. Zhen served as the Corporate Controller at Steelwedge Software Inc. from 2012 to 2014, Intelmate from 2011 to 2012 and Model N, Inc. from 2007 to 2011. Previously, Ms. Zhen served as a member of the board of directors of CalCPA Peninsula Silicon Valley Chapter. Ms. Zhen earned a Bachelor of Science degree in Business Administration with a concentration in Accounting from San Francisco State University. She is a member of the American Institute of Certified Public Accountants (AICPA) and a member of the California Society of Certified Public Accountants (CalCPA).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Code of Business Conduct</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has adopted the Innoviva, Inc. Code of Business Conduct that applies to all directors, officers and employees. The Code of Business Conduct, as amended through March 9, 2021, is available on the corporate governance section of our website at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">www.inva.com</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If the Company makes any substantive amendments to the Code of Business Conduct or grants a waiver from any provision of such code to any executive officer or director, the Company will promptly disclose the nature of the amendment or waiver, as required by applicable law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our web page address is </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">www.inva.com</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our investor relations website is located at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">http://investor.inva.com</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We make available free of charge on our investor relations website under &#x201c;SEC Filings&#x201d; our Annual Reports on Form 10&#x2011;K, Quarterly Reports on Form 10&#x2011;Q, Current Reports on Form 8&#x2011;K, our directors&#x2019; and officers&#x2019; Section 16 Reports and any amendments to those reports after filing or furnishing such materials to the SEC. The information found on our website is not part of this or any other report that we file with or furnish to the SEC. Innoviva and the Innoviva logo are registered trademarks of Innoviva, Inc. Trademarks, tradenames or service marks of other companies appearing in this report are the property of their respective owners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 1A.   RISK FACTORS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to a number of risks that if realized could affect its business, financial condition, results of operations, cash flows and access to liquidity materially. The Company&#x2019;s business is subject to uncertainties and risks including:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> face substantial competition for their intended uses in the targeted markets from products discovered, developed, launched and commercialized both by GSK and by other pharmaceutical companies, which could cause the royalties payable to us pursuant to the GSK Agreements to be less than expected, which in turn would harm our business and cause the price of our securities to fall.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are dependent on GSK for the successful commercialization and development of the products developed under the GSK Agreements. If GSK does not devote sufficient resources to the commercialization and development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our debt including our convertible subordinated notes and convertible senior notes are senior in capital structure and cash flow, respectively, to our common stockholders. Satisfying the obligations relating to our debt could adversely affect our liquidity or the amount or timing of potential distributions to our stockholders.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GSK has indicated to us that it believes its consent may be required before we can engage in certain royalty monetization transactions with third parties, which may inhibit our ability to engage in these transactions.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA, the EMA or other comparable regulatory authorities, or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of that product candidate.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on collaborations with third parties for the development of our product candidates, and we may seek additional collaborations in the future. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if any of our product candidates receives marketing approval, such product candidate may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We might not be able to successfully integrate our operations with those of Entasis and/or La Jolla and other assets that we may acquire. </span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time-consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to our Business</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK&#x2019;s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the GSK Agreements, GSK is responsible for the development and commercialization of products in the partnered respiratory programs. Royalty revenues from RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> are expected to represent the majority of our foreseeable future revenues from GSK. The amount and timing of revenue from such royalties are unknown and highly uncertain. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We have no control over GSK&#x2019;s marketing and sales efforts, and GSK might not be successful, which would harm our business and cause the price of our securities to fall.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our quarterly royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. The amount of royalties and milestone payments, if any, we receive will depend on many factors, including the following:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent and effectiveness of the sales and marketing and distribution support GSK provides to our partnered products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">market acceptance and demand for our partnered products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the treatment paradigm or standard of care for COPD or asthma, for instance through changes to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the competitive landscape of generic and branded products and developing therapies that compete with our products owned by GSK (such as Advair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) but which are not partnered with us and pricing pressure in the respiratory markets targeted by our partnered products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size of the market for our partnered products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the mix of sales of our partnered products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decisions as to the timing of product launches, pricing and discounts;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reprioritization of GSK&#x2019;s commercial efforts on other products owned by GSK (such as Advair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), which are not partnered with us;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GSK&#x2019;s ability to expand the indications for which our partnered products can be marketed;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a satisfactory efficacy and safety profile as demonstrated in a broad patient population;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance of, and ongoing satisfaction with, our partnered products by the medical community, patients receiving therapy and third-party payors;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">timing and amounts of payor rebate adjustments and prior period rebate adjustments;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seasonal fluctuations of demand;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of patients to be able to afford our partnered products or obtain health care coverage that covers our partnered products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safety concerns in the marketplace for respiratory therapies in general and with our partnered products in particular;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory developments relating to the manufacture or continued use of our partnered products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the requirement to conduct additional post&#x2011;approval studies or trials for our partnered products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GSK&#x2019;s ability to obtain regulatory approval of our partnered products in additional countries;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the unfavorable outcome of any potential litigation relating to our partnered products;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general economic conditions in the jurisdictions where our partnered products are sold, including microeconomic disruptions or slowdowns; or</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if our royalty revenue or operating results fall below the expectations of investors or securities analysts or below any guidance we may provide to the market, the price of our common stock could decline substantially.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">When the FDA or other applicable regulatory authorities approve generic products, including but not limited to generic forms of Advair, that compete with RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">, and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> or a generic form of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">, the royalties payable to us pursuant to the GSK Agreements will be less than anticipated, which in turn would harm our business and the price of our securities could fall.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once an NDA or marketing authorization application outside the United States is approved, the product covered thereby becomes a &#x201c;listed drug&#x201d; that can, in turn, be cited by potential competitors in support of approval of an ANDA in the United States. Agency regulations and other applicable regulations and policies provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an ANDA or other application for generic substitutes in the United States and in nearly every pharmaceutical market around the world. Numerous companies have brought to market generic forms of the ICS/LABA drug Advair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> since certain patents covering the Advair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> delivery device expired in 2016. In general, these manufactures are required to conduct a number of clinical efficacy, pharmacokinetic and device studies to demonstrate equivalence to Advair, per FDA&#x2019;s September 2013 draft guidance document. These studies are designed to demonstrate that the generic product has the same active ingredient(s), dosage form, strength, exposure and clinical efficacy as the branded product. These generic equivalents, which must meet the same exacting quality standards as branded products, may be significantly less costly to bring to market, and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a generic competitor, a significant percentage of the sales of any branded product and products that may compete with such branded product is typically lost to the generic product.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2019, Mylan announced that the FDA approved Wixela&#153; Inhu&#153; (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of ADVAIR DISKUS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In that same month, Teva announced that the FDA approved two of their products for adolescent and adult patients with asthma, one of which is AirDuo&#153; RespiClick</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (fluticasone propionate and salmeterol inhalation powder), a non-AB substitutable generic version of Advair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In January 2020, Astra Zeneca launched an authorized generic version of Symbicort. In December 2020, Hikma/Vectura announced that it received FDA approval and launched its generic version of GSK&#x2019;s Advair Diskus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2016, the FDA issued draft guidance documents covering Fluticasone Furoate/Vilanterol Trifenatate (FF/VI), the active ingredients used in RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Introduction of generic products that compete against ICS/LABA products, like RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, would materially adversely impact our future royalty revenue, profitability and cash flows. We cannot yet ascertain what impact these generic products and any future approved generic products will have on any sales of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, if approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reduced prices and reimbursement rates due to the actions of governments, payors, or competition or other healthcare cost containment initiatives such as restrictions on use, may negatively impact royalties generated under the GSK Agreements.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The continuing efforts of governments, pharmaceutical benefit management organizations (&#x201c;PBMs&#x201d;), insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care has adversely affected the price, market access, and total revenues of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and may continue to adversely</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">affect them in the future. In addition, we have experienced and expect to continue to experience increased competitive activity, which has resulted in lower overall prices for our products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (together, &#x201c;PPACA&#x201d;) and other legislative or regulatory requirements or potential legislative or regulatory actions regarding healthcare and insurance matters, along with the trend toward managed healthcare in the U.S., could adversely influence the purchase of healthcare products and reduce demand and prices for our partnered products. This could harm GSK&#x2019;s ability to market our partnered products and significantly reduce future revenues. For example, when GSK launched RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the treatment of COPD in the U.S. in October 2013, GSK experienced significant challenges gaining coverage at some of the largest PBMs, healthcare payors, and providers and lower overall prices than expected. Recent actions by U.S. PBMs in particular have increased discount levels for respiratory products resulting in lower net sales pricing realized for products in our collaboration. In addition, in certain foreign markets, the pricing of prescription drugs is subject to government control and reimbursement may in some cases be unavailable. We believe that pricing pressures will continue and may increase. This may make it difficult for GSK to sell our partnered products at a price acceptable to us or GSK or to generate revenues in line with our analysts&#x2019; or investors&#x2019; expectations, which may cause the price of our securities to fall.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">More recently, presidential administrations and the U.S. Congress have taken actions in an effort to modify or replace PPACA and to implement or pass other reforms to the healthcare system, including proposed legislation related to the pricing of pharmaceuticals. There is uncertainty with respect to any potential changes that may be proposed and what the impact, if any, will be on our business, including the impact on coverage and reimbursement for healthcare items and services covered by plans that were authorized by PPACA. However, we cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that additional state and federal healthcare reform measures will be considered and potentially adopted, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures and may adversely affect our operating results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">A portion of our current revenues are from royalties derived from sales of our respiratory products partnered with GSK, RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. If the treatment paradigm for the indications our partnered products are approved for change or if GSK is unable to, or does not devote sufficient resources to, maintain or continue increasing sales of these products, our results of operations will be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently depend, in part, on royalties from sales of our products partnered with GSK to support our existing operations. The treatment paradigm for COPD and asthma constantly evolves. For instance, in November 2018, the GOLD guidelines were revised to favorably position bronchodilator monotherapy and LABA/LAMA treatment ahead of ICS/LABA for the treatment of COPD unless the patient has frequent exacerbations, or an eosinophil count greater than 300 per cubic microliter. The use of ICS in COPD is also recommended for patients requiring triple therapy (LABA, LAMA, ICS). If the treatment paradigms were to change further, causing our partnered products to fall out of favor, or if GSK were unable, or did not devote sufficient resources, to maintain or continue increasing RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> sales, our results of operations would likely suffer, and the price of our securities could fall.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If the commercialization of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in the countries in which they have received regulatory approval encounters any delays or adverse developments, or perceived delays or adverse developments, or if sales or payor coverage does not meet investors&#x2019;, analysts&#x2019;, or our expectations, our business will be harmed, and the price of our securities could fall.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under our agreements with our collaborative partner GSK, GSK has full responsibility for commercialization of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. GSK has launched RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in a number of countries, including the United States, Canada, Japan, the United Kingdom, and Germany, among others. The commercialization of the products in countries where they are already launched and the commercialization launch in new countries are still subject to fluctuating overall pricing levels and uncertain timeframes to obtain payor coverage. Any delays or adverse developments or perceived additional delays or adverse developments with respect to the commercialization of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> including if sales or payor coverage does not meet investors&#x2019;, analysts&#x2019;, or our expectations, would significantly harm our business and the price of our securities could fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are dependent on GSK for the successful commercialization and development of products under the GSK Agreements. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our royalty revenues under the GSK Agreements may not meet our, analysts&#x2019;, or investors&#x2019; expectations, due to a number of important factors. GSK has a substantial respiratory product portfolio in addition to the partnered products that are covered by the GSK Agreements. GSK may make respiratory product portfolio decisions or statements about its portfolio which may be, or may be perceived to be, harmful to the respiratory products partnered with us. For instance, GSK has wide discretion in determining the efforts and resources that it will apply to the development and commercialization of our partnered products. In addition, GSK may determine to focus its commercialization efforts on its own products. For example, in January 2015, GSK launched Incruse</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (UMEC) in the U.S., which is a LAMA for the treatment of COPD. GSK may determine to focus its marketing efforts on Incruse, which could have the effect of decreasing the potential market share of ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and lowering the royalties we may receive for such product. Alternatively, GSK may decide to market to eventually compete directly against sales of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In the event GSK does not devote sufficient resources to the commercialization of our partnered products or chooses to reprioritize its commercial programs, our business, operations and stock price would be negatively affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any adverse change in FDA policy or guidance regarding the use of LABAs to treat asthma could significantly harm our royalty revenues and the price of our securities could fall.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 18, 2010, the FDA announced that LABAs should not be used alone in the treatment of asthma and it will require manufacturers to include this warning in the product labels of these drugs, along with taking other steps to reduce the overall use of these medicines. The FDA now requires that the product labels for LABA medicines reflect, among other things, that the use of LABAs is contraindicated without the use of an asthma controller medication such as an inhaled corticosteroid, that LABAs should only be used long term in patients whose asthma cannot be adequately controlled on asthma controller medications, and that LABAs should be used for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved. In addition, in March 2010, the FDA held an Advisory Committee to discuss the design of medical research studies (known as &#x201c;clinical trial design&#x201d;) to evaluate serious asthma outcomes (such as hospitalizations, a procedure using a breathing tube known as intubation, or death) with the use of LABAs in the treatment of asthma in adults, adolescents, and children. Further, in April 2011, the FDA announced that to further evaluate the safety of LABAs, it required the manufacturers of currently marketed LABAs to conduct additional randomized, double blind, controlled clinical trials comparing the addition of LABAs to inhaled corticosteroids versus inhaled corticosteroids alone. These post&#x2011;marketing studies have been completed and the FDA stated that treating asthma with LABAs in combination with ICS did not result in significantly more serious asthma-related side effects than treatment with ICS alone. The FDA subsequently removed the black box warning from the ICS/LABA package inserts. Although this concern appears to be resolved, it is unknown at this time what, if any, future concerns could impact the use of ICS/LABA and its potential impact on the prospects for FF/VI. Any adverse change in FDA policy or guidance regarding the use of LABAs to treat asthma could significantly harm our business and the price of our securities could fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any adverse developments to the regulatory status of either RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> or ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in the countries in which they have received regulatory approval, including labeling restrictions, safety findings, or any other limitation to usage, would harm our business and may cause the price of our securities to fall.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> are approved and marketed in a number of countries, it is possible that adverse changes to the regulatory status of these products could occur in the event new safety issues are identified, treatment guidelines are changed, or new studies fail to demonstrate product benefits. A number of notable pharmaceutical products have experienced adverse developments during commercialization that have resulted in the product being withdrawn, approved uses being limited, or new warnings being included. In the event that any adverse regulatory changes were to occur to any of our products, our business would be harmed, and the price of our securities could fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any adverse developments or results or perceived adverse developments or results with respect to the ongoing studies for FF/VI in asthma or COPD, for UMEC/VI in COPD, or any future studies would significantly harm our business and the price of our securities could fall, and if regulatory authorities in those countries in which approval has not yet been granted determine that the ongoing studies for FF/VI in asthma or COPD or the ongoing studies for UMEC/VI for COPD do not demonstrate adequate safety and efficacy, the continued development of FF/VI or UMEC/VI or both could be significantly delayed, they might not be approved by these regulatory authorities, and even if approved they may be subject to restrictive labeling, any of which might harm our business, and the price of our securities could fall.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we have announced the completion of, and reported certain top&#x2011;line data from, the Phase 3 registrational program for FF/VI in COPD and asthma, additional studies of FF/VI are underway or may commence in the future. Any adverse developments or perceived adverse developments with respect to any prior, current or future studies in these programs could significantly harm our business and the price of our securities could fall.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although the FDA, the European Medicines Agency, the Japanese Ministry of Health, Labour and Welfare and Health Canada and other jurisdictions have approved ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, it has not yet been approved in all jurisdictions.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any adverse developments or results or perceived adverse developments or results with respect to other pending or future regulatory submissions for the FF/VI program or the UMEC/VI program might significantly harm our business and the price of our securities could fall. Examples of such adverse developments include, but are not limited to:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not every study, nor every dose in every study, in the Phase 3 programs for FF/VI achieved its primary endpoint and regulatory authorities may determine that additional clinical studies are required;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safety, efficacy or other concerns arising from clinical or non&#x2011;clinical studies in these programs having to do with the LABA VI, which is a component of FF/VI and UMEC/VI;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analysts adjusting their sales forecasts downward from previous projections based on results or interpretations of results of prior, current or future studies;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safety, efficacy or other concerns arising from clinical or non&#x2011;clinical studies in these programs;</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities determining that the Phase 3 programs in asthma or in COPD raise safety concerns or do not demonstrate adequate efficacy; or</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any change in FDA (or comparable foreign regulatory agency) policy or guidance regarding the use of LABAs to treat asthma or the use of LABAs combined with a LAMA to treat COPD.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> face substantial competition for their intended uses in the targeted markets from products discovered, developed, launched and commercialized both by GSK and by other pharmaceutical companies, which could cause the royalties payable to us pursuant to the LABA Collaboration Agreement to be less than expected, which in turn would harm our business and cause the price of our securities to fall.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GSK has responsibility for obtaining regulatory approval, launching and commercializing RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for their intended uses in the targeted markets around the world. While these products have received regulatory approval and have been launched and commercialized in the U.S. and certain other targeted markets, the products face substantial competition from existing products previously developed and commercialized both by GSK and by other competing pharmaceutical companies and can expect to face additional competition from new products that are discovered, developed and commercialized by the same pharmaceutical companies and other competitors going forward. For example, sales of generic Advair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, GSK&#x2019;s approved medicine for both COPD and asthma, continue to have a negative impact on sales of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of the pharmaceutical companies competing in respiratory markets are international in scope with substantial financial, technical and personnel resources that permit them to discover, develop, obtain regulatory approval and commercialize new products in a highly efficient and low-cost manner at competitive prices to consumers. In addition, many of these competitors have substantial commercial infrastructure that facilitates commercializing their products in a highly efficient and low-cost manner at competitive prices to consumers. The market for products developed for treatment of COPD and asthma continues to experience significant innovation and reduced cost in bringing products to market over time. There can be no assurance that RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> will not be replaced by new products that are deemed more effective at lower cost to consumers. The ability of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to succeed and achieve the anticipated level of sales depends on the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commercial and development performance of GSK to achieve and maintain a competitive advantage over other products with the same intended use in the targeted markets.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If sales of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> are less than anticipated because of existing or future competition in the markets in which they are commercialized, including competition from existing and new products that are perceived as lower cost or more effective, our royalty payments could be less than anticipated, which in turn would harm our business and cause the price of our securities to fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to utilize all of our net operating loss carryforwards.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have net operating loss carryforwards and other significant U.S. tax attributes that we believe could offset otherwise taxable income in the U.S. As a part of the overall Spin-Off transaction, the transfer of certain assets by us to Theravance Biopharma and our distribution of Theravance Biopharma ordinary shares resulted in taxable transfers pursuant to applicable provisions of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;) and Treasury Regulations. The taxable gain recognized by us attributable to the transfer of certain assets to Theravance Biopharma generally equaled the excess of the fair market value of each asset transferred over our adjusted tax basis in such asset. Although we did not recognize any gain with respect to the cash we transferred to Theravance Biopharma, we may recognize substantial gain based on the fair market value of the other assets (other than cash) transferred to Theravance Biopharma. The determination of the fair market value of these assets is subjective and could be subject to adjustments or future challenge by the Internal Revenue Service (&#x201c;IRS&#x201d;), which could result in an increase in the amount of gain realized by us as a result of the transfer. Our U.S. federal income tax resulting from any gain recognized upon the transfer of our assets to Theravance Biopharma (including any increased U.S. federal income tax that may result from a subsequent determination of higher fair market values for the transferred assets), may be reduced by our net operating loss carryforward. The net operating loss carryforwards available in any year to offset our net taxable income will be reduced following a more than 50% change in ownership during any period of 36 consecutive months (an &#x201c;ownership change&#x201d;) as determined under the Code. Transactions involving our common stock, even those outside our control, such as purchases or sales by investors, within the testing period could result in an ownership change. We have conducted an analysis to determine whether an ownership change had occurred since inception through December 31, 2022 and concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. Subsequent changes in our ownership or sale of our stock could have the effect of limiting the use of our net operating losses in the future. There may be certain annual limitations for utilization based on the above-described ownership change provisions. In addition, we may not be able to have sufficient future taxable income prior to their expiration because net operating losses have carryforward periods. Future changes in federal and state tax laws pertaining to net operating loss carryforwards may also cause limitations or restrictions from us claiming such net operating losses. If the net operating loss carryforwards become unavailable to us or are fully utilized, our future taxable income will not be shielded from federal and state income taxation absent certain U.S. federal and state tax credits, and the funds otherwise available for general corporate purposes would be reduced.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If any product candidates in any respiratory program partnered with GSK were not approved by regulatory authorities or are determined to be unsafe or ineffective in humans, our business would be adversely affected and the price of our securities could fall.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA must approve any new medicine before it can be marketed and sold in the U.S. Our partner GSK must provide the FDA and similar foreign regulatory authorities with data from preclinical and clinical studies that demonstrate that the product candidates are safe and effective for a defined indication before they can be approved for commercial distribution. GSK will not obtain this approval for a partnered product candidate unless and until the FDA approves an NDA. The processes by which regulatory approvals are obtained from the FDA to market and sell a new product are complex, require a number of years and involve the expenditure of substantial resources. In order to market medicines in foreign countries, separate regulatory approvals must be obtained in each country. The approval procedure varies among countries and can involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Conversely, failure to obtain approval in one or more country may make approval in other countries more difficult.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical studies involving product candidates partnered with GSK may reveal that those candidates are ineffective, inferior to existing approved medicines, unacceptably toxic, or that they have other unacceptable side effects. In addition, the results of preclinical studies do not necessarily predict clinical success, and larger and later&#x2011;stage clinical studies may not produce the same results as earlier&#x2011;stage clinical studies.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Frequently, product candidates that have shown promising results in early preclinical or clinical studies have subsequently suffered significant setbacks or failed in later clinical or non&#x2011;clinical studies. In addition, clinical and non&#x2011;clinical studies of potential products often reveal that it is not possible or practical to continue development efforts for these product candidates. If these studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are substantially delayed or fail to prove the safety and effectiveness of product candidates in development partnered with GSK, GSK may not receive regulatory approval for such product candidates and our business and financial condition could be materially harmed and the price of our securities might fall.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Several well&#x2011;publicized Complete Response letters issued by the FDA and safety&#x2011;related product withdrawals, suspensions, post&#x2011;approval labeling revisions to include boxed warnings and changes in approved indications over the last several years, as well as growing public and governmental scrutiny of safety issues, have created a conservative regulatory environment. The implementation of new laws and regulations and revisions to FDA clinical trial design guidance have increased uncertainty regarding the approvability of a new drug. Further, there are additional requirements for approval of new drugs, including advisory committee meetings for new chemical entities, and formal risk evaluation and mitigation strategy at the FDA&#x2019;s discretion. These laws, regulations, additional requirements and changes in interpretation could cause non&#x2011;approval or further delays in the FDA&#x2019;s review and approval of any product candidates in any respiratory program partnered with GSK.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if product candidates in any respiratory program partnered with GSK receive regulatory approval, as is the case with RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">, commercialization of such products may be adversely affected by regulatory actions and oversight.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if GSK receives regulatory approval for product candidates in any respiratory program partnered with GSK, this approval may include limitations on the indicated uses for which GSK can market the medicines or the patient population that may utilize the medicines, which may limit the market for the medicines or put GSK at a competitive disadvantage relative to alternative therapies. These restrictions make it more difficult to market the approved products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, at the joint meeting of the Pulmonary&#x2011;Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA regarding the sNDA for BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as a treatment for asthma, the advisory committee recommended that a large LABA safety trial with BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> should be required in adults and in children ages 12&#x2011;17, similar to the ongoing LABA safety trials being conducted as an FDA Post&#x2011;Marketing Requirement by each of the manufacturers of LABA containing asthma treatments. The FDA did not concur with the recommendation. A pediatric program including patients 5&#x2011;17 years of age is currently ongoing.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the manufacturing, labeling, packaging, adverse event reporting, advertising, promotion and recordkeeping for the approved product remain subject to extensive and ongoing regulatory requirements. If we or GSK become aware of previously unknown problems with an approved product in the U.S. or overseas or at contract manufacturers&#x2019; facilities, a regulatory authority may impose restrictions on the product, the contract manufacturers or on GSK, including requiring it to reformulate the product, conduct additional clinical studies, change the labeling of the product, withdraw the product from the market or require the contract manufacturer to implement changes to its facilities. GSK is also subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies, as well as governmental authorities in those foreign countries in which any of the product candidates in any respiratory program partnered with GSK are approved for commercialization. The Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal and state statutes and regulations govern to varying degrees the research, development, manufacturing and commercial activities relating to prescription pharmaceutical products, including non&#x2011;clinical and clinical testing, approval, production, labeling, sale, distribution, import, export, post&#x2011;market surveillance, advertising, dissemination of information and promotion. Any failure to maintain regulatory approval would limit GSK&#x2019;s ability to commercialize the product candidates in any respiratory program partnered with GSK, which could materially and adversely affect our business and financial condition, and which may cause the price of our securities to fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquisitions or strategic investments we have made or may make could turn out to be unsuccessful.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our strategy, we frequently monitor and analyze acquisition or investment opportunities that we believe will create value for our shareholders.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Existing or future acquisitions and investments could involve numerous risks that may prevent us from fully realizing the benefits that we anticipated as a result of the transaction. These risks include the failure to derive any commercial value from the acquired technology, products and intellectual property including as a result of the failure to obtain regulatory approval or to monetize products once approved, as well as risks from lengthy product development and high upfront development costs without guarantee of successful results. Patents and other intellectual property rights covering acquired technology and/or intellectual property may not be obtained, and if obtained, may not be sufficient to fully protect the technology or intellectual property. We may be subject to liabilities, including unanticipated litigation costs, that are not covered by indemnification protection we may obtain. As we pursue or consummate a strategic acquisition or investment, we may value the acquired or funded company incorrectly, fail to successfully manage our operations as our asset diversity increases, expend unforeseen costs during the acquisition or integration process, or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">encounter other unanticipated risks or challenges. Once an investment is made, we may fail to value it accurately, properly account for it in our consolidated financial statements, or successfully divest it or otherwise realize the value which we originally invested or have subsequently reflected in our consolidated financial statements. Any failure by us to effectively limit such risks as we implement our acquisitions or strategic investments could have a material adverse effect on our business, financial condition or results of operations and may negatively impact our net income and cause the price of our securities to fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have a significant amount of debt including our convertible subordinated notes and convertible senior notes that are senior in capital structure and cash flow, respectively, to our common stockholders. Satisfying the obligations relating to our debt could adversely affect our liquidity or the amount or timing of potential distributions to our stockholders.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:9.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had $549.7 million in total debt outstanding, comprised primarily of $96.2 million in principal that remains outstanding under our convertible subordinated notes due 2023 (the &#x201c;2023 Notes&#x201d;), $192.5 million in principal outstanding under our convertible senior notes due 2025 (the &#x201c;2025 Notes&#x201d;) and $261.0 million in principal outstanding under our convertible notes due 2028 (the &#x201c;2028 Notes&#x201d;) (the 2023 Notes, 2025 Notes and 2028 Notes, hereinafter, the &#x201c;Notes&#x201d;). The Notes are unsecured debt and, with the exception of the 2028 Notes, are not redeemable by us prior to the maturity date. Holders of the Notes may require us to purchase all or any portion of their Notes at 100% of their principal amount, plus any unpaid interest, upon a fundamental change. A fundamental change is generally defined to include a merger involving us, an acquisition of a majority of our outstanding common stock, and, under the 2023 Notes, the change of a majority of our board of directors without the approval of the board of directors. In addition, to the extent we pursue and complete a monetization transaction or a transaction that modifies our corporate structure, the structure of such transaction may qualify as a fundamental change under the Notes, which could trigger the put rights of the holders of the Notes, in which case we would be required to use a portion of the net proceeds from such transaction to repurchase any Notes put to us.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Satisfying the obligations of this debt could adversely affect the amount or timing of any distributions to our stockholders. We may choose to satisfy, repurchase, or refinance this debt through public or private equity or debt financings if we deem such financings available on favorable terms. If any or all of the Notes are not converted into shares of our common stock before the maturity date, we will have to pay the holders the full aggregate principal amount of the Notes then outstanding. Any of the above payments could have a material adverse effect on our cash position. If we fail to satisfy these obligations, it may result in a default under the indenture, which could result in a default under certain of our other debt instruments, if any. Any such default would harm our business and the price of our securities could fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we lose key management personnel, or if we fail to retain our key employees, our ability to manage our business may be impaired.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our performance is substantially dependent on the continued service and performance of our management team, who have extensive experience and specialized expertise in our business.  None of our employees have employment commitments for any fixed period of time and all may leave our employment at will. If we fail to retain our qualified personnel or to replace them when they leave, our ability to manage our business may be impaired, which may cause the price of our securities to fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prolonged economic uncertainties or downturns, as well as unstable market, credit and financial conditions, may exacerbate certain risks affecting our business and have serious adverse consequences on our business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The global economic downturn and market instability has made the business climate more volatile and more costly. These economic conditions, and uncertainty as to the general direction of the macroeconomic environment, are beyond our control and may make any necessary debt or equity financing more difficult, more costly, and more dilutive. While we believe we have adequate capital resources to meet current working capital and capital expenditure requirements, a lingering economic downturn or significant increase in our expenses could require additional financing at less than attractive rates or on terms that are excessively dilutive to existing stockholders. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our stock price and could require us to delay or abandon clinical development plans.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of our partnered products will be dependent, in large part, on reimbursement from government health administration authorities, private health insurers, distribution partners and other organizations. As a result of negative trends in the general economy in the U.S. or other jurisdictions in which we may do business, these organizations may be unable to satisfy their reimbursement obligations or may delay payment. In addition, federal and state health authorities may reduce Medicare and Medicaid reimbursements, and private insurers may increase their scrutiny of claims. A reduction in the availability or extent of reimbursement could negatively affect our or our partners&#x2019; product sales and revenue.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we rely on third parties for several important aspects of our business. During challenging and uncertain economic times and in tight credit markets, there may be a disruption or delay in the performance of our third&#x2011;party contractors, suppliers or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">partners. If such third parties are unable to satisfy their commitments to us, our business and results of operations would be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our success in preclinical studies or clinical trials may not be indicative of results in current or future clinical trials.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success in preclinical testing and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Certain product candidates may fail to show the necessary safety and efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through initial clinical trials.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. There is a high failure rate for drugs and biologic products proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections because of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA, the EMA or other comparable regulatory authorities, or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of that product candidate.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We, or our potential collaborators, may not commercialize, market, promote, or sell any product candidate without obtaining marketing approval from the FDA, the EMA or other comparable regulatory authority, and we may never receive such approvals. Even if our product candidates appear sufficiently effective and/or safe in patients in well-controlled clinical trials, it is impossible to predict if or when these product candidates will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We may experience numerous unforeseen events prior to, during, or because of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA, the EMA or other comparable regulatory authority may change from the views they have expressed to us as to the design, implementation, and/or interpretation of our clinical trials;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trials of product candidates may produce negative or inconclusive results;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not be able to complete our clinical trials in a timely manner, if at all, for example because the number of patients required for clinical trials of our product candidates may be larger than we anticipate;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate, or we may fail to recruit suitable patients to participate in a trial;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may fail to comply with regulatory requirements applicable to them, to the FDA&#x2019;s or other comparable regulatory authority&#x2019;s, satisfaction;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulators may issue a clinical hold, or regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA, the EMA or other comparable regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with whom we enter into agreements for clinical and commercial supplies;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our product candidates, once exposed to greater numbers of patients, may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate the clinical trials or cause regulatory authorities to refuse to approve our product candidates or approve them only with significant restrictions on distribution or use;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">even if our clinical trials are successful, the FDA, the EMA or other comparable regulatory authorities may determine that the overall risk-benefit profiles of our product candidates are insufficient to support marketing authorization; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the approval policies or regulations of the FDA, the EMA or other comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials or other testing of those product candidates, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not obtain marketing approval at all;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, such as black box warnings or a REMS program;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be subject to additional post-marketing testing requirements; or</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be required to remove the product from the market after obtaining marketing approval.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product development costs may also increase if we experience delays in testing and we may be required to obtain additional funds to complete clinical trials. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately lead to the denial of regulatory approval of a product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are not successful in discovering, developing, and commercializing additional product candidates, our ability to expand and achieve our strategic objectives would be impaired.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although a substantial amount of our effort will focus on the continued clinical testing and potential regulatory approval of our product candidates, an element of our strategy is to develop and commercialize, either by ourselves or with a collaborator, our product candidates and discover and develop novel product candidates in other therapeutic areas. We are seeking to do so by utilizing our discovery research experience and capabilities to design active new compounds that target causative mechanisms of disease. Research efforts to identify and develop product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the research methodology used may not be successful in identifying potential product candidates;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">competitors may develop alternatives that render our product candidates obsolete or less attractive;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product candidates we develop may nevertheless be covered by third parties&#x2019; patents or other exclusive rights;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA, the EMA or other regulatory authorities may not approve or agree with the intended use of a new product candidate.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to develop and successfully generate revenue from other current and future product candidates, our future prospects may be harmed, and we will be more vulnerable to any problems that we or potential collaborators may encounter in developing and commercializing our current product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we or our collaborators experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to initiate, continue or complete clinical trials of our product candidates that we develop if we and our collaborators are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, the EMA or other comparable regulatory authority. We have limited experience enrolling patients in our clinical trials and cannot predict how successful we will be in enrolling patients in future clinical trials.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For instance, patients involved in our clinical trials are often in the hospital setting and the decision to participate can be made by the caregiver or doctor. Accordingly, seeking consent for patient participation may become difficult when the family and/or the patient may not be available to consider participation in a clinical trial and the providers/investigators seeking the consent often have no established relationship with the family or patient. The challenges of obtaining consent for patient participation have increased during the COVID-19 pandemic as hospitals have imposed restrictions on visitation by friends or family members who may be able to provide consent on behalf of patients. The COVID-19 pandemic may make patients less willing to seek medical attention or return for follow-up visits post-treatment. In addition, some of our competitors have ongoing clinical trials to treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors. If we are not successful at enrolling patients in one clinical trial, it may affect when we are able to initiate the next clinical trial, which could result in significant delays in our efforts to pursue regulatory approval of and commercialize our product candidates. Patient enrollment is affected by other factors including:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size and nature of the patient population;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the severity of the disease under investigation;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the eligibility criteria for participation in the clinical trial;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the design of the clinical trial;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the perceived risks and benefits of the product candidate under study;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to recruit clinical trial investigators with appropriate experience;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of drugs approved to treat the diseases under study;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patient referral practices of physicians;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain patient consents;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to monitor patients adequately during and after treatment;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of public health epidemics, such as the COVID-19 pandemic.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which would reduce the capital we have available to support current and future product candidates and may result in the need to raise additional capital earlier than planned and could cause the value of our common stock to decline and limit our ability to obtain additional financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts (generally referred to as adverse events), to their doctor. We are required to report adverse events to the FDA and other regulatory authorities. Often, it is not possible to determine whether the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm or refute these observations, if they occur. In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. Many times, side effects are only detectable after investigational drugs are tested in large-scale, Phase&#x202f;3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that any of our current product candidates or any future product candidates, have side effects or causes serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which could harm our business, prospects, operating results and financial condition.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed and our ability to generate revenue through their sale may be delayed or eliminated. Any of these occurrences may significantly harm our business, financial condition and prospects.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, if any of our product candidates receive marketing approval, regulatory authorities may require the addition of labeling statements, such as a &#x201c;black box&#x201d; warning or a contraindication, or the adoption of a REMS program to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the drug for distribution to patients and a communication plan to health care practitioners, and/or significant restrictions on distribution or use of the drug. Furthermore, if we or others later identify undesirable side effects caused by our product candidates, several potentially significant negative consequences could result, including:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may suspend or withdraw approvals of such product candidate;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require additional warnings on the label or impose distribution or use restrictions;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to change the way a product candidate is administered or conduct additional clinical trials, including one or more post-market studies;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could be sued and held liable for harm caused to patients;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to implement a REMS, including the creation of a medication guide outlining the risks of such side effects for distribution to patients, and/or other elements to assure safe use;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may need to conduct a recall; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reputation may suffer.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved, or could substantially increase commercialization costs and expenses, which could delay or prevent us from generating revenue from the sale of our products and harm our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interim &#x201c;top-line&#x201d; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may announce interim top-line or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on third parties to conduct the clinical trials for our product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with applicable regulatory requirements.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have engaged contract research organizations, or CROs, to conduct our ongoing and planned clinical trials. We also expect to engage CROs for any of our other product candidates that may progress to clinical development. We expect to rely on CROs, as well as other third parties, such as clinical data management organizations, medical institutions and clinical investigators, to conduct those clinical trials. Agreements with such third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, our product development activities would be delayed.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulatory standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Similar regulatory requirements apply outside the United States, including the International Council for Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use, or ICH.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also required to register certain ongoing clinical trials and post the results of certain completed clinical trials on government-sponsored, publicly accessible databases, such as ClinicalTrials.gov, within specified timeframes. Failure to do so by us or by third parties can result in FDA refusal to approve applications based on the clinical data, enforcement actions, adverse publicity and civil and criminal sanctions.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the results of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any NDA we submit. Any such delay or rejection could prevent us from commercializing our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also expect to rely on other third parties to store and distribute product supplies for our clinical trials. Any performance failure or regulatory noncompliance on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, resulting in additional losses and depriving us of potential product revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on collaborations with third parties for the development of our product candidates, and we may seek additional collaborations in the future. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have limited capabilities for drug development, and our product development programs and the commercialization of our product candidates will require substantial additional cash to fund expenses. As a result of these factors, we are, and expect to continue to be, dependent on collaborations relating to the development of our existing and future product candidates. We have had and will continue to have discussions on potential partnering opportunities with various pharmaceutical companies. In addition, we may seek third-party collaborators for the development and commercialization of our product candidates, particularly for the commercialization of our product candidates outside the United States. Likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies and we may face significant competition in seeking appropriate collaborators. If we fail to enter into or maintain collaborations on reasonable terms or at all, our ability to develop our existing or future product candidates could be delayed, the commercial potential of our products could change, and our costs of development and commercialization could increase. If we enter into any future collaboration arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#x2019; abilities to successfully perform the functions assigned to them in these arrangements.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our collaborations and any future collaborations we might enter into may pose a number of risks, including:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators often have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not perform their obligations as expected or contractually obligated;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#x2019; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such products;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not properly maintain or defend our or their intellectual property rights or may use our or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may be subject to geo-political actions, natural disasters or other occurrences, including public health epidemics such as the COVID-19 pandemic;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators&#x2019; decisions may limit the availability of the product supplies required for development, clinical and commercial activities.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator were to be involved in a business combination, the continued pursuit and emphasis on our drug development or commercialization program could be delayed, diminished or terminated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our reliance on third parties to manufacture our product candidates increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not own or operate manufacturing facilities to produce clinical or commercial supplies of the product candidates that we are developing or evaluating. We have limited personnel with experience in drug manufacturing and lack the resources and the capabilities to manufacture any of our product candidates on a clinical or commercial scale. We currently rely on third parties for supply of our product candidates, and our strategy is to outsource all manufacturing of our product candidates and approved products, if any, to third parties.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To conduct clinical trials of our product candidates, we will need to identify suitable manufacturers with the capabilities to manufacture our compounds in large quantities in a manner consistent with existing regulations. Our third-party manufacturers may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities and at any other time. If our manufacturers are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed, or infeasible, and regulatory approval or commercial launch of that product candidate may be delayed or not obtained, which could significantly harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we can establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails risks, including:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reliance on the third party for regulatory compliance and quality assurance;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possible breach of the manufacturing agreement by the third party;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possible misappropriation of our proprietary information, including our trade secrets and know-how;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">supply chain disruptions due to geo-political actions, natural disasters or public healthy crises, including epidemics such as the COVID-19 pandemic.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to develop product candidates and commercialize any products that receive marketing approval on a timely and competitive basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to win government or non-profit contracts or grants to fund our product development activities.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Historically, we have relied in part on funding from contracts or grants from government agencies and non-profit entities and it is part of our strategy to continue to do so. Such contracts or grants can be highly attractive because they provide capital to fund the ongoing development of our product candidates without diluting our stockholders. However, there is often significant competition for these contracts or grants. Entities offering contracts or grants may have requirements to apply for or to otherwise be eligible to receive certain contracts or grants that our competitors may be able to satisfy that we cannot. In addition, such entities may make arbitrary decisions as to whether to offer contracts or make grants, to whom the contracts or grants will be awarded, and the size of the contracts or grants to each awardee. Even if we can satisfy the award requirements, there is no guarantee that we will be selected to receive any contract or grant. If we are not successful in achieving this form of funding for our clinical trials, we will need to seek alternative means of funding which may not be available to the same extent, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our reliance on government funding for certain of our programs adds uncertainty to our research, development and commercialization efforts with respect to those programs and may impose requirements that increase the costs of the research, development and commercialization of product candidates developed under those government-funded programs.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aspects of certain of our development programs are currently being supported, in part, with funding from the NIH, NIAID, CARB-X and the DOD. Contracts and grants awarded by the U.S. government, its agencies and its partners, including our awards from the NIH, NIAID, CARB-X, and the DOD, include provisions that reflect the government&#x2019;s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">terminate agreements, in whole or in part, for any reason or no reason at all;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide grant support to potential competitor programs;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reduce or modify the government&#x2019;s obligations under such agreements without the consent of the other party;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">claim rights, including intellectual property rights, in products and data developed under such agreements;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">audit contract-related costs and fees, including allocated indirect costs;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspend the contractor or grantee from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspend or debar the contractor or grantee from doing future business with the government;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">control and potentially prohibit the export of products;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pursue criminal or civil remedies under the False Claims Act, False Statements Act and similar remedy provisions specific to government agreements; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limit the government&#x2019;s financial liability to amounts appropriated by the U.S. Congress on a fiscal-year basis, thereby leaving some uncertainty about the future availability of funding for a program even after it has been funded for an initial period.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not have the right to prohibit the U.S. government from using certain technologies developed by us, and may not be able to prohibit third-party companies, including our competitors, from using those technologies in providing products and services to the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government. The U.S. government generally takes the position that it has the right to royalty-free use of technologies that are developed under U.S. government contracts.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, government contracts and grants, and subcontracts and subawards awarded in the performance of those contracts and grants, normally contain additional requirements that may increase our costs of doing business, reduce our profits, and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">specialized accounting systems unique to government awards;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adhering to stewardship principles imposed by CARB-X as a condition of the award;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">public disclosures of certain award information, which may enable competitors to gain insights into our research program; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mandatory socioeconomic compliance requirements, including labor standards, non-discrimination and affirmative action programs and environmental compliance requirements.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As an organization, we are relatively new to government contracting and new to the regulatory compliance obligations that such contracting entails. If we fail to maintain compliance with those obligations, we may be subject to potential liability and termination of our contracts.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a U.S. government contractor, we are subject to financial audits and other reviews by the U.S. government of our costs and performance on our contracts, as well as our accounting and general business practices related to these contracts. Based on the results of its audits, the government may adjust our contract-related costs and fees, including allocated indirect costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to the Commercialization of Our Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if any of our product candidates receives marketing approval, such product candidate may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain approvals from the FDA, the EMA or other comparable regulatory agencies and can initiate commercialization of a product candidate we develop, the product candidate may not achieve market acceptance among physicians, patients, hospitals, including pharmacy directors, and third-party payors and, ultimately, may not be commercially successful. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on several factors, including:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efficacy and potential advantages compared to alternative treatments;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential and perceived advantages and disadvantages of the product candidates, including cost and clinical benefit relative to alternative treatments;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance by physicians, patients, operators of hospitals, including in-hospital formularies, and treatment facilities and parties responsible for coverage and reimbursement of the product;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of coverage and adequate reimbursement by third-party payors and government authorities;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to manufacture our product in sufficient quantities and yields;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the strength and effectiveness of marketing and distribution support;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of any side effects;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations or warnings, including distribution or use restrictions, contained in the product&#x2019;s approved labeling or an approved REMS;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular infections;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the approval of other new products for the same indications;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of market introduction of the approved product as well as competitive products;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the emergence of bacterial resistance to the product; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the rate at which resistance to other drugs in the target infections grow.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any failure by any of our product candidates that obtains regulatory approval to achieve market acceptance or commercial success could have a material adverse effect on our business prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than we do.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development and commercialization of new drug products is highly competitive. We face competition from major multi-national pharmaceutical companies, biotechnology companies, specialty pharmaceutical companies and generic drug companies with respect to our current and future product candidates. There are several large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of drug-resistant infections. Potential competitors also include academic institutions, government agencies and other public and private research organizations. Our competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective, more effectively marketed and sold or less costly than our product candidates, which could render our product candidates non-competitive and obsolete.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our competitors obtain marketing approval from the FDA, the EMA or other comparable regulatory authorities for their product candidates more rapidly than we do, it could result in our competitors establishing a strong market position before we are able to enter the market.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of such our competitors have greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do as an organization. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Our competitors also may obtain approval from the FDA, the EMA or other comparable regulatory agencies for their product candidates more rapidly than we may obtain approval for ours, which could result in product approval delays if a competitor obtains market exclusivity from the FDA or the EMA, or our competitors establish a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic drugs. Additional drugs may become available on a generic basis over the coming years. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic drugs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and adequate reimbursement may not be available for our current or any future product candidates, which could make it difficult for us to sell profitably, if approved.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market acceptance and sales of any product candidates that we or our collaborators commercialize will depend in part on the extent to which reimbursement for these drugs and related treatments will be available from third-party payors, including government health care programs (such as Medicare and Medicaid), government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. One payor&#x2019;s determination to provide coverage for a drug does not assure</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that other payors will also provide coverage and adequate reimbursement for the drug. Additionally, a third-party payor&#x2019;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines whether it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its list of covered drugs, or formulary, it will be placed. The position on a payor&#x2019;s formulary generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our drugs, and providers are unlikely to prescribe our drugs, unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our drugs and their administration.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A primary trend in the United States healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand, or the price of, any drug for which we obtain marketing approval for. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our current and any future product candidates that we develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any drugs that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reduced resources of our management to pursue our business strategy;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased demand for any product candidates or products that we may develop;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injury to our reputation and significant negative media attention;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant costs to defend the resulting litigation;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards paid to clinical trial participants or patients;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to commercialize any drugs that we may develop.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently hold product liability insurance coverage in an amount that may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">There are a variety of risks associated with marketing our product candidates internationally, which could affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We or our collaborators may seek regulatory approval for our product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">differing regulatory requirements in foreign countries;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market with low or lower prices rather than buying them locally;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">economic weakness, including inflation, or political instability in foreign economies and markets;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign taxes, including withholding of payroll taxes;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties staffing and managing foreign operations;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reduced level of reimbursement, pricing and insurance regimes compared to the United States;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods, fires, and public health epidemics, such as the COVID-19 pandemic.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These and other risks associated with our international operations may compromise our ability to achieve or maintain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Business and Managing Our Growth</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have pursued and may continue to pursue acquisitions. Acquisitions could be difficult to integrate, divert the attention of key personnel, disrupt our business, dilute stockholder value and impair our financial results.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our business strategy, we have pursued and intend to continue to pursue acquisitions of complementary businesses, products, services or technologies that we believe could accelerate our ability to compete in our existing markets or allow us to enter new markets. Any of these transactions could be material to our financial condition and results of operations. If we fail to properly evaluate or integrate acquisitions, we may not achieve the anticipated benefits of any such acquisitions, and we may incur costs in excess of what we anticipate. The failure to successfully evaluate and execute acquisitions or otherwise adequately address these risks could materially harm our business and financial results.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisitions also frequently result in the recording of goodwill and other intangible assets which are subject to potential impairments which could harm our financial results. As a result, if we fail to properly evaluate acquisitions or investments, we may not achieve the anticipated benefits of any such acquisitions, and we may incur costs in excess of what we anticipate. The failure to successfully evaluate and execute acquisitions or investments or otherwise adequately address these risks could materially harm our business and financial results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We might not be able to successfully integrate our operations with those of Entasis and/or La Jolla and other assets that we may acquire.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We completed the acquisition of Entasis on July 11, 2022, pursuant to which Entasis became a wholly owned subsidiary of Innoviva and the acquisition of La Jolla, on August 22, 2022, pursuant to which La Jolla became a wholly owned subsidiary of Innoviva. Our integration of the operations and personnel of each of Entasis and La Jolla and any other assets we may acquire may require significant efforts, including significant amounts of management&#x2019;s time, and result in additional expenses. Factors that will affect the success of the acquisitions include the strength of our combined product pipelines, our ability to execute our business strategy, our ability to adequately fund research and development and retain key employees, and results of clinical trials, regulatory approvals and reimbursement levels of any approved product. In addition, we cannot be certain that any technology or assets we acquire will be successfully developed, become profitable or remain so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Failure to realize the anticipated benefits from our acquisition of Entasis and La Jolla may affect our future results of operations and financial operations.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our acquisition of Entasis and La Jolla, we have integrated the research and development, commercial operations and personnel into our existing infrastructure. If there are unexpected difficulties in our integration of these acquired businesses, the anticipated benefits of the transaction may not be realized or may take longer to realize than expected. The anticipated benefits of the acquisition could be materially reduced by a number of factors, including the following:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the future revenue and gross margins of the acquired products may be materially different from those we originally anticipated;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could incur material unanticipated expenses;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">claims or lawsuits may arise from the acquisition transaction or from their previous business operations;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may experience difficulties in implementing effective internal controls over financial reporting as part of our integration actions; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential growth, expected financial results, perceived synergies and anticipated opportunities may not be realized through the ongoing integration actions.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The occurrence of any or all of these events may have an adverse effect on our business and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary drugs, intellectual property rights, technologies or businesses, as deemed appropriate to carry out our business plan. Any potential acquisition or strategic collaboration may entail numerous risks, including:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increased operating expenses and cash requirements;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the assumption of additional indebtedness or contingent liabilities;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assimilation of operations, intellectual property and drugs of an acquired company, including challenges associated with integrating new personnel;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the diversion of our management&#x2019;s attention from our existing drug programs and initiatives in pursuing such a strategic partnership, merger or acquisition;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing drugs or drug candidates and regulatory approvals; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technology and product candidates. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage that we may have, which could harm our business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and ability to achieve profitability. To protect our proprietary positions, we file patent applications in the United States and abroad related to our novel technologies and product candidates that are important to our business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent application and prosecution process are expensive and time-consuming. We, our current licensees, or any future licensors and licensees may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We or our current licensees, or any future licensors or licensees may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Therefore, these and any of our patents and applications may not be prosecuted and enforced in a manner consistent with our best interests. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If our current licensees, or any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised, and we might not be able to prevent third parties from making, using and selling competing products. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and/or unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Any of these outcomes could impair our ability to prevent competition from third parties.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. For example, European patent law currently restricts the patentability of methods of treatment of the human body more than United States law does. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Furthermore, recent changes in patent laws in the United States, including the America Invents Act of 2011, may affect the scope, strength and enforceability of our patent rights or the nature of proceedings that may be brought by us related to our patent rights.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be aware of all third-party intellectual property rights potentially relating to our current and future product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#x202f;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Similarly, should we own any patents or patent applications in the future, we may not be certain that we were the first to file for patent protection for the inventions claimed in such patents or patent applications. As a result, the issuance, scope, validity and commercial value of our patent rights cannot be predicted with any certainty. Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in derivation, ex-parte reexamination, or inter partes review proceedings in the USPTO or similar proceedings elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our pending and future patent applications may not result in patents being issued that protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection against competing products or processes sufficient to achieve our business objectives, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may seek to market generic versions of any approved products by submitting abbreviated new drug applications to the FDA in which they claim that patents owned or licensed by us are invalid, unenforceable and/or not infringed. Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid and/or unenforceable.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exclusivity or freedom to operate, a patent being held unenforceable, and/or in one or more or in patent claims being narrowed or invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products or limit the duration of the patent protection of our technology and products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest filing date of a non-provisional application to which the patent claims priority. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our candidates might expire before or shortly after our candidates are commercialized. Depending upon the timing, duration and conditions of any FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union, as discussed above. As a result, our revenue from applicable products could be reduced. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case, and our competitive position, business, financial condition, results of operations, and prospects could be materially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A third party may hold intellectual property rights, including patent rights, that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable terms, or at all, and we could be forced to accept unfavorable contractual terms. If we are unable to obtain such licenses on commercially reasonable terms, our business could be harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could materially harm our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors and other third parties may infringe our issued patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, trademarks, copyrights or other intellectual property. In addition, in a patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable or that one or more claims of a patent are invalid, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#x2019;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the basis that our patents do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive because of the proceedings. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a negative impact on our ability to compete in the marketplace.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could significantly harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our technology or product candidates, including interference proceedings before the USPTO. Intellectual property disputes arise in several areas including with respect to patents, use of other proprietary rights and the contractual terms of license arrangements. Third parties may assert claims against us based on existing or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are found to infringe a third-party&#x2019;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In some cases, we may not be able to obtain patent protection for certain licensed technology outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, even in jurisdictions where we do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we do pursue patent protection or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates and preclinical programs and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to seeking patent and trademark protection for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties prior to beginning research or disclosing proprietary information. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Despite these efforts and the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information due to our reliance on third parties, increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time-consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates and the activities associated with their development and commercialization, including their design, research, testing, manufacture, safety, efficacy, quality control, recordkeeping, labeling, packaging, storage, approval, advertising, promotion, sale, distribution, import, export, and reporting of safety and other post-market information, are subject to comprehensive regulation by the FDA, the EMA and other foreign regulatory agencies. Failure to obtain marketing approval for a product candidate will prevent us or a potential collaborator from commercializing the product candidate. We will rely on third parties to assist us in the process of filing and supporting the applications necessary to gain marketing approvals. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#x2019;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. We may not be able to successfully manufacture our products in compliance with applicable requirements such as GMPs. If any of our product candidates receives marketing approval, the accompanying label may limit its approved use more narrowly than we anticipate, which could limit sales of the product.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#x2019;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA, the EMA or other regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude us from obtaining marketing approval or prevent or limit commercial use. Any marketing approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. Any marketing approval that we, or any future collaborators, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be impaired.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Failure to obtain marketing approval in foreign jurisdictions would prevent certain of our product candidates from being marketed in these territories. Any approval we are granted for our product candidates in the United States would not assure approval of our product candidates in foreign jurisdictions.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To market and sell our products in the European Union, or EU, and any other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain approval from the FDA. The regulatory approval process outside the United States generally includes all the risks associated with obtaining approval from the FDA. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, denial of approval in one jurisdiction may impact the ability to obtain approval elsewhere. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we or our collaborators manufacture and market our products and compliance with such requirements may involve substantial resources, which could materially impair our ability to generate revenue.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if marketing approval of a product candidate is granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation, including the potential requirements to implement a REMS or to conduct costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. We must also comply with requirements concerning advertising and promotion for any of our product candidates for which we obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#x2019;s approved labeling. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved. In addition, manufacturers of approved products and those manufacturers&#x2019; facilities are required to comply with extensive FDA requirements including ensuring that quality control and manufacturing procedures conform to cGMP, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements, among other things. We and our contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMP. We must also comply with FDA requirements for adverse event reporting for commercial products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accordingly, assuming we receive marketing approval for one or more of our product candidates, we and our contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. We could also be subject to other civil or criminal penalties. Thus, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any product candidate for which we obtain marketing approval could be subject to post-marketing restrictions or recall or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and other federal and state agencies, including the U.S. DOJ, closely regulate compliance with all requirements governing prescription drug products, including requirements pertaining to marketing and promotion of drugs in accordance with the provisions of the approved labeling and manufacturing of products in accordance with cGMP requirements. The FDA and DOJ impose stringent restrictions on manufacturers&#x2019; communications regarding off-label use and if we market our products for indications other than their approved indications, we may be subject to enforcement action for off-label marketing. Violations of such requirements may lead to investigations alleging violations of the Food, Drug and Cosmetic Act and other statutes, including the False Claims Act and other federal and state health care fraud and abuse laws as well as state consumer protection laws.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our failure to comply with all regulatory requirements, and later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, may yield various results, including:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">litigation involving patients taking our products;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on our products, manufacturers or manufacturing processes;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the labeling or marketing of a product;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on product distribution or use;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">warning or untitled letters;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of the products from the market;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal to approve pending applications or supplements to approve applications that we submit;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recall of products;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspension or withdrawal of marketing approvals;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">damage to relationships with any potential collaborators;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unfavorable press coverage and damage to our reputation;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal to permit the import or export of our products;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure; or</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-compliance by us or any future collaborator with regulatory requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with regulatory requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-compliance with U.K. and EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, also can result in significant financial penalties. Similarly, failure to comply with the U.K.&#x2019;s or EU&#x2019;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our current and future relationships with healthcare professionals, principal investigators, consultants, customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to penalties.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, that may constrain the business or financial arrangements and relationships through which we research, sell, market and distribute any product candidates for which we obtain marketing approval. In addition, we may be subject to physician payment transparency laws and patient privacy and security regulation by the federal government and by the states and foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws that may affect our ability to operate include the following:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal civil and criminal false claims laws, including the federal False Claims Act, which impose criminal and civil penalties, including through civil whistleblower or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">qui tam</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the civil monetary penalties statute, which imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, which created additional federal criminal and civil statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the HITECH Act of 2009, and their respective implementing regulations, which impose obligations on &#x201c;covered entities,&#x201d; including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective &#x201c;business associates&#x201d; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Physician Payments Sunshine Act, created under Section&#x202f;6002 of Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, and its implementing regulations, which created annual reporting requirements for manufacturers of drugs, devices, biologicals and medical supplies for certain payments and &#x201c;transfers of value&#x201d; provided to covered recipients, including physicians, as defined by such law, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analogous state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or to adopt compliance programs as prescribed by state laws and regulations, or that otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and drug pricing; state and local laws requiring the licensure of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, the ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal statutes governing healthcare fraud. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the ACA provided that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efforts to ensure that our future business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with the law and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and pursue our strategy. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including future collaborators, are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Future legislation, and/or regulations and policies adopted by the FDA, the EMA or comparable regulatory authorities, may increase the time and cost required for us or our collaborators to conduct and complete clinical trials of our current and future product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and the EMA have each established regulations to govern the product development and approval process, as have other foreign regulatory authorities. The policies of the FDA, the EMA and other regulatory authorities may change. For example, in December&#x202f;2016, the 21st&#x202f;Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation, but not all its provisions have yet been implemented. Additionally, in August&#x202f;2017, the FDA issued final guidance setting forth its current thinking with respect to development programs and clinical trial designs for antibacterial drugs to treat serious bacterial diseases in patients with an unmet medical need. We cannot predict what if any effect the Cures Act or any existing or future guidance from the FDA or other regulatory authorities will have on the development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently enacted and future legislation, including relevant provisions of the Inflation Reduction Act, may increase the difficulty and cost for us and our collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other federal health reform measures have been proposed and adopted in the United States. For example, the Medicare Access and CHIP Reauthorization Act of 2015 ended the use of the statutory formula for clinician payment and established a quality payment incentive program, also referred to as the Quality Payment Program. This program provides clinicians with two ways to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. It is unclear how payment reductions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or the introduction of the Quality Payment Program will impact overall physician reimbursement under the Medicare program. It is also unclear if changes in Medicare payments to providers would impact such providers&#x2019; willingness to prescribe and administer our products, if approved.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, there has been heightened governmental scrutiny over the way companies set prices for their marketed products. For example, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and patient programs, and reform government program reimbursement methodologies for drug products. In particular, the recently passed Inflation Reduction Act contains provisions designed to limit the prices paid by Medicare for various prescription drugs.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us or our collaborators from being able to generate revenue, attain profitability, or commercialize our drugs.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#x2019;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates may be subject to government price controls that may affect our revenue.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There has been heightened governmental scrutiny in the United States and abroad of pharmaceutical pricing practices considering the rising cost of prescription drugs and biologics. In the United States, such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the former Trump Administration&#x2019;s budget proposal for fiscal year 2020 contained further drug price control measures that could be enacted during the 2020 budget process or in other future legislation, including, for example, measures to permit Medicare Part&#x202f;D plans to negotiate the price of certain drugs under Medicare Part&#x202f;B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. The former Trump Administration also released a &#x201c;Blueprint&#x201d;, or plan, to lower drug prices and reduce out-of-pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out-of-pocket costs of drug products paid by consumers.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HHS has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS&#x2019;s policy change that was effective January 1, 2019. On November 20, 2020, CMS issued an interim final rule through the CMS Innovation Center whereby Medicare Part B reimbursement for &#x201c;certain high-cost prescriptions drugs&#x201d; would be no more than most-favored-nation price (i.e., the lowest price) after adjustments, for a pharmaceutical product that the drug manufacturer sells in a member country of the Organization for Economic Cooperation and Development that has a comparable per-capita gross domestic product. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. While some of these and other measures may require additional authorization to become effective, members of Congress and the new Biden Administration have indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. For example, the recently enacted Inflation Reduction Act contains provisions designed to limit the prices paid by Medicare for various prescription drugs. At the state level, legislatures have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside of the United States, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to our Alliance with GSK</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because a portion of our current revenues and near-term projected revenues have historically been derived from products under the GSK Agreements, disputes with GSK could harm our business and cause the price of our securities to fall.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Historically, all of our current and near-term projected revenues have been derived from products under the GSK Agreements. We expect royalties from such products will likely continue to comprise a portion of our revenues in the future. Any action or inaction by either GSK or us that results in a material dispute, allegation of breach, litigation, arbitration, or significant disagreement between the parties may be interpreted negatively by the market or by our investors, could harm our business and cause the price of our securities to fall. Examples of these kinds of issues include but are not limited to non&#x2011;performance of contractual obligations and allegations of non&#x2011;performance, disagreements over the relative marketing and sales efforts for our partnered products and other GSK respiratory products, disputes over public statements, and similar matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because GSK is a strategic partner, it may take actions that in certain cases are materially harmful to our business or to our stockholders.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GSK is a strategic partner with rights and obligations under the GSK Agreements that cause its interests to differ from our interests and those of our stockholders. In particular, GSK has a substantial respiratory product portfolio in addition to the partnered products that are covered by the GSK Agreements. GSK may make respiratory product portfolio decisions or statements about its portfolio which may be, or may be perceived to be, harmful to the respiratory products partnered with us. For example, GSK could promote its non&#x2011;GSK/Innoviva respiratory products or a partnered product for which we are entitled to receive a lower percentage of royalties, delay or terminate the development or commercialization of the respiratory programs covered by the GSK Agreements, or take other actions, such as making public statements, that have a negative effect on our stock price. In this regard and by way of example, sales of Advair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, GSK&#x2019;s approved medicine for both COPD and asthma, continue to be significantly greater than sales of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and GSK has indicated publicly that it intends to continue commercializing Advair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Also, given the potential future royalty payments which GSK may be obligated to pay under the GSK Agreements, GSK may seek to acquire us in order to reduce those payment obligations. The timing of when GSK may seek to acquire us could potentially be when it possesses information regarding the status of drug programs covered by the GSK Agreements that has not been publicly disclosed and is not otherwise known to us. As a result of these differing interests, GSK may take actions that it believes are in its best interest but which might not be in our best interest or the best interest of our stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GSK has also indicated to us that it believes its consent may be required before we can engage in certain royalty monetization transactions with third parties, which may inhibit our ability to engage in these transactions.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GSK indicated to us that it believes that its consent may be required before we can engage in certain transactions designed to monetize the future value of royalties that may be payable to us from GSK under the GSK Agreements. GSK has informed us that it believes that there may be certain covenants included in these types of transactions that might violate certain provisions of the GSK Agreements. Although we believe that we can structure royalty monetization transactions in a manner that fully complies with the requirements of the GSK Agreements without GSK&#x2019;s consent, a third party in a proposed monetization transaction may nonetheless insist that we obtain GSK&#x2019;s consent for the transaction or restructure the transaction on less favorable terms. We have obtained GSK&#x2019;s agreement that (i) we may grant certain pre&#x2011;agreed covenants in connection with monetization of our interests in RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and vilanterol monotherapy, and (ii) it will not unreasonably withhold its consent to our requests to grant other covenants, provided among other conditions, that in each case, the covenants are not granted in favor of a pharmaceutical or biotechnology company with a product either being developed or commercialized for the treatment of respiratory disease. If we seek GSK&#x2019;s consent to grant covenants other than pre&#x2011;agreed covenants, we may not be able to obtain GSK&#x2019;s consent on reasonable terms, or at all. If we proceed with a royalty monetization transaction that is not otherwise covered by the GSK Agreement without GSK&#x2019;s consent, GSK could request that its consent be obtained or seek to enjoin or otherwise challenge the transaction as violating or allowing it to terminate the GSK Agreements. Regardless of the merit of any claims by GSK, we would incur significant cost and diversion of resources in defending against GSK&#x2019;s claims or asserting our own claims and GSK may seek concessions from us in order to provide its consent. Any uncertainty about whether or when we could engage in a royalty monetization transaction, the potential impact on the enforceability of the GSK Agreements or the loss of potential royalties from the respiratory programs partnered with GSK, could impair our ability to pursue a return of capital strategy for our stockholders ahead of our receipt of significant royalties from GSK, result in significant reduction in the market price of our securities and cause other material harm to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Risks Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our internal computer systems, or third-parties that we work with, may fail or suffer security breaches, which could result in a material disruption of our business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite the implementation of security measures, our internal computer systems and those of third-parties with whom we work (including our collaborative partner) are vulnerable to damage or disruption from computer viruses, software bugs, unauthorized access, natural disasters, terrorism, war, and telecommunication, equipment and electrical failures. In the event we or they were to experience any significant system failure, accident or security breach it could cause interruptions in our operations and adversely affect our business, financial condition and results of operations. Cybersecurity attacks in particular are evolving and include, but are not limited to, malicious software, attempts to gain unauthorized access to data and other electronic security breaches that could lead to disruptions in systems, misappropriation of our confidential, or otherwise protected, information and corruption of data.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, California recently enacted legislation that has been dubbed the first &#x201c;GDPR-like&#x201d; law in the United States. Known as the California Consumer Privacy Act (&#x201c;CCPA&#x201d;), it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. Having gone into effect January 1, 2020, the CCPA requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. The CCPA may significantly impact our business activities and require substantial compliance costs that adversely affect business, operating results, prospects and financial condition.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thus, any access, disclosure or other loss of information, including our data being breached at our partners or third-party providers, could result in legal claims or proceedings and liability under laws that protect the privacy of personal information, disrupt our operations and damage our reputation, which could adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to maintain proper and effective internal control over financial reporting or if the interpretations, estimates or judgments utilized in preparing our financial statements prove to be incorrect, our operating results and our ability to operate our business could be harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Sarbanes-Oxley Act requires, among other things, that we establish and maintain effective internal control over financial reporting and disclosure controls and procedures. Under the SEC&#x2019;s current rules, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Our independent registered public accounting firm is also required to report on our internal control over financial reporting. Our testing and our independent registered public accounting firm&#x2019;s testing may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses and render our internal control over financial reporting ineffective. We have and expect to continue to incur substantial accounting and auditing expense and to expend significant management time in complying with the requirements of Section 404. If we are not able to maintain compliance with the requirements of Section 404 in a timely manner, or if we or our independent registered public accounting firm identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to investigations or sanctions by the SEC, FINRA, The Nasdaq Global Select Market or other regulatory authorities. In addition, we could be required to expend significant management time and financial resources to correct any material weaknesses that may be identified or to respond to any regulatory investigations or proceedings.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also subject to complex tax laws, regulations, accounting principles and interpretations thereof. The preparation of our financial statements requires us to interpret accounting principles and guidance and make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated, and expenses incurred during the reporting periods. Our interpretations, estimates and judgments are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for the preparation of our financial statements. U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) presentation is subject to interpretation by the SEC, the Financial Accounting Standards Board and various other bodies formed to interpret and create appropriate accounting principles and guidance. In the event that one of these bodies disagrees with our accounting recognition, measurement or disclosure or any of our accounting interpretations, estimates or assumptions, it may have a significant effect on our reported results and may retroactively affect previously reported results. The need to restate our financial results could, among other potential adverse effects, result in our incurring substantial costs, affect our ability to timely file our periodic reports until such restatement is completed, divert the attention of our management and employees from managing our business, result in material changes to our historical and future financial results, result in investors losing confidence in our operating results, subject us to securities class action litigation, and cause our stock price to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees or third party providers, or employees or third party providers of our portfolio companies may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by employees, third party providers, or employees or third party providers of our portfolio companies. Misconduct by employees, third party providers, or employees or third party providers of our portfolio companies could include intentional failures to comply with applicable regulations, provide accurate information to regulatory authorities, comply with federal and state fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, the health care industry is subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. It is not always possible to identify and deter misconduct by employees, third party providers, or employees or third party providers of our portfolio companies, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred litigation and may incur additional litigation.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have been subject to various legal proceedings, and, in the future, we may be exposed to, or threatened with, litigation, claims and proceedings incident to the ordinary course of, or otherwise in connection with, our business. In addition, agreements entered into by us sometimes include indemnification provisions which may subject us to costs and damages in the event of a claim against an indemnified third party.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regardless of the merit of particular claims, litigation may be expensive, time-consuming, disruptive to our operations and distracting to management. In recognition of these considerations, we may enter into agreements or other arrangements to settle litigation and resolve such disputes. No assurance can be given that such agreements can be obtained on acceptable terms or that litigation will not occur. These agreements may also significantly increase our operating expenses.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If one or more legal matters were resolved against us or an indemnified third party in a reporting period for amounts in excess of management&#x2019;s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Further, such an outcome could result in significant compensatory, punitive or trebled monetary damages, disgorgement of revenue or profits, remedial corporate measures or injunctive relief against us that could materially adversely affect our financial condition and operating results.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we maintain insurance coverage for certain types of claims, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Failure to comply with the U.S. Foreign Corrupt Practices Act, or &#x201c;FCPA&#x201d;, as well as the anti-bribery laws of the nations in which we conduct business, could subject us to penalties and other adverse consequences.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the FCPA, which generally prohibits U.S. companies from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business and requires companies to maintain accurate books and records and internal controls. In addition, we are subject to the anti-bribery laws of other jurisdictions in which we conduct business. Our employees or other agents may engage in prohibited conduct without our knowledge under our policies and procedures and the FCPA and other anti-bribery laws that we may be subject to for which we may be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. federal income tax reform could adversely affect us.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 22, 2017, U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (TCJA), was signed into law, significantly reforming the U.S. Internal Revenue Code. The TCJA, among other things, includes changes to U.S. federal tax rates, imposes significant additional limitations on the deductibility of interest, allows for the expensing of capital expenditures, puts into effect the migration from a &#x201c;worldwide&#x201d; system of taxation to a territorial system and modifies or repeals many business deductions and credits.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The TCJA is a complex revision to the U.S. federal income tax laws with disparate and, in some cases, countervailing impacts on different categories of taxpayers and industries, and will require subsequent rulemaking and interpretation in a number of areas. The long-term impact of the TCJA on the overall economy, the industries in which we operate and our partners business cannot be reliably</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">predicted at this early stage of the new law&#x2019;s implementation. There can be no assurance that the TCJA will not negatively impact our operating results, financial condition, and future business operations. The estimated impact of the TCJA is based on our management&#x2019;s current knowledge and assumptions, following consultation with our tax advisors, and recognized impacts could be materially different from current estimates based on our actual results and our further analysis of the new law. The impact of the TCJA on holders of common stock is uncertain and could be materially adverse. This Annual Report does not discuss any such tax legislation or the manner in which it might affect investors in common stock. Investors should consult with their own tax advisors with respect to such legislation and the potential tax consequences of investing in common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to evolving and complex tax laws, which may result in additional liabilities and affect our results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to income taxes in the U.S. and other jurisdictions, and in the course of our business, we make judgments about the expected tax treatment of various transactions and events. Changes in tax laws, regulations, administrative practices, principles, and interpretations, as well as events that differ from our expectations, have affected and may adversely affect our effective tax rates, cash flows, and/or results of operations. Significant uncertainty currently exists regarding tax proposals introduced by the U.S., including modifications to certain aspects of the Tax Cuts and Jobs Act of 2017, such as the potential repeal or deferral of the provision requiring capitalization of research and development expenses. In addition, tax authorities in the U.S. and other jurisdictions in which we do business routinely examine our tax returns and are intensifying their scrutiny and examinations of profit allocations among jurisdictions, which could unfavorably impact our results of operations. Further actions taken with respect to tax-related matters by associations such as the Organization for Economic Co-operation and Development and the European Commission could influence tax laws in countries in which we operate. Modifications to key elements of the current U.S. or international tax framework could have a significant impact on our effective tax rate, results of operations, and cash flows.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The widespread outbreak of an illness or any other communicable disease, or any other public health crisis, could adversely affect our business, results of operations and financial condition.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The outbreak of the novel coronavirus (&#x201c;COVID-19&#x201d;) has negatively impacted the global economy, disrupted global supply chains, and created significant volatility and disruption of financial markets. The Company is closely monitoring developments related to the COVID-19 pandemic to assess its impact on the Company&#x2019;s business. It is possible that an extended period of global supply chain and economic disruption resulting from the COVID-19 pandemic could materially affect our results of operations and financial condition.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Under the Services Agreement with Sarissa Capital, we may rely on Sarissa Capital to assist in our strategic investing activity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 11, 2020, we entered into the Services Agreement pursuant to which Sarissa Capital provides substantial assistance to us in connection with our acquisition strategy. Pursuant to the terms of the Services Agreement, and subject to the limitations set forth therein, Sarissa Capital will, among other things: (i) assist Innoviva in the development of an overall acquisition and investment process and strategy; (ii) advise Innoviva on market trends, market dynamics and merger and acquisition activity; (iii) identify potential transaction targets; (iv) assist in due diligence of transaction targets and the negotiation and execution of transactions; (v) advise on the growth and operational plans, performance and integration of target companies once an investment or acquisition is made; and (vi) assist in the identification of director and officer candidates for target companies. The services are provided by Sarissa Capital personnel and we have limited or no ability to control the manner upon which the services are provided. In the event that Sarissa Capital fails to adequately perform the required services, our investment activity operations and financial performance may be negatively impacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our investment into the Partnership could subject us to various risks and uncertainties, any of which could impact our investment results and could materially and adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Historically, we have invested our cash reserves in short-term investments and marketable securities, primarily corporate notes, government securities, government agencies, and commercial papers. On December 11, 2020, we entered into the Partnership Agreement and invested $300 million of our cash reserves to be managed by Sarissa Capital as the investment manager to the Partnership.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we expect that a portion of our revenues will continue to be derived from our royalty management business, as a result of this investment, we may derive a material portion of our income from assets managed by Sarissa Capital. The investment strategy of Sarissa Capital will focus on a concentrated portfolio of &#x201c;long&#x201d; positions in publicly or privately traded securities (debt or equity) and derivatives of, and other financial instruments related to, each of the foregoing, specifically in the areas of healthcare, pharmaceuticals and biotechnology. The risks associated with this investment strategy may be substantially greater than the risks associated with traditional fixed-income investment strategies or other low-yield strategies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have limited rights to remove the general partner of the Partnership and do not have any right to participate in the management of the Partnership or the investment activity of Sarissa Capital. We are solely dependent on Sarissa Capital&#x2019;s management of our investment in the Partnership. We cannot provide assurance that Sarissa Capital will be successful in meeting our investment objectives. Unexpected market volatility or losses in the Partnership&#x2019;s securities portfolio could significantly and negatively affect our investment in the Partnership and therefore our investment results, financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Partnership Agreement limits our ability to withdraw our invested funds from the Partnership.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Partnership Agreement, subject to limited exceptions, we are not entitled to withdraw our funds invested in the Partnership until expiration of a &#x201c;lock-up&#x201d; period. Following the expiration of the lock-up period, we are able to make annual withdrawals subject to 25% gating provision such that we would receive our entire account in the Partnership over four fiscal quarters. Therefore, we are limited in our ability to obtain liquidity with respect to those funds and are further subjects to market fluctuations with respect thereto, particularly given the expected concentrated nature of the Partnership&#x2019;s portfolio.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sarissa Capital intends to continue to manage other third party capital and is not required to dedicate any minimum amount of time to the Partnership.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to managing the Partnership, Sarissa Capital, its principals and their affiliates may engage in investment and trading activities for their own accounts and/or for the accounts of third parties and is not required to afford the Partnership exclusivity or priority with respect to investment or trading activities. Affiliates of Sarissa Capital manage and expect to continue to manage other client accounts which have objectives similar to the Partnership. The Partnership Agreement does not include any specific obligations or requirements concerning allocation of time, effort or investment opportunities to us or impose any restriction on the nature or timing of investments for accounts that Sarissa Capital or its affiliates may manage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The price of our securities has been volatile and may continue to be so, and purchasers of our securities could incur substantial losses.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The price of our securities has been volatile and may continue to be so. Between January 1, 2022 and December 31, 2022, the high and low sales prices of our common stock as reported on The Nasdaq Global Select Market varied between $10.92 and $18.97 per share. The stock market in general and the market for biotechnology and biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the companies&#x2019; operating performance, in particular during the last several years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be unable to or elect not to return capital to our stockholders.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The payment of, or continuation of, capital returns to stockholders is at the discretion of our Board of Directors and is dependent upon our financial condition, results of operations, capital requirements, execution of our strategic initiatives, general business conditions, tax treatment of capital returns, potential future contractual restrictions contained in our credit agreement and other agreements and other factors deemed relevant by our Board of Directors. Future capital returns may also be affected by, among other factors: our views on potential future capital requirements for investments in acquisitions and our working capital and debt maintenance requirements; legal risks; stock or debt repurchase programs; changes in federal and state income tax laws or corporate laws; and changes to our business model. Our capital return programs may change from time to time, and we cannot provide assurance that we will continue to provide any particular amounts. Our announcement of future capital return programs does not obligate us to repurchase any specific dollar amount of debt or equity or number of shares of common stock. A reduction, suspension or change in our capital return programs could have a negative effect on our stock price.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Anti&#x2011;takeover provisions in our charter and bylaws and in Delaware law could prevent or delay a change in control of our company.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions of our Certificate of Incorporation and Bylaws may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions include:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requiring supermajority stockholder voting to effect certain amendments to our Certificate of Incorporation and Bylaws;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restricting the ability of stockholders to call special meetings of stockholders;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prohibiting stockholder action by written consent; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on by stockholders at meetings.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, some provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Unfavorable global economic and political conditions could adversely affect our business, financial condition or results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy, the global financial markets and the global political conditions. The United States and global economies are facing growing inflation, higher interest rates and potential recession. Portions of our future clinical trials may be conducted outside of the United States and unfavorable economic conditions resulting in the weakening of the United States dollar would make those clinical trials more costly to operate. Furthermore, a severe or prolonged economic downturn, including a recession or depression resulting from the current COVID-19 pandemic or political disruption such as the war between Ukraine and Russia could result in a variety of risks to our business, including weakened demand for our product candidates or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption, including any international trade disputes, could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our potential products. Any of the foregoing could seriously harm our business, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could seriously harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The enactment of proposed or future tax legislation may adversely impact our financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 16, 2022, President Biden signed the Inflation Reduction Act, or the IRA. The IRA contains a number of tax related provisions including a 15% minimum corporate income tax on certain large corporations as well as an exercise tax on stock repurchases, both provisions are effective for tax years beginning after December 31, 2022. We are in the process of evaluating the IRA to determine any impact on our financial condition and results of operations in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 1B.   UNRESOLVED STAFF COMMENTS</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 2.   PROPERTIES</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our headquarters consist of a lease of 2,111 square feet of office space in Burlingame, California, which expires in December 2023. Our other material leased property is a combination of office space and laboratory facility of approximately 20,000 square feet located in Waltham, Massachusetts, which expires in December 2025. We also have a smaller rented facility in Waltham, Massachusetts. We believe that these facilities are sufficient for our current operational needs and that suitable additional space will be available on commercially reasonable terms to accommodate expansion of our operations, if necessary.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 3.   LEGAL PROCEEDINGS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information called for by this Item is incorporated herein by reference in Item 8. &#x201c;Financial Statements and Supplementary Data,&#x201d; Note 13. &#x201c;Commitments and Contingencies&#x201d;.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 4.   MINE SAFETY DISCLOSURES</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p>
  <p style="text-indent:-9.17%;padding-left:8.4%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_5_market_for_registrant_s_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 5.   MARKET FOR REGISTRANT&#x2019;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock was traded on Nasdaq under the symbol &#x201c;THRX&#x201d; from October 5, 2004 until January 8, 2016. Upon changing our corporate name to Innoviva, Inc. on January 7, 2016, we changed the stock ticker symbol to &#x201c;INVA&#x201d; effective January 11, 2016.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 14, 2023, there were 64 stockholders of record of our common stock. As many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of Equity Securities by the Issuer</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table reflects share repurchases of our common stock for the three months ended December 31, 2022:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:30.157%;"></td>
    <td style="width:1.646%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.131%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.646%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.11%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.646%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.379999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.646%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:18.637999999999998%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Number of Shares Purchases</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Average Price Paid per Share</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 1, 2022 to October 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 1, 2022 to November 30, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 1, 2022 to December 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">647,394</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.13</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">647,394</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,496,562</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">647,394</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.13</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">647,394</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,496,562</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 31, 2022, the Board of Directors of Innoviva authorized and approved a stock repurchase program pursuant to which we may purchase up to $100.0 million of our outstanding common stock. The timing and amount of any share repurchases under the share repurchase program will be determined by Innoviva&#x2019;s management in its discretion based on ongoing assessments of the capital needs of the business, the market price of Innoviva&#x2019;s common stock, prevailing stock prices, general market conditions and other considerations. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. This program has no termination date, may be suspended or discontinued at any time at the Company&#x2019;s discretion and does not obligate the Company to acquire any amount of common stock.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The graph set forth below compares the cumulative total stockholder return on our common stock for the period commencing on December 31, 2017 and ending on December 31, 2022, with the cumulative total return of (i) the Nasdaq Composite Index, (ii) the Nasdaq S&amp;P Small Cap 600 Pharma Index and (iii) the Nasdaq Biotechnology Index over the same period. This graph assumes the investment of $100.00 on December 31, 2017 in each of (1) our common stock, (2) the Nasdaq Composite Index, (3) the Nasdaq S&amp;P Small Cap 600 Pharma Index and (4) the Nasdaq Biotechnology Index, and assumes the reinvestment of dividends.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The comparisons shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock. Information used in the graph was obtained from sources believed to be reliable including Nasdaq, Bloomberg and Reuters, but we are not responsible for any errors or omissions in such information.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, that might incorporate this Annual Report on Form 10&#x2011;K or future filings made by us under those statutes, this Stock Performance Graph section shall not be deemed filed with the SEC and shall not be deemed incorporated by reference into any of those prior filings or into any future filings made by us under those statutes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Among Innoviva, Inc., the Nasdaq Composite Index, Nasdaq Biotechnology Index, and Nasdaq S&amp;P Small Cap 600 Pharma Index.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img11029722_14.jpg" alt="img11029722_14.jpg" style="width:720px;height:398px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*    $100 invested on December 31, 2017 in stock or index, including reinvestment of dividends.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 6.   [</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.17%;padding-left:8.4%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_7_management_s_discussion_and"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 7.   MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis (&#x201c;MD&amp;A&#x201d;) is intended to facilitate an understanding of our business and results of operations. This discussion and analysis should be read in conjunction with our consolidated financial statements and notes included in this Annual Report on Form 10&#x2011;K. The information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10&#x2011;K, including information with respect to our plans and strategy for our business, our operating expenses, and future payments under our collaboration agreements, includes forward&#x2011;looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based upon current expectations that involve risks and uncertainties. You should review the section entitled &#x201c;Risk Factors&#x201d; in Item 1A of Part I above for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward&#x2011;looking statements contained in the following discussion and analysis. See the section entitled &#x201c;Special Note Regarding Forward Looking Statements&#x201d; above for more information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management Overview</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Innoviva, Inc. (referred to as &#x201c;Innoviva&#x201d;, the &#x201c;Company&#x201d;, the &#x201c;Registrant&#x201d; or &#x201c;we&#x201d; and other similar pronouns) is a company with a portfolio of royalties and innovative healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#x201c;GSK&#x201d;), including RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (fluticasone furoate/vilanterol, &#x201c;FF/VI&#x201d;) and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (umeclidinium bromide/vilanterol, &#x201c;UMEC/VI&#x201d;), and up until July 2022, TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the combination FF/UMEC/VI). We sold our 15% ownership interest in Theravance Respiratory Company, LLC (&#x201c;TRC&#x201d;) on July 20, 2022, and are no longer entitled to receive royalties on sales of TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> products. Under the Long&#x2011;Acting Beta2 Agonist (&#x201c;LABA&#x201d;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion; and royalties from the sales of ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which tier upward at a range from 6.5% to 10%.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expanded our portfolio of royalties and innovative healthcare assets through the acquisition of Entasis Therapeutics Holdings Inc. (&#x201c;Entasis&#x201d;) on July 11, 2022 and the acquisition of La Jolla Pharmaceutical Company (&#x201c;La Jolla&#x201d;) on August 22, 2022. Following the acquisitions, our commercial and marketed products include GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (eravacycline) for the treatment of complicated intra-abdominal infections in adults, and our development pipeline includes medicines for the treatment of bacterial infections, such as our lead asset sulbactam-durlobactam (&#x201c;SUL-DUR&#x201d;). As such, we have a wholly owned robust infectious disease and hospital operating platform as well as other assets in these therapeutic areas, such as a large equity stake in Armata Pharmaceuticals, a leader in bacteriophage development with potential use across a range of infectious and other serious diseases. We also have economic interests in other healthcare companies.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our company structure and organization are tailored to our focused activities of managing our respiratory assets partnered with GSK, commercializing our marketed products, developing of our product candidates, optimizing capital allocation, and providing for certain essential reporting and management functions of a public company. As of December 31, 2022, we had 101 employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Highlights</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the year ended December 31, 2022, the net income attributable to Innoviva stockholders was $213.9 million, a decrease of $52.0 million from net income attributable to Innoviva stockholders of $265.9 million in the year ended December 31, 2021. The lower net income was mainly driven by the decrease in fair values of equity and long-term investments, including $153.2 million in unrealized loss, and the decrease in our royalty revenues. These decreases were partially offset by a gain of $266.7 million recognized from the sale of TRC. Cash and cash equivalents totaled $291.0 million, and royalty and product sales receivable was $64.1 million as of December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate Updates</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 11, 2022, we completed the purchase of all of the issued and outstanding equity securities of Entasis not already owned by Innoviva for $42.4 million in cash consideration. Entasis brings to Innoviva an infectious disease focused research and development platform anchored by its lead asset SUL-DUR.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 20, 2022, we completed the sale of our 15% ownership interest in TRC to Royalty Pharma Investments 2019 ICAV (&#x201c;Royalty Pharma&#x201d;) for $282.0 million, including payment for our portion of TRC&#x2019;s cash balance of $4.4 million, and a potential $50.0 million sales-based milestone payments. We also received full ownership of equity and other investments that TRC owned prior to the transaction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 22, 2022, we completed the acquisition of La Jolla for a net cash price of $150.5 million. La Jolla brings to Innoviva an established product portfolio, including GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (eravacycline) for the treatment of complicated intra-abdominal infections in adults.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 31, 2022, our Board of Directors authorized a new share repurchase program under which we may repurchase up to $100.0 million of Innoviva's outstanding shares of common stock. The timing and amount of any share repurchases under the share repurchase program will be determined by our management in its discretion based on ongoing assessments of the capital needs of the business, the market price of Innoviva&#x2019;s common stock, prevailing stock prices, general market conditions and other considerations. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. This program has no termination date, may be suspended or discontinued at any time at our discretion and does not obligate us to acquire any amount of common stock. As of December 31, 2022, we have repurchased and retired 647,394 shares in the open market for total price of approximately $8.5 million. Subsequent to December 31, 2022 and through February 24, 2023, we have repurchased 1,522,947 shares in the open market for a total amount of approximately $19.2 million. All the repurchased shares were retired.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical Updates</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 30, 2022, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) granted priority review for SUL-DUR, an investigational drug for the treatment of infections caused by Acinetobacter </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">baumannii-calcoaceticus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> complex (&#x201c;ABC&#x201d;), including multi-drug resistant and carbapenem-resistant strains.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA is currently planning to hold an advisory committee meeting to discuss this New Drug Application. The target PDUFA date (or action date) is May 29, 2023.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the annual meeting of the Infectious Disease Society of America which took place from October 19 to October 23, 2022 in Washington, D.C., Entasis Therapeutics, a wholly owned subsidiary of the Company, had six presentations on SUL-DUR, reinforcing the positive safety and efficacy findings from the Company&#x2019;s pivotal Phase 3 ATTACK trial.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, at the same annual meeting of the Infectious Disease Society of America, La Jolla Pharmaceutical, another wholly owned subsidiary of the Company, had five abstracts on XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> focused primarily on its use in combination therapies.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrollment in the phase 3 registrational trial for zoliflodacin, a first-in-class oral antibiotic for the treatment of gonorrhea being developed in partnership with GARD-P, remains on track, and study completion is anticipated in 2023. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaborative Arrangements with GSK</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">LABA Collaboration</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2002, we entered into the LABA Collaboration Agreement with GSK to develop and commercialize once&#x2011;daily LABA products for the treatment of chronic obstructive pulmonary disorder (&#x201c;COPD&#x201d;) and asthma (the &#x201c;LABA Collaboration Agreement&#x201d;). For the treatment of COPD, the collaboration has developed three combination products:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;FF/VI&#x201d;) (BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is the proprietary name in the U.S. and Canada and RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is the proprietary name outside the U.S. and Canada), a once&#x2011;daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (&#x201c;ICS&#x201d;), fluticasone furoate (&#x201c;FF&#x201d;),</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;UMEC/VI&#x201d;), a once&#x2011;daily medicine combining a long&#x2011;acting muscarinic antagonist (&#x201c;LAMA&#x201d;), umeclidinium bromide (&#x201c;UMEC&#x201d;), with a LABA, vilanterol (VI), and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the combination FF/UMEC/VI), a once&#x2011;daily combination medicine consisting of an ICS, LAMA and LABA.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the launch and approval of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the U.S., Japan and Europe, in accordance with the LABA Collaboration Agreement, we paid milestone fees to GSK totaling $220.0 million during the year ended December 31, 2014. Although we have no further milestone payment obligations to GSK pursuant to the LABA Collaboration Agreement, we continue to have ongoing commercialization activities under the LABA Collaboration Agreement, including participation in the joint steering committee that are expected to continue over the life of the agreement. The milestone fees paid to GSK were recognized as capitalized fees paid, which are being amortized over their estimated useful lives commencing upon the commercial launch of the products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are entitled to receive royalties from GSK on sales of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion. On sales of ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, royalties are upward tiering and range from 6.5% to 10%. We no longer receive royalties on sales of TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> after we sold our royalty rights along with the sale of our ownership in TRC in July 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Strategic Partnership with Sarissa Capital</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Strategic Advisory Agreement</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 11, 2020, we entered into a Strategic Advisory Agreement (the &#x201c;Services Agreement&#x201d;) with Sarissa Capital Management LP (&#x201c;Sarissa Capital&#x201d;), pursuant to which Sarissa Capital provides a variety of strategic services to us in order to assist us in the development and execution of our acquisition strategy. The services are provided free of charge to us. Sarissa Capital is considered to be a related party due to its investment in Innoviva's common stock and its representation on our board of directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Partnership Agreement</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 11, 2020, Innoviva Strategic Partners LLC (&#x201c;Strategic Partners&#x201d;), our wholly owned subsidiary, entered into a subscription agreement (the &#x201c;Subscription Agreement&#x201d;) and an Amended and Restated Limited Partnership Agreement (the &#x201c;Partnership Agreement&#x201d;) pursuant to which Strategic Partners became a limited partner of ISP Fund LP (the &#x201c;Partnership&#x201d;). The general partner of the Partnership (the &#x201c;General Partner&#x201d;) is an affiliate of Sarissa Capital and, pursuant to an investment management agreement, Sarissa Capital acts as the investment adviser to the Partnership. Strategic Partners made a $300.0 million initial contribution into the Partnership. The Partnership was formed for the purposes of investing in equity securities in the healthcare, pharmaceutical and biotechnology industries. The Partnership Agreement provides for Sarissa Capital to receive a customary one percent management fee from the Partnership, payable quarterly in advance, measured based on the Net Asset Value of Strategic Partners&#x2019; capital account in the Partnership. In addition, the General Partner is entitled to a customary 10% annual performance allocation based on the Net Profits of the Partnership during the annual measurement period. The Partnership Agreement includes a lock-up period of thirty-six months after which Strategic Partners is entitled to make withdrawals from the Partnership as of such lock-up expiration date and each anniversary thereafter, subject to certain limitations.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, Strategic Partners received a distribution of $110.0 million from the Partnership to provide funding to Innoviva for a strategic repurchase of Innoviva common shares held by GSK. On March 30, 2022, Strategic Partners made an additional capital contribution of $110.0 million to the Partnership pursuant to the letter agreement entered into between Strategic Partners, the Partnership and Sarissa Capital Fund GP LP on May 20, 2021. The capital contribution is subject to a 36-month lock up period from the contribution date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management&#x2019;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#x2019;s judgments and estimates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business Combinations</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We use the acquisition method of accounting under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 805, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business Combinations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Each acquired company&#x2019;s operating results are included in our consolidated financial statements starting on the acquisition date. The purchase price is equivalent to the fair value of consideration transferred. Tangible and identifiable intangible assets acquired, liabilities assumed and any noncontrolling interest in the acquiree as of the acquisition date are recorded at the acquisition date fair value. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Amounts allocated to assets and liabilities are based upon fair values. Such valuations require us to make significant estimates and assumptions, especially with respect to the identifiable intangible assets. We make estimates of fair value based upon assumptions believed to be reasonable and that of a market participant. Significant estimates and assumptions may involve projected future revenues, earnings, cash flows, estimated probabilities of certain milestone achievements, discount rates, asset lives, among other items. Our estimates may also impact our deferred tax assets and liabilities. Unanticipated events and circumstances may occur that may affect the accuracy and validity of such assumptions, estimates or actual results. Our estimates are based on available historical information as well as future expectations, and the estimates are inherently uncertain. The separately identifiable intangible assets generally include marketed products, in-process research and development and collaboration agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition from Royalties</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize the royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on its methodology and assumptions to estimate rebates and returns, which it monitors and adjusts regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Our partner may make significant adjustments to its sales based on actual results recorded, which could cause our royalty revenue to fluctuate. We conduct periodic royalty audits to evaluate the information provided by our partner. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition from Product Sales</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We started recognizing revenue from product sales as a result of our acquisition of La Jolla. We apply the guidance on principal versus agent considerations under ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includ</span><span style="background-color:rgba(0,0,0,0);color:rgba(37,37,37,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">es being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.</span><span style="color:rgba(37,37,37,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to recognizing any revenue from product sales, we identify the contract, performance obligations, and transaction price, and allocate the transaction price to the performance obligations. Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#x2019; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#x201c;GPO&#x201d;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state&#x2019;s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Capitalized Fees Paid</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We review our Capitalized Fees for impairment on a product&#x2011;by&#x2011;product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#x2019;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#x2019;s residual value, if any. We derive the required cash flow estimates from near&#x2011;term forecasted product sales and long&#x2011;term projected sales in the corresponding market. Based upon our analyses of past, current and future sales and trends, there have been no indicators of impairment and no impairment charges have been recorded on the Capitalized Fees as of December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Variable Interest Entities</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary beneficiary of a variable interest entity (&#x201c;VIE&#x2019;) is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. To determine whether a variable interest that we hold could potentially be significant to the VIE, we consider both qualitative and quantitative factors regarding the nature, size and form of our involvement with the VIE.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#x2019;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#x2019;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity and Long-Term Investments</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We hold Series C preferred stock and preferred stock warrants in InCarda Therapeutics Inc. (&#x201c;InCarda&#x201d;), a privately held, clinical-stage biopharmaceutical company. The Series C preferred stock and warrants are classified as Level 3 financial instruments and recorded at fair value subject to remeasurement at each balance sheet date. We use the Black-Scholes-Merton pricing model to estimate the fair value of the warrants with the following input assumptions: the exercise price of the warrants, the risk-free interest rate computed based on the U.S. Treasury yield, the remaining contractual term as the expected term, and the expected stock price volatility calculated based on the historical volatility of the common stock of its public peer companies.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our other Level 3 financial instruments include the Gate Neurosciences Inc. (&#x201c;Gate&#x201d;) convertible promissory note and private placement positions held by ISP Fund LP as these securities are not publicly traded and the assumptions used in the valuation model for valuing these securities are based on significant unobservable and observable inputs including those of publicly traded peer companies. We measure the Gate convertible promissory note at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of equity value of Gate, risk-free rate, expected stock price, volatility of its peer companies, and the time until a financing is raised. Valuations models applied for the private placement positions held by ISP Fund LP may include the Black-Scholes-Merton pricing model, the Monte Carlo simulation model and other applicable valuation models. Key assumptions involve inputs to the Black-Scholes-Merton pricing model, probability rates of certain events and scenarios applied in the Monte Carlo simulation model and discount rates, as appropriate. </span><span style="background-color:rgba(0,0,0,0);color:rgba(37,37,37,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Monte Carlo simulation model also incorporates assumptions made based on transaction details such as the security's stock price, the expected term, maturity, risk-free interest rates and dividend yield, as well as volatility.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Factors Affecting Comparability</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adoption of Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06 effective January 1, 2022;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining noncontrolling interest in Entasis on July 11, 2022; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sale of our 15% ownership interest in TRC on July 20, 2022; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisition of La Jolla on August 22, 2022.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refer to Note 1, &#x201c;Description of Operations and Summary of Significant Accounting Policies&#x201d;, to the Consolidated Financial Statements for more information related to the adoption of ASU 2020-06. Refer to Note 5, &#x201c;Consolidated Entities and Acquisitions&#x201d;, to the Consolidated Financial Statements for more information related to our acquisitions of Entasis and La Jolla and the sale of our ownership interest in TRC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Revenue</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalty Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net revenue from GSK, as compared to the prior years, was as follows:</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:28.71%;"></td>
    <td style="width:1.202%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.09%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.202%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.09%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.202%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.09%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.202%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.654%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.3580000000000005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.202%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.654%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.348%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties - RELVAR/BREO</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">215,034</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234,066</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">221,536</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(19,032</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(8</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,530</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties - ANORO</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,405</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,935</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,992</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(6,530</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(15</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,057</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties - TRELEGY</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,029</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,688</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73,089</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(54,659</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(43</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,599</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total royalties</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">325,468</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">405,689</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">340,617</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(80,221</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(20</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,072</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: amortization of capitalized<br />&#160;&#160;&#160;fees paid</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(13,823</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(13,823</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(13,823</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalty revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">311,645</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">391,866</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">326,794</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(80,221</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(20</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,072</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Strategic alliance - MABA program</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(10,000</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net royalty revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">311,645</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">391,866</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">336,794</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(80,221</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(20</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,072</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*    Not Meaningful</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net revenue decreased to $311.6 million for the year ended December 31, 2022, compared to the year ended December 31, 2021. The decrease in total net royalty revenue was primarily due to the sale of our ownership interest in TRC, which received royalties stemming from sales of TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Royalties for RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased due to pricing pressures in the U.S. market and foreign currency rate changes.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net revenue increased to $391.9 million for the year ended December 31, 2021, compared to the year ended December 31, 2020. Royalties for RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> increased due to favorable adjustments, increased patient adherence and continued volume growth in certain markets. ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> decreased slightly mainly due to the increasing pricing pressure in the U.S. Royalties for TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were higher due to the continued growth in triple therapy class and expanded sales in new markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Product Sales</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net product sales we recognized from the date of acquisition of La Jolla, which occurred on August 22, 2022, to December 31, 2022 was $19.7 million, consisting of net sales of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for $14.2 million and $5.5 million, respectively. We derived approximately 96% of our net product sales for the same period from customers located in the U.S. and 4% for the rest of the world.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research &amp; Development</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses, as compared to the prior year period, were as follows:</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:26.159%;"></td>
    <td style="width:1.102%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.581%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.102%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.581%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.102%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.581%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.102%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.183%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.102%;"></td>
    <td style="width:9.442%;"></td>
    <td style="width:1.102%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.025%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.840999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="12" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,432</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">576</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,788</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,856</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,212</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(68</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*    Not Meaningful</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses consisted of the following:</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:25.673%;"></td>
    <td style="width:1.006%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.723%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.723%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.723%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.686%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.098%;"></td>
    <td style="width:9.05%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.529999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.807%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="12" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">External services</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,666</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">576</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,788</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,090</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,212</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(68</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation and related personnel costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,863</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,863</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facilities related</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,255</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,255</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">648</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">648</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,432</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">576</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,788</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,856</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,212</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(68</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*    Not Meaningful</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses for the year ended December 31, 2022 were mainly attributable to Entasis&#x2019; product development efforts for our lead product candidate, SUL-DUR. External services costs consist primarily of fees paid to consultants, contractors and contract manufacturing organizations.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses for the years ended December 31, 2021 and 2020 were attributable to the product development efforts of Pulmoquine Therapeutics Inc., which was dissolved at the end of 2021.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Selling, General &amp; Administrative</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative expenses, as compared to the prior years, were as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:26.279%;"></td>
    <td style="width:1.116%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.624%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.107%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.624%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.107%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.624%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.107%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.862%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.7909999999999995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.107%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.862%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.781999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,538</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,187</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,883</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,351</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">293</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,304</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative expenses increased by $47.4 million for the year ended December 31, 2022, compared to the year ended December 31, 2021, mainly attributable to the consolidation of Entasis' operating expenses starting February 17, 2022 and the consolidation of La Jolla&#x2019;s operating expenses starting August 22, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative expenses increased by $2.3 million for the year ended December 31, 2021, compared to the year ended December 31, 2020, mainly attributable to increased business development activities and higher legal expenses incurred for the arbitration between Theravance Biopharma, the Company and TRC. The legal costs for the years ended December 31, 2021 and 2020 were $3.3 million and $1.7 million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest and Dividend Income and Other Expense, Net</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest and dividend income and other expense, net, as compared to the prior years, were as follows:</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:27.353%;"></td>
    <td style="width:1.165%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.358%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.156%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.348999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.156%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.348999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.156%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.840999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.617000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.156%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.840999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.506%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest and dividend income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(6,369</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,839</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,524</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4,530</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">246</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(315</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,373</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,626</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">348</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(253</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(7</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,278</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*    Not Meaningful</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest and dividend income increased for the year ended December 31, 2022, compared to the year ended December 31, 2021, due to higher interest rates and higher average balances of our cash equivalents, money market funds and other interest-bearing investments. Other expense, net, primarily consisted of expenses incurred by ISP Fund LP.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest and dividend income increased for the year ended December 31, 2021, compared to the year ended December 31, 2020, primarily due to higher returns on investments, including those managed by ISP Fund LP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Expense</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense, as compared to the prior years, was as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:27.409%;"></td>
    <td style="width:1.168%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.378%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.158%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.369%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.158%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.369%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.158%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.859%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.6370000000000005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.158%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.655%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.5249999999999995%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,789</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,070</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,331</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3,281</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(17</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">739</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The change in interest expense for the year ended December 31, 2022, compared to the year ended December 31, 2021, was primarily due to the adoption of ASU 2020-06, which simplifies the accounting for convertible debt instruments. As a result of the adoption, the debt discount associated with the cash settlement feature of our convertible senior notes due 2025 (the &#x201c;2025 Notes&#x201d;) was adjusted to zero as of January 1, 2022. Interest expense for the year ended December 31, 2022 included the contractual interest expense and the amortization of debt issuance costs for our convertible subordinated notes due 2023 (the &#x201c;2023 Notes&#x201d;), the 2025 Notes and our convertible senior notes due 2028 (the &#x201c;2028 Notes&#x201d;). Interest expense for the year ended December 31, 2021 included the amortization of debt discount in addition to the contractual interest expense and the amortization of debt issuance costs for our 2023 Notes and 2025 Notes. The decrease in interest expense as a result of the adoption of ASU 2020-06 was partially offset by a higher debt balance and interest expense incurred for the deferred royalty obligation from the acquisition of La Jolla.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense increased slightly for the year ended December 31, 2021, compared to the year ended December 31, 2020, due to more debt discount and issuance costs being recognized through amortization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Loss on Debt Extinguishment</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognized a loss of $20.7 million due to the total premium payment of $20.4 million and the write-off of $0.3 million debt issuance costs in connection with the repurchase of $144.8 million aggregate principal amount of our 2023 Notes in March 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Gain on Sale of TRC</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognized a net gain of $266.7 million due to the sale of our ownership interest in TRC to Royalty Pharma, consummated on July 20, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in Fair Values of Equity Method Investments and Other Equity and Long-Term Investments</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair values of equity method investments, net, and other equity and long-term investments, net, as compared to the prior years, were as follows:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:27.353%;"></td>
    <td style="width:1.165%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.358%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.156%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.348999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.156%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.348999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.156%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.840999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.617000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.156%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.840999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.506%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair values of equity<br />&#160;&#160;&#160;method investments, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161,749</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(84,392</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(49,511</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">246,141</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(292</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(34,881</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair values of other<br />&#160;&#160;&#160;equity and long-term <br />&#160;&#160;&#160;investments, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(8,462</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(6,638</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(766</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,824</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(5,872</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">767</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:13.158%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The changes in fair values of equity method investments and other equity and long-term investments year over year reflect the realized gains and losses and net unrealized gains and losses in our strategic investments in Armata, InCarda, and Gate, and those investments managed by ISP Fund LP.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The changes in fair values of equity method investments are attributed mainly to changes in the fair value of our investments in Armata and Entasis. We recorded $152.5 million in unrealized losses, $78.7 million in unrealized gains and $19.0 million in unrealized gains associated with our Armata investments for the years ended December 31, 2022, 2021 and 2020, respectively. The unrealized gains or losses on our investments in Armata is driven primarily by the share price changes of its publicly traded security. The amounts for the years ended December 31, 2022, 2021 and 2020 also include $9.2 million in unrealized losses, $5.7 million in unrealized gains and $30.5 million in unrealized gains, respectively, we recorded from our then investments in Entasis. Refer to Note 6, &#x201c;Equity and Long-Term Investments and Fair Value Measurements&#x201d;, to the Consolidated Financial Statements for more information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The changes in fair values of other equity and long-term investments year over year reflect the realized gains and losses and net unrealized gains and losses in our strategic investments in InCarda, Gate, and those investments managed by ISP Fund LP.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense, net, as compared to the prior years, was as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:27.409%;"></td>
    <td style="width:1.168%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.378%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.158%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.369%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.158%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.369%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.158%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.859%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.6370000000000005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.158%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.655%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.5249999999999995%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,687</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,439</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,431</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(9,752</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(13</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,008</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, 2021 and 2020, we had net operating loss carryforwards for federal income taxes of $411.5 million, $92.9 million and $361.5 million, respectively. As of December 31, 2022, 2021 and 2020, we also had state net operating loss carryforwards of approximately $955.3 million, $648.6 million and $650.7 million, respectively, which will expire beginning 2029. As of December 31, 2022, 2021 and 2020, we had federal research and development tax credit carryforwards of nil, $42.1 million, and $43.6 million, respectively. As of December 31, 2022, we had state research and development tax credits of $33.3 million.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022, 2021 and 2020, we recognized $66.7 million, $76.4 million and $60.4 million of income tax expense, respectively, mainly based on the taxable income generated during those years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We had total unrecognized tax benefits of $16.3 million as of December 31, 2022. Our total unrecognized tax benefits as of December 31, 2021 and December 31, 2020 were $14.9 million and $15.2 million, respectively.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Utilization of net operating loss and tax credit carryforwards is subject to rules, provided by the Internal Revenue Code and similar state provisions, governing annual limitations tied to ownership changes. We conducted an analysis of the Company through December 31, 2022 to determine whether an ownership change had occurred since inception. The study concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. However, notwithstanding the applicable annual limitations, we estimate that no portion of our net operating loss or credit carryforwards will expire before becoming available to reduce federal and state income tax liabilities. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized. If we undergo another ownership change, the utilization of the pre-ownership change net operating loss carryforwards or pre-ownership change tax attributes, such as research tax credits, to offset the post-ownership change income may be subject to an annual limitation, pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. Similar rules may apply under state tax laws.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the acquisition of Entasis, we conducted a study of Entasis&#x2019; ownership changes and estimated that we will be able to utilize $157.4 million of its federal net operating losses, which are subject to annual limitations.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the acquisition of La Jolla, we also performed a preliminary analysis of its ownership changes and estimated that we will be able to utilize $254.0 million of its federal net operating losses, which are subject to annual limitations. <br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Income Attributable to Noncontrolling Interests</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to noncontrolling interests, as compared to the prior years, was as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:27.409%;"></td>
    <td style="width:1.168%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.378%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.158%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.369%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.158%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.369%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.158%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.859%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.6370000000000005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.158%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.655%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.5249999999999995%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to<br />&#160;&#160;&#160;noncontrolling interest</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,341</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102,983</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,412</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(96,642</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(94</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,571</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   The year ended December 31, 2022 represents the period from the initial date of consolidation of Entasis on February 17, 2022 to the date of the acquisition of Entasis on July 11, 2022, and the period from January 1, 2022 through the date of the sale of our ownership interest in TRC on July 20, 2022.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to noncontrolling interests for the year ended December 31, 2022 was $6.3 million compared to $103.0 million, a decrease of $96.6 million, which was mainly due to lower net income attributable to the sale of our ownership interest in TRC, offset with net loss attributable to Entasis&#x2019; noncontrolling interest.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to noncontrolling interests during the years ended December 31, 2021 and 2020 represents the 85% share of net income in Theravance Respiratory Company, LLC for Theravance Biopharma. The year over year increase from 2020 to 2021 was primarily due to the growth in prescriptions and market share for TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception, we have financed our operations primarily through private placements and public offerings of equity and debt securities and payments received under collaborative arrangements. For the year ended December 31, 2022, we generated gross royalty revenues of $325.5 million and net product sales revenues of $19.7 million. Cash and cash equivalents totaled $291.0 million, royalties receivable from GSK totaled $54.7 million and accounts receivable associated with our product sales totaled $9.4 million, as of December 31, 2022.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had three outstanding convertible notes, the 2023 Notes, the 2025 Notes and the 2028 Notes, in an aggregate principal amount of $549.7 million, of which $96.2 million matured and was fully paid in January 2023. The remainder amounts of $192.5 million and $261.0 million will become due in August 2025 and March 2028, respectively. Future interest payments associated with these notes total $46.0 million.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 31, 2022, our Board of Directors authorized a new share repurchase program under which we may repurchase up to $100.0 million of Innoviva's outstanding shares of common stock. As of December 31, 2022, we have repurchased Innoviva common stock in the open market for total price of approximately $8.5 million. This program has no termination date, may be suspended or discontinued at any time at our discretion and does not obligate us to acquire any amount of common stock.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, Strategic Partners received a distribution of $110.0 million from the Partnership to provide funding to Innoviva for a strategic repurchase of Innoviva common shares held by GSK. On March 30, 2022, Strategic Partners made an additional capital contribution of $110.0 million to the Partnership pursuant to the letter agreement entered into between Strategic Partners, the Partnership and Sarissa Capital Fund GP LP on May 20, 2021. The capital contributions will then be subject to a 36-month lock up period from the contribution date.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adequacy of Cash Resources to Meet Future Needs</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our cash and cash equivalents will be sufficient to meet our anticipated debt service and operating needs, as well our ongoing share repurchase program, for at least the next 12 months based upon current operating plans and financial forecasts. Our long-term capital requirements will depend on many factors including the amount of our royalty revenues, sales growth of our currently marketed products, timing of regulatory approval of our product candidates and outcome of our acquisitions and strategic investments.  If our current operating plans and financial forecasts change, we may require additional funding sooner in the form of public or private equity offerings or debt financings. Furthermore, if in our view favorable financing opportunities arise, we may seek additional funding in the form of public or private equity offerings or debt financings at any time. However, future financing may not be available in amounts or on terms acceptable to us, if at all. This could leave us without adequate financial resources to fund our operations as currently planned. In addition, from time to time we may restructure or reduce our debt, including through privately negotiated repurchases, tender offers, redemptions, amendments, or otherwise, all allowable with the terms of our debt agreements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows, as compared to the prior years, were as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:31.822%;"></td>
    <td style="width:1.332%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.212000000000002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.341%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.221%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.341%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.415%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.341%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.221%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.341%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.415%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">201,726</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">363,813</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">313,113</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(162,087</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,700</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(56,634</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,722</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(314,937</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(100,356</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">358,659</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(55,568</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(452,497</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(29,785</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">396,929</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(422,712</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows from Operating Activities</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash provided by operating activities for the year ended December 31, 2022 was $201.7 million, consisting primarily of our net income of $220.3 million and net changes in operating assets and liabilities of $6.9 million, partially offset by net non-cash items of  $25.4 million. Non-cash items included a net gain of $266.7 million recognized on the sale of TRC, partially offset by total non-cash charges of $241.3 million. Non-cash charges included a $153.3 million net decrease in fair values of equity method investments and other equity and long-term investments, $25.0 of deferred income taxes, $13.9 million of amortization of capitalized fees and depreciation of property and equipment and $5.6 million in amortization of acquired intangible assets, $20.7 million in loss on the extinguishment of debt, $7.3 million in stock-based compensation expense, $10.0 million in inventory fair value adjustments included in cost of products sold and $2.1 million in the amortization of debt discount and issuance costs. The changes in operating assets and liabilities included an increase in prepaid expenses of $21.4 million, a decrease in receivables from collaboration arrangements of $13.3 million and increases of $11.9 million and $10.0 million in accrued personnel-related expenses and other accrued liabilities and in income tax payable, respectively.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash provided by operating activities for the year ended December 31, 2021 was $363.8 million, consisting primarily of our net income of $368.8 million, adjusted for non-cash items such as $76.4 million of deferred income taxes, $13.8 million of depreciation and amortization, $9.1 million amortization of debt discount and issuance costs, $2.0 million of stock-based compensation expense, partially offset by a $89.3 million net increase in fair values of equity method investments and other equity and long-term investments and an increase in receivables from collaborative arrangements of $16.8 million.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash provided by operating activities for the year ended December 31, 2020 was $313.1 million, consisting primarily of our net income of $293.8 million, adjusted for non-cash items such as $60.4 million of deferred income taxes, $13.8 million of depreciation and amortization, $8.4 million amortization of debt discount and issuance costs, $1.7 million of stock-based compensation expense, partially offset by a $50.3 million increase in fair values of equity method investments and other equity and long-term investments and an increase in receivables from collaborative arrangements of $14.5 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows from Investing Activities</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities for the year ended December 31, 2022 of $56.6 million included $159.1 million in cash paid for the acquisition of La Jolla, net of cash acquired, $58.7 million in purchases of equity and long-term investments, $60.9 million in purchases of equity investments managed by ISP Fund LP, $50.0 million in purchases of a trading security managed by ISP Fund LP and $23.4 million in net purchases and sales of other investments managed by ISP Fund LP. Net cash used in investing activities was partially offset by $248.2 million in net proceeds from the sale of our ownership interest in TRC, $24.3 million in sales of equity investments managed by ISP Fund LP and $23.1 million in cash acquired through the consolidation of Entasis.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by investing activities for the year ended December 31, 2021 of $43.7 million was primarily due to $110.0 million net cash inflow from $301.0 million sales and $191.0 million purchases of equity and other investments managed by ISP Fund LP, offset by $66.3 million in purchases of various investment instruments including, but not limited to, common stock, warrants, convertible debt investment, money market funds and other securities.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities for the year ended December 31, 2020 of $314.9 million was primarily due to $300.0 million in the purchases of equity and other investments managed by ISP Fund LP and $100.9 million in purchases of common stock, warrants, money market funds, and other securities, offset by $86.0 million of proceeds received from maturities of marketable securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows from Financing Activities</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in financing activities for the year ended December 31, 2022 of $55.6 million included $165.1 million for the repurchase of convertible subordinated notes due 2023, $69.8 million in distributions to noncontrolling interest, $43.9 million for the purchase of Entasis noncontrolling interest, $21.0 million for purchases of capped call options associated with our 2028 Notes and $8.5 million for the repurchase of common stock. Net cash used in financing activities was partially offset by $252.5 million in net proceeds from the issuance of our 2028 Notes.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in financing activities for the year ended December 31, 2021 of $452.5 million was primarily due to a $394.1 million repurchase of our common stock from GSK and $59.5 million in distributions to noncontrolling interest.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in financing activities for the year ended December 31, 2020 of $29.8 million was primarily due to $30.5 million distributions to noncontrolling interest.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contractual Obligations</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, we completed a private placement of $261.0 million aggregate principal amount of unsecured convertible senior notes, the 2028 Notes, which will mature on March 15, 2028. Under the terms of the 2028 Notes, we will make interest payments of approximately 2.125% of outstanding principal. The principal balance of $261.0 million will become due in March 2028. As of December 31, 2022, our notes payable obligation also included $96.2 million related to our 2023 Notes, which matured and was fully paid in January 2023 and $192.5 million related to our 2025 Notes which are due in 2025. Under the term of the 2025 Notes, we will make interest payments of 2.5% of outstanding principal. Refer to Note 12, &#x201c;Debt&#x201d; to the Consolidated Financial Statements for more information.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our short-term and long-term obligations also include contractual payments related to our operating leases amounting to $4.1 million, with approximately $1.5 million payable through December 31, 2023 and approximately $1.3 million payable in each of the years 2024 and 2025. Refer to Note 13, &#x201c;Commitments and Contingencies&#x201d; to the Consolidated Financial Statements for more information.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our acquisition of La Jolla, we recognized its deferred royalty obligation in connection with La Jolla Royalty Agreement with HCR. Under the terms of the Agreement, HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> until either January 1, 2031 or when the maximum aggregate royalty payments have been made, whichever occurs first. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. The current maximum royalty rate is 14%. Starting January 1, 2024, the maximum royalty rate may increase by an additional 4%, if an agreed-upon, cumulative net product sales threshold has not been met. The La Jolla Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $225.0 million.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we have certain contingent payment obligations under various in-license agreements which we are required to make royalty payments or milestone payments upon successful completion and achievement of certain milestones. Refer to Note 4, &#x201c;License and Collaboration Arrangements&#x201d; to the Consolidated Financial Statements for more information.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also enter into agreements in the normal course of business with vendors for manufacturing, clinical trials and preclinical studies, and other services and products for operating purposes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 7A.   QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our debt bears fixed interest rates and we had no outstanding debt with variable interest rates. Our cash flows on these debt obligations are not subject to variability as a result of changes in interest rates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to changes in the fair value of certain of our investments in equity and debt securities. Fluctuations in the underlying fair value of the investments could result in material gains or losses. Refer to Note 6 &#x201c;Equity and Long-Term Investments and Fair Value Measurements&#x201d; to the Consolidated Financial Statements for more information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inflation has increased during the period covered by this Annual Report on Form 10-K and could continue to increase for the near future. Inflationary factors, such as increases in the cost of our raw materials, supplies, interest rates and overhead costs may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience some effect in the near future if inflation rates continue to rise. Significant adverse changes in inflation and prices in the future could result in material losses.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may face foreign exchange risk as a result of entering into transactions denominated in currencies other than U.S. dollars, including contracts with international vendors related to raw material purchases. Our royalty revenue from RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is also indirectly exposed to foreign exchange risk as GSK also markets and sells the products outside the U.S. The majority of our cash and cash equivalents, investments, and the majority of our vendor relationships are denominated in U.S. dollars. Therefore, we do not believe that the risk of a significant impact on our operating income from foreign currency fluctuations is substantial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements_and"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 8.   FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.796%;"></td>
    <td style="width:6.204%;"></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2022 and December 31, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_income"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Income for each of the three years in the period ended December 31, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_comprehensive"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Comprehensive Income for each of the three years in the period ended December 31, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_stockholders"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Stockholders&#x2019; Equity for each of the three years in the period ended December 31, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#reports_of_independent_registered_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reports of Independent Registered Public Accounting Firm (PCAOB ID </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fe76dd6b-16e2-42e9-96e3-beb61a94c643" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent_registered_public"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID 248)</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED BALANCE SHEETS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.886%;"></td>
    <td style="width:1.495%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.078%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.484%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.056000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffa14a0b-0669-4633-9f48-2ed1fe12cd71" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">291,049</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f62bfc4-4c71-41dd-a448-e171166ed977" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">201,525</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c7d6402-aeab-4103-8c8a-19e50bc4f90f" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,401</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44718965-473a-4b18-80ee-4290cac3bb05" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receivables from collaboration arrangements</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6bdb46e-bbd5-4c5a-a640-8df9dcc97773" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:ReceivablesLongTermContractsOrPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,672</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f7108ed-212e-4815-ad51-5d2d0f914143" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:ReceivablesLongTermContractsOrPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,711</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dacccc88-963c-4e95-94ae-e3a86194d7d8" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,897</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36adbd41-5a9d-415d-ab1e-8469998b1ec7" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_294d068e-2869-4653-a545-35d0c0c4c9ba" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,559</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4166ca6-74de-4e72-8a5c-020978004e6d" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,367</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57561e5a-7f91-4180-b08a-f19364a825b9" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8480d30-facc-46c9-bc77-955e12b7615e" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16447c94-1cd2-4c24-bd57-25a3fc62fed0" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">443,511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9021a528-96c0-43e3-b72a-30e62d7b67ee" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">313,673</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2e638a4-da6c-4005-b87f-5955c20f4f99" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3b3848a-6d6b-40b5-80b8-ef5c3b29989e" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity and long-term investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a9ea10d-3ad6-4811-b682-968dc083406d" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">403,013</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d77dc1f-5ad2-4233-952e-7fd6eca381d9" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">483,845</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized fees paid, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7de93ead-579d-4e74-aef8-366e379c570e" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:CapitalizedContractCostNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,607</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0820892-d7b3-4bd2-aca5-ac191e499c97" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:CapitalizedContractCostNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">111,430</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29ef1b62-c024-4e06-8a8e-04f7e6a25bd4" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,265</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86aa114a-7079-44e7-890c-0c82f9f6fea6" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a119989-a786-4e82-a004-390fecf27a09" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,713</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_105853ef-8b1e-48ee-82d1-16d0e79b52d5" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40c3f70b-5856-4220-b6dd-ea295f13a5d4" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">252,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02865d50-ae0a-4511-bc15-e8d3c06c5c81" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d185ecb-af69-4722-8471-72b3acbd998e" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b65cfd2-b3d8-4b7f-be48-057d05a17fcc" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,327</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1eacd42d-ae7a-4a9b-9d72-9e800043edbb" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,299</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e510278-5c25-4ba8-877d-9db379200e1f" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7887beb7-4756-4cde-aa97-992d5a6ae3d9" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,231,497</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b114434-a73f-4fda-aa27-8be2f3be6e14" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">926,395</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and Stockholders&#x2019; Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94987e30-8f5c-4ed5-88f6-610a1f1d1ff1" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,939</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_005ee45a-7f84-4f0b-b582-c9a58331b906" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued personnel-related expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15af0585-55d4-427a-91a3-fc56ef0de204" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75a4b244-1f08-40b7-bfae-f32684111dbf" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">619</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued interest payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33f0f984-40fe-4ced-8ecf-3349565835b6" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,359</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fad14d9-a375-4377-86ff-2eb3157fcf18" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,152</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89d837f9-c748-4443-b45a-0ff20cf7b565" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,094</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0ed24ad-e6e7-43c8-aa88-df7baab2991a" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Convertible subordinated notes due 2023, net of issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfdb2276-a4ef-48f0-9df6-728b040d785a" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:ConvertibleDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,193</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a293c13d-aa72-476f-b983-37f90db5e3ca" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:ConvertibleDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00ff1ae2-e0e3-499d-b588-970be21625c7" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a44dcb18-7146-469c-af20-5f5ba1be3887" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2dad4e6-3be7-4ba7-95cd-87d4b6c5e864" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,207</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_209d9899-cce9-4bc4-84ae-01c93eef1c3f" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,009</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c89c053-42cd-4b2c-994c-fc7536184b42" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134,968</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46760854-151b-4636-b68c-13d221f2a85d" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,807</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term debt, net of discount and issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_caf82ec1-e73c-4786-acaa-a9fee009883c" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">444,180</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64b278ca-cc00-4aec-b629-7c399fcd1454" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">394,653</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53cb5430-853e-4343-873b-780bd97eaa5e" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,918</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3865028c-3ce2-485c-81ec-71f3d2aa6b35" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85f8e1d9-e743-4979-88c9-d1a3449fc97f" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,771</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c00681c1-15cf-48ee-a9df-2dfa14854e72" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax payable, long-term</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c69696be-17ef-4121-8f1d-cf8e5697306a" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:IncomeTaxPayableNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f66f77df-2a3c-44ba-a47c-240ba6cec5c1" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="inva:IncomeTaxPayableNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_8a7a89c9-1023-44e8-a6a6-bd7e14049025;"><span style="-sec-ix-hidden:F_2e85503a-2fc3-4106-aa45-a099021141e5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (Note 13)</span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock: $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9aca373a-c4aa-44bd-a3c9-f9cb9e5e904f" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal"><ix:nonFraction id="F_0463b34b-6a5b-4139-93a7-68752c17668f" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.01</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3fcf65b-2171-4012-b6e5-2895dace5ee5" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_762d3acd-739c-4c44-84ac-da15b415adf4" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">230</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized,<br />&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3c210cd-6fde-4d4a-a872-9ae62aadb282" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_82c05776-f3e0-4bb4-a41c-30e26225a8c2" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c127a8a0-2705-4f3d-b57a-3e9cfb0f2981" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3bd87928-62ac-4f63-a208-07abb69b69ba" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac94ca89-9b2d-453f-960c-290dfb9def53" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5bed797-68f4-4476-8f7b-cc1d75a589f2" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock: $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4591183a-bc67-4d4a-86f8-c13e652332aa" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal"><ix:nonFraction id="F_1cfbb424-c6e2-4ecb-8223-34be53e9a89b" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.01</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_016a920b-3002-4847-9397-2c10982961b1" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_c145f654-bc24-4ad7-abb5-41a8b2f60e62" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">200,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized, <br />&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22dcb022-b361-40a2-b62e-f3b70ec1f56d" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_3224ac6a-66ff-4c20-98e2-b548def73510" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">69,188</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a42ee816-3f28-4419-bfaf-9b0f55fd564f" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_f17f600b-1931-4d7a-b5a5-6e39c16b8e3d" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">69,566</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;issued and outstanding as of<br />&#160;&#160;&#160;December 31, 2022 and December 31, 2021 respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9609fd5-29c1-4447-aef8-e7b7bc8a13e3" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">692</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd4942f7-ac04-40a3-a9d7-b99c33968d52" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">696</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treasury stock: at cost, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_081a2878-669f-4067-8ac1-9cd43a081b57" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_26d4ca81-482d-464c-8718-126ecaba4946" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">32,005</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares as of December 31, 2022<br />&#160;&#160;&#160;&#160;and December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52c10d5f-41b1-4fbe-8a3b-56c72dae4b34" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:TreasuryStockCommonValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">393,829</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b27496a5-0732-4ae3-ac14-af0f94abc9e3" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:TreasuryStockCommonValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">393,829</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a093c52-f021-4392-88dd-073489b97971" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,163,836</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9b07481-a8fe-4dd2-8cf9-25f350945e35" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,264,024</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4175af08-1b81-4e3a-8996-7c115d6d59d2" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">204,911</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_031d486d-1237-49f0-92d8-14014dbc76da" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">456,148</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Innoviva stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c967300-846f-43e4-b846-49747ea3129a" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">565,788</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77e0e694-c916-4b93-be7c-669692bd11fc" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">414,743</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncontrolling interests</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5350fb77-5710-4ef5-8fe5-85690545377f" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:MinorityInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4f9cd8c-4fec-4312-81cc-400270d0ed48" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:MinorityInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">111,192</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffa144c5-d0d2-4301-a0b2-8df881f1ab96" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">565,788</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b41bfd2-2fcf-4856-8f12-239c9c5cde34" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">525,935</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c241c7ee-22e3-4f19-bdc8-0a4ebdb82482" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,231,497</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_335284a6-b264-41fc-95b6-c7e0e3ad927a" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">926,395</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_income"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF INCOME</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:51.315%;"></td>
    <td style="width:1.472%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.686%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.481%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.686%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.481%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.88%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalty revenue from a related party, net<br />&#160;&#160;&#160;of amortization of capitalized fees paid <br />&#160;&#160;&#160;of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f35d57f-fa4a-4eb6-85fc-deb011d40201" contextRef="C_a01857da-29eb-401d-8a40-ba6e666521ec" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_25a64ae1-c1ee-4881-be58-782816e8b64a" contextRef="C_66c13dac-92c4-4ae1-b13e-27c3b81b27cd" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_42b05438-b74c-4ac9-a07e-e1570dddc88b" contextRef="C_a09a0970-3cec-406a-9c07-37e23fc89e0c" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,823</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;in each of the years ended <br />&#160;&#160;&#160;December 31, 2022, 2021 and 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9980bf7e-a8aa-45aa-bcd6-a4d531eabdab" contextRef="C_a01857da-29eb-401d-8a40-ba6e666521ec" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">311,645</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7602cb24-d20b-4b32-bd79-3255f12ad808" contextRef="C_66c13dac-92c4-4ae1-b13e-27c3b81b27cd" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">391,866</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03796f25-b984-40bc-8662-5f8056a6401d" contextRef="C_a09a0970-3cec-406a-9c07-37e23fc89e0c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">326,794</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue from collaborative arrangement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9cbfc654-518f-49c7-9007-f7e14c4736e9" contextRef="C_b4cfe9be-7f2a-4e82-81ce-72548c7e28d9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87104c64-1ac3-4394-a214-1025f57fbf67" contextRef="C_ec493f0e-c275-474e-89f4-31047349c878" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15759648-29db-40d9-bcfc-ecacfda24c86" contextRef="C_3eed0352-afa7-4942-b39b-760e5fbff0cd" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net product sales</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6a58764-1f64-448c-895a-d33433581c1f" contextRef="C_9f672909-6502-4136-b275-680e838ad815" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,694</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4266e63-255d-40aa-b20a-a232ae083f35" contextRef="C_974a2f30-5728-48a5-ab31-4e0b26a6014c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_441d7088-708b-4893-b543-bd3968b51688" contextRef="C_85dfe886-0475-4835-8057-5fdac892ef0d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5036a2dc-279e-43ec-b568-371855e6b283" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">331,339</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27cae3db-a7c3-41a5-a4c8-4e66d42e29fc" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">391,866</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a65b3bd-8cb0-46f6-ada3-e0e8fc092029" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">336,794</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost of products sold (inclusive of<br />&#160;&#160;&#160;amortization of inventory fair value<br />&#160;&#160;&#160;adjustments and excluding amortization<br />&#160;&#160;&#160;of acquired intangible assets)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5251dbab-4b84-4a27-97f0-270f17558c5c" contextRef="C_9f672909-6502-4136-b275-680e838ad815" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,793</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7eefe72b-f719-4476-963b-34b9b597c379" contextRef="C_974a2f30-5728-48a5-ab31-4e0b26a6014c" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1433eba2-6924-484f-a5df-5f5bbb23c8a3" contextRef="C_85dfe886-0475-4835-8057-5fdac892ef0d" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_820df8e3-984a-42b7-abd0-549d4f3f80d7" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,538</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8328a8bd-3484-4921-9260-8e11001a824e" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,187</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_865f3927-4420-4a01-b0fe-dd5cab2ae08a" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,883</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0dcec15-614b-4e08-87fc-3855f4c77a20" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,432</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_654d32de-973b-47e2-bbbf-3a7c2af06238" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">576</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b17b220a-b1aa-49f1-81fe-6a301720a367" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,788</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of acquired intangible assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_579a6601-281d-4e90-bad4-4e994bc81bca" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,581</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3e1c127-a32d-475b-8d3f-0fef030e9df9" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5c967bb-d7a6-4fb3-83cf-8a742b86d36d" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain on sale of Theravance Respiratory<br />&#160;&#160;&#160;Company, LLC (&#x201c;TRC&#x201d;)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_676eff52-1be4-4509-b4d4-c9694f3b9b91" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:DeconsolidationGainOrLossAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266,696</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50152f8c-4f16-4091-82e5-a1af54b38e1f" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:DeconsolidationGainOrLossAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95b4f24c-7df3-4c42-8408-a35f2e4d6c9e" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:DeconsolidationGainOrLossAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on extinguishment of debt</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c2c4353-0f84-401c-812f-53c90faa7977" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">20,662</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6781e19d-f333-41da-9266-438d1225c92c" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25e0dd87-b7aa-4645-a21b-837176e310b3" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair values of equity method<br />&#160;&#160;&#160;investments, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_031b0fda-79cb-48a6-b472-ae942b6fc2da" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">161,749</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ebf0179-f8ea-4092-bfcd-de334760a1cd" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,392</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfbf60fa-0697-4b3e-8bf5-d2f18b3426fa" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair value of other equity and<br />&#160;&#160;&#160;long-term investments, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bd08421-5fde-4aed-803a-0da52d3251a1" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:GainLossOnOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,462</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cc63ac4-5edc-4cb9-8592-8d11a7eafae2" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:GainLossOnOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,638</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eab60972-0044-4393-9adc-819e62a9047d" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:GainLossOnOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest and dividend income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51e06bc7-fece-44c5-9559-357593fe6582" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:InterestAndDividendIncomeOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,369</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da185db2-26b2-4dcf-92b0-af3a7fe3ea11" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:InterestAndDividendIncomeOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,839</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33a64ff8-f274-4ae2-9fa7-fc0d6c6a59d9" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:InterestAndDividendIncomeOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,524</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f8a65ad-6c96-4d62-87c7-dde5c1875ecf" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,789</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df5f8a4f-65c5-413a-afdc-6d4bfa3149bf" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,070</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71a172d6-0a2f-465e-a4f2-3fb09568e4f3" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,331</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other expense, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_234460ef-5d7b-416a-a5f1-79dd6674f9be" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,373</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2f23237-c365-4496-a019-9264bbe6f903" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,626</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2dd6390a-8c0b-46e9-85a5-710959855c7f" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c76b7667-109c-4698-bbaa-44c3d2ba0fe2" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,390</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d332ec06-0cba-4db8-95a4-22e7c0b7319d" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">53,410</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51952bb4-9ff1-43a7-a470-d6bd8008d258" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">17,451</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income before income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40ae883a-bfa7-4139-ac72-a7bd885619e9" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">286,949</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3cd46bfc-b19a-4c5d-847f-544a1fbe9209" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">445,276</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7efd31e-05eb-4d51-8d10-9d3d156d1435" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">354,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_747951dc-41dd-4a3e-b98c-0666a77faf55" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,687</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3eee3aa7-3648-4d27-b162-96b585d22705" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,439</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90f8a101-636c-4f52-9ada-422edcffdf5c" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,431</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a915d56-b38e-4b88-8ce9-2ec3b0c18e4a" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">220,262</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3afd013-f484-4eb2-955e-e90e1cd085fd" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">368,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36171a20-778a-4057-8f76-b6ff824fcc78" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">293,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to noncontrolling<br />&#160;&#160;&#160;interests</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac3fc47d-eff8-4e8b-b29c-f0c2f7e6b559" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1cfdf4f-fe09-4509-a514-18178e9a5f80" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102,983</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0ecfa99-09b1-4c7a-89bc-beb06b30ef17" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,412</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to Innoviva<br />&#160;&#160;&#160;stockholders</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6783e8dd-b3ce-4953-b20c-33ac6d55f622" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">213,921</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28d32350-ea3b-4ef0-bac0-13c7b987bd71" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">265,854</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c639770f-481e-478c-a0a6-9cadc1fa6f05" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">224,402</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net income per share attributable to<br />&#160;&#160;&#160;Innoviva stockholders</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06ccc68d-cc7d-4f28-b626-c9ff2f6a14f2" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.07</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_614f9468-2428-4994-b67a-cb110eefed8a" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98c9549d-807b-44ce-af72-b5ef72b2de2d" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diluted net income per share attributable to<br />&#160;&#160;&#160;Innoviva stockholders</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1e9d898-11ea-4049-8342-f7844aaf77f9" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.37</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93640f12-509e-4a10-9165-cbefe7fb5ea6" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.87</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69de7118-fbe8-409e-b7e1-38d74adc949d" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.02</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares used to compute Innoviva <br />&#160;&#160;&#160;basic and diluted net income per share:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares used to compute basic <br />&#160;&#160;&#160;net income per share</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1046bd7f-c22e-4a13-bdd5-a44e68398038" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">69,644</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6929fba5-5517-4bfa-a7c3-671349ae1d78" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">82,062</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b59dcaf3-a846-4970-a07e-841966e55e78" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">101,320</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares used to compute diluted <br />&#160;&#160;&#160;net income per share</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ab04d96-b731-4dd0-8eec-b140576cfa6e" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">95,248</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b91e611-8f67-4cd2-b99f-954f110f82c8" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">94,310</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f02d1dce-9907-41a4-81ba-ca3ed24bf26c" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">113,554</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_comprehensive"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:58.083%;"></td>
    <td style="width:1.274%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.559000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.283%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.559000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.283%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.959%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91f65247-1cb6-4fb6-8dd9-1391565dbcbb" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">220,262</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ef95e5d-eb4d-4775-bb4a-97d25c79e859" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">368,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbb99212-8593-4fbc-b42f-85abf2571a62" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">293,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reclassifications to net income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6eb3dffd-ce64-4e27-8562-afde457d03e1" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45643bf2-5976-42f5-9ad2-b2f0eccc4393" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c787becb-00b5-4480-ac22-fa85f9c467b0" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d45b7954-994f-4cf8-80ac-b437f86ab28c" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">220,262</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff88aa90-9410-413e-867d-1a1e037512c7" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">368,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6462eb3a-827c-4403-b765-af7e1296f0fd" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">293,787</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive income attributable to noncontrolling interests</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65a661a7-f84d-4f4c-aed6-750ab4f7b630" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5724582f-2c94-4765-97ab-a8753b61efe8" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102,983</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f26ec341-76ad-4b25-97e6-9005950bb1b3" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,412</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive income attributable to Innoviva stockholders</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d186e011-0019-4683-9c12-47977f6c4911" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">213,921</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45597322-c4dc-4794-8502-d8429af54696" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">265,854</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_857389ed-2588-4013-8b76-2ef2138201f6" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">224,375</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_stockholders"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#x2019; EQUITY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:28.626%;"></td>
    <td style="width:0.584%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.9919999999999995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.584%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.617%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.584%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.135999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.593%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.164%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.593%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.837%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.593%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.01%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.593%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.476999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.593%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.164%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.593%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.672%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Other</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paid-In</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Treasury Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncontrolling</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income (Loss)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of January 1, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d135a057-7149-4241-b104-c2575e8d893a" contextRef="C_331a70dd-7cba-4846-8cf2-0dcd886d6087" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">101,288</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39ff3a63-80fc-46ee-b5a1-16ef09b022f4" contextRef="C_331a70dd-7cba-4846-8cf2-0dcd886d6087" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,013</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec15830a-a611-4a49-9c37-2ff00df13691" contextRef="C_35170e33-91df-4d33-a732-d1197ad1bca9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,258,859</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbc899f5-6112-4b52-a7ce-38afcc85441b" contextRef="C_b00c2afd-3ef2-4717-a264-dd840bff9783" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09fbd640-845e-4736-b8de-755df17eb9fe" contextRef="C_716be5cd-91a6-46f4-a203-c3c353f3575d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">946,404</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89242625-25cc-4a21-878c-26106f41ae5c" contextRef="C_94003f87-2752-45fd-9a31-20cecedf555d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5dbb237-e847-4a94-92a1-b42b5590cbcc" contextRef="C_ea59fe25-23ca-4e88-abc7-36f9a00934f8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,621</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de9f48ad-d123-469e-aad3-ea8e74c6ca8b" contextRef="C_5afc9e88-7462-4e21-81dd-9bb66b6d8fd1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">342,116</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Distributions to noncontrolling interests</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c0789d4-42fd-4c48-b420-eeccea30fb40" contextRef="C_8200e2df-4805-452f-bcfe-d016a4e29503" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_794b2c2c-9f8f-4775-86b9-191906fae0a2" contextRef="C_1816159f-f867-4167-b36c-2cc22460814e" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9519bb7-bb81-435f-b517-fce6af221a63" contextRef="C_16264887-a1ec-4e23-98dd-1206cc8034cf" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_390f6e29-d22c-47fa-bb5e-b5292e672582" contextRef="C_de6c7395-9939-4c9f-99ac-cc5059cad3dc" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0eea3a5c-a1e5-4c1a-8cad-cb635d48ce24" contextRef="C_1a6e7bd4-d8ef-4aaa-8381-bf457ccf3981" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1ca30a9-9cda-4c74-a454-45f6e3484fa0" contextRef="C_2fa03dd5-7a6f-44af-9267-849f7de0b04b" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,474</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87e94ff7-853b-4e04-b311-221b0852b207" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,474</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity activity of noncontrolling interests in <br />&#160;&#160;&#160;a consolidated variable interest entity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ea60851-0d58-4c2d-9a5a-67783aed8949" contextRef="C_8200e2df-4805-452f-bcfe-d016a4e29503" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f99b414-62bb-4412-84e2-77199071231f" contextRef="C_1816159f-f867-4167-b36c-2cc22460814e" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2b8adae-3f5a-4240-8123-43b605d9b4f1" contextRef="C_16264887-a1ec-4e23-98dd-1206cc8034cf" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92ba6226-615d-4113-b426-a9c939fc097c" contextRef="C_de6c7395-9939-4c9f-99ac-cc5059cad3dc" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3e9e69b-541e-4959-9714-d0ce90385415" contextRef="C_1a6e7bd4-d8ef-4aaa-8381-bf457ccf3981" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd5574ef-b326-4a41-9988-0968c45b1e84" contextRef="C_2fa03dd5-7a6f-44af-9267-849f7de0b04b" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">366</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d29a30b-6457-462d-8c2e-5eb784bd97bd" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">366</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options and issuance of <br />&#160;&#160;&#160;common stock units and stock awards, net of <br />&#160;&#160;&#160;repurchase of shares to satisfy tax withholding</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b91562a1-3223-4390-aa93-e29bdeb62804" contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">104</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e790b98e-c29a-4531-9d8d-ec6aec832a7e" contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ce25205-8c54-49dc-86b9-4c39c1b757b8" contextRef="C_07d0dcab-49d7-4bf5-b5eb-1625e2fe2a1f" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">343</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0810c464-a1cf-43cb-b98e-fd2348dbd6bb" contextRef="C_24fc258b-a785-47f6-b359-705130868321" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bac8121-b2ca-4592-9221-209110cc51e0" contextRef="C_bfd9e7de-9f9b-458b-8962-ee3a5d4c660f" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87a442b2-a1ed-45ed-bdcc-51911916ef2b" contextRef="C_be6598b9-e8cb-47df-9144-93cf81d26295" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32c97ded-6560-48e3-a292-06d368617557" contextRef="C_892e4f08-128a-4e39-b8ba-c31860bb66fe" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_234f9bd3-ed25-4dfe-904d-618c5af2e477" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">344</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c60b7905-3761-40fa-ab77-3e0d40cfb4c7" contextRef="C_8200e2df-4805-452f-bcfe-d016a4e29503" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b959a93-110d-4418-b1d7-b7e6b95852da" contextRef="C_1816159f-f867-4167-b36c-2cc22460814e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,698</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93338fc9-3499-40a7-a5f2-51ec9100c66b" contextRef="C_16264887-a1ec-4e23-98dd-1206cc8034cf" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bea60194-c3aa-48ce-a459-86f7c0677f2e" contextRef="C_de6c7395-9939-4c9f-99ac-cc5059cad3dc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e252729-2551-4262-a05d-0a90f9d69863" contextRef="C_1a6e7bd4-d8ef-4aaa-8381-bf457ccf3981" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76b0cc3c-414a-4b6e-b37e-f1b43d736974" contextRef="C_2fa03dd5-7a6f-44af-9267-849f7de0b04b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf404eac-4a0b-4658-9f44-e9340692ca59" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,698</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddb4f7b4-7efa-447c-b6b4-be4abbf052ad" contextRef="C_8200e2df-4805-452f-bcfe-d016a4e29503" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3163c86-7e90-4090-8050-3d5dca221bbe" contextRef="C_1816159f-f867-4167-b36c-2cc22460814e" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_861bb67d-72bc-47f7-9df8-0c92e0273bc2" contextRef="C_16264887-a1ec-4e23-98dd-1206cc8034cf" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e4db440-5375-4187-b10b-fc3ddf312fc2" contextRef="C_de6c7395-9939-4c9f-99ac-cc5059cad3dc" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">224,402</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3476b7c-a16d-46d4-8978-ad354219a85f" contextRef="C_1a6e7bd4-d8ef-4aaa-8381-bf457ccf3981" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51f53d00-4bf9-4a7d-911a-4cf0e9cbeb44" contextRef="C_2fa03dd5-7a6f-44af-9267-849f7de0b04b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,412</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71097c77-f612-4f95-bb3b-5cecba18ccdb" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">293,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d42f0e0c-f5c2-455e-9ce3-90159092a672" contextRef="C_8200e2df-4805-452f-bcfe-d016a4e29503" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25ff77e2-d6ee-4819-adf8-33463d7a3821" contextRef="C_1816159f-f867-4167-b36c-2cc22460814e" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bca3f635-2d02-4be2-b125-77183dd59a80" contextRef="C_16264887-a1ec-4e23-98dd-1206cc8034cf" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_063aaf7f-04c6-4a2c-9956-eeac8aaaea6c" contextRef="C_de6c7395-9939-4c9f-99ac-cc5059cad3dc" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfaad911-7b70-4737-b231-8d5ea659c70a" contextRef="C_1a6e7bd4-d8ef-4aaa-8381-bf457ccf3981" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55f9246c-6036-40e5-aa15-217b8a35a1f7" contextRef="C_2fa03dd5-7a6f-44af-9267-849f7de0b04b" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45e675fb-a8f2-4970-b1c8-01b342634fbe" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b09186ca-86c0-48cc-9a96-3ff2a09f7701" contextRef="C_16a2d28f-c3aa-4dc0-a79e-e3f051ba1c79" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">101,392</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_734364a5-0dc8-4b55-ac62-c5655b9db49f" contextRef="C_16a2d28f-c3aa-4dc0-a79e-e3f051ba1c79" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,014</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd8bc3f1-29d9-454c-94a7-1eb79536e444" contextRef="C_ed938f8f-9dc7-47dc-b811-6331bcb70bcd" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,260,900</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e692bbdb-f746-4b9c-ab01-88674a3ba2a3" contextRef="C_99cd87c6-e3ec-4551-aa1e-6daadd1c00f9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a84c37ce-f72e-431a-899c-7f382b3dd768" contextRef="C_9c4ddbeb-ee5a-4ac2-80c1-fb1faed19718" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">722,002</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55261dca-5e9f-4dd1-ac57-04d3165c2b4f" contextRef="C_86d0f3a8-8fec-4fc2-be60-22b8b5cff09c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8b61098-2312-4aa0-856d-8f764d24cc63" contextRef="C_86d0f3a8-8fec-4fc2-be60-22b8b5cff09c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af1fb753-435a-4e42-9f4d-72d55c1e45fc" contextRef="C_b3fdbdd6-df91-4856-b880-a7ace484739f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55982c15-2cd0-463f-a7a4-5358d831f072" contextRef="C_f1759049-001a-42bc-8f15-3224ecf2b407" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">607,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Distributions to noncontrolling interests</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_074dae46-2263-4a60-b644-be851451480e" contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96694fe0-4b9f-4650-ac82-6460b1394979" contextRef="C_07d0dcab-49d7-4bf5-b5eb-1625e2fe2a1f" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_295688cd-569c-450f-b551-b9711e560b78" contextRef="C_24fc258b-a785-47f6-b359-705130868321" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51225bb9-cc37-4d5b-9fed-06590a7cd896" contextRef="C_bfd9e7de-9f9b-458b-8962-ee3a5d4c660f" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0570ad6-ec1f-4521-a6b0-43661cc73583" contextRef="C_be6598b9-e8cb-47df-9144-93cf81d26295" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fff7ce37-b4b6-4cb4-bf41-415c7a763f0d" contextRef="C_892e4f08-128a-4e39-b8ba-c31860bb66fe" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,457</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_062f2899-9cc4-42c6-b3ef-03859af3481a" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,457</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity activity of noncontrolling interests in <br />&#160;&#160;&#160;a consolidated variable interest entity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47204fd6-3974-4edd-a7d2-7e14709a26c6" contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74f51307-2171-4820-a2d2-854999295255" contextRef="C_07d0dcab-49d7-4bf5-b5eb-1625e2fe2a1f" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdea1402-c62c-4f9b-8674-3fcc54842c02" contextRef="C_24fc258b-a785-47f6-b359-705130868321" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4217ce7-3666-4e9f-b33e-6a7fc568b98a" contextRef="C_bfd9e7de-9f9b-458b-8962-ee3a5d4c660f" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16bbff58-b184-47a7-9517-25a1794647dc" contextRef="C_be6598b9-e8cb-47df-9144-93cf81d26295" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d8ca537-114b-4eeb-bf84-a0f0a99c9899" contextRef="C_892e4f08-128a-4e39-b8ba-c31860bb66fe" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b846cbe-0cff-46df-9b5b-c9bfb5d818a9" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options and issuance of<br />&#160;&#160;&#160;common stock units and stock awards, net of <br />&#160;&#160;&#160;repurchase of shares to satisfy tax withholding</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0274f4f-206f-42db-a49c-2d66f66860d0" contextRef="C_8200e2df-4805-452f-bcfe-d016a4e29503" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63ab6646-5897-49e0-9f41-8f949593de59" contextRef="C_8200e2df-4805-452f-bcfe-d016a4e29503" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01dd7805-0300-457c-9311-56013624f62b" contextRef="C_1816159f-f867-4167-b36c-2cc22460814e" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,107</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66e90dc2-1137-4276-bac7-fec694e8986a" contextRef="C_16264887-a1ec-4e23-98dd-1206cc8034cf" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_632a7d85-250e-4897-9298-0328ad72dfe8" contextRef="C_de6c7395-9939-4c9f-99ac-cc5059cad3dc" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1caa619-e69f-41b0-b718-680597fd86a9" contextRef="C_1a6e7bd4-d8ef-4aaa-8381-bf457ccf3981" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e67aeee-3000-44a8-8bcd-77970b92a211" contextRef="C_2fa03dd5-7a6f-44af-9267-849f7de0b04b" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_693a86ef-3cce-439e-97d3-e2b8fa0ea0f5" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,109</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a32b3f27-40a6-4981-b698-77a8edfa436b" contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8" name="us-gaap:TreasuryStockSharesAcquired" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">32,005</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d14a4ae-ec68-48b5-8454-674a6cf69d9f" contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">320</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68625d0c-089c-46c4-b0e1-3e80802315ba" contextRef="C_07d0dcab-49d7-4bf5-b5eb-1625e2fe2a1f" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_017bf663-6a9b-424e-98fb-68d1d4d62f2d" contextRef="C_24fc258b-a785-47f6-b359-705130868321" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f34d022-838c-4b87-a369-c7c2cba19953" contextRef="C_bfd9e7de-9f9b-458b-8962-ee3a5d4c660f" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67dd2d7c-3ed8-4783-b9d7-01cf65881dd6" contextRef="C_be6598b9-e8cb-47df-9144-93cf81d26295" name="us-gaap:TreasuryStockSharesAcquired" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">32,005</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c7d5a9a-1101-43bf-a4ca-759196e694b5" contextRef="C_be6598b9-e8cb-47df-9144-93cf81d26295" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">393,829</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79c26418-7235-45c3-ab90-e048190a2422" contextRef="C_892e4f08-128a-4e39-b8ba-c31860bb66fe" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9113422-96fa-42ac-a1d7-0b17725aa06e" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">394,149</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89038a7f-af3d-4cd6-b98c-93997d9f7bbf" contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85e0b262-ee0b-4e77-88f2-5ed6116c5e47" contextRef="C_07d0dcab-49d7-4bf5-b5eb-1625e2fe2a1f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,017</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22adb6ea-6714-4474-b786-a294441139f5" contextRef="C_24fc258b-a785-47f6-b359-705130868321" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_169450f5-a23a-423d-a5c2-a43e5a12294d" contextRef="C_bfd9e7de-9f9b-458b-8962-ee3a5d4c660f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc1bc3d9-fae0-4493-a723-21c1e5be1c6c" contextRef="C_be6598b9-e8cb-47df-9144-93cf81d26295" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1f8f7a2-2930-48ff-b5e6-a38adab3a47d" contextRef="C_892e4f08-128a-4e39-b8ba-c31860bb66fe" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fd51007-aec5-4502-b6fd-b3ed5afc5e97" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,017</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64ec2bef-c05b-4e23-83b5-85d9bb8b2d1d" contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67b275a9-b4d0-4cc9-b85b-ed4a8d3a92d1" contextRef="C_07d0dcab-49d7-4bf5-b5eb-1625e2fe2a1f" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9365f71-018d-4432-8b5d-4585b0b93e98" contextRef="C_24fc258b-a785-47f6-b359-705130868321" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c3bedd8-08d2-4650-8af5-83d757230731" contextRef="C_bfd9e7de-9f9b-458b-8962-ee3a5d4c660f" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">265,854</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62a80325-3910-4071-a32d-8a85f26a4265" contextRef="C_be6598b9-e8cb-47df-9144-93cf81d26295" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b089bf3-7a84-46ba-b61d-7dea13e6e1d0" contextRef="C_892e4f08-128a-4e39-b8ba-c31860bb66fe" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102,983</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9484962a-7599-47b5-8b79-76710c7a7b84" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">368,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b47c910-9f7d-4868-9ca8-6a4ec3a2e9be" contextRef="C_6a053a42-fce9-401c-8cfb-e85edab1757f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">69,566</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1c2e370-2793-40b9-983e-d5467b15a2b6" contextRef="C_6a053a42-fce9-401c-8cfb-e85edab1757f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">696</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7732f461-8b97-451d-a8cd-b2358fedaf60" contextRef="C_f9f855c6-99ff-45d5-bdf0-1bbca9152b56" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,264,024</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdbf81d8-7d85-4d7e-ab1b-d6add5ee168e" contextRef="C_d4c99a87-e213-4345-a8ee-cea346b72126" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a45ebc92-95b9-4554-adc8-0d81ead0d104" contextRef="C_ad8f45f5-b03e-455b-875b-da3585e6e901" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">456,148</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5010f12-20ff-4f99-a423-5b7310b9a3fa" contextRef="C_e6adac0f-99fa-4f60-8e56-74a08935e56a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">32,005</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7119a221-55ca-4c7d-bfef-98da55da8cb8" contextRef="C_e6adac0f-99fa-4f60-8e56-74a08935e56a" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">393,829</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccabf4d8-f943-4108-9e6a-2dd0e896d1c4" contextRef="C_0aeb2ace-977a-42ee-96fb-3b9b90a42f4c" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">111,192</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_709f5edb-ff4a-491c-8728-6b05da9e9f17" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">525,935</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_464685a2-4b4f-4d9b-b1f5-911c9d18b2b2;"><span style="-sec-ix-hidden:F_9f0bad49-93fa-4614-803a-31125d7d8918;"><span style="-sec-ix-hidden:F_d6ac2f39-dcb6-4aaf-82a3-69ebb7891582;"><span style="-sec-ix-hidden:F_490b67c1-915e-4461-9105-5bfc1a0f9c4a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cumulative adjustment due to adoption of <br />   ASU 2020-06</span></span></span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_090f059f-8e2f-4d99-b6e7-955ef9ac1298" contextRef="C_8a92f3b2-2579-4b68-b675-6468f004fa64" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,467</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6d82fb6-d296-43eb-a437-2129ac16c4c8" contextRef="C_afbd1fdf-91b2-49f5-a71e-24558788a9c5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3eb2ca7-9108-4303-a5f1-431127bf5dba" contextRef="C_a428dc65-c5ce-4719-a4dc-1d99f661076d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66e34e3a-a086-4826-90a6-764dd33d1db0" contextRef="C_592136c4-250e-4250-b700-73aee7f30946" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,229</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Distributions to noncontrolling interests</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d5a09d7-b334-4740-9f22-55da19ee0c93" contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ef049d9-eb85-411a-9bff-4f832f0433fa" contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,811</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eca78dff-8079-4497-aee9-32c90680ced1" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,811</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recognition of noncontrolling interest upon<br />&#160;&#160;&#160;initial consolidation of Entasis</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2e524c5-a478-409c-b4f4-aea8a6240801" contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8" name="inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,471</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5e3d9ea-65b1-41f1-b767-60e1614885fa" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,471</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity activity of noncontrolling interests in <br />&#160;&#160;&#160;a consolidated variable interest entity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_531fe12b-4e0d-41d1-85a5-6aa9a9acf638" contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8261dae6-d09d-4b99-9987-6774c4cddbcd" contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_523f068a-5cf6-4ffc-85bd-b0347b864357" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derecognition of noncontrolling interests upon <br />&#160;&#160;&#160;sale of TRC</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37e8433c-e0f3-410c-8f2f-fb7e27c5a9bd" contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a295b0e3-6566-41a3-a303-f3e8a3c17a58" contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77ed4aea-b006-4462-92c6-355d3314c434" contextRef="C_50f6e318-ebf2-4aff-955a-5ec178352190" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_447d8bd6-d77c-46bb-9c52-1ac7d501422f" contextRef="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ee7a65b-4f9a-486c-83ce-52de6510e0c9" contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18c54641-b490-48ce-9450-69c0f81dbf7e" contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,304</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e12e12c4-a6e7-4e60-a4cb-92f4ee5a2d83" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,226</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Derecognition of noncontrolling interests upon <br />&#160;&#160;&#160;acquisition of Entasis noncontrolling interest</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebc667bf-8e7d-4fad-a2ce-dfbaf70efa42" contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869" name="inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7596c80a-b3e6-4a9f-81c0-29013766ab6f" contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1" name="inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">14,153</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e0eaa13-1996-4be3-a14b-626735000f76" contextRef="C_50f6e318-ebf2-4aff-955a-5ec178352190" name="inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87c3720c-e39c-4571-acb9-f1d4f7263c50" contextRef="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230" name="inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_062ab92d-31b9-4d59-b501-0e795808c3a0" contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67" name="inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2d1fe2f-f3fb-4a92-b2ac-0eb97083618a" contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8" name="inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,009</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a51a9378-3f6d-4ca5-b4c8-38a3cdc5275b" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">42,162</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options and issuance of <br />&#160;&#160;&#160;common stock units and stock awards, net of<br />&#160;&#160;&#160;repurchase of shares to satisfy tax withholding</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1e4bd7c-3ede-490f-9b21-c111719b6dab" contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">269</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2c665eb-055b-4c93-9b8b-b8b315fd0c35" contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ac4338b-fb4f-4b49-9cff-dceb0aa02ff8" contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">286</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77d46774-4880-47ea-96f6-13c224bf296b" contextRef="C_50f6e318-ebf2-4aff-955a-5ec178352190" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3428f95d-d1d9-49e2-a349-793df9e2859b" contextRef="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0fe30b62-d595-4e41-a8ac-bb6855d59900" contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee421b02-8dc0-4df5-9b34-bbd0932d887a" contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5768f2b-7b28-4214-b955-578bc581d5be" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">288</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capped call options associated with convertible <br />&#160;&#160;&#160;senior notes due 2028</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3a0716a-da6e-488b-b408-1ca03ffe01f1" contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35856006-1f60-4bee-8c3e-d7b45fadf902" contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">16,585</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b21506f0-fd25-4ef3-9eed-e9317d1e455d" contextRef="C_50f6e318-ebf2-4aff-955a-5ec178352190" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_284a9a2e-4607-4f00-a952-70b14f002a3e" contextRef="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_717ca7ff-6a2e-483d-89db-8f514c0f9187" contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3228f643-490e-4643-9ec6-7cdc60f76606" contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fb20df2-c713-4500-9b49-ed994413ed6c" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="INF" format="ixt:numdotdecimal">16,585</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion of convertible subordinated notes <br />&#160;&#160;&#160;due 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c49e3994-643b-4c4c-b3a1-70e23bdae5c5" contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7182e84d-e0fe-4191-9884-648eba00026b" contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c201d21-96be-4e28-95fe-c297cf00f8ef" contextRef="C_50f6e318-ebf2-4aff-955a-5ec178352190" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b5deffc-d12f-4612-a7ee-4869a4527c21" contextRef="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9069a23f-b1ff-48a7-a55f-a287d76583ff" contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca2f3510-d2f8-429c-a786-5de8d93cfb77" contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0bfa283-6f3d-4c5e-90cf-fbc5fe5cd033" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a4e7138-4ffd-4b11-b16e-5dadbc6014a3" contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869" name="us-gaap:TreasuryStockSharesAcquired" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">647</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb255e8c-3043-4fa3-83a2-df33a8f6eae4" contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da9cdb22-18bd-4f3c-8f60-702413495264" contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,497</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3728cf0a-470b-4865-8b4d-fed48964c4b3" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,503</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_777799a1-f60a-4d86-8c50-f8dfc7b14b12" contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35887c31-5a6c-4a38-a4d1-9a75938eeb17" contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,225</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6773e86-23e9-4520-93b6-f5e48cbc3ff4" contextRef="C_50f6e318-ebf2-4aff-955a-5ec178352190" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29e2fbf0-e0fd-4410-9b17-598ac81071b9" contextRef="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69c33f92-52ec-4c11-87a5-c2f7faf93f34" contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed08fa3f-3c13-4758-b3c5-4846eb7f728b" contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42207b40-3496-42cb-bc6f-b15eca37be28" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,347</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a599d39-070b-4980-9f66-efdc265f45f8" contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4b3e3fe-4ebe-4e06-9951-3945147ee6f9" contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ab98ffc-45ac-4866-90d8-4e6731382092" contextRef="C_50f6e318-ebf2-4aff-955a-5ec178352190" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17eac5cb-28be-480f-b048-e3717533180a" contextRef="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">213,921</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8dc5a6e3-4b68-450c-ad59-5fa0711c9953" contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc4daa1f-29a0-4d94-a1d3-16d812f581f3" contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16d5a7bf-1df9-44cb-a7ca-beb4ea3ecd75" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">220,262</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f68a0c39-bc26-4fdc-aee4-d9148ade2085" contextRef="C_148b7599-6dc0-4526-80ae-e58d4cb847c3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">69,188</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d34019d-285b-426b-be51-cac46e3192ed" contextRef="C_148b7599-6dc0-4526-80ae-e58d4cb847c3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">692</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19222542-cf87-4448-b247-4f801b85d97e" contextRef="C_c69e13b2-db45-4b02-9138-80f02fcf96a4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,163,836</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e65c7bb6-a34a-4f88-b4e4-9430ac6e5e7e" contextRef="C_a7b3b46b-f87a-4221-a2f4-8bb306339707" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22cba2b9-a561-4b36-b628-3fb16c44209f" contextRef="C_9aeccb9a-f0c1-46ac-b1b4-641f1442275d" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">204,911</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_424107a3-6244-4337-b79b-8f03ce04e9e4" contextRef="C_2989da91-3f0d-4f40-9d12-9977d248744f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">32,005</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d456a8e-e401-4ba7-b62c-d349a066a359" contextRef="C_2989da91-3f0d-4f40-9d12-9977d248744f" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">393,829</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbc390e9-97d1-4281-8830-66249b149aba" contextRef="C_ce4ecb89-132b-48b5-b413-d18d79b1b130" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a689e531-ea01-4dae-9546-a32d9c19a050" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">565,788</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:51.779%;"></td>
    <td style="width:1.492%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.469%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.492%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.469%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.492%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.806%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91af4684-e08f-4dfb-a349-085e9a2baf28" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">220,262</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df2cb629-0381-445b-a47e-75b80cf5b06d" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">368,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25709006-2088-4641-8008-d9b083a32037" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">293,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net income to net cash provided by operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income taxes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56441984-a37d-441a-aa28-932b3a1117d6" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,006</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_568cbc87-37d1-47a1-91ea-ac268af753e7" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,432</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00ef2583-e567-495c-878e-c56656ee6c3f" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,420</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of capitalized fees and depreciation of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1af5812d-7484-4e1f-84b7-e217ab8e64b6" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,931</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c5b066d-8a96-4d26-b07d-a44feca83b1d" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,832</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_154614c4-dc3b-46a9-9471-1eaad482e758" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,840</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of acquired intangible assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e84ac999-30a3-409d-9f14-3fb584d8c546" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,581</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_012deacb-0901-4cd3-a61a-67a27aaa9093" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85450aa7-49fa-4a71-ac8d-bd18ae938e03" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value adjustments included in cost of products sold</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9bd0448a-4f04-432e-996b-1a31cb6f9d0c" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:FairValueAdjustmentsIncludedInCostOfProductSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,023</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bacec573-7467-4da5-b7d9-2c19a5f167b0" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:FairValueAdjustmentsIncludedInCostOfProductSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbee73ec-3778-44f9-b31c-eb971052d6ec" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:FairValueAdjustmentsIncludedInCostOfProductSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_796b39ca-a5e9-4593-aff3-e3419eeed3a2" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,347</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6cbf670-6442-4657-8363-a6f407363a2b" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,017</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b690842e-3b7d-429d-bf01-413368feca3f" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,698</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt discount and issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2cd0426-4163-4c75-95ff-a8ad46ecd48b" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,055</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9958f727-033d-4883-a08a-22afe367ba84" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,136</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a813590-99d5-4950-be64-c3a4471d1ff6" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,397</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair values of equity method investments, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3ed547b-169d-48b7-8c50-cf8215b1eb75" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">161,749</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd7721d1-9f28-40f8-9b4c-393dcfe732d9" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,392</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d180a1de-b778-42ed-b636-119bad335961" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair values of other equity and long-term investments, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e2edf85-fdc0-4ef5-93f8-39f86581c418" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:UnrealizedOtherGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,462</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca0d45ca-2f8e-4834-b05a-a6786eb9b91e" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:UnrealizedOtherGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,917</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_644dc88a-ab97-47e0-b355-82665d2e7c3f" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:UnrealizedOtherGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on extinguishment of debt</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec834e49-4221-4f58-bcd0-4fffaebd3b25" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">20,662</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1dd57470-0dee-4b5e-90a7-a3e79cc5c1df" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91ac264b-bb7e-4053-a835-ca8d2dacf60c" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net gain on sale of TRC</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59b0ccfe-ec12-4e24-a0db-36316e35db81" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:DeconsolidationGainOrLossAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266,696</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94e77ae1-2061-4cd7-a45e-9d1f81faf303" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:DeconsolidationGainOrLossAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f8516eb-ad7f-4252-95ad-db5adf093927" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:DeconsolidationGainOrLossAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of discount on short-term investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97b7924c-1885-49bf-9d16-443443303a91" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b8416f5-1e9f-435d-8809-5e14eae9d35b" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85eafdf7-c120-4680-897b-2e96095450ed" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">343</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of lease guarantee</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40d489d6-3809-4bef-9910-97e64d71980f" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncreaseDecreaseInDeferredLeasingFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb4c6e75-61dc-40c6-8066-c31038b10472" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncreaseDecreaseInDeferredLeasingFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8517535-7b7f-490a-910e-3be78066543c" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncreaseDecreaseInDeferredLeasingFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other non-cash items</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96fcbc28-faba-47a5-b924-242e5bf25241" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,402</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6533a778-303f-44bd-b4f5-d78ae825659c" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3fc6565-8340-4ece-a6e9-174281f263d9" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fbe12d0-9621-4a34-8616-9c9f72ac50d0" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,525</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d9fdd48-a339-4b63-9f8d-55e8c0125272" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8944717b-2f6e-4716-949f-f082aa6527cf" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receivables from collaboration arrangements</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c88aca4-3732-41ad-aa43-6675913e6793" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">13,319</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5df3d89e-e5cf-4264-86b9-bd757784b860" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,780</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6c50541-fb7b-4f36-ae2a-29be309576b4" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,504</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7f4c456-d718-4641-a9e6-45bbb5e58af0" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95c629ae-1154-4d87-9153-442b79a58aa7" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d9f3691-7d3f-4935-87bb-af4a0c320cd1" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db341937-696f-4a3d-b90d-a76b0ecfbe7e" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,350</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8c5bbc5-c4c8-473d-829e-6c79e0a26a0f" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">203</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb8190e8-7f0b-4149-b220-62e5d9b2b7e3" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">678</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00107acd-53f8-4752-9b07-a4a1b6fcb5c6" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_036384e0-3d52-4fcd-984d-efdf65f25ec2" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36f56be1-8944-47bc-95ab-0ffb4e8c221d" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77033039-abec-4f2e-b4e0-4a618a1d69d7" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1330a2a-485e-4ad2-b0b8-1c1bbc558b98" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fa56fc0-7281-4276-bba1-d4e3cd359112" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued personnel-related expenses and other accrued liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8fd0ef3-4b25-473c-acee-67054c4ed203" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,913</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20b0e5f4-1d37-4b60-9963-08ff5f510186" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">257</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce7d37d6-9a99-435c-843d-98f43623e72a" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">804</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued interest payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39db0b8e-c510-40e5-9bf0-f4f506a20093" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">207</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0af0891-05b7-4b90-98f6-0db00cd22c19" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f877bfa-b609-4203-ba14-8f2784e54138" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2338b206-adb5-4981-8a21-a26e35deb47a" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">755</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53e3def4-f144-48e4-828c-df34ea8ccc17" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cb0a8fa-5d11-412b-be2a-2d61325006eb" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b48086e-9913-4f12-90c8-d9dad8b6244b" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,026</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_999ef877-19be-4d58-b375-47d4b5c977a5" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f809645e-cec7-435a-ae6f-636833c27ac4" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2238ff01-2247-40b8-948d-7b681b73f8ba" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">201,726</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e0d695c-de15-44c6-b3f4-15e71b5b5d22" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">363,813</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edf6b218-9a2d-41f1-a2f1-7c7bbd1ecd2c" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">313,113</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b4d9b3d-2f80-4ed4-9153-38c2aff37d81" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04b899a4-6061-49a3-8788-cbdc9cd961cf" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68944a78-3b60-400f-b621-7571e45cf3ba" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2f2b9e4-b7c9-4975-8bd7-5ed0d22c3e52" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4a16f3f-895f-411e-90c3-f5188e6afd08" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7f493a0-47bf-4ccc-8ecd-238e3849c653" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,943</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of equity and long-term investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6b64c3f-6fc5-4bb0-bb76-e703211b16ae" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,725</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27cfb315-aadc-492c-a105-731197bf1f02" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28eaacc8-1f59-47c5-b8aa-55d88870555c" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,981</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of equity investments managed by ISP Fund LP</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3884e75-f989-40ec-8784-d2a3a53478d7" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:PurchasesOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,910</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7fd8acb-e607-458c-bd4a-8512c2f73cf8" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:PurchasesOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">190,970</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7755f4c-189b-4f95-9394-7af386df074d" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:PurchasesOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,877</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of trading security managed by ISP Fund LP</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3964fbc-7e7d-4df8-a7f5-20251450af11" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:PurchasesOfTradingSecurityManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd94d96b-a4f6-4462-a458-907c9e97a126" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:PurchasesOfTradingSecurityManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64a3f51d-8bb4-4202-8991-7131ee7849c0" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:PurchasesOfTradingSecurityManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of equity investments managed by ISP Fund LP</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bcd7aa48-f359-4ba8-9eef-e927c96238ca" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:SaleOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,281</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06db4836-64da-40de-ab79-7053104cedb7" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:SaleOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,440</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3745ba12-4a46-411e-a51d-5dd752defe8c" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:SaleOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase and sales of other investments managed by ISP Fund LP, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9125cc66-931b-4078-8fd8-3809f1553886" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_389feae9-188e-42b7-bef2-d2a12fd9e190" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">279,530</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_546de689-eaca-4d09-9a84-ebf675d3fd7e" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">285,123</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e999159b-2eb4-4cae-8aa3-ac0894dd25d5" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38b80993-a0c3-4cc7-8e1e-0be1cecec1c5" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e85557a-350e-46d1-8c03-a198a8cb24e5" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from sale of ownership interest in TRC, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d378007-a40d-4389-b259-94b1e62e05b7" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:NetProceedsFromSaleOfVariableInterestEntityEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">248,191</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37778c14-4397-4921-8490-216efeeac7dc" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:NetProceedsFromSaleOfVariableInterestEntityEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_610e2219-7cc9-4a16-a2c0-1215aef4ccc1" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:NetProceedsFromSaleOfVariableInterestEntityEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash acquired through the consolidation of Entasis</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1584bb63-b19d-4d12-83ae-7fb094012ef8" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,070</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee284282-5f31-417c-9b6f-9ac19e39870b" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e2a9d40-f079-4520-b84b-0f7c10e63bd8" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for the acquisition of La Jolla, net of cash acquired</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7471a9f-54bc-45f8-ab5d-d41b3e8091e2" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">159,103</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecdd0e53-20d8-4a61-ac41-d39232bd3669" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3be5f737-c367-44bd-90aa-3038589f63a1" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fc91531-5f0e-45f4-8c23-51109ad96045" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">56,634</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c8dbaa7-22a9-4b3d-9130-7db013b11ee6" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,722</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09b53f0e-47b0-40fa-8df1-8fc27f75d31f" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">314,937</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Distributions to noncontrolling interests</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e92123b-654d-4ff4-b78e-e80d05a87943" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:PaymentsToMinorityShareholders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,811</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_013cdd14-5121-4f4d-ac8d-860be00cc0fd" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:PaymentsToMinorityShareholders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,457</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_899db423-39da-4ff3-be5e-c8d435f83466" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:PaymentsToMinorityShareholders" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,474</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of Entasis noncontrolling interest</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c5527c6-07e2-49ae-9409-5c573e379d66" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:PurchaseOfEntasisNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,910</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c785063c-3f43-4667-9cd3-e51f2e6f1583" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:PurchaseOfEntasisNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27d118fa-240e-46ee-880b-15a01fb0ffbf" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:PurchaseOfEntasisNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repurchase of common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4235e96b-14bf-460d-b1e9-d83bde91013f" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,503</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4dfa4ca9-8d8c-4ddb-b44a-0fb9354524bf" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">394,149</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7d9d33b-4f0b-4c6b-a35f-a998e8326e81" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Repurchase of shares to satisfy tax withholding</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5db59ffb-176a-4e2d-998a-aad93d1911df" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_091750fa-56ee-42c7-83cb-2d4d49611d45" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fada53b-38b4-44ed-9bcf-2ac8f688a0eb" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuances of common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8109a26e-db9b-40b7-8a52-994752be034c" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">370</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58242b74-a7c2-4ebd-89ef-e7d7f2f80c0e" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,169</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eee6ad8f-bb3f-4cd8-a82f-b8bd99a498a2" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">436</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net proceeds from the issuance of variable interest entity&#x2019;s equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_675ecd08-909a-4ad8-9dc3-6848ac29bd85" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:NetProceedsFromIssuanceOfVariableInterestEntityEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_936fe78f-d79c-46e9-820c-cea40e739657" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:NetProceedsFromIssuanceOfVariableInterestEntityEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1c400ba-0318-4bdf-905b-93f315c62d1c" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:NetProceedsFromIssuanceOfVariableInterestEntityEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">345</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment for repurchase of convertible subordinated notes due 2023</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ddf8638-1437-4ec9-a180-aa963c1c74b5" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165,131</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_230682b6-142c-4db3-956b-f8c16d816ed4" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02da083f-dc6a-44d9-9694-dd2704261336" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of capped call options associated with convertible senior notes due 2028</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_992416e6-1a5f-4bdc-9cf0-e07d3039460a" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,037</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d3b11f7-ff65-45a7-8e9a-8814f7e18faa" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd4b1d8b-56fd-430c-bbcb-8bec5b1ca2fd" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of convertible senior notes due 2028, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af24e247-30b5-4399-b0cb-f3c2f046769d" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">252,536</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b07f017c-0501-4205-861c-abafff2e62e8" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07308d06-a996-4602-af20-975a5b4d1ac7" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86de4f7c-b528-4940-900a-44406e577eaa" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,568</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_933d2be9-a133-49a0-9060-21bd253d56fd" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">452,497</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbd7515e-d759-475b-8abb-0f6895b7ca57" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">29,785</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16e84fb5-47be-4925-8d90-488ca2a579da" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,524</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f542074c-64c4-4bd5-abf8-7175fd4edf96" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44,962</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7d09422-fa25-4b0d-a42b-fb9c34f2dade" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,609</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dad4e6a-f0d9-4f66-8f29-51615e4a9d16" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">201,525</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3284f99e-1678-4ada-9f01-2ccb187f4ee8" contextRef="C_f1759049-001a-42bc-8f15-3224ecf2b407" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">246,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a467ee7d-5ab8-4159-a71f-a4d4faa4cd4f" contextRef="C_5afc9e88-7462-4e21-81dd-9bb66b6d8fd1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">278,096</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9783d2d1-d713-4bb9-ae50-c7bdb1d49f79" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">291,049</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5900507-1b4d-4a45-a286-7c22e6bc9af8" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">201,525</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98a168e5-71a4-4239-a25f-0356e00b9041" contextRef="C_f1759049-001a-42bc-8f15-3224ecf2b407" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">246,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:51.873%;"></td>
    <td style="width:1.495%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.494%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.495%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.32%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.495%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.831000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental Disclosure of Cash Flow Information:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_896840db-6f26-4b9d-a7bb-fbe14169b45d" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,736</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11c20919-2cab-4bd5-b281-d97216be538b" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16300703-62b7-483b-a73a-904b1e24d0c3" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32ee0e8c-b51b-4753-a91e-1ea305d99a31" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,855</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b00da6b-9ea7-413d-a700-5e174185fb8e" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53b928ca-fe7c-487c-8a19-c52ce3493488" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental Disclosure of Non-cash Investing and Financing Activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adoption of ASU 2020-06</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64478ebf-a799-4b7d-aff8-9b6ddf61c9fc" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:NonCashActivity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6707fd3-9ac7-4d6b-9592-7c3d7c29e5d9" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="inva:NonCashActivity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbf869cc-6494-47b0-830c-1990ba4ef7ed" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="inva:NonCashActivity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_16c4f3e2-77f0-4fcd-b81a-0746dad96288" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.  DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of Operations</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Innoviva, Inc. (referred to as &#x201c;Innoviva&#x201d;, the &#x201c;Company&#x201d;, or &#x201c;we&#x201d; and other similar pronouns) is a company with a portfolio of royalties and innovative healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#x201c;GSK&#x201d;), including RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(fluticasone furoate/vilanterol, &#x201c;FF/VI&#x201d;) and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(umeclidinium bromide/vilanterol, &#x201c;UMEC/VI&#x201d;), and up until July 2022, TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(the combination FF/UMEC/VI). We sold our </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ed14cb7-6d0d-4b30-862a-6c71a30c1a7e" contextRef="C_b6fe683b-fcbf-4fcd-a6b7-3a89c78e4ee9" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% ownership interest in Theravance Respiratory Company, LLC (&#x201c;TRC&#x201d;) on July 20, 2022, and are no longer entitled to receive royalties on sales of TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> products. Under the Long-Acting Beta2 Agonist (&#x201c;LABA&#x201d;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as follows: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_526d11ac-967d-47bb-82a3-49d5297346f8" contextRef="C_8a492117-f656-4dab-adc6-be5db6e4dc3e" name="inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on the first $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f3bc4d1-f286-40dc-ad93-a57fa5bcff22" contextRef="C_8a492117-f656-4dab-adc6-be5db6e4dc3e" name="inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion of annual global net sales and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0545c4bc-f7f7-42e1-a57e-030a577287db" contextRef="C_8a492117-f656-4dab-adc6-be5db6e4dc3e" name="inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for all annual global net sales above $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62a003e8-d773-4993-8661-13c316567b23" contextRef="C_8a492117-f656-4dab-adc6-be5db6e4dc3e" name="inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion; and royalties from the sales of ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which tier upward at a range from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d89e7e26-6b76-4df2-bcf1-f60c89cd0613" contextRef="C_0a4c2cad-c447-47db-88d7-dca325de6712" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f466c54-e0f0-4e4b-9650-6f92b09c87db" contextRef="C_94397c13-ded5-4700-8d54-52976b909049" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expanded our portfolio of royalties and innovative healthcare assets through the acquisition of Entasis Therapeutics Holdings Inc. (&#x201c;Entasis&#x201d;) on July 11, 2022 and the acquisition of La Jolla Pharmaceutical Company (&#x201c;La Jolla&#x201d;) on August 22, 2022. Our commercial and marketed products include GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Our development pipeline includes medicines for the treatment of bacterial infections, such as our lead asset sulbactam-durlobactam (&#x201c;SUL-DUR&#x201d;). As such, we have a wholly owned robust infectious disease and hospital operating platform, as well as other assets in these areas, such as a large equity stake in Armata Pharmaceuticals, a leader in bacteriophage development with potential use across a range of infectious and other serious diseases.  We also have economic interests in other healthcare companies.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2c35a896-dda7-4130-a367-73f18fab4782" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#x201c;VIE&#x201d;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_19ad1374-46d0-430a-94b2-2f839739da16" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:PresentationReclassificationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation Reclassification</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain amounts in prepaid expenses and other current assets, other assets and changes in fair values of equity and long-term investments, net, reported in the Company's prior year financial statements have been reclassified to conform to the current year presentation. These reclassifications had no net effect on the net income or net cash flows as previously reported.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_15b5e9c9-f288-44f4-8fe2-8f9fd0d52042" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:FactorsAffectingComparabilityPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Factors Affecting Comparability</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors below and as discussed in Note 5, &#x201c;Consolidated Entities and Acquisitions&#x201d;.</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adoption of Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06 effective January 1, 2022;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining noncontrolling interest in Entasis on July 11, 2022;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sale of our </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c784dc3c-3d14-49a4-96ac-25a5e3c233c8" contextRef="C_b6fe683b-fcbf-4fcd-a6b7-3a89c78e4ee9" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% ownership interest in TRC on July 20, 2022; and</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisition of La Jolla on August 22, 2022.</span></div></div></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_15dec71d-daf9-4495-8d8e-a2d5cbc5fd4a" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Management&#x2019;s Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9ab80c57-bd3a-4f2a-8f49-9aa2d9889a51" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers and Partners</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#x201c;API&#x201d;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK&#x2019;s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts&#x2019; or investors&#x2019; expectations, due to a number of important factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also started recognizing revenue from product sales as a result of our acquisition of La Jolla Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e54de09-0cf2-4f9e-9047-64c623b58040" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:NumberOfCustomers" unitRef="U_Customer" decimals="0" format="ixt-sec:numwordsen">Three</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of our customers each account for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53f43a84-b5b8-4dda-804d-0c9b536f5f94" contextRef="C_6a6afb3d-ff23-4bc0-870f-2ba1de52231b" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">33</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_670d57a3-a193-4fa1-95c8-99a75c9cc9a8" contextRef="C_ae9baafd-ad15-49ea-bd45-fcc80a92f494" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">29</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d311ec9-3924-4ead-939c-7a3516db2b40" contextRef="C_f2fd0a10-b4dd-4ad0-a2ee-0219d554486f" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">28</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respectively, of our net product sales from the time of our acquisition of La Jolla through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These same customers account for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f12de711-173b-4015-8fa2-d9da6538dcd2" contextRef="C_6b106910-d499-49e8-b2c4-ca13347b8e1f" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">23</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ed26ca6-429d-4b86-a679-9b92de900ccc" contextRef="C_1e9dfcc6-abf8-428e-99c1-2f4e7d75a1e1" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">37</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_081b8803-6ee4-43c4-b6b5-ffda4910a63a" contextRef="C_bce10091-26f4-4aa8-ad2d-b5ecfe6c2aa9" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">37</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#x201c;Accounts receivables, net&#x201d; on our consolidated balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e1eadf82-3759-45fa-a9ea-f698b737b0fb" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We operate in a single segment, which is to provide capital return to stockholders by maximizing the potential value of our portfolio of royalties and innovative healthcare assets. Our Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Innoviva at the consolidated level using information about our revenues, operating results and other key financial data as needed. Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net sales of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Refer to Note 3, &#x201c;Revenue Recognition&#x201d;, for more information on our revenues for the periods presented. Our long-term assets are located within the United States.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7547f908-2f70-462f-88c3-373fd8749bd7" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ConsolidationVariableInterestEntityPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Variable Interest Entities</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary beneficiary of a variable interest entity (&#x201c;VIE&#x2019;) is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#x2019;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#x2019;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a9766b5f-140d-4913-bf0f-50e3d692caf3" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:BusinessCombinationsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business Combination</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When we acquire an entity in a business combination, we recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establish the acquisition date as the fair value measurement point. We recognize and measure goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. Acquisition-related expenses and related restructuring costs are expensed as incurred.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, we typically use the income method. This method starts with a forecast of all of the expected future net cash flows for each asset. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Some of the more significant estimates and assumptions inherent in the income method or other methods include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows and the assessment of the asset&#x2019;s life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory, or economic barriers to entry. Determining the useful life of an intangible asset also requires judgment as different types of intangible assets will have different useful lives and certain assets may even be considered to have indefinite useful lives.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1e1ff176-ab15-452c-8bff-bf77ed899ce3" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_249bbf36-5b28-40c4-837c-6b6e6d10a01e" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments in Marketable Securities</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We invest in short-term investments and marketable securities, primarily corporate notes, government securities, government agencies, and government commercial papers. We limit the amount of credit exposure with any one issuer, industry or geographic area for investments other than instruments backed by the U.S. federal government. We classify our marketable securities as available-for-sale securities and report them at fair value in cash equivalents or short-term marketable securities on the consolidated balance sheets with related unrealized gains and losses included as a component of stockholders&#x2019; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. Realized gains and losses, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and dividend income.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We regularly review all of our investments for other-than-temporary declines in estimated fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in estimated fair value of an investment is below the amortized cost basis and the decline is other-than-temporary, we reduce the carrying value of the security and record a loss for the amount of such decline to other expense, net.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7f059b8e-336a-4d02-a982-0279a0c1cb08" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f57111ee-2094-4e21-af16-9fa5d7075471" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value on a first in, first out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0bdad1d7-6fe5-4dae-90cf-0460f754d2aa" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, which consisted of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements, were not material as of December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7eb15296-0743-490e-86c2-e60fb0623f92" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:49.167%;"></td>
          <td style="width:1.667%;"></td>
          <td style="width:49.167%;"></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of remaining lease terms or useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment, furniture and fixtures</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0b6b6aaf-70c2-4383-808c-7399fe383de9" contextRef="C_5c8ba09c-4a2f-49c9-b6ed-a569b29e1d50" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_07f1b0fb-e1e0-43e6-9f67-6af2936715aa" contextRef="C_fc1deebf-6f63-4335-bca2-8ee328f41791" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software and computer equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e2bbcbf3-c5e8-46a9-9714-0abb58e1c566" contextRef="C_2bc5e510-4f44-48df-99c8-e241a16a04b5" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 years</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_45274200-24f9-44a0-9309-9186f734383d" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:EquityMethodInvestmentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity and Long-Term Investments</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 825, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of other equity and long-term investments, net, on the consolidated statements of income.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we conclude that we do not have an ability to exercise significant influence over an investee, we may elect to account for the equity investment without a readily determinable fair value using the measurement alternative under ASC Topic 312, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments - Equity Securities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This measurement alternative allows us to measure the equity investment at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also invest in ISP Fund LP, which investments consist of money market funds, trading and equity securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered in December 2020, we became a limited partner of this partnership, and our contributions are subject to a 36-month lock-up period which restriction prevents us to have control and access to the contributions and related investments. These investments are classified as long-term investments on the consolidated balance sheets.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_db9b95ca-d9b3-43f3-a3c9-46f5ab65ae55" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Quoted prices for identical instruments in active markets.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;Unobservable inputs and little, if any, market activity for the assets.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4f8f1c07-3db1-4524-af43-bc8387fe4ba7" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:CapitalizedFeesPaidPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Capitalized Fees Paid</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#x201c;Capitalized Fees&#x201d;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_df28e1da-7046-494b-8daa-8110a7c35c5f" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:CapitalizedFeePaidEstimatedUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#x2019;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#x2019;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_44487e95-078a-480b-8134-1d5d33d312cb" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill and Intangible Assets</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#x2019;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#x2019;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_698f3f11-75a0-46dc-8917-89edcda5d2f9" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_264ac7b4-c762-475b-bdc8-60d29b091099" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We apply the guidance on principal versus agent considerations under ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includ</span><span style="background-color:rgba(0,0,0,0);color:rgba(37,37,37,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">es being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalty Revenue</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize the royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on its methodology and assumptions to estimate rebates and returns, which it monitors and adjusts regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Our partner may make significant adjustments to its sales based on actual results recorded, which could cause our royalty revenue to fluctuate. We conduct periodic royalty audits to evaluate the information provided by our partner. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Product Sales</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#x2019; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#x201c;GPO&#x201d;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state&#x2019;s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9e341e8f-8ad3-4d31-bbc4-fb0d4f5fca39" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research expenses based on the progress of the studies and progress of research manufacturing activities.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_24b6d4ab-8175-4809-b675-d52045776ded" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:InterestExpensePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Expense on Deferred Royalty Obligation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#x201c;Debt&#x201d;, for more information.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_621e7bf5-e821-4e87-8ea9-4be0b6641036" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Stock&#x2011;Based Compensation Awards</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#x201c;ESPP&#x201d;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#x201c;simplified&#x201d; method as described in Staff Accounting Bulletin No. 107, &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,&#x201d; for the expected option term. We use our historical volatility to estimate expected stock price volatility.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units (&#x201c;RSUs&#x201d;) and restricted stock awards (&#x201c;RSAs&#x201d;) are measured based on the fair market values of the underlying stock on the dates of grant.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#x2019;s best estimate as to whether it is probable that the shares awarded are expected to vest.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9b4e31d6-e872-4930-a026-0516fb39be0f" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#x201c;more likely than not&#x201d; standard.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_252a611e-89b6-4b53-8f9f-a40b1fbb11b8" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Income</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive income is comprised of net income and other comprehensive income (loss). Other comprehensive income (loss) consists of changes in unrealized and realized gains and losses on our marketable securities and the related tax impact of these changes.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_52ae26fc-df54-4878-a163-18c3218417c3" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:RelatedPartyTransactionsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Related Parties</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions with GSK were considered related party transactions up until May 2021, when we completed the share repurchase agreement with GSK to buy back all of its shares of common stock in Innoviva. GSK is no longer considered a related party after the completion of the share repurchase. Transactions with GSK are described in Note 3, &#x201c;Revenue Recognition and Collaborative Arrangements.&#x201d;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sarissa Capital ow</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ned </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_598bd2e7-3635-43f9-b91e-f6c0d4b8692b" contextRef="C_2137129a-9873-421f-b2c8-dd60cf04b4e3" name="inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">9.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ur outstanding common stock as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Transactions with Sarissa Capital are described in Note 5, &#x201c;Consolidated Entities and Acquisitions&#x201d;. Sarissa Capital is considered to be a related party because two of its principals are members of our board of directors.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_62ce5c6f-f397-4d62-95c2-0c53881f9997" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting Pronouncements Adopted by the Company</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, the FASB issued ASU 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt-Debt with Conversion and Other Options (Subtopic</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">470-20) and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which is intended to simplify the accounting for convertible instruments by removing certain separation models in Subtopic 470-20 for</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">convertible instruments. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new standard also requires the if-converted method to be used to calculate diluted earnings per share (&#x201c;EPS&#x201d;) for convertible instruments. Effective January 1, 2022, we adopted the new standard using the modified retrospective approach and assessed the effect of this adoption on the accounting for our outstanding convertible notes. The effect of the adoption on our 2025 Notes (as defined below) resulted in a decrease to the opening balance of accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c169904-c9ff-4ade-9537-82a66594c213" contextRef="C_353f3f99-bbf5-4207-bc66-407db6f33a5a" name="inva:DecreaseToAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, a reduction to additional paid-in capital of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10e2e822-9c25-4662-9e2d-fdc636592681" contextRef="C_353f3f99-bbf5-4207-bc66-407db6f33a5a" name="inva:ReductionToAdditionalPaidInCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">65.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, an increase to the balance of the notes by an aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78c632e5-ae8a-4996-b39f-4d6d48ffeab7" contextRef="C_f935b07f-6611-49a5-95c9-c3a28c0fd4ed" name="inva:IncreaseToConvertibleNotes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and an increase to deferred tax assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d31a04dc-0159-4bd8-abda-c02768bf6632" contextRef="C_353f3f99-bbf5-4207-bc66-407db6f33a5a" name="inva:IncreaseInDeferredTaxAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The dilutive EPS of our 2025 Notes will be computed under the if-converted method going forward. There was no financial impact from the implementation of the standard for our 2023 Notes (as defined below). Refer to Note 12, &#x201c;Debt&#x201d;, for more information.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, the FASB issued ASU 2021-08, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business Combinations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Topic 805), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Contract Assets and Contract Liabilities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognized and measured by the acquirer on the acquisition date in accordance with ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the third quarter of 2022, we elected to early adopt ASU 2021-08 effective July 1, 2022. The adoption did not have a material impact on our consolidated financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_28cc57e4-1056-413a-a77a-ab0dc1859dea" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.  NET INCOME PER SHARE</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock outstanding. Diluted net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock and dilutive potential common stock equivalents then outstanding. Dilutive potential common stock equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method, as well as common stock issuable upon assumed conversion of our convertible subordinated notes due 2023 (the &#x201c;2023 Notes&#x201d;), our convertible senior notes due 2025 (the &#x201c;2025 Notes&#x201d;), and our convertible senior notes due 2028 (the &#x201c;2028 Notes&#x201d;) using the if-converted method.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2025 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. Our current intent is to settle the principal amount of th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e 2025 Notes in cash upon conversion. The impact of the assumed conversion premium to diluted net income per share was historically computed using the treasury stock method until the adoption of ASU 2020-06. As the average market price per share of our common stock as reported on The Nasdaq Global Select Market was lower than the initial conversion price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6468508e-54c8-427e-92b2-014b07860df1" contextRef="C_e1aa07de-fcc2-48ae-85fd-403ac523f2e3" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">17.26</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, there was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd86681d-c7ad-495d-afef-80cc055b4fae" contextRef="C_6e288046-0f09-4c78-b427-4c133f35ca3f" name="inva:IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_fc14c802-bdc4-4430-894e-629fbbdf3e08" contextRef="C_a7955fc6-6a0b-47e2-b852-f7b1e5cc5350" name="inva:IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dilutive effect of the assumed conversion premium for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021 and 2020 respectively. The dilutive EPS of the notes was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4d6dc2c-a6a3-404c-b348-d0a88aaa506a" contextRef="C_02211f41-81dd-4ee9-8d76-5d38e227447b" name="inva:DilutiveEpsOfNotes" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.31</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per sh</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are using the if-converted method for the year ended December 31, 2022 as a result of the adoption of ASU 2020-06.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_82fc6415-fa69-45ce-8934-9bb33d8384ce" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table shows the computation of basic and diluted net income per share for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.638%;"></td>
        <td style="width:1.409%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.979000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.008%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.578%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.409%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.979%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands except per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to Innoviva stockholders, basic</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f0f2f0e-6536-4c36-acee-ffe2fea5ad4e" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">213,921</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_293d67e7-866a-4bf4-9dad-31251d4db4cc" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">265,854</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edc3a7c9-5a15-434b-837a-ae6f9ad3caea" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">224,402</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Add: interest expense on 2023 Notes, net of tax effect</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c515da19-a106-4021-bb51-bcc0dd373d89" contextRef="C_32dbf528-70de-47c3-9e65-d8c113adb297" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2add44a-f09f-4b69-9843-0f6918293daf" contextRef="C_eec2ed38-0112-4b50-a764-67406d54c678" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,736</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe0fa733-4242-4bcc-88a2-0863e7e42c9c" contextRef="C_ccb9cff0-df82-484b-91d7-3221007e9ea4" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,717</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Add: interest expense on 2025 Notes, net of tax effect</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f81a349-7ae9-4995-96da-df42a1196aa9" contextRef="C_98afe62c-821a-4537-b552-da050d3c5568" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,583</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8970328f-5bbe-4deb-9423-becc90d7c216" contextRef="C_d6464796-f61e-480a-9439-0d5437aeff80" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c155445c-8da3-4b2f-983c-446654478bde" contextRef="C_dc5624db-df9d-4192-9bd1-604ef2b78e37" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Add: interest expense on 2028 Notes, net of tax effect</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5551f2a1-b107-4bf2-ad1b-11b0e11f68b4" contextRef="C_04636ba8-4bff-4dfa-bb5d-8f341cc9b324" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,626</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e9bfc86-6f96-43e5-bea9-1d85166bfebf" contextRef="C_20d483d2-f9e7-4620-9d3b-694ecd5af926" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad15c002-b8cf-429f-b1a5-1b960b074077" contextRef="C_2ae54ce1-89e0-4a29-9584-2ca3a58b8d7e" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to Innoviva stockholders, diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47d18be6-5b76-4f04-8996-4bcb43bd141d" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">225,569</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e04b31e4-be5d-4bf8-84c4-c35476a9cb00" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">270,590</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7208605e-1b29-49e3-89dc-e0dc146271af" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">229,119</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares used to compute basic net income<br />&#160;&#160;&#160;per share attributable to Innoviva stockholders</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7259e344-594d-4228-a36c-0c6dd8f10809" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">69,644</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4081e4cb-69ce-482b-8272-90cfe7292c46" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">82,062</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b57dfa1-4994-4b2c-98c7-04fa56445016" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">101,320</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of 2023 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35ca1678-5afc-47a4-896b-473c10dd9ca8" contextRef="C_32dbf528-70de-47c3-9e65-d8c113adb297" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">6,188</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d903ba24-bbc5-4ef3-9b64-3e50343c89e8" contextRef="C_eec2ed38-0112-4b50-a764-67406d54c678" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">12,189</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18e2efa4-379d-4805-b26e-9c0c4fb12a25" contextRef="C_ccb9cff0-df82-484b-91d7-3221007e9ea4" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">12,189</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of 2025 Notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0705277-4f79-42af-ad36-b751dd9a3b91" contextRef="C_98afe62c-821a-4537-b552-da050d3c5568" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">11,150</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7557b637-11ee-4faf-b096-911be9ba08f0" contextRef="C_d6464796-f61e-480a-9439-0d5437aeff80" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a5237cb-2ca9-4d17-821d-1dcd0660a0a5" contextRef="C_dc5624db-df9d-4192-9bd1-604ef2b78e37" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of 2028 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a88d0c7b-d9b1-4617-8bd8-c0587abfbf48" contextRef="C_04636ba8-4bff-4dfa-bb5d-8f341cc9b324" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">8,158</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2061daa-ba5c-46a6-a923-16e0bf248ab6" contextRef="C_20d483d2-f9e7-4620-9d3b-694ecd5af926" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea186b27-ddd1-4bdf-a90d-b140ac56770e" contextRef="C_2ae54ce1-89e0-4a29-9584-2ca3a58b8d7e" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of options and awards granted under equity<br />&#160;&#160;&#160;incentive plan and employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_837bb571-cd01-49aa-8a1f-83207a178441" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">108</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7456a17-36b9-4441-ae8e-86c84e18b949" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">59</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7df44bf9-21f9-4c9d-a6bb-4ad61e04603e" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares used to compute diluted net income<br />&#160;&#160;&#160;per share attributable to Innoviva stockholders</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4600c968-ebe6-43d6-b659-78af520bbfcd" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">95,248</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_627827e4-6fb8-4571-b7e5-ba041e3f8e47" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">94,310</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_513fd7bb-4cd5-4ee1-bcf2-196e9121b44a" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">113,554</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income per share attributable to Innoviva stockholders</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a83256e9-2116-46d8-a72b-f2b022dd4f62" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.07</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65451f49-ff66-48d0-af2f-09d98cecf058" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9fd97b3e-6905-444f-ac1e-debe996a7684" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_751f5869-19f1-4dfc-a703-0b382de6303f" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.37</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f8ab089-41b6-443a-bb41-f3da872b0394" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.87</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5695f9e-1e59-41d9-b635-5ec650d67a6a" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.02</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Anti&#x2011;dilutive Securities</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ea7cfcbd-f243-4286-9c82-18039febd081" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#x2011;dilutive:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:52.353%;"></td>
        <td style="width:1.844%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.583%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.027%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.583%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.027%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.583%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding options and awards granted under equity incentive<br />&#160;&#160;&#160;plan and employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_878e9ddd-9c73-439a-8fd9-8591d59cf97f" contextRef="C_9600166d-2800-4110-aac1-2f841a170cbb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">648</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0214525-9ff5-4476-9d20-f23cfec61233" contextRef="C_8020a62f-296d-4e43-981f-bbe959befede" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">979</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d719594d-5575-4ba0-a36e-65a2d97dbe0a" contextRef="C_53339bec-ba31-4b54-aa6a-0f92f4e9a13e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">1,193</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding stock warrant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28f2d66e-5468-45a6-bcdc-a9f3b8960d7d" contextRef="C_429f62d7-eb47-4068-90e0-c5530e1e1a8d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">282</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03a3c635-befc-4bfc-bb57-0b9c214d6371" contextRef="C_86245344-c6d4-4840-98eb-541f5a63c983" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80992e77-766a-41d1-8b17-48f95ae0f111" contextRef="C_1c0f3b4a-32d1-4930-9562-67d67a9ae07c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6fcfd77-0084-4642-ba40-187d4c786ff6" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">930</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5e91d19-bc37-4651-8234-e059515c40cb" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">979</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_079bf5bc-1c6f-417b-8341-eea323d7d954" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">1,193</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0a2f1dad-14f8-4ef7-8943-459837d27584" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.  REVENUE RECOGNITION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Revenue from Collaboration Arrangement</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 13, 2022, Innoviva&#x2019;s wholly owned subsidiary, Innoviva TRC Holdings, LLC (&#x201c;ITH&#x201d;) entered into an equity purchase agreement (&#x201c;TRC Equity Purchase Agreement&#x201d;) with Royalty Pharma Investments 2019 ICAV (&#x201c;Royalty Pharma&#x201d;) to sell our ownership interest in TRC. As a result of the sale of our ownership interest in TRC, which was consummated on July 20, 2022, we are no longer entitled to receive </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_061e66bc-ca95-4f8b-afa2-7cfd800d04c6" contextRef="C_5977bcd8-fc31-490c-827a-9db6ad3d5078" name="inva:PercentageOfRoyaltyPaymentsNotEntitledToReceive" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of royalty payments made by GSK stemming from sales of TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We retained our royalty rights with respect to RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_691656d3-8dac-44fb-ae47-ca110be44dca" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net revenue recognized under our GSK Agreements was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.213%;"></td>
        <td style="width:1.013%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.063%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.063%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.004%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.64%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties - RELVAR/BREO</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8ba4813-708c-4569-8cfa-77e6f85723f9" contextRef="C_5cd517a3-e6ab-4830-97d8-59d7687a4f18" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">215,034</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a35fa89d-3e65-45de-a021-7e6fa75c15be" contextRef="C_676e4e88-33ae-4484-8dfc-e0acec87e7a1" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">234,066</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6922d983-bb98-4a62-82ca-a5660d061caa" contextRef="C_238e19e1-e3b1-4349-834a-98123138313f" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">221,536</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties - ANORO</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c975d32-d607-43a9-bfac-62e69b0d3f5d" contextRef="C_12567e61-7617-4c87-b922-068faca8ecd2" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,405</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b598aa7-095f-4039-94db-b70b96c493bd" contextRef="C_6ef35e49-a54c-4f19-af9c-bb154b983308" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,935</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47e9c144-3a3d-4623-8bf4-0ceedefb8d02" contextRef="C_375a042d-32ca-4692-acf8-8877c36d21ae" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,992</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties - TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_070ab747-3ff0-43ab-ab7c-2df737234964" contextRef="C_fb4a498e-2f50-4c71-a55e-558ce1139356" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,029</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59e862ea-7c9a-402d-aa79-4489e0bc0b8c" contextRef="C_3b24b3e3-6e06-4dcd-8419-f71edb3c36c3" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,688</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3cbdb43d-63a2-4f8b-8be2-bb65e768510f" contextRef="C_75ae1480-904e-4b6a-9936-f2f684cc1cce" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73,089</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total royalties</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65a9ef7e-0be1-49b3-9dfb-6c776a325191" contextRef="C_dcd3daed-e03d-43b3-995a-2376fd31c571" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">325,468</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81d8de7b-2bc6-4d0d-8ec2-88fc52067b83" contextRef="C_5825419d-fd73-4fa4-a6ed-aa1e87d36fa0" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">405,689</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ca11364-81fb-41a1-8e83-766550eb1c3b" contextRef="C_e03c9a47-30dc-46ba-ba0f-c21cd67ac704" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">340,617</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: amortization of capitalized<br />&#160;&#160;&#160;fees paid</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ee5ee7e-d639-4078-b76b-37eda6a8ac51" contextRef="C_dcd3daed-e03d-43b3-995a-2376fd31c571" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,823</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18f3ed8a-13eb-4df5-b719-81aabb8faea8" contextRef="C_5825419d-fd73-4fa4-a6ed-aa1e87d36fa0" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,823</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b0fcda8-2e5a-413a-a275-30809059de6c" contextRef="C_e03c9a47-30dc-46ba-ba0f-c21cd67ac704" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,823</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalty revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9dfb7c4-7c76-4fcd-85e7-ddeec492577a" contextRef="C_dcd3daed-e03d-43b3-995a-2376fd31c571" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">311,645</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0401d0f-3571-499a-b71c-172a055eaded" contextRef="C_5825419d-fd73-4fa4-a6ed-aa1e87d36fa0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">391,866</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73592a36-58e8-4e35-b859-db07c16070a4" contextRef="C_e03c9a47-30dc-46ba-ba0f-c21cd67ac704" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">326,794</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Strategic alliance - MABA program</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7002e176-c98d-4ae5-99f8-9c8911ea0b91" contextRef="C_283916fc-d81b-4ecf-99aa-3b90c5c75493" name="inva:StrategicAllianceMabaProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f249b3e1-9c0b-4382-8d4e-5a40caefee28" contextRef="C_cccb0641-aa44-4b1c-a0d0-fd6d4158c2b4" name="inva:StrategicAllianceMabaProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39b485ea-26e0-4dec-8489-6a2483d0fff8" contextRef="C_0bc981e7-59dd-45eb-91b4-c1399903b025" name="inva:StrategicAllianceMabaProgram" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net royalty revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ca5a9af-4236-4b36-9dc7-76086b307684" contextRef="C_b62fd465-f5dd-40eb-aa36-8c18ef36ea86" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">311,645</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe2a09db-8b2c-49a1-ad4b-45a2181bbcff" contextRef="C_2ec07c39-1f00-4f12-9dfe-a75a6a1075ea" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">391,866</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b975180-d246-42e7-9c6c-75dd6b1a8fc0" contextRef="C_936c37a5-d79d-48ab-8b0a-483fe51759c2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">336,794</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">LABA Collaboration</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the launch and approval of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the U.S., Japan and Europe, we paid milestone fees to GSK totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_794b0d0a-f86e-441f-8dc4-65d21304dff8" contextRef="C_507fe221-0e42-48ef-9715-fb7f62c2affb" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">220.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, 2014. The milestone fees paid to GSK were recognized as capitalized fees paid, which are being amortized over their estimated useful lives commencing upon the commercial launch of the product. The amortization is recorded as a reduction to the royalties from GSK.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are entitled to receive annual royalties from GSK on sales of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as follows: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2427a668-a5a3-4a23-a1a6-8f7aeaf66462" contextRef="C_1331927b-9f86-4b7d-81d5-27a5846306f8" name="inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on the first $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_adbe931c-16ea-40df-8810-bf165bbdb1d9" contextRef="C_1331927b-9f86-4b7d-81d5-27a5846306f8" name="inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion of annual global net sales and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45265d5c-91cf-4174-898b-52b2ecacf29b" contextRef="C_1331927b-9f86-4b7d-81d5-27a5846306f8" name="inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for all annual global net sales above $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edf78583-1411-481f-b8d1-9b5bc65248bc" contextRef="C_1331927b-9f86-4b7d-81d5-27a5846306f8" name="inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion. Sales of single&#x2011;agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the LABA Collaboration, such as ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, royalties are upward tiering and range from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06f36741-2d42-43b5-a485-9d036b513bb1" contextRef="C_d59a34b7-1a2d-4e81-b069-63e808ef44cb" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47544d1a-06c0-4a9b-b968-8e5d6a288a93" contextRef="C_e61918a2-0f31-4d42-984d-dedda7b852ed" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also entitled to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a259b091-94b5-467d-ac0a-c8680b5a53af" contextRef="C_77fb24cf-b9f6-407a-ba9c-858247b06623" name="inva:PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to TRC in connection with the Spin-Off, including TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which royalties are upward tiering and range from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f197308-02e9-4b20-96b8-246df3eb12bb" contextRef="C_cd8c3695-a759-4ca6-9be7-64a5775cc175" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7f32927-c0d3-4858-85ef-37198d4018de" contextRef="C_b8bfe4f9-1bc3-43e2-b056-965fbab72a8a" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2004 Strategic Alliance</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2020, we recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43b87ea2-d22b-4c1f-8665-2f80c7e2aeed" contextRef="C_71ef9fc1-7268-4619-8fc8-2922d4e683a5" name="us-gaap:GainLossOnContractTermination" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in revenue from a termination fee paid in connection with the termination of the Bifunctional Muscarinic Antagonist-Beta2 Agonist (&#x201c;MABA&#x201d;) program under the Strategic Alliance Agreement with GSK.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Product Sales</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net product sales we recognized from the date of acquisition of La Jolla, which occurred on August 22, 2022, to December 31, 2022 were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d05a0aa-08ec-46b7-9421-bef97aac5dad" contextRef="C_dd16336a-4a72-4552-8d5c-b8332029c781" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, consisting of net sales of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57b667ef-59f4-45af-ae2e-c292264664cf" contextRef="C_4d7d202f-bfb9-44a0-8281-04c234b04110" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6755624-d76d-4fd3-90aa-f1a66ac639f4" contextRef="C_acc278fb-4048-4edf-b4c0-fffa88f0aada" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. We derived approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26ecb390-3303-4e29-bfec-a3dab2a36813" contextRef="C_3014405b-7e86-4ca8-9b06-d944fd32e11a" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">96</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2a35dce-cdbe-4e41-8e26-63577fbfbae4" contextRef="C_dc90f4aa-923b-4d08-8914-8e2e4b24dcfd" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of our net product sales for the same period from customers located in the U.S. and the rest of the world, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_25a30460-f138-406a-88bf-bf2563ccfc5c" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:LicenseAndCollaborationArrangementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.  LICENSE AND COLLABORATION ARRANGEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Out-License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Zai Lab</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entasis entered into a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. (&#x201c;Zai Lab&#x201d;), pursuant to which Zai Lab licensed exclusive rights to durlobactam and SUL-DUR, in the Asia-Pacific region (&#x201c;the Zai Agreement&#x201d;). Under the terms of the Zai Agreement, Zai Lab will fund most of the registrational clinical trial costs in China for SUL-DUR, with the exception of Phase 3 patient drug supply of licensed products. Zai Lab will conduct development activities and plan and obtain regulatory approval in a specified number of countries in the Asia-Pacific region beyond China after receipt of regulatory approval of a licensed product in China. Zai Lab is also solely responsible for commercializing licensed products in the Asia-Pacific region and will commercialize licensed products for which it has obtained regulatory approval. We are obligated to supply Zai Lab with the licensed products for clinical development and, if the licensed product is approved, for commercial use for a certain period unless Zai Lab notifies otherwise. Zai Lab may take over manufacturing responsibilities for its own commercialization activities within a specified time period following the effective date of the Zai Agreement.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We ar</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e eligible to receive up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5f62d7b-8231-4704-838f-947082fd47bc" contextRef="C_dd7cfa80-9759-4df0-9de9-4910b0bcbdbb" name="inva:FuturePotentialMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">91.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in research and development support payments and development, regulatory and sales milestone payments related to SUL-DUR, imipenem and other combinations with the licensed products. Zai Lab will pay us a tiered royalty equal to from a high-single digit to low-double digit percentage based on annual net sales of licensed products in the territory, subject to specified reductions for the market entry of competing products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f65fa3a2-f242-4090-aa44-c9bfa3bcbb26" contextRef="C_c5fa27cc-5d17-4a15-b456-34db9e1c8687" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> revenue was recognized under the Zai Agreement from the acquisition date of Entasis. Payments received for research support and reimbursable clinical trial costs are recorded as a reduction to research and development expense during the period in which the qualifying expenses are incurred. Such amounts recorded from the date of acquisition of Entasis to December 31, 2022 are not material.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GARDP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entasis entered into a collaboration agreement with the Global Antibiotic Research and Development Partnership (&#x201c;GARDP&#x201d;) for the development, manufacture and commercialization of the product candidate zoliflodacin in certain countries (&#x201c;the GARDP Collaboration Agreement&#x201d;). Under the terms of the GARDP Collaboration Agreement, GARDP will use commercially reasonable endeavors to perform and fully fund the Phase 3 registrational trial, including the manufacture and supply of the product candidate containing zoliflodacin, in uncomplicated gonorrhea. We recorded reimbursements from GARDP under this agreement as reduction to research and development expense. Relevant amounts from the date of acquisition of Entasis to December 31, 2022 are not material.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, under the GARDP Collaboration Agreement, GARDP was granted a worldwide, fully paid, exclusive and royalty-free license, with the right to sublicense, to use our zoliflodacin technology in connection with GARDP&#x2019;s development, manufacture and commercialization of zoliflodacin in low-income and specified middle-income countries. We retained commercial rights in all other countries worldwide, including the major markets in North America, Europe and Asia-Pacific. We also retained the right to use and grant licenses to our zoliflodacin technology to perform our obligations under the GARDP Collaboration Agreement and for any purpose other than gonorrhea or community-acquired indications. If we believe that the results of the Phase 3 registrational trial of zoliflodacin would be supportive of an application for marketing approval, we are obligated to use our best efforts to file an application for marketing approval with the FDA within six months of the completion of the trial and to use commercially reasonable endeavors to file an application for marketing approval with the European Medicines Agency (&#x201c;EMA&#x201d;). Each party is responsible for using commercially reasonable efforts to obtain marketing authorizations for the product candidate in their respective territories.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PAION AG</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the PAION AG (&#x201c;PAION&#x201d;) License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the European Economic Area, the United Kingdom and Switzerland (collectively, the &#x201c;PAION Territory&#x201d;). We are entitled to receive potential commercial milestone payments of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e361813-8eb7-4038-9d80-2c705934e5ea" contextRef="C_39cf12a7-a194-4f3f-a151-0889b4253c28" name="inva:FuturePotentialMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">109.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and double-digit tiered royalty payments. Royalties payable in a given jurisdiction under the PAION License will be subject to reduction on account of generic competition and after patent expiration in that jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA&#174; and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the PAION Territory. We have not recognized any revenue from PAION related to commercial milestones from the date of acquisition of La Jolla to December 31, 2022. Royalty revenue recognized under this agreement from the date of acquisition of La Jolla to December 31, 2022 was not material.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">La Jolla also entered into the PAION commercial supply agreement (the &#x201c;PAION Supply Agreement&#x201d;) whereby La Jolla will supply PAION a minimum quantity of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through July 13, 2024. The PAION supply agreement will automatically renew until the earlier of July 13, 2027, or until a new supply agreement is executed. During the initial term of the supply agreement, we will be reimbursed for direct and certain indirect manufacturing costs at cost. Amounts recognized under this agreement from the date of acquisition of La Jolla to December 31, 2022 were not material.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Everest Medicines Limited</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Everest Medicines Limited (&#x201c;Everest&#x201d;) License, La Jolla granted Everest an exclusive license to develop and commercialize XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the treatment of complicated intra-abdominal infections (&#x201c;cIAI&#x201d;) and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the &#x201c;Everest Territory&#x201d;). We are eligible to receive an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2925b995-12ad-442b-842f-97ba7cc1519a" contextRef="C_80058a16-9c51-485f-8884-e6849191bd21" name="inva:RegulatoryMilestonePaymentsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million regulatory milestone payment and up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a403aa57-c5cf-426e-a668-d2eaf696004b" contextRef="C_80058a16-9c51-485f-8884-e6849191bd21" name="inva:SalesMilestonePaymentsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in sales milestone payments. We are also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (i) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (iii) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e3085b5b-18cc-413f-8e70-6a97671804de" contextRef="C_d7e11212-8609-4fda-a248-41d5348f3383" name="inva:RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years after the first commercial sale of a product in such jurisdiction in the Everest Territory. We have not recognized any revenue from Everest related to regulatory and sales milestones from the date of acquisition of La Jolla to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022. Royalty revenue recognized under this agreement from the date of acquisition of La Jolla to December 31, 2022 was not material.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A new drug application (&#x201c;NDA&#x201d;) was submitted with the China National Medical Products Administration (&#x201c;NMPA&#x201d;) for XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the treatment of cIAI in patients in China in 2021. XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was approved in Singapore by the Health Science Authority in 2020.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">La Jolla also entered into the Everest commercial supply agreement (the &#x201c;Everest Supply Agreement&#x201d;) whereby La Jolla will supply Everest a minimum quantity of XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through December 31, 2023 and will transfer to Everest certain XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-related manufacturing know-how. We will be reimbursed for direct and certain indirect manufacturing costs at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d82a7dd8-d4f3-460c-bb0b-15d9baafef84" contextRef="C_a8932c51-4ee5-4ba0-82b7-47753c1c9a9a" name="inva:PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">110</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of cost through December 31, 2023. We initially recognized a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d990b634-3cd0-4b81-81e8-9bd95d328cd6" contextRef="C_dadd5411-7bb4-4843-b9b2-3fddc474ba05" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million partial prepayment for XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as deferred revenue, of which, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b97d1007-24fb-48c1-9ab0-e15ad6ce3480" contextRef="C_a8932c51-4ee5-4ba0-82b7-47753c1c9a9a" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recognized as revenue for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">In-License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">George Washington University</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the George Washington University (&#x201c;GW&#x201d;) License, GW exclusively licensed to La Jolla certain intellectual property rights relating to GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under the GW License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We are obligated to pay a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b616c0d5-6fe9-467f-ba8c-8dfc3f476717" contextRef="C_1aa9bc6a-6c60-4a2b-9e33-2d8d6bc2de04" name="inva:PercentageOfRoyaltyPayableOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% royalty on net sales of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7743f961-065b-495c-99ba-1773d75e2682" contextRef="C_1aa9bc6a-6c60-4a2b-9e33-2d8d6bc2de04" name="inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. From the date of acquisition of La Jolla to December 31, 2022, the amounts recognized under this agreement were not material.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Harvard University</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Harvard University (&#x201c;Harvard&#x201d;) License, Harvard exclusively licensed to La Jolla certain intellectual property rights relating to tetracycline-based products, including XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. For each product covered by the Harvard License, we are obligated to make certain payments for the following: (i) up to approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7d54ed1-738e-4c0b-8ec4-034dfa1c1776" contextRef="C_6a2877be-4f3b-4a25-870f-05069f62cb38" name="inva:ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the achievement of certain clinical development and regulatory milestones; (ii) a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_739aeea5-05e6-4734-abdb-78aefdb20aa0" contextRef="C_6a2877be-4f3b-4a25-870f-05069f62cb38" name="inva:PercentageOfRoyaltyPayableOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% royalty on direct U.S. net sales of XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, starting at a minimum royalty rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be5bb615-f034-42e6-95b7-0b19b33c5acc" contextRef="C_6a2877be-4f3b-4a25-870f-05069f62cb38" name="inva:PercentageOfMinimumRoyaltyRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, with step-ups to a maximum royalty of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91f861e8-e406-4630-9cc7-abad22dea84a" contextRef="C_6a2877be-4f3b-4a25-870f-05069f62cb38" name="inva:PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% based on the achievement of annual net product sales thresholds; and (iv) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87a78243-8e85-4092-86e6-9072ff276cd1" contextRef="C_6a2877be-4f3b-4a25-870f-05069f62cb38" name="inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. From the date of acquisition of La Jolla to December 31, 2022, amounts recognized under this agreement were not material.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Paratek Pharmaceuticals, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Paratek Pharmaceuticals, Inc. (&#x201c;Paratek&#x201d;) License, Paratek non-exclusively licensed to La Jolla certain intellectual property rights relating to XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, including non-exclusive rights to certain issued patents and patent applications covering XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We are obligated to pay Paratek a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3231d1e-24f1-472b-927c-76665cc04fd5" contextRef="C_d2c072bc-c407-4f39-8c36-301e061f1ca8" name="inva:PercentageOfRoyaltyPayableOnNetSales" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% royalty based on direct U.S. net sales of XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our obligation to pay royalties with respect to the licensed product is retroactive to the date of the first commercial sale of XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and shall continue until there are no longer any valid claims of the Paratek patents, which will expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6cfe3c77-3030-4421-98d5-699d2ab0b12a" contextRef="C_d2c072bc-c407-4f39-8c36-301e061f1ca8" name="inva:ClaimExpirationDate" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. From the date of acquisition of La Jolla to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, amounts recognized under this agreement were not material.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dac67ad3-1249-49c3-8da4-1aa59afeda19" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:ConsolidatedEntitiesAndAcquisitionsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. CONSOLIDATED ENTITIES AND ACQUISITIONS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Consolidated Entities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Theravance Respiratory Company, LLC</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Up until July 20, 2022, we consolidated TRC under the VIE model as we determined that TRC was a VIE and we were the primary beneficiary of the entity because we had the power to direct the economically significant activities of TRC and the obligation to absorb losses of, or the right to receive benefits from, TRC. We held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79d79c14-7513-4b46-9976-041eb445f3bf" contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69" name="inva:OwnershipInterestInConsolidatedEntities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% ownership interest of TRC. The primary source of revenue for TRC is the royalties generated from the net sales of TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> by GSK.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As discussed in Note 3, &#x201c;Revenue Recognition&#x201d;, on July 13, 2022, ITH entered into the TRC Equity Purchase Agreement to sell our ownership interest in TRC. Upon the closing of the transaction on July 20, 2022, we received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38e3bf72-b173-44ec-b7e4-270c72facd23" contextRef="C_c85a10d8-967e-4263-82f9-7532cc5b50dc" name="inva:ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">277.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash from Royalty Pharma. We are also entitled to receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_350540ee-47da-4b77-9b59-356bbdb774bf" contextRef="C_470cc2e5-a00e-4451-811a-42f58ffbce14" name="inva:ContingentSalesBasedMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in contingent sales-based milestone payments in the future. In connection with the closing of the transaction, we also received our portion of TRC&#x2019;s remaining cash balance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e0b7989-bd7d-4fb0-9e80-07eea2d46d7e" contextRef="C_470cc2e5-a00e-4451-811a-42f58ffbce14" name="inva:CashDistributionReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from Royalty Pharma rather than through a cash distribution from TRC.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the closing of the transaction and as part of the agreement, TRC distributed its ownership interests and investments in InCarda Therapeutics, Inc., ImaginAb, Inc., Gate Neurosciences, Inc. and Nanolive SA, which had a total carrying value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94b48be6-594e-4da3-8ef7-7c50670980eb" contextRef="C_c85a10d8-967e-4263-82f9-7532cc5b50dc" name="us-gaap:EquityMethodInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">39.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to ITH. We accounted for the transaction similar to an upstream sale between a parent and a VIE under ASC 810-10. As such,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITH </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recorded the transferred investments at their respective carrying values and no gain or loss was recognized in the consolidated statement of income.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6c765c10-3de1-4c9a-acaa-81478337378c" contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The summarized financial information for TRC as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021 and for the relevant periods through the sale date in 2022 are presented as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance sheet</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"></td>
        <td style="width:1.794%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.881%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_678dbc81-a047-451a-a58f-f90654fc5b94" contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,713</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receivables from collaborative arrangements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_697ee9d6-e8f9-4fb3-b1f0-fba0edc9372f" contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0" name="us-gaap:DueFromRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,492</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bda9dace-f602-4ca5-9627-5e36c8982319" contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity and long-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8909cdf-477a-4799-bc9d-2ef6c5b4ffc3" contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,695</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d066799f-8e42-4bd6-a7fc-4d09531366e4" contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">130,971</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and LLC Members&#x2019; Equity</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3815119d-fa06-4153-81c1-17c5214eb943" contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">252</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LLC members&#x2019; equity</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_458f20b6-d7e5-4e2a-9437-e28ec00628c3" contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0" name="us-gaap:MembersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">130,719</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and LLC members&#x2019; equity</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5f5e607-2998-40f3-9249-5f9fd863e7dd" contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">130,971</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.112%;"></td>
        <td style="width:0.995%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.276%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.45%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.276%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.45%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.443000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalty revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86dc67a7-1dc7-4bb6-ae4c-31c620a7a8c0" contextRef="C_776c1f34-bbdc-44d5-80e8-a6cccdaa9570" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,029</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98a0fa34-bfcb-411a-92b3-5062e6f9910c" contextRef="C_55981a3b-c27e-47a6-bec2-2df69c4457cd" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,688</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3742c219-905a-48fe-86c8-33365a383f87" contextRef="C_3542ed0a-f698-456b-b13d-df3808be4d52" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73,089</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue from collaborative arrangements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e86b34eb-a400-4de8-a6d1-bda0467868f1" contextRef="C_f6111456-3ab3-4369-86bb-70377a24aea5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a38f3c97-fdb8-4f00-9091-1923e15698c0" contextRef="C_77f70987-1a99-49d7-a124-ec8a7e4706b5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fa7d1f1-4912-4c20-acc4-de592d5a64a9" contextRef="C_4b3a5f9b-38bc-43b9-a48b-838362ad8efb" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acb2f52d-086e-48bc-98c6-39e21bc6a54e" contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,029</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c820748f-06d6-4a57-9482-76de9ecd3733" contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,688</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e86bf1c5-e873-417a-9942-d251b15b5e2b" contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,089</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_521f41f8-3102-4803-8dd3-d66c56b3ac30" contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">332</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ec83a3a-1181-43ef-a15b-50e557b6f143" contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,956</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2b49101-c1b2-4d2d-9475-041a7955e7a0" contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,612</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income from operations</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c392004-41b0-4c06-b69e-3c3989f1da72" contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71,697</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef4a669e-84af-4e93-a59a-e7e80f5e6640" contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122,732</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db40794b-d0e9-45b2-abba-fb3f524dd8e5" contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">80,477</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d9bf4a0-4bf1-43e0-b158-8e543323249a" contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc45e58a-7c37-4347-8239-30a4a8625107" contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3732e541-5006-4acc-b367-cfa92115e2e6" contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Realized loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a60f2bef-ef0a-446d-8d7c-bfb962574365" contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69" name="inva:RealizedLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,386</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f303a35-1dc7-49a1-9257-893ab105849c" contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0" name="inva:RealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1059cbcf-ca20-4b0b-a329-ba17c65e0449" contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38" name="inva:RealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fa0aea7-9d32-43e0-8b99-2f28dfa45057" contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3d08855-136a-44d2-b946-f3beb0c817da" contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a406f92c-df9a-4bf7-8897-c35e9a2d9ab1" contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair values of other equity and<br />&#160;&#160;&#160;long-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58a6e17d-816a-4800-b40a-497386e20e19" contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69" name="us-gaap:GainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,884</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35369e73-be35-4e15-ab61-f7bf7cf72b44" contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0" name="us-gaap:GainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,541</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dabee276-d1fc-4f0d-8c23-4a092d8b1429" contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38" name="us-gaap:GainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,147</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_498794db-f6ff-4500-b278-62cc95d92aa2" contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,438</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8af723af-c819-4e74-b7bd-591d01c78f98" contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">121,191</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_167587f4-80f0-46d2-ba33-7d91029e053c" contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,662</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:footnote id="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71" xml:lang="en-US"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</span></p></ix:footnote></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ISP Fund LP</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, Innoviva Strategic Partners LLC, our wholly owned subsidiary (&#x201c;Strategic Partners&#x201d;), contributed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_393a18ff-87e4-4f59-b623-31230e0f60b5" contextRef="C_3da5364e-c3cc-4073-9770-65a8da75a030" name="us-gaap:LimitedPartnersContributedCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">300.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to ISP Fund LP (the &#34;Partnership&#34;) for investing in &#x201c;long&#x201d; positions in the healthcare, pharmaceutical and biotechnology sectors and became a limited partner. The general partner of the Partnership (&#34;General Partner&#34;) is an affiliate of Sarissa Capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Partnership Agreement provides for Sarissa Capital to receive management fees from the Partnership, payable quarterly in advance, measured based on the Net Asset Value of Strategic Partners' capital account in the Partnership. In addition, the General Partner is entitled to an annual performance fee based on the Net Profits of the Partnership during the annual measurement period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Partnership Agreement includes a lock-up period of thirty-six months after which Strategic Partners is entitled to make withdrawals from the Partnership as of such lock-up expiration date and each anniversary thereafter, subject to certain limitations.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, Strategic Partners received a distribution of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9587a82d-8a9b-4f28-abf5-2db84eff985a" contextRef="C_93e0e07a-b332-46ca-be2f-706ee21b9d8b" name="us-gaap:LimitedPartnersCumulativeCashDistributions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">110.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from the Partnership to provide funding to Innoviva for a strategic repurchase of the Company's shares held by GSK. On March 30, 2022, Strategic Partners made an additional capital contribution of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3731579-0b9e-4445-9c04-31d4b95ad0c6" contextRef="C_2abf6f42-38e2-40d9-a0d2-9871c5194249" name="us-gaap:LimitedPartnersContributedCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">110.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Partnership pursuant to the letter agreement entered into between Strategic Partners, the Partnership and Sarissa Capital Fund GP LP on May 20, 2021. The capital contribution is subject to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2f0236ed-aaae-4f1b-b812-a8d8ba596d9b" contextRef="C_f39c54bb-13a8-4982-a1a5-05cf42acdcd2" name="inva:PartnershipAgreementLockUpPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lock up period from the contribution date</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consolidate ISP Fund LP under the VIE model as we have determined that ISP Fund LP is a VIE and we are the primary beneficiary of the entity via our related party relationships with Sarissa Capital entities.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, we continued to hold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edc755d6-03a7-48f7-9911-a49de6dbaa82" contextRef="C_006d6f8d-3460-4b4e-a5bd-62c377110a66" name="inva:PercentageOfEconomicInterestInPartnership" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the economic interest of Partnership. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, total assets of the Partnership were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f53fa3a7-d305-4fa5-bf82-9fd8f3ef3879" contextRef="C_9d306884-7dee-45a2-9203-d77e41d65ae4" name="us-gaap:Assets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">320.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec1f9a51-68cc-4403-a005-2054d31a8dc8" contextRef="C_f25f9085-e7bd-462a-8c86-23de80c89333" name="us-gaap:Assets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">195.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, of which the majority was attributable to equity, debt and long-term investments. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, total liabilities of the Partnership w</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ere $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d70129dc-2555-497a-be31-803b7e21c9c2" contextRef="C_9d306884-7dee-45a2-9203-d77e41d65ae4" name="us-gaap:Liabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mill</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ion and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b09271f4-06cd-44f3-8bfc-da84d7f5c7d8" contextRef="C_f25f9085-e7bd-462a-8c86-23de80c89333" name="us-gaap:Liabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The Partnership's assets can only be used to settle its own obligations. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the Partnership incurred</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cbe553c-396c-443e-83a8-dc204a7a7c1f" contextRef="C_006d6f8d-3460-4b4e-a5bd-62c377110a66" name="us-gaap:InvestmentIncomeInvestmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million in net investment-related expenses, generated $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a70cd8e-cc04-4783-a5b8-73f49a93b282" contextRef="C_006d6f8d-3460-4b4e-a5bd-62c377110a66" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million interest income, recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5833325-776b-445a-89d5-adbaf326cb82" contextRef="C_006d6f8d-3460-4b4e-a5bd-62c377110a66" name="us-gaap:GainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net realized gains and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d00f0c00-9161-40f1-acd4-fa3c63e6d7c5" contextRef="C_006d6f8d-3460-4b4e-a5bd-62c377110a66" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net unrealized losses as changes in fair values of other equity and long-term investments, net, on the consolidated statements of income. During the year ended December 31, 2021, the Partnership incurred</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e29e5f78-ed25-46c6-a8c1-139c8e6566db" contextRef="C_3251587b-f79c-4e54-ba80-2c3e2d36881d" name="us-gaap:InvestmentIncomeInvestmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net investment-related expense, generated $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61b844cf-2bb1-4caa-9e7c-63ebcc7f6891" contextRef="C_3251587b-f79c-4e54-ba80-2c3e2d36881d" name="us-gaap:InvestmentIncomeInterestAndDividend" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million interest and dividend income, and recorded net $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_316076a8-3da1-48f1-9427-b4a635e92e6f" contextRef="C_3251587b-f79c-4e54-ba80-2c3e2d36881d" name="us-gaap:GainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million realized gains and net $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5febf443-ad25-4595-9e43-197e2a75c13e" contextRef="C_3251587b-f79c-4e54-ba80-2c3e2d36881d" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million unrealized losses as changes in fair values of other equity and long-term investments, net, on the consolidated statements of income. We account for the long-term investments held by ISP Fund LP as equity investments measured at fair value and an investment in convertible notes as trading security.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquisitions</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Entasis Therapeutics Holdings Inc.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We started investing in Entasis in 2020 as part of our capital allocation strategy of deploying cash generated from royalty income and investing in different life sciences companies. Entasis is an advanced, late clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products. During the second quarter of 2020, we purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1aa76c99-e8a8-4ebf-857c-0fcce1ad52ab" contextRef="C_64c565f8-b8c8-4b5e-8680-bd30e909b71f" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">14,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock as well as warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1ea64cf-cfd5-40bb-81ed-aeaddb09a5ce" contextRef="C_d36b2a4f-1056-4575-a198-9dd2e9d0fa87" name="inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">14,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of common stock of Entasis for approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d488521-d6a6-4dcf-a19a-59a1c1c78e94" contextRef="C_33ced285-7a79-4d44-9fd4-1c555534d19d" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash. During the third quarter of 2020, we purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82821955-e836-42fe-b6b4-843d39069a52" contextRef="C_412716b4-7218-40f6-adc0-a9a7b2226300" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,672,897</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Entasis common stock as well as warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa30c432-d5a2-4eb5-9c67-a448956adb10" contextRef="C_6a9f3a87-35e9-4510-9ef5-42186f58a55d" name="inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,672,897</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of its common stock for approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2a2bdf6-b8c3-4612-b72a-b9d5f6067b0e" contextRef="C_bb7f1b9c-c794-42e0-872f-0ba49fe65cad" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash. Effective in June 2020, after certain conditions were met with respect to the sales of Entasis equity shares, Innoviva had the right to designate </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_322d7a72-0791-40da-9039-ad40f9ca5a61" contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223" name="inva:SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" unitRef="U_Director" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> members to Entasis&#x2019; board of directors. During the second quarter of 2021, Innoviva&#x2019;s wholly owned subsidiary, Innoviva Strategic Opportunities, LLC (&#x201c;ISO&#x201d;) entered into a securities purchase agreement with Entasis to acquire </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8650c5b9-b879-4956-b4b4-65189c57ea82" contextRef="C_91dd5dfc-a8fa-4797-a5f1-1cbcfbb0101d" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Entasis common stock and warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eeb014e1-7a8a-497f-a2f2-e463ab259aa6" contextRef="C_5713e251-00d3-4344-8351-32137ba92c7f" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of Entasis common stock for approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b31b2756-cd20-45d5-9608-d75098d0e6d5" contextRef="C_46102164-0773-400f-906c-f458fc8d0c96" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of Entasis&#x2019; common stock was measured based on its closing market price at each balance sheet date. The warrants had an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44460c84-9a40-4933-95d8-de9a0a501474" contextRef="C_d8114345-dec6-4194-93e9-3a1b415dbb83" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e013fda-1d27-4c4a-ae72-b4c616f72df9" contextRef="C_ba934ce3-7b7f-485e-9ba2-cec7f54bb480" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:numdotdecimal">2.675</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for those warrants acquired in the second and third quarter of 2020, respectively. The warrants acquired in the second quarter of 2021 had an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf25b911-c264-427c-bb7a-a153af00b081" contextRef="C_bb6b6c9e-02d0-4be8-b0ad-089e8436ed15" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. All of the warrants were exercisable immediately within </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3e8976d9-c095-4f5f-b06f-79eea450f9f5" contextRef="C_9d895e55-890d-4019-93ff-8bf714b8997b" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_5c7b9d47-577c-442c-8ac5-7da0ec91f57e" contextRef="C_7bb172e8-abbc-4585-873a-e59b32f846e6" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_70aa63f0-4e3f-4a37-a71e-c4f69411f5f4" contextRef="C_b335fc75-9e6c-4232-9459-e0730898b34c" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the issuance date of the warrants and included a cashless exercise option. We used the Black-Scholes-Merton pricing model to estimate the fair value of these warrants.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 17, 2022, ISO entered into a securities purchase agreement with Entasis pursuant to which ISO purchased a convertible promissory note for a total purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc792e20-88c5-4540-b4fe-8b66b4755c15" contextRef="C_71a8eb9a-e948-4bab-961c-28016a550572" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The note bore an annual interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1d4e95e-3573-4c3a-9240-cc2e003d8790" contextRef="C_71a8eb9a-e948-4bab-961c-28016a550572" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.59</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and was due to mature and become payable on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_281316dc-d99b-4982-a1d9-732dcc1f26b6" contextRef="C_eee47a4c-1fd8-4bc9-916a-4c43bdc117fd" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 18, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless it was converted at a conversion price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0c23186-119c-4203-b7ac-86bf051747f4" contextRef="C_71a8eb9a-e948-4bab-961c-28016a550572" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.48</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> before the maturity date. With this financing, we determined that we had both (i) the power to direct the economically significant activities of Entasis and (ii) the obligation to absorb the losses, or the right to receive the benefits, that could potentially be significant to Entasis and therefore, we were the primary beneficiary of Entasis. Accordingly, we consolidated Entasis&#x2019; financial position and results of operations effective on February 17, 2022. Our equity ownership interest remained at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9971abdf-4717-4848-9229-e727719915af" contextRef="C_31d13e09-7b0b-45f3-8c0c-c5750ed2e05f" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">59.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% as of February 17, 2022, and the fair values of our holdings of Entasis common stock and warrants were remeasured and estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_909e5bf9-582c-4a04-8780-b336fefc535c" contextRef="C_32d6e1d8-d581-4a23-a3d6-067540daf4c9" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">64.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40326ac4-aa2e-451e-bc6c-655ee11c65f2" contextRef="C_faf804e2-dcb7-4016-8d35-d20f9d798b45" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">31.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The remeasurement resulted in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_368e9bc5-00c3-467b-8b6e-c9b27ff1592d" contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million loss in the first quarter of 2022 which was included in changes in fair values of equity method investments, net, on the consolidated statements of income for the year ended December 31, 2022.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We completed our acquisition of Entasis&#x2019; remaining noncontrolling interest on July 11, 2022. We remeasured our holdings in Entasis as of that date and recognized a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f36a9872-338b-441e-af8c-f9d950abd8cd" contextRef="C_c2438911-cddb-444f-87c4-9270c2e0d009" name="inva:BusinessAcquisitionsOfChangeInFairValueOfInvestment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million loss, which was included in changes in fair values of equity method investments, net, on the consolidated statement of income for the year ended December 31, 2022. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d24e3e3-85ab-4b03-b27d-5a91148b0eb9" contextRef="C_c2438911-cddb-444f-87c4-9270c2e0d009" name="us-gaap:RepaymentsOfConvertibleDebt" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payments were made toward the convertible promissory note through the date of acquisition of Entasis. In connection with the acquisition, all of the Entasis warrants were replaced with Innoviva warrants (the &#x201c;Replacement Warrants&#x201d;) of equivalent value and bearing the same terms. The Replacement Warrants are classified as equity.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognized the difference between the acquisition price and the carrying value of the acquired noncontrolling interest on July 11, 2022 in our additional paid-in capital.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair values assigned to assets acquired and liabilities assumed as of February 17, 2022 were based on management&#x2019;s best estimates and assumptions. After the acquisition in July 2022, we adjusted the preliminary estimates of fair value of assets acquired and liabilities assumed based on new and additional information related to product sales forecast provided by Entasis and deferred tax liabilities.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, we recorded measurement period adjustments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06a5a051-e079-450a-93f3-d18ec00e4beb" contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223" name="us-gaap:GoodwillPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million decrease in goodwill, primarily related to a decrease in estimated purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94c06862-0038-40a3-b326-92247d4162f1" contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223" name="inva:MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, an increase in noncontrolling interests of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58f60120-2d36-4fda-95db-7e2dbac2936f" contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223" name="us-gaap:MinorityInterestPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and an increase in intangible assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9adedabd-6b4b-4a70-b94a-96264dfb9573" contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223" name="us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The cumulative impact of the measurement period adjustments included in the consolidated net income for the year ended December 31, 2022 was not material.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has completed a preliminary valuation and expects to finalize it as soon as practical, but no later than one year from the acquisition date. The purchase accounting for this transaction is not yet finalized.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_064aa016-ed12-4baf-8063-93fdd24adc37" contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table represents the adjusted fair values of the assets acquired and liabilities assumed by us in the transaction:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"></td>
        <td style="width:1.794%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.881%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 17, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44939635-2168-4449-bc96-02f14b8f192a" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,070</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a5b095a-5fce-48ce-8d66-5b969b1b1d1c" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,554</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c822daf-f1e8-4b58-a0d9-3be61e05ca08" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,959</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f852d7d9-276f-4d55-bd04-e1812d4bff2b" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">185</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_178447ed-df0f-4de3-8816-c5986589afa0" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">959</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_129308f1-ccf8-4e36-b410-2606c0187e19" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,260</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e31b833-dc4f-4291-aeef-6b259a48bd8f" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">107,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c01b9e84-48dd-486d-ab83-082a892fc7c0" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">302</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets acquired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_abfdb16c-2f3c-46fd-ad1e-e94b282dd30f" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">149,789</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12ab55d4-4d41-4421-a363-5ad80e0a2028" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,583</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued personnel-related expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acd5080c-c2e0-4ac6-9d6d-c0d20f48130e" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,058</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52f67d9e-0655-4afa-8c3a-c03508887031" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,096</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b92fbe1e-3621-4a44-9e42-42824ff101f0" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,336</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities assumed</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8f87624-29a4-480f-9788-e13088b826ae" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,073</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets acquired, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20e85d73-5f8f-4768-8508-8b55b2c49b52" contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134,716</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The goodwill arising from the acquisition of Entasis is primarily attributable to Entasis&#x2019; assembled workforce and the value associated with growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refer to Note 8, &#x201c;Goodwill and Intangible Assets&#x201d;, for more discussion on the intangible assets recognized as part of this acquisition.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our consolidated net income for the year ended December 31, 2022 included the net loss attributable to noncontrolling interest since the consolidation date until the date of acquisition </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e44c6bd4-cf8e-4363-8a79-e2d736142398" contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">13.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">La Jolla Pharmaceutical Company</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 22, 2022, ISO acquired La Jolla for a total consideration of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_552aba39-b057-4e58-82f9-1b170ecd94b0" contextRef="C_97660a37-a4d7-4e93-aa09-8f8b998393d8" name="us-gaap:BusinessCombinationConsiderationTransferred1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">206.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. ISO acquired La Jolla at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_abf068f2-552c-4525-a62d-3bd83417712f" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessAcquisitionSharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.23</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. La Jolla is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla brings to Innoviva an established product portfolio, including GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (eravacycline) for the treatment of cIAIs.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair values assigned to assets acquired and liabilities assumed are based on management&#x2019;s best estimates and assumptions as of August 22, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, we recorded measurement period adjustments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4ea727e-c688-4941-906b-76e7f5ac1bc2" contextRef="C_6cb7b433-593e-4c62-95c5-c68106abd3d7" name="us-gaap:GoodwillPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million increase in goodwill, primarily related to a decrease in inventory and intangible assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92dce771-c259-4612-95e3-37b2a02f6252" contextRef="C_6cb7b433-593e-4c62-95c5-c68106abd3d7" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">7.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_279247c0-5e05-42dc-ad44-ffad8bdc0ecc" contextRef="C_6cb7b433-593e-4c62-95c5-c68106abd3d7" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, and an increase in deferred tax liabilities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03eae049-e466-4d2e-91b1-fb08af516064" contextRef="C_6cb7b433-593e-4c62-95c5-c68106abd3d7" name="inva:IncreaseDecreaseInDeferredTaxLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, partially offset by a decrease in other long-term liabilities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2bebc147-7536-4961-a81e-4f1d5689d5a2" contextRef="C_6cb7b433-593e-4c62-95c5-c68106abd3d7" name="inva:MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">8.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The cumulative impact of the measurement period adjustments included in the consolidated net income for the year ended December 31, 2022 was not material.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have completed a preliminary valuation and expect to finalize it as soon as practicable, but no later than one year from the acquisition date. The purchase accounting for this transaction is not yet finalized.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We incurred approximate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ly $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_124adacc-590d-4b31-bbef-ba7428ed563d" contextRef="C_6cb7b433-593e-4c62-95c5-c68106abd3d7" name="us-gaap:AcquisitionCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in acquisition-related costs in connection with this acquisition and such amount is included in selling, general and administrative exp</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">enses for the year ended December 31, 2022.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_553aa9c8-1f29-410d-993b-64e2566c55c0" contextRef="C_6cb7b433-593e-4c62-95c5-c68106abd3d7" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the adjusted allocation of the fair values assigned to the assets acquired and liabilities assumed as of the date of the acquisition:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"></td>
        <td style="width:1.794%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.881%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 22, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa5b7012-9353-41bc-8b2e-6e4614f01d52" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47,415</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c01bf1e3-a386-41a6-a38a-e178574d1703" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">471</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eafb9551-7f35-4e6d-a36b-0b0823506088" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,876</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b49d9acb-5bf5-486f-90df-bc75d66f7bdc" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,200</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37c7c808-db92-47f1-81b4-ec69c760c1ac" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,261</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ff1a0ce-58da-426b-8360-c3f2a560cd63" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">907</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9eb0eb24-95ce-480d-af81-7524c2100da3" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_411036e1-f1fe-49bc-979c-01a3be2f445f" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">226</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d07bb7c4-8d86-4df3-9f00-2c021c131a81" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,453</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b5314b6-56f3-4302-9082-6403a64b26b1" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">151,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d675b27-9911-4549-b74f-9a5c5560d4eb" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">710</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets acquired</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_058933e0-ba86-4159-bea0-d7f76c6267c4" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">290,532</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b11e0415-54be-4e54-bd23-c5d7c9832026" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,237</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_934aa8ea-264b-48d9-b4e5-4d4c107c52ee" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,849</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bee6eea6-aba4-4946-a0a7-d114864fcab8" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,362</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af5e06da-ce54-4d46-a34f-871d2d5d379d" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,944</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80d10efd-93d3-4be9-8cfc-079e7ccba806" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,581</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities assumed</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4404724d-f4da-4842-a37f-0dff625a69cf" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,973</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets acquired, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4b0a68b-26d2-45cb-a45e-e16ada701f04" contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206,559</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The goodwill arising from the acquisition of La Jolla is primarily attributable to La Jolla&#x2019;s assembled workforce and the value associated with leveraging the workforce to develop and commercialize new drug products in the future and growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refer to Note 8, &#x201c;Goodwill and Intangible Assets&#x201d;, for more discussion on the intangible assets recognized as part of this acquisition.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pro Forma Financial Information</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7dd9bbf9-90bf-45b4-9718-1943527ef9fc" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents certain unaudited pro-forma financial information for the years ended December 31, 2022 and 2021 as if the consolidation of Entasis and La Jolla occurred on January 1, 2021. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2021, or of results that may occur in the future. The unaudited pro forma financial information combines the historical results of the Entasis and La Jolla with the Company&#x2019;s consolidated historical results and includes certain adjustments including, but not limited to, fair value adjustments to equity investments in Entasis&#x2019; common stock and warrants, fair value adjustments to inventory, amortization of intangible assets, and interest expense on deferred royalty obligations and acquisition-related costs.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.399%;"></td>
        <td style="width:1.502%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.6%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.502%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29964cdf-1188-43df-b447-ecaebafc9c74" contextRef="C_15fd9d26-7d1b-4c32-bc1c-d97f9e0dd0c8" name="us-gaap:BusinessAcquisitionsProFormaRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">357,880</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_967e0cd9-e9c4-4149-9ae7-d5f2153a6799" contextRef="C_4f4721dc-8199-4105-9ec9-a169e1f0086c" name="us-gaap:BusinessAcquisitionsProFormaRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">435,398</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c82b98c-249c-446b-a7da-9992136addce" contextRef="C_15fd9d26-7d1b-4c32-bc1c-d97f9e0dd0c8" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">204,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_464d6224-b4b3-4c59-bd39-9b8d45abfcd8" contextRef="C_4f4721dc-8199-4105-9ec9-a169e1f0086c" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">281,719</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to Innoviva stockholders</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38938b3a-3687-4cb3-9b68-0add4f004755" contextRef="C_15fd9d26-7d1b-4c32-bc1c-d97f9e0dd0c8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">214,390</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b30245c3-d491-400f-8108-0f662321500f" contextRef="C_4f4721dc-8199-4105-9ec9-a169e1f0086c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">197,535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3dea71c6-c9ec-4f72-970d-2583ab2a09e5" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Method Investment in Armata</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the first quarter of 2020, Innoviva acquired </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43e49a4e-ceca-4e8b-97e1-2024defaa014" contextRef="C_28a088e4-0dee-445b-90da-54cb1133ddc8" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,710,800</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock as well as warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9050dec-5a4d-4f2c-bbdd-57f78bf8981b" contextRef="C_b92b149a-66d4-4743-8737-7ac6c96eb78c" name="inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,710,800</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of common stock of Armata Pharmaceuticals, Inc. (&#x201c;Armata&#x201d;) for approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_015e1c6f-a9b2-400f-a315-a62e4c68b091" contextRef="C_4e529e8a-034a-4095-b62a-b22926e66498" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash. Armata is a clinical stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the first quarter of 2021, ISO entered into a securities purchase agreement with Armata to acquire </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09901c6b-5b33-4510-8a3f-018e0d3acada" contextRef="C_4b40705b-aebd-47f7-baf6-3520cd3218b6" name="inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,153,847</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Armata common stock and warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfa784d2-ad91-46af-8b5e-0b961b97012a" contextRef="C_a7908317-48f4-4013-9edd-7fd23e773791" name="inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,153,847</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of Armata common stock for approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cff8af51-8390-4570-aa33-a181f9eb1c01" contextRef="C_8dd6f727-6b68-40d1-9cf3-bc4664dc52cd" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Armata also entered into a voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f3e13b4-7542-40fe-82d8-29a556f4b83a" contextRef="C_b9cae3f5-7d7b-44a5-96e4-e89f716538d3" name="inva:VotingAgreementMaximumVotingRightsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">49.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of Armata&#x2019;s common stock for voting on the matters related to election or removal of Armata&#x2019;s board members. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#x2019;s product candidates for marketing and commercial distribution. During the fourth quarter of 2021, ISO also purchased an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad060c5f-a293-4f77-9a01-0473549ac433" contextRef="C_44d06045-6a65-4a7d-ad2c-0c393e7cddf9" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,212,122</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Armata common stock for approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08385c89-c39e-4552-9bc7-7b23b0f94021" contextRef="C_44d06045-6a65-4a7d-ad2c-0c393e7cddf9" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 9, 2022, ISO entered into a securities purchase agreement with Armata to acquire </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccacf2b7-1584-40ea-9025-f5eaa71ae265" contextRef="C_9367326d-93f1-4347-bc8c-ea4df5b4b7d8" name="inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Armata common stock and warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de84b9e6-069b-4874-b1d7-74c2814ae937" contextRef="C_6063f5cf-dd80-437b-b1b3-9141091e7037" name="inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of common stock with an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80ad6058-101d-474c-a30e-faee8845bbec" contextRef="C_6063f5cf-dd80-437b-b1b3-9141091e7037" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">5.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22b6b57d-e93b-4837-bfcd-608d875ea43c" contextRef="C_13f5a4a8-8af1-45cd-bfa0-3c008efc367c" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">45.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The investment closed in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20642b11-37b0-4ef4-9300-31c7c7076e90" contextRef="C_b9cae3f5-7d7b-44a5-96e4-e89f716538d3" name="inva:SecuritiesPurchaseAgreementNumberOfTranches" unitRef="U_Tranche" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> tranches on February 9, 2022 and March 31, 2022. The investment is intended to aid Armata in advancing its clinical pipeline and strengthening its bacteriophage platform. On February 9, 2022, Armata also entered a second amended and restated voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42013e46-26cb-4f7c-82fc-1e4f67f329ee" contextRef="C_83077a73-bb79-4182-b3f3-f8a33937add7" name="inva:VotingAgreementMaximumVotingRightsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">49.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of Armata&#x2019;s common stock for voting on the matters related to election or removal of Armata&#x2019;s board members or amend the bylaws of Armata to reduce the maximum number of directors or set the number of directors who may serve on the board of Armata. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#x2019;s product candidates for marketing and commercial distribution. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_088cc42b-a01a-4d03-afaf-19cf730b18d4" contextRef="C_83077a73-bb79-4182-b3f3-f8a33937add7" name="inva:SpecialTermReDesignatingBoardMemberToBoardOfInvestee"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0a169ed-f880-427c-86f9-36dda472222c" contextRef="C_3209a07a-0aa1-4b9b-907d-d83100cde8c5" name="us-gaap:VariableInterestEntityOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">12.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding shares of Armata&#x2019;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#x2019;s board of directors, and for so long as the Company and ISO hold at least </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9412816-0c60-4e54-a6db-20daffde43e1" contextRef="C_38a0f685-2b21-4d8e-aa54-1e3d3d0df2e0" name="us-gaap:VariableInterestEntityOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, but less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93d11913-5351-4253-bd74-e02bd2ca66b9" contextRef="C_33e742dc-e3d7-4460-84e9-9ec66d586b4d" name="us-gaap:VariableInterestEntityOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">12.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, of the outstanding shares of Armata&#x2019;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#x2019;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> As of December 31, 2022,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f60822ae-95ae-4ed2-bc3e-8274d225eb42" contextRef="C_8f59c417-5760-4636-8972-e9f5a4490a93" name="inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" unitRef="U_Director" decimals="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98f3e485-3764-444d-8791-e84b442b7e3d" contextRef="C_8f59c417-5760-4636-8972-e9f5a4490a93" name="inva:NumberOfBoardMembersOfInvestee" unitRef="U_Director" decimals="0" format="ixt-sec:numwordsen">eight</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">members of Armata&#x2019;s board of directors are also members of the board of directors of Innoviva. As of December 31, 2022 and 2021, we owned approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77e968a5-fba8-409a-9e64-2740923566d4" contextRef="C_9ce8be5c-e87f-4f02-aa59-8b21ebff6e2b" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">69.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% an</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0adcf9ba-9c3d-457e-90b5-f86f2bdfe451" contextRef="C_01ddf3ce-393e-4a0e-9c61-5439a63de921" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">59.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respectively, of Armata&#x2019;s common stock.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investments in Armata provide Innoviva and ISO the ability to have significant influence, but not control over Armata&#x2019;s operations. Armata&#x2019;s business and affairs are managed under the direction of its board of directors, which Innoviva and ISO do not control. Based on our evaluation, we determined that Armata is a VIE, but Innoviva and ISO are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We account for both Armata&#x2019;s common stock and warrants under the equity method using the fair value option. The fair value of Armata&#x2019;s common stock is measured based on its closing market price. The warrants purchased in 2020, 2021 and 2022 have an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_400fc6c9-b9ff-482e-bed3-2ea67c179b99" contextRef="C_61f224cf-c012-4c9e-a814-7844fb193f6f" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">2.87</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2159838f-4c73-4b0c-ac53-f108170994f6" contextRef="C_a5469324-8168-4017-8117-1393b1043fb1" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3d90b53-855d-4730-858c-3260f617f71d" contextRef="C_e25220e7-99ed-4348-b545-ac306b1dcf61" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, respectively. All warrants are exercisable immediately within </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3f423f1b-a312-4755-9970-5fe48df7cd75" contextRef="C_61f224cf-c012-4c9e-a814-7844fb193f6f" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_e3b43238-9001-496d-8c1c-e9b4c03bbaeb" contextRef="C_a5469324-8168-4017-8117-1393b1043fb1" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_71bd0d3b-d96a-476a-85e8-0adc01f65bc1" contextRef="C_e25220e7-99ed-4348-b545-ac306b1dcf61" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the issuance date of the warrants and include a cashless exercise option. We use the Black-Scholes-Merton pricing model to estimate the fair value of these warrants with the following input assumptions: Armata&#x2019;s closing market price on the valuation date, the risk-free interest rate computed based on the U.S. Treasury yield, the remaining contractual term as the expected term, and the expected stock price volatility calculated based on the historical volatility of the common stock of Armata and its peer companies.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of Dece</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mber 31, 2022, the fair values of our holdings of Armata common stock and warrants were estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf46feb4-ddac-4195-95a8-3e66986810f5" contextRef="C_432870a0-b84a-44de-a37b-e2b21c245d8d" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">31.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e6f2504-1179-4b8e-92e8-f51979d5d679" contextRef="C_d061c9e4-9a0b-4b25-b83f-bf29e8dbc3c7" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. As of December 31, 2021, the fair values of our holdings of Armata common stock and warrants were estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a6b8260-f22c-4936-9291-f1fb44b10204" contextRef="C_e0f2d71d-8e5b-4880-912e-cb4bc6a346e6" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">88.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fea3d0a-e556-4bee-98b1-f4b1fb4cf9f8" contextRef="C_49055080-48eb-4604-9031-96d7f9cda5c1" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">58.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The total fair value of both financial instruments in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_165ea258-89e7-485b-b213-84bca9481e54" contextRef="C_836c70a9-4623-4b63-8ab6-169221b585c7" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">39.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c4267e8-d1dc-4240-9092-bec874c9a3b5" contextRef="C_9005816e-b3a5-4468-8183-9e0fc2383e1e" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">146.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded as equity and long-term investments on the consolidated balance sheets as of December 31, 2022 and 2021, respectively. We recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0348a340-a7c3-4288-970c-bf9eb0a72198" contextRef="C_b9cae3f5-7d7b-44a5-96e4-e89f716538d3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">152.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million unrealized losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bb2297f-df4f-41bb-85cd-473b38e62858" contextRef="C_5d0145a4-6b73-42eb-8fa3-e5ad7079aeb2" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">78.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million unrealized gains as changes in fair values of equity method investments, net, on the consolidated statements of income for the years ended December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_53ce1297-acb9-4393-8876-90517656db97" contextRef="C_b9cae3f5-7d7b-44a5-96e4-e89f716538d3" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag regardless of the date of our investments as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Balance Sheet Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.94%;"></td>
        <td style="width:2.262%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.57%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.262%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.968%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07071560-1606-4dd1-adb4-67a6e5a36124" contextRef="C_8b1298b5-e265-402c-a375-7a6c3874e7ba" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,245</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6acfe50-64f1-4e57-bb32-6ae5aeb55e81" contextRef="C_f25bc928-3562-4b6b-b70a-81d5cabd17d6" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,178</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71c13276-d3af-43d5-a549-10d3fd97a0aa" contextRef="C_8b1298b5-e265-402c-a375-7a6c3874e7ba" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,636</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac5655a4-a23d-4394-9ad1-fd81f43969a4" contextRef="C_f25bc928-3562-4b6b-b70a-81d5cabd17d6" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,493</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_864e5133-2b4e-46ba-a719-dbd914d68c1e" contextRef="C_8b1298b5-e265-402c-a375-7a6c3874e7ba" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,004</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e0478ba-214f-4e76-8871-2a1451c9cdc8" contextRef="C_f25bc928-3562-4b6b-b70a-81d5cabd17d6" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,254</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48ad43fe-f637-4991-9f9b-1857140810a9" contextRef="C_8b1298b5-e265-402c-a375-7a6c3874e7ba" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,300</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82f4ce67-e6f5-40cb-8fb5-eefbbaee443e" contextRef="C_f25bc928-3562-4b6b-b70a-81d5cabd17d6" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,662</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Statement Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.034%;"></td>
        <td style="width:1.11%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.577%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.11%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.394%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.09%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.683%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Twelve Months Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddf6f8d1-5703-4860-a2e7-f9925a79850d" contextRef="C_66038b3d-4a2d-4124-9988-d7ed75e02d5d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,446</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73c11393-881d-4377-a936-70cea7d58e04" contextRef="C_93c757ad-d7f6-4687-bcce-bed6a5cfc531" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,989</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4711ea9e-1900-4618-b4b1-8c950eb734ea" contextRef="C_5c9aad10-5990-4d65-89ff-a00df760aa5e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">319</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e1688c7-dd7e-4945-aa6d-512a6c13dc94" contextRef="C_66038b3d-4a2d-4124-9988-d7ed75e02d5d" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">32,666</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23407890-c061-4d7b-bd84-b19929bd99ea" contextRef="C_93c757ad-d7f6-4687-bcce-bed6a5cfc531" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24,227</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91f35849-ca3b-4182-892f-86b574667a4e" contextRef="C_5c9aad10-5990-4d65-89ff-a00df760aa5e" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,134</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80b83271-bdf9-4a5b-9bf1-972ac3e5672c" contextRef="C_66038b3d-4a2d-4124-9988-d7ed75e02d5d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">32,650</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82ab42cf-6f5c-4f9e-92b3-fb1baeae10da" contextRef="C_93c757ad-d7f6-4687-bcce-bed6a5cfc531" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">23,732</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_144f934e-66ad-4f39-8973-bca18c3476f5" contextRef="C_5c9aad10-5990-4d65-89ff-a00df760aa5e" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Method Investment in Entasis</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the consolidation of Entasis&#x2019; financial position and results of operations in February 2022, we accounted for Entasis as an equity method investment. Refer to Note 5, &#x201c;Consolidated Entities and Acquisitions&#x201d;, for more information.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1dc72967-6188-4df3-bc30-89a78c5f7704" contextRef="C_9bd4526f-35d6-4207-93b9-c8a7c2cbe092" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The summarized financial information, including the portion we did not own, is presented for Entasis on a one quarter lag regardless of the date of our investments as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Balance Sheet Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.276%;"></td>
        <td style="width:1.795%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.929%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f75e2b54-61d3-4f92-9b85-b46fbc7726a6" contextRef="C_afaf4531-656e-4b03-aaf3-eae9277b1b15" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,746</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b86c7cf7-6fcb-4dcc-a053-9f21f4bf5a81" contextRef="C_afaf4531-656e-4b03-aaf3-eae9277b1b15" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,020</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d05145d-9bef-4905-b4ab-eaec956ab172" contextRef="C_afaf4531-656e-4b03-aaf3-eae9277b1b15" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,348</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bacc1aa-016d-4b0c-905d-430b841bdcac" contextRef="C_afaf4531-656e-4b03-aaf3-eae9277b1b15" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">183</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Statement Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.668%;"></td>
        <td style="width:2.249%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.917%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.249%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.917%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Twelve Months Ended<br />September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Six Months<br />Ended September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c640ee16-10ca-4cfb-95d2-c1a1f1229a7a" contextRef="C_d895b864-cb0d-4144-94d3-dd388365edb0" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">52,323</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d0de308-1c14-4a4e-a6ec-17a0931afa2e" contextRef="C_bc3e2576-1b0b-4887-9679-84a1bff0d7ca" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">26,080</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1c675d7-d90d-478f-9f35-7ea6fc40e6e9" contextRef="C_d895b864-cb0d-4144-94d3-dd388365edb0" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">125,413</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6e14458-ff77-4bcc-835c-b5ea4e5688b0" contextRef="C_bc3e2576-1b0b-4887-9679-84a1bff0d7ca" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24,529</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Investment in InCarda</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the third quarter of 2020, TRC purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7a41008-fae1-4dc3-b7e3-c007470a10f5" contextRef="C_50f48cec-18c8-457e-b20c-0910ae62e850" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">20,469,432</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series C preferred stock and a warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57df645f-ed80-4eea-9c22-bbb06e8c86c2" contextRef="C_c906192d-d614-4f00-bca0-46d8da21845f" name="inva:SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,117,358</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of Series C preferred stock of InCarda Therapeutics, Inc. (&#x201c;InCarda&#x201d;) (the &#x201c;InCarda 2020 Warrant&#x201d;) for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b185559-378b-4d9d-9a4d-d1e91b0464ff" contextRef="C_47e6ee25-6bf5-41cf-80de-9652c932b3be" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which included $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db3f97c3-4ed2-4af1-bea1-d5f8f3f7405f" contextRef="C_50f48cec-18c8-457e-b20c-0910ae62e850" name="inva:DebtInstrumentTransactionCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of transaction costs. InCarda is a privately held biopharmaceutical company focused on developing inhaled therapies for cardiovascular diseases. The investment is intended to fund the ongoing clinical development of InRhythmTM (flecainide for inhalation), InCarda&#x2019;s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#x2019;s ownership interests and investments in InCarda. ITH has the right to designate one member to InCarda&#x2019;s board of directors. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b1b2f82-0aa2-4b32-966c-afc341d8100b" contextRef="C_96b9f402-f543-4b27-a705-44de9fb1db9f" name="inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" unitRef="U_Director" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of InCarda&#x2019;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cb2891d-b91d-4aeb-8e7e-09598de13c88" contextRef="C_96b9f402-f543-4b27-a705-44de9fb1db9f" name="inva:NumberOfBoardMembersOfInvestee" unitRef="U_Director" decimals="INF" format="ixt-sec:numwordsen">eight</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> board members was designated by ITH. The InCarda 2020 Warrant is exercisable immediately with an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3434e41c-8dfa-41d4-bc66-5a6b17ca079d" contextRef="C_c4982d06-6abd-4b3b-a27d-5ce207408578" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.7328</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. In September 2021, TRC and InCarda entered into an amendment to extend the expiration date of the InCarda 2020 Warrant from October 6, 2021 to March 31, 2022. On March 9, 2022, TRC and InCarda entered into an amendment to further extend the expiration date of the InCarda 2020 Warrant from March 31, 2022 to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5b0d2763-86d6-47a0-a20f-3093a73cfd12" contextRef="C_421fbd90-baa7-4fc2-a696-1d4532ffc1a0" name="inva:ExtendedExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The InCarda 2020 Warrant is recorded at fair value and subject to remeasurement at each balance sheet date.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 9, 2022, TRC entered into a Note and Warrant Purchase Agreement (the &#x201c;InCarda Agreement&#x201d;) with InCarda to acquire a convertible promissory note (the &#x201c;InCarda Convertible Note&#x201d;) and warrants (the &#x201c;InCarda 2022 Warrant&#x201d;) for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd0b77b7-f98d-4e67-a00e-303f0027d3db" contextRef="C_b379ab38-d0be-476e-a799-edfb4d18808f" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The InCarda Convertible Note bears an annual interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2753f756-be27-4a82-aa6c-0af3cdb2e918" contextRef="C_70bef282-aa1e-40ca-bbc9-61204a5b14c2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and will convert into Series D preferred stock upon a qualified financing, non-qualified financing, or maturity conversion. A qualified financing is defined as the first issuance or series of related issuances by InCarda of its equity securities following March 9, 2022 from which InCarda receives immediately available gross proceeds of at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9217ee48-e27a-49a1-b03c-dc95030dbcd5" contextRef="C_ef07e831-a84d-46db-aeb8-00314c87ec4b" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (excluding the aggregate amount of any notes converted into equity securities pursuant to the conversion of notes or any other debt securities converted into equity securities) (the &#x201c;Qualified Financing Amount&#x201d;). A non-qualified financing is defined as the first issuance or series of related issuances by InCarda of its equity securities following March 9, 2022 from which InCarda receives immediately available gross proceeds of less than the Qualified Financing Amount. The InCarda 2022 Warrant entitles TRC to purchase a number of shares of equity securities equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff843e11-b6c0-4329-8e7b-28603022b9f0" contextRef="C_f30142e1-26a2-4c83-99ca-64d73afa243d" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the principal amount of the InCarda Convertible Note divided by the number of shares issued in InCarda&#x2019;s next equity financing, which is defined as the earliest to occur of specific financing events, including capital raises through public offerings. The InCarda 2022 Warrant expires on March 9, 2027. The InCarda Convertible Note and InCarda 2022 Warrant are measured at fair value.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 15, 2022, the principal amount and the accrued interest of the InCarda Convertible Note were converted into equity securities. In addition, TRC participated in InCarda&#x2019;s Series D preferred stock financing by investing $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0442d879-587c-4f48-b27f-980fb8dac6a1" contextRef="C_67669f2c-13f6-4732-9377-f8c04349b09d" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. In connection with the new round of financing, InCarda recapitalized its equity structure resulting in TRC owning </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9351429-99fa-43b7-b0df-54395cc5d56a" contextRef="C_5312202a-22d7-4d9a-824b-4d80ac1dd701" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,093,886</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of InCarda&#x2019;s common</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">stock, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_020a8fe8-8daa-49d6-880e-82f77a6d482c" contextRef="C_b372f4b9-70bb-4a82-8853-c638fa566549" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">37,350</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its Series A-1 preferred stock, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c4670b0-a0a5-4f8c-9dfe-3cb7610fccd1" contextRef="C_50f48cec-18c8-457e-b20c-0910ae62e850" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">20,469,432</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its Series C preferred stock, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dc41cc3-e6d1-4202-8c16-213e9191b012" contextRef="C_3eb9313e-795c-4ac2-b142-a5922e05f973" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,771,780</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its Series D-1 preferred stock, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68d23bae-78c3-449a-92a4-21de5b71d879" contextRef="C_b3984c86-3600-4ad8-878a-2b917b585a43" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,369,802</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its Series D-2 preferred stock, a warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6f3eafa-157f-42fe-a387-47daabe573c0" contextRef="C_69d1b8aa-4af1-4156-8bdb-c7f20d548e88" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,117,358</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its Series C preferred stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc1207f7-1bcb-40de-82d9-047cc92d970a" contextRef="C_49c795a8-613b-4bce-862e-f82adaa95de1" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.73</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and a warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddd8d548-9598-4d94-9e09-1f6ae09af7e6" contextRef="C_ce65868a-35fd-4e2c-8c9d-86e62db676f1" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,490,033</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its Series D-1 preferred stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ef6272d-7e8b-4123-a4dd-2fa436f8bf26" contextRef="C_a9729f5e-1b98-42eb-9368-262a78500403" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">0.20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, we held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26b12285-4667-42c7-9141-e36151e787ad" contextRef="C_96b9f402-f543-4b27-a705-44de9fb1db9f" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">9.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01e184a7-6421-4561-aa9f-71eb64760b4e" contextRef="C_b7c08163-5751-4218-b1ca-b2546c9f4635" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">13.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of InCarda equity ownership, respectively. Our investment in InCarda does not provide us with the ability to control or have significant influence over InCarda&#x2019;s operations. Based on our evaluation, we determined that InCarda is a VIE, but we are not the primary beneficiary of the VIE.  We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We account for our investments in InCarda under the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer. Due to InCarda&#x2019;s equity recapitalization in the second quarter of 2022, TRC reassessed the value of its investments in InCarda using the Option Pricing Model Backsolve valuation methodology. Key assumptions used in the valuation model include an expected holding period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_73ce9899-6991-4d32-abba-faa9a31e0e76" contextRef="C_9355643f-3d44-439f-a87f-deec9514dc9b" name="inva:ExpectedHoldingPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66026895-52f7-4014-86c6-d1a913d49a55" contextRef="C_9355643f-3d44-439f-a87f-deec9514dc9b" name="inva:RiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d965e774-17b7-4ff4-b26f-5586134811ef" contextRef="C_9355643f-3d44-439f-a87f-deec9514dc9b" name="inva:DividendYield" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and an estimated volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e69f8f7b-55a5-4ec9-a339-165b7ef23bc8" contextRef="C_9355643f-3d44-439f-a87f-deec9514dc9b" name="inva:PercentageOfEstimatedVolatility" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">122.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. The estimated volatility is calculated based on the historical volatility of a selected peer group of public companies comparable to InCarda. We recognized an impairment charge of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ff68512-aa4b-459e-86d4-3048a824bf00" contextRef="C_16124fa1-bc15-44d0-adf6-79a805b582fd" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as a result of the valuation. There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df7fa1cc-080f-47f9-83f1-e60a2f67c5d4" contextRef="C_4d3c3fb3-98ab-4ad6-a151-b473b325e723" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairment or other change to the value of our investments in InCarda as of December 31, 2021.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ba2e99c-ef4d-4270-978f-2d9f898637e5" contextRef="C_2276852d-99f8-449f-9f8f-9a1d7ddf7c39" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in fair value of InCarda&#x2019;s Series C preferred stock and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d70f279f-dd3f-492f-9eb2-5b214b714cb4" contextRef="C_a97f4d78-4d9f-4a85-ba1d-e3c8a7909bfa" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in fair value of Series C warrants and Series D warrants (the &#x201c;InCarda Preferred Stock Warrants&#x201d;). As of December 31, 2022, we recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4b7e853-c939-494f-a6cf-22f1fd954ff8" contextRef="C_a1a5f0dc-847a-45a8-ad9c-42c8df5a3705" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for InCarda&#x2019;s Series D-1 preferred stock, Series D-2 preferred stock, and common stock using the measurement alternative. As of December 31, 2021, we recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c599604-d2fb-43b9-87c2-a511bbe96f24" contextRef="C_ffc2073e-976b-4b32-9c37-71e4c30ee0f5" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in fair value of the InCarda 2020 Warrant. As of December 31, 2021, we recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb62feb7-b84d-4c46-8b75-07eda916a532" contextRef="C_7f74dd91-9ab3-47f8-86b1-ab0b359a7b86" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the investment in InCarda&#x2019;s Series C preferred stock using the measurement alternative. We recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1bb7370-25d4-4367-9377-d1c4b599af6e" contextRef="C_bf93a6aa-8431-42fa-b295-0929da337285" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_573b1615-f9dd-4c1d-af37-a518b5b16048" contextRef="C_4e7f2983-a46f-475a-ac66-4031d4994ae7" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million unrealized loss as changes in fair values of other equity and long-term investments, net, on the consolidated statements of income for the years ended December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Investment in ImaginAb</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 18, 2021, TRC entered into a securities purchase agreement with ImaginAb, Inc. (&#x201c;ImaginAb&#x201d;) to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48fe7db8-14cd-47e7-9ca9-8fb82577da28" contextRef="C_faceb50e-f20b-4852-8586-ecbbd210fdd7" name="inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,051,724</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of ImaginAb Series C preferred stock for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40619b15-9387-4198-88a5-267ebf724318" contextRef="C_9ff0d1ff-97a5-44b9-b6c1-09183a2ca1b7" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. On the same day, TRC also entered into a securities purchase agreement with one of ImaginAb&#x2019;s common stockholders to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3ff04d2-7864-4f78-8973-8355ceb992cf" contextRef="C_192456a0-bad3-4bac-8b5f-fc4b793611f8" name="inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,097,157</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of ImaginAb common stock for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87f64a22-4355-4fb4-84f0-ea00b5c8e050" contextRef="C_76ed3040-752a-4fbc-b4b9-e70787083404" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. ImaginAb is a privately held biotechnology company focused on clinically managing cancer and autoimmune diseases via molecular imaging. $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f07286d-7391-4943-b9dd-e5edb3ba2025" contextRef="C_547286c7-fffc-4b6d-aa24-854799abba90" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was incurred for investment due diligence costs and execution and recorded as part of the equity and long-term investment on the consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#x2019;s ownership interests and investments in ImaginAb. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81b851b1-2d6b-43f8-80fb-e6b5b9780e76" contextRef="C_77c4d3bf-3c11-40c8-aa43-61402306a12b" name="inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" unitRef="U_Director" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of ImaginAb&#x2019;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95187cdc-4ca0-46c9-9460-b2853c2ad2d5" contextRef="C_77c4d3bf-3c11-40c8-aa43-61402306a12b" name="inva:NumberOfBoardMembersOfInvestee" unitRef="U_Director" decimals="INF" format="ixt-sec:numwordsen">six</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> board members is designated by ITH, and ITH held</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_226ede22-f669-407d-9ac4-182d8ffc5562" contextRef="C_77c4d3bf-3c11-40c8-aa43-61402306a12b" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">12.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ImaginAb&#x2019;s equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ownership. As of December 31, 2021, TRC held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d730c8a-77c5-4479-a262-8e4a5d5495dc" contextRef="C_aea68a38-c031-44ae-8b1c-3569bc07a0e7" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">14.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of ImaginAb equity ownership.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our investment in ImaginAb does not provide us with the ability to control or have significant influence over ImaginAb&#x2019;s operations. Based on our evaluation, we determined that ImaginAb is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because ImaginAb&#x2019;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in ImaginAb&#x2019;s Series C preferred stock and common stock using the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer. As of  December 31, 2022 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and 2021, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_389d7a80-c479-4a36-8a4c-e00d59a4bf71" contextRef="C_77c4d3bf-3c11-40c8-aa43-61402306a12b" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_8cdb30df-b1e8-424d-bfcc-af0d333c7d68" contextRef="C_aea68a38-c031-44ae-8b1c-3569bc07a0e7" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.4</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded as equity and long-term investments on the consolidated balance sheets and there was no change to the fair value of our investment in ImaginAb.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Promissory Note in Gate Neurosciences</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 24, 2021, TRC entered into a Convertible Promissory Note Purchase Agreement with Gate Neurosciences, Inc. (&#x201c;Gate&#x201d;) to acquire a convertible promissory note (the &#x201c;Convertible Note&#x201d;) with a principal amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92699d57-e7f9-4607-be19-335f2e4d2e1d" contextRef="C_cbe9c478-819e-42cc-915c-04157a313403" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Gate is a privately held biopharmaceutical company focused on developing the next generation of targeted nervous system therapies, leveraging precision medicine approaches to develop breakthrough drugs for psychiatric and neurologic diseases. The investment is intended to fund its ongoing development and research. The Convertible Note bears an annual interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63c776e6-174b-4ed6-b365-f8ef750c8215" contextRef="C_3f794c11-9aa6-4337-8539-a68ea7a89d87" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and will convert into common stock shares upon a qualified event or into shares of shadow preferred stock (&#x201c;Shadow Preferred&#x201d;) upon a qualified financing. A qualifying event can be a qualified initial price offering, a qualified merger, or a merger with a special-purpose acquisition company (&#x201c;SPAC&#x201d;). Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d8baf4dd-1955-4861-b555-487cda45583b" contextRef="C_dda65400-d844-4684-b486-4ce48278b7bc" name="inva:NumberOfCommonStockIssuedDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#x201c;Capped Conversion Price&#x201d;) and the qualified event price (the &#x201c;Qualified Event Price&#x201d;). The Capped Conversion Price is calculated as $50.0 million divided by the number of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Gate are at least $35.0 million, and (iii) the stated or implied equity valuation of Gate is at least $80.0 million. </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH its debt investment in Gate. We have accounted for the Gate Convertible Note as a trading security, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of equity value of Gate, risk-free rate, expected stock price, volatility of its peer companies, and the time until a financing is raised. As of December 31, 2022 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, the fair value of the Gate Convertible Note was estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_727b65dc-ec85-45b6-ae19-44b11f6f20cd" contextRef="C_b56a4e8a-6960-4138-a57e-8ccc853dd6b5" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14bf974b-0443-453b-ab96-b0a5b0e1ce65" contextRef="C_2e87648d-cc31-4ce1-9ec1-efcc2c23941b" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, and recorded as equity and long-term investments on the consolidated balance sheets. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_143def3b-ed9a-4266-aa7f-ad3ee7f6a6de" contextRef="C_2dcd6e7e-1bb4-4f65-ae76-a45c841c8639" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrealized gain and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8815c27b-336b-4739-ab70-58a98b2be3d7" contextRef="C_df1e5c6b-3532-43eb-bfbb-32de7d69dfa7" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrealized loss as changes in fair values of other equity and long-term investments, net, on the consolidated statements of income for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Investment in Nanolive</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 18, 2022, TRC entered into an investment and shareholders agreement with Nanolive SA (&#x201c;Nanolive&#x201d;) to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_feda7d5b-be5f-4fcf-9314-431961f9f5f0" contextRef="C_1f7d116a-6a4c-4c15-ba57-35c3c1ecdd1e" name="inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,750,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Nanolive Series C preferred stock for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e53feeb6-978b-44d6-969a-a3dfd6a89d3a" contextRef="C_922cb55e-d579-4403-bdee-2933b4cbd111" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (equivalent to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f8f8607-d59d-423e-b41b-3f2faa056e09" contextRef="C_922cb55e-d579-4403-bdee-2933b4cbd111" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_CHF" scale="6" decimals="-5" format="ixt:numdotdecimal">9.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million CHF). Nanolive SA is a Swiss privately held life sciences company focused on developing breakthrough imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e9f9669-5374-4bd3-8f4b-3a35f9c8d430" contextRef="C_ef336b9b-40a1-496c-9596-1c6f52048c42" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was incurred for investment due diligence costs and execution and recorded as part of the equity and long-term investment on the consolidated balance sheets. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#x2019;s ownership interests and investments in Nanolive. ITH has the right to designate one member to Nanolive&#x2019;s board. ITH also has the right to designate another member, who will be mutually acceptable to ITH and another majority common stockholder, to Nanolive&#x2019;s board. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb8a9431-4a3e-4772-809e-4109663b2ada" contextRef="C_12bcde56-3f0c-4b2f-8eca-3b4cd31cef94" name="inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" unitRef="U_Director" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of Innoviva designees is serving on Nanolive&#x2019;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d65441d-68d0-4e5b-9262-4d0d4914d19c" contextRef="C_12bcde56-3f0c-4b2f-8eca-3b4cd31cef94" name="inva:NumberOfBoardMembersOfInvestee" unitRef="U_Director" decimals="INF" format="ixt-sec:numwordsen">seven</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-member board. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, we held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8e39009-fc06-4703-b3e0-46bb6db74faa" contextRef="C_12bcde56-3f0c-4b2f-8eca-3b4cd31cef94" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">15.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of Nanolive equity ownership.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our investment in Nanolive does not provide us with the ability to control or have significant influence over Nanolive&#x2019;s operations. Based on our evaluation, we determined that Nanolive is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because Nanolive&#x2019;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in Nanolive&#x2019;s Series C preferred stock using the measurement alternative. As of  December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf45a054-eeaf-43ee-aeb8-411a994bd6b6" contextRef="C_12bcde56-3f0c-4b2f-8eca-3b4cd31cef94" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded as equity and long-term investments on the consolidated balance sheets and there was no change to the fair value of our investment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Available-for-Sale Securities</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0ba9bb7a-8587-4d58-93ec-131fc0f9783d" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.883%;"></td>
        <td style="width:1.553%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.133999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.563%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.133999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.563%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.133999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.563%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.475%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2769ce1-6e57-4189-82bf-0320009c398c" contextRef="C_74da3b8a-5055-48ca-bb11-71f8c49ad956" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">263,469</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46f2d473-be14-45e0-bd3f-88d1ffb40cc2" contextRef="C_74da3b8a-5055-48ca-bb11-71f8c49ad956" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4974520-3462-491d-ba7f-e59c61419650" contextRef="C_74da3b8a-5055-48ca-bb11-71f8c49ad956" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_065f3d03-454a-409c-b707-3411450de866" contextRef="C_74da3b8a-5055-48ca-bb11-71f8c49ad956" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">263,469</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9bb718fb-be1a-42cc-a54e-205bd04d6a50" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">263,469</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe1df1fa-cf95-4078-8ed6-4395ca751a13" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4416c5a-e099-4365-803b-2ed7effe0376" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_492a832d-1bc7-4bff-a929-c66b3e1f86a3" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">263,469</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds are included in cash and cash equivalents on the consolidated balance sheets.</span></div></div>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.883%;"></td>
        <td style="width:1.553%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.133999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.563%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.133999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.563%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.133999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.563%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.475%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5bf8e1c8-f663-4fd3-a775-9c0173609862" contextRef="C_e4693a06-73d0-43e9-970e-27d36a30e4b0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145,132</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13064dda-8ed2-4197-9462-3233b6e646b6" contextRef="C_e4693a06-73d0-43e9-970e-27d36a30e4b0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92d64aad-a8aa-4799-a07a-ce78039e04c4" contextRef="C_e4693a06-73d0-43e9-970e-27d36a30e4b0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_afe13dec-76d8-453c-8941-b3e094fe42de" contextRef="C_e4693a06-73d0-43e9-970e-27d36a30e4b0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145,132</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a98f893-de05-443e-b0e7-67fb1e05261b" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145,132</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d8391d5-9da7-4a3c-a82a-e95e039a6b72" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd4142a3-18b9-4e1e-9980-a2b18a60f884" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48babb9d-a7dd-411c-b6e9-fd4bb26c21cf" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145,132</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_30a29ac4-a358-403f-922e-b22439018a34" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds are included in cash and cash equivalents on the consolidated balance sheets.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, all investments were money market funds, and there was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d0d6ec5-55bb-4294-97d1-b1a2383b8576" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> credit loss recognized.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_73ac4d6c-e3c5-45e0-b22b-6147027893f5" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our available-for-sale securities, equity and long-term investments are measured at fair value on a recurring basis and our debt is carried at amortized cost basis. The estimated fair values were as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:42.189%;"></td>
        <td style="width:1.418%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.956999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.408%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.956999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.408%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.956999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.408%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.299%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2022 Using:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Price<br />in Active<br />Markets for</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br />Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identical</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Observable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Types of Instruments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d5cc6ee-8fcb-44cd-8811-594451d2ee11" contextRef="C_9d320509-4249-4817-85c1-0897de8b2875" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">263,469</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77e9e049-a6c9-4a81-92f2-c084dc804806" contextRef="C_2bb91c3f-a494-494f-95f3-8e82d7a8ba80" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">263,469</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments held by ISP Fund LP </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3fdd078f-51c8-441a-bc63-74e8c5af4fba" contextRef="C_39efe5a8-fdf1-4e75-a1c6-ce190c067d56" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">265,982</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e20c2f4f-cc35-4c06-b838-d820cfd05871" contextRef="C_ab967707-220b-4a3c-b5c1-3b1d1f192c17" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,578</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1fa47be-e26f-49c6-9689-9c7c455a418b" contextRef="C_fa2052dc-83db-4d14-bb22-476be0ffb9e9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">320,560</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22ec90f9-d52e-4741-95dc-4feb3f616906" contextRef="C_7b234623-662e-464a-ac46-f26ea16b01cc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,095</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_204fb3cf-2c72-4ad8-ac66-4534ee5d6872" contextRef="C_d25498d0-9e4d-4ee3-9937-2ee1a353b204" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,095</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_121aa3a7-4b00-4ae4-a16f-e8ffd24b9e46" contextRef="C_1c21adc5-4d90-4234-8636-2bd75a4b4f4d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,059</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76ee2cd6-7e7b-4c54-94cc-46df34651442" contextRef="C_87e97c41-b41b-4af2-ab13-cf95548ea435" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,059</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_431cd787-08e1-43ca-80c9-aabd9f56bce0" contextRef="C_e5766cee-a03e-4c21-8d34-5eef3d851a41" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">605</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_214b7042-2276-4150-b0a3-23dfdb220ef3" contextRef="C_3476905e-b09a-418b-a03e-4f699aa88fc9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">605</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Convertible debt investment - Gate Note</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cac7423b-0de7-44c9-9b38-4e1fb378de6e" contextRef="C_161e223f-b687-4431-bc47-286346549fa0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7abf01d1-5996-41a3-a1dd-cb473046791f" contextRef="C_a82881ba-2b0c-4f06-bda8-ddec8bb16fb8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a4ed7f8-5279-4514-920e-e9ae6f4b8c8c" contextRef="C_508ec2d0-8cb9-4e9c-9ae3-821ebe4d8f78" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">560,546</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b113b590-cb54-42c9-aea7-8ca765428b51" contextRef="C_06e9721c-182a-4413-aa61-bad3afc7b434" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,059</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a3d50aa-993b-44ae-a18a-938fc0338e41" contextRef="C_8a0c9ff2-8643-499c-bef2-5ff0feb5293d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,883</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5fa989b-4b72-4a04-8ac1-350be86ad815" contextRef="C_7b619186-bedd-4f77-a50f-71d5615f05fa" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">639,488</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_203204be-b7ba-4a5d-bdc1-a93b06f3da62" contextRef="C_4cba0f99-f007-421e-b754-c13fe2c48144" name="inva:ConvertibleSubordinatedDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,089</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_781ae318-bd45-44c1-af0f-c59a02bd7c2e" contextRef="C_940c56ba-ea2f-4556-9041-85af949e6f93" name="inva:ConvertibleSubordinatedDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,089</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bc7be0b-5e3f-44b9-8ab6-4211a47af4c1" contextRef="C_4cba0f99-f007-421e-b754-c13fe2c48144" name="inva:ConvertibleSeniorDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">197,807</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f276a7d-bcf1-4453-89bb-9f801470c42e" contextRef="C_940c56ba-ea2f-4556-9041-85af949e6f93" name="inva:ConvertibleSeniorDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">197,807</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f406ff4-67cb-4b15-9e50-bc202277f2b9" contextRef="C_3ec4a281-c777-436a-bc57-5fae20c64ea6" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">211,768</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38ee33f8-feae-494f-89e1-1dfaaa2b179a" contextRef="C_940c56ba-ea2f-4556-9041-85af949e6f93" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">211,768</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total fair value of debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9fb27bd-4fe3-49bd-83a4-fde6373388a3" contextRef="C_3ec4a281-c777-436a-bc57-5fae20c64ea6" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">505,664</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c8096bc-10f2-4164-bc02-036cbdbc3006" contextRef="C_940c56ba-ea2f-4556-9041-85af949e6f93" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">505,664</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent value rights</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89b700a2-bdb7-4a64-9f4c-28d703bd8b1b" contextRef="C_e64b6004-f679-415f-b389-067903b29e9e" name="inva:ContingentValueRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">595</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8d7a183-d574-408c-bb5f-93c79c2e6b88" contextRef="C_9f0ef079-42c1-4987-9230-951829c1a9cd" name="inva:ContingentValueRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">595</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities at estimated fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7984e985-a20b-43a1-beec-88e48f6f8c16" contextRef="C_3ec4a281-c777-436a-bc57-5fae20c64ea6" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">505,664</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58ec3c13-2192-4787-b529-4ef4dd331606" contextRef="C_e64b6004-f679-415f-b389-067903b29e9e" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">595</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3b366a5-07e7-405d-bf1e-92a7748f0c92" contextRef="C_9f0ef079-42c1-4987-9230-951829c1a9cd" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">506,259</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_575e1359-ac7d-4d28-a8d2-44d2392097f1" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce09d3af-850b-4264-9b21-979339aa380f" contextRef="C_29f0ba10-c2ca-4f06-b767-8af5d73dfda3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">295.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in equity investments, which included private placement positions and convertible notes of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b78e1020-4be4-4f12-81e1-756968848aba" contextRef="C_5fa7258b-a8a4-4978-9f93-639f24732e53" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">54.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_233c0ba3-bce8-4c65-a156-e9de984ddb53" contextRef="C_973bdb10-2dc0-4260-8de9-4c602b8d6d62" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in money market funds. Our total capital contribution of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5450b349-0fd3-4ebd-8e41-2c94f8c389fd" contextRef="C_62138785-e6ec-474a-9927-12031239b970" name="us-gaap:LimitedPartnersContributedCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">300.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million is subject to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4c7b0dce-8bc6-41c4-9c1e-97e630443d43" contextRef="C_3b80a067-6f7f-440f-919a-9b96d0afd716" name="inva:PartnershipAgreementLockUpPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lock-up period from the date of such capital contributions.</span></ix:footnote></div></div>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:41.931%;"></td>
        <td style="width:1.418%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.032%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.407%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.032%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.407%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.032%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.407%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.334999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2021 Using:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in Active</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Markets for</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identical</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Observable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Types of Instruments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2397cd13-a109-41b8-9532-d5ae2fc701ac" contextRef="C_b5917fe5-11ac-449e-b814-c92fd58e4ce4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145,132</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cca47e1-7a5a-496a-876d-90e17aea1597" contextRef="C_d412530e-32f1-46d9-9ba9-881230cd54e2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145,132</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments held by ISP Fund LP </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5206e769-270f-4857-aebd-f5a635bf2283" contextRef="C_a88168cf-1d99-4dfc-90ff-08a54f07f704" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">193,677</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_148f5b6e-664c-4651-a517-7669a8556d7c" contextRef="C_5344bb21-de35-4c37-a9d5-00a950034cac" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,068</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbecb97d-2479-4c89-ac9e-9028c435f74c" contextRef="C_2f726f21-debb-4664-8555-842fbb037578" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">195,745</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b046544a-9c6e-438b-a15d-bb603ff3e627" contextRef="C_13412d83-cfbd-464c-9c34-a973a9caf860" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,101</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6d057a3-ec47-4db8-9f93-499ae140e3fd" contextRef="C_3f8b66a1-3a27-4782-83da-ba9f7e42a440" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,101</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2476efb6-894a-45f9-ba70-12d15ce119de" contextRef="C_529cdd05-9d97-48df-bfe5-ae228fa9889c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,595</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f5d76c9-70c6-448a-acdd-dec5dc8c63ac" contextRef="C_c844f75a-7bd8-4650-befd-f25662e94508" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,595</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Entasis Common Stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e087bb63-3f62-422d-913c-1b251935f6a3" contextRef="C_2075bc58-bfcf-44dd-85f6-c2f80538247e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,794</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69aaf0ae-f1e2-41f1-949a-25eff939507d" contextRef="C_00652450-632d-460a-ac6b-98ad2aecada7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,794</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Entasis Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_021a7c50-ccb1-4162-ba64-acd7df113414" contextRef="C_a5a2a364-b173-4ae1-ab6f-e2302488dee0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,914</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbbc1134-2099-4962-9ffe-920fe1b8f7e7" contextRef="C_be87ba60-82c5-4092-a52b-166288166d4b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,914</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf120614-cc7d-4f35-824c-324b56d24e6b" contextRef="C_c321cb39-f5e8-42ab-b6ee-7480dacfaf27" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">411</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af613946-a1ae-4d45-8ccc-298df70219ba" contextRef="C_95e0527f-161f-4b7c-9dae-e5bbe64ee040" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">411</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Convertible debt investment - Gate Note</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1228d44-2ec2-456f-a547-dd55cb97074f" contextRef="C_494cf265-665e-4bbf-b3fc-fe7700a6a612" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49e7e86d-f89a-4981-8773-c8de7d845eb0" contextRef="C_611351f3-6fef-4e71-8874-413587b99402" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79727c17-b74f-466d-b1c1-8b673a06e1b6" contextRef="C_df021323-12d6-4b65-922a-6ba6dda7e339" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">489,704</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59b0938c-fd22-48b8-9a3b-4e19aac11025" contextRef="C_3a796252-a67b-414a-b751-63b9b85b975a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,509</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f433f27-8f6c-4e4d-994f-474963cb3d8e" contextRef="C_435ca12f-523f-4739-86cf-686a945e5797" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,579</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a64e4501-41de-45eb-bbbb-8f39d6e79e7a" contextRef="C_8df9d62f-9d01-41f9-9bda-746317ef7f2a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">606,792</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d621ef6c-49c1-448d-81e4-002cb132f9d2" contextRef="C_0e7db92f-80b2-4ff0-a803-9c8f7437c5ee" name="inva:ConvertibleSubordinatedDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261,769</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9b577cc-a842-4a6f-b1e3-d6c2d9530e38" contextRef="C_c9ec2c09-fd7a-47dc-bc8d-518a4c5588a5" name="inva:ConvertibleSubordinatedDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261,769</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30860e19-99c5-41ef-8120-15aa95a02e45" contextRef="C_0e7db92f-80b2-4ff0-a803-9c8f7437c5ee" name="inva:ConvertibleSeniorDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">234,498</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31348f56-d12e-43f1-9094-4e31c3545aea" contextRef="C_c9ec2c09-fd7a-47dc-bc8d-518a4c5588a5" name="inva:ConvertibleSeniorDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">234,498</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total fair value of debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d9ade93-c009-4f4b-99e8-55197fc3ecb2" contextRef="C_0e7db92f-80b2-4ff0-a803-9c8f7437c5ee" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">496,267</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_461533e0-78ac-4dac-a2eb-35635cd8035d" contextRef="C_c9ec2c09-fd7a-47dc-bc8d-518a4c5588a5" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">496,267</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_4def478b-9e06-438e-961a-d2a1b65d4c32" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e0d8d2a-9596-4e29-aa5b-8ed6be4c8007" contextRef="C_d1735a85-987d-4b96-a5cd-b22f73816924" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">192.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million equity investments and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bd39d35-d497-4566-90a8-3399d8308e84" contextRef="C_9d42290f-ab32-4e25-95da-79728346288a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million money market funds, are subject to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_44f2c8d4-a5eb-477e-894b-b22ca325e761" contextRef="C_5ba64f62-a97d-4706-a41e-89bb10ec307f" name="inva:PartnershipAgreementLockUpPeriod" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-month lock-up period from our initial contribution date, December 11, 2020.</span></ix:footnote></div></div></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair values of our equity investments in Armata&#x2019;s and Entasis&#x2019;s common stock and public traded investments held by ISP Fund LP are based on the quoted prices in active markets and are classified as Level 1 financial instruments. The fair values of the warrants of Armata and Entasis classified within Level 2 are based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">InCarda&#x2019;s equity securities, Gate's convertible note, private placement positions and convertible notes held by ISP Fund LP, and contingent value rights are classified as Level 3 financial instruments as these securities are not publicly traded and the assumptions used in the valuation model for valuing these securities are based on significant unobservable and observable inputs including those of publicly traded peer companies.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair values of our 2023 Notes, 2025 Notes and 2028 Notes are based on recent trading prices of the respective instruments.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b7122a24-60a8-4dc4-bbd4-09272ed49cca" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:CapitalizedFeesPaidDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. CAPITALIZED FEES PAID</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c56d195d-d835-4e53-8225-95c95a88ebc4" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:CapitalizedContractCostTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.362%;"></td>
        <td style="width:1.739%;"></td>
        <td style="width:16.039%;"></td>
        <td style="width:1.739%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.093%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.739%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.287%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization period</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2013-2030</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6604d889-4f5f-4644-8752-309fb21bb025" contextRef="C_938323ae-b1cf-434a-be7f-895d09c3f4f5" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_558d85c5-bd4b-4ed8-b825-cb60ab327224" contextRef="C_1f716eb1-7bc2-436b-be0b-e1913992c7a5" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Europe</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2013-2029</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e589715f-9c81-4370-9c29-7aa80260f7d0" contextRef="C_b21c6819-077d-4af6-bc82-465ef43a2339" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_952206ae-031f-4e9e-93ef-5ce633c242e3" contextRef="C_8c2a82e7-af19-4a3f-9713-a56397f35d56" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Japan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2013-2029</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbd72872-06de-4984-adbd-0b46d6850f58" contextRef="C_dba05bba-de09-4343-af7e-9fb38e51a065" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cf882bb-b58b-43b9-95c9-32230753f458" contextRef="C_5be2f762-e576-4a23-bf25-e027f2186039" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross carrying value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc4dc889-029c-4d57-b63d-1df049bfe1d3" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">220,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e94b28b3-a4d3-405e-b238-e74d64fa70c2" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">220,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84dfc54d-fb31-49ec-a414-ab329f2056bc" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:CapitalizedContractCostAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122,393</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05c0043a-5adc-4eea-a1cd-bb624e624b28" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:CapitalizedContractCostAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,570</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net carrying value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1cc2000-3f4e-46f8-b25a-dece1e66be0b" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:CapitalizedContractCostNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,607</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d301af9e-306f-475c-a1b7-f0cadc9279e6" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:CapitalizedContractCostNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">111,430</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These milestone fees are amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization recorded as a reduction in revenue from collaborative arrangements. As of December 31, 2022, the weighted average remaining amortization period was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ec3b9466-a735-49ef-9af6-b7146df8cda0" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:CapitalizedFeesPaidWeightedAverageUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> y</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ears.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional information regarding these milestone fees is included in Note 3, &#x201c;Revenue Recognition&#x201d;. Amortization for each of the years ended December 31, 2022, 2021 and 2020 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a989f5fc-ff5e-4ed0-8833-bdcdf63c1949" contextRef="C_a01857da-29eb-401d-8a40-ba6e666521ec" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_1a28b372-ca71-40f0-8c29-2c0532e20585" contextRef="C_66c13dac-92c4-4ae1-b13e-27c3b81b27cd" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_7af1ad96-c496-47d9-8282-155b00c03cba" contextRef="C_a09a0970-3cec-406a-9c07-37e23fc89e0c" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.8</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The remaining estimated amortization is </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2101ce1d-84da-416e-b5bc-f53e18f0b6d4" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_8e5d93b8-381f-43ce-a705-ba6a997c1559" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_ab6c1d2c-3b37-429c-ab4e-6959d9c92893" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_8d4a15aa-6128-4011-9ea5-c22568978304" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.8</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_2214fc13-a135-4176-9e10-3d32422ab21f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">each</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the years from 2023 to 2027 and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ddcc080-9cb9-4697-9168-a444f4d68367" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thereafter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_eb54fa93-b53e-4bf1-b9f9-0f2594fe6abd" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. GOODWILL AND INTANGIBLE ASSETS</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill and intangible assets acquired are recognized at fair value as of the acquisition date. The carrying amount of goodwill as of December 31, 2022 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b3f99b7-3eba-4c03-94a0-9a15b20c6424" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">26.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We have not recognized any impairment losses related to goodwill and intangible assets during the periods presented.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets with definite lives are amortized over their estimated useful lives. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b5fd36e6-a4fa-49cf-b9b2-03d3a5b95426" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock" escape="true" continuedAt="F_b5fd36e6-a4fa-49cf-b9b2-03d3a5b95426_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying basis and accumulated amortization of recognized intangible assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 were as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_b5fd36e6-a4fa-49cf-b9b2-03d3a5b95426_1"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.438%;"></td>
        <td style="width:1.112%;"></td>
        <td style="width:11.146%;"></td>
        <td style="width:1.102%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.333%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.102%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.333%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.102%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.333%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Useful Life</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Carrying</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketed products</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c931f3a6-a8b4-470a-946b-2e07b61d9cce" contextRef="C_2496c994-d13e-4a41-b18c-1c9ff1040e5d" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4a17b80f-e258-479f-b82e-e0b6dfabc0b2" contextRef="C_5b484229-9ff6-4262-be39-4c53a0370b53" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61988858-a0ef-4f3f-a1ff-dd0695b8eaba" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:IntangibleAssetsMarketedProductsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">151,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7158887-a25f-4683-be31-b853faac7f8d" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:IntangibleAssetsMarketedProductsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,581</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d3e5060-bb60-4dde-a0f5-aa59ea67bf2e" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:IntangibleAssetsMarketedProductsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145,419</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In-process research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b83375e-a47e-4538-919e-3e04d63bad6b" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:IntangibleAssetsInProcessResearchAndDevelopmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5c19a98-9bde-4a68-b8c0-0d2df92c1996" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:IntangibleAssetsInProcessResearchAndDevelopmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration agreement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_053b18b2-163d-40c5-b851-dc1fc5a33efb" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:IntangibleAssetsCollaborationAgreementGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82798bbe-3cfa-4933-b27f-d9a2baa9e0f1" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:IntangibleAssetsCollaborationAgreementNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4faf0de0-e069-44e7-b88a-177f12d8f36b" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">258,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f560df3-bdc7-4eb2-aceb-d3d3cad1289b" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,581</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c0c89df-2753-42cd-9eee-61ea26cfda25" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">252,919</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets recognized as a result of the acquisition of Entasis amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18346be1-01cc-4163-8a0f-962efd0e0ec1" contextRef="C_834647f0-edd8-451a-9b07-12ae7db8308b" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">107.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which consisted of Entasis&#x2019; in-process research and development related to its antibacterial therapeutic product candidates and a collaboration agreement amounting to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be9ba9ba-022b-4669-9384-b6c8f17558e6" contextRef="C_5ade68fe-6e7d-408e-8079-b75ae0d3ebb4" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">72.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cb59c89-94ff-488e-a6a9-cfa2438933cd" contextRef="C_11135088-2eb4-4727-a68e-256cf6c9a775" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The useful lives of these intangible assets will be determined upon commercialization of the underlying product candidates; thus, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c93dbb12-3f52-439c-a312-c40ff735a54b" contextRef="C_392be0e2-bd01-417a-94b2-2ef2c1b381d8" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> amortization expense of determinable assets was recognized during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets recognized as a result of the acquisition of La Jolla amounting to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac0f84e0-fb23-4ce8-988a-c4ef60be8671" contextRef="C_86b3b196-2603-41a6-85b5-4466e0d2b8da" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">151.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million pertain to product rights and developed technologies on La Jolla&#x2019;s currently marketed products. These are intangible assets with determinable lives and are amortized over their estimated useful lives. We recognized amortization expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4d0db88-aa6e-4d9f-b129-7edfab50070f" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Future amortization expense is expected to be $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6aef5c70-cd94-40b8-acb1-06d08ef96309" contextRef="C_86b3b196-2603-41a6-85b5-4466e0d2b8da" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_a3a9cc15-39e1-4f68-b8ce-9bbd09914f1f" contextRef="C_86b3b196-2603-41a6-85b5-4466e0d2b8da" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_150822f3-7c01-4268-83fd-a7cf22c82ee9" contextRef="C_86b3b196-2603-41a6-85b5-4466e0d2b8da" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_74ea6f0d-4ea0-4d01-bdef-522590488f60" contextRef="C_86b3b196-2603-41a6-85b5-4466e0d2b8da" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.4</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for each of the years from 2023 to 2027 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30c4d4a2-05c0-4a48-a5ad-1febb3f2560d" contextRef="C_86b3b196-2603-41a6-85b5-4466e0d2b8da" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">68.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million thereafter.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_17fc2d15-41e5-4d62-9579-046c9b725eea" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. BALANCE SHEET COMPONENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inventory</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f792c48e-206b-4b6e-bce7-57a2651a5484" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.252%;"></td>
        <td style="width:1.784%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.964%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Raw materials</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d0d3edc-e7c3-48c4-ab05-2f4154a637c2" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:InventoryRawMaterialsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,757</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23608efc-5ab7-4567-a077-acd9d485410c" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:InventoryWorkInProcessNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,052</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finished goods</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db6a066d-019f-42bb-9b00-b13e102c1126" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,088</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total inventory</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86219660-003b-4238-b37d-7a177801125f" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,897</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, total inventory included net fair value adjustments resulting from the acquisition of La Jolla of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df630fc8-9b03-4105-9214-3064c4f66863" contextRef="C_c728d113-afc3-4116-a5d3-755dcf10b52b" name="inva:FairValueAdjustmentsOfInventoryFromAcquistion" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">49.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which will be recognized as cost of products sold when sales occur in future periods. The fair value adjustments recorded as part of cost of products sold amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79246c9e-9ba7-4fea-b450-e181070a2dfc" contextRef="C_8f698f68-0c0f-4134-b100-4f1a9c7c7c0a" name="inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a145c373-5074-413a-9f10-a5e1b7af1e93" contextRef="C_a2b80c7a-b827-400e-b441-ce92d2d12b34" name="us-gaap:InventoryGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> inventory as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Accrued Liabilities</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_06a90728-adcc-409a-bbe0-84b591e0297e" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.399%;"></td>
        <td style="width:1.502%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.6%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.502%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued contract manufacturing expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aae9a5ae-e79a-403f-8c33-b13fb3d46cb3" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:AccruedContractManufacturingLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,382</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2197405-4d23-46ec-ada3-8072f36b03bb" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="inva:AccruedContractManufacturingLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued clinical expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f6c7c69-95fc-456e-9054-002c2d48861d" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:AccruedClinicalLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">692</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cff4dcc-bd08-4fef-bf96-d700266a5e0a" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="inva:AccruedClinicalLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d4e0b3b-029a-4ab4-ace9-7ae67e542483" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:AccruedResearchLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">349</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da785943-018f-4e55-b87e-e0d3f0634960" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="inva:AccruedResearchLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba1d0f71-379f-4927-bd69-2af01d178f3a" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:AccruedProfessionalServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,977</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d91b86f3-ab50-449e-9843-d222ac199043" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="inva:AccruedProfessionalServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">894</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44529633-d0c9-413b-8ec9-ae7dbd25a69d" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,316</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_089892d9-0b75-4222-a792-145e818a1e0e" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of deferred royalty obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_953cf1b8-4219-43b8-a1fc-8c349b42f0ac" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:DeferredRoyaltyObligationCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,639</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58a2f01f-99b7-4c55-9d37-1bbed5ce9cdc" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="inva:DeferredRoyaltyObligationCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued license fees and royalties</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a8a0269-34a2-47c7-b0f4-f5b2e9177764" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:AccruedLicenseFeesAndRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">943</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d5a8d9c-43b9-4ebf-9bf4-50c07f52f23c" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="inva:AccruedLicenseFeesAndRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d08b7d8-2529-4780-8799-5916da345a6a" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,909</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e636e940-5a84-4042-8285-0a8ed2a991b4" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:OtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other accrued liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a535bbf1-ca4d-487e-8bf9-d1ab1d96f354" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,207</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27f5de2f-a6c6-488d-9870-235c5c74b782" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,009</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Long-Term Liabilities</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d04afe4d-4ffa-431b-994c-aa4c75bc5724" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.252%;"></td>
        <td style="width:1.784%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.964%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term portion of deferred royalty obligation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf80d1e5-e684-4dd5-aa02-24609b9aa9bc" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:DeferredRoyaltyObligationNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,947</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term portion of lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0ccf2a9-606c-4ac7-aa80-cfea3521ec09" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,376</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent value rights liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c18a2840-5649-4c90-a80b-581a359675ec" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:ContingentValueRightsLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">595</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other long-term liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61b99f55-990b-407e-a9c1-9c4d0dc96d1c" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,918</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_991e407d-890b-4d13-9d3b-89a052dff9e2" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> other long-term liabilities as of December 31, 2021.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a8cdf0de-28ab-463c-82dc-99cff2a503bc" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. STOCK&#x2011;BASED COMPENSATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Incentive Plans</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2012, we adopted the 2012 Equity Incentive Plan (the &#x201c;2012 Plan&#x201d;). The 2012 Plan provides for the grant of incentive stock options, nonstatutory stock options, RSAs, RSUs and Stock Appreciation Rights to employees, non-employee directors and consultants. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, total shares remaining available for issuance under the 2012 Plan were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec742614-b930-4f11-a12b-7139b0b67a61" contextRef="C_873e7b0b-00b1-48d4-b5e4-b4a6e7d0eff2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,838,270</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2004 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), our employees may purchase common stock through payroll deductions at a price equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ec66399-dad0-4987-9d48-790e20929695" contextRef="C_20021136-8c2b-48e8-bb1e-b92302a7d43e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The ESPP provides for consecutive and overlapping offering periods of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e43e282a-a227-43c2-b89e-505346090ac1" contextRef="C_20021136-8c2b-48e8-bb1e-b92302a7d43e" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24 months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in duration, with each offering period composed of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddba829a-d82c-4abf-9df7-c39e4815b66d" contextRef="C_20021136-8c2b-48e8-bb1e-b92302a7d43e" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" unitRef="U_Item" decimals="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> consecutive </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d767746c-ce7c-43aa-bdae-fea8cc4686cf" contextRef="C_20021136-8c2b-48e8-bb1e-b92302a7d43e" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> purchase periods. The purchase periods end on either May 15 or November 15. ESPP contributions are limited to a maximum of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_378a2305-3584-4802-aaf0-503beefda9b7" contextRef="C_bf38e94a-771f-41f7-b87c-9a8cf1a2bfaf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of an employee&#x2019;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58ebf8bd-46b3-4db7-a73f-2936ff83e3bb" contextRef="C_20021136-8c2b-48e8-bb1e-b92302a7d43e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. An employee may not purchase shares with a value greater than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20518f19-f5dd-49a2-908b-13924c1e9a82" contextRef="C_20021136-8c2b-48e8-bb1e-b92302a7d43e" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in any calendar year.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, total shares remaining available for issuance under the ESPP were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11144eef-7aab-40dd-a122-6209963216c1" contextRef="C_bf38e94a-771f-41f7-b87c-9a8cf1a2bfaf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">160,995</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Director Compensation Program</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our non-employee directors receive compensation for services provided as a director. Each member of our board of directors who is not an employee receives both cash and equity compensation for services as a director, member of a committee of the board of directors, lead independent director and chairman, as applicable. In October 2017, both the cash and equity components of the compensation program were amended, effective immediately (the &#x201c;October 2017 Amendments&#x201d;).</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each of our independent directors receives periodic automatic grants of equity awards under a program implemented under the 2012 Plan. These grants are non&#x2011;discretionary. Only our independent directors or affiliates of such directors are eligible to receive automatic grants under the 2012 Plan. Under the program, each individual who first became a non-employee director will, on the date such individual joins the board of directors, automatically be granted a one&#x2011;time grant of RSUs covering a number of shares of our common stock calculated as $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_331e5604-1e24-4a4b-8793-fb87a34f75fc" contextRef="C_37ba5274-8715-4011-ab28-b8eda0d172d2" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">125,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_691da6f2-1636-4f92-98be-e7e3999b3619" contextRef="C_1c748875-71fe-4003-b725-ef74b25e3855" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share (the &#x201c;Initial RSUs&#x201d;), plus a one&#x2011;time grant of RSUs covering a number of shares of our common stock calculated as $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4576346-5ddf-406d-83c3-9824d2ba4a30" contextRef="C_37ba5274-8715-4011-ab28-b8eda0d172d2" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">225,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6eebda48-760a-49ab-a587-a509b13fcd81" contextRef="C_1c748875-71fe-4003-b725-ef74b25e3855" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, which would be pro-rated for the number of whole months remaining until the anniversary of the prior year&#x2019;s stockholders&#x2019; meeting, rounded down to the nearest whole share (the &#x201c;Pro Rata RSUs&#x201d;). The Initial RSUs vest in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57f9955a-12c7-4ac1-9ae6-41bdd33cee44" contextRef="C_e5ee6d05-e981-4946-800e-de9d31604888" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> equal annual installments, while Pro Rata RSUs vest in a single installment at the sooner of the next annual stockholder meeting or the one-year grant anniversary, in each case subject to the non-employee director&#x2019;s continuous service through the applicable vesting date.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annually, upon his or her re&#x2011;election to the board of directors at the Annual Meeting of Stockholders, each non-employee director is automatically granted an RSU covering a number of shares of our common stock calculated as $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72072464-7686-46b5-9355-bca19119bd3a" contextRef="C_5dd1e719-80fe-4711-a19b-c407c3e1587a" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">225,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfe8c6e7-1660-4250-8e07-333bd6458a1f" contextRef="C_0d234c0c-f63c-4792-acb9-96224e1a9014" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">250,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share. These RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the non-employee director&#x2019;s continuous service through the applicable vesting date. Following the amendment to our non-employee director compensation program, both the annual RSUs and Initial RSUs described above remained unchanged with the exception that the number of shares of our common stock subject to each award has been reduced.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These RSUs will vest in full upon the director&#x2019;s death, the occurrence of a change in control or, with respect to awards made after the October 2017 Amendments, the director&#x2019;s disability before the director&#x2019;s service terminates. Director RSUs carry dividend equivalent rights to be credited with an amount equal to all cash dividends paid on the underlying shares of common stock while unvested. Dividend equivalents are subject to the same terms and conditions, including vesting, as the RSUs to which they attach and are paid in cash upon vesting.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock&#x2011;Based Compensation Expense</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9cbae0d8-5799-4d8d-b7c8-bfd0a0591baa" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock&#x2011;based compensation expense is included in the consolidated statements of income as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.423%;"></td>
        <td style="width:1.008%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.008%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.008%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.707%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4649a00a-1865-467e-a560-23073d4cb515" contextRef="C_077c554a-e6a5-43dd-991a-36356231105e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,305</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f01c12b3-c2eb-4b94-bf30-4090af9eb211" contextRef="C_4722bfe5-dfa7-4d44-bbd1-d47edc793461" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5559fcd6-7d94-4716-b14c-2db780bab5f5" contextRef="C_0741d536-3cd1-4bb3-a3d8-4a8b9e768e1c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,698</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c25efe31-c10a-4088-a28b-58b372797ec5" contextRef="C_7a637d38-c05d-4d65-9849-9fabc00c0938" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,042</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de588f10-bdac-44b3-a183-f544ac4edb44" contextRef="C_546bf034-6546-4012-bb5a-e1fa071bebc2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5947bcc-a2e0-463c-b9b0-0202620beb23" contextRef="C_c9fa8159-64b4-4582-868c-ef082d816dac" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b592c3f-0b1a-49d8-9a33-2da2656512c6" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,347</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e36f4462-e8c1-40fc-9ee3-8dc298124fd7" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fc9a9e1-1d6f-495e-9b73-07726308026f" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,698</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8cd36799-2367-4fba-b382-abd9d10ad1c6" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock&#x2011;based compensation expense included in the consolidated statements of income by award type is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.52%;"></td>
        <td style="width:1.487%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.540000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.487%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.540000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.487%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.940000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bc2fc86-974b-40b8-83fa-a21ae6275382" contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,057</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9bd04c91-c1d2-443a-aa33-de04933a5878" contextRef="C_a386f2f5-a2d5-44d9-be1d-92de778d3a08" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">490</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6182905a-5a1a-409c-b0cc-38a0f271c8e2" contextRef="C_8d4db9d3-f0ac-411c-b4be-66a68e66086e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">242</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce3fb0a3-4bee-441d-9385-fd5f6414d4a2" contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,053</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_687805a4-80b8-4fe8-b8af-881a43bf05be" contextRef="C_b353aac4-69f8-4721-bb91-b64e5c3524b9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92013cd1-6598-4d40-b966-811c9e3f8753" contextRef="C_c0cc6f7b-c585-47f1-8084-1c731c93f71e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,149</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSAs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f54add1c-caa2-4d13-8fbf-c94cfd7a1611" contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f28e779-943c-4acc-802b-3e88d2a00958" contextRef="C_eddd93e6-6ae6-44b1-8b18-2af265b00535" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">200</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc103f01-b904-495c-95d3-8dea6c5cd254" contextRef="C_dbcbd115-0d6a-4e3b-8ad7-7e5315f18708" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e10de987-656b-44c5-9b69-2533afe7e9d1" contextRef="C_20021136-8c2b-48e8-bb1e-b92302a7d43e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f42bbbb-a169-4970-bde7-fb18c5d94257" contextRef="C_0420bbef-96b0-4a85-a0f8-18bc3bd3a1fd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7151a92b-a8c2-4374-b26a-97dbcfafe110" contextRef="C_5ba508af-5e54-40ad-899c-3cb351c9a5ec" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76970b92-868e-41a4-8a7d-cfd579837946" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,347</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_211f7c5f-f3bd-41a5-abdd-03461f5a4e6a" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39af200b-318c-44c8-a1a9-6320e6a04e01" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,698</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eff20a45-0a63-4668-a488-55db9d845256" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:60.185%;"></td>
        <td style="width:1.808%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.413999999999998%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.351%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.243%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized Compensation Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Amortization Period (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_946c0b43-0008-4023-b5df-ade6089681c4" contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,550</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_318a6c4d-050f-4ed5-a9d5-a8946a2821a3" contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8301d511-513f-44a4-83da-55d31e5596d3" contextRef="C_4225ffae-2b85-4646-9d44-6752e738321b" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,776</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d01dff65-34ae-4c50-a1b0-76baee3fdf77" contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSAs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86ec0c93-573a-4a14-8818-eebcce378eee" contextRef="C_d577f45e-f619-4e15-880c-f1fd5f863799" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">388</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3f4abe74-8863-4efd-9786-75a3274efd81" contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total unrecognized compensation expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4604dfdd-f070-4a1e-9c09-977d5ae797c2" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,714</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation Awards</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_a73e9064-ffeb-4daf-a049-63fe56df5220" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:31.657%;"></td>
        <td style="width:0.963%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.326%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.311%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.977%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.34%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.311%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.977%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.34%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.006%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.778%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of outstanding options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Exercise Price of Outstanding Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of outstanding RSUs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of outstanding RSAs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdf48bcf-f028-4ab2-85b2-df15c8c21a6a" contextRef="C_e262e47d-f2f5-4208-90c1-3bcda7144a65" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3d95162-1362-44a9-b51b-b1d6d8b87b00" contextRef="C_e262e47d-f2f5-4208-90c1-3bcda7144a65" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">20.79</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04dc9ca5-943b-4cdc-b6f9-a0f78946d864" contextRef="C_c88e8766-779e-489b-97e4-b86fcdc4511b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">116</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a70950df-5622-449c-a7c2-aa1b082be897" contextRef="C_c88e8766-779e-489b-97e4-b86fcdc4511b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">12.82</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7fe5322-574d-417e-86db-7b9d4387ee43" contextRef="C_90bb4c16-e20f-46dc-b959-d3bb3d63c67d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_622f237f-5acb-4488-9a58-910ddb540ec3" contextRef="C_90bb4c16-e20f-46dc-b959-d3bb3d63c67d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.35</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0fec715-334e-4500-8308-f8c69b7ae413" contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">492</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5eafe8d4-a666-48bf-820f-e0fcf76d175b" contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.92</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2dcc6f7f-c8d9-49bc-8ff6-aa22f7c8ab84" contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">676</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3c2e039-bf41-45f9-a0f7-784e3742621e" contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">11.06</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d498894f-4508-4b5a-a1a9-abe32a49c349" contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21789102-40fb-46f9-9098-1906e28174d7" contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">16.67</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bcc4acf-3a82-4cff-8e47-73bde58ddbdb" contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd52c68b-b86a-4924-ac13-0df6a0cacff9" contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">17.11</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41d0b51f-e028-4e6d-93cb-0baa9e6e35a1" contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9457fa90-a6f2-49f9-b063-54e9984b3b26" contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9fcd736-a84c-400f-9921-a7c35e8da0de" contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a52844a3-b2d1-40fc-808d-e84c563352cd" contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Released RSUs and RSAs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_389e9f63-934a-4a05-8de6-3a94332eb534" contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3fd52f31-16ff-4156-a37b-d55ded3e832f" contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9476876b-7b8c-4e33-8078-a5c39c64faa3" contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">233</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c84636d9-71ec-4b83-8de6-3a78ae6edb18" contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">9.90</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8c58806-256a-493f-a667-23100565d30a" contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0770733-217f-4b7c-93d6-cc666297dd2f" contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2e996ec-d7a1-44c4-90c1-2422db0e88cb" contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">295</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90ef06c2-6425-4314-84b8-b7bcf4601d4d" contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">28.01</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e18800df-c518-4014-a383-e86ffcb5683e" contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">41</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13e0a6c6-5a57-47b0-81d1-9a0a5f03dbe2" contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">8.80</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1cb379a-6b8d-4d2f-8295-00fd46af4ca5" contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" unitRef="U_shares" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dead00fd-fc88-431c-b25d-e19d4bb69ced" contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_595ed31a-5767-4de2-ae4d-9bfb87f30253" contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">948</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7e1982c-2823-4dfb-b447-84951234103d" contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">15.56</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a49fcb0d-0e4f-47bb-bdfe-8254f2bdaa59" contextRef="C_4225ffae-2b85-4646-9d44-6752e738321b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">518</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c81efb0-565b-4585-842f-ae1a887a758d" contextRef="C_4225ffae-2b85-4646-9d44-6752e738321b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">12.16</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3ea0384-651f-49ee-ab95-c7c6b528b73f" contextRef="C_d577f45e-f619-4e15-880c-f1fd5f863799" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eeacd384-0572-411a-bf55-81c376b55633" contextRef="C_d577f45e-f619-4e15-880c-f1fd5f863799" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.97</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest <br />&#160;&#160;&#160;as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f6aeebc-6eb4-42a3-bc31-11b35d508848" contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">948</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4d2d2a8-e0c3-475f-8dcf-92cab65f353d" contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">15.56</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c973c6d6-f07c-4426-86e6-d7aed35123cb" contextRef="C_4225ffae-2b85-4646-9d44-6752e738321b" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">518</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14f86c3f-6d77-47f5-a2c6-b020529c6a0b" contextRef="C_4225ffae-2b85-4646-9d44-6752e738321b" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">12.16</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0c7ff1f-797d-406e-8dd8-466a49bce388" contextRef="C_d577f45e-f619-4e15-880c-f1fd5f863799" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1641c701-f7e9-4e01-af07-f560127a7257" contextRef="C_d577f45e-f619-4e15-880c-f1fd5f863799" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the aggregate intrinsic value of options outstanding and options exercisable was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8979d928-ffed-4faa-9d74-51267e05f260" contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cb353724-9097-4f41-89b1-e22ac6c2610e" contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t material</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021, the aggregate intrinsic value of the options outstanding was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1376941e-0c37-49b7-8459-265e504ab4c7" contextRef="C_e262e47d-f2f5-4208-90c1-3bcda7144a65" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the aggregate intrinsic value of options exercisable was immaterial. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49e3d95c-e59c-46a5-983c-18ad7c9236b2" contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">290</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options were exercisable. The weighted average remaining contractual term of options outstanding was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1b0ab645-3982-473a-ac2e-0def378dab7a" contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.01</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c54b0988-0d30-4685-b481-c80596fdb978" contextRef="C_a386f2f5-a2d5-44d9-be1d-92de778d3a08" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.43</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years as of December 31, 2022 and 2021, respectively.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total intrinsic value of the options exercised was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5fc643c-7065-4d6b-9e71-1f0fc1798486" contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t material as of December 31, 2022. The total intrinsic value of the options exercised was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4900f038-359e-4230-9523-73f5e7e53f92" contextRef="C_a386f2f5-a2d5-44d9-be1d-92de778d3a08" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_453f35fc-4553-408b-aeb8-bae66036085a" contextRef="C_8d4db9d3-f0ac-411c-b4be-66a68e66086e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2021 and 2020, respectively. The total estimated fair value of options vested was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1a97aa1-d31b-4cad-8b38-d40eb0f7c143" contextRef="C_a386f2f5-a2d5-44d9-be1d-92de778d3a08" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021. The total estimated fair value of options vested was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_095604a5-b5eb-4caa-9a06-e36e77e03609" contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ff391fa3-17ed-49a4-8c4b-a7eb7de384fc" contextRef="C_8d4db9d3-f0ac-411c-b4be-66a68e66086e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t material for the year ended December 31, 2022 and 2020, respectively.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total estimated fair value of RSUs vested was $2.3 million, $1.1 million and $1.3 million for the year December 31, 2022, 2021 and 2020.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total estimated fair value of RSAs vested was not material for the year ended December 31, 2022, 2021, and 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Valuation Assumptions</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ee7e738b-3b4f-48c9-ba8f-5c03822e27c8" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average assumptions used in calculating the estimated value of our stock options on the date of grant as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.741%;"></td>
        <td style="width:1.474%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.955%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.464%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.955%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.464%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.946%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8eb013fc-50eb-4f2a-a755-f0bacb8d1d84" contextRef="C_5440a9c2-207c-4fb3-b81e-e1b717693af2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ccb3cc83-d2c4-4f4c-8bd0-d942ca15ff8a" contextRef="C_fe02af8a-5018-4690-9673-9a7063d85b4a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8293e117-50d8-40ec-9aa4-12d56edb7e8e" contextRef="C_7cb7feed-1acc-460a-b96e-c4eeb94c9ae0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f78aab1e-f250-4ab7-b1e9-fd10c84efb6e" contextRef="C_5440a9c2-207c-4fb3-b81e-e1b717693af2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.04</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dd527153-dd9d-42b5-950a-4700e8395806" contextRef="C_fe02af8a-5018-4690-9673-9a7063d85b4a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.11</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2cbf4a81-4f52-40ab-a30f-79cf957b6c7e" contextRef="C_7cb7feed-1acc-460a-b96e-c4eeb94c9ae0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.11</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db860bfe-c610-4e68-98a5-75b4817d868c" contextRef="C_5440a9c2-207c-4fb3-b81e-e1b717693af2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">38.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2bfe5cb-c4df-4e48-b9f7-a42a48fe361e" contextRef="C_fe02af8a-5018-4690-9673-9a7063d85b4a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">44.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e115f6d3-a4f1-4264-8115-e79706e3638b" contextRef="C_7cb7feed-1acc-460a-b96e-c4eeb94c9ae0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">46.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b119ad9-3c14-4718-9251-a193a1c2d3d1" contextRef="C_5440a9c2-207c-4fb3-b81e-e1b717693af2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b98df59d-40eb-4464-9583-c5e91148c9f2" contextRef="C_fe02af8a-5018-4690-9673-9a7063d85b4a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3d3446c-5f71-4028-ab2b-0877f30b1751" contextRef="C_7cb7feed-1acc-460a-b96e-c4eeb94c9ae0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average estimated fair value of stock options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af3e8eb7-3c07-4799-b2c9-862a81c1166d" contextRef="C_5440a9c2-207c-4fb3-b81e-e1b717693af2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.43</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_412797d0-c967-434a-9cab-6967a87fa784" contextRef="C_fe02af8a-5018-4690-9673-9a7063d85b4a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.84</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc3d4823-5438-47db-9028-7b261314dd23" contextRef="C_7cb7feed-1acc-460a-b96e-c4eeb94c9ae0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.28</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_08628a03-3017-46a4-83b0-b9cbd307f886" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; Equity</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 31, 2022, our board of directors authorized a new share repurchase program under which we may repurchase up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_65e8bc03-dc37-4620-a97b-48d97984b0b0" contextRef="C_f7e84609-a139-4ee7-8f30-bd52dd4de851" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of our outstanding shares of common stock. The timing and amount of any share repurchases under the share repurchase program will be determined by our management in its discretion based on ongoing assessments of the capital needs of the business, the market price of our common stock, prevailing stock prices, general market conditions and other considerations. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. This program has no termination date, may be suspended or discontinued at any time at our discretion, and does not obligate us to acquire any amount of common stock. As of December 31, 2022, we have repurchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb34957d-c976-4c10-8eec-e389793f3f09" contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">647,394</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30c17bbc-3710-4db6-bb20-e7a354023082" contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869" name="inva:CommonStockAcquiredAverageCostPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.13</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10a38b78-8a1e-49ee-b52f-0e2ba5ba25c9" contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Subsequent to December 31, 2022 and through February 24, 2023, we have repurchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e228388-db4d-420f-984e-725b998979e9" contextRef="C_e21d4ed9-45f2-4010-8231-c9ee66700c0c" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">1,522,947</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf810c75-b80a-4aed-92da-c4f067665682" contextRef="C_225556d0-78ae-4d3f-a563-0e5f56e17bdb" name="inva:CommonStockAcquiredAverageCostPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">12.63</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_641bbc49-4e91-4c70-b45a-c577a66da8fa" contextRef="C_225556d0-78ae-4d3f-a563-0e5f56e17bdb" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. All the repurchased shares were retired.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6e2fe99c-f329-4e4f-a9ef-e5058e2fc961" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. DEBT</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b9846e37-eccc-4bea-86c1-fbfa149ae0a4" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our debt consists of:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.265%;"></td>
        <td style="width:1.498%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.772%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.498%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.966000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_817a431e-6c56-4ec9-a1d5-fd7aa2b49d26" contextRef="C_db24b4c5-31a5-4774-89a4-c8ee79bc160f" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,204</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f50c3e9-1391-447c-ab78-10e91d53b568" contextRef="C_e0e7a33a-815b-42a2-be04-e2cbe14d7628" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">240,984</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d65e4a32-3307-4c62-bf86-7295c16341d0" contextRef="C_975e5da7-351c-4671-96f0-b5f31daa46d0" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">192,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6beb6149-2112-4519-8a06-a00fed755d85" contextRef="C_3f8a395a-d382-4590-8d7a-2cc22d27ec5d" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">192,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_452848d6-b6e3-470d-9f22-2a9e21960155" contextRef="C_87d07c35-75b2-4cc6-9d24-9604a851da8f" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b6b637f-86be-44a6-a527-1ebbd52acc95" contextRef="C_4cc2b7aa-5de5-44f3-bfb9-3a6bc72ba7cc" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdadef31-edc0-4f19-9270-e9ca6daf3f7b" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">549,704</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16ecf6dc-f429-4f90-873a-5c7cdfd464a5" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">433,484</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2be14dd0-2cf5-4a4e-8c03-cf3b9ede8f38" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,331</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7ec226a-f039-4fba-8dee-47fa7110d3e4" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,831</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total debt, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87529182-981c-4648-a437-1075130c6c01" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">540,373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56949bdf-aa88-4f3c-8aec-09ce005fc275" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">394,653</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Less: Current portion of long-term debt, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17c44fd4-82ba-44b1-aaf0-24d43640cb46" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,193</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f575a754-f475-423c-b982-7054e41dee2a" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term debt, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a637dd0a-6101-445d-ae1c-fe864a45277f" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">444,180</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f78c0932-6d5d-49fa-af71-7301137e5f6e" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">394,653</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Subordinated Notes Due 2023</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2013, we completed an underwritten public offering of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f623463c-3e35-4b23-b779-38a054a483c3" contextRef="C_5d2ad42a-8c00-45ec-8588-2ffd6e64e9db" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">287.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million aggregate principal amount of unsecured convertible subordinated notes, with maturity date of January 15, 2023. The financing raised proceeds, net of issuance costs, of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc57ab98-7faa-4975-b0f0-505f084f8d4d" contextRef="C_4fdff83b-7c27-43e0-9faa-0d7971a875c1" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">281.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, less $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70dd6b55-9185-4a0e-94d6-f9cae0edb4e6" contextRef="C_c0c14dc4-3f99-40d8-a419-fb1d3a855ff6" name="us-gaap:DerivativeCostOfHedge" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">36.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87ffbbfb-f25f-490e-ae4d-112697ded482" contextRef="C_eeedca61-ff8b-43cf-9322-e4e591891f4a" name="inva:NumberOfDerivativeInstrumentsPurchased" unitRef="U_Item" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> privately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negotiated capped call option transactions in connection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the issuance of the notes. The 2023 Notes bear interest at the rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19d164d8-7749-42e3-8fe6-b38ee77e7ada" contextRef="C_5d2ad42a-8c00-45ec-8588-2ffd6e64e9db" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="5" format="ixt:numdotdecimal">2.125</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per year that is payable semi-annually in arrears in cash on January 15 and July 15 of each year, beginning on July 15, 2013.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2023 Notes were convertible, at the option of the holder, into shares of our common stock at an initial conversion rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86c2ae96-eb8c-44f7-b18a-ac3c96f47b4c" contextRef="C_4fdff83b-7c27-43e0-9faa-0d7971a875c1" name="inva:ConversionRate" unitRef="U_shares" scale="0" decimals="4" format="ixt:numdotdecimal">35.9903</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares per $1,000 principal amount of the 2023 Notes, subject to adjustment in certain circumstances, which represents an initial conversion price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_067ec2d1-b0d8-429e-b4fb-f3748d765b92" contextRef="C_5d2ad42a-8c00-45ec-8588-2ffd6e64e9db" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">27.79</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the offering of the 2023 Notes, we entered into two privately negotiated capped call option transactions with a single counterparty. The capped call option transaction is an integrated instrument consisting of a call option on our common stock purchased by us with a strike price equal to the initial conversion price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6429131-ce48-4043-91c1-85d7570349b2" contextRef="C_c0c14dc4-3f99-40d8-a419-fb1d3a855ff6" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">27.79</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for the underlying number of shares and a cap price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5d620bd-7f37-4efe-ade0-3796d76522c6" contextRef="C_eeedca61-ff8b-43cf-9322-e4e591891f4a" name="us-gaap:DerivativeCapPrice" unitRef="U_UsdItem" scale="0" decimals="2" format="ixt:numdotdecimal">38.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, both of which are subject to adjustments consistent with the 2023 Notes. The cap component is economically equivalent to a call option sold by us for the underlying number of shares with an initial strike price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18b61989-066f-46c9-a5ad-30f401c94985" contextRef="C_eeedca61-ff8b-43cf-9322-e4e591891f4a" name="us-gaap:DerivativeCapPrice" unitRef="U_UsdItem" scale="0" decimals="2" format="ixt:numdotdecimal">38.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. As an integrated instrument, the settlement of the capped call coincides with the due date of the convertible debt. Upon settlement, we would receive from our hedge counterparty a number of shares of our common shares that would range from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9497ea9d-48c3-4c2a-8c8e-d16fecc6d0a9" contextRef="C_ca10358b-8c3c-4daf-beb4-bf93df5c5577" name="inva:NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, if the stock price was below $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15a1bf2b-4649-4b29-a4ae-1143e84e258e" contextRef="C_e26b8922-044d-455a-825e-2cbd6970866c" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">27.79</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, to a maximum of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a11e067-5409-4134-a23f-a03c9d5734ce" contextRef="C_760e546c-c33b-4240-91c4-bc5ba9131a71" name="inva:NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,779,659</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, if the stock price is above $38.00 per share. However, if the market price of our common stock, as measured under the terms of the capped call transactions, exceeds $38.00 per share, there is no incremental anti-dilutive benefit from the capped call.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the partial conversion by certain holders of the 2023 Notes in July 2014, and dividends declared and paid in 2014 and 2015, the conversion rate with respect to our 2023 Notes was adjusted in total to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_880d9e98-7aad-45b3-ac18-9ddbbafe80bc" contextRef="C_41da565b-a64a-4074-a703-94289af0897b" name="inva:ConversionRate" unitRef="U_shares" scale="0" decimals="4" format="ixt:numdotdecimal">50.5818</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock per $1,000 principal amount of the 2023 Notes, which represents a conversion price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4a28574-923b-41be-af9d-eaebd7946421" contextRef="C_ac5e1f2a-cef7-4391-8f23-5ab0d707cb92" name="inva:CappedCallStrikePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">19.77</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. As a result of the conversion rate adjustments, the capped call strike price and cap price were also adjusted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5bfac29c-8db3-4c25-b3e4-34d5f469e9df" contextRef="C_931f2e1a-1b03-4282-9cfd-4d87cffcdb25" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">19.77</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79493d95-3846-41e0-bcb4-8f451a0014b4" contextRef="C_4440fd71-0092-4f2b-a8d0-66d0304e4b87" name="us-gaap:DerivativeCapPrice" unitRef="U_UsdItem" scale="0" decimals="2" format="ixt:numdotdecimal">27.04</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2016, we retired a portion of our 2023 Notes with a face value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bce73673-bbbf-4bdf-a4d9-b5bbbbfe5be1" contextRef="C_b203b0f4-9fcb-40af-9c5b-8e2482e2f95a" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and carrying value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0b33235-e240-4eea-b423-176c1097a3f9" contextRef="C_b203b0f4-9fcb-40af-9c5b-8e2482e2f95a" name="us-gaap:DebtInstrumentRepurchaseAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million by way of purchase in the open market.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 7, 2022, we used $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_702264ac-efd5-4e88-90c6-4444d0ccb9a4" contextRef="C_3016f145-17f8-4f1a-82c7-f26a7aa8c466" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">165.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from the sale of the 2028 Notes to repurchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d635f24-d3f0-4f67-93a5-ce61dc79c35e" contextRef="C_3016f145-17f8-4f1a-82c7-f26a7aa8c466" name="inva:DebtInstrumentRepurchasePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">60</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the 2023 Notes with a face value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_609f1c51-fe72-4318-8cfd-768db6304387" contextRef="C_443136d7-7ad0-44e7-a11c-023a948f7f76" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">144.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The carrying value of the repurchased 2023 Notes was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_930375a0-bee4-40cd-92db-6773a83db301" contextRef="C_443136d7-7ad0-44e7-a11c-023a948f7f76" name="us-gaap:DebtInstrumentRepurchaseAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">144.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Accrued interest was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c677aa60-83d2-456b-8e1b-57b9d47dfd36" contextRef="C_443136d7-7ad0-44e7-a11c-023a948f7f76" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and unamortized debt issuance costs were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6b70a24-a112-4818-ada4-c38617706193" contextRef="C_443136d7-7ad0-44e7-a11c-023a948f7f76" name="us-gaap:UnamortizedDebtIssuanceExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on the date of repurchase. We recognized a loss on the extinguishment of the 2023 Notes of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2423bacd-6653-4932-a4ac-40da6161a0d3" contextRef="C_3016f145-17f8-4f1a-82c7-f26a7aa8c466" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in other expense, net, in the consolidated statement of operations. The repurchase reduced the outstanding principal balance to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59a8c04d-f092-4cca-ac15-692a256b62c8" contextRef="C_443136d7-7ad0-44e7-a11c-023a948f7f76" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">96.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and unamortized debt issuance costs to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1512bbf-e6b5-41a1-899e-2db6d651ec64" contextRef="C_443136d7-7ad0-44e7-a11c-023a948f7f76" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The annual effective interest rate of the 2023 Notes changed from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0c073cf-ed92-49fd-9e25-24071c9d5125" contextRef="C_439a2891-953d-43ed-8e7a-3e4c09d85e29" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.36</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf31a30d-374e-4cc5-afa4-21e3f0960fc2" contextRef="C_1e690336-d9c4-4186-8f97-2aa319621487" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.37</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 18, 2022, certain 2023 Notes holders converted their notes of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b9557e4-a881-4c5b-8ce5-6f91f62cda41" contextRef="C_c50e19a1-f680-4297-ba13-d0cc4e167f05" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand into Innoviva&#x2019;s common stock. The outstanding principal balance was reduced slightly to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef763c5d-0522-4859-b274-c0f6dee071ad" contextRef="C_b36371f8-68e7-4572-9b2d-995236afdd29" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">96.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b3d82245-e41a-45fa-bee3-af0cc23f9c76" contextRef="C_32dbf528-70de-47c3-9e65-d8c113adb297" name="us-gaap:ConvertibleDebtTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our outstanding 2023 Notes balances consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.265%;"></td>
        <td style="width:1.498%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.772%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.498%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.966000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e587b9df-2624-4d07-a295-5d31b5b2bcca" contextRef="C_db24b4c5-31a5-4774-89a4-c8ee79bc160f" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,204</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0dcc63a-06fd-40ab-b341-8c2f883b0b2b" contextRef="C_e0e7a33a-815b-42a2-be04-e2cbe14d7628" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">240,984</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt issuance costs, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b75d8460-5980-4bc8-8d82-c8d07e750b3f" contextRef="C_db24b4c5-31a5-4774-89a4-c8ee79bc160f" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35f480b8-0d5b-4b41-b0e5-2b0312c0848e" contextRef="C_e0e7a33a-815b-42a2-be04-e2cbe14d7628" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">620</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f06fdcc-7813-4b55-aaf2-725a0d1d79ec" contextRef="C_db24b4c5-31a5-4774-89a4-c8ee79bc160f" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,193</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95a4cd47-ef3d-41ca-b08c-b8fb869c3640" contextRef="C_e0e7a33a-815b-42a2-be04-e2cbe14d7628" name="us-gaap:LongTermDebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">240,364</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a35bc66d-f68e-4ae6-9ddd-b503d276cf26" contextRef="C_32dbf528-70de-47c3-9e65-d8c113adb297" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2023 Notes for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.52%;"></td>
        <td style="width:1.487%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.540000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.487%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.540000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.487%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.940000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fea69e71-260a-48f9-b097-b6f902a32596" contextRef="C_2889d5e4-431b-4019-8db7-26884c76cb7f" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,617</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dec873e-d2a3-465f-820d-41c762d79ac6" contextRef="C_82199548-5f77-4397-8b16-459c147af958" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,121</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f086c5ad-3c90-4804-9684-1283233ff441" contextRef="C_e8422a9e-f163-4920-b53e-2d0b99405fc9" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,121</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8874eb00-061d-46c3-be5e-76e158010e1b" contextRef="C_2889d5e4-431b-4019-8db7-26884c76cb7f" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">302</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89a55a64-7ae5-4e64-945d-13a14d10291d" contextRef="C_82199548-5f77-4397-8b16-459c147af958" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">580</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b57407c4-e772-48db-8e50-c28ed1ba94bd" contextRef="C_e8422a9e-f163-4920-b53e-2d0b99405fc9" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">567</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25db4e6b-ffd3-43d6-a9bf-0c4a6c9fc7bf" contextRef="C_2889d5e4-431b-4019-8db7-26884c76cb7f" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,919</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e44c4548-f737-4768-b788-cf0964482d25" contextRef="C_82199548-5f77-4397-8b16-459c147af958" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,701</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f171181f-7579-4f9a-bade-c0c5af11fc81" contextRef="C_e8422a9e-f163-4920-b53e-2d0b99405fc9" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,688</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2023 Notes were fully paid upon their maturity date in January 2023.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Senior Notes Due 2025</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 7, 2017, we completed a private placement of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_039805a8-b080-4759-8e0b-19accc340a62" contextRef="C_fd54577e-ca59-4227-b618-f18cb6ef69e3" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">192.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million aggregate principal amount of our 2025 Notes. The proceeds include the 2025 Notes sold pursuant to the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58ea36fe-6e40-44ee-a466-8f968b38aea5" contextRef="C_5d3e731d-77ad-41c9-8fb2-80c5c772794f" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_88c11449-00f2-4f3a-8c30-d20dd5a6f5e8" contextRef="C_5d3e731d-77ad-41c9-8fb2-80c5c772794f" name="inva:PortionOfDebtInstrumentFaceAmountExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.5</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million over-allotment option granted by us to the initial purchasers, which option was exercised in full. The 2025 Notes were sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The 2025 Notes are senior unsecured obligations and bear interest at a rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b58940b0-ecc9-4be7-a3ec-5b068031dca1" contextRef="C_fd54577e-ca59-4227-b618-f18cb6ef69e3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per year, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on February 15, 2018.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2025 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate for the 2025 Notes is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c892ca6f-a3d7-4dfe-9301-c3aec6b29f97" contextRef="C_a12f3c2b-1e4a-41a5-98c5-e299cd3ff20e" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" unitRef="U_pure" scale="0" decimals="4" format="ixt:numdotdecimal">57.9240</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock per $1,000 principal amount of the 2025 Notes (which is equivalent to an initial conversion price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47146212-034f-4ed3-a990-5da68566c3a7" contextRef="C_37b32554-8570-46f1-ad40-8f1d76b0a567" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">17.26</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share), representing a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86260ba6-05de-48ae-9ec0-054b7abf6900" contextRef="C_37b32554-8570-46f1-ad40-8f1d76b0a567" name="inva:DebtInstrumentConvertibleConversionPremium" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% conversion premium over the last reported sale price of the Company&#x2019;s common stock on August 1, 2017, which was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fa5bdf8-c0b3-4421-985a-91b79525b8c4" contextRef="C_3df3cdfa-bdca-4ba3-afb8-18a6a9c0e333" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.28</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The conversion rate is subject to customary anti-dilution adjustments in certain circumstances. The 2025 Notes will mature on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fd7a86ce-dec1-496c-bab5-54d8620d5778" contextRef="C_a12f3c2b-1e4a-41a5-98c5-e299cd3ff20e" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 15, 2025</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, unless repurchased or converted in accordance with their terms prior to such date. Prior to February 15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods. From, and including, February 15, 2025, until the close of business on the second scheduled trading day immediately preceding the maturity date, the 2025 Notes will be convertible at any time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of the 2025 Notes may convert all or a portion of their 2025 Notes prior to the close of business on February 15, 2025 only under the following circumstances:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">after September 30, 2017, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dd1f508-9bb4-4750-a1c7-d59da0ca422a" contextRef="C_98afe62c-821a-4537-b552-da050d3c5568" name="inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">130</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the current conversion price of the 2025 Notes;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94259da0-fbc2-45b6-abfe-8d57fef07352" contextRef="C_98afe62c-821a-4537-b552-da050d3c5568" name="inva:DebtConversionConvertedInstrumentAverageTradePricePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">98</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the product of our closing common stock price and the conversion rate of the 2025 Notes on such day; and,</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental changes (as defined in the indenture governing the 2025 Notes) or a transaction resulting in our common stock converting into other securities or property or assets. </span></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On or after February 15, 2025, holders of the 2025 Notes may convert their 2025 Notes at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2025 Notes.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of default or a fundamental change (as defined above), holders of the 2025 Notes may require us to repurchase all or a portion of their 2025 Notes at price equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d2ad514-16fa-4887-807b-fa30d401f0eb" contextRef="C_02211f41-81dd-4ee9-8d76-5d38e227447b" name="inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the principal amount of the 2025 Notes, plus any accrued and unpaid interest.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective January 1, 2022, we adopted ASU 2020-06 using a modified retrospective method, under which financial results reported in prior periods were not adjusted. The adoption of ASU 2020-06 had a material impact on the 2025 notes. Refer to Note 1, &#x201c;Description of Operations and Summary of Significant Accounting Policies&#x201d;, for further information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the adoption of ASU 2020-06, we separately accounted for the liability and equity components of the 2025 Notes by allocating the proceeds between the liability component and the embedded conversion option (&#x201c;equity component&#x201d;) due to our ability to settle the conversion obligation of the 2025 Notes in cash, common stock or a combination of cash and common stock, at our option. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature using the income approach. The allocation was performed in a manner that reflected our non-convertible debt borrowing rate for similar debt. The equity component of the 2025 Notes of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d09cb842-6fba-447b-bd8b-c192a919b736" contextRef="C_f935b07f-6611-49a5-95c9-c3a28c0fd4ed" name="us-gaap:DebtInstrumentUnamortizedDiscount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">67.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recognized as a debt discount and represents the difference between the proceeds from the issuance of the 2025 Notes and the fair value of the liability of the 2025 Notes on the date of issuance. The excess of the principal amount of the liability component over its carrying amount (&#x201c;debt discount&#x201d;) was amortized to interest expense using the effective interest method over the term of the 2025 Notes. The equity component was not remeasured as long as it continued to meet the conditions for equity classification. Additionally, we separated the total issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_224a86e7-8ac3-4e66-a027-50de89eaef6d" contextRef="C_98afe62c-821a-4537-b552-da050d3c5568" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million incurred into liability and equity components in proportion to the allocation of the initial proceeds, resulting in liability issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb5eccc8-a24d-46a9-87d5-6f655d466a7b" contextRef="C_98afe62c-821a-4537-b552-da050d3c5568" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and equity issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25ee2968-54b7-4e4c-8ea3-da3348ba57b6" contextRef="C_98afe62c-821a-4537-b552-da050d3c5568" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance costs attributable to the liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">component </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">were amortized on a straight-line basis, which approximated the effective interest rate method, to interest expense over the term of the 2025 Notes. The issuance costs attributable to the equity component were netted against the equity component in additional paid-in capital. The annual effective interest rate of the liability component of the 2025 Notes was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38db790d-a4eb-4121-acb0-b385cd053fc8" contextRef="C_92728848-49b6-4fe1-8f74-6dcb6ee6a998" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">8.87</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon adoption of ASU 2020-06 on January 1, 2022, we combined the liability and equity components of the 2025 Notes assuming that the instrument was accounted for as a single liability from inception to the date of adoption. We similarly combined the liability and equity components of the issuance costs. The issuance costs are presented as a deduction from the outstanding principal balance of the 2025 Notes and are amortized on a straight-line basis over the term of the 2025 Notes under the effective interest rate method. As of January 1, 2022, the annual effective interest rate on the 2025 Notes was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_102c180d-e4ff-4fac-bb4a-2140040073ac" contextRef="C_9efe7ef9-0fdb-45f7-9960-db3353139806" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.88</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_913a944c-bbd3-42a0-9849-590b9376ddb6" contextRef="C_98afe62c-821a-4537-b552-da050d3c5568" name="us-gaap:ConvertibleDebtTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our outstanding 2025 Notes balances consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.265%;"></td>
        <td style="width:1.498%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.772%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.498%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.966000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liability component</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2c5afbf-c959-47d4-ae7f-1a3de6841109" contextRef="C_975e5da7-351c-4671-96f0-b5f31daa46d0" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">192,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af532fb0-98d6-4165-83da-fc544583a920" contextRef="C_3f8a395a-d382-4590-8d7a-2cc22d27ec5d" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">192,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c31ba29-378c-4fe6-8598-ed59edc57e1e" contextRef="C_975e5da7-351c-4671-96f0-b5f31daa46d0" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,917</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84568c4d-13a8-43eb-9ffe-d24473098caa" contextRef="C_3f8a395a-d382-4590-8d7a-2cc22d27ec5d" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,211</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4730745a-f535-4720-92a7-1909954faf66" contextRef="C_975e5da7-351c-4671-96f0-b5f31daa46d0" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">190,583</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2dee919a-732b-4afb-ae31-3599183ca4b6" contextRef="C_3f8a395a-d382-4590-8d7a-2cc22d27ec5d" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154,289</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity component, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_459419f9-0dfa-4b5f-acbe-de57b2caa8bc" contextRef="C_975e5da7-351c-4671-96f0-b5f31daa46d0" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b24f8f0-d533-403c-b290-aef9593d35a3" contextRef="C_3f8a395a-d382-4590-8d7a-2cc22d27ec5d" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,361</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4918c993-18c0-4298-a044-3351f7aa0db0" contextRef="C_98afe62c-821a-4537-b552-da050d3c5568" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.423%;"></td>
        <td style="width:1.008%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.008%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.923%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.008%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.707%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_caccbdc8-45f1-43d1-a10d-3c4394f2f7db" contextRef="C_02211f41-81dd-4ee9-8d76-5d38e227447b" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,813</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_140b7c01-c796-4e3e-8e8b-9c22032ac413" contextRef="C_6e288046-0f09-4c78-b427-4c133f35ca3f" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,813</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99f74fff-84ed-4934-acb1-733c9aef9b1c" contextRef="C_a7955fc6-6a0b-47e2-b852-f7b1e5cc5350" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,813</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6530f324-1121-42dc-8e0a-e8050a82aaa8" contextRef="C_02211f41-81dd-4ee9-8d76-5d38e227447b" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">692</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fe37491-86d1-4187-a433-f52746eb74ba" contextRef="C_6e288046-0f09-4c78-b427-4c133f35ca3f" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">657</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5355d21a-0dbc-4d9d-b8e1-8ae47d8bcc2c" contextRef="C_a7955fc6-6a0b-47e2-b852-f7b1e5cc5350" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">601</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt discount</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_333cf855-73f5-4a84-903d-53039bfedd99" contextRef="C_02211f41-81dd-4ee9-8d76-5d38e227447b" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36b0e0ce-670d-4c7c-8336-9db022ea5cf2" contextRef="C_6e288046-0f09-4c78-b427-4c133f35ca3f" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,898</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8840988c-b18d-4e9e-9775-1c424a654422" contextRef="C_a7955fc6-6a0b-47e2-b852-f7b1e5cc5350" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,230</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a1c5b7d-2325-4dfa-b1f1-cac9ba501a5a" contextRef="C_02211f41-81dd-4ee9-8d76-5d38e227447b" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,505</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac0bc2ff-7aee-4558-be78-8b5e2baa1502" contextRef="C_6e288046-0f09-4c78-b427-4c133f35ca3f" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,368</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04d0861e-20d1-4da8-b07b-8875242b29aa" contextRef="C_a7955fc6-6a0b-47e2-b852-f7b1e5cc5350" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,644</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Senior Notes Due 2028</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, we completed a private placement of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_adde91c8-ecf1-4bfc-963f-dd89973da5d3" contextRef="C_b3aac9f2-453c-4c3b-bd1b-f1503e5f3a1f" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">261.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million aggregate principal amount of our 2028 Notes, which will mature on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3c267b42-5c22-46dc-a2b6-7bed26d0274e" contextRef="C_93969c86-aa8a-4cdb-96b4-ca743740fab3" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 15, 2028</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The proceeds include the 2028 Notes sold pursuant to the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_221090af-75c2-4937-82de-3a8be69fed71" contextRef="C_8021ae84-5f41-4763-9cbd-85aedc0bb507" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">45.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million over-allotment option granted by us to the initial purchasers, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69eb58e4-4ffa-424f-800f-81015f7e8d27" contextRef="C_8021ae84-5f41-4763-9cbd-85aedc0bb507" name="inva:PortionOfDebtInstrumentFaceAmountExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">36.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was exercised. The 2028 Notes were sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The net proceeds from the sale of the $261.0 million aggregate principal amount of 2028 Notes were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfe05e7e-b12c-464a-a2e9-bad597b3aaaf" contextRef="C_93969c86-aa8a-4cdb-96b4-ca743740fab3" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">252.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after deducting the initial purchasers&#x2019; discounts and commissions and our estimated offering expenses. We used approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59994af2-4d5f-4fa8-a9d6-38f941f0b4b7" contextRef="C_cee61bd9-edd6-431b-94c0-5db6bc13f016" name="inva:PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the net proceeds from the offering to fund the cost of entering into the capped call transactions described below. In addition, we used $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7fc85249-33e8-4f42-8249-c7f40806f97b" contextRef="C_e611e3bf-95e5-47ba-b2ae-1c43a06561de" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">165.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the remaining net proceeds to repurchase $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_755c5cbb-84a2-4640-a5f7-d40ffe3eb34e" contextRef="C_875d8b01-4f11-410a-9178-6e2dadcb8eea" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">144.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million aggregate principal amount of the 2023 Notes in separate and individually negotiated transactions with certain holders of the 2023 Notes, which closed concurrently with the issuance of the 2028 Notes. We expect to use the remaining net proceeds for general corporate purposes.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2028 Notes bear interest at an annual rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f897408-e1ab-4e4a-9fb1-4788ea9c95e9" contextRef="C_4b4d9d60-6153-4fc7-8983-cb3d99a8f061" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="5" format="ixt:numdotdecimal">2.125</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% that is payable semi-annually in arrears in cash on March 15 and September 15 of each year, beginning on September 15, 2022.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2028 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_347f56b3-f9bd-432e-8658-e3e4509f84f5" contextRef="C_c144de1c-726a-4b34-8527-25bd42031613" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" unitRef="U_pure" scale="0" decimals="4" format="ixt:numdotdecimal">38.1432</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares per $1,000 principal amount of the 2028 Notes, subject to customary anti-dilution adjustment in certain circumstances, which represented an initial conversion price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59eacaf1-6522-49ee-a8a0-a0e8b4fb0471" contextRef="C_f8534932-ac9d-4cc5-9b1b-d50687f54e10" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">26.22</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to September 15, 2027, the 2028 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods, and will be convertible on or after September 15, 2027, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2028 Notes.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of the 2028 Notes may convert all or a portion of their 2028 Notes prior to the close of business on September 15, 2027, only under the following circumstances:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">after March 31, 2022, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_876ffcf0-69ed-4436-b0bf-8a564ff94041" contextRef="C_93969c86-aa8a-4cdb-96b4-ca743740fab3" name="inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">130</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the current conversion price of the 2028 Notes;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce5c5742-bf6a-4498-bd15-d841d9cf6208" contextRef="C_93969c86-aa8a-4cdb-96b4-ca743740fab3" name="inva:DebtConversionConvertedInstrumentAverageTradePricePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">98</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the product of our closing common stock price and the conversion rate of the 2028 Notes on such day; and,</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental changes (as defined in the indenture governing the 2028 Notes) or a transaction resulting in our common stock converting into other securities or property or assets.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On or after September 15, 2027, holders of the 2028 Notes may convert their 2028 Notes at any time until the close of the business on the second day immediately preceding the maturity date of the 2028 Notes.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2028 Notes will be redeemable, in whole or in part, at our option at any time, and from time to time, on or after March 20, 2025, and on or before the 75th scheduled trading day immediately before the maturity date but only if the last reported sale price per share of our common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the 2028 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, calling any 2028 Note for redemption will constitute a make-whole fundamental change (as defined in the indenture governing the 2028 Notes) with respect to that 2028 Note, in which case the conversion rate applicable to the conversion of that 2028 Note will be increased in certain circumstances if it is converted after it is called for redemption.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we undergo a fundamental change, subject to certain conditions, holders may require us to purchase for cash all or any portion of their 2028 Notes. The fundamental change purchase price will be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0129f43-dd96-4ea1-a816-ac6acbe0ba42" contextRef="C_93969c86-aa8a-4cdb-96b4-ca743740fab3" name="inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the principal amount of the 2028 Notes to be purchased plus any accrued and unpaid interest to, but excluding, the fundamental change purchase date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6e3ef555-d570-4bcc-b532-d4f895aa96e4" contextRef="C_04636ba8-4bff-4dfa-bb5d-8f341cc9b324" name="us-gaap:LineOfCreditFacilityCovenantTerms"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.</span></ix:nonNumeric></span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions. The cap price of the capped call transaction is initially $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d730f76-289f-4e69-b588-77e4043a2e90" contextRef="C_5e575930-339e-44e7-8b69-11dba2c9c328" name="us-gaap:DerivativeCapPrice" unitRef="U_UsdItem" scale="0" decimals="4" format="ixt:numdotdecimal">33.9850</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and is subject to certain adjustments under the terms of the capped call transactions. The capped call transactions cover, subject to customary adjustments, the number of shares of common stock initially underlying the 2028 Notes. The capped call transactions are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the aggregate principal amount of converted 2028 Notes, as the case may be, with such reduction or offset subject to a cap.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The annual effective interest rate on the 2028 Notes is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8cf0d26-2d2f-4c6a-ba65-dcbae9158832" contextRef="C_87d07c35-75b2-4cc6-9d24-9604a851da8f" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.70</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5ac92b16-9940-4e84-bc39-064947a69f70" contextRef="C_04636ba8-4bff-4dfa-bb5d-8f341cc9b324" name="us-gaap:ConvertibleDebtTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our outstanding 2028 Notes balance consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.252%;"></td>
        <td style="width:1.784%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.964%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liability component</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89800a86-3354-461f-bb64-a7b54e83ed79" contextRef="C_87d07c35-75b2-4cc6-9d24-9604a851da8f" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb738130-d4ae-4da5-b617-956910fad83d" contextRef="C_87d07c35-75b2-4cc6-9d24-9604a851da8f" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,403</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db244b89-1a71-448b-a740-c6826926448a" contextRef="C_87d07c35-75b2-4cc6-9d24-9604a851da8f" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">253,597</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e2e95117-0bb8-445e-807a-c253b57fb967" contextRef="C_04636ba8-4bff-4dfa-bb5d-8f341cc9b324" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2028 Notes from the issuance through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.287%;"></td>
        <td style="width:1.802%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.911%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Issuance through</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e1a6ccf-1931-4741-b790-0aa92ad8f8a1" contextRef="C_40d9b41f-8564-4e43-91f2-98018ace4541" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,514</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8928097a-1627-49c6-b17d-d5d8c956065f" contextRef="C_40d9b41f-8564-4e43-91f2-98018ace4541" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,061</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_031c9087-45f0-4f35-9767-ea73f52ac582" contextRef="C_40d9b41f-8564-4e43-91f2-98018ace4541" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,575</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt Maturities</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_40925803-ff90-455c-abea-74ad6749d9a8" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate scheduled maturities of our long-term debt as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 are as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"></td>
        <td style="width:1.794%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.881%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_664ee05f-18c0-4393-8920-047219279888" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,204</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca195a91-0e15-49d3-8815-dd04d32ec468" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_966c9395-5811-43bf-911a-1e6f1ad0f4bd" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">192,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c78d32e-f27d-4fa4-a93b-25e27ba451a5" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2cfd61b0-740e-4b9c-9737-a02358917549" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_260d037c-ef70-41f7-ab9c-ccdc3358ffb7" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d427985f-c4ae-4960-a019-393bc5c0b40a" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">549,704</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Royalty Obligation</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our acquisition of La Jolla, we recorded the fair value of its deferred royalty obligation in connection with La Jolla&#x2019;s royalty financing agreement (&#x201c;La Jolla Royalty Agreement&#x201d;) with HealthCare Royalty Partners (&#x201c;HCR&#x201d;). Under the terms of the La Jolla Royalty Agreement, HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> until either January 1, 2031 or when the maximum aggregate royalty payments have been made, whichever occurs first. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. The current maximum royalty rate is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_497cacbc-7596-4f07-8c0c-357940c4bf2a" contextRef="C_b4c52322-2f44-4631-88a7-a410b93eca72" name="inva:RoyaltyAgreementMaximumPotentialPayoutPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">14</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. Starting January 1, 2024, the maximum royalty rate may increase by an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8062c63-5fe0-45f6-b164-5e3a740f5886" contextRef="C_b4c52322-2f44-4631-88a7-a410b93eca72" name="inva:RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, if an agreed-upon, cumulative net product sales threshold has not been met. The La Jolla Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb56fb18-759c-415d-8b21-71c6c6b9393b" contextRef="C_b4c52322-2f44-4631-88a7-a410b93eca72" name="inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">225.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From the date of our acquisition of La Jolla through December 31, 2022, we recognized interest expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b90ea8f-0ad5-4c4c-af64-40f62e9ae05f" contextRef="C_9e7a9b82-3d75-4c07-8fd4-3439f3f270c1" name="us-gaap:InterestExpenseBorrowings" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on the deferred royalty obligation. The carrying value of the deferred royalty obligation and accrued interest as of December 31, 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6596785-bf33-4b78-87bc-229843a7f166" contextRef="C_09f7a472-62b7-4efe-90de-d979015c8cfa" name="inva:DeferredRoyaltyObligationAndAccruedInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">70.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7eecf986-dab8-440a-84dc-b1829532dfea" contextRef="C_32a14238-9913-4ca5-a7cb-512e18bd93f7" name="inva:RoyaltyObligationPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">67.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million of which </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was classified as part of other long-term liabilities on the consolidated balance sheet and the remaining $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7655205f-8636-4768-8abd-1466bb9c03cc" contextRef="C_c518252b-f9c2-461f-b418-d8ec329b7c60" name="us-gaap:InterestAndDividendsPayableCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was classified as other accrued liabilities on the consolidated balance sheet. From the date of acquisition of La Jolla through December 31, 2022, we made royalty payments to HCR of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b722b3af-e60b-4fe4-a434-173c9cc77c30" contextRef="C_9e7a9b82-3d75-4c07-8fd4-3439f3f270c1" name="inva:RoyaltyPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The deferred royalty obligation was valued using Level 3 inputs, and its carrying value as of December 31, 2022 approximates fair value. The fair value of the deferred royalty obligation was calculated as the discounted deferred royalty obligations based on risk-adjusted revenue projections for GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The annual effective interest rate of the deferred royalty obligation was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52200d81-4d2e-407d-80ba-889ccb4955e0" contextRef="C_9e7a9b82-3d75-4c07-8fd4-3439f3f270c1" name="inva:InterestRateOfDeferredRoyaltyObligation" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">7.34</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the La Jolla Royalty Agreement, if we are unable to meet certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, HCR would have the right to terminate the La Jolla Royalty Agreement and demand payment of either $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03345e08-5bde-411c-b6a9-d3bfa7fe40e7" contextRef="C_b4c52322-2f44-4631-88a7-a410b93eca72" name="inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">125.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million or $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00da8744-c77e-4df8-a2e4-e4c390bce5fc" contextRef="C_b4c52322-2f44-4631-88a7-a410b93eca72" name="inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">225.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (depending on which obligation we have failed to meet) less aggregate royalties already paid to HCR. As of December 31, 2022, inclusive of the aggregate royalties paid to HCR by La Jolla under the La Jolla Royalty Agreement prior to our acquisition, La Jolla paid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22879cba-e6ad-4b12-b7e0-527472b0d89e" contextRef="C_b4c52322-2f44-4631-88a7-a410b93eca72" name="inva:PaymentsForRoyaltyAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">aggregate royalties to HCR. In the event that we fail to pay such amount if and when due in a timely manner, HCR would have the right to foreclose on the GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-related assets. HCR has no recourse against any asset other than GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain contract provisions within the La Jolla Royalty Agreement that could result in an acceleration of amounts due under the La Jolla Royalty Agreement are recognized as embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. We determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, we determined that the fair value of the embedded derivatives is not material and, therefore, not recognized as of December 31, 2022. We estimate the fair value of the embedded derivatives for each reporting period until either the features lapse or the La Jolla Royalty Agreement is terminated, whichever occurs first. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss on the consolidated statements of income.</span></p></ix:nonNumeric></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_25c374b8-c2bd-4d89-b388-0beb97eb7949" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. COMMITMENTS AND CONTINGENCIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Lease</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have operating leases for our corporate headquarters, office spaces and laboratory facilities.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operating leases include a facility lease consisting of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2ef93ba-d06f-4aee-b113-16f38495c678" contextRef="C_0690f27e-7810-4f26-b005-086fd5e63db8" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">20,062</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office and laboratory space in Waltham, Massachusetts. Effective April 2022, we exercised our renewal option for to extend the lease term for three additional years through December 2025.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2019, we entered into an operating lease for our headquarters in Burlingame, California for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74082a87-9899-49ff-ab3d-d0338802d091" contextRef="C_d984fd86-fecd-403b-b06f-fd6cf9bdd507" name="us-gaap:NetRentableArea" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">2,111</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> rentable square feet. The lease commenced in November 2019 with a term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_73893738-ee85-428b-aa7d-acd3031222eb;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">thirty-six</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> calendar months, which was subsequently amended to expire in December 2023.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b84f73f6-0a4b-471f-b5da-3f606e29b5ad" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease costs are as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.28%;"></td>
        <td style="width:1.798%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.922%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Straight line operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23507953-6a78-4b45-ab82-e0ce8bf3475a" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,585</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6372f6c7-11c8-419d-ab97-74cb59e97076" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">155</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6a2c002-74bf-4ecf-a2ae-cc4022d4f767" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,740</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_38c23dc4-0e00-4264-a463-563f1815a572" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental cash flow information related to leases are as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.28%;"></td>
        <td style="width:1.798%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.922%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of <br />&#160;&#160;&#160;operating lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77638ba9-9e9d-4fbd-a46c-0f19dbf4ca3d" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">790</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets obtained in exchange <br />&#160;&#160;&#160;for operating lease obligations</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_679b2bed-011c-4431-ba1a-7456c032669b" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,323</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets obtained through acquisitions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55bd4a85-bffd-478d-bb64-4f51ae1738a3" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:RightOfUseAssetsObtainedThroughAcquistions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,185</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our operating leases have a weighted-average remaining lease term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8acb6566-3679-4cba-9828-d4c05244cbe2" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and the weighted-average incremental borrowing rate used to determine the operating lease right-of-use assets and lease liabilities was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a87d0eb-a058-46b6-a1bf-07b6a1dddcbb" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:OperatingLeaseWeightedAverageIncrementalBorrowingRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not presented the comparative information above for the years ended December 31, 2021 and 2020 as our operating lease during those years was not material.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f1d6fb62-0771-4b72-85f8-2b4ea968a25b" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="inva:ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our operating leases as presented on the consolidated balance sheets:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.424%;"></td>
        <td style="width:2.002%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.587%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.002%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.985%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e4f1a71-fe5e-48c2-a3b1-81bd8bfe7c44" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,265</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4aaf262-9ae3-4735-9777-05a3bd7ac418" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_41a23557-411b-40b9-88d7-b7d2076397f5;"><span style="-sec-ix-hidden:F_890207b9-615b-4ab9-910d-0ca859f06d2a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of lease liabilities included within<br />   Other accrued liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c025b267-97e6-48c3-9a1f-6ec01c8e2943" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,316</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f6041f6-a90c-4426-bca8-c2e0bc4a448a" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_49451cf0-b5b9-4245-8fca-d0d88b0b3246;"><span style="-sec-ix-hidden:F_547a2096-ca1f-487c-b0b5-45f04c844618;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term portion of lease liabilities included within<br />   Other long-term liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_adaac0e9-02c4-4dce-88b2-91ad67204c0a" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,376</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddf06473-dc57-4cf3-908e-75aa76157524" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6297c0fc-afd0-4e36-bb37-a229fc7d5a4b" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,692</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13c2b03d-608b-4092-87df-dea1d9b2f430" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_02c7ec2d-4e38-47b5-805b-dedeb9b628e8" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments on our operating leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.291%;"></td>
        <td style="width:1.798%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.911999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_308b26a5-e66b-4cbc-8983-58568edd4797" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,542</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d4842ee-a46b-4642-91b8-81a4a641459e" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,269</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05b45038-53bb-4663-b4f9-67b916c408dc" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,289</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d8fa7c7-1cb9-42fa-b920-6b9579682fd1" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7536593e-718b-43bf-8bbe-95f4bcb3dd35" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">408</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3451ccf-8373-47b0-8191-f423166e0e6e" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,692</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company is involved in legal proceedings in the ordinary course of its business. We are not currently a party to any material legal proceedings except as discussed below.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 15, 2022, La Jolla received a paragraph IV notice of certification (the &#x201c;Notice Letter&#x201d;) from Gland Pharma Limited (&#x201c;Gland&#x201d;) advising that Gland had submitted an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the U.S. prior to the expiration of U.S. Patent Nos.: 9,220,745; 9,572,856; 9,867,863; 10,028,995; 10,335,451; 10,493,124; 10,500,247; 10,548,943; 11,096,983; and 11,219,662 (the &#x201c;GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Patents&#x201d;), which are listed in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#x201c;Orange Book&#x201d;). The Notice Letter alleges that the GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Gland&#x2019;s ANDA.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 29, 2022, La Jolla filed a complaint for patent infringement of the GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland&#x2019;s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is a new chemical entity and La Jolla filed a complaint for patent infringement within 45 days of receipt of the Notice Letter, the FDA cannot approve Gland&#x2019;s ANDA any earlier than 7.5 years from the approval of the GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed. We intend to vigorously enforce our intellectual property rights relating to GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given the early stage of this matter, we cannot reasonably estimate a potential future loss or a range of potential future losses, if any, and have not recorded a contingent liability accrual as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indemnifications and Other Contingencies</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ordinary course of business, we may provide indemnifications of varying scope and terms to vendors, directors, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by us, our negligence or willful misconduct, violations of law, or intellectual property infringement claims made by</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">third </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">parties. In addition, we have entered into indemnification agreements with directors and certain officers and employees that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers, or employees. No material demands have been made upon us to provide indemnification under such agreements, and thus, there are no claims that we are aware of that could have a material effect on our consolidated financial statements. We also maintain director and officer insurance, which may cover certain liabilities arising from our obligation to indemnify our directors. To date, we have not incurred any material costs and, as of December 31, 2022, we have not accrued any liabilities in the consolidated financial statements as a result of these provisions.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_08660d2e-ba2b-4c22-b229-b61a22d99641" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. INCOME TAXES</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_19f04e85-c295-4714-935a-a1e406de3abc" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense consists of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.419%;"></td>
        <td style="width:1.484%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.712%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.484%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.508%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.484%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.907%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_872534a2-4204-4f48-ae44-2c98d1294c24" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,822</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5622c6fe-34af-4f97-871b-058b0a4b63f0" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74756052-9d71-4d02-a9ab-8ace37bb9a18" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11c603d8-5f1f-4d82-8b84-bcc7bdc421f2" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">464</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0971f155-d5e7-49ae-a873-8c6afb523e4e" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eaac7d6f-e7df-4e36-9eec-86e2d8bf2cee" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a8b18b7-fec2-49ee-90a8-63ca03e95def" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,286</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_daa7abaa-2640-46fe-9e21-ce7444172f10" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a08785ca-d1ef-4b7f-aa38-23796efb8153" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc80d519-ca0b-4488-bfb9-e2f2457c02a7" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,026</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fab8bdc-0809-4ae8-a4a9-7698d1a8f54c" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,893</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f29da669-da99-4706-a882-ebe26d9bcbe1" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,408</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a9df4ce-5242-4f2c-ac27-bce540efa539" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">625</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e42a5cfc-da05-403d-82e4-43933f446bc6" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,539</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c5724e7-b73d-491c-acc1-bc6be1b35ef3" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c215345-a310-45fb-98d0-27daf2233693" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,401</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e597e83-0164-4646-a544-70a2fef6a112" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,432</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fae3c2e-8845-4c0b-ae5b-d32fc88d5280" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,420</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income tax expense, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bca5a9a-75af-4f69-8f6d-21cbac6b4f5b" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,687</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91e43204-2a44-4176-9eec-05acc8794a3d" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f289664-5a40-43bb-bbe1-6c1d39dc5384" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,431</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b61824fc-7f9a-4aac-9439-f45471d547a4" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The impacts of the differences between the expected U.S. federal statutory income tax to our income tax expense are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.315%;"></td>
        <td style="width:1.472%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.686%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.686%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.88%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected tax at federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de12ec8b-5d80-4670-a4d2-dc199a742dd0" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,928</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b2ff811-ca04-44e1-9a96-05156592d177" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93,507</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a138b55-44e7-4300-89db-4097b13d53fa" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74,392</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51c87171-2a14-4e28-9da1-53a3dbb0efea" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,414</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad0aab0f-df50-4039-89d9-d81154e0eded" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">848</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fa7fc89-2229-4665-870e-6842283b4a4d" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and state research credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d26665d-c6fb-4860-9d9e-73eeae3b5b64" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,453</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c7d729d-7fa3-4674-b6fc-ea6d273ef115" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,260</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea3eb281-c35d-4964-85b5-b216299f9654" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncontrolling interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98b73de4-52ff-4bf8-b51f-e77262840535" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,468</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d55feb52-1d10-4545-90b7-f9bedf814198" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">21,626</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_feffe534-c59d-49ee-a92c-fcc61ae5bb8f" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">14,577</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impact of consolidation and deconsolidation of subsidiaries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ffe4eaa-86da-4095-8007-0b4d51890f40" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,897</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbd2c7b4-609c-488c-b925-ef68e5fdb10a" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bba10584-1e03-4b1e-b4f0-463a23589f6e" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f737e14-1c47-4795-a32c-7256fa25c268" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">125</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74a62a5a-7a34-4025-9fed-70f7fc4f2e87" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,129</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0b69f7b-b7a7-4665-8406-e45209db429b" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">839</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3cf344d5-1318-482c-9af0-d29c3ece6867" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,180</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11bfe002-3ad0-46df-b831-c63af76b185b" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,321</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15240979-71fc-49ae-950f-06de94851bd7" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">197</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense (benefit), net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64faac50-416f-419a-9952-9dade7d5203a" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,687</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c129660-9b0a-44c0-9d6d-7a432132b81d" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78cf5198-9594-4b60-bd2f-afa4b0af3863" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,431</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b5f9e8e4-b440-4b47-984c-e1b6a752559f" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_b5f9e8e4-b440-4b47-984c-e1b6a752559f_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant components of our deferred tax assets and deferred tax liabilities are as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_b5f9e8e4-b440-4b47-984c-e1b6a752559f_1"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.313%;"></td>
        <td style="width:1.998%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.748%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.998%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.942%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31e4f802-f542-480b-b201-be6bf705dce0" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">149,646</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ee0f1e0-377e-4149-9f7a-a4b3a91ec8ef" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,813</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9327f2a8-2108-4048-a149-45505f77caf3" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,230</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d45822a5-0740-4e04-b50b-65467d83c117" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,467</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on investment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_890df4e1-3c00-42c8-8252-36bc80c5eda6" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,032</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a22635f3-0b28-4bfc-8ce4-e9100f7467df" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred royalty obligation, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10a53fa7-f254-4a69-af96-7ed61f4fb695" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:DeferredTaxAssetsDeferredRoyaltyObligationNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,404</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1725233e-e6f3-4e7b-b1ca-0de47770fe9b" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="inva:DeferredTaxAssetsDeferredRoyaltyObligationNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67bef30a-b827-401e-96f1-b4b53f214a11" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,527</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f8b091b-bd60-4c06-a4f6-3c3f0cf98219" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">743</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f529bdf7-00b2-40a4-aeff-cc5d700e5149" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">202,839</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffa4a1b0-d671-4978-b0ab-9878649b5bb6" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">119,023</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78502548-52aa-44a2-b99c-0e88a2fbd002" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">144,808</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfddbe9d-652f-46c6-9a92-1fadfb458368" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,744</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_670ec869-62d0-49ca-bced-8077d737d593" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6a3b0cc-b8ba-4a34-930a-b8bd14f5de0d" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,279</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bf8e9ae-c643-43c5-b726-5e5c7e1cb2ec" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:DeferredTaxLiabilitiesDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50,587</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64b22032-0ba0-4718-ac9f-c718db7bfae5" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="inva:DeferredTaxLiabilitiesDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,158</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized gain on investment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41638774-27fb-46f6-bffe-3e3863bf40f7" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DeferredTaxLiabilitiesInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfcfe8f7-94dd-499d-8f9a-db82c4b228c1" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DeferredTaxLiabilitiesInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,794</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory fair value adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5243b21d-5c2b-4ea4-b904-a1417ae980ed" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,410</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_377c6998-7c75-46d2-b21c-20f652feaee8" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7899bef4-65d5-48e7-8570-b17cf3963a60" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">805</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0a65248-a5bb-4cc4-9589-a8270d7b0014" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e5babe8-03b7-4dc5-87d8-c30163b8814a" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c109e71-031e-4715-a6e8-ceffe444df07" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,327</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We record deferred tax assets if the realization of such assets is more likely than not to occur. Significant management judgment is required in determining whether a valuation allowance against the deferred tax assets is required. We have considered all available evidence, both positive and negative, such as our historical operating results and predictability of future taxable income, in making such determination. We are also required to exercise significant management&#x2019;s judgment in forecasting future taxable income. Specifically, we evaluate the following criteria when considering a valuation allowance:</span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the history of tax net operating losses in recent years;</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">predictability of operating results;</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">profitability for a sustained period of time; and</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">level of profitability on a quarterly basis.</span></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had federal net operating loss carryforwards of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f83798e6-3340-47b5-88d5-d51af6434174" contextRef="C_aceba262-3c48-4f1a-bb24-393e5d13eb1c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">411.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which will expire beginning 2032. As of December 31, 2022, we also had state net operating loss carryforwards of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75b1dcc5-a838-4454-9568-0ed1e3a012b4" contextRef="C_de713b03-f9a9-4480-b3f1-0fc2adfaf825" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">955.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which will expire beginning 2029 and state research tax credits of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d529a67f-fb79-46ff-a339-93e51edd1eaf" contextRef="C_50fc44f2-33ae-4838-8017-374904e41b9f" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">33.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which do not expire.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Utilization of net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted an Internal Revenue Code of 1986, as amended, Section 382 (&#x201c;Section 382&#x201d;) analysis of the Company through December 31, 2022 to determine whether an ownership change had occurred since inception. The Section 382 study concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. However, notwithstanding the applicable annual limitations, no portion of our net operating loss or credit carryforwards is expected to expire before becoming available to reduce federal and state income tax liabilities as a result of those identified ownership changes. If we undergo another ownership change, the utilization of the pre-ownership change net operating loss carryforwards or pre-ownership change tax attributes, such as research tax credits, to offset the post-ownership change income may be subject to an annual limitation, pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. Similar rules may apply under state tax laws.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#toc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></a></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the acquisition of Entasis, we conducted a study of Entasis&#x2019; ownership changes and estimated that we will be able to utilize $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c74e5d9d-6f86-4c01-be59-7761f2817f96" contextRef="C_09f49082-679c-4f54-a8ef-7379e98314ed" name="inva:FederalNetOperatingLossesEstimatedUtilizationAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">157.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of its federal net operating losses, which are subject to annual limitations.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the acquisition of La Jolla, we also performed a preliminary analysis of its ownership changes and estimated that we will be able to utilize $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0555218-3a2e-4571-810f-54833162f2d1" contextRef="C_86b3b196-2603-41a6-85b5-4466e0d2b8da" name="inva:FederalNetOperatingLossesEstimatedUtilizationAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">254.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of its federal net operating losses, which are subject to annual limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December 31, 2022 and 2021, we had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c759c7b-c3d6-49f6-9bb8-798a6b5a881a" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_aeaaf3bc-cf0d-4978-a8c2-aa7b4299de22" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> accrued interest or penalties due to the Company's net operating losses available to offset any tax adjustments.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Uncertain Tax Positions</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e993c943-7fd1-477a-89cb-229df1e01390" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:76.35%;"></td>
        <td style="width:2.339%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.312%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efce97a6-f30d-4a7e-8c61-f653879e99ca" contextRef="C_5afc9e88-7462-4e21-81dd-9bb66b6d8fd1" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,342</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in tax portions for 2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac44931c-941d-44a1-90a7-a47cc9a9f353" contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">157</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c872719-bdea-429e-994b-4d8d855dcb43" contextRef="C_f1759049-001a-42bc-8f15-3224ecf2b407" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,185</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in tax portions for 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4a67b94-61dd-433b-b23d-58079aed6eb5" contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">313</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c0b5218-8c38-4c51-b38b-7b2e0a7d306a" contextRef="C_14af044e-180c-4ba7-afe8-2099db903530" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,872</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase in tax portions for 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_abf0561a-54dc-42b1-b1b6-10d477af1313" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,452</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37712227-4159-4e2b-970e-2a0780f8cd42" contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,324</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to taxation in the U.S. and various state jurisdictions. The tax years 2004 through 2013, 2015 and forward remain open to examination by the federal and most state tax authorities due to net operating loss and overall credit carryforward positions.</span></p></ix:nonNumeric></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d2e91346-9256-4775-b561-939650f5def7" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. SUBSEQUENT EVENTS</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 10, 2023, we entered into a Secured Convertible Credit Agreement (the &#x201c;Credit Agreement&#x201d;) with Armata, under which we extended a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_96e24b41-a007-42d6-957d-b9158392012a" contextRef="C_b78012d3-6ecc-432d-b96a-e66ef1252516" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term loan facility in an aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d484fa2f-2308-4de9-a825-a7d78a516d88" contextRef="C_89b41b07-63fa-44a6-be15-5461c1916d4a" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at an interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfd579e4-8fd0-4549-9b25-ab23a7e7f5a0" contextRef="C_89b41b07-63fa-44a6-be15-5461c1916d4a" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">8.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per annum. Pursuant to the Credit Agreement, the balance on the loan, including all accrued and unpaid interest thereon, will convert into shares of Armata's common stock upon the occurrence of a qualified financing, as defined in the Credit Agreement. Any portion of the balance on the loan, including all accrued and unpaid interest thereon, may also be converted into shares of Armata's common stock at our option once a registration statement covering the resale of such securities has been declared effective by the SEC. The loan is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 2, 2023, ITH entered into a Note Amendment Agreement (the &#34;Note Amendment Agreement&#34;) with Gate to amend the Convertible Promissory Note Purchase Agreement entered into in November 2021 between TRC and Gate to acquire the Gate Convertible Note (refer to Note 6, &#x201c;Equity and Long-Term Investments and Fair Value Measurements&#x201d;). Pursuant to the Note Amendment Agreement, the principal amount of the Gate Convertible Note was increased from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1554ace-bf2c-42e2-9c20-a2d1526962a1" contextRef="C_e02457d0-db2e-4c20-9634-fdad76ee8508" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32a112d4-a51b-469e-bc20-952abd7834e7" contextRef="C_30ae7ed9-ac4b-45ec-bc1f-029433db9949" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which represents the original principal and accrued interests as of the amendment date. All other material terms of the Gate Convertible Note were unchanged.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;" id="reports_of_independent_registered_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REP</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Stockholders and the Board of Directors of Innoviva, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheet of Innoviva, Inc. and subsidiaries (the &#34;Company&#34;) as of December 31, 2022, the related consolidated statements of income, comprehensive income, stockholders' equity, and cash flows, for the year ended December 31, 2022, and the related notes (collectively referred to as the &#34;financial statements&#34;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the year ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Internal Control &#x2014; Integrated Framework (2013)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 28, 2023, expressed an unqualified opinion on the Company's internal control over financial reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in Accounting Principle</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As discussed in Note 1 to the financial statements, effective January 1, 2022, the Company adopted Accounting Standards Update 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, using the modified retrospective approach.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Entities and Equity and Long-term Investments &#x2013; Primary Beneficiary Determination for Variable Interest Entities &#x2013; Refer to Notes 1, 5, and 6 to the consolidated financial statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Critical Audit Matter Description</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company invests in equity and debt securities of private and public companies. The Company evaluates its interests in these entities to determine whether they meet the definition of a variable interest entity (VIE) or a voting interest entity (VOE) and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both 1) the power to direct the activities that most significantly impact the economic performance of the VIE and 2) a variable interest that absorbs losses or receives benefits from the VIE that could potentially be significant to the VIE. To determine whether a variable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interest that the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE. The Company will reconsider whether an entity is a VIE and whether the Company is the primary beneficiary of the entity upon the occurrence of certain types of events. The determination of the primary beneficiary of a VIE requires significant management judgment. As of December 31, 2022, the carrying values of the Company&#x2019;s consolidated VIEs&#x2019; total assets and total liabilities were $320.6 million and $1.6 million, respectively. Additionally, as of December 31, 2022 the carrying value of the Company&#x2019;s investments in unconsolidated VIEs was $377.9 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We identified the primary beneficiary determination for the Company&#x2019;s VIEs as a critical audit matter due to the complexity of the accounting principles related to the determination of the primary beneficiary of a VIE and the significant judgment required by management in evaluating the Company&#x2019;s role in establishing the VIE, their ongoing rights and responsibilities and identifying which party, if any, has power over those activities. This required a high degree of auditor judgment and an increased extent of effort, including the involvement of professionals with consolidation accounting expertise, when performing audit procedures to evaluate the Company&#x2019;s determination of whether it is the primary beneficiary for its VIEs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">How the Critical Audit Matter Was Addressed in the Audit</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audit procedures related to the primary beneficiary determination for VIEs included the following, among others:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We tested the effectiveness of controls over the Company&#x2019;s primary beneficiary determination for its VIEs, including management&#x2019;s determination of the party that has the power to direct the activities that most significantly impact the economic performance of the VIE and a variable interest that absorbs losses or receives benefits from the VIE that could potentially be significant to the VIE.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We evaluated the appropriateness of the Company&#x2019;s accounting conclusions for consolidated and unconsolidated VIEs through the following:</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the investment structures and terms of the agreements, including reading the purchase agreements and other related documents which govern the formation and activities of the entity (the Contractual Arrangements). </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tested whether the Company appropriately determined the primary beneficiary by evaluating the Contractual Arrangements of the entity to determine if the Company has the power to direct activities that most significantly impact the economic performance of the VIE, and if the Company has the obligation to absorb losses of the entity or the right to receive benefits from the entity that could be significant to the VIE.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For certain VIEs, with the assistance of professionals with expertise in consolidation accounting, evaluated the appropriateness of the Company's determination of the primary beneficiary of the VIE.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the Company&#x2019;s disclosures related to the primary beneficiary determination of its consolidated entities and unconsolidated VIEs.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Jose, California</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company's auditor since 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;" id="report_of_independent_registered_public"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Stockholders and Board of Directors of Innoviva, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheet of Innoviva, Inc. (a Delaware corporation) and subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2021, the related consolidated statements of income, comprehensive income, changes in stockholders&#x2019; equity, and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as of December 31, 2021, and the results of its</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operations and its</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cash flows for each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for opinion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#x201c;PCAOB&#x201d;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ GRANT THORNTON LLP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We served as the Company&#x2019;s auditor from 2019 to 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Francisco, California</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:-8.696%;padding-left:8.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_9_changes_in_and_disagreements_with"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 9A. CONTROLS AND PROCEDURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted an evaluation as of December 31, 2022, under the supervision and with the participation of our management, including our chief executive officer and chief accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures, which are defined under SEC rules as controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized and reported within required time periods specified in the Commission&#x2019;s rules and forms and controls and procedures that are designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#x2019;s management including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decision regarding required disclosure. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance levels.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a&#x2011;15(f) of the Exchange Act. Internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on criteria established in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Internal Control&#x2014;Integrated Framework</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Management&#x2019;s assessment included evaluation of such elements as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies, and our overall control environment. Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2022.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management&#x2019;s assessment of the effectiveness of internal control over financial reporting as of December 31, 2022 excluded the internal control over financial reporting at La Jolla and Entasis, which constituted approximately 33% of total assets and 6% of total revenue in our consolidated financial statements as of and for the year ended December 31, 2022. We acquired La Jolla on August 22, 2022 and Entasis on July 11, 2022 and had not completed our evaluation of the internal controls of the acquired businesses as of December 31, 2022.  This exclusion was in accordance with Securities and Exchange Commission guidance that an assessment of a recently acquired business may be omitted in management&#x2019;s report on internal controls over financial reporting in the year of acquisition.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our independent registered public accounting firm, Deloitte &amp; Touche LLP, has audited our internal control over financial reporting as of December 31, 2022. Their attestation report on the audit of our internal control over financial reporting is included below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Limitations on the Effectiveness of Controls</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all frauds. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within Innoviva have been detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, we completed our acquisitions of Entasis and La Jolla. We are currently in the process of integrating the acquired operations and processes into our internal control environment and implementing necessary changes to our internal control over financial reporting, including, but not limited to, the creation of new controls related to inventory management, research and development activities and product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other than the above, there have been more material changes to our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) for the year ended December 31, 2022 which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Stockholders and the Board of Directors of Innoviva, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the internal control over financial reporting of Innoviva, Inc. and subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2022, based on criteria established in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Internal Control &#x2014; Integrated Framework (2013)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Internal Control &#x2014; Integrated Framework (2013)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> issued by COSO.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2022, of the Company and our report dated February 28, 2023, expressed an unqualified opinion on those financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As described in Management&#x2019;s Report on Internal Control over Financial Reporting, management excluded from its assessment the internal control over financial reporting at Entasis Therapeutics Holdings Inc. which was acquired on July 11, 2022, and La Jolla Pharmaceutical Company which was acquired on August 22, 2022, and whose financial statements constitute 33% of total assets and 6% of total revenue in the consolidated financial statement amounts as of and for the year ended December 31, 2022. Accordingly, our audit did not include the internal control over financial reporting at Entasis Therapeutics Holdings Inc. and La Jolla Pharmaceutical Company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#x2019;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#x2019;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Definition and Limitations of Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d6a63689-607e-4ca5-96c5-1a5b2355d526" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deloitte &amp; Touche LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_81b80a36-695a-46b3-b02a-24cacc866f4f" contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Jose, California</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 9B. OTHER INFORMATION</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_9c_disclosure_regarding_foreign_jur"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 9C. DISCL</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_10_directors_executive_officers_and"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item is incorporated by reference from our proxy statement for our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 11. EXECUTIVE COMPENSATION</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item is incorporated by reference from our proxy statement for our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.012%;padding-left:8.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_12_security_ownership_of_certain"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other than with respect to the Securities Authorized for Issuance under Equity Compensation Plans below, the information required by this Item is incorporated by reference from our proxy statement for our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Authorized for Issuance under Equity Compensation Plans</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides certain information with respect to all of our equity compensation plans in effect as of December 31, 2022:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:55.87%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.581999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.682%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.593%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.682%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.604000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.014%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan Category</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of securities to be issued upon exercise of outstanding options and vesting of outstanding restricted stock units and restricted stock awards</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted&#x2011;average exercise price of outstanding options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity compensation plans approved by security holders</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,465,720</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.56</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,999,265</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">&#160;(3)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes 947,906 shares issuable upon exercise of outstanding options and 517,814 shares issuable upon vesting of outstanding RSUs and RSAs.</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Does not take into account outstanding restricted stock units as these awards have no exercise price.</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes 160,995 shares of common stock available under our Employee Stock Purchase Plan.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_13_certain_relationships_and"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item is incorporated by reference from our proxy statement for our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_14_principal_accounting_fees_and"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item is incorporated by reference from our proxy statement for our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_15_exhibits_and_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)   The following documents are filed as part of this Annual Report on Form 10&#x2011;K:</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.    Financial Statements:</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following financial statements and schedules of the Registrant are contained in Part II, Item 8, &#x201c;Financial Statements and Supplementary Data&#x201d; of this Annual Report on Form 10&#x2011;K:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.796%;"></td>
    <td style="width:6.204%;"></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_income"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Income for each of the three years in the period ended December 31, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_comprehensive"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Comprehensive Income for each of the three years in the period ended December 31, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_stockholders"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Stockholders&#x2019; Equity for each of the three years in the period ended December 31, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#reports_of_independent_registered_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reports of Independent Registered Public Accounting Firm (PCAOB ID 34)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent_registered_public"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID 248)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.    Financial Statement Schedules:</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements, financial notes or supplementary financial information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)   Exhibits required by Item 601 of Regulation S&#x2011;K:</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item is set forth on the exhibit index that follows the signature page of this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;" id="item_16_form_10_k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITEM 16. FORM 10&#x2011;K SUMMARY</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="exhibits"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.583%;"></td>
    <td style="width:2.0%;"></td>
    <td style="width:55.0%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:7.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.398%;"></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed Herewith</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date/Period</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">End Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122020321/ny20004305x1_ex2-1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement and Plan of Merger, dated as of May 23, 2022, by and among Innoviva, Inc., Innoviva Merger Sub, Inc. and Entasis Therapeutics</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5/24/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122025657/ny20004741x1_ex2-1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement and Plan of Merger, dated as of July 10, 2022, by and among Innoviva, Inc., Innoviva Acquisition Sub, Inc. and La Jolla Pharmaceutical Company</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/11/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746904024286/a2140025zex-3_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S&#x2011;1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/26/2004</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465907036933/a07-10633_1ex3d4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificate of Amendment of Restated Certificate of Incorporation</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10&#x2011;Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/31/2007</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465916088785/a16-1366_1ex3d1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificate of Ownership and Merger Merging LABA Merger Sub, Inc. with and into Theravance, Inc., as filed with the Secretary of State of the State of Delaware, effective on January 7, 2016</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/8/2016</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465917007849/a17-4037_1ex3d1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws, amended and restated as of February 8, 2017</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/9/2017</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465907015079/a07-1942_1ex4d1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specimen certificate representing the common stock of the registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/31/2006</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465913004773/a12-25051_9ex4d1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indenture, dated as of January 24, 2013 by and between Theravance, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/25/2013</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465913004773/a12-25051_9ex4d1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of 2.125% Convertible Subordinated Note Due 2023 (included in Exhibit 4.4</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465917049927/a17-18560_4ex4d1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indenture (including form of Note) with respect to Innoviva&#x2019;s 2.50% Convertible Senior Notes due 2025, dated as of August 7, 2017, between Innoviva and The Bank of New York Mellon Trust Company, N.A., as trustee</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8/7/2017</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465920022807/ex-4d9.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Registrant&#x2019;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.9</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/19/2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465922031613/tm228653d1_ex4-1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indenture (including form of Note) with respect to Innoviva's 2.125% Convertible Senior Notes due 2028, dated as of March 7, 2022, between Innoviva, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/8/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465910041932/a10-12639_1ex10d4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Stock Purchase Plan, as amended April 27, 2010</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10&#x2011;Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/30/2010</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914058343/a14-13984_1ex10d1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration Agreement between the registrant and Glaxo Group Limited, dated as of November 14, 2002</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10&#x2011;Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/30/2014</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746904020116/a2136994zex-10_13.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Investors&#x2019; Rights Agreement by and among the registrant and the parties listed therein, dated as of May 11, 2004</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S&#x2011;1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/10/2004</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746914001691/a2218387zex-10_13.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Strategic Alliance Agreement between the registrant and Glaxo Group Limited, dated as of March 30, 2004</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/31/2013</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746910001540/a2196645zex-10_22.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Cash Bonus Program, as amended</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/31/2009</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746910001540/a2196645zex-10_47.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment to Change in Control Severance Plan effective December 16, 2009</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.47</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/31/2009</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746910001540/a2196645zex-10_48.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2009 Change in Control Severance Plan adopted December 16, 2009</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.48</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/31/2009</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465910060202/a10-21843_1ex10d2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Amended and Restated Governance Agreement among the registrant, Glaxo Group Limited, GlaxoSmithKline plc and GlaxoSmithKline LLC, dated as of November 29, 2010</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11/29/2010</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746912001614/a2207068zex-10_34.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment to Strategic Alliance Agreement, dated October 3, 2011</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.34</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/31/2011</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465912053222/a12-11849_1ex10d38.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2012 Equity Incentive Plan, as approved by the board of directors February 8, 2012 and approved by stockholders May 16, 2012 and forms of equity award</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10&#x2011;Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.38</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/30/2012</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465913003879/a12-25051_8ex10d1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Base Capped Call Transaction, dated January 17, 2013</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/23/2013</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465913003879/a12-25051_8ex10d2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Capped Call Transaction, dated January 18, 2013</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/23/2013</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914017128/a14-7412_1ex10d1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Master Agreement by and among Theravance, Inc., Theravance Biopharma, Inc. and Glaxo Group Limited, dated March 3, 2014</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/6/2014</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914017128/a14-7412_1ex10d2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration Agreement Amendment by and between Theravance, Inc. and Glaxo Group Limited, dated March 3, 2014</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/6/2014</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914017128/a14-7412_1ex10d3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Strategic Alliance Agreement Amendment by and between Theravance, Inc. and Glaxo Group Limited, dated March 3, 2014</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/6/2014</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p>
  <hr style="page-break-after:always;" />
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.583%;"></td>
    <td style="width:2.0%;"></td>
    <td style="width:55.0%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:7.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.398%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914044231/a14-14482_1ex10d2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transition Services Agreement between Theravance and Theravance Biopharma, dated June 2, 2014</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/5/2014</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914044231/a14-14482_1ex10d3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Matters Agreement between Theravance and Theravance Biopharma, dated June 2, 2014</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/5/2014</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914044231/a14-14482_1ex10d4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee Matters Agreement between Theravance and Theravance Biopharma, dated June 1, 2014</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/5/2014</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914044231/a14-14482_1ex10d5.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Theravance Respiratory Company, LLC Limited Liability Company Agreement between Theravance and Theravance Biopharma, dated May 31, 2014</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/5/2014</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465915036218/a15-7167_1ex10d64.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment/Clarification to Transition Services Agreement between Theravance and Theravance Biopharma, dated March 2, 2015</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10&#x2011;Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.64</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/31/2015</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.21+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465915054328/a15-16369_1ex10d2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to 2009 Change In Control Severance Plan (Renamed 2009 Severance Plan)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/29/2015</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746918001016/a2234562zex-10_76.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Notice of Performance&#x2011;Based Restricted Stock Award and Restricted Stock Award Agreement under 2012 Equity Incentive Plan (director form)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.76</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/23/2018</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.23+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465918047409/a18-14089_1ex10d81.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to 2009 Severance Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10&#x2011;Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.81</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/26/2018</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.24+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914018000502/i25948910b.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter with Marianne Zhen, dated September 7, 2018</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9/11/2018</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.25+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914020000275/i35135265b.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter between Innoviva, Inc. and Pavel Raifeld, dated May 20, 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5/26/2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.26+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914022000493/i5271437b.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter between Innoviva, Inc. and Pavel Raifeld, dated April 29, 2022</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5/2/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.27</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000119312520316331/d69428dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Strategic Advisory Agreement, dated as of December 11, 2020, by and between Sarissa Capital Management LP and Innoviva, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/14/2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.28</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000119312520316331/d69428dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Limited Partnership Agreement of ISP Fund LP, dated as of December 11, 2020, by and among ISP Fund LP, Sarissa Capital Fund GP LP, Innoviva Strategic Partners LLC and the other parties named therein</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8&#x2011;K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/14/2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.29</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914021000501/i052021b.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Share Repurchase Agreement, dated as of May 2021, by and between Innoviva, Inc. and Glaxo Group Limited</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5/20/2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.30</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914021000501/i052021c.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Letter Agreement, dated as of May 20, 2021, by and among Innoviva Strategic Partners LLC, ISP Fund LP and Sarissa Capital Fung GP LP</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5/20/2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.31</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465922031613/tm228653d1_ex10-1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capped Call Confirmation dated March 2, 2022, by and among Innoviva, Inc., Bank of America, N.A., Goldman Sachs &amp; Co. LLC and Deutsche Bank AG, London Branch</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/8/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.32</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122020321/ny20004305x1_ex10-1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to the Investor Rights Agreement, dated May 23, 2022, by and among Innoviva, Inc. and Entasis Therapeutics Holdings Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5/24/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.33</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122025657/ny20004741x1_ex10-1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Support Agreement, dated July 10, 2022, by and among Innoviva, Inc., Innoviva Acquisition Sub, Inc., Tang Capital Partners, LP and Kevin C. Tang Foundation</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/11/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.34</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122025945/ny20004764x1_ex10-1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity Purchase Agreement, dated July 13, 2022, by and among Innoviva, Inc., Innoviva TRC Holdings LLC and Royalty Pharma Investments 2019 ICAV</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/13/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.35</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122025945/ny20004764x1_ex10-2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment to Collaboration Agreement, dated July 13, 2022, by and among Innoviva, Inc., Glaxo Group Limited, and Theravance Respiratory Company, LLC.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7/13/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="inva-ex21_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">List of Subsidiaries</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="inva-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="inva-ex23_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Ernst &amp; Young LLP Independent Registered Public Accounting Firm of Armata Pharmaceuticals, Inc.**</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#power_of_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney (see signature page to this Annual Report on Form 10&#x2011;K)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="inva-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rule 13a&#x2011;14 under the Securities Exchange Act of 1934</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="inva-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rule 13a&#x2011;14 under the Securities Exchange Act of 1934</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="inva-ex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certifications Pursuant to 18 U.S.C. Section 1350</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p>
  <hr style="page-break-after:always;" />
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7.583%;"></td>
    <td style="width:2.0%;"></td>
    <td style="width:55.0%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:7.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.398%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Audited Consolidated Financial Statements of Armata Pharmaceuticals, Inc. at December 31, 2022, for the year ended December 31, 2022**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+     Management contract or compensatory plan or arrangement required to be filed pursuant to Item 15(b) of Form 10&#x2011;K.</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*     Confidential treatment has been granted for certain portions which are omitted in the copy of the exhibit electronically filed with the Securities and Exchange Commission. The omitted information has been filed separately with the Securities and Exchange Commission pursuant to Innoviva, Inc.&#x2019;s application for confidential treatment.</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">**   To be filed by amendment to this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">#     Furnished herewith.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">142</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.426%;"></td>
    <td style="width:3.417%;"></td>
    <td style="width:49.157%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INNOVIVA, INC.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ PAVEL RAIFELD</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pavel Raifeld<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;" id="power_of_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Pavel Raifeld, as their true and lawful attorney&#x2011;in&#x2011;fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to the Annual Report on Form 10&#x2011;K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney&#x2011;in&#x2011;fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she could do in person, hereby ratifying and confirming all that said attorney&#x2011;in&#x2011;fact and agent, or his substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.815%;"></td>
    <td style="width:3.0%;"></td>
    <td style="width:37.824%;"></td>
    <td style="width:3.0%;"></td>
    <td style="width:18.361%;"></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signature</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ PAVEL RAIFELD</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pavel Raifeld</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer<br />(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ MARIANNE ZHEN</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marianne Zhen</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Accounting Officer (Principal<br />Financial Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ GEORGE BICKERSTAFF</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">George Bickerstaff, III</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairman of the Board</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ ODYSSEAS KOSTAS</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Odysseas Kostas, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ MARK DIPAOLO</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mark DiPaolo, Esq.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ JULES HAIMOVITZ</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jules Haimovitz.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ SARAH SCHLESINGER</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sarah Schlesinger, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ DEBORAH L. BIRX</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deborah L. Birx, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ SAPNA SRIVASTAVA</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sapna Srivastava, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">143</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>2
<FILENAME>inva-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIST OF SUBSIDIARIES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:60.565%;"></td>
    <td style="width:1.639%;"></td>
    <td style="width:21.102%;"></td>
    <td style="width:1.639%;"></td>
    <td style="width:15.056%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jurisdiction</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ownership<br>Interest</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advanced Medicine East, Inc</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Innoviva Strategic Partners LLC</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Innoviva Royalty Sub LLC</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Innoviva TRC Holdings LLC</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Innoviva Strategic Opportunities LLC</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ISP Fund LLP</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Innoviva Specialty Therapeutics Holdings LLC</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Innoviva Specialty Therapeutics Inc.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entasis Therapeutics Holdings Inc.</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entasis Therapeutics Inc.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entasis Therapeutics Limited</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United Kingdom</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entasis Therapeutics Security Corporation</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Massachusetts</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entasis Therapeutics (Ireland) Limited</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ireland</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">La Jolla Pharmaceutical Company</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">La Jolla Pharma, LLC</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tetraphase Pharmaceuticals, Inc.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">La Jolla Pharmaceutical Holdings, LLC</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">La Jolla Pharmaceutical I B.V.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Netherlands</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">La Jolla Pharmaceutical II B.V.</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Netherlands</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">La Jolla Pharmaceutical III B.V.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Netherlands</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100%</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>3
<FILENAME>inva-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in Registration Statement Nos. 333-119559, 333-129669, 333-150753, 333-159042, 333-173923, 333-181763, and 333-197950 on Form S-8 of our reports dated February 28, 2023, relating to the financial statements of Innoviva, Inc. and the effectiveness of Innoviva, Inc.'s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Jose, California</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>4
<FILENAME>inva-ex23_2.htm
<DESCRIPTION>EX-23.2
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have issued our report dated February 28, 2022, with respect to the consolidated financial statements included in the Annual Report of Innoviva, Inc. on Form 10-K for the year ended December 31, 2022. We consent to the incorporation by reference of said report in the Registration Statements of Innoviva, Inc. on Forms S-8 (File No. 333-119559, File No. 333-129669, File No. 333-150753, File No. 333-159042, File No. 333-173923, File No. 333-181763, and File No. 333-197950).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ GRANT THORNTON LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Francisco, California</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>inva-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 302 of the Sarbanes&#x2011;Oxley Act of 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Pavel Raifeld, certify that:</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.           I have reviewed this Annual Report on Form 10&#x2011;K of Innoviva, Inc.;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.           The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#x2011;15(e) and 15d&#x2011;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15(d)&#x2011;15(f)) for the registrant and have:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">c)            Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d)           Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.            The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.0%;"></td>
    <td style="width:44.0%;"></td>
    <td style="width:2.0%;"></td>
    <td style="width:49.0%;"></td>
   </tr>
   <tr style="height:0.7pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ PAVEL RAIFELD</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);text-indent:3.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:3.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pavel Raifeld</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);text-indent:3.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:3.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);text-indent:3.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:3.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>6
<FILENAME>inva-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Accounting Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 302 of the Sarbanes&#x2011;Oxley Act of 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Marianne Zhen, certify that:</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.           I have reviewed this Annual Report on Form 10&#x2011;K of Innoviva, Inc.;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.           The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#x2011;15(e) and 15d&#x2011;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15(d)&#x2011;15(f)) for the registrant and have:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">c)           Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d)           Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.           The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">b)          Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.0%;"></td>
    <td style="width:44.444%;"></td>
    <td style="width:1.778%;"></td>
    <td style="width:48.778%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ MARIANNE ZHEN</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);text-indent:3.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:3.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marianne Zhen</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);text-indent:3.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:3.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chief Accounting Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);text-indent:3.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:3.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>inva-ex32.htm
<DESCRIPTION>EX-32
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AND PRINCIPAL ACCOUNTING OFFICER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Pavel Raifeld, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#x2011;Oxley Act of 2002, that the Annual Report of Innoviva, Inc. on Form 10&#x2011;K for the fiscal year ended December 31, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and that information contained in such Annual Report on Form 10&#x2011;K fairly presents in all material respects the financial condition of Innoviva, Inc. at the end of the periods covered by such Annual Report on Form 10&#x2011;K and results of operations of Innoviva, Inc. for the periods covered by such Annual Report on Form 10&#x2011;K.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:3.0%;"></td>
    <td style="width:47.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ PAVEL RAIFELD</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pavel Raifeld</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Marianne Zhen, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#x2011;Oxley Act of 2002, that the Annual Report of Innoviva, Inc. on Form 10&#x2011;K for the fiscal year ended December 31, 2022 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and that information contained in such Annual Report on Form 10&#x2011;K fairly presents in all material respects the financial condition of Innoviva, Inc. at the end of the periods covered by such Annual Report on Form 10&#x2011;K and results of operations of Innoviva, Inc. for the periods covered by such Annual Report on Form 10&#x2011;K.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:3.0%;"></td>
    <td style="width:47.0%;"></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ MARIANNE ZHEN</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:3.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marianne Zhen</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:3.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chief Accounting Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:3.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:3.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A signed original of this written statement required by Section 906 has been provided to Innoviva, Inc. and will be retained by it and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img11029722_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2##ML# 2(  A$! Q$!_\0
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M^AFL?^^C_A7R=_8EM_?E_,?X4?V);?WY?S'^%'UB ?V+BNR^\^L?^%J>!O\
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MKY._L2V_OR_F/\*/[$MO[\OYC_"CZQ /[%Q79?>?6/\ PM3P-_T,UC_WT?\
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M4?V);?WY?S'^%'UB ?V+BNR^\^L?^%J>!O\ H9K'_OH_X4?\+4\#?]#-8_\
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M6IX&_P"AFL?^^C_A7R=_8EM_?E_,?X4?V);?WY?S'^%'UB ?V+BNR^\^L?\
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M^%?)W]B6W]^7\Q_A1_8EM_?E_,?X4?6(!_8N*[+[SZQ_X6IX&_Z&:Q_[Z/\
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M6IX&_P"AFL?^^C_A7R=_8EM_?E_,?X4?V);?WY?S'^%'UB ?V+BNR^\^L?\
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M^%?)W]B6W]^7\Q_A1_8EM_?E_,?X4?6(!_8N*[+[SZQ_X6IX&_Z&:Q_[Z/\
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M4?V);?WY?S'^%'UB ?V+BNR^\^L?^%J>!O\ H9K'_OH_X4?\+4\#?]#-8_\
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MR_F/\*/[$MO[\OYC_"CZQ /[%Q79?>?6/_"U/ W_ $,UC_WT?\*/^%J>!O\
MH9K'_OH_X5\G?V);?WY?S'^%']B6W]^7\Q_A1]8@']BXKLOO/K'_ (6IX&_Z
M&:Q_[Z/^%'_"U/ W_0S6/_?1_P *^3O[$MO[\OYC_"C^Q+;^_+^8_P */K$
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M+4\#?]#-8_\ ?1_PKY._L2V_OR_F/\*/[$MO[\OYC_"CZQ /[%Q79?>?6/\
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ME_,?X4?V);?WY?S'^%'UB ?V+BNR^\^L?^%J>!O^AFL?^^C_ (4?\+4\#?\
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M_P *^3O[$MO[\OYC_"C^Q+;^_+^8_P */K$ _L7%=E]Y]8_\+4\#?]#-8_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@##N/\ D/K_ +Z_R%;E8=Q_R'U_WU_D*W*VJ[1]#R\N^.M_B84445B>H%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %8>I?\ (6B^B_SK<K#U+_D+1?1?YUM0^(\O-_X"]4;E%%%8GJ!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM1^UZ'EYE\5'_&C<HHHK$]0**** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5AQ_\ (P'_ 'S_ "K<K#C_ .1@/^^?Y5M1^UZ'
MEYE\5'_&C<HHHK$]0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,MKYMK;K*I5G@AP^#UP23CZCFM:56$8V:/-Q^7XBOB/:4Y::==CA'4*[*&#
M$@$=Z;117.>X%%.2-Y7"1HSL>@49-6FTG4D4LVGW2J.I,+ #]*!.26[*=%%%
M PHHHH **4 LP !)/  [U8ETZ^AB\V6SN(X_[[Q,!^>* ;2W*U%%% !1110
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MHHKF/="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/C^YM9[*ZDMKJ%X9XF*O&ZX92.Q%15[)\=-"AB?3]=B0+)*QMIR!]X@94_7
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MT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %8<?_(P'_?/\JW*PX_\ D8#_ +Y_E6U'[7H>7F7Q4?\
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M%%%<Y[(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?. ZVS_ZN'V8?Q-ZYX_G7IO^BZ?; ?N;:!. .$4?TJ2:5(())I6VQQJ68^@
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M\H^KT75C.]O(S?BQ\/K30X4US1X?)M'D"7%NOW8V/1E] >F.QQBO**^H_B7
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M9RU1ZF-HK&T$Z<M-SZWJ)K6W=BSP1,QZDH"34M?,GQ%U._A^(&L1Q7US&BS
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M8>A9B?ZUI6TIQ1R9;^\QE:JMMOQ_X!5HHHKF/="BBB@ HHHH **** "BBB@
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M20L ?QI5JJ5X6'EF72FH8CFTOMZ,N>'= O?$VM0:78(#+(<LY^[&HZLWL/\
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M)H]O>Z=%YM[8EOW2CYI4;&0/4@@''UJJBYJ6AC@IJAC_ -YIJT?.U?0OP/\
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M^L4E)704444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\Q6\(N-*S/)Q-:%;,%.#NKK]#Y7KZO\  O\ R(>A?]>47_H(KY0KZO\  O\
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M^ ?%&IZB+*/1KR%\X>2XB:-$'J6(_ER>V:=>+<]$3E&(I1PMI22M<]A^!_\
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MV/\ Z)2NK$_ >!D7^\R_PO\ -'1_ C_D8M4_Z]!_Z&*];\:_\B-KW_7A-_Z
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M?I\TJ10SSJLCLVT!<\\^N,X]ZRZ*%N*2;BTG8^AOBSXGMM)\'MI5E/$;B^Q
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M@*X/]*Y7)N5V?01H1I8?V5/9(^OJ^3O&P(\=:Z#_ ,_\Q_\ 'S7UC7S]\4/
MFL1>*KK5=/L+B[LKQO-)@C+F-\?,& Y'/.?>NO$1;CH?.Y)5A"M)2=KHX'0?
M^1BTS_K[B_\ 0Q7U_7@OP[^%NHW6I0:MKMO+9VENXDC@D!625@<C(ZJN1WY/
MZU[U1AXM)MAG5>G5J1C!WMN?*_Q$_P"2@ZW_ -?)_D*[WX!_Z_7O]V#^<E<%
M\1/^2@ZW_P!?)_D*[WX!_P"OU[_=@_G)6-/^-]YZF,_Y%ORC^AZ#\2?^2=ZU
M_P!<!_Z$*^7[>WFN[F*VMXVDFF<1QHO5F)P /QKZ@^)/_).]:_ZX#_T(5X/\
M,4BD^(^C+-C:)'89_O"-BOZ@55=7FD<V3S]GA*D^S;_ ]9\*?!_1=*M8YM9B
M74;\@%U<_ND/H%_B^IZ^@KJKR\\*>&E$5R^E:?D9$6U$)'LHYK?KX_UMK]M<
MO3JGF?;O.;S_ #,YW9YK2I)4DN5''A*53,:DG5F]/ZT/JC2?%>A:Y=-:Z7J<
M%U.J&1DC)R%! S^9'YTWQA_R).O?]@ZX_P#1;5Y7\#_#^HPZI=:[- 8[&2U:
MWB=^#(Q=6RH[@;3SZGZX]4\8?\B3KW_8.N/_ $6U7&3E"[.;$4(4,4J=-W2:
M/DJOI_X6?\DUT?\ W9/_ $:]?,%?37PFE67X:Z4 1E#*K>Q\UOZ$5SX;XSV\
M]_W>/K^C.0^/G^HT'_>G_E'7BE>__&K0+_5M%TZ[L+:6Y-I*XD2)2S!7 YP.
MHRH_.O$)]#U:UT_[?<:;=PVF\)YTD+*I8YXR1[&IKI\[-<HJ0^J1C?77\SZ(
M^$>W_A6VF[>NZ;=]?-;^F*P/CMO_ .$:TS'^K^V?-]=C8_K4GP.U=+GPS=Z4
MS_OK2<NJ_P#3-QQ_X\&_,5U7Q!\,OXJ\)7-C JF[C(FMMQQ\Z]L^X)'XUT6Y
MJ-EV/%<E0S)RGMS?G_PY\L5V7PJ#GXE:1LZ@RD_3RGS7+WFFWVGW1MKRSG@G
M!V^7)&5.?H:]@^#O@B^LKU_$.IVS0#RS':1R##G/5R.PQP,]<GVKEI1;FCZ'
M'UX0PTFWNFE\SV6OD#7F5_$6ILGW3=RD?3>:^J_$>L1>'_#U]JDQ %O$64'^
M)NBC\20*^169G<LQ)9CDD]S6V)>R/+R"#]^?31'V7#_J(_\ ='\J^</C'_R4
M2Z_ZX1?^@U]'P_ZB/_='\J^</C'_ ,E$NO\ KA%_Z#5XCX#ER3_>GZ/\T<%4
MMM<2VEU#<P.4FA=9$8=F!R#^=145Q'UC5]#Z_P!"U6+7-"L=4AQLN85DP/X2
M1R/P.1^%>-_%?PG+<_$#2Y+5,#62D)('212%)_[Y*G\#6W\#==^TZ->Z'*_S
MVC^="#_<;J!]&Y_X%7I]UI]M>7%G//$'DM)3+"W]UBI7^3']/2N^RJP1\:IR
MR_%R2Z7^Y[?H2VUO%:6L-M"NV*%%C11V4# 'Y5\P_$G6O[<\=:C,C;H8&^S1
M<\;4X./JVX_C7T3XNUD>'_">I:GN DAA(B_ZZ'Y5_P#'B*^2R2223DGJ36>)
MEHHG?D5&\I5GZ?YB4445R'T84H)5@02".01VKT+P=\,#XO\ "EQJ<.H_9[M9
MVBBC=,HP !Y(Y&2>O/3I6!K'@+Q/H<I6[TBX9!TE@7S4/XKG'XX-4X22O8YX
MXNA*;I\VJZ&WX4^+&NZ!+'!?RMJ6G@@,DQS(@_V7Z_@<CZ5]"Z9J-MJ^F6VH
M6;[[>XC$B$C!P?7WKY5TWPEX@U:Y2WL](O'9CC<T151]6. /Q-?3_AC1O^$?
M\,Z?I1<.UM$%=AT+=6(]LDUU8=S>CV/ SJEAXVE3MS/>QYK\=]+A.GZ7JRH!
M.LIMF8#EE(+ 'Z%3^9KA_A'_ ,E*TS_=F_\ 135VGQWU6+[/I6D*P,N]KEQG
M[HQM7\\M^5</\*95A^)6DEB &,J_B8GQ^N*SG;VWW'9A5+^S)7[2_4^G*^,Y
MO]?)_O'^=?9E?*6K^#M=L=?N=/&DWDKB9A&8X&82+G@J0.1C%7B4W8Y<BG&+
MJ*3MM^IA6]O-=W,5M;QM)-,XCC1>K,3@ ?C7T#X4^#^BZ5:QS:S$NHWY +JY
M_=(?0+_%]3U]!7EGP[L6M?BCI=GJ$+12PSN'CD&"KJC$#\P*^G*6'IIW;-,Y
MQE2$HTJ;LFKZ&!>7GA3PTHBN7TK3\C(BVHA(]E'-3Z3XKT+7+IK72]3@NIU0
MR,D9.0H(&?S(_.OE?6VOVUR].J>9]N\YO/\ ,SG=GFO4O@?X?U&'5+K79H#'
M8R6K6\3OP9&+JV5'<#:>?4_7%0K.4N5(QQ.5TZ.'=6<[O\&>J>,/^1)U[_L'
M7'_HMJ^2J^M?&'_(DZ]_V#KC_P!%M7R548G='3D/\.?J?3_PL_Y)KH_^[)_Z
M->N+^/G^HT'_ 'I_Y1UU_P )I5E^&NE $90RJWL?-;^A%8GQJT"_U;1=.N["
MVEN3:2N)$B4LP5P.<#J,J/SK62O1T[(X,/)0S-N6GO2_4\ KT[X%_P#([7O_
M &#G_P#1D=<#/H>K6NG_ &^XTV[AM-X3SI(652QSQDCV-=K\%;I+?Q]Y;'!N
M+22)>>IRK?R4URTM)JY]!CVI86IRZZ'NGBD%O".M =383@?]^VKY&K[)NK:.
M\LY[67/ES1M&V/0C!_G7R[J_@#Q+I6JR67]D7ER Y6.:WA9TD'8@@>G;M6^)
MBW9H\G(ZT(J<).ST-WX+?\C^/^O23^E>_:Q_R!+_ /Z]I/\ T$UY_P#"_P"'
M,_AHMK&K';J,L91(%;(A4XSN(ZL<?0?R] UC_D"7_P#U[2?^@FM*,7&&IPYE
M6A6Q=X.Z5D?'M>G_  [^*?\ PCEJFD:Q')+IZD^3-'R\.>Q'=<\^H]^E>85T
M.M^!_$7A^".XO]-E%NZAO.C^=5XZ,1]T_6N.#E%WB?48JG1K15*MUV_X!].Z
M3KVE:[;^?I=_!=)C)\MOF7ZKU'XBL_Q)X*T/Q3 ZZA9H+@C"748"RIZ<]_H<
MBOEBSN[JQNH[BSGE@N$.4DB8JP/L17UCX7N=0O/"^FW&JH4OI(%:8$8.?4CL
M2,'';-==.HJFC1\UC<%+ M5*<]_O/F'Q5X;NO"GB"?2[H[]GS12XP)8ST8#_
M #@@BL6O6?CP\1U_2D&/.%JQ;UVEN/Y-7DU<E2*C)I'TN"K2K4(U);L****@
MZ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.;U/2P6!AA(M1=V]SW?X6_$33I-$M]"U:[CMKNU'EP23-M26/^$;CP".F.X
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M_P"A5JUR8CXSZ/)O]T7JPHHHK$]0**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#C_Y& _[Y_E6Y6''_P C
M ?\ ?/\ *MJ/VO0\O,OBH_XT;E%%%8GJ!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &'<?\A]?]]?Y"MRL.X_Y#Z_[Z_R%;E;5=H^AY>7?'6_Q,****Q/4"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"L/4O^0M%]%_G6Y6'J7_ "%HOHO\ZVH?$>7F_P# 7JC<HHHK$]0**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2,W&>F3FK/\ ;B_\\#_WU_\ 6K"M2G*=TCU\LQ^'HX=0J2L]>YKT5D?VXO\
MSP/_ 'U_]:C^W%_YX'_OK_ZU9>QJ=CT/[5P?\_X/_(UZ*R/[<7_G@?\ OK_Z
MU']N+_SP/_?7_P!:CV-3L']JX/\ G_!_Y&O161_;B_\ / _]]?\ UJ/[<7_G
M@?\ OK_ZU'L:G8/[5P?\_P"#_P C7HK(_MQ?^>!_[Z_^M1_;B_\ / _]]?\
MUJ/8U.P?VK@_Y_P?^1KT5D?VXO\ SP/_ 'U_]:C^W%_YX'_OK_ZU'L:G8/[5
MP?\ /^#_ ,C7HK(_MQ?^>!_[Z_\ K4?VXO\ SP/_ 'U_]:CV-3L']JX/^?\
M!_Y&O161_;B_\\#_ -]?_6H_MQ?^>!_[Z_\ K4>QJ=@_M7!_S_@_\C7HK(_M
MQ?\ G@?^^O\ ZU']N+_SP/\ WU_]:CV-3L']JX/^?\'_ )&O161_;B_\\#_W
MU_\ 6H_MQ?\ G@?^^O\ ZU'L:G8/[5P?\_X/_(UZ*R/[<7_G@?\ OK_ZU']N
M+_SP/_?7_P!:CV-3L']JX/\ G_!_Y&O161_;B_\ / _]]?\ UJ/[<7_G@?\
MOK_ZU'L:G8/[5P?\_P"#_P C7HK(_MQ?^>!_[Z_^M1_;B_\ / _]]?\ UJ/8
MU.P?VK@_Y_P?^1KT5D?VXO\ SP/_ 'U_]:C^W%_YX'_OK_ZU'L:G8/[5P?\
M/^#_ ,C7HK(_MQ?^>!_[Z_\ K4?VXO\ SP/_ 'U_]:CV-3L']JX/^?\ !_Y&
MO161_;B_\\#_ -]?_6H_MQ?^>!_[Z_\ K4>QJ=@_M7!_S_@_\C7HK(_MQ?\
MG@?^^O\ ZU']N+_SP/\ WU_]:CV-3L']JX/^?\'_ )&O161_;B_\\#_WU_\
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M\\#_ -]?_6H_MQ?^>!_[Z_\ K4>QJ=@_M7!_S_@_\C7HK(_MQ?\ G@?^^O\
MZU']N+_SP/\ WU_]:CV-3L']JX/^?\'_ )&O161_;B_\\#_WU_\ 6H_MQ?\
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MP/\ WU_]:CV-3L']JX/^?\'_ )&O6''_ ,C ?]\_RJ7^W%_YX'_OK_ZU45O
MNH_:MAQDG;GVQ6E.E-7NNAP8['X>JZ?)*]I)O?8Z6BLC^W%_YX'_ +Z_^M1_
M;B_\\#_WU_\ 6K/V-3L=_P#:N#_G_!_Y&O161_;B_P#/ _\ ?7_UJ/[<7_G@
M?^^O_K4>QJ=@_M7!_P _X/\ R->BLC^W%_YX'_OK_P"M1_;B_P#/ _\ ?7_U
MJ/8U.P?VK@_Y_P '_D:]%9']N+_SP/\ WU_]:C^W%_YX'_OK_P"M1[&IV#^U
M<'_/^#_R->BLC^W%_P">!_[Z_P#K4?VXO_/ _P#?7_UJ/8U.P?VK@_Y_P?\
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MN#_G_!_Y&O161_;B_P#/ _\ ?7_UJ/[<7_G@?^^O_K4>QJ=@_M7!_P _X/\
MR->BLC^W%_YX'_OK_P"M1_;B_P#/ _\ ?7_UJ/8U.P?VK@_Y_P '_D:]%9']
MN+_SP/\ WU_]:C^W%_YX'_OK_P"M1[&IV#^U<'_/^#_R(KC_ )#Z_P"^O\A6
MY7-27@?4!=;" "#MSZ5>_MQ?^>!_[Z_^M6E2E-I670X,%C\/3G5<Y6O)M;[&
MO161_;B_\\#_ -]?_6H_MQ?^>!_[Z_\ K5G[&IV._P#M7!_S_@_\C7HK(_MQ
M?^>!_P"^O_K4?VXO_/ _]]?_ %J/8U.P?VK@_P"?\'_D:]%9']N+_P \#_WU
M_P#6H_MQ?^>!_P"^O_K4>QJ=@_M7!_S_ (/_ "->BLC^W%_YX'_OK_ZU']N+
M_P \#_WU_P#6H]C4[!_:N#_G_!_Y&O161_;B_P#/ _\ ?7_UJ/[<7_G@?^^O
M_K4>QJ=@_M7!_P _X/\ R->BLC^W%_YX'_OK_P"M1_;B_P#/ _\ ?7_UJ/8U
M.P?VK@_Y_P '_D:]%9']N+_SP/\ WU_]:C^W%_YX'_OK_P"M1[&IV#^U<'_/
M^#_R->BLC^W%_P">!_[Z_P#K4?VXO_/ _P#?7_UJ/8U.P?VK@_Y_P?\ D:]%
M9']N+_SP/_?7_P!:C^W%_P">!_[Z_P#K4>QJ=@_M7!_S_@_\C7HK(_MQ?^>!
M_P"^O_K4?VXO_/ _]]?_ %J/8U.P?VK@_P"?\'_D:]%9']N+_P \#_WU_P#6
MH_MQ?^>!_P"^O_K4>QJ=@_M7!_S_ (/_ "->BLC^W%_YX'_OK_ZU']N+_P \
M#_WU_P#6H]C4[!_:N#_G_!_Y&O161_;B_P#/ _\ ?7_UJ/[<7_G@?^^O_K4>
MQJ=@_M7!_P _X/\ R->BLC^W%_YX'_OK_P"M1_;B_P#/ _\ ?7_UJ/8U.P?V
MK@_Y_P '_D:]%9']N+_SP/\ WU_]:C^W%_YX'_OK_P"M1[&IV#^U<'_/^#_R
M->BLC^W%_P">!_[Z_P#K4?VXO_/ _P#?7_UJ/8U.P?VK@_Y_P?\ D:]%9']N
M+_SP/_?7_P!:C^W%_P">!_[Z_P#K4>QJ=@_M7!_S_@_\C7HK(_MQ?^>!_P"^
MO_K4?VXO_/ _]]?_ %J/8U.P?VK@_P"?\'_D:]%9']N+_P \#_WU_P#6H_MQ
M?^>!_P"^O_K4>QJ=@_M7!_S_ (/_ "->BLC^W%_YX'_OK_ZU']N+_P \#_WU
M_P#6H]C4[!_:N#_G_!_Y&O161_;B_P#/ _\ ?7_UJ/[<7_G@?^^O_K4>QJ=@
M_M7!_P _X/\ R->BLC^W%_YX'_OK_P"M1_;B_P#/ _\ ?7_UJ/8U.P?VK@_Y
M_P '_D:]%9']N+_SP/\ WU_]:C^W%_YX'_OK_P"M1[&IV#^U<'_/^#_R->BL
MC^W%_P">!_[Z_P#K4?VXO_/ _P#?7_UJ/8U.P?VK@_Y_P?\ D:]%9']N+_SP
M/_?7_P!:C^W%_P">!_[Z_P#K4>QJ=@_M7!_S_@_\C7HK(_MQ?^>!_P"^O_K4
M?VXO_/ _]]?_ %J/8U.P?VK@_P"?\'_D:]%9']N+_P \#_WU_P#6H_MQ?^>!
M_P"^O_K4>QJ=@_M7!_S_ (/_ "->BLC^W%_YX'_OK_ZU']N+_P \#_WU_P#6
MH]C4[!_:N#_G_!_Y&O161_;B_P#/ _\ ?7_UJ/[<7_G@?^^O_K4>QJ=@_M7!
M_P _X/\ R->BLC^W%_YX'_OK_P"M1_;B_P#/ _\ ?7_UJ/8U.P?VK@_Y_P '
M_D:]%9']N+_SP/\ WU_]:C^W%_YX'_OK_P"M1[&IV#^U<'_/^#_R->BLC^W%
M_P">!_[Z_P#K4?VXO_/ _P#?7_UJ/8U.P?VK@_Y_P?\ D:]%9']N+_SP/_?7
M_P!:C^W%_P">!_[Z_P#K4>QJ=@_M7!_S_@_\C7HK(_MQ?^>!_P"^O_K4?VXO
M_/ _]]?_ %J/8U.P?VK@_P"?\'_D:]%9']N+_P \#_WU_P#6H_MQ?^>!_P"^
MO_K4>QJ=@_M7!_S_ (/_ "->BLC^W%_YX'_OK_ZU']N+_P \#_WU_P#6H]C4
M[!_:N#_G_!_Y&O161_;B_P#/ _\ ?7_UJ/[<7_G@?^^O_K4>QJ=@_M7!_P _
MX/\ R->BLC^W%_YX'_OK_P"M1_;B_P#/ _\ ?7_UJ/8U.P?VK@_Y_P '_D:]
M%9']N+_SP/\ WU_]:C^W%_YX'_OK_P"M1[&IV#^U<'_/^#_R->BLC^W%_P">
M!_[Z_P#K4?VXO_/ _P#?7_UJ/8U.P?VK@_Y_P?\ D:]%9']N+_SP/_?7_P!:
MC^W%_P">!_[Z_P#K4>QJ=@_M7!_S_@_\C7HK(_MQ?^>!_P"^O_K4?VXO_/ _
M]]?_ %J/8U.P?VK@_P"?\'_D:]%9']N+_P \#_WU_P#6H_MQ?^>!_P"^O_K4
M>QJ=@_M7!_S_ (/_ "->BLC^W%_YX'_OK_ZU']N+_P \#_WU_P#6H]C4[!_:
MN#_G_!_Y&O161_;B_P#/ _\ ?7_UJ/[<7_G@?^^O_K4>QJ=@_M7!_P _X/\
MR->BLC^W%_YX'_OK_P"M1_;B_P#/ _\ ?7_UJ/8U.P?VK@_Y_P '_D:]%9']
MN+_SP/\ WU_]:C^W%_YX'_OK_P"M1[&IV#^U<'_/^#_R->BLC^W%_P">!_[Z
M_P#K4?VXO_/ _P#?7_UJ/8U.P?VK@_Y_P?\ D:]%9']N+_SP/_?7_P!:C^W%
M_P">!_[Z_P#K4>QJ=@_M7!_S_@_\C7HK(_MQ?^>!_P"^O_K4?VXO_/ _]]?_
M %J/8U.P?VK@_P"?\'_D:]%9']N+_P \#_WU_P#6H_MQ?^>!_P"^O_K4>QJ=
M@_M7!_S_ (/_ "->BLC^W%_YX'_OK_ZU']N+_P \#_WU_P#6H]C4[!_:N#_G
M_!_Y&O161_;B_P#/ _\ ?7_UJ/[<7_G@?^^O_K4>QJ=@_M7!_P _X/\ R->B
MLC^W%_YX'_OK_P"M1_;B_P#/ _\ ?7_UJ/8U.P?VK@_Y_P '_D:]%9']N+_S
MP/\ WU_]:C^W%_YX'_OK_P"M1[&IV#^U<'_/^#_R->BLC^W%_P">!_[Z_P#K
M4?VXO_/ _P#?7_UJ/8U.P?VK@_Y_P?\ D:]%9']N+_SP/_?7_P!:C^W%_P">
M!_[Z_P#K4>QJ=@_M7!_S_@_\C7HK(_MQ?^>!_P"^O_K4?VXO_/ _]]?_ %J/
M8U.P?VK@_P"?\'_D:]8>I?\ (6B^B_SJ7^W%_P">!_[Z_P#K51NKP7%XDX0J
M%QQGT-:4J4XRNT<&8X_#UJ*C3E=W7<Z6BLC^W%_YX'_OK_ZU']N+_P \#_WU
M_P#6K/V-3L=_]JX/^?\ !_Y&O161_;B_\\#_ -]?_6H_MQ?^>!_[Z_\ K4>Q
MJ=@_M7!_S_@_\C7HK(_MQ?\ G@?^^O\ ZU']N+_SP/\ WU_]:CV-3L']JX/^
M?\'_ )&O161_;B_\\#_WU_\ 6H_MQ?\ G@?^^O\ ZU'L:G8/[5P?\_X/_(UZ
M*R/[<7_G@?\ OK_ZU']N+_SP/_?7_P!:CV-3L']JX/\ G_!_Y&O161_;B_\
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M@?\ OK_ZU']N+_SP/_?7_P!:CV-3L']JX/\ G_!_Y&O161_;B_\ / _]]?\
MUJ/[<7_G@?\ OK_ZU'L:G8/[5P?\_P"#_P C7HK(_MQ?^>!_[Z_^M1_;B_\
M/ _]]?\ UJ/8U.P?VK@_Y_P?^1KT5D?VXO\ SP/_ 'U_]:C^W%_YX'_OK_ZU
M'L:G8/[5P?\ /^#_ ,C7HK(_MQ?^>!_[Z_\ K4?VXO\ SP/_ 'U_]:CV-3L'
M]JX/^?\ !_Y&O161_;B_\\#_ -]?_6H_MQ?^>!_[Z_\ K4>QJ=@_M7!_S_@_
M\C7HK(_MQ?\ G@?^^O\ ZU']N+_SP/\ WU_]:CV-3L']JX/^?\'_ )&O161_
M;B_\\#_WU_\ 6H_MQ?\ G@?^^O\ ZU'L:G8/[5P?\_X/_(UZ*R/[<7_G@?\
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M@?\ OK_ZU'L:G8/[5P?\_P"#_P C7HK(_MQ?^>!_[Z_^M1_;B_\ / _]]?\
MUJ/8U.P?VK@_Y_P?^1KT5D?VXO\ SP/_ 'U_]:C^W%_YX'_OK_ZU'L:G8/[5
MP?\ /^#_ ,C7HK(_MQ?^>!_[Z_\ K4?VXO\ SP/_ 'U_]:CV-3L']JX/^?\
M!_Y&O161_;B_\\#_ -]?_6H_MQ?^>!_[Z_\ K4>QJ=@_M7!_S_@_\C7HK(_M
MQ?\ G@?^^O\ ZU']N+_SP/\ WU_]:CV-3L']JX/^?\'_ )&O161_;B_\\#_W
MU_\ 6H_MQ?\ G@?^^O\ ZU'L:G8/[5P?\_X/_(UZ*R/[<7_G@?\ OK_ZU']N
M+_SP/_?7_P!:CV-3L']JX/\ G_!_Y&O161_;B_\ / _]]?\ UJ/[<7_G@?\
MOK_ZU'L:G8/[5P?\_P"#_P C7HK(_MQ?^>!_[Z_^M1_;B_\ / _]]?\ UJ/8
MU.P?VK@_Y_P?^1KT5D?VXO\ SP/_ 'U_]:C^W%_YX'_OK_ZU'L:G8/[5P?\
M/^#_ ,C7HK(_MQ?^>!_[Z_\ K4?VXO\ SP/_ 'U_]:CV-3L']JX/^?\ !_Y&
MO161_;B_\\#_ -]?_6H_MQ?^>!_[Z_\ K4>QJ=@_M7!_S_@_\C7HK(_MQ?\
MG@?^^O\ ZU']N+_SP/\ WU_]:CV-3L']JX/^?\'_ )&O161_;B_\\#_WU_\
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M\\#_ -]?_6H_MQ?^>!_[Z_\ K4>QJ=@_M7!_S_@_\C7HK(_MQ?\ G@?^^O\
MZU']N+_SP/\ WU_]:CV-3L']JX/^?\'_ )&O161_;B_\\#_WU_\ 6H_MQ?\
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M-6OH^K.0Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH
MY_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P
M?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^
M"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H
M_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_
M /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X
M+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN
M@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\
MX03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*
MFA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_
M .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$
M$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J
M:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_
M (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH
MY_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P
M?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^
M"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H
M_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_
M /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X
M+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN
M@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\
MX03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*
MFA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_
M .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$
M$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J
M:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_
M (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH
MY_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P
M?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^
M"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H
M_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_
M /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X
M+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN
M@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\
MX03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*
MFA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_
M .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$
M$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J
M:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_
M (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH
MY_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P
M?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^
M"Z'_ .)KY^T_1M+?]I9]*?3;-M.^V3+]D,"F' A8@;,8QGGI7U#7S7IG_)U;
M_P#7[/\ ^B&H ]T_X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN
M@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\
MX03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*
MFA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_
M .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$
M$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J
M:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_
M (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH
MY_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P
M?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^
M"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H
M_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_
M /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X
M+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN
M@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\
MX03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*
MFA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_
M .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$
M$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J
M:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_
M (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH
MY_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P
M?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^
M"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H
M_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_
M /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X
M+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN
M@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\
MX03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*
MFA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_
M .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$
M$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J
M:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_
M (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH
MY_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P
M?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^
M"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H
M_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_
M /0J:'_X+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X
M+H?_ (FN@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN
M@HH Y_\ X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN@HH Y_\
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MZ^@?^$$\'_\ 0J:'_P""Z'_XFO#/%7_)TEG_ -?ME_Z+CKZ3H Y__A!/!_\
MT*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z
M'_XFC_A!/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\ X+H?_B:/^$$\
M'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_
M (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH
M** .?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/
M!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_
M ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\ X+H?_B:/
M^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"
MIH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_
M^)KH** .?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH Y_
M_A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0
MJ:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\ X+H?
M_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?
M_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\
M@NA_^)KH** .?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@H
MH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'
M_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\
MX+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X
M03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*F
MA_\ @NA_^)KH** .?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_X
MFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^
M$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"I
MH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^
M)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__
M $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""
MZ'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@
M#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH** .?_X03P?_
M -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@
MNA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!
M/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'
M_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:
MZ"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH** .?_X0
M3P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\ T*FA
M_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XF
MC_A!/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\
M0J:'_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H
M?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH** .
M?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\
MT*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z
M'_XFC_A!/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\ X+H?_B:/^$$\
M'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_
M (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH
M** .?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/
M!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_
M ."Z'_XFC_A!/!__ $*FA_\ @NA_^)KH** .?_X03P?_ -"IH?\ X+H?_B:/
M^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"
MIH?_ (+H?_B:Z"B@#G_^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_
M^)KH** .?_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFN@HH Y_
M_A!/!_\ T*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#G_^$$\'_P#0
MJ:'_ ."Z'_XFOG[XJZ-I>G?&71[&QTVSM;.1;7?;P0*D;9E(.5 P<C@U]0U\
MU_&'_DN>A_[EI_Z-:@#W3_A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_
M .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y
M_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__
M $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""
MZ'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$
M\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^
M"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@
MHH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!
M/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'
M_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:
M/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*
MFA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\
MXFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_
M /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\
M0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H
M?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P
M?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+
MH?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B
M@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\
M'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_
M (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_
MX03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:
M'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B
M:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\
M^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"
MIH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_
M^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!_
M_0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA
M_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH**
M.?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?
M_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\
M@NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A
M!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?
M_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)K
MH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X
M03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*F
MA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_X
MFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]
M"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_
M .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y
M_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__
M $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""
MZ'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$
M\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^
M"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@
MHH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!
M/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'
M_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:
M/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*
MFA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\
MXFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_
M /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\
M0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H
M?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P
M?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+
MH?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B
M@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\
M'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_
M (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_
MX03P?_T*FA_^"Z'_ .)KH** .?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:
M'_X+H?\ XFN@HH Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B
M:Z"B@#G_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)KH** .?\
M^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XFN@HH Y_P#X03P?_P!"
MIH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B:Z"B@#YB^.6C:7I'CO0[?3--L[*&
M2V1GCMH%C5CYK#)"@ G%?3M?.'[07_)0] _Z]$_]&M7T?0!\X?L^_P#)0]?_
M .O1_P#T:M?1]?.'[/O_ "4/7_\ KT?_ -&K7T?0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\U
MZ9_R=6__ %^S_P#HAJ^E*^:],_Y.K?\ Z_9__1#4 ?2E%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'S9XJ_Y.DL_^OVR_]%QU])U\V>*O^3I+/_K]LO\
MT7'7TG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?-?QA_Y+GH?^Y:?^C6KZ4KYK^,/_)<]#_W+3_T:U '
MTI1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !113$FBE+".1'*G#!6!Q]: 'T444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MSA^T%_R4/0/^O1/_ $:U?1]?.'[07_)0] _Z]$_]&M7T?0!\X?L^_P#)0]?_
M .O1_P#T:M?1]?.'[/O_ "4/7_\ KT?_ -&K7T?0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\U
MZ9_R=6__ %^S_P#HAJ^E*^:],_Y.K?\ Z_9__1#4 ?2E%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'S9XJ_Y.DL_^OVR_]%QU])U\V>*O^3I+/_K]LO\
MT7'7TG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?-?QA_Y+GH?^Y:?^C6KZ4KYK^,/_)<]#_W+3_T:U '
MTI1110 4444 >1_&'XH:SX%U+3;'1X+1FN(6FEDN$+\9P  ",=#G\*XF/XO?
M%6:))8O#JO&X#*ZZ7,0P/0@YY%)^TG_R-6C?]>3?^AFO>_"?_(FZ'_V#[?\
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MT+(3SQQD'ID<FO0I(TFB>*5%>-U*LK#(8'J"*^2;Z'_A6GQT"VC&.UM;]'4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'S9XJ_Y.DL_^OVR_]%QU])U\V>*O^3I+/_K]LO\
MT7'7TG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?-?QA_Y+GH?^Y:?^C6KZ4KYK^,/_)<]#_W+3_T:U '
MTI1110 4444 ?-G[2?\ R-6C?]>3?^AFNDT/]H'PIIN@:;83:?K32VUK%"Y2
M&(J650#C,G3BN;_:3_Y&K1O^O)O_ $,UZAX;^&?@N[\+:1<S^';*2::RADD=
ME.68H"2>?6@#%A_:*\'RS1Q_8-;3>P7<T$6!D]3B3->NUR,?PO\ !$4J2)X:
ML0Z,&4["<$?C774 ?*GP@_Y+A'_OW?\ Z"]?5=?*GP@_Y+A'_OW?_H+U]5T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'SA^T%_R4/0/^O1/_1K5]'U\X?M!?\ )0] _P"O1/\ T:U?1] '
MSA^S[_R4/7_^O1__ $:M?1]?.'[/O_)0]?\ ^O1__1JU]'T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?->F?\ )U;_ /7[/_Z(:OI2OFO3/^3JW_Z_9_\ T0U 'TI1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!\V>*O^3I+/\ Z_;+_P!%QU])U\V>*O\
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M+);Q/*RKU(4$D#\J +%%>??#KXJ6WQ"OKZUATN:R:UC63+RAPP)QV P:]!H
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M .OV?_T0U 'TI1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG%U9PW 7:)8U< ]LC-?-/[2'_(]:9_V#%_\ 1LE?1^D_\@:Q_P"O>/\ ]!%
M&3XP\;:+X(TL7NKSD%R1#;Q@&28CLH_F3P,CU%>/2_M#ZW>2R/I'A-&M8S\Q
M=WD('N5  _I[USNKE_BG\>_[+N)G_L^.Y>V0*W"P0ABVWTW;6.?5A7T[86%I
MI=C#96-O';VL*[8XHUPJCV% 'E/@KX\Z7XAU&+2]:LCI5W*P2.7S-\+MZ$D
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M ->\7_H35UOQ4^+?_"*ZC>>&?[":Y^T6/_'R;KR\>8&7A=AR!]1WKDOV:?\
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M>_L;S6M/2\DL=WDK(QV?-C.Y<X;H.#D5MV]O!:0)!;PQPPH,+'&H55'L!TH
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M_P!ANY_F]?4]?+&C?\G-2?\ 8;N?YO0!]3T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S7\8?^2YZ'
M_N6G_HUJ^E*^:_C#_P EST/_ '+3_P!&M0!]*4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7$_%K1]0U[X;:GIVEVKW-W(8
MF2)",L%D5CC/L#7;44 >9_ WP[JWAKP1=VFLV,EG<2ZA),D<F,E#'&H/!XY4
M_E7IE%% !3)E+0R*!DE2!3Z* / /@;X'\2^&O&M_>:SI$]G;G3W@$DA7#.9(
MR ,'GA6Y'%>_T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)  Y)-9LGB30HIO)DUK3DESC8UT@;/TS0!IT4BLKJ&1@RD9!!R"*6@ HHHH
M**** "BBB@ HHHH **** "BJFI:I8:/9/>ZE>06ELA :6>0(H)Z#)INEZOIN
MMV?VS2[ZWO;?<5\V"0.NX=1D=Z +M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !117#^/?B?I?P_N+*#4+*\N7NT9U^SA<*%('.2/
M6@#N**K:=>QZEIEI?PJRQ7,*3('Z@,H(S[\U9H **** "BBB@ HHHH ****
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ML-*1_"C@KG_OK:/QK!^&7QF\.:#X'M='UMKF&YL0ZH8X2XE4L6&,=#SCGTH
M]]HK+\.:]:>)_#]IK-BDR6UTI9%F4!P Q'(!(ZCUKQT?&?Q"WQ=_X1I;2Q.F
M_P!K_P!GX\MO,V^;Y9;=NZ]^F* /=J*** "OECXF?\G"?]O=E_Z!'7U/7RQ\
M3/\ DX3_ +>[+_T".@#ZGKP_]I3_ )%[0_\ K[?_ - KW"O#_P!I3_D7M#_Z
M^W_] H [SX2_\DK\/_\ 7N?_ $-JN?$C_DFOB/\ [!\W_H)JG\)?^25^'_\
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M\>;!9SQO@Y&Y70']17T+XT_Y$7Q#_P!@RY_]%-0!X?\ LT_\AG7_ /KWB_\
M0FKWCQ+_ ,BKJ_\ UY3?^@&O!_V:?^0SK_\ U[Q?^A-7T+?6PO;"YM6QMFB:
M,Y]P1_6@#YV_9K_Y&'7/^O1/_0Z^D*^1_AEXJC^&?CN^CUV"9(C&]G<K&NYH
MG5@<X[\J1^-?0_A3XF>'O&FL7.FZ*UU*]O#YS2R0[$(R!@9.<Y([4 >*_M(?
M\CUIG_8,7_T;)7T?I/\ R!K'_KWC_P#017SA^TA_R/6F?]@Q?_1LE?1^D_\
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M T>3[LV !^?TKS'X>^'M5^)_Q*E\6:K#C3XKD7,SD?(SKC9"N>H&%S[#GJ*
M/INSB:"R@B<Y=(U5C[@8KY>^ O\ R563_KTG_FM?4]?+'P%_Y*K)_P!>D_\
M-: /J>OFC]I'_D<M)_[!_P#[4>OI>OFC]I'_ )'+2?\ L'_^U'H ^B])_P"0
M-8_]>\?_ *"*\'\;_%#Q+XF\:?\ "(^!WD@"S-;F:+ DG=<[B&_@08)R.P)S
MVKWC2?\ D#6/_7O'_P"@BOE>TO)?A9\;)KG5+25K>&YES@ L\$FX*Z^O!!_
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M)P *S1XCT-I_)&M:<9?^>8NDW?EF@#3HH!! (.0>A%% !1110 4444 %%%%
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MH:YIADSC9]KCSGTQFM4$$9!R* "BBB@ HJM+J%E!<+;S7EO'.^-L;R@,<],
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M9KWC]F__ )$74_\ L)M_Z*CK=^.5S8P_"S48[QD\V9XDME/4R;P>/HH8_3-
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MAOA43WD6W5]0 EN,CF)?X8_PSD^Y/H*]&H \H^/_ (C.D> UTR&3;<:K,(B
M<'RE^9_UVCZ,:^5\'&<<>M>G_'CQ%_;7Q#ELHWW6^EQBV4 \;S\SGZY(7_@-
M:?B/X??8/@!HFK"'%[#-]MN#CGRY\ ?D!#^M 'IOP'\1G6_A\EE-(7N=+E-N
M<G),9^9#],$J/]VO4*^5O@#XB_LCQ\=-E?%OJL)BP3QYBY9#_P"A#_@5?5-
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M^\R_+CN2/2K/P%TZ\O\ 4_$GC&ZB:.+4IV6'/\9+L[GZ E1GUSZ4 >WT444
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MB:+S-P.,J>A^7MQR.*\,^)&O_$/5-)AMO%^EM:6,=UNB?[+Y:F0*P #=^"U
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MRKR%SG'TR3^=;E% ''_\*K\#?]"S8_\ ?)_QH_X57X&_Z%FQ_P"^3_C7844
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MQ/K6[110!R_B'X=>$_%5T;K6-&AGN2NTSHS1N?3)0C./?-6/#7@CPYX0$O\
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MQWK )C2XDDAR,":X8DL_T7<?Q/L:]L\7>$-.\:Z2FF:I)<K;),LV+>386(!
M!X.1S_*M/2M+LM$TJVTS3X%@M+9!'%&O8?U/<GN: +E%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S7\8?\
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M? +"-2" H.06(/M@<D ^@**\K^$&O^-]5N=7LO&,-RK6BQ&%KFT$+?-NR.%
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MN?LX8>*8O/QRAL3MS_O;\_I7KOP[\-0^%? VF:;&@68Q":X('WI6 +$_3I]
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M+OM()$ ]6\L94?B!7HWPP^+EMXZ9M-OX$L]9C3>$0GRYU'4IGD$=U.>.<GG
M!Z;17FOQF\3>)/"7AVQU30)XXH_M'E7):%9#@CY3SP!D$?B*UOA;XPF\;>"8
M-2NS']NBD>"Y\L8&]>0<=LJ5/U)H [2BBO!])^*?BCQ+\9$T/2IX/[$%XZ%/
M(4[H(\[FW=<D D<]Q0![Q17.^-?&>F^!] ?5-1)<D[(($/S3/CA1Z#U/8?E7
MBEOX]^+OCUY;GPO8"UL0Q0>1%$%^ADFZD>V/I0!]&T5\XCXJ_$GP)JL,'C33
M_M-O)SB6)(V9>^R2,;21[YKWW0M;L/$>BVNK:;-YMI<IN0XP1V(([$'((]J
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M\;_&S:1IDSV^DH2\<+,1'%$./,DQ]YCQZ\G ]:]M^,>H2:;\*M;DB;;)+&D
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M^A!CNK*X65588PZ-G!'U% 'W)K37::%J+6 8W@MI# %&29-IVX]\XKY&-_\
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MBBB@ HHHH **** "BBB@ HHHH *^:],_Y.K?_K]G_P#1#5]*5\UZ9_R=6_\
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M-T/_ +!]O_Z+6LOXG?\ ),O$7_7D] 'FW[--U(^D>(+0L?+BGAD5>P+*P/\
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M]/W#\)%_QH ^F*^6/C?_ ,EA3_KE;U]3U\K?&R1'^,0".K%8[=6P<X/H?S%
M'U37RY^T5_R4:U_[!D7_ *,DKZCKY<_:*_Y*-:_]@R+_ -&24 ?4=<G\3O\
MDF7B+_KR>NL!! (.0>A%<G\3O^29>(O^O)Z /-/V:/\ D'>(O^NL'\GK5_:'
M\.?VCX/MM;B3,VF38D('_+*3 /Y,$_,UE?LT?\@[Q%_UU@_D]>T:WI4&NZ'?
M:5<C]S>0/"QQG&X8R/<=?PH X#X$^(?[:^'4-G(^;C3)#;-D\E/O(?I@[?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M W$X&:\Z^/?C[4="6S\.:3<26LMW#Y]S/&VU_+R555/49*MDCT [F@#UN_\
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M0!Y3^S/<2-:>)+8L?*C>WD49Z%A(#_Z"/RKWJOG_ /9E_P"9I_[=/_:U?0%
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M?]^I/_B:[*ZMH;VSGM+A-\,\;1R+G&588(_(UYK_ ,*!\#?\^]]_X%'_  H
MZ32OB9X-UO4X-.T[78)[N<[8XPCKN.,XR5 [5TUU9VM]#Y-W;0W$08-LE0.N
M0<@X/<&N&T+X-^$/#NM6VK6-O=?:K9MT1DN"R@X(SC\:SOC=XYO?!_AJUM=+
MD,-_J3NBSCK%&H&\K_M?,H![9)ZXH ]"OM9TK2L#4-2LK/C(^T3K'Q^)%>3_
M !I\3^$]=^'EW:V>MZ;>7\,T4D$<,ZR-G< Q7!_NLW2N;^'_ ,$H/%6B0>(O
M$VIWC-? RQPPL-Y4GAG=@<D]<#VY[5;^)GPB\*^%/A_?ZOIL=W]L@,01I9]P
M^:15.1CT)H Z3]G6=Y?AS=(QXBU*5%^GEQM_-C5;]I#_ )$73/\ L)K_ .BI
M*D_9Q_Y)YJ'_ &%9/_1451_M(?\ (BZ9_P!A-?\ T5)0!:^ GA;2['P/;>(4
MA#ZEJ!D#S.,E$61D"+Z [<GU)]A7JMU:P7MK+:W4*36\R%)(W&592,$$5P7P
M0D1_A%HJJZL4,ZL <[3Y\AP?3@@_C7H5 'RE\/!+X0^/*Z3%*?)6\GT]_P#I
MHGS!<_BJ'\*^B?B#_P DY\2?]@RX_P#19KYUT&1?$/[1JW%H1)$^L2SHPZ%$
M+-G\ES7T5\0?^2<^)/\ L&7'_HLT >$_L]^%M+UO7-3U74(1/)I8A-O&XR@=
M]_SD=R-G'USU KZ:KY]_9FD02>)XRZAV%JP7/) \W)Q[9'YBOH*@#Y4^-FEC
MPM\4H]2TS%N]S''?IY8QLE#$$CW)3=]37U'8W(O=/MKI<8GB608_V@#_ %KY
MH_:*OHKKQ]9V<3!GM;%%D ZJS,S8_(J?QKZ0T2T>PT#3K.08>"UBB8>ZJ ?Y
M4 ?)]GX<A\6_'2\T2XE:."XU:[,K+U*(TCD#T)"D9[9KZXLK*VTZRAL[."."
MVA0)'%&,*JCH *^8_ W_ "<S)_V$]0_] FKZCH \8_:-UJ6R\*:;I,3E1J%P
MSR@?Q)& <?3<RG\!6W\#?#=KHWP\M+]8U-YJ>9YI=OS;<D(N?0 9^I-<A^TQ
M:NUKX<NP#Y<;W$3>F6$9'_H)KT?X37T5_P#"[07B=6\NW\E@.S(2I!_*@#LV
M574JRAE(P01D$5\E^+K5/AW\;Q/IP\JWANXKN*-!@!'P60#TY9?I7UK7RG\8
M&7Q!\:3IUJ1(VZWLOE_OG&1^;8H ^CO&GA]?%'@[5-&8 O<P$1$]I!\R'_OH
M"O"?V=]>;3_%.I>'K@E!>Q>9&C=I8\Y&/4J6S_NU]*5\K>/K>3X=?'!-8MD*
MV\EPFHQA?XE8_O5_$[Q]"* /H#XC>(?^$8\ ZOJ:/LG$)B@.>?,?Y5(^A.?P
MKRG]F_PYQJOB29/2SMR1]&<_^@#\ZC_:)\31W<.AZ%9RB2.5?M\FSG<"-L?\
MW/Y5Z_X"\.CPKX'TK22H6:*$-/[RM\S_ *DCZ 4 >!_'S56U3XDVNCR3B.UL
M88XR3T1I,,S?]\E/^^:]ETOXA?#O1]+M=-L?$-A%:VT:Q1(&/  ^G)]Z\*^,
M]K'!\:+F2]0FUN/LTC#.,QA%5N>WW6KV=?@9\/W0.FFS,K#((O)""/\ OJ@#
M%^*GC'P1XG^'VHV,&N65S>H%FM44G=YBGMQU(W#\:K_LW:B\_A;5].9R1;7:
MR*#_  AUZ#\4-='_ ,**\ _] N?_ ,"Y/_BJZGPMX+T'P9;3P:'9FW6X8/*6
MD9V<CIRQ/3)X]Z /GWX^ZA-JWQ*MM(1ODM+>.)%/3?(=Q/X@H/PKZ/\ #^B6
MGAS0;+2+*-4@M8@@VC&X]V/N3DGZU\S?&<?V;\:'O7SM86UQ^"JH_P#9*^J8
MY$FB26-@\;J&5@>"#T- ' _&'PSIFN^ =2O+R ?:].MWN+:=0 Z%1G;G^Z>X
M_J*X3]F;_CW\2_[]M_*6O4?B7)'%\-/$;2.J V,B@L<<D8 ^I) KR[]F;_CW
M\2_[]M_*6@#WNBBB@#GO'/B%?"W@K5=8W 200$0Y[RM\J?\ CQ'X5X]^SCX?
M:6ZU?Q-<*6*XM(7;G+'#R'Z_<Y]S4W[2'B/;#I7AN%^7)O+@#T&50?GO/X"L
M'0/AW\6[#1K==(U)[&SE43+#'?\ EXW 'D#H?6@#VOXG^'?^$G^'NJV*)NN$
MB^T6^.OF)\P ^H!7_@5>4_LW^(]ESJOAN9^) +RW!/<85Q^(V'\#3/\ A"?C
M=_T,,_\ X,S7G^G+JOPL^*%B^K*(Y[29'N/+;<'B<?-@CK\K'\10!]D5\L?#
M/_DX3_M[O?\ T"2OJ9'5T5T8,K#((.017RQ\.V6V_:)V2''^G7T>3Z[9: /J
MBOG?]I?_ )"/AW_KE/\ S2OHBOG7]I:1#JOA^,.ID6"9F4'D LN"1[X/Y&@#
MV[P7_P B+X>_[!EM_P"BEKYZU@1?\-. :N5,7]IP_?Z8V+Y><]ON5]"^"_\
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M J2BB@ HHHH **** "BBB@#YP_:"_P"2AZ!_UZ)_Z-:OH^OG#]H+_DH>@?\
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MWQP1(WJJ &@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OFO3/\
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M@'3>H.* ,OPG_P B;H?_ &#X/_1:UF?$T$_#+Q%@?\N,G\JZN@@$$$9!Z@T
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MWLWG76E6,\N<[Y;=&;/KDBK=O;06D7E6T$<,8.=D:!1^0H +8RM:PM<*%F*
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M(R0D[?E8C(SS7'_M%?\ ).;7_L)Q?^BY*T/@+_R2NS_Z^)O_ $,T >F4444
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M <\X[KXL^+O%O@RYTK4]$M%N=*"R"]1X=Z9XV[F'S+QG!R!ZYKT^B@#PB/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S7IG_ "=6_P#U^S_^
MB&KZ4KYKTS_DZM_^OV?_ -$-0!]*4444 %%%% !1110 4444 %%%% !6;X@T
M:'Q#X?OM'N))(X;R%HF>/&Y0>XS6E10!QGP^^'5E\/;6^AM+ZXNS>.C.TRJ-
MNT$# 'U-=G110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ,AG7_\ KWB_]":O</&G_(B^(?\ L&7/_HIJ\/\ V:?^0SK_ /U[Q?\ H34
M>L?%J^N].^%^MW5E<RVUPB1A987*LN94!P1R."1^-<G^SWJVHZKX7U5M1O[J
M[:.\"H;B5I"H* X!).!FND^,_P#R237O]R+_ -')7'_LV?\ (JZS_P!?J_\
MH H V_CWJ=_I?P^@ET^]N+25]0CC9X)"C%=CG&1SC('Y5YIHWQ#\;^)O#VD^
M#_"OVN34DB;[;J$CYD(WL1\['Y%"E1N/)/ ]_0/VBO\ DG-K_P!A.+_T7)5C
MX 6%K;_#=+R*!%N;FXD\Z4#YGVMA<GT [?7UH \P\0_#3XD^%+"77SK3W1@'
MFSR65]*98P,DL=P!('))&>I^M>E_!/XC7?C#3[K2M9G675+)0ZRX ::(\9('
M=3@$]]P[YKU66*.>%X945XW4JZL,A@>"#7R[\!0;?XK3PQL0GV2=#[@,O^ H
M ^GKV\@T^QN+VZD$=O;QM+*YZ*JC)/Y"OF'4_&WC;XL^*VTGP[+<6=DV3';0
MRF,+&/XYG'7M[9P ,]?9/C;>M9?"C5@C%7G,4((..#(N1^*@URO[-^E10^%M
M5U8I^_N;SR-Q_N(@(Q^+M^5 '+S> ?BKX B_MG2]8^W+%\\T-K</+QU.Z-P
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M+TR-O4<$$?4_8]?/G[2UC:QS>'[Y($6ZF$\<DH&&=5V%0?7&X_G0!ZW\-_\
MDFOAS_L'P_\ H(KJ*Y?X;_\ )-?#G_8/A_\ 01744 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\U
M_&'_ )+GH?\ N6G_ *-:OI2OFOXP_P#)<]#_ -RT_P#1K4 ?2E%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>=>.OA#IGCS7X-6O-2N[9X
MX%@:.$*0RAB>,C@_,?7M7HM% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZV4_>;Z= /8"OFOP_P"$/B9X9UH:OIOAZZ%\ P$LL*2$;NI&[/)YY]S78?\
M"0_'C_H&S_\ @%#_ (4 >_:E:?;]+N[/('GPO%D]MRD?UKY<^!\>G1?$:?2M
M<L[:5I[:2".*ZA5P)E93C##@X5Z][^&M[XNOO#DTGC*V,&H+<LL8,:H6BVJ0
M2%XZEA^%>>_$_P"#VIW6O/XI\'MB\>3SIK5'\MQ*.?,C;(&2>2..>1G.* /7
M/^$3\-_]"_I7_@%'_A1_PB?AP'(\/Z5_X!Q_X5X7:_$CXQ:3MM+OPS->2CY
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYK^,/\ R7/0_P#<M/\
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MQ&T=N_M[T >LT44Q)HY&94D1F0X8!@2/K0 ^BBB@ HHHH ***\=UCXZKI7Q
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M;V'B#2[F<G:(H;M&8GV .37S?HUI?_'+XDW3:GJ,EM90QM,(U.3%"&"A(P>
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M7A'P*^)%]J=V_A36[E[B58R]E/*V7(7[T9)Y/'(ST (]*]=\6>([;PGX7O\
M6[H;DMH\K'G!D<G"K^)(H T;W4++3+<W%_>6]I".LD\JQJ/Q)Q5&Q\5>'=3N
M!;V&OZ7=SGI'!>1R,?P!S7S1X9\,^)/C9XCO-2U74VBM(#^]G9=RQYY$<29
M[?AU.2>>SU?]FV%;,OHFO2_:U&0EW&-KG_>7E?R- 'O=?+FI_P#)SJ?]AB#^
M2U[C\+[7Q+8^"XK/Q5YGV^"9XT,KAV,0/RY8$Y[X.>F*\.U/_DYU/^PQ!_):
M /J.J,VLZ7;7BV<^I6<5TV L$DZJYSTPI.:XOXI_$RV\":3]GM2DVMW*'[/"
M>1&.GF./3T'<CV->=?"GX77GB'45\9^+?-D223[1;PS'YKA\Y\Q_]G/('?Z=
M0#I?VCKAH_ >GP*2!+J*EO<"-^/S(_*O4M!A6W\.Z9 @ 6.TB0 =@$ KS/\
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M -?ME_Z+CKZ3KYL\5?\ )TEG_P!?ME_Z+CKZ3H **** "BBB@ HHHH ****
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M)Z^Y />-+\0:-K8;^RM6L;[:,L+:X60K]0#Q6@[K&C.[!4499F. !7R5X]\
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MQT!;)Q]*Z&YNK>SMWN+J>*"!!EI)7"JOU)X%>"?LR_\ ,T_]NG_M:N\^./\
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MDMHA ^?7*8.:QO GPJ@\!>*-1U&QU*2>QNK<1);RI\\9W \L.&Z>@Z_GTO\
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M;7&/]8HC"9_W=I/ZUYQISZO\&OBM'I\ET9K0R(LP4E4N8'X#%<\$9)]B/3J
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MQ.\97WC36+*\O]%?2Y(+?RE1BQ+C<3GE1ZFOKZPT^STNSCL["UAMK:,82*%
MJC\!7S1^T-JUCJ'C2RMK.Y2:6RM3%<!#D1N6)VD^N.OI0!](Z$2?#^FDG)-K
M%DG_ '!7S5\4U5_C_&K ,IGL@01D$82OI30?^1>TS_KTB_\ 0!7S9\4?^3@8
M?^OBR_DE 'U'7E7[0:*WPS!8 E;Z(K['##^1->JUY7^T%_R3(_\ 7[%_[-0!
M+\ F)^%UN">EU,!^=<'^T=H]Q!KNC^($ \AX/LI;/W71F<9'N&/_ 'R:[OX
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MR#K;_KDG\A7S)^T5_P E&M?^P9%_Z,DKZ;L/^0=;?]<D_D*^9/VBO^2C6O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_7HG_H= 'IGQQ_Y))J_^_!_Z.2L/]G'_ ))YJ'_85D_]%15N?''_ )))J_\
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MB&QFL5L0T!;S96#C9C/ 4^GK7KVJ6$>JZ1>Z=,S+%=P/ [+U =2I(]^:MT4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.EG&90I';</E]NM '>T5PF@_&'P5X@NTM(-4-M<.0$CNXS%N/H&/RY]LUW=
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MQ@N/4*.BCZ<^I-;GBZPU+5/".JZ?I$D4=_<V[0Q/*Q51NX/(!(."<>^*VJ*
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M1=.>%;J<QE#,Q5?ED5CD@'L#VK-^$?@S4_ WA*YTW57MWN)KU[@>0Y90I1%
M)('/R'\Z[ZB@"IJFFVVL:5=Z;>IOMKJ)HI%_V6&./>OG9_@GX^\,:O+/X6U=
M3&QV+/!=&WD9,CAQT_#)Z5]*44 <+\+_  QXB\-:->?\)-J;7U_=W'F\SM-Y
M8V@8+-W^G' K$^+/PED\<S0:KI5Q#;ZI#'Y3I,"$F3.1DCH1D]CGIQBO5:*
M/GO0/AI\4QJ.G6VHZ_-!I-I/&Y4ZB[KL0@X51[# !P..U>X^(/#^G>)]$N-)
MU2#S;6<8(!PRD<AE/8@UIT4 ?.D_P0\;^%M4>\\'Z\C(>%99FMY2.N&'W6'X
M\^@J7_A!/C3K"^1?^(7M86X;?J! Q[^6#FOH:B@#AOAE\/6^'^E7<$VHF]NK
MR42RN$VJI Q@9))ZGD_E6_XJ\,:=XO\ #]QH^IH3#+RKKPT;CHRGU'^([UM4
M4 ?-/_"F?B-X5U&5_#.K*T;\>;:W9MV=>V]3@?ADUTOACX(:E?ZPFL_$#56U
M&5#D6OG-+OQT#NW;_9'Y]J]QHH \A^%WPPUKP7XUU;5;][(V=Q!)%"MNY+<R
M*PXV@ 86O7J** "LCQ3I<^M^$]7TJV:-9[RSE@C,A(4,RD#) /&36O10!Y9\
M&OAWK/@)=:.L26C&],'EBWD+8V;\YR!_?'Y&NG^)/AN]\6^!-0T73GA6ZG,9
M0S,57Y9%8Y(![ ]JZRB@#@?A'X,U/P-X2N=-U5[=[B:]>X'D.64*410"2!S\
MA_.N^HHH \6\-?"?Q!I'QED\5W$U@VFF[NIP$E8R%95D"C&W&?G&>>QZU[31
M10 4444 ><>/O@YHGC69[^%SINK,/FN(D!24_P"VO&3[@@_6O+%^"_Q)\/S2
M#1-50)]X/9W[P%C[@XY_SFOIJB@#YG_X4E\1?$$R'7-8AV Y+7=[).PSUP,'
MG\17K7PX^%EA\/A<7"7DE[J%R@CDF9=BJH.<*N3CG&22>@Z5WU% ')_$GPW>
M^+? FH:+ISPK=3F,H9F*K\LBL<D ]@>U9OPC\&:GX&\)7.FZJ]N]Q->O<#R'
M+*%*(H!) Y^0_G7?44 %<=\0?AUI?Q TR.*Z<VU]!G[-=HN2F>H(_B4^GY&N
MQHH ^<+7X6_%?PEYD'A[64:U8YVVUX44^Y1P #]/SJRWPI^*/B?]SXC\3B*T
M)^>.2[>4'Z1K\I_$BOH:B@#(\+Z#'X8\,Z?HL4[SI9Q>7YKC!<YR3CMR>E>:
M_$WX+/XIU9M>T"ZAM-2<#SX9<JDK#HX89*MC';!QV.<^PT4 ?/D7@7XT:A$-
M+O?$36]CC:TKWN25QSRH+GIT/]33/$7[.]XEIID'AZ[MI945_MMQ=R-&78D8
MVJ 0% SQU^M?0U% !7E7Q9^$LGCF:#5=*N(;?5(8_*=)@0DR9R,D=",GL<].
M,5ZK10!\]Z!\-/BF-1TZVU'7YH-)M)XW*G47==B$'"J/88 .!QVKZ$HHH *K
M:C9C4-,N[)G*"XA>(L!G&Y2,_K5FB@#YJL_@%X]TR9Y-.U_3+5V&TO!>3QLP
M]#B.K4OP5^)ERGE7/BVUDB)Y5]1N6'Y%*^BZ* /&_!7P!TS0[Z+4=>O!JEQ$
M0T=NL>V%6'=L\O\ H/4&O9*** /%M<^$_B#4OC1#XLAFL1IJWUK=$-*PDVQA
M-PQMQGY#CGN*]IHHH ;(I>)T'5E(KQKX1?"K7_ WBN\U/5IK%H)+)K=!;RLS
M%BZ-GE1QA#^8KV>B@ KP/QQ\#M9E\4S:]X0O88C-,;CR6D,+P2$Y)1AVSD]L
M5[Y10!Y%\-O!?C[3O$_]L>+M:EFACMFBCMWO&F)+8ZC[H QZYS4?Q-^"S^*=
M6;7M NH;34G \^&7*I*PZ.&&2K8QVP<=CG/L-% 'SY%X%^-&H1#2[WQ$UO8X
MVM*][DE<<\J"YZ=#_4TSQ%^SO>)::9!X>N[:65%?[;<7<C1EV)&-J@$!0,\=
M?K7T-10 5XMKGPG\0:E\:(?%D,UB--6^M;HAI6$FV,)N&-N,_(<<]Q7M-% !
M7BWAKX3^(-(^,DGBNYFL3IQN[J<!)6,A659 HQMZ_.,\]C7M-% !7E7QD^'.
MM>/'T>31Y+1?L8F$BW$A3._9C& ?[I_2O5:* ,OPUILVC^%='TNX9&GL[*&W
MD:,DJ61 I(SCC(K4HHH *^=/VD=#:'6-(U^,'9/";60CLR$LOXD,?^^:^BZY
M+XE>%!XQ\#WVF(@:[4>?:$]I5Z#\1E?^!4 :?A#61XA\'Z3JV<M=6J/)[/C#
MC\&!%>:_M(?\B+IG_837_P!%25!^SOKT\VBZGX;NUD633Y1+$'4C:CYW+[88
M$X_VJG_:0_Y$73/^PFO_ **DH XSPY\'V\4_#;0_$6@W_P!AUS]]OWNP24K,
MX4AARC  #(XX'3K2W/PH^*WB-H[+6]6+VB,,-=ZBTJ?[VT9)/U&:]6^"7_)(
M="_[>/\ T?)7H% '(?#[X>Z=X TA[:U<W%Y.0US=.N#(1T '91DX'N:ZV2-)
M8WCD17C<%65AD$'J"*=10!X#XJ_9_O8=5;4_!FI);@-YB6TTC1O"?^F<@S^&
M<8]36;)\._C+JT;V%_K<PM7.QS/JA9&'N%R2/8BOI"B@#S3X;?!_3_ TW]I7
M=P+_ %@KM679M2 'J$'7)Z;CV[#G/<^(-'B\0^'M0T>>1HX[R!H2ZC)7(ZCZ
M5I44 ?.D?PJ^*7A)GA\-:^LMH3E5@NS$#[F-_E!^A/UJ>W^"OC7Q7J<5UXV\
M0_N(QT$QGD [JH^ZN?7GZ&OH2B@"IIFF6>C:9;:;80+!:6R".*->P'\S[]Z\
MU^+/PED\<S0:KI5Q#;ZI#'Y3I,"$F3.1DCH1D]CGIQBO5:* /GO0/AI\4QJ.
MG6VHZ_-!I-I/&Y4ZB[KL0@X51[# !P..U?0E%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\X?M!?\E#T#
M_KT3_P!&M7T?7SA^T%_R4/0/^O1/_1K5]'T ?.'[/O\ R4/7_P#KT?\ ]&K7
MT?7SA^S[_P E#U__ *]'_P#1JU]'T %%%% !1110 4444 %%%% !1110 444
M4 %%%% %*71],GD,DVG6<DC=6>!23^)%6H88K>)8H8DCC7@(B@ ?@*?10 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %?->F?\G5O_U^S_\ HAJ^E*^:],_Y
M.K?_ *_9_P#T0U 'TI1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1ZQ^T!*\?PQ=4SMDO(5?Z<G^8%0?L[QQI\.)V0Y9]1E+^QV(/Y 4 ;4WP5\
MS69MQH8B)7 E2XDWCWR6//US7@VJV>J_!/XF1-9W3S0 +*C$;1<6['!1QTSP
M1]0",<5]<5\\_M,+&+[PXP/[TQW 8>V8\?S- 'T!9W45]907ENVZ&>-98V]5
M89!_(U\@ZTVL_P#"Y];A\/M(NJ7&IW5O"8CAOG9E;![<$\]NO%?3OPZ:1OAO
MX<,GWO[.A'X;!C],5\_Z-_R<U)_V&[G^;T >F^&/@'X7T[2U&OQ/JNH.,ROY
MSQQH>X0*0<>YR>_'2O)_BGX)'PT\5Z?>Z'/-':7&9[5F;+0R(1E<]P,J03ZX
MYQFOK*O!_P!I?_D'^'?^NL_\DH ]8T^2S\<>!+62_MU:UU6Q1IX0Q &]064$
M<\'//M7S;\:?!NB^#->TVUT2W>"&>U,D@>5GRVXC^(GM7T-\,?\ DF7AW_KR
M2O&/VD_^1JT;_KR;_P!#- 'H&E?!'P)=:/8W$VF3M)+;QNY^UR#)*@GO79>*
MK:&S^'6MVMN@2&'29XXT'\*B)@!^0K1T'_D7M,_Z](O_ $ 53\:?\B+XA_[!
MES_Z*:@#Y(\#Z/KGBV];PGI<YBM+V1)[QL?*JQYPS>H&XX'<D>V/H.V^ G@R
MVBM<"_-S ZN;@7'S2$'/(QM /L!]:X/]FG_D,Z__ ->\7_H35]&4 >*?M >.
M+G1["V\,Z=,T4]]&9;IT.&$.2H4'_:(;/LN.]1?#?X'Z*= MM5\3P/>7=W&L
MJ6Q=HT@4C(!P02V#SG@=,<9KA/C>?M/Q@:&X)$*Q6\>?12 3_,U]5@ # &!0
M!Y#XT^!'AW4-&FE\.6IT[4HE+1JLC/',1_"P8G&>Q'ZURO[/GC*[CU6?PC>R
MNUN\;36BOUB=>60>@(R<=B#ZFOHBOE+P9^Z_:-"VIR@U6\52.Z?O1_*@#W'X
MS_\ ))->_P!R+_T<E<?^S9_R*NL_]?J_^@"NP^,__))->_W(O_1R5Q_[-G_(
MJZS_ -?J_P#H H T/VBO^2<VO_83B_\ 1<E:'P%_Y)79_P#7Q-_Z&:S_ -HK
M_DG-K_V$XO\ T7)6A\!?^25V?_7Q-_Z&: ,#]H#QO<Z/I]KX:TZ9HI[^,RW3
MH2&$.<!0?1B&S[+CO5OP!\$- L= MKOQ)8B_U2=!(\<K,$@R,[ H(!([DYYZ
M5YE\>'ED^*\B9Y2V@6/=TZ9[\8R37;?9_P!H+_G]@_*S_P#B: %^+/P>T.S\
M+W.O>';7[%<62^9/ CDQRQY^8@'.".O&!@'BNB^!'BZZ\1^#IK&_F::[TN18
MA(QRS1,,ID]R,,/H!7)ZAH_QXU73KG3[VX@EM;F)H9H_]$&Y&&",A<C@]JZ3
MX)> ->\%'6I=<ABA-WY*Q(DH<_+OR3C@?>% &5^T/XPN=/L;+PS93-$;U#/=
ME3@M%G:J9]"0V?\ ='K3_AM\$M!?PQ:ZIXFM6O;V]C$RPF1T2%&&5&%();!R
M<],XQQFN&^/\AF^*,<<V5B2RA0'_ &=S$G\R:^IE540*HPJC  ["@#Y[^(_P
M9'AVQN/$/@V6XAB@B<W5GYI)6(J0Y1CR1M)RI)R,\]J9^S1_R$?$7_7*#^;U
M[9XT_P"1%\0_]@RY_P#135XG^S1_R$?$7_7*#^;T ?1%%%% 'S7^T1J=S<>,
M]+T:69XK"*U6;!^[N=V!?'? 4#\_6O6=.^$/@2UTJ*U&AV]TNP9N)6+/)_M;
M@>,^V!Z57^*7PPA\?V4-Q;3I;:O:J5AE<?)(IYV/CD#/(/.,G@YKQ^V\0_$[
MX1!+74+:2;2D(1$N1YT&.P213E?89'TH ]S\(?#?1/!&K:C>Z,URB7J(AMY'
MWK'M)/RD\]^Y->9?&GX=>&= \*W&O:;8O#?SWJ[V\YROSEBV%)P.:]%^'GQ-
MTOX@6LJP1-::C;J&GM';=P>-RM_$N>.@([CD9P_V@O\ DF1_Z_8O_9J .2^$
MOPN\*>*_ L6J:O8RS7;7$B%UN'08!XX!Q7M7AOPSI7A/21IFCVY@M0[2;2[.
M2QZDDDGL/RKAO@#_ ,DO@_Z^YOYBO4* /ECPU_R<U/\ ]AN]_G+7U/7RQX:_
MY.:G_P"PW>_SEKZGH \$_:9_X]_#7^_<_P HJ]3^&_\ R37PY_V#X?\ T$5Y
M9^TS_P >_AK_ '[G^45>I_#?_DFOAS_L'P_^@B@#QC]H+Q9=WOB*#PE9O(+:
MW5)+B-,_O9GY4$=P 5(]V]A7;^%?@1X6L-#A37[,ZCJ4B9G<S2(B$_PH%(X'
M3)Y/MG%>7^(&^U?M,1BY& =9M4P>X!C"_G@5]44 ?,7Q0^$T_@FRN-8\.W-P
M^BS 17D#OEH@6!&3_$FX+UY!QUZUVO[-W_(FZM_V$/\ VFE=9\9_^22:]_N1
M?^CDKD_V;O\ D3=6_P"PA_[32@#E/VB/#S:?XGT_Q';*46]C\N5UXQ+'C!SZ
ME<8_W*]U\%>(%\4>#=*UD$%[B &7':0?*X_[Z!K'^+'AO_A)_AWJ5M&F^ZME
M^UV_'.],D@>Y7<OXUY]^S?XB\VPU7PY*_P T+"[@!_NMA7'T!"G_ ($: -_]
MH#Q#_97@)=,BDVSZI,(R >?*3YG/Y[!_P*IO@+X<_L7X?KJ$J;;G59#.21SY
M8^5!].K?\"KS3XM7,_CCXR6?AJS<E+=H[)2.0'8[I&_#.#_N5]+65I#I]C;V
M5L@2"WC6*-1V51@#\A0!/1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\U_&'_DN>A_[E
MI_Z-:OI2OFOXP_\ )<]#_P!RT_\ 1K4 ?2E%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %17%M!=Q&*Y@CFC)R4D0,/R-2T4 ,BBCAB6**-
M8XU&%1!@ >PI]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\X
M?M!?\E#T#_KT3_T:U?1]?.'[07_)0] _Z]$_]&M7T?0!\X?L^_\ )0]?_P"O
M1_\ T:M?1]?.'[/O_)0]?_Z]'_\ 1JU]'T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?->F?\G5
MO_U^S_\ HAJ^E*^:],_Y.K?_ *_9_P#T0U 'TI1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M (J!A!_@L<,P_&3C]:]2\%?#CP_X%A<Z9"\EY(NV6\G.Z1AZ#& H]@/3.<4
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MKZ(3;36_V1V X5U9F&?J&/\ WR:]4^''C_2O%?A6R=KZ%-2@B6*[@DD"N'4
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MF989)5#PMW5AGC'Z]1Q4WBOPEI'C+1GTS5X"\6=T<B'#Q-_>4]C^A[UX[/\
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M *^:_C#_ ,EST/\ W+3_ -&M7TI7S7\8?^2YZ'_N6G_HUJ /I2BBB@ HHHH
M**\0^.GCWQ%X6U?2K'0]0-E'+ TTK(BL7.[ 'S X P>GK6!:CX]WMC#>V\MQ
M);SQK+&PFM!N5AD'!.>AZ4 ?1U%?,C?%3XG>!M2B@\46QGC;GRKRW5-Z]]DB
M 9/O\V/2OH#PEXHL/&/ARVUG3]PBERKQO]Z-Q]Y3]/U!![T ;=%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SA^T%_P E#T#_ *]$
M_P#1K5]'U\X?M!?\E#T#_KT3_P!&M7T?0!\X?L^_\E#U_P#Z]'_]&K7T?7SA
M^S[_ ,E#U_\ Z]'_ /1JU]'T %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %?->F?\G5O_ -?L_P#Z
M(:OI2OFO3/\ DZM_^OV?_P!$-0!]*4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ?-GBK_ ).DL_\ K]LO_1<=?2=?-GBK_DZ2S_Z_;+_T7'7TG0 4444
M%?.'Q"\)^(;[XZ)J%IHFH3V3W%HXN8K=FBPJH&)8# Q@]3VKZ/HH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;6ML5\L'JP1V!9L=,M7TS\-;GPO+X,M(/"<_F6, VN'XE#GDF0=F)Y]/3C%
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ME 'H_P /_']I\0-,N[VTL9[06TPB992#G(!R"*YC]H+24OOAQ]NV_O-/NHY
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M+GQAJ09H+65Y!(W_ "UN7R3^08D^Y6O9_BG,8/A?XA=>IM&3_OHA?ZT >(?
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M_H K4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#YP_:"_Y*'H'_7HG_HUJ^CZ^</V@O\ DH>@?]>B?^C6
MKZ/H ^</V??^2AZ__P!>C_\ HU:^CZ^</V??^2AZ_P#]>C_^C5KZ/H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^:],_P"3JW_Z_9__ $0U?2E?->F?\G5O_P!?L_\ Z(:@#Z4H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ^;/%7_)TEG_U^V7_ *+CKZ3K
MYL\5?\G26?\ U^V7_HN.OI.@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *^:_C#_P EST/_ '+3_P!&M7TI
M7S7\8?\ DN>A_P"Y:?\ HUJ /I2BBB@ HHHH ^;/VD_^1JT;_KR;_P!#->]^
M$_\ D3=#_P"P?;_^BUKP3]I/_D:M&_Z\F_\ 0S7=>'_C5X&L/#>EV=QJ4RSV
M]I%%(HM9#AE0 C./44 =_P"*/"NE>+M&FTW5+9)%=2(Y=H+PL>C(>Q'Z]#Q7
MS?\  G4[K2/BBFE!SY5['+!,@Y4LBLX/X;2,^YKO_%?[0NBPZ7/#X:AN;F_=
M2L<\T6R.(]-V#R3W Q]:P?@!X&OCJ[>+K^%XK9(F2S+C!F9N&<?[(&1GN3[&
M@#T7XX_\DDU?_?@_]')6'^SC_P D\U#_ +"LG_HJ*MSXX_\ ))-7_P!^#_T<
ME8?[./\ R3S4/^PK)_Z*BH ]@KX]U72;C6_CCJ>EI>M93W6L3QI< '*9=MO0
M@],#KWK["KYG^-GAK4O#'CN'QCIBNMO<R1S"9!Q#<)C@^F< CU.[TH Z#_A0
MOB3_ *'V?_OB3_XY4=Q^S[KMU$8KCQL\T9Y*20NP_(O78>&?CAX1UK34DU*]
M72KX#][!.&VY]5<#!'Y'VJQJ_P ;_ VEP,T>IO?RCI%:0LQ/_ FPOZT :_PZ
M\%?\(%X7_L@WQO':=IWE\O8,L , 9/&%'>L_XPZOI.E_#C4H]5B6?[8GD6T!
M."TIY5AZ;2-V?;WKI?#OB&V\0^%[/7D1K:WN(C+MF890 G.3T[5\XZ_J%[\:
M_BM;Z98.ZZ5 Q2%L<1P _/*1ZMV_X"* /.]+4:1JFD:GJFFO/IS2K-Y;@A;B
M-7PP![\@BON#3;^UU73+:_L95EM;B-9(G7H5(R*X7XC?#:S\0?#Z/2M*MDCN
MM*CW:<H]A@QY_P!H#\\$UY]\ ?'36MU)X,U.0JKLSV)?C8_5X_QY(]\^M 'H
M/QQ_Y))J_P#OP?\ HY*P_P!G'_DGFH?]A63_ -%15N?''_DDFK_[\'_HY*P_
MV<?^2>:A_P!A63_T5%0!T'QM_P"20Z[_ -N__I1'7+_LW?\ (FZM_P!A#_VF
ME=S\4M,FUCX9Z]9V\9EE-N)50=3L8/Q[_+7BWP.^(FA>$[34]+UVZ-I'/*L\
M,QC9U)QM93M!(Z CC'7GID ^F*Y;XE2^3\-/$;>MA*OYKC^M6_"_C+1/&,-W
M-HETUQ%;2B)W,;("2,Y&X XKF/CCJ L/A5J2!L/=/%;K^+AC_P".JU ' _LS
MQ$W'B6;LJ6R_F9#_ $KZ#KQK]G'3/L_@S4M19<-=WNP'U5%&#^;-^5>RT %%
M%>7V?QZ\&2BX6]EN[&:%V3RY(&??@XRI3/ZXH \D\6_\G)+_ -ABS_\ :5?4
M\\T5M;R3S.$BB4N[MT50,DFOE#P_-+\0?CU;ZG:P,L+ZBMZ5?JD,1!&[T.%4
M?4XKZ@\1V$FJ^%]6TZ$XEN[*:!,''+(5'\Z /!;[XG^.?B)XHDT?P.IL[0;B
MK*JAS&/^6DCM]P>PQUQR:UO^%2_$R]4-?_$"4/P=J7EPR@_I_*N+^#/BW3O
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M>[#XW> #8_:?[:8-C_4_9I?,SZ8VX_'./>@#C?VE;Q$T;0;'<-\EQ)-C/95
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\V>*O^3I+/_K]LO_1<
M=?2=?-GBK_DZ2S_Z_;+_ -%QU])T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S7IG_)U;_\
M7[/_ .B&KZ4KYKTS_DZM_P#K]G_]$-0!]*4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?-GBK_DZ2S_Z_;+_T7'7TG7S9XJ_Y.DL_^OVR_P#1<=?2= !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5\U_&'_DN>A_[EI_Z-:OI2OFOXP_\EST/_<M/_1K4 ?2E%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?.'[07_)0] _Z]$_]&M7T?7SA^T%
M_P E#T#_ *]$_P#1K5]'T ?%_@S3_&E_KU]%X0>Y74$C8W!@N5A;9N&<EF /
MS8KN?^$:^/'_ #\:K_X-H?\ XY5C]GW_ )*'K_\ UZ/_ .C5KZ/H ^:/^$:^
M/'_/QJO_ (-H?_CE'_"-?'C_ )^-5_\ !M#_ /'*^EZ* /FC_A&OCQ_S\:K_
M .#:'_XY1_PC7QX_Y^-5_P#!M#_\<KZ7HH ^:/\ A&OCQ_S\:K_X-H?_ (Y1
M_P (U\>/^?C5?_!M#_\ '*^EZ* /FC_A&OCQ_P _&J_^#:'_ ..4?\(U\>/^
M?C5?_!M#_P#'*^EZ* /FC_A&OCQ_S\:K_P"#:'_XY1_PC7QX_P"?C5?_  ;0
M_P#QROI>B@#YH_X1KX\?\_&J_P#@VA_^.4?\(U\>/^?C5?\ P;0__'*^EZ*
M/FC_ (1KX\?\_&J_^#:'_P".4?\ "-?'C_GXU7_P;0__ !ROI>B@#YH_X1KX
M\?\ /QJO_@VA_P#CE'_"-?'C_GXU7_P;0_\ QROI>B@#YH_X1KX\?\_&J_\
M@VA_^.4?\(U\>/\ GXU7_P &T/\ \<KZ7HH ^:/^$:^/'_/QJO\ X-H?_CE'
M_"-?'C_GXU7_ ,&T/_QROI>B@#YH_P"$:^/'_/QJO_@VA_\ CE'_  C7QX_Y
M^-5_\&T/_P <KZ7HH ^:/^$:^/'_ #\:K_X-H?\ XY1_PC7QX_Y^-5_\&T/_
M ,<KZ7HH ^:/^$:^/'_/QJO_ (-H?_CE'_"-?'C_ )^-5_\ !M#_ /'*^EZ*
M /FC_A&OCQ_S\:K_ .#:'_XY1_PC7QX_Y^-5_P#!M#_\<KZ7HH ^:/\ A&OC
MQ_S\:K_X-H?_ (Y1_P (U\>/^?C5?_!M#_\ '*^EZ* /FC_A&OCQ_P _&J_^
M#:'_ ..4?\(U\>/^?C5?_!M#_P#'*^EZ* /FC_A&OCQ_S\:K_P"#:'_XY1_P
MC7QX_P"?C5?_  ;0_P#QROI>B@#YH_X1KX\?\_&J_P#@VA_^.4?\(U\>/^?C
M5?\ P;0__'*^EZ* /FC_ (1KX\?\_&J_^#:'_P".4?\ "-?'C_GXU7_P;0__
M !ROI>B@#YH_X1KX\?\ /QJO_@VA_P#CE'_"-?'C_GXU7_P;0_\ QROI>B@#
MYH_X1KX\?\_&J_\ @VA_^.4?\(U\>/\ GXU7_P &T/\ \<KZ7HH ^:/^$:^/
M'_/QJO\ X-H?_CE'_"-?'C_GXU7_ ,&T/_QROI>B@#YH_P"$:^/'_/QJO_@V
MA_\ CE'_  C7QX_Y^-5_\&T/_P <KZ7HH ^:/^$:^/'_ #\:K_X-H?\ XY1_
MPC7QX_Y^-5_\&T/_ ,<KZ7HH ^:/^$:^/'_/QJO_ (-H?_CE'_"-?'C_ )^-
M5_\ !M#_ /'*^EZ* /FC_A&OCQ_S\:K_ .#:'_XY1_PC7QX_Y^-5_P#!M#_\
M<KZ7HH ^:/\ A&OCQ_S\:K_X-H?_ (Y1_P (U\>/^?C5?_!M#_\ '*^EZ* /
MFC_A&OCQ_P _&J_^#:'_ ..4?\(U\>/^?C5?_!M#_P#'*^EZ* /FC_A&OCQ_
MS\:K_P"#:'_XY1_PC7QX_P"?C5?_  ;0_P#QROI>B@#YH_X1KX\?\_&J_P#@
MVA_^.4?\(U\>/^?C5?\ P;0__'*^EZ* /FC_ (1KX\?\_&J_^#:'_P".4?\
M"-?'C_GXU7_P;0__ !ROI>B@#YH_X1KX\?\ /QJO_@VA_P#CE'_"-?'C_GXU
M7_P;0_\ QROI>B@#YH_X1KX\?\_&J_\ @VA_^.4?\(U\>/\ GXU7_P &T/\
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M (1KX\?\_&J_^#:'_P".4?\ "-?'C_GXU7_P;0__ !ROI>B@#YH_X1KX\?\
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M_P"?C5?_  ;0_P#QROI>B@#YH_X1KX\?\_&J_P#@VA_^.4?\(U\>/^?C5?\
MP;0__'*^EZ* /FC_ (1KX\?\_&J_^#:'_P".4?\ "-?'C_GXU7_P;0__ !RO
MI>B@#YH_X1KX\?\ /QJO_@VA_P#CE'_"-?'C_GXU7_P;0_\ QROI>B@#YH_X
M1KX\?\_&J_\ @VA_^.4?\(U\>/\ GXU7_P &T/\ \<KZ7HH ^:/^$:^/'_/Q
MJO\ X-H?_CE'_"-?'C_GXU7_ ,&T/_QROI>B@#YH_P"$:^/'_/QJO_@VA_\
MCE'_  C7QX_Y^-5_\&T/_P <KZ7HH ^:/^$:^/'_ #\:K_X-H?\ XY1_PC7Q
MX_Y^-5_\&T/_ ,<KZ7HH ^:/^$:^/'_/QJO_ (-H?_CE'_"-?'C_ )^-5_\
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ME'_"-?'C_GXU7_P;0_\ QROI>B@#YH_X1KX\?\_&J_\ @VA_^.4?\(U\>/\
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M_P#QROI>B@#YH_X1KX\?\_&J_P#@VA_^.4?\(U\>/^?C5?\ P;0__'*^EZ*
M/FC_ (1KX\?\_&J_^#:'_P".4?\ "-?'C_GXU7_P;0__ !ROI>B@#XLU'3_&
M<7Q#BLK][D^*C+$$9KE6DWE1Y?[P-CIMYSQ7>?\ "-?'C_GXU7_P;0__ !RI
M/%7_ "=)9_\ 7[9?^BXZ^DZ /FC_ (1KX\?\_&J_^#:'_P".4?\ "-?'C_GX
MU7_P;0__ !ROI>B@#YH_X1KX\?\ /QJO_@VA_P#CE'_"-?'C_GXU7_P;0_\
MQROI>B@#YH_X1KX\?\_&J_\ @VA_^.4?\(U\>/\ GXU7_P &T/\ \<KZ7HH
M^:/^$:^/'_/QJO\ X-H?_CE'_"-?'C_GXU7_ ,&T/_QROI>B@#YH_P"$:^/'
M_/QJO_@VA_\ CE'_  C7QX_Y^-5_\&T/_P <KZ7HH ^:/^$:^/'_ #\:K_X-
MH?\ XY1_PC7QX_Y^-5_\&T/_ ,<KZ7HH ^:/^$:^/'_/QJO_ (-H?_CE'_"-
M?'C_ )^-5_\ !M#_ /'*^EZ* /FC_A&OCQ_S\:K_ .#:'_XY1_PC7QX_Y^-5
M_P#!M#_\<KZ7HH ^:/\ A&OCQ_S\:K_X-H?_ (Y1_P (U\>/^?C5?_!M#_\
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M (1KX\?\_&J_^#:'_P".4?\ "-?'C_GXU7_P;0__ !ROI>B@#YH_X1KX\?\
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M_P"?C5?_  ;0_P#QROI>B@#YH_X1KX\?\_&J_P#@VA_^.4?\(U\>/^?C5?\
MP;0__'*^EZ* /FC_ (1KX\?\_&J_^#:'_P".4?\ "-?'C_GXU7_P;0__ !RO
MI>B@#YH_X1KX\?\ /QJO_@VA_P#CE'_"-?'C_GXU7_P;0_\ QROI>B@#YH_X
M1KX\?\_&J_\ @VA_^.4?\(U\>/\ GXU7_P &T/\ \<KZ7HH ^:/^$:^/'_/Q
MJO\ X-H?_CE'_"-?'C_GXU7_ ,&T/_QROI>B@#YH_P"$:^/'_/QJO_@VA_\
MCE'_  C7QX_Y^-5_\&T/_P <KZ7HH ^:/^$:^/'_ #\:K_X-H?\ XY1_PC7Q
MX_Y^-5_\&T/_ ,<KZ7HH ^:/^$:^/'_/QJO_ (-H?_CE'_"-?'C_ )^-5_\
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M]+T4 ?-'_"-?'C_GXU7_ ,&T/_QRC_A&OCQ_S\:K_P"#:'_XY7TO10!\T?\
M"-?'C_GXU7_P;0__ !RC_A&OCQ_S\:K_ .#:'_XY7TO10!\T?\(U\>/^?C5?
M_!M#_P#'*/\ A&OCQ_S\:K_X-H?_ (Y7TO10!\T?\(U\>/\ GXU7_P &T/\
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M;0__ !RC_A&OCQ_S\:K_ .#:'_XY7TO10!\T?\(U\>/^?C5?_!M#_P#'*/\
MA&OCQ_S\:K_X-H?_ (Y7TO10!\T?\(U\>/\ GXU7_P &T/\ \<H_X1KX\?\
M/QJO_@VA_P#CE?2]% 'S1_PC7QX_Y^-5_P#!M#_\<H_X1KX\?\_&J_\ @VA_
M^.5]+T4 ?-'_  C7QX_Y^-5_\&T/_P <H_X1KX\?\_&J_P#@VA_^.5]+T4 ?
M-'_"-?'C_GXU7_P;0_\ QRC_ (1KX\?\_&J_^#:'_P".5]+T4 ?-'_"-?'C_
M )^-5_\ !M#_ /'*/^$:^/'_ #\:K_X-H?\ XY7TO10!\T?\(U\>/^?C5?\
MP;0__'*/^$:^/'_/QJO_ (-H?_CE?2]% 'S1_P (U\>/^?C5?_!M#_\ '*/^
M$:^/'_/QJO\ X-H?_CE?2]% 'S1_PC7QX_Y^-5_\&T/_ ,<H_P"$:^/'_/QJ
MO_@VA_\ CE?2]% 'S1_PC7QX_P"?C5?_  ;0_P#QRC_A&OCQ_P _&J_^#:'_
M ..5]+T4 ?-'_"-?'C_GXU7_ ,&T/_QRC_A&OCQ_S\:K_P"#:'_XY7TO10!\
MT?\ "-?'C_GXU7_P;0__ !RC_A&OCQ_S\:K_ .#:'_XY7TO10!\T?\(U\>/^
M?C5?_!M#_P#'*/\ A&OCQ_S\:K_X-H?_ (Y7TO10!\T?\(U\>/\ GXU7_P &
MT/\ \<H_X1KX\?\ /QJO_@VA_P#CE?2]% 'S1_PC7QX_Y^-5_P#!M#_\<H_X
M1KX\?\_&J_\ @VA_^.5]+T4 ?-'_  C7QX_Y^-5_\&T/_P <H_X1KX\?\_&J
M_P#@VA_^.5]+T4 ?-'_"-?'C_GXU7_P;0_\ QRC_ (1KX\?\_&J_^#:'_P".
M5]+T4 ?-'_"-?'C_ )^-5_\ !M#_ /'*/^$:^/'_ #\:K_X-H?\ XY7TO10!
M\T?\(U\>/^?C5?\ P;0__'*/^$:^/'_/QJO_ (-H?_CE?2]% 'S1_P (U\>/
M^?C5?_!M#_\ '*/^$:^/'_/QJO\ X-H?_CE?2]% 'S1_PC7QX_Y^-5_\&T/_
M ,<H_P"$:^/'_/QJO_@VA_\ CE?2]% 'S1_PC7QX_P"?C5?_  ;0_P#QRC_A
M&OCQ_P _&J_^#:'_ ..5]+T4 ?-'_"-?'C_GXU7_ ,&T/_QRC_A&OCQ_S\:K
M_P"#:'_XY7TO10!\T?\ "-?'C_GXU7_P;0__ !RC_A&OCQ_S\:K_ .#:'_XY
M7TO10!\T?\(U\>/^?C5?_!M#_P#'*/\ A&OCQ_S\:K_X-H?_ (Y7TO10!\T?
M\(U\>/\ GXU7_P &T/\ \<H_X1KX\?\ /QJO_@VA_P#CE?2]% 'S1_PC7QX_
MY^-5_P#!M#_\<H_X1KX\?\_&J_\ @VA_^.5]+T4 ?%_C/3_&EAKUC%XO>Y;4
M'C4VYGN5F;9N.,%6('S9K[0KYP_:"_Y*'H'_ %Z)_P"C6KZ/H ^</V??^2AZ
M_P#]>C_^C5KZ/KYP_9]_Y*'K_P#UZ/\ ^C5KZ/H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^:]
M,_Y.K?\ Z_9__1#5]*5\UZ9_R=6__7[/_P"B&H ^E**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /FSQ5_R=)9_P#7[9?^BXZ^DZ^;/%7_ "=)9_\ 7[9?
M^BXZ^DZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KYK^,/_)<]#_W+3_T:U?2E?-?QA_Y+GH?^Y:?^C6H
M^E**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^</V@O^2AZ!_UZ)_Z-
M:OH^OG#]H+_DH>@?]>B?^C6KZ/H ^</V??\ DH>O_P#7H_\ Z-6OH^OG#]GW
M_DH>O_\ 7H__ *-6OH^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYKTS_DZM_^OV?_ -$-7TI7
MS7IG_)U;_P#7[/\ ^B&H ^E**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/FSQ5_R=)9_]?ME_Z+CKZ3KYL\5?\G26?_7[9?\ HN.OI.@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)JP"",@Y%?%/CFP\56VJ6]YXO>9M0OH?/59GRZIN( ('"=#\HZ>@K["\-?\
M(K:1_P!>4/\ Z * -2D)"@DD #DDTM?+WBOQ#XB^+'Q%?PMI=T8--6=X8H=Y
M6,JF=TLF/O="0.W '/4 ^BW\4>'HY#&^NZ8K@X*F[C!!^F:TXI8YXEEBD62-
MAE70Y!'L:\/7]FK3?LFU_$=V;G'WQ;KLS_NYS^M>?6][XC^"7C\6$ET9K3*O
M+$K'RKF%OX@IZ-P>>H([CJ ?6E%(K*Z!U(*L,@CN*6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YP_:"_Y*'H'_ %Z)_P"C
M6KZ/KYP_:"_Y*'H'_7HG_HUJ^CZ /G#]GW_DH>O_ /7H_P#Z-6OH^OG#]GW_
M )*'K_\ UZ/_ .C5KZ/H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^:],_Y.K?_ *_9_P#T0U?2
ME?->F?\ )U;_ /7[/_Z(:@#Z4HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ^;/%7_ "=)9_\ 7[9?^BXZ^DZ^;/%7_)TEG_U^V7_HN.OI.@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"CXNGQM,^CZO#%!J\:&2-XLA+A1UP#T8=<9YY/&*]3E8I$[#J%)%?*&M6R^
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MPQC"(H51Z # I]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'SA^T%_R4/0/^O1/_1K5]'U\X?M!?\ )0] _P"O1/\ T:U?
M1] 'SA^S[_R4/7_^O1__ $:M?1]?.'[/O_)0]?\ ^O1__1JU]'T %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?->F?\ )U;_ /7[/_Z(:OI2OFO3/^3JW_Z_9_\ T0U 'TI1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEN%1C@,40M@_E0!H45Y;\)OBAJ7Q O=3M]0L+2W^R1HZ-;[N<D@@Y)]*]2H
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MMDF4$]?+8C'UQ)^AKZ$TB^.JZ)8W[PF$W=M',8F.=FY0=I^F<5\S>-/!^O\
MPJ\;#Q)H$3G31,9;>=$W+$&SF*0#H,$CW'?/0 ^IJ\ _:5U2/;H.DJV9,R7,
MB^@X53^/S_E3!^TO)]AP?"ZF[QC=]L_=Y]<;,_AG\:Y_PKX1\1_%WQI_PD?B
M&)X]*WJTTI4HCHO2*('MVSVR3DGJ >Y_"S3'TCX8Z!:R+M<VWG,/3S&,G/O\
MU=?2*JH@1%"JHP !@ 5XSXW^.MQX3\7W^AQ>'TN%M"B^;)<E"^4#9QM.!SZT
M <?^TC_R.6D_]@__ -J/7T'X:_Y%72/^O*'_ - %?(OQ$\>R_$'5[74)=/2R
M-O!Y 192^[YBV<X'K7>Z=^T7=Z?IEI9#PW XMX4B#F[(W;5 SC;[4 >]>*M6
M?0O"6KZK$ 9;2TEEC!&1O"DKGVSBOGKX#Z#:^)_&>IZUK&+R>R59E$WS;YI&
M/SD'J1@_B0:^@HQ!XO\ !4?VJ!X8-7T\&2(G+1B6/D9]1N_2OF6"+QA\$/%L
MMT;/S;5P8C(RDV]U'GCYAT;OZ@]L'D ^M*^:_P!H3PIINC:KINMZ=$EO)J!D
M6XCCPH9UVD.!ZG<<_0'J36\O[2UAY&7\-7(F_NBZ4K^>W/Z5Q%_+XP^.?B>V
M:'3_ +/809C1@#Y%LI/S,SG[S' Z<G P* /H3X;ZM<ZY\.]#U"\9GN9+<+([
M=7*DKN/UVY_&NIK/T/2+?0-"L=)M,^19PK"I/5L#J?<GG\:T* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G#]H+_DH>@?\
M7HG_ *-:OH^OG#]H+_DH>@?]>B?^C6KZ/H ^</V??^2AZ_\ ]>C_ /HU:^CZ
M^</V??\ DH>O_P#7H_\ Z-6OH^@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYKTS_DZM_\ K]G_
M /1#5]*5\UZ9_P G5O\ ]?L__HAJ /I2BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#YL\5?\ )TEG_P!?ME_Z+CKZ3KYL\5?\G26?_7[9?^BXZ^DZ "BB
MB@ KY4_:"_Y*:?\ KRB_]FKZKKY4_:"_Y*:?^O*+_P!FH ]3_P"&>?!7_/75
M?_ A?_B*GL_@%X-LKV"Z1M2=X9%D57N%*D@YP?EZ<5J_\+H^'WF^7_PD2;LX
MS]EFQ^>S%=1HOB31/$4+2Z/JEK>JOWA#("R_4=1^- &I7CGB7X-ZAXV^(=_J
M^MZP8M'^1;6*$[I=H09 R-J#.?7)SQ7L=-DD2)"\CJBCNQP* /,Y?@'X%>R,
M"6MY'*00+A;IBX]\'Y?TKPAEU'X2?%4Q17.XV,ZAGQ@3P. <,/=3T['Z5]6:
MOXM\/Z#:/<ZGK%G;QH,X,H+'Z*.2?8"OF-H+OXQ?%^:YLK65;&69#(S#(AMT
M 7+=@2%Z>IQ0!]:@@C(.17R]\6-8U'QM\5X?"D$YCM(+J.R@0D[/-8@-(P[D
M%B/H/<U]0U\S?&?PSJGA7Q_'XST]&-K/-%<),%R(;A,?*WU*AAGKDCM0!ZAI
MOP*\"65BD%UILM],%P]Q-<R*S'Z(P _ 5X]\6_A[;_#O5=-U/0;FXCM;EF,:
MLY+P2I@_*W7'(QWX/->S^$OC)X6\1:.;B]OX-+O88]UQ;W+[0,=2C'[X]AS[
M5Y'XZ\07WQG\:6.B>&+61[&T+".612H.<;I7_NK@# //XG% 'OW@76I?$7@;
M1M6N#F>XME,I QEQ\K''N0:Z&LWP]HT'AWP]8:/;,6BLX%B#GJV!RQ^IR?QK
M2H ***XKXM7MUIWPNUNZLKF6VN$2,++"Y5ES*@.".1P2/QH [6BOEKPS\4_%
M?_"*P>%M"%YJ&OW5RY%U,QF:.,@85-Q/.=Q);A1^8TKWX0?%">U;5)]?6XO\
M%S!_:$IE]=H8C;GVSCWH ^DZ*^>OA%\5M87Q%%X4\43RSB9S#!/<Y\V*4?P.
M3R<D8YY!Q^'T%*YCB=U0NRJ2%'<^E #Z*^<UL/C#\2Y7GEN)M$TUR0L<CM:Q
M[?3:HWN/=@0?6JFL_"/XA>&=/FU?3_$+W3P+YLJ6EU*DO R2N<;L >N3V% '
MTO6?KL\MKX?U*X@<I+%:RNC#LP0D'\Z\N^"/Q*U'Q8EWHFM2>??VD0FBN<8:
M6/(4AL<9!*\]\^V2WXK^$O'>J:I=:GHFOR6VC)8_O;5;V2(?*&+_ "*,-D>O
M7I0!E_ /Q7K_ (@UO6(=7U:ZOHX[='19Y-VUBV,C/2O=Z^-/AUX>\6>(=0O8
MO">JOI\\42M,R7;P;E)P!E.O->^_#'PGXZ\/ZK?7'BO7I-0MI( D,3WLD^'W
M9W?... 1^- %WQM\(=#\<ZW%JU]=WUM<+$L+BW9=KJ"2/O*<'DC\J[FPLH--
MTZUL+92L%M$D,8)R0J@ <_05\^_M ^(-9TOQEIEOI^K7UG#]@639;W#QC>9'
M&[Y2.< ?E7T!IDCRZ59R2,6=X$9F/4DJ.: +5%>/_%[XKW7ABZ3PYX="MK$B
M@S3;=Y@#?=55[N<@\] 1P<\<I;?![XC>(+9=1UCQ.UO=2 .L-Q<RNZ'L&QPO
MT&<?I0!]%T5\Q0^*O'?P=\3PZ;X@N9=1TQ\-Y;S&5)(\X+1,W*D>G'N.0:^E
M;"^M]3TZVO[2026US$LT3C^)6&0?R- %BBOFOXB>,]3\._'8RMJ>H#3+*6V=
M[6&=@K1[$9U"YQSD]?6IEB^)WQB:34+6Z&CZ&6(@1IGBC8 ]MH+2$?WB,9SC
M'2@#Z.HKY+O;CXA?!W7K9;G4)3#)\R+YS2VUPHP",-W&0.@(R,=J^F]'UB/Q
M5X1M]4TV7RQ?6VZ-NOE.000?=6R/PH \X^/OB/6?#VCZ,='U*XL6GGD$C0/M
M+ *,#(Y[UW/PZO[O5/A[H=]?3O/=36P:25SEF.3R:^:?B/X6\;^';2QD\6:W
M)J,,LCK &OI)]K #)P_3C%;_ (8\!?%'4_#.GWNC>)YK;3IH@UO"-4FC"+GI
MM P/PH ^GJ*Q/"&GZII7A/3K'6[PWFI0Q8GG,C2%VR3]YN3@$#)]*VZ "BBB
M@ HHKYK^(OC35/#GQU,QU+4!IME+;.]I#.P5H_+1G4+G'.3^= 'TI17S@EK\
M3OC&)=2@NUTC1<D6\3S/#$^.PV@LY]6(QUQZ5SJ:]X[^$'BN*SU.[GF@X=K>
M28RP7$1/)0GH>O(P01SQ0!]8T5\_ZQX_\6_%'66T/P!'/8Z;&!Y]ZS>4Q![L
MX^XOH%^8X/T')>(_"GQ$^& AUIM9D>'S &N+.ZD=5;L)%8#(.,<@@XQZ4 ?5
MM%<9\,?&W_"=>$(]0G6.._A<P74<?"AQR& ]""#]<CM7._'_ %2_TKP#9RZ=
M>W%I))J4<;O;RF-F7RY#@D'ID _A0!ZK17 ?!>_O-2^&&G7%]=3W4YDF4RSR
M%V($C #)YX'%=_0 5A^-/^1%\0_]@RY_]%-7A7P.\0ZUJ?Q+NX+_ %>_NH6M
M)G,<]P[J6#K@X)QGD_G7NOC3_D1?$/\ V#+G_P!%-0!X?^S3_P AG7_^O>+_
M -":O?-=GEM?#^I7$#E)8K65T8=F"$@_G7@?[-/_ "&=?_Z]XO\ T)JZGXK^
M$O'>J:I=:GHFOR6VC)8_O;5;V2(?*&+_ "*,-D>O7I0!E_ /Q7K_ (@UO6(=
M7U:ZOHX[='19Y-VUBV,C/2O=Z^-/AUX>\6>(=0O8O">JOI\\42M,R7;P;E)P
M!E.O->^_#'PGXZ\/ZK?7'BO7I-0MI( D,3WLD^'W9W?... 1^- %WQM\(=#\
M<ZW%JU]=WUM<+$L+BW9=KJ"2/O*<'DC\J[FPLH--TZUL+92L%M$D,8)R0J@
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M]5.AV21_1AV]CD>U %FP\7>'-4M$NK+7-/EA<9!%PH(]B"<@^QYKA/B[X_\
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MA^S[_P E#U__ *]'_P#1JU]'U\X?L^_\E#U__KT?_P!&K7T?0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5\UZ9_R=6__7[/_P"B&KZ4KYKTS_DZM_\ K]G_ /1#4 ?2E%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ0QQL4/'F(Z !^_WLD\@D'I].5X!^TO-9D>'H,J;Y?.? (RL9V#D>A(X^AH
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M7T=XXUJ?P]X(UC5K4#[3;6S-$2,@.> <=\$@_A0!%XB^('A7PI*8=8UF""X
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M\X5Y7S\S>N 0!Z<^M>L^'_@]X,T.PBADTBWU"X"CS;B\3S"[=SM.0H]@/SH
M\4^,GQ$T'QY!HXTB.[62S:;>;B,)PX3I@G^[7OWPUD:3X:>'&8Y(L(E_ # _
M05X_^T)H>AZ+:Z"NE:7IUA+*\QD%K;I$SJ F,[0,CK7KWPQ_Y)EX=_Z\DH \
M8_:3_P"1JT;_ *\F_P#0S7T'H/\ R+VF?]>D7_H KY]_:31AXFT5\?*;-@#[
MASG^8KW_ ,.2+-X8TF5#E'LX64^Q04 5O&G_ "(OB'_L&7/_ **:O#_V:?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'SA^T%_P E#T#_ *]$_P#1K5]'U\X?M!?\E#T#
M_KT3_P!&M7T?0!\X?L^_\E#U_P#Z]'_]&K7T?7SA^S[_ ,E#U_\ Z]'_ /1J
MU]'T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?->F?\G5O_ -?L_P#Z(:OI2OFO3/\ DZM_^OV?
M_P!$-0!]*4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-GBK_ ).DL_\
MK]LO_1<=?2=?-GBK_DZ2S_Z_;+_T7'7TG0 4444 %?/&K:=\7_!7B#4;K1GN
M]0TV>YDF18L72%68G'EG+*>>< ?4U]#T4 ?-K_$;XR7JFT@T"ZAFQM+QZ1)O
M!]3N! _*IO"7P6\1>(M>&M^.Y9$B9Q))#+-YD]QCH&()VKT'7.. !U'T910
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M/A_1[@6^IZYIMG.<?N[BZ1&QZX)SCWJ_9WUIJ-LMS974%S WW98) ZGZ$<4
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M:],_Y.K?_K]G_P#1#5]*5\UZ9_R=6_\ U^S_ /HAJ /I2BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG>2FQ'G213$>:%')='0#E>O3H.O:K>F?%WQKI^DV=E;> )F@MX$BC(@FY55
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M@U+4[+1].GU#4;F.VM(%W22R' 4?Y[=Z /%-(_9PMGC$WB'7[F6Y<[I%LU
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M[F_B3<+>X10)L=E(^Z?3.>?3J/0?@BJK\(M$(4 L;@D@=3Y\@_I7H- 'S]\
M/'5Y)?R^$=3N'DC\LR6/FG+(5^]&,]L<@=MIKUWX@_\ ).?$G_8,N/\ T6:^
M=]*5=)_:2\NW4!!K4J*J=%5RPQ^ :OHCX@_\DY\2?]@RX_\ 19H ^8/ FJ>+
M;[3Y_!GA0&*74)_.N+A&*LL84 Y;^!?4CD\ =<'TR']FNS.FXG\17'V\KDND
M \H'Z$Y(_$55_9E52WBAMHW 6H!QR ?._P !7T#0!\H^"]<UGX3?$DZ%JLQC
ML6G6&]B+9BVMC;,OIP0<]<9!KZNKYB_:.M8XO'.GW"!0\^GKOQU)5W&3^&!^
M%?1NA7#7?A[3+EP0TUI%(<]<E : /DFX\2W_ (6^*'B6^TM,WTEW>6\+8R49
MY"-P'<CL/7'TKN]*_9YU;6-+.HZYKQM-5N<RM"T/G%2>?WC;AECWQT]36%X-
MMX;K]I1XYXED0:K?.%89&Y1*RGZ@@'\*^J* .#UC6$^%/PIM3.Z75U96T=I
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M7O@?\0QI5Y=&XTF5E:5!GRYH6./,53T<8/XJ1DBOJ96#*&4@@C(([U\E>/\
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M[,]LK77B2Z*C>B6\:M[,9"1_XZ*^A*\!_9FE79XEBS\V;9L>W[T5[]0!X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OFO3/\ DZM_^OV?_P!$
M-7TI7S7IG_)U;_\ 7[/_ .B&H ^E**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8U5W3<(PS@%B._7]:YSX*>.-?\:Z;JLFN%)?LLL:PSI$$W;@Q9>.#C _[ZH
M]3HHHH **** "BBB@ HHKYD^(5_>1_M$P1I=SJBWEBJJLA  *QY 'H<G\S0!
M]-T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117#_&&:6W^%.NR
M0RO'($B 9&(.#*@/(]B10!W%%>.?LYW,]QX-U3SII)-E^0N]B<#RUZ9KV.@
MHHHH **** "BBB@ HHHH **** "BOGWQS\6O&.A_$^YT73A"+2":*..V:W#-
M,&53UZ\YXQ[5]!4 %%%% !1110 4444 %%%% !117A/[2=U<6]IX<2&>6-7>
MX+!'(#$"/&<>F3^= 'NU%<U\/)9)OAUX>EED:21K"(LSG))VCJ:Z6@ HHHH
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MZ_PSQ8&?^^=GY&OIBN+^*'@F3QUX0?3K9X8[Z&59[9Y20NX9!!(!(!4G\<4
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MQ"OD:QXD-O;,/G22^8@CTVQC!_&O7_ '@Y/ WA:+1EO&NV$C2O*4V LWH,G
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M!U-+:\N7\R6"YSL+]V5UR5^F#SW'2N0_X5M\9(O]&CUF\,!Z[-9<)^6[/Z4
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MH"./6L__ (0[XX1?Z*FN3M%_SU&H@]/<_-V_6@"3]I6]L)+G0;)&1K^)99)
M#RD;;0,_4J<?0^M>J?"NWN+;X7^'X[K<)/LH<;NNUB67_P =(KSCPM\ +AM6
M75/&>J)>MO\ ,:VA=G\UO^FDC $CU '/K7NRJJ($10JJ,  8 % "T444 %%%
M% !1110 4444 ?.'[07_ "4/0/\ KT3_ -&M7T?7SA^T%_R4/0/^O1/_ $:U
M?1] 'SA^S[_R4/7_ /KT?_T:M?1]?.'[/O\ R4/7_P#KT?\ ]&K7T?0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5\UZ9_R=6_\ U^S_ /HAJ^E*^:],_P"3JW_Z_9__ $0U 'TI
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!\V>*O\ DZ2S_P"OVR_]%QU]
M)U\V>*O^3I+/_K]LO_1<=?2= !1110 53U35;#1=/EO]3NX;2UB&7EE; 'M[
MGVZFKE?+?Q8US4?'?Q03PO82,;:VN5LH(LD*9B<.[#V)(SV"^YH ]8?X]>!$
MNO)%[=LF<><MJVSZ\_-^G:L#XY:UIFO_  HLK_2;V&[M7U./$D39P?+DX(Z@
M^QYK?TSX$^";31TM+VPDO;HH!+=M/(C%L=5"L HST&/KFO&/BA\-;_X?C=97
M<]QX=O)EV[VY24!MJN!P3@MAL>O3N >U_ K_ ))1IO\ UUG_ /1C5Z1T&37F
M_P "O^24:;_UUG_]&-7.?M >.+G1["V\,Z=,T4]]&9;IT.&$.2H4'_:(;/LN
M.] '8ZY\8/!.@W+6L^KBXG0X=+1#+M/NP^7\,YJII?QP\"ZG.L+:E+9NV,&[
MA9%SZ%AD#ZD@5RGPW^!^BG0+;5?$\#WEW=QK*EL7:-(%(R <$$M@\YX'3'&:
MTO&GP(\.ZAHTTOARU.G:E$I:-5D9XYB/X6#$XSV(_6@#UN*6.>))89%DC<!E
M=#D,#T((ZBJ6N:WI_AS1KC5M4G\BRMP#))M+8R0HX ).20/QKP?]GSQE=QZK
M/X1O97:W>-IK17ZQ.O+(/0$9..Q!]37I'QM_Y)#KO_;O_P"E$= '2>%_%VB^
M,=/DOM$NC<012&)RT;(5; .,,!V(K<KQ?]F[_D3=6_["'_M-*]HH Y2W^)'A
M:Z\6MX8AU!FU597A,7D.%WJ"67=C'&#[<5U=?+F@?\G.R_\ 88N_Y25]1T ?
M*_P%X^*LA/\ SZ3_ ,UKVC6_C1X(T.]>TDU)[N9#M<6<1D53_O<*?P)Z5\Q^
M%=+US7?%#:1H,CQW-Z'AE=6VA8B<N6(Z+@<^O3G.*^CM$^ _@O3M-6'4;.34
M[HKB2XEF=,GOM5& 4>G4^] '3^%OB%X9\9%H]'U)9+A!N:WD4QR >NT]1[C-
M=/7R5\1_"%Q\*_&EC?:)=2I;2DW%E(3\\;*1N0GOC(^H;!KZ@\,ZROB'PQIF
ML*H7[9;)*RCHK$?,/P.1^% 'S;\3/^3A/^WNR_\ 0(Z^IZ^6/B9_R<)_V]V7
M_H$=?4] %'5M8TW0K![[5;V"SM4ZR3.%&?0>I]AS7G\_Q\\"Q7!C2ZO9E!(\
MV.U;:?SP?TKRC4+C4/C9\6?[-BNGCT>W9_*V\K%;J<&0#^\W'XL!T%>UVWP<
M\!6]D+7^P(I1@!I)97,C'UW;N/PP* -WPWXR\/\ BZW:71-3BNM@R\?*R)]4
M;! ]\8K=KY3\;Z#=?!SXAV.HZ!<2"UE'G6X=LG:#AXG]1T_ CN,U]1Z=?1:G
MIEI?P$F&ZA2://\ =901^AH LT444 >1_M%?\DYM?^PG%_Z+DI?@]K>F>'_@
MU;:AJU[#:6J7$V9)6QD[SP!U)]AS2?M%?\DYM?\ L)Q?^BY*\T^&'PUU#Q_:
MP3ZO>7$/ANQ=EAC5L&5R<L$'0#/5L>PZ< 'K2_'OP(;KR?MEX$SCSC:ML^O]
M[]*]!TO5;#6M/BO],NXKJUE&4EB;(/M['VZBO/-;^!/@V^T66VTRQ;3[T(?)
MN5GD?#=MP9B",]>_IBO+/@KKVH>%?B1)X8O&*V]W+);3PD\).F<,/?*[?Q]J
M /H;QI_R(OB'_L&7/_HIJ\/_ &:?^0SK_P#U[Q?^A-7N'C3_ )$7Q#_V#+G_
M -%-7A_[-/\ R&=?_P"O>+_T)J /?-<UC3]!T:ZU/59A%8P+F5RA;@D # !)
MR2!^-4/"?BO0?%FG2W/A^<2V\,GER#R6CVMC/0@=CVK"^,__ "237O\ <B_]
M')7'_LV?\BKK/_7ZO_H H ]4\2^*-(\(Z4-2UJY-O;&01*PC9R6.2  H/8'\
MJ@7QKX=/A>'Q(^J0Q:3,"8YY04W$$@@*1DG(/ &>*X+]HK_DG-K_ -A.+_T7
M)7G/PU^'>I_$6SL[C7+V>+PWI@:&VB0X,A+%F">@R>6Z] .G !ZM'\>O CW?
MDF]NT3./.:U;9]>/F_3O7H6G:C9:M817VGW45U:RC*2Q,&5OQKR_Q5\"/"UW
MX?N!H-E)8ZG%&6@99W<2,!D*P=CP>F1C'Z5QG[.7B*XBUK4O#DK$VTT)NH@3
M]R12%8 >X;G_ '10!]&US'BCX@^&?!Q$>L:FD=PPW+;QJ9)"/7:.@]S@5<\8
M:^OA;PCJ>M,H8VL!9%/1G/RH#[%B!7S9\,?!,WQ1\4ZAJWB"ZFEM(&$ET^XA
MYY&SA0>PXYQT& ,9X /;M%^-'@G6[U;./4GM9G.U/M<1C5CG^]T'XD=:\;^(
MO/[1D1'_ #^V'_H,5>H^(?@+X0U/36CTFVDTJ]5?W4T<KR*3V#JY.1],'WKP
M*+3-6T7XI:9IFMES?6FH6L3%GW90,@3![KMVX]L4 ?:%%%% !1110!C^)?%&
MD>$=*&I:U<FWMC((E81LY+')  4'L#^549_B!X8MO"D'B6;5$32[@'R9&1@T
MA!(*JF-Q.0>W;TKB?VBO^2<VO_83B_\ 1<E>8?#7P+J/Q+:V&K74T7AW1U,,
M83@L68N43MG+99NN,#TP >Z^%?BKX6\8ZJ=,TRXN!>;6=8YX2N]1U(/(_/!K
M<\0>+= \+0K)K>JV]GN&51SEV'J$&6/X"L'P[\)O"_A;Q#%K6D174-Q%&T8C
M:<NAW#!)!R<_CBL36O@II_B;QW?^(=;U2XFMK@H8[.(;"NU57#.2>.#P /K0
M ]OC]X&6;8)[YEY_>"U.W]3G]*[3PWXPT#Q=;//H>I1703'F( 5=,_WE8 CZ
MXQ6 _P &_ +V9MAX?B52.'6:3>..N[=FO";&SG^&?QXMM,M+N1K=+Z* NQ^_
M;S;>&Z D!Q[97- 'UC7,6?Q"\,ZAXME\+VU^7U:)W1HO)<#<@)8!B,9&#W[5
MT]?'>M-K/_"Y];A\/M(NJ7&IW5O"8CAOG9E;![<$\]NO% 'T;XD^+7@_PO=O
M9WFI&>[0D/!:(9&0^A/W0?;.:L^%_B;X4\7W/V32]3'VSDBVG0QNP']W/#?@
M37)^&/@'X7T[2U&OQ/JNH.,ROYSQQH>X0*0<>YR>_'2O)_BGX)'PT\5Z?>Z'
M/-':7&9[5F;+0R(1E<]P,J03ZXYQF@#ZRJ*ZNK>RM9+JZGC@MXE+22RL%51Z
MDGI5#PUJ_P#;_AC2]7V!#>6L<S(#D*S*"1^!R*\$_:"\67=[XB@\)6;R"VMU
M22XC3/[V9^5!'< %2/=O84 >BWGQW\"6MT85OKFX .#)#;,4_,X)_ 56^(OB
MG1/%?P6UZ\T34(KN)5A#A<AD/G)PRG!'XBHO"OP(\+6&APIK]F=1U*1,SN9I
M$1"?X4"D<#ID\GVSBO.OBA\)I_!-E<:QX=N;A]%F BO('?+1 L",G^)-P7KR
M#CKUH [7]F[_ )$W5O\ L(?^TTKVBO%_V;O^1-U;_L(?^TTK<^-GC>X\(^$X
M[;3I3%J6INT44BG#1QJ!O8>_*@>F[/:@#<\1_%'PAX6N&MM0U9&NU.&M[=3*
MZGT.WA3[$BL6R^._@2[G$3WUU:Y) >>V;;^:YQ7 _"7X.:=KNBQ>(_$RR7$5
MR2;:TW,@*@XWN003D@X'ISSGCNO$/P+\'ZKI<D6F69TN] /E7$4CL ?]I6)!
M'Y'WH ]'LKZTU*SBN[&YBN;:4;HY87#*P]B*6\NX+"RGO+J01V]O&TLKD$[5
M49)X]A7S-\'?$>I>#OB))X2U!V%K=7#VLL).1'<+D*R_4C;[Y'H*^@_&G_(B
M^(?^P9<_^BFH K>'/'WAOQ79WMWI6HAH++'VAYD:(1@@D$E@!C@\^U<Y>?'3
MP)9WQMAJ%Q.%.#-!;LT8_'C/U -?/?P^\-Z[XTO)_#FG73VVFS,D^H2?P*J9
MVD_WC\QPO<\]LCWY_@+X';1OL26ERMUL(%]]H<R;O[Q7.S\-N* .ZT'Q'I'B
M?3A?Z-?Q7=OG:60X*GT93RI]B*YWQ-\5_"'A2[:SOM1,MXAP]O:H9&3V8] ?
M8G-?,VD7/BOPAXKU/PYH5Q(FHW,K:<ZP]78/@%?0\'#=@37N?A;X">&['2@?
M$D;ZIJ4HW2MYSHD9/4+M()^ISGKQ0!V?A3XB>&?&;R1:/J >YC&YK>5#'(!Z
M@'J/IG'>NIKY(^(GAA_A7\0;*ZT2>18#MO+-G;)C(;!0GN./Q#8.>:^KM.O%
MU'2[2^1=JW,*3 9S@,H/]: .9U;XA^$=(\51:%J%Z$U4LB!?L[MM+XVC<%P,
MY'?O76R2)%&TDC!40%F8] !WKY:^)G_)PG_;W9?^@1U]2NBR(R.H96!!![B@
M#@?^%V_#S_H8?_)*X_\ C='_  NWX>?]##_Y)7'_ ,;J _ KP 23_94XSV%W
M+_\ %5X?\4-"\-:=XMMO#/@[3I&O$81W#"9Y"\K$!8U!.,CO[G'8T ?4VAZ[
MIOB328=4TFZ%S93;@D@5ES@D'A@".0>HI^K:QINA6#WVJWL%G:IUDF<*,^@]
M3[#FLGP'X9_X0_P7IVBM())84+3.#P9&)9L>P)P/85\_:A<:A\;/BS_9L5T\
M>CV[/Y6WE8K=3@R ?WFX_%@.@H ]7G^/G@6*X,:75[,H)'FQVK;3^>#^E=CX
M;\9>'_%UNTNB:G%=;!EX^5D3ZHV"![XQ6%;?!SP%;V0M?[ BE& &DEE<R,?7
M=NX_# KPWQOH-U\'/B'8ZCH%Q(+64>=;AVR=H.'B?U'3\".XS0!]65EZ[XCT
M?PS8&^UG4(;.WS@-(>6/HJCEC[ &K>G7T6IZ9:7\!)ANH4FCS_=901^AKY4U
M>YU'XQ?%L6,-RR6C3/%;$@E8+=,DOCU(&?<D#/2@#VB#X\^!)KL0->W<2DX\
MZ2U;9^F3^G>N(_:+OK34M*\*WEC<Q7-M*;EHY8F#*PQ'T(KN_P#A17@,Z7]C
M_LV<2[<?:Q<OYN?[W7;GVVX]J\ ^(_@?5? 6H0Z;/=/<Z1*SS6,N<*3P&!7L
MWW<^O'X 'T_\-_\ DFOAS_L'P_\ H(KJ*Y?X;_\ )-?#G_8/A_\ 01744 %%
M%% !7.>(_'GACPHVS6=8@MYL9$ R\GM\B@D?4C%='7DD'P&T>[\2:EK'B'4+
MC4C=W4DZ6Z$Q* S$X9@2S'GL10!;3X_>!FEV&>^1>/G:U./T.?TKO="\0Z1X
MET\7VC7\-Y;YP6C/*GT8'E3[$"N3O_@OX$O;!K5-%6U8J0D\$KB1#ZY)(/X@
MUXS\)9;SPC\:Y/#K7!:%YKBQN,9"R&,,5;'U48]F/K0!]2UC>(?%FA>%+5;C
M6]3@LT?.Q6)+OCKM498_@*OZGJ$&DZ5>:C<DB"T@>>3'7:JEC^@KY7\,Z1J/
MQJ^)%U=:M<R1VJCSIV3GRH@<+$F>!UX^C'D]0#V:+X]> Y)Q&U[=QJ3CS&M7
MVCWXR?TKO-/US2]5TG^U+"_@N;':6,\3Y4 #)SZ$=P>17%S? [P#+8FV72)(
MGQ@3I=2>8#Z\L0?Q&/:F?#KX82>!+S7H7U%;W2[]8UAC8$, -V[>.F<,!D=>
M>!0!YA\</'GAKQAIFD0Z#J7VN2WFD:4>1)'M!4 ??49Z=J[+P!\6/!&B> ]&
MTW4=;\F\M[<)+']EF;:<GC*H0?P-<3\;/A_X=\&:=I,^AV<EN]S-(LFZ9WR
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OFO3/^3JW_P"OV?\
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MW_DD.N_]N_\ Z/CKRSX >';O5O%]YXLNU8PVH=4E(_UD\GWL?12V?]X5[/\
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MG_ZYXKYW^%5I?>-_C(_B&=#Y<$TE_<,.BEL[%!^I&/93Z4 ?1?C3_D1?$/\
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MZ]KY8T;_ ).:D_[#=S_-Z^IZ^6-&_P"3FI/^PW<_S>@#ZGKP?]I?_D'^'?\
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MG5O_ -?L_P#Z(:@#Z4HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^;/%7
M_)TEG_U^V7_HN.OI.OFSQ5_R=)9_]?ME_P"BXZ^DZ "BBB@ KE?&_@#1?'FG
MI;ZFCQSPY,%U"0)(\]1SP0>X/Z'FNJHH \ 7]F<?:OF\5$V_7BQP_7I_K,=.
M_P"E=Q/\&/#R>![GPWISRVC7+QO-?.HDED*'(W=!CV&!7H]% '/>"?"L?@OP
MM;:'%=/=+"SMYK(%+;F+=,GUK6U32['6M-GT[4K6.YM)UVR12#((_H?0CD5;
MHH \-UC]FW3;BX>31]>GLXR<B&X@$P'L&!4X^H-+HW[-NF6]PDNL:[<7D8()
MAMX1"#[%B6./I@U[C10!3TO2K'1=-@T[3;6.VM(%VQQ1C@#^I]SR:N444 >/
M>+?V?M'US4I;_1[\Z0\I+/ (!)$6_P!D9!7/IR/04GA;]GO0]'O([O6KZ35W
MC(98/*\J'/\ M#)+?F!Z@U[%10!YU%\)K2'XG#QHNJ2AA(9!9B$!0?+V8W9Z
M?A7HM%% 'E_A;X):-X?N-5-[=MJMKJ,!@>WFA"!5W!LY!SD$#!&,=:Y?5/V:
M[66\:32O$4EO;,W$5Q;>8R#_ '@PS^7XU[Q10!YMX%^#&A>#+Q-1EFDU/4T_
MU<\R!4C/JJ9.#[DGVQ7I-%% 'F?B/X.V?B+Q^GBJ35YX7$D,C6ZP@@F,*!AL
M\9VCL:],HHH Y+QK\.M \=VZ#4X7CNXAB*[@(61!Z$X(8>Q_#%>63_LSGS_]
M'\4@0D])+'+*/P?G]*^@** /&]"_9T\/6$Z3:MJ5WJ90Y\I5$$;?4 EL?1A7
MLE%% !1110!ROQ \$P^/?#J:3->O9A+A9Q*D8?D!AC!(_O&N=OO@EX>U+PCI
MVC7,LOVS3XC'%J,:A9""Q;#+T*Y)X/3L1DUZ910!X#;_ +,ZBZ!N?%):W!Z1
MV6UV'U+D#]:]A\*^$='\&:2-.T>W\N,G=)(YW22M_>8]_P"0[5NT4 4]6T]-
M6T:^TV1V2.[MY(&=>JAU*DC\ZXOX<_"VW^'ES?SQ:I+>O=HB$/$(PH4D^ISU
MKT"B@#$\7>'(O%OA:^T*:X>W2[50944,5*L&'!Z\J*R?AWX @^'VE75C#?R7
MIN9O-9WC"8X P "?2NQHH Y7Q_X)A\>^'4TF:]DLPEPLZRH@?D!A@@D=F-6/
M!'A.+P3X7@T2&[>Z6)W<RN@4DL<]!TKHJ* "O-/!?P?M/!GBV;7H=7FNF=)$
M6%X0NT,0>2#SC'H*]+HH *\F\9? ;1/$NIRZEIU[)I-U,VZ94B$D3L>K!<@@
MGO@X]J]9HH \0T#]G'2[.\2?7-8EU"-3G[-#%Y*M[,VXDCZ8/O73:[\'=.U?
MQAI>O6]^UC%IX@5+.*!=F(FR #D8';H:])HH "0!DG KY4FTX_%GXYWSV"9T
MYKA6FF'*B"(*F[_@048]V%?2'B_3=3UCPIJ.FZ/=16M[=1>4LTN=JJ3ANG.=
MN0#ZFL;X:_#ZV\ : ]KYB7&H7+;[JY5<!B/NJ.^T G\23WQ0!VE%%% '*^/_
M  3#X]\.II,U[)9A+A9UE1 _(##!!([,:L>"/"<7@GPO!HD-V]TL3NYE= I)
M8YZ#I7144 %><^//@YH?C>].I">73M38 //$H=9 !@;D.,G'&01^->C44 >$
M:=^S9;1W:MJGB2:XM4;B*"V\MF'^\6;'Y?C73:I\$-#N]?TC4=.NFTVWTU(E
M%K%$&$FQR^2Q.<G/).:]1HH *\SM/@[9VGQ)?QB-7G9VNY+K[*81@,^<C=GI
MECVKTRB@ KB/B-\.8/B':V$,VHR61LW=E9(@^[< """1Z"NWHH R_#FBIX=\
M.:?H\<S3)9PK$)&&"V.^.U5_%?A+2/&6C/IFKP%XL[HY$.'B;^\I[']#WK<H
MH \!G_9G4W6;?Q25MR3Q)9;G4=N0X!_2NWTGX,>'=&\,:EI=LTK7FH6S6\NH
MR@-(H/91T SV'7N37H]% ''_  [\!0_#_1[K3X;][W[1<>>7>,)CY0N, GTK
MK+BWAN[>2WN(DFAE4I)'(H964\$$'J*DHH \7U_]G/1+^Z>?1=4GTP,<^0\?
MGHOLN2& ^I-9VF_LTVJ3*^J>))9HL_-';6PC)_X$S-_*O>:* ,KP]X;TGPKI
M*:;H]HMM;*=Q )+.W=F)Y)JSJVGIJVC7VFR.R1W=O) SKU4.I4D?G5RB@#S_
M .'/PMM_AY<W\\6J2WKW:(A#Q",*%)/J<]:] HHH \U?X/VC_$L>,O[7G#_:
MA<_9?)&-P'3=GIGVKTJBB@#@?B/\+[?XARZ?++JDMBUFKJ-D0D#AL>XQ]VNR
MTC3TTG1;'38Y&D2TMXX%=A@L$4+D_E5RB@#S/Q'\';/Q%X_3Q5)J\\+B2&1K
M=8003&% PV>,[1V->AZC8Q:GIEW83EA%=0O"Y4X(5E(./?!JS10!XA_PS7H_
M_0P7W_?E*3_AFO1_^A@OO^_*5[A10!RO@'P-:^ =#GTRTO)KI9K@W#/* ""5
M5< #_=%,\:_#K0/'=N@U.%X[N(8BNX"%D0>A."&'L?PQ76T4 ?/\_P"S.?/_
M -'\4@0D])+'+*/P?G]*W-"_9T\/6$Z3:MJ5WJ90Y\I5$$;?4 EL?1A7LE%
M!7#>/?A;H?CW9<7+26>HQKM2[A )*_W7!^\/R/O7<T4 >!VG[-$2W8-YXH>2
MV!&5ALPCL._)<A?R-=EK_P %]!U3PI9>'],E;2X;6?SS*L8E:9BI4ER2,GW[
M=,8KTJB@#-\/Z0F@>'=/TB.9IDLK=(!(PP6VC&<=J\#^/^HGQ#XTT3PQIL1N
M+VU5@53DF28IA/KA5/\ P*OHTYP<8SVS7F7@3X67.A^+=0\5>(KZWU#5[AW:
M(PJ=D1<G<W/?!VCT&?7@ [#P7X>'A3P=I>B;P[VL.)&7H78EG(]MS&MZBB@
MKRGQG\"=#\4:I+J=C>RZ5=SL7GV1"6-V/5MN1@GO@X]J]6HH \/T3]G'3K>\
M2?7-;FU"),?Z/#%Y(8#L6W$X^F/K740?![2[/XBV_BNSO6MHH"ACT^.!0B[8
MP@ ;/3C/2O2** "O._'?P=T'QM=G4/,DT[4V&'N(%#+)Z;T/4^X(->B44 >
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M]H+_ )*'H'_7HG_HUJ^CZ /G#]GW_DH>O_\ 7H__ *-6OH^OG#]GW_DH>O\
M_7H__HU:^CZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "OFO3/\ DZM_^OV?_P!$-7TI7S7IG_)U
M;_\ 7[/_ .B&H ^E**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /FSQ5_R
M=)9_]?ME_P"BXZ^DZ^;/%7_)TEG_ -?ME_Z+CKZ3H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OFOXP_\
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M_:4>,^)-$C _>+:.6^A?C^1KW?P=$\'@C0(I<^8FFVZMD=Q&H- 'R;>:+?\
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MFM]J/F(C?[*'CWYR?2K/@#PQ=>$/"5OH]Y?_ &Z:-W<R\X&YLX&><5Y+XO\
MBWXFU_Q>WA?P$NW$I@$Z(K23L/O$%N%08//H,Y% 'NT^E:=<V1LI["UEM6&T
MPO$I0CTQC%?+UK9IX)_:*M]/TXO';KJ<<**&Z1S!?E]P!)C\*[1?A9\4M2C#
MZEX\DA+#)B2\G8 ^A P/RKSB/1[[0/CGI.EZE?M?WD&KV0DN69B7RT;#EN>
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M#IL_@SXM1:[8C8+EX]0A(Z"53\X_[Z&3_O5].:7J,&KZ3::E:MN@NH4FC/\
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M>"YAMV1G&Q"!&&"\X "UZ-_PO3QW_P!"C!_X#3_XT <SXXAE^''QP_M2V0K
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M -%FOF3X4^!)/'NO-;74LBZ-8D3705\;BW"J/0MM.3Z*?:OIOX@_\DY\2?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#YP_:"_Y*'H'_ %Z)_P"C6KZ/KYP_
M:"_Y*'H'_7HG_HUJ^CZ /G#]GW_DH>O_ /7H_P#Z-6OH^OG#]GW_ )*'K_\
MUZ/_ .C5KZ/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *^:],_Y.K?_ *_9_P#T0U?2E?->F?\
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M!PZY&/P-=_%^TO:,%\[PO,AS\VR]#8^F4&:/V=M T>YTC4]:GCBN-4%R;?\
M> ,8H]JG(!Z;B3S_ +./6O;9=+T^=-DMA:R(?X7A4C^5 '%^#/B_X9\9WBV$
M#366HOG9;72@>9@9.U@2#].#[5R'[2.DW5UH.C:I#&[P64TB3%>0GF!=I/ME
M,9]_>O-_B=8Z=H_Q=6#PI%'%*DD+"&WX6.YS]U0.G.W@="37UC<VMO>VTEM=
M01SP2J5DBE4,K ]B#P10!Y'\+OBGX4A\"Z=IFI:E#IUY8Q>2\<^5#@9PRG&#
MD=NN?PSS7Q<^*EAXHT:?PSX9B>_A;$UW>"-@JI&0WRCKU RQXQTSG([N]^ _
M@6\N3,EG=6N6W&."X(4^V#G ^F*Z+3OAUX5TK0;O1K/28X[6\B,5RVYC)*I]
M7SN_7 [4 <1^SC_R3S4/^PK)_P"BHJC_ &D/^1%TS_L)K_Z*DKTKPQX4T?P?
MICZ=HMLT%M)*9F5I&<ER "<L3V4?E7FO[2'_ "(NF?\ 837_ -%24 <+\+/B
MM/X(L[?2?$%O.VA7 :6TG5,M%\[!BH_B3<&SCD'/7I7I/BCX[>%=.T.670[W
M^TM1=,01"%U52>C.6 P!Z=>W'6F?#3PMHOBOX):%9:WI\5W$IN"A;(9#Y\G*
ML.1^!JW:? 7P+:W0F>UO+E0<B*:Y.S_QW!/XF@#SCX ^%;S5/%4_BV]1S;VH
M<12O_P M9W!#$>N%+9]V%>U_$3PNWC#P1J&D18%RZB2W).!YBG*C\<8_&NCM
M+.VL+2*TL[>*WMXEVQQ1*%51Z #I4U 'RQ\*?B,?ASJ5[H7B"VGCL9ILR?*=
M]K*!@DIU(. #WX'6O9[SXU^ K2T>==;^T,!D0PP2%V]AE0/S(K8\3_#SPMXO
M?S=7TJ.2YQ@7,9,<OMEEQG'H<BN7M_@#X&AG\R2"^G7=GRY+HA?I\H!Q^- '
MD-K;:G\;OBH]XUO)%IB,GFGJ+>V4\+G^\W/XDGH*^K418T5$4*JC  Z 51TC
M1=,T&P6QTFQ@L[9>1'"FT$^I]3[GFK] 'RYX&_Y.9D_[">H?^@35]1UR>G_#
M;PMI?BM_$UI8.FJ-))+YIG<@/("'(4G'.YOSKK* //?C)X/G\7^!Y$L8S)J%
MC)]I@C YD !#(/<@Y'J0!7F/PA^+ECX7TW_A&O$IF@MHI&-O=;"PBR<F-E R
M!NR<C/7FOI"N/\1_"[PAXIN7N]1TE!=ORUQ;N8G8^K;>&/N030!%<?%SP';1
M&1_$=LP':-7<_D%--\&_%#1O'.MWVGZ3;W82TB$OGS*%#C..!DG\ZQK?X ^!
MH) TD%_<#.=DMT0/I\H!_6NZT+PQHGAFV:WT73+>R1L;S$OS/CIN8\M^)H U
MJ*** "OD?P/J<7PR^+,JZ_%+'' TMK,Y4LT8;I)@<D' /'4'C-?7%<SXI^'_
M (9\8E7UC34DN$&%N(V,<H'IN'4>QR* ,G5OC'X'TO3FNEUF*]?;E(+4%W<^
MGH.G<BOGJVUJ\\2?&O1-=O;/[*^H:M:31QX./+$B(N">O"]>Y!KWO2?@?X'T
MJ\6Y.GS7CJVY4NYBZ#_@(P#^.:W]1^'WAK5/$MEX@NK G4;+RS Z2NJKY9RG
MR@XX/M0!T]?&-_J.K:1\6M7U'1 YU"UU.[FC")N^56<OD=QLW9]LU]G5\M^!
MO^3F)/\ L)ZA_P"@34 >I>'/CQX1U33$DU:Z;2KY5_>PR1.ZD]RC*#D>QP?:
MO)?BGX\?XF>(K#2- MYI;*!RELNTA[B5L#=M[#C S[D]<#VK7/@KX*UV]>\>
MPELYI#N<V<OEJQ]=N"H_ "MGPM\._#'@YVFTC352Y88-S*QDDQZ GH/IB@"U
MX*\.KX4\&Z7HN0SVT/[UEZ&1B6<CVW$_A7SW^T5_R4:U_P"P9%_Z,DKZCKY<
M_:*_Y*-:_P#8,B_]&24 =MX&^.%M;6_]B^.O.L=3M#Y373Q,1(1QB10,J_J<
M8/7BLKXN_&+2=7\/2^'O#4[70NL"ZNMC(JH"#M7(!)..3TQZYX]6\5?#;POX
MRE%QJNGC[6!C[3 QCD(]"1PWX@XK,T#X,^"O#]XEW%ISW=Q&<H]Y)Y@4^NWA
M<_A0!C_ ;PA<>'?",^IWT317>JNL@1A@K"H.S([$[F/T(JE^TA_R(NF?]A-?
M_14E>R5B>*/"6C>,=.CL-;MFGMXY1,@61D(< C.5([$T <U\$O\ DD.A?]O'
M_I1)7H%9VA:'I_AO1;?2-+A,-E;AA&A<L1EBQY)).22?QK1H ^4O&NEZG\*_
MBPFNV4!-H]RUW:.<A'5L[XB>W!9?7!![U[/I/QO\#ZCI\5Q<ZH;"<@>9;SQ.
M60]QE5((]Q^E=SJNCZ=KM@]CJEE!>6K]8YD##/J/0^XYKSVY^ 7@:>X\R.WO
MK=<Y\J*Z)7Z?,"?UH \Z^+?Q4MO&EM!X9\,)<7%O),IEE\L@W# _(B+U(S@\
M@$D#\?7?A3X-D\%>"8+.Z4#4+ES<W0!SM<@ +GV  ^N:N^&?ASX5\(R";2=*
MC6Z Q]IE)DD_ M]W\,5U5 %;4;"#5-,NM/NEW6]U"\,B^JL"#^AKXUMM6U3P
M#>^*-!&1)<PR:=-S@##@;Q_P'<!_OU]IUQ6O_"CP?XFU>75=2TQGO)@/,>.=
MTWX& 2 <9P!0!R_[/?AS^R_!4^L2IB?5)LJ2.?*3*K_X]O/Y5Z9K^D0Z_P"'
M]0TB<[8[R!X2V,[<C /X'!_"K&GV%KI6G6]A90B&UMHUBBC&2%4# '-6: /D
M_P #>*+_ .#WC>_TW7;.;[-+B*ZB3J,'Y94S]X8)QTR&KWN/XN> Y;83CQ';
M*I&=K*ZL/^ E<UL>(_!OA[Q;"L>MZ7#=E!A)#E9$'H'4A@/;.*XH_L_>!_.+
M[-1"_P#//[3\O\L_K0!;MOC5X6U+Q1I^A:3]KO9+R81?:%BV1H3_ +V&/Y5V
MGB+2$U_PYJ6D2-M6\MWAW?W200#^!P:R_#OP\\*>%95GTG1H(KD#BXD)DD'K
MAF)(_#%=/0!\E?#OQ9<?"GQS>V6MVLJ6\A^S7L8'S1E3E7 _B R?J&R*]KUC
MXZ>"=.TUKBROWU&X*YCMH874L>VXLH"C]?8UT?BKX>^&?&1236-.62X0;5N(
MV,<@'IN'4>QS6%H_P1\$:/>+=#3Y;V1#E!>2^8@/^Z, _B#0!\W>+]3U[Q!K
M]OXAUV%XCJ.'M5(PHA#8 4==O7GOR>]?:M<OXE^'OAKQ;>6EUK%BTTMJFR(I
M,\8"YSC"D5U% !7GWQH\1_\ "/?#>^6-]MSJ&+.+'7YL[S_WP&_$BO0:Y_Q5
MX*T+QI!;0ZY:O.ELQ>+9,R8)&#]TC/04 >8?LX^'OLV@ZEX@E3$EY*+>$G_G
MFG+$?5CC_@%>WU0T;1K#P_I%OI6F6X@L[=2L<8).,DD\GDDDD_C5^@#(\4Z'
M'XD\+:GHTN,7=NT:D]%?&5;\& /X5\Y_ 779-!^(,^AW>8TU%&A9&XVS1Y*Y
M_P#'Q]2*^HZXT_"SPC_PE/\ PD8TYUU+[3]KWK.X7S<[MVW..O..E '&_M(?
M\B+IG_837_T5)7"_"SXK3^"+.WTGQ!;SMH5P&EM)U3+1?.P8J/XDW!LXY!SU
MZ5W7[2'_ "(NF?\ 837_ -%25<^&GA;1?%?P2T*RUO3XKN)3<%"V0R'SY.58
M<C\#0 _Q1\=O"NG:'++H=[_:6HNF((A"ZJI/1G+ 8 ].O;CK7 ? 'PK>:IXJ
MG\6WJ.;>U#B*5_\ EK.X(8CUPI;/NPKT>T^ O@6UNA,]K>7*@Y$4UR=G_CN"
M?Q->CVEG;6%I%:6=O%;V\2[8XHE"JH] !TH P?B#_P DY\2?]@RX_P#19KR/
M]F7_ )FG_MT_]K5[OJ.GVVJZ;=:?>Q^9:W430RIN(W(PP1D<C@]JQ?"G@;0/
M!2W:Z':/!]K*&8M*SEMN=OWB<8W'\Z .CHHHH *\5^./Q+O/#X7PQH[-#=W,
M/F7-TIPT<;$@*GH3@Y/8=.3Q[57+>(OASX3\6:BNH:WI(NKI8Q$)!/+'\H)(
M&$8 ]30!X)\*?$?@'P8G]JZQ/<W&MN"%VVI9+9?13W8]S^ [D^J?\+^\#?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KYKTS_DZM_P#K]G_]$-7TI7S7IG_)U;_]?L__ *(:@#Z4HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXUH:9XL\.ZS+Y6FZYIUW+_SSAN49_P#OD'- &Q1110 44CNL:,[L%11EF8X
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M% 'MM%4])U6QUS2[?4]-N%N+.X7?'(O<?0\@YX(/2KE !1110 4444 %%%%
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MNT@8X!SUH ])HJGI-]_:FC6.H>7Y?VJWCGV9SMW*&QGOC-7* "BBB@ HHHH
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M^&/_ "3+P[_UY)6UX@@DN?#6JV\0)DELYD0#KDH0*Q?AC_R3+P[_ ->25UE
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M[<GAE8=^ >^#P1U%=_JW[0L^IVJV'A70+G^U;GY(VFQ(48_W47.\^F<?0]*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMN3@$CJ[?[(X]SD#W'C6ECXO_$V-]3M-5N;*Q+$(Z7!M(F]0H3E@.F3GZYH
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MF21VVJ32/@>JO@-@=N?:@#Z2HKQWX,?%._\ %TT^A:ZR2:A#%YT-RJA?-0$
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M'/7.<@ ]XHHKY@TKXO:OX=\=>()]8U"]U"TC^T1VUDS_ "&02 (/10 #R.U
M'T_17S<UA\9O'EM_;D5W<V%M(-]O;0W9M R\$;5!!(]"Y_&HO OQ>U_PMXC?
M1/&UQ<36:L8I7NE+36KCOG&YAV(.?4>X!]+45\\7?B[XB?%?4;B+P8D^EZ+
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M71O^OUO_ $ UT/P3\:?\)3X,2SNI2VI:7M@F+')=/^6;_D,'W4GO7/?M)_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF 2&X7MD'/%85BMI-J4*ZG//%:M(//EB02.H[D D9/XU]8_ [_DDFD?[\_\
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M(_"KE]8VNIV,UE?6\=Q:S*4DBD7*L/<5X_\ LZ^(OMOA:^T&5\RZ?-YD0/\
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M3X$@M+= D<:#@#^I]^]>;_M 6D-Q\,WGD0&2VNXGC;N"25/Z,:]3KS/X]?\
M)*[S_KXA_P#0Q0!3_9YF:3X;2HQR(M0E1?8;4/\ ,FO5W=8T9W8*BC+,QP /
M4UY)^SK_ ,DYNO\ L)R_^BXZY?\ :)\6W\6H6GA:VE:*R>W6YN0O!E)9@JGV
M&W./4^U 'J5_\6/ FFR-'<>)+1F7KY :8?F@->-?&OQ_X8\9Z/I<.BW3W%S;
M7#,VZ!TPA7!P6 [@5Z'X5^!?A/3M(MSK%FVI:@\8::265E16/)"JI Q]<FN+
M^._@_P .^&_#VESZ-I-O932W91VB!!9=A./SH ]2^$3M)\*M 9CDB!E_ .P'
MZ"O*?VEO^0SH'_7O+_Z$M>J?!_\ Y)1H'_7)_P#T8]>5_M+?\AG0/^O>7_T)
M: /=/"?_ ")NA_\ 8/M__1:UL5C^$_\ D3=#_P"P?;_^BUK8H **** "BBB@
M#YL\5?\ )TEG_P!?ME_Z+CKZ3KYL\5?\G26?_7[9?^BXZ^DZ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#C_(QWH ^=/V;_\ D>M3_P"P8W_HV.OINOF3]F__ )'K4_\ L&-_Z-CKZ;H
M*YOX@_\ ).?$G_8,N/\ T6:Z2N;^(/\ R3GQ)_V#+C_T6: /(_V9?^9I_P"W
M3_VM7>?''_DDFK_[\'_HY*X/]F7_ )FG_MT_]K5WGQQ_Y))J_P#OP?\ HY*
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M(KYW^*OPJC\ PV_B'P_?7"VAN GEN_[RW<@E65QC(XQZCCD]@#Z?KY8^(/\
MR<@?^PA8?^BX:]U^%GB2Z\4_#W3=1OFWW@#0S/C&]D8KN^I !/N37A7Q$!C_
M &C=[C"F_L&!]MD7^!H ^IZXWQG\3?#_ (%O;:TU87;37$9E1;>(-A<XR<D=
M\_E795B:YX0\/^)98I=9TFVO9(5*QO*O*@\XS0!P7_#0W@K_ )Y:K_X#K_\
M%UWWA;Q1IWC#0H]7TOS?LTCLF)DVL"IP<C)K)_X57X&_Z%FQ_P"^3_C71Z5I
M&GZ'IZ6&EVD5I:(25BB& "3DF@"[1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'SA^T%_R4/0/^O1/_ $:U?1]?.'[0
M7_)0] _Z]$_]&M7T?0!\X?L^_P#)0]?_ .O1_P#T:M?1]?.'[/O_ "4/7_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#>B6ND:?X:U%;2V4K&'T>5C@DGD[?4FKL^M?''Q1&;..PU*RC<;6V6@M"?\
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MS;X,\/ZU;?M%RWL^D7\5H-0OG-P]NXCVLDNT[L8P=PP>^17TE110 4A 8$$
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M/_1K5]'T ?.'[/O_ "4/7_\ KT?_ -&K7T?7SA^S[_R4/7_^O1__ $:M?1]
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7S7IG_)U;_]?L__ *(:OI2OFO3/^3JW_P"OV?\ ]$-0
M!]*4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q^C_  R\
M,Z%XID\1V-M.NH.TC9:=F52^=V!^)Z^M=A10 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!\V>*O\ DZ2S_P"OVR_]%QU])U\V>*O^3I+/_K]L
MO_1<=?2= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5\U_&'_DN>A_[EI_Z-:OI2OFOXP_\EST/_<M/_1K4
M ?2E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A 92K $$8(/>E
MHH Y[P]X'\-^%+NYNM$TQ+.:Y 64K([ @'. &) 'TQ3_ !9X/TCQII<>GZS%
M))!'*)D\N0H58 C.1[$UO44 9OA_0;#PSH=MH^F1M'9VP81JSECRQ8DD^I)/
MXUI444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 4444 %%%% 'S9XJ_P"3I+/_ *_;+_T7'7TG7S9XJ_Y.DL_^OVR_]%QU])T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?AW?8;Z3[4X'\2.<3+[G.YA]5H ^EZ*9%*DT22Q,'C=0RL.A!Y!I] !1110
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MG;N4'&?QJU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)GCC0G^%0A!./4GGVZ5P_P 6?A5:^"+2W\2^&9KF"WBF598C(2T#?PNK]<9
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MC7#6]UX@@>9205MT>;!'490$ _C6CX>\?^%?%,QAT;6K>YGY/DD-'(0.I"N
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?->F?\G5O_ -?L_P#Z(:OI
M2OFO3/\ DZM_^OV?_P!$-0!]*4444 %%%% '(S>(O R>,UTZ6;3?^$B\Q4&;
M<&7>1P-^WKC'>NNKY<U/_DYU/^PQ!_):^HZ ,'3/&GAW6=:N-'T[58;C4+?=
MYL* Y&TX;DC!P3V-4->^)W@WPW>-9ZGKD*72G#0Q(\K(?1M@.T^QQ7S!9SZ^
MOQ%UBR\-&0:CJ%Q<6BF/A@K298@_P\+RW89KVG0OV>?#T&E@:[<W5[J,@S))
M#+Y:(?11C)^IZ^@H ]&\/>,_#OBM'.B:M!=L@RT8RLBCU*, P'OBMBYN8;.U
MFNKF18H(4:221C@*H&23[ "ODGQ9H5]\'_B1:3:;<R21(5NK21N"\>2&C?'7
MH5/J#GC-?5;):>(_#I212UEJ5IAES@F.1.1^1H ^>?C[XLT3Q*GA]-%U2"]6
M W!F$1)V9\O;GZX;\J]'\#?$3P9I?@30K&Y\06<-Q#91)+&S$%7VC<#QZYKR
M/XR_#S1? 7]B?V.]VWVWS_-^T2!_N>7C& ,??-=YX3^!OA'6?"6C:I=OJ7GW
M=G%/*$G4+N903@;>!S0![:CI)&LB,&1@"K*<@@]Q7,:]\1_"'AJY:VU77+>*
MX4X:&,-*ZGT94!*_CBN1^-/C:7P7X6M-'T>0V]]?*8TD0_-#"H )![$Y !^I
MZBN=^&_P/TJ^\/V^L^*TFN;B]431VHD:-8T/(W%2"6(P>HQG% 'I.B_%+P5X
M@NDM;#7H#</@+%.CPEB>PW@ GV&:["O!OB9\$-%L?#-WK/AF*6UFLHS-+:F1
MI$DC'+$%B2"!D]><8K?^ WC.Z\1^&;G2M1F::[TMD5)7.6>%L[<GN05(SZ8H
M ]:KD]:^)G@SP]=-:ZEK]M'.IVO'$&F9#Z,$!Q^-<C\=?'5SX9T"WTC3)VAO
M]2W;Y4.&BA'7![%B<9] :Y7X9_ [3=8\/6VN>)9+AS>*)8+2)]@$9Z%SU)(P
M1@C /OP >N:#\1?"/B6Y%MI.NVTUPW"PN&B=OHK@$_A6CKOBG0_#*P-K6IV]
MD)RPB\UL;]N,X^F1^=>3>*?V>;%H#=>$[Z:TO8SN6"YD+1L1Z.!N4^YS^'6N
M\\1?#C2_&FD:/!XCDN9+NPAVF>WEVEF*J')R#D$J#0!\_>$->TJQ^/CZW=7T
M46F&_O9!<L?DVNLH4_CN'YU](Z7\0/">M:C%I^G:[:7-W-GRXD8Y; )../0&
MOF#PSX/TS5_C(_A2Y:X&G"\NX,HX$FV-9"O.,9^09XKZ!\-_!GPKX6UZVUFQ
M-^]U;;C&)Y@R@E2N<!1V)H Z/Q9JWAC2-.BE\4R6:VCR;8Q=0^8"^#T7!YQG
MG%:&BWFF7^C6MUHSPOITB9@,"[4VYQP.,=#Q7D7[2?\ R*NC?]?K?^@&NT^#
M_P#R2C0/^N3_ /HQZ .XKD-9^*7@G0;EK:^\06WGJ2&C@5IBI'8[ <'ZUYW\
M??']UIB0^%=+N&ADN(O-O98VPWEG(6//;."3[8[$TO@;X!:2=$@O?%7GSWMP
M@D^RQR&-( 1D*2.2WKSCMSU(!Z#H_P 5/!.N7*6UEX@M_/? 5)U>$DGL"X )
M^E=C7@GQ#^!&EVF@7.J^%C-#/:1F62TED,BR(HR=I/(;&3U(/3BKO[/_ (ZN
M]7M;GPQJ4[32V40FM)'.6\K(4H3Z*2N/8XZ"@#U_6=:TWP_IDFHZK=I:VD9
M:5\X!)P!@<FH;/Q-HM_H/]N6^I6YTO!)NG;8@ .#DMC'/K7$?'K_ ))7>?\
M7Q#_ .ABO&_A]X0\0_$JQM=)FO9+3PQI;L691PSL2Q"CHS\]3PH^N" >Z?\
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ML\)1-I5DNGBRQ!+9*<B$XXP>ZGL?K5/6/C3X)TS3)+J#5DOI]A,5M;JQ9V[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&.=J*.O)/('3'/N'PR\(6_@SP9;V,5Q%=33L;B>XA.4D=@/NGNH  ![XSWH
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M#\-?\BKI'_7E#_Z *U*R_#7_ "*ND?\ 7E#_ .@"M2@ HHHH **** "BBB@
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MEKZCKY<U/_DYU/\ L,0?R6OJ.@#Y<^%W_)P,W_7Q>_R>OJ.OESX7?\G S?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ_XQV[77PFUZ-<Y$<<G'HLJ,?Y5PO[-FI6QT76=+,J"Z6Y6X$9/S%"H7('<
MKSZ9'K0![G7+_$=E7X;>(RW3^SYA^)4X_6NE2:*5G6.1':-MKA6!VGK@^AKA
M_C)?"P^%6MMGYI42%1Z[G4'],_E0!YK^S.&^V>)&'W!';@_7,F/ZU]"UX?\
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M4A\R[N /];)CM_LCH!_4FNJK/_MW1_\ H*V/_@0G^-: ((R#D4 %?-'[2/\
MR.6D_P#8/_\ :CU])275O"VV6>)&ZX9P#7S3^T;-%-XPTIHI$D L,$JP/_+1
MZ /H?PU_R*ND?]>4/_H K4K$\-WUHOA?2 ;J $64((,@_N"MN@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(T1NWNOLOV<[LL#\N[=[]<5ZK10 5P?Q/^'4GQ#T_3[>+4EL6M)6?+0^8&#
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MC?LX@WBW'B+7VN$!!:&U0@OQW=CQ^73N*]NTO2K'1-,@T[3;:.VM(%VQQ(,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5ZG<7$=K:RW,A/EQ(9&(&> ,F@#GO&7CO1O MG;7.L?:"MRY2-8(]Y) R>I
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M6%P[Z'XJC16XS(CPMCT)0G-3V?[.EW=W(EU[Q2\J@\K!$68C_?<\?D:]]HH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI*2CCVVD9KR'XU_$WP[XLT2WT/19)KIH;M;EKG84CX1UVC."3\_ICCO7;_\
M#.W@SS_,^TZQM_YY_:$V_P#H&?UKC?C5X6\,>"O!^EZ;HNGPV]U=7?F/*QWS
M.B(0<L<G&77@8' H [SX EC\+X0W07<P7GMD?US7BJ7%U\)_C+)<75L[06UR
MYVJ/];;29 9<\9VG(YZC![U[]\&M-;3?A7HR."'G1[@Y]'<E?_'=M;OBCP5X
M?\8VR0ZWIZ7!C_U<H)62/Z,.<>W2@#+MOBOX&NK,72^([.-2 2DI*./;:1FO
M(?C7\3?#OBS1+?0]%DFNFANUN6N=A2/A'7:,X)/S^F..]=O_ ,,[>#//\S[3
MK&W_ )Y_:$V_^@9_6N-^-7A;PQX*\'Z7INBZ?#;W5U=^8\K'?,Z(A!RQR<9=
M>!@<"@#O/@"6/POA#=!=S!>>V1_7->H5Y_\ "'2I;'X1Z5"',<]S%).'Q]W>
MS%3^16O.&^#WQ3+$_P#"9PG)ZG4[K)_\<H ^AZX/XS_\DDU[_<B_]')7%>%_
MA;\1M*\4:;?ZEXMCFLK>=9)XDO[B0R(#RNUE .>G)[UVOQG_ .22:]_N1?\
MHY* /#?A+\.Y/'T[2ZI=2KH.G2<P))@R2-@E0/X00!N;KT ]1]#2_#CP;+I9
MTX^&M-6 KMRMNHD'&,A\;MWOG->=_LV?\BKK/_7ZO_H KVR@#Y(M(;GX5_&R
M&TAGD:""[2(LW!EMI,=>Q.UO^^E]J^M)8Q-$\;9VNI4X]#7RU\=AYWQ:6.V)
M$WV>!?\ @9)Q^A%?4-[>6^G6-Q>W<HBMK>-I99&Z*JC)/Y"@#AO#/P9\'>'$
M#-IXU.YSGSM0 EQ]$QM'Y9]ZU_$/P\\,>(M(FL9]'LH6:,K%<00*DD)QP5(
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M>Q>-/"^@ZKHVI:A?Z197-[%8RB.>6%6=<*Q&#UX/->._LT_\AG7_ /KWB_\
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M#VF1QXVG-LC%A[D@D_B:Y7XI_%.'P%;Q65E$ESK5PGF1QR9V1)DC>V,$Y((
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M $:U?2E?-?QA_P"2YZ'_ +EI_P"C6H ^E**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ^</V@O^2AZ!_P!>B?\ HUJ^CZ^</V@O^2AZ!_UZ)_Z-:OH^
M@#YP_9]_Y*'K_P#UZ/\ ^C5KZ/KYP_9]_P"2AZ__ ->C_P#HU:^CZ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*U^W:5>6G_/>!XO^^E(_K7->"_AOH/@2:[FT@W;272JLAN)0W R1C 'K77T
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M%EDB,1@<#=&"7&XC'&UORKK*^7/ W_)S,G_83U#_ - FKZCH **** "BBB@
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M_P#7)_Y&@#GO#'Q%\,>,;^>QT2_:XN(8_-96@=/DR!D%@.Y'YUU-?,G[-_\
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M9/U- 'IM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?.'[07_)0] _Z]$_]
M&M7T?7SA^T%_R4/0/^O1/_1K5]'T ?.'[/O_ "4/7_\ KT?_ -&K7T?7SA^S
M[_R4/7_^O1__ $:M?1] !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7S7IG_)U;_]?L__ *(:OI2O
MFO3/^3JW_P"OV?\ ]$-0!]*4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9P?J!6CX;\/6'A70+71]-0K;VZXW-]YV/)9CW)/-:U% !1110 4444 %%%%
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M?M+?\@;0/^OB7_T%: .[^#__ "2C0/\ KD__ *,>NXKA_@__ ,DHT#_KD_\
MZ,>NXH ^=_VA?!5M9O:^*["%8C<2^1>J@P&<@E7^IP03WX[UZ3\&O$LOB7X=
M6<ER^^ZLF-G*Q.2VP#:3[[2OXYJM\=E1OA1J)?[RS0%/KYBC^1-<U^S87_X1
MC6@?N?;5Q]=@S_2@#V6^O8-.T^YOKE]EO;1--*WHJ@DG\A7S?\'+2?QI\6]1
M\4WJ%EMC)='/($LA*HOX#=C_ '17HGQ\\1_V/X .G1/MN-5E$( Z^6OS.?\
MT%?^!5+\!_#O]B_#R*]D3;<:I(;EB1SL'RH/I@%O^!4 >/WV?A=\>#,H,=C'
M>>8 .GV:7J!Z[0Q'U6OJX$, 000>017@W[2'AWS+72O$<2?-&QLYR!_"<LA_
M [Q_P(5Z#\(?$?\ PDGPXTV:1]US:+]CGSUW)@ GZKM/XT =S1110!D>)O$N
MF^$M!N-8U20I;PX 5<%Y&/15'<G_ .OT%>*_\+N\<Z_+,_A7P>)K2-L;OLTU
MRP'7#%" "0.GY5M?M'VMW+X.TR>)6:VAO?WV!D*2A"D^@ZC_ ($*UO@MXO\
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M1+;BJ2*RMTQ\VT?G7+?#OXGZKX&TBZL;#1H[Z.>?SF=BWRG:!CCZ5[Q\;?\
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MJY]%! QZY/>K?Q$\!Z3XUT"9+N-8KZ"-FMKQ5^>,@9P?53W!_GS0!XK^S?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$URLH !D"D87'(&X=QWH ]*HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBL3Q=XCB\)>%K[79K=[B.T528D8 L68*.3TY84 ;=%<A\//'L'Q T
M:YU"&PDL_(G,+1O('R=H.00!Z^E=?0 4444 %%%% !1110 4444 %%%% !17
M.:CX^\*Z3K8T:_UNV@U#*@POGY2W0$XP.HZGO71T %%%% !1110 4444 %%%
M% !117#_ !'^)-O\.X-/>;39;UKUI JI*$"A-N<D@_WA0!W%%9V@:O'K_A_3
M]7BB:*.\@298W.2H89P:T: "BBB@ HHHH **** "BBB@ HHHH **** "B@D
M9)P*YS1_'OA;Q!JC:;I6M6UU>*"?*3(+ ==I(PWX9H Z.BBB@ HHHH ****
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MWYH \/\ V9G7RO$R9^8-;''M^]KWVOD7P=XEU+X/^.[VVU2RE>/FWNX =I8
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M_P"22:O_ +\'_HY*P_V<?^2>:A_V%9/_ $5%6Y\<?^22:O\ [\'_ *.2L/\
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M;"8+J,_PMZ'CD9R",CL:](LOVE-(:V4W^@WT5Q_$L$B.OX$[3^E 'N%1S_\
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M[)X$_P"2>>&O^P5:_P#HI:\;_:9_X^/#7^Y<_P XJ]D\"?\ )//#7_8*M?\
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M+$MQN$-M&W1I6SC/L "3]*\-\+>%_&_Q?$^KZKXFN+731*4!)8AF')$<2D*
M..>/QYKU?XU^&[SQ)\.YH["(S7%E.MXL2_><*&5L#N=K$X[XKS/X1_%[1_"G
MATZ#KT<\212M)#<11[QACDJP'((.3D9_3D M>(OV?].T+PKJFK#7;N>:RM9;
M@*8557*J2!U)'2IOV9?^9I_[=/\ VM2^-/BY/XWLYO"_@C3;J;[7$RW5S+&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPPV5P]NTZ1*[$J2N6=_D3..!U]Z /?**^<+S1_CKIEJVH&_O9MB[GBAN8Y6
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MI46HZ5IVL6PMM3L+6]@#!Q%<PK*H8=\,",\G\ZMT4 <__P ()X/_ .A4T/\
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M0\/V4MPYW/(J;&<^I*XR?K6MH^@Z3X?M3;:1IUM91$Y98(PNX^I/4GZUHT4
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M<O<ZCX?LIKASEY0FQF/J2N"?QKIJ* ,S2?#FBZ#:/:Z5I=I:0R?ZQ8H@-_\
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M_P /Z5=W+XWS3V<<CM@8&6(R> !6Q10!S_\ P@G@_P#Z%30__!=#_P#$T?\
M"">#_P#H5-#_ /!=#_\ $UT%% %73],L-)M?LNFV-M96^XMY5M$L:9/4X4 9
MJ'4]!T?6C$=5TFQO_*SY?VJW279G&<;@<9P/RK0HH Y__A!/!_\ T*FA_P#@
MNA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@"IIVEZ?I%M]FTRPM;*WW%O*MH5C7
M)ZG"@#/%6Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^</V@O\ DH>@?]>B
M?^C6KZ/KYP_:"_Y*'H'_ %Z)_P"C6KZ/H ^</V??^2AZ_P#]>C_^C5KZ/KYP
M_9]_Y*'K_P#UZ/\ ^C5KZ/H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^:],_Y.K?\ Z_9__1#5
M]*5\UZ9_R=6__7[/_P"B&H ^E**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY^_:2T2!#HVN1HJSR%[68@<N  RY^GS?G[5ZC\*[]]2^%_A^X=R["V\DD_\
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M+F]<#!>>Z=2Q]?D*BO%?&>@:9X9^-=KI>D6WV:RBN;1DC\QGP3L)Y8D]3ZT
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M5_A;X>*G(^RX_$,0: .QKY8^ O\ R563_KTG_FM?4]?+'P%_Y*K)_P!>D_\
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M='_PI_P#_P!"Y!_W]D_^*KI="\/:3X9L#8Z-8Q6=L7,A2//+' )).23@#\J
M.2O?C5X%T^_N+.?5)?.MY&BDVVLA&Y3@X..>1UJ*+XX^ I9DC759@78*"UK(
M ,^ORU<O?@]X"U"^GO+G00\\\C2R,+J=068Y)P' ')[5'#\%_A]!/'-'X? >
M-@RYNYR,@Y'!?!_&@#O:*** "BBB@ KYK^,/_)<]#_W+3_T:U?2E?-?QA_Y+
MGH?^Y:?^C6H ^E**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^</V@O
M^2AZ!_UZ)_Z-:OH^OG#]H+_DH>@?]>B?^C6KZ/H ^</V??\ DH>O_P#7H_\
MZ-6OH^OG#]GW_DH>O_\ 7H__ *-6OH^@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYKTS_DZM_^
MOV?_ -$-7TI7S7IG_)U;_P#7[/\ ^B&H ^E**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /FSQ5_R=)9_]?ME_Z+CKZ3KYL\5?\G26?_7[9?\ HN.OI.@
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MPQ>,C:=PX.>E?4%% !7B'[1/A:6_TO3?$%G;O+-:L;>?RU+'RVY4G'8,"/\
M@=>WT4 ?+_P5T#4/$7Q(&N:K',\>G1>:99D(W28"1CZ@9/\ P&OJ"BB@#R+X
MS_"^Y\71Q:YHB*^JVT?ERP$@>?&#D8/3<,GKU!]A7"Z/\</%?A"VBTCQ%H9N
MGMP$!N=]O.5'&&)!S]<?7-?2]-DC25"DB*ZGLPR* /GN7X]^*M?)MO#/A11.
MW (WW3+] JJ,_7BO9O!+Z_+X/T^3Q0,:RRN;@;57&7;;D+P#MVUOJH50J@!0
M, #M2T %%%% !1110 4444 %?-?QA_Y+GH?^Y:?^C6KZ4KYK^,/_ "7/0_\
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M(.0: %HHHH *BN93#:RR@ E$+ 'V&:D9E52S$ #J2:@O_P#D'7/_ %R?^1H
M\C^$7Q4U[QUXEOM.U:&Q2&*T-PAMXV4@AU7'+'C#?I7LE?,G[-__ "/6I_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KYKTS_DZM_\ K]G_ /1#5]*5\UZ9_P G5O\ ]?L_
M_HAJ /I2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YL\5?\ )TEG_P!?
MME_Z+CKZ3KYL\5?\G26?_7[9?^BXZ^DZ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@"&ZM+:^MVM[NWBN(&QNCF0.IQSR#Q3
MX88K>%(88TBB085$4*JCT '2GT4 %%%% !1110 4444 %%%% !1110 4444
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M> HN?^^3\WT+5B?M)_\ (U:-_P!>3?\ H9KWGPQ%'/X(T:*5%>-]-@5E89#
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M0XSU&0?7@UV>H>/O%_Q:O8=!\&PRZ;:"%&OKC>4PQ'S;G'*IG( '+8_ =/\
MM&PH_P /[&4@;X]20*<=C')D?H/RK3^ MK!#\+K2:*%$EGGF:5P.7(<J,GO@
M "@#R'Q9\'O$W@333XAM=42Y2W8-++:LT<L63][W&>X.>>G6O7_@QX^N_&OA
MVY@U1E?4M.94DE QYJ,#M8CU^5@<>@]:[3Q9"EQX.UN&0 H]A.I!'_3-J\)_
M9J=AKNO1@_*UM&Q'N&./YF@#T[XV32V_PHU>2&5XWW0C<C$'!E0$9'M6)^SO
M<3W'P]O3/-)*4U215WL6VCRHC@9Z#))_&M?XX_\ ))-7_P!^#_T<E8?[./\
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M7M/@K7/^$D\%:1JQ;=)<6RF4_P#30?*__CP-<W\:M!_MSX9Z@R+NFL"+V/\
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M;_$/BK0_"ED+O6]1ALXF.$#9+.?]E1DG\!7GEW^T1X.MR1!;:K<GL4@15/\
MWTX/Z4 >;>$_$WB;X6_$./PYKEU-+IYF6&> R%X]KXVRQD].H/&,@$'GI]25
M\;?$_P :67C?Q;%K&G6UQ:HEJD16;&XLK,<\$]B/RK[)H ^7/'/BFY\,?'^]
MU0O<30V<L3"W64J&'D+\OL"3S^-:<'@CX@_%V+^VM<U1=/T^7Y[6WEW;-O8I
M$.@Q_$>3UYZUC^-+>&[_ &E%MKB))8)M5L8Y(W&5=2(@01W!%?5     P!T
MH ^1[VU\9?!'Q/;E+M?*F!="C%K>Z48W!E..1D ]",@@]#7U/H.LV_B'0+'5
M[7_4W<*RJ,\KD<J?<'(_"O*?VD88V\&:5,5!D34 BMW ,;DC_P ='Y5U'P48
MM\(M"+$DXG'/H)Y!0!W]%%% %;4+Z#2]-NK^Z;9;VT332-Z*H)/Z"OG#X,64
M_C'XKZCXIOEW"V,ETW<"64D(OT WX_W17H/Q^\1_V1X"&F1/BXU6418!Y\I<
M,Y_/:/\ @55/@?)H/ASP"DMWK.FPWVH3-/*DEU&KHH^5%()]!G_@5 '(_M%^
M'VLO$.F^(K<%5NX_)E9>,21\J<^I4X_X!7M_@;Q"OBGP5I6L;@9)X )L=I5^
M5_\ QX'\*Y'XLS^'O%'P[U&U@UO2Y;NW NK=5NXRQ=.2 ,\DJ6'XUR7[-_B/
M=#JOAN9^4(O+<'T.%<?GL/XF@#W'5'9-)O71BK+ Y!!P0=IKYV_9UOKNX\;Z
MHDUU/(AT]G*O(6!;S$YY[\GGWKZ(U;_D#7W_ %[R?^@FOG#]F_\ Y'K4_P#L
M&-_Z-CH ^FZ^9/CS?WEO\4+-8;N>-4LX64)(0%.]N1CI7TW7RY\?_P#DJ5M_
MUY0_^AO0!]1U\[^/?''B3QOX];P1X2N9+:V65K9VC;8977.]F<<A!@\#KC/.
M0*^B*^6O"=Y!X#^/EZFN-]GA-Q<0F:7@*)"2CD]@1MY]&H Z"[_9SU:*T:\L
M_%*3:H!N"O T88^GF;B1]<?E7 >#]%U[Q7XHF\.R>([K3=0C#XCN)9#N=#\R
M<'@C!/X&OK:\UG3=/TUM2N[^WALE4N9VD&S'L>_X5\V?#7S?%7Q\GUZQA=+-
M;FZO';&-B.'"@^Y+C]: /H_P_IT^D>'=.TZZNFNY[6W2*2=LYD90 3SS6E11
M0 444V21(HVDD=41 69F.  .I)H YWQ]K</A_P ":SJ$S %;9TC!.-TC#:H_
M,BO%OV;=)F?7-8UDH1!%;"U#D<%F8,0/H$'YBJ'Q(\67OQ6\8V?A;PPK3V$,
MI$;#A9Y/XI3Z(HS@^F3WQ7OO@SPK9^#/"]IHUI\WEC=-+C!ED/WF/]/0 #M0
M!YU^T?=&/P/IMLK$>=J"L0#U"QOQ^9'Y5N? FSCM?A3ITJ+AKJ:>9SZD2%,_
MD@KE?VE58Z%H+_PBYD!^I4?X&NU^"SJ_PDT+:0<+,#]?.>@#O:^4/CE&=-^+
MDUY#Q))%!< _[04+_P"R"OJ^OE;]H-P_Q,55Y*V,2GZY8_UH ^IXW$L22+T9
M0P_&G5#:(8K."-OO+&JG\!4DDB11M)(ZHB LS,<  =230!SOC[6X?#_@36=0
MF8 K;.D8)QND8;5'YD5XM^S;I,SZYK&LE"((K86H<C@LS!B!] @_,50^)'BR
M]^*WC&S\+>&%:>PAE(C8<+/)_%*?1%&<'TR>^*]]\&>%;/P9X7M-&M/F\L;I
MI<8,LA^\Q_IZ  =J -^BBFR2)%&TDCJB("S,QP !U)- '.^/M;A\/^!-9U"9
M@"MLZ1@G&Z1AM4?F17BW[-NDS/KFL:R4(@BMA:AR."S,&('T"#\Q5#XD>++W
MXK>,;/PMX85I["&4B-APL\G\4I]$49P?3)[XKWWP9X5L_!GA>TT:T^;RQNFE
MQ@RR'[S'^GH !VH WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G#]H+_DH>@?\ 7HG_
M *-:OH^OG#]H+_DH>@?]>B?^C6KZ/H ^</V??^2AZ_\ ]>C_ /HU:^CZ^</V
M??\ DH>O_P#7H_\ Z-6OH^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYKTS_DZM_\ K]G_ /1#
M5]*5\UZ9_P G5O\ ]?L__HAJ /I2BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#YL\5?\ )TEG_P!?ME_Z+CKZ3KYL\5?\G26?_7[9?^BXZ^DZ "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHJG;ZOIEW=O:6VHVDUS'G?#'.K.N
M.N5!R* +E%%% !1110 4444 %%%% !17S[\>?%WB'0?&&G6NDZQ>64#6"RLD
M$I0,QD<9..O %>\Z=*\VEVDLC;G>%&8^I*C- %FBOG3X@>,O$FG?'%=,L]:O
M(+!;FT46Z2$1X94+ KT.23U]:^BZ "BBB@ HHHH **** "BO&/V@/$NM>'K7
M01H^IW-CY[S^:8'VE]H3&2.?XC^=>C^!;VYU+P'H5[>3--<SV43RR-U9BHR3
M0!T%%%% !1110 4453O=6T[361;_ %"UM3)]P3S*F[Z9/- %RBD!#*&4@@C(
M([TM !1110 4444 %%%% !17C'[0'B76O#UKH(T?4[FQ\]Y_-,#[2^T)C)'/
M\1_.O1_ M[<ZEX#T*]O)FFN9[*)Y9&ZLQ49)H Z"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *^:_C#_P EST/_ '+3_P!&M7TI7S7\
M8?\ DN>A_P"Y:?\ HUJ /I2BBB@ HHHH ^;/VD_^1JT;_KR;_P!#->]^$_\
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M_H8+[_ORE/\ @=\.-8\,:EJ6L:_8&TG:(6]LC.K$@G+GY2<=%'YU[;0!X?\
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M\0?^2<^)/^P9<?\ HLUTE8GC&PN=4\%:Y8647FW5S8S111Y W.R$ 9/ Y]:
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MF_\ L;X^_P#/6^_\#[;_ .+K8\*Z7\:X/%6F2:Q+<_V8MPGVKS;NW=?*S\W
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M/V??^2AZ_P#]>C_^C5KZ/H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^:],_P"3JW_Z_9__ $0U
M?2E?->F?\G5O_P!?L_\ Z(:@#Z4HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8W^DZI]IT*3>MWEO+<+L;"NO1_FVX([\X% 'M=8>L>,O#7A^7R=5UNQM9O\
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M_P"@Q5]1T 07=Y:Z?:O=7MS#;6\8R\LSA$7ZD\"N:@^)O@FXNQ;1^)M/\TG
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MM&  >W@'FX[R-\SG_OHF@#?HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KYK^,/_)<]#_W+3_T:U?2E?-?QA_Y+GH?^Y:?^C6H ^E**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^</V@O\ DH>@
M?]>B?^C6KZ/KYP_:"_Y*'H'_ %Z)_P"C6KZ/H ^</V??^2AZ_P#]>C_^C5KZ
M/KYP_9]_Y*'K_P#UZ/\ ^C5KZ/H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^:],_Y.K?\ Z_9_
M_1#5]*5\UZ9_R=6__7[/_P"B&H ^E**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME?+>EJ%_:=D   _MF<\?\#KZDKY<TS_DYU_^PQ/_ ":@#ZCKY<^#'_):I_\
M<NOYU]1U\K_"V>/2/CN]M<NJ%Y[JURW'S_-@?B5Q^- 'U17@G[3/_'OX:_W[
MG^45>]UX)^TS_P >_AK_ '[G^45 'IOPMBCB^&'AY8T5 ;-6(48R3DD_4DDU
MO:]<O9^'=3NHB1)#:2R*1UR$)'\JP_AC_P DR\._]>25TMY:QWMC<6DN?+GC
M:-L>C#!_G0!\U?LXVL<OCC4;A]I>'3V" ]06=,D?@,?C7TY7R5\,]:_X5O\
M%.6UULBWA/F6%V[ XC^8$-]-RKSZ'-?6<<B31)+$ZO&X#*ZG(8'H0>XH \Y^
M.UO'-\*-1D<+NAF@D3([^8J\?@Q_6L+]F^:1_!.IPMDI'J!*_C&F?Y?K5/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\U_&'_DN>A_[EI_Z-:OI2OFOXP_\ )<]#_P!R
MT_\ 1K4 ?2E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 444PS1"41&1!(1D)N&3^% #Z*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *^:],_Y.K?\ Z_9__1#5]*5\UZ9_R=6__7[/_P"B&H ^E**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@A>::1(XHU+.[MA5 ZDD]!7F6M?'OP7I5R]O ][J3+D%[.(%,_[S,N1[C(H
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M#5OX8\!:7:QPB.XGA6XNFQ\S2N 3GZ9V_04 >,R?%[XF>$KZ/_A)M*#PN?\
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M$P:NT:+>VERD:28^9D?(*_3.#^!]:L?L\7$TWPWFCD^Y!J$J1<_PE48_JQH
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M9_\ T0U?2E?->F?\G5O_ -?L_P#Z(:@#Z4HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ^;/%7_)TEG_U^V7_HN.OI.OFSQ5_R=)9_]?ME_P"BXZ^DZ "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-XVCZ7%8:G!$TEN\!(#LH)",.A!Z9ZBM+X)?\DAT+_MX_P#2B2N\G_X]Y?\
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MBR6UJ\AP8\#:SD>HQA1P!C/H*G[3/_'QX:_W+G^<5>R>!/\ DGGAK_L%6O\
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M9_\ T0U?2E?->F?\G5O_ -?L_P#Z(:@#Z4HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ^;/%7_)TEG_U^V7_HN.OI.OFSQ5_R=)9_]?ME_P"BXZ^DZ "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.A?]O'_I1)7>3_\ 'O+_ +A_E65X4\-VOA'PU9Z'92S2V]J&VO,06.YRYS@
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M>&?%&HRZC%)<:;>3,7E-O@I(QZL5/0_0BL_P_P#L]^&=*NTN=3N[G52AR(9
M(XB?=1DGZ9QZYH \K^%FH'5OCW9:D8O*-Y<WEQY><[=\4K8SWZU]6S_\>\O^
MX?Y5Q5G\+-&L?B&/&,%S=)=*6*6PV"%<QF/  7.,'@9KM9_^/>7_ '#_ "H
M^+_AYXSG\">*4U>*W%Q T9@NH^YB9E)P>QRJD?3'>OJO3?B1X/U33!?P^(=/
MCBV[G2XG6*2/V96((/\ /MFOG_X!:;9:OXSU:PU"VCN;2?2)%DBD&0P\V'_.
M>U>@:C^S?H-Q>F6PUB]M(&;/DLBR[1Z!N#CZY_&@#S?XG^*G^)OCVRT_04DG
MMH3]ELQC'FNS?,^.P/'7LN3BOJ'0=*CT+P_IVDQ'<EG;1P!O[VU0,_CC-<UX
M)^%OAWP,QN+&*2YU!EVF\N2&< ]0H  4?3GU)KM: /D;XIWUQI?QQU'4+/'V
MJUNK:>'*[AO6.-EX[\@5[SX,^+OAKQ3ID;W5_;:9J*KB:UNI1'\W<HS8##]?
M45XWXLY_:=@!_P"@Q8?RAKT[Q1\!/#6O7TE[83SZ3-(=SI H:(GU"'&/P./:
M@#D?CG\2M,U32D\,:'>1W8>19;RX@<-'A>50$<,<X)QP,#\.^^"?AF;PW\/(
M#=QF.ZU"0W;HPY52 $!_X"H/_ C5/PM\"/#'AZ^COKR2?5;B,AD6X $2D=]@
MZGZDCVKU*@#Y[_:9_P"/CPU_N7/\XJ]D\"?\D\\-?]@JU_\ 12UE>/OAII?Q
M!:P;4+R\MFL@X3[.5PP?;G.0?[H_6NITG3H='T:QTNW9V@L[>.WC9SEBJ*%&
M<=\"@"6]M(K^QN+.89BGB:)Q_LL,']#7R?X1UBZ^#_Q/N;?5XI3;INM;I4'+
MQD@K(H[]%8>Q(KZWKE_&'P^\/>.($75[5O/C&(KJ!MDJ#T!Z$>Q!% %FV\<>
M%+NT6ZA\1Z4867<"UVBD#W!((^AKP?XT_$*U\975AX;\.2->VT<V^22)21/,
M?E54[D#)Y[D\=*Z9_P!FK2C/E/$5XL/]QH%+?]]9 ].U=SX.^$_ACP7.MW9V
M\EUJ"C N[I@SKD<[0  OX#/O0!?^'7AA_"'@;3=)FQ]J5#)<8.?WCG<P_#./
MPIWQ#\._\)3X$U72U3=.\)DM_7S4^9?S(Q^)KIZ* /BW2O&MSI?P[USPLN_;
MJ%Q$ZD?P*,^9^>V,?G7T3\#O#G]@_#FVN)4VW.IL;M\]=AX0?3: ?^!&L[4O
MV?/"^HZS<W_V[4H%N)C*T$;)M7)R0N5R!Z>E>K0016MO%;PH$BB0(BCHJ@8
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M#EDR?F4G)XZ=Z[6_T^TU2PFL;^WCN+69=DD4BY5A7DFK?LY^&[N=Y=-U&^L
MQSY1Q,B_3.&Q]2: /1M1\;>%])A:6^U_3HE49V_:%9C]%!)/X"IO#7B?2_%N
MD_VGI$SRVOFM$&="A)7KP>>XKR_3_P!F_P /02*U_K&HW2C^",)$#]>"<?C7
MJN@^']+\,Z3'IFD6JVUI&20@)8DGJ23DD_6@#P[]IG_CX\-?[ES_ #BK5^$W
MQ@TLZ):>'?$<\6G7-G"D-O<RG9%+&H 4,3PK 8Y/!ZYS65^TS_Q\>&O]RY_G
M%75Q_"GP[XX\ ^&;NZ22TU$:1:C[7;8#.!"N X(PW\_>@"_\1OBKH?A_PS=1
M:9JEM>ZM<1M%;I:S+)Y1(QO8@G '7U)Q]1P?[./AF8WNH^)IHRL"Q_9+<D??
M8D,Y'TPH_P"!'TK?TK]G'P_:W:RZCJU[?1*<^2JB)6]F(R<?0BO7["PM-+L8
M;&QMX[>U@79'%&N%4>PH L4444 <'\4?B+%X T.-H8Q-JMYN6UB;[JXQEV]A
MD<=R?J1X9\/8/#>L^(I_$_C[Q!:L_FF1;6X<EIY/[S@# 0=E[X]!@^^^.?AG
MHGC^:REU6>^ADM%94:UD5=P;!YW*WIVQUKD?^&<?!_\ T$M<_P"_\/\ \:H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ^</V@O\ DH>@?]>B?^C6KZ/KYP_:
M"_Y*'H'_ %Z)_P"C6KZ/H ^</V??^2AZ_P#]>C_^C5KZ/KYP_9]_Y*'K_P#U
MZ/\ ^C5KZ/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *^:],_Y.K?\ Z_9__1#5]*5\UZ9_R=6_
M_7[/_P"B&H ^E**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /FSQ5_R=)9
M_P#7[9?^BXZ^DZ^;/%7_ "=)9_\ 7[9?^BXZ^DZ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 %%%% !1110 4444 %%%% 'BWQ\\):]XFDT&31=,FO5MQ.LOE8RI;9CC/\
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M[_H$:K_X(S_\11_PG7QN_P"@1JO_ ((S_P#$4 ?2]%?-'_"=?&[_ *!&J_\
M@C/_ ,11_P )U\;O^@1JO_@C/_Q% 'TO17S1_P )U\;O^@1JO_@C/_Q%'_"=
M?&[_ *!&J_\ @C/_ ,10!]+T5\T?\)U\;O\ H$:K_P"",_\ Q%'_  G7QN_Z
M!&J_^",__$4 ?2]%?-'_  G7QN_Z!&J_^",__$4?\)U\;O\ H$:K_P"",_\
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M_P )U\;O^@1JO_@C/_Q%'_"=?&[_ *!&J_\ @C/_ ,10!]+T5\T?\)U\;O\
MH$:K_P"",_\ Q%'_  G7QN_Z!&J_^",__$4 ?2]%?-'_  G7QN_Z!&J_^",_
M_$4?\)U\;O\ H$:K_P"",_\ Q% 'TO17S1_PG7QN_P"@1JO_ ((S_P#$4?\
M"=?&[_H$:K_X(S_\10!]+T5\T?\ "=?&[_H$:K_X(S_\11_PG7QN_P"@1JO_
M ((S_P#$4 ?2]?->F?\ )U;_ /7[/_Z(:F?\)U\;O^@1JO\ X(S_ /$5RL5K
M\2H/&!\5)X=UD:N9&D\W^RI,;F4J?EV8Z$T ?8-%?-'_  G7QN_Z!&J_^",_
M_$4?\)U\;O\ H$:K_P"",_\ Q% 'TO17S1_PG7QN_P"@1JO_ ((S_P#$4?\
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MU\;O^@1JO_@C/_Q% 'TO17S1_P )U\;O^@1JO_@C/_Q%'_"=?&[_ *!&J_\
M@C/_ ,10!]+T5\T?\)U\;O\ H$:K_P"",_\ Q%'_  G7QN_Z!&J_^",__$4
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MTO17S1_PG7QN_P"@1JO_ ((S_P#$4?\ "=?&[_H$:K_X(S_\10!]+T5\T?\
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MO_@C/_Q%'_"=?&[_ *!&J_\ @C/_ ,10!]+T5\T?\)U\;O\ H$:K_P"",_\
MQ%'_  G7QN_Z!&J_^",__$4 ?2]%?-'_  G7QN_Z!&J_^",__$4?\)U\;O\
MH$:K_P"",_\ Q% 'TO17S1_PG7QN_P"@1JO_ ((S_P#$4?\ "=?&[_H$:K_X
M(S_\10!]+T5\T?\ "=?&[_H$:K_X(S_\11_PG7QN_P"@1JO_ ((S_P#$4 ?2
M]%?-'_"=?&[_ *!&J_\ @C/_ ,11_P )U\;O^@1JO_@C/_Q% 'TO17S1_P )
MU\;O^@1JO_@C/_Q%'_"=?&[_ *!&J_\ @C/_ ,10!]+T5\T?\)U\;O\ H$:K
M_P"",_\ Q%'_  G7QN_Z!&J_^",__$4 ?2]%?-'_  G7QN_Z!&J_^",__$4?
M\)U\;O\ H$:K_P"",_\ Q% 'TO17S1_PG7QN_P"@1JO_ ((S_P#$4?\ "=?&
M[_H$:K_X(S_\10!]+T5\T?\ "=?&[_H$:K_X(S_\11_PG7QN_P"@1JO_ ((S
M_P#$4 ?2]%?-'_"=?&[_ *!&J_\ @C/_ ,11_P )U\;O^@1JO_@C/_Q% 'TO
M17S1_P )U\;O^@1JO_@C/_Q%'_"=?&[_ *!&J_\ @C/_ ,10!]+T5\T?\)U\
M;O\ H$:K_P"",_\ Q%'_  G7QN_Z!&J_^",__$4 ?2]%?-'_  G7QN_Z!&J_
M^",__$4?\)U\;O\ H$:K_P"",_\ Q% 'TO17S1_PG7QN_P"@1JO_ ((S_P#$
M4?\ "=?&[_H$:K_X(S_\10!]+T5\T?\ "=?&[_H$:K_X(S_\11_PG7QN_P"@
M1JO_ ((S_P#$4 ?2]%?-'_"=?&[_ *!&J_\ @C/_ ,11_P )U\;O^@1JO_@C
M/_Q% $GBK_DZ2S_Z_;+_ -%QU])U\?7EM\2K[Q<GBFX\.ZRVK))'(LHTJ0#<
M@ 7Y=F.@%=5_PG7QN_Z!&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'
M_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!
M&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q
M% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_
MPG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J
M_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'
M_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!
M&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q
M% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_
MPG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J
M_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'
M_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!
M&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q
M% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_
MPG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J
M_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'
M_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!
M&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q
M% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_
MPG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J
M_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'
M_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!
M&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q
M% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_
MPG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J
M_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'
M_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!
M&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q
M% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_
MPG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J
M_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'
M_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!
M&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q
M% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_
MPG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J
M_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'
M_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!
M&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q
M% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_
MPG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J
M_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'
M_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!
M&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q
M% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_
MPG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J
M_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'
M_"=?&[_H$:K_ .",_P#Q% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!
M&J_^",__ !% 'TO17S1_PG7QN_Z!&J_^",__ !%'_"=?&[_H$:K_ .",_P#Q
M% 'TO17S1_PG7QN_Z!&J_P#@C/\ \11_PG7QN_Z!&J_^",__ !% 'TO7S7\8
M?^2YZ'_N6G_HUJ9_PG7QN_Z!&J_^",__ !%<KK=K\2O$7B"WUS4O#NLR7]N$
M$<BZ5(H&QMR\!,=30!]@T5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@
MC/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+
MT5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;
MO^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/
M_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U
M\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@
MC/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+
MT5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;
MO^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/
M_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U
M\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@
MC/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+
MT5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;
MO^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/
M_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U
M\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@
MC/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+
MT5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;
MO^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/
M_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U
M\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@
MC/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+
MT5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;
MO^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/
M_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U
M\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@
MC/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+
MT5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;
MO^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/
M_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U
M\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@
MC/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+
MT5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;
MO^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/
M_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U
M\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@
MC/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+
MT5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;
MO^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/
M_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U
M\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@
MC/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+
MT5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;
MO^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/
M_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U
M\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@
MC/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+
MT5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;
MO^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/
M_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U
M\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@
MC/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+
MT5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;
MO^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/
M_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U
M\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@
MC/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+
MT5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;
MO^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/
M_P 11_PG7QN_Z!&J_P#@C/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U
M\;O^@1JO_@C/_P 10!]+T5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@
MC/\ \10!]+T5\T?\)U\;O^@1JO\ X(S_ /$4?\)U\;O^@1JO_@C/_P 10!]+
MT5\T?\)U\;O^@1JO_@C/_P 11_PG7QN_Z!&J_P#@C/\ \10!8_:"_P"2AZ!_
MUZ)_Z-:OH^OD#Q';_$KQ=JMKJ&L^'=9FN+=1'&RZ5(@"AMW0)ZDU]?T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img11029722_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &F U # 2(  A$! Q$!_\0
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M_A1_P^*\)?\ 1.-=_P# V'_"OS/Q1BC^P\#_ "O[P/TP_P"'Q7A+_HG&N_\
M@;#_ (4?\/BO"7_1.-=_\#8?\*_,^C%']AX'^5_>!^F'_#XKPE_T3C7?_ V'
M_"C_ (?%>$O^B<:[_P"!L/\ A7YGXHQ1_8>!_E?W@?IA_P /BO"7_1.-=_\
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M)_8'\<Z=\%_"OQ@^#^M>!;'3_BUX4L[NZ>VLPR3>)HHHW* ,>2W*@;>JR*P
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M1G8[LL3@#O7Q.TC3.\CMOD=F=W(P68G)./<DT^ZA6&ZGB203)'(R+*O <!B
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MZ-_WT:/9X+_GS_Y,P]KY'S;_ ,/63_T1#Q9_W^_^U4?\/63_ -$0\6?]_O\
M[57TEY\G_/1O^^C1Y\G_ #T;_OHT>SP7_/G_ ,F8>U\CYM_X>LG_ *(AXL_[
M_?\ VJC_ (>LG_HB'BS_ +_?_:J^DO/D_P">C?\ ?1H\^3_GHW_?1H]G@O\
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M@]X-N%\,V%X\<GV^Z1KIFD$BNTCC()9MN.H X["N#\;?L+ZIXX\ _"+P7?\
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MGOBO_L#WG_HAZX'_ ()/_P#)IT?_ &';W^4==]\1/^2>^*_^P/>?^B'K@?\
M@D__ ,FG1_\ 8=O?Y1U6(_W"7^)?J;TCBO\ @KM:_P!H>"OA?9[MGVG7I(=V
M,[=T:C.,^]>2-_P2U@#$#XC/MSVTH?G_ *S\/PKV'_@K)_R+_P (/^QD;_T%
M:^D)/]8377@\35P^"I^S?5_F.I+E/@W_ (=:V_\ T4:3_P %(_\ CM'_  ZU
MM_\ HHTG_@I'_P =K[OHK7^TL5_.C'GD?"'_  ZUM_\ HHTG_@I'_P =H_X=
M:V__ $4:3_P4C_X[7W?11_:6*_G0<\CX0_X=:V__ $4:3_P4C_X[1_PZUM_^
MBC2?^"D?_':^[Z*/[2Q7\Z#GD?"'_#K6W_Z*-)_X*1_\=H_X=:V__11I/_!2
M/_CM?=]%']I8K^=!SR/A#_AUK;_]%&D_\%(_^.T?\.M;?_HHTG_@I'_QVON^
MBC^TL5_.@YY'PA_PZUM_^BC2?^"D?_':/^'6MO\ ]%&D_P#!2/\ X[7W?11_
M:6*_G0<\CX0_X=:V_P#T4:3_ ,%(_P#CM'_#K6W_ .BC2?\ @I'_ ,=K[OHH
M_M+%?SH.>1\(?\.M;?\ Z*-)_P""D?\ QVC_ (=:V_\ T4:3_P %(_\ CM?=
M]%']I8K^=!SR/A#_ (=:V_\ T4:3_P %(_\ CM'_  ZUM_\ HHTG_@I'_P =
MK[OHH_M+%?SH.>1\(?\ #K6W_P"BC2?^"D?_ !VC_AUK;_\ 11I/_!2/_CM?
M=]%']I8K^=!SR/A#_AUK;_\ 11I/_!2/_CM'_#K6W_Z*-)_X*1_\=K[OHH_M
M+%?SH.>1\(?\.M;?_HHTG_@I'_QVC_AUK;_]%&D_\%(_^.U]WT4?VEBOYT'/
M(^$/^'6MO_T4:3_P4C_X[1_PZUM_^BC2?^"D?_':^[Z*/[2Q7\Z#GD?"'_#K
M6W_Z*-)_X*1_\=H_X=:V_P#T4:3_ ,%(_P#CM?=]%']I8K^=!SR/A#_AUK;_
M /11I/\ P4C_ ..T?\.M;?\ Z*-)_P""D?\ QVON^BC^TL5_.@YY'PA_PZUM
M_P#HHTG_ (*1_P#':/\ AUK;_P#11I/_  4C_P".U]WT4?VEBOYT'/(^$/\
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MH **** "BBB@ HHHH **** "E]?I24OK]*71@?,W[&__ "D"^/\ _P!>C?\
MH^&OT&K\^?V-_P#E(%\?_P#KT;_T?#7Z"UQYK_O7R7Y([%L?GO\ \%B/^1#^
M%_\ V'IO_1!K] [/_CS@_P"N:_RK\_/^"P__ "(?PO\ ^P]-_P"B#7V]XP^)
M7A7X6^&;;6/%_B#3_#6E,T=N+W4[A88C(RDJFYCC)"MQ[&LZW^YT/^WOS0SJ
MZ*\:/[9GP*7&?BUX1R1G']JQ9QZXS7KMC?V^J6=O>6DR7-K<1K+%-$VY)$8
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MH6.-%&%55'0 #&.F,5-16B).?^(G_)/?%?\ V![S_P!$/7 _\$G_ /DTZ/\
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MT;_T?#7Z#5^?/[&__*0+X_\ _7HW_H^&OT%KCS7_ 'KY+\D=BV/SW_X+#_\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** .?\ B)_R3WQ7_P!@>\_]$/7
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M*.C+LC[3@^*6GZAXH\=>'--T_4-5UKPA:VMS>6EO$ T[7$3RPPPY(#.RH.N
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M_8LAS-+F9_WROA@RC.":X;5M!?P(NL^*/B+X=\1>(;!=7EOHOBUX%U[[0UM
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M\=NOV4_ ]UX6\&Z$9=;BM?"+7$NDS6VHF&YADESF0R*H)92<KC'N"*Z'P?\
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M;Z9>2$Y9I(0/X_X@K -W%=%XV^!GACQM<:%=YU#PYJNAQ&WTW5/#MS]CN;:
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M 55HX\#)53M&\M@8KN?!7C*T\:>%]%UB/R[2;4[&&_\ [/:=7EA61 X4@<G
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M+10 FT4;12T4 )M%&T4M% ";11M%+10 FT4;12T4 )M%&T4M% ";11M%+10
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M77CJ?Q?/9>=KL^F?V/++)(S1/:EBQ0Q$[.2>N*:I-+<.9'QQIOPU\3:?\-O
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MY9HY RD%<D'@YJ']HG]H*T^".FZ3IULMG?>,/$4K6VDV%]=I;VX*CYI[B1B
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M_NT0,S<<Y4$8(KSGP)^TEI6MZY\7+W6=9TFU\#>$;[3HK+6H-Q1H+FW1RTC
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M-7'FO^]?)?DCL6Q^>O\ P6%4)X"^%X48']O3'C_K@:^_3&TVC^6KK&S0;0[
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M>1PJLTJ)]Q7<#+!<\ GCM5-?!N@)#' NA:8L,5W]NCC%G&%2Y)SYP&WB3/\
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M1E%%)N&<=Z %HI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEG7_ #\C_P" 4_\ Y$^<_P#AE'Q#_P!%8U[\Y/\ X[1_PRCXA_Z*QKWYR?\
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MS_X91\0_]%8U[_R)_P#':/\ AE'Q#_T5C7OSD_\ CM?1E%'LH]OQ#_7+.O\
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M/H=I(%2S75O:F,3S0P&1A''YL@4R-V5<D9/7@9)P>*^0/ EO\/[W]J7P/<_
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M:+I6B:=<27JQ-;QQAH[IR.VR-CM'?H*^E:*/9H?,>+:W^R#\*]0^'M[X>MO
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M65G-=B[6*6Q>W5EV^003(K @ @\9YKQOPS^R/XRTOX>_%C2+R>T?5)X8=/\
M!,BW*GRK6VN7NK42,?\ 5MYC*"3TQZ"OL:BATXL.9GR[J7[*>J:M^SWX*T2\
MM](U/QQH>JMXDO;75"9-/U&^F=VNH9"/X7#[0PZ%%/2M?X?_  +>;Q7<7.H?
M"'P1\.M%.FW-D\NF3+?:G-)-&8V,4JX6)-K-G.2W'3FOHNBG[.(N9GQOX?\
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MH7UR;&421-Y]R\JLI]PW0\CH:D\=_#K6O%WQZ^&?B!XH)/"?A>"_NI\S@/\
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MOZ5I-[<C,%O?7L4,DH)QE$=@6&>..]?F!X7\0^'[[XK?LYZ_X=TSP%X-AO\
M5U T?PO<R7.J0(6"L=0N7.YF8L0(W^;KR0:]&^Q?"B_\9_M*G]H)[:/7X=94
MV,ERX74H].7)A_L_><[CA 1'U!P>*"57;Z'UMK?QTET?]IC0OA/_ &-";;4M
M%FU=M6:Y(:'RRP\OR]N"/ESG=7HEKXOT"]T>YU:VU[2[C2;4MY]_#>Q/;P[>
MH:0,57&1G)XS7YY?M2:#XD\>?'KP5IWP@U&6TGNOAQ(;&6:21+B:Q D)C5I/
MG#N@V@GGYCSWK0^+GB#POX@_8Q^"S>&]-70_AVGB2SM/%>FVY8&V*;EF6Y/7
MF3+%FY)9:!*M)7T/OFP\<>&M5FCAL?$>CWLTD+7*1VVH0R,\*YW2*%8DH,'+
M#@8//%&E^./#6NWT-EIGB/1]3O)XS-%;66H0SRR1@D%U5&)*@@@D# P:^$]'
MM_AQ#^W=XA7X9C2!X<'P\OC*-"*FR67[.^=FWY0-FS<%_B)S\VZD_9K^'L.C
M_P#!/;Q'XP\&Z);CXCW>GZFL6L6MN#?^6)2CQQR?> $:,=JG&><9S07[9O9'
MWCIOC#0-:U2YTS3M>TO4-3M2PN+&TO8I9X=IPV^-6++@\'(X/%2P^)-'N)M1
MABU?3Y9M-_X_HX[J-FM.,_O@#^[X_O8K\Y6@^'-KX"_9KN?A&VF_\+;GU6Q%
MXVCN#J;@K_I_VT+\VW?N_P!8,!<X^6NPL_''AOX=_%K]LB#Q-K-CHEWJ$.;2
M"\E"27>Z%P!$IYDY8<+GK0+V[ZH^Y%\9>'FM]/N!K^E&WU%MEE,+Z+9=-_=B
M.[#GV7-3:'XET?Q1#)+HNKZ?K,43;)'TZ[CN C?W6*$X/L>:_-:Z\/Z?XK^
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MY::1W.Z",<DJ25)( QCD)=:RND?J[KWC+P]X5D@CUOQ!I.BR3@F)-2OXK9I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%%( HHHI[ %%%% !2^OTI*7U^E
M+HP/F;]C?_E(%\?_ /KT;_T?#7Z"U^?7[&__ "D"^/\ _P!>C?\ H^&OT&KC
MS7_>ODOR1V+82C%+17D#$VT;:6BCE78!-M%+119 %?$WQ/\ ^3_-(_[ Z_\
MHIZ^V:^)OBA_R?YI'_8'7_T4]9U-EZGWW!W^]8K_ *\5/R1[G7C/C_\ 9W7X
M@?M!^$?B'?7MA<:-HNEW.FW.A7EIYWVL2AASGY-HW#((YQ[U[-15'A2BI;F%
M'X!\+P^%SX:C\-:/'X</71UL(A9GG<?W6W;][GI2:Y\/_"_BBQLK+6?#>D:O
M9V/_ !Z6U_8Q3Q6_ 4>6KJ0N  . .@]*WJ*!V1C6O@GPY86>JVEMX?TNWM-6
M=I-1@BLHUCO6889IE Q(2"<E@<TSPKX#\,^!8YX_#?AS2?#Z7!!F72[&*V$I
M'3<$4;L>];E% N5&9KGA71/$S6;:QH^GZL;.3S;;[=;),87Z;DW [3[CMQ4?
MAOP;X>\'6L]KH&A:;H=K.Y>6'3+..W21NFYE0 ,<=S6O10'*MSE=/^$O@72U
M5;/P5X=LPMRE\HM])@C"W"?<E "_?7LW4<\U:\0?#OPGXMU&WU#7/"^BZSJ%
ML (+S4-/AGFAP<@*[J2.>>.]=!10'*D9\OAO1YO$$&O2:38OKD$1AAU)K=/M
M,49SE%EQN"\GY<XKS_XJ?!F7Q1\/M3T#P/J.G^ ;R_NOM=U)#I,$UI?L>'6Z
MA*8D#\9)YR!S7J%% .*:L?/GP;_9=O\ P5\3+OQUXNUO1-7U,:/_ &%8:9X=
MT9=-TZVM2Q9\PY(+,6;V^8U[KH.@:7X5TV'3M%TVTT?3H<F.SL($AA0DDDJB
M@ 9)STZDU>HH%&*BK(P=&^'_ (5\.:U=ZQI/AG1]+U>\+&YO[*PBAGF+$EM\
MBJ&.223D\D\TFL?#[PMX@UE-7U3PSHVIZM''Y*W][I\,MP$P5V^8REL8)'T-
M;]%!5D8*^ ?#$=MI5LOAO2%M])D\W3HEL8@MD_\ >A 7$1XZIBKMOX:T>SUZ
M[UR#2K&'6KM%BN-2CMD6YFC7&U'D W,!@8!) P/2M&B@+(Y,_"7P-Y\\Y\%>
M'3<3SK=SS?V5!ODF4Y61FV9+@DD,>>O>NO967[Z,H(W<\?E_2FC[P]:^./AS
M\3?$/PV^.WC?4_$.JSW_ ,-M>\7W'A[=<2,XT2^5(S;MDGY8I0S)Q@!L>N:"
M6U!H^M=+\+Z3X>N+^YTS2;+3+C4)?M%W-9VR0M<R=WD91ESG^)LG)-8UQ\)O
M ]U<:C<3>"_#TT^I8-](^E0%KK#!LR-MR^& ;DGD UY=\/O'&I>'O$WQ^OFT
MS7_&']G>,H[>UTG1Q]JN%C:T@RL,;LJA 6+$ @=377^#_C1J/BOQ#::7<?"O
MQ_X;BG+;M4UK2XHK2# )^=EE8C.,#CJ:"5*+TL=7XD^&OA'QI]F?Q#X4T/Q!
M]DC\F!M3TZ&X:%#C"J74[1P.E:NH>';'6M%FTF^TNWU#29(Q#)8S6JR6[(N,
M(8RNT@8&%(QQ7SUJ6K?$1OVO/AXFO7=KIGA*[BUN+3-#T^5Y&D2*W!%S=-PK
MNVX%4 P@&>IKC?B]-9^*/V@/'#^(-"^)6LZ)X;TO3[:"+P7=7%O#$662::=M
MDB!SM=1A<M\IXXH%SJU['TCXD^%.F77PM\3>!O#6G:;X6M]8TZ[L42PLEB@A
MDFA9#(8HP,GY@3CKBN=^!O[/^B_!WP+X4TN]T[1]6\5:!8_8CXC7342X==[D
M .P\Q5 DQC->1_%[Q5X:A\ _!;^RO$NN3?"/5;QHKPZ1?3R:M?1^46@4L/\
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M;-2ZQHNG>(M+GTW5K"UU33K@;9K.\A66*49SAE8$'H.OI5RB@=E:Q@Z3\/\
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M9^65!E%%%9F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWW-_\71]<P?:7X![-'E__#7_ ,&/^BC:1^4O_P 11_PU_P#!C_HHVD?E+_\
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M^4O_ ,17J'_#!OP"_P"B8:1_WW-_\71_PP;\ O\ HF&D?]]S?_%T?7,'VE^
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MG_\ B:/^&D/AI_T.%C^3_P#Q->E?\,@?"'_H2;'_ +[E_P#BZ/\ AD#X0_\
M0DV/_?<O_P 71RS\@^N<+?RU_P#R0\U_X:0^&G_0X6/Y/_\ $T?\-(?#3_H<
M+'\G_P#B:]*_X9 ^$/\ T)-C_P!]R_\ Q='_  R!\(?^A)L?^^Y?_BZ.6?D'
MUSA;^6O_ .2'FO\ PTA\-/\ H<+'\G_^)H_X:0^&G_0X6/Y/_P#$UZ5_PR#\
M(?\ H2;'_ON7_P"+H_X9 ^$/_0DV/_?<O_Q='+/R#ZYPM_+7_P#)#S7_ (:0
M^&G_ $.%C^3_ /Q-'_#2'PT_Z'"Q_)__ (FO2O\ AD#X0_\ 0DV/_?<O_P 7
M1_PR!\(?^A)L?^^Y?_BZ.6?D'USA;^6O_P"2'FO_  TA\-/^APL?R?\ ^)H_
MX:0^&G_0X6/Y/_\ $UZ5_P ,@?"'_H2;'_ON7_XNC_AD#X0_]"38_P#?<O\
M\71RS\@^N<+?RU__ "0\U_X:0^&G_0X6/Y/_ /$T?\-(?#3_ *'"Q_)__B:]
M*_X9 ^$/_0DV/_?<O_Q='_#(/PA_Z$FQ_P"^Y?\ XNBU3R#ZYPM_+7_\D/-?
M^&D/AI_T.%C^3_\ Q-'_  TA\-/^APL?R?\ ^)KTK_AD#X0_]"38_P#?<O\
M\71_PR!\(?\ H2;'_ON7_P"+HY9^0?7.%OY:_P#Y(>:_\-(?#3_H<+'\G_\
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M?]#A8_D__P 31_PTA\-/^APL?R?_ .)KTK_AD#X0_P#0DV/_ 'W+_P#%T?\
M#(/PA_Z$FQ_[[E_^+HY9^0?7.%OY:_\ Y(>0^*OVAOAU>^%]9MK?Q7933SV4
MT4<:A\LS1L !\O<UTO\ P3T;_C'\?]A:Y_#A*[=OV0?A$.G@BQ_[^2?_ !5>
MB^#?!&B_#_0TT?P]IL.EZ;&S.MO",+N/4\TXQES)R,LQSK*/[(J9;ET*EYSC
M)N?+]E-:6]3H:***U/SP**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L_Q!K=MX;T
M._U6\++:6-O)<S,BEF"(I9B .IP.E:%<?\8/^24^,_\ L"WO_HEJ /FK3_\
M@K)^SK?WUO;'Q+J=MYTBQ^=<:1.L<>3C<QQP!W-?7&GZI!JVGVU]93QW5E<Q
MK-#<1'*2(P!5E/<$$&OR0^ OPD_:2^-_[(^@^"M"TOX=V?PTUJ!K9=:OHB=3
MB@\\EW)!/S @XPN< 8QP:]O\?>#O%6G_ +6GP3^!6D_$KQ7X8\*1> 3%?2:!
MJ#6\ER8!.#(H(*K(WEJ-^"P &* /MJQ^*FE:A\3-2\#1VFK+K%A:)>2W$FFS
M+9,C;<*ER1Y;/\P^4'/!]#76M,0 0,\X/%? 'C#QQXN\&_M"?'OPC9>,_$4V
MC>&OA/\ :M-CNM3EE:&Z2%,70)/^O)R3(,$DFO'X-<^*VA_#_P#9>\86OQN\
M<2ZY\2-031=36[NTGM(;=V"*T<#*5,JJQ_>/N8MAL\4 ?K#YGMUH:1EQD=?T
MKX)^#WQ"U_X2_%#]IKP)K_Q0UVY\*>#M*M]2TWQ#XJ<:G=Z8TD1W29;'FX.T
MK'P"0!C)Y\R^%/Q4\7>%_P!I?X'+HOBWXJZYX.\;M<V]Y>?$.=5M-8&P,9+2
MT.6@56(()Z@C:=I.0#]0O,;(&./7%'FGL,U^=G[-G@?QM^TAKWQPO-8^+WC_
M $]- \57VF:'8:7KTEO;PN4)!EV_,\:GRMJ!@%VMC[QKG_!G[0WCKXO^ _@K
M\%;?Q+J^E_$M?$]SIGB_4+6YE2]2RTYMTCO*#N_>HT8+$\D-UH _1/XA>/M*
M^&/@G6O%FNR2Q:-I%LUW=R01-*ZQKU(0<L?85\MQ_P#!6K]G::1(UU[6=S$*
M/^)-/U/X5ZO^VNHB_9%^*PRP"^'K@9)R<;?YU\D?LSV_[5TGPM^&YTKPO\*I
MO!!L++R+B]C)OFLL+\S_ #X\S9[=: /T?M[P7%O',O*2*'4D8R",BI?,..G?
MI7PAXZ@\8_%3_@HEXC^&UO\ $WQ=X/\ ",?@B/49+/P]?F E@\:YB)#+$V]T
M)=0&(5ESAC7E%C^TU\3=-_87CAC\7ZA+XDNOB$W@E/%EPXDO+:S+D^:SGG>
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M_";XW^$/ 5MX]\5Z_P"%_'FD:I:WMOK>JO<WEG/!"K+=VUP</$2&*D#Y<X(
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M?<W5OI[-@A;B:*-HX2 02'88!R>* /GO1YO'>A?&:+XH6O[+OC0>)X]"3P\
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M+JUEM+FV<C<HDAE177(Y!(P>U '>T444 %%%% !1110 4444 %%%% !1110
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MU#PY:3>*I;"6%];*:@N^%870.\<*'F0\?.1T&:Z+]K#P_JF@_M"> /'T^O\
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MA\J,L;[-N>S 5]Q;67)[>V:C7+9QNZXZ\4 ?!'CCP[>_\,E_M@0P:3="]O\
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MVT%1E,*<-Q]* .S^ /Q@N/C+X+O-2U#13X>UK2]4NM%U33O/$Z174#[7\N0
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M=,_9?\7:3X;^&27.IZ?JVO6'Q$;QOXDN%9H8,RQW D2W&"6"&6-5#8R%))%
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MTR/[@P-OM3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ>.![4@B08(4 CIQ110 H4+T%+M'3''6BB@  QTI:** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img11029722_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'J R$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**^=?B
MI^UA/X4^)US\// OP^USXG^+M.MDO=5M=)GBMH=/BD&8]\LGREV[+UH ^BJ*
M\?\ @C^T=X<^-G@75/$$,%WX=N=$GDM-<TG60([C2YHQN=)0.P )#=P*\@D_
MX*!*NGR>,(_A+XMD^$ G,8\>JT7E&,/L^T?9O]9Y.[^/ICF@#Z_HKR'XO?M
MV/PUT'PO<:/I5QXUUGQ7<QVN@:3ILR1M?%H_,\SS&^58P@W%CV(XJS\(_CMI
MWQ0\,^(;Z_L)?">J>%[N6QU[2]0D5CI\T:AV)D&%9-A#!QC@T >JT5Y[\$_B
MD?C)X"M_%D.C76B:;?3S?V>MXX9[FV5RL=Q@ %1(!N"GG!%>@)]T=Z '4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7P1-JGCFS_;*^*FK?L^Z%8>*@]O;V?C$>(YS:Z?#J$2D1QV\PR[2
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M-$\1_%C5IO%/B^WT^X\V+P]X=MHD653+QN>7RQ'N'!W/C[M?:7P]\"V'PO\
MA_H'A/2@YT_1-/BL8"Q&]@B!=Q]SR2>F37D?P[^!^N^*-)^*^O?$."/3/%OQ
M CN-+-O!*LW]E:6(G@MK=74E2=K-*Q'!=SZ4 9_PB_:ZT#Q3K7A+P\/!.N>#
MO#?B*!H?!VL:DB+:ZND*Y"(JG=$3&-RAP-PZ5]+1L&C5AP",U\7_  S^!'Q6
MU+7?@QX?\;:)IFB>&OA)(\T.M66HI</KDJPF"#9"!NA782S;\'/ K[0C 6,
M=* 'U6NKG[.,^5++[1KNJS24 9Z:J O_ !Z7?_?DT[^UA_SZ7?\ WY-7Z* *
M']K#_GTN_P#OR:/[6'_/I=_]^35^B@"A_:P_Y]+O_OR:/[6'_/I=_P#?DU?H
MH H?VL/^?2[_ ._)H_M8?\^EW_WY-7Z* *']K#_GTN_^_)H_M8?\^EW_ -^3
M5^B@"A_:P_Y]+O\ [\FC^UA_SZ7?_?DU?HH H?VL/^?2[_[\FC^UA_SZ7?\
MWY-7Z* *']K#_GTN_P#OR:/[6'_/I=_]^35^B@"A_:P_Y]+O_OR:/[6'_/I=
M_P#?DU?HH H?VL/^?2[_ ._)H_M8?\^EW_WY-0^*/$^D^#- O=;UW4K71](L
MH_-N;Z\D$<4*=V9CP!7E*_MF_ D$_P#%X/!N20?^0U!_\50!ZY_:P_Y]+O\
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MH_M8?\^EW_WY-7Z* *']K#_GTN_^_)H_M8?\^EW_ -^35^B@"A_:P_Y]+O\
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M@>+O WA+QGJD.G^$OA;I6GZWXTO=0NECMY=8,*"UMI9&(!"'=,V<C<8J]_\
MCO\ %/3O@O\ #75O%M[;_;;RU18=/M%CWRW5Y*=D$,8 ))>0J.*^4/B9\)U^
M#_PW^#MUX_9=2T6;QB-?^(EY<1M/"U[/"Y228*/F@BEVH"> %3- 'V[X<\4Z
M/XNTFUUC1-6LM:TNXR8;S3YTFA?MD,I(/IP:VZ^4_P!C%M/U+QO\:]:\(1+%
M\,M1\01/H9MXS':S2K;H+F:W! 'EL_=?E)!Q7U90 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 445\T>-/VM/&?A/Q;K.C6?[
M/'Q&\0VMA=R6\6JZ?!$;>[56($L9+9V,!D9[&@#Z7HKYZ_9S_:Z@_: O?&<,
MW@C7O \/A5A'J%UKC1>4LHR7BRA.&0#)ST%<=+_P4.T*.%O$0^'GC.3X7BY^
MRCQ^EFIT\C=L\[9GS/*W9&_&* /K:BO*OB]\?M*^%?A_P]>6NG7WB_5/$=S'
M::'H^C;6FU!W0R JS$*J! 6+DXZ5/\(_CEI7Q9\.Z[J!MKKPUJ&@74EAK>DZ
MMM2;39HUW,KL"5(V$,'!P0: /3J*\_\ @U\5H?C-X'A\5V&FWNF:5=SS1V+7
MVT/=PHY5+A0.B28W*#S@BN^3.T9ZT .HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ***9(=O.<4@'TAKSOXF_'CP;\)5B3Q!JZPWTHS%IUNIEN9>.R#D?
M4U\W^*?VXO%6M2-'X6\*0:+:$D+>:U+YDI]Q%'P/Q-=M'!UZWPKY@?:+-VW8
M-5+[6+33@3<W<-N!R?.D"C]37YP>)OBS\2_&$>S5O'NI6\3$[H-)1+1&'H<9
M)_,5Q<F@6EQS=2WFH29R7O+V61B?Q;%>K#)Y+^)4L4?I)K7QU\ ^'\_;?&.B
MPL.J&]C+#Z@$UQ#?M=?!K29)Q!XMTH2R.9)5M(G8NYZL=J_,?<U\*1^'M*A;
M<FFV@;^]Y"D_F15R.WAA_P!7#%'_ +B!?Y"NN.445O-L#[+N/VX/A1)&T?\
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M@EQZ4 .^#O[6'@OQ3K'A;PIIOAC7O"NAZO \/A+5-3LUAL=8B@7!6W(8D'8
MP#A21R*^C4^Z*^(_AE\'?BIX@USX&^'/%_A&#PQH?PDD>>77UU".=-:D2 V\
M(MXU^9 02S>9@] *^VX_]6O&..E #ZKW-Y#:#,TJQ#L6.*L4F!0!136K';S>
M0GZ.#3O[:L/^?N+_ +ZJYM'H/RI-J_W1^5 %3^VK#_G[B_[ZH_MJP_Y^XO\
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M[H_*@"I_;5A_S]Q?]]4?VU8?\_<7_?56]J_W1^5&U?[H_*@"I_;5A_S]Q?\
M?5']M6'_ #]Q?]]5;VK_ '1^5&U?[H_*@"I_;5A_S]Q?]]4?VU8?\_<7_?56
M]J_W1^5&U?[H_*@"I_;5A_S]Q?\ ?5']M6'_ #]Q?]]5;VK_ '1^5&U?[H_*
M@"I_;5A_S]Q?]]4?VU8?\_<7_?56]J_W1^5&U?[H_*@"I_;5A_S]Q?\ ?5']
MM6'_ #]Q?]]5;VK_ '1^5&U?[H_*@"I_;5A_S]Q?]]4?VU8?\_<7_?56]J_W
M1^5&U?[H_*@"I_;5A_S]Q?\ ?5']M6'_ #]Q?]]5;VK_ '1^5&U?[H_*@"I_
M;5A_S]Q?]]4?VU8?\_<7_?56]J_W1^5&U?[H_*@"I_;5A_S]Q?\ ?5']M6'_
M #]Q?]]5;VK_ '1^5&U?[H_*@"I_;5A_S]Q?]]4?VU8?\_<7_?56]J_W1^5&
MU?[H_*@"I_;5A_S]Q?\ ?5']M6'_ #]Q?]]5;VK_ '1^5&U?[H_*@"I_;5A_
MS]Q?]]4?VU8?\_<7_?56]J_W1^5&U?[H_*@"I_;5A_S]Q?\ ?5']M6'_ #]Q
M?]]5;VK_ '1^5&U?[H_*@"I_;5A_S]Q?]]4?VU8?\_<7_?56]J_W1^5&U?[H
M_*@"I_;5A_S]Q?\ ?5']M6'_ #]Q?]]5;VK_ '1^5&U?[H_*@"I_;5A_S]Q?
M]]4?VU8?\_<7_?56]J_W1^5&U?[H_*@"I_;5A_S]Q?\ ?5']M6'_ #]Q?]]5
M;VK_ '1^5&U?[H_*@"M'JEI<2!(KB-W/\*G-6A^=)L7CY1^5.H **** "F>6
MOIQ3Z* &&)6X(R/3M2[!3J* &>4AZJ#SG\?6D\E>N.>_/6I** (_)3:!MP!T
MQ3U4*, 8%+10 4444 %%%% !1110 4444 %%%% !1110 4444 )7S!_P4F_Y
M,_\ &'_76S_]*8Z^GZ^8/^"DW_)H'C#_ *ZV?_I3'7;@?]ZI^J _%8?G4D-Q
M+;R"2*5XW'1E8@BHZ6OVMZJS*1V.D_%_Q?HL:QVVM2M&O 6X42C\C76Z;^TQ
MXBM55;NRL[OU;!0G\!7D% &TYK"5&E+>(SZ L_VI(AG[5X?D;WAN /YBM>V_
M:<\/R+^_TW4(#WVA7_J*^:?PI,5A]3HL#ZEC_:0\),N674$_WK<8_G4@_:+\
M'D9,EXO_ &Q'^-?*V*6I^HTNX'U*W[2'A!>AO7^D(_QJO<?M,>%H_P#56VH2
M^QB _K7S#2T+ TNX'T3=?M1:;'_J-"NG'9I)U7^E8FH?M/ZC)G['H\$8_P"F
MKEOY5XC1UZ\_6KC@Z2V ]#U7X^>,M1X2_BLH_P#GG;PC_P!"ZUQNK>)-5UZ1
MFU#4;F[W=5DD)'Y5G?AQZ45T1I0CM$!,<8_ASD+V%>R_LD_\EHLO^O6?^2UX
MW7LG[)/_ "6BR_Z]9_Y+7'F/^Z5/0EG[$_ W_D$Q_2O6J\E^!O\ R"8_I7K5
M?C'1"%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKP_XO?M7Z!\*
M_&$7@^R\/^(O'WC%K<7DF@^$[#[5<6\!/$DI)5$!QQELGTH ]PHKRWX*_M%>
M%?CEX<U/5-&:[TNXT><VVL:7K,!MKO3)0,E)T/W> 3G..#S7D[?\%$O JW#Z
MC_PBOC)OA^MW]B_X3]-(+:,7W;-PD#;C'O\ EW[<>] 'U517FOQ;^.^B?"70
M=#OYK6^\17NO74=EHVDZ)$)KG4)74N!'E@H7:"Q8D #O4WPE^-FC?%SP[JFI
MVL-UHESI%U)8ZMI6KHL5SIMQ&,O', 2H^4AMP)!!SF@#T2BN%^#_ ,6+#XT>
M#T\4Z/8WMIHMQ<316<M]&L9NHXW*">,!C^[<@E2<$CG%=R.10 M%%% !1110
M 4444 %%%% !1110 4444 %%%% "5\O_ /!2;_DS_P 8?]=;/_TICKZ@KY?_
M ."DW_)G_C#_ *ZV?_I3'7;@?]ZI^J _%>EI*6OVPI!1111<84444 %%%%(
MHHHH **** "BBB@ KV3]DG_DM%E_UZS_ ,EKQNO9/V2?^2T67_7K/_):\[,?
M]TJ>A+/V)^!O_()C^E>M5Y+\#?\ D$Q_2O6J_&.B$+1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%% !1110 5[)^R3_P EHLO^O6?^2UXW7LG[)/\ R6BR_P"O6?\ DM>=F/\
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MI MS87",'AD5  P& 02.* /LOS&R/EKSGX@?M)?#'X4Z]:Z+XP\<Z)X=U:Y
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M-K_S\P_]_!_C1_:-K_S\P_\ ?P?XTOV"V_Y]XO\ O@?X4?8+;_GWB_[X'^%
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M_!_C1_:-K_S\P_\ ?P?XTOV"V_Y]XO\ O@?X4?8+;_GWB_[X'^% "?VC:_\
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M'V"V_P"?>+_O@?X4 )_:-K_S\P_]_!_C1_:-K_S\P_\ ?P?XTOV"V_Y]XO\
MO@?X4?8+;_GWB_[X'^% "?VC:_\ /S#_ -_!_C1_:-K_ ,_,/_?P?XTOV"V_
MY]XO^^!_A1]@MO\ GWB_[X'^% "?VC:_\_,/_?P?XT?VC:_\_,/_ '\'^-+]
M@MO^?>+_ +X'^%'V"V_Y]XO^^!_A0 G]HVO_ #\P_P#?P?XT?VC:_P#/S#_W
M\'^-+]@MO^?>+_O@?X4?8+;_ )]XO^^!_A0 G]HVO_/S#_W\'^-']HVO_/S#
M_P!_!_C2_8+;_GWB_P"^!_A1]@MO^?>+_O@?X4 )_:-K_P _,/\ W\'^-']H
MVO\ S\P_]_!_C2_8+;_GWB_[X'^%'V"V_P"?>+_O@?X4 )_:-K_S\P_]_!_C
M1_:-K_S\P_\ ?P?XTOV"V_Y]XO\ O@?X4?8+;_GWB_[X'^% "?VC:_\ /S#_
M -_!_C1_:-K_ ,_,/_?P?XTOV"V_Y]XO^^!_A1]@MO\ GWB_[X'^% "?VC:_
M\_,/_?P?XT?VC:_\_,/_ '\'^-+]@MO^?>+_ +X'^%'V"V_Y]XO^^!_A0 G]
MHVO_ #\P_P#?P?XT?VC:_P#/S#_W\'^-+]@MO^?>+_O@?X4?8+;_ )]XO^^!
M_A0 +?6\C!4GC=CT57!J>H4LX8VW)#&C>JH!4P&* %HHHH *C:,]CM!]./QJ
M2B@")8V&>>>N?_K4>6V,%N/K4M% $?EGG)S2>6V[.<GWJ6B@")HV9<$C%2*N
MU0*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2OE__@I-_P F?^,/
M^NMG_P"E,=?4%?+_ /P4F_Y,_P#&'_76S_\ 2F.NW _[U3]4!^*]+24M?MA2
M"BBBD,**** "BBB@ HHHH **** "BBB@ KV3]DG_ )+19?\ 7K/_ "6O&Z]D
M_9)_Y+19?]>L_P#):\[,?]TJ>A+/V)^!O_()C^E>M5Y+\#?^03']*]:K\8Z(
M0M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[3#_ ,]4_P"^A1]IA_YZI_WT*B_LNS_Y](?^_:T?V79_\^D/_?M: )?M,/\
MSU3_ +Z%'VF'_GJG_?0J+^R[/_GTA_[]K1_9=G_SZ0_]^UH E^TP_P#/5/\
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M %?R/F8A54GJRC!/%31KM0#VIU% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBN,^(GQG\!_"6.U?QIXOT;PN+IML']J7B0&0_[(8\T =G15#1->TWQ+I-M
MJ>DW]MJ6G7*!X;JTE62*13T*L#@UQC?M"_#)?'!\&MX]\/#Q4'\LZ0=1B^T;
M\9V[,YSCMUH ]"HK#\9>./#WP\T&;6_$^LV6@Z1"0)+W4)UBB4GH-Q/4^E2>
M$_&&B>.]!M=;\.ZM::UI%T-T-[8S++%( <'##WH V**R/#7B[1/&5I<76A:K
M::O;6]S)9S36<HD5)HSMDC)'\2G@CM6O0 4444 %%%% !1110 4444 %%%%
M!1110 4444 )7S!_P4F_Y- \8?\ 76S_ /2F.OI^OE__ (*3?\F?^,/^NMG_
M .E,==N!_P!ZI^J _%>EI*6OVPI!1112&%%%% !1110 4444 %%%% !1110
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MNP%;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2_V-8_\ /G#_ -\"@"WO7^\/SHWK_>'YU4_L:Q_Y\X?^^!1_8UC_ ,^</_?
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MGDE<G/SMUIEEG[9!G_GJG\Q47^-2V?S7<"]O,7.?J*F+>AWUX1AAZB@K:/\
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MI.H7=_8Z58V=]=G-Q=6]ND<LW?YV RWXUI444 %)2T4 %%%% !1110 4444
M%%%% !1110 4444 )7S!_P %)O\ DS_QA_UUL_\ TICKZ?KY?_X*3?\ )G_C
M#_KK9_\ I3'7;@?]ZI^J _%>EI*6OVPI!1112&%%%% !1110 4444 %%%% !
M1110 5[)^R3_ ,EILO\ KUG_ )+7C=>R?LD_\EHLO^O6?^2UYV8_[I4]"6?L
M1\#?^03']*];KR7X&_\ ()C^E>M5^,=$(6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "HKK_CUF_W&_E4M177_ !ZS
M?[C?RH*C\2/Q+U3_ )#6H_\ 7S+_ .AFJX[U8U3_ )#.H_\ 7S+_ .AFJX[U
MXDMV?Z:8;^##_"OR%HHHJ3J"BBB@ HHHH **** "BBB@ HHHH 3_ !J6Q_X_
M(/\ KJO\Q47^-2V/_'Y!_P!=5_F*<>AQXG_=ZOH_R/T6_9__ ./I/H/Y5]21
M_P"K7Z5\N? #_CZ3Z#^5?4<?^K7Z5[:V/\TJ_P#%EZL=1113, HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***HW5XEG;S3S3+%%"K2/)(P554#.23P
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MR9_XP_ZZV?\ Z4QUVX'_ 'JGZH#\5Z6DI:_;"D%%%%(84444 %%%% !1110
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MO\:/[#LO^>3?]_&_QH NU\P_\%)LG]C_ ,8\?\M;/_TICKZ1_L.R_P">3?\
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MB_NCT_YZ-_C7MK8_S2K_ ,67JR_15+^P[+_GDW_?QO\ &C^P[+_GDW_?QO\
M&F8%VBJ7]AV7_/)O^_C?XT?V'9?\\F_[^-_C0!=HJE_8=E_SR;_OXW^-']AV
M7_/)O^_C?XT 7:*I?V'9?\\F_P"_C?XT?V'9?\\F_P"_C?XT 7:*I?V'9?\
M/)O^_C?XT?V'9?\ /)O^_C?XT 7:*I?V'9?\\F_[^-_C1_8=E_SR;_OXW^-
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MMG_Z4QUVX'_>J?J@/Q7I:2EK]L*04444AA1110 4444 %%%% !1110 4444
M%>R?LD_\EHLO^O6;^2UXW7LG[)/_ "6BR_Z]9_Y+7G9C_NE3T)9^Q/P-_P"0
M3']*]:KR7X&_\@F/Z5ZU7XQT0A:*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *BNO\ CUF_W&_E4M177_'K-_N-_*@J
M/Q(_$O5/^0SJ/_7S+_Z&:KCO5C5/^0SJ/_7S+_Z&:KCO7B2W9_IIAOX,/\*_
M(6BBBI.H**** "BBB@ HHHH **** "BBB@!/\:EL?^/R#_KJO\Q47^-2V/\
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M^5?4<?\ JU^E?+GP _X^D^@_E7U''_JU^E>VMC_-*O\ Q9>K'4444S ****
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M?LLZO\/K];KQYXF-P/&SVUVTUQ>P?9R]RU\A8X*3XVE@"IX%?I5&P9 5.10
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M[&M?27_O^_\ C1_8UKZ2_P#?]_\ &@"[15+^QK7TE_[_ +_XT?V-:^DO_?\
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MKOAC0-)TR?5=:_8Q\7:=I%NGG7-W#J-O*T,8Y9]B+EL#G KH_'?PO_9S\/\
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MTE:4*V#@=ASS2+#C'SG([U\X_M4:=XBA^ ^E_$BT0V/C_P "1P>(@D!.UV1
M;RU(!^9'0R+CV%>Z> _&5C\0O!.@^)M.S]@UBQAOX-W4)(@8 ^XSC\* -_;[
MTSR0,X/6I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNW'K7V9X7\%:+X+\.VN@:%I5EI6B6L?E0Z?:0B.%$]-H]>_KGFO.[/\ 8_\
M@QI_C(>++?X;>'XO$ F^T"\6UZ29SO"9V@^X% &%H.LZXW[$\6I?$)=FM'P:
M\NJK+R2WV<Y+Y[D8)]\T[]A&SO+#]D'X50WH9;@:,C$2')VLS,O_ (Z5Q[4_
M]K?PUXG^)?@"R^&OAJSNBGC"\2PU75DCS!IVG [[EI&_O.@**O4EJ]H\/^'[
M+POH6G:/IL0MM.T^WCM+:%>B11J%5?R H TJ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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@B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img11029722_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_3.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '$ Q<# 2(  A$! Q$!_\0
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M2KV]UNWS.FOAYX9Q4]I*ZMLU_FMF=913=U.K$YPHHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I,T'I7SU'^TOJ7]O#4CX9M_^%;-XE_X1,:Y]M/VLWGF^1Y_D;=OD&?\
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MA_\ #G_@RB_^*JN2?9@>@T5Y]_PT)\,?^A_\.?\ @RB_^*H_X:$^&/\ T/\
MX<_\&47_ ,53Y)_RL9Z#17GW_#0GPQ_Z'_PY_P"#*+_XJC_AH3X8_P#0_P#A
MS_P91?\ Q5')/^5@>@T5Y]_PT)\,?^A_\.?^#*+_ .*H_P"&A/AC_P!#_P"'
M/_!E%_\ %4<D_P"5@>@T5Y]_PT)\,?\ H?\ PY_X,HO_ (JC_AH3X8_]#_X<
M_P#!E%_\51R3_E8'H-%>??\ #0GPQ_Z'_P .?^#*+_XJC_AH3X8_]#_X<_\
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MIA9^SJJS_/S1K3J1J1YD34445SFH4444 %%%% !1110 4444 %%%% !1110
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MA)4'YE !-%D!].WGQ+\':?J\NDW7BK0[;587CCEL9M1A2=&D8+&K(6W LS*
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M_P -!^"/^?O5O_">U#_XQ1_PT)X(_P"?O5O_  GM0_\ C%'+/LP/+]!\'?M
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M ,-?&?PCL/%OAOQ';Z5-HK:[>:KI&J:?=.\MQ'<S/*5EB9!Y;+N X8YKK_\
MAH3P1_S]ZM_X3VH?_&*/^&A/!'_/WJW_ (3VH?\ QBERS[,#O-8_Y!-[_P!<
M)/\ T$URGP+_ .2*?#[_ +%[3_\ TFCK$U3X_P#@N;3+N..ZU8N\+JH'A_4>
M25./^6%;GP3M;BQ^$'@6WNX)+6YAT"PCE@F0H\;BW0%6!Y!!R"#SG-59J.J
M[>BBBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 2ODY?C-XZ^RK\3#K<7_")MXT/A<>%!9IM^Q?;/L0G\[_6>?YO
M[SKMVG;CO7UE7@8_9AN?^$@6U_X2IA\/AXC/BO\ X1S["OG?;?-\[ROM&[_4
M><?-V[=V>-V* '_M2?$W6/AY'X(M;#69_#VFZUJLEIJ.IZ;IXU#4(T6!W006
MV&+;G4!W"ML7G'.:Z;]F7Q]J_P 3/@SH?B'7)H+K4+EIT:X@C$1F1)G2.22(
M$^5(R*I>/^%B1QC%4/&'P8\3>)-7T#Q-;^,8;;QGX?O+Y].OI=+5[;['<X5K
M:6$."2JJF) P.5SW(KJ/@Y\+T^$_A.?3#J,FL:A?:A<ZMJ%_)$L0GNKB0R2L
ML:\1KDX"CH!U)R: .0_:&Y\6_!8 9_XK6'I_UY75>T;J\"_:P\+Z9XTNOA)H
MFLVWVW2KWQG!'/;[VCW@6ETP^92&'('0BO2?AU\'?"7PGCO8_"NE'2DO65[@
M?:9IMY7./]8[8QD],4 =K1110 4444 %%%% #6_6L+QAX1TSQOX?OM'U:W6X
MLKR%X) 0-RAE*DJ3T.">16\:3;GK1TLRH3E3DI1=FNI\C_#'4/$W[,OCB'P%
MJ7A_4=0\&^(/$?V#P_K5YJZSM!!Y(V1^6<L /+8]AS7UKU)[5X-^V1X-N/$G
MPM@U+2[+4M0U_0=4MM1L(]+W&8,)%5R%7EOD+<5W7PA^,&E_&+2]3N],LM2T
MV32[UM/N[75;?R)HIE568%<GLPK*/NOE;/?QZ>-H0S!1]YW4[=U:S^:?WW,[
MX_? VQ^.GA.UTJXO6TC4+&]AO]/U6*%99;25&!W(K<<@8Y]:\=T7XW:W^SY\
M:-7\'_&'QD-2\/ZAI\>H:)XCOX8K9=RG;+"4B7J6(QD_P^]?617=U'TS5.ZT
MFRU"0/<V<%PZ\!IHE<@>G(/%>OAL;RT7AZ\>:G9V6ETWK=/6VQ\K4HW?/3=G
M^!Y7I?[77P=UC4K73K+Q_I,][=3+!#"K/N>1CA5&5ZDU[!GUS^5<'\2/@?X5
M^*GAO^Q-8L3!:"XBNEDTXBVF22-MR%9%&1@UY#XV_8_N["QL+[X=^,=>L/$E
MC?0W*/X@UNZNK.2-&W-&\8;D-@#\ZJ-+!5;<LW!^>J^]6_(3E6CO%/\  ^F]
MWS=<4_<*^8?&GC3]H/X96NF:SJUCX9\6:0=0@@OK#PQIUU)?+;LW[R1 SX.T
M _G7;^!?VIO"?C#Q9>^';RRUCP?JEM:+?&+Q7:KI_F1%M@*;F^;G/Y5G/+Z\
M8>TA::[QU^\<<1!NTM'YGLXI:S-)\2:7KT3RZ9J%KJ42-M9[.=90#Z$J3@UH
M+)N&<5Y[]UV9TK570^BDW49I +1113 **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:*0O@9QFD#!JX;FX[-%-)Q3EZ4 +1113 **** "BBB@ HHHH **** "BBB@
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M8M%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQGBO0@<U\:S"3]C'XP:>IU-U^$_BRZNI)K=HECATJ\;#C;M!8KM7'U->R?\
M#8GP=7_F>++_ +]2_P#Q%"ETEN;8S+9.I[3!Q<Z<M59-V\GYIGL]%>,?\-C_
M  =_Z'>R_P"_<O\ \32?\-C_  =VY/CG3T'JR2@?^@U7-'N</]G8RU_8R_\
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MW5X+_P +>^-7_1"__+GM?\*/^%O_ !H"Y/P+/_A36O\ A4_4:O\ -'_P./\
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M*B\_^+H_X8U\#?\ 09\:?^%1>?\ Q=>]T4?VIC?^?K^\/JU'^1'SGX@_8O\
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M%N^#C_KG4G_#:'PM_P"@IJG_ ();O_XW3YX]S%Y3F$79T)?<SW7=1N%>%_\
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M\H;<9-/HH 9Y>!PQ%*J!<XIU% 'C'[2/_']\(C_U/NG_ /HFXKV>O&?VD?\
MC\^$G_8^Z=_Z*N*]FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!NSWQ2&/T.*?10 W;SG--\D9R./PJ2B@"/R$'0
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MU'Y29Y56]>!Q1RN]TRGF$*T>7%4E)]U[K_R_ \/_ .&U/AK_ '_$'_A/W?\
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M-Q@LN02,X)!]F?[I^E?/'Q^US6/%&@0V]KIOQ1TJTM=9FLKN#P3;0)=ZA"B
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MA^S'\8_@G+I?AZYL-:DN[S1-;AU1@US+-)%B-XBG[L!(R<DGDXQWKIC^R?\
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M_+\;/ $U[\0]7GU*SNUU6/R[19&5@L@+Y)XZCUJWXD^#7@X6GPD\1^%_C/\
M#6#XA>!O#\?ARX;7)[>]TK5+94(*O&9 ZX9G((.1N[4 ,M?^"@'B?5?V9_C)
MK=A<>&M0\>_#B]M[;^UM)5I])U.":;;'<Q(6R P608W'! Y[5J:A^U3\;/AW
MK7P)\1>,K?PG<^$/B9<V]HVB:9:S)>:?YR1LCF=G(=L2;B H (*\]:KZY\*?
M#WB+]FCQ_P"!=4^/W@G4?&7C&YCN;C4#>6MOIMB$E#BWMX8VW+$H# 9)Y-:_
MQB\"^#OB3X=^ .GVGQE\!V<OPWO;*[O9)M5B9;Q88HD81@/\N?+.-WJ* /)?
M"NF_%_Q!^VA^TKI]GXOTNXU*UT 0W"MI\N)K5H,P06O[S]PZEERWS MDXYKK
MO$-YX@\0?L6_#+PMX<\!>)?$7A#Q#X*%@=2\#RXU2PU%$'EPSJ2,6DC!ED.>
MS!AR >\L]'T/PC^V!XB^+GACXU?#F+P]XKM[2UUW2-1OHGN0L,:J/L[K*%!8
MH#E@>IX/%>_^'?BK\&O"&GG3]$\;>"])L?-DG^SVNKVL:;Y'+NV _5F9F/N3
M0!XI\-=+\11_M9?#"'6K2UL]?TCX2>1XBBT[:MM!*]U"(X0J\ ;XY"H' "G'
M%?7R_=%>66?Q4^#&GZ]J.MVWC;P5!K&HQQ17E\FK6HFN$B!$:NV_)"AFP.V3
M6M_PT!\+_P#HH_A/_P '=M_\70!\1?$/P+XFU;_@JYH=K9?$35-+N;CPRU_;
MW,-E;NUG;!I-UFBLI4QMM.7(W_.>>!7(? O0_B-JGCS]KF_\%_$ ^ ;71]>N
M]0:2VTV&[GN[A!.RHQE!"187G:-Q+#GCGZ/^+?A?X;^/_CQX4^+/AW]H#0?!
M?B?1;$Z7-Y%[87<=W9F1G:/$DGR$[W7<,G!&,8IOPP\%?"3X:3?&=XOC9X;U
M _$J[GNIO,U"T3[ 94D7"XE/F8\SOC[M 'A'C/\ ;(^+GB;]F#]G?QAH.O6W
MAWQ;XM\3OHNI3QVD<EO<A9&B4LC*<*=H8A2#DG!%>P_&KX@_$_X4^)OA1\#]
M#^(,^K^-O'U_=27'CG6-,@WV-K$H9EA@C41[L9QD'ISUR.4M_P!FWX/0?"'X
M3>!/^%_^'VA^'_B!M>BOOM5GNO&,ID\IE\_"#G&03]*]<_:(T7X+_M +X<U$
M_%_0_"?C'PS=&\T/Q+I.MVGVBSD.-RE6?#HVU<J>N![Y /.K/XW_ !-^#/QM
M\<_!OQ9XM_X3GS/!EYXF\/\ BB6PAMKVUDCAD;RYDC C8 H2#M[#KDUQ]Y^T
MU\3XO^"64/Q63Q7<#X@/<JC:U]F@W[?[0\K'E[/+^Y\OW?UYKU7X6_#_ .$7
MA7QEXF\;>.?CIHGQ,\=>(-/;2+G6-1U.QM(X;)AAH(((GVQ@]R#],9.?(-4_
M9)^&NH?"&^^%H_:OMH_A^MW]MTO16NM.*V<ADWD22"0/.O+84E0&.[&10!WW
MB;XT?$WXL?M%> _@WX2\9MX#MU\'V_B;7/$%OI\%U=W4CQC$:+*I11DJ3@=S
MZ 5Y#XE^*'Q/\4?"W]M?P;\1O%<?BG_A$;*TM;%K>SBM845VE+,JH,C<J1DA
MF;!!Q72?M#>.?@CX/^,_PUUC3?C-J'@3QQI&A)I0\8Z!I\&K:=<V:AE,-PH+
M@294D#!QO7@\$<'^S/HW@+XI6_[55C>_$ZVTGPKX]N[6PTWQ#XBOH4O[SR_-
M>6Y,4K(2"9%QP!S@8Q0!L6/Q*^,7[-O[.O[._C^#Q]!JF@ZU+INC2^"VTJ%+
M1+22,E")L&4R[$^9BV-S<# Y_13XM#'PI\9C_J"7O_HAZ^5/B-\(_A%\0O@/
M\+_AG)\=?#ME!X&NK*YCU);ZS=[PV\;( R>< F[=G@G&.]?0OBSXQ?"WQ5X7
MUC1F^)OA2V74K*:S,RZS:L8Q(A3<!YG.,YQ0!\X_\$]_!'ACQK_P3]T2R\4:
M5I]YIES#J<=U)>0(^(_/E!8DCC R<]L"O!_V:_C9XA^%_P#P3_TU=(\;:5X0
M:;QG=:5;:OJT4EU<PV1VNZV%LL;F>;<Q(4C:-QS73^'/V0O"GAWP:O@R#]M6
M>#P2RO%-H5CJ5K;PR1.29$ ^TD -DYX.<]*]6\>? ?X :W\,_AWX5\'_ !?T
M/P)>> +S[?H.L6NL6=S+'.2&DDE1W"RL[*K'..1Z<4 <'\$/CM\8/B=XH^.W
MPPT_QKK=UJ&C>'DU7PQKWB#08-/U6.X*QLJR0!-OEONP-R9VD'@FI)OVQ/'7
MQ9^#_P"SSX<\&ZZVC_$_QMK#:=KMU%;Q--:Q6;;+QS&ZE4+<-ROKC%=[\*_#
M'PR^ OQ>\8?&'6/VB]+\7W^L:/Y>M_;KBS9Y&BVMYL0@?*J%C"K"B'@8!/%>
M%_L2CX4WO[87Q?\ B[:^)-'T7P9#=SP>&EU>^CM#++<$-<311R%2$P".G20#
MM0!^F?B+PSIWBKP[?Z#J\'V_3-0MFM+N&0D>=$R[74E<'D9Z8ZU^>/Q=\ ^$
M?V@O'?@?X ? _P )VEKX3\!ZU%J'B'Q?91DVVF;22]K%.23),V23\Q^8+_=)
M'V'\2/BG\/?&W@+Q!X>TWXP^&O#5]J5G):0ZM;:M:R2VC.I7S%4R#+ $XY%?
M'?PZ_9;T7X4Z7:Z1X7_;<?1-$@N#<?V=I]]:0Q,Q;+D@77);N3F@#S?XQQ^)
MH?CS^U4/A'X-M?B5I.I::(/%6H:M;H'T.8QOYBVY=P9<;78*HZQCKL!/WQ^P
MO_PCJ_LF_#:'PKJLVM:/#I@C6[N(O*D,@=C*K)D[=LA=<9/ ')ZU\[_%K]FG
MX0^./B%XK\3^$_VE(OAS%XP&/$FE:1KMJ]OJ.00Q(\U=N[+9!W#+-QR17TA\
M'_%'P1^!_P -]#\$^&?B#X8BT;28/)B,^O6SR2$DLSNV_EF8DGH.> !Q0![A
M17 _\- ?"_\ Z*-X3_\ !W;?_%T?\- ?"_\ Z*-X3_\ !W;?_%T =]17 _\
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MOZQ^,=SXBOW^$7B3Q;<?#ZUTMIV^Q00I'Y=OJ"IG;F2[BE4N<84X]* /IO\
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M?\,A?!+_ *)7X4_\%47^%>O44 >0_P##(7P2_P"B5^%/_!5%_A1_PR%\$O\
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M3O'OQ(\7^&O@_P"%_#>H:?X.DCM=4U?Q1?S0QW=X\8D^S6RPJ2"JLN9'^7+
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M[(*CJZ.=^$"[X_*!Y)!V]:^R;5/+C5"S,44+N;O@=: )J*** "BBB@ HHHH
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ML00?QH \B_:>_P"//X9_]CWH_P#Z&]>TUXI^U!_QY_#3_L?-'_\ 1CU[3N%
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M 4444 %(U+10 W'^<48-.HH ;@T8-.HH 04M%% "8'I2T44 %)2T4 %)2T4
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M/VHA_P 2[X;'/_,]Z-_Z-:O:MM "T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44E&<]* /%?VHO\
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MBBB@ HHI-PSC/- "T444 %%%% !124;@>AH 6BBB@ HHHH ***3(H 6BBB@
MHHHH **** "D)Q2TC?=- ' _%/XL0_#M]$TZUT6^\3^(]<FDATW1=.*+)-Y:
M;Y79Y&"(B*,EF/4@#DUJ?#+XAZ;\4/"-OK^F17%K'))+;SV=XFR>UN(G,<L,
MB@D!E=2#@X/4<&O//C5IVKZ'\4OAMX_L-"U#Q'IN@IJ%CJ%EI$8ENXX[J*,)
M,D9(WA6B 8 Y ?..*T_V9O">K^&/ >IW6N6$FD:AK^O:CKQTV9@TEHES<,\<
M4A!(WA-NX \$D=J ,[]J3_D%_#C_ +'O1?\ T<:]KKAOB_\ "F'XN>';+3)-
M9U#P_<6.I6VJVNH:9Y?G13P-N0@2*RD9Z@BN1_X49XY_Z+IXO_\  '3?_D:@
M#V?-<;\6?B)%\+_!_P#;LUC)J$?VZSLC#$X0YN+F. -D]@9 <=\8KB/^%%^.
MO^BZ>+O_   TW_Y'K'\6?LO^)/&VC_V5K?QK\77EB9X+GR?L>GIF2&598SD6
MX/#HIQWQ0![]'A05]#BG[J\7_P"%&^.^?^+Z^+?_  7Z;_\ (]'_  HWQY_T
M73Q9_P""_3?_ )'H ]HW49KQ?_A1WCS_ *+IXL_\%VF__(]+_P */\>=OCIX
MK_\ !=IO_P CT >S[A7&?%[X@P_"OX=ZYXMGLY-0BTN%93:Q.$:3+JN QX'W
MJXK_ (4?X]_Z+KXJ_P#!;IO_ ,CUC>,/V8_%'CSPU?\ A_7/C7XJO-)OD$=Q
M#]@T]-Z@AA\P@R.0.E 'T I^49X]J7(KQ?\ X4CX^/3XZ>*/_!9IO_QBC_A2
M'Q _Z+KXH_\ !7IO_P 8H ]HR*,BO%_^%(_$#_HNOBC_ ,%>F_\ QBC_ (4C
M\0?^BZ^)_P#P5:;_ /&* /:,BF3.$C=NNT$UXW_PI/XA?]%U\3?^"K3?_C%(
MWP2^(+*0?CIXEP1C_D%:;_\ &* .V^$?CZ/XI?#G0?%L5G)I\6JV_GK:RN':
M+YBN"PZ]*[+<*\ \(_LT>+/ ?AK3O#^A?&OQ-9Z3I\?DVT#:9I[E4R3@L8,G
MDGFMC_A2OQ#_ .BZ^)/_  4:;_\ &* /9\BC<*\8_P"%*_$3_HNOB3_P4:;_
M /&*/^%*_$3_ *+KXC_\%&F__&* /9]PIK,-I_PKQK_A2OQ%_P"BZ^(O_!/I
MW_QFD/P7^(HY_P"%Z>(O_!/IW_QF@#MO /Q$B\;Z[XTTV.R>T;PUJW]E22/(
M&$[>1%-O7'08E P?[M=EFOGWP_\ LT^,/#.H:Y>Z;\;?$4-SK=Y_:%\[:5I[
M^9-Y:1;@##\HV1H,#CC/>MO_ (4Q\1_^BZ>(/_!+IO\ \9H ]GS1NKQC_A3'
MQ'_Z+KK_ /X)=-_^,T?\*9^)'_1==?\ _!)IO_QF@#V?--9O;)KQK_A3/Q(_
MZ+KKW_@DTW_XS1_PIGXD_P#1==>_\$>G?_&: .Q\+_$2+Q1X^\;^&$LGAE\,
M26<<EPS@K<>?#YHP ,C XYKM5^Z*^?M)_9I\9:#XCU[7;+XV:]%J>N-"U_*V
MCZ>PD,4?EQX4Q87"\<=:V_\ A37Q+[?'77/_  1:=_\ &J /9\T9KQG_ (4W
M\2_^BZ:W_P""+3O_ (U1_P *<^)?;XZ:W^.@Z=_\:H ]FW4;J\9_X4[\3/\
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M76\_\);3_P#XF@#V;=1FO&?^%3_%K_HNEW_X2VG_ /Q-'_"J/BS_ -%TN_\
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M,RB(32 ':A<\*"<#/..M:-)M'7'- 'RCI/Q\^(G_  I[Q%=ZL-'@\=S>//\
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MC%9_PG_9D\-?!WXF>+_%FB>>IUV&V@BM9;F>7[,D2$.-TDC;]S?-D\KC XH
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M;PY'>)(8FMWU:W$@<'!4KOR"#QBNLCG610R\J>C=B/7Z4 244SS!G%'F+Q0
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M4L -Q.*]*_:"^$,7Q[^#_B3P!<:I)HL.MQ1PO?PP"9H=DJ29"$@'_5XY(ZT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 2C:/2BB@!:3 ]*** "C ]*** #:/0?E1110 8'I1@>E%% !1@>E
M%% !M'I1M'I110 M)@9SCFBB@ P/2@*!T&*** #:/0?E1M'I110 48'I110
M8'I1@>E%% !@>E&!Z444 +1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img11029722_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_4.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $N S # 2(  A$! Q$!_\0
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M ?J'_P -S>!/^@IIW_@0W_Q-'_#<W@3_ *"FG?\ @0W_ ,37Y>;1Z"C:/04
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M?_6J7EV5JS]J]=/(;BHJY]^_\/!/@K_T/FB_]_G_ /B*/^'@GP5Z?\)YHO\
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M_@G3\3/B)X)TSQ)_:6@>'$U2/?IVG:W,T=U=C&04 &/F'(^M>>_#S]ECQ?\
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M-!2CK8TDG%(^N_V1_P#DV3X[?]=;/_T&N17[H^@KK?V1U#?LR?';_KK9D?\
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M*Y ;#>3(' /ID?RJD2]#Y[_X89\!_P#0+T__ +\M_P#%4?\ ##/@/_H%Z?\
M]^6_^*KZ07.?:E.:7-I<9\W?\,,^ _\ H%Z?_P!^6_\ BJ/^&&? ?_0+T_\
M[\M_\57TCS1DT<VMAV/F[_AAGP'_ - O3_\ ORW_ ,51_P ,,^ _^@7I_P#W
MY;_XJOI')'>J]OJ5M>1A[>ZBN$W%=\+AUR.HR*%*X6/G;_AAGP'_ - O3_\
MORW_ ,51_P ,,^ _^@7I_P#WY;_XJOI$9;/:F\\\]JI ?.'_  PSX#_Z!>G_
M /?EO_BJ/^&&? ?_ $"]/_[\M_\ %5]'!CN//:I*!+4^;?\ AAGP'_T"]/\
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M>=H->+Z-X1UY?AC^R1;G0M3CGT_6@]Y$;9P;-=S<S#&4'N:]7_:(T_6OA_\
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M/L*[OX.^&]9M='_:62YTJ\B>_P!?O9+7SH63[4I@4*8QCY@?4=:\I\%S:_\
M#/1?V6-?N_"6O7ECHVC:A%K,-O9.T]@C.HWO&!N^B=2.E5%)3CZ?C8(:Q3>]
MV?2?@O\ :*UC2_&FO^#?BKHNG^&_$6FZ6^NV]SI,[SV5[9H/WC1LX5MZ'@KB
MN0A_:L^(^H> V^*ME\/]/;X5J3/LENY!K368;#7(B"^7MQE@-V=M<_>:#J'[
M5WQCUWQ5I&F:AIGA'2_"=YH&GWVKVDEH]S>W R2D4@#!%Z$D?2N<L?BIK>A_
MLO/\%I/!7B(?%.'2V\-Q:?#I\C6LK,OE+.+K;Y03:=_+9XQ66KBWUM^K&M_+
M_@'1:MXRTS6OVM+CQ9IXCU72+KX9'4H89"0D\9D8A6'H1@&NBT+]IR/P_P#
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M>&X)QBMXMRD[D-<L5;R.[_:=O)/AKXL^'_Q&L@T=Q::K'HVH^6O_ !\6LS8
M([A7);)KW[Y70%3^[?$JJ>O/.<^F.U>!_M06;?$7Q1\//AW8RYO;[4TUB\*G
M/EVD#;PY]G(*^F:]\553*+P%50">R] M73O=KH14DK+N)12TE7U%'5!1113*
MU"BBB@-3IO#_ /R*6O?5*P^Y^M;OA]2?">N@<DE*PPIY..#S7@8CXV?1Y?\
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MC3OM_CT ?\2G3F([F?!]@>:\QB_;0\.-H<6M3^ ?B3:: \*W)U:X\-.MLD#
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MH^/_ /H$Z;_X$?\ UZ[4J1AN0QZX'6FLQX8_<![_ ,Z .,_M'Q__ - C3?\
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M37,FH:/>%!:OIZ^9)<LY 6.-.K'KQ[&CV3E]H?.NQZ9]E\+_ //]=_\ ?O\
M^M2_9?#7!.H7@0?*,QX'/X9(KB/$7B*#PMX=N];NX+N>UM(_-DCLX2\WE@9)
M">PY/TJ3P[X@TWQ9H>GZSI5R+O3;Z(36UP#\C@\\^A]J:HOG:Y@OU-K3_ /P
M_P!-\2:CXAMQ<)K^I($N;YU+.T:_P*#]Q>^!BMG[+X790?MUY@=%\O\ ^M7/
M9Y/&QOXE]Z*2HRC[JD+G3U:.@^R^%_\ G_N_^_?_ -:C[+X7_P"?^[_[]_\
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MPW_S^77_ 'S1]F\-_P#/Y=_]\UR>CZ[I_B31[/6-,O(;S3KZ!9H+N(Y5XV'
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M%IOB;5?CAH7P-TCQUXHL/"^GZ,VO:MKAU#?K%TQE*1PK<XRJ@X)XY'%=#;?
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M(_ W6Y=,E:#4-1DBTZ*X4X:,RL%W#WQFO8K739;6T@MTM)ECAC6-5$;8
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M+H(XW_A5'AG_ *!W_D1O\:/^%4>&/^@<?^_C?XUV5%"NE89QO_"J/#/?3O\
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M;G_";:U_S]#_ +X%'_";:U_S]#_O@5AT4>RI_P H<S-S_A-M:_Y^A_WP*/\
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MH3_]_A1_PFGB;_H4)_\ O\* .ZHKA?\ A-/$W_0H3_\ ?X4'QIXGQ_R)\_\
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M!MM]SG**Z/\ L'1/^AAC_P"_=']@Z)_T,,?_ '[H]O#^D/D9SE%='_8.B?\
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M*]OG_P $^(O%GA=M#\&_$3Q%X3N[Z_M_"EM<-;:M=$2W>I:FZA9KMV Q)L3
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M@9Y/2G51L;D74<$J#Y617/&,!AD"K]-Z!%W$HI:*10E%+10 E%+10 E%+10
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M?:SW5U+';6T"&26:9@JHHY))/2OG#X9W5UKG[7GB?7=?MF\%:]<:)%&GA>[
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MN1D'9( 2".X&*\0OO@!J.A_L<ZMX>L;62?QCJD<>L:U([_OKVY\Q99ER.20
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M-'_"HM+_ .?_ %/_ ,"C0!V_%'%<1_PJ+2_^?_4__ HT?\*BTO\ Y_\ 4_\
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MS_:FUGQR]O"?#ESX>33XY1, _FB4,?D//3O7OW_"=7O_ #Z69'IY5(WCB]W
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M^V @.4!X+A,^^*%_$4>G*4]CZU\*_&CP1XV\(7GBC0_$5GJ.@V2N]S>1E@(
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M .@?$KQ7=Z%=Z#J%U#_:/AF&Q$4]C;RL%0+/G+L,C*XKZE61;B,2Q\Q21K(
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M%_\ 47L?^_E<WY:_W1^5'EK_ '1^5=')4_F)YD=)_P (7_U%['_OY1_PA?\
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M 'U7/;1Z"C:/04!R5/YCH?\ A$_^HK9?]]4?\(G_ -16R_[ZKGMH]!1M'H*
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M_"/XV?#[QSIJ);6OB&[70-9A5<)+OR(G9?52&YZ\UYQX.^%?C.2U\#?#._\
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MR6>GVL?E1V-DK$1HJ=L@ _C7L'QT^);?"7X6ZYXDCC6XU*WC$5E#(<+)</\
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MB\6O&T=PY>3][)=7!^0JW(V9Z<5$I<DD@BKJ]S[)NM3M=/5#=WT%F'.U3<W
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M'645JCZW9G!P78'\?\:K7FJVNFA6O-1M[(-]TW5PL6[Z;F&:\X_9AN?$.H?
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M_NT_($U=2>R_4\ /@W4-#_8'^)/B368&M_%7C#3[GQ'J4<D@++++@HF[T"!
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M_0T0_P#@-1_PC/C/_H:(?_ :@9W7/K1SZUPO_",^,_\ H:(?_ :C_A&?&?\
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M''<O'<0L+@X1#G 0 8VXYYKO/B9XQ_X6/^T9:>%_&GA#Q1\1?"FA>%K+4HM
M\/VHFCENKA?FN+@;TW 8^7G@UTS2YN7^M#.'\-2/O-;N%H5D26-XV&0X8%2/
M7-)'J%M-(8X[B&23KM1P3CZ9KX+T9_$7AGX?_'W1K'PQXF\(_#D:.+_0;+Q!
MMCN+"9@1+%"@=F6+(4KD^M:_AGX<>"?A'^QO9^/FU6;PSXHOM!A6^\:1H]UJ
M$GG%=ZQJ6P6?.U1VR*QD[)OT_$I:M176_P"%C[<CU*UN)#'%<PR2?W$D!/Y
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MY"CRW]_R%>TC2[,_\ND/_?L4?V59?\^D/_?L4_KLR?9(\6\M_?\ (4>6_O\
MD*]I_LJR_P"?2'_OV*/[*LO^?2'_ +]BCZ[4#V1XMY;^_P"0H\M_?\A7M/\
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M/?-<CXU^ ^E>+OA_HGARPG?P_)X?EBNM)U*W16>TGCSA]A.'SEL@\'-?5_\
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MN?G:U/COP+\/=9^'7QP\:R:7:%O"/BZ(:C]OBQML-14;-A4]<J,CW-8?@/\
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MU7XG?&OP9]OTZ2'P9X8#:JUZV"MS>?\ +.)><_(<YSZU]>_V39*NW[+#C&"
M@ /M35TFT5B?LT62 &^08..E!'UCI8\C;&"2#R,;<#Y<T<_YQ7K_ /9=GU-I
M"3Z^6*7^R;/_ )](?^_8H*6+FMCQ_P#SVH_SVKV#^RK/_GUA_P"_8H_LJS_Y
M]8?^_8H']<J'C_\ GM1_GM7L']E6?_/K#_W[%']E6?\ SZP_]^Q0'URH>/\
M^>U'^>U>P?V59_\ /K#_ -^Q1_95G_SZP_\ ?L4!]<J'E&F3);ZG:2ROY<:2
MJS,?3->LV]Q'=1I+$ZR1R<JP/6F_V39_\^D/_?L5-';K"H2,!$4855' H.:I
'4E5?-(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img11029722_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_5.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $A M(# 2(  A$! Q$!_\0
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M_AXCX.]3_P" DU?G)10!^C?_  \1\'>I_P# 2:C_ (>(^#O4_P#@)-7YR44
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M=UI"Q265OM^1X1M&]]W&W!XK6.6Y?4FZ=-3>ZV?0:CHS](/^'IOP8_Z"E_\
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M^@9:?^!8_P * /(:*]>_X92^(_\ T#+3_P "Q_A1_P ,I?$?_H&6G_@6/\*
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MX)[?M/>#UOAH$EEHHOX?L]V+'Q&L0N(_[KX'(Y/YTWPE_P $]?VGO .I-?\
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M7T1MW2?E7QKJ'A#6/%__  4 \<VVB>-=3\%74/@VQD>;2[>WF>9#-C:PG1U
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MAGACD6.4\#)=3G'-=?-\,_#4WB_2?%']EQ)KNDV;Z?8W4991;V[XW1J@.W'
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M'6NR VU;=T6+1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %<5\3O^/&Q_ZZG_ -!KM:XKXG?\>-C_ -=3_*MZ'\6),MCSZBBBO>MU
M. ****!A1110 4444 'I^='H<4447'<,9SWSU/<T=1CMG.***!!Z=L=,<8H[
MYQ_];Z444;/0-]&%%%%%@"BBB@ HHHH **** %7[PKH]4_Y%_0/^N+?SKG!U
M%='JG_( T#_KB_\ .O/QOPH]# _Q3&HHHKQSZ4**** "BBB@ HHHH *.,$$
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M=%<9_P *OM?^@SK'_@6?\*/^%7VO_09UC_P+/^% '9T5QG_"K[7_ *#.L?\
M@6?\*/\ A5]K_P!!G6/_  +/^% '9T5QG_"K[7_H,ZQ_X%G_  H_X5?:_P#0
M9UC_ ,"S_A0!V=%<9_PJ^U_Z#.L?^!9_PH_X5?:_]!G6/_ L_P"% '9T5QG_
M  J^U_Z#.L?^!9_PH_X5?:_]!G6/_ L_X4 =G17&?\*OM?\ H,ZQ_P"!9_PH
M_P"%7VO_ $&=8_\  L_X4 =G17&?\*OM?^@SK'_@6?\ "C_A5]K_ -!G6/\
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M/_UZ/^$RG_Z!^G_]^*]?VE3^4X]#G]R^M&Y?6N@_X3*?_H'Z?_WX_P#KT?\
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M_P"O1SU/Y0M$Y_<OK1N7UKH/^$RG_P"@?I__ 'X_^O1_PF4__0/T_P#[\?\
MUZ.>I_*%HG/[E]:-R^M=!_PF4_\ T#]/_P"_'_UZ/^$RG_Z!^G_]^/\ Z]'/
M4_E"T3G]R^M&Y?6N@_X3*?\ Z!^G_P#?C_Z]'_"93_\ 0/T__OQ_]>CGJ?RC
MM$Y_S%'.[ ]:Z76,)H'A_)7_ %3#.>.M1?\ "83L?^0?I_\ WX_^O6W?^()(
M=)TB;[-;.9XV8JT>0N#QM':N3$RDXKF5CLPFE3W3C]P[LN?K1N7^\OYUN_\
M"6S_ //C8_\ ?JC_ (2V?_GQL?\ OU7EGO<]3^4PMR_WE_.C<O\ >7\ZW?\
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M?SK=_P"$MG_Y\;'_ +]4?\);/_SXV/\ WZH#GJ?RF%N7^\OYT;E_O+^=;O\
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M(8YRT99E/3 (/O2_!U?B_P#$SP9X2^+%EXR>:_UJ]6YN_"-VR1Z3'IC,04C
MC,@G5-I#%B"V>,5Z]\,_@[#\/=7^(5W+J/\ :T'B_5&U.2WDB$8MU:,1M%D$
M[NAYXZUY_P"'_P!E'5_#MG8^$8O'US_PJO3=1&H6F@0VS1WR@/YBVSW@DR8
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MU!\(_#NM?&;]I)_%^J:_=>-/#=IX;N=$NM1.A3:-9*9C_J(89B9"VWEG/'S
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M+1W1X)\+?A/XOA\=76O^*],\(^%M(73VL(/#?A&!9(KAY#^\GGG:&-R0 %5
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MY'0?V/H7_0?;_P !C1_8^A?]!]O_  &-<_11[-_S,?-Y'0?V/H7_ $'V_P#
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M;G9A/?J6V'_V5H?_ $&6_P"_!H_LO0_^@RW_ 'X-8=%>8>_[-_S,W/[+T/\
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M:5,(-62[DN+% 0EO<30,5=@@5'&>J\U-_A\[?B.7NWOTO^!]R?$+XA:9\,?
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M'O5=;!TN)13FC;E<'<#CIC)]#GIWYZ<4Q?FST. #P<\'^5)Z"%HHHH$%%%%
MPHHHH **** %7[PKH]4_Y%_0/^N+?SKG%^\*Z/5/^0!H'_7%_P"=>?C?A1Z&
M!_BF-1117CGTH4444 %%%% !1110 444N#@\<<$$?7!!]#Z4#$HH52Q/&/8<
M_D>A%')(&UBYXV+@\^U&UQ!12D=ASZ-T!_/I1_>]C@\Y[9_ ^U4XM!W$HHHJ
M0"BBB@ HHHH **** $;[IKUW1_\ D%V?_7)?Y"O(F^Z:]=T?_D%V?_7)?Y"K
MB>;C?A1?HHHH/,(V7)%<9I_PC\/:;\5=5^(D$5POB;4]-CTJYE,Q,1MXVWJ
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M,=9 Z-;(3B,J1@8Z*2*ZK7/V8?!OB#7/%^I7#ZO#_P );:"UUFSM=0>.UNB
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M\BOEBC\Z=H93( RXV@$G!Q7J?BCPS:^,_"^JZ!JL'G6&J6LEI<QH2-T;J58
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MC[AI&52WTKFG_9 -OI%]X2TSQ]KND_#"]NC<W'A.WABR5=]\L*79_?)$S?P
MX ) ZU47JD_^&?7Y,);NW_#]ON..M?\ A)?C%^TQK?AO5?%'B3PMX<3PEI^J
M2:+H]\]G+%=R8W#S$^9<9(*CKWKQ>XAU;XN:/\ Y/$_BGQ#=:C8^.=0\/&_L
M]0>WEDAA639*Q7_EOA0/,ZXSZU]M:#\$=.\.?%[5/'MI>3&>_P!'M]$_LYD7
MR8H82"K!OO$X&.:X!OV/;&T\'Z'I6E^*]2TW5=#\23^)--UC[)#*T$TQ8NAB
M8;&7#$#/-5%\KBWT?^8OYEWM;Y)7/H:SC\B!(@S.(U";G;<QP,9)[GUJ>H+2
M-XH@LC;VP-S[0-QQR<#U-3TAA1110 5Q7Q._X\;'_KJ?_0:[6N*^)W_'C8_]
M=3_Z#6^'_BQ)EL>?4445[O5G %%%%,84444 %%%% !1]U@PZ]#WR/\]J** $
MV \'!)XW%!Q^%.W%F4MNX'\1SC'I244 +N/T/0'[VWZ9Z#F@NS*H))51M"EB
M=H'I_7\*2BG;J 4444K@%%%% !1110 4444 *OWA71ZI_P B_H'_ %Q;^=<X
MOWA71ZI_R+^@?]<6_G7GXWX4=^!_BF-1117CGTP4444 %%%% !1112; &)+%
MNK?>W$D'/X4]IY-P8.V5Y7GD>P]J9118/4<LKQKA7( .0.N3ZFDW%L;B2H]>
MOY_6DHIAH..&X)QSC@8P.](SM)@L2>.A8DBDHH#0**** "BBB@ HHHH ****
M $;[IKUW1_\ D%V?_7)?Y"O(F^Z:]=T?_D%V?_7)?Y"KB>;C?A1?HHHH/,"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XKXG?\>-C_ -=3
M_P"@UVM<5\3O^/&Q_P"NI_\ 0:WP_P#%B3+8\^HHHKW>K. ****8PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!5^\*Z/5/^0!H'_7%OYU
MSB_>%='JG_(OZ!_UQ;^=>?C?A1WX'^*8U%%%>.?3!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 C?=->NZ/\ \@NS_P"N2_R%>1-]
MTUZ[H_\ R"[/_KDO\A5Q/-QOPHOT444'F%#4]9LM'C1[Z[BM%<[5:5MH)]JH
M?\)UX>_Z#-G_ -_A6E?:/9:HJK>6L5TJG<JS(& /XU4'A'0QQ_9%E_WX7_"@
M"'_A.O#W_09L_P#O\M'_  G7A[_H,V?_ '^6IO\ A$=$_P"@39?]^%_PH_X1
M'1/^@39?]^%_PH A_P"$Z\/?]!FS_P"_RT?\)UX>_P"@S9_]_EJ;_A$=$_Z!
M-E_WX7_"C_A$=$_Z!-E_WX7_  H A_X3KP]_T&;/_O\ +1_PG7A[_H,V?_?Y
M:F_X1'1/^@39?]^%_P */^$1T3_H$V7_ 'X7_"@"'_A.O#W_ $&;/_O\M'_"
M=>'O^@S9_P#?Y:F_X1'1/^@39?\ ?A?\*/\ A$=$_P"@39?]^%_PH A_X3KP
M]_T&;/\ [_+1_P )UX>_Z#-G_P!_EJ;_ (1'1/\ H$V7_?A?\*/^$1T3_H$V
M7_?A?\* (?\ A.O#W_09L_\ O\M'_"=>'O\ H,V?_?Y:F_X1'1/^@39?]^%_
MPH_X1'1/^@39?]^%_P * (?^$Z\/?]!FS_[_ "T?\)UX>_Z#-G_W^6IO^$1T
M3_H$V7_?A?\ "C_A$=$_Z!-E_P!^%_PH A_X3KP]_P!!FS_[_+1_PG7A[_H,
MV?\ W^6IO^$1T3_H$V7_ 'X7_"C_ (1'1/\ H$V7_?A?\* (?^$Z\/?]!FS_
M ._RT?\ "=>'O^@S9_\ ?Y:F_P"$1T3_ *!-E_WX7_"C_A$=$_Z!-E_WX7_"
M@"'_ (3KP]_T&;/_ +_+1_PG7A[_ *#-G_W^6IO^$1T3_H$V7_?A?\*/^$1T
M3_H$V7_?A?\ "@"'_A.O#W_09L_^_P M'_"=>'O^@S9_]_EJ;_A$=$_Z!-E_
MWX7_  H_X1'1/^@39?\ ?A?\* (?^$Z\/?\ 09L_^_RT?\)UX>_Z#-G_ -_E
MJ;_A$=$_Z!-E_P!^%_PH_P"$1T3_ *!-E_WX7_"@"'_A.O#W_09L_P#O\M'_
M  G7A[_H,V?_ '^6IO\ A$=$_P"@39?]^%_PH_X1'1/^@39?]^%_PH A_P"$
MZ\/?]!FS_P"_RT?\)UX>_P"@S9_]_EJ;_A$=$_Z!-E_WX7_"C_A$=$_Z!-E_
MWX7_  H A_X3KP]_T&;/_O\ +1_PG7A[_H,V?_?Y:F_X1'1/^@39?]^%_P *
M/^$1T3_H$V7_ 'X7_"@"'_A.O#W_ $&;/_O\M'_"=>'O^@S9_P#?Y:F_X1'1
M/^@39?\ ?A?\*/\ A$=$_P"@39?]^%_PH A_X3KP]_T&;/\ [_+1_P )UX>_
MZ#-G_P!_EJ;_ (1'1/\ H$V7_?A?\*/^$1T3_H$V7_?A?\* (?\ A.O#W_09
ML_\ O\M'_"=>'O\ H,V?_?Y:F_X1'1/^@39?]^%_PH_X1'1/^@39?]^%_P *
M (?^$Z\/?]!FS_[_ "T?\)UX>_Z#-G_W^6IO^$1T3_H$V7_?A?\ "C_A$=$_
MZ!-E_P!^%_PH A_X3KP]_P!!JS_[_"N8\=:W8:U:VJ6%Y#>O'(69(G!*@KC)
MKK?^$1T3_H$V7_?A?\*=;^&-(M68PZ7:Q,W!*0J,_I5PER24A-7/(/+;TS^(
MI/+?T_45[1_8MA_SY0?]^Q1_8MA_SYP?]^Q7;]<E?8P]BKW/%_+?T_6CRW]/
MUKVC^Q;#_GS@_P"_8H_L6P_Y\X/^_8H^N2[#]DCQ?RW]/UH\M_3]:]H_L6P_
MY\X/^_8H_L6P_P"?.#_OV*/KDNP>R1XOY;^GZT>6_I^M>T?V+8?\^<'_ '[%
M']BV'_/G!_W[%'UR78/9(\7\M_3]:/+?T_6O:/[%L/\ GS@_[]BC^Q;#_GS@
M_P"_8H^N2[![)'B_EOZ?K1Y;^GZU[1_8MA_SYP?]^Q1_8MA_SYP?]^Q1]<EV
M#V2/%_+?T_6CRW]/UKVC^Q;#_GS@_P"_8H_L6P_Y\X/^_8H^N2[![)'B_EOZ
M?K1Y;^GZU[1_8MA_SYP?]^Q1_8MA_P ^<'_?L4?7)=@]DCQ?RW]/UH\M_3]:
M]H_L6P_Y\X/^_8H_L6P_Y\X/^_8H^N2[![)'B_EOZ?K1Y;^GZU[1_8MA_P ^
M<'_?L4?V+8?\^<'_ '[%'UR78/9(\7\M_3]:/+?T_6O:/[%L/^?.#_OV*/[%
ML/\ GS@_[]BCZY+L/V2/%]KC^'/XBM_5)HVT/1(DF5I8XF5DSR,FO2?[%L/^
M?.#_ +]BD_L/3^OV*#/_ %S%85JSK1LS:C^ZES(\B_#]11_P']:]>_L6P_Y\
MX/\ OV*/[%L/^?.#_OV*YCT/KDNQY#_P']:/^ _K7KW]BV'_ #YP?]^Q1_8M
MA_SYP?\ ?L4!]<EV/(?^ _K1_P !_6O7O[%L/^?.#_OV*/[%L/\ GS@_[]B@
M/KDNQY#_ ,!_6C_@/ZUZ]_8MA_SYP?\ ?L4?V+8?\^<'_?L4!]<EV/(?^ _K
M1_P']:]>_L6P_P"?.#_OV*/[%L/^?.#_ +]B@/KDNQY#_P !_6C_ (#^M>O?
MV+8?\^<'_?L4?V+8?\^<'_?L4!]<EV/(?^ _K1_P']:]>_L6P_Y\X/\ OV*/
M[%L/^?.#_OV* ^N2['D/_ ?UH_X#^M>O?V+8?\^<'_?L4?V+8?\ /G!_W[%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%+J 4444P
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img11029722_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_6.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &@ R<# 2(  A$! Q$!_\0
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M0QR,<_2O%?VCM0-O^R)H%SG!:'3?UC%>H:HUSJG[.;G2B9KRX\. VX1AESY
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MBMN5MY(( XX [5ZY10!X?>_#SQ[\/OV?M;\-^'?$<FNZ]:VGDZ1.MLEO-%&
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M0(^'('RDU^:EUXL'P%_:8^,WQQ$,EPGAWXASZ->I$,L]M=VEV /H)DA/X4?
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M:^ OB#X(\<?$SQ!H>L^/4T>ZUC7KRWM-!O8VE9&M;33%)9D"@XFP-I7G#$$
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M<$ES/)C.V-%+,<>P!KY*;_@JI\"%8XOM><9X9=);!'J/FZ5T4</6Q%_90;]
M/L*BOCS_ (>K? G_ )_/$'_@I;_XJC_AZM\"?^?SQ!_X*6_^*KJ_LW&_\^9?
M<QV/L.BOCS_AZM\"?^?SQ!_X*6_^*H_X>K? G_G\\0?^"EO_ (JC^S<;_P ^
M9?<PL?8=9WB"WDOM%U&UB"^;/;21)N.!N92!GVS7R;_P]6^!/_/YX@_\%+?_
M !5(?^"JGP(;K=^(/_!2W_Q5']FXW_GS+[F%CQ_X9_LT_M?^!?@F/@U87WP[
MT/P=="XMI]922>?4;>"YE9YF0X"LV)' ^4'&!D'!'M7B;]DOQ+\-[WX->(_A
M+<Z;J6M?#G2I-";2O$4KV\&J6LJ@2-YJ*QCD#[GZ$<X[<U?^'JOP(QC[9X@Q
M_P!@EO\ XJF_\/4O@-MQ]K\08_[!+?\ Q5']FXW_ )\R^YA8YGQ)^PWXV\<_
M OXS+J^LZ/!\3?B/J]MKLEO9ESIMHULX:"T#D;F&"RF3'4@XXYUM _9^^-'B
MG]HG3OB5XWM/">EVUOX(NO#*Z?HM_+,T4K[PC,SQC<&+;LC[H(')&3H?\/4O
M@-_S]^(/_!2W_P 51_P]2^ W_/UK_P#X*6_^*H_LW&_\^9?<PL>7^"?V,_CG
M>_!7X=_!?QA-X.M/ ^AZW%K-_J^GW<TMZ8HYGD%JL9C522S?ZS=T8#'RDGJO
MB'^PKXH^*&K?M,1ZC?Z;I]C\0+S2;_P_=+,TICFLPW%PFT;58G'!/!SVKI_^
M'J?P'Y_TOQ![_P#$I;_XJC_AZI\",8^U^(/_  4M_P#%4?V;C?\ GS+[F%BY
M\ ?V6[W2[[Q#)XU^%?PP\$:9J&C2:*]OX,AE>]NEF7;<,]R=FR-E) C52W?=
MQ7%?'S_@GO;Z+\.?"VC?L_\ A[1]+O=-\76WB:[M?$6H3S6T[002(@;S"Y8$
MLH*< @FNI_X>I? ?_G[\0?\ @I;_ .*H'_!5/X#C'^E^(/\ P4M_\51_9N-_
MY\R^YA8Y/X??LQ_'#QG^T!\/?&WQ/L_ASX1TGP9+/>0+X%M6CN+Z21 GE2%O
MX.,]<8R,9.10NOV)?B1-\(_$?AI3HO\ :6H?%<>-(?\ 3F\O[ )"V"?+XDQ_
M#C'O7=_\/4O@/P?M?B#(_P"H2W_Q5'_#U3X$?\_?B#_P4M_\51_9N-_Y\R^Y
MA8NV_P"S+XSA^(_[4NN9TQK+XD:9;6>AC[4=XD2S>%O/&SY!N8=-W%<CIO[)
M?Q0^'FD_L^^*_"?_  C^H^//AWHLVA:IH^I7CQ65Y;S(P)CF5"0RECR5YR/3
MGHO^'JGP(_Y^_$'_ (*6_P#BJ3_AZI\!_P#G[\0?^"EO_BJ/[-QO_/F7W,+'
M,>%_ OQS_9H\ _&KQBZ^%=3\=^+O%MKJ5C:VHGN;:9)9%C>%(P%??A\(">V2
M>M>\_M9_#_QS\7/V>M<\%>"FL+?7=>6&RNY[Z<Q1P6K,#<%< Y8J"H7_ &NO
M%>6_\/5/@1_S^>(/_!2W_P 51_P]4^ __/WX@_\ !2W_ ,51_9N-_P"?,ON8
M6/.O''_!+I/!/AWPYK?PD\9>(KGQ[X8U&TOM-M_$^L*=.7RW4R!56',? R,9
MZ8[Y'I'BSX'_ !G\ ?&KQ]\0_A.GAF[NOB!I%M!J%MKM[)$='U"&(1K/%B)A
M.G?:=N2/2F?\/4_@/T^U^(/3_D$M_P#%4?\ #U+X#X(^U^(,'_J$M_\ %4?V
M;C?^?,ON86-;QE\#_BS)\<_@S\3+:?P[XKUGP[H\VC>(EN)9-.CD,I7S+BW4
M*_8MA#@9 Z \<KX0_8M\2?\ #,?QM^'/B&738]7\5^*=0\0Z)=6\YDCA9C#)
M:O(VT%#YD.& !PI/)S6G_P /4O@-Q_I?B#CC_D$M_P#%4?\ #U+X#'G[7X@_
M\%+?_%4?V;C?^?,ON86,[0_V%]:UC]BKQ#\,/%&MVJ_$3Q)J$FOZIK:LT\4N
MHF8.AD. 739&B'CU('%:W[/_ .RO?Z1J&MGQM\*_A?X-TJ^T-]&DB\'13/?W
MGG)LN&>Y.SRXF7(\L*3DYW<5%_P]2^ __/WX@_\ !2W_ ,51_P /4?@-_P _
M6O\ _@I;_P"*H_LW&_\ /F7W,+#O'W_!.SP=I?PYM--^#3'X>>*M)UN#Q'I>
MIS3S7B"\B78!)YC,=A7(('&<$@\UJ_"#P7^U'KWQ:TCQ#\6?&'AC0/"^D6[Q
M_P#".^#T=X]6>0'YI_-!*[<*00?H!EB<G_AZE\!SUN_$'_@I;_XJ@?\ !5+X
M#CI=^(!_W"6_^*H_LW&_\^9?<P.6UC]DGXOZ+X)^(?P>\,7OA>3X8^--7FU!
MO$6H33+J6EPW$@>>$6X7;*WR[5;>!\V3[>F> _V9=:\"_M9:;XULFM&\#:;\
M/[;PE;%[@_;&DA=-I9-N-NQ/O;NO:N;_ .'J/P&VX^U^(,8Q_P @EO\ XJE_
MX>I? ?K]K\0?^"EO_BJ/[-QO_/F7W,+'FUC^PW\3-+_91\#^#XIM ;QIX5\?
M+XN2TEO7%G=QB1R(C,$RAP^?N]J]Y^!_P9\;>&?VEOB3\3?%-KI-C;>+-'TN
M!+33KUKAH;F&,>>F2BY0,3M;J0!D#I7'_P##U+X#_P#/WX@Q_P!@EO\ XJC_
M (>I_ ?_ )^_$'_@I;_XJC^S<;_SYE]S"QR5]^R'\7=!\!^/?@MX7O/"[?"_
MQ=JTU^?$=]-+_:>FV]Q(KS0?9PNV5OD 5MZ\-D^W6:Y^R7XIC^+WCW6-&DTY
M_#>I?"Y?!.EFXNBL_P!I10JF1=I 3"\L#^%+_P /4O@/D'[7X@S_ -@EO_BJ
M/^'JGP'&<7>O_P#@I;_XJC^S<;_SYE]S"QYUJG[!?BNUT#X,:N?#G@SQ[KOA
M7PR?#>L^%_$T[C3YERS1W$,P1L.C''*<@\8KN?%W['_BZZ^#/PU?PW8^!_#G
MQ(\%>)$\40Z3H=I+9Z'--D;X#DN^=JQ@R'J5/ SQ;/\ P52^ Q_Y>_$'_@I;
M_P"*IW_#U3X$?\_?B#_P4M_\51_9N-_Y\R^YA8WOV?\ X-_%32OVGOB!\5/B
M+#X=M(O$FB6=A;66@W<DXMC$R_NV+HI; !R_<G@ 5]35\=#_ (*J? =3D7?B
M ?\ <);_ .*IW_#U;X$_\_GB#_P4M_\ %4?V;C?^?,ON86/L.BOCS_AZM\"?
M^?SQ!_X*6_\ BJ/^'JWP)_Y_/$'_ (*6_P#BJ/[-QO\ SYE]S"Q]AT5\>?\
M#U;X$_\ /YX@_P#!2W_Q5'_#U;X$_P#/YX@_\%+?_%4?V;C?^?,ON86/L.BO
MCS_AZM\"?^?SQ!_X*6_^*KT#X(_MS?"W]H'QH/"OA2^U(ZPUN]RD=]8M"KHG
MWL-D\CTK.I@<52BY3IM)>0'T'124M<(@HHHH **** "BBB@ HI&SCCK7RAXI
M_P""FGP2\'^)=4T.]U#6I;S3KF2TG:WTQGC\Q&*MM;/(!!&?:MJ5&K6=J46_
M09]845\=_P##U;X$_P#/YX@_\%+?_%4O_#U;X$_\_GB#_P %+?\ Q5=:RW&-
M75*7W!8^PZ*^//\ AZM\"?\ G\\0?^"EO_BJ/^'JWP)_Y_/$'_@I;_XJG_9N
M-_Y\R^YA8^PZ*^//^'JWP)_Y_/$'_@I;_P"*H_X>K? G_G\\0?\ @I;_ .*H
M_LW&_P#/F7W,+'*7OP;_ &HOAA\>/BSXK^%<'P_FT/QIJ<=Z#XBN)VG58X]B
MX5-H4Y)R#GM6BW[!.N_\,VZCX=N/%=I>?%2^\5+X[N-;EA;['-JRON6-D'/E
M;25R,<G.,<5L?\/4_@/S_I?B#G_J$M_\50?^"J7P';K=Z_\ ^"EO_BJ/[-QO
M_/F7W,+&AHO[/?Q&^*OQ6UCXB_%0Z!X;U!?"EUX4T?1_#MS+>1QK< ^;=2RN
MJ9.6(" =.IX&?)/#_P"R'\>1X6^!O@O58_!L7AOX9>)HM0^V6NH3-=:A LKM
MYNTQ;4*JQ&S)+%NHQSZ7_P /4O@/DG[7X@R?^H2W_P 51_P]4^!'_/YX@_\
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M[-QO_/F7W,+'V)17QY_P]6^!/_/YX@_\%+?_ !5'_#U;X$_\_GB#_P %+?\
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MNS*R%A@GY^@]#7G,=K<3;3%;32AB0#'$S D=0"!S64*L*D.>+T_K_("'8O\
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M(YEN!(S*%C(& 04YSZUI4J4Z2O.2[ >=[%'55].E&Q>NU<?2O=OA#^Q[XO\
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MQ'U7H7]H_!_]B/4]<T/P?X>U;Q7IWC>YTN:[GTF/41;1"=HSLWJQ*Y&Q2Q.
MP[UWWB;X9>$-'^,GQ=FM/#6EV-S>?"-M;NM*6V1HM/U!L@F-"#Y38 /&#SGO
M7R]X1_:\U'X>_LRV_@#PM=ZWH7C./7I-4.O6LJ"(Q.27C.269CWR,5Y)'\9?
M'4.N>(]93Q7J7]K>([5K+5[QI TE] W#12$@_*1Q@8P.!BB.7UZDIRVU[O57
M5OR8S[:\0ZEXO^+WPS_9.\/:?HOAC6+GQ#;37=U;:KIB)8YMFC92QC"M'& "
M62,C>0 0:D^,F@:1KG[-3Z[?1:#JOBG1/'MIIPU;0_#8TBVB8W,:2V\!P&FC
M7.SS& R0?3)^*-)^.GQ#T'PMIGAO3O&>KV6@Z9<I>6-C#/A+:9'WH\9QN7#9
M.,XY/&#BKOBC]H[XH^-M/N+#Q!X[UC6+*XEAGEM[J160R1,&C8+MP"I /&.1
MSFJ_LJNIJS7*F_NO_DQ'W_\ &?0=*UCXJ?M2W%_IMG?367@C2Y;::Y@21[=S
M#-\T;,,J>.JX[5YWXF\;:A\&OV18KWXA^'O#6J_$?QI;>5H>D1>&K:W?3;,Q
MA#/,8XP2X5MW)'S,H_O5\>7WQ]^(^J7VOWEYXSU2YNO$%JECJLLCH6O8$!"1
MR?+T 9@,8ZUT,G[7_P ;)K-K1_B;KSVS1F)HB\>"A&"OW.F.*7]EUTH0;32M
MU[*W8#[7F\,_"/X8:/X$\&3Z-=^(/#.L^$OMEQINC^"CJMSJ3R("]\-00F2-
MU.&V@8  Z<5Y9X&5/A7^SG\&-6\#^"]+\2ZAXP\5RVNN7FHZ8M_/M2X*16P+
M*6B)0;@5(*E,YY-?+.D_'SXDZ#X*E\(:=XXUJR\,2H\3Z9#<D1['^\@.-RJ?
M0$#D^M1>!?CE\0OACH]UI/A+QEJ_A[3+I_-FM;&?:C/@#< 0=IP!RN,]ZJ.4
MU^5IR3UO9MZ[^6XSU;_@HO@_M;>-SV\JTS_X#)7UQK&=%^+7[//@RP^'7AR_
M\+>+= 0:U=2:%"\MSB##_OMF4,:G?Q@G/)-?FEXV\::_\1M>N]<\2ZM<:WK5
MTJI-?71!D<*H5<X '   XKZ'^-'[</B3Q98^$[#X>ZSXB\%Z?I^@1Z1J=L)T
M5;N1 !YB[2V!C(SD-S5XC UI4J-"*^&+3]0/=_@S\,HOAGJ\3P1>$+3P)J_C
MRYTO399- ?6]7U:..=HD@#-F."$;6&X;2H4GFNCTJ^_X5#H7[7NC>$]+TVST
MW0;J*^T^R?38IXTDFA#.C(RGS$R,K&V54=!VKX!\(_'SXD> ?#<_A_PYXWUK
M1=%FD:5[.TN-J%V(+,#C*DD9.TC)SZU8TO\ :*^)VB^+-7\36'CC5K3Q!JZ)
M'J&H1N@>Z5  @<;=IP  #C-93RK$3E)N2=[?@TP/MOX:_#'P?XR\7_LRG6M!
MTZ42^ K[6I+>.S3;?7T9MRADC4#SBNYV"GKM]*XWQ)??#WX@:_\ !.^M]*U"
M^\2CQM:V%QK5QX'_ +"T_4+4W)+VKQ\Q,\1.W&2QYW=Z^0;GXP>.+R_\-WLO
MBK4C>>&U*:-.DH1[!202(BH& <#.<YZ=*O>*/CY\1_&VO:-K6O>--6U;5-%F
M6YTVXN)03:2J00\:@!0P('.,U7]EU^?F<]->KZW\O- ?;GC#^P_B!;_M9>&K
MKPCX:T[2_!*_:-&;3M*BAG@G0,YD,H7<Q9U!*DXP=H&.*VOBK\0DU#6/V:%\
M4^#?^$S\.WVB?VQJ.EZ/H27%P9XXE*-$D:;A&C-N,*X4X&1QBOS^C^,WCJ.;
MQ5,GBG4%E\5@KKKAESJ((((E^7G@D<8ZFKEK\?OB38^&]%T"V\;ZQ;Z-HLT=
MQIMI'.%%I)&249"!N&-QXSC!(Z4_[)J**LT[>?\ =L_Q$?37[7GAW3O%WP.M
M?'/AW4/"VOZ'IVNFTFOK7PT^AZK922\K:.JD1RJ@**Q*[@1G/6N<_8O^'^D?
M'_X?_$/X67EM:KK+W%AKFFWWEJMQ'&DZ)<J)<9V[-N$[Y/K7@'Q"^-_Q ^+%
MO9V_C+QAJOB.WLV9X(;V4;(V( +!5 !/ Y()].]9'@?Q_P")/AGKZZYX4UJ[
M\/ZNL;0B\LF"OL;&Y>01@X%=4,#6C@G0<ES7NG\]!GZ8?%KPO\-M/TGQ;\=]
M TG16T7P_P"&-2\.6^GK8P[!JT=T8$E\O&UF'(Y&< 4?".2'PE^T%\%=-TG3
M=+L(=:^%$5WJ#0Z?"LDLZ(6$F\+D,23N/\0QG.*_-:X^)WBVZ\%77A";Q#?2
M^%[J\-_/I3.##)<%@QE/&=Q89Z]:T(_C=X^AU_P]KD?BW4H]8\/68T_2;U)%
M62SM@NT0I@8V8)&"#UKC>3UN7EE.^Z_#3\0/L*T^,VN>'_V$]6\:G2M#NM>N
M/'\R^1>:/"UI%R%8K;%=@)1-N<<;BPY.:\5_X*!>&='\*_M&WL.AZ7::/;7F
MCV-_):V<8CB\Z1&W,JCA<[1G%>3>*OC7X]\<:+?:/K_BS4=7TN^O?[1NK2X9
M=DUSM"^:P"CYL #\*Q_&GCOQ%\1]:_MCQ1K%UKNJ^2EO]KNR"_EI]Q> .!DU
MW83+ZE"K[2Z7Q7^=K?=J!]LJ;SX4^$_@3H/@+X4Z+\0;#QAX9GO]5M[O3HYI
M]2O7B^=3<L"R"+.[:I'"XS6--X U'Q_^Q-\+?!T%@^GZEJGQ%DL#:JK!K7<T
MH=?F)8!!G[V<;>:^8_!_[0GQ,^'_ (9?P[X;\<ZUHNA-N_T"UN,1KN^]LR"4
MS_LD>O6H?#?QW^(G@[2],T[1/&.IZ;8Z7<R7ME!"ZE8)Y%97E7<I.YA(X))/
MWC7-_9U9-N-KWO>[UW_S0'ZF>)/ NF>.]6\>?#&/X@^$[OPM?^&8?#VD>$[6
M_C.HV%]:JQ$IB[,&Y('(\M3ZU\C>!=)BT[]B'1]+\0Z!=Z[';_%^*UU#0K2)
MGGNPJ;)($0<EC@@ <GBODW2_'/B'1?&:^+K#6+NT\4+<O>#5HG G\Y\[WSCD
MG<<\<YK3U3XP>.-:TN[TZ]\4ZE/8W6JG79H?,";M0/6YRH!$GN"*FGE5>BE#
MG3C>+^Y68'VU^T/X=T3XI_!?XA:IX$?PQ)I_A^2.ZN]"U3PFVC:SX<1/E,4<
MR[?,=MK964'Y> <X-?GM@<GUYKT+QE^T-\3OB)X=70/$_CK6M<T561_L5W."
MC%?NEL %L=?F)YYZUY[7I9;A:F$ING4=]0"BBBO5 **** "OJ+_@F-_R>'IG
M_8'O?_0%KY=KZB_X)C?\GAZ9_P!@>]_] 6O.S'_<ZO\ A9+/V8'>EI!WI:_(
MD(****8!1110 4444 )7\\OQ,_Y*UX\_[#U[_P"CWK^AJOYY?B9_R5KQY_V'
MKW_T>]?8\-_Q:GH-'/T445]X4%%%% !1110]F!]8?\$R6"_M-!O+\T+HEZ2G
M][Y1Q_2O5_A;\5O!?Q&^"_[15OX3^%&D_#FXLO#LC75UI=T9FN]S3 !@47&T
MJS=_O&O@71]<U/P[>&[TG4KW2KLJ4^T6-P\$FT]1N0@X/<9Q2V&O:GI,5Y%8
MZE>645ZNRZCMKAXUN%_NR!2 XY/#9')KQ,3EBQ%6=5RU]W\'J!^BOP]7QSHN
MC_LQV?PFTUIOAWJMBK>+I-.M$EMKBY; NA?/@X &_&XCN!GI5OX5Z[H?AN^^
M)6B>!O"WC#3O"-QXT<67CCX<V\-[*A7:?LDD0$DGV</Y@!*&/:W45^<^D^+M
M>T#3KG3]+UW5-+T^ZS]HM+&]EAAFR,'>BL V1QR.E-\/^+-<\)/.^A:WJ6AM
M.H69M,O);8R 9P&V,,@9/6N2>3RES)S6OD]=;]P/T;\!^#/$_@3XV?M16&DZ
MOIGBOQ?)X5M;RVFM]/AMHVN7$I1)+=<QK("!D#[Q(8C)JYX(?6-2UC]E'5/B
M3%/%\69]1U".9M0MUBU&:P6*;RS<K@,,?(1N Y)XR37PQ\*/CU>?##0?B=82
M:?)K-[XWTG^S9-0EO&26U<EV\\DJ3(V7SU!R.M<'/XT\176MPZU/X@U:?6H5
M"1:E+?RM<HO/"REMP')Z'N:A977E4DY22MU[^[;[O(#]"]:\0>.-0_9?^-VF
M^&;[4I+ZT^(5YIZ0V:&0VUE+*IF1E525A)DD9R>,%N17IVG?#_Q!H_A+XF^"
M?%NIZUXQT^W\%8MPNAP6'AN+$)*1V*("995/)D! &!P&YK\IK/QIXBT[^T/L
MGB'5K3^T"3>_9[^6/[42""9<,/,X)^]GJ:L?\+&\6E+=#XLUXI;1M# O]J3X
MB1@%9$&_Y5( ! X( ISR>IM&:2O?;R7ZH#]%O@NK2:C^Q00"P.@ZF<^O^C@_
MRJ#]FE_B-\)?A_\ $?XDW+>)/$>AKJNIVOA/P+I=O).ES.]W+ON'1%+!/,SR
M>!ASU(K\Z+?QGXALSIQ@U_58#IJ&.Q\J^E3[(I&&6'#?NP1U"XS5ZP^*/C72
MK=;>R\9>(K*!<D16VK7$:C)R<!7 &3D_4FG/*9RBX\Z:?E_>;_4#]"/@?KVM
MZ/\  >#Q&OA[QO?_ !"U#QS</XKL_!MO;1ZCY_F,8H;Y9U+);;#&-ORX# D@
M$FL7P;*8[;]J/6?A9X3O?"?Q4A>V%GH4:03W^GQL!]H%NL1= 2V]BJ$X.WC.
M!7P19>/O%&FWU]>V?B?6K.]OSNO+JVU*:.6Y(Z&1E8%R/5LU2T?Q%JWA[4#?
MZ5JU]I5^0P-W8W4D$V#U&]2#S]:;RB3E.7.M7V>W;?Y ?8'_  4#/B.3X:?L
M_OXPA:W\22:+<'4%= C>=^Y+;@. YR"W3DFN@^%>I?%32?V"?!%U\)8KZ?7E
M\9W*SG2[99[E83(_"J0<(7V!\<;2<D+FOB'6/$VL>(1 -6U?4-5%ON\D7UW)
M.(MQRVW>QVY/7'7%>DK^T/JUC\!/#?PXTF*[T6ZT76;G5DUZPU!X9I!*KJT(
M5 "HQ)R=YSCI6E3 5(X6G0C9VE=]K:_Y@?;/BWP%>C]H?XS>)O 7B ^&I=)T
M/3WUZU\(:-#J.M7-Y(&,L=FI_P!2[!?G<9.XJ2IP:[J36-3T?]N#X-1(U_I8
M\1> YCK,%\(EN;V:)':-;HQ@*\J-UV\9Z<8%?E+I?BO7-"U.XU+3-<U/3=1N
M<^?>6=[+#-+DY.YU8,V2,G)YI\WC#Q!<76GW4NO:I+<Z?G['/)?2M):Y.3Y3
M%LI_P$BL'D\[V<UM;;RM^8'W_P"$VO=<_9EE_P"%N&_5I_BQ:IKCZS&T4QC\
MR(*)05!"[1$.1]TCM6O^U_XBDC^'_P 8]"U'P'XVU3P]!Y*Z9JVJK80Z)I$B
MHH@DTXC9(48%053>>H(&37YU:GXT\1:W:W%KJ/B#5M0M;B43SP7=]+*DL@
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M]]?S%'G1_P!]?S%?<?\ PZSM/^BCS?\ @I'_ ,=H_P"'6=I_T4>;_P %(_\
MCM/^TL+_ #_@'M(GPYYT?]]?S%'G1_WU_,5]Q_\ #K.T_P"BCS?^"D?_ !VC
M_AUG:?\ 11YO_!2/_CM']I87^?\  /:1/ASSH_[Z_F*/.C_OK^8K[C_X=9VG
M_11YO_!2/_CM'_#K.T_Z*/-_X*1_\=I?VEA?Y_P#VD3X<\Z/^^OYBCSH_P"^
MOYBON/\ X=9VG_11YO\ P4C_ ..T?\.L[3_HH\W_ (*1_P#':?\ :6%_G_ /
M:1/ASSH_[Z_F*/.C_OK^8K[C_P"'6=I_T4>;_P %(_\ CM'_  ZSM/\ HH\W
M_@I'_P =I?VEA?YOP#VD3X<\Z/\ OK^8H\Z/^^OYBON/_AUG:?\ 11YO_!2/
M_CM'_#K.T_Z*/-_X*1_\=H_M+"?S?@'M(GPYYT?]]?S%'G1_WU_,5]Q_\.L[
M3_HH\W_@I'_QVC_AUG:?]%'F_P#!2/\ X[1_:6%_G_ /:1/ASSH_[Z_F*/.C
M_OK^8K[C_P"'6=I_T4>;_P %(_\ CM'_  ZSM/\ HH\W_@I'_P =H_M+"?S?
M@'M(GPYYT?\ ?7\Q1YT?]]?S%?<?_#K.T_Z*/-_X*1_\=I/^'6=K_P!%'F_\
M%(_^.T?VEA?Y_P  ]I$^'?.C_OK^8H\Z/^^OYBON/_AUG:?]%'F_\%(_^.T?
M\.L[3_HH\W_@I'_QVC^TL)_-^ >TB?#GG1_WU_,4>='_ 'U_,5]Q_P##K.T_
MZ*/-_P""D?\ QVD_X=9VO_11YO\ P4C_ ..T?VEA?Y_P#VD3X=\Z/^^OYBCS
MH_[Z_F*^X_\ AUG:?]%'F_\ !2/_ ([1_P .L[3_ **/-_X*1_\ ':/[2PO\
M_P" >TB?#GG1_P!]?S%'G1_WU_,5]Q_\.L[3_HH\W_@I'_QVC_AUG:?]%'F_
M\%(_^.T?VEA?Y_P#VD3X<\Z/^^OYBOJ3_@F*P;]L+3"#D?V/>_\ H"UWW_#K
M.T_Z*/-_X*1_\=JY^R/\%4^ /_!06R\(QZLVMHOAR>Z^UM (3^\C!QMR>F/6
MN3&8RA6PM6%-W?*^E@YD]C]3Q2TWO3J_+D4%%%%, HHHH **** $K^>3XGR*
MOQ;\>[F"_P#$^O>I_P"F[U_0V:_&'X<_LFQ?M,?$CXMZA-XF?P^=*\2W$&R.
MS$XDWRRG/WUQC;T]Z^LX?JQHSJ3F[*P72W/F#SH_[Z_F*/.C_OK^8K[B_P"'
M6=K_ -%'F_\ !4/_ ([2_P##K.T_Z*/-_P""D?\ QVOK_P"TL+_/^!/M(GPY
MYT?]]?S%'G1_WU_,5]Q_\.L[3_HH\W_@I'_QVC_AUG:?]%'F_P#!2/\ X[3_
M +2PO\_X![2)\.>='_?7\Q1YT?\ ?7\Q7W'_ ,.L[3_HH\W_ (*1_P#':/\
MAUG:?]%'F_\ !2/_ ([2_M+"_P _X![2)\.>='_?7\Q1YT?]]?S%?<?_  ZS
MM/\ HH\W_@I'_P =H_X=9VG_ $4>;_P4C_X[3_M+"_S_ (![2)\.>='_ 'U_
M,4>='_?7\Q7W'_PZSM/^BCS?^"D?_':/^'6=I_T4>;_P4C_X[1_:6%_G_ /:
M1/ASSH_[Z_F*/.C_ +Z_F*^X_P#AUG:?]%'F_P#!2/\ X[1_PZSM/^BCS?\
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M #_@'M(GPYYT?]]?S%'G1_WU_,5]Q_\ #K.T_P"BCS?^"D?_ !VC_AUG:?\
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M^><;9VZ=9 ,,?XL\YIUWX/T/4+>WM[K1=/N8+6W>SABEMD=8864*\2@CA"H
M*C@@ 5/(RN9'SE_:5IXFNO'M_P"+_'FM^%F\+66EG31IE^T!M8'LHI3="$<7
M32RLPPX8';M R:Y3Q]\1I?.N_&.@ZGXD:2#Q;:Z?!K.I:^EI"&^TQ12VD6EJ
M3O0*7'[Q%8DEL\"OK+4O /AC6]0T^^U#P]I5_>:<JI97%S9QR26RKR%C8J2
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M\,O$VO>))M<;5_'GV$:?<VEM]GM88I[N-3'B/<)"L8&_<#@X&*]FT7X%^!=
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M7]N9)%$UQNC;?D'(YBCX4@?+TJ]HO@O1_#WB#6];TZT-KJ6M2K<7\B3/LFE
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MV [><9/-,\*_!+PUX/UC1=4L/MSZCIKWTWVNZN#+)=S7?E^?-<,1EW/E)C&
MO8=JZ#P;X,T_P+IEU8::9S!<ZA=:E)Y[AF\VXE:60 X&%W,<#L,=>M7%2OJ2
M;M%%%:DA1110 4444 %%%% !1110 5\T^#_^4I]K_P!BB?\ T57TM7S3X/\
M^4I]K_V*)_\ 15=%/^'6_P #_0N'Q'Z!=Z=3>].KY0Z@HHHH **** "BBB@!
M*_.+]A?_ )&[X]_]C:__ *'-7Z.U^<7["_\ R-WQ[_[&U_\ T.:O=RW^'6]%
M^9$MCZPHHHK4Y0HHHI@%%%% !1110 4444 'MTKS#XH>*/&-K\1O GA3PG>Z
M9I@UZ._EO;S4+)KDP) B,K1H&4%LMC!..<YXP?4*\H^*WPQU'Q[\4/AYJ-M=
MZEI6GZ/#J)GU72;I8)[:21(UBP&!WAL.,%6'KVJ)WMH5H>9M^TEXRU+Q!!X*
M@M%M_$FGS:A%K.KZ1H<VK1-]FF6*-HK5&!42;PS%F^3!7DXK?\/?%CXE>*O$
M'A#1KFPMO!%U<Z-J6IZLNJ:5(TS_ &2Y2-'AB=E*+-&VX!LE<CK79_\ #.OA
MBS@T=M)O-:T+6-+-R8M?T^^QJ$QN'WW'G2.K"7>P#'<IY QMP*V?"GP=\/\
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M'_#Q[X-_\]]?_P#!9_\ 9UW?5*_\C.;E9]045\O_ /#Q[X-_\]]?_P#!9_\
M9T?\/'O@W_SWU_\ \%G_ -G1]5K_ ,C#E9]045\O_P##Q[X-_P#/?7__  6?
M_9T?\/'O@U_SWU__ ,%G_P!G1]5K_P C#E9]045\O_\ #Q[X-_\ /?7_ /P6
M?_9T?\/'O@W_ ,]]?_\ !9_]G1]5K_R,.5GU!17R_P#\/'O@W_SWU_\ \%G_
M -G1_P /'O@W_P ]]?\ _!9_]G1]5K_R,.5GU!17R_\ \/'O@W_SWU__ ,%G
M_P!G1_P\>^#?_/?7_P#P6?\ V='U6O\ R,.5GU!17R__ ,/'O@W_ ,]]?_\
M!9_]G1_P\>^#?_/?7_\ P6?_ &='U6O_ ",.5GU!17R__P /'O@W_P ]]?\
M_!9_]G1_P\>^#?\ SWU__P %G_V='U6O_(PY6?4%%?+_ /P\>^#?_/?7_P#P
M6?\ V='_  \>^#?_ #WU_P#\%G_V='U6O_(PY6?4%%?+_P#P\>^#?_/?7_\
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M_P!G1_P\>^#7_/?7_P#P6?\ V='U6O\ R,.5GU!17R__ ,/'O@W_ ,]]?_\
M!9_]G1_P\>^#?_/?7_\ P6?_ &='U6O_ ",.5GU!17R__P /'O@W_P ]]?\
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M^A<TG_P!B_\ B:/^$!\,?]"YI'_@#%_\37044^:7<#G_ /A ?#'_ $+FD?\
M@#%_\31_P@/AC_H7-(_\ 8O_ (FN@HHYI=P.?_X0'PQ_T+FD?^ ,7_Q-'_"
M^&/^A<TC_P  8O\ XFN@HHYI=P.?_P"$!\,?]"YI'_@#%_\ $T?\(#X8_P"A
M<TC_ , 8O_B:Z"BCFEW Y_\ X0'PQ_T+FD?^ ,7_ ,31_P (#X8_Z%S2/_ &
M+_XFM^DW#.":7/+N!@_\(#X8_P"A<TC_ , 8O_B:/^$!\,?]"YI'_@#%_P#$
MUOT4<TNX&!_P@/AC_H7-(_\  &+_ .)H_P"$!\,?]"YI'_@#%_\ $UOT4<TN
MX&!_P@/AC_H7-(_\ 8O_ (FC_A ?#'_0N:1_X Q?_$UOT4<TNX&!_P (#X8_
MZ%S2/_ &+_XFC_A ?#'_ $+FD?\ @#%_\36_11S2[@8'_" ^&/\ H7-(_P#
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M#X8_Z%S2/_ &+_XFC_A ?#'_ $+FD?\ @#%_\36_D4#':CFEW P/^$!\,?\
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MX&_X*!*&_:J_9:!Z'7?_ &[LZ]3++?64VKV3?W)L#SH_L\_M;!B#\<KX$?\
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M[HH\M?[HH_M;%_S?@@/S _X=N_$#_HKWB#\Y_P#X]1_P[=^('_17O$'YS_\
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M_P#Z3I7HO_<H_P")_DAGJE%%%><(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $KXA_X*^?\ )K.G?]C+:_\
MHBYK[>KXA_X*^?\ )K.G?]C+:_\ HBYKT\K_ -]I>J ^Q?!?_(FZ#_UX6_\
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MGZ@C\*:Q,6[>SC_X"@YY'SC_ ,()^U]_T7/1_P#P#'_QBC_A!/VOO^BYZ/\
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M3UYKTYHV#-D'@G/<<4?6)=E]P+B*H]L/1_\ !4/\CPO_ (1G]HW_ **K8_\
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M5?&__KX7_P!&5[K7A7PL_P"3JOC?_P!?"_\ HRO=:X<1\?R1^E\1_P"]T_\
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M^=7?QJ^-6F_!WXB^,9/BE<7$WPZ\4C18+?\ LJW7^UHS<*':Z;;G[KJJJFW
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MYIZ]P17L7CCQ=\9/B1\4OC!J?AV?5[&Z\(:['IVEW"^,+;2=+TF.-LJ+FTF
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M!X_FUW3K"TM;"YF:TGL;B%I9;I6;#$Q+%,#T&0N>M>D:'^SEX"T/0[#2]/\
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M/&.J_$#7O'_@OPWI-T/%>J7<A.FW&M&?=#;:9&3B/RU8QOM)4$@'T&Y^P_\
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M'B_]"MZ^]:YLT_WA?X8_D=*V1\:?$K_D_72/^P ?_1<E>T5XO\2O^3]=(_[
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MBBBLC\R./^+W_))?&W_8#OO_ $0]?%W_  3P_P"36= _Z_[W_P!&5]H_%_\
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M,5W7_@*_R"R/@S_AA[]H;_HY.\_\!I?_ (ND_P"&(?VAEY'[2MYD'_GWE_\
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MS?\ ?N7_ !H_X9+^,G_1:9O^_<O^-?86Y<9R,497U%'MYA_K9F?]S_P73_\
MD3X]_P"&2_C)_P!%IF_[]R_XT?\ #)?QD_Z+3-_W[E_QK["W+ZBC<OJ*/;S#
M_6S,_P"Y_P""Z?\ \B?'O_#)?QD_Z+3-_P!^Y?\ &C_ADOXR?]%IF_[]R_XU
M]A9'M2Y!]*/;S#_6S,_[G_@NG_\ (GQY_P ,E_&3_HM,W_?N7_&C_ADOXR?]
M%IF_[]R_XU]A!E;H0:7BCV\P_P!;,S_N?^"Z?_R)\>?\,E_&3_HM,W_?N7_&
MC_ADOXR?]%IF_P"_<O\ C7V$S*H)) %+D>U'MYA_K9F?]S_P73_^1/CS_ADO
MXR?]%IF_[]R_XT?\,E_&3_HM,W_?N7_&OL/CVI-R]<BCV\P_ULS/^Y_X+I__
M ")\>_\ #)?QD_Z+3-_W[E_QH_X9+^,G_1:9O^_<O^-?86Y1U(HW+ZBCV\P_
MULS/^Y_X+I__ ")\>_\ #)?QD_Z+3-_W[E_QH_X9+^,G_1:9O^_<O^-?86Y?
M44HP>G-'MYA_K9F?]S_P73_^1/CS_ADOXR?]%IF_[]R_XUTOP5_94\3?#_XM
M1>./$_C9?$]]%:/:+^X97(88Y9CV%?3U&!Z4O;3:L9U>*LSK4IT'**C-.+M"
M";3W5U%,C3[V3SS4M)2U@?((****!A1110 4444 (W"YKX"G_P"">'Q0T#QE
MXLU7P-\;7\+:?KVI2ZC):P6CABSLS .0V"1N(!]*^_:*Z\/BJN%;=)VN!\%_
M\,/?M#=_VE+S_P !I?\ XNC_ (8>_:&_Z.3O/_ :7_XNOO3BDR.:Z_[4Q7=?
M^ K_ "%9'P9_PP]^T-_T<G>?^ TO_P 71_PP]^T-_P!')WG_ (#2_P#Q=?>>
MY1W%&Y0,Y&*/[4Q7=?\ @*_R'9'P9_PP]^T-_P!')WG_ (#2_P#Q='_##W[0
MW_1R=Y_X#2__ !=?>>Y?4>E&Y<XR,T?VIBNZ_P# 5_D%D?!G_##W[0W_ $<G
M>?\ @-+_ /%T?\,/?M#?]')WG_@-+_\ %U]Z<4<4?VIBNZ_\!7^061\%_P##
M#W[0W_1R=Y_X#2__ !='_##W[0W_ $<G>?\ @-+_ /%U]Y[E]12Y'M1_:F*[
MK_P%?Y!9'P7_ ,,/?M#?]')WG_@-+_\ %T?\,/?M#?\ 1R=Y_P" TO\ \77W
MGN7U%+Q[4?VIBNZ_\!7^061\%_\ ##W[0W_1R=Y_X#2__%T?\,/?M#?]')WG
M_@-+_P#%U]Z<#KBDW*>A!H_M3%=U_P" K_(+(^#/^&'OVAO^CD[S_P !I?\
MXNC_ (8>_:&_Z.3O/_ :7_XNOO3BCBC^U,5W7_@*_P @LCX+_P"&'OVAO^CD
M[S_P&E_^+H_X8>_:&_Z.3O/_  &E_P#BZ^].*3<OJ*/[4Q7=?^ K_(+(^#/^
M&'OVAO\ HY.\_P# :7_XN@_L/?M"_P#1R=YC_KVE_P#BZ^].*,C/49H_M3$]
MU_X"O\@LCY1_91_8Y\2_ ?XH>*O'?B[QZ/&VM:Y8K922_9FC<X=6W.S,<G"*
M*^JN>3FGY7&>,4N1[5YU:K.O+GJ/4#Y\^-7[).F_&;QW'XK_ .$IU3P[J*6R
MVI^PJIW*I.""2"."17%?\, +_P!%4\3_ *?_ !5?6_!]*7(]J<:U2*LF?5X?
MBG.,+1AAZ->T(JR5HNR[:H^1_P#A@!?^BJ>)_P!/_BJ/^& %_P"BJ>)_T_\
MBJ^M]RGH11N4=2*KZQ5[_D;_ .N&>?\ 01_Y+#_Y$^2/^& %_P"BJ>)_T_\
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M*V,$ AE8&KOQ:^*&I^$M?\*>%O#.DVNL^+/$TLXM(M0NC;VL$,"!YIY756;
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M.0*],^'?@.U^''AF/1[74-2U8^;)<3W^L737-U<32,6=W<^I/"J H&   ,4
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M>&O%7[1OQ \?ZP=8T&\LQ)X7,&IZ/',VF9LKV2ZFMX9G :=]N"7 "JTBKV-
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MRS>:M:^+/#VG^-KC2?A_XLO6OM9T&+3D>X9Y-OVE(+K>#$DVS+ HQ!9MI&>
M"CK7[4WB;3T\6ZY;^!K2Y\%^%_$*:)?7YU7;=3HY@ G@A\O!V&==RLP)Q\N:
M]/\ B]\4;GX=Q^'M.T?25U[Q1XDU#^S=*T^2<00EQ&\LDLTF&*QHD;$D*3T
M!S7+ZM^SC%J?P_\ '_A1->>"+Q9KG]M?:/L@/V,![=A$%WC>,6X&[(^]TXYZ
MGXM_"Q_B3;Z#=6&KR>'?$OA[4!J>DZK';K.L,OEM&Z21$@21O&[*RY!Z$$$
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M#_4/#%M96MGNEU%I;>VC$BJI)5A]F!" -G?C/'(!H^*/VJO%7PWT;5+CQEX
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MAP<D*.33KK]I_P )Z1)!9ZA_:5S)#;V3ZMJ>F:7-+8:;)=1H\0G< F,,)$8
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M-\&V_@S2YK2&YFO9[FZFO;J[N,>9/-*Q9W(4 #J      *Z&@ HHHH ****
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M.-2\+_"*\\,7O]A0ZI>178?^P--6PL(GFW;52)!DJ@95+'YFVY/)Q7&?#'X
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53M'=B:W: "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img11029722_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_7.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &Z T8# 2(  A$! Q$!_\0
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M,'4CAE((-25L>8%%)NHH 6BDS10 M%%% !1110 4444 %%%% !1110 4444
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M[W8]3\/ZY!XCT73]3M@RV][;QW,0D&&VNH89'8X/2M(5R?PIC5?AGX2('/\
M9-K_ .B5KK%IQ;<4V<U6/)4E%;)L6BBBK,@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!K=O2OG#]J"U\:77B3PLGAW7X=)TW/^D0O<B++;P=[*3^\4 ?=
M&>_'-?2-?+G[7VL?V9XL\&)NQY@?_P!#6HE#VBL=F#Q4L'65:,5)J^C5UJ?3
M=LK>1'YC!Y-HW,O )QR:YG4OBIX7TN^>TEU5);B,XDCM8WFV?[Q0$#\:Y/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCA9?_"<@_P */JL/^?T?Q_\ D0/N;=1NKX9_X5%^U)U_X:%E_P#"<@_PI/\
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MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I*6DH \^^/^N_\(W\&/&VI!MC6VC7<@;T;R6P?S(KR/\ X)U^
M'ET?]E+P,SI^^NK62[D)[M)*[9_+%='^W1JATG]E/XE7 ;:1H\J*?=BJ_P!:
MV/V1]-72/V<OAW;8VE=#M"?J8E8_J:]%>[@_67Z >O\ DI_=7\J/)3^ZOY4[
MS%_O#TI2P%>< SR4_NK^5'DI_=7\J=O'K1N'K0 WR4_NK^5'DI_=7\J<9%!
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MC//6O. ;Y*?W5_*CR4_NK^5+YB^M*9%4X+#- #?)3^ZOY4>2G]U?RI3(B]6
MI5D5NAS0 WR4_NK^5>*_M-_%/_A#_A1K;>%];M;?Q+)<V>F1R6TD<LUF;B[B
M@>7R^<,@D)&1@-C(KVN3M]:\:\4?LE_"WQ##XDEMO"6FZ!KVOQO]I\0:5;)#
M?B1I5F\T28SN$L:/SP2HS0!E?#^/4/AU^T/J'P]&NZSX@\/7OAB/78/[=O'O
M)[:XCN?(EVS/\VV0,C%"2 4.W .*\R^-R^,5^*'Q"\2:KI7Q ;X=^';.Q\J;
MPWXC?2(T@6%Y;RYCB##[2P+ $#&!%@$DXKV/0_@AX@T^[\2>(+SX@W&H>/\
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M\_$7_?8H FZ57OQ_H[#W'\Z=]NMO^?B+_OL5%<7-O-$R"YC&>A#BFMP/CO\
MX)E_\B/\25S]WQOJ8_5*^T*X/X<?#?PO\+;?4;?P]9V6E07]W)?7$=L0%DG?
M&^0\]3@?E7:_;K;_ )^(O^^Q71B:JK57474">BH/MUM_S\1?]]BC[=;?\_$7
M_?8KF GHJ#[=;?\ /Q%_WV*/MUM_S\1?]]B@">BH/MUM_P _$7_?8H^W6W_/
MQ%_WV* )Z*@^W6W_ #\1?]]BE6[@D8*LT;-Z!@: )J*2EH **** "BF2 \'&
M1[5\>?M9:7\15^*7PMUB]\56VG^ U\>Z/8V/AW3(G66\9RS-->2D\[60A8U&
MW!R<G& #[&HKY@^.>BI\9OVGO!7PJU^2YD\"Q>';WQ+J6EV]S) NHSK-'!!'
M*T;!C&N]WVY ) SG%>-^+O'FN_L^^#_VC/AMX.U:^BMM!N=$3PQ+=7+SS:3%
MJICBECCD<EML3,[1@DD9'I0!^@=%?&_B+X7:#^R7\7O@O?>!Y=1L8/%&LMX9
M\06MQ?SW,>J"2W=TN95D=AYRRQ@[ACAV'2N$\/3WWAGXT6NL:FNLZ=\0=-\9
MZOJ'C'5KA+A;,>%TBN&A)D;]R;?RQ:[%7YMRG SF@#] Z*^:OV?O'WA^Y\7:
MGJWBGQ'8Z?\ $GQZT>H6GABZO%%U9:6JG[#;B+/#F+=*PZEI6]*^E: "BDJ)
MKRW4D&>,'T+B@":BH/MUM_S\1?\ ?8H^W6W_ #\1?]]B@">BH/MUM_S\1?\
M?8H^W6W_ #\1?]]B@">BH/MUM_S\1?\ ?8H^W6W_ #\1?]]B@">D:H?MUM_S
M\1?]]BG&ZAVAO.CVY^]N&*0'QC^V1\W[4G[,B=<^(;D_DD=?9EM&IAB;:-VW
M ..<>E<!XX^$?A7XA^+_  SXEU6T@O\ 5O#<[W6EW!F8&VD8 ,P"L > /O9'
M%=Y'>6T:*IN(L@8Y<5UUJJG3IP7V5^MP+'EKZ4>6O7&:9'=0R<I+&X_V6!IJ
MWUO(P59XF8] '!-<H$NP9SCFC8/2H_MD&\IYT>[.-N\9I/MUL?\ EXB_[[%
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M3E7;WS0 5%]EA_YXQ_\ ?(J:B@"'[)#_ ,\8_P#O@4?9(?\ GC'_ -\"IJ*
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M^!_QBUH^+/#%C\5K&/X>^);F>6:?4["2?6].MY_]=:VLHD$?E@$A"RY0-CG
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M?0XIX]/9I6\J S!5D<1YVERJ[=Q&0"P'4U\P6?[=%SQ]N\*:M"O\1M?)F/\
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MC[+<_P#/\_\ W[7_  H$7**I_9;G_G^?_OVO^%.CMYUD4O=M(O\ =V*,_D*
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MKOQR^$GAKP9X@L;CP;;7%M\2?&>JS6^BPM>2O9:;=3QD7VK1VV[8DB6_F,7
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M?\:HW7Q \/6B_/JUK_P%]W\J+,2H5I;0;^1M6#:IHK*^DZ_JFGD=%^TF1/\
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MKTVQU[QKI/A&2'7(?$4S6^EVUA/<;H"LJ*T@G:2%OE52"JMG'%>&;&B^$/\
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MLKK&1PS]2 !7T"GW?2@!2< FJG]IQ?\ /.?_ +\/_A5RDH J?VG%_P \Y_\
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MTOIOC.(:#\0-5\3Z)<^)+/36#:='I]Q<6T4+VLG!='B4K(S@,6)!%?:7QA^
MT_Q!\7:#XS\->++[P)XZT2"6RM]:L[:*[CFM)6#26\\$GRR)N56'((89K#\/
M_LFZ,WA/X@Z=XUUS4/'>M>/42/7]<O$2VDD6--D*V\<8VP+%PR@9PPSDT <_
M^U'!'H/Q2_9KN-+MDAN[?QE_9T0APK+:R64PEB&/X=J@[>GRCTKSSQ9\+_$O
MP2M[35=6;2KKP'X0\7W_ (TTJXM9Y&U35KR\,ZV^G>04P',UV5\S<V0!P.:]
MA\ _LS:OI7CKP[XD\=_$G5?B-/X5AEA\/VM]806D=FTB>6T\OE_Z^;R_D\QL
M<%N,DUZ#XY^&,?CKQAX.U:_U"1M*\-74FHQZ,L8,=S>;=D$TCYSB(-(54#&Y
M@?X10!\^?"'XR0_!VZN- UKP_?:HUSXECL/%OCJ"6+[,GB*]V/Y B)\QHHS)
M# )!PN$&.IK[ KY^UK]E.WU;Q_=:FWBN^C\(7^OV_BK4/":VD;1W&I0A-D@N
M#\ZQ%HHW,8'++G<,D5] T (3C%53J4:LP,<W'I"Y'\JMT4 4_P"TXO\ GG/_
M -^'_P */[3B_P"><_\ WX?_  JW10!4_M.+_GG/_P!^'_PH_M.+_GG/_P!^
M'_PJW10!4_M.+_GG/_WX?_"OQ3_X*+2";]L3QRXR!Y=A]Y2I'^AP^M?MO7XE
M_P#!1S_D\CQS_P!<[#_TCAKZKAO_ 'Q_X6!\V4445^G%A1110 4444 (>U?H
M/_P3TNDA\(6882'_ (F$WW8V;N/05^?![5^AG_!.[_D3[/\ ["$W\Q7R_$7^
MY+_$A'Z66NI1?9X_DGZ?\\'_ ,*E_M.+_GG/_P!^'_PJ:U_X]X_I4M?EY)4_
MM.+_ )YS_P#?A_\ "C^TXO\ GG/_ -^'_P *MT4 5/[3B_YYS_\ ?A_\*/[3
MB_YYS_\ ?A_\*MT4 5/[3B_YYS_]^'_PH_M.+_GG/_WX?_"K=% %3^TXO^><
M_P#WX?\ PH_M.+_GG/\ ]^'_ ,*MT4 5/[3B_P"><_\ WX?_  KG?B+J$;^
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M_P!E?Q_\8M3\6:YXRAUB>*'P1IOBA(3,D$LZV]M<S")$R96E\TH. BJ,Y)-
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M6/V,;**7PIX19M^381'B1AV]C7Y3M]UOI7ZO_L6_\BEX0_[!\/\ *OC.)_\
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M)/\ O\_^-7** *?]E6_I)_W^?_&C^RK?TD_[_/\ XU<HH I_V5;^DG_?Y_\
M&OQ3_P""BT:P_MB>.47=M\NP^\2?^7.'UK]N*_$K_@HY_P GD>.?^N=A_P"D
M<-?5<-_[X_\ "P/FRBBBOTXL**** "BBB@!#VK]!_P#@GG:QS>$;,ON_Y"$W
MW79>X]#7Y\'M7Z&?\$[_ /D3[/\ ["$W\Q7R_$7^Y+_$A'Z66NEV_P!GC_UG
M3_GL_P#C4O\ 95OZ2?\ ?Y_\:FM?^/>/Z5-7Y>24_P"RK?TD_P"_S_XT?V5;
M^DG_ '^?_&KE% %/^RK?TD_[_/\ XT?V5;^DG_?Y_P#&KE% %/\ LJW])/\
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M&OB2\\(_\(UXKUN3Q7I?PY^,^@V4OB:Z*(]UI_F(^VY90%,D32JCM@9.,\T
M?47PS_:-NO%?CX>"?&?@36?AMXGN;!]4TZUU:X@N(KZV0J)#'+"S*'0LNZ,\
M@'/2JOPU_:ELOB-XNT;2AX9U+1]$\2?;?^$:UVXGB>+51:-B8^6I+Q @%DW_
M 'E';I6)\<-]]^V%^SQ9V<BF\@37+NZB RWV7[*J$GT4NR#GC-<'XX^"-_\
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M=M_WVW^% %RBJ>;[_GG;?]]M_A1F^_YYVW_?;?X4 7*;)]QOI57-]_SSMO\
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M3:=\)_C]\--=\1WWCS0_!&H^';Z'6;\H][]CGN8)I;:Y= H=H]N[<1G;UZ4
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M_P \[;_OMO\ "@"Y15/-]_SSMO\ OMO\*,WW_/.V_P"^V_PH N5^)7_!1O\
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M$_A9^C7[-'WH_P#KFO\ (5]-+TKY=_9I^U!DVI ?W:_>=O0>U?2P-]_<MO\
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M8KY?B+_<E_B0C]-[7_CWC^E35#:_\>\?TJ:OR\D**** "BBB@ HHHH ****
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M1%-BA9+F3,@<Y55& 2:^JESCD8- "DX&:IG5K4'!F /?@_X5=HH I?VO:?\
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M**6D]B)_"S]$?V:M0MHVC#2@'RUZ@^@]J^EEU>TQ_KQ^1_PKYR_9H8[H^?\
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MUK[*3M]*^9J?%(_SNSO_ )&F)_QR_-CZ***R/%"BBB@ HHHH **** "BBB@
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M+_$A'Z;VO_'O']*FJ&U_X]X_I4U?EY(4444 %%%% !1110 4444 %<W\2/\
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M2/\ KW7^M?92=OI7S-3XI'^=V=_\C3$_XY?FRM]DN?\ G^D_[]I_A1]DN?\
MG^D_[]I_A5RBLCQ2G]DN?^?Z3_OVG^%.CMYXW!:[>1?[I11_(5:HH 04M%%
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MI7RQ_F]7_C3]65/LES_S_2?]^T_PH^R7/_/])_W[3_"KE%(P*?V2Y_Y_I/\
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M.A%NBJGVZ3_GRN/_ !S_ .*H^W2?\^5Q_P".?_%4 6Z*J?;I/^?*X_\ '/\
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M20^*](TS2;_XF:5I=S;:&^K73Q1HDI7S 0N2%)507"E@. >2*^!O&%WJFE_
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MBB@ I:2EI/8B?PL_1G]F?[T?_7-?Y"OIM>E?,O[-'WH_^N:_R%?32]*^6/\
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MXY^/O^1\\2_]A.Z_]'/6#6[X\4)XZ\2*HVK_ &G=<#_KL]85?4QV1_HWE_\
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M_P"CFK^A\]J_G@^*G_)4O&?_ &&KS_T<U?<<+_Q*OHOS&CEZ***_0"@HHHH
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ML**** "BBB@!#VK]!_\ @GIY_P#PB%GY2Q$?VA-]\L.X]*_/@]J_0S_@G?\
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M2_M:U_YZ_P#CC?X4?VO:_P#/7_QQO\* +M%4O[7M?^>O_CC?X4?VO:_\]?\
MQQO\* +M-D^X?I53^U[7_GK_ ..-_A2-JUJRD"7G']QO\*!GXZ^/O^1\\2_]
MA.Z_]'/6#6[X\8-X\\2D<C^T[K'_ '^>L*OJ8[(_T:R__<J/^&/Y(****H]
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MIX-?5%%% "-4%C;FUM(HB<E1BK%% !1110 4444 )7Y@_P#!1/\ 8]\>:_\
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MI7T)\;?@_H_QR^%.N>"=<+16NI6_EQ7<:9DM9UP8ITY^\C@,.>Q&>:Y/X?\
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M_N]^<YRV,=Z /=:*0<@&EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 9+C;R*\RUCXI7<GQTT3X=:':VUVZ:;)K7B"ZG)S96I)CMD0 \
MR2RANO 2)O45Z;)]W\:^<?@C([?M@?M(&\)^T*WAY;3S.OV7[ 2=O^SYID_'
M- '72?M=?!FTU#3[&?XE:!'=WT[VT,<ET%)E21HV5LC"'>K#YL9QQ7<^)OBI
MX*\$WR67B'Q?H&@WKQB5;?4]3@MI&0D@,%=@2,@\^QKXC\%^$=%E_P"";OQE
MNGTJS>YO+CQ1=W$S0J7EEBOK@1.QQDE!&F/3:*]+\:?"/QS\1-'\#:MH?PV^
M#GC:W/AJP2;4OB);33:@)/*!959(''E\@CG.6;B@#UGXC?M#:9H_P]O]:^'J
MV7Q.UM+JVL+?3= ODN0L\\@1'G:+?Y42Y+,Q'"J:YCPO\9OB5X1^,GA7P!\5
M='\,*WBZTO+C1M4\)37#(DUK&)9K>>.;YO\ 5DD.IP<8QSQS?A?7I?V0?AGX
MO\7_ !)\&_#;P19;[=+.T^&-N\;ZE,=RK%()(HP7+$!>P!<D@"IO@)9V_CKX
MD?\ "T?B'XM\-W7Q FLY+71?">CZM#<P^';%OFD0;7/FSL%S++C  P/E&: ,
MO6/VDOC3IOP^UCXM-X \/:=\-M+DGGDT/5;BY@\0R6$,K))<<J(D<A6=8V&2
M,<\C/:>,_CMXR\4?$BQ\"?"/3-!O-870X?$>I:GXJ>=+2UMIV*V\*I#\[2N5
M8]<*%R<YKRWQ'\5M _;(UZ?1KCQEHOA?X&Z5?;+XW.JP07WBN>"3F)59]T5D
M'498X:7'&%YKM?#_ (CT;X;_ +:WCE==O[+1M/\ %7A32[O1;RZE6&WN5M6E
MCFCC=B%+('1MH/W6!H VM)_:1\0^(/@+XF\:VWAFVA\5^"]1GL/$_APS-*$:
MT<-=K!(,9)A/FQD@YW $9KW;PWX@L/%N@Z;K>EW"W>F:C;1WEK.O22-U#*WY
M$5\U?LAPVFM>&?COXNWK<^%_%GC;5K_3KAO]3=62PQPF9<]49HY!GH0OI75?
ML$23/^Q_\+O/:1C_ &5^Z,N=QB$KB//_  #;0![]TZ4M%% !1110 4444 %%
M%% !24M% "5Q/QB^)EA\'OAMKOBR^B:Z6PA @LXO]9=7#L$A@3_:>1D7\?:N
MWKYP_;59%T3X4K=Y&E-\0]%%YD?)CS6\O=[>9Y?XXH [W4/C=X>^&>A:.GQ/
M\2:'X7\1SZ6-0O+7SF2($%%D$6[)95=P@Y+'CBMGPK\;? 'C/P1)XQTCQCHM
M[X6C;RY-6^V)';Q,"!M=F(V')'#8/(]:\<^)F@Z=KG[>7PEDO[2&\-CX6UBY
MM_.4,(Y?,A7> >,@,<'MFN.\*^#;W7_B%^U=H/AOP[X5URYFU[2)HM&\61,V
MDRR-8PM(TR(C')QNX4_, : /I33OCC\-=8U"WL[#X@>%;V^N76*&WM]:MI)9
M7)P%50^6)/0"O$-?^/'QMNM)\8^-_#?@/P]:^!/#-Q>1C3?$DUU;:SJL%KN\
MZ>'"^7"K;6\L.&W 9S@BN?\  O[//Q'T?QIH>H7_ ,%_V=-*L[:]BFFO=#L;
MA;Z! P)D@)M@!(!RN2.<<U4^(WQ@TS]JKQ5KOPXL?&>D>$?A+IERVG^)]>N-
M5@@O=<D3'FV%FC."D/.V2<CYAE5SR: /3M=^.7CKQO<>"=.^%'ABPG?Q'H*^
M(Y]>\5"==-L+=MH2!O)&7G8L?E## 7)XK%L/VNK_ ,,_#OXBW?CCPS#'XX\#
MZK!HMQI.A7#26^JW5P$-H+9W 91*9%&'!*X.<U=^.7[1>G?".V\*_#OX?OH<
MOC'7+ -HPU"^BM]*TNP0!!>3R%AF-0/D1<M(5P.YKP_X\?"/1O"_['^JR>'O
M&<GC'5H?%6F^)_&'BS2+J.>[FE%PAN+D>66\L1H R(/NK&/0T ?1O@7QE\;K
M/QYH^D_$+P9X>FT'6()G_M;PC=S2#1Y44,L-VLV-X<$J)(^-PZ '-=)\*_BE
M>>+O%GC;P?KMM;V'B?PK?JDL5L6\NZL9E+VET@8DC<F589.'C;'%?.>GZ)\/
M_A[^TI\'T^"&K1W5QXD%Y)XFL]/U:2]@O=,$&Y;RYR[ 2"79L<X)+,/:O3]-
MPG_!0+5_L(PDGP[MVU+;T,@OV%ON]]OFX]LT ?1N!Z44M% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )7F'CKXHWFC?%?
MP3X T&VM[W5];,VH7[7);98Z9  )9<*1EWD>.-!TR23D+BO4*^;_  JQ;_@H
M!X^%UN,J^!-*%D&[0F[N/,V_\#QGZ#VH [#Q%^UA\(/".I-8:S\1-#TV]2\D
ML)()[C#1SQML='&/D ;C<V!GOQ7;>(/BAX+\'_9#KOB[0=$6]C\^U_M'4X(/
M/CX^=-[#<O(Y&1S7RO\ !_P9H>H?#7]K"YN]*M+N>_\ %7B&WNI)HE=I8TME
MVQDD9VC+$#L6)JOX=^&/C'XE?L\_!*ZT#P!\*/'2V_A2UCFN?B3;RS3PGRTV
MK 4ADPF!SDCD"@#ZDM?C%X#UC3]4U#2_&.AZO;Z3;->7K:7J$5VUO"H)+LL3
M,0.#VYZ5YC^SU^U!<_'SXF>/-&@\,W?A[P_H=K87.FS:I"\%[?1W'FD3M$W^
MKC81@H",D9)ZX"_LW_";Q=X!UK69_$OP[^$G@RWN+=(XIOAU:RQ3SL&R5GWP
MQ@H!R,9YJI\*6_XS;^.XSS_8OAW_ -%W- '.0_M*?%CQCH_C'Q]X)\&>&[WX
M9^&[N\MTAU*]GCU;6H[1BMQ-;E5\J(91PBR9+;><9JW\8OVK-6M%^%4/PUO/
M!\+>.=/N-:_M+QS<RVUE:V,<,;AV:-@0S-*J]^>W4UX]XHFT3P#X ^+]IX1^
M.4.A_#J&^U2+4/!EQI:#6K;4)-WFV=E)(X81RR,-G[I_OG:3UKM?AYX?^%7@
MNR^!'@+XO^$M/;QG:^!XTT[6/$<,36"LBH)[-3(VWSQD-@KG X/:@#V/PWXJ
M^+C_  ;U[Q'J:^ _$7B:*-[O2(_",]U+I]] JABADD.[S&PZJRDJ"5)SR*])
M^&OC[2?BIX!T#Q=H<IFTK6;2.\@+?>4,,E6]&4Y4CU!KYX_8QM](M?B;\?(/
M ^S_ (53'KMFFBK:$&P6]%M_Q,5ML?+L$GE_=^7.<5T/[!&1\ YDCW?V='XF
MUQ-/!^Z+4:C/Y87_ &<=* /HRBBB@ HHHH **** "BBB@ I,#TI:* $VCTKG
M/B+XXTKX9^!]<\5ZY/\ 9M)T>SDO+F3OM12<#W)P .Y(KI*^<OV_G9?V<;P.
M2-/;6]'74./D^RF_@\W?_L[>M '8Z3\<M.\*^ ?"NJ?%75-(\#ZYKME-?BPE
MF*)&J)YKQAG)RT<;)NYY;.!T%;O@?X[?#WXD>%]0\2^'/&.CZGH6G,4O;Y;E
M4CM"!D^:7QY?']X"O(OVCM$TW7_VG/V:;74K2&]M%U#6;B.&90R"2.R5HVP>
M#@@$>X%8,?A>;4/VIOVAM(T+1- U&\U+P=HCC2]>B/\ 9EW<,UVO^E*JL64A
M5#':3@"@#WN/X_?"^ZD2&+XC^$9I9&"I&FNVK%F)P !YG)->6ZY\6/C7XF\1
M>-6^'O@SPY:>&O"=V]AYGC![NWNM:FCC5Y3:B-=J1?-M61MRL?;./-=+_9M^
M)]MJ5G--\#/V98(HYD=Y;2PN1,BA@2R'[*,,!R.>N*W?C1\<E^-/CC7_ (/^
M%/&>E^"?#^FR"R\8>,+S488+A P^>PL$=@3,5R'FQMCS@9:@#HYOVL=4\?>$
M?A./AKH-G-XQ^(]G-J%G;>()G6TTRW@4&YEG:,;G"L510F-Q8'@5H>&?VE-:
MTOPW\6;+X@Z3IFE^./AQ8'4;V'2IG>PU"W>!YK>: OAU5RC(5;D,.M<7KUKX
M1^#O[1/[/^IZ9<V&G?#=?#6J>%M.U))U:SBF/D201F;.W,BQ2 $GDJ><FN9U
MCQ%X6U[XI?M1>/K_ $>Y\??#;3_#VEZ)J-IHY$RZA)&KR7,<9#J&,2NFXAAC
M)QTH [K]GWXQ?&KXKZCX>O-5U/X.OHMU:Q7VIZ1H.H7D^LV44B!@K1EF19%+
M*#NX!!YKU[P3\4[K5/BWXS^'^OVMO9ZMI,<.IZ9)!NVWVFS?*LF&)P\<JO&^
M..4('S5\R_$C3_A$GB[]GR^^"EMX>MO&%UXBM'LF\)K$DLFC&)S=_:1'R80F
M,F3^+'?->J^-/+7]O7X9FT!%ZW@S6%O=O_/J)X#'GV\W&/K0!](\4;1UQS2)
MTIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C+
MN&#7E>L_"[4-/^/FC_$;0I;:..ZTM]$\1VLS%3<6Z,9;6:,@']Y'(77!QE93
MS\HKU6HI.9%!Y&* ,&W^'OAFW\+WGAR'P_IL/A^]\[[3I<=JBVTWG,6EWQ@;
M3O9F+9')))ZUN6=E!I]G#:6L,=O:P1K%%#$H5$11@* .   !BI8_NBG4 <WX
MV^''A?XE:2FE^+?#VE^)M-203+9ZM:1W,(<# ;:X(R,GGWKF?#/[-/PG\$ZQ
M'JWA[X:>$M#U.-)(DO-/T:WAF5'0HZAU0$!E9E/J"1WKTJB@#R"3]C_X'2,6
M/P@\#$GN?#]J3_Z!79^+OA3X-\?:+9:1XF\*Z+X@TFQ*M:V6IV$=Q% 57:-B
MN"%P...U=910!YI\8/ NK>)?A'J7@OP<;'05U*!=*:;;Y26-E)A)VB15QO$1
M<(O R0<C%=EX1\,Z=X+\-Z7H&D0"UTO2[2*RM81_!'&H51[G K13[[CL#Q4D
M?WF^@H DHHHH **** "BBB@ HHHH **** "N"^.'PMM?C)\+]=\*W$YLIKJ)
M9+.^09:TNHV$D$Z^Z2*C?@17>TV3B-L>E ')^%_#LE[;Z!K?BC2M);QS9Z>+
M:>_M4$AB9@OG)#(5#"-F7...V>E;.F^%])T75-4U*PTVTL]0U21);^Z@@5);
MIT4(C2L!ER% 4$] ,5>AXDP.!M_K4] #=GOFO);C]D?X)WEQ)/<?"/P1/-(Q
M=Y)- MF9F)R224Y)->N44 >:^(OV;/A5XN:R?7/AOX3UA[&UCL;5K[1H)O(M
MTSLB3<IVHN3A1P,FMSP1\(_!7PST^]L?"/A/1/#%E?-NNK72-/BMHK@XVY=4
M4!N"1SVKKJ* ./\ !OPE\$_#>XOYO"OA'0_#<M\V^ZDTJPBMVF.<_.449Y]:
MYGX3_"^^\,^-/'WC;Q');3^)?%-\@46K%TL].MP8[2W#$ DX+R-QC?*P&0,U
MZG)_#]:B'WA^?ZT 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img11029722_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_8.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &Q T$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[Y_:4^-DG
MP#^']OXF32QJV_4(K)H#)L(#JYW ^HV@?C7S/_P\RF_Z$IO_  +7_"O3/^"C
MO_)O]I_V';7_ - EK\SZH#[D_P"'F4W_ $)3?^!:_P"%'_#S*;_H2F_\"U_P
MKX;HIDGW)_P\RF_Z$IO_  +7_"C_ (>93?\ 0E-_X%K_ (5\-T4 ?<G_  \R
MF_Z$IO\ P+7_  H_X>93?]"4W_@6O^%?#=% 'W)_P\RF_P"A*;_P+7_"C_AY
ME-_T)3?^!:_X5\-T4 ?<G_#S*;_H2F_\"U_PH_X>93?]"4W_ (%K_A7PW10!
M]R?\/,IO^A*;_P "U_PH_P"'F4W_ $)3?^!:_P"%?#=% 'W)_P /,IO^A*;_
M ,"U_P */^'F4W_0E-_X%K_A7PW10!]R?\/,IO\ H2F_\"U_PH_X>93?]"4W
M_@6O^%?#=% 'W)_P\RF_Z$IO_ M?\*/^'F4W_0E-_P"!:_X5\-T4 ?<G_#S*
M;_H2F_\  M?\*/\ AYE-_P!"4W_@6O\ A7PW10!]R?\ #S*;_H2F_P# M?\
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M?^%8Z@/^XG%_\17R#;_LMR:I^RC/\;=*\3+?I9WGV._T$61$EL?-$;,9=YR
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MI_\ $T?\/+H_^A(G_P# U/\ XFOAG<A?9N4MZ;AFAI$C;#,JGW(H^KT.PO\
MB''#6_LG_P"!,^YO^'ET?_0D3_\ @:G_ ,31_P /+8_^A'G/_;ZG_P 37PRT
MB*NYG4+_ 'MPQ70> _ ^L_$CQ19^'_#UI]NU2Z)\N+>%7:!RQ8]%'<T/#T.Q
ME6\/N%L/3E5JPM&*NVY/1'V-_P /*X_^A&GQ_P!?J?\ Q-'_  \NC_Z$>?\
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M!]/_ +3VB^+_ -H3]N;P9\,O$'AZ/PUIVGR16%A%;NTB/IV[S7N%D"C(9(\
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M_P +_,FHHHKS#^?3Y9_X*._\F_VG_8=M?_0):_,^OTP_X*._\F_VG_8=M?\
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M]IK]D3Q+^S'XQ\/:-JVHV^M6&N@"TU>T@>*+S-X5XV5B2&7<IX/(->=?!?\
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M$<N_%UO<-87T;1S226,AC5G3D^6VZ(<GD;?>MJ.:3Q&*J4Z35K:>M[7_ *Z
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MX^.WB?S#XO?[WA/\+_,FHHHKS#^?3Y9_X*._\F_VG_8=M?\ T"6OS/K],/\
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M7N#7 ,NWITIM%;**B[H^SH8+#X:K5K4HVE4=Y/NTK?D%%%%6=H4444 %%%%
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M_P!]?_7KZVVCTHVCTH ^2?\ AW#X#_Z#&I_]]?\ UZ/^'</@/_H,:G_WU_\
M7KZVVCTHVCTH ^2?^'</@/\ Z#&I_P#?7_UZ/^'</@/_ *#&I_\ ?7_UZ^MM
MH]*-H]* /DG_ (=P^ _^@QJ?_?7_ ->C_AW#X#_Z#&I_]]?_ %Z^MMH]*-H]
M* /DG_AW#X#_ .@QJ?\ WU_]>C_AW#X#_P"@QJ?_ 'U_]>OK;:/2C:/2@#Y)
M_P"'</@/_H,:G_WU_P#7H_X=P^ _^@QJ?_?7_P!>OK;:/2C:/2@#Y)_X=P^
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M9/+^U3O(L<<6[!P69AT!^E4L75?VV+GD>/?\.\?@A_T"_$/_ (.#_P#$T?\
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M.5 .><4?6*O\PUQ-G#=EC)_^!'&_\,=_"W_GQU?_ ,&)_P#B:/\ ACOX6?\
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M^REX"^%/C8^+] MM3_X2*;3VTZ^OK_49;N34(V=6+7!D)\QP5 !R,#C&* /
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MFVTEU<RG^&-%R3C_ #UI\L&KZB.C_M>)L8TJR/\ WU_C1_;$*_\ ,*L_R?\
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M0MV@E+A&.3Y;E3GV(K,_X0VP_OWG_@5)_C6]10!@_P#"&V']^\_\"I/\:/\
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MPFO[V6-?O2"&)68(.['C-6?"O[1'P_\ &'PPNOB)8^)+>+PE9"07M]?*UO\
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MLA%M^Y$ *#>&'WLXV]LU]/>'/".D>#]-73=!T2ST/30Y?[)IMJEO%N/WFVH
M 3W(ZU-:^'[*RU"]OK?3;>WOKXH;NZB@599R@PF]@,M@<#.<4#Y8W3YCPW]N
M13_PS=K4C(S6L>HZ9)=*@R?)%[#NR.X!'3TYJ]^U1!X,O-'\)77B;7]1\'WB
M:U&=#\7:7&"-+NV4[7F8G:L3J"IW?*>!7J_C3P;9^/O".L^&]7@:73=5M9+2
M=<'.UU(+#W'4?2L+X?\ @O5H_A;I?AGQY;6&NW=K;_V?<L8Q/!>0Q_+'(RN.
M&9 A9<$ YH'*S;U1\U^"]%;7_P!JZRUFT\87OQ>N_"OA;4&UC58Q!':.\Z;+
M>PA2+]TCD!R<$YWY8\8IOQ+^+'P>\??LA:O9Z7INCZ3J=] UII_@VTBB74K/
M53)M2-(% <.L@!W 8P.#S7UUX?\ ">E>$]/^PZ#HMEHEENW_ &?3K1+>/<>^
MU !G\,U37X=^&X_$;>(4\+Z3'X@;DZLNG1?:SV_UNW=^N:"5!+JBAX,U9=%T
M#PEX=US4K5?%\FCP-)I]S=+]IN'2-5E95)W.H<'<P&.37Q9I'AGX0^._ /Q#
M\7_%W7X[+XK0ZA?&_-UJ+6MWI\D+L+-(+8,!(H CVG:V[WK[PN/#.G7FM6NL
MSZ1:RZQ:QM!;ZA);JUQ#&W+(DA&Y5)Z@'FL_5?AOX8UW7(=:U+PKI&H:S%CR
M]0NM.BDN$QTVN5W#'UH*<.:UVCS#P5X/LOC/^S[X"U3XM:8K:S;Z6M]=7#2/
M9S6I\L[WWQ,K1[HQEE! (SD5XW=!X?">B^.+&ZD\$^%_%^NV/ANPO=/86S:-
MX:C9_*V/_P LC<N Y?@X=.:^S+[3(M4M9K2]M$O+2=#'-;SQ!XY%/!0J1C:1
MD$="*@O?#MAJ6CMI-[IEO=Z4T0@:QFMU: Q #";",;1@ #H * <5W/+?V9?$
M%[JFE^,;"XUFZ\2:#HGB6XTW2=9OIQ<27-JJHQ5IO^6NQF9-_MWYK%_8IP_P
M7OI(@PLIO%6MR69/3R#=L4*^W6O2_&'A75;3X::GH'@&ST_1+^6T:SL%5/L]
MM9[_ )6D"HO\ +,% Y(P35_X>^ K#X:>!="\*Z1$ZZ=H]HEK"67YGP/F=O=F
M)8_6@27O+78WJ*=Y,G]QORH\F3_GFWY4SHYD-HIWDR?\\V_*CR9/^>;?E0*Z
M+&F_\A"U_P"NJ_SKU^O(M-C<:A:_(W^M4_=/K7KP[U1Y>,?O(6BBB@\\KWEA
M!J$+0W$2S1-]Y'&0:S_^$/T7_H&6O_?L5L44 8__  A^B_\ 0,M?^_8H_P"$
M/T7_ *!EK_W[%;%% &/_ ,(?HO\ T#+7_OV*/^$/T7_H&6O_ '[%;%% &/\
M\(?HO_0,M?\ OV*9_P (IHFX+_9EKD_],Q6T>>#TKYH_;@\<ZCX>\(^!/#>C
M^+;GP1?^+?%-GICZY:W26LEK:*&DN7$C_*I\M" 3QD@4 >_-X1T51G^R[8_]
MLQ21^$]$DSC2[;_OV*^6-%^!V@ZMJUM::=^UY\0]4O9' BLK?QAI\KS$<[0J
MPY/ Z"NU^(7[9^C^ ?%GB31]-\">,?&EEX6*+XBUG0+));72V*!RKEG5G98R
M'8(#@4 >Z_\ "'Z+_P! RU_[]BF-X3T53C^RK8_]LQ7EOCS]K/PCX3TOPG)H
MEGJGC[6?%EI]OT30O#-N)[N[ML!C.0S*L<8!Y9R!G@<UYS\4_P!L"QUO]E/X
MM^+- MM6\)>+?#,$FEW>DZM&+>_TR^D"K$3@E>D@=6!(X]J /IK_ (0_1?\
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M&>YM+[2O$DL=S)$L<6_[7 RJIC56X8?=.<=JCFCV*MYGU#_PD&I]KZ8_1_\
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MJ _Y?9O7[U?/'CQ?%?PM_9Y\/>%V\6:AJOC[5[NRT&+Q!(Y:X:ZN)AYLBMU
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MFJ=RD@#.!3",HMVL>[?VYJ/>]F'U>C^W-1Y_TV;C_;_6O/?BIKWC/1-#LX?
M?AJ'Q'XAU"Y^S1->W AM+ ;2?M$YZF-<?=498D"O)O@#\3/%VJ_L8R^-=4NY
M/$7B^VM-9N1-.-WFS03W*QJ /X5V* OH *"KQ4N6Q]-_VYJ R/MLV>XW=O6D
M_MS4-P'VV7_OJOD7X7_%>Y\#^(]+GUCQ]?>,O#>H> #XMUBXU"X2X%A=AT&V
M':!Y2R!F B/< #D&O<?@G;^)Y/!"ZYXON;HZSKT[:JUC(3Y>F0R8\FT1?X=D
M>W=ZN6- U*$NAZ5_;6HCK=S?]]&C^W-0_P"?R;_OJO%_#?B[4_#7[07B#P+J
MU]-?Z?K.GCQ#H4MPV6MPKB.ZM >Z*VR11V#$=J]:H&E%[(O?VYJ'_/Y-_P!]
M4?VYJ'_/Y-_WU5&B@?*NQK:?K%])?6ZM=RE6D4,N[KS7JE>/Z;_R$+3_ *ZK
M_.O7_6J/,QBLXCJ***#SPHJK>7T&GPF:YF2")3@O(VT9-4?^$NT;_H*6?_?X
M4 ;%%8__  EVC?\ 04L_^_PH_P"$NT;_ *"EG_W^% &Q16/_ ,)=HW_04L_^
M_P */^$NT;_H*6?_ '^% &N>AKX;_;&^(?PMM_VJOA;H'Q?O=*3P1I.B:CJU
MS9ZU:M<V]Q=2E(;<&,(P) 65N1VK[-_X2[1O^@I9_P#?X5#)XB\/3,"][I[D
M# +.IH ^7_@WXT_8Y\2?$;2;/X7:?X%?QUF233?[+T$V]PK+&Q8I)Y*[3MW<
MYZ5X)XZ^-'A^6XUSQ5X;N?$GPH_:?:[:UO/A]IMO<7EKX@GCD\N/SH'B\N:.
M2-1^_&W RW. :_1N/Q%X>B;<E[IZ-ZJZ@TX^)M!:42G4+ RCH_F+G\Z /CW4
M/BMH7[.O[6'B'Q=\6(I/"]EK?@K2[30[R&TDGM5DC9VN[&,QJV',I!"]P,]Z
MC^+WC#5_C[X!^$.CZ]X./A$^/_'MO*NE3Y:YETBT+7"O=*5&UI$B7*'.T.HS
MUK[&D\3:#*H5]0L74'(#2*>:<WBK0W96;4;%F7H3*N1]* /GCQI'+XZ_;J\'
MZ5; FT\#^#[S5V3&%CNKQQ;P'IUV))7Q?\*;#P;X0^&D?@W7OB-\<+/XQ?:K
MFVU'X:^%=3EMOM5Y),X:2)##Y8AD#!C*SXP237ZK_P#"4Z'O+_VC8[B,%O-7
M)'I3?^$FT'S?-_M"Q\W&-_F+G\Z /DKP!\+=+TG]J[X6>";&UNCHOPK^'TMW
M FH2+/+;W=W,L(1W50K.(U8[E 'R\5POQ_\ #6L?%S6_VM]6T/3[K5+O2- T
MGPG916@S+/&C"\O8D4<D_,1@<L>E?>/_  E6AABPU&Q#$8)\U<FA?%6AQ[BN
MHV*ECDXE49H ^?/AW^U9X8^+7BCP=X,^%NB'Q5HUK"&\0ZC<VLMK:^'X8HAY
M<1#Q_-<;P%$8Z8)S@5Y[\(/%A\'?LK?'GXT; VI>)=4US6+67'S311E[>R0>
MOW !VRW'6OL2/Q1H4.0FH6* G)VRJ,TW_A)= \KR_M]AY?39YBX_*@#XL\%^
M!9M%\6?LE_#1(OM#>%/#5[XNOX'X)N/LZQP$^_G32#\Z\"\>?'*WU[X*>.=0
M\3_%;XD+\7F6]6\^'?AN)]-L]-;>ZCST2'F!4VEI&?+@C/6OU2/BC0BX<ZC8
MEP,!O-7./2FGQ)H#,[&_L"SC#'S%RP]#ZT <U\!?"\'@GX)> -!MBK0Z=H5E
M;JR+@-MA0$_B<G\:^1_A?^T5H?[-/_"X/"_B+2M3O?B[J7C35-1TOPW#93/<
MZZD[@V1BD"E3'LVJ6S\@4\<8K[A_X2S1!@#4[(8X'[Y::WBC06D60ZA8F1>C
M&5<C\: /D3QIX]L?@?\ M1^"_B-\6--3PEH%]X".EIJ-O!)=:?I6J-<B:>WW
MHGRLR\!RHW8QZUYA\8O%VK?$K2?C;\9=)TR^TCP_KGA^P^''A&>\MWAFU7S[
MP>;=",@,(R\NU&(R5],&OT*D\4:%,FQ]0L77^ZTJD4-XHT)E53J-B57& 95P
M,=* /FGP%X;AF_;0M-*MHR-,^&GP\M-+@"XVQW%W(-R_7RH$.?>OK!?NBL4>
M*="5F8:C8AFZGS5R:?\ \)=HW_04L_\ O\* -BBL?_A+M&_Z"EG_ -_A1_PE
MVC?]!2S_ ._PH V**Q_^$NT;_H*6?_?X4?\ "7:-_P!!2S_[_"@#8HK'_P"$
MNT;_ *"EG_W^%'_"7:-_T%+/_O\ "@#8HK'_ .$NT;_H*6?_ '^%'_"7:-_T
M%+/_ +_"@#8HK'_X2[1O^@I9_P#?X4?\)=HW_04L_P#O\* -BBL?_A+M&_Z"
MEG_W^%'_  EVC?\ 04L_^_PH V**Q_\ A+M&_P"@I9_]_A1_PEVC?]!2S_[_
M  H V**Q_P#A+M&_Z"EG_P!_A1_PEVC?]!2S_P"_PH V**Q_^$NT;_H*6?\
MW^%'_"7:-_T%+/\ [_"@#8HK'_X2[1O^@I9_]_A1_P )=HW_ $%+/_O\* -B
MBL?_ (2[1O\ H*6?_?X4?\)=HW_04L_^_P * -=J\3U/_D)7?_75OYUZJ/%>
MCR,JC5+0DG  F&3[5YQJ&BZA+?W+K9S%6D8@A#@C/:N_!RBI.YA5Z&115_\
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MC(DW?*$[8K[6^%>DZKX>^&?A'3->E:?6K+2K:"]D9MQ,JQJ&!/<@\9]J[/\
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MNV5I+6Z@D,<L99>& 93AAU&#0!Z%]C@_YX1_]\#_  H^QP?\\(_^^!_A4]%
M$'V.#_GA'_WP/\*/L<'_ #PC_P"^!_A4]% $'V.#_GA'_P!\#_"C['!_SPC_
M .^!_A4]% $'V.#_ )X1_P#? _PH^QP?\\(_^^!_A4]% $'V.#_GA'_WP/\
M"C['!_SPC_[X'^%3T4 0?8X/^>$?_? _PH^QP?\ /"/_ +X'^%3T4 0?8X/^
M>$?_ 'P/\*/L<'_/"/\ [X'^%3T4 0?8X/\ GA'_ -\#_"C['!_SPC_[X'^%
M3T4 0?8X/^>$?_? _P */L<'_/"/_O@?X5/10!!]C@_YX1_]\#_"C['!_P \
M(_\ O@?X5/10!!]C@5@1!'G_ '!7CFI7$PU&Z E< 2L -QXYKVDUXGJ7_(2N
M_P#KJW\Z[\'\3,*O0B^TS?\ /5_^^C1]IF_YZO\ ]]&HZ*]8YB3[3-_SU?\
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M7#EL=0+F8C(E?'^\:/M,W_/5_P#OHUYG^SO\2+WXI?"31M9U51'KT!ET[5$
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M!(5&M7NUOM$F5/,,6WRQU#-N]*"/:KEO8^R_M$F ?-?'^\:>IGD3>IF9<XW
MG%1G'FD[=^&Z9X]_\^U?*?C_ .!-MH?@'QO\0OBAX\UB'Q7;M=7MCK&DZQ<6
MMKIL:Y-I!##E5+9"@JP;<3WH-)-15TCZOCDFE8!&D<]<*Q-(LLLC;5>1F] Q
MS7R#XG\13^)-%^ H^,FI7/A_PQJV@7-WK\XN)+*)]3$,9@6>6,JR$HTC*N<%
M^W2I/!?BS7OB1\,?AGX%U[5+FRGGM#KGBK5KR8VTL.CPW#"U624X*/<%(@6.
M&*JQR,F@A33W1]=+)*QP'D)]F/UI//D_YZO_ -]&N1\=>';?XF_#S4].T[4S
M"M]:$V.J:;< F*8'=%)'(AP=KJIZXX[]*Q/V??B1<?%CX1^'_$5_&L&KLDEG
MJ<*]([V%S'.!]67./]J@N\3TGSY/^>C_ /?1H\^3_GH__?1J.B@HD\^3_GH_
M_?1H\^3_ )Z/_P!]&HZ*!EW39I3J-J/,<J95R"Q]:]<]:\@TW_D(6O\ UU7^
M=>O^M6>5C-XCJ***#SPHJK?:A'IUNT\P<QJ0#Y:%VY]AS6;_ ,)CIWI=?^ D
MO_Q- &Y16'_PF.G>EU_X"2__ !-'_"8Z=Z77_@)+_P#$T ;E%8?_  F.G>EU
M_P" DO\ \31_PF.G>EU_X"2__$T ;9KY9^-?PSB^.O[6WPWT'Q#H$VJ>!_"6
MBW7B&Y^T6[&QFOI)$BMXRY&UV4*[&//0@D8KZ+/C#3B,8N__  $E_P#B:9_P
MEFF_]/?_ ("2_P#Q- 'SLGAS4/V<?VK'U+1=)O+KX<_$U<:E;Z=:M)%I&LPI
M\DY5 =D<Z#:3P-XR>M?/^M?!+Q#XW_9/\,>)=:\&:UKZ77Q%NO&WB3PO;B6T
MU.>QDEG3Y%RD@DCC*$*"&P.*_0G_ (2S3@Q.;O\ \!)?_B:4^+=-SG_2\_\
M7I+_ /$T ?%O[._P=^&.L?%RS\5>#_@KXM\/>'_#<3WL7BCQCJFI0W#7FW B
MMK&>1O,^4ON=@ . ,DUSWP=^+WCCP'\&/%'A6#X1^,)?BGXWU34M6T^X_LMT
ML)VO7/EW%Q<' A\M-H9'PW[L<<BOO(>+-.&.;PD=S:2__$TO_"7:=ZW?_@)+
M_P#$T ?&7C3P;_PI7P/X"^%?Q'^&MQ\2?@Y:^'8HI-4\.:9-=W]EK:LS22XB
M821H^]MCH RDG+5R\GA?XA>)OV:)/ ]WIOBX^&O%?Q!T[3?#MOX@1Y]5L-!\
MZ.9GO&P6CB'DL 7Y564$U]Z_\)=IHR0+H'_KSE_^)I&\6:<V.;P?2TE_^)H
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M>EU_X"2__$T ;E%8?_"8Z=Z77_@)+_\ $T?\)CIWI=?^ DO_ ,30!N45A_\
M"8Z=Z77_ ("2_P#Q-'_"8Z=Z77_@)+_\30!M-7BFI_\ (2N_^NK?SKU)?%VG
MR,% NLGCFTE'_LM>?:AH-W)?W+CR<-(3S,H/7TSQ7?@VE)MG/5Z&+16G_P (
M]>?],/\ O^G^-'_"/7G_ $P_[_I_C7I\\>YA9F916G_PCUY_TP_[_I_C2?\
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M;F".& ^89'%?:'_"177_ $ =0_*/_P"*H_X2*Z_Z 6H?E'_\50!\[^(?@_\
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MS^&_@=_C1=^%6ULQWE]->6WV_6+. P*TEKI=M#"<#S6;,DF=N6/S9P&_!O\
M:LN_ ;?&RY?Q?XD^)?@7P9X>M]9M;[Q9IQLM22[D+@6S9CC9HWPC*Q0<'C-
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ML,&/0D \5'.^@[+0]JO?BAX7L/ ,?C:36(7\+R1)-'J$*F02*[!5"JH+%BQ
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M[;_P,_\ L:/[0\0?] >V_P# S_[&@#>HK!_M#Q!_T![;_P #/_L:/[0\0?\
M0'MO_ S_ .QH WJ*P?[0\0?] >V_\#/_ +&C^T/$'_0'MO\ P,_^QH WJ*P?
M[0\0?] >V_\  S_[&C^T/$'_ $![;_P,_P#L: -ZBL'^T/$'_0'MO_ S_P"Q
MH_M#Q!_T![;_ ,#/_L: -ZBL'^T/$'_0'MO_  ,_^QH_M#Q!_P! >V_\#/\
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MOLNE_P#00G_\!O\ Z]'V72_^@A/_ . W_P!>O4]HNS,;&;16E]ETO_H(3_\
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M6&2IYQS70?M)^ +SXF? WQ9X?TS/]K26HN; #^*XA821K^)7;^(KU_[-I?\
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M&_RN58YX/04 ??%%?(V@_LHZYI=KX-\8W?QG\367Q2FN[6[U+4+_ %%I=.U
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MOPIP3STKZ5H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ)XEU!E2[N2!B(1*ORQ)&<%$&0,<YKV?R?$G_/?3/^_;_P"-'D^)/^>^F?\
M?M_\: /$?A[^R?K6D^-O#WB/XA_$_5/B>_A6-D\-V5]IT-G#8N5V>?((R?/G
M"_*)&P>37/ZG^PQ=7-QKOA^P^*>N:5\)->U*;5-4\#6]G#^^>:3S)H4O,^9'
M!(V=T8'1B,U]'>3XD_Y[Z9_W[?\ QH\GQ)_SWTS_ +]O_C0!XOXS_97U:^^*
M=CXT\"?$*\^&[KHD/AR]L;#2[>[66PB?='' TH/V=AG&X!ONCBLG2OV$_#EO
M\%_&'@'4O$NL:G<>(O$#^)&\1EMM_;7@9&AD#DMN:/RUY/7+<#/'OWD^)/\
MGOIG_?M_\:/)\2?\]],_[]O_ (T >-?#O]F/Q+IOQ%T/QI\2/BCJ'Q-U7P]!
M-;Z'%+I4&G067FJ$DE9(B?-E*C;O8C@GBNX^/WP;7X\> ?\ A$KG56TG3I=1
ML[V[*0"8W$4$Z3&#!88#E%&[G'H:ZWR?$G_/?3/^_;_XT>3XD_Y[Z9_W[?\
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MFMRR;#,1]YR,G!9B3C)ZUV]8/D^)/^>^F?\ ?M_\:/)\2?\ /?3/^_;_ .-
M&]16#Y/B3_GOIG_?M_\ &CR?$G_/?3/^_;_XT ;U%8/D^)/^>^F?]^W_ ,:/
M)\2?\]],_P"_;_XT ;U%8/D^)/\ GOIG_?M_\:/)\2?\]],_[]O_ (T ;U%8
M/D^)/^>^F?\ ?M_\:/)\2?\ /?3/^_;_ .- &]16#Y/B3_GOIG_?M_\ &CR?
M$G_/?3/^_;_XT ;U%8/D^)/^>^F?]^W_ ,:/)\2?\]],_P"_;_XT ;U%8/D^
M)/\ GOIG_?M_\:/)\2?\]],_[]O_ (T ;U%8/D^)/^>^F?\ ?M_\:/)\2?\
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M?3;EM8LO'=_;6&C1PLL<CF7.YY Y&Q8@KE^X*XZUY!JOP_\ BG^QOX4U#4O
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MU_UU?_T(U7KYI[GV4?A04444B@J&\O+?3K.>ZN[B.TMH4,DD\SA(XU'5F8D
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MV,XO#VI:[?:'\7_B5H+ZW>OJ-\FGZE;QK-,YR6/[C)QT&>@KZ<^W60ZZ:O\
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M^"O 'Q.D^,?Q4^*%GH_B/5V\1ZCI%U<:^D<\.CZ;9GRXH%#Y$0"@N6X+%LT
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M3M-?2M !1110 4444 %%%% !1110 AKQ/4_^0E=_]=6_G7M;5XIJ?_(2N_\
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MJG@E201V%?1EJ)'AA\Q52=D!=4.X*Y S@^@.>>X KXV\5? WX&P_LL:O\1?
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MM/.S-MBC1!'\TC$@!>Y-?1^GW+ZAIT%ZUK<6?G1K(T%P@$D)8 ^6X!(#C."
M3S7@?Q#C'Q2_:N\$>"YAYN@^#=.;Q9J$3<I)>LWE6:N.^P%G [\YH-IWMH]3
M9U#XN^/XU^'GART\(Z/%\2/$MA/J=WIE_>RI8Z;'"H+JSJ"Y<F1$ Z ELGBG
M6W[1#>(/A5X*\0Z#HRW/B7Q=>+ING:)=2_(LZR%;DR.O/E1*DC%@.<+QS75_
M$CX2Q?$+5-#UNUU_4O"7B311/'::SI7EM(D,RA98F60%65@J^X*@@@U\U:-Y
M_AN30-2\"^39Z;+JR^ /!5]J:?:DMXB[OJ.ILF0)))I$95Z9"^]!%Y1W/J_X
MB:]K'A?P7K&L:'IL>MZGI]N;I=/D9D^T*A#.JD<ABH;;G()QGBK7@_Q5IGCO
MPGH_B/1KC[3I6J6R7=M(.Z. 1D=F!)!_W:X[X%^--:\7P^*]%\42VM]K'AG7
M)M%N-1LX!!%>)L1UE\K)"L5?# <9'%<A^Q5)M^"=W91OOL=.\3:S867HMO'=
MMY:CV&3B@M3U5NI[Q1110;!1110!:TW_ )"%K_UU7^=>OUY!IO\ R$+3_KJO
M\Z]?]:L\K&_%%CJ***#SA-U4M<T/3_$VCWNDZM90:CIE[$T%S:748DCFC889
M64\$$5+?68OK=HO.F@SC]Y VUACWK,_X1<?]!;5/_ H_X4 >):3^P#\$])U.
MWN5\,W=W:6THF@TB^U>[N-.B8'*[;5Y#'@'H-N!Z5Z%KO[/W@KQ%\5]"^)%W
MITR>+]%M_LEK>6UW+"AA^8K')&C!)%4LQ 8'!-=7_P (N/\ H+:I_P"!1_PH
M_P"$7'_06U3_ ,"C_A0!F_#GX6>'?A5X9ET#P[9M;:;-=W%[+'-*TS233R&2
M5F9B2=S,>/PKS+0_V&?@QX>\91^);/PBOVJ&Y-[;V,UY/)I]M<$Y,L5HSF)&
MSSD+P:]?_P"$7'_06U3_ ,"C_A1_PBX_Z"VJ?^!1_P * /E^U_9=TWXX?'?X
MR^)?B3X<U&VM9+W3M/\ #=XMU+9W"V]M;D2RV\T3!PDKRD,,X.WI7M4G[,GP
MW;X,W7PJ3PW!!X'NHRD^GPNZM(Q8,96E!WF0L Q<G=D=:[;_ (14<?\ $UU3
M_P "C_A1_P (N/\ H+:I_P"!1_PH \\\6?LH_#?QOX#\.>$M9TBYN[#PZH72
MKS^T+A;^U/=EN@XERW?YN>];OPW^ /@/X2^$;WPUX9\/6]II6H%FU!9RUQ)?
M,R[6:>20EI21QEB:Z;_A%Q_T%M4_\"C_ (4?\(N/^@MJG_@4?\* /,/AC^QO
M\*/A!XM'B7PUX;:#5HD>*SDO+V>Z2PC<G<ELDKLL*G)&$ XXZ55\;_L3?!_X
MA>,KOQ-K7AAI;^_=9=1M[>^G@M-1D7H]Q;HXCE;W8'/>O6?^$7'_ $%M4_\
M H_X4?\ "+C_ *"VJ?\ @4?\* .5^)W[/W@7XO>%=.\/>)-$CDT[2W633?L,
MCVDM@RKM!@DB*M'\ORX4@8XIO@W]G?X?>!/AQJ/@32O#EM_PC.IK*NHVMWNN
M&OS(,.\\CDM(Q'\3$FNL_P"$7'_06U3_ ,"C_A2-X7PI(U;5,_\ 7T?\* //
M/A'^R=\,_@?KUSK?A30Y8=8E@^RI?7][->RV\&<^3"TSMY2=/E7 X%<QJ'[
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MB(_C;7?#\EUK<R1I=B.]GBMKWRQB/[1 CA)=HP!O!Z"O2/\ A%Q_T%M4_P#
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M1QM8 CD<$\U1\(>$M,\!^%=*\.:);M::1I<"VUI SES'&O09/)/7D\\UU/\
M;7_3A8_]^!1_;7_3A8_]^!2YF^@?,\4\3?LJ_#/Q=XHO==U/09WN;^59[ZS@
MOYX;*]D'1Y[=6$<AXY)'/>N\MO NBV?B\>)H;+9JRZ<NDHP<B*.V5]X1(_NK
M\P&2.3M [5U_]M?].%C_ -^!1_;7_3A8_P#?@4O.P_F>0>/OV:_ 'Q+\12Z[
MK>E7::I/&L-U/INH3V7VQ%&%6X$3*)0!P-V>..E2?$#]G+P#\3/"_A_PYK.C
MS0Z'H$@ETVRTN[ELDMV"[5(\L@Y SCW)/<UZW_;7_3A8_P#?@4?VU_TX6/\
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M'4AA5K2_^0G:?]=E_F*JU:TO_D)VG_79?YBHEL_0(_$O4LZE_P A"Z_ZZO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img11029722_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_9.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %[ PT# 2(  A$! Q$!_\0
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MZ[?\-;_"7_H<['\S_A1_PUO\)?\ H<['\S_A7Y$[?84;?84 ?KM_PUO\)?\
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MKW3]-NM3N5M(;K5)O)MDD;A=[A3M!) SBIEPWAXIMU'IZ?Y ?NM_PV9\$?\
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M=Y\2/V)_B7\*_@[9?$O7;331X=N8[:4PV]RS7<"S@&,R1E %Y95.&."16_\
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M_(55'(<)7CSTJS:^7^0'[X_\-F?!'_HIF@?^!/\ ]:C_ (;,^"/_ $4S0/\
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M:]HOC2;P[;?V7:V+I#;74:G=L\TQMB0D-@!@<#CFOAWXI?MD1_$[P!K'A?\
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MV'/L*P=)^.6L:1X4^(&A1Z=8R6WC21YKV1R^^W+,6Q'STR3UJ%3J)MMGSO\
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MR5;PC_V!7_\ 1[5\@5]?_P#!3#_DJWA'_L"O_P"CVKY K(^*84444Q!1110
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M21_"7&7_ "4&,_QL_.G_ (*8?\E6\(_]@5__ $>U?(%?7_\ P4P_Y*MX1_[
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MKV_ #T_XZ?M)>.?VCI]'F\<WEG?3:3&T5L]I9K =K$%MV"=QRHKRQ88@1B-
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M*L(?S9&D8X50V =Q) H ^DO^%;^$N/\ BGM-_P# 9?\ "C_A7'A+_H7M-_\
M 9?\*^:/#W[:&I>%?#?QD?Q_!X?UO5/AW%:S_;?!ER7LM5%S\L,:AV8Q2"4K
M&P9CC.:[;POXX^/?A_Q#H%U\1/#?A*Y\(ZI%(]^_AMYUN?#Q$1E!N#,Q69!M
M*%HP#NQQB@#V+_A6WA/_ *%[3?\ P&7_  H_X5MX3''_  CVF_\ @,O^%?'2
M_MU>,+CP1<?%2"3X<Q^ H7DN5\(3:P1XEFL$D*M,"'\M9BHWB'8<CC=DU[;X
M^^)7Q2UC5K;_ (5[9>%/#WA$Z7;ZF?%WC:61K>Z:8%E@AAB=&!5=I9W('S8
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M?]"[IO\ X#+_ (5TM% '-?\ "M/"G_0NZ;_X#+_A1_PK3PI_T+NF_P#@,O\
MA72T4 <U_P *T\*?]"[IO_@,O^%'_"M/"G_0NZ;_ . R_P"%=+10!S7_  K3
MPI_T+NF_^ R_X4?\*T\*?]"[IO\ X#+_ (5TM% '-?\ "M/"G_0NZ;_X#+_A
M1_PK3PI_T+NF_P#@,O\ A72T4 <U_P *U\*?]"[IO_@,O^%5=4\#^'M(TV\N
MK+0]/M[A('VR+;ID?*1Z5U]9OB3_ ) .H?\ 7!_Y54?B0GL>0>?W\BU&>?\
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ML>6#H**T5T;Y1G4+'_OX?\*/[''_ $$++_OZ?\*^@YX]SAL9U<S\3+SQ18^
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MZ2W.J75Y R3RI(_RAD9AL!P-J@#%?2_]B_\ 40LO^_I_PI/[%':_LA_VU/\
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MEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2LWQ)_R -0_P"N#_RK3K-\2?\
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MS=VZD?Z'&0.7FD#&1NR C^*O/_"OC#P+XB_8@\9>%[6\_M*YD\275M:Z9HK
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M@O7[WF]U+1[2ZG/K(T*EC^)R:#=2UL=?11107<**** N>A> /^0._P#UV/\
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M?\)AH7_0:T[_ ,"X_P#&OE/_ (=6_ G_ * M[_X'W'_QRC_AU;\"?^@+>_\
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M?\)AH7_0:T[_ ,"X_P#&OE+_ (=6_ G_ * M[_X'W'_QRC_AU;\"?^@+>_\
M@?<?_'*/9X/_ )^O_P !_P""!]6_\)AH7_0:T[_P+C_QH_X3#0O^@UIW_@7'
M_C7RE_PZM^!/_0%O?_ ^X_\ CE'_  ZM^!/_ $!;W_P/N/\ XY1[/!_\_7_X
M#_P0/JS_ (3#0O\ H-:=_P"!<?\ C1_PF&A?]!K3O_ N/_&OE/\ X=6_ G_H
M"WO_ ('W'_QRC_AU;\"?^@+>_P#@?<?_ !RCV>#_ .?K_P# ?^"!]6?\)AH7
M_0:T[_P+C_QI?^$PT+_H-:=_X%Q_XU\I?\.K?@3_ - 6]_\  ^X_^.4?\.K?
M@3_T!;W_ ,#[C_XY1[/!_P#/U_\ @/\ P0/JW_A,-"_Z#6G?^!<?^-'_  F&
MA?\ 0:T[_P "X_\ &OE+_AU;\"?^@+>_^!]Q_P#'*/\ AU;\"?\ H"WO_@?<
M?_'*/9X/_GZ__ ?^"!]6?\)AH7_0:T[_ ,"X_P#&C_A,-"_Z#6G?^!<?^-?*
M?_#JWX$_] 6]_P# ^X_^.4?\.K?@3_T!;W_P/N/_ (Y1[/!_\_7_ . _\$#Z
ML_X3#0O^@UIW_@7'_C2_\)AH7_0:T[_P+C_QKY2_X=6_ G_H"WO_ ('W'_QR
MC_AU;\"?^@+>_P#@?<?_ !RCV>#_ .?K_P# ?^"!]6_\)AH7_0:T[_P+C_QH
M_P"$PT+_ *#6G?\ @7'_ (U\I?\ #JWX$_\ 0%O?_ ^X_P#CE'_#JWX$_P#0
M%O?_  /N/_CE'L\'_P _7_X#_P $#ZM_X3#0O^@UIW_@7'_C2?\ "8:%_P!!
MK3O_  +C_P :^4_^'5OP)_Z M[_X'W'_ ,<H_P"'5OP)_P"@+>_^!]Q_\<H]
MG@_^?K_\!_X('U9_PF&A?]!K3O\ P+C_ ,:7_A,-"_Z#6G?^!<?^-?*7_#JW
MX$_] 6]_\#[C_P".4?\ #JWX$_\ 0%O?_ ^X_P#CE'L\'_S]?_@/_! ^K?\
MA,-"_P"@UIW_ (%Q_P"-'_"8:%_T&M._\"X_\:^4O^'5OP)_Z M[_P"!]Q_\
M<H_X=6_ G_H"WO\ X'W'_P <H]G@_P#GZ_\ P'_@@?5O_"8:%_T&M._\"X_\
M:/\ A,-"_P"@UIW_ (%Q_P"-?*7_  ZM^!/_ $!;W_P/N/\ XY1_PZM^!/\
MT!;W_P #[C_XY1[/!_\ /U_^ _\ ! ^K/^$PT+_H-:=_X%Q_XU0\0>+-#ET.
M_1=:T[+0.!_I<?I_O5\Q?\.KO@3_ - 2]_\  ^X_^.5'<?\ !+[X":7;3W<W
MAV\NHX8V<PG4KA-V!ZB3BFJ>$NK5&_\ MW_@CMH>B+KVE8_Y"VG_ /@7'_\
M%4O]NZ5_T%M/_P# R/\ ^*KQ7_A@S]GWJ? %YSSSKMU_\51_PP;^SY_T(%W_
M .#VZ_\ BJ]VU#O+[E_F<-H=6>U?V[I7_06T_P#\#(__ (JC^W=*_P"@MI__
M (&1_P#Q5>*_\,&_L^?]"!=_^#VZ_P#BJ/\ A@W]GS_H0+O_ ,'MU_\ %4K4
M.\ON7^86AW/:O[>TO_H+:>/I>1__ !7^<5P?Q@^'WA?XO_#K5/"5QK>F:-%?
MO [7UH;=I8S%.DW ) Y,>T^S5R/_  P;^SY_T(%W_P"#VZ_^*H_X8-_9\_Z$
M"[_\'MU_\50XT)*SYON7^8_<[G1?$SX8Z'X[\1:+XFT?QHG@GQ=HT<MO9ZQI
M<MM(/L\A!>&2"0[)$) (SC!YKG]-_9^\,6]LSZGXZ?7M8OM<L];UO5M0N+<R
M:J;4[H;9D4A8H58*0J],?C3?^&#?V?/^A N__![=?_%4?\,&_L^?]"!=_P#@
M]NO_ (JH]GA[W][[E_F.\>Y[.VJZ%)<K/-=Z/<2*0=TTT+'@],D]*\ET_P"
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MQ1XPMO$OAOQ$GDIHMP]O%'80E-KQHZ$,^3\VYR2"!BN'_P"&#?V?/^A N_\
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M300R 7+ES&I5OX#]T^HS6#_PP#^SY_T(-Y_X/KO_ .*H_P"& ?V?/^A!O/\
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M_P#BJ/\ A@']GS_H0;S_ ,'UW_\ %4<N"_Y^2_\  ?\ @E<U7^4]N_M_2?\
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MM57,LGEQMMBPP^<_+UYX-> ?&KXQ?#[XU? 'X:>"/AEJUGJGC&\UC0SI6@V
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M_P"@=:?]^%_PH_X1_2_^@=:?]^%_PH D_MBP_P"?VW_[^K_C1_;%A_S^V_\
MW]7_ !J/_A']+_Z!UI_WX7_"C_A']+_Z!UI_WX7_  H D_MBP_Y_;?\ [^K_
M (T?VQ8?\_MO_P!_5_QJ/_A']+_Z!UI_WX7_  H_X1_2_P#H'6G_ 'X7_"@"
M3^V+#_G]M_\ OZO^--DU:Q;&+ZWXY_UJ_P"--_X1_2_^@=:?]^%_PIK:#I:X
M_P")=:<_],$_PH YNZ\ ?#N_NIKFZ\.>%[FYF<R232V%LSNQ.2S$KDDDYR?6
MM71=/\->&K1[31X-)TFT=B[P6*10HS$ $E5 !. !^%0Z]>^$?"MO'/KDVBZ-
M!(VU)-0>&!6;T!?&35ZUT_1+ZUBN;6TL;JWE7?'+#'&ZR+V*D#!% &?I.@^$
MO#]Y->:78:'IMY-_K+BT@ABD?O\ ,R@$]ZK:IX,\"ZY>R7NI:)X=U"]DQON+
MNTMY9'P.I9@2?_K5T7_"/Z7_ - ZT_[\+_A4-YI>BZ?:S7-S:6-O;PJ7DFEC
M1$10,DDD8  [F@"K]A\-KI!TD0:4-**>6;#;%]GVGJOE_=Q[8K'M?A_\/+&X
MBN+;PYX7M[B)@\<L-C;(Z,.C*0N01UR*Z*STO1;^WCGMK.QGMY5#QRQ1HRNI
M&000,$$=Q4W_  C^E_\ 0.M/^_"_X4 1R7]A-&R/=VKJX*LK2*00>Q&>>*I:
M)8^'?#5NT&CQ:3I4#-O:*R2*%&8]6(7 )K1_X1_2_P#H'6G_ 'X7_"C_ (1_
M2_\ H'6G_?A?\* ,NQTGPQI>I7.HV5KH]IJ5S_K[R".*.67_ 'G4!F_$U9M5
MT6Q>YDMCIUO)=2>;<M%Y:F9\!=SD?>.!C)YP!5O_ (1_2_\ H'6G_?A?\*/^
M$?TO_H'6G_?A?\* ,R'3_#=JMBL-MI$26+%[18TB46Q((8QC^ D$@E<9R:)-
M-\-3"=7MM'99[A;N4/'$?,F7&V5N.7&U<,>1@<UI_P#"/Z7_ - ZT_[\+_A1
M_P (_I?_ $#K3_OPO^% %65M&N+V"]E?3Y+VW#+#<L8S)&K?>"MU /<#KBFP
MPZ!:SWDT*Z;#+>MNNGC$:FX.,9D(^\<<<YXJY_PC^E_] ZT_[\+_ (4?\(_I
M?_0.M/\ OPO^% &9-IOAF;11HTEMI$FD*NP6#QQ&W '0>7C;C\*L:6NBZ'8Q
M66G'3M/LXAB.WM?+CC0=3A5P!^%6_P#A']+_ .@=:?\ ?A?\*/\ A']+_P"@
M=:?]^%_PH Q+/PYX/TV99+33=!M9%G^U"2&W@1A-@CS,@??P2-W7!ZUO_P!L
M6'_/[;_]_5_QJ/\ X1_2_P#H'6G_ 'X7_"L[6?\ A&_#UO%-J4&GV44TR6\;
M31(-\KG:B+QRQ/0"@#5_MBP_Y_;?_OZO^-']L6'_ #^V_P#W]7_&N'TWXC?#
M76-6UC3++4]&N;_2(WFO8(T4F)$)61A\N'"L"K;<[3P<&NJTVQT+6+"WO;*U
ML+JTN(UEBGAB1DD1AD,#CD$4 7O[8L/^?VW_ ._J_P"-']L6'_/[;_\ ?U?\
M:C_X1_2_^@=:?]^%_P */^$?TO\ Z!UI_P!^%_PH D_MBP_Y_;?_ +^K_C1_
M;%A_S^V__?U?\:C_ .$?TO\ Z!UI_P!^%_PH_P"$?TO_ *!UI_WX7_"@"3^V
M+#_G]M_^_J_XT?VQ8?\ /[;_ /?U?\:C_P"$?TO_ *!UI_WX7_"C_A']+_Z!
MUI_WX7_"@"3^V+#_ )_;?_OZO^-']L6'_/[;_P#?U?\ &H_^$?TO_H'6G_?A
M?\*/^$?TO_H'6G_?A?\ "@"3^V+#_G]M_P#OZO\ C1_;%A_S^V__ ']7_&H_
M^$?TO_H'6G_?A?\ "C_A']+_ .@=:?\ ?A?\* )/[8L/^?VW_P"_J_XT?VQ8
M?\_MO_W]7_&H_P#A']+_ .@=:?\ ?A?\*/\ A']+_P"@=:?]^%_PH D_MBP_
MY_;?_OZO^-4M<OK:\T:^B@N(IY6@<+'&X9CQZ"K/_"/Z7_T#K3_OPO\ A5/6
M=*LK'2;VXM[.W@FCA<K)'$JL..Q XJH_$A/8\L&GW6!_H\O_ 'P:7[!<_P#/
MO+_WP:<NJWVT?Z9<?]_6_P :7^UK[_G\N/\ OZW^-?0WGTL<0S[!<_\ /O+_
M -\&C[!<_P#/O+_WP:?_ &M??\_EQ_W];_&C^UK[_G\N/^_K?XT7J>0$?]GW
M.1_H\H_X :HWGA&SU"]@O+O0[6[O;?\ U-U<6*22QXZ;78$K^!K2_M:^_P"?
MRX_[^M_C1_:E\>EY<9_ZZMS^M+WY;V#0R-5\#:;KUPL^J>'+'5)U78LM]IT<
M[JN2<!G4G&23CIS26/@32M*(:Q\,Z?8L'$H-KIL4>' (#?*H^8 GGMGCO6G_
M ,)!/]J:U&IN;I8Q*T N/G"$D!BN<A201NQC(I/^$BF6Z2U.J,MTZ&5+<W/[
MQD!P7"YR5!(!/J1ZU*3>MD&A!J'AU-8M#::AI4>H6K$%K>\MA-&2.Y5A@_E4
MEIHIL+6.VMM/^S6T8VI#!!Y<:#T"J,#\*D7Q!.]S);KJ;M<QHLCP"X)D16SM
M8KG(!P<'H<5+_:U]_P _EQ_W];_&J]_?09G:?X5MM)>=[#0[?3VG.Z9K2R2$
MRMZOM7YC[FH?$_@V'QCX9U30-6L9KG2]3M9+.YA*GYHW4JW\\CWQ6E;>()KQ
M7:WU-[A4=HF,-QO"N#AD.#PP[CJ*2W\0S7@<V^J-<B-VB<PW.\(ZG!4X/!&>
MG4>E+WOAT Y7X?\ @/6-#^'.E>&O%'D^(KBQMA8O<-;EH[J%/EB,B.,;M@7<
M.1D$BNDTWP^FC6JVNG:3'IULIRL%E;"&-?HJ@ ?E3+/QI#J-]<V5GX@@O+VV
MXGM;>_626(_[:*Q*\^HHU#QM;Z3<6]O?^(K?3[BY.V"&[OUB>8YQA S M^&:
M2YM] ([/PC9Z;>S7MGH-K9WTV?-NK:Q2.63/7>ZJ&;\3S4]KX>2SGN)[?2H[
M>XN6W3S16P1YCC&78#+<9ZG/O5LZM?9Q]KN,^GFG\NO6J-]XT@TNYMK:^\0P
M6-S<G$$-U?K$\O./D5F!;GTI^]IL S3?"-IH[SR:?H5OI\L[;IGL[)(6E/JQ
M11N/US5F316EN8KA]/WSPAA',8,NFX8.UNJY YQC/>F:IXN30X%GU/7$TR!F
MV":]O!"A8]%#,P&3Z=:ENO$4MC");G5&MHBRH'FN=BEF.  2<$DD #J2>*/>
M\@(+CPU%=7UO?3:1#-?VX(ANI+16EASUV.1N4>PKCX?A7J-Y\8[GQSJI$Z6>
MEC2=$LXHV_T6-VWW$KDCF1V"J,9PJXSS7<S>()[62&.;4VBDG?RXEDN-K2M@
MG:@)^8X!.!S@$U+_ &K?#C[9/GOB5O\ &G[_ )"&?8+G_GVE_P"^#1]@N?\
MGWE_[X-/_M:^_P"?RX_[^M_C1_:U]_S^7'_?UO\ &G^\\@T&?8+G_GWE_P"^
M#1]@N?\ GWE_[X-/_M:^_P"?RX_[^M_C1_:U]_S^7'_?UO\ &C]YY!=$9L+K
M_GVE_P"^#6SKEI.VK7)6"1@2.0A/85DMJM[_ ,_EQ_W];_&MC6[^ZCU2X1;J
M954@ "1@.@]Z\W&<UH\QZF7WYWRF=]BN?^?>;_O@T?8KG_GWF_[X-/\ [2O/
M^?NX_P"_K?XT?VE>?\_=Q_W];_&O,/=O/R&?8KG_ )]YO^^#1]BN?^?>;_O@
MT_\ M*\_Y^[C_OZW^-']I7G_ #]W'_?UO\: O/R,C5/!&F:],DNJ>'+'5)$7
M:LE_IT<[*N2=H+J2!GG'3FGZ3X.L/#[2'2O#]GI)D $AL+".W+XZ;BBC/?KG
MK6I_:5Y_S]S_ /?UO\:/[2O.]W<#_MJWU]?2@FSOS61FV/A&QTUKHV>@6MD;
MK_CX^S6$<?GC_IIM4;_Q]:==^%K2^T]+"ZT.WNK", )9SV2O"N!\H","HQVP
M.,<4FF>-K+6[B:#3?$=KJ,\'^NBL]129XN<?,J,2OXXJW_;[B[^R?VHWVOR_
M/^S_ &G]YY><;]N<[<\9QB@-?(R+/X<Z#IMU%<V?A+2K2YB.8Y[?288Y$/JK
M! 0?QJY)X3LY=534WT*V?4T&U;YK)#.H'0"0KN&/]ZGZ9XQMM;,XTS7X-2-N
MVR<6=\LQB;^ZVUCM/L<=*O'4KT?\O5QUQ_K6']:!1B[:)#/L5S_S[S?]\&N%
M\%_"W4/ OQ \8ZII[;?#OB26/47T_P I_,M]0"[)I%.-NR10C$==PKL_^$H7
M['/=_P!LK]D@9EFN/M@\N(J<,'?=A2#U!/'?%&F>*4URS6[TW6H]2M6.%N+.
M\$T9(Z@,K$$CTH!\[[%>P\(V6EWLUY9Z#:V5Y/Q+=6MBD<LGKO=5#-^)I=0\
M*VFKW%O/J&AVU_/;G,$MU9+*\1]59E)4_2G6_C*UO-3GTZW\06]QJ,'^NLH;
M]7GCQUW1AMR_B*L7_B$Z5:RW5[JILK6(9DGN;KRHT'JS,P"C/K0"YK=!EQH*
M7EQ:W%SIBW-Q:N9+>::U#O"Q&"4)&4)]1VK)F^&?AVXF>6;P;HTTLAW/+)H\
M#.Q)R224R3D]3DT0?%;P]=31PP>-]'GFD8(D<6MP,S,>P DR3TX'K6I_PED7
M]J?V7_;D8U39YHL#>C[1L_O^7NW;??&*!:O>PU?#-NFEC3%T:%=-V;/L2V:B
MWVYR1Y6-NW/.,8]J?J'A^/6+-[6_TM+ZTDP&MKJV$T1QZJP((_"I?^$@<7GV
M0ZFPNO+\T6_VG]Z8P<%PN<[0>,],\4L6O23S3Q1ZFTDT&!-&ESN:(D9 8 Y7
M(YY'(H'[VRL<)\7OA1?_ !0\'VWA.,II_A^ZNX?[7B\E@TUC&P<V\0487>RH
MI/&%SCFN\6PG10J6DB(HPJK&0 !T XJ3^TKS_G[N,]_WK?XT?VE>?\_=Q_W]
M;_&@:YUV&?8KG_GWF_[X-'V*Y_Y]YO\ O@T_^TKS_G[N/^_K?XT?VE>?\_=Q
M_P!_6_QH*O/R&?8KG_GWF_[X-'V*Y_Y]YO\ O@T_^TKS_G[N/^_K?XT?VE>?
M\_=Q_P!_6_QH"\_(\'^ :-%_P48^+JNK(W_"(:=\K#!ZP5]L+U-?$_P%D>?_
M (*,?%UY':1SX0T[+,<GK!7VQT)KOQGQ1_PQ_)'@U/CD?'_Q2_Y2;?!3_L4M
M4_\ 09Z^P>]?'WQ2_P"4FWP4_P"Q3U3_ -!GK[!I8GX:7^']69"T4F:,UQ@+
M129HS0 M%)FC- "T4F:,T +39!N STS2YIKD8Y&?2@#X[_9A^&WAC]IB+QI\
M5/B5H=CXRUJ^\1:AI5A:ZU"MU;:786TS1100PN"B$X+,P&6)ZUZ;I/P=N/V9
M_"OQ$O?A98W&NC4BE]H_@:XND@T^RN=H1U@=B/*B8_.RYP,';BN6T?X=?%?]
MG7Q3XK7X9:'H/CKP'XBU2;68M%U+5&TR[TF[F^:<)+Y;K)"S_,%P"N36!XO_
M &:_BY\2OA5\5;G7_%]I9^/O&ALQ;Z+8W4_]D:;9V[JPLE?AB95#"24 $ENF
M* %T;]H[Q_X%^-GP_P#"/C#QE\._'%OXOO)-/ET_PJK0WND3")I%<@S2>9%E
M"A8A3DCUKGH?B;\6?C9\$OC#KNNW?AG3O FEQ>)-#-A;V,IO[L0":-)O,,FQ
M /E4KM.[:QXR*-,_9O\ '^I?$'X0Z_:_"WP!\,="\(Z\+J]TG0;Q9KN>-H7C
M,OG+"BE5R,1\L<YSQ7H_@'X%^*_#O[,OQ0\$7L%FNNZ_>^(+BQ1;H&)DO)9&
M@W/CY<AQGTH \X^'_P 5OC/\%?@E\+O&WBNT\+2_#J:VTK3+W0;*"9-1TRUF
M6.&&Z,[.5E8%D+QA!C=@$XKT;XP?$KXNZ+XB\2S6GB/X>_"_PSI)"Z9)XQD$
M\VM@1AFERL\8MX]V4&06^4G&,9XJS^#'QR^('P[\!_"?QWI_AG2O!VBG39-9
M\1:?J3W%UJD-H4=;:.#RQY3,R(&DW$?*2O7%07G[-WQ!TOXN?$74U\ ^!?'K
M^*=1DO--\;>*KHO/HUN\85;9K5HF+)$02HC90=W)[T 6H_VN/B/\1O"O[/%Y
MX#T71+75_B9'J<=Y#J@DDM[)[9!NF5E(8HI65PO5QM7(SFMR3]JGQ;\$'^)^
MA_%NVTG6=7\(^'XO$]AJGAZ)[6#5+620PK$T<C/Y,HF"I]X@A@U>+6OPU^)7
MP+_X8_\ !FGP:3-X[T.;Q0GV:YNS]BO4\EIF3S54E-\;8!VG:Q&0<5[#J7[+
M_B_X_1_$_7/BD--\+:OXL\/0^&M+TG2+@WT>E6\,QN$FED*J)9&GVL0  %4#
M- '+>'?VT/$WAO7/!>H>+/'GPO\ %FE>)M2M=,N_#?A&Z)U'19+DA8W#F9_M
M"HY59/D3&21P*WK/XR?'_P >6_Q6U+PO+X,TS2_ GB'5-/A75+*>635H[;YA
M#E)0(2JC:9/FW%ON@"K/@OX6_%^YU;PCI6J_#[X8^$;71KF"75_%FFPPWEQJ
MT<1Y2WMS OV=I" 2[,2G.WG%=[\)?A#XD\(>#/C-INI0VZ7?BKQ+K.J::(KC
M>K07* 0ESCY3GJ.<8H \U\9_MM7^K:-\)K'P]J7A7P#J_C?PZOB:\UKQG<?Z
M%IEMA1Y:('0S2NY*J-P "DFL=OVXO$5G\(/C,T>H>%?%7C7X=PV-W#K7AQFG
MTK5;>Y=0C! Y,<@PZLF\X."">E6;']E7QOX/\,?!?Q%IVA>&/%?BKPCX3C\+
MZYX7U]T-K>PC:X:"X*.(Y(Y <,5P0Q!K1\6? /XI?$#X"_%?2KW0_!WAG6?%
M"6L>C>%M CBCAL8HI49C/>"-3-(^"W3:N..M #M<^,G[0O@_XF^!/!^HKX$O
MK[XC6]T=+\BWN8X]!E@B6:7SB7)NE$1;&/++.HZ UT?@?XY_%J;3/B_X2O-"
MT'Q9\3? EY9V]O-82'3]/OHKN%9HII!([&(1H6+@,<[>.374_$KX2^(_$_[1
M'P)\86$=JVA^$!JPU9Y)@LJ>?9>3%L7'SY?KR,=:\I^,'[+/Q!\=:U^T!=:3
M<:?;6WB_4O#M]IUI<7;)'JL%C;!+FSN2@#1)(R[<C.1^- &OX/\ VB/'7A?]
MH#P7X \7>,_A_P"/K?Q4EVI7PFC07>DS0Q>8OF(9I-\;G*ACM(*FN7^'7[67
MQ1^)VM'4=#U'P'/=PZR]C>_"BZ9K3Q!:6JW!A:0SRRA6E"#S=HCVD<*2>*F\
M-_LZ^/Y_C+\)O&*?#3P-\-/#_A:[NH[K1?#EVDMT5FMRAG>40HKJI"JL8!/+
M$GM5?XF_L\?%[XR6/_"+^+/!W@&\U:/44F@^+=O,(+^"!)_,5TM4B#K.$ C
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M?"U_:7UWK&FZ@TT^M-:?\>X6':/(!(1GW,>AQUK1O/ GQ3^&OBKQ]_PKO2]
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MX(/_ +.C_AY?H/\ T2#XI?\ @@_^SK[&R:,FCVV&_P"?/_DS ^.?^'E^@_\
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M_D,\)S&Y4$C<,'%'ML-_SY_\F8'G?_#R[0?^B0?%+_P0?_9T?\/+M!_Z(_\
M%+_P0?\ V=?8H;WI<FE[;#?\^?\ R9@?'/\ P\NT'_HC_P 4O_!!_P#9T?\
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M/^&\O#/_ $3?XD_^"$?_ !='_#>7AK./^%;_ !)S_P!@$?\ Q=>M?%7XS/\
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M7S,D;OSH]MA_Y'][#3L>8ZQ^V;X%\12:=)J?PJ^(E\=-NEO;3SM!R(9U!"R
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M3<_'2A1:B.YZKSWZ]Z*!T '([45T:D!1110(#6WKW_(8NO\ >'\A6(:V]?\
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MV.HL=V\QG:(@O)!5CMQS0!]&?\(_<_\ 0=U#_P A_P#Q%'_"/W/_ $'=0_\
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M ,11_P (_<_]!W4/_(?_ ,17CG@W]JZ+6_%V@:%XG^'_ (J^'8\3,T?A^_\
M$$,(@OY I<1'RY&,,I0%A'( 3SW!%3?![]J)/C3XON],T+P#XDBT?3]0O=+O
M_$=P(%LK>ZMV93'_ *S>^[:.54@;P#B@#UW_ (1^Z_Z#FH?^0_\ XBC_ (1^
MY_Z#NH?^0_\ XBO ?VNOC!J_PA^(WP,N+%M9NM-U+7KRTOM&T2/S)M3S92>3
M#LR W[TH>2 .IX%=+X%_:GT3Q!-XOT[Q3X>UKX>>(_"FGC5]3T?7(XWE-B5)
M%S$\+.DJY4J=I)#<$9- 'K/_  C]S_T'-0_\A_\ Q%'_  C]S_T'-0_\A_\
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MO3AIOB75M+^&?C+6]"\*W]W9>(=6LHK<V^G?9W*R/\TH,N%'F%8P2JD9YXH
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M1Q<S-'^U8/\ H&6O_C_^-']JP?\ 0,M?_'_\:SJ*/9Q#F9H_VI;_ /0,M?\
MQ[_XJE_M2#_H&6O_ (__ /%5YS\5]:\::3X=CC\!Z#:ZSKUU(85N-0N1#::>
MFTDW$O\ $X'95Y)]J\Y^"/BKQ]XS_9)T[6+&^M];^(-Y;7:V]YJSA87N!<2(
M'?C[J@9"^B@5G[M^6S#4^B_[5M_^@9:_^/?_ !5']J0?] RU_P#'O\:^3?#^
MN:[X#^/7@?PA8?%'5/B5J6H"=?%VCZA+#.NEJD6[[2GEJ#; 2?*(R>0P]*])
MC\7:WJ?QL\;)I@N]2TGPGH$%N-&MY0J7VI3L9L9/ =8UC4$GCS#1'D:V'J>T
M_P!JP?\ 0-M?_'O\:4ZK .NF6H_[Z_\ BJ^;/V??&GQ$\0_&KXDZ9\0GMK%[
M*RTVXM-!T^;SK?38Y0YV;L#?)M W-T)X' KB_C9JWC;X<^'?$GC7Q)\5KCPO
MXM:[E/A/P7I<\,ME=PK($AA:#87N7E##<V1L+ =N5[MKV#4^Q_[4@_Z!EK_X
M_P#_ !5)_:EO_P! RU]?XO\ XJL#P_/>WFAZ;/J-K]AU&:VB>YM<Y$4I0%TS
MWP<C\*\U^&OC#5/B'\2/B#K,-W<'PMX=N&\.Z=IL+ 1W-W" ]U.P/5][+&A/
M  /K5\L1:GM/]J08S_9EKC_@7^-']JV_?3;7_P >_P#BJ^8OA/\ $#XF^(/V
MHM4T?QQ:P^'=-F\'C5K#PQ:W0G%KNO1$'G<##3D*V=O"AL#OF&PA\:?'[Q%\
M1]4TKXA:YX(TWPUJ<VB:#9Z*8U@FG@0&2>[5U)E!D^79D#;G%1[MM+E:GU'_
M &I;_P#0,M?_ !__ .*I?[4@_P"@9:_^/?\ Q5?(.C_&3Q1\=-%^#GAK3=8N
M/"=_XILK^_\ $.L:/M%Q%'8OY,J6Y8$(7F&=V"0M>A?!O7==\-_%;QM\,=>\
M07GBN'2[.TUC2-4U0JUX;:;<KPS.H <HXX<#D-STI+EOL#N>^?VI!_T#+7_Q
M[_XJC^U(/^@9:_\ CW_Q5>!?%_7/$'BKXP>#?A?H6OWWA6UU#3;O7M8U;265
M+W[/"ZQ)%"[ A"TC#+8)P,"O/-8^)WC?X8>$_C=X2;Q#=>)=:\(VEG?Z-K]\
MBM>+976U6:8* '> ^8P;'( )]*<N1.UA),^P/[4@_P"@9:_^/?\ Q5']J0?]
M RU_\>_QKY1T+XO7WP^F^)NF:?XCO/B-8Z:NDP>&;N^N5NY[S4[V)A]E\Y
MZAPCD=44MVKWOP7X;O\ 1?!&GZ+K&N76M:K';>1?:J9L3/.P.]E(^[@L=H'0
M >E"4'T#4[/^U+?_ *!EK_X]_P#%4?VI!_T#+7_Q[_XJO'/@#XVU3Q!H>O\
MAWQ#<F]\3>$-6FT:^NW&&NU7#V]P1ZO$RD_[0->HU:A%ZIBYI&C_ &K!_P!
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M?B1\0=92\G_X170KH^'=-T^-@(KB>(!KFY/]YM["-.P"MZTR[+JCV7^T8?\
MGPM?_'O\:/[0A_Z!]KT_VO\ &OF#X:_$+XG:]^U2^C^-K.'PQHMUX.FU73_#
M%M="<P8O8XA)<N!AIR WW>%#8]<K9V_C+]H#QM\2;C3/B#KO@72O"NHMH>C6
MNA-&J7%U%$'EGN@ZGS5WD+LX&W/K2(;A;8^G_P"T8>G]GVW_ (]_C1_:4/\
MT#[7_P >_P :^/M'^,_BWXV^&_@WX5T_6)O"^L^*EU%_$6MZ.%%Q%'IS>5.+
M8L"$:27:<X.%)KT3X/ZYKOA+XP^,?A;KOB.^\6VMGIUKKFCZGJI5KT02EDDA
MF=0 ^UP,/C)#8/2@:Y6[6/??[2A_Z!]K_P"/?XT?VE#_ - ^U]_O?XUX+\9]
M<\0^)/BKX&^%^@:]>^%H=8LKS6M6UC2V5;Q+6W*H(H68$(SNZY;!.!@5YYJ_
MQ+\<?"CP_P#''P@=?N_%FK^%-)M]8T'6M017O5M;@;'\[: ':$[F#8Y Y]*
M?)=Z?B?7O]HP_P#0/MO_ ![_ !H;48?^@?:C_OK_ !KY/\-_&&Z^'-Y\2;"S
M\3WGQ*TK3+#2'\/W5[<K=SW6JWJNOV03( &!<1OMZH&/:O>O OAO4]%\!V&C
M:]KMSK&MK;&/4-5\W]\9WR7V$?="LQ"8Z!1Z4QQY)+8[7^T(?^?"V_\ 'O\
M&C^T(?\ GPMO_'O\:\@_9_\ &VJ^(O#^O>'_ !!<&\\3^#M7GT*_NW&&O!&
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M-R1L+.(VV@-D-MK[W_X2G1N!_:EKC_KJ*/\ A*=&_P"@K;?]_10!\,> =#\
M>/OBC\/(=!T;XS>*M7T[5(]3OU\7ZKJ$-EX=DB4GS9OM"[)7#90)&3NR?F /
M/N_[#VFW6E?##Q/'>V<]E/+XTUZ?9<0-$SJUZY5P& )!&"#W%>X?\)5HW/\
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M]_11_P );HW_ $$[7_OZ* ->BLC_ (2W1O\ H)VO_?T4?\);HW_03M?^_HH
MUZ*R/^$MT;_H)VO_ ']%'_"6Z-_T$[7_ +^B@#7HK(_X2W1O^@G:_P#?T4?\
M);HW_03M?^_HH UZ*R/^$MT;_H)VO_?T4?\ "6Z-_P!!.U_[^B@#7HK(_P"$
MMT;_ *"=K_W]%'_"6Z-_T$[7_OZ* ->BLC_A+=&_Z"=K_P!_11_PENC?]!.U
M_P"_HH UZ*R/^$MT;_H)VO\ W]%'_"6Z-_T$[7_OZ* ->LWQ)_R =0_ZX/\
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M7EFD_P!IW8DXX' ' KIO[#U'_GRG_P"^#6D'&*M<4M]"C15[^P]1_P"?*?\
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M +X%344&)#]D@_YXQ_\ ? H^R0?\\8_^^!4U% $/V2#_ )XQ_P#? H^R0?\
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M* (?LD'_ #QC_P"^!1]D@_YXQ_\ ? J:B@"'[)!_SQC_ .^!1]D@_P">,?\
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M_@6?_B: -VBL+[9KO_0,MO\ P+/_ ,31]LUW_H&6W_@6?_B: -VBL+[9KO\
MT#+;_P "S_\ $T?;-=_Z!EM_X%G_ .)H W:*POMFN_\ 0,MO_ L__$T?;-=_
MZ!EM_P"!9_\ B: -VBL+[9KO_0,MO_ L_P#Q-'VS7?\ H&6W_@6?_B: -VBL
M+[9KO_0,MO\ P+/_ ,31]LUW_H&6W_@6?_B: -VBL+[9KO\ T#+;_P "S_\
M$T?;-=_Z!EM_X%G_ .)H W:*POMFN_\ 0,MO_ L__$T?;-=_Z!EM_P"!9_\
MB: -VBL+[9KO_0,MO_ L_P#Q-'VS7?\ H&6W_@6?_B: -VBL+[9KO_0,MO\
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MP]K<MR+;Q)K]W.VHZ;;7&1)$8@I$WEAF"?,!C QQ7TQ]GTO_ )_I_P#P'_\
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M]P2/QH;CT#4\#_9NMW\1>)OBS\0EW?V?XK\0I#8/GB6ULHOLR2CV8A\>PKW
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MKV/XW:'X;\(_ G1?"/QN\6ZWXNMM8UNVT]/%T-M%87%G>23%[6=FAVI (V
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MR=05>-U<,K@<@=*]^T341K.CV-^(_*%U!'/Y><[=RAL9]LU^=&J)?>!_@O\
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M+&A8C/;./>MBN$^.Q\+'X0>*8_&]Y=6'A.>T,&I7-F&\V.)V"$C:K$<L 3C
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M3WHE-Z?W@@MR=TK+@%20,[.2.F:[ZW\-Z1/I>D6$NFVMS8V(@-K#/$LB1%%
M1E!& 0.AKY)TZSN=0_8C^-,5NC32_P!JZ_(47.YE6Y+. !U^4'CO52DTQV1Z
MMX=_:5U6ZO\ PK<^)OA]?^$_"?BR=+;1=<GU"&=FDD!: 7,"@-!YBCY>6Y8
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MZL^?K?Q)"T5GZAHZZD4,D]Q#M_Y]Y3&/QQ5/_A$X/^?[4?\ P+>@Q-RBL/\
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M>#]1\67^EV,D%UXJO?[0U9FG=_/F,2Q;@"<)\BJ,+@<9K7_X1.#_ )_M1_\
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M (%O0!N45A_\(G!_S_:C_P"!;T?\(G!_S_:C_P"!;T ;E%8?_")P?\_VH_\
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M(.1'<+$RB51V#@UZW_;$V<?9[/.<?Z@4+K,S*2+>T(]1;BF$DVOA//\ Q?\
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MUK0_MF7_ )][3_P'%']M3?\ /O9_^ XI#CS15DC.W#UHW#UK1_MJ;_GWL_\
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M4&%6ZCH?1?[0&L7RW'@SPIH][<:?J/B7Q)#;-/:2&.2.S@W7%S@@Y4%(PG_
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M237$LO[0DM%1B8[<OL#L0,+E@< D$X;'2FN:UE(5D=8V@:BR@%%('3,R\?\
MCU"Z!J*C 10/03+C_P!"KCH_&^@R^.I_!T>I0R>)K>Q&I3:<OS216^\()'.,
M+EF "G!(YQ7+>/OVB/AU\,?$"Z)XE\21:?J7EK-+"EO--]GC8X#S,B,(E/JY
M'%*\OY@^1ZS_ ,(_J SB-1GTF7_&E'A_45! 10#U'G+@_P#CU<%XT^)WA3X?
M^%X/$.O:U;6FCW+(MO<1[IOM+.,HL*H&:0D<@*#Q3OA[\3/#'Q5T9]4\*ZK%
MJMG'*8)2J-')#(.J21N R-CG# &G=O3F_ 5O([H>';\$'RUR#D?OEX]^M'_"
M/:A_SS7_ +^K_C7"?$+XE^&/A7H\6J>*=5CTRTGF$$(\MY9)Y2.$CB0%G..?
ME!]ZK>'OC%X*\4^![SQ?I>OVD_AVQ$AN[Q]T8M?+&7657 9& YVD T7DMY E
M=7L;?Q"^#_\ PLC3;#3-7>3^RX;^&_N;..:/9?>4V](I223Y>\*Q Z[<'C-=
M1_PC]^[$F),YQ_K4_P :X/P+\3_#'Q)T^]OM U(74-DVVZ2XADMI8,KO!DCE
M"NJE?F!(P1R*T/#_ (PTGQ5X4A\2:3.U[HTT+7$5RL#@RQJ3\RH5#,#@XP/F
M&,9S2]YZIE'6?\([?_\ /)/^_J_XT?\ ".W_ /SR3_OZO^-<WX;\0:9XNT&P
MUK1[N._TN^B$UO<QYVR*>^",@\'(/(((K2VCTI^_;<5UV-+_ (1V_P#^>2?]
M_5_QH_X1V_\ ^>2?]_5_QK-VCTHP/2G:?<+KL:)\.WW>- .I_>I_C6OK6BW<
MVJ3NB*58C&9%'8>]<L0/2MO7_P#D,77^\/Y"O-QE_=NSU,OOSRL+_8-]_P \
MT_[^+_C1_8-]_P \T_[^+_C6?17FGN6EW-#^P;W_ )YI_P!_%_QH_L&]_P">
M:?\ ?Q?\:SZ* M+N:']@7W_/-/\ OZG^-*NA7R\A$'TD3_&LZO(?&W[67PK^
M'?BK4?#>N^(YX-:T]D6[M;;2;NY\EF0.H+11,N2I'&>] FVMY'M_]A7Q7;L3
M&,8\Q/\ &C^PK]3D(@/J)5!_G7%:C\0O#^D^#[/Q1>7S6^B7GV?R)F@D+N9V
M580(]N\,S,HQCC.>U<+XV_:R^%OP]\6:CX9UWQ%<0ZUI[*EY;VNE7=UY3%0P
M5GBB9<[2.,]"*!-N/4]N_L"^P!Y<>.W[Q/\ &N6T_P"$:Z/\1-6\76<DEO=:
MO9PV>H6:R1F"=XC^ZG/<2*I9,@\J1GH*NZ-JMMK^CV.IV3F6RO8$N()&C9"R
M. 5)5AE>HX(!JHOBS2)/%LGAF.\6378K(7\MJJ%C' 7**[MC:N6R "03@D=*
M!OFZLZC^PK_&-JX]/-7_ !I?[$U!00%4 ]A*N/YUR'_"<:"?'!\&KJ<+^)UL
M&U-]-7F1+8.J>8QQA?F=0 3D@YQQ7*_$+]H?X>?"O78]'\3^(X]/U)XA.]O'
M;S3F",G DE,:-Y2G^\Y X- :VW/6!H-\I!")D=_-7/\ .C^P[_.=JY]?-7/\
MZX3QA\4/"O@/PE!XGUS6[6UT.X\O[/=1EIA<EQE!"J!FD+#D!032?#OXH>%O
MBOI$VI^%=6CU6U@E,$X\MXI8),9V21N Z-CG# 4!>7<[S^P[]6W!5#9SD2KG
M^=!T&_8Y**QZY,JY_G7#_$#XE>&?A7HJZQXIU1-*LGF6"+,;RR32GHD<: L[
M8YPH)JIX7^,/@KQGX-OO%FD>(+:XT#3Q(;V[<-$;3RUW.)D<!D8#G! - >]?
M<]";0;YL91#C@?O5X_6H[S0=2N+>6**7[+.\;)'<(R,T1(P' )QD'!&?2N'\
M _%/PM\3K.\NO#>IB\2S91<QSPR6TL6Y=RLR2A6",O(;&".E7_#_ (TT?Q5X
M43Q+I%R][HTD<DT=Q' X,J(2&*+@,P)4XP#N !&<T![SZEKX=_"6+X9>#=.\
M.:3&6M+169IYYD:6XE=B\LTC \N[LS$^IKH_[!O?^>:?]_%_QKG?#GB'3/%V
M@V&M:->1ZAI5]$L]M<P_=D0]#R 1Z8/((P>E:7% TI6T9H?V#??\\T_[^+_C
M1_8-]_SS3_OXO^-9]% 6EW-#^P;W_GFG_?Q?\:/[!OO^>:?]_%_QK/HH#WNY
MZ/X)M9+/2WCE"AO.)^4@CMW!KHQWKE_ '_('D_Z[G^0KJ!5'AUOXC%HHHH,0
MHHHH **** /GS]OI5;]D_P <AD5TVVH97&01]KAZCTKQWPGXROO@-\!?C/\
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M2C_BH_\ J%_^1*VZ* ,3_BH_^H7_ .1*/^*C_P"H7_Y$K;HH Q/^*C_ZA?\
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M2J?$S6$G3=XZ''?\*[M?^?N;\EH_X5W:_P#/W-^2UV-%0;>WJ=SCO^%=VO\
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'08-N3NS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img11029722_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_10.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $# P0# 2(  A$! Q$!_\0
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M_P#]_(__ (JO@.B@#[\_X>8Z/_T)]_\ ]_(__BJ/^'F.C_\ 0GW_ /W\C_\
MBJ^ Z* /OS_AYCH__0GW_P#W\C_^*H_X>8Z/_P!"??\ _?R/_P"*KX#HH ^_
M/^'F.C_]"??_ /?R/_XJC_AYCH__ $)]_P#]_(__ (JO@.B@#[\_X>8Z/_T)
M]_\ ]_(__BJ/^'F.C_\ 0GW_ /W\C_\ BJ^ Z* /OS_AYCH__0GW_P#W\C_^
M*H_X>8Z/_P!"??\ _?R/_P"*KX#HH ^_/^'F.C_]"??_ /?R/_XJC_AYCH__
M $)]_P#]_(__ (JO@.B@#[\_X>8Z/_T)]_\ ]_(__BJ/^'F.C_\ 0GW_ /W\
MC_\ BJ^ Z* /OS_AYCH__0GW_P#W\C_^*H_X>8Z/_P!"??\ _?R/_P"*KX#H
MH ^_/^'F.C_]"??_ /?R/_XJC_AYCH__ $)]_P#]_(__ (JO@.B@#[\_X>8Z
M/_T)]_\ ]_(__BJ/^'F.C_\ 0GW_ /W\C_\ BJ^ Z* /OS_AYCH__0GW_P#W
M\C_^*H_X>8Z/_P!"??\ _?R/_P"*KX#HH ^_/^'F.C_]"??_ /?R/_XJC_AY
MCH__ $)]_P#]_(__ (JO@.B@#[\_X>8Z/_T)]_\ ]_(__BJ/^'F.C_\ 0GW_
M /W\C_\ BJ^ Z* /OS_AYCH__0GW_P#W\C_^*H_X>8Z/_P!"??\ _?R/_P"*
MKX#HH ^_/^'F.C_]"??_ /?R/_XJC_AYCH__ $)]_P#]_(__ (JO@.B@#[\_
MX>8Z/_T)]_\ ]_(__BJ/^'F.C_\ 0GW_ /W\C_\ BJ^ Z* /OS_AYCH__0GW
M_P#W\C_^*H_X>8Z/_P!"??\ _?R/_P"*KX#HH ^_/^'F.C_]"??_ /?R/_XJ
MC_AYCH__ $)]_P#]_(__ (JO@.B@#[\_X>8Z/_T)]_\ ]_(__BJ/^'F.C_\
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MHQ9\UC.$N#L#4E3JTY^Z[-IR:3:3]Y[*R:OZH^A?^'DOAK'_ "*.K8_WXO\
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M_P#8"_\ ;B2OD2J-&%%%%,04444 %%%% !1110 4444 %%%% !1110 4444
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MP]X /CBV@LUN["UO+E8K+33*,[IRXPZ@@X7(X%>K?M1_&;PI\,/B=X6E\0>
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M_P 2>-]'T8W?A;PYC^U;\7$2?9\@-]TL&;AA]T'K7Z4_L*^-/#'@7]A?2/\
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M1M\:OV89HKJW/UY:K44TE%%4,**** "O:?V./^3BO"O^])_Z#7BU>T_L<?\
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M>_Q2]=+_ ._Q_P */^'>_P 4O72_^_Q_PH ^9Z*^F/\ AWO\4O72_P#O\?\
M"C_AWO\ %+UTO_O\?\* /F>BOIC_ (=[_%+UTO\ [_'_  H_X=[_ !2]=+_[
M_'_"@#YGHKZ8_P"'>_Q2]=+_ ._Q_P */^'>_P 4O72_^_Q_PH ^9Z*^F/\
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M_P .N_'_ /T.OA+_ +[N/_C=;.64M.R2;Z[/\A\T>YNZI^U1\"/@UX-^)#?
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M_P#]#KX2_P"^[C_XW2_\.O/B!_T.OA+_ +[N/_C=']HX1Z<XXR5SR?\ 9O\
M^12^*G_7CIW_ *5&MS!]*^A?A+_P3]\:>!_#OCFVNO%'ARZ?5K6TBB:W>;$9
MCG+DME.F...]7O\ AA3QA_T,WA__ +[E_P#B*^0QV*HU,1*49']*^'/$>5Y7
MD[HXVNHR<V_P1\VX/I1@^E?27_#"GC'_ *&;P_\ ]]R__$4?\,*>,?\ H9O#
M_P#WW+_\17#[>E_,?J?^NO#_ /T%+\?\CYMP?2C!]*^DO^&%/&/_ $,WA_\
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M'_(^;<'THP?2OI+_ (84\8_]#-X?_P"^Y?\ XBC_ (84\8_]#-X?_P"^Y?\
MXBCV]+^8/]=>'_\ H*7X_P"1\VX/I7M/['*E?VB/"AQP6D_]!KJ?^&%/&/\
MT,WA_P#[[E_^(KT;]GG]DOQ-\/?B[H>O7FN:/>VUGO9X;9I-Y!7'&5 K*K6I
MN#2D>!G_ !=D>*RG$T*.)3E*$DEKV]#[M.!14<J_-P>U%?/\I_%LJDHNR)V
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MM54. 5/0Y/U[\"?BM8?'#X0^%O'6FP/:VNMV:W)MY#EH9,E9$)[[75AGOC-
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M0>W!P:?X?\3:5XJM;J?2;Z&_CM;F2RN&AR##/&V)(V4@$$'KD>XR#7F7P/\
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MV\4>\A2=AW(>&P>*]7&L7XR1H-UG_KM%_P#%4O\ ;-__ - &Z/\ VVB_^*H
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MX^_LY^&=<^&O@'P;H/BSP_+>W=QX<\5W>N+:?V5'<2-(%NK9D+RF-G./+."
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M_0"NO^_T7_Q5']N:A_T KK_O]%_\50!MT5B?VYJ'_0"NO^_T7_Q5']N:A_T
MKK_O]%_\50!MT5B?VYJ'_0"NO^_T7_Q5']N:A_T KK_O]%_\50!MT5B?VYJ'
M_0"NO^_T7_Q5']N:A_T KK_O]%_\50!MT5B?VYJ'_0"NO^_T7_Q5']N:A_T
MKK_O]%_\50!MT5B?VYJ'_0"NO^_T7_Q5']N:A_T KK_O]%_\50!MT5B?VYJ'
M_0"NO^_T7_Q5']N:A_T KK_O]%_\50!MT5B?VYJ'_0"NO^_T7_Q5']N:A_T
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M%&EZ5\/;6SO5O8'^(\TDLNI7$4Y<EWM_+R9R'(WF3:,9P:^T?[8U+_H 7/\
MW_B_^*H_MC4O^@!<'_MO%_\ %4 <1^RU\/M9^%/[/O@7P?X@C@BUG1-,CLKI
M;67S8MRD\JV!D$8/2O5:P5UC4EZ:!<?]_P"+_P"*IW]N:G_T +C_ +_Q?_%4
M ;E%8?\ ;FI_] "X_P"_\7_Q5']N:G_T +C_ +_Q?_%4 ;E%8?\ ;FI_] "X
M_P"_\7_Q5']N:G_T +C_ +_Q?_%4 ;E%8?\ ;FI_] "X_P"_\7_Q5']N:G_T
M +C_ +_Q?_%4 ;E%8?\ ;FI_] "X_P"_\7_Q5']N:G_T +C_ +_Q?_%4 ;E%
M8?\ ;FI_] "X_P"_\7_Q5']N:G_T +C_ +_Q?_%4 ;E%8?\ ;FI_] "X_P"_
M\7_Q5']N:G_T +C_ +_Q?_%4 ;E%8?\ ;FI_] "X_P"_\7_Q5']N:G_T +C_
M +_Q?_%4 ;E%8?\ ;FI_] "X_P"_\7_Q5']N:G_T +C_ +_Q?_%4 ;E%8?\
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M_LVS_P"@K!_W[?\ PH_LVS_Z"L'_ '[?_"CVD?,=C.HK1_LVS_Z"L'_?M_\
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M/_A3]RUM0V/'_@'\([[X7:)KUUX@U2'5_%_BC5)=8UF\M8RD'G. !%$IY\M
M HSR<DU'I_PKU#Q%XX\=^)/%C0HVIV3Z!H<=M-YGV'3&0^9(6 ^62:1BS =
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M58LF6QP=%:/V&P_Z"B_]^'H^PV'_ $%%_P"_#U[?.K'$D9U%:/V&P_Z"B_\
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MR#G_ (]W_P *Q_#?@/PSX1@OHM'FBLEOKR34+HK#*S37$AR\C,Q))/ Y/
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MXU\*?A_K7A/XR?&7Q!J5M'%I?B75+*ZTV19E8RQQ6B1N2H.4PZD8.*YB6_\
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M@7PUI7B+5]>M7BBUG5DACO;SRI&>98@1&O).U5R3M7 R2>O-:WV*Q_Z"*_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *XCXG?\>^G_\ 71_Y"NWKB/B=_P >^G_[[_R%=&'_ (L29;'
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M7QX^-7BV>3S'TK4+?PIIW_3"WAC\R0+Z%I7)/KM'I5+QXW@W]F7X,W7P_P!
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MRY953>8]^-JL5!*@D;L'&<5\W^$?CAHVE^+M8^(NNZ5KVK:QXFLGNM(TO2+
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MZ ?_ )-I_A1_:NL?] /_ ,FT_P * -JBL7^U=8_Z ?\ Y-I_A1_:NL?] /\
M\FT_PH VJ*Q?[5UC_H!_^3:?X4?VKK'_ $ __)M/\* -JBL7^U=8_P"@'_Y-
MI_A1_:NL?] /_P FT_PH VJ*Q?[5UC_H!_\ DVG^%']JZQ_T _\ R;3_  H
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M65W;0&<20F)%VHP!&PYQD<F@#ZWHI%X4"G4 )12T4 )12T4 )12T4 )12T4
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M.:]EUK2W\1K9+JOA*PU-;&Y2]M1>2QR^1<)G9*FY3M=<G##D9-:?]I:S_P!
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M_P"!J_\ Q-']J:S_ - 1/_ U?_B: -NBL3^U-9_Z B?^!J__ !-']J:S_P!
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M;#61FT5I?8]-_P"@FW_@,W^-'V/3?^@FW_@,W^-7SH7*S-HK2^QZ;_T$V_\
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M@Z2U\M/L'_"+BY#A\G?YGG*!C&,8[YKU3['I_P#T$6_\!V_QH^QZ?_T$6_\
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M !H^QZ?_ -!)O_ =O\:"N9&?16A]CT__ *"3?^ [?XT?8]/_ .@DW_@.W^-
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MF,]W8[O0 T ?:!SVZUR?P[^*'A[XI6.IWGAR^:_M],U*XTBZ=H'BV7,#;94
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M'0_#%OX?U[P1X@N)5TF\=$0"YAD5&*R*5(R4^93VKZ._M#7?^@1;_P#@9_\
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M+6"T:)B<?:-X(('M6U&2C44F3+8\[HKJ/^%=ZIC[\'_?S_ZU'_"N]3_OP_\
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*1,MB2BBBF!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img11029722_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %M!Q(# 2(  A$! Q$!_\0
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M !RC_AH3PU_T!/$'_@-'_P#'*\+HK+ZR^QZ']@T_YV>Z?\-">&O^@)X@_P#
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M_AH3PU_T!/$'_@-'_P#'*/\ AH3PU_T!/$'_ (#1_P#QRO"Z*/K+[!_8-/\
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M8R>2TU55/G>J;^ZW^9[_ /\ #0GAK_H">(/_  &C_P#CE'_#0GAK_H">(/\
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MRO"Z*/K+[!_8-/\ G9[I_P -">&O^@)X@_\  :/_ ..4?\-">&O^@)X@_P#
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M_P#QRC_AH3PU_P! 3Q!_X#1__'*\+HH^LOL']@T_YV>Z?\-">&O^@)X@_P#
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MK_H">(/_  &C_P#CE'_#0GAK_H">(/\ P&C_ /CE>%T4?67V#^P:?\[/=/\
MAH3PU_T!/$'_ (#1_P#QRC_AH3PU_P! 3Q!_X#1__'*\+HH^LOL']@T_YV>Z
M?\-">&O^@)X@_P# :/\ ^.4?\-">&O\ H">(/_ :/_XY7A=%'UE]@_L&G_.S
MW(_M#^& ZJ=&U\,W0&WCR?\ R)3O^&A/#7_0$\0?^ T?_P <KY_G_P"0G:?1
M_P"57*;Q#26AE3R6G.4ESO1V_!/]3W3_ (:$\-?] 3Q!_P" T?\ \<H_X:$\
M-?\ 0$\0?^ T?_QRO"Z*7UE]C7^P:?\ .SW3_AH3PU_T!/$'_@-'_P#'*/\
MAH3PU_T!/$'_ (#1_P#QRO"Z*/K+[!_8-/\ G9[I_P -">&O^@)X@_\  :/_
M ..4?\-">&O^@)X@_P# :/\ ^.5X711]9?8/[!I_SL]T_P"&A/#7_0$\0?\
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M] 3Q!_X#1_\ QRC_ (:$\-?] 3Q!_P" T?\ \<KPNBCZR^P?V#3_ )V>Z?\
M#0GAK_H">(/_  &C_P#CE'_#0GAK_H">(/\ P&C_ /CE>%T4?67V#^P:?\[/
M=/\ AH3PU_T!/$'_ (#1_P#QRC_AH3PU_P! 3Q!_X#1__'*\+HH^LOL']@T_
MYV>Z?\-">&O^@)X@_P# :/\ ^.4?\-">&O\ H">(/_ :/_XY7A=%'UE]@_L&
MG_.SW3_AH3PU_P! 3Q!_X#1__'*/^&A/#7_0$\0?^ T?_P <KPNBCZR^P?V#
M3_G9[I_PT)X:_P"@)X@_\!H__CE'_#0GAK_H">(/_ :/_P".5X711]9?8/[!
MI_SL]T_X:$\-?] 3Q!_X#1__ !RC_AH3PU_T!/$'_@-'_P#'*\+HH^LOL']@
MT_YV>Z?\-">&O^@)X@_\!H__ (Y1_P -">&O^@)X@_\  :/_ ..5X711]9?8
M/[!I_P [/=/^&A/#7_0$\0?^ T?_ ,<H_P"&A/#7_0$\0?\ @-'_ /'*\+HH
M^LOL']@T_P"=GNG_  T)X:_Z GB#_P !H_\ XY1_PT)X:_Z GB#_ ,!H_P#X
MY7A=%'UE]@_L&G_.SW3_ (:$\-?] 3Q!_P" T?\ \<H_X:$\-?\ 0$\0?^ T
M?_QRO"Z*/K+[!_8-/^=GNG_#0GAK_H">(/\ P&C_ /CE'_#0GAK_ * GB#_P
M&C_^.5X711]9?8/[!I_SL]T_X:$\-?\ 0$\0?^ T?_QRG1?M ^&Y9XHAHVOJ
MTCJB[K>/J3@?\M*\)I8?^0GIO_7[#_Z&*J&(<I)6,<1DU.E2E44GHC[.HHHK
MJ/GCQ7]H7_CV\-?]?4O_ *"*\:KV7]H7_CV\-?\ 7U+_ .@BO&JXL3\2/J<A
M_@2]?T04445SGN!1110 4444 %=5IWPW\6ZKI\%]9:09+:==\;FXB7</7!8&
MN5KWO4?[9_X4EHO]A?;_ +;Y4&/L._S-N#G[G.*TIP4KWZ'#C<1.CR*%O>=M
M3QS7/"NN>&V0:OITML).$<D,I/IN4D9]LUCU[SXP:_C^!JIXD8'5W,8_>$;M
MWFY'_ O+SG\:K:IX/^'_ (<T#3=:U>RN/+D@13;PS2$SR,H.?O#& #T(')]J
MJ5'73\3"EF?N+VD;N[7NZWMV/#Z*]6\/>#/"K:-J?B_6O/&A"YD%E;*S ^4'
M*KN(.XMG  SVY)[6G\'>#?&7A*^U/PC;W5E>68),,KLQ8@9VL&9AR.A!Z_E4
M^R=C:68THRLT[)V;MHGV9X_77Q^!C)\-IO%_]H@>6^W[+Y/7]X$SOW>^>E=3
MH/@_PKHO@&+Q/XNAFNOM6#%!'(RD YVA=K#+$#/)QCZ5T&OQZ*GP)U ^'Y)&
MTUW1XQ)G<A-PF5.>>#G_ .OUJHTM&Y=C&MC[SC"E?XDF[:/NCP>BO1_%/A;1
MM-^%.@:U:6ACU&ZDB6:;S7.\-&['Y2<#E1T%$WA;1D^"5MXB6T(U5Y"&G\U^
M1YS)C;G;T [5'LW^%SI6-IN*E9ZRY?G_ )'G%6+*PO-2N!;V-I/=3D$B.",N
MV!U.!S7JY\(>"_!/ABPO/%\%S?7][R(89&4KP"0H#+PN1DD]3[XK6^'DG@A/
M&UU%X=@NWFDM_,AFD+;8EP-Z88@YS@Y(/?FJ5+5)LQJ9DE3E.G!M+K;1V\SP
MZXMYK6=X+B&2&:,[7CD4JRGT(/(J, DX R37HGQ6N_#4NMW,&FZ?<PZQ'=-]
MMN)&)23C^$;SWQV%1_!S2K;5/':O<H'%G;O<HI&07#*H)^F[/U J>3W^5&ZQ
M5L-[>46M+V,NU^&?C&\M5N8M#F$;#(\R1(VQ_NLP/Z5S5[97.G7DMI>0207$
M1VO'(N&4_2N[\;_$+Q#)XQO8['4[FSMK*X:&&*%]H.PX)8#[V2,X.:;HFJ:1
MXQ\2W%_XS%Q/<"!(X+>QA<F=@,'(3)S@9Z@<TW&#=HF=.MB(P]I5BK6O97O_
M ,$\_HKVZY\!>%]=\*ZE>:7H&K:'>6L;/&+X2(7(7<.&9@5/3(Y%9?@OP5X8
MU;X<S:UK*21/!,[RW4<CY$:8) 4''(R.A/-/V,KV%_:=+D<K/1I6ZZ_,\EHK
MU^]\*>"O$?P_U+7?#%M<V4U@'+>:[DL4 8A@6(Y4Y!![CW%5O#'@WPSIO@(^
M*_%L4URDW,4$;LN%SM4#:1ECUY.,8Z<TO9.X_P"T:?*Y-.][6MK<YK3_  &;
M_P"'UYXJ_M$)]F9A]F\G.[! ^]NXZ^E/U7X?_P!F> ;/Q1_:T4OVD1G[-Y6,
M;NP;=R1W&!W]*]+N4T)?@KK$GAQI3ITJNZI+G=$Q9<J<\\$>_P!37'^(/"&B
M6/PBTO7;:T*:E,(3)-YKG=N!S\I.!^ K1TTE\CEI8VI.?O2:]^UK+:VS[>NK
M/,*Z_7_ IT+P7I'B'^T?/_M#R_W'D[?+W(7^]N.>F.@KM;GPCX&\$^']-/BN
M"YN]0O1\QAD?Y#@;B &4;5R.3DGT[58^*L-G;_"_P]#I\QFLDFB6"4]73RFV
MD_ABI]E9.YH\P]I5IQI72;M>VC]#Q.I;:VGO+A+>U@DGGD.$CB0LS'T ')KV
M+2M!^'MRMG;VOAS7]52;:C:@D$XB4GC+$%0!]%Q4^F>'/#W@[XO0:>8+F9KJ
M!9].;?D6[$N&#<C(PIQD'K^-)47IJ7+,H6DE%W2;U\OF>,7EC=Z=<FWO;6>V
MG4 F*>,HP!Z<'FH*]E^*_P#PC]]KW]E0Z=<'Q/<-!''=%R(MK$  C=Z''W:O
MR> ?"'AU;33]0\/ZYK-S(@,M[:P3/&A/KL( ^@#'&,^XZ+NTF$<RBJ<93B[R
MZ?KOL>%UW?P\\#V/BBWU2_UBXN;;3K&,$R0LJY;!)Y8$8"C)^HJO\2?!L/@[
M7XXK-W>QNH_-A\PY9"#@KGOCCGT/XUU^L?\ %%?!&TTT?N[_ %@AI>,, WS-
MD>RA4/UHC"TGS=!XC$^TI0]B]9M)?K]QX_)L\QO+W;,G;NZX[9IM%%9'HA11
M10 4444 %%%% %.U_P"0A>_5/Y5<JG:_\A"]^J?RJY53W^[\CFPG\-^LO_2F
M%%%%2=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %/2O^0;%^/\
MS5RJ>E?\@V+\?YFKE54^-G/@_P#=J?\ A7Y!1114G0%%%% !1110 4444 (>
MAJII?_(-B_'^9JV>AJII?_(-B_'^9JE\#^7ZG-+_ 'F/^&7YQ+E%%%2=(444
M4 %%%% !1110 4C?=/TI:1ONGZ4 ]BKI?_(.A_'^9JW532_^0=#^/\S5NJG\
M3.?"?[O3]%^04445)T!1110 4444 %%%% #7^XWTJMIG_(.A^A_F:LO]QOI5
M;3/^0=#]#_,U2^!_UW.:7^\Q_P +_.);HHHJ3I"BBB@ HHHH **** "BBB@"
MG:_\A"]^J?RJY5.U_P"0A>_5/Y5<JI[_ '?D<V$_AOUE_P"E,****DZ0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** (;K_CSF_ZYM_*DL_\ CR@_W!_*ENO^/.;_
M *YM_*DL_P#CR@_W!_*J^P<W_,3_ -N_J3T445)TA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4Y_\
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MZI_*KE4[7_D(7OU3^57*J>_W?D<V$_AOUE_Z4PHK9\( -XUT$$ @ZC;@@_\
M71:]R\5^/[_0/'^FZ"EE:W%E=I%OW!O,R[E>#G'8<8JH04E=LSQ.+G2J*G"'
M,VF][;?(^=**]E\>> M/U'XD:186$B:>=5BE>8I%N5612V[;D?>QCMTSZUSN
MO_"Y?#NC7EW>>(;3[7#N:&RV /-&'VAA\V03D' !QG&:'2DK^0J>8T)J-W9R
MZ:][?FCSRBO3K/X/[+*UDUSQ)9:3=W0_=VLBAF)/\.2ZY/L,US6N> =9T7Q3
M;Z#L%S/=D?9I(P0L@)QGGIC'/I].:3IR2NT:0QM"<G&,OZ1RU;,/A/6[CP[)
MK\5B6TN/.Z?S$XP<'Y<[NOM7>M\%XXV2TE\66":J\>\69C&3]/GW$9[[:U=%
M_P"3=[[_ '9?_1E4J3UYCGJYC#EBZ+O[R3T>SOZ=CRZ?PEKMMX>CU^;3V33)
M,%9RZ\@G .W.[!/M6+7IVIZ9KZ?!JTO9O$1ETMA'MT[[*HVC?@?O,[C@X./\
M*2V^$#SZ/I>K2Z_;6UC=6JW-Q+/'L%ON52HY;#?>/)V]/>DZ;?PHN&.A%-U9
M+=I63Z?K_2/,JV==\)ZYX:CMY-7L&MEN,^42ZMG&,_=)P>1P:W/&_P .[CP=
M:6E\FH17]C<ML69$V$,1D<9.00"00>U;'Q1TKQ#;#08-3UU]9:Y\P01K:+$4
M;Y!C"_>)W 9//'O1R-)W6Q7UN,YT_9R5I7[WT[?K<\RHKU.+X,B&"V75_%%C
MI]_<#]W:L@8L?0$N-Q]< UCZ%\-FU2?5_MNMV>GVNF73VLL\@R&93R1DJ /J
M:7LI]AK'X=IM2T7D_P#+7Y'"5LW?A/6['0(-<N+$IIL^WRYO,0YST^4'(Z=Q
M73^)?A@VC>'&U[3-<MM7L8R/,>%,8!.,@AF!P3SSQ75^*_\ D@6C?[MO_(U2
MIO7F[&<\=%N'LG=2E9[GBE%%%9'H%/2O^0;%^/\ ,U<JGI7_ "#8OQ_F:N55
M3XV<^#_W:G_A7Y!17IOP, /C>\) XTYR/;]Y'7<^'?&UQXI\::QX6U73+*6S
MA,ZHRH3E4?;APQ(.0?:KC24DG?<YL1CY4JDHQA=12;UM^AXCH/A;6O$S7"Z/
M9&Y-N 9<2(FT'./O$9Z'I6/7T#\-M+MM%\<>,M.L\_9X9(1&"<[0=YV_AG'X
M5R*_!:::QN!;>(K&XU2W4>=9Q+D(Q&0I;=D9[944W1?*FB8YG3564:CLO=MO
MU5]3RRBE961BK JP."",$&O4_A1JN@VNJ:781Z5YVMW4L@EO)>1"@5BNSW(&
M#C'7J:SA'F=CLQ%9T:;FHWL>5T5WWQD 'Q#N2 !F"(GW^6N!I27*VBJ%7VM*
M-2UKJXAZ&JFE_P#(-B_'^9JV>AJII?\ R#8OQ_F::^!_+]3.7^\Q_P ,OSB7
M***]-^!@!\;WA('&G.1[?O(Z(1YI)%XFM[&E*I:]CS*MC0_"VM>)5NFTBR-R
M+4*9L2(NT'./O$9^Z>GI7MWAWQM<>*?&FL>%M5TRRELX3.J,J$Y5'VX<,2#D
M'VJ/X<Z3;Z/XK\<:99?ZB*6!8P3G:")"%S[9Q^%:QHIM:Z'FU<SG"$[PM))/
M>ZLVEY=SY]HKU)_@Q.^FW,ECXAL[S4;5?WMG$F0KXSLW;N#Z94?A7EM92A*.
MYZ-'$TJ]_9N]@HKO?#GQ0N?"VA6FG:=HUB9(F9I[F7):;+$]L8(! R2>E=G\
M;=/L6\.:;JWV6.+4'N%C+@88H49B#ZX('7ID^M4J:<6T]C"6,G"O&E.%E)M)
MW[>1X?2-]T_2EI&^Z?I69W/8JZ7_ ,@Z'\?YFK=5-+_Y!T/X_P S5NJG\3.?
M"?[O3]%^045ZQ\"%4^(=48J-PM0 <<CYQ76^%_&D_C'Q5K'AK6-+LI;2 2[6
M5"055PN&#$@YSU&.G2KC232=]SEKYA*E4G%0NHI-N_?RL>):'X6UKQ*MTVD6
M1N1:A3-B1%V@YQ]XC/W3T]*QZ]\^&&F0:7XE\<:;:-F"&>*./G.!F7 S[=/P
MKE7^#$[Z;<R6/B&SO-1M5_>V<29"OC.S=NX/IE1^%-T7RIH4<RIJK*%1V2Y;
M;]5?4\MHHKU7P?XS\1VNAV-AX9\'I<+$WEW%T(G82MU.64*%.".I/:LXQ3=F
M=F(JRI1YHJ_J['E5%>R?&^'3A:Z1.8H8M8<GS5CQN\O'.['4!NA/OCO7C=$X
M\LK"PN(^L4E4M:XU_N-]*K:9_P @Z'Z'^9JR_P!QOI5;3/\ D'0_0_S-"^!_
MUW%+_>8_X7^<2W117K'P(53XAU1BHW"U !QR/G%$(\TK%8JO["E*K:]CR>BO
M4/BGIUOJVG:3XVTV,""_B5+D*!\LF."<=_O*?]T5L_%E%\WP0NT8RXQCM^YX
MJG3M?78YX8]2=-<OQ7OY-+5'BU%?17Q*\?:EX+O=-BL;:TFBN4=I!.K$_*1P
M"&&.OH:P==M=%^(OPZN_$]G8QV6JV*NTVP<DH S*Q &X;3D'M^=4Z23:3U1E
M2S&4HQJ3IVC+2][_ 'Z(\3HKU7X16L6EZ=KWB^Z3,=C T47NV-S#Z_< _P!X
MU/\ &6PAU"ST7Q99C,%W"L3M]1O3]"P_ 5/L_<YC;Z\OK/L+:;7\[7L>1T44
M5F=Q3M?^0A>_5/Y5<JG:_P#(0O?JG\JN54]_N_(YL)_#?K+_ -*84445)TA1
M110 4444 %%>O_ 50=3UIL#<(8@#CIRU=)X0\8R^.]9U;0-;TFSEMH$=@Z(=
MI <+M8,3R<YR".E:QI)I.^YYE?,)4JDXJ%U&UW?OY6/GRBO2-,^%C>(;CQ!_
M9^HK"-.U"6T@B>/<'"MP2V>./8U3U/X9R0Z]I^CZ-K-KJMS="3S2@"K;;,9W
MX9L#GZ\8Q4^SE:]CH6.H.7+S:_/M<X.BO6?^%*PO+)9P>+K*34XTW-:>2,K]
M<.6 ]]M<EHWP^UC5O%USX>8+;S6F3<RM\RQKQ@C'7.1@=Z'3DN@0QV'FFU+;
M5[K0Y.BO7(O@QITUG-=Q^-;1[:#(FF2W4I&1UW-YN!COFLO0OA-)X@T1=2M-
M;A"&Y>+F'Y?+5B#)NW>@R!C\>]/V4^Q*S+#6;YM%Y/\ R/-Z*]%@^%L%WKMS
M9VOBBPEL+:WCGEO0HV@N6 7 8C^$G.[N*=K'PI6U\.W6LZ+XCL]8@M5+RB%0
M %49;!5V!('..*7LI;V*^OX?F4>;?R?7Y'G%%>A^'?A5<>(_"UGK4&JQ0^?(
MRR1RQ86)%9@6W;N>G3'?K6C/\$[F6"UN=(\065_:RGYYBFQ53NP(9@P_*FJ4
MVKV%+,,-&3C*6JTZGE=%>A>)?A:^B^&FUW3M;@U:TC(\PPQXPI.,J0S!L'KT
MKA;"*&?4;6&YD\J"25%DDR!M4D G)]!4RBXNS-J6(IUHN=-W2*]%?2'BS4M8
M\#V%C'X6\.6T^EHO^D;8V8J/3"D'D9^8Y]_?@O!\>E>//B5<ZQ?K8V:C8R:7
M*JR"Y/EE2!G&<%=YX/7\:MTK-1OJ<5+,7.G*LX6BEWN_1KH>645ZG\2?!6DV
M^N27&EZMIT-U<W,,"Z/$BH8=R@;L*V0"<-]T?>_-\?P<LC<K8R^,[!=289%H
ML8+'Z#S Q[]J7LI7LC6.8T/9QG)VOY/_ "_'8\IHKUSP#X!M+/QU?V.O3V,\
M]@ $LI8PXN5=21(H;J ,=C@GG%4O'O@G2(/%,(T[6;%);^_CMFTZ"-0;0, -
MQ4-TSVP.M'LI<MP68476]DNU[_UY'F%%=5XN\&'PMXHM=%^W_:O/CC<3>3LQ
MN8KC&X],>M:/B'X97>C^*=+T&SOTO9]04LKM%Y03!.<\G@ $_P!*GDEV-EBZ
M+47S;IM>BW.$HKTS5_A-;:;I^H21>*[*XOK&W>XELA& X"KN/\9(X'<5YG1*
M+CN51Q%.NKTW?[_U"BBBI-@HHHH **** (;K_CSF_P"N;?RI+/\ X\H/]P?R
MI;K_ (\YO^N;?RI+/_CR@_W!_*J^P<W_ #$_]N_J3T45[E#%IWPI\ V>J-IL
M5UKE[M&^3JK,-V,]E4#''4_7(<(<WH&)Q/L>5)7E)V2/#:*[_P 1?$>'Q=X:
MGM-7T>W3559&M;NW7 4;AN!W$D?+GN<^@J[8?"!QI=O>Z_XAL]&:XQY<4JAC
MR,@$LRC=[#-')=^[J3];5.-ZZY7?;>_I8\SHKL?%?P[U#PIJ-E#+<1W%G>2"
M.*ZC4@!N.&'8\YZ\C\:ZB?X)&TO0EWXFM;>T?:D4TL(5I)#GY I?Z=\G/2A4
MIMVL$L?AXQ4G+1[;GDU%>IR?!2YM-0D74/$%C::?E5ANG7#2.W 786 !_P"!
M'MC/.,'7_AU=^'_%NE:+->))!J4R10W2QXQE@IRF>HW XSSQS0Z4UN@AC\/4
M?+&5^O4XJBO6?^%)-#J+6UYXFM;=)'"6A:$>9<':"<(7&,'(X)Z9XJ&+X*W,
M5\\.J>(+*RB>7R[1]NYK@XSPI9<'VR3P>W)?L9]B/[3PO\_X/_(\LHKJ-=\"
MZGHOB^'PZFVZN+G:UNZ# D5B1DCMC!SZ8-=<OP8B$JV,OBVP35FCW_8A&"W3
M_?W8]]M)4Y/2QI/'8>"4I2WU6^QY317<^'OAI>ZQXEU70[R\6QN=.3<Q$7FA
M\D8QR.""#GWZ4[7_ (:2Z+;V,,&KVU_K%S<);OIT &Z)F4MG.[...I ZYH]G
M*U[#^NT.?DYM3A*VK7PEKM[H$VN6^GL^FPAB\^]1@+U."<D#V%=X/@ND9BM;
MKQ980ZI*FY;/RP2?H2X8C/?;46BZ/X@'PIU>>#Q&(=.A,ZR6"VRN) N-V)#R
M >>G]:I4FOB1A/'TY13I26Z6J?7MI_P#RZBN]\._#BVU;P[;ZUJ?B:QTFWN"
MPB$P!)VL5YW,HZ@^M4_&WP^NO!T5K=K?17]A<G:EQ&NW#8R 1D\$<@@GH?QC
MV<K7-XXRC*I[)2UVZ]//8QM>\+:UX8:W76+(VQN 3%^\1]P&,_=)QU'6L>O9
M/CY_Q\:#_N3_ ,TKCOA. ?B9I&?^FW_HEZJ4$JG(C*ABY3P?UB2ULW]USC*T
M-&T34?$&H+8:7;&XN64L$#!>!U))( KWE_'6JO\ %.7PI_9MM<:<'5&=4;S$
M!0,68Y*X!/H*YF[\/-:?&LV/AB_71Y)+4S.\<*RK&2I+*$/&#@'';/TJO9+H
M[ZV,(YC)IJ45%\O,M;JWG97/)]2TV\T?49M/OX3#=0G;)&2#@XSU'!X(JI7?
MW'@K6O$WQ,U/29=06YN(6#W5^\6Q=N%P=HXSR  /2MV+X,:=-9S7<?C6T>V@
MR)IDMU*1D==S>;@8[YJ?92;T1N\PH4XQ]I+5I/1/K\OS//+7PIK=[H$^N6]B
M7TV#=YDWF(,8Z_*3D]>PK&KWWP/I#:C\)-5TBUN(G,LUQ!'.>$(R &^G>N(U
MWX4/IWAF;6]+UVVU:& %I1"@  !PQ#!F!QW''0_2G*D[)HSI9C!U)4ZCM9V6
M_P"/](\YHKWV'P#X9;X8?9CJ>D@MACKI@C^4^:#C=N_X!][_  K@-"^&?]N7
MFK.FNVD>D:?*T1U':&63'.0-V ,8).['/>DZ,E;S+IYE0FI-Z<KML_Z^6YP-
M%=5XR\'0^%DL)K76;;5;6]$GES0* !LVYZ,P_B'>N5J&FG9G93J1JQ4X/1E.
M?_D)VGT?^57*IS_\A.T^C_RJY3ELOZZF-#XZG^+_ -MB%%%%2=(4444 %%%%
M !1110 4444 %>Z>$]3NM(^!%Q?V,PBNH/-:-]H;:?,]"".]>%T5<)\CN<V*
MPRQ$8Q;V:?>]NAN:YXP\0>(XUCU;4YKB)3D1X5$SZE5 !->_3C4]4\.:,_@K
M6M/T[3EC42R/$'*I@8 !! (YR#@Y[BOF6BG"JXWOK<QQ. C545"T>6^EDUKY
M'NWQ-D23Q?X$D219$:Z#!U/# R1<CVKEOCF0?&UG[:<G_HR2O,J*<JO-?3<6
M'P'L7!\U^5-;=W<]P\,:=_PE_P #QH%A=VZ7L<C!A*Q 0B;S!NP"1D'KBG_#
M>T_LOP?XQL9)HY#:W$\32*?E;;'C(]CBO#**:JVL[;$3RYR4X\^DGS;;/[SV
M/X%$"W\39('R0']):T/A?K0U+P#-X>L-4CT[6K=G,#NJN2I;=N"L,,,DJ?3\
MJ\,HI1J\J2ML.MERJRG)R^)I[;65OF>V>*K7QSIOA+4Y=?\ &-@8FC\L6L5O
M'FX#8!7=L4@X)Z9Z56\?$?\ "D/"HR/O6W_HAZ\<HH=6]QPP'*XMM:.^D4NG
MD>L_#70_$IT0:GX9\16<323%;C3[E24&.YQDY(QT .,<UTGBVYTJ7XG>$%B>
M!]5CGQ=-"1P.-H;OG.< ]C[UX%10JMHVL*>7N=9U7+OTMNK:OK8];^(3#_A=
M>B\CA[3/M^]KHO$)'_"__#?(_P"/$C_T?7@5%'M=7IUN']G^[&/-M%QV[]=S
MWG3"#^T3K./^?-?_ $5%5N#P$$^)TWBP:O:M812O+)'GYTDVE2I[ #.<YSVQ
MWKR;X>^)[/PEXG_M*^BGE@,#Q%8 "V3C'!(';UK*\4:K#KGB?4=3MT=(;F8R
M(LF-P'OCO5^TCRW:ZG.\#6]KR1E9<BC>V_0]0B:_\8_$77M5\+>((+">S6*&
MWW#*72X(;/7*[E_NGJ*O?%.6)? %K;:_+8S>(_,7ROLN>#GYB >=NW@]LX]J
M\+J]HU]%I>M65_/;?:8[:993#OV;]IR!G!QR!VJ?:Z-=S=Y?:<9J6D;65E?1
M;7\SU3Q\1X0^%VB^%8R%N;K#W &3]WYW_P#'R,>P->.UT?C7Q;-XRUW^T9;?
M[,B1+%'")-^P#)/.!G))/2N<J*DE*6FQT8*C*E2]_P")W;]6%%%%0=84444
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MUU,09)-H7.  .  .@%'/[MGO>XUA+5^>.D>7E_$^B?'-VUI=VTZ^ 8?$L3Q
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M)3TK_D&Q?C_,U<JGI7_(-B_'^9JY55/C9SX/_=J?^%?D>G? O_D=KW_L'/\
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M?PS<2SZ1>&VEE38[>6KY&<_Q T4Y*,DV&,HRKT)4X[L[CX97\.N:1JO@;49
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MJ4VHI91_NFG!617R70'*KQD$#CIQ7B&O>)]9\3S0S:Q>FY>%2L?[M4"@]>%
M%+H/BG6?#$L\FCWIMFG 63]VCA@.G# ^II^V5[6TV$\LJ^SYN?W[\W]V]_2^
MQCT4^:9[B>2>4@R2,78@ 9).3P.!3*YSV2G:_P#(0O?JG\JN53M?^0A>_5/Y
M5<JI[_=^1S83^&_67_I3"BBBI.D**** "BBB@#V#X"_\A'6_^N47\VJOJ'Q>
M&F?;K/0?#5CIL[2LK3HP.Y@<;BJJN3]2?QKS[0?%&L^&)9Y-'O/LSSJ%D/EH
M^X#I]X'UK+ED>:5Y9&W.[%F/J3UK7VK44HGG/+XU,1.K55T[6WZ=SVSX33RO
MX#\37#2N9FEE<R$_,6\K.<^N:Y_X&SV\?B^\BDP)Y;,B(GOAE) _#G\#7%:3
MXLUO0]-NM/TV^,%K=9\Y!&C;LC!Y()''H167:W5Q8W4=S:S203QG<DD;%64^
MQ%"J)<OD*6!E)5DW\=K?(]3\/^$/$=O\86O9=/N(K:.]FG>Z9?W;(V[HW0Y!
MQ@<\\UVFBW2WGQ7\5M;B*2TBM(8;@J<NT@'\..N/F4]\@5Y!-\3_ !G/;-;O
MKDH1A@E(HU;_ +Z"@_K72?"#7-"TN?5?[3O(;/4KA0(;NXZ;>=PW'@<X)!ZX
M'I6D)QNDCCQ6%K^SE4J6;45%)7[K4W=5?1O!7@;6;#0=-UR9M21TDDN[*:-8
ME92I)9T48 )QU.>I[TS0V9/V>+\JQ4[)AD''!DP:Z*W\6:=X?T^\GUSQS9>(
M%9?W<%O#"&_W=L9.<].>*\-'B[6H]"GT*"[\K2968FV$:$ %MV-Q&[&?>G*2
MB_D3AZ%2O%KM)-MWU^]+;T.X^$OAC2-4T_5M6U"Q74IK0A8;,X.?E)Z$X);H
M,\<5W<$QN/AIXEE_X15?#J-9W.VW"JID'E'YRH52#VY':O!-#\1ZOX;N7N-(
MOI+61UVOM 96'NI!!_*M6Z^(_BV]@NX+G6'DBNX3!,ABCVE""" -ORY#'D8/
M3T%1"K&,;'1B<!7JUG--6NK7;TMTML=Y"[)^S5,58J=V,@XX-T 1^53Z&S+^
MSQ?%6(.R8<'L9.:\K'BK6AX:/AT7I_LHG)M_+3^]O^]C=][GK3H/%FN6_AV3
M0(KXKI<F=T'EH<Y.3\V-W7WI>U7X6+E@*C35UK/F^7^9ZCX4Y^ 6LY_NW'\A
M7C5K;37MY!:6Z;YYY%CC7(&YF. ,GCJ:U+3Q9K=CH$^AVU\4TV?=YD/EH<[N
MOS$9'3L:R8)I;:>.>%VCEC8.CJ<%6!R"/QJ)R4DO(ZL/AYTI5&[>\[K_ ()[
M'X,U#XD:)K%GHU_I-W=:?O5':XCR(4S@E91QQUP2>F!5G5;:PL/V@M&-HD<9
MEAWW 3C]ZRRC)'8D;3^.>]<!_P +3\:^5Y?]N/MQC/D19_/;FN7.HWK:B-0:
M[F:]$@D\]G)?<.ASUS6CJI)):G)' 5)3E.7+&Z:]V^M^K/3/''A:\U+XNF2\
MM9XM)O;JUA-WM(0Y15(#=,Y4CZX]17?Q:?8:'XML-*TKP'$\*J';5BB@0^X<
MJ26'IN!KPW5_'?B;7;2.UU'59)88Y!(JK&D9##H<J 3C-7#\3_&9@2$ZY+M7
M&#Y4>XX]6VY/XGFFJD$VS.I@<3.G"#:T5K7=O)Z;O\#TR29(OVB(E8X,MEL7
MZ^63_(&N1\6:9?67Q?CU2YM)H;"35+;9<NA$;?=/#=#T/Y5Q5YXGUJ^UY-<N
M+]SJ4>W;.BJA&W@<* /TYJ?7?&?B#Q+;16VKZBUS#$V]$\I$ ;&,_*!G@GK4
MNI%I^MS6E@JM.<7=6Y>5[_@>H_$?PGK>L_$?2+JPL))K8Q1*TR_<C*R,6W'M
MP0??MFIOB/)J\7Q*\-2Z% MQJ202-%$Q&'QN+ Y(_AW=_IS7F3?$;Q<VFC3S
MKEQ]G";.%4/C&/OXW?CFJUWXU\17NJV>J3ZDYO;-=EO*L:*4'.1@  ]3UINI
M'6U]3.G@<0N53<6HIKKK==?U/8KC1-/^(&D:C=:UX8N="U6W0_Z5*NT,P!^8
M-QO48&<CIT/>OGZNFU3XA>*]9L'LK[6)7MY!M=$C2/</0E5!(]JYFHJ34MCK
MP.'J4%)3>G1)MI?>%%%%9G<%%%% !1110!#=?\><W_7-OY4EG_QY0?[@_E2W
M7_'G-_US;^5)9_\ 'E!_N#^55]@YO^8G_MW]2>O>O&NF3^/?AMH^HZ'']HE@
M"R&%6!;&W:ZCU8$=/8UX+6SH?BO7?#9?^R-2EME<Y9  R$^NU@1GWQ3A)*Z>
MS(Q>'G4<*E-VE%Z7V+MGX5UO3#%K.J:-=6^F6EQ$UP]Q'LPN]1]UL$]<< UZ
M1\9?#VLZW>Z1=Z793WUN(F3_ $=2^UB0<D#H",<].*\SUGQWXF\0636>IZK)
M-;,06B$:(&P<C.T#/(!J32_B%XKT:Q2RL=8E2WC&$1XTDVCT&Y20/:J4H)..
MMF8SH8F4XUO=YHWTUM9_J>E>.4?3/ ?@S2+YU&H)=6VZ,L"0$0JWUP649K/^
M/3$:AH>">(I2/;E:\PU'7=4U?4UU'4+V6XNU(*R.?NXY  Z >P%3:]XHUGQ/
M+#+K%Z;EX%*QGRT3:#U^Z!3E5337H30P$Z=2G-M:<U_GV/3OCV[>;H2;CM*S
MDKGC/R<UL_$;_D;_ (=_]?X_]&05XSKWBK6O$[6[:Q>FY-N&$7[M$VYQG[H&
M>@ZU/J/C3Q#JUWIUU?:@99M.?S+5O)1?+;*G/"C/*KUSTINJFY/O8BGE]2,*
M46U[O-?Y[=#T+XCL?^%S^'1DX'V3'M^_:E^*<CGXL>'(][;%CMV"YX!,[Y./
MP'Y"O--2\4:SJ^LP:O?7IEO[?9Y4OEHNW:=R\  <'GI1JOBC6=;U:#5-1O3-
M>VZJL4OEHNT*Q8<* .I)Z4G43OYLNE@:D73NU[L6OFSW7Q#/;6_QF\+M< #?
M:S1QL3C#D,!^>2/J:;K^J7>E^+&:V^&B:C/N#1:G$%W.<#DL(R5(Z<GM7ANM
M>*=:\0WD%WJE\TUQ;C$4BHL93G/&T#OWK7B^*/C2*W6%=<D* 8!:&-F_[Z*Y
M_6K]LM3F_LNHE#9M*S5VEO?H>I^"]1O-3^*7B&?4-,&G78LX4DM_-$A7&W!+
M  '(Q7GWA*YCB^-Z2W,G#:A<KN<]682*OZD5S>G^,_$.EZK=:I::G(M[=C$\
MSHLA<?\  @16/+<S373W4DC&=W,C.."6)R3Q[U#J7MY,ZJ> E%S3LE**CI?3
M2W7_ #/2_B/X-\2ZK\0[R:RTNYNH;H1F&5!E  @!!8\+R#P2*W?#$;P_ ?7(
MI%VNGVE6'H1C-< OQ/\ &:6PMQKDNP#:"8HRV/\ >*Y_'-9EOXOUZUT.XT6+
M4&&GW)8RQ&-&+EOO?,1NY^M'/!2;74AX3$SI1I3<?=<=K]#U?1?#VD:#\/-,
MU>#PF/$>H7BH\B&,2$%AGN&VJ.G ^OK1\8 P^'6B![%+!OM,>;1""L'[I_D!
M  P.G%>7Z-X[\3>'[#[#IFJR0VP)(C,:.%SR<;@<<\\5#K'C#7]?L(K'5=1>
MZMXI#*BNB AN>=P&3]X\9Q3=6/+9$QP%?ZPJLFFDV]W>W:VQZ1\?/^/C0?\
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MB@ HHHH **** "EA_P"0GIO_ %^P_P#H8I*6'_D)Z;_U^P_^ABKI_&CDQ_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#=?\
M'G-_US;^5)9_\>4'^X/Y4MU_QYS?]<V_E26?_'E!_N#^55]@YO\ F)_[=_4G
MHHHJ3I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)>6[Q&3"A0%W@'@9SD=ZZSPQK^CR_#_3=.TCQ59>'KZ%5^T-/'&27Q\_RR$
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M *">N_\ @4G_ ,11]6?</[>A_(_O/!Z*]X_X9^\*_P#03UW_ ,"D_P#B*/\
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M'U9]P_MZ'\C^\\'HKWC_ (9^\*_]!/7?_ I/_B*/^&?O"O\ T$]=_P# I/\
MXBCZL^X?V]#^1_>>#T5[Q_PS]X5_Z">N_P#@4G_Q%'_#/WA7_H)Z[_X%)_\
M$4?5GW#^WH?R/[SP>BO>/^&?O"O_ $$]=_\  I/_ (BC_AG[PK_T$]=_\"D_
M^(H^K/N']O0_D?WG@]%>\?\ #/WA7_H)Z[_X%)_\11_PS]X5_P"@GKO_ (%)
M_P#$4?5GW#^WH?R/[SP>BO>/^&?O"O\ T$]=_P# I/\ XBC_ (9^\*_]!/7?
M_ I/_B*/JS[A_;T/Y']YX/17O'_#/WA7_H)Z[_X%)_\ $4?\,_>%?^@GKO\
MX%)_\11]6?</[>A_(_O/!Z*]X_X9^\*_]!/7?_ I/_B*/^&?O"O_ $$]=_\
M I/_ (BCZL^X?V]#^1_>>#T5[Q_PS]X5_P"@GKO_ (%)_P#$4?\ #/WA7_H)
MZ[_X%)_\11]6?</[>A_(_O/!Z*]X_P"&?O"O_03UW_P*3_XBC_AG[PK_ -!/
M7?\ P*3_ .(H^K/N']O0_D?WG@]%>\?\,_>%?^@GKO\ X%)_\11_PS]X5_Z"
M>N_^!2?_ !%'U9]P_MZ'\C^\\'HKWC_AG[PK_P!!/7?_  *3_P"(H_X9^\*_
M]!/7?_ I/_B*/JS[A_;T/Y']YX/17O'_  S]X5_Z">N_^!2?_$4?\,_>%?\
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M%'U9]P_MZ'\C^\\'HKWC_AG[PK_T$]=_\"D_^(H_X9^\*_\ 03UW_P "D_\
MB*/JS[A_;T/Y']YX/17O'_#/WA7_ *">N_\ @4G_ ,11_P ,_>%?^@GKO_@4
MG_Q%'U9]P_MZ'\C^\\'HKWC_ (9^\*_]!/7?_ I/_B*/^&?O"O\ T$]=_P#
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M%'U9]P_MZ'\C^\\'HKWC_AG[PK_T$]=_\"D_^(H_X9^\*_\ 03UW_P "D_\
MB*/JS[A_;T/Y']YX/17O'_#/WA7_ *">N_\ @4G_ ,11_P ,_>%?^@GKO_@4
MG_Q%'U9]P_MZ'\C^\\'HKWC_ (9^\*_]!/7?_ I/_B*/^&?O"O\ T$]=_P#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L_6?\
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MMX^8''4]*]1H **** "BO./C5XJUGPCX,M+_ $.[%K=2WZ0-)Y2/\ACD8C#
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MB_E[MN]NBKGMDD#\:\Q\5_$+Q1/\+-+\;:+#_9(-WBXM7V3B2$L55BS(" 6
M' !^;K0![+15+1]3@UK1;'5+;_4W<"3H#V# ''ZU=H S[+_D+:G_ +T?_H K
M0KRGQS\0-1\'>*+B"SM[66.9(W8S(S$'!'&&''%<W_PO36_^?'3_ /OR_P#\
M<IM1C\4DC>EAJ]6/-3@VCWJBO!?^%Z:W_P ^.G_]^7_^.4?\+TUO_GQT_P#[
M\O\ _'*5X?S(T^H8K_GVSWJBO!?^%Z:W_P ^.G_]^7_^.4?\+TUO_GQT_P#[
M\O\ _'*+P_F0?4,5_P ^V>]45X+_ ,+TUO\ Y\=/_P"_+_\ QRC_ (7IK?\
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M4?\ "]-;_P"?'3_^_+__ !RB\/YD'U#%?\^V>]45X+_PO36_^?'3_P#OR_\
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M_P"%Z:W_ ,^.G_\ ?E__ (Y1>'\R#ZABO^?;/>J*\%_X7IK?_/CI_P#WY?\
M^.4?\+TUO_GQT_\ [\O_ /'*+P_F0?4,5_S[9[U17@O_  O36_\ GQT__OR_
M_P <H_X7IK?_ #XZ?_WY?_XY1>'\R#ZABO\ GVSWJBO!?^%Z:W_SXZ?_ -^7
M_P#CE'_"]-;_ .?'3_\ OR__ ,<HO#^9!]0Q7_/MGM6A_P#($M/]S^M:%?/]
MI\:M8L[6.WCLK I&, M$^?\ T94W_"]-;_Y\=/\ ^_+_ /QRB\/YD'U#%?\
M/MGO5%>"_P#"]-;_ .?'3_\ OR__ ,<H_P"%Z:W_ ,^.G_\ ?E__ (Y1>'\R
M#ZABO^?;/>J*\%_X7IK?_/CI_P#WY?\ ^.4?\+TUO_GQT_\ [\O_ /'*+P_F
M0?4,5_S[9[U17@O_  O36_\ GQT__OR__P <H_X7IK?_ #XZ?_WY?_XY1>'\
MR#ZABO\ GVSWJBO!?^%Z:W_SXZ?_ -^7_P#CE'_"]-;_ .?'3_\ OR__ ,<H
MO#^9!]0Q7_/MGO59^A?\@*R_ZY"O%?\ A>FM_P#/CI__ 'Y?_P".5#:?&K6+
M.TBMH[*P*1KM!:)\_P#HRB\/YD'U#%?\^V?0%%>"_P#"]-;_ .?'3_\ OR__
M ,<J6V^.>K&YC%Q86)AW#>%1U)'?!WG!_ T)P>BDOO$\#BDKNF_N/=:*S]%U
MJRU_3([^PE#Q/U'\2'NI'8UH4VFG9G+N%%%%( HHHH **** ,^R_Y"NI_P"_
M'_Z *T*S[+_D*ZG_ +\?_H K0H \W^(TJ0^._A[)(P5/[2D3<>F650!^)-=O
MK[I%X<U221@J+:2LS$X  0\U2\7>$M.\9:+_ &=J!ECV.)8)X6Q)#(.C*?QK
MEIOAOXBU2U_LW7?B!J%]I!PKVT5G'#)(H_A:4$EO?/6@"S\%4:/X1:$KJ5)$
M[8/H9Y"/T-=#XL\(Z5XST8Z;JD;[0V^*:([9(7'1E/K^E)K'AMKKP<_A_1=0
MET3$4<5O<VP.Z!5*GC!!Y QU'4U1U;PIK5[8:4FG^,-0T^]L;?R7N!&LJW)P
MH+R1MP3E<]>YH Y*#4/%?PX\4:)H^L:M_;V@ZM<BSM[B9<7,$A("ACGYAR.2
M3WZ=#ZS7":9\.[IO$5IKOBGQ)<Z_>V.3:(UNEO#"Q_B$:Y!;IS_@,;D.@:A%
MXWN-=;7[I["6U$"Z40?*C88^<?-C/!_A!YZT ;]>#>%?"DWB?X Z:^GDQZUI
MMS->:=*OWA*LK':#_M8QZ9VGM7O-<YX%\*#P5X3MM#%[]L\AY&\[RO+W;F+?
M=R>F<=: /.=$\4Q>,?B3X&U90$N#IUW%=1#CRIE4AEQV]1[$5MV'_)R6J?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!/A^_P 5],O?%/B37]1^VM=-';^0XQ&0 <X8' Y "KC 'Y=3\,OA[X@TJ_\
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M6&-DTB JP.<X X((^G:M7X;>"-)T/X<7'B6+5[RPNM4TAUGN9'4QVN0?WB@
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MF,^->B/K<C_W7YL****Y3V HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH **** "BBB@ KF_&?@C2O'6E0V&JM<1K#*)HI;9PLB-@C@D$8(/I7244
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M7$EM$JJ'V9 Z9! ]SZU7\6:#X@^'^@2^*-(\9:WJ$EDR/<VFJ3B:&9"P!"C
MV?>[=OPKJ/B'X4U+7H])U70I88]:T:Y^T6HG^Y*#C<A/;.!^6.,Y&!KEK\0/
M'VF?\(]J'AZU\/Z=.Z?;;LWZ7#NBL&(C51P20.M "^/]9UJ[OO A\.:C)I\F
MKR2#)8E-KQJ064<,5#$@'C(%=OX9\.R^';:>&77-5U8S.',FHS^8R''(7@87
MOCM6%XF\,7MSXD\#R:7:;K#2+AS.WF*OE1[%5>"03TQQFNYH **** "BBB@
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MKV2R*1!)%MFPKMDG=@]#@@?A7HWA;5=0N_A;<ZA<7<LMXL5R1,Q^8%2V.?;
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M:M;:A9:J4>_TVY-O+(@P']\>N0:ZRJ3NKF%6FZ4W"70****9F%%%% !1110
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M2-IVG75RB11AFA@9P#@\$@'GFN#_ .$%\3_] /4/_ 23_P")KZ>LO^0MJ?\
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M/_D"6G^Y_6M"CV-'^7\0_MC&?S+[CY1_X07Q/_T ]0_\!)/_ (FC_A!?$_\
MT ]0_P# 23_XFOJZBCV-'^7\0_MC&?S+[CY1_P"$%\3_ /0#U#_P$D_^)H_X
M07Q/_P! /4/_  $D_P#B:^KJ*/8T?Y?Q#^V,9_,ON/E'_A!?$_\ T ]0_P#
M23_XFC_A!?$__0#U#_P$D_\ B:^KJ*/8T?Y?Q#^V,9_,ON/E'_A!?$__ $ ]
M0_\  23_ .)H_P"$%\3_ /0#U#_P$D_^)KZNHH]C1_E_$/[8QG\R^X^4?^$%
M\3_] /4/_ 23_P")IL?@GQ)+&LD>C7[HPR&6UD(/X[:^L*S]"_Y 5E_UR%'L
M:/\ +^(?VQC/YE]Q\P_\(+XG_P"@'J'_ ("2?_$U+;> /$T]S'"=&OEWL%W-
M;NH'U)  'N:^J:*:I45]G\1/-\8U;F7W'*^"?!-GX1TX !9;^1?WTV/_ !U?
M;^?\NJHHJVVW=GF^;"BBBD 4444 %%%% &?9?\A74_\ ?C_] %:%9]E_R%=3
M_P!^/_T 5H4 %%%% !114%S>VMF(S=7,, D<1IYL@7>QZ*,]3[4 3T444 %4
M=4T;3]:B@BU&W%Q'!.EPB,Q"^8OW20#A@,]#D=..*O5!<WMK9B,W5S# )'$:
M>;(%WL>BC/4^U $]%%% !1110 4444 %%%% &+X9\,67A6PN+.QDN)([BZDN
MG,[ D.Y&0, <<5M5#=7=M8V[7%W<16\*_>DE<(H^I/%2@AE#*00>01WH 6BB
MB@ HHHH **@O;ZTTVTDN[ZZ@M;:/&^:>0(BY.!ECP.2!3K6ZM[VUCN;2>*>W
ME7='+$X9''J"."* ):*KV]_9W=Q<06UW!--;,$GCCD#-$Q&0& .5./6K% !1
M110 4444 %%%% !1110 4444 0W?_'E/_P!<V_E4>F?\@JS_ .N"?^@BI+O_
M (\I_P#KFW\JCTS_ )!5G_UP3_T$4 6J\]C\6>*O%&JZG#X/L](CT[3KAK5[
MW5#(PGE7[P14P0!D<GK7H5?.VGZ1X-\(ZGJ^F?$*PO[>4WLDMEJ DNA#<PMR
MN/*;&X<YX[X[4 >F:7XPU[7-"\06MKI]G;>*]%?RY+65FEAD.-RE<%3AP& R
M>#C.:S/^%L/J?A?2/["M(9O%&I3_ &4:?+NVV\JX\UI ""$4<]1P1Z&G>'=7
M\#>%/"^O>)-"TV^M+%2@EEN!,#>, =@C\UB3R^.@Y-<=;:3K7@:\L?BCJ,"L
MVHS.=8LHX@/LL$S#:R\9W#C/?) [DT >@Z[XQU__ (2>'PEX9L+&[UE+5;F]
MNKLLEM;@X'W5);))SC/ (Z\XD.I>)+KPGXIL?$VE6]K=6MA(4NK-V:WN5:-^
M4W<@@KR#SR/6N;O-9M_!/Q7O_%&I),WAW7[" QZC#&TL<3JJ@ [02 0,_B,=
M\=*WB^V\7>%/%$NFV=V--AL)!!?31-&MT6C?=L5@#A<+R>N[IQR <S%XLOO!
M?[/NAZQIT-O+<)%#&%N%8IAF(/"D']:[WQWK]UX7\$ZIK5E'#)<VL:LBS E"
M2P'(!![^M>:ZGHM[K?[,FG6]A \]Q%;0SB)!EG"O\V!WX)/X4>//B;I/BWX;
M:G9:':7]W<RP*UT/L[(ED P9O,<C;GC  )R: .X\5>.9O#WAO2+BWL!?:QJ[
M10V=HK;5:1P"22>BC/ZCIU'G_P 3-0\<1^%8;3Q1I6E-;SWL#)>:5(Y6)@P.
MR17YYYY'&>.];GCNWO;33/ OBBVM)KN#198Y+J&%2S")T4,X'?&W\,^F:QOB
M5\0-*\7>$8[?P]#>7ULEW!)<WOD-'#!AP I+@98D@8'N<\4 =YXQU5;#QAX-
MM3INGW1O+N6,37,&^2WPH.8FS\I/<^U4=?\ ''B&S^(;^%=%T:VOY)+!+F)I
M',8B)<AGD;/W  . ,DGK3?B#SX_^'O\ V$)O_0%IMN/^,B[L_P#4M#_TH6@"
MSX<\7^(T\;/X3\6V&GQ7LEK]KM;G3F<PRJ#@C#\@]?RZ<BF/XJ\6>(/$>L:;
MX2M-'BMM(E%O-<ZJ96\V7&2%6/& .F3FJ>M@_P##0WA@XX_LJ?\ ]J5Q$LW_
M !7WB]KBU\:?;3J!1I?"@5HF@"@1K*!T?')[Y)Z'- 'HWPU\4>)_%!U9]>BT
MB)+&Z>R,=DLH=9D/S;MQ(*X(P0:[BZN8;*SGN[AQ'!!&TDCGHJJ,D_D*X[X:
M:CX6ET>YTOPU%<VS6<N;NWO49;@2-_')GDDXZ^V.*J?%_4)QX6MO#UBQ%]K]
MW'81D?PHQ!=OIC@^S4 <#<:7>S?#Z3XEK$W]L_VQ_;,8P-PM@VP1G_9V#=]*
M]:\0^,K71?A_/XL@B-W;BVCGA13C?YA4+D]AEAGVS7.K\';,:<-/_P"$R\8_
M8O*\G[,-3'E^7C&S;LQMQQCIBL7P+K]MHWP]UOP]XDM)[U/#]XUA<Q1P>:6@
M=CM8KW7[W_ 5&,T =CX>U#QS<7=C-J]IH,VEWB;C)ITL@>W!0LI._(<$X7Y>
MYSTJ+P]JPN?BEXOTL:;I\/V)+0_:H8-L\^^/<?,?/S8SQP,"N#\-W^E+X^T>
M#X9WNIS:3*[G5K1TE-I F,@CS!\K9ST/7 ]JZGPOO_X75\02@&[R;#&>F?(&
M,T 6[[4/BD[W%S8:+X=AM8F;9;75Q))/*H/&"F$!(]?6M[P3XHC\9>$K'7(X
M# ;@,'B)SL=6*L >XR./:O&M%N_#E]:71^(/]N7_ (P\^0'2P]RK]?E6%(R%
MVGZXZ]L5U?PO\+Z7XE^#&GZ5KMD;BW6ZF<Q&1X\.LKCJI!]>] 'K5%<]X9\#
M^'/!S7+:#IWV0W043?OY)-VW./OL<?>/2NAH **** "BBB@ HHHH S[K_D-Z
M?_N3?^RUH5GW7_(;T_\ W)O_ &6M"@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH @^Q6G_/K#_W[%>$_$?78=5\1-:VBQK9V.8E** '?^)N/IC\/>O4_
M'_B3_A'?#<C0OMO;G,-OZ@GJWX#]<5Y#X&\-GQ)XCBAE4FS@Q-<GU4'A?Q/Z
M9KGK.[4$>WEE-0C+%5-EM_7X'IGPO\-?V1H9U.YCVW=\ PR.4B_A'X]?R]*\
MF\2:K/XB\37=YDOYLOEP*.<(#A0/Y_4U])E!Y90# Q@8[5\P0%M)UJ(SJ2UG
M=*9%]=C\C]*FJN6*B;994=:K4K2^+3^OR/>O"/@RP\-:?&3#'+J+*#-<,,G/
M<+Z >U;M_IUEJEJUM?6T5Q"PP5D7/Y>A]ZFMYXKJWCN('#Q2J'1UZ,",@U)7
M2DDK(\.I5J3GSR>I\Y^-/#?_  B_B%[.-F:UD42V[-R=I.,$^H((_*O1?!W_
M "1R[_ZXW?\ -ZYKXNZA!=>)K6UB8,]I 1(1V9CG'Y '\:Z7P=_R1R[_ .N-
MW_-ZYH)*HTCW<1.<\'2E/=M?J>;>!_\ D=M%_P"O@?\ H)KU"\X^.&GD]],.
M/SDKR_P/_P CMHO_ %\#_P!!->U^)_!T'B*XMKV.]N+#4+8$17,!Y ]#_P#K
M'6BDFXZ=PS&I&&(2F[)Q:^^YTM%<+_P@_B'_ *'K4O\ OC_[*GP^"M?BGCD;
MQOJ+JKABI3[P!Z?>K?FEV/']C2_Y^K[G_D4;R?7O%WC#5-*T[6GTFSTO8I,2
MY>1CWZ@XX/?'3UJ;_A!/$O\ T/NH?]^F_P#CE:.M^!AJ&M-K&F:O=:5?2*%F
M>#D2 <#(R.>!^55/^$)\1?\ 0\ZC_P!^_P#[*HY7?5?B=:KPY4J<U%66CC?7
MKK9E>[\-ZOHN@:U<ZCXHNM2A-A*@AF0A02/O<L?\FL32R$U#X<%CC-K*!GZ"
MM^;X>ZG?I]GU3Q?J5U9L1YD&W;O'IG)_E6UKO@S3]:TJSLT>2S>QQ]DF@.&B
MP /Q' _+K1ROHAK$TU[LI7O>[2M;1K:R[G1T5PG_  @_B$# \<ZECW4__%4'
MP-XA8$'QSJ6#Z*1_[-5\TNQQ^PH_\_5]S_R&_#[GQ#XQ8=#J1P?^!/7>UB>&
M/#-KX7TUK6WDDFDE<R332?>D8]ZVZ<$TK,G%5(U*KE';3\%8****HYPHHHH
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MM:%9]U_R&]/_ -R;_P!EK0H **** "BBB@ HHHH **** "BBB@ HHHH *0D
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M/:!N\;F3 /U42#\J[WP!X:T[1O 6FV<=O!*+FV2:Z<J&%P[J"Q8_Q#GC/;%
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M59;=U:4&0@$I@MQD+W/%+=?%'P39:H--N/$-JMT3M( 9E4^C.!M4_4C%>?\
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MPB\[[29!Y>S&0V[IBL?0O'_A;Q)?_8=*U:.>ZVEEB:)XRZCJ5WJ-P^F:\_\
M _AUO''[/%OH4MVT#2-(L<V-VTI.67([C(Q]*Z#3?%&K:7XHT;P[XST6Q6\N
M0ZZ;J5BP:)V5<,-I&Z,[2!QQSCI0!Z+1110 4444 %%%% !1110!GV7_ "%M
M3_WH_P#T 5H5GV7_ "%M3_WH_P#T 5H4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 9^A_P#('@_X%_Z$:T*S]#_Y \'_  +_ -"-:% !
M1110 4444 %%%% !1110 5GZ'_R!K;_=/\S6A6?H?_(&MO\ =/\ ,T :%%%%
M !1110 4444 %%%% !1110!GZ'_R!+3_ '/ZUH5GZ'_R!+3_ '/ZUH4 %%%%
M !1110 4444 %%%% !6?H7_("LO^N0K0K/T+_D!67_7(4 :%%%% !1110 44
M44 %%%% !1110!GV7_(5U/\ WX__ $ 5H5GV7_(5U/\ WX__ $ 5H4 <3XL\
M/ZEJGQ \%:E:VHEL=.>[-Y(74>6'C4+P3ELD'H#[UTVGZ#H^DS23:=I-C9RR
M_P"L>WMTC9_J5 S6A10!6.GV1U$:B;.W-\(O)%SY2^:(\YV;L9VYYQTS1>:?
M9:@L*WMG;W(AE6:(31*_ER#HZY'##)P1SS5FB@""[L[6_MVM[RVAN8&^]'-&
M'4_4'BJ^FZ)I.C*RZ7I=E8J_WA:VZ1 _7:!5^B@"L=/LCJ(U$V=N;X1>2+GR
ME\T1YSLW8SMSSCIFB\T^RU!85O;.WN1#*LT0FB5_+D'1UR.&&3@CGFK-% %>
M^L+/4[5K6_M(+NW;[T4\8D0_4$8J$VR:1HTL6D:="OD1,;>T@58E9@"0HZ*,
MGCL.:O44 <5\+O"MWX6\)%-3B2/5KZXDN[U4*D*['A1MXX '3C.:[6BB@"M:
M:?96#3M9V=O;FXE,TQAB5/-D/5VP.6/<GFFZAI6G:O (-2L+6]A!R([F%9%S
MZX8$5;HH IZ?I.FZ3"8M-T^ULXCU2VA6,?DH%%QI.FW=];WUSI]I-=VW^HGD
MA5I(O]UB,K^%7** *]]86>IV<EG?VD%W:R8WPSQB1&P01E3P<$ _A4DMO#/;
MM;S0QR0LNUHW4%2/0@\8J2B@#,T_PWH6DS&;3=%TZSE/5[:U2-C^*@58U'2M
M.UBV%MJ=A:WL 8.(KF%9%##H<,",\G\ZMT4 5+[2]/U.S^QW]C:W=KD'R;B%
M9$XZ?*1CBK,<:11K'&BI&@"JJC 4#H *=10!7O;&SU*SDM+^U@NK:3&^&>,.
MC8.1E3P>0#^%3@!5"J  . !VI:* *EEI6G::T[6%A:VIG?S)C!"J>8W]YL#D
M^YJM?>&]"U.Y6YU#1=.N[A?NRW%JDC#Z$@FM2B@!J1I%&L<:*B*,*JC  ]A5
M6/2--BU274X]/M$U"5=DETL*B5UXX+XR1P._85<HH **** "BBB@ HHHH **
M** (;O\ X\I_^N;?RJ/3/^059_\ 7!/_ $$5)=_\>4__ %S;^51Z9_R"K/\
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M\10\Y(8'J>CDYXY6X\$:)=:H-2E_M,WB[]DJZM=J4#'+*N),*I('RC X''%
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MK%Y;27$L^K71NKAIV4X)Z*N ,*,G .3[US0^$&BV]Q,=-UGQ#I=G,Y=["QU
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M44 %%%% !1110 4444 %%%% !1110 4444 9]U_R&]/_ -R;_P!EK0K/NO\
MD-Z?_N3?^RUH4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %9^L_\>47_ %]VW_HY*T*S]9_X\HO^ONV_]')0!H4444 9^H?\A#2?
M^OEO_1,E:%9^H?\ (0TG_KY;_P!$R5H4 %%%% !1110 4444 %%%% !1110
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M10!#=_\ 'E/_ -<V_E4>F?\ (*L_^N"?^@BI+O\ X\I_^N;?RJ/3/^059_\
M7!/_ $$4 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH S[K_D-Z?\ [DW_ ++6A6?=?\AO3_\
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M S_L-]_T%YO^_,?_ ,31]AOO^@O-_P!^8_\ XFM"B@#/^PWW_07F_P"_,?\
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M_P#B:-#_ .0/!_P+_P!"-:% &?\ 8;[_ *"\W_?F/_XFC[#??]!>;_OS'_\
M$UH44 9_V&^_Z"\W_?F/_P")H^PWW_07F_[\Q_\ Q-:%% &?]AOO^@O-_P!^
M8_\ XFC[#??]!>;_ +\Q_P#Q-:%% &?]AOO^@O-_WYC_ /B:/L-]_P!!>;_O
MS'_\36A10!G_ &&^_P"@O-_WYC_^)K/T6RO3H]N1JLP&#QY4?J?:N@K/T/\
MY UM_NG^9H /L-]_T%YO^_,?_P 31]AOO^@O-_WYC_\ B:T** ,_[#??]!>;
M_OS'_P#$T?8;[_H+S?\ ?F/_ .)K0HH S_L-]_T%YO\ OS'_ /$T?8;[_H+S
M?]^8_P#XFM"B@#/^PWW_ $%YO^_,?_Q-'V&^_P"@O-_WYC_^)K0HH S_ +#?
M?]!>;_OS'_\ $T?8;[_H+S?]^8__ (FM"B@#G]$LKTZ-:D:K,!LZ>5'Z_2M#
M[#??]!>;_OS'_P#$T:'_ ,@2T_W/ZUH4 9_V&^_Z"\W_ 'YC_P#B:/L-]_T%
MYO\ OS'_ /$UH44 9_V&^_Z"\W_?F/\ ^)H^PWW_ $%YO^_,?_Q-:%% &?\
M8;[_ *"\W_?F/_XFC[#??]!>;_OS'_\ $UH44 9_V&^_Z"\W_?F/_P")H^PW
MW_07F_[\Q_\ Q-:%% &?]AOO^@O-_P!^8_\ XFL_1+*].B69&JS*/+''E1\?
MI705GZ%_R K+_KD* #[#??\ 07F_[\Q__$T?8;[_ *"\W_?F/_XFM"B@#/\
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M^_,?_P 31]AOO^@O-_WYC_\ B:T** ,_[#??]!>;_OS'_P#$T?8;[_H+S?\
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M S_L-]_T%YO^_,?_ ,31]AOO^@O-_P!^8_\ XFM"B@#/^PWW_07F_P"_,?\
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M/_XFC[#??]!>;_OS'_\ $UH44 9_V&^_Z"\W_?F/_P")H^PWW_07F_[\Q_\
MQ-:%% &?]AOO^@O-_P!^8_\ XFC[#??]!>;_ +\Q_P#Q-:%% &?]AOO^@O-_
MWYC_ /B:/L-]_P!!>;_OS'_\36A10!G_ &&^_P"@O-_WYC_^)H^PWW_07F_[
M\Q__ !-:%% &?]AOO^@O-_WYC_\ B:/L-]_T%YO^_,?_ ,36A10!G_8;[_H+
MS?\ ?F/_ .)H^PWW_07F_P"_,?\ \36A10!G_8;[_H+S?]^8_P#XFC[#??\
M07F_[\Q__$UH44 9_P!AOO\ H+S?]^8__B:/L-]_T%YO^_,?_P 36A10!G_8
M;[_H+S?]^8__ (FC[#??]!>;_OS'_P#$UH44 9_V&^_Z"\W_ 'YC_P#B:/L-
M]_T%YO\ OS'_ /$UH44 9_V&^_Z"\W_?F/\ ^)H^PWW_ $%YO^_,?_Q-:%%
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M6X#D#<VXGGG/Y>E)X[O=$?XJI8>-KF5O#L>F++! COY*S%R-THCYSP<$\=*
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MBBB@ HHHH **** "BBB@#/NO^0WI_P#N3?\ LM:%9]U_R&]/_P!R;_V6M"@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/UG_CRB
M_P"ONV_]')6A6?K/_'E%_P!?=M_Z.2@#0HHHH S]0_Y"&D_]?+?^B9*T*S]0
M_P"0AI/_ %\M_P"B9*T* ,#QCK^H>&]"^WZ;H-UK=QYJI]DMBV[!SEN%8X&/
M3O7F.I?'?7-&A2;5/AOJ-C$[;5>ZN'B5CUP"T(R:]KDD2&)Y975(T4LS,<
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MSCYQ7?Z]<O9>'=3NH\[X+261<''*H2/Y5Y9^S?$B^ ]2F ^=]3="?811D?\
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M_$4?\+>\7_\ 01_\@1?_ !%<)11]<J^7W+_(/[&P7\G_ )-+_,[O_A;WB_\
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MM[Q?_P!!'_R!%_\ $5PE%'URKY?<O\@_L;!?R?\ DTO\SN_^%O>+_P#H(_\
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MA6?H7_("LO\ KD* -"BBB@ HHHH **** "BBB@ HHHH S[+_ )"NI_[\?_H
MK0K/LO\ D*ZG_OQ_^@"M"@#C_&'A.]\0^(_"FHVLUO'#I%Z;B=968,R_+PN
M<GY>^*["BB@#DXO"]ZGQ7F\5&6W^PR:0+ 1[CYGF>:'SC&-N!ZY]JCU'PG?7
MGQ3T?Q1'-;BRLK*2WDC9F\PLV[! QC'S>M=A10!YQ#X0\7>'/$FN7OAB]T:2
MRUFX^U2IJ2R^9!(<YV[/O#D\$CL/K8\)^"_$'AZQ\3B76[>34]5G-Q!?+#G;
M(4^\T9&!\V> 2,5W]% 'F&H^#?'/BZ2PLO%6HZ!'I=I=)=%M-BE\^8KG ._A
M<Y/(]>]:WBCP;J\WBF#Q7X5U*VL]82W-K-%=QEH+F/.0&V\C![CT'3'/<T4
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M"@ HHHH Y[QGK\OAW0&N[=%:XDD$4>X9"DY.3^ ->4GQWXF))_M609](T_\
MB:[[XJ_\BO;_ /7XO_H+UX_TIH1T/_"=>)O^@M)_W[3_ .)H_P"$Z\3?]!:3
M_OVG_P 37/=:,XI@=#_PG7B;_H+2?]^T_P#B:/\ A.O$W_06D_[]I_\ $USV
M1ZT9&,T =#_PG7B;_H+2?]^T_P#B:/\ A.O$W_06D_[]I_\ $USU&<4 >JZ+
MX@U7Q+X/NX+2]:+7;/YPZJN9EZC@C'/(^N*Q/"?Q)U)-5BL]<F6:VF?89F4*
MT3'@$XQD9Z^E<UX<UJ30-;M[^/)13ME0?QH>H_K]16G\1="BL]3CUBQPVGZD
M/,5EZ!R,G\^OYUTX=0E>G);G/7YHVG%GN-%<=\.O$G]N: +>=\WMEB.3)Y=?
MX6_H?<5V-<TXN$G%F\9*2N@HHHJ2@HHHH *\-\3?'B]LO$%Q::)IUG+9V\AB
M,MSN+2E3@E=I&T9Z9S7N5?//B_X):Z-<NKK0!!=V4\C2K&THC>/)R5YX(]#F
MKA:^I,K]#V+POXRLO$WA >($1H8T5_M$1.3$R#+#/?U'L17 Q?&FZ.J@RZ7
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M[APNTLVY@064$;LD$," <?70\%^ _$]WX^?QSXV:VBOUC*6]G P81DKMYP2
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M/^1KS2O2_C3_ ,C>?^N,?\C7FE<F,^->B/K<C_W7YL****Y3V HHHH ****
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MB)'!F/S%@#SC ZXK5\>>,]2TWP%H?B#0N);ZZM&$1"GS8Y%+>7D@@9X&1R*
M/1**\]N-4\3>"/#.K>)?%>LVVHJL"M%I]O:K$D$S, $5Q\SKD@9//4U2BL/B
MK=:*FMKXFL(KQXA.NC?V<ACY&0AE)W9[?7OWH Z?XB>)+SPCX$U+7+"*"6YM
M?*V).I*'=*B'(!!Z,>]5_$WBN]T6^\)P6\-NZZQ?);SF16)12N<K@C!^N:XO
MQCXJ7QI^SC?ZV(1#+*(4FB!R%D6YC!Q['&1[$5K^/?\ D+_#C_L+1?\ H(H
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M)KF/%?\ R-NK?]?3_P ZKZ$]ZFO6+:<,WGG+Y8[$]\^V,Y]J:;3NA-75F/\
M#^JW7@_Q2))T9/*<P747JN<-^74?2OH.&6.>%)HG#QR*&5AT(/(->+?%1+%?
M%*&W(^UM"#=!>@;^'\<?IBNZ^&+W[>#H?M@_=!V%L3U,?O[9SCVKKQ*4X1J]
M3EH/EFZ9V5%%%<1UA7@OQ=^(NO:?XKET+2+R2P@M$0R218#RNRANO8 $#COF
MO>JX#QY\*M-\;7B:@+J2PU!4"-*B!UD4=-RY'(]<U4&D]29)M:&-\&?'NI^)
MH[W2=8F^T7-HBRQ7! #.A."&QU(..?>J^M^.-9FUB?[+=-;012%8XT Z XR<
M]36'9^%=<^#6NQ^(BRZIHC+Y%ZUNI5XXV(^8J3V(!SGVXS783:;X+\32'5['
MQ';013?/*@E08)ZY#$%3]:Z*4J<9-R6AYN8TL35IJ-!V:>NMC.\=+#XN^$,N
MM7<2)J&G'?'*HP<A@&Q[$'IZX]*\@TCXB^+-%GBDM];NY8XL?N+F0RQL/0AN
MWTQ7JGBG5(O%5E%\/? :I=QG#7MX&_=1HK9Y?OEL$D?09SPS2/V?+:*>*36-
M;>XC4@R06\.P-[;B2<?@/PJ&XZ]CKI1J*$5)W:6K\SU[1]0&KZ)8:DJ&,7=O
M'.$/\.Y0<?K7C6L_\G-Z=](__1+5[?##';P1PPH$BC4(B*.% & !7B&M<?M-
M::3QD1_^B6K.'4WET/3O%7CK0O!K6JZQ/+&]SN,:QQ%R0N,GCIU%96C_ !<\
M):YJUMIEG=7)N;E]D0>W906],]JZV^TG3M4"#4+"UNQ'DIY\*OMSUQD<5XCX
MBL;/3_VAM M["U@MH@8"8X(PBY^?)P._2B*3!MH]4^(6M_\ "/\ @35K]7VS
M>28H3WWO\JX^A.?PKD/A%X6B;X5W,=RG_(:\TN2.?+(V+^@)_&LC]H/6MMII
M.A1O@RNUU*/8?*OZEORJ72OCCX9TG2+/3H-)U3RK6%(5^6/HH _O>U-)\N@F
MUS:B_ C4);,Z[X7NSB>SG\U5/UV/^JK^=/\ VAAGPWHX];QO_19KCO#_ (QL
M&^.$>MZ?'-;6.J2^3+'-@$&10"3@D8W@&NQ_:'_Y%K1_^OQO_19IV]],5_=+
M&E?''PE9:196DD>I&6"W2-ML"D950#CYO:N:\4>(-6^,=Y9:)X=TJY@TN*;S
M);J=< '&-S$<  $\9))->J#PII&N>!H;":RMT^U6"+YJ1*&5B@PP..H.#7GG
MP:URYT'7M2\"ZN=DT<KM;@G@.OWU'L1\P_'UI*VZ&[[,V?C+8Q:9\)[.P@SY
M5M<6\*9]%4@?RKL?AY_R3OP__P!>,7_H-<O\=O\ DG8_Z_8O_9JZCX>?\D[\
M/_\ 7C%_Z#2?PC7Q&!\;?^29W?\ U\0_^ABM7X6?\DRT'_KW/_H1K)^-Q ^&
MET"<9N(0/?YQ6M\+1CX9:#G_ )]__9C1]D/M'G/QP=8_&_A:1V"HH#,Q.  )
M5R37JK>.O":J6/B32L#_ *>D_P :\I^.,$=SXU\+V\HS'*/+< XRIE4']#7;
M?\*6\#Y_Y!DW_@5)_C3=K*XE>[L>>>.]9@^*'CW1-"\/[KFUMF(DN I"G<1O
M;_=55Z]R?I7T'6/H/A;0_#,+1:/IL-H'^^R@EW^K')/YUL5,G?1%)=PHHHJ1
MA6?K/_'E%_U]VW_HY*T*S]9_X\HO^ONV_P#1R4 :%%%% &?J'_(0TG_KY;_T
M3)6A6?J'_(0TG_KY;_T3)6A0!5U+4;72--N=1OI?*M+:,RRR;2VU0,DX )/X
M4ZPOK?4].MK^SD\RUNHDFA?:1N1@"IP>1D$=:P/B/_R3;Q'_ -@^;_T$U/X$
M_P"2>>&O^P5:_P#HI: +MKXATN]U^^T.WNM^I6"H]S#L8; X!4[B,'((Z$UI
MUYCX7_Y+[XZ_Z];/_P!%1U'IWCCQOXBU77M*T+1M*\S3-3N+;[=>O(D C1L(
MI526:0X8DC '''- 'J5%<5X+\;W.M66M1Z_:1:?J6AS-'?+$Q,> "0ZYYQ@'
MUZ9[UB:;XQ^('B:P;7_#^@:0NBEF-O;WLTBW5TBDC*D?(N<=_P!>M 'J%%<+
MX@\>7]G_ &!IFD:,9O$.M0B:.SNG,8M5VAF,IZ\<C'^R?QSI/&GC#PIJNFQ>
M-=-TAM.U"X6V2^TEY-L,C?=#K)R>_3L#Z4 >ET5Y[XF\;^(--^(<'A;1='M]
M0>ZTP7,1=BGER&5E+2-G'EA5)P!DG !YK+'Q!\:Z7XD;PKJWANQO=;N(EEL9
M-.E=;9E)(9G+Y(5<')]L8Y!H ]6HKS_0?%WB6#QPGA7Q=8:;'<75LUS9W.FL
MYC<*>5(?G. >>.G3FJ]UXW\5W/C[7_"NA:-8W,EE]G:&ZN&9(H5>(,QF()+'
M<0%"@'&?2@#TBN:\/^+X];O?$4$EK]ECT6\:V>4R[A(%&2^,#;].:R/"_C+6
MI/&%SX1\5V%E;:LEO]J@GL68P7$><' ;Y@?KZ'ICG/\ A^P76OB*Q57 U>0[
M6&0?E/!'I0!WNCZUIWB#3(M2TJZ2ZLY20DJ @$@X/7GJ*OUYMX8\<6>F_!2W
M\67FFV=E$B2G['IT7E1EO.9%5%R<9.,_4FI++Q!\252TU2_\.:2^EW#Q[[.U
MED-Y C$?,V?E8C.2!S]* /1:*X_7+OX@R:O/;^'=,T**QBV[+K4YY&,^5!.$
MCY7!)'/7&>]4_#GBWQ#XCTC7;%+'3[/Q1I,_V=TF9VM68\ALK\V" W'7IZT
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M^]?YA_;."_G_ /)9?Y'"45W?_"H?%_\ T#O_ "/%_P#%T?\ "H?%_P#T#O\
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MA6?H7_("LO\ KD* -"BBB@ HHHH **** "BBB@ HHHH S[+_ )"NI_[\?_H
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M3W..E=!XVTVZU#X%ZA::=X6;3+J8QLND6<2NR8N4.=L8P25&XX'&3GI7J-%
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M-8^$5G??8IXI)I;>:2 H=T60<@CM@G%<WX<^-*:#X;T[26\-7DS6=ND)D$N
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M@G_9/<@&KXL\1V'Q6.D>'?"BW-[%]OCN;R^^SO'%;QIG.2P'S'/'T]Z]DHH
M\XN/^3C+7_L63_Z4-3M3!_X7_HAQQ_8DW_H9KT6B@#SK7_\ DNOA'_L'W?\
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M+"]OSL,0BQN)X_3WKW>B@#ROX(1)%8>*%AL[BSA_MJ4Q6UQGS(D*J55LDG<
M0#DDUZI110 4444 %%%% &?9?\A;4_\ >C_] %:%9]E_R%M3_P!Z/_T 5H4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9^A_\@>#_@7_
M *$:T*S]#_Y \'_ O_0C6A0 4444 %%%% !1110 4444 %9^A_\ (&MO]T_S
M-:%9^A_\@:V_W3_,T :%%%% !1110 4444 %%%% !1110!GZ'_R!+3_<_K6A
M6?H?_($M/]S^M:% !1110 4444 %%%% !1110 5GZ%_R K+_ *Y"M"L_0O\
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M;2JD\E>&_(>YJWK_ ,)?"T^EW^H7TVHR:@D4DPU.XOI&DB(!;=C(7 QTQVH
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M.C7?'HF:]_HH ^?_ /A$O$/_ $!KS_OW1_PB7B'_ * UY_W[KZ HIW ^?_\
MA$O$/_0&O/\ OW1_PB7B'_H#7G_?NOH"BBX'S_\ \(EXA_Z UY_W[H_X1+Q#
M_P! :\_[]U] 447 \VT+1M2\+>#[R_@T^:76[L;(XE3+1+VS^K'\!6#X4^'F
MJ7NK17>LVS6]G&_F.LQ^>8]<8]">I->ST5K"M*$6H]3*=)3DF^@=!@4445B:
MA1110 5R]]XCFMM7NXC<6EO;VLT4'E21,\DQD4$,""-JY;:#@C*G.*ZBH);*
MTGGCGFM89)H_N2/&"R_0GI0!RK>.HA:6++"SS.T?GJJ<$%<OLRPZ' Y_#-7K
M?Q;:ZAK-K8V!WJTA65G7'RF-V4J<^J$'/3!K9?3+"0.'L;9A)M#AHE.[;TSQ
MSCM4B6=K'(TB6T*R,=Q94 )/3.?Q-/01R]GXYMIKN]CDB+H)56R$ W/.I;9G
M!P,[AGKC:RFDNO'$9MI9K.!\)-&B>8H_?*PC;*_,,?+)W[UU1MK<B,&",^4,
M1_(/D^GIT'Y5&=.L6#@V=N0X"MF)?F & #QSQQ1H!B1>,]->4 &5P[*%"Q8*
M9V#YLGGYG4<>OH,TFG>,;6^:U4PS)+=1QR)!L&Z,,"26;=@CITY]O3=%A9@Q
MD6D ,1!C_=CY"!@$>G'%(--L55%%E;A48.H$2_*PS@CC@\GGWHT&<M>>+KFP
M\27=O<+'_9]O*R-B!L[%@64L)-V"V6 V;<X.>QJ])XWTJ)?WB7:N54K&8?F?
M=GH.IQM.3T]"<BM][6WDW>9!$VX[CN0')QMS^7'TJ'^R]/V%/L-MM*JN/)7&
M!T'3H.U&@&2?&FE>9.@%PWD%_,*QY"J@RS=>G;USVIUCXE6YUQ]/EMI8E<)Y
M#%1]XHS%6()&<*3QQQUK86RM4+E+:%2Y)8B,#=GKGUS2Q6=K;JBPVT,83[H1
M -O&.,=."?SI <[H?BE]2U;4K&81JT(>2V"J07C5RN[.3D=!G@YW<8 )IVGC
M1[6*W?57@N!<6D=POV&)MT;/C]VRECR>2#D9VMQ76QV5I#*TL5K"DCDEG6,
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MQCYE /O7116UO"D:Q011K&"$"( %!ZX]*:MC:*'"VL $F[>!&/FSUSZY[T:
M8<_C73+9I%FBNU9#M \K.]LJ"JX/)&]<]N>,U%J7C2VMK">6W@G\W9-Y#31[
M4=XUR1U!SVQUX/I6^VGV30^2UG;F+&-AB7;CCC&/8?D*<]E:2%2]K"Q7.W,8
M.,]<?7O1H!@2^-=.MRS3+<*%'S1^5\\94R;]W../*;IZ<9R*Z:J%WHUC>W-M
M/-;HS6\AE4;%(9B&&3D<XW$_6K]( HHHH *S]9_X\HO^ONV_]')6A6?K/_'E
M%_U]VW_HY* -"BBB@#/U#_D(:3_U\M_Z)DK0K/U#_D(:3_U\M_Z)DK0H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,^R_Y"
MVI_[T?\ Z *T*S[+_D+:G_O1_P#H K0H **** "BBB@ HHHH **** "BBB@
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M_I0!H?#S5M1UWP!H^IZL,7MQ!ND.W&_#$*V!_>4!OQKIZ1$6-%1%"JHP% P
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MH_L2P_N2_P#@1)_\50!H45G_ -B6']R7_P ")/\ XJC^Q+#^Y+_X$2?_ !5
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M .!$G_Q5']B6']R7_P ")/\ XJ@#0HK/_L2P_N2_^!$G_P 51_8EA_<E_P#
MB3_XJ@#0K/T/_D#6W^Z?YFC^Q+#^Y+_X$2?_ !5-30=.C0(D,BJ.@6>0 ?\
MCU &E16?_8EA_<E_\")/_BJ/[$L/[DO_ ($2?_%4 :%%9_\ 8EA_<E_\")/_
M (JC^Q+#^Y+_ .!$G_Q5 &A16?\ V)8?W)?_  (D_P#BJ/[$L/[DO_@1)_\
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M2_\ @1)_\51_8EA_<E_\")/_ (J@#0HK/_L2P_N2_P#@1)_\51_8EA_<E_\
M B3_ .*H ++_ )"NI_[\?_H K0K-&@Z<K,RPR!F^\1/)D_7YJ=_8EA_<E_\
M B3_ .*H T**S_[$L/[DO_@1)_\ %4?V)8?W)?\ P(D_^*H T**S_P"Q+#^Y
M+_X$2?\ Q5']B6']R7_P(D_^*H T**S_ .Q+#^Y+_P"!$G_Q5']B6']R7_P(
MD_\ BJ -"BL_^Q+#^Y+_ .!$G_Q5']B6']R7_P ")/\ XJ@#0HK/_L2P_N2_
M^!$G_P 51_8EA_<E_P# B3_XJ@#0HK/_ +$L/[DO_@1)_P#%4?V)8?W)?_ B
M3_XJ@#0HK/\ [$L/[DO_ ($2?_%4?V)8?W)?_ B3_P"*H T**S_[$L/[DO\
MX$2?_%4?V)8?W)?_  (D_P#BJ -"BL_^Q+#^Y+_X$2?_ !5']B6']R7_ ,")
M/_BJ -"BL_\ L2P_N2_^!$G_ ,51_8EA_<E_\")/_BJ -"BL_P#L2P_N2_\
M@1)_\51_8EA_<E_\")/_ (J@#0HK/_L2P_N2_P#@1)_\51_8EA_<E_\  B3_
M .*H T**S_[$L/[DO_@1)_\ %4?V)8?W)?\ P(D_^*H T**S_P"Q+#^Y+_X$
M2?\ Q5']B6']R7_P(D_^*H T**S_ .Q+#^Y+_P"!$G_Q5']B6']R7_P(D_\
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,<$^H% &A1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img11029722_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &? M # 2(  A$! Q$!_\0
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M_P ^,7ZT?\(MI?\ SXQ?K6M10!D_\(MI?_/C%^M'_"+:7_SXQ?K6M10!D_\
M"+:7_P ^,7ZT?\(MI?\ SXQ?K6M10!D_\(MI?_/C%^M)_P (OI7_ #XQ?K6L
MV=IQUKRCXF-J&K?$KP;H6F:]J6EF7S[R_CL)@@>VC &""#R7.,CT- 'H(\+Z
M4>EE%^M+_P (MI?_ #XQ?K7(#XV^';71-3U%X]2\G3+K['=*UL3(C!@A8@'[
MN2.:W_'?Q"TCX<^'7US6C<1Z>A57>&!I"N>A('0>YH T/^$6TO\ Y\8OUIO_
M  C.D_\ /E%^M8'B;XHZ9HL.N0[+X3:=IZ7[S0VAD7RI,A73D!]IY*YK#N/B
M=J'A_7O"GAC^SK_Q#J%]9_;+S48;81KY*KRX3=PQ9E&.@S0!WG_"+Z4?^7&+
M]:7_ (1;2_\ GQB_6N6T'XU>'=?NM-MK<7T<U_)/&HFM641&$'>9&Z(.#C)Y
MJ>T^,'A^\O\ 3H$-TEKJ4YMK+4)("MM<2@$[$<]2<''&#@T =#_PB^E?\^47
MZT?\(OI7_/E%^M9_C#QL/"TNFVL6GW&I7^HR/';P1$(OR*68O(WRH !U/7.*
MP=%^,VG>(O#ND7VG6%S<ZAJDT]O!IA91()(2PF#-G:%7;RV<<CUH ZT^&-*'
M6RB_6E_X1?2N/]"BY^M>;ZS\8];CUSP;8V?A2\MVU:^N;6YM[V6.*1#"K$A<
MG#*<!@X."*J/\6;/PO8>/=:LO#NN7[Z7J:Q:G;2W"Y4[%S)$KMA8P"#@>A-
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MP=G3ODU*OA+Q#'\0?%GB(16KO<:7%8:63-TVJS,",?+F0CGT45Z5M'I2[0:
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M<11[&4J,E6 X.1S7T0OW16N$Q=/&4E5I;%4:T*T>:#%HHHKL-PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)\4_\
MB_??[G]16M63XI_Y%^^_W/ZB@ \+?\@"Q_ZY_P!36M63X6_Y %C_ -<_ZFM:
M@"AKFD)KVDW=A)//;1W,;1-);,%D"D8."0<''M7-VWPKTRU\+Z5HJ7NHXTK_
M (\K_P Y1=0<8X8+CIQR*[.B@#DI_AEHSZ-INGV_VBP.FL9+6\M9=L\;L"';
M<0<ELG.1SFMOP[X?L_"^D6^FZ?&8[2!=J*Q))YR6)/)))))/4FM*B@#G_'W_
M ")NKG_IW85M6?\ QYP?[B_RK%\??\B;J_\ U[M6U9_\>D'^XO\ *@":BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ II;!Q2FN3\9?$SP_P"!8R=4U!%N#]RUB^>5CZ!1S6=2I&G'FF[(F4E%
M7;L=5OKG/%GQ"T#P3:&;6-1BM2>$BSND<GH%4<DUY]_;WQ"^)C%='LQX-T5_
M^7^]7=<R+ZJG;\:Z+PC\%/#_ (;NOM]VLFNZR>6U#4F\Q\^P/ KS_K%:O_ C
M9?S/;[MS#VDY_ M.Y\V?'+6=8\=ZU!KAT?4K70MGE6?VJ(@'!Y;';/O7<?!/
MX?>.]0\("2U\3W7A?3VD)@M3;!R?5ANZ U],M;QR+L>-&3^Z1D5(%"C &!7%
M3RE>V=:I-MOY'/'!KVG/*5SR3_A4'B^;F;XF:IS][RX47\J5O@=K,W^M^)/B
M0CMY<@6O6P!BEKT/J-#L_O?^9U>PI]OQ9Y'_ ,,_R2?\?'CKQ-/_ 'MUV1FL
M?Q=^S+;ZEH=Q%9>(=5GOE&Z :A=-)$&'J*]UIK 9![T2R_#233C^+)^K4GI8
M^6/AW^RUJ;:NUQXK9;:RC! AM)_GE8]]P' KU.']FGP2@^:WO93_ --+QS_6
MO4Z?65#*\+0AR\O-ZZBIX6E3C9(\RC_9P\ +]_1/.]?,N)#GZ_-5B+]GKX>0
MYV^&+7GKEW/\VKT6BNM8/#K:FON1K[&G_*CA%^"/@:-0J>&; 8Z9CS_,UXWJ
M?[)%S-XFD:TUB*'19)2^UE8S1H3G8.Q] <\5]/4W:.U85<OPU>W-#;Y&=3#T
MJEDT<GIWPH\(Z?;00IX=TV0QJ%\R2U0LV!U)(Y-7O^%>^&.O_"/Z;G_KT3_"
MN@I:[%1IK111JJ<%HD8B>"= C7:NBZ>J^@MD_P *FA\*Z/;Y\O2[-,]=MN@_
MI6K15>RA_*BN6/8\N\??L\^&O'FH1WSF;2[M0$=[(*JR*/52,9]ZZ_PKX!T3
MP=HL&EZ?91_9H1PTJAW8]R2>I-=%16$<+0A4=6,$I/J1&C3C+F2U*@TFQ_Y\
M[?\ []+_ (4?V38_\^5O_P!^E_PJW173RKL:<J[%3^R;'_GRM_\ OTO^%8/C
M3X;Z%XZT.32]0M%2)B'66!0DD;#HP(%=3142I0G%QDKIB<8R5FCSGX:_ W0O
MAG>3WMG)/>7\R^7]HN",JN<X ' ^M>BC@4M%%*E"C!0IJR%"$::Y8JR"BBBM
M2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K)\4_\B_??[G]16M63XI_Y%^^_W/ZB@ \+?\@"Q_ZY_P!36M63X6_Y
M %C_ -<_ZFM:@ I,TM<!\8'U%=)TL6L%W<Z:VHQ#5([!2TWV7G<5"_,1G;G;
MSC- '?;AG&>: P/ /-?/7A76+GQ-X@T_PX]Q=2>$Y]6OUMI'D9))XH8U*PEL
M[B [,>N?E&>E>E_!G6+K6/!:/=RO<O;7=U9QW$G6:.*9T1R>YV@#/?% &WX^
M_P"1-U?_ *]VK9M,?9(/]Q?Y5RWQ,OKJW\-W\$%C+.LML^ZX4C9%TZ@G)_"M
M:UM]7^SPXN+3&Q<?NF]/K3MYBN;/XT?C65]GUC_GYM/^_3?XT?9]8_Y^+3_O
MTW^-/E\Q7\C5_&C\:ROL^L?\_%I_WZ;_ !H^SZQ_S\6?_?IO\:.7S"_D:OXT
M?C65]GUC_GXM/^_3?XT?9]8_Y^+3_OTW^-'+YA?R-7\:,^]97DZRO_+>S/\
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MS>1J45E^=K'_ #ZVO_?X_P"%'GZO_P ^MK_W^/\ A1R>@^;R-2CBLO[1J_\
MSZVO_?X_X4OG:Q_SZ6N/^NQ_PHY'Y!?R-04OXUE"XU93_P >,'X3_P#UJ7[5
MJO\ SXP_]_O_ *U'+YBN:GXT?C67]JU7_GQA_P"__P#]:C[5JO\ SXP_]_\
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M?^1?OO\ <_J*UJR?%/\ R+]]_N?U% !X6_Y %C_US_J:UJR?"W_( L?^N?\
M4UK4 %4M4T>SURSDM-0MHKRTD^_#,@93^!J[10!BOX.T:31UTI].MGTU3E;4
MQ#8#Z@>M:=K:16,$<,*+%#&H1(XUVJJCH *GHH Y_P ??\B;J_\ U[M6U9_\
M>D'^XO\ *L7Q]_R)NK_]>[5M6?\ QZ0?[B_RH FHHHH **** "BBB@ HHHH
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MOP^'C]3PWPK63[O^6_YG/F>:XC.Z_-7>B[=/+_,Z"SLX[&&.&%%BAC0(D:#
M51P *L4BTZOJ4DEH<844450!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %(32TQ\8R: !I H)/ '7->)V?_ !>KXH&[;]YX1\-RE80?NW=WW;W"
MUN?&CQ9>0V]EX2T$Y\0:XWDJR_\ +"'^.0^G'2NR\%>$;3P1X:L=(LEQ';H
M7[NQY9C[DYKT*?\ L]+VK^*6WIW_ $/.J?[355-?#'?U[&\J[33Z:.N*=7G>
MIZ 4444QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !63XI_Y%^^_W/ZBM:LGQ3_R+]]_N?U%
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M?LL*]MSV#P:]F_A72&T^#R+)K:,Q1XQM7 Q6XO<U#:VL=C;Q00H(X8U"HJ\
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M_P"1-U?_ *]VK:L_^/2#_<7^58OC[_D3=7_Z]VK:L_\ CT@_W%_E0!-1110
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MG5[>W;:L<I53SW ZUTUG_P ><'_7-?Y4 34444 %%%% !1110 4444 %%%%
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M]E7K6V'_ 'M25?Y+T1X%/WI2FQ]%%%>D= 4444 %%%% !1110 4444 %%%%
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M;(YK*3SXV/NH^9?Q&*Y?P3\59/%7B&TGO+B31M)OEF;2K62U&R\CCR"YF/\
M%P6"CMZT =__ ,(1H4FCVNF7&F6][96K>9%'=H)=KY)+Y;//)YJ_HNBVNAV)
MM;12L1D:0[CDY8Y-<;X'\:ZIXD\>>*M.NX4@TVRBMI;)-N'*R!B6;Z[<UZ$N
M<<]: "L6S\)Z59VTEN+*.6.1I"4F4/\ *[[V09'"[N<=.*VZ* .'\4?"70/%
M6L6NI74<\,\&<"UD"*Y+!B3QG.X Y!!K9;P3H=QI=C8W6F6U[;V7_'N+F-9#
M&?[P)'!]ZW'ZBO/;#QEJ5C\0O&.GZK=0R:-IFGPW\ BBVM$K;]P8Y^8_)^M
M':Z+H]MH=C'9VBE8HRS#<<G+$DD_B:T*\J^&_P 2+KQAX@A.IRR:6;ZU-YIV
MD26NT26Y/$OFG[S8QD# &:]5H *R?%/_ "+]]_N?U%:U9/BG_D7[[_<_J* $
M\+_\B_9?]<_ZFO&_B)=^'Y_B-J=IXAU3Q(&M[>":VL]"2=(XP0<N[1#YG)]3
MT %>R>&.?#]E_P!<_P"IKRCQ^VI>%_B=%XDN=*\0:[IA@>VCM=&A::,1F$@J
MZ*1\QD_B/ % &A\*?B[::I=6'AF=-9FU"8W#03ZG9O"Q@C/REV8#+$'M7KA7
M=WQ7!_!JQUX>!--E\50^5J_F2R11R$/+;P,Y,<;-_>"$ X]*[T#:,4 )MH50
MO2G44 <_X^_Y$W5_^O=JVK/_ (](/]Q?Y5B^/O\ D3=7_P"O=JVK/_CT@_W%
M_E0!-1110 4444 %%%% !1110 4444 %%%% "'H:\V^.6N2V'@MM,M6Q?ZQ,
MMC"HZ_,?F/Y9KTENAKR*^4>-/CG:VH_>67ARV\Z3^[Y[]!]1Q7E9C-JBJ<7[
MTVHKY[_<CU<M@O;^VGM33E]VR^;LCT;PKHD?ASP_I^F1*%CM8%C&/4#FL+XN
M^,/^$(\"ZGJ*'_2V3R+51U:9_E4#\\_A77K^[7KFO'?%W_%P_C3HWA\?O=*\
M/)_:-ZO56F/^K0^XZ_G5XB7L*"A3W=HK\OR/'Q%24KR>\G^+.R^$O@L^"? >
MFV$G-VZ?:+ICU,S_ #-^O'X5VN*11\HI:[:=-4H*FMD.*Y586BBBM2@HHHH
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M5+9=TUJC9D0=B1VJW8:Q9:I-=16EW#<R6LGDSI$X8Q/C.UL=#[4 7:R?%/\
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M">GX5W(///6OMK8JCAO84*_[Q[U.2/\ Y*G=+Y\S]#QW3A7J>TK0M'^7F_\
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M4+G^SXKB*\ETO"F&XFB&(V8GG Z[>Y H L_"6,KX+MY#J5GJAFEDE,NGP>1
MA+'Y$3JH7ISS79UD>&-!'AW3WM_/-S))-)/),R!"[.<DX' _^M6O0 4444 <
M_P"/O^1-U?\ Z]VK:L_^/2#_ '%_E6+X^_Y$W5_^O=JVK/\ X](/]Q?Y4 34
M444 %%%% !1110 4444 )TJ)KJ*.18WD1';HK, 3^%2G.#CK7QEXVU35Y/&F
MI/>SW"W\=RRJ%8EEP?E"@>W:@#[-W9S4%Q<QVZEI76-!U9F 'ZUY?HOA7QYX
M@TFSDU'Q0=+1XES!;P#S<8_B)[U'KWPMT70]$O\ 5M:U'4M6%G"TI^TW)"D@
M>@K.I*-.#G)V2U*C&522C!:O]3$U3QEHM_\ &MK_ %*_ACTW0K7R[<YW>9,W
M4J!UP*Z;4_CQI4%K//8Z9J6HP1(7:5("D>T=]QJI\#_ ]E:^";34[W3X7O[Y
MFN 98PQC0GY5&>@ J+XSW4NNWFC^ =, CDU>3?>-&,".V4Y;./7%>32DJ&'=
M=:N;O_X%M]QUYE5Y9^R_D]U>JW^]GA>NV.O>*+BY\:W]A,MIJDI^SN?F"QCA
M1CL*](^#GA/Q7J6CW1L]9GT#2Y)!M7RLM*<<E<_='\Z]U\O3?#^DP6SF&VLH
M46.,28"@ 8'6IHM4L/L8GCN81:@<2*X"BMZ-6CAX^QE47,M7KKY]3@I4IP@K
M+<X8?!J&\PVK^(M9U1NX>X\L'VP.U:=C\'O"&GD.-%BN7ZE[EC*3^9-+?_$J
MT:1K72+6;6+K./W*_(#[M5;^Q?%'B;!U*^71[5O^7>TY<CT+=J\FIG]&I)TL
MOIRKS7\OPKUF_=_-GI+!3BN:NU!>>_W;FE>:MX7\'*4$=I;2+T@MHU+?D!7.
M^(-4U[QMI-Q;:?I,EM8.,M)<-AW'7 %=9HO@?2-#P\-J))AR9ICO<GZFMM,[
M3T SQBN*OEN9YQ2E2QM94J<E\,%=^CD]_DD:1KT,-)2HQYI+K+]%_F> ^$_!
M6J:MKL<,]M<6D"-^^D(*$+Z UZS:?"W0+5@S6AN&_O3N7/ZUU.W"CN?6I:XL
MBX(RO):4J<HJK)N]Y)/Y);'1C<XQ.,ES)\B[)F=:^']/LL""RMX0.FR,#^E7
M?+P, *!]*DHK[NGAZ-%<M."BO))'C2G*3O)W(A&5Z=*-G<TYF"Y).!W->.ZC
M^UA\.]-\4OH4VJR"9)/)DNEB)@1\XP7^O>NZGAZM>ZI1;.>I5A2UJ2M<]?/R
MUQ7Q(^+WAKX6Z>)]9O<74G$%A!\]Q.W8*@YY]37E7C+]HS4O%S7-A\/8X+>P
MB.RX\5:I\EK#Z^6#]]JY7X?^&;F]U62_\*Z?/XJ\13']]XS\0K^ZC]?(0] *
M]6CELHKGQ&GE_F^GYGGU<=!/DI:LUO$#>*?BQ9G4O'6I_P#"M_ +'<FEQR[;
MV]7MYAZ@'^Z/UK<\)ZE?7&DQZ%\)_#$>@:&!M?6K^+8&_P!H+U<^YKLO#OP+
ML5U!=8\5WTWBO6>H>Z_U$?LD?2O48[=((U2-0B*,!5  'X45<92A:%-<R7_@
M/W?:^9G3PM2;<I>[?[_OZ?(\"\0?LKGQ';I=W/B>ZNM=<YN+NZ0.DGH O\('
M:O3OA?\ #&R^&/A\Z=:S-<S2R>;/<.,&1OIV%=DJ[6)IU<-7&5ZU/V527N]C
MKHX*A0G[2G&S&A:-O/:G45Q':%(5S2T4#&[?6G444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 E8>L>.- \/W0MM2U:ULKC;N\N:0!L>N*W:R
MM2\*:-K%Q]HOM+M;N?&WS)HE9L>F30!SVJ_&#PII]A/<1:S:7DL:%EMX907D
M/8 5YCH/[25[-KL2ZG96\6FRN%8Q9W1*3C<3W]Z]=U#X;^&KZRGMCHUG")5*
M^9%"JNON#V(KSW0_V;;'3=<BNKO46O;.-]ZVOEXW8Z!CGD4 =]_PM3PA_P!#
M%8?]_A3[CQM9ZKH>J7/AS4+#4+RSA:7:TA* @9&[;S@XJS_P@'AK_H!:?_X#
MK_A46I^&8--T'5(= TRRM[VZ@>)5 $2LQ4@;B!TH Y;P_P#&BQCT#2)/$3QP
MZW?:8=5:STZ&215@'WB"1SCO6['\2M#U**_6SOC%+!8?V@LTT+*AA*G$JY'S
M*,<XKSW3_AIXR@CT#?!I0?3O#MQI#XNG(:5P KCY?N_+]>:L:-\./%MI=6[S
MPZ6!'X7;125N')\[+$-]W[G(]Z .HT_XM:+:V.D6]UJ#ZKJEYI@U-!I]E)F>
M'^*1$P<#GIG-6I/C1X2CATZ?^TP]I?&)4ND0F*,R-MC$C8^0LW #8YKS&RAU
M?P=X^^'VA0'3;G7K/PU-;2PS7#+&QWQ\JV,Y."0".1FC1?V>=6\)Z\LEDGA_
M6M.U!DGU#^UX':2UF#%F:W X*\\*W0C- 'J?_"W?#/\ :T^G"[E,]OJ*Z5,W
MD/LBN6 *HS8QSD8/2H]2^,GA71[ZYM;R_:!X8I9M[0OLD6/_ %FQL88KW KA
M]5^&OBVZU+Q)/!%I9CO_ !)9ZM%YERV1! J*5;Y>&/E_0;O:J.G_  6\1Z/'
MKUE!:>&KNVDBN_[/U25)%O\ ,Y;Y)#@@ ;B-PY( H ]";XT^&$MI[@SW7E0V
M\5VS?9)!^XD^[*..4]^U=M;W"W$:2(0R.H96!R"#SD5X9??"WQG<:5>VBQ:4
MOG>&(-$5C=./WJ=7/R_=KV;P[;7%EH=A;W:QK<Q6\<<@B)*!E4 X)[9% &E6
M7K6I76FQ++;:=+J0!_>1PLH<+Z@$C/TK4K+UK29M6B6&._N+"/=F1K8@.X]
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M4F\?^/[9=5CO]1TZTN]/\/+JABLH$F4S+*5(+Y((8#D#&.U 'T#28&?>O._
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M>F ,#:3ZU]6%AWXHW+ZYKTJ.9XJA&48SW."KEN%K.+E#8\N_X9I^'_?1W_\
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M4ZS6*VZLDZ_\M<C)?\2375"ONL'1]E1C?63U;[L^.BEK)==1:***[BPHHHH
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M*@([KQDY..],T7X7:9H<EHL5]J=Q96;![2PN;HO!;D?=VC&>,\9)Q78;G/\
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M "BBB@ HHHH *BG:18V,2"1\$A6. 3Z9J6DSCK0!S?\ :OB?OH%E_P"#(_\
MQJC^U?$W_0OV?_@R_P#M5=%YJ;MNX;L9QGMZT[<#WH YL:CXK8\:-I7XZI)G
M_P!$4OV[Q9_T!M)_\&DG_P CUT>X?THS2 YLW_BWMHVD_P#@SD_^,4?:O%QY
M&G:./^WV4_\ M*NDW#KGBC<*8'-_:O%W_0/T?_P-E_\ C5'VGQ=_SX:,OO\
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M:U6W3K)+@%Y3ZL>]=%LZ<UC/&>SI^PPJY8]7U?J:4\)SS]MB-9=.R]!JJ$
M&!3Q2;?>EKRSTQ:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&&:6J^H7T&F6<M
MU<S1V]M"I>260X5%'4D]A0!Y1JW@?QA=?&:WU6+5,>&O(99+8$@["0#'O[9/
MS;0.W6N5\037'PUTWQ"UY=7EWX&U2XN+7<9Y&DTFZ#E8R'W;O); !Y^5AZ&O
M8-$^(6@^*/MJ6=_'OMO,\R.1@K&-#@R ?W/1JP?"=YX$U0ZKX>TE+:2"ZD9I
MK:5C(E[E%=I$W,=RX<9(XS0!?US6Y_!?A/2C901S;42+%R9I,#9GJBNQ.?6H
M/#?Q OM5TS6+NZL[=?L-NTZ1VZSJ7(4G'[R-?3MFN[CB$**B?*BC 7T'I3B@
M*X/(]^: /&OA7K&J?\)%I[^(XC=:KX@L&OX;VWO&DAC12#Y/E<*FT, ",DG/
M-1?$;Q\T/CSPO;"[O["TM]:CMY8([:0"YS&Q)9@N"H., 5Z"OPXT6QL=0ATR
MRBL9;Q"CR*6. 3DX^;Y>><#%;+:!:7%OIT=U&+I[%EDADDZK(HP'^O6@#B['
MS8?CAJP^VW;VLVAPSFWEF+11MYKJ61.BG &>YKB?A/J%\OCF(WLMQ+8Z@MV^
MGZM]I>1=659"2)(R<0M&.@ &X'->PIX,T>/Q(_B 62C67C\EKO<VXIV7&<8_
M"F:3X%T'0M2GO]/TR&UNYBQ:2//\1RVT9PN3UP!F@#<7(IU(!BEH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "LGQ3_ ,B_??[G]16M63XI_P"1?OO]
MS^HH /"W_( L?^N?]36M63X6_P"0!8_]<_ZFM:@ HHHH \X^($::AX_\#Z=?
M*LNCW#W;20R<QRS)$#&&!X/&\@'TJ?X'W4]UX#C,KM)!'>7<5H[$DM;K.ZQG
M)ZC:.#Z8KKM:\/Z?XBLS::G9PWML2&\N5<C(Z$>AJU9V<.GV\<%O$EO;QJ$C
MBC "JHZ  4 <I\4FU)O"FJPVD%O);R6<BR22RE&0D8&!@YKYQC_9P^(LT28O
M;$@J/^7MAU'^[7TKXO\ B-H7A2\AT^_:XNKZ=-ZV5C9RW4NS.-S*BG:,]SBK
M?A/QMH_C*SEGTNX9S"WERPSP/!-$WHR. P_$5SU,+A<0T\12C.VUU<YZM%U?
MMRCZ.U_4^;;3]G+QM N);31KP=Q-?2X/Y8K5M?@?XNM>!X6\'RD?\]Y9I/YU
M]._A1CVKHIT\)35HX:G_ . G'_9]._Q/[SY^L_A[X^T_'V;PIX%BQZ0G_"O+
M/C[;^*[&XTF#Q)I^E6,>QS ^D1D1L3C()]1CI[U]J5S?CV3PY;^'[B?Q1%:R
MZ7&02+J'S06/ "K@DL3T"C-=U.KAN9*MAXN'56,J^7*I3<83:9\J_ >'Q]>V
MNL0^"Y[2S@W1F>:Z4 ;P#A5.T\\UW>H?#WX[ZI_K/%T,'/\ R[3B,?I'7J'@
M?X@>$/M5IH.DVMQHKS#=;6UWI<UDLO&3L+H QQSCK7HE='UZ%&7+AJ48Q6RL
MF31RWEI*-2I)OUL?(.I?LZ_%W5\_;/%\\^?75''\EJO;_LG>*^#?VVFZL1_S
M^:G<$'ZXQ7V+171_;6)M9**]%8O^RZ/64OO/EC3_ -G/7M-P4\$^!Y2.AN#+
M)_.O$/%'A:_T/Q%>:5=:8;6\,SJ+6WBRK9/2,#JO-?HI+(D,3O(ZQQJ"S,QP
M !U)KS=OC5X)GN(YG-V\*R>6FJOI%Q]F!SC(F,>T#/\ %G%;X;/*M&3<X)_>
M<V(R>G6BHPFU8\XT#X8_$9?#^GPPV?A:R1+=%59K)'E48X#DJ<M4\WP9^(-W
MS+J>@1\?\L+&)?\ V2OH:%UD4,I# @$%3D5)7GO,J]VXI+Y'='+Z5K2;?S_R
M/FQOV=?%-TV;O6+:5?[L<<:?^R4G_#*L5Q@WMLMUZG[6%S_XY7TI0:G^TL7_
M #_D5_9^'ZQOZML^4?''[,L^FZ0]]H\-O8I:HTDZ2732>8!Z?+P:[SX+?"OQ
M!\+[.\F^SV-[=WX0L_VAEVHH)"CCU)KTCQ=\1M!\)3P6>H//<7=PI9;.SM)+
MF4IW8HBG"^YJWX2\;Z/XTM99=,F<M VR:WN(7@FB/8-&X##\L45<RQ-:C["I
M*Z%3R_#TJOMH1LR);[Q2 /\ B6:=_P"!3?\ Q-'V[Q3_ - S3O\ P*;_ .)K
MI.#S17F'I'-_;O%/_0,T[_P*;_XFC[=XI_Z!FG?^!3?_ !-=)44UU#;&,2R)
M&9'")N(&YCT ]Z .4L?$7B/49+M(M,L0UM,8'W7+?> !X^7W%7/MWBG_ *!F
MG?\ @4W_ ,36Y-<6UB4\QXX3-($7.!O<]![DXJQ0!S?V[Q3_ - S3O\ P*;_
M .)H^W>*?^@9IW_@4W_Q-=)10!S?V[Q3_P! S3O_  *;_P")JHWB+Q&NK)IQ
MTRQ%P\)G'^DMC:&Q_=ZUULC".-W/102:P_#/B[1_&6CIK.CW*7]JVY!+&N6!
M4D,N.H.0>* (?MWBG_H&:=_X%-_\31]N\4_] S3O_ IO_B:VM,U*VU:SCNK6
M430R?=8>QP0?<&K5 '-_;O%/_0,T[_P*;_XFC[=XI_Z!FG?^!3?_ !-=)0PR
M* .0U7Q%XCT>QDN[C3+#RD(!VW+$\D ?P^]6Q?\ BDX/]F:?@\_\?3?_ !-6
M->\4Z9H,]E;Z@7 NRVQA&61=HR6<CH!ZFMF&:.:-7C=9$8;E93D$>H- '/?;
MO%/_ $#-._\  IO_ (FC[=XI_P"@9IW_ (%-_P#$UTG%% '-_;O%/_0,T[_P
M*;_XFC[=XJS_ ,@S3L?]?3?_ !-=)6)XN\8:3X(THZCK%U]EM@P1=J-([L>B
MJJ@EC]!0!E:7XC\1:O#++!IE@%CF>$[KEARIP?X:N?;O%/\ T#-._P# IO\
MXFH-/^(_A:^U:TTJTU:VDO[J,31P1@Y(/(!XPK?[)P:ZN@#F_MWBG_H&:=_X
M%-_\31]N\4_] S3O_ IO_B:Z2B@#F_MWBG_H&:=_X%-_\35.3Q'XCBU6'3CI
MEC]HFB:9?]);;M4@'/R^]=7<W4-G"\T\B0Q(,L\A  'N:;=36]C%)=7#)#'&
MN6E? "K[GL* ,+[=XI_Z!FG?^!3?_$T?;O%/_0,T[_P*;_XFNC5E;H0:6@#F
M_MWBG_H&:=_X%-_\31]N\4_] S3O_ IO_B:Z2@C@T <?JGB+Q'H\,<L^F6.V
M25(5VW+'YG8 ?P^IJY]O\4DG_B6:?QQ_Q]-_\35C3?$FEZW)J44,XD_LZZ^R
M7)F0JB3 !MH)&&(W#D9YXZUIV.H0W_F^4^YHG\N16!#*WH0>E &)]N\4_P#0
M,T[_ ,"F_P#B:/MWBG_H&:=_X%-_\37244 <W]N\4_\ 0,T[_P "F_\ B:/M
MWBG_ *!>G_\ @4W_ ,3725@^+O&>D^"[."?5)W0SR>5!;V\+S33OUPD: LV.
MIP.* +GAO6/[?T6VOS'Y1EW H#G!5BIY^HK3KE_!/Q \/>-K>Z&BW7[RS<I<
M6DT+V\\#9/WXG 9<G/.,&NG'04 +5'6]-36M*NK"262!+F)HC+$0'4$8R,@C
M/X5>I* /.? /PFB\%S:I*-0DD>\$D*K'C:L18E"<C.\ G)Z'TK(T;X5M\-VU
MW7=/OS/<6UK,UA%-]QE\E?\ 7\9)WH3E<<&O7:BNK6*\MIH)D$D,J-&ZGNI&
M"/RH \PTSXY6D?@^#5=5T_4+>X6QMKN>/R%7>LB$^:F6^YE6ZX/ XYK:/Q?T
M6.:\647$,-I8)J,L\BJJ^4R!EV@L&8D,!D# /!(I&^#?AF32TL'M;PQ1E#'*
M;Z8S1A%*HJR;MP0*2 H..3Q5N/X6^'DE#-:7%P!:&R"W%U+(BQ%0I"AF.#A5
MY'/% '*>)OCM"O@]-3\/65Q>7LR^:(9H,""(2K&[R?,.,GC&:W]:^,FB^'[Z
MZM[R&^:.V60/=6\'F1&5(_,>$8.[?MYZ8]ZEU3X1^'=9M;6&[M[R0V\1A687
M\RRO&2"4=PVYAD#@D]*EO/A7X=U"ZN[F>QD>2\B,<^+F15;*>67V[L!RGREQ
M@XH R[KXS6:^%=9UBWTK4I'TWR2]G-$L4KK-M\M@"W0A@?4>E4-%^,XAU+6;
M3Q#;36"6M[<PQ72PX@2.* 3;';<<N$W$XR.",UTT?POT!;/4[4VUQ)!J,44%
MP);F1RRQ*!'@EOE*@#D>G-0'X1^'/.$SVUU<O]JDO")[N616E>/RG+ M@[D)
M&#Q0!2M?C3HUUX;M-;C@OGM;J[-DD;1*C)(!GYF9@@!'0[N>@YXJEXJ^,T=C
MH-])IEI,NIH]U!%]LB_<B6  N&*MG!4Y'KWQ71W'PVT>ZT.#1Y5O&L(9-XC:
M^F8L,8V.Q;+KCC:3C@5FZM\$O"NLWDUQ<VEX&E9I&2&_GCC#,NQR$5L LH .
M.N* ,'P_\<6AL[MO$%A.LT=Y-;0RV4(\B78 0@+-G?M/? J_JWQUT^W\-G6-
M.T?5M6@%LMPQMH5Q#NSM60EN#QVR!W-:,WP7\+S)+&]E<M&SB4*;Z;]W)QET
M^;Y6.T9(P3WIZ_!WPR+/[+]DO#;-"8)8S?38F7)(\SYOG()."<D4 9FJ?'C1
M] U:RTN_T_51J%XJ&*&*W63<S;<)\K''WARV![UK:3\6M'UC1=1U2..\A@LE
MB=HYH@LCB0?N]HSSN/ R1S[<U7N/@IX6N-2BOY;:^:YBE69#_:-P!O  #$!\
M$X4<GTJ_8?#'0--T^]L(K"0VMY!%:S))<R/N2,$1XRW!&>",'\J *5]\7=/T
MN.U-]I^J6<KKON89(%WV<?F^4))<,?E+\ KNR.>E4[7XZ:)<W/E"TU6-2Y02
MR6FT<.T><9SC>A7IG-:\WPL\/W4]E//:W-Q<6JE!+<74LC3(7W[)6+$RJ&&0
M'R >E5)O@_H*PRR6MM<)>_>CDEO9B!()&D5CAO[[$GUSB@"OIOQNT74K$7$=
MKJ4<DT<4EI:S0!);M9"53RP6ZY!')'2HH?COH-Q/'%%;:K)E8GFD^R82W\R3
MRU#DGJ'X.W/2D\)?!G3M-\&VVD:PC7]Z$3SKR.XF!#H25,+,Q:( G("D=:U9
MOA#X:F,F;2X02111,([R505C?>N<-UW<D]2>M &$W[1'AI]8FTNUM]6U"\C,
MN!:6FY'$8)<AR0O&#U(Z>]7_  Q\9+'Q%X9U/7WL;RRTZUN_L<'G*N^Z8L%4
M(N>I9@N#CK5V;X1^')+U+LVUXLJ>=Y:I?3!(Q*NV0*H; !!/ 'OQ3K#X2^&]
M-\-WN@V]C,NE7CB22WDNI7VNN"'1BQ*," <@CD"@#!A^*.I^+/%^EZ-H-G-8
MQF&:XO9M0MU/E&*7RI(6 ?*L#GD9!.!TR1+IGC36XO!.E:]J=_ 52XF:^%O9
M,3)#&7^5%W9#?)U&:Z+1_ASHVBZM;ZI:P7$=[# ]N'>ZD8.KOO<N"V'9FY+'
M)/K35^&.A1R7I2"Y\J\657A^UR^6AD^^T:;L(6R<E<'DT 8LGQVT2'1;K4I;
M'58(K=8I6BFMU23RY%+(^"W0@'CKQTJ?4/C1I%AJALA8ZE<;6A$DT4<>R,2X
MV.0SAMF6 + 8I]U\$_"UW'B2UO=PCCB5EU"=65$4HJ@[\@;214FH_"^Q6&4V
M$2R7$T'V%SJ,\TR);D ,$4M@-@#GU'- &>GQRTF?6;O3O[/UB!K2]6QEN'M!
MY6]U)C96W?,K8.",^^*XZ+XM:[K?B7Q-I%U'9I9:>5CDCA.[AF7&Q_XVPP.,
M8Z].,^BQ_"7P[#*LB6MRI66WFPEW*J[X%Q$=H; P.P'/>JFI_#30-'AO=4M[
M QS@M.B>:YABD)&72+.U6/J!F@#K/"W_ " +'_KG_4UK5D^%?^0!8_\ 7/\
MJ:UJ "BBB@ IK]..33J:PSCG% 'GFO:+K5UXLU&3PKJS:'J+6\)NWO\ 2_M-
MG<@;@A5MRG>HR" <8(X[UL>%?"^HZ3=76H:WJRZQJ]S&D3S1VPMXHXU)(54!
M/&22223S7%_%">*S\0>=XFN/$4/AT0H+7^P&E6,R\^9YWE?.3]W;VQ[UN?"L
MW+?;A#)K4OA\JIM#X@W&XW'.[:6^?9TQNYS0!Z)2TE+0 5R7Q T\7UG9+'->
MVMXM[$UK=6-MYY@FP5$CJ>-F"0V>QZBNMKE/B!-XGALM/_X11+%]0:^C$RZB
MY6(P[6W9*_-G.W&.>* ,?3?!?BR_U"V_X2GQ19ZE86T\=REII^F?9C(Z'*EW
M:1C@, <+CIR:]#KSFQ_X6=<:OIJWX\,VFFQW"M<_8I9FEDCP<JH9<9Y!_"O1
MJ "BBB@#/\00V]UH.I07<4D]K);2++%"I9W0J054#J2.@]:\_L?"OCB_LX8%
M\:0PZ'-"JB.;1%6^2,KRA8OM#8XR4X]*[#Q]'>S>!?$*:;YAU%M/N!;>2</Y
MOEMLV^^[&*X#3_$GBG0?AGIJZCHFK>(=1GT^)&ET\*+I9R@#+*"1MPQ^]R,=
M: /4-%T^+2--MK"W39:VL*00J3DA%4* ?P J_6=X?6]CT/3DU)UDU%;:(7++
MT,FT;R/^!9K1H *:WW>>E.IKC<M 'GOB+1M9N_%5Y)X7U9]#U-K>(W,MYIWV
MBTN%!(7#9!#KSG![C(K8\)^%-2TV[GU/7-636=9GB6!YH;<6\4<:DD(B GN2
M222:S_%6H:IX3O-7U2VL=2UTW5O'%96-DH98Y0&ZC^')()8^E8OP?_X6#I^H
M7&E>-)/[0A6P@NH]0$87%P[/YL&1]X(-HS0!ZJ.@I:0=/2EH *YSQQX#TOXA
M:;#IVLQ//91SK<>5'(T99ES@%E(('/8UT=% 'GFE_ /P/H^J6FHVNB>7>6LB
MRPR-=SOL8=\,Y'Z5Z'110 4444 ,EC\R-TS@,I'YUYGH'P5D\+>$8M(T?Q'>
M:5?0F4)J=M$A=U=R^)$8%6(R<'K7I]% &-X1\-IX3T&UTQ)Y;OR5.^YF(WRN
M3EG;'<DDULT44 %(PW+BEHH \X\7_!UO%OBFVUD^+?$.F")&0VMC=JD8RN/D
M!0XSWZYK<\ _#V#X>V-U:6VK:KJ<,\OFXU2X$QC8]0F%& ?2NKHH 2EHHH *
MY_Q=X9N/$$=G+8WXTS4;*4RV]RT(F525*G*$@'ACWXKH** /-?#/P7C\-W,,
MW]M75YONO[0OO.C3?>77.)"_55 . @XXKTFEHH **** .;\?V.F:IX/UNTUJ
M8P:1+:NEW(I(98MOS8QSG'ISSQ7A]EX9^%;:C86NJ_#_ %SP_!?8%K?:J\P@
MD((P&(F8H22,;P.M?1&K:3;:WIUS8W:>9;7$9CD7ID$>OK[UQ5E\((?M-[-J
M^OZKX@\ZV>S@COG3;;1-UVA5&7X'SG)H [JWC6%$C1=J(NT#K@#H*GJ"TM?L
MEO#$':3RT5-S\DX&,GWJ>@ I&^Z?I2TA&X$'I0!XK)H6@_%;Q5X@T>+7M5L;
M+3-4QJ>A1!(H[JY54<2+*!O"\HQ"MU'.*[WP!IECI+:W!!>:A?7_ -L)O9]3
M=6F+[1M^Z NW9MQ@=.O-06WPET6UN/$,J/=!M:OO[1F99BLD4^Q4+1N,%?E5
M1CVK5\%^"K+P/ILUK:3WE[)/,T\]WJ$YFGF<]V<]<  #T H Z"BBB@ K@OBY
M;WECHR>(]*NQ9ZOI*/Y+- )DD60JK1LA9>I"<Y&"/3-=[7)?$;X8Z+\4-+BL
M=9%R(XF+1M;7+Q$$XSD*0&Z=&S0!SG@7PC$EY9ZG<:W+J7B:VGN&U.::W6"2
M42@ PF/^"-2J%>2/ESDY.?3E^Z*XGPW\&?"GA+7EUK3+*YBU-8VA\^6_N)24
M/52'<@CZBNWH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K)\4_\B_??[G]16M63XI_Y%^^_P!S^HH /"W_
M " +'_KG_4UK5D^%O^0!8_\ 7/\ J:UJ "BBB@ IK]*=3)/N^W>@#Q[XG>&I
MK_Q+=W5UX7N/&L,MJEO8V\%T(ULGPV\NI88W$@[^2 ,"ND^%OAO6?!]F=)OI
M6N;!+:&2%I)C*8)2,2PAC\Q0'!!/8UC1>&];C^-WBO6;.]CC@FTFQ2WA:;='
MO1I"XECSE=P*X;V..E;W@6/Q#?:[J^K:U8VFF0S1QV]O;V=W]H6;9G,I8 8S
MG '7 &: .Z'04M)2T %>=?&KPSJWBC2_#D>D-*DEGK]G>7+6\WE2"W0L)"I[
MG#?=[UZ+6#XLT275X]/FA423:?=I>)$6VB4JK+M)_P"!9^JB@#F=:M_&5]KF
MCZ<+"UETV&\CN)=<CN-CK&AW%##U+-C;P<8)->B5XA%X/^)&H>-3XN>[_LEI
M]1L[?^PUN_,ACTU"WG,W\)E?(/'3&*]OH **** *&NZ8-:T74-/,C0BZMY(/
M,4X*[E(R/<9KR/QGX3\=^++_ $^VTMY/#6G:#9326UQ!>@MJ%WY16!2!_P L
MPWS'=U]*]KI-H]* ,OPNNHKX<TL:P4.K"UA^V>7ROG[!YF,=MV:U:2EH *2E
MHH ;L'/% 4#ZTZB@ HHHH **** "BBB@ HHHH 2O.?"/Q:EU[XBZ_P"#]1TH
MZ7?Z<HE@E$OF1W<7&64X&"N1D>]>C=.:^>_%,-WJ&K:AXI\,V%Q>>(?#^L>?
M';M;O%]LM718Y(E+ ;LGG(]* .]OOBM=R?$ZX\&Z1I"7LUKIQO[B\GN/*C!W
M;1&O!R<XR>U4-#^.1U+P/X<UFXT=EU?Q%.T&F:/:SB1Y,$Y9G( 4*%)8] ,>
MM<U8R)X;^,L3WD-\_P#Q3<B7=RMI*\9NGF\QDW!<$X/'L *YOP/H>IZ?X7^$
MGBR'3+V[7PR+VSU+3UMV2X2.?(,JQL 6VX4X]#Q0![=I_BW6X=>T[2M8T,6S
M7JRLEY:SB6%=BYVMP"&//;'%:OBKQ-'X9L8I"AN+NYF2VM;<$ RRMT'T[GV%
M1:+XJMO$DZG3X+B:W7/F7$\#Q!#_ '0' )/TXKE_BI#)#XH^'VI/D:?9ZPRW
M!'13)$R(Q]MQ_6@#L/\ A);+3X575-2L+6[0*)X_/4!&;H.3GD],U:M=;L;V
MZN+>WOK>>>WP98HY59HP>A8#I7S]XZ@LF\8?%G?I%U-]JT*&*-UL)'6>=0P(
M0[>6!*]*&>UGUF&*&RU*P2X\#/;SW%O9O&1*!G9N*@>8!G&3W]Z /H#3]>T_
M5FD6QO[:[:-BC>3*KD,.H(!ZUY[=?%C6D\6:'I=KHEK<V>MW5U#9W;W1C(2W
M4%V9=IZX;&#R,5Y5\,/$5O>:]+?II%Y8:^NBQZ5I\9TF:W25E.&F+NN-_P P
MR/0$YKN_&SVGA+XC?"N!;>Z:STA+T3S0VDLJ0J]N$4L44_>8?K0!Z;XPU^Z\
M,Z2=4CMUN[2V/F7B XD6$?>=!W*CG'<"MFQO(M0M8;F"198)D62.13PRD9!'
MU%<5?^-K'7/"/BF[CAN(]-L[62(3W4+P^<QC).U7 /4@9QR35[X2:9=:+\,?
M"]C?<7<&G0)*N,%6V X_#I0!UU%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !63XI_Y%^^_P!S^HK6K)\4_P#(OWW^Y_44 'A;
M_D 6/_7/^IK6KCM$\8:=I^EVUM*TGFQIM;:G&<U>_P"$\TO_ *;?]\?_ %Z
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M/-+_ .FW_?'_ ->C_A/-+_Z;?]\?_7H Z.BN<_X3S2_^FW_?'_UZ/^$\TO\
MZ;?]\?\ UZ .CHKG/^$\TO\ Z;?]\?\ UZ/^$\TO_IM_WQ_]>@#HZ*YS_A/-
M+_Z;?]\?_7H_X3S2_P#IM_WQ_P#7H Z.BN<_X3S2_P#IM_WQ_P#7H_X3S2_^
MFW_?'_UZ .CHKG/^$\TO_IM_WQ_]>C_A/-+_ .FW_?'_ ->@#HZR?%/_ "+]
H]_N?U%4O^$\TO_IM_P!\?_7JCK7C#3M0TNZMHFE\V1, %,=Q0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img11029722_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #G ID# 2(  A$! Q$!_\0
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MCX3_ !/U'PUIVDZ7=65JD3++=+*6^:)7_A;_ &J\^/\ P4&\<#KH.A\^TO\
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M]Q#_ %@S:&]>1]3?\/!_&_\ T =#_P"^9?\ XND_X>#>-_\ H Z'_P!\R_\
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MRUQ1Q1_867?\^@_UAS3_ )_R/J7_ (>#^-_^@!H7_?,O_P 71_P\'\;_ /0
MT+_OF7_XNOEKBCBC^PLN_P"?0?ZPYI_S_D?4O_#P?QO_ - #0O\ OF7_ .+H
M_P"'@_C?_H :%_WS+_\ %U\M<4<4?V%EW_/H/]8<T_Y_R/J7_AX/XW_Z &A?
M]\R__%T?\/!_&_\ T -"_P"^9?\ XNOEKBCBC^P\N_Y]!_K#FG_/^1]NZ/\
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M='_#P?QO_P! #0O^^9?_ (NOEKBCBK_L++O^?1E_K#FG_/\ D?4O_#P?QO\
M] #0O^^9?_BZ/^'@_C?_ * &A?\ ?,O_ ,77RUQ1Q1_867?\^@_UAS3_ )_R
M/J7_ (>$>./^@%H?Y2__ !='_#PCQO\ ] '0_P#OF7_XNOEOY:W+;P)XEO+>
M*>#P]JDT,J[TF2QE9&7_ +XJ)9-ED/BIQ-(Y]F]3X*LCZ(_X>#>-_P#H :%_
MWS+_ /%4?\/!_&__ $ =#_[YE_\ BZ^:=5\/ZKHFS^T-,N[#?]W[7 T6[_OJ
MJ QW-5')<NG\-.(I<09O#2=:1]2_\/!_&_\ T -"_P"^9?\ XNC_ (>#^-_^
M@!H7_?,O_P 77RUQ1Q3_ +"R[_GT1_K#FG_/^1]2_P##P?QO_P! #0O^^9?_
M (NC_AX/XW_Z &A?]\R__%U\M<4<4?V%EW_/H/\ 6'-/^?\ (^I?^'@_C?\
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M_P" R5']N95_-_Y*:_ZM9S_+_P"3'Q>GB#54U;^U5U.[35=^_P"W>>_G;O\
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M ,!EI?\ AW78_P#0X7/_ (#+1+/LLE]K_P E"/#.<Q^&/_DR/BN_U>^U2_\
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M 'RE9%%') CFF:__  F&K_\ /\W_ 'RE'_"8:O\ \_S?]\I6111R0#FF:_\
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M .?UO^^4H_X3#5_^?YO^^4KX_P#'W[0?QU^&7A+4/$OB#X5>&K/2K!-\C_\
M"4;V;^ZBKM^9O]FNYUG]HK4/!/P-\.^,?%GA::Q\5:[+%:6?A>SE\V66ZE=_
M*BW/_L?.U1:D+WSZ'_X3#5_^?YO^^4H_X3#5_P#G];_OE*^9?"O[0_C'2O'F
MA>&OB?X"C\'_ /"0,T6F:A8ZBEU;M+]_RI?D^5J]%^)GQ+E\"ZQX-TBSL5U+
M4_$>K?8HH7;9Y42H[2R_\ 1*.6 >^>J_\)AJ_P#S_-_WRE'_  F&K_\ /\W_
M 'RE?,.L?$[]H337O)4^$_AG^SX-SFXF\4(G[I?XV^7Y:D^#/[3VI^,/@_XC
M^(OC7PY!X5T32VE\B:WN?M"7D2_?9?D3^/[M*T ]\^FO^$PU?_G];_OE*/\
MA,-7_P"?YO\ OE*^16_:R\=:#I.G^,?$_P +9-(^&EY+%_Q-DU%);NUBE?Y)
M9;?^%:^H+6ZBO+>&>)E>*5=ZNG\2TXPA(/?-K_A,-7_Y_F_[Y2C_ (3#5_\
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M,5Y%^]MYOOP2K\DL3?[2MO6KY(!S2/0O^$PU?_G^;_OE*/\ A,-7_P"?YO\
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M75_A+I/BNVUBYL;E]6U^\U6#["SOMBE?>B/N1/FJXQD$CE/VM/$^N;OA_P"
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MXJQ:S@5(****T)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YB^)S_\
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MX>ZA\5O@SXK\)Z1/;6VI:I:_9X)KYG2)6WH_S[4=O_'*7V1_:/+_ -I;S_\
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M;[O]RJE'^4.8W_V?_C%J/Q4T[Q!8^(='CT3Q7X:U!M+U6QMY?-B\W[R/$_\
M==:X7]F2\_L?XP?'7PA$S?V?8Z]%J4"_W7NHMTO_ (]78? 7X4ZK\*='\5:Y
MXQU6RU+Q5XBU!M7UBXT]76TM_DVK%%N^;8JK]YZYS]DG2Y]8'CWXEW,7D_\
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M6\\.[9N5OOI47ACPQIG@SP_I^AZ+;+8:581+;VMNC._E*O\ !\U>D?V#HO\
MSSG_ .^J/[!T7_GG/_WU1[6(N61Q5%=K_8.C?\\YO^^J/[!T;_GG-_WU1[6(
M>S.*HKM?[!T;_GG-_P!]4?V#HW_/.;_OJCVL1^S.*HKM?[!T;_GG-_WU1_8.
MC?\ /.;_ +ZH]K$/9G%45VO]@Z-_SSF_[ZH_L'1O^><W_?5'M8A[,XJBNU_L
M'1O^><W_ 'U1_8.C?\\YO^^J/:Q#V9Q5%=K_ &#HW_/.;_OJC^P=&_YYS?\
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M=7_O;W2OFSX6_#'X>>*+O0M'N?VG/B%>^.1;Q/>Z+9^/=X^T[5:5 NS[F_\
MAK(L^Z**\R^-GQ"\5>!M%LK/P3X0N_%OB/5&:WM?FV6EK\G^MN'_ (5KS?\
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M/F+/7:*^%=.^/WC'XJ?MC_#VYTR^N]-^%MU+?V6G6Z2M$FJ-%%\]PR?Q+O\
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M?^?Z2C_A)]5_Y_I*/9R#FB=7Y,G]UJ/)D_NM7*?\)/JO_/\ 24?\)/JO_/\
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MN]=FW?OKXJ_9I^"/@G]H>S^(WC;XD:#!XJ\0:IXAO+)O[67S7L+>)]J16_\
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M&H!1111J 4444:@%%%%&H!1111J 4444:@%%%%&H&_X?_P"/:3_>K4K+\/\
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M_P#GDG_?-'V6W_YY)_WS110 OD0[=OEIM_W:3[+;_P#/)/\ OFBB@ ^RV_\
MSR3_ +YH^RV__/)/^^:** #[+;_\\D_[YH^RV_\ SR3_ +YHHH /LMO_ ,\D
M_P"^:/LMO_SR3_OFBB@ ^RV__/)/^^:/LMO_ ,\D_P"^:** #[+;_P#/)/\
MOFC[+;_\\D_[YHHH /LMO_SR3_OFC[+;_P#/)/\ OFBB@ ^RV_\ SR3_ +YH
M^RV__/)/^^:** #[+;_\\D_[YH^RV_\ SR3_ +YHHH /LMO_ ,\D_P"^:/LM
MO_SR3_OFBB@ ^RV__/)/^^:/LMO_ ,\D_P"^:** #[+;_P#/)/\ OFC[+;_\
M\D_[YHHH /LMO_SR3_OFC[+;_P#/)/\ OFBB@ ^RV_\ SR3_ +YH^RV__/)/
M^^:** #[+;_\\D_[YH^RV_\ SR3_ +YHHH /LMO_ ,\D_P"^:/LMO_SR3_OF
MBB@ ^RV__/)/^^:/LMO_ ,\D_P"^:** #[+;_P#/)/\ OFC[+;_\\D_[YHHH
M /LMO_SR3_OFC[+;_P#/)/\ OFBB@ ^RV_\ SR3_ +YH^RV__/)/^^:** #[
M+;_\\D_[YH^RV_\ SR3_ +YHHH /LMO_ ,\D_P"^:/LMO_SR3_OFBB@ ^RV_
M_/)/^^:/LMO_ ,\D_P"^:** #[+;_P#/)/\ OFC[+;_\\D_[YHHH /LMO_SR
M3_OFC[+;_P#/)/\ OFBB@ ^RV_\ SR3_ +YH^RV__/)/^^:** )(X4B^ZJI_
(NU)110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img11029722_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img11029722_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 7V"L8# 2(  A$! Q$!_\0
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MJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\
M"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"K
MU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *
MO44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O4
M4 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]
M10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10
M!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU%
M %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %
M'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44
M4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?
M[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1
M_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_L
MJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^
MRH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH
M/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*
M@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_
MOR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#
M^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_
M)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[
M\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\G
MYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR
M?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F
M/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^
M8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_
MPH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC
M_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"
MC^RH/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\
M*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/
M[*@_OR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH
M_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_L
MJ#^_)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^
MRH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH
M/[\GYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*
M@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_
MOR?F/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#
M^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_
M)^8_PJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[
M\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\G
MYC_"KU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR
M?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F
M/\*O44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^
M8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_
MPJ]10!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC
M_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"
MKU% %'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\
M*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O
M44 4?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ
M]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]1
M0!1_LJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU
M% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU%
M%'^RH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44
M 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4
M?[*@_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!
M1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_
MLJ#^_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'
M^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^R
MH/[\GYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[
M*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@
M_OR?F/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ
M#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^
M_)^8_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/
M[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\
MGYC_  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_O
MR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?
MF/\ "C^RH/[\GYC_  J]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)
M^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8_PH_LJ#^_)^8_PJ]10!1_LJ#^_)^8
M_P */[*@_OR?F/\ "KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GY
MC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_"C^RH/[\GYC_"KU% %'^RH/[\GYC_
M  H_LJ#^_)^8_P *O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/
M\*/[*@_OR?F/\*O44 4?[*@_OR?F/\*/[*@_OR?F/\*O44 4?[*@_OR?F/\
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M^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M65Q?Q+T>WOO"L][Y2_:K0JZ2 ?-MR 1GTP<_A5*^\17!^$,6H"1OM4T*V_F
M\YW;&/UP#^- &IJ7Q(\.Z;=M;&>6X=#AC;IN4'TR2 ?PS6OH?B72_$4+2:=<
M;V3[\;#:Z?4?UZ5G>!-$MM*\+6;I"@GNHEFFDQDMN&0,^@&!BN7U*"/PU\6=
M,FLD$4&HA4DC484EB5/'UVM]: /3Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#'U7_ (^E_P!P?S-%&J_\?2_[
M@_F:* +6E?\ 'JW^^?Y"KU4=*_X]6_WS_(5>H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q]5_X^E_W!
M_,T4:K_Q]+_N#^9HH M:5_QZM_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **Q_$.O1:':*^T23R
M'$<><?4GVKSNZ\2:Q=REVOYH\GA8G* ?E7FXS-*.&ER/5^1T4L-.HK[(]<HK
MS+2?&6HV,H6ZD:[@/4.?F'N#_C7I-O<175O'/"X>.10RL.XK7!X^EBD^3=="
M:M&5)ZDE%%%=IB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% &/JO_ !]+_N#^9HHU7_CZ7_<'\S10!:TK_CU;_?/\A5ZJ
M.E?\>K?[Y_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_<'\S10!:TK_CU;_?/\A5ZJ.E?\>K?[Y_D*O4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS_(5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-LEO:PI%"@PJ(, 5-17LX?#4Z"M'?N>)B,54KN\MNP4445T',%%%% !1110
M4444 %%%% !61K_AVQ\06GE7*;95'[N91\R'^H]JUZ*F<(S7+)714)RA+FB[
M,\'USP_?:!>>1=QY1O\ 5RK]UQ[>_M3_  _XDOO#UUYENV^%C^\@8_*_^!]Z
M]LO]/M=3LWM;R%987ZJ>WN#V/O7D7BCP;=: YGAW3V!/$F.4]F_QZ?2O#Q&#
MGAY>TI/3\CWL-C:>)C[*JM?S/4]$UZQU^S$]I)\P_P!9$WWD/N/ZUIU\^:?J
M-WI5XEU9S-%*O<="/0CN*]=\+^,;3Q!&(9=L%^!\T1/#^Z_X=1^M=V$QT:ON
MSTE^9P8S 2H^_#6/Y'34445Z!YP4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!CZK_Q]+_N#^9HHU7_ (^E_P!P?S-% %K2O^/5O]\_R%7JHZ5_QZM_
MOG^0J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1&O\3'EG/J3WJ_117LQBHJRV/$E)R=Y/4****8@HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'CY4/=EK'\CQ_P ->*[WP]/M4F:S8YD@8\?5?0U[!I6KV>M62W5E*'0\,O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM90K'&.I[L?4GN:NUW4,MI1C^]7,_P #SL5F$ZKM#1'+V_@/2X90\LEQ,!_
MS  _7 S72Q11P1+%$BI&HPJJ, "GT5UT<-1H?PXI'#.I*?Q,****W("BBB@
MHHHH **** "BBB@ IDL4<\+Q2H'C<%64]"#3Z*&KZ,#A-3\ R&8OILZ>6?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"JA%"J % P !P!2T5[=&A"C'E@CPJ^(J5I<TV%%%%;&(4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?5?\
MCZ7_ '!_,T4:K_Q]+_N#^9HH M:5_P >K?[Y_D*O51TK_CU;_?/\A5Z@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHJO>WUKIMJ]U>3)#"G5F/Z#U/M2;25V-)MV18KA_%'C^"PWV>DE)[K
MHTW5(S[?WC^GUZ5S7B?QU=:OOM+'?;61X)SAY![^@]JY."WFNIT@MXGEE<X5
M$&237CXK,6_<H_?_ )'M87+4O?K_ '?YBW-S/>7#W%S*\LSG+.YR374>&/ ]
MUK6RZO-UM8GD''SR#_9'8>_\ZZ7PQ\/XK/9>:PJS7'5;?JB?7^\?T^M=WTHP
MN7.7OUON_P PQ69*/N4/O_R*UAI]IIEHEK9P+#"O15[^Y/<^]6:**]A))61X
MK;;NPHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *S];TJ+6M(N+&7 \Q?D8C[K#H?SK0HI2BI)Q>S'&3BU);H^
M=[FWEM+F6WG0I+$Q1U/8BO6/A]KO]IZ-]BF?-S9@+S_%'_"?PZ?EZUA_$K0O
M+GCUF!/EDQ'/CLW\+?B./P'K7)>'M8DT/6H+U<E%.V51_$AZC^OU KY^FW@\
M39[?H?15(K&X;F6_ZGO-%,AECN(8YHF#QR*&5AT(/(-/KZ$^<"BBB@ HHHH
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M9V]A;);6L*0PH,*BC %3UZF%P4*.KUE_6QY6*QTZ_NK2/];A1117:<(4444
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M &I;^C_E1_:EOZ/^57-J_P!T?E1M7^Z/RH I_P!J6_H_Y4?VI;^C_E5S:O\
M='Y4;5_NC\J *?\ :EOZ/^5']J6_H_Y5<VK_ '1^5&U?[H_*@"G_ &I;^C_E
M1_:EOZ/^57-J_P!T?E1M7^Z/RH I_P!J6_H_Y4?VI;^C_E5S:O\ ='Y4;5_N
MC\J *?\ :EOZ/^5']J6_H_Y5<VK_ '1^5&U?[H_*@"G_ &I;^C_E1_:EOZ/^
M57-J_P!T?E1M7^Z/RH I_P!J6_H_Y4?VI;^C_E5S:O\ ='Y4;5_NC\J *?\
M:EOZ/^5']J6_H_Y5<VK_ '1^5&U?[H_*@"G_ &I;^C_E1_:EOZ/^57-J_P!T
M?E1M7^Z/RH I_P!J6_H_Y4?VI;^C_E5S:O\ ='Y4;5_NC\J *?\ :EOZ/^5'
M]J6_H_Y5<VK_ '1^5&U?[H_*@"G_ &I;^C_E1_:EOZ/^57-J_P!T?E1M7^Z/
MRH I_P!J6_H_Y4?VI;^C_E5S:O\ ='Y4;5_NC\J *?\ :EOZ/^5']J6_H_Y5
M<VK_ '1^5&U?[H_*@"G_ &I;^C_E1_:EOZ/^57-J_P!T?E1M7^Z/RH I_P!J
M6_H_Y4?VI;^C_E5S:O\ ='Y4;5_NC\J *?\ :EOZ/^5']J6_H_Y5<VK_ '1^
M5&U?[H_*@"G_ &I;^C_E1_:EOZ/^57-J_P!T?E1M7^Z/RH I_P!J6_H_Y4?V
MI;^C_E5S:O\ ='Y4;5_NC\J *?\ :EOZ/^5']J6_H_Y5<VK_ '1^5&U?[H_*
M@"G_ &I;^C_E1_:EOZ/^57-J_P!T?E1M7^Z/RH I_P!J6_H_Y4?VI;^C_E5S
M:O\ ='Y4;5_NC\J *?\ :EOZ/^5']J6_H_Y5<VK_ '1^5&U?[H_*@"G_ &I;
M^C_E1_:EOZ/^57-J_P!T?E1M7^Z/RH I_P!J6_H_Y4?VI;^C_E5S:O\ ='Y4
M;5_NC\J *?\ :EOZ/^5']J6_H_Y5<VK_ '1^5&U?[H_*@"G_ &I;^C_E1_:E
MOZ/^57-J_P!T?E1M7^Z/RH I_P!J6_H_Y4?VI;^C_E5S:O\ ='Y4;5_NC\J
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M &I;^C_E1_:EOZ/^57-J_P!T?E1M7^Z/RH I_P!J6_H_Y4?VI;^C_E5S:O\
M='Y4;5_NC\J *?\ :EOZ/^5']J6_H_Y5<VK_ '1^5&U?[H_*@"G_ &I;^C_E
M1_:EOZ/^57-J_P!T?E1M7^Z/RH I_P!J6_H_Y4?VI;^C_E5S:O\ ='Y4;5_N
MC\J *?\ :EOZ/^5']J6_H_Y5<VK_ '1^5&U?[H_*@"G_ &I;^C_E1_:EOZ/^
M57-J_P!T?E1M7^Z/RH I_P!J6_H_Y4?VI;^C_E5S:O\ ='Y4;5_NC\J *?\
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MOZ/^57-J_P!T?E1M7^Z/RH I_P!J6_H_Y4?VI;^C_E5S:O\ ='Y4;5_NC\J
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MJ_W1^5&U?[H_*@"G_:EOZ/\ E1_:EOZ/^57-J_W1^5&U?[H_*@"G_:EOZ/\
ME1_:EOZ/^57-J_W1^5&U?[H_*@"G_:EOZ/\ E1_:EOZ/^57-J_W1^5&U?[H_
M*@"G_:EOZ/\ E1_:EOZ/^57-J_W1^5&U?[H_*@"G_:EOZ/\ E1_:EOZ/^57-
MJ_W1^5&U?[H_*@"G_:EOZ/\ E1_:EOZ/^57-J_W1^5&U?[H_*@"G_:EOZ/\
ME1_:EOZ/^57-J_W1^5&U?[H_*@"G_:EOZ/\ E1_:EOZ/^57-J_W1^5&U?[H_
M*@"G_:EOZ/\ E1_:EOZ/^57-J_W1^5&U?[H_*@"G_:EOZ/\ E1_:EOZ/^57-
MJ_W1^5&U?[H_*@"G_:EOZ/\ E1_:EOZ/^57-J_W1^5&U?[H_*@"G_:EOZ/\
ME1_:EOZ/^57-J_W1^5&U?[H_*@"G_:EOZ/\ E1_:EOZ/^57-J_W1^5&U?[H_
M*@"G_:EOZ/\ E1_:EOZ/^57-J_W1^5&U?[H_*@"G_:EOZ/\ E1_:EOZ/^57-
MJ_W1^5&U?[H_*@"G_:EOZ/\ E1_:EOZ/^57-J_W1^5&U?[H_*@"G_:EOZ/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?5?\ CZ7_ '!_,T4:
MK_Q]+_N#^9HH M:5_P >K?[Y_D*O51TK_CU;_?/\A5Z@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MO)_%%_)?:_<[V)2%S$@[ *<?J<FO5998X(7EE=4C0%F9C@ #N:\:U*\M;_5K
MRXLV8PO,S*6&"<G.<>E>%GTG[&,4^IW8&+<G*Q6H!P<CK12JK.P5068G  ')
M-?*GHF5?-(]VYDD>1C_$[$G]:@56=@JJ68] !DFO8=*\#:3%;12W]H)[PJ#)
MO<E0?3 .*Z.UL+.R7;:6L$ ](HPO\J^HHY75E%.H[$RS6$5:,;GB5GX5UR_P
M8-,N-IZ-(NP?FV*W[/X9:K-@W5S;6X] 2[#\!Q^M>K45VPRRBOB;9RSS6M+X
M4D</9_#'2XL&[N[FX;T7"*?PY/ZUOV?A30K''DZ9 2/XI%\P_FV:V:*ZX8:C
M#X8HY)XJM/XI,1$6-0J*%4= !@"EHHK<YPHHHH **** "BBB@ HHHH ****
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M "%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,?5?^/I?]P?S-%&J_P#'TO\ N#^9HH M:5_QZM_OG^0J
M]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?/3G*<G*3NV%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,(J,5H?/3G*<G*3NV%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%%
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MA\].<IR<I.[844451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH PO%VAC7="EA10;F+]Y ?]H=OQ''Y5X@0R-@Y5@?H0:^C
M*\B^(.A?V;K'VZ%,6UX2W'19/XA^/7\_2O(S/#W2JQ^9[&58BS=&7R._\(:Y
M_;NA1RR-FYB_=S^[#O\ B.?SK>KQ3P9KO]B:ZAE;%K<8CF]!Z-^!_0FO:ZZ\
M%B/;4M=UN<F.P_L:NFSV"BBBNPX@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,?5?\ CZ7_ '!_,T4:K_Q]+_N#^9HH M:5_P >K?[Y_D*O
M51TK_CU;_?/\A5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JZCJ%O
MI=D]U<L1&G8=6/8#WKS^^\<ZI/,WV0I;19^4!0S?B3_A5KX@74C:A;6FX^6D
M7F8]221_(?K7'5\MFN8U?;.E3=DNQZ6&P\>7FDKW+^L:[JNLV(M+F[)C!W$*
MH7?Z9Q6'IFCWFK:DMC:Q[I2?F)Z(.Y)]*NUW/P\D7_3X]B[OD;=CD]1@FN7
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MIJ&NEH4)MK(_\L4/+#_:/?Z=*P+:UGO;A+>VA>:5SA409)KQ\1F+E[E'[_\
M(]G#98H^_7^[_,OC5+G4+R26]G>::3G<Q_0>@]JGKLO#GPZBM]EUK)$LHY%L
MI^1?]X]_IT^M;=]X)TJ[F,L?F6Q)R5B(V_D1Q^%>=5RC$55[1;OH]Q5L704[
M0V_ \RKTKP3I4EAI;W,PVR71#!3U"CI^>2?RJ?3O!VEZ?,)BKW$B\@S$$#\
M,5T%=V695*A/VM7?HCBQ&)4URQV"BBBO=.(**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M11176<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS^)H [RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:9X=!A8FYOB,K:Q'+?\  C_"/U]J?X/\1OXHT=[Y[9;<K,T6P/NS@ YS@>M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:ZG72[G\$S_*O;** /"WT/5H_OZ7>KVR8&_PJN]E=Q_ZRUF7!Q\T9'->^44
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF)_SUD_.@"]15'^S$_YZR?G1_9B?\]9/SH O451_LQ/^>LGYT?V8G_/63\Z
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MC^S$_P">LGYT 7J*H_V8G_/63\Z/[,3_ )ZR?G0!>HJC_9B?\]9/SH_LQ/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.$3N?\]Z]RL+&WTVQAL[5-D,2[5']3[FO)P6'=>HZM3;\V>OCL0L/35&GO\
MDBS1117O'SX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 445A:YXLTW0PT;OY]T.D$9Y'U/;^?M0!N,RHI9B H&22>
M!7%^(?'MK;1RVNEGS[@@KYP/R)[C^\?TKC-;\4ZEKC%9I/*M\\01\+^/K^-8
ME  22<DY)J6.YN(5VQ3RQKG.%<@5%10!:74[],[+ZY7/I*P_K3UUC5%(*ZE>
M CN)V_QKO=)\':!K.DVU]&+E/,7YE67HPX(Y'J#5MOASHI7 DO%/J)%_^)H
M\Z_M[6/^@M?_ /@2_P#C4G_"2ZW_ -!6[_[^FN^_X5MH_P#S\W__ '\3_P")
MJ/\ X5IIO_/[=_\ CO\ A0!Q*^*==48&J7&/=LT]?%VOIG&IS<^H!_F*[!OA
MG99.W4+@#T*J:8WPRMCC9J4H^L0/]: .57QGXA4Y&I/GWC0_TI__  G'B/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-X>JX2V.:G)TYV9ZI10#D9%%>P=H4444 %%%% !1110 4444 %%%% !1110
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M7O4X1IQ48[(^>J5)5).<MV%%%%60%%%% !1110 4444 %%%% !1110 4444
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M."#]:] \/_$$'9;:R,'H+E1_Z$/ZC\J /0**9%+'-$LL3J\;#*LIR"/8T^@
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M4#  & !2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ72X#_=D4?PL.O\ C^-:->Q&2DKH[$TU=!1113&%%%% !1110 4444 %%%%
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M5[>1UE3G*,G9/\SFQ5"=2'-%7L>@44 @@$'(/0T5]4>2%%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ8]Q@-*WR1*>[?X#K7E-Y>W-_<-/=3-+(>['I[#T%0'6M1U=B;^[DG*<J&P
M/7 '%%?-9IC98BIRK2*Z'72PWL-'N/AFDMY5EAD:.13E64X(KT?PYXJ@O-/*
MZE=0PW$7#-(X0./7G]:\UJK?X\@>NZL<!C*F'J^[L]T5/#QK-19[3_PD.B_]
M!C3_ /P)3_&C_A(=%_Z#&G_^!*?XUX)17N_VK/\ E17]D0_F9[W_ ,)#HO\
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M7=A^.X#]*YZ\^+GC>\4H=:,*'M!#&A_,+G]:TK+X&^,;H_OTL;,?]-KC=_Z
M&KH;+]GJ[=<W_B"&(_W8+<R9_$LO\JXO:\/X;;D?RYO\RK59'EE[XJ\0:BNV
M]US49T_NR7+E?RSBLDDL2222>YKZ)L_@#X<B4&[U'4KA_P#99(U/X;2?UKH;
M3X1>"+0+C11,X_BFGD?/U&['Z4GQ1EM%6I1;]$E^J#V$WN?*E6[/2]0U!PEE
M8W-RQZ+#"SD_D*^P;3PMX?L-OV30]-@*C :.U0'\\9K6KBJ\9+_EW1^]_P#
M_4I8?NSY(L?AIXSU!L0^'KQ/^NX$/_H9%=!9? OQA=#,_P!@L_::?<?_ !P-
M7TO17G5>+L;+X(Q7R;_7]"UAX]3PFR_9ZN&4&^\0Q1MW6"V+_J6'\JZ"S^ 7
MAF%0;J_U*X?OAT13^&TG]:]6JO<W]G9C-S=0Q>SN ?RKSZO$.8S^*K9>5E^2
M*]E!=#Y,^(>B6GAWQSJ.EV$3Q6D/E^4KL6.#&I)R>O)-5="\+76MQO-O$%N.
M%D9<[CZ ?UKZ5UWQ;IH@9;%([JZ(VB1HOE3WY'/\JX%W:1V=R2S'))K7%\<5
MH86-##Q_>)).3=]NMK;OSN<M113T9XKJ&GW.EWCVMTFV1>A[,/4>U>^_L_JP
M\(ZDQ!"F^.#C@_NUJ'2=4?2KP3"))HSP\3C(8?T/O7:VWCK254(;6XA'HJ*5
M'Y'^E9XOB^.88+ZO5ARRTN[Z:=E;]2J+BG=LZRBL.'Q?HDV!]LV'T>-A^N,5
M>AUG3)\>5J%LQ/;S0#^5>$JL'LT=:G%[,O44U'61=R,&'J#FG5904444 %%%
M% !1110 4444 %%%% !1110 4444 (0&!! (/!![U\[_ !)\*7_@/5/[5T5F
M_L2Z?_4D92"0\E".RGL?P[<_1-5=2TVTU?3;C3[^%9K6X0I(C=Q_0]P>Q%>A
MEV-^JU;SCS0?Q)]5_FNA$X\RTW/F+3O&%I<X2\4V\G][JA_PKHDD25 \;JZ-
MR&4Y!KB?'7@R[\%:^]E-NDM),O:W!'$B>_\ M#H1^/0BI/ _B:UT/5!;:M#]
MHTBY(69?XH3VD0CD$=QW'T&/I\=PYAZ]#ZUE[W5TMT_3JGY/TT,8UFGRS/3M
M(\4ZKHVU(+@R0#_EC+\R_AW'X5WVC^/=,U#;'=_Z%.>/G.4/T;M^.*YO4? $
MC6ZWFB727EM(H>-2PW,I&00W1N/I7(7%M/:3-#<PO%*O5'7!%?$-6T9TGOJL
MKJ&5@RD9!!R#2UXAI7B'4]&8?9+EA'G)B?YD/X=OPKO='^(5A=[8M00VDIXW
M_>C/X]1_GF@#LJ*9%+'/$LL,B21L,JR'(/T(K,TOQ'I^KWMS:6CL9+<\[A@.
M,XROJ,T :U%%% !1110 4444 %%%% !1110 4444 %%%<]XQULZ-HC&%]MU.
M?+B(ZCU;\!^I% '0T5P'A?QM!!H\T>L7,C30M^[8Y9Y%/;W(/KZBLG6_'U_J
M&Z&Q!LX#QN!_>-^/;\/SH [S6?$^F:(I6XFWSXX@CY?\?3\:\ZUOQMJ>K;HH
MF^R6QX\N(_,1[MU_+ KFV8LQ9B2Q.23U)KI=$\$:GJNV69?LEL>=\@^9A[+_
M (XH YI59V"J"S$X  R2:Z_1/ %_?[9M0)LX#SM(S(P^G;\?RKN]&\,Z9HB@
MVT.Z;',\G+G_  _"MB@#.TK0]/T:+996ZH2,-(>7;ZG_ "*T:** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'U7_CZ7_<'\S11
MJO\ Q]+_ +@_F:* +6E?\>K?[Y_D*O51TK_CU;_?/\A5Z@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *Y#QEX@^RQ'3+5_WT@_>L/X%/;ZG^7UK
M8\0ZW'HNGEQAKB3*PH>Y]3["O*999)Y7EE<O(Y+,QZDUP8S$<JY([G/7J67*
MA8();F=((4+R.0JJ.YKU?0-%BT73UA&&F?YI7'\1_P !63X.\/\ V& :A=)_
MI,J_NU(_U:G^I_E^-=73P>'Y%SRW84:?*N9[A114%[>VNG6<MW>W$=O;Q#<\
MLK!54>Y-=Z3;LCH)ZXOQK\2]%\&1M#(_VO4R/ELXFY'H7/\ "/U]!7G'CKXW
M378ET[PKO@A.5>_88=A_TS'\(]SS["O&I)'FE:21V>1R69F.2Q/4DU]AE/"T
MZEJN,T7\O5^O;\_0YZE>VD3?\5^-=:\8WHGU.X_=(<Q6T?$47T'<^YR:YZO3
MO OP=U+Q%Y=_K/FZ=IA 95QB:8?[(/W1[GVP#UKU0?!?P0!_R#IS[_:I/\:]
MVMGV6Y>UAX:V_E2LOQ7];F2I3GJ?+M7]$UB[\/ZU:ZK8E!<VS[TWKE3Q@@CT
M()%?2?\ PI?P1_T#9O\ P*D_QKS'X@_!Z[\/K+J>@B6\TQ1NDA/S2P#N?]I?
M?J._3-5A^(LOQD_8.ZYM/>2L_+=A*E..IZUX%^)&E>-;81*1::H@S):.W)_V
MD/\ $/U'?U/:5\0V]Q-:7$=Q;2O#/$P9)(V*LI'0@CH:][^'OQFAO_*TKQ1(
MD%UPL5\?E23V?LI]^A]N_P [G/#4Z%ZV$5X]5U7IW7X^IK3K7TD>QT4 @C(Y
M%%?(G0%%%% !1110 4444 %%%% !1110 4444 %%%% !15>[O[.PC\R\NH8%
M]9'"Y^F:Y;4/B1HUKE;59KQQTV+M7\SS^AK*I7IT_CE8UIT*E3X(W.QIDDL<
M,9DED5$'5F. /QKR;4/B1K-UE;58;-#T*KO;\SQ^E<O>:A>:A)YEY=33MV,C
MEL?3TK@J9I37P*_X'H4LIJ2^-V_$]?U#QWH-AE1=&YD'\-NN[_Q[I^M<IJ'Q
M/O)<KI]E% O9Y3O;\N /UKA8HI)Y!'%&\CGHJ#)/X5T6G^ ]>O\ #-:BU0_Q
M7#;?TY/Z5R/&8JL[4U]QV+!86@KU'][,S4/$&K:KD7E_-(IZINVI_P!\CBLV
MO3;7X;Z;91&XU?46=%&6VD1(/J3D_P JCF\1^&M _=Z'IL4\Z\"8KP/^!'YC
M_GFG'+J]1WJ.WXL4\RH4U:FK_@CD[:POTT\7$UE<1P*<"5XR%/XUGROOD)[=
MJU-6\2ZKK)(NKDB(_P#+&/Y4_+O^.:R*[,)EM/#5'43NW_3/)Q&*=;I8N).H
M@WN<8ZUM>&/',^CN+6\4S6!8D ?>BR>WJ/:N9PK<,,BHYK9X55Q\T3?=<?R/
MH?;^E>=5PD\%6=:EL_P\CTL'*CB*?LZF_P#6Q] 6=[;:A:I<VDRS0N,JZFIZ
M\(T'Q%?>'[KS;5]T3']Y"WW7_P #[U[!H/B.Q\06OF6K[95'[R%C\R?XCWKU
ML+C85U9Z2_K8X<7@9T'=:Q_K<UZ*YOQ7XYT+P?;[]3NLW##,=K%\TK_AV'N<
M"OG[QG\5]=\6>9:Q.=.TQN/LT#'<X_VVZGZ<#VKZ;+<CQ6/?-%<L.[_3O_6I
MYLZL8GKGC/XQZ+X=\RTTPKJFHCC$;?N8S_M,.I]A^)%>%:MXZ\0:YK46IZA?
M/(\+[HH5^6*,=P%]QQGJ>YKGH89;B9(8(WEE<A41%)9B>P ZUZ]X,^!U[?\
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ME;T12Q_2H^E>W1QI$@2-%11T"C KE?$/@\:C<?:K!HXIG/[U6X5O]KCO_/\
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M"BBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=_P_*N3DC>*1HY$9'4X*L,$'Z4 ?0/49%%>*:3XGU71B%MKDM"/^6,OS)_\
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MP]XBTO7;2Z%@Z('"R$NN-AX;//I7J=%% !1110 4444 %%%% !1110 4444
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M9A_?&$'_  'O^.:ZI(TB14C1411@*HP!3J* "BJ]]?V>F6K7-]=0VL"]9)I
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MP3P[IJ=1Z-OX?6W?TLNM^AV87)ISESU'9?B=9X@\<ZCK0:"'-I:'@QHWS/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *ANKJ"RMGN+B01Q(,LQI;FYAL[9[BXD$<2#+,:\M\0^()M;NL
M#*6J']W'_4^_\JY\1B%2CYF=2HH+S$U_7Y];NLG*6R']W%G]3[U%HFB7&M7@
MBB&V)>9)2.%'^/M2:-HUSK5X(81MC7F20CA!_C[5ZII^GV^F6:6MLFU%ZGNQ
M]3[UP4*$J\N>>QSTZ;J/FD+86%OIMFEM;)MC7\V/J?>K-%%>LDDK([$K!111
M3 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **1W6-&=V"HHRS$X 'K7@7
MQ.^+C:AYVA^&YREIREQ>H<&;U5#V7U/?Z=?0R[+:^/J^SI+3J^B_KL1.:@KL
MU_B;\75LQ-H?AFX#7/*7%\AXC]5C/=O]KMVYY'@WSRR?Q.['ZDDTZWMYKNYC
MM[>)Y9Y6")&BY9F/0 #J:^C/AI\*(?#BQ:OK:)-JY&Z.+ADMO\7]^W;UK[Z4
M\%D&%LM9/[Y/]%^7J<OO59&3\,OA"+3R=<\36X:XX>WL9!Q'Z-(/[W^SV[\\
M#VBBBOS['X^MCJKJUGZ+HO)'7""BK(*.M%%<11P'BKPK]FWZAI\?[GK+$H^Y
M[CV_E].E+PSX9?5I!<W(*62GZ&0^@]O4_P"1Z92  # & .PKD>#INIS].QBZ
M$>:XD<:0QK'&@1%&%51@ 4ZBBNLV"BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/TKQ'I>L@"TN5\T]89/E<?AW_#-:M?/H)4@@D$<@CM73:3XZU?30(Y7%Y".
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MA=-TZWTNR2UMDPB]2>K'U/O5NBBO7225D=J5M$%%%%, HHHH **** "BBB@
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MUOU+P].E)>_?Y?\ #,N>"_#_ (*\,>7?:M<G5M37YE"P-Y,1_P!D,!N/N?P
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MG\*/[0?_ )]9/\_A0!>HJC_:#_\ /K)_G\*/[0?_ )]9/\_A0!>HJC_:#_\
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M^LG^?PH_M!_^?63_ #^% %ZBJ/\ :#_\^LG^?PH_M!_^?63_ #^% %ZBJ/\
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ML2MHB]15'^T'_P"?63_/X4?V@_\ SZR?Y_"F,O451_M!_P#GUD_S^%']H/\
M\^LG^?PH O451_M!_P#GUD_S^%']H/\ \^LG^?PH O451_M!_P#GUD_S^%']
MH/\ \^LG^?PH O451_M!_P#GUD_S^%']H/\ \^LG^?PH O451_M!_P#GUD_S
M^%']H/\ \^LG^?PH O451_M!_P#GUD_S^%']H/\ \^LG^?PH O451_M!_P#G
MUD_S^%']H/\ \^LG^?PH O451_M!_P#GUD_S^%']H/\ \^LG^?PH O451_M!
M_P#GUD_S^%']H/\ \^LG^?PH O451_M!_P#GUD_S^%']H/\ \^LG^?PH O45
M1_M!_P#GUD_S^%']H/\ \^LG^?PH O451_M!_P#GUD_S^%']H/\ \^LG^?PH
M O451_M!_P#GUD_S^%']H/\ \^LG^?PH O451_M!_P#GUD_S^%']H/\ \^LG
M^?PH O451_M!_P#GUD_S^%']H/\ \^LG^?PH O451_M!_P#GUD_S^%']H/\
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M] GL](N3>7EXAAC2.-LKNX).1UP>!US6YX,T=_#_ (4M[:X&V<@S3#T8\X_
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M%)/U..:NP6\-K"L-O#'%$OW4C4*H^@% $E%%% !1110 4444 %%%% !1110
M5A^,C(O@K6S#GS18S%,==VPXK<J*YMXKNUEMIUW12H4=<XR",&KIR49J35[
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M*M/^_0H \0KKO %S9_VL]C=VL$IG7,3R1ABK#G&2.A'\J]!_X1K1/^@5:?\
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M*-%GQMU"-?\ ?!3^8%:$-[:W'^HN89?]R0-_*MHSC+9EJ2>S)Z***H84444
M%%%% !1110 4R66."%Y975(T&69C@ 42RQPQ-+*ZI&@RS,< "O-/$WB5]8F,
M%N62R0\#H9#ZG^@K"O7C2C=[F=2HH(;XE\22:S.88"R62'Y5Z%SZG^@K,TO2
M[G5[U;:V7D\LQZ(/4TFF:9<ZM>K;6RY8\LQZ*/4UZII&D6VC68@@&6/,DA'+
MGU_^M7G4:4\1/GGL<T(.H^9BZ3I-MH]F+>W7)ZO(>KGU-7Z**]>,5%61V))*
MR"BBBF,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=RQ'^[( X_H:PKOP3J]ODQ)'<*/^>;X/Y'%?->SQ-+:_YE\M6&QT]IXYTF?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>(?&'P+XC\1>++:_P!(TUKN
MW^QK$S)(H*L'<D$$CLPKV^BN[+\?4P%;VU-)NUM29P4E9GR=_P *J\;_ /0
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M?_T6U:8^3CA*LHNS49?DQ0^)'U@JJB*B*%51@ #  I:**_&3T0HHHH ****
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M7_<'\S11JO\ Q]+_ +@_F:* +6E?\>K?[Y_D*O51TK_CU;_?/\A5Z@ HHHH
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MNO@MX1FT5=/@AGMY X<WBONF8@$8)8$8.>@ Z#TK'_X9^\/_ /06U/\ ./\
M^)KURBO(AG6805HU7^?YFGLX=CR/_AG[P_\ ]!;4_P X_P#XFM;PU\'-$\,Z
M_;:Q!?W\\UL6*)*4"Y*D9.%SW->C445,ZQ]2#A.JVGH]@5."UL%%%%>66%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@/\ Z#O_ )*3_P#Q%?%8O(L=AJG)[-R7>*;7X;?,Z8U8M;G<45P__"X? ?\
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MD4="\.6NBQ!AB6Z8?/*1T]AZ"MJBBO5A",%RQV.Q))6044450PHHHH ****
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M\GC<ZQN,TJ3T[+1?\'YW-XTXQV"BBBO+- HHHH **** "BBB@ HHHH ****
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M^!CZ^A_ \<CYFFAEMIWAFC>.6-BKHXPRD=01V-?;]>5?%?X9#Q#!)KFC0_\
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M(-?I^19K/,:#E4C:479VZG'5AR/0****]PR-[PQX-UOQ=>>1I5HSHIQ)</\
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M9?JV;QHQ6^IY'_PS]X?_ .@MJ?YQ_P#Q-'_#/WA__H+:G^<?_P 37KE%<O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!&D44:A$1%PJJ.  !T%/HHKX!NYUA1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_VA_\ 7^'O
M]VX_G'7B-?4WQ(^'3>/!IS1ZD+.2S\P?-%O#A]ON,8V_K7!_\,\W?_0QP_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'U7_ (^E_P!P?S-%
M&J_\?2_[@_F:* +6E?\ 'JW^^?Y"KU4=*_X]6_WS_(5>H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OE+XM_\ )4=:_P!Z
M+_T4E?5M?,GQ5\.ZU<?$C5;BWTB^F@E,31R16[NK#RU'! QU!'X5]3PE.,,;
M-R=O=?YHPKKW3SBBM7_A&/$'_0#U/_P$D_PH_P"$8\0?] /4_P#P$D_PK]#]
MO2_F7WHY+,]Q_9^_Y%/4_P#K^_\ ::UZY7EWP,TR_P!,\*7XO[*XM6DO2R+/
M&4+#8HR ><9[UZC7Y3GDE+,:KB[J_P"AW4O@04445Y)H%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B^(?#T.MVV1B.[0?
MNY/7V/M_*MJBIG!37++832DK,\>@T6_GU0Z<L#+< X8-T4>I/I[UZ=HNBV^B
MV8BB&Z5N9)2.7/\ A[5I8&<XY]:6L*&%C2=]V9TZ2AJ%%%%=)J%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-WQZ'
M_%?6_P#V#X__ $.2O+J]1^/?_(_6W_8.C_\ 0Y*\NK]=R3_D7T?0X*GQL*]
M^%7@6P\:ZI>#4IYDM[)4<Q18!D+$\%NPX[#OU%>?U[5^SS_Q_P"O?]<H?YO2
MSRO4H8"I4I.TE;7YI!32<TF>TZ1HFF:!9"STJQAM(!_#&N-Q]2>I/N>:OT45
M^2RG*<G*3NV=]K!1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &/JO_'TO^X/YFBC5?\ CZ7_ '!_
M,T4 6M*_X]6_WS_(5>JCI7_'JW^^?Y"KU !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!EZIX:T36YDFU32;.\EC7:KS0AF ZXR>U4/\ A /"'_0MZ9_X
M#K71T5O'%5X+EC-I>K%RKL<Y_P (!X0_Z%O3/_ =:TM*T'2=#65=*TVULA*0
M9/(B";\=,XZXR?SK1HHGB:TURSFVO-L+)!1116 PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?
M5?\ CZ7_ '!_,T4:K_Q]+_N#^9HH M:5_P >K?[Y_D*O51TK_CU;_?/\A5Z@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#'U7_CZ7_<'\S11JO_'TO^X/YFB@"UI7_'JW^^?Y"KU4=*_X
M]6_WS_(5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH Q]5_X^E_W!_,T4:K_ ,?2_P"X/YFB@"UI7_'J
MW^^?Y"KU4=*_X]6_WS_(5>H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH Q]5_X^E_W!_,T4:K_P ?2_[@
M_F:* +6E?\>K?[Y_D*O51TK_ (]6_P!\_P A5Z@ HHHH **** "BBB@ HI&(
M52Q. !DU0T;6K+7K 7M@[-"7*992IR/8T :%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!CZK_Q]+_N#^9HHU7_CZ7_<'\S10!:TK_CU
M;_?/\A5ZJ.E?\>K?[Y_D*O4 %%%% !1110 4444 >?3^)?$'BC5;[3?#,-M%
M:6Y,<MW<=R<CCTZ''!]>*/#.F>+_  K-::;)!97>E/+B1X6RT6X\MS@_H:R;
M:;4OAKKE]Y]A)=:-=ON$T7\/)QST!P<$'&?6N[T/Q=HOB$A+&['GXR8)1M<?
MAW_#- #?&>IW6C^$KZ_LG"7$00(Q4-C+JN<'CH37(:</B1JFG6]];ZQ:"&=
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MPK;^'-,B08"VL8Q_P$5Q'C ?9OBAX:N4X:0QQDCO^\(_DU 'I-%%% !1110
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MZ% #Z*9YT7_/5/\ OH4>=%_SU3_OH4 /HIGG1?\ /5/^^A1YT7_/5/\ OH4
M/HIGG1?\]4_[Z%'G1?\ /5/^^A0 ^BF>=%_SU3_OH4>=%_SU3_OH4 /HIGG1
M?\]4_P"^A1YT7_/5/^^A0 ^BF>=%_P ]4_[Z%'G1?\]4_P"^A0 ^BF>=%_SU
M3_OH4>=%_P ]4_[Z% #Z*9YT7_/5/^^A1YT7_/5/^^A0 ^BF>=%_SU3_ +Z%
M'G1?\]4_[Z% #Z*9YT7_ #U3_OH4>=%_SU3_ +Z% #Z*9YT7_/5/^^A1YT7_
M #U3_OH4 /HIGG1?\]4_[Z%'G1?\]4_[Z% #Z*9YT7_/5/\ OH4>=%_SU3_O
MH4 /HIGG1?\ /5/^^A1YT7_/5/\ OH4 /HIGG1?\]4_[Z%'G1?\ /5/^^A0
M^BF>=%_SU3_OH4>=%_SU3_OH4 /HIGG1?\]4_P"^A1YT7_/5/^^A0 ^BF>=%
M_P ]4_[Z%'G1?\]4_P"^A0 ^BF>=%_SU3_OH4>=%_P ]4_[Z% #Z*9YT7_/5
M/^^A1YT7_/5/^^A0 ^BF>=%_SU3_ +Z%'G1?\]4_[Z% #Z*9YT7_ #U3_OH4
M>=%_SU3_ +Z% #Z*9YT7_/5/^^A1YT7_ #U3_OH4 /HIGG1?\]4_[Z%'G1?\
M]4_[Z% #Z*9YT7_/5/\ OH4>=%_SU3_OH4 /HIGG1?\ /5/^^A1YT7_/5/\
MOH4 /HIGG1?\]4_[Z%'G1?\ /5/^^A0 ^BF>=%_SU3_OH4>=%_SU3_OH4 /H
MIGG1?\]4_P"^A1YT7_/5/^^A0 ^BF>=%_P ]4_[Z%'G1?\]4_P"^A0 ^BF>=
M%_SU3_OH4>=%_P ]4_[Z% #Z*9YT7_/5/^^A1YT7_/5/^^A0 ^BF>=%_SU3_
M +Z%'G1?\]4_[Z% #Z*9YT7_ #U3_OH4>=%_SU3_ +Z% #Z*9YT7_/5/^^A1
MYT7_ #U3_OH4 /HIGG1?\]4_[Z%'G1?\]4_[Z% #Z*9YT7_/5/\ OH4>=%_S
MU3_OH4 /HIGG1?\ /5/^^A1YT7_/5/\ OH4 /HIGG1?\]4_[Z%'G1?\ /5/^
M^A0 ^BF>=%_SU3_OH4>=%_SU3_OH4 /HIGG1?\]4_P"^A1YT7_/5/^^A0 ^B
MF>=%_P ]4_[Z%'G1?\]4_P"^A0 ^BF>=%_SU3_OH4>=%_P ]4_[Z% #Z*9YT
M7_/5/^^A1YT7_/5/^^A0 ^BF>=%_SU3_ +Z%'G1?\]4_[Z% #Z*9YT7_ #U3
M_OH4>=%_SU3_ +Z% #Z*9YT7_/5/^^A1YT7_ #U3_OH4 /HIGG1?\]4_[Z%'
MG1?\]4_[Z% #Z*9YT7_/5/\ OH4>=%_SU3_OH4 /HIGG1?\ /5/^^A1YT7_/
M5/\ OH4 /HIGG1?\]4_[Z%'G1?\ /5/^^A0 ^BF>=%_SU3_OH4>=%_SU3_OH
M4 /HIGG1?\]4_P"^A1YT7_/5/^^A0 ^BF>=%_P ]4_[Z%'G1?\]4_P"^A0 ^
MBF>=%_SU3_OH4>=%_P ]4_[Z% #Z*9YT7_/5/^^A1YT7_/5/^^A0 ^BF>=%_
MSU3_ +Z%'G1?\]4_[Z% #Z*9YT7_ #U3_OH4>=%_SU3_ +Z% #Z*9YT7_/5/
M^^A1YT7_ #U3_OH4 /HIGG1?\]4_[Z%'G1?\]4_[Z% #Z*9YT7_/5/\ OH4>
M=%_SU3_OH4 /HIGG1?\ /5/^^A1YT7_/5/\ OH4 /HIGG1?\]4_[Z%'G1?\
M/5/^^A0 ^BF>=%_SU3_OH4>=%_SU3_OH4 /HIGG1?\]4_P"^A1YT7_/5/^^A
M0 ^BF>=%_P ]4_[Z%'G1?\]4_P"^A0 ^BF>=%_SU3_OH4>=%_P ]4_[Z% #Z
M*9YT7_/5/^^A1YT7_/5/^^A0 ^BF>=%_SU3_ +Z%'G1?\]4_[Z% #Z*9YT7_
M #U3_OH4>=%_SU3_ +Z% #Z*9YT7_/5/^^A1YT7_ #U3_OH4 /HIGG1?\]4_
M[Z%'G1?\]4_[Z% #Z*9YT7_/5/\ OH4>=%_SU3_OH4 /HIGG1?\ /5/^^A1Y
MT7_/5/\ OH4 /HIGG1?\]4_[Z%'G1?\ /5/^^A0 ^BF>=%_SU3_OH4>=%_SU
M3_OH4 /HIGG1?\]4_P"^A1YT7_/5/^^A0 ^BF>=%_P ]4_[Z%'G1?\]4_P"^
MA0 ^BF>=%_SU3_OH4>=%_P ]4_[Z% #Z*9YT7_/5/^^A1YT7_/5/^^A0 ^BF
M>=%_SU3_ +Z%'G1?\]4_[Z% #Z*9YT7_ #U3_OH4>=%_SU3_ +Z% #Z*9YT7
M_/5/^^A1YT7_ #U3_OH4 /HIGG1?\]4_[Z%'G1?\]4_[Z% #Z*9YT7_/5/\
MOH4>=%_SU3_OH4 /HIGG1?\ /5/^^A1YT7_/5/\ OH4 /HIGG1?\]4_[Z%'G
M1?\ /5/^^A0 ^BF>=%_SU3_OH4>=%_SU3_OH4 /HIGG1?\]4_P"^A1YT7_/5
M/^^A0 ^BF>=%_P ]4_[Z%'G1?\]4_P"^A0 ^BF>=%_SU3_OH4>=%_P ]4_[Z
M% #Z*9YT7_/5/^^A1YT7_/5/^^A0 ^BF>=%_SU3_ +Z%'G1?\]4_[Z% #Z*9
MYT7_ #U3_OH4>=%_SU3_ +Z% #Z*9YT7_/5/^^A1YT7_ #U3_OH4 /HIGG1?
M\]4_[Z%'G1?\]4_[Z% #Z*9YT7_/5/\ OH4>=%_SU3_OH4 /HIGG1?\ /5/^
M^A1YT7_/5/\ OH4 /HIGG1?\]4_[Z%'G1?\ /5/^^A0 ^BF>=%_SU3_OH4>=
M%_SU3_OH4 /HIGG1?\]4_P"^A1YT7_/5/^^A0 ^BF>=%_P ]4_[Z%'G1?\]4
M_P"^A0 ^BF>=%_SU3_OH4>=%_P ]4_[Z% #Z*9YT7_/5/^^A1YT7_/5/^^A0
M ^BF>=%_SU3_ +Z%'G1?\]4_[Z% #Z*9YT7_ #U3_OH4>=%_SU3_ +Z% #Z*
M9YT7_/5/^^A1YT7_ #U3_OH4 /HIGG1?\]4_[Z%'G1?\]4_[Z% #Z*9YT7_/
M5/\ OH4>=%_SU3_OH4 /HIGG1?\ /5/^^A1YT7_/5/\ OH4 /HIGG1?\]4_[
MZ%'G1?\ /5/^^A0 ^BF>=%_SU3_OH4>=%_SU3_OH4 /HIGG1?\]4_P"^A1YT
M7_/5/^^A0 ^BF>=%_P ]4_[Z%'G1?\]4_P"^A0 ^BF>=%_SU3_OH4>=%_P ]
M4_[Z% #Z*9YT7_/5/^^A1YT7_/5/^^A0 ^BF>=%_SU3_ +Z%'G1?\]4_[Z%
M#Z*9YT7_ #U3_OH4>=%_SU3_ +Z% #Z*9YT7_/5/^^A1YT7_ #U3_OH4 /HI
MGG1?\]4_[Z%'G1?\]4_[Z% #Z*9YT7_/5/\ OH4>=%_SU3_OH4 /HIGG1?\
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MK=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=%
M%3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S
M;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X
M?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C
M1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9M
MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</
M_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1J
MW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!
M4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LV
MV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'
M_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT
M?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;
M?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_
M -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&
MK=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=%
M%3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S
M;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X
M?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C
M1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9M
MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</
M_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1J
MW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!
M4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LV
MV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'
M_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT
M?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;
M?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_
M -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&
MK=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=%
M%3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S
M;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X
M?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C
M1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9M
MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</
M_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1J
MW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!
M4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LV
MV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'
M_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT
M?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;
M?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_
M -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&
MK=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=%
M%3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S
M;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X
M?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C
M1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9M
MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</
M_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1J
MW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!
M4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LV
MV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'
M_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT
M?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;
M?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_
M -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&
MK=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=%
M%3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S
M;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X
M?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C
M1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9M
MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</
M_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1J
MW10!4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!
M4_LVV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LV
MV_N'_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'
M_OHT?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT
M?V;;?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;
M?W#_ -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_
M -]&K=% %3^S;;^X?^^C1_9MM_</_?1JW10!4_LVV_N'_OHT?V;;?W#_ -]&
MK=% #(HDA38@PO7K3Z** "BBB@ HHHH Q]5_X^E_W!_,T4:K_P ?2_[@_F:*
M +6E?\>K?[Y_D*O51TK_ (]6_P!\_P A5Z@ HHHH **** "BBB@"&>TMKIHF
MN+>*9HFWQF1 Q1O49Z'WJ:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** ,?5?^/I?]P?S-%&J_P#'TO\ N#^9HH M:5_QZM_OG^0J
M]5'2O^/5O]\_R%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** ,?5?^/I?]P?S-%&J_\ 'TO^X/YFB@"U
MI7_'JW^^?Y"KU4=*_P"/5O\ ?/\ (5>H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q]5_P"/I?\ <'\S
M11JO_'TO^X/YFB@"UI7_ !ZM_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,
M?5?^/I?]P?S-%&J_\?2_[@_F:* +6E?\>K?[Y_D*O51TK_CU;_?/\A5Z@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#'U7_CZ7_<'\S11JO\ Q]+_ +@_F:* +6E?\>K?[Y_D*O51TK_C
MU;_?/\A5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#'U7_CZ7_<'\S11JO_ !]+_N#^9HH M:5_QZM_
MOG^0J]5'2O\ CU;_ 'S_ "%7J "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,?5?\ CZ7_ '!_,T4:K_Q]
M+_N#^9HH M:5_P >K?[Y_D*O51TK_CU;_?/\A5Z@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'U7_CZ7
M_<'\S11JO_'TO^X/YFB@"UI7_'JW^^?Y"KU4=*_X]6_WS_(5>H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH Q]5_X^E_W!_,T4:K_ ,?2_P"X/YFB@"UI7_'JW^^?Y"KU4=*_X]6_WS_(
M5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH Q]5_X^E_W!_,T4:K_P ?2_[@_F:* +6E?\>K?[Y_D*O5
M1TK_ (]6_P!\_P A5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#'U7_ (^E_P!P?S-%&J_\?2_[@_F:
M* +6E?\ 'JW^^?Y"KU4=*_X]6_WS_(5>H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q]5_X^E_W!_,T4
M:K_Q]+_N#^9HH M:5_QZM_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M #\1_E_]:KU% %'RM1_Y^(_R_P#K4>5J/_/Q'^7_ -:KU% %'RM1_P"?B/\
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M)<)"9TW.,@@#'\JU*HS_ /(4M_\ =_QH /*U'_GXC_+_ .M1Y6H_\_$?Y?\
MUJO44 4?*U'_ )^(_P O_K4>5J/_ #\1_E_]:KU% %'RM1_Y^(_R_P#K4>5J
M/_/Q'^7_ -:KU% %'RM1_P"?B/\ +_ZU'E:C_P _$?Y?_6J]10!1\K4?^?B/
M\O\ ZU'E:C_S\1_E_P#6J]10!1\K4?\ GXC_ "_^M1Y6H_\ /Q'^7_UJO44
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M\O\ ZU'E:C_S\1_E_P#6J]10!1\K4?\ GXC_ "_^M1Y6H_\ /Q'^7_UJO44
M4?*U'_GXC_+_ .M1Y6H_\_$?Y?\ UJO44 4?*U'_ )^(_P O_K4>5J/_ #\1
M_E_]:KU% %'RM1_Y^(_R_P#K4R7^T(8FD:="%ZX _P *T:KWW_'E+]/ZT 5X
MUU"6-76>/##(R/\ ZU.\K4?^?B/\O_K58M/^/2+_ '14U %'RM1_Y^(_R_\
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M_K5>HH RX'OKA6*3H-IP<@?X5-Y6H_\ /Q'^7_UJ-,_U4O\ OU>H H^5J/\
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M^5J/_/Q'^7_UJ/*U'_GXC_+_ .M5ZB@"CY6H_P#/Q'^7_P!:CRM1_P"?B/\
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M_;Q[WG0C.. /\*D$>HD ^?'^7_UJ=JG_ !Z#_>%7%^X/I0!2\K4?^?B/\O\
MZU'E:C_S\1_E_P#6J]10!1\K4?\ GXC_ "_^M1Y6H_\ /Q'^7_UJO44 4?*U
M'_GXC_+_ .M1Y6H_\_$?Y?\ UJO44 4?*U'_ )^(_P O_K4>5J/_ #\1_E_]
M:KU% %'RM1_Y^(_R_P#K4>5J/_/Q'^7_ -:KU% %'RM1_P"?B/\ +_ZU'E:C
M_P _$?Y?_6J]10!1\K4?^?B/\O\ ZU0N]\EPD)G3<XR" ,?RK4JC/_R%+?\
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M )^(_P O_K5>HH H^5J/_/Q'^7_UJA@>^N%8I.@VG!R!_A6I5'3/]5+_ +]
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M#_6VW^__ (5>H H^5J/_ #\1_E_]:CRM1_Y^(_R_^M5ZB@"CY6H_\_$?Y?\
MUJ/*U'_GXC_+_P"M5ZB@"CY6H_\ /Q'^7_UJ/*U'_GXC_+_ZU7J* */E:C_S
M\1_E_P#6H\K4?^?B/\O_ *U7J* */E:C_P _$?Y?_6H\K4?^?B/\O_K5>HH
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M44 %%%% !1110 4444 %%%% "!0"2  3UI:** "BBB@ HHHH **** "BBB@
MHHHH **** #K2 !1@  >U+10 4444 %%%% !1110 4444 %%%% !1110 4A
M(P1D>]+10   # &!1110 4444 %%%% !1110 4444 %%%% !1110 A4'&0#C
MIFEHHH **** "BBB@ HHHH **** "BBB@ HHHH *3:-V[ SZTM% !1110 44
M44 %%%% !1110 4444 %%%% !1110 @4+T 'TI:** "BBB@ HHHH **** "B
MBB@ HHHH **** $(!&",CWI0 !@# HHH **** "BBB@ HHHH **** "BBB@
MHHHH *0J#C(!QTS2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% ";03
MD@9'>EHHH **** "BBB@ HHHH **** "BBB@ HHHH *0* 20 ">M+10 4444
M %%%% !1110 4444 %%%% !1110 4=:** $ "C   ]J6BB@ HHHH **** "B
MBB@ HHHH **** "BBB@!"H88(!'O2T44 %%%% !1110 4444 %%%% !1110
M4444 %)M!.2!D=Z6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0* 2
M0 ">M+110 4444 %%%% !1110 4444 %%%% !1110 4@4+T 'TI:* "BBB@
MHHHH **** "BBB@ HHHH **** "D(!&",CWI:*    8 P**** "BBB@ HHHH
M **** "BBB@ HHHH **** $*@XR <=,TM%% !1110 4444 %%%% !1110 44
M44 %%%% !2;1NW8&?6EHH **** "BBB@ HHHH **** "BBB@ HHHH **** $
M"@$D  GK2T44 %%%% !1110!CZK_ ,?2_P"X/YFBC5?^/I?]P?S-% %K2O\
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M%%% !1110 4444 %%%% !1110 4444 %%17%Q#:6TEQ<2+'#$I9W8X"@=37
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MB7J63'"SY&2/IC'_ (]0!Z)15+2]6L=9LEO+"X6:%N,CJI]".H-7: "BBB@
MHHHH **** "BBB@ HHHH ***Q/$?BC3_  S:I)=EI)I3B*"/EW/]![T ;=%<
M!;?%&W2]6WUC2+O30_W7?+<>I& <?3-=W!/%<P)/!(DL3C<CH<AAZ@T 2444
M4 %%%% !1110 4444 %%%% !1110 45R?B/QQ#HU\NF6-E+J6ID9,$.?D^N
M3GO@#\JS]*^)EM+?_8-;T^72IR<!I2=H/^UD K_+Z4 =Y12*P90RD%2,@CO2
MT %%%% !1110 4444 %%%% !1110 445PFH_$9OMTUMH.CW&JK!_K9HPVT?3
M /'OQ0!W=%<GX:\?:;XAF^R2(UE?]!!*V0Q]%/&3[8!KK* "BBB@ HHHH **
M** "BBB@ HHHH ***@O;RWT^SEN[N58H(EW.[= * )Z*\YF^)]T0UU9^&[J;
M3%./M+%@"/7(4@?G76>'?%.F>)K8R64I$J#]Y!)PZ?AW'N* -JBBB@ HHHH
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MVM;BZC5L-,I"@^ZYZ_I77Z-K5CKVGK>V$N^(G!!&&1O0CL: -"BBB@ HHHH
M**** "BBB@ HHHH **** "BJNHZC::38R7M],L-O&,LQ_D!W-<-'\7-*:\$;
MV%TEL6QYYP2/<K_]>@#T.BHK:YAO+:.YMY5EAD4,CJ<A@:EH **** "BBB@
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M;T/'T])KSGXI"*:318;8@ZL;G]RJ_>VG_P"RVX_&O1J "BBB@ HHHH ****
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MR#[T;>H_P[UYW8^)-8\ 33:#JEL]Z@7-BRGKG@ ?[)].HZ4 >LT5B>%EUO\
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M&B8;N(EYX$'#CNP'?W'?Z]6:;XPUWQA?65MHT LHX=LE_<.H=?\ ='L?3K]
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M;I['>!]:] M[B&[MX[BWE66&10R.IR&![UPNK2QVOQATR:1UCC_LYFD=C@
M2\Y_"@#K]8T73]=LC::A;K+'U4]&0^H/8UQ*_"A4=HD\07:V#'YK<)@L/<[L
M?^.TK:EJGCW6Q!I,\UCH=G(&DNTRKRL.1C^@[=3V%>BT 4]+TNST;3X[&QA$
M4$8X'<GN2>YJY110 4444 %%%% !1110 45FZ]K-OH&C7&HW ++$/E0'EV/
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M2Y]&T2"RN;R2[F0$O+(<\DY(&><#WH H^%/"D'ARU9W?[1J,_P UQ<MR6/7
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M9SWSZCU[=AW->@4 ,BBC@A2&%%CC10JHHP% Z "GT44 %%%% !1110 4444
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M]@TRTLPV_P"SPI%N]=J@9_2@#+\,>%[3PU9,D;&>[E.ZXN7'S2'^@]JW:**
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M,J>1!O&#)C:,_DOYG':O0: &QQI%&L<:*B* JJHP !V IU%% !1110 4444
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MF:[D')!/0=<#U]?RJ_X=TU](\/6%A(09(80KD'C=U./Q)K3H **** "BBB@
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M3>& V[):XM5&<@\D@=U/<=NH]M32OB=H-Y9>9?2M8W"CYXG1F!/^R0.1^1H
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M$&)%9&*,>^,9(^A_6J.F3GQC\1H=;LHG73--B\H3.N/-;#8Q^+9^@[9H O\
MB;P"WB+Q1!J#W:QV?E!)T&=YVDGY>W/OT]Z[&SL[>PM(K6UB6*")=J(HX J>
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q]5_X^E_W!_,T4:K_P ?
M2_[@_F:* +6E?\>K?[Y_D*O51TK_ (]6_P!\_P A5Z@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#AOB-]OT]-+UZ
MSD<KI\^98L_*0V!D_P#H/_ JVTTK3]<U72O$\<KL8H#Y2]5(8'!QV(R?\BM7
M4+&'4M/N+*X7=%/&48>Q'7ZUQ7PYOIK&34/"U\W^D6$C-%_M(3SCVR0?^!4
M=]7G_P /H_L'B+Q1IB\0PW(:-1V&7'\MOY5Z!7D@\2CPSXP\4&.!KB\N9E2V
MB )W/D]<=N>G4T >EWU]I1NHM)OI;=IKM3LMI0&\P#U!X_/KBJ]EX5T+3KO[
M5::7;Q3@Y#A<E3[9Z?A6+X3\)SV]TVO:\_VC69_F^;D0 ]AVSCCCIT%=E0 4
M444 %%%% !1110 4444 %>?ZC?77AOXG07%S<.VFZK&(OF/RQD< #TPV#]'-
M>@5S/CO0O[=\,3I$N;JW_?PX')('(_$9'UQ0!J0:'96^O7.LQJPN[F)8I"3D
M8&.0.QX'Y"KMU;I=VDUM(,I*C1L/8C!K"\$Z[_;_ (9M[AWW7,7[F?/7>._X
MC!_&NBH X7X42,WA.:-C_JKQT'TVJ?YDUMW-WX<\0:K+H-RD%Y=0)YC(R9"=
MCANQ&1G![_6O,O#FN:G'87?A[0X7.I7EX[F;H(8\*"<]CP>>WU(KT[PMX6M/
M#-@8XSYMW+S/<,.7/]![4 7=+T#2M%#?V=8PVY?[S*,L1Z9/.*T:** "BBB@
M HHHH **** "BBB@#S_P3>W6E>(]6\,:C,\LBR-<6\DC9+@\GGW!#?\ ?5==
MHVAV6@VTUO8HRQRS-,0S9P3CC/IP*Y'XBV<VG76G>*[)?W]E($FQ_$A/&?;D
MJ?\ >KN+&\AU"Q@O+=MT,Z"1#[$4 <[\1K9;GP/?DC+1;)%/H0PS^A-:GANX
M$GA/2YY7 _T.(NS'CA!DFJGCK_D2=5_ZY#_T(5P>EW.J^,]+L/#NG[[73+6!
M$OKG'WL#[H_P[]^* .WBA\+>-A-<"U@O#!(8FE*%6R.GS#!(]*W;'3[/3+86
MUC;16\(YV1K@9]3ZGWJ/2M*L]%T^*QL8A'#&/Q8]R3W)J[0 4444 %%%% !1
M110 4444 9?B.PGU/P[?V=K*\4\L1$;*<$GKC/H<8/L:YSP=>1>+/!4NDZEO
M:6 ?9K@9PV/X3]>/S4UV]>;W0_X0[XF17(^33=9^5_[JR$\G\&(/T8T >@6-
MG%I]A;V4 (B@C6-,]< 8Y]ZXCXA((-<\+WZ\21WH0GU&Y3_0_G7?UP'Q3E6"
MST>9\[([T,V/0#- '::EJ5II-A+>WLRQ01C+,>_L!W/M6/#X>\+:]%#JT>F6
MTJSCS%<(5W9]0,9/UKF;&QOOB)J::IJB/;Z# Q^S6N<&8^I_J?P'<UZ/'&D4
M:QQHJ(H"JJC  '8"@!(HHX8EBB18XT&%11@ >@%/HHH **** "BBB@ HHHH
M*X[XD6U\?#\6H6,TB2:?.MPR*>"!W([X.#],UV-,FACN()(95#QR*4=3W!&"
M* .;AL[#QE!H.OL[!K4F58UY7=QN4_1E'/M73UYWX&FD\/>)=3\)W3ML#F:T
M+?Q#_P"NN#^!KT2@#S_PQ'_9_P 3_$EC'Q%)&LY4=,DJW_M0UV.H:GIEI+!9
MW]Q"C7C>7'%)SYA/;'IVY]:\YU3Q!#X:^)VN7TL;2NUDD<4:_P <A$1 )[#@
M_E6YX7\+W=WJ'_"2^)?WFHR?-!;L/E@';CL?0=OKT -^#PCX?MKP7<.D6J3
MY!"<*?4#H/P%;5%% !1110 4444 %%%% !1110!P'BN\NO#GCC2M<>:1M-G7
M[+,A;Y8_7^C?\!-=:=$L7U]-<VL;M8#""&^4J3G./7K^=0>*M$7Q!X=NK' \
MTKOA)[2#D?X?0FLKX=ZTVJ>&UM;@D7=@?L\JMUP/ND_AQ]5- '7$ @@C(/45
MP'PR3[(VOZ<N?+MKTA1^:_\ LHKOZ\;LO$%[I&N^)=,TJV:?4[[4'2 @9"8=
M\M^H]NI/2@#TC4-0T#4-63P[?>1<W3J7$#IN P,]>QQD^M3Z9X;T;1I6ET_3
MH8)3P7 RV/0$Y(K.\)>$H_#\+W-R_P!IU6X^:XN&.3D\E03V]^_Y8Z:@ HHH
MH **** "BBB@ HHHH *\_P!"O;K0OB)J>B7]P\D.H,;BV>0YR>H'Y CZH*]
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M=OT.,?C6S10!P6B"W^('@.&ROII$GMG5)60_-N7H3]5_7/I7>(BQHJ(H55&
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M=MI5O'.#E6VYVGU / _"L3PIX4N1>'Q#XA;S]6F^9$;I .W'K_*NUH ****
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M;^?6@"]I?A[2-%+-IUA# S#!=1EB/3)YQ6G110 4444 %%%% !1110 4444
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M7EOJ>I_&KM%% !1110 4444 %%%% !45S"UQ:30K*T32(R"1.JDC&1[BI:*
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M!/*'^H/8U7\1:'=ZOX@\/S*JFQLYVFGRW(( *\=^1C\:YSQ3X6O-!U$^)_#
M,;IEKBV0<$=R!W4]Q^(]@#TBO._',,GA_P 1Z9XLM5.U7$%VJC[R_P#UUR/P
M6NG\+>*;/Q1IPG@(CN$P)X">4/\ 4'L:NZUIL&M:1=Z9,0!-'CW4_P +?@1G
M\* +L,T=Q!'/$P>.10Z,.A!&0:RHO"^DQ>(9=<6WS>R#[S'*J<8W =B1W_\
MKUS_ ,-M4E?3;G0KW*WFF2&,JW79D_R.1],5W% !1110 4444 %%%% !1110
M 5Q?B_QV?#&LV5DMJLZ.GFW!S\P0D@;??C//]<UVE<I'X9DN_&>L:AJ<$4UC
M<6J6\"DYRN!N!'4$%?UXH Z'3M1M=5L8KVRF66"495A_(^A]JM5Y5-#J7PQU
MG[1;B2Z\/W+_ #H3RA_HP['H1^GI>G:C:ZK8Q7ME,LL$HRK#^1]#[4 <%IW_
M !1_Q*GT\Y73M7&^'T5R3@?GE?Q%>CUQ_P 1-&.J^'3>6N3>:>QFC9#S@?>
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M364FH>%KYL7%A(S19_B0GG'MD@_\"JIX2NKWPGXI?PGJ,ADM9LO9RGIW(QZ
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MK==H^Z3^1'_ : .@70]-367U=;2,7[IL,W?'3Z9QQGKBM"BB@ HHHH ****
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M:K_Q]+_N#^9HH M:5_QZM_OG^0J]5'2O^/5O]\_R%7J "BBB@ HHHH ****
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M 3S6W"'C!V^G].U;= &7;^'["U\076MQ(XO+F,1O\WRX&.@]3@9^GUK4HHH
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MYV@^G\ZW: ,K1_#UAH<]]+9*ZM>R^;)N;(!YX4=@,G\ZU:** "BBB@ HHHH
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M_(=!QUT[#P]8:;K%_JELCK<7I!E!;Y1ZX'N>3UYK5HH **** "BBB@ HHHH
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MK\GF,/\ EH<?S[_3KV>J>'M/UB]L+N[1C+8R>9$5;&3P<'U&0#^%:@ 50J@
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MV1/ 4=0H_#(^J^];VE>'H-*U;5-0CE:234) [;ARF,\ ^F2?T]* .".I^*O
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MW=6T5Y:36TZ!X9D*.I[@C!JIHNCVN@Z5%IUGO,,>2#(V6))R2:T** "BBB@
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M&/&&G>*(2("8;I!F2WD/S#W![CW_ )5G?$?1GOM!74;7(O--;ST91SM_B_+
M;_@- '7S0Q7$+PSQ)+$XPR.H96'H0>M075Y8Z39^9=3PVMO&, L0H '8?X"J
MGAO64U[0+34$(W2)B11_"XX8?G^F*9K/AC2?$$UO+J5KYS09V8<KD'L<'D4
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M/^ BO0HI8YX4FB</'(H9&'0@\@T 9NM>(]+T"V::_ND1@,K$IS(_T7_(KFO
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MQZE;F586W(0Q4C/49'8U=LK&UTZU2UL[>."!.B(,#_\ 7[T 6**** "BBB@
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M<'\: .:\(0W/B#Q7?>+KBW:"U=/)LT<<L.!N_(?FQ]*[^D1%C1410JJ,!0,
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M'>,-%U#2+:S26.SN+>)8S;RL%^Z,94GJ/UH I^%/%>J)K;^&_$J;=07/DS8
M\SC.#C@\<@CKCUJGX@_XI#XA6>NIE;#41Y5UCH&Z$_\ H+?@:6_N+?Q'\4-)
M&EL)ET]2US<1\J "3C/?GC_@5=AXET"'Q)HLNG3/Y18AXY=NXHP[XR.V1^-
M&OU&114%C:BQL+>T61Y!!$L8=SEFP,9/O4] !1110 4444 %%%% !1110!P7
MQ7$H\/V4@0O;1W:M,H[\''X=1^(KL]-O;34-.@NK%T>VD0%"O0#TQVQTQVI]
M[9V^H64MI=Q++!*NUT/<5P'_  JZX@FEAL/$=U;:?*<O  <D>APP!^I% &#K
MEM+?>+=2UCPI&L8TM%DFEAZ229.XJ.AXSD=]IZYY],\-ZW#XE\/PWP109 4F
MCZA7'##Z=_H13],TK3?#&B&VA"Q6L2EY9)#RW'+,:Y?X50LNA7\X7;;S7C&%
M?8 #/]/PH K>$6;PMXTU#PO,S?9;@^?9EOIG_P!!&/JE>C5@ZWX7@UK5M+U$
MSO!-8R;\QCF1<YVY[<C]3ZUO4 %%%% !1110 4444 %%%9^N:HNBZ)>:BR;_
M "(RP7.-QZ ?F10!H5R3^';J]^(IU>^19+"VMU%I\V</WR/4'<?Q'I47@OQU
M%XC4V=ZJ6^IKDA%X65?5<]QW'X_3LJ ,SQ!I,6MZ'=V$J!C)&?+)'W7 ^4C\
M:Y_X7WKWG@V..0DFUF>$$^G##_T+%=G7EW@S7[+PUX8UBYO'X6_<11C[TC;1
MP/R_"@#T'7-*BUO1;O3I< 3(0K$?=;JI_ X-<Q\-M5EFTJ?1+SY;W3)#$5/7
M9GC\B"/RJ3PA!KVI7\WB+5[B2".X3;;V(.%"=02/Y=SG-:T'A>"V\7W'B"*=
MT>>'RW@484MQEB>_0<>O- &[1110 4444 %%%% !1110 4444 <KX-\/7.E/
MJ5_J:*=2O+EV9P<_)GC!]"<G\O2N:\>7]I#XYT.2WADN;ZT_>2Q6XR[X(9$_
M0_0'->GUBZ-X7T[1+JZNX%DENKF1G>>=MS@$YV@^GZGO0!S%O\1[JUU2&U\0
M:'+IL4YPDK$_+VR00,CU(Z>E:'Q%T9M2\/"_M<B[TYO/C9.NW^+'Y _\!JE\
M4[FVDT6VTP*)=0N)U,$2C+#L3^.<>^:[2PMFM]+MK68B1HX$C<G^(A0#0!3\
M,ZRFO^'[34%QO=<2K_=<<,/S_0BM:L+PSX9A\,07<-O<22Q3SF5488$8Z #U
M.._?%;M !1110 4444 %%%% !1110 5YWX$NET_Q1XDTJ[(2Y:X:=6<XWJ"<
MG\B#^)KT2N$\?^#YM4 UC2=RZE$A61$.#,F,<?[6./<<>E %635/%'C2[N/^
M$=G33])A8HMS)PTS#T."?RQ[^E.\/^*-:TKQ"GAWQ3AI9B!;W( ^8G@#(Z@]
M >N>OM/X#\6Z.=&MM(E9+&[ME\LQS':)#W8$]R<DCK5/Q7=6OB/QGH&FZ8ZW
M$]K/YL\L1R(TRI(R.XV_GB@!_C>*3PYXHTSQ9;*?++""[4#J,8_5<C_@(KT*
M*6.>%)HG#QR*&1AT(/(-4M;TF'7-&N=-G.U)DP&QG:PY!_ @&G:-IHT?1K73
MEF>86\83S'ZG_ >@]* +U%%% !1110 4444 %%%% !7&_$])W\%3^2"566-I
M<?W<_P".VNRIDT,=Q"\,R*\4BE71AD,#U!H S/#5_9:CX=LIK KY(B5-B_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ,?5?^/I?]P?S-%&J_\ 'TO^X/YFB@"UI7_'JW^^?Y"KU4=*_P"/5O\
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M@!3\(_#A=&OFOM5DBNIHF_T9%R44?WCGO[=OKT] HHH **** "BBB@ HHHH
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ML[?>=N[$^M:5% !1110 4444 %%%% !1110 51UFWN+O1+ZVM"HN)H'CC+'
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M@4-L..#@\'%244 <7IW@-Y-474_$>I/JMS&<Q1L,1K^'].!]:[2BB@ HHHH
M**** "BBB@ HHHH **** "BBB@#'USPOI'B) -0M0TBC"S(=KK^/?Z'(JOH7
M@O1?#TQGL[=FN",>=,VY@/;L/P%=!10 4444 %%%% !1110 4444 %%%% !1
M110 5C>)+'6-1L%M]'U".R=FQ+(RDML_V2.A_P Y%;-% &/X;\-V?AK3OLUM
MEY'.Z:=OO2-ZGV]!6Q110 4444 %%%% !1110 4444 1SB5K>586"RE"$+=
MV.,UQ5A\/[>;P/#I&I(J7H9Y?.3DQR$]0>XP%!'?%=S10!YGX;\27OA/4QX:
M\2G;".+:Z)RH7MSW7T/;H?;TII$1"[NJH.2Q.!6)XKT+3=<T65-1=81"I=+D
M\&$^OT]1W_*O.?#&FZYXOM(]+N;Z3_A'[.0@R@$&7'1 3R1]>F?H* .H\2>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH Q9O#&GW'B5-=N!)-<QQA(T=LHA'\0'K_P#K
MZUM444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !6+J7A?3]6UJTU.]$DK6JE4A
M9LQDYR"5]?Y\9Z5M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C:UX9L
M-?N[*>_\QUM&++#N_=OG^\._2M@ *H50 !P .U+10 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %9&O^';/Q'#;0WSS>5#*)=D;X#^S>WZUKT4 ,BBC@A2&%%CC1
M0JHHP% Z "GT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7K^A6WB+3?L-W),
MD7F*Y\I]I..Q]1_^OM5VSL[>PM(K6UB6*")=J(HX J>B@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,?5?^/I?]P?S-%&J_P#'TO\ N#^9HH M:5_QZM_OG^0J]5'2O^/5O]\_R%7J
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ,?5?^/I?]P?S-%&J_\ 'TO^X/YFB@"UI7_'JW^^?Y"KU4=*
M_P"/5O\ ?/\ (5>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"(KYW-\@J86LH86,IQ:O>U];OLC6G54E[QW%%</_PN'P'_ -!W_P E)_\
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M?_()O/\ K@__ *": ,SPIXE3Q3I4E]';-;B.8PE&?=G"J<YP/[U;M<#\(O\
MD5+K_K^?_P! CJ-OB'>)K>JZ4FFBZNXKCR+**$$%\%@Q<YZ# /&.OXT >A45
MYY/XU\2>'[VW/B71[>*QG?:)+=LE?QW$$CTXSSBN_DGBBMGN'D40HA=GSP%
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MTWQUH%].&,4"B1@HR2 Y/% 'I]%>>WGBOQG#9MJR>';>/357>4D8F4)_>(#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:C', 8VMI V?3::X_P"' \SX>W27$GEPF29=Y_A3:,G\.:AU"?QMXHM#I?\
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MY_D*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 4-4T73=:@$.HV<5P@Z%A\
MR_0CD?@:NQQK%$D:#:B *H] *=10 4444 %%%% !1110 4444 %%%% '(^!/
M#M_X?M]12^$8,\^]-C[N,5UU%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 0W-K;WMN]O=0QS0N,,DBA@?P-0Z;I=EH]F+2P@$$ 8L$!)Y/)ZU<HH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *HZQID6LZ1<Z=.S+'.FTLO5>X/YXJ]10!P&G:9X[\/6BZ=9/I5[:1\1/-N#
M(/P(]?>K6G>$]6OO$$&M^)KV"66V_P"/>VM@0B'J"3QWY[]N>,5VM% &-XJM
M-1O_  Y=V>EA/M,Z^7EVV@*3\WZ9'XT>%M$_X1_P[:Z>Q4RH"TK+T+DY/^'T
M%;-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 56U"![G3;J"/&^6%T7/3)! JS10!S'@/0[WP_X>:SOP@F,[281MPP
M0!U_"NGHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#'U7_CZ7_<'\S11JO\ Q]+_ +@_F:* +6E?\>K?[Y_D*O51TK_CU;_?/\A5
MZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#'U7_CZ7_<'\S11JO_ !]+_N#^9HH M:5_QZM_OG^0J]5'
M2O\ CU;_ 'S_ "%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** ,?5?\ CZ7_ '!_,T4:K_Q]+_N#^9HH
M CAO);16B54/S$G(-2?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
M-%% !_:T_P#<C_(_XT?VM/\ W(_R/^-%% !_:T_]R/\ (_XT?VM/_<C_ "/^
6-%% $$DLE[+N8*"%QQ_GWHHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>inva-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T16:25:37.1753+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.inva.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:inva="http://www.inva.com/20221231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" namespace="http://fasb.org/srt-types/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inva-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inva-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inva-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="inva-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2">
        <link:definition>100020 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2" id="DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2">
        <link:definition>100030 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet1" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet1">
        <link:definition>100040 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2" id="DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2">
        <link:definition>100050 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2" id="DisclosureIncomeTaxesDeferredTaxesDetails2">
        <link:definition>100060 - Disclosure - INCOME TAXES - Deferred Taxes (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100070 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome" id="StatementConsolidatedStatementsOfIncome">
        <link:definition>100080 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical" id="StatementConsolidatedStatementsOfIncomeParenthetical">
        <link:definition>100090 - Statement - CONSOLIDATED STATEMENTS OF INCOME (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome" id="StatementConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>100100 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100110 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100120 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100130 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShare" id="DisclosureNetIncomePerShare">
        <link:definition>100140 - Disclosure - NET INCOME PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognition1" id="DisclosureRevenueRecognition1">
        <link:definition>100150 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangements" id="DisclosureLicenseAndCollaborationArrangements">
        <link:definition>100160 - Disclosure - LICENSE AND COLLABORATION ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions1" id="DisclosureConsolidatedEntitiesAndAcquisitions1">
        <link:definition>100170 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements">
        <link:definition>100180 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaid1" id="DisclosureCapitalizedFeesPaid1">
        <link:definition>100190 - Disclosure - CAPITALIZED FEES PAID</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" id="DisclosureGoodwillAndIntangibleAssets">
        <link:definition>100200 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponents" id="DisclosureBalanceSheetComponents">
        <link:definition>100210 - Disclosure - BALANCE SHEET COMPONENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>100220 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>100230 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>100240 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>100250 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>100260 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>100270 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100280 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100290 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareTables" id="DisclosureNetIncomePerShareTables">
        <link:definition>100300 - Disclosure - NET INCOME PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionTables" id="DisclosureRevenueRecognitionTables">
        <link:definition>100310 - Disclosure - REVENUE RECOGNITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables" id="DisclosureConsolidatedEntitiesAndAcquisitionsTables">
        <link:definition>100320 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables">
        <link:definition>100330 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidTables" id="DisclosureCapitalizedFeesPaidTables">
        <link:definition>100340 - Disclosure - CAPITALIZED FEES PAID (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" id="DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>100350 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>100360 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>100370 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>100380 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100390 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100400 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails">
        <link:definition>100410 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>100420 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails">
        <link:definition>100430 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails" id="DisclosureNetIncomePerShareDetails">
        <link:definition>100440 - Disclosure - NET INCOME PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" id="DisclosureNetIncomePerShareBasicAndDilutedEpsDetails">
        <link:definition>100450 - Disclosure - NET INCOME PER SHARE - Basic and Diluted EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails" id="DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails">
        <link:definition>100460 - Disclosure - NET INCOME PER SHARE - Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails" id="DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails">
        <link:definition>100470 - Disclosure - REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails" id="DisclosureRevenueRecognitionDetails">
        <link:definition>100480 - Disclosure - REVENUE RECOGNITION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails" id="DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - LICENSE AND COLLABORATION ARRANGEMENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails" id="DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails">
        <link:definition>100500 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails" id="DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails">
        <link:definition>100510 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund LP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails" id="DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails">
        <link:definition>100520 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" id="DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails">
        <link:definition>100530 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails" id="DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails">
        <link:definition>100540 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla Pharmaceutical Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails" id="DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails">
        <link:definition>100550 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails">
        <link:definition>100560 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Armata (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails">
        <link:definition>100570 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Summarized Financial Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails">
        <link:definition>100580 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in InCarda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails">
        <link:definition>100590 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in ImaginAb (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails">
        <link:definition>100600 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Convertible Promissory Note in Gate Neurosciences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails">
        <link:definition>100610 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Nanolive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails">
        <link:definition>100620 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet">
        <link:definition>100630 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" id="DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails">
        <link:definition>100640 - Disclosure - CAPITALIZED FEES PAID - Schedule of Capitalized Fees Paid (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" id="DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails" id="DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails">
        <link:definition>100660 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails" id="DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails">
        <link:definition>100670 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>100680 - Disclosure - BALANCE SHEET COMPONENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails" id="DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails">
        <link:definition>100690 - Disclosure - BALANCE SHEET COMPONENTS - Schedule Of Other Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails" id="DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails">
        <link:definition>100700 - Disclosure - BALANCE SHEET COMPONENTS -Schedule of Other Long-term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails" id="DisclosureStockBasedCompensation2012PlanAndEsppDetails">
        <link:definition>100710 - Disclosure - STOCK-BASED COMPENSATION - 2012 Plan and ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails" id="DisclosureStockBasedCompensationDirectorCompensationProgramDetails">
        <link:definition>100720 - Disclosure - STOCK-BASED COMPENSATION - Director Compensation Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>100730 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails" id="DisclosureStockBasedCompensationCompensationAwardsDetails">
        <link:definition>100740 - Disclosure - STOCK-BASED COMPENSATION - Compensation Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" id="DisclosureStockBasedCompensationValuationAssumptionsDetails">
        <link:definition>100750 - Disclosure - STOCK-BASED COMPENSATION - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>100760 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" id="DisclosureDebtScheduleOfDebtDetails">
        <link:definition>100770 - Disclosure - DEBT - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails" id="DisclosureDebtConvertibleSubordinatedNotesDetails">
        <link:definition>100780 - Disclosure - DEBT - Convertible Subordinated Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails" id="DisclosureDebtConvertibleSeniorNotesDetails">
        <link:definition>100790 - Disclosure - DEBT - Convertible Senior Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails" id="DisclosureDebtDebtMaturitiesDetails">
        <link:definition>100800 - Disclosure - DEBT - Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100810 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails">
        <link:definition>100820 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Components of Least Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails">
        <link:definition>100830 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Cash Flow Information Related to Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails">
        <link:definition>100840 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Operating Lease Information Presented in Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails">
        <link:definition>100850 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" id="DisclosureIncomeTaxesIncomeTaxExpenseDetails">
        <link:definition>100860 - Disclosure - INCOME TAXES - Income tax expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails" id="DisclosureIncomeTaxesReconciliationDetails">
        <link:definition>100870 - Disclosure - INCOME TAXES - Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails" id="DisclosureIncomeTaxesDeferredTaxesDetails">
        <link:definition>100880 - Disclosure - INCOME TAXES - Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails" id="DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails">
        <link:definition>100890 - Disclosure - INCOME TAXES - Additional Tax Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100900 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" name="BalanceSheetDisclosuresOfVariableInterestEntityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CapitalizedFeesPaidFutureAmortizationAbstract" name="CapitalizedFeesPaidFutureAmortizationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" name="ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConsolidatedEntitiesDisclosureAbstract" name="ConsolidatedEntitiesDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" name="ConvertibleDebtInstrumentLiabilityComponentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DenominatorAbstract" name="DenominatorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" name="IncomeStatementDisclosuresOfVariableInterestEntityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NetIncomeLossPerShareAbstract" name="NetIncomeLossPerShareAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NumeratorAbstract" name="NumeratorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NameOfEventAxis" name="NameOfEventAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AccruedClinicalLiability" name="AccruedClinicalLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_AccruedContractManufacturingLiability" name="AccruedContractManufacturingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_AccruedLicenseFeesAndRoyalties" name="AccruedLicenseFeesAndRoyalties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_AccruedProfessionalServices" name="AccruedProfessionalServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_AccruedResearchLiability" name="AccruedResearchLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" name="AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" name="AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment" name="BusinessAcquisitionsOfChangeInFairValueOfInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CapitalizedFeePaidEstimatedUsefulLife" name="CapitalizedFeePaidEstimatedUsefulLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" name="CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" name="CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" name="CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" name="CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" name="CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" name="CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_CapitalizedFeesPaidWeightedAverageUsefulLife" name="CapitalizedFeesPaidWeightedAverageUsefulLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CappedCallStrikePrice" name="CappedCallStrikePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_CashDistributionReceived" name="CashDistributionReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_CashDividendForfeited" name="CashDividendForfeited" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" name="CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" name="ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ClaimExpirationDate" name="ClaimExpirationDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" name="ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" name="CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" name="CollaborativeArrangementRoyaltyRateDefinedLevelOne" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" name="CollaborativeArrangementRoyaltyRateDefinedLevelTwo" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" name="CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_CommonStockAcquiredAverageCostPerShare" name="CommonStockAcquiredAverageCostPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ContingentSalesBasedMilestonePayment" name="ContingentSalesBasedMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ContingentValueRightsLiability" name="ContingentValueRightsLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ConversionRate" name="ConversionRate" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ConvertibleSeniorDebtFairValueDisclosures" name="ConvertibleSeniorDebtFairValueDisclosures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ConvertibleSubordinatedDebtFairValueDisclosures" name="ConvertibleSubordinatedDebtFairValueDisclosures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" name="DebtConversionCommonStockPriceToConversionPriceRatioPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_DebtConversionConvertedInstrumentAdjustedSharesIssued" name="DebtConversionConvertedInstrumentAdjustedSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" name="DebtConversionConvertedInstrumentAverageTradePricePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_DebtConversionConvertedInstrumentSharesIssued" name="DebtConversionConvertedInstrumentSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_DebtInstrumentConvertibleConversionPremium" name="DebtInstrumentConvertibleConversionPremium" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_DebtInstrumentPrincipalAmount" name="DebtInstrumentPrincipalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" name="DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_DebtInstrumentRepurchasePercentage" name="DebtInstrumentRepurchasePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_DebtInstrumentTransactionCost" name="DebtInstrumentTransactionCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_DecreaseToAccumulatedDeficit" name="DecreaseToAccumulatedDeficit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_DeferredRoyaltyObligationAndAccruedInterest" name="DeferredRoyaltyObligationAndAccruedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_DeferredRoyaltyObligationCurrent" name="DeferredRoyaltyObligationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_DeferredRoyaltyObligationNonCurrent" name="DeferredRoyaltyObligationNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" name="DeferredTaxAssetsDeferredRoyaltyObligationNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" name="DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_DeferredTaxLiabilitiesDepreciationAndAmortization" name="DeferredTaxLiabilitiesDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" name="DeferredTaxLiabilitiesInventoryFairValueAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_DemandLettersSentByStockholders" name="DemandLettersSentByStockholders" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" name="DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest" name="DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" name="DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_DilutiveEpsOfNotes" name="DilutiveEpsOfNotes" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_DividendYield" name="DividendYield" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ExpectedHoldingPeriod" name="ExpectedHoldingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ExtendedExpirationDate" name="ExtendedExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_FairValueAdjustmentsIncludedInCostOfProductSales" name="FairValueAdjustmentsIncludedInCostOfProductSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_FairValueAdjustmentsOfInventoryFromAcquistion" name="FairValueAdjustmentsOfInventoryFromAcquistion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_FairValueOfNonControllingInterestInSubsidiary" name="FairValueOfNonControllingInterestInSubsidiary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_FederalNetOperatingLossesEstimatedUtilizationAmount" name="FederalNetOperatingLossesEstimatedUtilizationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_FuturePotentialMilestonePayment" name="FuturePotentialMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_GainLossOnOtherInvestments" name="GainLossOnOtherInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" name="GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_IncomeTaxPayableNonCurrent" name="IncomeTaxPayableNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_IncreaseDecreaseInDeferredTaxLiabilities" name="IncreaseDecreaseInDeferredTaxLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_IncreaseInDeferredTaxAssets" name="IncreaseInDeferredTaxAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_IncreaseToConvertibleNotes" name="IncreaseToConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" name="IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_IntangibleAssetsCollaborationAgreementGross" name="IntangibleAssetsCollaborationAgreementGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_IntangibleAssetsCollaborationAgreementNet" name="IntangibleAssetsCollaborationAgreementNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" name="IntangibleAssetsInProcessResearchAndDevelopmentGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" name="IntangibleAssetsInProcessResearchAndDevelopmentNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" name="IntangibleAssetsMarketedProductsAccumulatedAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_IntangibleAssetsMarketedProductsGross" name="IntangibleAssetsMarketedProductsGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_IntangibleAssetsMarketedProductsNet" name="IntangibleAssetsMarketedProductsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_InterestRateOfDeferredRoyaltyObligation" name="InterestRateOfDeferredRoyaltyObligation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" name="MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" name="MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" name="MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares" name="NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NetOperatingLossEstimatingDate" name="NetOperatingLossEstimatingDate" type="dtr-types:gYearListItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity" name="NetProceedsFromIssuanceOfVariableInterestEntityEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_NetProceedsFromSaleOfVariableInterestEntityEquity" name="NetProceedsFromSaleOfVariableInterestEntityEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_NonCashActivity" name="NonCashActivity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance" name="NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NumberOfBoardMembersOfInvestee" name="NumberOfBoardMembersOfInvestee" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_NumberOfCommonStockIssuedDescription" name="NumberOfCommonStockIssuedDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" name="NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_NumberOfCustomers" name="NumberOfCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NumberOfDerivativeInstrumentsPurchased" name="NumberOfDerivativeInstrumentsPurchased" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" name="NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate" name="OperatingLeaseWeightedAverageIncrementalBorrowingRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_OperatingLossCarryforwardsIndefinitePeriod" name="OperatingLossCarryforwardsIndefinitePeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares" name="OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_OwnershipInterestInConsolidatedEntities" name="OwnershipInterestInConsolidatedEntities" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PartnershipAgreementLockUpPeriod" name="PartnershipAgreementLockUpPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PaymentOfManagementAndIncentiveFee" name="PaymentOfManagementAndIncentiveFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_PaymentsForRoyaltyAgreement" name="PaymentsForRoyaltyAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_PercentageOfEconomicInterestInPartnership" name="PercentageOfEconomicInterestInPartnership" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" name="PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PercentageOfEstimatedVolatility" name="PercentageOfEstimatedVolatility" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" name="PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PercentageOfMinimumRoyaltyRate" name="PercentageOfMinimumRoyaltyRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" name="PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" name="PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PercentageOfRoyaltyPayableOnNetSales" name="PercentageOfRoyaltyPayableOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" name="PercentageOfRoyaltyPaymentsNotEntitledToReceive" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PortionOfDebtInstrumentFaceAmountExercised" name="PortionOfDebtInstrumentFaceAmountExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" name="ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" name="PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_PurchaseOfEntasisNoncontrollingInterest" name="PurchaseOfEntasisNoncontrollingInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" name="PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" name="PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" name="PurchasesOfEquityInvestmentsManagedByIspFundLp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_PurchasesOfTradingSecurityManagedByIspFundLp" name="PurchasesOfTradingSecurityManagedByIspFundLp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_RealizedLoss" name="RealizedLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" name="RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ReductionToAdditionalPaidInCapital" name="ReductionToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ReductionToResearchAndDevelopmentExpense" name="ReductionToResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_RegulatoryMilestonePaymentsReceivable" name="RegulatoryMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" name="RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_RightOfUseAssetsObtainedThroughAcquistions" name="RightOfUseAssetsObtainedThroughAcquistions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_RiskFreeInterestRate" name="RiskFreeInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" name="RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" name="RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_RoyaltyAgreementMaximumPotentialPayoutPercent" name="RoyaltyAgreementMaximumPotentialPayoutPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" name="RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" name="RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_RoyaltyObligationPayable" name="RoyaltyObligationPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_RoyaltyPayments" name="RoyaltyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_SaleOfEquityInvestmentsManagedByIspFundLp" name="SaleOfEquityInvestmentsManagedByIspFundLp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" name="SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_SalesMilestonePaymentsReceivable" name="SalesMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementAmount" name="SecuritiesPurchaseAgreementAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementNumberOfTranches" name="SecuritiesPurchaseAgreementNumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" name="SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" name="SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" name="SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" name="SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" name="SpecialTermReDesignatingBoardMemberToBoardOfInvestee" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_StateNetOperatingLossesEstimatedUtilizationAmount" name="StateNetOperatingLossesEstimatedUtilizationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_StrategicAllianceMabaProgram" name="StrategicAllianceMabaProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_UnrealizedOtherGainLossOnInvestments" name="UnrealizedOtherGainLossOnInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" name="UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" name="UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" name="UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_VotingAgreementMaximumVotingRightsPercent" name="VotingAgreementMaximumVotingRightsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NameOfEventDomain" name="NameOfEventDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" name="ConsolidatedEntitiesAndAcquisitionsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ArmataPharmaceuticalsIncMember" name="ArmataPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_BurlingameCaliforniaMember" name="BurlingameCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CollaborativeArrangementsMember" name="CollaborativeArrangementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CommercialSupplyAgreementMember" name="CommercialSupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CommonStockAndWarrantsMember" name="CommonStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConsolidatedInvesteesMember" name="ConsolidatedInvesteesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConvertibleNoteAndWarrantsMember" name="ConvertibleNoteAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConvertiblePromissoryNoteMember" name="ConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConvertiblePromissoryNotePurchaseAgreementMember" name="ConvertiblePromissoryNotePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CustomerOneMember" name="CustomerOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CustomerThreeMember" name="CustomerThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CustomerTwoMember" name="CustomerTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_EntasisLeaseMember" name="EntasisLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_EntasisTherapeuticsHoldingsIncMember" name="EntasisTherapeuticsHoldingsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_EquityIncentivePlan2012Member" name="EquityIncentivePlan2012Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_EquityIncentivePlansAndESPPMember" name="EquityIncentivePlansAndESPPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_EquityInvestmentsAndMoneyMarketFundsMember" name="EquityInvestmentsAndMoneyMarketFundsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_EverestMedicinesLimitedMember" name="EverestMedicinesLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_GateNeuroscienceMember" name="GateNeuroscienceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_GeorgeWashingtonUniversityMember" name="GeorgeWashingtonUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_GiaprezaMember" name="GiaprezaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_GSKMember" name="GSKMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_HarvardUniversityMember" name="HarvardUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_HealthCareRoyaltyPartnersMember" name="HealthCareRoyaltyPartnersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ImaginabMember" name="ImaginabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_Incarda2020WarrantsMember" name="Incarda2020WarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_InCardaConvertibleNoteMember" name="InCardaConvertibleNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IncardaMember" name="IncardaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_InnovivaCommonStockMember" name="InnovivaCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_InnovivaMember" name="InnovivaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" name="InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IspFundLpMember" name="IspFundLpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LabaCollaborationMember" name="LabaCollaborationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LaboratoryEquipmentFurnitureAndFixturesMember" name="LaboratoryEquipmentFurnitureAndFixturesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LaJollaMember" name="LaJollaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LaJollaPharmaceuticalCompanyMember" name="LaJollaPharmaceuticalCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LongActingBeta2AgonistAnoroMember" name="LongActingBeta2AgonistAnoroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LongActingBeta2AgonistRelvarBreoMember" name="LongActingBeta2AgonistRelvarBreoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NanoliveMember" name="NanoliveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" name="NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NewPrincipalAmountMember" name="NewPrincipalAmountMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NoteAmendmentAgreementMember" name="NoteAmendmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" name="OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_OneDirectorMember" name="OneDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_OneOfImaginabsCommonStockholderMember" name="OneOfImaginabsCommonStockholderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_OptionPricingModelBacksolveValuationMember" name="OptionPricingModelBacksolveValuationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_OtherAccruedLiabilitiesMember" name="OtherAccruedLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_OutstandingStockWarrantMember" name="OutstandingStockWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PaionAgMember" name="PaionAgMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ParatekPharmaceuticalsIncMember" name="ParatekPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_Percent2.50ConvertibleDebtMember" name="Percent2.50ConvertibleDebtMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PreferredStockWarrantsMember" name="PreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PrivatelyNegotiatedCappedCallOptionMember" name="PrivatelyNegotiatedCappedCallOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PrivatePlacementPositionsAndConvertibleNotesMember" name="PrivatePlacementPositionsAndConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_QualifiedFinancingMember" name="QualifiedFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ResearchAndDevelopmentSupportMember" name="ResearchAndDevelopmentSupportMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_RoyaltyFinancingAgreementMember" name="RoyaltyFinancingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SarissaCapitalManagementLpMember" name="SarissaCapitalManagementLpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SecuredConvertibleCreditAgreementMember" name="SecuredConvertibleCreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeniorUnsecuredConvertibleNotesMember" name="SeniorUnsecuredConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeriesA1PreferredStockMember" name="SeriesA1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeriesCPreferredStockAndWarrantsMember" name="SeriesCPreferredStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeriesCWarrantsAndSeriesDWarrantsMember" name="SeriesCWarrantsAndSeriesDWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeriesD1AndD2PreferredStockAndCommonStockMember" name="SeriesD1AndD2PreferredStockAndCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeriesD1PreferredStockMember" name="SeriesD1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeriesD1WarrantMember" name="SeriesD1WarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeriesD2PreferredStockMember" name="SeriesD2PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeriesD2WarrantMember" name="SeriesD2WarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" name="ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SoftwareAndComputerEquipmentMember" name="SoftwareAndComputerEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_StrategicAllianceAgreementMember" name="StrategicAllianceAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TheravanceRespiratoryCompanyLlcMember" name="TheravanceRespiratoryCompanyLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TrelegyElliptaMember" name="TrelegyElliptaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TwoDirectorsMember" name="TwoDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TwoThousandTwentyEightNotesMember" name="TwoThousandTwentyEightNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TwoThousandTwentyFiveNotesMember" name="TwoThousandTwentyFiveNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TwoThousandTwentyThreeNotesMember" name="TwoThousandTwentyThreeNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_WalthamMassachusettsMember" name="WalthamMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_WarrantsAcquiredInSecondQuarterOf2020Member" name="WarrantsAcquiredInSecondQuarterOf2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_WarrantsAcquiredInSecondQuarterOf2021Member" name="WarrantsAcquiredInSecondQuarterOf2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_WarrantsAcquiredInThirdQuarterOf2020Member" name="WarrantsAcquiredInThirdQuarterOf2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_WarrantsPurchasedIn2020Member" name="WarrantsPurchasedIn2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_WarrantsPurchasedIn2021Member" name="WarrantsPurchasedIn2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_WarrantsPurchasedIn2022Member" name="WarrantsPurchasedIn2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_XeravaMember" name="XeravaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ZaiLabMember" name="ZaiLabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" name="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" name="ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CapitalizedFeesPaidDisclosureTextBlock" name="CapitalizedFeesPaidDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CapitalizedFeesPaidPolicyTextBlock" name="CapitalizedFeesPaidPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" name="CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock" name="ConsolidatedEntitiesAndAcquisitionsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_FactorsAffectingComparabilityPolicyTextBlock" name="FactorsAffectingComparabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock" name="LicenseAndCollaborationArrangementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PresentationReclassificationPolicyTextBlock" name="PresentationReclassificationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" name="PriorPeriodImmaterialCorrectionPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_RelatedPartyTransactionsPolicyTextBlock" name="RelatedPartyTransactionsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" name="ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock" name="ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>inva-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T16:25:39.1736+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncreaseToConvertibleNotes" xlink:label="inva_IncreaseToConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtConversionConvertedInstrumentSharesIssued" xlink:label="inva_DebtConversionConvertedInstrumentSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementNumberOfTranches" xlink:label="inva_SecuritiesPurchaseAgreementNumberOfTranches"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CustomerTwoMember" xlink:label="inva_CustomerTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable" xlink:label="us-gaap_CapitalizedContractCostTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares" xlink:label="inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RelatedPartyTransactionsPolicyTextBlock" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncomeTaxesTable" xlink:label="inva_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RiskFreeInterestRate" xlink:label="inva_RiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems" xlink:label="us-gaap_CapitalizedContractCostLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchaseOfEntasisNoncontrollingInterest" xlink:label="inva_PurchaseOfEntasisNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfDerivativeInstrumentsPurchased" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ClaimExpirationDate" xlink:label="inva_ClaimExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetIncomeLossPerShareAbstract" xlink:label="inva_NetIncomeLossPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_HealthCareRoyaltyPartnersMember" xlink:label="inva_HealthCareRoyaltyPartnersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PaymentOfManagementAndIncentiveFee" xlink:label="inva_PaymentOfManagementAndIncentiveFee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CommonStockAndWarrantsMember" xlink:label="inva_CommonStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NonCashActivity" xlink:label="inva_NonCashActivity"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" xlink:label="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ReductionToAdditionalPaidInCapital" xlink:label="inva_ReductionToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD1PreferredStockMember" xlink:label="inva_SeriesD1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DividendYield" xlink:label="inva_DividendYield"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CashDistributionReceived" xlink:label="inva_CashDistributionReceived"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyAgreementMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NameOfEventDomain" xlink:label="inva_NameOfEventDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BurlingameCaliforniaMember" xlink:label="inva_BurlingameCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfEstimatedVolatility" xlink:label="inva_PercentageOfEstimatedVolatility"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RightOfUseAssetsObtainedThroughAcquistions" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoDirectorsMember" xlink:label="inva_TwoDirectorsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConversionRate" xlink:label="inva_ConversionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:label="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FairValueOfNonControllingInterestInSubsidiary" xlink:label="inva_FairValueOfNonControllingInterestInSubsidiary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" xlink:label="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EverestMedicinesLimitedMember" xlink:label="inva_EverestMedicinesLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WalthamMassachusettsMember" xlink:label="inva_WalthamMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OtherAccruedLiabilitiesMember" xlink:label="inva_OtherAccruedLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertibleNoteAndWarrantsMember" xlink:label="inva_ConvertibleNoteAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CommercialSupplyAgreementMember" xlink:label="inva_CommercialSupplyAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RegulatoryMilestonePaymentsReceivable" xlink:label="inva_RegulatoryMilestonePaymentsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentConvertibleConversionPremium" xlink:label="inva_DebtInstrumentConvertibleConversionPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquity" xlink:label="us-gaap_MembersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD2PreferredStockMember" xlink:label="inva_SeriesD2PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OperatingLossCarryforwardsIndefinitePeriod" xlink:label="inva_OperatingLossCarryforwardsIndefinitePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyPayments" xlink:label="inva_RoyaltyPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedContractManufacturingLiability" xlink:label="inva_AccruedContractManufacturingLiability"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoanRestructuringModificationDomain" xlink:label="us-gaap_LoanRestructuringModificationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsMarketedProductsGross" xlink:label="inva_IntangibleAssetsMarketedProductsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" xlink:label="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ReductionToResearchAndDevelopmentExpense" xlink:label="inva_ReductionToResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsAcquiredInSecondQuarterOf2021Member" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2021Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtConversionConvertedInstrumentAdjustedSharesIssued" xlink:label="inva_DebtConversionConvertedInstrumentAdjustedSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedClinicalLiability" xlink:label="inva_AccruedClinicalLiability"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfMinimumRoyaltyRate" xlink:label="inva_PercentageOfMinimumRoyaltyRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" xlink:label="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity" xlink:label="inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD1WarrantMember" xlink:label="inva_SeriesD1WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_XeravaMember" xlink:label="inva_XeravaMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LicenseAndCollaborationArrangementsDisclosureTextBlock" xlink:label="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD2WarrantMember" xlink:label="inva_SeriesD2WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares" xlink:label="inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EquityInvestmentsAndMoneyMarketFundsMember" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DilutiveEpsOfNotes" xlink:label="inva_DilutiveEpsOfNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsPurchasedIn2022Member" xlink:label="inva_WarrantsPurchasedIn2022Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NoteAmendmentAgreementMember" xlink:label="inva_NoteAmendmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertiblePromissoryNoteMember" xlink:label="inva_ConvertiblePromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesA1PreferredStockMember" xlink:label="inva_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisLeaseMember" xlink:label="inva_EntasisLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTableTextBlock" xlink:label="us-gaap_CapitalizedContractCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidPolicyTextBlock" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OutstandingStockWarrantMember" xlink:label="inva_OutstandingStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PaymentsForRoyaltyAgreement" xlink:label="inva_PaymentsForRoyaltyAgreement"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance" xlink:label="inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedProfessionalServices" xlink:label="inva_AccruedProfessionalServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsCollaborationAgreementNet" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetProceedsFromSaleOfVariableInterestEntityEquity" xlink:label="inva_NetProceedsFromSaleOfVariableInterestEntityEquity"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsCollaborationAgreementGross" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredRoyaltyObligationCurrent" xlink:label="inva_DeferredRoyaltyObligationCurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OwnershipInterestInConsolidatedEntities" xlink:label="inva_OwnershipInterestInConsolidatedEntities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" xlink:label="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsPurchasedIn2020Member" xlink:label="inva_WarrantsPurchasedIn2020Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ResearchAndDevelopmentSupportMember" xlink:label="inva_ResearchAndDevelopmentSupportMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EquityIncentivePlansAndESPPMember" xlink:label="inva_EquityIncentivePlansAndESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DecreaseToAccumulatedDeficit" xlink:label="inva_DecreaseToAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedLicenseFeesAndRoyalties" xlink:label="inva_AccruedLicenseFeesAndRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RealizedLoss" xlink:label="inva_RealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:label="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SaleOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCumulativeCashDistributions" xlink:label="us-gaap_LimitedPartnersCumulativeCashDistributions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FairValueAdjustmentsOfInventoryFromAcquistion" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TrelegyElliptaMember" xlink:label="inva_TrelegyElliptaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfEconomicInterestInPartnership" xlink:label="inva_PercentageOfEconomicInterestInPartnership"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OptionPricingModelBacksolveValuationMember" xlink:label="inva_OptionPricingModelBacksolveValuationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedResearchLiability" xlink:label="inva_AccruedResearchLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PartnershipAgreementLockUpPeriod" xlink:label="inva_PartnershipAgreementLockUpPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" xlink:label="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GiaprezaMember" xlink:label="inva_GiaprezaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsAcquiredInSecondQuarterOf2020Member" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2020Member"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_Percent2.50ConvertibleDebtMember" xlink:label="inva_Percent2.50ConvertibleDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" xlink:label="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsPurchasedIn2021Member" xlink:label="inva_WarrantsPurchasedIn2021Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuredConvertibleCreditAgreementMember" xlink:label="inva_SecuredConvertibleCreditAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PaionAgMember" xlink:label="inva_PaionAgMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EquityIncentivePlan2012Member" xlink:label="inva_EquityIncentivePlan2012Member"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsAcquiredInThirdQuarterOf2020Member" xlink:label="inva_WarrantsAcquiredInThirdQuarterOf2020Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PreferredStockWarrantsMember" xlink:label="inva_PreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentRepurchasePercentage" xlink:label="inva_DebtInstrumentRepurchasePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OneOfImaginabsCommonStockholderMember" xlink:label="inva_OneOfImaginabsCommonStockholderMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CustomerThreeMember" xlink:label="inva_CustomerThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NanoliveMember" xlink:label="inva_NanoliveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncomeTaxesLineItems" xlink:label="inva_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DenominatorAbstract" xlink:label="inva_DenominatorAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ExpectedHoldingPeriod" xlink:label="inva_ExpectedHoldingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncreaseInDeferredTaxAssets" xlink:label="inva_IncreaseInDeferredTaxAssets"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_VotingAgreementMaximumVotingRightsPercent" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredRoyaltyObligationNonCurrent" xlink:label="inva_DeferredRoyaltyObligationNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_Incarda2020WarrantsMember" xlink:label="inva_Incarda2020WarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PresentationReclassificationPolicyTextBlock" xlink:label="inva_PresentationReclassificationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaMember" xlink:label="inva_LaJollaMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DemandLettersSentByStockholders" xlink:label="inva_DemandLettersSentByStockholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesCPreferredStockAndWarrantsMember" xlink:label="inva_SeriesCPreferredStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CommonStockAcquiredAverageCostPerShare" xlink:label="inva_CommonStockAcquiredAverageCostPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InCardaConvertibleNoteMember" xlink:label="inva_InCardaConvertibleNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAllegations" xlink:label="us-gaap_LossContingencyAllegations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CashDividendForfeited" xlink:label="inva_CashDividendForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FuturePotentialMilestonePayment" xlink:label="inva_FuturePotentialMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InterestRateOfDeferredRoyaltyObligation" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" xlink:label="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsMarketedProductsNet" xlink:label="inva_IntangibleAssetsMarketedProductsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SalesMilestonePaymentsReceivable" xlink:label="inva_SalesMilestonePaymentsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyFinancingAgreementMember" xlink:label="inva_RoyaltyFinancingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredRoyaltyObligationAndAccruedInterest" xlink:label="inva_DeferredRoyaltyObligationAndAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfRoyaltyPayableOnNetSales" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCovenantTerms" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PrivatePlacementPositionsAndConvertibleNotesMember" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PortionOfDebtInstrumentFaceAmountExercised" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralPartnerMember" xlink:label="us-gaap_GeneralPartnerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="us-gaap_InterestExpenseDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD1AndD2PreferredStockAndCommonStockMember" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsTextBlock" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ContingentSalesBasedMilestonePayment" xlink:label="inva_ContingentSalesBasedMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidWeightedAverageUsefulLife" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OneDirectorMember" xlink:label="inva_OneDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseBorrowingsAbstract" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAbstract" xlink:label="us-gaap_CapitalizedContractCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetOperatingLossEstimatingDate" xlink:label="inva_NetOperatingLossEstimatingDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidDisclosureTextBlock" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="country_JP"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FederalNetOperatingLossesEstimatedUtilizationAmount" xlink:label="inva_FederalNetOperatingLossesEstimatedUtilizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment" xlink:label="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentTransactionCost" xlink:label="inva_DebtInstrumentTransactionCost"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementMember" xlink:label="inva_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumeratorAbstract" xlink:label="inva_NumeratorAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyObligationPayable" xlink:label="inva_RoyaltyObligationPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncomeTaxPayableNonCurrent" xlink:label="inva_IncomeTaxPayableNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ImaginabMember" xlink:label="inva_ImaginabMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SummaryOfSignificantAccountingPoliciesTable" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCommonStockIssuedDescription" xlink:label="inva_NumberOfCommonStockIssuedDescription"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtMember" xlink:label="us-gaap_DebtMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="inva_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeePaidEstimatedUsefulLife" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_UnrealizedOtherGainLossOnInvestments" xlink:label="inva_UnrealizedOtherGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:label="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CappedCallStrikePrice" xlink:label="inva_CappedCallStrikePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate" xlink:label="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchasesOfTradingSecurityManagedByIspFundLp" xlink:label="inva_PurchasesOfTradingSecurityManagedByIspFundLp"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_StrategicAllianceMabaProgram" xlink:label="inva_StrategicAllianceMabaProgram"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_QualifiedFinancingMember" xlink:label="inva_QualifiedFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredLeasingFees" xlink:label="us-gaap_IncreaseDecreaseInDeferredLeasingFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ParatekPharmaceuticalsIncMember" xlink:label="inva_ParatekPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FactorsAffectingComparabilityPolicyTextBlock" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCostOfHedge" xlink:label="us-gaap_DerivativeCostOfHedge"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InnovivaCommonStockMember" xlink:label="inva_InnovivaCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCustomers" xlink:label="inva_NumberOfCustomers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SarissaCapitalManagementLpMember" xlink:label="inva_SarissaCapitalManagementLpMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SoftwareAndComputerEquipmentMember" xlink:label="inva_SoftwareAndComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CustomerOneMember" xlink:label="inva_CustomerOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_StateNetOperatingLossesEstimatedUtilizationAmount" xlink:label="inva_StateNetOperatingLossesEstimatedUtilizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoanRestructuringModificationAxis" xlink:label="us-gaap_LoanRestructuringModificationAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NameOfEventAxis" xlink:label="inva_NameOfEventAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInvestmentExpense" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GeorgeWashingtonUniversityMember" xlink:label="inva_GeorgeWashingtonUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NewPrincipalAmountMember" xlink:label="inva_NewPrincipalAmountMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ExtendedExpirationDate" xlink:label="inva_ExtendedExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InnovivaMember" xlink:label="inva_InnovivaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncreaseDecreaseInDeferredTaxLiabilities" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FairValueAdjustmentsIncludedInCostOfProductSales" xlink:label="inva_FairValueAdjustmentsIncludedInCostOfProductSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ZaiLabMember" xlink:label="inva_ZaiLabMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_HarvardUniversityMember" xlink:label="inva_HarvardUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseToConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in convertible notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseToConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase To Convertible Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseToConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase to convertible notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average trading price percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Average Trade Price Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The average trading price per $1,000 of Notes with respect to product of the closing common stock price and the conversion rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of differences between expected U.S. federal statutory income tax to income tax expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to Innoviva stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income attributable to Innoviva stockholders, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income attributable to Innoviva stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Price in Active Markets for Identical Assets, Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables from collaboration arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Receivables from collaborative arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due from Related Parties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due from Related Parties, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty rate for sales above first level of annual global net sales (as a percent)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Royalty Rate Defined, Level Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross carrying value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone fees paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross carrying amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total gross carrying amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial conversion, shares per $1,000 principal amount | shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion Converted Instrument Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The initial number of shares per $1,000 principal amount issued in exchange for the original debt being converted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementNumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of tranches</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementNumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of tranches</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementNumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement, Number of Tranches</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementNumberOfTranches_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of tranches in which the Company agreed to purchase common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total estimated fair value of equity instruments vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total estimated fair value of options vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ratio of repurchase price to the principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Ratio of repurchase price to the principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Instrument, Ratio of repurchase price to the principal amount of debt instrument that was repurchased.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition share price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Assets, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capped call options associated with convertible senior notes due 2028</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CONSOLIDATED ENTITIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Including Portion Attributable to Noncontrolling Interest Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net income loss including portion attributable to noncontrolling interest shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Describes the entity's accounting policies for transactions entered with related parties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development, gross carrying amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets In-process Research and Development, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross amount of In-process research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total carrying value of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryCurrentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Current [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risk free interest rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits would affect the effective income tax rate if recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of operating lease liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Fees paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other Long Term Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Noncurrent Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseOfEntasisNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of Entasis noncontrolling interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseOfEntasisNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Entasis noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseOfEntasisNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of entasis noncontrolling interest.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of derivative instruments purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Derivative Instruments Purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of derivative instruments purchased.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Released RSUs and RSAs (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClaimExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Claim Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClaimExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Claim expiration date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetIncomeLossPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income per share attributable to Innoviva stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetIncomeLossPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetIncomeLossPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HealthCareRoyaltyPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HealthCare Royalty Partners</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HealthCareRoyaltyPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Royalty Partners [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HealthCareRoyaltyPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Health care royalty partners member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaymentOfManagementAndIncentiveFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of management and Incentive fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaymentOfManagementAndIncentiveFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Management and Incentive fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaymentOfManagementAndIncentiveFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for management and annual performance incentive fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock and warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock And Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to common stock and warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonCashActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adoption of ASU 2020-06</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonCashActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonCashActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash activity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for the acquisition of La Jolla, net of cash acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid for the Acquisition of La Jolla Pharmaceutical Company, Net of Cash Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for the acquisition of La Jolla Pharmaceutical Company, net of cash acquired.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Share based Compensation Requisite Service Period Recognition Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital share based compensation requisite service period recognition shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction to Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction to Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction to additional paid in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D 1 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D 1 Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D 1 preferred stock member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of noncontrolling interests upon sale of TRC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition of Noncontrolling Interests Upon Sale of TRC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of noncontrolling interestsupon sale of TRC.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividend Yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dividend yield.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative effect period of adoption adjustment member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashDistributionReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash distribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashDistributionReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Distribution Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashDistributionReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of cash distribution received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum potential royalty payout</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreement Maximum Potential Payout Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty agreement, maximum potential payout, percent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketed products, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NameOfEventDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Event [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NameOfEventDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Name Of Event [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BurlingameCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Burlingame, California</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BurlingameCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Burlingame California [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BurlingameCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Burlingame, California.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued personnel-related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strike price for the underlying number of shares (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Strike Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Portion of debt retired, face value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Repurchased Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Repurchased Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, Weighted average remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reclassifications to net income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized upon termination of contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Contract Termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity and Long-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used to compute Innoviva basic and diluted net income per share:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedInvesteesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Investees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedInvesteesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Investees [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedInvesteesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consolidated investees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEstimatedVolatility_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEstimatedVolatility_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Estimated Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEstimatedVolatility_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of estimated volatility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained through acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right of Use Assets Obtained Through Acquistions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right of Use Assets Obtained Through Acquistions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases, Operating [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operating Lease Information Presented In Balance Sheet</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Balance sheet Information Related To Operating Lease Table Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Balance sheet Information Related To Operating Lease Table Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Directors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Directors [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Directors.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rest of the world</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-US [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConversionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConversionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Subsidiary or Equity Method Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Disclosures of Variable Interest Entity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance sheets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueOfNonControllingInterestInSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of noncontrolling interests in a consolidated variable interest entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueOfNonControllingInterestInSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Non-controlling Interest in Subsidiary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueOfNonControllingInterestInSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The fair value of noncontrolling interest in a consolidated variable interest entity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receivables from collaborative arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Due from Related Parties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Due from Related Parties, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Promissory Note Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note purchase agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total duration of consecutive and overlapping offering periods</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Consecutive and Overlapping Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the consecutive and overlapping offering period for the offering of share-based payment awards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash acquired through the consolidation of Entasis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired from Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term accrued interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Dividends Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest and Dividends Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Financing and Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payment of Financing and Stock Issuance Costs, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive income attributable to noncontrolling interests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest Decrease From Distributions To Noncontrolling Interest Holders Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minority interest decrease from distributions to noncontrolling interest holders shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Distributions to noncontrolling interest (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory equipment furniture and fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment, Furniture And Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment, furniture and fixtures.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EverestMedicinesLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Everest Medicines Limited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EverestMedicinesLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Everest Medicines Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EverestMedicinesLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Everest Medicines Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum contributions as a percentage of employee's eligible compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WalthamMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Waltham Massachusetts Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WalthamMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Waltham Massachusetts Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OtherAccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OtherAccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OtherAccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Accrued Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of components of the income tax expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Proceeds from sale of equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash at end of period shown in the condensed consolidated statements of cash flows</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash, cash equivalents and restricted cash at end of period shown in the consolidated statements of cash flows</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory fair value adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Inventory Fair Value Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities inventory fair value adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Duration of purchase period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Purchase Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the duration of each purchase period within each consecutive and overlapping purchase period for offering of share-based payment awards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible subordinated notes due 2023, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2020-06</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToMinorityShareholders_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Distributions to noncontrolling interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToMinorityShareholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Noncontrolling Interests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior Period Immaterial Correction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prior Period Immaterial Correction [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for reporting prior period immaterial correction.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleNoteAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible note and warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleNoteAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In Carda Convertible Note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleNoteAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Note and Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleNoteAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible note and warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, equipment and leasehold improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of the Company's Board members currently serving on the Investee's Board.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of the Company's Board Members Currently Serving on the Board of Investee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Investee's Board members currently representing the Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommercialSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Supply Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommercialSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Supply Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommercialSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial supply agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares used to compute basic net income per share attributable to Innoviva stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used to compute basic net income per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Long-term Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RegulatoryMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional regulatory milestone payments receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RegulatoryMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Payments Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RegulatoryMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone payments receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Incremental Common Shares Attributable to Conversion of Debt Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketed products, Accumulated amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Marketed Products, Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated amortization amount of Marketed Products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentConvertibleConversionPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion premium (as a percent)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentConvertibleConversionPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentConvertibleConversionPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage above the last reported sale price of the Company's common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MembersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Members' Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MembersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Members' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MembersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">LLC members' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of reimbursed for direct and certain indirect manufacturing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Reimbursed For Direct And Certain Indirect Manufacturing Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of reimbursed for direct and certain indirect manufacturing costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs to acquire equity securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSAs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RELVAR/BREO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Acting Beta2 Agonist Relvar Breo [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Long-Acting Beta2 Agonist, RELVAR/BREO, which is being developed and commercialized by entering into a strategic alliance with GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Theravance Respiratory Company, LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Theravance Respiratory Company Llc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the variable interest entity, Theravance Respiratory Company, LLC ("TRC").</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition Of NonControlling Interests Upon Acquisition Of Entasis Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of offering periods</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Number of Purchase Periods</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of purchase periods having duration of six months each.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average estimated fair value of shares granted (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LimitedPartnersContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Capital contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LimitedPartnersContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributed to partnership for investing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LimitedPartnersContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Limited Partners' Contributed Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D 2 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D 2 Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D 2 preferred stock member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OperatingLossCarryforwardsIndefinitePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, indefinite period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OperatingLossCarryforwardsIndefinitePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Indefinite Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OperatingLossCarryforwardsIndefinitePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryforwards which can be carry forward indefinitely.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Expense on Deferred Royalty Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible notes, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Convertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling interests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stockholders' Equity Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedContractManufacturingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued contract manufacturing expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedContractManufacturingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Contract Manufacturing Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedContractManufacturingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued contract manufacturing liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued personnel-related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Personnel- Related Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of accrued personnel-related expenses due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoanRestructuringModificationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Restructuring Modification [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketed products, gross carrying amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Marketed Products, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross amount of Marketed products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total long-term debt, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total long-term debt, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt, net of discount and issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock owned by a related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Common Stock Ownership Percentage By Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage of ownership of common stock in the reporting entity owned by related parties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted net income per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted net income per share attributable to Innoviva stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of anti-dilutive securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derecognition Of Non Controlling Interests Upon Acquisition Of Entasis Minority Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derecognition of non controlling interests upon acquisition of entasis minority interest.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction to research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction to Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction to Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to share repurchase agreement with Glaxo Group Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Agreement With Glaxo Group Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share repurchase agreement with GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants acquired in second quarter of 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Acquired In Second Quarter Of2021 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Information related to warrants acquired in the second quarter of 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remeasurement loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity Securities, FV-NI, Realized Gain (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition-related costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquisitionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquisition Costs, Period Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of products sold (inclusive of amortization of inventory fair value adjustments and excluding amortization of acquired intangible assets)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Services Sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentAdjustedSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjusted conversion, shares per $1,000 principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentAdjustedSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Adjusted Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentAdjustedSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The adjusted number of shares per $1,000 principal amount issued in exchange for the original debt being converted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedClinicalLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedClinicalLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedClinicalLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Clinical Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMinimumRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of minimum royalty rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMinimumRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Minimum Royalty Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMinimumRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of minimum royalty rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Incremental Common Shares Attributable to Share-based Payment Arrangements, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual global sales level used to determine royalty rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Specified Sales Level for Determining Royalty Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Income, Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum number of additional shares into which warrants may be converted under the securities purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of additional shares into which warrants may be converted under the securities purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement, Warrants, Number of Securities Called by Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The maximum number of additional common stock shares into which the warrants may be converted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity activity of noncontrolling interest in a consolidated variable interest entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes to noncontrolling interest from a consolidated variable interest entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes to noncontrolling interest from a consolidated variable interest entity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net shares settlement payable to the entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares Receivable on Settlement of Derivative Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of shares payable to the entity on settlement of derivative instruments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Fair Value per Share at Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Borrowings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Borrowings, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from the issuance of variable interest entity's equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Of Variable Interest Entity Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow from the issuance of variable interest entity's equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D1 Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D1 Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D1 Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PutOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock prices above $38.00 per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PutOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Put Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional disclosures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XeravaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">XERAVA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XeravaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">XERAVA [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XeravaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">XERAVA.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LICENSE AND COLLABORATION ARRANGEMENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Collaboration Arrangements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and collaboration arrangements disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible senior notes due 2028, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LabaCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Acting Beta2 Agonist (LABA) Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LabaCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laba Collaboration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LabaCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the collaboration with GSK to develop and commercialize once-daily LABA products and combination products RELVAR.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Discount (Premium)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price as a percentage of fair market value of stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Product Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock repurchased and retired during period, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work-in-process</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Work in Process, Net of Reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investment ownership percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity investment ownership percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to acquire equity securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term of options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D2 Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D2 Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D2 Warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Depreciation and Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New principal amount convertible note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">New principal amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Increase (Decrease), Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax (liabilities)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other comprehensive income loss net of tax portion attributable to parent shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">REVENUE RECOGNITION</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and of Significant Suppliers and Partners</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Retirement of treasury stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Shares, Retired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armata</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Armata Pharmaceuticals Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion rate for shares of common stock per $1,000 principal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan facility in aggregate amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investments and Money market funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Investments And Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to equity investments and money market funds.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeCapPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cap price for the underlying number of shares (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeCapPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Cap Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amortization of capitalized fees paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of capitalized fees paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt, Fair Value Disclosures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BALANCE SHEET COMPONENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Liability and Equity Components of Convertible Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock prices below $27.79 per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Call Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">SUBSEQUENT EVENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average shares used to compute diluted net income per share attributable to Innoviva stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used to compute diluted net income per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DilutiveEpsOfNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive EPS of note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DilutiveEpsOfNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dilutive EPS of Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DilutiveEpsOfNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of net income (loss) for the period available to convertible notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income tax, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Purchased in 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Purchased In 2022 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants purchased in 2022 member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Business acquisition, net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfBoardMembersOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The total number of Board members of the Investee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfBoardMembersOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Board Members of the Investee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfBoardMembersOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of the Investee's Board members</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NoteAmendmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Note Amendment Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NoteAmendmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Note Amendment Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NoteAmendmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Note amendment agreement member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertable promissory note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GainLossOnOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair value of other equity and long-term investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GainLossOnOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value of other equity and long-term investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GainLossOnOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Other Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GainLossOnOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain loss on other investments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized loss from fair value changes in equity investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss from fair value changes in equity investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A1 preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 preferred stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A1 preferred stock member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entasis Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entasis Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entasis Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock repurchased and retired during period, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased and Retired During Period, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt maturities for years ending December 31:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Capitalized Fees Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of discount on short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Amortization of Discount and Premium, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Consolidated Entities and Business Acquisitions by Acquisition [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of consolidated entities and business acquisitions by acquisition.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Fees Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized fees paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OutstandingStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OutstandingStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Stock Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OutstandingStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding stock warrant member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of unrecognized stock-based compensation cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaymentsForRoyaltyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for royalty agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaymentsForRoyaltyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Royalty Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaymentsForRoyaltyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments For Royalty Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest Increase Decrease From Subsidiary Equity Shares Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncontrolling interest increase decrease from subsidiary equity shares issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity activity of noncontrolling interest from a consolidated variable interest entity (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic alliance - MABA program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Strategic Alliance Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the strategic alliance with GSK for initiating three new full discovery programs and giving GSK option to license exclusive development and commercialization rights of products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareRepurchaseProgramDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Privately-negotiated capped call option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Privately Negotiated Capped Call Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the capped call option entered in connection with the offering of convertible debt.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalty revenue from a related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entasis Therapeutics Holdings Inc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entasis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entasis Therapeutics Holdings Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Entasis Therapeutics Holdings Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax expense (benefit), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income tax expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total income tax expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred royalty obligation, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Royalty Obligation, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets deferred royalty obligation, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of deferred tax assets and deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedProfessionalServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedProfessionalServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedProfessionalServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Professional Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">INCOME TAXES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement, net carrying amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Collaboration Agreement Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible assets collaboration agreement net.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants purchased under the securities purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of warrants issued or sold by the subsidiary or equity method investee per stock transaction.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Warrants, Number of Warrants Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum number of additional shares into which warrants may be converted under the securities purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetProceedsFromSaleOfVariableInterestEntityEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of ownership interest in TRC, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetProceedsFromSaleOfVariableInterestEntityEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds from Sale of Variable Interest Entity Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetProceedsFromSaleOfVariableInterestEntityEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Proceeds from sale of variable interest entity equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement, gross carrying amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Collaboration Agreement Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible assets collaboration agreement gross.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of deferred royalty obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Royalty Obligation, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current portion of deferred royalty obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net decrease in tax portions for 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OwnershipInterestInConsolidatedEntities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership interest in LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OwnershipInterestInConsolidatedEntities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership Interest in Consolidated Entities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OwnershipInterestInConsolidatedEntities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ownership interest in consolidated entities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of economic interest under Equity Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from sale of economic interest under Equity Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from sale of economic interest under Equity Purchase Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants purchased in 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Purchased In2020 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to warrants purchased in 2020.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographic Concentration Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Concentration Risk [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Stock-Based Compensation Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, annual interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt Instrument, annual interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ResearchAndDevelopmentSupportMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Support</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ResearchAndDevelopmentSupportMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Support [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ResearchAndDevelopmentSupportMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Development Support [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest and penalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net increase in tax portions for 2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increase Resulting From Current Period Tax Positions Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits increase resulting from current period tax positions Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized debt issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Issuance Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pro rata shares grant, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation, Arrangement by Share Based Payment Award, Additional Equity Grant Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The additional value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Revenue from Contract with Customer, Excluding Assessed Tax, Before Amortization Of Capitalized Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer before amortization of capitalized fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Special terms on re-designating board member to board of investee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Special Term Re Designating Board Member To Board Of Investee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Special Terms on amended and restated investor rights agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Interest and Dividend, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest and Dividend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlansAndESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity incentive plans and ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlansAndESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plans And E S P P [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlansAndESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to options, Equity Incentive Plans and Employee Stock Purchase Plans.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development, net carrying amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets In-process Research and Development, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net amount of In-process research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Gain on Investment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DecreaseToAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease to accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DecreaseToAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Decrease to Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DecreaseToAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Decrease to accumulated deficit.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS' EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Released RSUs/RSAs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Innoviva stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LLC members' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stockholders' Equity Attributable to Parent, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stockholders' Equity Attributable to Parent, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">LLC members' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedLicenseFeesAndRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued license fees and royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedLicenseFeesAndRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued License Fees and Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedLicenseFeesAndRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued license fees and royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Principal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Principal Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Instrument Principal Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at the end of the period (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock: $0.01 par value, 200,000 shares authorized, 69,188 and 69,566 issued and outstanding as of December 31, 2022 and December 31, 2021 respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Realized Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Realized loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Disclosures of Variable Interest Entity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income statements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Debt discount and issuance costs, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt discount and issuance costs, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Unamortized debt discount and issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales of equity investments managed by ISP Fund LP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of equity investments managed by ISP FUND LP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of equity investments managed by ISP FUND LP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares to be purchased under the securities purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities to be purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement, Total Number of Shares To Be Purchased Under the Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The total number of shares to be purchased under the terms of a securities purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the Company's Employee Stock Purchase Plan (the "ESPP").</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Old Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Old Debt Instrument Interest Rate Before Repurchase Of Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Old debt instrument interest rate before repurchase of notes member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible debt investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of outstanding RSUs and PSUs/RSAs and PSAs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recognition of noncontrolling interest upon initial consolidation of Entasis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recognition Of Noncontrolling Interest Upon Initial Consolidation Of Entasis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LimitedPartnersCumulativeCashDistributions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Limited Partners' Cumulative Cash Distributions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LimitedPartnersCumulativeCashDistributions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Distribution from partnership</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total interest and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee exercised the right during the reporting period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in maximum potential payout percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreement Increase In Maximum Potential Payout Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty agreement increase in maximum potential payout percent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net fair value adjustment of inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustments Of Inventory From Acquistion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of net fair value adjustment of inventory resulting from the acquisition.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TrelegyElliptaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TRELEGY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TrelegyElliptaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trelegy Ellipta [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TrelegyElliptaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Trelegy Ellipta.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Principal Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestInPartnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Economic Interest In Partnership</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestInPartnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of economic interest held in Partnership.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestInPartnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Economic interest of the Partnership (in percent)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables from collaboration arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Long-Term Contracts or Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Subordinated Debt, Fair Value Disclosures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value portion of subordinated debt obligations which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OptionPricingModelBacksolveValuationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Backsolve Valuation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OptionPricingModelBacksolveValuationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Pricing Model Backsolve Valuation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OptionPricingModelBacksolveValuationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option Pricing Model Backsolve valuation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment towards convertible promissory note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Convertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Europe</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Europe [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedResearchLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedResearchLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedResearchLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Research Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PartnershipAgreementLockUpPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lock-up period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PartnershipAgreementLockUpPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Partnership Agreement, Lock-Up Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PartnershipAgreementLockUpPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The period of time in which contributors to an investment fund have waived the right of redemption, as defined in the partnership agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of equity investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Other than Temporary Impairment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares purchased under the securities purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares to be purchased under the securities purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets measured at estimated fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Senior Debt, Fair Value Disclosures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value portion of long-term notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Senior debt has the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of investee's board members which may be designated by the Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement Rights To Designate Investee Board Members Number Of Board Members</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of the investee's board members which the Company has the right to designate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares an employee may purchase during any purchase period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercised (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GiaprezaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GIAPREZA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GiaprezaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GIAPREZA [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GiaprezaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GIAPREZA.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetRentableArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rentable square feet</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetRentableArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Rentable Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants acquired in second quarter of 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Acquired In Second Quarter Of2020 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to warrants acquired in the second quarter of 2020.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of annual installments that RSUs granted to newly appointed independent directors will vest.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of annual installments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award number of annual installments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income attributable to Innoviva stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Percent2.50ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Percent2.50ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percent2.50 Convertible Debt [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Percent2.50ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the information pertaining to 2.50% convertible senior notes due 2025.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The total number of warrants to be purchased under the terms of a securities purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement, Total Number of Warrants To Be Purchased Under Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants to be purchased under the securities purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current portion of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of lease liabilities included within Other accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase and sales of other investments managed by ISP Fund LP, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase and sales of other investments managed by ISP Fund LP, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase and sale of other investments managed by ISP FUND LP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase and sale of other investments managed by ISP FUND LP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Gain on sale of Theravance Respiratory Company, LLC ("TRC")</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net gain on sale of TRC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net gain on sale of TRC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of capped call options associated with convertible senior notes due 2028</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases of Capped Call Options Associated with Convertible Senior Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of capped call options associated with convertible senior notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of shares to satisfy tax withholding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Scheduled Maturities of Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to warrants purchased in 2021.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Purchased In2021 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants purchased in 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of maximum royalty based on achievement of annual net product sales thresholds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Maximum Royalty Based On Achievement Of Annual Net Product Sales Thresholds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of maximum royalty based on achievement of annual net product sales thresholds.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities at estimated fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities measured at estimated fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive effect of the assumed conversion premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable To Conversion Of Debt Securities, Treasury Stock Method</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">NET INCOME PER SHARE</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of weighted-average assumptions used to calculate estimated value of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual grant of shares, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award, Annual Equity Grant, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of shares granted annually to independent directors upon re-election the to Board.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Income Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IspFundLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ISP Fund LP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IspFundLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Isp Fund Lp [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IspFundLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to ISP Fund LP, an investment managed by Sarissa Capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unamortized Debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Award [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Straight line operating lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at the end of the period (in dollars per shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentValueRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value rights liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentValueRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent value rights liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentValueRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuredConvertibleCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secured Convertible Credit Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuredConvertibleCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secured Convertible Credit Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuredConvertibleCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Secured convertible credit agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Impact of consolidation and deconsolidation of subsidiaries</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of consolidation and deconsolidation of subsidiaries</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price to current conversion price ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Common Stock Price to Conversion Price Ratio, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of common stock price as a percentage of conversion price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaionAgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PAION AG</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaionAgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PAION AG [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaionAgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">PAION AG [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total net revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armata outstanding shares percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlan2012Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2012 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlan2012Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan2012 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlan2012Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the 2012 Equity Incentive Plan as approved by shareowners.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty payable as a percentage of payments received from sublicensees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty on payments received from sublicensees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty On Payments Received From Sublicensees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization YearThree</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInThirdQuarterOf2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants acquired in third quarter of 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInThirdQuarterOf2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Acquired In Third Quarter Of2020 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsAcquiredInThirdQuarterOf2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to warrants acquired in the third quarter of 2020.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized fees paid, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net carrying value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pro Forma Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrants Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRepurchasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of notes repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRepurchasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Repurchase Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRepurchasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Portion of debt Instrument, repurchased.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal and state research credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state research credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument principal amount percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareRepurchaseProgramAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments for change in estimated purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Period Adjustments, Increase Decrease In estimated Purchase Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) in estimated purchase price during measurement period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneOfImaginabsCommonStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to one of ImaginAb's common stockholders.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneOfImaginabsCommonStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Of Imaginabs Common Stockholder [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneOfImaginabsCommonStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One of ImaginAb's Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments for change in value of Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Inventories</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Inventories, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NanoliveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nanolive</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NanoliveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nanolive [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NanoliveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nanolive [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on investment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Unrealized Losses On Investment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets unrealized losses on investment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DenominatorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DenominatorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Denominator [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DenominatorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of equity securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity and long-term investments at fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExpectedHoldingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected holding period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExpectedHoldingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Holding Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExpectedHoldingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected holding period of equity method investment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to collaborative arrangements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from collaborative arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity component, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in deferred tax assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of economic interest in any future payments made under the agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Economic Interest on Future Payments Under Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of economic interest in any future payments made under the agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of maximum voting rights under voting agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Voting Agreement, Maximum Voting Rights, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of maximum voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-Dilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Amortization Period (Years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term of options outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Changes in fair values of other equity and long-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair values of equity and long-term investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gain on equity investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of deferred royalty obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Royalty Obligation, Non Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term portion of deferred royalty obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued interest payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Long-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Purchases of equity and long term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Warrants and Series D Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C warrants and Series D warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C warrants and Series D warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of changes in unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">'Total assets acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments for change in value of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Pronouncements Adopted by the Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Incarda2020WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incarda 2020 Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Incarda2020WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">InCarda 2020 Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Incarda2020WarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">InCarda 2020 Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on extinguishment of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">DEBT</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs, Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of property, equipment and leasehold improvements useful lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Useful Life [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PresentationReclassificationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Presentation Reclassification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PresentationReclassificationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Presentation Reclassification [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PresentationReclassificationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Presentation reclassification.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">La Jolla [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">La Jolla [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">La Jolla [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payments for acquire variable interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of securities purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyEightNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyEightNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Eight Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyEightNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty eight notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commitments and contingencies (Note 13)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets acquired, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of royalty payments not entitled to receive</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments the company is not entitled to receive.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DemandLettersSentByStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Demand letters sent by stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DemandLettersSentByStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Demand Letters Sent By Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DemandLettersSentByStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of demand letters that were sent to the Company by purported stockholders.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities and Acquisitions Disclosure Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consolidated entities and acquisitions disclosure abstract.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCPreferredStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C preferred stock and warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCPreferredStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock And Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCPreferredStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to series C preferred stock and warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty rate for first level of annual global net sales (as a percent)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Royalty Rate Defined, Level One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of notes payable, net of debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAcquiredAverageCostPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares repurchased average price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAcquiredAverageCostPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Acquired Average Cost Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAcquiredAverageCostPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Acquired Average Cost Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stockholders' equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">InCarda Convertible Note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Carda Convertible Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">In Carda Convertible note.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net product sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of acquired intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAllegations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Complaints filed by stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAllegations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Allegations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-cash items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashDividendForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividend forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashDividendForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Dividend Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashDividendForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of cash dividend forfeited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FuturePotentialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future potential milestone payment receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FuturePotentialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Potential Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FuturePotentialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future potential milestone payment receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total fair value of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total consideration paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total consideration paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets before valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Carrying Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Rate of Deferred Royalty Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest rate of deferred royalty obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net decrease in tax portions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of capped calls in connection with convertible senior notes due 2028</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases Of Capped Calls In Connection With Convertible Senior Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of capped calls In connection with convertible senior notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketed products, net carrying amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Marketed Products, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net amount of Marketed Products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SalesMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales milestone payments receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SalesMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestone Payments Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SalesMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestone payments receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest and dividend income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest and Dividend Income, Operating, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Dividend Income, Operating</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and dividend income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Add: interest expense on Notes, net of tax effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest on Convertible Debt, Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible senior notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Senior Unsecured Convertible Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowing which takes priority over other debt securities and can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate royalty payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreement Required Payment For Breach Of Agreement Payment Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty agreement required payment for breach of agreement payment two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Assumptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Released RSUs/RSAs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-Sale Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments for change in value of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Indefinite-Lived Intangible Assets, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition and Collaborative Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyFinancingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Financing Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyFinancingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Financing Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyFinancingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty financing agreement member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Balance Sheets and Income Statements of VIE</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accumulated Amortization of Recognized Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite and Indefinite Lived Intangible Assets[Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of finite and indefinite lived intangible assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares remaining available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationAndAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred royalty obligation and accrued interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationAndAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Royalty Obligation and Accrued Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationAndAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred royalty obligation and accrued interest.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payable on net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payable On Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty payable, as a percentage of net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, covenant terms description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Covenant Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">STOCK-BASED COMPENSATION</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement Positions And Convertible Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement Positions And Convertible Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Placement Positions And Convertible Notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Innoviva Strategic Opportunities, LLC.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Innoviva Strategic Opportunities Limited Liability Corporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Innoviva Strategic Opportunities, LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Portion of debt instrument face amount, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Portion of Debt Instrument Face Amount, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Portion of debt instrument face amount, exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount and issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Debt Issuance Costs and Discounts, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Debt Instrument Interest Rate After Repurchase Of Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New debt instrument interest rate after repurchase of notes member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonrecurring basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Nonrecurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General Partner</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General Partner [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion price of convertible notes into common stock (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price (dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets obtained in exchange for operating lease obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D 1 And D 2 Preferred Stock And Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D 1 And D 2 Preferred Stock And Common Stock Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D 1 and D 2 preferred stock and common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross decrease in tax portions from current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair values of equity method investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair values of equity method investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Equity Method Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible subordinated notes due 2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CONSOLIDATED ENTITIES AND ACQUISITIONS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities and Acquisitions [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consolidated entities and acquisitions text block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Goodwill [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentSalesBasedMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent sales based milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentSalesBasedMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Sales Based Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentSalesBasedMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent sales based milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of capitalized fees and depreciation of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Capitalized Fees and Depreciation of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of capitalized fees and depreciation of property and equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GateNeuroscienceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gate Neurosciences Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GateNeuroscienceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gate Neuroscience [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GateNeuroscienceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gate Neuroscience [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at the end of the period (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization after 2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization After Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of equity award activity and related information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining amortization period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Weighted Average Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized fees paid weighted average useful life.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Period Adjustments Increase Decrease In Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Period Adjustments Increase Decrease In liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement period adjustments increase decrease In liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Credit loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One Director</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">One Director.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock: at cost, 32,005 shares as of December 31, 2022 and December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Borrowings [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GSKMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GSKMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">G S K [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GSKMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents GSK, with whom the entity has agreements and arrangements, such as those for developing and commercializing different products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of computation of basic and diluted net income per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Differences between the expected U.S. federal statutory income tax to income tax expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetOperatingLossEstimatingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss estimating date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetOperatingLossEstimatingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Estimating Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetOperatingLossEstimatingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Operating Loss Estimating Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss attributable to noncontrolling interests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to noncontrolling interests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaPharmaceuticalCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">La Jolla Pharmaceutical Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaPharmaceuticalCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">La Jolla Pharmaceutical Company [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaPharmaceuticalCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">La jolla pharmaceutical company member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CAPITALIZED FEES PAID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for information about capitalized fees paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of net revenue from collaborative arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_JP_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Japan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_JP_lbl" xlink:role="http://www.xbrl.org/2003/role/label">JAPAN</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities assumed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FederalNetOperatingLossesEstimatedUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating losses estimated utilization amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FederalNetOperatingLossesEstimatedUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal Net Operating Losses Estimated Utilization Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FederalNetOperatingLossesEstimatedUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal net operating losses estimated utilization amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisitions of Change in Fair Value of Investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisitions of change in fair value of investment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net carrying amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One time grant of shares, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation, Arrangement by Share Based Payment Award, Initial Equity Grant Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument transaction cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Transaction Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities purchase agreement member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net carrying amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of available-for-sale securities measured at fair value on a recurring basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Decrease in goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments for change in value of goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumeratorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumeratorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Numerator [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumeratorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyObligationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Obligation Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyObligationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Obligation Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyObligationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty obligation payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic net income per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net income per share attributable to Innoviva stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price of Outstanding Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued personnel-related expenses and other accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxPayableNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable, long-term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxPayableNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Payable Non Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxPayableNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax payable non current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to ImaginAb.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Imaginab [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ImaginAb</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net decrease in tax portions for 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistAnoroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ANORO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistAnoroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Acting Beta2 Agonist Anoro [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistAnoroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Long-Acting Beta2 Agonist, ANORO, which is being developed and commercialized by entering into a strategic alliance with GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Information related to various accounting policies of the entity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">New principal amount convertible note</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCommonStockIssuedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock issued description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCommonStockIssuedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Stock Issued Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCommonStockIssuedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock issued description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty rate for combination products (as a percent)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Annual Royalties as Percentage of Net Sales for Combination Products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty rate for combination products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Current portion of long-term debt, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of outstanding options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liabilities and Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Standards or Updates Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Not Yet Adopted, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gain</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain from fair value changes in equity investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Unrealized Gain</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized fees paid, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fee Paid Estimated Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized fee paid estimated useful life.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Retirement of treasury stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrealizedOtherGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair values of other equity and long-term investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrealizedOtherGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Other Gain Loss on Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrealizedOtherGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrealized other gain loss on investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Instrument, Liability Component [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">n/a</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of deferred tax assets and deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CappedCallStrikePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capped call strike price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CappedCallStrikePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capped Call Strike Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CappedCallStrikePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capped call strike price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes converted into common stock, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net increase in tax portions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for repurchase of debt instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment for repurchase of convertible subordinated notes due 2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Unsecured Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination recognized identifiable assets acquired and liabilities assumed other accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total debt, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total debt, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Long-Term and Short-Term, Combined Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at the end of the period (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest Outstanding, Weighted-Average Fair Value per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted Average Fair Value per Share of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, weighted average incremental borrowing rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Incremental Borrowing Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease Weighted Average Incremental Borrowing Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfTradingSecurityManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of trading security managed by ISP Fund LP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfTradingSecurityManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases of Trading Security Managed by Isp Fund Lp</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfTradingSecurityManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of trading security managed by Isp fund Lp.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible subordinated notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Subordinated Debt [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceMabaProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic alliance - MABA program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceMabaProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">strategic alliance - MABA program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceMabaProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">strategic alliance - MABA program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyThreeNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyThreeNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyThreeNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Fees Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid To A Related Party [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for capitalized fees paid to a related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties payable period after first commercial sale of product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Payable Period After First Commercial Sale Of Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties payable period after first commercial sale of product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_QualifiedFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Qualified Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_QualifiedFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Qualified Financing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_QualifiedFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Qualified Financing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Products and Services [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables from Net Product Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade Accounts Receivable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredLeasingFees_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of lease guarantee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredLeasingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Leasing Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Related Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum value of shares an employee may purchase in a calendar year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award Maximum Amount As A Contribution Of Eligible Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount the employee may contribute of employee's eligible compensation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Released RSUs and RSAs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ParatekPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paratek Pharmaceuticals, Inc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ParatekPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paratek Pharmaceuticals, Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ParatekPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Paratek Pharmaceuticals, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of equity investments managed by ISP Fund LP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases of Equity Investments Managed by Isp Fund Lp</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of Equity Investments Managed by Isp Fund Lp</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Term of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Factors Affecting Comparability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Factors Affecting Comparability Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Factors affecting comparability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeCostOfHedge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for capped call options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeCostOfHedge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Cost of Hedge</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Innoviva's Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Innoviva Common Stock Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Innoviva's Common Stock Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of customers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Customers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of customers.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SarissaCapitalManagementLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sarissa Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SarissaCapitalManagementLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sarissa Capital Management Lp [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SarissaCapitalManagementLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">This member stands for Sarissa Capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GOODWILL AND INTANGIBLE ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Inventory, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SoftwareAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software and computer equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SoftwareAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software And Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SoftwareAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Software and computer equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value, Inputs, Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs, Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of stock-based compensation expense included in the consolidated statements of operations by award type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Management's Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StateNetOperatingLossesEstimatedUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State net operating losses estimated utilization amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StateNetOperatingLossesEstimatedUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State Net Operating Losses Estimated Utilization Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StateNetOperatingLossesEstimatedUtilizationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">State net operating losses estimated utilization amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred tax (liabilities)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax (liabilities)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoanRestructuringModificationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Restructuring Modification [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Fees paid, Future amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Future Amortization [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized fees paid future amortization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity and long-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NameOfEventAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Event [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NameOfEventAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Name Of Event [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyFiveNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyFiveNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Two Thousand Twenty Five Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyFiveNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Five Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyFiveNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty five notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Investment Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment-related expenses, net of investment-related income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of shares repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Principal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncardaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">InCarda</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncardaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incarda [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncardaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to InCarda.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments for change in value of noncontrolling interests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Noncontrolling Interest, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income attributable to Innoviva stockholders, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right-of-Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination recognized identifiable assets acquired and liabilities assumed operating lease right-of-use assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loans Payable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of amortized cost and estimated fair values for available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GeorgeWashingtonUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">George Washington University</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GeorgeWashingtonUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">George Washington University [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GeorgeWashingtonUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">George Washington University.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewPrincipalAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Principal Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewPrincipalAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Principal Amount [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewPrincipalAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New principal amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relationship to Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income attributable to Innoviva stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical development and regulatory milestones amount payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Development And Regulatory Milestones Amount Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical development and regulatory milestones amount payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExtendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extended expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExtendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extended Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExtendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Extended expiration date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Innoviva [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Innoviva [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Innoviva [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Shares, Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected tax at federal statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-employee director</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Distributions to noncontrolling interests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of fair value adjustments of Cost of products sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Fair Value Adjustments of Cost of Products Sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of fair value adjustments of cost of products sold.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments increase decrease in deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Tax Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in deferred tax liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueAdjustmentsIncludedInCostOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value adjustments included in cost of product sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueAdjustmentsIncludedInCostOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustments Included In Cost Of Product Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueAdjustmentsIncludedInCostOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value adjustments included in cost of product sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Portion of debt retired, carrying value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Repurchase Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair values of other equity and long-term investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss on other equity investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrealized Gain (Loss) on Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Required payment for breach of agreement, payment one</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreement Required Payment For Breach Of Agreement Payment One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty agreement required payment for breach of agreement payment one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities and Acquisitions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities and Acquisitions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consolidated entities and acquisitions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted (in dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ZaiLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Zai Lab</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ZaiLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Zai Lab [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ZaiLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Zai Lab.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfTreasuryStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Treasury Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HarvardUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard University</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HarvardUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard University [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HarvardUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard University.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of Non-cash Investing and Financing Activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncreaseToConvertibleNotes" xlink:to="inva_IncreaseToConvertibleNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" xlink:to="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostGross" xlink:to="us-gaap_CapitalizedContractCostGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtConversionConvertedInstrumentSharesIssued" xlink:to="inva_DebtConversionConvertedInstrumentSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementNumberOfTranches" xlink:to="inva_SecuritiesPurchaseAgreementNumberOfTranches_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" xlink:to="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CustomerTwoMember" xlink:to="inva_CustomerTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="us-gaap_CapitalizedContractCostTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_VariableInterestEntityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares" xlink:to="inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RelatedPartyTransactionsPolicyTextBlock" xlink:to="inva_RelatedPartyTransactionsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncomeTaxesTable" xlink:to="inva_IncomeTaxesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RiskFreeInterestRate" xlink:to="inva_RiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchaseOfEntasisNoncontrollingInterest" xlink:to="inva_PurchaseOfEntasisNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfDerivativeInstrumentsPurchased" xlink:to="inva_NumberOfDerivativeInstrumentsPurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ClaimExpirationDate" xlink:to="inva_ClaimExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="inva_NetIncomeLossPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_HealthCareRoyaltyPartnersMember" xlink:to="inva_HealthCareRoyaltyPartnersMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PaymentOfManagementAndIncentiveFee" xlink:to="inva_PaymentOfManagementAndIncentiveFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CommonStockAndWarrantsMember" xlink:to="inva_CommonStockAndWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NonCashActivity" xlink:to="inva_NonCashActivity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" xlink:to="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:to="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ReductionToAdditionalPaidInCapital" xlink:to="inva_ReductionToAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD1PreferredStockMember" xlink:to="inva_SeriesD1PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DividendYield" xlink:to="inva_DividendYield_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CashDistributionReceived" xlink:to="inva_CashDistributionReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyAgreementMaximumPotentialPayoutPercent" xlink:to="inva_RoyaltyAgreementMaximumPotentialPayoutPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NameOfEventDomain" xlink:to="inva_NameOfEventDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BurlingameCaliforniaMember" xlink:to="inva_BurlingameCaliforniaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnContractTermination" xlink:to="us-gaap_GainLossOnContractTermination_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedInvesteesMember" xlink:to="inva_ConsolidatedInvesteesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfEstimatedVolatility" xlink:to="inva_PercentageOfEstimatedVolatility_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RightOfUseAssetsObtainedThroughAcquistions" xlink:to="inva_RightOfUseAssetsObtainedThroughAcquistions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:to="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TwoDirectorsMember" xlink:to="inva_TwoDirectorsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConversionRate" xlink:to="inva_ConversionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:to="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FairValueOfNonControllingInterestInSubsidiary" xlink:to="inva_FairValueOfNonControllingInterestInSubsidiary_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" xlink:to="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:to="inva_LaboratoryEquipmentFurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EverestMedicinesLimitedMember" xlink:to="inva_EverestMedicinesLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WalthamMassachusettsMember" xlink:to="inva_WalthamMassachusettsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OtherAccruedLiabilitiesMember" xlink:to="inva_OtherAccruedLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" xlink:to="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToMinorityShareholders" xlink:to="us-gaap_PaymentsToMinorityShareholders_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" xlink:to="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertibleNoteAndWarrantsMember" xlink:to="inva_ConvertibleNoteAndWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CommercialSupplyAgreementMember" xlink:to="inva_CommercialSupplyAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RegulatoryMilestonePaymentsReceivable" xlink:to="inva_RegulatoryMilestonePaymentsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" xlink:to="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentConvertibleConversionPremium" xlink:to="inva_DebtInstrumentConvertibleConversionPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MembersEquity" xlink:to="us-gaap_MembersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" xlink:to="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LongActingBeta2AgonistRelvarBreoMember" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TheravanceRespiratoryCompanyLlcMember" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LimitedPartnersContributedCapital" xlink:to="us-gaap_LimitedPartnersContributedCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD2PreferredStockMember" xlink:to="inva_SeriesD2PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OperatingLossCarryforwardsIndefinitePeriod" xlink:to="inva_OperatingLossCarryforwardsIndefinitePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpensePolicyTextBlock" xlink:to="us-gaap_InterestExpensePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyPayments" xlink:to="inva_RoyaltyPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedContractManufacturingLiability" xlink:to="inva_AccruedContractManufacturingLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoanRestructuringModificationDomain" xlink:to="us-gaap_LoanRestructuringModificationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsMarketedProductsGross" xlink:to="inva_IntangibleAssetsMarketedProductsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:to="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" xlink:to="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ReductionToResearchAndDevelopmentExpense" xlink:to="inva_ReductionToResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" xlink:to="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsAcquiredInSecondQuarterOf2021Member" xlink:to="inva_WarrantsAcquiredInSecondQuarterOf2021Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquisitionCosts" xlink:to="us-gaap_AcquisitionCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtConversionConvertedInstrumentAdjustedSharesIssued" xlink:to="inva_DebtConversionConvertedInstrumentAdjustedSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedClinicalLiability" xlink:to="inva_AccruedClinicalLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfMinimumRoyaltyRate" xlink:to="inva_PercentageOfMinimumRoyaltyRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" xlink:to="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" xlink:to="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" xlink:to="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseBorrowings" xlink:to="us-gaap_InterestExpenseBorrowings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity" xlink:to="inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD1WarrantMember" xlink:to="inva_SeriesD1WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PutOptionMember" xlink:to="us-gaap_PutOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_XeravaMember" xlink:to="inva_XeravaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock" xlink:to="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LabaCollaborationMember" xlink:to="inva_LabaCollaborationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD2WarrantMember" xlink:to="inva_SeriesD2WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="inva_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares" xlink:to="inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesRetired" xlink:to="us-gaap_TreasuryStockSharesRetired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ArmataPharmaceuticalsIncMember" xlink:to="inva_ArmataPharmaceuticalsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EquityInvestmentsAndMoneyMarketFundsMember" xlink:to="inva_EquityInvestmentsAndMoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeCapPrice" xlink:to="us-gaap_DerivativeCapPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAmortization" xlink:to="us-gaap_CapitalizedContractCostAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CallOptionMember" xlink:to="us-gaap_CallOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DilutiveEpsOfNotes" xlink:to="inva_DilutiveEpsOfNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsPurchasedIn2022Member" xlink:to="inva_WarrantsPurchasedIn2022Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfBoardMembersOfInvestee" xlink:to="inva_NumberOfBoardMembersOfInvestee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NoteAmendmentAgreementMember" xlink:to="inva_NoteAmendmentAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertiblePromissoryNoteMember" xlink:to="inva_ConvertiblePromissoryNoteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GainLossOnOtherInvestments" xlink:to="inva_GainLossOnOtherInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesA1PreferredStockMember" xlink:to="inva_SeriesA1PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EntasisLeaseMember" xlink:to="inva_EntasisLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostTableTextBlock" xlink:to="us-gaap_CapitalizedContractCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidPolicyTextBlock" xlink:to="inva_CapitalizedFeesPaidPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OutstandingStockWarrantMember" xlink:to="inva_OutstandingStockWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PaymentsForRoyaltyAgreement" xlink:to="inva_PaymentsForRoyaltyAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance" xlink:to="inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_StrategicAllianceAgreementMember" xlink:to="inva_StrategicAllianceAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="us-gaap_ShareRepurchaseProgramDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EntasisTherapeuticsHoldingsIncMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" xlink:to="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedProfessionalServices" xlink:to="inva_AccruedProfessionalServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsCollaborationAgreementNet" xlink:to="inva_IntangibleAssetsCollaborationAgreementNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:to="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NetProceedsFromSaleOfVariableInterestEntityEquity" xlink:to="inva_NetProceedsFromSaleOfVariableInterestEntityEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsCollaborationAgreementGross" xlink:to="inva_IntangibleAssetsCollaborationAgreementGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredRoyaltyObligationCurrent" xlink:to="inva_DeferredRoyaltyObligationCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:to="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OwnershipInterestInConsolidatedEntities" xlink:to="inva_OwnershipInterestInConsolidatedEntities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" xlink:to="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsPurchasedIn2020Member" xlink:to="inva_WarrantsPurchasedIn2020Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicConcentrationRiskMember" xlink:to="us-gaap_GeographicConcentrationRiskMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ResearchAndDevelopmentSupportMember" xlink:to="inva_ResearchAndDevelopmentSupportMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:to="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:to="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" xlink:to="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EquityIncentivePlansAndESPPMember" xlink:to="inva_EquityIncentivePlansAndESPPMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesInvestments" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DecreaseToAccumulatedDeficit" xlink:to="inva_DecreaseToAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedLicenseFeesAndRoyalties" xlink:to="inva_AccruedLicenseFeesAndRoyalties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentPrincipalAmount" xlink:to="inva_DebtInstrumentPrincipalAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RealizedLoss" xlink:to="inva_RealizedLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SaleOfEquityInvestmentsManagedByIspFundLp" xlink:to="inva_SaleOfEquityInvestmentsManagedByIspFundLp_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EmployeeStockPurchasePlanMember" xlink:to="inva_EmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" xlink:to="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" xlink:to="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LimitedPartnersCumulativeCashDistributions" xlink:to="us-gaap_LimitedPartnersCumulativeCashDistributions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" xlink:to="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FairValueAdjustmentsOfInventoryFromAcquistion" xlink:to="inva_FairValueAdjustmentsOfInventoryFromAcquistion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TrelegyElliptaMember" xlink:to="inva_TrelegyElliptaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfEconomicInterestInPartnership" xlink:to="inva_PercentageOfEconomicInterestInPartnership_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:to="inva_ConvertibleSubordinatedDebtFairValueDisclosures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OptionPricingModelBacksolveValuationMember" xlink:to="inva_OptionPricingModelBacksolveValuationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedResearchLiability" xlink:to="inva_AccruedResearchLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PartnershipAgreementLockUpPeriod" xlink:to="inva_PartnershipAgreementLockUpPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:to="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:to="inva_ConvertibleSeniorDebtFairValueDisclosures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" xlink:to="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GiaprezaMember" xlink:to="inva_GiaprezaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsAcquiredInSecondQuarterOf2020Member" xlink:to="inva_WarrantsAcquiredInSecondQuarterOf2020Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_Percent2.50ConvertibleDebtMember" xlink:to="inva_Percent2.50ConvertibleDebtMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" xlink:to="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeconsolidationGainOrLossAmount" xlink:to="us-gaap_DeconsolidationGainOrLossAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" xlink:to="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsPurchasedIn2021Member" xlink:to="inva_WarrantsPurchasedIn2021Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" xlink:to="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" xlink:to="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IspFundLpMember" xlink:to="inva_IspFundLpMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ContingentValueRightsLiability" xlink:to="inva_ContingentValueRightsLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuredConvertibleCreditAgreementMember" xlink:to="inva_SecuredConvertibleCreditAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:to="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" xlink:to="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PaionAgMember" xlink:to="inva_PaionAgMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EquityIncentivePlan2012Member" xlink:to="inva_EquityIncentivePlan2012Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" xlink:to="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsAcquiredInThirdQuarterOf2020Member" xlink:to="inva_WarrantsAcquiredInThirdQuarterOf2020Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PreferredStockWarrantsMember" xlink:to="inva_PreferredStockWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentRepurchasePercentage" xlink:to="inva_DebtInstrumentRepurchasePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" xlink:to="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OneOfImaginabsCommonStockholderMember" xlink:to="inva_OneOfImaginabsCommonStockholderMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CustomerThreeMember" xlink:to="inva_CustomerThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NanoliveMember" xlink:to="inva_NanoliveMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" xlink:to="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_IncomeTaxesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DenominatorAbstract" xlink:to="inva_DenominatorAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ExpectedHoldingPeriod" xlink:to="inva_ExpectedHoldingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CollaborativeArrangementsMember" xlink:to="inva_CollaborativeArrangementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncreaseInDeferredTaxAssets" xlink:to="inva_IncreaseInDeferredTaxAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" xlink:to="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_VotingAgreementMaximumVotingRightsPercent" xlink:to="inva_VotingAgreementMaximumVotingRightsPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredRoyaltyObligationNonCurrent" xlink:to="inva_DeferredRoyaltyObligationNonCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:to="inva_SeriesCWarrantsAndSeriesDWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_Incarda2020WarrantsMember" xlink:to="inva_Incarda2020WarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PresentationReclassificationPolicyTextBlock" xlink:to="inva_PresentationReclassificationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LaJollaMember" xlink:to="inva_LaJollaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementAmount" xlink:to="inva_SecuritiesPurchaseAgreementAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TwoThousandTwentyEightNotesMember" xlink:to="inva_TwoThousandTwentyEightNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" xlink:to="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DemandLettersSentByStockholders" xlink:to="inva_DemandLettersSentByStockholders_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:to="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesCPreferredStockAndWarrantsMember" xlink:to="inva_SeriesCPreferredStockAndWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CommonStockAcquiredAverageCostPerShare" xlink:to="inva_CommonStockAcquiredAverageCostPerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InCardaConvertibleNoteMember" xlink:to="inva_InCardaConvertibleNoteMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAllegations" xlink:to="us-gaap_LossContingencyAllegations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CashDividendForfeited" xlink:to="inva_CashDividendForfeited_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FuturePotentialMilestonePayment" xlink:to="inva_FuturePotentialMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InterestRateOfDeferredRoyaltyObligation" xlink:to="inva_InterestRateOfDeferredRoyaltyObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" xlink:to="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsMarketedProductsNet" xlink:to="inva_IntangibleAssetsMarketedProductsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SalesMilestonePaymentsReceivable" xlink:to="inva_SalesMilestonePaymentsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDividendIncomeOperating" xlink:to="us-gaap_InterestAndDividendIncomeOperating_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeniorUnsecuredConvertibleNotesMember" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyFinancingAgreementMember" xlink:to="inva_RoyaltyFinancingAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredRoyaltyObligationAndAccruedInterest" xlink:to="inva_DeferredRoyaltyObligationAndAccruedInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfRoyaltyPayableOnNetSales" xlink:to="inva_PercentageOfRoyaltyPayableOnNetSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCovenantTerms" xlink:to="us-gaap_LineOfCreditFacilityCovenantTerms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PrivatePlacementPositionsAndConvertibleNotesMember" xlink:to="inva_PrivatePlacementPositionsAndConvertibleNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:to="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PortionOfDebtInstrumentFaceAmountExercised" xlink:to="inva_PortionOfDebtInstrumentFaceAmountExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" xlink:to="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralPartnerMember" xlink:to="us-gaap_GeneralPartnerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebtAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD1AndD2PreferredStockAndCommonStockMember" xlink:to="inva_SeriesD1AndD2PreferredStockAndCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock" xlink:to="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_ScheduleOfGoodwillTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ContingentSalesBasedMilestonePayment" xlink:to="inva_ContingentSalesBasedMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" xlink:to="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GateNeuroscienceMember" xlink:to="inva_GateNeuroscienceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidWeightedAverageUsefulLife" xlink:to="inva_CapitalizedFeesPaidWeightedAverageUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" xlink:to="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OneDirectorMember" xlink:to="inva_OneDirectorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseBorrowingsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GSKMember" xlink:to="inva_GSKMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAbstract" xlink:to="us-gaap_CapitalizedContractCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NetOperatingLossEstimatingDate" xlink:to="inva_NetOperatingLossEstimatingDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LaJollaPharmaceuticalCompanyMember" xlink:to="inva_LaJollaPharmaceuticalCompanyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidDisclosureTextBlock" xlink:to="inva_CapitalizedFeesPaidDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FederalNetOperatingLossesEstimatedUtilizationAmount" xlink:to="inva_FederalNetOperatingLossesEstimatedUtilizationAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment" xlink:to="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentTransactionCost" xlink:to="inva_DebtInstrumentTransactionCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementMember" xlink:to="inva_SecuritiesPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumeratorAbstract" xlink:to="inva_NumeratorAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyObligationPayable" xlink:to="inva_RoyaltyObligationPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncomeTaxPayableNonCurrent" xlink:to="inva_IncomeTaxPayableNonCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ImaginabMember" xlink:to="inva_ImaginabMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" xlink:to="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LongActingBeta2AgonistAnoroMember" xlink:to="inva_LongActingBeta2AgonistAnoroMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="inva_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfCommonStockIssuedDescription" xlink:to="inva_NumberOfCommonStockIssuedDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtMember" xlink:to="us-gaap_DebtMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="inva_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeePaidEstimatedUsefulLife" xlink:to="inva_CapitalizedFeePaidEstimatedUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_UnrealizedOtherGainLossOnInvestments" xlink:to="inva_UnrealizedOtherGainLossOnInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CappedCallStrikePrice" xlink:to="inva_CappedCallStrikePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfUnsecuredDebt" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="inva_ConsolidatedEntitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate" xlink:to="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchasesOfTradingSecurityManagedByIspFundLp" xlink:to="inva_PurchasesOfTradingSecurityManagedByIspFundLp_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleSubordinatedDebtMember" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_StrategicAllianceMabaProgram" xlink:to="inva_StrategicAllianceMabaProgram_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TwoThousandTwentyThreeNotesMember" xlink:to="inva_TwoThousandTwentyThreeNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" xlink:to="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" xlink:to="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_QualifiedFinancingMember" xlink:to="inva_QualifiedFinancingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAccountsReceivableMember" xlink:to="us-gaap_TradeAccountsReceivableMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLeasingFees" xlink:to="us-gaap_IncreaseDecreaseInDeferredLeasingFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_IncomeStatementRelatedDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ParatekPharmaceuticalsIncMember" xlink:to="inva_ParatekPharmaceuticalsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" xlink:to="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FactorsAffectingComparabilityPolicyTextBlock" xlink:to="inva_FactorsAffectingComparabilityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeCostOfHedge" xlink:to="us-gaap_DerivativeCostOfHedge_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InnovivaCommonStockMember" xlink:to="inva_InnovivaCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfCustomers" xlink:to="inva_NumberOfCustomers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SarissaCapitalManagementLpMember" xlink:to="inva_SarissaCapitalManagementLpMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SoftwareAndComputerEquipmentMember" xlink:to="inva_SoftwareAndComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CustomerOneMember" xlink:to="inva_CustomerOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_StateNetOperatingLossesEstimatedUtilizationAmount" xlink:to="inva_StateNetOperatingLossesEstimatedUtilizationAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoanRestructuringModificationAxis" xlink:to="us-gaap_LoanRestructuringModificationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidFutureAmortizationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NameOfEventAxis" xlink:to="inva_NameOfEventAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TwoThousandTwentyFiveNotesMember" xlink:to="inva_TwoThousandTwentyFiveNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInvestmentExpense" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncardaMember" xlink:to="inva_IncardaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesMember" xlink:to="us-gaap_EquitySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableMember" xlink:to="us-gaap_LoansPayableMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GeorgeWashingtonUniversityMember" xlink:to="inva_GeorgeWashingtonUniversityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NewPrincipalAmountMember" xlink:to="inva_NewPrincipalAmountMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" xlink:to="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ExtendedExpirationDate" xlink:to="inva_ExtendedExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InnovivaMember" xlink:to="inva_InnovivaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="us-gaap_TreasuryStockSharesAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" xlink:to="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncreaseDecreaseInDeferredTaxLiabilities" xlink:to="inva_IncreaseDecreaseInDeferredTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FairValueAdjustmentsIncludedInCostOfProductSales" xlink:to="inva_FairValueAdjustmentsIncludedInCostOfProductSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="us-gaap_DebtInstrumentRepurchaseAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="inva_ConsolidatedEntitiesAndAcquisitionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ZaiLabMember" xlink:to="inva_ZaiLabMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_ClassOfTreasuryStockTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_HarvardUniversityMember" xlink:to="inva_HarvardUniversityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>inva-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T16:25:35.3652+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="inva-20221231.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="inva-20221231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="inva-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome" xlink:href="inva-20221231.xsd#StatementConsolidatedStatementsOfIncome" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical" xlink:href="inva-20221231.xsd#StatementConsolidatedStatementsOfIncomeParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome" xlink:href="inva-20221231.xsd#StatementConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="inva-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="inva-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:href="inva-20221231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShare" xlink:href="inva-20221231.xsd#DisclosureNetIncomePerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognition1" xlink:href="inva-20221231.xsd#DisclosureRevenueRecognition1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangements" xlink:href="inva-20221231.xsd#DisclosureLicenseAndCollaborationArrangements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions1" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitions1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaid1" xlink:href="inva-20221231.xsd#DisclosureCapitalizedFeesPaid1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" xlink:href="inva-20221231.xsd#DisclosureGoodwillAndIntangibleAssets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="inva-20221231.xsd#DisclosureBalanceSheetComponents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="inva-20221231.xsd#DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="inva-20221231.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebt" xlink:href="inva-20221231.xsd#DisclosureDebt" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="inva-20221231.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="inva-20221231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="inva-20221231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="inva-20221231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="inva-20221231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareTables" xlink:href="inva-20221231.xsd#DisclosureNetIncomePerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionTables" xlink:href="inva-20221231.xsd#DisclosureRevenueRecognitionTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidTables" xlink:href="inva-20221231.xsd#DisclosureCapitalizedFeesPaidTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="inva-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="inva-20221231.xsd#DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="inva-20221231.xsd#DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables" xlink:href="inva-20221231.xsd#DisclosureDebtTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="inva-20221231.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="inva-20221231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails" xlink:href="inva-20221231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="inva-20221231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails" xlink:href="inva-20221231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails" xlink:href="inva-20221231.xsd#DisclosureNetIncomePerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" xlink:href="inva-20221231.xsd#DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails" xlink:href="inva-20221231.xsd#DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails" xlink:href="inva-20221231.xsd#DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails" xlink:href="inva-20221231.xsd#DisclosureRevenueRecognitionDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails" xlink:href="inva-20221231.xsd#DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" xlink:href="inva-20221231.xsd#DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="inva-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails" xlink:href="inva-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails" xlink:href="inva-20221231.xsd#DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="inva-20221231.xsd#DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails" xlink:href="inva-20221231.xsd#DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails" xlink:href="inva-20221231.xsd#DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails" xlink:href="inva-20221231.xsd#DisclosureStockBasedCompensation2012PlanAndEsppDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails" xlink:href="inva-20221231.xsd#DisclosureStockBasedCompensationDirectorCompensationProgramDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="inva-20221231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails" xlink:href="inva-20221231.xsd#DisclosureStockBasedCompensationCompensationAwardsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" xlink:href="inva-20221231.xsd#DisclosureStockBasedCompensationValuationAssumptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails" xlink:href="inva-20221231.xsd#DisclosureStockholdersEquityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" xlink:href="inva-20221231.xsd#DisclosureDebtScheduleOfDebtDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails" xlink:href="inva-20221231.xsd#DisclosureDebtConvertibleSubordinatedNotesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails" xlink:href="inva-20221231.xsd#DisclosureDebtConvertibleSeniorNotesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails" xlink:href="inva-20221231.xsd#DisclosureDebtDebtMaturitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="inva-20221231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails" xlink:href="inva-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails" xlink:href="inva-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails" xlink:href="inva-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="inva-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:href="inva-20221231.xsd#DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails" xlink:href="inva-20221231.xsd#DisclosureIncomeTaxesReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails" xlink:href="inva-20221231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails" xlink:href="inva-20221231.xsd#DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="inva-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncomeTaxPayableNonCurrent" xlink:label="inva_IncomeTaxPayableNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CapitalizedContractCostNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="inva_IncomeTaxPayableNonCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleDebtCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DeconsolidationGainOrLossAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="inva_GainLossOnOtherInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestAndDividendIncomeOperating" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FairValueOfNonControllingInterestInSubsidiary" xlink:label="inva_FairValueOfNonControllingInterestInSubsidiary"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" xlink:label="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" xlink:label="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance" xlink:label="inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CashDividendForfeited" xlink:label="inva_CashDividendForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares" xlink:label="inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares" xlink:label="inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_26"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_27"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="us-gaap_TreasuryStockSharesRetired" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_FairValueOfNonControllingInterestInSubsidiary" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockSharesAcquired" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_CashDividendForfeited" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_ProfitLoss" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NonCashActivity" xlink:label="inva_NonCashActivity"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchaseOfEntasisNoncontrollingInterest" xlink:label="inva_PurchaseOfEntasisNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FairValueAdjustmentsIncludedInCostOfProductSales" xlink:label="inva_FairValueAdjustmentsIncludedInCostOfProductSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchasesOfTradingSecurityManagedByIspFundLp" xlink:label="inva_PurchasesOfTradingSecurityManagedByIspFundLp"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity" xlink:label="inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SaleOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" xlink:label="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_UnrealizedOtherGainLossOnInvestments" xlink:label="inva_UnrealizedOtherGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetProceedsFromSaleOfVariableInterestEntityEquity" xlink:label="inva_NetProceedsFromSaleOfVariableInterestEntityEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" xlink:label="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredLeasingFees" xlink:label="us-gaap_IncreaseDecreaseInDeferredLeasingFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsToMinorityShareholders" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="inva_NonCashActivity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="inva_PurchaseOfEntasisNoncontrollingInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inva_FairValueAdjustmentsIncludedInCostOfProductSales" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_PurchasesOfTradingSecurityManagedByIspFundLp" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_SaleOfEquityInvestmentsManagedByIspFundLp" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inva_UnrealizedOtherGainLossOnInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_NetProceedsFromSaleOfVariableInterestEntityEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeconsolidationGainOrLossAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredLeasingFees" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognition1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LicenseAndCollaborationArrangementsDisclosureTextBlock" xlink:label="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_LicenseAndCollaborationArrangementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsTextBlock" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="inva_ConsolidatedEntitiesAndAcquisitionsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaid1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAbstract" xlink:label="us-gaap_CapitalizedContractCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidDisclosureTextBlock" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAbstract" xlink:to="inva_CapitalizedFeesPaidDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PresentationReclassificationPolicyTextBlock" xlink:label="inva_PresentationReclassificationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FactorsAffectingComparabilityPolicyTextBlock" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidPolicyTextBlock" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RelatedPartyTransactionsPolicyTextBlock" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="inva_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_PresentationReclassificationPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_FactorsAffectingComparabilityPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_CapitalizedFeesPaidPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_InterestExpensePolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_RelatedPartyTransactionsPolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:to="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAbstract" xlink:label="us-gaap_CapitalizedContractCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTableTextBlock" xlink:label="us-gaap_CapitalizedContractCostTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAbstract" xlink:to="us-gaap_CapitalizedContractCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_Percent2.50ConvertibleDebtMember" xlink:label="inva_Percent2.50ConvertibleDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_Percent2.50ConvertibleDebtMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaMember" xlink:label="inva_LaJollaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SummaryOfSignificantAccountingPoliciesTable" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CustomerOneMember" xlink:label="inva_CustomerOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CustomerTwoMember" xlink:label="inva_CustomerTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CustomerThreeMember" xlink:label="inva_CustomerThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCustomers" xlink:label="inva_NumberOfCustomers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeePaidEstimatedUsefulLife" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DecreaseToAccumulatedDeficit" xlink:label="inva_DecreaseToAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ReductionToAdditionalPaidInCapital" xlink:label="inva_ReductionToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncreaseToConvertibleNotes" xlink:label="inva_IncreaseToConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncreaseInDeferredTaxAssets" xlink:label="inva_IncreaseInDeferredTaxAssets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_LaJollaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_LabaCollaborationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistAnoroMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_NumberOfCustomers" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CapitalizedFeePaidEstimatedUsefulLife" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_DecreaseToAccumulatedDeficit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_ReductionToAdditionalPaidInCapital" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_IncreaseToConvertibleNotes" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_IncreaseInDeferredTaxAssets" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="inva_SummaryOfSignificantAccountingPoliciesLineItems" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SoftwareAndComputerEquipmentMember" xlink:label="inva_SoftwareAndComputerEquipmentMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inva_LaboratoryEquipmentFurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inva_SoftwareAndComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SarissaCapitalManagementLpMember" xlink:label="inva_SarissaCapitalManagementLpMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_SarissaCapitalManagementLpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DilutiveEpsOfNotes" xlink:label="inva_DilutiveEpsOfNotes"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DilutiveEpsOfNotes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetIncomeLossPerShareAbstract" xlink:label="inva_NetIncomeLossPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DenominatorAbstract" xlink:label="inva_DenominatorAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumeratorAbstract" xlink:label="inva_NumeratorAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_NumeratorAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_EarningsPerShareDilutedLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_DenominatorAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_NetIncomeLossPerShareAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EquityIncentivePlansAndESPPMember" xlink:label="inva_EquityIncentivePlansAndESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OutstandingStockWarrantMember" xlink:label="inva_OutstandingStockWarrantMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inva_EquityIncentivePlansAndESPPMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inva_OutstandingStockWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_StrategicAllianceMabaProgram" xlink:label="inva_StrategicAllianceMabaProgram"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TrelegyElliptaMember" xlink:label="inva_TrelegyElliptaMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistAnoroMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_StrategicAllianceMabaProgram" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_TrelegyElliptaMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TrelegyElliptaMember" xlink:label="inva_TrelegyElliptaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GiaprezaMember" xlink:label="inva_GiaprezaMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_XeravaMember" xlink:label="inva_XeravaMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_GeographicConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_LongActingBeta2AgonistAnoroMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_LabaCollaborationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_TrelegyElliptaMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_GiaprezaMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_XeravaMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_GainLossOnContractTermination" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ZaiLabMember" xlink:label="inva_ZaiLabMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CommercialSupplyAgreementMember" xlink:label="inva_CommercialSupplyAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ResearchAndDevelopmentSupportMember" xlink:label="inva_ResearchAndDevelopmentSupportMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PaionAgMember" xlink:label="inva_PaionAgMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FuturePotentialMilestonePayment" xlink:label="inva_FuturePotentialMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EverestMedicinesLimitedMember" xlink:label="inva_EverestMedicinesLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ReductionToResearchAndDevelopmentExpense" xlink:label="inva_ReductionToResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GeorgeWashingtonUniversityMember" xlink:label="inva_GeorgeWashingtonUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RegulatoryMilestonePaymentsReceivable" xlink:label="inva_RegulatoryMilestonePaymentsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_HarvardUniversityMember" xlink:label="inva_HarvardUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SalesMilestonePaymentsReceivable" xlink:label="inva_SalesMilestonePaymentsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ParatekPharmaceuticalsIncMember" xlink:label="inva_ParatekPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfRoyaltyPayableOnNetSales" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfMinimumRoyaltyRate" xlink:label="inva_PercentageOfMinimumRoyaltyRate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ClaimExpirationDate" xlink:label="inva_ClaimExpirationDate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_ZaiLabMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_CommercialSupplyAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_ResearchAndDevelopmentSupportMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_PaionAgMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_FuturePotentialMilestonePayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_EverestMedicinesLimitedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ReductionToResearchAndDevelopmentExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_GeorgeWashingtonUniversityMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_RegulatoryMilestonePaymentsReceivable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_HarvardUniversityMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_SalesMilestonePaymentsReceivable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_ParatekPharmaceuticalsIncMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfRoyaltyPayableOnNetSales" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfMinimumRoyaltyRate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ClaimExpirationDate" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OwnershipInterestInConsolidatedEntities" xlink:label="inva_OwnershipInterestInConsolidatedEntities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:label="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:label="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" xlink:label="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquity" xlink:label="us-gaap_MembersEquity"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ContingentSalesBasedMilestonePayment" xlink:label="inva_ContingentSalesBasedMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CashDistributionReceived" xlink:label="inva_CashDistributionReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RealizedLoss" xlink:label="inva_RealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_OwnershipInterestInConsolidatedEntities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_OperatingExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MembersEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="inva_IspFundLpMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_ContingentSalesBasedMilestonePayment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_CashDistributionReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_VariableInterestEntityLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="inva_RealizedLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_ProfitLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCumulativeCashDistributions" xlink:label="us-gaap_LimitedPartnersCumulativeCashDistributions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralPartnerMember" xlink:label="us-gaap_GeneralPartnerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfEconomicInterestInPartnership" xlink:label="inva_PercentageOfEconomicInterestInPartnership"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInvestmentExpense" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PaymentOfManagementAndIncentiveFee" xlink:label="inva_PaymentOfManagementAndIncentiveFee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PartnershipAgreementLockUpPeriod" xlink:label="inva_PartnershipAgreementLockUpPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_LimitedPartnersCumulativeCashDistributions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_GeneralPartnerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="inva_IspFundLpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_LimitedPartnersContributedCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_PercentageOfEconomicInterestInPartnership" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_VariableInterestEntityLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_PaymentOfManagementAndIncentiveFee" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_PartnershipAgreementLockUpPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_GainLossOnInvestments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_Assets" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementMember" xlink:label="inva_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertiblePromissoryNoteMember" xlink:label="inva_ConvertiblePromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" xlink:label="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CommonStockAndWarrantsMember" xlink:label="inva_CommonStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsAcquiredInSecondQuarterOf2021Member" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2021Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsAcquiredInThirdQuarterOf2020Member" xlink:label="inva_WarrantsAcquiredInThirdQuarterOf2020Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsAcquiredInSecondQuarterOf2020Member" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2020Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment" xlink:label="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_SecuritiesPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNoteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="dei_LegalEntityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_CommonStockAndWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsAcquiredInSecondQuarterOf2021Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsAcquiredInThirdQuarterOf2020Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsAcquiredInSecondQuarterOf2020Member" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_MinorityInterestPeriodIncreaseDecrease" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncreaseDecreaseInDeferredTaxLiabilities" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AcquisitionCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_IncreaseDecreaseInDeferredTaxLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CommonStockAndWarrantsMember" xlink:label="inva_CommonStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OneDirectorMember" xlink:label="inva_OneDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsPurchasedIn2020Member" xlink:label="inva_WarrantsPurchasedIn2020Member"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoDirectorsMember" xlink:label="inva_TwoDirectorsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsPurchasedIn2021Member" xlink:label="inva_WarrantsPurchasedIn2021Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsPurchasedIn2022Member" xlink:label="inva_WarrantsPurchasedIn2022Member"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementNumberOfTranches" xlink:label="inva_SecuritiesPurchaseAgreementNumberOfTranches"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_VotingAgreementMaximumVotingRightsPercent" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_CommonStockAndWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="inva_OneDirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2020Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="inva_TwoDirectorsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2021Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2022Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_TitleOfIndividualAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementNumberOfTranches" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_VotingAgreementMaximumVotingRightsPercent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AssetsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncomeStatementRelatedDisclosuresAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_ProfitLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NameOfEventDomain" xlink:label="inva_NameOfEventDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_QualifiedFinancingMember" xlink:label="inva_QualifiedFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OptionPricingModelBacksolveValuationMember" xlink:label="inva_OptionPricingModelBacksolveValuationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesCPreferredStockAndWarrantsMember" xlink:label="inva_SeriesCPreferredStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NameOfEventAxis" xlink:label="inva_NameOfEventAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_Incarda2020WarrantsMember" xlink:label="inva_Incarda2020WarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InCardaConvertibleNoteMember" xlink:label="inva_InCardaConvertibleNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" xlink:label="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertibleNoteAndWarrantsMember" xlink:label="inva_ConvertibleNoteAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentTransactionCost" xlink:label="inva_DebtInstrumentTransactionCost"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesA1PreferredStockMember" xlink:label="inva_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD1PreferredStockMember" xlink:label="inva_SeriesD1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD2PreferredStockMember" xlink:label="inva_SeriesD2PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD1WarrantMember" xlink:label="inva_SeriesD1WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD2WarrantMember" xlink:label="inva_SeriesD2WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ExpectedHoldingPeriod" xlink:label="inva_ExpectedHoldingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RiskFreeInterestRate" xlink:label="inva_RiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DividendYield" xlink:label="inva_DividendYield"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD1AndD2PreferredStockAndCommonStockMember" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfEstimatedVolatility" xlink:label="inva_PercentageOfEstimatedVolatility"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ExtendedExpirationDate" xlink:label="inva_ExtendedExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NameOfEventDomain" xlink:to="inva_QualifiedFinancingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="inva_OptionPricingModelBacksolveValuationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesCPreferredStockAndWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NameOfEventAxis" xlink:to="inva_NameOfEventDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_IncardaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_Incarda2020WarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaConvertibleNoteMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ConvertibleNoteAndWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="inva_NameOfEventAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_DebtInstrumentTransactionCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesA1PreferredStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1PreferredStockMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD2PreferredStockMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1WarrantMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD2WarrantMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_ExpectedHoldingPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesCWarrantsAndSeriesDWarrantsMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_RiskFreeInterestRate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_DividendYield" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1AndD2PreferredStockAndCommonStockMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_PercentageOfEstimatedVolatility" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_ExtendedExpirationDate" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ImaginabMember" xlink:label="inva_ImaginabMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OneOfImaginabsCommonStockholderMember" xlink:label="inva_OneOfImaginabsCommonStockholderMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ImaginabMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_OneOfImaginabsCommonStockholderMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCommonStockIssuedDescription" xlink:label="inva_NumberOfCommonStockIssuedDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_GateNeuroscienceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCommonStockIssuedDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NanoliveMember" xlink:label="inva_NanoliveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_NanoliveMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EquityInvestmentsAndMoneyMarketFundsMember" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PrivatePlacementPositionsAndConvertibleNotesMember" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtMember" xlink:label="us-gaap_DebtMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PreferredStockWarrantsMember" xlink:label="inva_PreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PartnershipAgreementLockUpPeriod" xlink:label="inva_PartnershipAgreementLockUpPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ArmataPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_IspFundLpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ConvertibleSubordinatedDebtFairValueDisclosures" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_EquityInvestmentsAndMoneyMarketFundsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ConvertibleSeniorDebtFairValueDisclosures" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_IncardaMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_PrivatePlacementPositionsAndConvertibleNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_GateNeuroscienceMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DebtMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ContingentValueRightsLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_PreferredStockWarrantsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_CounterpartyNameAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_PartnershipAgreementLockUpPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LimitedPartnersContributedCapital" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable" xlink:label="us-gaap_CapitalizedContractCostTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems" xlink:label="us-gaap_CapitalizedContractCostLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAbstract" xlink:label="us-gaap_CapitalizedContractCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="country_JP"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidWeightedAverageUsefulLife" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAbstract" xlink:to="us-gaap_CapitalizedContractCostTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="us-gaap_CapitalizedContractCostLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="inva_CapitalizedFeesPaidWeightedAverageUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="inva_CapitalizedFeesPaidFutureAmortizationAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_GoodwillLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsMarketedProductsGross" xlink:label="inva_IntangibleAssetsMarketedProductsGross"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsCollaborationAgreementGross" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsMarketedProductsNet" xlink:label="inva_IntangibleAssetsMarketedProductsNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsCollaborationAgreementNet" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FairValueAdjustmentsOfInventoryFromAcquistion" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_InventoryCurrentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_FairValueAdjustmentsOfInventoryFromAcquistion" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedContractManufacturingLiability" xlink:label="inva_AccruedContractManufacturingLiability"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedClinicalLiability" xlink:label="inva_AccruedClinicalLiability"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedResearchLiability" xlink:label="inva_AccruedResearchLiability"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedProfessionalServices" xlink:label="inva_AccruedProfessionalServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredRoyaltyObligationCurrent" xlink:label="inva_DeferredRoyaltyObligationCurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedLicenseFeesAndRoyalties" xlink:label="inva_AccruedLicenseFeesAndRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_AccruedContractManufacturingLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_AccruedClinicalLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_AccruedResearchLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_AccruedProfessionalServices" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_DeferredRoyaltyObligationCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_AccruedLicenseFeesAndRoyalties" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredRoyaltyObligationNonCurrent" xlink:label="inva_DeferredRoyaltyObligationNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_DeferredRoyaltyObligationNonCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_ContingentValueRightsLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EquityIncentivePlan2012Member" xlink:label="inva_EquityIncentivePlan2012Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EquityIncentivePlan2012Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InnovivaMember" xlink:label="inva_InnovivaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CommonStockAcquiredAverageCostPerShare" xlink:label="inva_CommonStockAcquiredAverageCostPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfTreasuryStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_ShareRepurchaseProgramAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_CommonStockAcquiredAverageCostPerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_HealthCareRoyaltyPartnersMember" xlink:label="inva_HealthCareRoyaltyPartnersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OtherAccruedLiabilitiesMember" xlink:label="inva_OtherAccruedLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyFinancingAgreementMember" xlink:label="inva_RoyaltyFinancingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyAgreementMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredRoyaltyObligationAndAccruedInterest" xlink:label="inva_DeferredRoyaltyObligationAndAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyObligationPayable" xlink:label="inva_RoyaltyObligationPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyPayments" xlink:label="inva_RoyaltyPayments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InterestRateOfDeferredRoyaltyObligation" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PaymentsForRoyaltyAgreement" xlink:label="inva_PaymentsForRoyaltyAgreement"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_HealthCareRoyaltyPartnersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="inva_OtherAccruedLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentPrincipalAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LoansPayableMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_RoyaltyFinancingAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementMaximumPotentialPayoutPercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseBorrowings" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DeferredRoyaltyObligationAndAccruedInterest" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyObligationPayable" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyPayments" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_InterestRateOfDeferredRoyaltyObligation" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PaymentsForRoyaltyAgreement" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InnovivaCommonStockMember" xlink:label="inva_InnovivaCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="us-gaap_InterestExpenseDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCostOfHedge" xlink:label="us-gaap_DerivativeCostOfHedge"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfDerivativeInstrumentsPurchased" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtConversionConvertedInstrumentSharesIssued" xlink:label="inva_DebtConversionConvertedInstrumentSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConversionRate" xlink:label="inva_ConversionRate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtConversionConvertedInstrumentAdjustedSharesIssued" xlink:label="inva_DebtConversionConvertedInstrumentAdjustedSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CappedCallStrikePrice" xlink:label="inva_CappedCallStrikePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentRepurchasePercentage" xlink:label="inva_DebtInstrumentRepurchasePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="us-gaap_CallOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inva_InnovivaCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="us-gaap_PutOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeCostOfHedge" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_NumberOfDerivativeInstrumentsPurchased" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionConvertedInstrumentSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_ConversionRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionConvertedInstrumentAdjustedSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_CappedCallStrikePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeCapPrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchaseAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRepurchasePercentage" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentPrincipalAmount" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtAbstract" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseBorrowingsAbstract" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:label="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" xlink:label="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentConvertibleConversionPremium" xlink:label="inva_DebtInstrumentConvertibleConversionPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCovenantTerms" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PortionOfDebtInstrumentFaceAmountExercised" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="inva_DebtInstrumentPrincipalAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="us-gaap_LongTermDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeCapPrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentConvertibleConversionPremium" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCovenantTerms" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PortionOfDebtInstrumentFaceAmountExercised" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseBorrowingsAbstract" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisLeaseMember" xlink:label="inva_EntasisLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BurlingameCaliforniaMember" xlink:label="inva_BurlingameCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WalthamMassachusettsMember" xlink:label="inva_WalthamMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate" xlink:label="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAllegations" xlink:label="us-gaap_LossContingencyAllegations"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DemandLettersSentByStockholders" xlink:label="inva_DemandLettersSentByStockholders"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="inva_EntasisLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inva_BurlingameCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NetRentableArea" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inva_WalthamMassachusettsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAllegations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inva_DemandLettersSentByStockholders" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RightOfUseAssetsObtainedThroughAcquistions" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inva_RightOfUseAssetsObtainedThroughAcquistions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="inva_DeferredTaxLiabilitiesDepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncomeTaxesTable" xlink:label="inva_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncomeTaxesLineItems" xlink:label="inva_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OperatingLossCarryforwardsIndefinitePeriod" xlink:label="inva_OperatingLossCarryforwardsIndefinitePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetOperatingLossEstimatingDate" xlink:label="inva_NetOperatingLossEstimatingDate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FederalNetOperatingLossesEstimatedUtilizationAmount" xlink:label="inva_FederalNetOperatingLossesEstimatedUtilizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_StateNetOperatingLossesEstimatedUtilizationAmount" xlink:label="inva_StateNetOperatingLossesEstimatedUtilizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="inva_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_OperatingLossCarryforwardsIndefinitePeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesTable" xlink:to="inva_IncomeTaxesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_NetOperatingLossEstimatingDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_FederalNetOperatingLossesEstimatedUtilizationAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_StateNetOperatingLossesEstimatedUtilizationAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoanRestructuringModificationDomain" xlink:label="us-gaap_LoanRestructuringModificationDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NewPrincipalAmountMember" xlink:label="inva_NewPrincipalAmountMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuredConvertibleCreditAgreementMember" xlink:label="inva_SecuredConvertibleCreditAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoanRestructuringModificationAxis" xlink:label="us-gaap_LoanRestructuringModificationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NoteAmendmentAgreementMember" xlink:label="inva_NoteAmendmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoanRestructuringModificationDomain" xlink:to="inva_NewPrincipalAmountMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_ArmataPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_SecuredConvertibleCreditAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoanRestructuringModificationAxis" xlink:to="us-gaap_LoanRestructuringModificationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_NoteAmendmentAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LoanRestructuringModificationAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>26
<FILENAME>inva-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T16:25:35.3053+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="inva-20221231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2" xlink:href="inva-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet1" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2" xlink:href="inva-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2" xlink:href="inva-20221231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome" xlink:href="inva-20221231.xsd#StatementConsolidatedStatementsOfIncome" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome" xlink:href="inva-20221231.xsd#StatementConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="inva-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" xlink:href="inva-20221231.xsd#DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails" xlink:href="inva-20221231.xsd#DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" xlink:href="inva-20221231.xsd#DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails" xlink:href="inva-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails" xlink:href="inva-20221231.xsd#DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails" xlink:href="inva-20221231.xsd#DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails" xlink:href="inva-20221231.xsd#DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" xlink:href="inva-20221231.xsd#DisclosureDebtScheduleOfDebtDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails" xlink:href="inva-20221231.xsd#DisclosureDebtConvertibleSubordinatedNotesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails" xlink:href="inva-20221231.xsd#DisclosureDebtConvertibleSeniorNotesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails" xlink:href="inva-20221231.xsd#DisclosureDebtDebtMaturitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails" xlink:href="inva-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails" xlink:href="inva-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:href="inva-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:href="inva-20221231.xsd#DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails" xlink:href="inva-20221231.xsd#DisclosureIncomeTaxesReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails" xlink:href="inva-20221231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_CapitalizedContractCostNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNet" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockCommonValue" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="inva_IncomeTaxPayableNonCurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="8" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncomeTaxPayableNonCurrent" xlink:label="inva_IncomeTaxPayableNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="inva_RealizedLoss" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_GainLossOnInvestments" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RealizedLoss" xlink:label="inva_RealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet1">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="inva_ContingentValueRightsLiability" order="0" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="inva_IntangibleAssetsMarketedProductsNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="inva_IntangibleAssetsCollaborationAgreementNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsMarketedProductsNet" xlink:label="inva_IntangibleAssetsMarketedProductsNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsCollaborationAgreementNet" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="inva_DeferredTaxLiabilitiesDepreciationAndAmortization" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_CostsAndExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="inva_GainLossOnOtherInvestments" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_InterestAndDividendIncomeOperating" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_InterestExpense" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_DeconsolidationGainOrLossAmount" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" order="2" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsToMinorityShareholders" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="inva_PurchaseOfEntasisNoncontrollingInterest" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_PurchasesOfTradingSecurityManagedByIspFundLp" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inva_FairValueAdjustmentsIncludedInCostOfProductSales" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_SaleOfEquityInvestmentsManagedByIspFundLp" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inva_UnrealizedOtherGainLossOnInvestments" order="10" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_NetProceedsFromSaleOfVariableInterestEntityEquity" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="11" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" order="13" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="16" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="17" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeconsolidationGainOrLossAmount" order="18" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="19" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLeasingFees" order="20" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="21" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="22" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" order="24" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="25" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="26" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="29" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="31" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="32" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="33" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="34" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="us-gaap_PaymentsToMinorityShareholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchaseOfEntasisNoncontrollingInterest" xlink:label="inva_PurchaseOfEntasisNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchasesOfTradingSecurityManagedByIspFundLp" xlink:label="inva_PurchasesOfTradingSecurityManagedByIspFundLp"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FairValueAdjustmentsIncludedInCostOfProductSales" xlink:label="inva_FairValueAdjustmentsIncludedInCostOfProductSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SaleOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes" xlink:label="inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_UnrealizedOtherGainLossOnInvestments" xlink:label="inva_UnrealizedOtherGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetProceedsFromSaleOfVariableInterestEntityEquity" xlink:label="inva_NetProceedsFromSaleOfVariableInterestEntityEquity"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity" xlink:label="inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired" xlink:label="inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredLeasingFees" xlink:label="us-gaap_IncreaseDecreaseInDeferredLeasingFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_MembersEquity" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquity" xlink:label="us-gaap_MembersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_Goodwill" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" order="11" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="inva_ConvertibleSubordinatedDebtFairValueDisclosures" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="inva_ConvertibleSeniorDebtFairValueDisclosures" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="inva_IntangibleAssetsCollaborationAgreementGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="inva_IntangibleAssetsMarketedProductsGross" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsCollaborationAgreementGross" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsMarketedProductsGross" xlink:label="inva_IntangibleAssetsMarketedProductsGross"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_AccruedClinicalLiability" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_DeferredRoyaltyObligationCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_AccruedLicenseFeesAndRoyalties" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherLiabilities" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_AccruedResearchLiability" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_AccruedContractManufacturingLiability" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_AccruedProfessionalServices" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedClinicalLiability" xlink:label="inva_AccruedClinicalLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredRoyaltyObligationCurrent" xlink:label="inva_DeferredRoyaltyObligationCurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedLicenseFeesAndRoyalties" xlink:label="inva_AccruedLicenseFeesAndRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedResearchLiability" xlink:label="inva_AccruedResearchLiability"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedContractManufacturingLiability" xlink:label="inva_AccruedContractManufacturingLiability"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AccruedProfessionalServices" xlink:label="inva_AccruedProfessionalServices"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="inva_DeferredRoyaltyObligationNonCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="inva_ContingentValueRightsLiability" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredRoyaltyObligationNonCurrent" xlink:label="inva_DeferredRoyaltyObligationNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense" xlink:label="us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:label="us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="inva_DeferredTaxLiabilitiesDepreciationAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="4" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>27
<FILENAME>inva-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T16:25:37.4067+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome" xlink:href="inva-20221231.xsd#StatementConsolidatedStatementsOfIncome" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical" xlink:href="inva-20221231.xsd#StatementConsolidatedStatementsOfIncomeParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="inva-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables" xlink:href="inva-20221231.xsd#DisclosureDebtTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails" xlink:href="inva-20221231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="inva-20221231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails" xlink:href="inva-20221231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails" xlink:href="inva-20221231.xsd#DisclosureNetIncomePerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" xlink:href="inva-20221231.xsd#DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails" xlink:href="inva-20221231.xsd#DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails" xlink:href="inva-20221231.xsd#DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails" xlink:href="inva-20221231.xsd#DisclosureRevenueRecognitionDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails" xlink:href="inva-20221231.xsd#DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails" xlink:href="inva-20221231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet" xlink:href="inva-20221231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" xlink:href="inva-20221231.xsd#DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="inva-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails" xlink:href="inva-20221231.xsd#DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="inva-20221231.xsd#DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails" xlink:href="inva-20221231.xsd#DisclosureStockBasedCompensation2012PlanAndEsppDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails" xlink:href="inva-20221231.xsd#DisclosureStockBasedCompensationDirectorCompensationProgramDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="inva-20221231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails" xlink:href="inva-20221231.xsd#DisclosureStockBasedCompensationCompensationAwardsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" xlink:href="inva-20221231.xsd#DisclosureStockBasedCompensationValuationAssumptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails" xlink:href="inva-20221231.xsd#DisclosureStockholdersEquityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails" xlink:href="inva-20221231.xsd#DisclosureDebtScheduleOfDebtDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails" xlink:href="inva-20221231.xsd#DisclosureDebtConvertibleSubordinatedNotesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails" xlink:href="inva-20221231.xsd#DisclosureDebtConvertibleSeniorNotesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="inva-20221231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails" xlink:href="inva-20221231.xsd#DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="inva-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DeconsolidationGainOrLossAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="inva_GainLossOnOtherInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestAndDividendIncomeOperating" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" xlink:label="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FairValueOfNonControllingInterestInSubsidiary" xlink:label="inva_FairValueOfNonControllingInterestInSubsidiary"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" xlink:label="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" xlink:label="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest" xlink:label="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" xlink:label="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance" xlink:label="inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CashDividendForfeited" xlink:label="inva_CashDividendForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares" xlink:label="inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares" xlink:label="inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="us-gaap_TreasuryStockSharesRetired" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_FairValueOfNonControllingInterestInSubsidiary" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockSharesAcquired" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_CashDividendForfeited" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables">
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_Percent2.50ConvertibleDebtMember" xlink:label="inva_Percent2.50ConvertibleDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_Percent2.50ConvertibleDebtMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails">
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SummaryOfSignificantAccountingPoliciesTable" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaMember" xlink:label="inva_LaJollaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CustomerOneMember" xlink:label="inva_CustomerOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CustomerTwoMember" xlink:label="inva_CustomerTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CustomerThreeMember" xlink:label="inva_CustomerThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCustomers" xlink:label="inva_NumberOfCustomers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeePaidEstimatedUsefulLife" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DecreaseToAccumulatedDeficit" xlink:label="inva_DecreaseToAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ReductionToAdditionalPaidInCapital" xlink:label="inva_ReductionToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncreaseToConvertibleNotes" xlink:label="inva_IncreaseToConvertibleNotes"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncreaseInDeferredTaxAssets" xlink:label="inva_IncreaseInDeferredTaxAssets"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_LaJollaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_LabaCollaborationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistAnoroMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_NumberOfCustomers" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CapitalizedFeePaidEstimatedUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_DecreaseToAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_ReductionToAdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_IncreaseToConvertibleNotes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_IncreaseInDeferredTaxAssets" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SoftwareAndComputerEquipmentMember" xlink:label="inva_SoftwareAndComputerEquipmentMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inva_LaboratoryEquipmentFurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inva_SoftwareAndComputerEquipmentMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SarissaCapitalManagementLpMember" xlink:label="inva_SarissaCapitalManagementLpMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_SarissaCapitalManagementLpMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DilutiveEpsOfNotes" xlink:label="inva_DilutiveEpsOfNotes"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DilutiveEpsOfNotes" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetIncomeLossPerShareAbstract" xlink:label="inva_NetIncomeLossPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DenominatorAbstract" xlink:label="inva_DenominatorAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumeratorAbstract" xlink:label="inva_NumeratorAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" xlink:label="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_NumeratorAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_DenominatorAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_NetIncomeLossPerShareAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EquityIncentivePlansAndESPPMember" xlink:label="inva_EquityIncentivePlansAndESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OutstandingStockWarrantMember" xlink:label="inva_OutstandingStockWarrantMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inva_EquityIncentivePlansAndESPPMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inva_OutstandingStockWarrantMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_StrategicAllianceMabaProgram" xlink:label="inva_StrategicAllianceMabaProgram"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TrelegyElliptaMember" xlink:label="inva_TrelegyElliptaMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistAnoroMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_StrategicAllianceMabaProgram" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_TrelegyElliptaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TrelegyElliptaMember" xlink:label="inva_TrelegyElliptaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GiaprezaMember" xlink:label="inva_GiaprezaMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_XeravaMember" xlink:label="inva_XeravaMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnContractTermination" xlink:label="us-gaap_GainLossOnContractTermination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_GeographicConcentrationRiskMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_LongActingBeta2AgonistAnoroMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_LabaCollaborationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_TrelegyElliptaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_GiaprezaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RoyaltyMember" xlink:to="inva_XeravaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_GainLossOnContractTermination" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ZaiLabMember" xlink:label="inva_ZaiLabMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CommercialSupplyAgreementMember" xlink:label="inva_CommercialSupplyAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ResearchAndDevelopmentSupportMember" xlink:label="inva_ResearchAndDevelopmentSupportMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PaionAgMember" xlink:label="inva_PaionAgMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FuturePotentialMilestonePayment" xlink:label="inva_FuturePotentialMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EverestMedicinesLimitedMember" xlink:label="inva_EverestMedicinesLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ReductionToResearchAndDevelopmentExpense" xlink:label="inva_ReductionToResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GeorgeWashingtonUniversityMember" xlink:label="inva_GeorgeWashingtonUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RegulatoryMilestonePaymentsReceivable" xlink:label="inva_RegulatoryMilestonePaymentsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_HarvardUniversityMember" xlink:label="inva_HarvardUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SalesMilestonePaymentsReceivable" xlink:label="inva_SalesMilestonePaymentsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ParatekPharmaceuticalsIncMember" xlink:label="inva_ParatekPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfRoyaltyPayableOnNetSales" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfMinimumRoyaltyRate" xlink:label="inva_PercentageOfMinimumRoyaltyRate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ClaimExpirationDate" xlink:label="inva_ClaimExpirationDate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_ZaiLabMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_CommercialSupplyAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_ResearchAndDevelopmentSupportMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_PaionAgMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_FuturePotentialMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_EverestMedicinesLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ReductionToResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_GeorgeWashingtonUniversityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_RegulatoryMilestonePaymentsReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_HarvardUniversityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_SalesMilestonePaymentsReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_ParatekPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfRoyaltyPayableOnNetSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfMinimumRoyaltyRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ClaimExpirationDate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OwnershipInterestInConsolidatedEntities" xlink:label="inva_OwnershipInterestInConsolidatedEntities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:label="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:label="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" xlink:label="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquity" xlink:label="us-gaap_MembersEquity"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CollaborativeArrangementsMember" xlink:label="inva_CollaborativeArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ContingentSalesBasedMilestonePayment" xlink:label="inva_ContingentSalesBasedMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CashDistributionReceived" xlink:label="inva_CashDistributionReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RealizedLoss" xlink:label="inva_RealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_OwnershipInterestInConsolidatedEntities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MembersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CollaborativeArrangementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="inva_IspFundLpMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_ContingentSalesBasedMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_CashDistributionReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_EquityMethodInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="inva_RealizedLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_GainLossOnInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCumulativeCashDistributions" xlink:label="us-gaap_LimitedPartnersCumulativeCashDistributions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralPartnerMember" xlink:label="us-gaap_GeneralPartnerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfEconomicInterestInPartnership" xlink:label="inva_PercentageOfEconomicInterestInPartnership"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInvestmentExpense" xlink:label="us-gaap_InvestmentIncomeInvestmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PaymentOfManagementAndIncentiveFee" xlink:label="inva_PaymentOfManagementAndIncentiveFee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PartnershipAgreementLockUpPeriod" xlink:label="inva_PartnershipAgreementLockUpPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_LimitedPartnersCumulativeCashDistributions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_GeneralPartnerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="inva_IspFundLpMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_LimitedPartnersContributedCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_PercentageOfEconomicInterestInPartnership" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_InvestmentIncomeInvestmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_PaymentOfManagementAndIncentiveFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_PartnershipAgreementLockUpPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_GainLossOnInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementMember" xlink:label="inva_SecuritiesPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertiblePromissoryNoteMember" xlink:label="inva_ConvertiblePromissoryNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" xlink:label="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CommonStockAndWarrantsMember" xlink:label="inva_CommonStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsAcquiredInSecondQuarterOf2021Member" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2021Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsAcquiredInThirdQuarterOf2020Member" xlink:label="inva_WarrantsAcquiredInThirdQuarterOf2020Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsAcquiredInSecondQuarterOf2020Member" xlink:label="inva_WarrantsAcquiredInSecondQuarterOf2020Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment" xlink:label="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNoteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_CommonStockAndWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsAcquiredInSecondQuarterOf2021Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsAcquiredInThirdQuarterOf2020Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsAcquiredInSecondQuarterOf2020Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_MinorityInterestPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" xlink:label="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPeriodIncreaseDecrease" xlink:label="us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" xlink:label="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionCosts" xlink:label="us-gaap_AcquisitionCosts"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncreaseDecreaseInDeferredTaxLiabilities" xlink:label="inva_IncreaseDecreaseInDeferredTaxLiabilities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_GoodwillPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_IncreaseDecreaseInInventories" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AcquisitionCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="inva_IncreaseDecreaseInDeferredTaxLiabilities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CommonStockAndWarrantsMember" xlink:label="inva_CommonStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OneDirectorMember" xlink:label="inva_OneDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsPurchasedIn2020Member" xlink:label="inva_WarrantsPurchasedIn2020Member"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoDirectorsMember" xlink:label="inva_TwoDirectorsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsPurchasedIn2021Member" xlink:label="inva_WarrantsPurchasedIn2021Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WarrantsPurchasedIn2022Member" xlink:label="inva_WarrantsPurchasedIn2022Member"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementNumberOfTranches" xlink:label="inva_SecuritiesPurchaseAgreementNumberOfTranches"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_VotingAgreementMaximumVotingRightsPercent" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_CommonStockAndWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="inva_OneDirectorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2020Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="inva_TwoDirectorsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2021Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2022Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementNumberOfTranches" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_VotingAgreementMaximumVotingRightsPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AssetsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncomeStatementRelatedDisclosuresAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NameOfEventDomain" xlink:label="inva_NameOfEventDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_QualifiedFinancingMember" xlink:label="inva_QualifiedFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OptionPricingModelBacksolveValuationMember" xlink:label="inva_OptionPricingModelBacksolveValuationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesCPreferredStockAndWarrantsMember" xlink:label="inva_SeriesCPreferredStockAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NameOfEventAxis" xlink:label="inva_NameOfEventAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NameOfEventDomain" xlink:label="inva_NameOfEventDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_Incarda2020WarrantsMember" xlink:label="inva_Incarda2020WarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InCardaConvertibleNoteMember" xlink:label="inva_InCardaConvertibleNoteMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" xlink:label="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertibleNoteAndWarrantsMember" xlink:label="inva_ConvertibleNoteAndWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentTransactionCost" xlink:label="inva_DebtInstrumentTransactionCost"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesA1PreferredStockMember" xlink:label="inva_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD1PreferredStockMember" xlink:label="inva_SeriesD1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD2PreferredStockMember" xlink:label="inva_SeriesD2PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD1WarrantMember" xlink:label="inva_SeriesD1WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD2WarrantMember" xlink:label="inva_SeriesD2WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ExpectedHoldingPeriod" xlink:label="inva_ExpectedHoldingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RiskFreeInterestRate" xlink:label="inva_RiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DividendYield" xlink:label="inva_DividendYield"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeriesD1AndD2PreferredStockAndCommonStockMember" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PercentageOfEstimatedVolatility" xlink:label="inva_PercentageOfEstimatedVolatility"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ExtendedExpirationDate" xlink:label="inva_ExtendedExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NameOfEventDomain" xlink:to="inva_QualifiedFinancingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="inva_OptionPricingModelBacksolveValuationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesCPreferredStockAndWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="inva_NameOfEventAxis" xlink:to="inva_NameOfEventDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="inva_NameOfEventAxis" xlink:to="inva_NameOfEventDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_IncardaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_Incarda2020WarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaConvertibleNoteMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ConvertibleNoteAndWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="inva_NameOfEventAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_DebtInstrumentTransactionCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesA1PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD2PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD2WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_ExpectedHoldingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesCWarrantsAndSeriesDWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_RiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_DividendYield" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1AndD2PreferredStockAndCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_PercentageOfEstimatedVolatility" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_ExtendedExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ImaginabMember" xlink:label="inva_ImaginabMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OneOfImaginabsCommonStockholderMember" xlink:label="inva_OneOfImaginabsCommonStockholderMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ImaginabMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_OneOfImaginabsCommonStockholderMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCommonStockIssuedDescription" xlink:label="inva_NumberOfCommonStockIssuedDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_GateNeuroscienceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCommonStockIssuedDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NanoliveMember" xlink:label="inva_NanoliveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" xlink:label="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_NanoliveMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EquityInvestmentsAndMoneyMarketFundsMember" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PrivatePlacementPositionsAndConvertibleNotesMember" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtMember" xlink:label="us-gaap_DebtMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PreferredStockWarrantsMember" xlink:label="inva_PreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PartnershipAgreementLockUpPeriod" xlink:label="inva_PartnershipAgreementLockUpPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ArmataPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_IspFundLpMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ConvertibleSubordinatedDebtFairValueDisclosures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_EquityInvestmentsAndMoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ConvertibleSeniorDebtFairValueDisclosures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_IncardaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_PrivatePlacementPositionsAndConvertibleNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_GateNeuroscienceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DebtMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ContingentValueRightsLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_PreferredStockWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_PartnershipAgreementLockUpPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LimitedPartnersContributedCapital" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems" xlink:label="us-gaap_CapitalizedContractCostLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable" xlink:label="us-gaap_CapitalizedContractCostTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP" xlink:label="country_JP"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidWeightedAverageUsefulLife" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="inva_CapitalizedFeesPaidWeightedAverageUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="inva_CapitalizedFeesPaidFutureAmortizationAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_ScheduleOfGoodwillTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsMarketedProductsGross" xlink:label="inva_IntangibleAssetsMarketedProductsGross"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsCollaborationAgreementGross" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsMarketedProductsNet" xlink:label="inva_IntangibleAssetsMarketedProductsNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IntangibleAssetsCollaborationAgreementNet" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FairValueAdjustmentsOfInventoryFromAcquistion" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_FairValueAdjustmentsOfInventoryFromAcquistion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EquityIncentivePlan2012Member" xlink:label="inva_EquityIncentivePlan2012Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EquityIncentivePlan2012Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InnovivaMember" xlink:label="inva_InnovivaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CommonStockAcquiredAverageCostPerShare" xlink:label="inva_CommonStockAcquiredAverageCostPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfTreasuryStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_ShareRepurchaseProgramAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_CommonStockAcquiredAverageCostPerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_HealthCareRoyaltyPartnersMember" xlink:label="inva_HealthCareRoyaltyPartnersMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OtherAccruedLiabilitiesMember" xlink:label="inva_OtherAccruedLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyFinancingAgreementMember" xlink:label="inva_RoyaltyFinancingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyAgreementMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DeferredRoyaltyObligationAndAccruedInterest" xlink:label="inva_DeferredRoyaltyObligationAndAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyObligationPayable" xlink:label="inva_RoyaltyObligationPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyPayments" xlink:label="inva_RoyaltyPayments"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InterestRateOfDeferredRoyaltyObligation" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PaymentsForRoyaltyAgreement" xlink:label="inva_PaymentsForRoyaltyAgreement"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_HealthCareRoyaltyPartnersMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="inva_OtherAccruedLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentPrincipalAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LoansPayableMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_RoyaltyFinancingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementMaximumPotentialPayoutPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseBorrowings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DeferredRoyaltyObligationAndAccruedInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyObligationPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_InterestRateOfDeferredRoyaltyObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PaymentsForRoyaltyAgreement" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_InnovivaCommonStockMember" xlink:label="inva_InnovivaCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="us-gaap_InterestExpenseDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCostOfHedge" xlink:label="us-gaap_DerivativeCostOfHedge"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfDerivativeInstrumentsPurchased" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtConversionConvertedInstrumentSharesIssued" xlink:label="inva_DebtConversionConvertedInstrumentSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConversionRate" xlink:label="inva_ConversionRate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtConversionConvertedInstrumentAdjustedSharesIssued" xlink:label="inva_DebtConversionConvertedInstrumentAdjustedSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_CappedCallStrikePrice" xlink:label="inva_CappedCallStrikePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentRepurchasePercentage" xlink:label="inva_DebtInstrumentRepurchasePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="us-gaap_CallOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inva_InnovivaCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="us-gaap_PutOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeCostOfHedge" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_NumberOfDerivativeInstrumentsPurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionConvertedInstrumentSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_ConversionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionConvertedInstrumentAdjustedSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_CappedCallStrikePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeCapPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchaseAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRepurchasePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentPrincipalAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseBorrowingsAbstract" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:label="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" xlink:label="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentConvertibleConversionPremium" xlink:label="inva_DebtInstrumentConvertibleConversionPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCovenantTerms" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_PortionOfDebtInstrumentFaceAmountExercised" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="inva_DebtInstrumentPrincipalAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeCapPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentConvertibleConversionPremium" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCovenantTerms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PortionOfDebtInstrumentFaceAmountExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_ConvertibleDebtInstrumentLiabilityComponentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseBorrowingsAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisLeaseMember" xlink:label="inva_EntasisLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_BurlingameCaliforniaMember" xlink:label="inva_BurlingameCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_WalthamMassachusettsMember" xlink:label="inva_WalthamMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate" xlink:label="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAllegations" xlink:label="us-gaap_LossContingencyAllegations"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_DemandLettersSentByStockholders" xlink:label="inva_DemandLettersSentByStockholders"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="inva_EntasisLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inva_BurlingameCaliforniaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NetRentableArea" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inva_WalthamMassachusettsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAllegations" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inva_DemandLettersSentByStockholders" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails">
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncomeTaxesLineItems" xlink:label="inva_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_IncomeTaxesTable" xlink:label="inva_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_OperatingLossCarryforwardsIndefinitePeriod" xlink:label="inva_OperatingLossCarryforwardsIndefinitePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NetOperatingLossEstimatingDate" xlink:label="inva_NetOperatingLossEstimatingDate"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_FederalNetOperatingLossesEstimatedUtilizationAmount" xlink:label="inva_FederalNetOperatingLossesEstimatedUtilizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_StateNetOperatingLossesEstimatedUtilizationAmount" xlink:label="inva_StateNetOperatingLossesEstimatedUtilizationAmount"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" xlink:label="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_IncomeTaxesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_OperatingLossCarryforwardsIndefinitePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_NetOperatingLossEstimatingDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_FederalNetOperatingLossesEstimatedUtilizationAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_StateNetOperatingLossesEstimatedUtilizationAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoanRestructuringModificationDomain" xlink:label="us-gaap_LoanRestructuringModificationDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NewPrincipalAmountMember" xlink:label="inva_NewPrincipalAmountMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_SecuredConvertibleCreditAgreementMember" xlink:label="inva_SecuredConvertibleCreditAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoanRestructuringModificationAxis" xlink:label="us-gaap_LoanRestructuringModificationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoanRestructuringModificationDomain" xlink:label="us-gaap_LoanRestructuringModificationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="inva-20221231.xsd#inva_NoteAmendmentAgreementMember" xlink:label="inva_NoteAmendmentAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoanRestructuringModificationDomain" xlink:to="inva_NewPrincipalAmountMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_ArmataPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_SecuredConvertibleCreditAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LoanRestructuringModificationAxis" xlink:to="us-gaap_LoanRestructuringModificationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LoanRestructuringModificationAxis" xlink:to="us-gaap_LoanRestructuringModificationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_NoteAmendmentAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LoanRestructuringModificationAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280522018528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 14, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INNOVIVA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">000-30319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3265960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1350 Old Bayshore Highway, Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Burlingame<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">238-9600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $0.01 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INVA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 923,930,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,126,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001080014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specified portions of the registrant&#8217;s definitive Proxy Statement to be issued in conjunction with the registrant&#8217;s 2023 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, are incorporated by reference into Part III of this Annual Report. Except as expressly incorporated by reference, the registrant&#8217;s Proxy Statement shall not be deemed to be a part of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Jose, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280523809344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 291,049<span></span>
</td>
<td class="nump">$ 201,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">9,401<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesLongTermContractsOrPrograms', window );">Receivables from collaboration arrangements</a></td>
<td class="nump">54,672<span></span>
</td>
<td class="nump">110,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">55,897<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="nump">29,559<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,933<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">443,511<span></span>
</td>
<td class="nump">313,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity and long-term investments</a></td>
<td class="nump">403,013<span></span>
</td>
<td class="nump">483,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized fees paid, net</a></td>
<td class="nump">97,607<span></span>
</td>
<td class="nump">111,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">3,265<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">26,713<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">252,919<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,299<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,231,497<span></span>
</td>
<td class="nump">926,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,939<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued personnel-related expenses</a></td>
<td class="nump">8,022<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="nump">4,359<span></span>
</td>
<td class="nump">4,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">2,094<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible subordinated notes due 2023, net of issuance costs</a></td>
<td class="nump">96,193<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">21,207<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">134,968<span></span>
</td>
<td class="nump">5,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of discount and issuance costs</a></td>
<td class="nump">444,180<span></span>
</td>
<td class="nump">394,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">70,918<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="nump">5,771<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxPayableNonCurrent', window );">Income tax payable, long-term</a></td>
<td class="nump">9,872<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.01 par value, 200,000 shares authorized, 69,188 and 69,566 issued and outstanding as of December 31, 2022 and December 31, 2021 respectively</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock: at cost, 32,005 shares as of December 31, 2022 and December 31, 2021</a></td>
<td class="num">(393,829)<span></span>
</td>
<td class="num">(393,829)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,163,836<span></span>
</td>
<td class="nump">1,264,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(204,911)<span></span>
</td>
<td class="num">(456,148)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Innoviva stockholders' equity</a></td>
<td class="nump">565,788<span></span>
</td>
<td class="nump">414,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">111,192<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">565,788<span></span>
</td>
<td class="nump">525,935<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 1,231,497<span></span>
</td>
<td class="nump">$ 926,395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncomeTaxPayableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax payable non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncomeTaxPayableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesLongTermContractsOrPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesLongTermContractsOrPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280521991360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">69,188<span></span>
</td>
<td class="nump">69,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">69,188<span></span>
</td>
<td class="nump">69,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares</a></td>
<td class="nump">32,005<span></span>
</td>
<td class="nump">32,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280522114320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 331,339<span></span>
</td>
<td class="nump">$ 391,866<span></span>
</td>
<td class="nump">$ 336,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">63,538<span></span>
</td>
<td class="nump">16,187<span></span>
</td>
<td class="nump">13,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">41,432<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">5,581<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on sale of Theravance Respiratory Company, LLC ("TRC")</a></td>
<td class="num">(266,696)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">20,662<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Changes in fair values of equity method investments, net</a></td>
<td class="nump">161,749<span></span>
</td>
<td class="num">(84,392)<span></span>
</td>
<td class="num">(49,511)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GainLossOnOtherInvestments', window );">Changes in fair value of other equity and long-term investments, net</a></td>
<td class="num">(8,462)<span></span>
</td>
<td class="num">(6,638)<span></span>
</td>
<td class="num">(766)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Interest and dividend income</a></td>
<td class="num">(6,369)<span></span>
</td>
<td class="num">(1,839)<span></span>
</td>
<td class="num">(1,524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">15,789<span></span>
</td>
<td class="nump">19,070<span></span>
</td>
<td class="nump">18,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">3,373<span></span>
</td>
<td class="nump">3,626<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">44,390<span></span>
</td>
<td class="num">(53,410)<span></span>
</td>
<td class="num">(17,451)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">286,949<span></span>
</td>
<td class="nump">445,276<span></span>
</td>
<td class="nump">354,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense, net</a></td>
<td class="nump">66,687<span></span>
</td>
<td class="nump">76,439<span></span>
</td>
<td class="nump">60,431<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">220,262<span></span>
</td>
<td class="nump">368,837<span></span>
</td>
<td class="nump">293,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="nump">6,341<span></span>
</td>
<td class="nump">102,983<span></span>
</td>
<td class="nump">69,412<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Innoviva stockholders</a></td>
<td class="nump">$ 213,921<span></span>
</td>
<td class="nump">$ 265,854<span></span>
</td>
<td class="nump">$ 224,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share attributable to Innoviva stockholders</a></td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share attributable to Innoviva stockholders</a></td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used to compute Innoviva basic and diluted net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute basic net income per share</a></td>
<td class="nump">69,644<span></span>
</td>
<td class="nump">82,062<span></span>
</td>
<td class="nump">101,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted net income per share</a></td>
<td class="nump">95,248<span></span>
</td>
<td class="nump">94,310<span></span>
</td>
<td class="nump">113,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue from a related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 311,645<span></span>
</td>
<td class="nump">$ 391,866<span></span>
</td>
<td class="nump">$ 326,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_CollaborativeArrangementsMember', window );">Revenue from collaborative arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">19,694<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold (inclusive of amortization of inventory fair value adjustments and excluding amortization of acquired intangible assets)</a></td>
<td class="nump">$ 13,793<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_GainLossOnOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_GainLossOnOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1-5)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_CollaborativeArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_CollaborativeArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280528507120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of capitalized fees paid</a></td>
<td class="nump">$ 13,823<span></span>
</td>
<td class="nump">$ 13,823<span></span>
</td>
<td class="nump">$ 13,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280523178608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 220,262<span></span>
</td>
<td class="nump">$ 368,837<span></span>
</td>
<td class="nump">$ 293,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassifications to net income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">220,262<span></span>
</td>
<td class="nump">368,837<span></span>
</td>
<td class="nump">293,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interests</a></td>
<td class="nump">6,341<span></span>
</td>
<td class="nump">102,983<span></span>
</td>
<td class="nump">69,412<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Innoviva stockholders</a></td>
<td class="nump">$ 213,921<span></span>
</td>
<td class="nump">$ 265,854<span></span>
</td>
<td class="nump">$ 224,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518564448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative effect period of adoption adjustment member</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th">
<div>Common stock </div>
<div>Cumulative effect period of adoption adjustment member</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative effect period of adoption adjustment member</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th">
<div>Accumulated Other Comprehensive Income (Loss) </div>
<div>Cumulative effect period of adoption adjustment member</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative effect period of adoption adjustment member</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th">
<div>Treasury Stock </div>
<div>Cumulative effect period of adoption adjustment member</div>
</th>
<th class="th"><div>Noncontrolling Interest</div></th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>Cumulative effect period of adoption adjustment member</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 342,116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,013,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,258,859,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (946,404,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,621,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to noncontrolling interests</a></td>
<td class="num">(30,474,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,474,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity', window );">Equity activity of noncontrolling interest in a consolidated variable interest entity</a></td>
<td class="nump">366,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding</a></td>
<td class="nump">1,109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">293,814,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="num">(27,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">607,837,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,014,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(722,002,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to noncontrolling interests</a></td>
<td class="num">(59,457,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,457,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity', window );">Equity activity of noncontrolling interest in a consolidated variable interest entity</a></td>
<td class="num">(259,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(259,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding</a></td>
<td class="nump">344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(394,149,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (320,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (393,829,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,005)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,017,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,017,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">368,837,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,854,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,983,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 525,935,000<span></span>
</td>
<td class="nump">$ 28,229,000<span></span>
</td>
<td class="nump">$ 696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,264,024,000<span></span>
</td>
<td class="nump">$ 65,467,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(456,148,000)<span></span>
</td>
<td class="nump">$ 37,238,000<span></span>
</td>
<td class="num">$ (393,829,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">69,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions to noncontrolling interests</a></td>
<td class="num">$ (69,811,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,811,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis', window );">Recognition of noncontrolling interest upon initial consolidation of Entasis</a></td>
<td class="nump">38,471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity', window );">Equity activity of noncontrolling interest in a consolidated variable interest entity</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc', window );">Derecognition of noncontrolling interests upon sale of TRC</a></td>
<td class="num">(61,226,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,304,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest', window );">Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest</a></td>
<td class="num">(42,162,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,153,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,009,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding</a></td>
<td class="nump">288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Capped call options associated with convertible senior notes due 2028</a></td>
<td class="nump">16,585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,585,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Conversion of convertible subordinated notes due 2023</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(8,503,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(647)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">220,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,921,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,341,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 565,788,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,163,836,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (204,911,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (393,829,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">69,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes to noncontrolling interest from a consolidated variable interest entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognition of non controlling interests upon acquisition of entasis minority interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognition of noncontrolling interestsupon sale of TRC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition Of Noncontrolling Interest Upon Initial Consolidation Of Entasis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e34017-109320<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=123466103&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280522989296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 220,262<span></span>
</td>
<td class="nump">$ 368,837<span></span>
</td>
<td class="nump">$ 293,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">25,006<span></span>
</td>
<td class="nump">76,432<span></span>
</td>
<td class="nump">60,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment', window );">Amortization of capitalized fees and depreciation of property and equipment</a></td>
<td class="nump">13,931<span></span>
</td>
<td class="nump">13,832<span></span>
</td>
<td class="nump">13,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">5,581<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FairValueAdjustmentsIncludedInCostOfProductSales', window );">Fair value adjustments included in cost of product sales</a></td>
<td class="nump">10,023<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,347<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">2,055<span></span>
</td>
<td class="nump">9,136<span></span>
</td>
<td class="nump">8,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Changes in fair values of equity method investments, net</a></td>
<td class="nump">161,749<span></span>
</td>
<td class="num">(84,392)<span></span>
</td>
<td class="num">(49,511)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_UnrealizedOtherGainLossOnInvestments', window );">Changes in fair values of other equity and long-term investments, net</a></td>
<td class="num">(8,462)<span></span>
</td>
<td class="num">(4,917)<span></span>
</td>
<td class="num">(766)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">20,662<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Net gain on sale of TRC</a></td>
<td class="num">(266,696)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of discount on short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(343)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLeasingFees', window );">Amortization of lease guarantee</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">3,402<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(3,525)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent', window );">Receivables from collaborative arrangements</a></td>
<td class="nump">13,319<span></span>
</td>
<td class="num">(16,780)<span></span>
</td>
<td class="num">(14,504)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(21,350)<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="num">(678)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(3,341)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">92<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued personnel-related expenses and other accrued liabilities</a></td>
<td class="nump">11,913<span></span>
</td>
<td class="num">(257)<span></span>
</td>
<td class="nump">804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(755)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax payable</a></td>
<td class="nump">10,026<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">201,726<span></span>
</td>
<td class="nump">363,813<span></span>
</td>
<td class="nump">313,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchases of equity and long term investments</a></td>
<td class="num">(58,725)<span></span>
</td>
<td class="num">(66,278)<span></span>
</td>
<td class="num">(87,981)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchasesOfEquityInvestmentsManagedByIspFundLp', window );">Purchases of equity investments managed by ISP Fund LP</a></td>
<td class="num">(60,910)<span></span>
</td>
<td class="num">(190,970)<span></span>
</td>
<td class="num">(14,877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchasesOfTradingSecurityManagedByIspFundLp', window );">Purchases of trading security managed by ISP Fund LP</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SaleOfEquityInvestmentsManagedByIspFundLp', window );">Sales of equity investments managed by ISP Fund LP</a></td>
<td class="nump">24,281<span></span>
</td>
<td class="nump">21,440<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp', window );">Purchase and sales of other investments managed by ISP Fund LP, net</a></td>
<td class="num">(23,371)<span></span>
</td>
<td class="nump">279,530<span></span>
</td>
<td class="num">(285,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(67)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NetProceedsFromSaleOfVariableInterestEntityEquity', window );">Proceeds from sale of ownership interest in TRC, net</a></td>
<td class="nump">248,191<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired through the consolidation of Entasis</a></td>
<td class="nump">23,070<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired', window );">Cash paid for the acquisition of La Jolla, net of cash acquired</a></td>
<td class="num">(159,103)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(56,634)<span></span>
</td>
<td class="nump">43,722<span></span>
</td>
<td class="num">(314,937)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions to noncontrolling interest</a></td>
<td class="num">(69,811)<span></span>
</td>
<td class="num">(59,457)<span></span>
</td>
<td class="num">(30,474)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchaseOfEntasisNoncontrollingInterest', window );">Purchase of Entasis noncontrolling interest</a></td>
<td class="num">(43,910)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(8,503)<span></span>
</td>
<td class="num">(394,149)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Repurchase of shares to satisfy tax withholding</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuances of common stock</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity', window );">Net proceeds from the issuance of variable interest entity's equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Payment for repurchase of convertible subordinated notes due 2023</a></td>
<td class="num">(165,131)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes', window );">Purchases of capped call options associated with convertible senior notes due 2028</a></td>
<td class="num">(21,037)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of convertible senior notes due 2028, net of issuance costs</a></td>
<td class="nump">252,536<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(55,568)<span></span>
</td>
<td class="num">(452,497)<span></span>
</td>
<td class="num">(29,785)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">89,524<span></span>
</td>
<td class="num">(44,962)<span></span>
</td>
<td class="num">(31,609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">201,525<span></span>
</td>
<td class="nump">246,487<span></span>
</td>
<td class="nump">278,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">291,049<span></span>
</td>
<td class="nump">201,525<span></span>
</td>
<td class="nump">246,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">11,736<span></span>
</td>
<td class="nump">9,933<span></span>
</td>
<td class="nump">9,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">53,855<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-cash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NonCashActivity', window );">Adoption of ASU 2020-06</a></td>
<td class="num">$ (28,228)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of capitalized fees and depreciation of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for the acquisition of La Jolla Pharmaceutical Company, net of cash acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_FairValueAdjustmentsIncludedInCostOfProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustments included in cost of product sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_FairValueAdjustmentsIncludedInCostOfProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of variable interest entity's equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NetProceedsFromSaleOfVariableInterestEntityEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds from sale of variable interest entity equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NetProceedsFromSaleOfVariableInterestEntityEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NonCashActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NonCashActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase and sale of other investments managed by ISP FUND LP</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchaseOfEntasisNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of entasis noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchaseOfEntasisNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of capped call options associated with convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchasesOfEquityInvestmentsManagedByIspFundLp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of Equity Investments Managed by Isp Fund Lp</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchasesOfEquityInvestmentsManagedByIspFundLp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchasesOfTradingSecurityManagedByIspFundLp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of trading security managed by Isp fund Lp.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchasesOfTradingSecurityManagedByIspFundLp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SaleOfEquityInvestmentsManagedByIspFundLp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of equity investments managed by ISP FUND LP</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SaleOfEquityInvestmentsManagedByIspFundLp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_UnrealizedOtherGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized other gain loss on investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_UnrealizedOtherGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLeasingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the book value of deferred leasing fees. Amortization of these fees over the terms of the leases reduces deferred leasing fees. Originating new leases increases the balance of deferred leasing fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLeasingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280607388432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.  DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of Operations</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Innoviva, Inc. (referred to as &#8220;Innoviva&#8221;, the &#8220;Company&#8221;, or &#8220;we&#8221; and other similar pronouns) is a company with a portfolio of royalties and innovative healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#8220;GSK&#8221;), including RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(fluticasone furoate/vilanterol, &#8220;FF/VI&#8221;) and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(umeclidinium bromide/vilanterol, &#8220;UMEC/VI&#8221;), and up until July 2022, TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(the combination FF/UMEC/VI). We sold our </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% ownership interest in Theravance Respiratory Company, LLC (&#8220;TRC&#8221;) on July 20, 2022, and are no longer entitled to receive royalties on sales of TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> products. Under the Long-Acting Beta2 Agonist (&#8220;LABA&#8221;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as follows: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on the first $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion of annual global net sales and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for all annual global net sales above $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion; and royalties from the sales of ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which tier upward at a range from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expanded our portfolio of royalties and innovative healthcare assets through the acquisition of Entasis Therapeutics Holdings Inc. (&#8220;Entasis&#8221;) on July 11, 2022 and the acquisition of La Jolla Pharmaceutical Company (&#8220;La Jolla&#8221;) on August 22, 2022. Our commercial and marketed products include GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Our development pipeline includes medicines for the treatment of bacterial infections, such as our lead asset sulbactam-durlobactam (&#8220;SUL-DUR&#8221;). As such, we have a wholly owned robust infectious disease and hospital operating platform, as well as other assets in these areas, such as a large equity stake in Armata Pharmaceuticals, a leader in bacteriophage development with potential use across a range of infectious and other serious diseases.  We also have economic interests in other healthcare companies.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#8220;VIE&#8221;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation Reclassification</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain amounts in prepaid expenses and other current assets, other assets and changes in fair values of equity and long-term investments, net, reported in the Company's prior year financial statements have been reclassified to conform to the current year presentation. These reclassifications had no net effect on the net income or net cash flows as previously reported.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Factors Affecting Comparability</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors below and as discussed in Note 5, &#8220;Consolidated Entities and Acquisitions&#8221;.</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adoption of Accounting Standards Update (&#8220;ASU&#8221;) 2020-06 effective January 1, 2022;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining noncontrolling interest in Entasis on July 11, 2022;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sale of our </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% ownership interest in TRC on July 20, 2022; and</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisition of La Jolla on August 22, 2022.</span></div></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Management&#8217;s Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers and Partners</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#8220;API&#8221;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK&#8217;s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts&#8217; or investors&#8217; expectations, due to a number of important factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also started recognizing revenue from product sales as a result of our acquisition of La Jolla Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of our customers each account for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respectively, of our net product sales from the time of our acquisition of La Jolla through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These same customers account for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#8220;Accounts receivables, net&#8221; on our consolidated balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We operate in a single segment, which is to provide capital return to stockholders by maximizing the potential value of our portfolio of royalties and innovative healthcare assets. Our Chief Operating Decision Maker (&#8220;CODM&#8221;) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Innoviva at the consolidated level using information about our revenues, operating results and other key financial data as needed. Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net sales of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Refer to Note 3, &#8220;Revenue Recognition&#8221;, for more information on our revenues for the periods presented. Our long-term assets are located within the United States.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Variable Interest Entities</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary beneficiary of a variable interest entity (&#8220;VIE&#8217;) is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#8217;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business Combination</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When we acquire an entity in a business combination, we recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establish the acquisition date as the fair value measurement point. We recognize and measure goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. Acquisition-related expenses and related restructuring costs are expensed as incurred.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, we typically use the income method. This method starts with a forecast of all of the expected future net cash flows for each asset. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Some of the more significant estimates and assumptions inherent in the income method or other methods include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows and the assessment of the asset&#8217;s life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory, or economic barriers to entry. Determining the useful life of an intangible asset also requires judgment as different types of intangible assets will have different useful lives and certain assets may even be considered to have indefinite useful lives.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments in Marketable Securities</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We invest in short-term investments and marketable securities, primarily corporate notes, government securities, government agencies, and government commercial papers. We limit the amount of credit exposure with any one issuer, industry or geographic area for investments other than instruments backed by the U.S. federal government. We classify our marketable securities as available-for-sale securities and report them at fair value in cash equivalents or short-term marketable securities on the consolidated balance sheets with related unrealized gains and losses included as a component of stockholders&#8217; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. Realized gains and losses, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and dividend income.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We regularly review all of our investments for other-than-temporary declines in estimated fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in estimated fair value of an investment is below the amortized cost basis and the decline is other-than-temporary, we reduce the carrying value of the security and record a loss for the amount of such decline to other expense, net.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value on a first in, first out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, which consisted of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements, were not material as of December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:49.167%;"/>
          <td style="width:1.667%;"/>
          <td style="width:49.167%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of remaining lease terms or useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment, furniture and fixtures</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software and computer equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
        </table></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity and Long-Term Investments</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 825, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of other equity and long-term investments, net, on the consolidated statements of income.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we conclude that we do not have an ability to exercise significant influence over an investee, we may elect to account for the equity investment without a readily determinable fair value using the measurement alternative under ASC Topic 312, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments - Equity Securities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This measurement alternative allows us to measure the equity investment at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also invest in ISP Fund LP, which investments consist of money market funds, trading and equity securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered in December 2020, we became a limited partner of this partnership, and our contributions are subject to a 36-month lock-up period which restriction prevents us to have control and access to the contributions and related investments. These investments are classified as long-term investments on the consolidated balance sheets.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Quoted prices for identical instruments in active markets.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Unobservable inputs and little, if any, market activity for the assets.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Capitalized Fees Paid</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#8220;Capitalized Fees&#8221;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#8217;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#8217;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill and Intangible Assets</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We apply the guidance on principal versus agent considerations under ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includ</span><span style="background-color:rgba(0,0,0,0);color:rgba(37,37,37,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">es being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalty Revenue</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize the royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on its methodology and assumptions to estimate rebates and returns, which it monitors and adjusts regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Our partner may make significant adjustments to its sales based on actual results recorded, which could cause our royalty revenue to fluctuate. We conduct periodic royalty audits to evaluate the information provided by our partner. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Product Sales</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#8217; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#8220;GPO&#8221;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state&#8217;s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research expenses based on the progress of the studies and progress of research manufacturing activities.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Expense on Deferred Royalty Obligation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#8220;Debt&#8221;, for more information.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Stock&#8209;Based Compensation Awards</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#8220;ESPP&#8221;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#8220;simplified&#8221; method as described in Staff Accounting Bulletin No. 107, &#8220;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,&#8221; for the expected option term. We use our historical volatility to estimate expected stock price volatility.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units (&#8220;RSUs&#8221;) and restricted stock awards (&#8220;RSAs&#8221;) are measured based on the fair market values of the underlying stock on the dates of grant.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#8217;s best estimate as to whether it is probable that the shares awarded are expected to vest.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#8220;more likely than not&#8221; standard.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Income</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive income is comprised of net income and other comprehensive income (loss). Other comprehensive income (loss) consists of changes in unrealized and realized gains and losses on our marketable securities and the related tax impact of these changes.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Related Parties</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions with GSK were considered related party transactions up until May 2021, when we completed the share repurchase agreement with GSK to buy back all of its shares of common stock in Innoviva. GSK is no longer considered a related party after the completion of the share repurchase. Transactions with GSK are described in Note 3, &#8220;Revenue Recognition and Collaborative Arrangements.&#8221;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sarissa Capital ow</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ned </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ur outstanding common stock as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Transactions with Sarissa Capital are described in Note 5, &#8220;Consolidated Entities and Acquisitions&#8221;. Sarissa Capital is considered to be a related party because two of its principals are members of our board of directors.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting Pronouncements Adopted by the Company</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, the FASB issued ASU 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt-Debt with Conversion and Other Options (Subtopic</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which is intended to simplify the accounting for convertible instruments by removing certain separation models in Subtopic 470-20 for</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">convertible instruments. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new standard also requires the if-converted method to be used to calculate diluted earnings per share (&#8220;EPS&#8221;) for convertible instruments. Effective January 1, 2022, we adopted the new standard using the modified retrospective approach and assessed the effect of this adoption on the accounting for our outstanding convertible notes. The effect of the adoption on our 2025 Notes (as defined below) resulted in a decrease to the opening balance of accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, a reduction to additional paid-in capital of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, an increase to the balance of the notes by an aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and an increase to deferred tax assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The dilutive EPS of our 2025 Notes will be computed under the if-converted method going forward. There was no financial impact from the implementation of the standard for our 2023 Notes (as defined below). Refer to Note 12, &#8220;Debt&#8221;, for more information.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, the FASB issued ASU 2021-08, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business Combinations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Topic 805), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Contract Assets and Contract Liabilities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognized and measured by the acquirer on the acquisition date in accordance with ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the third quarter of 2022, we elected to early adopt ASU 2021-08 effective July 1, 2022. The adoption did not have a material impact on our consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280512493808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.  NET INCOME PER SHARE</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock outstanding. Diluted net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock and dilutive potential common stock equivalents then outstanding. Dilutive potential common stock equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method, as well as common stock issuable upon assumed conversion of our convertible subordinated notes due 2023 (the &#8220;2023 Notes&#8221;), our convertible senior notes due 2025 (the &#8220;2025 Notes&#8221;), and our convertible senior notes due 2028 (the &#8220;2028 Notes&#8221;) using the if-converted method.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2025 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. Our current intent is to settle the principal amount of th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e 2025 Notes in cash upon conversion. The impact of the assumed conversion premium to diluted net income per share was historically computed using the treasury stock method until the adoption of ASU 2020-06. As the average market price per share of our common stock as reported on The Nasdaq Global Select Market was lower than the initial conversion price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.26</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, there was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dilutive effect of the assumed conversion premium for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021 and 2020 respectively. The dilutive EPS of the notes was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.31</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per sh</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are using the if-converted method for the year ended December 31, 2022 as a result of the adoption of ASU 2020-06.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table shows the computation of basic and diluted net income per share for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.638%;"/>
        <td style="width:1.409%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.979000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.578%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.409%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.979%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands except per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to Innoviva stockholders, basic</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">213,921</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">265,854</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">224,402</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Add: interest expense on 2023 Notes, net of tax effect</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,736</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,717</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Add: interest expense on 2025 Notes, net of tax effect</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,583</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Add: interest expense on 2028 Notes, net of tax effect</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to Innoviva stockholders, diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225,569</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">270,590</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">229,119</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares used to compute basic net income<br/>&#160;&#160;&#160;per share attributable to Innoviva stockholders</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,644</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82,062</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101,320</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of 2023 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,188</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,189</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,189</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of 2025 Notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,150</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of 2028 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,158</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of options and awards granted under equity<br/>&#160;&#160;&#160;incentive plan and employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares used to compute diluted net income<br/>&#160;&#160;&#160;per share attributable to Innoviva stockholders</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95,248</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94,310</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,554</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income per share attributable to Innoviva stockholders</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.37</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.87</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.02</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Anti&#8209;dilutive Securities</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#8209;dilutive:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:52.353%;"/>
        <td style="width:1.844%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.583%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.027%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.583%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.027%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.583%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding options and awards granted under equity incentive<br/>&#160;&#160;&#160;plan and employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">648</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">979</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,193</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding stock warrant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">282</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">930</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">979</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,193</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280512493808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.  REVENUE RECOGNITION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Revenue from Collaboration Arrangement</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 13, 2022, Innoviva&#8217;s wholly owned subsidiary, Innoviva TRC Holdings, LLC (&#8220;ITH&#8221;) entered into an equity purchase agreement (&#8220;TRC Equity Purchase Agreement&#8221;) with Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) to sell our ownership interest in TRC. As a result of the sale of our ownership interest in TRC, which was consummated on July 20, 2022, we are no longer entitled to receive </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of royalty payments made by GSK stemming from sales of TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We retained our royalty rights with respect to RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net revenue recognized under our GSK Agreements was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.213%;"/>
        <td style="width:1.013%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.063%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.063%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.64%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties - RELVAR/BREO</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">215,034</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234,066</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">221,536</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties - ANORO</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,405</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,935</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,992</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties - TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,029</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73,089</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total royalties</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">325,468</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">405,689</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">340,617</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: amortization of capitalized<br/>&#160;&#160;&#160;fees paid</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,823</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,823</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,823</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalty revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">311,645</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">391,866</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">326,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Strategic alliance - MABA program</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net royalty revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">311,645</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">391,866</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">336,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">LABA Collaboration</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the launch and approval of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the U.S., Japan and Europe, we paid milestone fees to GSK totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">220.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, 2014. The milestone fees paid to GSK were recognized as capitalized fees paid, which are being amortized over their estimated useful lives commencing upon the commercial launch of the product. The amortization is recorded as a reduction to the royalties from GSK.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are entitled to receive annual royalties from GSK on sales of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as follows: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on the first $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion of annual global net sales and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% for all annual global net sales above $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion. Sales of single&#8209;agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the LABA Collaboration, such as ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, royalties are upward tiering and range from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also entitled to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to TRC in connection with the Spin-Off, including TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which royalties are upward tiering and range from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2004 Strategic Alliance</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2020, we recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in revenue from a termination fee paid in connection with the termination of the Bifunctional Muscarinic Antagonist-Beta2 Agonist (&#8220;MABA&#8221;) program under the Strategic Alliance Agreement with GSK.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Product Sales</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net product sales we recognized from the date of acquisition of La Jolla, which occurred on August 22, 2022, to December 31, 2022 were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, consisting of net sales of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. We derived approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of our net product sales for the same period from customers located in the U.S. and the rest of the world, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280607463136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND COLLABORATION ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_LicenseAndCollaborationArrangementsDisclosureTextBlock', window );">LICENSE AND COLLABORATION ARRANGEMENTS</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.  LICENSE AND COLLABORATION ARRANGEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Out-License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Zai Lab</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entasis entered into a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. (&#8220;Zai Lab&#8221;), pursuant to which Zai Lab licensed exclusive rights to durlobactam and SUL-DUR, in the Asia-Pacific region (&#8220;the Zai Agreement&#8221;). Under the terms of the Zai Agreement, Zai Lab will fund most of the registrational clinical trial costs in China for SUL-DUR, with the exception of Phase 3 patient drug supply of licensed products. Zai Lab will conduct development activities and plan and obtain regulatory approval in a specified number of countries in the Asia-Pacific region beyond China after receipt of regulatory approval of a licensed product in China. Zai Lab is also solely responsible for commercializing licensed products in the Asia-Pacific region and will commercialize licensed products for which it has obtained regulatory approval. We are obligated to supply Zai Lab with the licensed products for clinical development and, if the licensed product is approved, for commercial use for a certain period unless Zai Lab notifies otherwise. Zai Lab may take over manufacturing responsibilities for its own commercialization activities within a specified time period following the effective date of the Zai Agreement.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We ar</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e eligible to receive up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in research and development support payments and development, regulatory and sales milestone payments related to SUL-DUR, imipenem and other combinations with the licensed products. Zai Lab will pay us a tiered royalty equal to from a high-single digit to low-double digit percentage based on annual net sales of licensed products in the territory, subject to specified reductions for the market entry of competing products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> revenue was recognized under the Zai Agreement from the acquisition date of Entasis. Payments received for research support and reimbursable clinical trial costs are recorded as a reduction to research and development expense during the period in which the qualifying expenses are incurred. Such amounts recorded from the date of acquisition of Entasis to December 31, 2022 are not material.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GARDP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entasis entered into a collaboration agreement with the Global Antibiotic Research and Development Partnership (&#8220;GARDP&#8221;) for the development, manufacture and commercialization of the product candidate zoliflodacin in certain countries (&#8220;the GARDP Collaboration Agreement&#8221;). Under the terms of the GARDP Collaboration Agreement, GARDP will use commercially reasonable endeavors to perform and fully fund the Phase 3 registrational trial, including the manufacture and supply of the product candidate containing zoliflodacin, in uncomplicated gonorrhea. We recorded reimbursements from GARDP under this agreement as reduction to research and development expense. Relevant amounts from the date of acquisition of Entasis to December 31, 2022 are not material.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, under the GARDP Collaboration Agreement, GARDP was granted a worldwide, fully paid, exclusive and royalty-free license, with the right to sublicense, to use our zoliflodacin technology in connection with GARDP&#8217;s development, manufacture and commercialization of zoliflodacin in low-income and specified middle-income countries. We retained commercial rights in all other countries worldwide, including the major markets in North America, Europe and Asia-Pacific. We also retained the right to use and grant licenses to our zoliflodacin technology to perform our obligations under the GARDP Collaboration Agreement and for any purpose other than gonorrhea or community-acquired indications. If we believe that the results of the Phase 3 registrational trial of zoliflodacin would be supportive of an application for marketing approval, we are obligated to use our best efforts to file an application for marketing approval with the FDA within six months of the completion of the trial and to use commercially reasonable endeavors to file an application for marketing approval with the European Medicines Agency (&#8220;EMA&#8221;). Each party is responsible for using commercially reasonable efforts to obtain marketing authorizations for the product candidate in their respective territories.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PAION AG</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the PAION AG (&#8220;PAION&#8221;) License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the European Economic Area, the United Kingdom and Switzerland (collectively, the &#8220;PAION Territory&#8221;). We are entitled to receive potential commercial milestone payments of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and double-digit tiered royalty payments. Royalties payable in a given jurisdiction under the PAION License will be subject to reduction on account of generic competition and after patent expiration in that jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA&#174; and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the PAION Territory. We have not recognized any revenue from PAION related to commercial milestones from the date of acquisition of La Jolla to December 31, 2022. Royalty revenue recognized under this agreement from the date of acquisition of La Jolla to December 31, 2022 was not material.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">La Jolla also entered into the PAION commercial supply agreement (the &#8220;PAION Supply Agreement&#8221;) whereby La Jolla will supply PAION a minimum quantity of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through July 13, 2024. The PAION supply agreement will automatically renew until the earlier of July 13, 2027, or until a new supply agreement is executed. During the initial term of the supply agreement, we will be reimbursed for direct and certain indirect manufacturing costs at cost. Amounts recognized under this agreement from the date of acquisition of La Jolla to December 31, 2022 were not material.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Everest Medicines Limited</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Everest Medicines Limited (&#8220;Everest&#8221;) License, La Jolla granted Everest an exclusive license to develop and commercialize XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the treatment of complicated intra-abdominal infections (&#8220;cIAI&#8221;) and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the &#8220;Everest Territory&#8221;). We are eligible to receive an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million regulatory milestone payment and up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in sales milestone payments. We are also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (i) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (iii) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years after the first commercial sale of a product in such jurisdiction in the Everest Territory. We have not recognized any revenue from Everest related to regulatory and sales milestones from the date of acquisition of La Jolla to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022. Royalty revenue recognized under this agreement from the date of acquisition of La Jolla to December 31, 2022 was not material.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A new drug application (&#8220;NDA&#8221;) was submitted with the China National Medical Products Administration (&#8220;NMPA&#8221;) for XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the treatment of cIAI in patients in China in 2021. XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was approved in Singapore by the Health Science Authority in 2020.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">La Jolla also entered into the Everest commercial supply agreement (the &#8220;Everest Supply Agreement&#8221;) whereby La Jolla will supply Everest a minimum quantity of XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> through December 31, 2023 and will transfer to Everest certain XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-related manufacturing know-how. We will be reimbursed for direct and certain indirect manufacturing costs at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of cost through December 31, 2023. We initially recognized a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million partial prepayment for XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as deferred revenue, of which, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recognized as revenue for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">In-License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">George Washington University</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the George Washington University (&#8220;GW&#8221;) License, GW exclusively licensed to La Jolla certain intellectual property rights relating to GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Under the GW License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We are obligated to pay a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% royalty on net sales of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. From the date of acquisition of La Jolla to December 31, 2022, the amounts recognized under this agreement were not material.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Harvard University</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Harvard University (&#8220;Harvard&#8221;) License, Harvard exclusively licensed to La Jolla certain intellectual property rights relating to tetracycline-based products, including XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. For each product covered by the Harvard License, we are obligated to make certain payments for the following: (i) up to approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the achievement of certain clinical development and regulatory milestones; (ii) a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% royalty on direct U.S. net sales of XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, starting at a minimum royalty rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, with step-ups to a maximum royalty of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% based on the achievement of annual net product sales thresholds; and (iv) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. From the date of acquisition of La Jolla to December 31, 2022, amounts recognized under this agreement were not material.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Paratek Pharmaceuticals, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Paratek Pharmaceuticals, Inc. (&#8220;Paratek&#8221;) License, Paratek non-exclusively licensed to La Jolla certain intellectual property rights relating to XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, including non-exclusive rights to certain issued patents and patent applications covering XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We are obligated to pay Paratek a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% royalty based on direct U.S. net sales of XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our obligation to pay royalties with respect to the licensed product is retroactive to the date of the first commercial sale of XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and shall continue until there are no longer any valid claims of the Paratek patents, which will expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. From the date of acquisition of La Jolla to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, amounts recognized under this agreement were not material.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_LicenseAndCollaborationArrangementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaboration arrangements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_LicenseAndCollaborationArrangementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280607447648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntitiesDisclosureAbstract', window );"><strong>Consolidated Entities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntitiesAndAcquisitionsTextBlock', window );">CONSOLIDATED ENTITIES AND ACQUISITIONS</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. CONSOLIDATED ENTITIES AND ACQUISITIONS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Consolidated Entities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Theravance Respiratory Company, LLC</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Up until July 20, 2022, we consolidated TRC under the VIE model as we determined that TRC was a VIE and we were the primary beneficiary of the entity because we had the power to direct the economically significant activities of TRC and the obligation to absorb losses of, or the right to receive benefits from, TRC. We held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% ownership interest of TRC. The primary source of revenue for TRC is the royalties generated from the net sales of TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> by GSK.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As discussed in Note 3, &#8220;Revenue Recognition&#8221;, on July 13, 2022, ITH entered into the TRC Equity Purchase Agreement to sell our ownership interest in TRC. Upon the closing of the transaction on July 20, 2022, we received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">277.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash from Royalty Pharma. We are also entitled to receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in contingent sales-based milestone payments in the future. In connection with the closing of the transaction, we also received our portion of TRC&#8217;s remaining cash balance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from Royalty Pharma rather than through a cash distribution from TRC.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the closing of the transaction and as part of the agreement, TRC distributed its ownership interests and investments in InCarda Therapeutics, Inc., ImaginAb, Inc., Gate Neurosciences, Inc. and Nanolive SA, which had a total carrying value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to ITH. We accounted for the transaction similar to an upstream sale between a parent and a VIE under ASC 810-10. As such,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ITH </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recorded the transferred investments at their respective carrying values and no gain or loss was recognized in the consolidated statement of income.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The summarized financial information for TRC as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021 and for the relevant periods through the sale date in 2022 are presented as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance sheet</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"/>
        <td style="width:1.794%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.881%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,713</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receivables from collaborative arrangements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,492</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity and long-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,695</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130,971</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and LLC Members&#8217; Equity</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">252</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LLC members&#8217; equity</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130,719</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and LLC members&#8217; equity</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130,971</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.112%;"/>
        <td style="width:0.995%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.276%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.45%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.276%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.45%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.443000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalty revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,029</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73,089</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue from collaborative arrangements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,029</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83,089</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">332</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,956</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,612</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income from operations</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,697</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122,732</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80,477</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Realized loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39,386</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair values of other equity and<br/>&#160;&#160;&#160;long-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,884</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,541</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,147</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,438</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,662</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ISP Fund LP</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, Innoviva Strategic Partners LLC, our wholly owned subsidiary (&#8220;Strategic Partners&#8221;), contributed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to ISP Fund LP (the "Partnership") for investing in &#8220;long&#8221; positions in the healthcare, pharmaceutical and biotechnology sectors and became a limited partner. The general partner of the Partnership ("General Partner") is an affiliate of Sarissa Capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Partnership Agreement provides for Sarissa Capital to receive management fees from the Partnership, payable quarterly in advance, measured based on the Net Asset Value of Strategic Partners' capital account in the Partnership. In addition, the General Partner is entitled to an annual performance fee based on the Net Profits of the Partnership during the annual measurement period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Partnership Agreement includes a lock-up period of thirty-six months after which Strategic Partners is entitled to make withdrawals from the Partnership as of such lock-up expiration date and each anniversary thereafter, subject to certain limitations.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, Strategic Partners received a distribution of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from the Partnership to provide funding to Innoviva for a strategic repurchase of the Company's shares held by GSK. On March 30, 2022, Strategic Partners made an additional capital contribution of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the Partnership pursuant to the letter agreement entered into between Strategic Partners, the Partnership and Sarissa Capital Fund GP LP on May 20, 2021. The capital contribution is subject to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lock up period from the contribution date</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consolidate ISP Fund LP under the VIE model as we have determined that ISP Fund LP is a VIE and we are the primary beneficiary of the entity via our related party relationships with Sarissa Capital entities.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, we continued to hold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the economic interest of Partnership. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, total assets of the Partnership were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">320.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">195.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, of which the majority was attributable to equity, debt and long-term investments. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, total liabilities of the Partnership w</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ere $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mill</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ion and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The Partnership's assets can only be used to settle its own obligations. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the Partnership incurred</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million in net investment-related expenses, generated $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million interest income, recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net realized gains and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net unrealized losses as changes in fair values of other equity and long-term investments, net, on the consolidated statements of income. During the year ended December 31, 2021, the Partnership incurred</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net investment-related expense, generated $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million interest and dividend income, and recorded net $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million realized gains and net $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million unrealized losses as changes in fair values of other equity and long-term investments, net, on the consolidated statements of income. We account for the long-term investments held by ISP Fund LP as equity investments measured at fair value and an investment in convertible notes as trading security.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquisitions</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Entasis Therapeutics Holdings Inc.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We started investing in Entasis in 2020 as part of our capital allocation strategy of deploying cash generated from royalty income and investing in different life sciences companies. Entasis is an advanced, late clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products. During the second quarter of 2020, we purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock as well as warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of common stock of Entasis for approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash. During the third quarter of 2020, we purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,672,897</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Entasis common stock as well as warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,672,897</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of its common stock for approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash. Effective in June 2020, after certain conditions were met with respect to the sales of Entasis equity shares, Innoviva had the right to designate </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> members to Entasis&#8217; board of directors. During the second quarter of 2021, Innoviva&#8217;s wholly owned subsidiary, Innoviva Strategic Opportunities, LLC (&#8220;ISO&#8221;) entered into a securities purchase agreement with Entasis to acquire </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Entasis common stock and warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of Entasis common stock for approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of Entasis&#8217; common stock was measured based on its closing market price at each balance sheet date. The warrants had an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.675</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for those warrants acquired in the second and third quarter of 2020, respectively. The warrants acquired in the second quarter of 2021 had an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. All of the warrants were exercisable immediately within </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the issuance date of the warrants and included a cashless exercise option. We used the Black-Scholes-Merton pricing model to estimate the fair value of these warrants.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 17, 2022, ISO entered into a securities purchase agreement with Entasis pursuant to which ISO purchased a convertible promissory note for a total purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The note bore an annual interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.59</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and was due to mature and become payable on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 18, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless it was converted at a conversion price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.48</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> before the maturity date. With this financing, we determined that we had both (i) the power to direct the economically significant activities of Entasis and (ii) the obligation to absorb the losses, or the right to receive the benefits, that could potentially be significant to Entasis and therefore, we were the primary beneficiary of Entasis. Accordingly, we consolidated Entasis&#8217; financial position and results of operations effective on February 17, 2022. Our equity ownership interest remained at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% as of February 17, 2022, and the fair values of our holdings of Entasis common stock and warrants were remeasured and estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The remeasurement resulted in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million loss in the first quarter of 2022 which was included in changes in fair values of equity method investments, net, on the consolidated statements of income for the year ended December 31, 2022.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We completed our acquisition of Entasis&#8217; remaining noncontrolling interest on July 11, 2022. We remeasured our holdings in Entasis as of that date and recognized a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million loss, which was included in changes in fair values of equity method investments, net, on the consolidated statement of income for the year ended December 31, 2022. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payments were made toward the convertible promissory note through the date of acquisition of Entasis. In connection with the acquisition, all of the Entasis warrants were replaced with Innoviva warrants (the &#8220;Replacement Warrants&#8221;) of equivalent value and bearing the same terms. The Replacement Warrants are classified as equity.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognized the difference between the acquisition price and the carrying value of the acquired noncontrolling interest on July 11, 2022 in our additional paid-in capital.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair values assigned to assets acquired and liabilities assumed as of February 17, 2022 were based on management&#8217;s best estimates and assumptions. After the acquisition in July 2022, we adjusted the preliminary estimates of fair value of assets acquired and liabilities assumed based on new and additional information related to product sales forecast provided by Entasis and deferred tax liabilities.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, we recorded measurement period adjustments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million decrease in goodwill, primarily related to a decrease in estimated purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, an increase in noncontrolling interests of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and an increase in intangible assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The cumulative impact of the measurement period adjustments included in the consolidated net income for the year ended December 31, 2022 was not material.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has completed a preliminary valuation and expects to finalize it as soon as practical, but no later than one year from the acquisition date. The purchase accounting for this transaction is not yet finalized.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table represents the adjusted fair values of the assets acquired and liabilities assumed by us in the transaction:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"/>
        <td style="width:1.794%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.881%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 17, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,070</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,554</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,959</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">959</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,260</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107,500</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets acquired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149,789</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,583</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued personnel-related expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,058</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,096</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,336</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities assumed</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,073</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets acquired, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,716</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The goodwill arising from the acquisition of Entasis is primarily attributable to Entasis&#8217; assembled workforce and the value associated with growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refer to Note 8, &#8220;Goodwill and Intangible Assets&#8221;, for more discussion on the intangible assets recognized as part of this acquisition.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our consolidated net income for the year ended December 31, 2022 included the net loss attributable to noncontrolling interest since the consolidation date until the date of acquisition </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">La Jolla Pharmaceutical Company</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 22, 2022, ISO acquired La Jolla for a total consideration of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">206.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. ISO acquired La Jolla at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.23</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. La Jolla is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla brings to Innoviva an established product portfolio, including GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (eravacycline) for the treatment of cIAIs.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair values assigned to assets acquired and liabilities assumed are based on management&#8217;s best estimates and assumptions as of August 22, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, we recorded measurement period adjustments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million increase in goodwill, primarily related to a decrease in inventory and intangible assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, and an increase in deferred tax liabilities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, partially offset by a decrease in other long-term liabilities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The cumulative impact of the measurement period adjustments included in the consolidated net income for the year ended December 31, 2022 was not material.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have completed a preliminary valuation and expect to finalize it as soon as practicable, but no later than one year from the acquisition date. The purchase accounting for this transaction is not yet finalized.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We incurred approximate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ly $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in acquisition-related costs in connection with this acquisition and such amount is included in selling, general and administrative exp</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">enses for the year ended December 31, 2022.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the adjusted allocation of the fair values assigned to the assets acquired and liabilities assumed as of the date of the acquisition:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"/>
        <td style="width:1.794%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.881%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 22, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,415</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">471</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,876</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,200</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,261</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">907</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">226</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">710</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets acquired</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">290,532</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,237</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,849</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,362</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,944</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,581</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities assumed</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83,973</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets acquired, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">206,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The goodwill arising from the acquisition of La Jolla is primarily attributable to La Jolla&#8217;s assembled workforce and the value associated with leveraging the workforce to develop and commercialize new drug products in the future and growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Refer to Note 8, &#8220;Goodwill and Intangible Assets&#8221;, for more discussion on the intangible assets recognized as part of this acquisition.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pro Forma Financial Information</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents certain unaudited pro-forma financial information for the years ended December 31, 2022 and 2021 as if the consolidation of Entasis and La Jolla occurred on January 1, 2021. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2021, or of results that may occur in the future. The unaudited pro forma financial information combines the historical results of the Entasis and La Jolla with the Company&#8217;s consolidated historical results and includes certain adjustments including, but not limited to, fair value adjustments to equity investments in Entasis&#8217; common stock and warrants, fair value adjustments to inventory, amortization of intangible assets, and interest expense on deferred royalty obligations and acquisition-related costs.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.399%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.6%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">357,880</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">435,398</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">204,987</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">281,719</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to Innoviva stockholders</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">214,390</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConsolidatedEntitiesAndAcquisitionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated entities and acquisitions text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConsolidatedEntitiesAndAcquisitionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConsolidatedEntitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConsolidatedEntitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280607372000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Method Investment in Armata</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the first quarter of 2020, Innoviva acquired </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,710,800</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock as well as warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,710,800</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of common stock of Armata Pharmaceuticals, Inc. (&#8220;Armata&#8221;) for approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash. Armata is a clinical stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the first quarter of 2021, ISO entered into a securities purchase agreement with Armata to acquire </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,153,847</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Armata common stock and warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,153,847</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of Armata common stock for approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Armata also entered into a voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of Armata&#8217;s common stock for voting on the matters related to election or removal of Armata&#8217;s board members. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution. During the fourth quarter of 2021, ISO also purchased an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,212,122</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Armata common stock for approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 9, 2022, ISO entered into a securities purchase agreement with Armata to acquire </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Armata common stock and warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of common stock with an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The investment closed in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> tranches on February 9, 2022 and March 31, 2022. The investment is intended to aid Armata in advancing its clinical pipeline and strengthening its bacteriophage platform. On February 9, 2022, Armata also entered a second amended and restated voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of Armata&#8217;s common stock for voting on the matters related to election or removal of Armata&#8217;s board members or amend the bylaws of Armata to reduce the maximum number of directors or set the number of directors who may serve on the board of Armata. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding shares of Armata&#8217;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#8217;s board of directors, and for so long as the Company and ISO hold at least </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, but less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, of the outstanding shares of Armata&#8217;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#8217;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> As of December 31, 2022,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">eight</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">members of Armata&#8217;s board of directors are also members of the board of directors of Innoviva. As of December 31, 2022 and 2021, we owned approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% an</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respectively, of Armata&#8217;s common stock.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investments in Armata provide Innoviva and ISO the ability to have significant influence, but not control over Armata&#8217;s operations. Armata&#8217;s business and affairs are managed under the direction of its board of directors, which Innoviva and ISO do not control. Based on our evaluation, we determined that Armata is a VIE, but Innoviva and ISO are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We account for both Armata&#8217;s common stock and warrants under the equity method using the fair value option. The fair value of Armata&#8217;s common stock is measured based on its closing market price. The warrants purchased in 2020, 2021 and 2022 have an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.87</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, respectively. All warrants are exercisable immediately within </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the issuance date of the warrants and include a cashless exercise option. We use the Black-Scholes-Merton pricing model to estimate the fair value of these warrants with the following input assumptions: Armata&#8217;s closing market price on the valuation date, the risk-free interest rate computed based on the U.S. Treasury yield, the remaining contractual term as the expected term, and the expected stock price volatility calculated based on the historical volatility of the common stock of Armata and its peer companies.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of Dece</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mber 31, 2022, the fair values of our holdings of Armata common stock and warrants were estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. As of December 31, 2021, the fair values of our holdings of Armata common stock and warrants were estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The total fair value of both financial instruments in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">146.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded as equity and long-term investments on the consolidated balance sheets as of December 31, 2022 and 2021, respectively. We recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million unrealized losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million unrealized gains as changes in fair values of equity method investments, net, on the consolidated statements of income for the years ended December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag regardless of the date of our investments as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Balance Sheet Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.94%;"/>
        <td style="width:2.262%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.57%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.262%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.968%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,245</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,178</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,636</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,493</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,004</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,300</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,662</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Statement Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.034%;"/>
        <td style="width:1.11%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.577%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.11%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.394%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.09%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.683%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Twelve Months Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,446</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,989</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">319</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,666</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,227</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,134</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,650</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,732</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Method Investment in Entasis</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the consolidation of Entasis&#8217; financial position and results of operations in February 2022, we accounted for Entasis as an equity method investment. Refer to Note 5, &#8220;Consolidated Entities and Acquisitions&#8221;, for more information.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The summarized financial information, including the portion we did not own, is presented for Entasis on a one quarter lag regardless of the date of our investments as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Balance Sheet Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.276%;"/>
        <td style="width:1.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.929%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,746</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,348</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">183</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Statement Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.668%;"/>
        <td style="width:2.249%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.917%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.249%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.917%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Twelve Months Ended<br/>September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Six Months<br/>Ended September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,323</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,080</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125,413</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,529</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Investment in InCarda</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the third quarter of 2020, TRC purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,469,432</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series C preferred stock and a warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,117,358</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of Series C preferred stock of InCarda Therapeutics, Inc. (&#8220;InCarda&#8221;) (the &#8220;InCarda 2020 Warrant&#8221;) for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which included $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of transaction costs. InCarda is a privately held biopharmaceutical company focused on developing inhaled therapies for cardiovascular diseases. The investment is intended to fund the ongoing clinical development of InRhythmTM (flecainide for inhalation), InCarda&#8217;s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#8217;s ownership interests and investments in InCarda. ITH has the right to designate one member to InCarda&#8217;s board of directors. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of InCarda&#8217;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">eight</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> board members was designated by ITH. The InCarda 2020 Warrant is exercisable immediately with an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7328</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. In September 2021, TRC and InCarda entered into an amendment to extend the expiration date of the InCarda 2020 Warrant from October 6, 2021 to March 31, 2022. On March 9, 2022, TRC and InCarda entered into an amendment to further extend the expiration date of the InCarda 2020 Warrant from March 31, 2022 to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 31, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The InCarda 2020 Warrant is recorded at fair value and subject to remeasurement at each balance sheet date.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 9, 2022, TRC entered into a Note and Warrant Purchase Agreement (the &#8220;InCarda Agreement&#8221;) with InCarda to acquire a convertible promissory note (the &#8220;InCarda Convertible Note&#8221;) and warrants (the &#8220;InCarda 2022 Warrant&#8221;) for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The InCarda Convertible Note bears an annual interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and will convert into Series D preferred stock upon a qualified financing, non-qualified financing, or maturity conversion. A qualified financing is defined as the first issuance or series of related issuances by InCarda of its equity securities following March 9, 2022 from which InCarda receives immediately available gross proceeds of at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (excluding the aggregate amount of any notes converted into equity securities pursuant to the conversion of notes or any other debt securities converted into equity securities) (the &#8220;Qualified Financing Amount&#8221;). A non-qualified financing is defined as the first issuance or series of related issuances by InCarda of its equity securities following March 9, 2022 from which InCarda receives immediately available gross proceeds of less than the Qualified Financing Amount. The InCarda 2022 Warrant entitles TRC to purchase a number of shares of equity securities equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the principal amount of the InCarda Convertible Note divided by the number of shares issued in InCarda&#8217;s next equity financing, which is defined as the earliest to occur of specific financing events, including capital raises through public offerings. The InCarda 2022 Warrant expires on March 9, 2027. The InCarda Convertible Note and InCarda 2022 Warrant are measured at fair value.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 15, 2022, the principal amount and the accrued interest of the InCarda Convertible Note were converted into equity securities. In addition, TRC participated in InCarda&#8217;s Series D preferred stock financing by investing $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. In connection with the new round of financing, InCarda recapitalized its equity structure resulting in TRC owning </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,093,886</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of InCarda&#8217;s common</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">stock, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,350</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its Series A-1 preferred stock, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,469,432</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its Series C preferred stock, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,771,780</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its Series D-1 preferred stock, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,369,802</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its Series D-2 preferred stock, a warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,117,358</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its Series C preferred stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.73</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and a warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,490,033</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its Series D-1 preferred stock at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, we held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of InCarda equity ownership, respectively. Our investment in InCarda does not provide us with the ability to control or have significant influence over InCarda&#8217;s operations. Based on our evaluation, we determined that InCarda is a VIE, but we are not the primary beneficiary of the VIE.  We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We account for our investments in InCarda under the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer. Due to InCarda&#8217;s equity recapitalization in the second quarter of 2022, TRC reassessed the value of its investments in InCarda using the Option Pricing Model Backsolve valuation methodology. Key assumptions used in the valuation model include an expected holding period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a risk free interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and an estimated volatility of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. The estimated volatility is calculated based on the historical volatility of a selected peer group of public companies comparable to InCarda. We recognized an impairment charge of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as a result of the valuation. There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairment or other change to the value of our investments in InCarda as of December 31, 2021.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in fair value of InCarda&#8217;s Series C preferred stock and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in fair value of Series C warrants and Series D warrants (the &#8220;InCarda Preferred Stock Warrants&#8221;). As of December 31, 2022, we recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for InCarda&#8217;s Series D-1 preferred stock, Series D-2 preferred stock, and common stock using the measurement alternative. As of December 31, 2021, we recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in fair value of the InCarda 2020 Warrant. As of December 31, 2021, we recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the investment in InCarda&#8217;s Series C preferred stock using the measurement alternative. We recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million unrealized loss as changes in fair values of other equity and long-term investments, net, on the consolidated statements of income for the years ended December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Investment in ImaginAb</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 18, 2021, TRC entered into a securities purchase agreement with ImaginAb, Inc. (&#8220;ImaginAb&#8221;) to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,051,724</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of ImaginAb Series C preferred stock for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. On the same day, TRC also entered into a securities purchase agreement with one of ImaginAb&#8217;s common stockholders to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,097,157</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of ImaginAb common stock for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. ImaginAb is a privately held biotechnology company focused on clinically managing cancer and autoimmune diseases via molecular imaging. $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was incurred for investment due diligence costs and execution and recorded as part of the equity and long-term investment on the consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#8217;s ownership interests and investments in ImaginAb. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of ImaginAb&#8217;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> board members is designated by ITH, and ITH held</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ImaginAb&#8217;s equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ownership. As of December 31, 2021, TRC held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of ImaginAb equity ownership.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our investment in ImaginAb does not provide us with the ability to control or have significant influence over ImaginAb&#8217;s operations. Based on our evaluation, we determined that ImaginAb is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because ImaginAb&#8217;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in ImaginAb&#8217;s Series C preferred stock and common stock using the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer. As of  December 31, 2022 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and 2021, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded as equity and long-term investments on the consolidated balance sheets and there was no change to the fair value of our investment in ImaginAb.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Promissory Note in Gate Neurosciences</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On November 24, 2021, TRC entered into a Convertible Promissory Note Purchase Agreement with Gate Neurosciences, Inc. (&#8220;Gate&#8221;) to acquire a convertible promissory note (the &#8220;Convertible Note&#8221;) with a principal amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Gate is a privately held biopharmaceutical company focused on developing the next generation of targeted nervous system therapies, leveraging precision medicine approaches to develop breakthrough drugs for psychiatric and neurologic diseases. The investment is intended to fund its ongoing development and research. The Convertible Note bears an annual interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and will convert into common stock shares upon a qualified event or into shares of shadow preferred stock (&#8220;Shadow Preferred&#8221;) upon a qualified financing. A qualifying event can be a qualified initial price offering, a qualified merger, or a merger with a special-purpose acquisition company (&#8220;SPAC&#8221;). Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#8220;Capped Conversion Price&#8221;) and the qualified event price (the &#8220;Qualified Event Price&#8221;). The Capped Conversion Price is calculated as $50.0 million divided by the number of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Gate are at least $35.0 million, and (iii) the stated or implied equity valuation of Gate is at least $80.0 million. </span></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"/></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH its debt investment in Gate. We have accounted for the Gate Convertible Note as a trading security, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of equity value of Gate, risk-free rate, expected stock price, volatility of its peer companies, and the time until a financing is raised. As of December 31, 2022 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, the fair value of the Gate Convertible Note was estimated at $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, and recorded as equity and long-term investments on the consolidated balance sheets. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrealized gain and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrealized loss as changes in fair values of other equity and long-term investments, net, on the consolidated statements of income for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Investment in Nanolive</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 18, 2022, TRC entered into an investment and shareholders agreement with Nanolive SA (&#8220;Nanolive&#8221;) to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,750,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Nanolive Series C preferred stock for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (equivalent to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million CHF). Nanolive SA is a Swiss privately held life sciences company focused on developing breakthrough imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was incurred for investment due diligence costs and execution and recorded as part of the equity and long-term investment on the consolidated balance sheets. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#8217;s ownership interests and investments in Nanolive. ITH has the right to designate one member to Nanolive&#8217;s board. ITH also has the right to designate another member, who will be mutually acceptable to ITH and another majority common stockholder, to Nanolive&#8217;s board. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of Innoviva designees is serving on Nanolive&#8217;s </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-member board. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, we held </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of Nanolive equity ownership.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our investment in Nanolive does not provide us with the ability to control or have significant influence over Nanolive&#8217;s operations. Based on our evaluation, we determined that Nanolive is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because Nanolive&#8217;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in Nanolive&#8217;s Series C preferred stock using the measurement alternative. As of  December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recorded as equity and long-term investments on the consolidated balance sheets and there was no change to the fair value of our investment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Available-for-Sale Securities</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.883%;"/>
        <td style="width:1.553%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.133999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.563%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.133999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.563%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.133999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.563%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.475%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,469</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,469</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,469</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,469</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds are included in cash and cash equivalents on the consolidated balance sheets.</span></div></div>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.883%;"/>
        <td style="width:1.553%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.133999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.563%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.133999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.563%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.133999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.563%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.475%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,132</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,132</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,132</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,132</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds are included in cash and cash equivalents on the consolidated balance sheets.</span></div></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, all investments were money market funds, and there was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> credit loss recognized.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our available-for-sale securities, equity and long-term investments are measured at fair value on a recurring basis and our debt is carried at amortized cost basis. The estimated fair values were as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:42.189%;"/>
        <td style="width:1.418%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.956999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.408%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.956999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.408%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.956999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.408%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.299%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2022 Using:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Price<br/>in Active<br/>Markets for</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identical</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Observable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Types of Instruments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,469</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,469</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments held by ISP Fund LP </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">265,982</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54,578</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">320,560</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,095</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,095</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,059</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,059</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">605</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">605</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Convertible debt investment - Gate Note</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">560,546</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,059</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,883</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">639,488</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,089</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,089</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197,807</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197,807</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">211,768</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">211,768</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total fair value of debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">505,664</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">505,664</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent value rights</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">595</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">595</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities at estimated fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">505,664</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">595</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">506,259</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">295.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in equity investments, which included private placement positions and convertible notes of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in money market funds. Our total capital contribution of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million is subject to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lock-up period from the date of such capital contributions.</span></div></div>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:41.931%;"/>
        <td style="width:1.418%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.032%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.407%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.032%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.407%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.032%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.407%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.334999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2021 Using:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in Active</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Markets for</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identical</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Observable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Types of Instruments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,132</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,132</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments held by ISP Fund LP </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">193,677</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,068</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">195,745</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,101</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,101</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,595</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,595</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Entasis Common Stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Entasis Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,914</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,914</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">411</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">411</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Convertible debt investment - Gate Note</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">489,704</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,509</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,579</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">606,792</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">261,769</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">261,769</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234,498</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234,498</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total fair value of debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">496,267</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">496,267</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million equity investments and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million money market funds, are subject to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-month lock-up period from our initial contribution date, December 11, 2020.</span></div></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair values of our equity investments in Armata&#8217;s and Entasis&#8217;s common stock and public traded investments held by ISP Fund LP are based on the quoted prices in active markets and are classified as Level 1 financial instruments. The fair values of the warrants of Armata and Entasis classified within Level 2 are based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">InCarda&#8217;s equity securities, Gate's convertible note, private placement positions and convertible notes held by ISP Fund LP, and contingent value rights are classified as Level 3 financial instruments as these securities are not publicly traded and the assumptions used in the valuation model for valuing these securities are based on significant unobservable and observable inputs including those of publicly traded peer companies.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair values of our 2023 Notes, 2025 Notes and 2028 Notes are based on recent trading prices of the respective instruments.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280607657856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITALIZED FEES PAID<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAbstract', window );"><strong>Capitalized Contract Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidDisclosureTextBlock', window );">CAPITALIZED FEES PAID</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. CAPITALIZED FEES PAID</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.362%;"/>
        <td style="width:1.739%;"/>
        <td style="width:16.039%;"/>
        <td style="width:1.739%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.093%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.739%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.287%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization period</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2013-2030</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Europe</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2013-2029</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Japan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2013-2029</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross carrying value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">220,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">220,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122,393</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,570</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net carrying value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,607</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,430</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These milestone fees are amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization recorded as a reduction in revenue from collaborative arrangements. As of December 31, 2022, the weighted average remaining amortization period was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> y</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ears.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional information regarding these milestone fees is included in Note 3, &#8220;Revenue Recognition&#8221;. Amortization for each of the years ended December 31, 2022, 2021 and 2020 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The remaining estimated amortization is </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_2214fc13-a135-4176-9e10-3d32422ab21f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">each</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the years from 2023 to 2027 and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thereafter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about capitalized fees paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280607657856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLE ASSETS</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. GOODWILL AND INTANGIBLE ASSETS</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill and intangible assets acquired are recognized at fair value as of the acquisition date. The carrying amount of goodwill as of December 31, 2022 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We have not recognized any impairment losses related to goodwill and intangible assets during the periods presented.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets with definite lives are amortized over their estimated useful lives. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying basis and accumulated amortization of recognized intangible assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 were as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.438%;"/>
        <td style="width:1.112%;"/>
        <td style="width:11.146%;"/>
        <td style="width:1.102%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.333%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.102%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.333%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.102%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.333%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Useful Life</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Carrying</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketed products</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,581</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,419</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In-process research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,100</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,100</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration agreement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,400</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,400</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">258,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,581</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">252,919</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets recognized as a result of the acquisition of Entasis amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which consisted of Entasis&#8217; in-process research and development related to its antibacterial therapeutic product candidates and a collaboration agreement amounting to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The useful lives of these intangible assets will be determined upon commercialization of the underlying product candidates; thus, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> amortization expense of determinable assets was recognized during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets recognized as a result of the acquisition of La Jolla amounting to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million pertain to product rights and developed technologies on La Jolla&#8217;s currently marketed products. These are intangible assets with determinable lives and are amortized over their estimated useful lives. We recognized amortization expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Future amortization expense is expected to be $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for each of the years from 2023 to 2027 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million thereafter.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280607517760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">BALANCE SHEET COMPONENTS</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. BALANCE SHEET COMPONENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inventory</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.252%;"/>
        <td style="width:1.784%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.964%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Raw materials</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,757</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,052</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finished goods</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,088</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total inventory</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,897</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, total inventory included net fair value adjustments resulting from the acquisition of La Jolla of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which will be recognized as cost of products sold when sales occur in future periods. The fair value adjustments recorded as part of cost of products sold amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> inventory as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Accrued Liabilities</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.399%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.6%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued contract manufacturing expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,382</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued clinical expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">692</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">349</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,977</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">894</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,316</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of deferred royalty obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,639</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued license fees and royalties</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">943</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,909</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other accrued liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,207</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,009</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Long-Term Liabilities</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.252%;"/>
        <td style="width:1.784%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.964%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term portion of deferred royalty obligation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,947</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term portion of lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,376</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent value rights liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">595</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other long-term liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,918</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> other long-term liabilities as of December 31, 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280607514240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. STOCK&#8209;BASED COMPENSATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Incentive Plans</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2012, we adopted the 2012 Equity Incentive Plan (the &#8220;2012 Plan&#8221;). The 2012 Plan provides for the grant of incentive stock options, nonstatutory stock options, RSAs, RSUs and Stock Appreciation Rights to employees, non-employee directors and consultants. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, total shares remaining available for issuance under the 2012 Plan were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,838,270</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2004 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), our employees may purchase common stock through payroll deductions at a price equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The ESPP provides for consecutive and overlapping offering periods of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in duration, with each offering period composed of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> consecutive </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> purchase periods. The purchase periods end on either May 15 or November 15. ESPP contributions are limited to a maximum of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of an employee&#8217;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. An employee may not purchase shares with a value greater than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in any calendar year.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, total shares remaining available for issuance under the ESPP were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,995</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Director Compensation Program</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our non-employee directors receive compensation for services provided as a director. Each member of our board of directors who is not an employee receives both cash and equity compensation for services as a director, member of a committee of the board of directors, lead independent director and chairman, as applicable. In October 2017, both the cash and equity components of the compensation program were amended, effective immediately (the &#8220;October 2017 Amendments&#8221;).</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each of our independent directors receives periodic automatic grants of equity awards under a program implemented under the 2012 Plan. These grants are non&#8209;discretionary. Only our independent directors or affiliates of such directors are eligible to receive automatic grants under the 2012 Plan. Under the program, each individual who first became a non-employee director will, on the date such individual joins the board of directors, automatically be granted a one&#8209;time grant of RSUs covering a number of shares of our common stock calculated as $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share (the &#8220;Initial RSUs&#8221;), plus a one&#8209;time grant of RSUs covering a number of shares of our common stock calculated as $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, which would be pro-rated for the number of whole months remaining until the anniversary of the prior year&#8217;s stockholders&#8217; meeting, rounded down to the nearest whole share (the &#8220;Pro Rata RSUs&#8221;). The Initial RSUs vest in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> equal annual installments, while Pro Rata RSUs vest in a single installment at the sooner of the next annual stockholder meeting or the one-year grant anniversary, in each case subject to the non-employee director&#8217;s continuous service through the applicable vesting date.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annually, upon his or her re&#8209;election to the board of directors at the Annual Meeting of Stockholders, each non-employee director is automatically granted an RSU covering a number of shares of our common stock calculated as $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share. These RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the non-employee director&#8217;s continuous service through the applicable vesting date. Following the amendment to our non-employee director compensation program, both the annual RSUs and Initial RSUs described above remained unchanged with the exception that the number of shares of our common stock subject to each award has been reduced.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These RSUs will vest in full upon the director&#8217;s death, the occurrence of a change in control or, with respect to awards made after the October 2017 Amendments, the director&#8217;s disability before the director&#8217;s service terminates. Director RSUs carry dividend equivalent rights to be credited with an amount equal to all cash dividends paid on the underlying shares of common stock while unvested. Dividend equivalents are subject to the same terms and conditions, including vesting, as the RSUs to which they attach and are paid in cash upon vesting.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock&#8209;Based Compensation Expense</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock&#8209;based compensation expense is included in the consolidated statements of income as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.423%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.707%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,305</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,042</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,347</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock&#8209;based compensation expense included in the consolidated statements of income by award type is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.52%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.540000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.540000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.940000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,057</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">490</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">242</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,053</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,280</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,149</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSAs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">194</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">200</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">273</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,347</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:60.185%;"/>
        <td style="width:1.808%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.413999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.351%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.243%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized Compensation Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Amortization Period (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,550</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,776</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSAs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">388</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total unrecognized compensation expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,714</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Compensation Awards</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:31.657%;"/>
        <td style="width:0.963%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.326%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.311%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.977%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.34%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.311%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.977%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.34%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.778%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of outstanding options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Exercise Price of Outstanding Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of outstanding RSUs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of outstanding RSAs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">766</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.82</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.35</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">492</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.92</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">676</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.06</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.67</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Released RSUs and RSAs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">233</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.90</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.51</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">295</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.01</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">948</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.56</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">518</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.16</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.97</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest <br/>&#160;&#160;&#160;as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">948</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.56</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">518</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.16</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the aggregate intrinsic value of options outstanding and options exercisable was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t material</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021, the aggregate intrinsic value of the options outstanding was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and the aggregate intrinsic value of options exercisable was immaterial. As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">290</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> options were exercisable. The weighted average remaining contractual term of options outstanding was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.01</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.43</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years as of December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total intrinsic value of the options exercised was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t material as of December 31, 2022. The total intrinsic value of the options exercised was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2021 and 2020, respectively. The total estimated fair value of options vested was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021. The total estimated fair value of options vested was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t material for the year ended December 31, 2022 and 2020, respectively.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total estimated fair value of RSUs vested was $2.3 million, $1.1 million and $1.3 million for the year December 31, 2022, 2021 and 2020.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total estimated fair value of RSAs vested was not material for the year ended December 31, 2022, 2021, and 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Valuation Assumptions</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average assumptions used in calculating the estimated value of our stock options on the date of grant as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.741%;"/>
        <td style="width:1.474%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.955%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.464%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.955%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.464%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.946%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.04</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.11</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.11</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average estimated fair value of stock options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.43</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.84</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.28</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280607372000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#8217; Equity</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 31, 2022, our board of directors authorized a new share repurchase program under which we may repurchase up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of our outstanding shares of common stock. The timing and amount of any share repurchases under the share repurchase program will be determined by our management in its discretion based on ongoing assessments of the capital needs of the business, the market price of our common stock, prevailing stock prices, general market conditions and other considerations. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. This program has no termination date, may be suspended or discontinued at any time at our discretion, and does not obligate us to acquire any amount of common stock. As of December 31, 2022, we have repurchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">647,394</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Subsequent to December 31, 2022 and through February 24, 2023, we have repurchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,522,947</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.63</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. All the repurchased shares were retired.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280526003360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. DEBT</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our debt consists of:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.265%;"/>
        <td style="width:1.498%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.772%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.498%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.966000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,204</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">240,984</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">261,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">549,704</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">433,484</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,331</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,831</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total debt, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">540,373</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">394,653</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Less: Current portion of long-term debt, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,193</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term debt, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">444,180</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">394,653</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Subordinated Notes Due 2023</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2013, we completed an underwritten public offering of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">287.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million aggregate principal amount of unsecured convertible subordinated notes, with maturity date of January 15, 2023. The financing raised proceeds, net of issuance costs, of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">281.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, less $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> privately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negotiated capped call option transactions in connection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the issuance of the notes. The 2023 Notes bear interest at the rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.125</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per year that is payable semi-annually in arrears in cash on January 15 and July 15 of each year, beginning on July 15, 2013.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2023 Notes were convertible, at the option of the holder, into shares of our common stock at an initial conversion rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35.9903</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares per $1,000 principal amount of the 2023 Notes, subject to adjustment in certain circumstances, which represents an initial conversion price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.79</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the offering of the 2023 Notes, we entered into two privately negotiated capped call option transactions with a single counterparty. The capped call option transaction is an integrated instrument consisting of a call option on our common stock purchased by us with a strike price equal to the initial conversion price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.79</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for the underlying number of shares and a cap price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, both of which are subject to adjustments consistent with the 2023 Notes. The cap component is economically equivalent to a call option sold by us for the underlying number of shares with an initial strike price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. As an integrated instrument, the settlement of the capped call coincides with the due date of the convertible debt. Upon settlement, we would receive from our hedge counterparty a number of shares of our common shares that would range from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, if the stock price was below $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.79</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, to a maximum of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,779,659</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, if the stock price is above $38.00 per share. However, if the market price of our common stock, as measured under the terms of the capped call transactions, exceeds $38.00 per share, there is no incremental anti-dilutive benefit from the capped call.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the partial conversion by certain holders of the 2023 Notes in July 2014, and dividends declared and paid in 2014 and 2015, the conversion rate with respect to our 2023 Notes was adjusted in total to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.5818</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock per $1,000 principal amount of the 2023 Notes, which represents a conversion price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.77</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. As a result of the conversion rate adjustments, the capped call strike price and cap price were also adjusted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.77</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.04</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2016, we retired a portion of our 2023 Notes with a face value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and carrying value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million by way of purchase in the open market.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 7, 2022, we used $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from the sale of the 2028 Notes to repurchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the 2023 Notes with a face value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The carrying value of the repurchased 2023 Notes was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Accrued interest was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and unamortized debt issuance costs were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on the date of repurchase. We recognized a loss on the extinguishment of the 2023 Notes of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in other expense, net, in the consolidated statement of operations. The repurchase reduced the outstanding principal balance to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and unamortized debt issuance costs to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The annual effective interest rate of the 2023 Notes changed from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.36</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On April 18, 2022, certain 2023 Notes holders converted their notes of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> thousand into Innoviva&#8217;s common stock. The outstanding principal balance was reduced slightly to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our outstanding 2023 Notes balances consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.265%;"/>
        <td style="width:1.498%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.772%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.498%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.966000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,204</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">240,984</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt issuance costs, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">620</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,193</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">240,364</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2023 Notes for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.52%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.540000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.540000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.940000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,617</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,121</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,121</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">580</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">567</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,919</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,701</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2023 Notes were fully paid upon their maturity date in January 2023.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Senior Notes Due 2025</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 7, 2017, we completed a private placement of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million aggregate principal amount of our 2025 Notes. The proceeds include the 2025 Notes sold pursuant to the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million over-allotment option granted by us to the initial purchasers, which option was exercised in full. The 2025 Notes were sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The 2025 Notes are senior unsecured obligations and bear interest at a rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per year, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on February 15, 2018.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2025 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate for the 2025 Notes is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57.9240</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock per $1,000 principal amount of the 2025 Notes (which is equivalent to an initial conversion price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.26</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share), representing a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% conversion premium over the last reported sale price of the Company&#8217;s common stock on August 1, 2017, which was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.28</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The conversion rate is subject to customary anti-dilution adjustments in certain circumstances. The 2025 Notes will mature on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 15, 2025</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, unless repurchased or converted in accordance with their terms prior to such date. Prior to February 15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods. From, and including, February 15, 2025, until the close of business on the second scheduled trading day immediately preceding the maturity date, the 2025 Notes will be convertible at any time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of the 2025 Notes may convert all or a portion of their 2025 Notes prior to the close of business on February 15, 2025 only under the following circumstances:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">after September 30, 2017, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the current conversion price of the 2025 Notes;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the product of our closing common stock price and the conversion rate of the 2025 Notes on such day; and,</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental changes (as defined in the indenture governing the 2025 Notes) or a transaction resulting in our common stock converting into other securities or property or assets. </span></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On or after February 15, 2025, holders of the 2025 Notes may convert their 2025 Notes at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2025 Notes.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of default or a fundamental change (as defined above), holders of the 2025 Notes may require us to repurchase all or a portion of their 2025 Notes at price equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the principal amount of the 2025 Notes, plus any accrued and unpaid interest.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective January 1, 2022, we adopted ASU 2020-06 using a modified retrospective method, under which financial results reported in prior periods were not adjusted. The adoption of ASU 2020-06 had a material impact on the 2025 notes. Refer to Note 1, &#8220;Description of Operations and Summary of Significant Accounting Policies&#8221;, for further information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to the adoption of ASU 2020-06, we separately accounted for the liability and equity components of the 2025 Notes by allocating the proceeds between the liability component and the embedded conversion option (&#8220;equity component&#8221;) due to our ability to settle the conversion obligation of the 2025 Notes in cash, common stock or a combination of cash and common stock, at our option. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature using the income approach. The allocation was performed in a manner that reflected our non-convertible debt borrowing rate for similar debt. The equity component of the 2025 Notes of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was recognized as a debt discount and represents the difference between the proceeds from the issuance of the 2025 Notes and the fair value of the liability of the 2025 Notes on the date of issuance. The excess of the principal amount of the liability component over its carrying amount (&#8220;debt discount&#8221;) was amortized to interest expense using the effective interest method over the term of the 2025 Notes. The equity component was not remeasured as long as it continued to meet the conditions for equity classification. Additionally, we separated the total issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million incurred into liability and equity components in proportion to the allocation of the initial proceeds, resulting in liability issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and equity issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance costs attributable to the liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">component </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">were amortized on a straight-line basis, which approximated the effective interest rate method, to interest expense over the term of the 2025 Notes. The issuance costs attributable to the equity component were netted against the equity component in additional paid-in capital. The annual effective interest rate of the liability component of the 2025 Notes was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.87</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon adoption of ASU 2020-06 on January 1, 2022, we combined the liability and equity components of the 2025 Notes assuming that the instrument was accounted for as a single liability from inception to the date of adoption. We similarly combined the liability and equity components of the issuance costs. The issuance costs are presented as a deduction from the outstanding principal balance of the 2025 Notes and are amortized on a straight-line basis over the term of the 2025 Notes under the effective interest rate method. As of January 1, 2022, the annual effective interest rate on the 2025 Notes was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.88</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our outstanding 2025 Notes balances consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.265%;"/>
        <td style="width:1.498%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.772%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.498%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.966000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liability component</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,917</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,211</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">190,583</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">154,289</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity component, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,361</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.423%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.707%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,813</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,813</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,813</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">692</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">657</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">601</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt discount</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,898</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,230</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,505</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,368</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,644</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Convertible Senior Notes Due 2028</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, we completed a private placement of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">261.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million aggregate principal amount of our 2028 Notes, which will mature on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 15, 2028</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The proceeds include the 2028 Notes sold pursuant to the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million over-allotment option granted by us to the initial purchasers, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was exercised. The 2028 Notes were sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The net proceeds from the sale of the $261.0 million aggregate principal amount of 2028 Notes were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">252.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million after deducting the initial purchasers&#8217; discounts and commissions and our estimated offering expenses. We used approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the net proceeds from the offering to fund the cost of entering into the capped call transactions described below. In addition, we used $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the remaining net proceeds to repurchase $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million aggregate principal amount of the 2023 Notes in separate and individually negotiated transactions with certain holders of the 2023 Notes, which closed concurrently with the issuance of the 2028 Notes. We expect to use the remaining net proceeds for general corporate purposes.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2028 Notes bear interest at an annual rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.125</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% that is payable semi-annually in arrears in cash on March 15 and September 15 of each year, beginning on September 15, 2022.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2028 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38.1432</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares per $1,000 principal amount of the 2028 Notes, subject to customary anti-dilution adjustment in certain circumstances, which represented an initial conversion price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to September 15, 2027, the 2028 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods, and will be convertible on or after September 15, 2027, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2028 Notes.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of the 2028 Notes may convert all or a portion of their 2028 Notes prior to the close of business on September 15, 2027, only under the following circumstances:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">after March 31, 2022, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the current conversion price of the 2028 Notes;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the product of our closing common stock price and the conversion rate of the 2028 Notes on such day; and,</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental changes (as defined in the indenture governing the 2028 Notes) or a transaction resulting in our common stock converting into other securities or property or assets.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On or after September 15, 2027, holders of the 2028 Notes may convert their 2028 Notes at any time until the close of the business on the second day immediately preceding the maturity date of the 2028 Notes.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2028 Notes will be redeemable, in whole or in part, at our option at any time, and from time to time, on or after March 20, 2025, and on or before the 75th scheduled trading day immediately before the maturity date but only if the last reported sale price per share of our common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the 2028 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, calling any 2028 Note for redemption will constitute a make-whole fundamental change (as defined in the indenture governing the 2028 Notes) with respect to that 2028 Note, in which case the conversion rate applicable to the conversion of that 2028 Note will be increased in certain circumstances if it is converted after it is called for redemption.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we undergo a fundamental change, subject to certain conditions, holders may require us to purchase for cash all or any portion of their 2028 Notes. The fundamental change purchase price will be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the principal amount of the 2028 Notes to be purchased plus any accrued and unpaid interest to, but excluding, the fundamental change purchase date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.</span></span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions. The cap price of the capped call transaction is initially $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33.9850</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and is subject to certain adjustments under the terms of the capped call transactions. The capped call transactions cover, subject to customary adjustments, the number of shares of common stock initially underlying the 2028 Notes. The capped call transactions are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the aggregate principal amount of converted 2028 Notes, as the case may be, with such reduction or offset subject to a cap.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The annual effective interest rate on the 2028 Notes is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our outstanding 2028 Notes balance consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.252%;"/>
        <td style="width:1.784%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.964%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liability component</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">261,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,403</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">253,597</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2028 Notes from the issuance through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.287%;"/>
        <td style="width:1.802%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.911%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Issuance through</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,514</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,061</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,575</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt Maturities</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate scheduled maturities of our long-term debt as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 are as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"/>
        <td style="width:1.794%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.881%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,204</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">261,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">549,704</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Royalty Obligation</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our acquisition of La Jolla, we recorded the fair value of its deferred royalty obligation in connection with La Jolla&#8217;s royalty financing agreement (&#8220;La Jolla Royalty Agreement&#8221;) with HealthCare Royalty Partners (&#8220;HCR&#8221;). Under the terms of the La Jolla Royalty Agreement, HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> until either January 1, 2031 or when the maximum aggregate royalty payments have been made, whichever occurs first. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. The current maximum royalty rate is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. Starting January 1, 2024, the maximum royalty rate may increase by an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, if an agreed-upon, cumulative net product sales threshold has not been met. The La Jolla Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From the date of our acquisition of La Jolla through December 31, 2022, we recognized interest expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on the deferred royalty obligation. The carrying value of the deferred royalty obligation and accrued interest as of December 31, 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million of which </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was classified as part of other long-term liabilities on the consolidated balance sheet and the remaining $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was classified as other accrued liabilities on the consolidated balance sheet. From the date of acquisition of La Jolla through December 31, 2022, we made royalty payments to HCR of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The deferred royalty obligation was valued using Level 3 inputs, and its carrying value as of December 31, 2022 approximates fair value. The fair value of the deferred royalty obligation was calculated as the discounted deferred royalty obligations based on risk-adjusted revenue projections for GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The annual effective interest rate of the deferred royalty obligation was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the La Jolla Royalty Agreement, if we are unable to meet certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, HCR would have the right to terminate the La Jolla Royalty Agreement and demand payment of either $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million or $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million (depending on which obligation we have failed to meet) less aggregate royalties already paid to HCR. As of December 31, 2022, inclusive of the aggregate royalties paid to HCR by La Jolla under the La Jolla Royalty Agreement prior to our acquisition, La Jolla paid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">aggregate royalties to HCR. In the event that we fail to pay such amount if and when due in a timely manner, HCR would have the right to foreclose on the GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-related assets. HCR has no recourse against any asset other than GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain contract provisions within the La Jolla Royalty Agreement that could result in an acceleration of amounts due under the La Jolla Royalty Agreement are recognized as embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. We determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, we determined that the fair value of the embedded derivatives is not material and, therefore, not recognized as of December 31, 2022. We estimate the fair value of the embedded derivatives for each reporting period until either the features lapse or the La Jolla Royalty Agreement is terminated, whichever occurs first. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss on the consolidated statements of income.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280525899408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. COMMITMENTS AND CONTINGENCIES</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Lease</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have operating leases for our corporate headquarters, office spaces and laboratory facilities.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operating leases include a facility lease consisting of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,062</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office and laboratory space in Waltham, Massachusetts. Effective April 2022, we exercised our renewal option for to extend the lease term for three additional years through December 2025.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2019, we entered into an operating lease for our headquarters in Burlingame, California for approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,111</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> rentable square feet. The lease commenced in November 2019 with a term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_73893738-ee85-428b-aa7d-acd3031222eb;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">thirty-six</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> calendar months, which was subsequently amended to expire in December 2023.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease costs are as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.28%;"/>
        <td style="width:1.798%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.922%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Straight line operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,740</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental cash flow information related to leases are as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.28%;"/>
        <td style="width:1.798%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.922%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of <br/>&#160;&#160;&#160;operating lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">790</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets obtained in exchange <br/>&#160;&#160;&#160;for operating lease obligations</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,323</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets obtained through acquisitions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our operating leases have a weighted-average remaining lease term of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and the weighted-average incremental borrowing rate used to determine the operating lease right-of-use assets and lease liabilities was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not presented the comparative information above for the years ended December 31, 2021 and 2020 as our operating lease during those years was not material.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our operating leases as presented on the consolidated balance sheets:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.424%;"/>
        <td style="width:2.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.587%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.985%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,265</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_41a23557-411b-40b9-88d7-b7d2076397f5;"><span style="-sec-ix-hidden:F_890207b9-615b-4ab9-910d-0ca859f06d2a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of lease liabilities included within<br/>   Other accrued liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,316</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_49451cf0-b5b9-4245-8fca-d0d88b0b3246;"><span style="-sec-ix-hidden:F_547a2096-ca1f-487c-b0b5-45f04c844618;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term portion of lease liabilities included within<br/>   Other long-term liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,376</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,692</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments on our operating leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.291%;"/>
        <td style="width:1.798%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.911999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,542</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,269</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,289</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">408</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,692</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company is involved in legal proceedings in the ordinary course of its business. We are not currently a party to any material legal proceedings except as discussed below.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 15, 2022, La Jolla received a paragraph IV notice of certification (the &#8220;Notice Letter&#8221;) from Gland Pharma Limited (&#8220;Gland&#8221;) advising that Gland had submitted an Abbreviated New Drug Application (&#8220;ANDA&#8221;) to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in the U.S. prior to the expiration of U.S. Patent Nos.: 9,220,745; 9,572,856; 9,867,863; 10,028,995; 10,335,451; 10,493,124; 10,500,247; 10,548,943; 11,096,983; and 11,219,662 (the &#8220;GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Patents&#8221;), which are listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;Orange Book&#8221;). The Notice Letter alleges that the GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Gland&#8217;s ANDA.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 29, 2022, La Jolla filed a complaint for patent infringement of the GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland&#8217;s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is a new chemical entity and La Jolla filed a complaint for patent infringement within 45 days of receipt of the Notice Letter, the FDA cannot approve Gland&#8217;s ANDA any earlier than 7.5 years from the approval of the GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed. We intend to vigorously enforce our intellectual property rights relating to GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given the early stage of this matter, we cannot reasonably estimate a potential future loss or a range of potential future losses, if any, and have not recorded a contingent liability accrual as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indemnifications and Other Contingencies</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ordinary course of business, we may provide indemnifications of varying scope and terms to vendors, directors, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by us, our negligence or willful misconduct, violations of law, or intellectual property infringement claims made by</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">third </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">parties. In addition, we have entered into indemnification agreements with directors and certain officers and employees that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers, or employees. No material demands have been made upon us to provide indemnification under such agreements, and thus, there are no claims that we are aware of that could have a material effect on our consolidated financial statements. We also maintain director and officer insurance, which may cover certain liabilities arising from our obligation to indemnify our directors. To date, we have not incurred any material costs and, as of December 31, 2022, we have not accrued any liabilities in the consolidated financial statements as a result of these provisions.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280525875696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. INCOME TAXES</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense consists of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.419%;"/>
        <td style="width:1.484%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.712%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.484%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.508%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.484%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.907%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,822</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">464</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,286</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,893</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">625</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,539</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,401</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,420</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income tax expense, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,687</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,431</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The impacts of the differences between the expected U.S. federal statutory income tax to our income tax expense are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.315%;"/>
        <td style="width:1.472%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.686%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.686%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.88%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected tax at federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,928</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93,507</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,392</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,414</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">848</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and state research credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,260</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncontrolling interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,468</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,626</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,577</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impact of consolidation and deconsolidation of subsidiaries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,897</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,129</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">839</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,180</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,321</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense (benefit), net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,687</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,439</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,431</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant components of our deferred tax assets and deferred tax liabilities are as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.313%;"/>
        <td style="width:1.998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.748%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.942%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149,646</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,813</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,230</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,467</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on investment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,032</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred royalty obligation, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,404</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,527</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">743</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">202,839</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119,023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144,808</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,744</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,031</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54,279</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,587</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,158</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized gain on investment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory fair value adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,410</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">805</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,327</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We record deferred tax assets if the realization of such assets is more likely than not to occur. Significant management judgment is required in determining whether a valuation allowance against the deferred tax assets is required. We have considered all available evidence, both positive and negative, such as our historical operating results and predictability of future taxable income, in making such determination. We are also required to exercise significant management&#8217;s judgment in forecasting future taxable income. Specifically, we evaluate the following criteria when considering a valuation allowance:</span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the history of tax net operating losses in recent years;</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">predictability of operating results;</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">profitability for a sustained period of time; and</span></div></div><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">level of profitability on a quarterly basis.</span></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had federal net operating loss carryforwards of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">411.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which will expire beginning 2032. As of December 31, 2022, we also had state net operating loss carryforwards of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">955.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which will expire beginning 2029 and state research tax credits of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which do not expire.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Utilization of net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted an Internal Revenue Code of 1986, as amended, Section 382 (&#8220;Section 382&#8221;) analysis of the Company through December 31, 2022 to determine whether an ownership change had occurred since inception. The Section 382 study concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. However, notwithstanding the applicable annual limitations, no portion of our net operating loss or credit carryforwards is expected to expire before becoming available to reduce federal and state income tax liabilities as a result of those identified ownership changes. If we undergo another ownership change, the utilization of the pre-ownership change net operating loss carryforwards or pre-ownership change tax attributes, such as research tax credits, to offset the post-ownership change income may be subject to an annual limitation, pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. Similar rules may apply under state tax laws.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the acquisition of Entasis, we conducted a study of Entasis&#8217; ownership changes and estimated that we will be able to utilize $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of its federal net operating losses, which are subject to annual limitations.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the acquisition of La Jolla, we also performed a preliminary analysis of its ownership changes and estimated that we will be able to utilize $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">254.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of its federal net operating losses, which are subject to annual limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December 31, 2022 and 2021, we had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> accrued interest or penalties due to the Company's net operating losses available to offset any tax adjustments.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Uncertain Tax Positions</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:76.35%;"/>
        <td style="width:2.339%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.312%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,342</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in tax portions for 2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in tax portions for 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">313</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,872</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase in tax portions for 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,452</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,324</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to taxation in the U.S. and various state jurisdictions. The tax years 2004 through 2013, 2015 and forward remain open to examination by the federal and most state tax authorities due to net operating loss and overall credit carryforward positions.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280526049184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. SUBSEQUENT EVENTS</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 10, 2023, we entered into a Secured Convertible Credit Agreement (the &#8220;Credit Agreement&#8221;) with Armata, under which we extended a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term loan facility in an aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million at an interest rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% per annum. Pursuant to the Credit Agreement, the balance on the loan, including all accrued and unpaid interest thereon, will convert into shares of Armata's common stock upon the occurrence of a qualified financing, as defined in the Credit Agreement. Any portion of the balance on the loan, including all accrued and unpaid interest thereon, may also be converted into shares of Armata's common stock at our option once a registration statement covering the resale of such securities has been declared effective by the SEC. The loan is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 2, 2023, ITH entered into a Note Amendment Agreement (the "Note Amendment Agreement") with Gate to amend the Convertible Promissory Note Purchase Agreement entered into in November 2021 between TRC and Gate to acquire the Gate Convertible Note (refer to Note 6, &#8220;Equity and Long-Term Investments and Fair Value Measurements&#8221;). Pursuant to the Note Amendment Agreement, the principal amount of the Gate Convertible Note was increased from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which represents the original principal and accrued interests as of the amendment date. All other material terms of the Gate Convertible Note were unchanged.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280524332384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#8220;VIE&#8221;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PresentationReclassificationPolicyTextBlock', window );">Presentation Reclassification</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Presentation Reclassification</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain amounts in prepaid expenses and other current assets, other assets and changes in fair values of equity and long-term investments, net, reported in the Company's prior year financial statements have been reclassified to conform to the current year presentation. These reclassifications had no net effect on the net income or net cash flows as previously reported.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FactorsAffectingComparabilityPolicyTextBlock', window );">Factors Affecting Comparability</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Factors Affecting Comparability</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors below and as discussed in Note 5, &#8220;Consolidated Entities and Acquisitions&#8221;.</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adoption of Accounting Standards Update (&#8220;ASU&#8221;) 2020-06 effective January 1, 2022;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining noncontrolling interest in Entasis on July 11, 2022;</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sale of our </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% ownership interest in TRC on July 20, 2022; and</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisition of La Jolla on August 22, 2022.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Management's Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Management&#8217;s Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and of Significant Suppliers and Partners</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers and Partners</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#8220;API&#8221;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK&#8217;s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/BREO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ANORO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ELLIPTA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Our royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts&#8217; or investors&#8217; expectations, due to a number of important factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also started recognizing revenue from product sales as a result of our acquisition of La Jolla Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of our customers each account for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respectively, of our net product sales from the time of our acquisition of La Jolla through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. These same customers account for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#8220;Accounts receivables, net&#8221; on our consolidated balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We operate in a single segment, which is to provide capital return to stockholders by maximizing the potential value of our portfolio of royalties and innovative healthcare assets. Our Chief Operating Decision Maker (&#8220;CODM&#8221;) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Innoviva at the consolidated level using information about our revenues, operating results and other key financial data as needed. Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net sales of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and XERAVA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Refer to Note 3, &#8220;Revenue Recognition&#8221;, for more information on our revenues for the periods presented. Our long-term assets are located within the United States.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Variable Interest Entities</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary beneficiary of a variable interest entity (&#8220;VIE&#8217;) is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#8217;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combination</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business Combination</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When we acquire an entity in a business combination, we recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establish the acquisition date as the fair value measurement point. We recognize and measure goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. Acquisition-related expenses and related restructuring costs are expensed as incurred.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, we typically use the income method. This method starts with a forecast of all of the expected future net cash flows for each asset. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Some of the more significant estimates and assumptions inherent in the income method or other methods include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows and the assessment of the asset&#8217;s life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory, or economic barriers to entry. Determining the useful life of an intangible asset also requires judgment as different types of intangible assets will have different useful lives and certain assets may even be considered to have indefinite useful lives.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments in Marketable Securities</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We invest in short-term investments and marketable securities, primarily corporate notes, government securities, government agencies, and government commercial papers. We limit the amount of credit exposure with any one issuer, industry or geographic area for investments other than instruments backed by the U.S. federal government. We classify our marketable securities as available-for-sale securities and report them at fair value in cash equivalents or short-term marketable securities on the consolidated balance sheets with related unrealized gains and losses included as a component of stockholders&#8217; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. Realized gains and losses, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and dividend income.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We regularly review all of our investments for other-than-temporary declines in estimated fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in estimated fair value of an investment is below the amortized cost basis and the decline is other-than-temporary, we reduce the carrying value of the security and record a loss for the amount of such decline to other expense, net.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inventory</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value on a first in, first out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, which consisted of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements, were not material as of December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:49.167%;"/>
          <td style="width:1.667%;"/>
          <td style="width:49.167%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of remaining lease terms or useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment, furniture and fixtures</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software and computer equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity and Long-Term Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity and Long-Term Investments</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 825, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of other equity and long-term investments, net, on the consolidated statements of income.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we conclude that we do not have an ability to exercise significant influence over an investee, we may elect to account for the equity investment without a readily determinable fair value using the measurement alternative under ASC Topic 312, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments - Equity Securities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This measurement alternative allows us to measure the equity investment at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also invest in ISP Fund LP, which investments consist of money market funds, trading and equity securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered in December 2020, we became a limited partner of this partnership, and our contributions are subject to a 36-month lock-up period which restriction prevents us to have control and access to the contributions and related investments. These investments are classified as long-term investments on the consolidated balance sheets.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Quoted prices for identical instruments in active markets.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;Unobservable inputs and little, if any, market activity for the assets.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidPolicyTextBlock', window );">Capitalized Fees Paid</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Capitalized Fees Paid</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#8220;Capitalized Fees&#8221;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#8217;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#8217;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill and Intangible Assets</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We apply the guidance on principal versus agent considerations under ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includ</span><span style="background-color:rgba(0,0,0,0);color:rgba(37,37,37,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">es being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalty Revenue</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize the royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on its methodology and assumptions to estimate rebates and returns, which it monitors and adjusts regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Our partner may make significant adjustments to its sales based on actual results recorded, which could cause our royalty revenue to fluctuate. We conduct periodic royalty audits to evaluate the information provided by our partner. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Product Sales</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#8217; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#8220;GPO&#8221;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state&#8217;s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research expenses based on the progress of the studies and progress of research manufacturing activities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpensePolicyTextBlock', window );">Interest Expense on Deferred Royalty Obligation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Expense on Deferred Royalty Obligation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#8220;Debt&#8221;, for more information.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Fair Value of Stock-Based Compensation Awards</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Stock&#8209;Based Compensation Awards</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#8220;ESPP&#8221;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#8220;simplified&#8221; method as described in Staff Accounting Bulletin No. 107, &#8220;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Share-Based Payment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,&#8221; for the expected option term. We use our historical volatility to estimate expected stock price volatility.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units (&#8220;RSUs&#8221;) and restricted stock awards (&#8220;RSAs&#8221;) are measured based on the fair market values of the underlying stock on the dates of grant.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#8217;s best estimate as to whether it is probable that the shares awarded are expected to vest.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#8220;more likely than not&#8221; standard.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Income</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive income is comprised of net income and other comprehensive income (loss). Other comprehensive income (loss) consists of changes in unrealized and realized gains and losses on our marketable securities and the related tax impact of these changes.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RelatedPartyTransactionsPolicyTextBlock', window );">Related Parties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Related Parties</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions with GSK were considered related party transactions up until May 2021, when we completed the share repurchase agreement with GSK to buy back all of its shares of common stock in Innoviva. GSK is no longer considered a related party after the completion of the share repurchase. Transactions with GSK are described in Note 3, &#8220;Revenue Recognition and Collaborative Arrangements.&#8221;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sarissa Capital ow</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ned </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ur outstanding common stock as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Transactions with Sarissa Capital are described in Note 5, &#8220;Consolidated Entities and Acquisitions&#8221;. Sarissa Capital is considered to be a related party because two of its principals are members of our board of directors.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Adopted by the Company</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting Pronouncements Adopted by the Company</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, the FASB issued ASU 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt-Debt with Conversion and Other Options (Subtopic</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which is intended to simplify the accounting for convertible instruments by removing certain separation models in Subtopic 470-20 for</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">convertible instruments. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new standard also requires the if-converted method to be used to calculate diluted earnings per share (&#8220;EPS&#8221;) for convertible instruments. Effective January 1, 2022, we adopted the new standard using the modified retrospective approach and assessed the effect of this adoption on the accounting for our outstanding convertible notes. The effect of the adoption on our 2025 Notes (as defined below) resulted in a decrease to the opening balance of accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, a reduction to additional paid-in capital of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, an increase to the balance of the notes by an aggregate amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and an increase to deferred tax assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The dilutive EPS of our 2025 Notes will be computed under the if-converted method going forward. There was no financial impact from the implementation of the standard for our 2023 Notes (as defined below). Refer to Note 12, &#8220;Debt&#8221;, for more information.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, the FASB issued ASU 2021-08, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business Combinations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Topic 805), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Contract Assets and Contract Liabilities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognized and measured by the acquirer on the acquisition date in accordance with ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the third quarter of 2022, we elected to early adopt ASU 2021-08 effective July 1, 2022. The adoption did not have a material impact on our consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized fees paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_FactorsAffectingComparabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Factors affecting comparability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_FactorsAffectingComparabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PresentationReclassificationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Presentation reclassification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PresentationReclassificationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RelatedPartyTransactionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the entity's accounting policies for transactions entered with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RelatedPartyTransactionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 10<br> -Section 05<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=28365394&amp;loc=d3e23770-108382<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280525867520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of property, equipment and leasehold improvements useful lives</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
         <tr style="visibility:collapse;">
          <td style="width:49.167%;"/>
          <td style="width:1.667%;"/>
          <td style="width:49.167%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shorter of remaining lease terms or useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment, furniture and fixtures</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Software and computer equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280525885328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net income per share</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table shows the computation of basic and diluted net income per share for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.638%;"/>
        <td style="width:1.409%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.979000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.578%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.409%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.979%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands except per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to Innoviva stockholders, basic</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">213,921</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">265,854</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">224,402</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Add: interest expense on 2023 Notes, net of tax effect</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,736</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,717</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Add: interest expense on 2025 Notes, net of tax effect</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,583</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Add: interest expense on 2028 Notes, net of tax effect</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to Innoviva stockholders, diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225,569</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">270,590</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">229,119</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares used to compute basic net income<br/>&#160;&#160;&#160;per share attributable to Innoviva stockholders</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,644</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82,062</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101,320</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of 2023 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,188</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,189</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,189</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of 2025 Notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,150</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of 2028 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,158</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dilutive effect of options and awards granted under equity<br/>&#160;&#160;&#160;incentive plan and employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares used to compute diluted net income<br/>&#160;&#160;&#160;per share attributable to Innoviva stockholders</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95,248</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94,310</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,554</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income per share attributable to Innoviva stockholders</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.37</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.87</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.02</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#8209;dilutive:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:52.353%;"/>
        <td style="width:1.844%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.583%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.027%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.583%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.027%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.583%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding options and awards granted under equity incentive<br/>&#160;&#160;&#160;plan and employee stock purchase plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">648</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">979</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,193</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding stock warrant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">282</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">930</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">979</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,193</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280525987952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of net revenue from collaborative arrangements</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net revenue recognized under our GSK Agreements was as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.213%;"/>
        <td style="width:1.013%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.063%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.063%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.004%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.64%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties - RELVAR/BREO</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">215,034</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234,066</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">221,536</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties - ANORO</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,405</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,935</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,992</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalties - TRELEGY</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,029</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73,089</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total royalties</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">325,468</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">405,689</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">340,617</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: amortization of capitalized<br/>&#160;&#160;&#160;fees paid</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,823</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,823</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,823</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalty revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">311,645</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">391,866</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">326,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Strategic alliance - MABA program</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net royalty revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">311,645</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">391,866</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">336,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518089680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntitiesAndAcquisitionsLineItems', window );"><strong>Consolidated Entities and Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Pro Forma Information</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents certain unaudited pro-forma financial information for the years ended December 31, 2022 and 2021 as if the consolidation of Entasis and La Jolla occurred on January 1, 2021. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2021, or of results that may occur in the future. The unaudited pro forma financial information combines the historical results of the Entasis and La Jolla with the Company&#8217;s consolidated historical results and includes certain adjustments including, but not limited to, fair value adjustments to equity investments in Entasis&#8217; common stock and warrants, fair value adjustments to inventory, amortization of intangible assets, and interest expense on deferred royalty obligations and acquisition-related costs.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.399%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.6%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">357,880</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">435,398</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">204,987</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">281,719</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income attributable to Innoviva stockholders</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">214,390</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntitiesAndAcquisitionsLineItems', window );"><strong>Consolidated Entities and Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table represents the adjusted fair values of the assets acquired and liabilities assumed by us in the transaction:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"/>
        <td style="width:1.794%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.881%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 17, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,070</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,554</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,959</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">959</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,260</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107,500</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets acquired</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149,789</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,583</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued personnel-related expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,058</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,096</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,336</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities assumed</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,073</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets acquired, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,716</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember', window );">La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntitiesAndAcquisitionsLineItems', window );"><strong>Consolidated Entities and Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the adjusted allocation of the fair values assigned to the assets acquired and liabilities assumed as of the date of the acquisition:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"/>
        <td style="width:1.794%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.881%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 22, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,415</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term marketable securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">471</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,876</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,200</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,261</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">907</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">226</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">710</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets acquired</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">290,532</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,237</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,849</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,362</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,944</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,581</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities assumed</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83,973</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets acquired, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">206,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember', window );">Theravance Respiratory Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntitiesAndAcquisitionsLineItems', window );"><strong>Consolidated Entities and Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Balance Sheets and Income Statements of VIE</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The summarized financial information for TRC as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021 and for the relevant periods through the sale date in 2022 are presented as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance sheet</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"/>
        <td style="width:1.794%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.881%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,713</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receivables from collaborative arrangements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,492</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity and long-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,695</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130,971</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and LLC Members&#8217; Equity</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">252</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LLC members&#8217; equity</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130,719</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and LLC members&#8217; equity</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130,971</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.112%;"/>
        <td style="width:0.995%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.276%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.45%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.276%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.45%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.443000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalty revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,029</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73,089</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue from collaborative arrangements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total net revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,029</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83,089</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">332</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,956</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,612</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income from operations</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71,697</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122,732</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80,477</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Realized loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39,386</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair values of other equity and<br/>&#160;&#160;&#160;long-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,884</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,541</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,147</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,438</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121,191</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81,662</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConsolidatedEntitiesAndAcquisitionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated entities and acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConsolidatedEntitiesAndAcquisitionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518481680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of amortized cost and estimated fair values for available-for-sale securities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.883%;"/>
        <td style="width:1.553%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.133999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.563%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.133999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.563%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.133999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.563%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.475%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,469</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,469</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,469</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,469</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds are included in cash and cash equivalents on the consolidated balance sheets.</span></div></div>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:36.883%;"/>
        <td style="width:1.553%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.133999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.563%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.133999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.563%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.133999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.563%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.475%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,132</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,132</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,132</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,132</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds are included in cash and cash equivalents on the consolidated balance sheets.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of available-for-sale securities measured at fair value on a recurring basis</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our available-for-sale securities, equity and long-term investments are measured at fair value on a recurring basis and our debt is carried at amortized cost basis. The estimated fair values were as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:42.189%;"/>
        <td style="width:1.418%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.956999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.408%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.956999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.408%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.956999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.408%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.299%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2022 Using:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Price<br/>in Active<br/>Markets for</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant<br/>Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identical</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Observable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Types of Instruments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,469</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">263,469</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments held by ISP Fund LP </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">265,982</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54,578</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">320,560</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,095</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,095</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,059</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,059</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">605</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">605</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Convertible debt investment - Gate Note</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">560,546</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,059</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,883</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">639,488</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,089</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,089</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197,807</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197,807</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">211,768</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">211,768</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total fair value of debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">505,664</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">505,664</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent value rights</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">595</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">595</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities at estimated fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">505,664</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">595</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">506,259</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">295.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in equity investments, which included private placement positions and convertible notes of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in money market funds. Our total capital contribution of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million is subject to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lock-up period from the date of such capital contributions.</span></div></div>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:41.931%;"/>
        <td style="width:1.418%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.032%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.407%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.032%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.407%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.032%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.407%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.334999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2021 Using:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in Active</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Markets for</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identical</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Observable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Types of Instruments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,132</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,132</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments held by ISP Fund LP </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">193,677</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,068</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">195,745</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,101</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88,101</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,595</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,595</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Entasis Common Stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - Entasis Warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,914</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,914</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">411</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">411</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Convertible debt investment - Gate Note</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">489,704</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99,509</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,579</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">606,792</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">261,769</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">261,769</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234,498</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">234,498</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total fair value of debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">496,267</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">496,267</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million equity investments and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million money market funds, are subject to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-month lock-up period from our initial contribution date, December 11, 2020.</span></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Balance Sheets and Income Statements of VIE</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag regardless of the date of our investments as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Balance Sheet Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.94%;"/>
        <td style="width:2.262%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.57%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.262%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.968%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,245</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,178</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,636</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,493</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,004</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,300</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,662</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Statement Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.034%;"/>
        <td style="width:1.11%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.577%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.11%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.394%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.09%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.683%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Twelve Months Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,446</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,989</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">319</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,666</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,227</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,134</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,650</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,732</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Balance Sheets and Income Statements of VIE</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The summarized financial information, including the portion we did not own, is presented for Entasis on a one quarter lag regardless of the date of our investments as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Balance Sheet Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.276%;"/>
        <td style="width:1.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.929%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,746</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,348</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncurrent liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">183</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Statement Information</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.668%;"/>
        <td style="width:2.249%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.917%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.249%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.917%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Twelve Months Ended<br/>September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Six Months<br/>Ended September 30,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,323</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,080</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125,413</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,529</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280525987952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITALIZED FEES PAID (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAbstract', window );"><strong>Capitalized Contract Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostTableTextBlock', window );">Schedule of Capitalized Fees Paid</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.362%;"/>
        <td style="width:1.739%;"/>
        <td style="width:16.039%;"/>
        <td style="width:1.739%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.093%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.739%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.287%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization period</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2013-2030</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Europe</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2013-2029</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Japan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2013-2029</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross carrying value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">220,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">220,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122,393</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,570</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net carrying value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,607</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,430</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost capitalized in obtaining or fulfilling contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280521895232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Accumulated Amortization of Recognized Intangible Assets</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying basis and accumulated amortization of recognized intangible assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 were as follows:</span><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.438%;"/>
        <td style="width:1.112%;"/>
        <td style="width:11.146%;"/>
        <td style="width:1.102%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.333%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.102%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.333%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.102%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.333%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Useful Life</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Carrying</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketed products</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,581</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,419</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In-process research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,100</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72,100</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration agreement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,400</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,400</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">258,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,581</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">252,919</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of finite and indefinite lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280522015488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, net</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.252%;"/>
        <td style="width:1.784%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.964%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Raw materials</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,757</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,052</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finished goods</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,088</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total inventory</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,897</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.399%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.6%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.502%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued contract manufacturing expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,382</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued clinical expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">692</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">349</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,977</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">894</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,316</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of deferred royalty obligation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,639</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued license fees and royalties</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">943</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,909</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other accrued liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,207</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,009</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of Other Long-term Liabilities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.252%;"/>
        <td style="width:1.784%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.964%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term portion of deferred royalty obligation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,947</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term portion of lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,376</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent value rights liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">595</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other long-term liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,918</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280527862608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock&#8209;based compensation expense is included in the consolidated statements of income as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.423%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.707%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,305</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,042</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,347</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of stock-based compensation expense included in the consolidated statements of operations by award type</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock&#8209;based compensation expense included in the consolidated statements of income by award type is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.52%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.540000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.540000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.940000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,057</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">490</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">242</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,053</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,280</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,149</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSAs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">194</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">200</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">273</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ESPP</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,347</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of unrecognized stock-based compensation cost</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:60.185%;"/>
        <td style="width:1.808%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.413999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.351%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.243%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized Compensation Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Amortization Period (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,550</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,776</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSAs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">388</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total unrecognized compensation expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,714</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of equity award activity and related information</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:31.657%;"/>
        <td style="width:0.963%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.326%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.311%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.977%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.34%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.311%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.977%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.34%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.006%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.778%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands, except per share data)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of outstanding options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Exercise Price of Outstanding Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of outstanding RSUs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of outstanding RSAs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">766</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.82</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.35</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">492</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.92</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">676</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.06</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.67</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Released RSUs and RSAs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">233</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.90</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.51</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">295</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.01</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.80</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">948</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.56</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">518</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.16</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.97</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest <br/>&#160;&#160;&#160;as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">948</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.56</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">518</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.16</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of weighted-average assumptions used to calculate estimated value of stock options</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average assumptions used in calculating the estimated value of our stock options on the date of grant as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.741%;"/>
        <td style="width:1.474%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.955%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.464%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.955%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.464%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.946%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.04</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.11</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.11</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average estimated fair value of stock options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.43</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.84</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.28</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280522429664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our debt consists of:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.265%;"/>
        <td style="width:1.498%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.772%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.498%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.966000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,204</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">240,984</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025 Notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2028 Notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">261,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">549,704</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">433,484</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,331</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,831</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total debt, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">540,373</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">394,653</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Less: Current portion of long-term debt, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,193</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total long-term debt, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">444,180</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">394,653</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Aggregate Scheduled Maturities of Long-Term Debt</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate scheduled maturities of our long-term debt as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 are as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.325%;"/>
        <td style="width:1.794%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.881%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,204</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">261,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">549,704</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Summary of Liability and Equity Components of Convertible Notes</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our outstanding 2023 Notes balances consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.265%;"/>
        <td style="width:1.498%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.772%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.498%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.966000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,204</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">240,984</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt issuance costs, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">620</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,193</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">240,364</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Components of Interest Expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2023 Notes for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.52%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.540000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.540000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.940000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,617</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,121</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,121</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">302</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">580</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">567</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,919</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,701</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Summary of Liability and Equity Components of Convertible Notes</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our outstanding 2025 Notes balances consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.265%;"/>
        <td style="width:1.498%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.772%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.498%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.966000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liability component</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,917</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,211</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">190,583</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">154,289</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity component, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,361</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Components of Interest Expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.423%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.923%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.707%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,813</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,813</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,813</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">692</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">657</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">601</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt discount</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,898</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,230</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,505</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,368</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,644</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Summary of Liability and Equity Components of Convertible Notes</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our outstanding 2028 Notes balance consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.252%;"/>
        <td style="width:1.784%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.964%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liability component</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">261,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,403</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net carrying amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">253,597</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Components of Interest Expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2028 Notes from the issuance through </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.287%;"/>
        <td style="width:1.802%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.911%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of Issuance through</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual interest expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,514</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,061</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total interest and amortization expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,575</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280521809328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Cost</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease costs are as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.28%;"/>
        <td style="width:1.798%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.922%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Straight line operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,740</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental cash flow information related to leases are as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.28%;"/>
        <td style="width:1.798%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.922%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of <br/>&#160;&#160;&#160;operating lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">790</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets obtained in exchange <br/>&#160;&#160;&#160;for operating lease obligations</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,323</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets obtained through acquisitions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock', window );">Schedule of Operating Lease Information Presented In Balance Sheet</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our operating leases as presented on the consolidated balance sheets:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.424%;"/>
        <td style="width:2.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.587%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.985%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,265</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_41a23557-411b-40b9-88d7-b7d2076397f5;"><span style="-sec-ix-hidden:F_890207b9-615b-4ab9-910d-0ca859f06d2a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current portion of lease liabilities included within<br/>   Other accrued liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,316</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_49451cf0-b5b9-4245-8fca-d0d88b0b3246;"><span style="-sec-ix-hidden:F_547a2096-ca1f-487c-b0b5-45f04c844618;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term portion of lease liabilities included within<br/>   Other long-term liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,376</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,692</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments on our operating leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.291%;"/>
        <td style="width:1.798%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.911999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ending December 31,</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,542</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,269</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,289</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">408</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,692</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Balance sheet Information Related To Operating Lease Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280521893392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of the income tax expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense consists of the following:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.419%;"/>
        <td style="width:1.484%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.712%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.484%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.508%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.484%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.907%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,822</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">464</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,286</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,893</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">625</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,539</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,401</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,420</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income tax expense, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,687</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,431</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of differences between expected U.S. federal statutory income tax to income tax expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The impacts of the differences between the expected U.S. federal statutory income tax to our income tax expense are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.315%;"/>
        <td style="width:1.472%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.686%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.686%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.481%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.88%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected tax at federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,928</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93,507</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,392</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,414</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">848</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and state research credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,260</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncontrolling interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,468</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,626</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,577</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impact of consolidation and deconsolidation of subsidiaries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,897</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,129</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">839</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,180</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,321</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense (benefit), net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,687</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,439</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60,431</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and deferred tax liabilities</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant components of our deferred tax assets and deferred tax liabilities are as follows:</span><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:56.313%;"/>
        <td style="width:1.998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.748%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.942%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149,646</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,813</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,230</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,467</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on investment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,032</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred royalty obligation, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,404</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,527</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">743</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">202,839</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119,023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144,808</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,744</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,031</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54,279</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,587</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,158</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized gain on investment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,794</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inventory fair value adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,410</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">805</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,327</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of changes in unrecognized tax benefits</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:76.35%;"/>
        <td style="width:2.339%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.312%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,342</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in tax portions for 2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,185</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net decrease in tax portions for 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">313</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,872</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase in tax portions for 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,452</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,324</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280512457136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Operations (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Customer</div>
</th>
<th class="th"><div>Jul. 20, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCustomers', window );">Number of customers | Customer</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeePaidEstimatedUsefulLife', window );">Capitalized fees paid, estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">ASU 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DecreaseToAccumulatedDeficit', window );">Decrease to accumulated deficit</a></td>
<td class="nump">$ 37.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ReductionToAdditionalPaidInCapital', window );">Reduction to Additional Paid in Capital</a></td>
<td class="nump">65.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncreaseInDeferredTaxAssets', window );">Increase in Deferred Tax Assets</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_TheravanceRespiratoryCompanyLlcMember', window );">Theravance Respiratory Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Receivables from Net Product Sales | La Jolla [Member] | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Receivables from Net Product Sales | La Jolla [Member] | Customer Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Receivables from Net Product Sales | La Jolla [Member] | Customer Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">Two Thousand Twenty Five Notes [Member] | ASU 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncreaseToConvertibleNotes', window );">Increase in convertible notes</a></td>
<td class="nump">$ 35.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember', window );">Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | RELVAR/BREO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne', window );">Royalty rate for first level of annual global net sales (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate', window );">Annual global sales level used to determine royalty rate</a></td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo', window );">Royalty rate for sales above first level of annual global net sales (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember', window );">Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember', window );">Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeePaidEstimatedUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized fee paid estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeePaidEstimatedUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate for combination products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DecreaseToAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease to accumulated deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DecreaseToAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncreaseInDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncreaseInDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncreaseToConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase to convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncreaseToConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ReductionToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction to additional paid in capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ReductionToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_TheravanceRespiratoryCompanyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_TheravanceRespiratoryCompanyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_LaJollaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_LaJollaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inva_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inva_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inva_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inva_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inva_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inva_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518470528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_LaboratoryEquipmentFurnitureAndFixturesMember', window );">Laboratory equipment furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_LaboratoryEquipmentFurnitureAndFixturesMember', window );">Laboratory equipment furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_SoftwareAndComputerEquipmentMember', window );">Software and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_LaboratoryEquipmentFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_LaboratoryEquipmentFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_SoftwareAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_SoftwareAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280607388432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Related Party Transactions (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember', window );">Sarissa Capital</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty', window );">Percentage of common stock owned by a related party</a></td>
<td class="nump">9.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock in the reporting entity owned by related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280522405344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE (Details) - 2025 Notes - Convertible senior notes - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 07, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod', window );">Dilutive effect of the assumed conversion premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DilutiveEpsOfNotes', window );">Dilutive EPS of note</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (dollars per share)</a></td>
<td class="nump">$ 17.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DilutiveEpsOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DilutiveEpsOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518507024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE - Basic and Diluted EPS (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Innoviva stockholders, basic</a></td>
<td class="nump">$ 213,921<span></span>
</td>
<td class="nump">$ 265,854<span></span>
</td>
<td class="nump">$ 224,402<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Innoviva stockholders, diluted</a></td>
<td class="nump">$ 225,569<span></span>
</td>
<td class="nump">$ 270,590<span></span>
</td>
<td class="nump">$ 229,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute basic net income per share attributable to Innoviva stockholders</a></td>
<td class="nump">69,644<span></span>
</td>
<td class="nump">82,062<span></span>
</td>
<td class="nump">101,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute diluted net income per share attributable to Innoviva stockholders</a></td>
<td class="nump">95,248<span></span>
</td>
<td class="nump">94,310<span></span>
</td>
<td class="nump">113,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NetIncomeLossPerShareAbstract', window );"><strong>Net income per share attributable to Innoviva stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share</a></td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share</a></td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="nump">$ 2.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Add: interest expense on Notes, net of tax effect</a></td>
<td class="nump">$ 2,439<span></span>
</td>
<td class="nump">$ 4,736<span></span>
</td>
<td class="nump">$ 4,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive effect</a></td>
<td class="nump">6,188<span></span>
</td>
<td class="nump">12,189<span></span>
</td>
<td class="nump">12,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Add: interest expense on Notes, net of tax effect</a></td>
<td class="nump">$ 4,583<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive effect</a></td>
<td class="nump">11,150<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Add: interest expense on Notes, net of tax effect</a></td>
<td class="nump">$ 4,626<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive effect</a></td>
<td class="nump">8,158<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NetIncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NetIncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestOnConvertibleDebtNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestOnConvertibleDebtNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280517717568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER SHARE - Anti-Dilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">930<span></span>
</td>
<td class="nump">979<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_EquityIncentivePlansAndESPPMember', window );">Equity incentive plans and ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">979<span></span>
</td>
<td class="nump">1,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_OutstandingStockWarrantMember', window );">Outstanding Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_EquityIncentivePlansAndESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_EquityIncentivePlansAndESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_OutstandingStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_OutstandingStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518507616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 331,339<span></span>
</td>
<td class="nump">$ 391,866<span></span>
</td>
<td class="nump">$ 336,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Less: amortization of capitalized fees paid</a></td>
<td class="num">(13,823)<span></span>
</td>
<td class="num">(13,823)<span></span>
</td>
<td class="num">(13,823)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">311,645<span></span>
</td>
<td class="nump">391,866<span></span>
</td>
<td class="nump">326,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_CollaborativeArrangementsMember', window );">Revenue from collaborative arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_GSKMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">311,645<span></span>
</td>
<td class="nump">391,866<span></span>
</td>
<td class="nump">336,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_GSKMember', window );">GSK | Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees', window );">Royalties</a></td>
<td class="nump">325,468<span></span>
</td>
<td class="nump">405,689<span></span>
</td>
<td class="nump">340,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Less: amortization of capitalized fees paid</a></td>
<td class="num">(13,823)<span></span>
</td>
<td class="num">(13,823)<span></span>
</td>
<td class="num">(13,823)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">311,645<span></span>
</td>
<td class="nump">391,866<span></span>
</td>
<td class="nump">326,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_GSKMember', window );">GSK | RELVAR/BREO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees', window );">Royalties</a></td>
<td class="nump">215,034<span></span>
</td>
<td class="nump">234,066<span></span>
</td>
<td class="nump">221,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_GSKMember', window );">GSK | ANORO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees', window );">Royalties</a></td>
<td class="nump">38,405<span></span>
</td>
<td class="nump">44,935<span></span>
</td>
<td class="nump">45,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_GSKMember', window );">GSK | TRELEGY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees', window );">Royalties</a></td>
<td class="nump">72,029<span></span>
</td>
<td class="nump">126,688<span></span>
</td>
<td class="nump">73,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_GSKMember', window );">GSK | Revenue from collaborative arrangements | Strategic alliance - MABA program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_StrategicAllianceMabaProgram', window );">Strategic alliance - MABA program</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer before amortization of capitalized fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_StrategicAllianceMabaProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>strategic alliance - MABA program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_StrategicAllianceMabaProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_CollaborativeArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_CollaborativeArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=inva_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=inva_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_TrelegyElliptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_TrelegyElliptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_StrategicAllianceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_StrategicAllianceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280512309968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 13, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 331,339<span></span>
</td>
<td class="nump">$ 391,866<span></span>
</td>
<td class="nump">$ 336,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Milestone fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Milestone fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember', window );">La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Product Sales | Geographic Concentration Risk | La Jolla Pharmaceutical Company | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Product Sales | Geographic Concentration Risk | La Jolla Pharmaceutical Company | Rest of the world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inva_StrategicAllianceAgreementMember', window );">Strategic alliance - MABA program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Revenue recognized upon termination of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,645<span></span>
</td>
<td class="nump">391,866<span></span>
</td>
<td class="nump">326,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_GiaprezaMember', window );">GIAPREZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_XeravaMember', window );">XERAVA | La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_CollaborativeArrangementsMember', window );">Revenue from collaborative arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_GSKMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive', window );">Percentage of royalty payments not entitled to receive</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,645<span></span>
</td>
<td class="nump">391,866<span></span>
</td>
<td class="nump">336,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_GSKMember', window );">GSK | Long-Acting Beta2 Agonist (LABA) Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Milestone fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements', window );">Percentage of economic interest in any future payments made under the agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_GSKMember', window );">GSK | Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,645<span></span>
</td>
<td class="nump">$ 391,866<span></span>
</td>
<td class="nump">$ 326,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_GSKMember', window );">GSK | RELVAR/BREO | Long-Acting Beta2 Agonist (LABA) Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne', window );">Royalty rate for first level of annual global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate', window );">Annual global sales level used to determine royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo', window );">Royalty rate for sales above first level of annual global net sales (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_GSKMember', window );">GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_GSKMember', window );">GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_GSKMember', window );">GSK | TRELEGY | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_GSKMember', window );">GSK | TRELEGY | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate for combination products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of economic interest in any future payments made under the agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments the company is not entitled to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_StrategicAllianceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_StrategicAllianceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_GiaprezaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_GiaprezaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_XeravaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_XeravaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_CollaborativeArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_CollaborativeArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=inva_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=inva_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_TrelegyElliptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_TrelegyElliptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280524285776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AND COLLABORATION ARRANGEMENTS - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_ZaiLabMember', window );">Zai Lab | Research and Development Support</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FuturePotentialMilestonePayment', window );">Future potential milestone payment receivable</a></td>
<td class="nump">91.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_PaionAgMember', window );">PAION AG</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FuturePotentialMilestonePayment', window );">Future potential milestone payment receivable</a></td>
<td class="nump">109.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember', window );">Everest Medicines Limited</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RegulatoryMilestonePaymentsReceivable', window );">Additional regulatory milestone payments receivable</a></td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SalesMilestonePaymentsReceivable', window );">Sales milestone payments receivable</a></td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct', window );">Royalties payable period after first commercial sale of product</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember', window );">Everest Medicines Limited | Commercial Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts', window );">Percentage of reimbursed for direct and certain indirect manufacturing costs</a></td>
<td class="nump">110.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_GeorgeWashingtonUniversityMember', window );">George Washington University</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyPayableOnNetSales', window );">Percentage of royalty payable on net sales</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees', window );">Percentage of royalty on payments received from sublicensees</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_HarvardUniversityMember', window );">Harvard University</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyPayableOnNetSales', window );">Percentage of royalty payable on net sales</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees', window );">Percentage of royalty on payments received from sublicensees</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable', window );">Clinical development and regulatory milestones amount payable</a></td>
<td class="nump">$ 15.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfMinimumRoyaltyRate', window );">Percentage of minimum royalty rate</a></td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds', window );">Percentage of maximum royalty based on achievement of annual net product sales thresholds</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_ParatekPharmaceuticalsIncMember', window );">Paratek Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyPayableOnNetSales', window );">Percentage of royalty payable on net sales</a></td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ClaimExpirationDate', window );">Claim Expiration Date</a></td>
<td class="text">2023-10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ClaimExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Claim expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ClaimExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical development and regulatory milestones amount payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_FuturePotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future potential milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_FuturePotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum royalty based on achievement of annual net product sales thresholds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfMinimumRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum royalty rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfMinimumRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reimbursed for direct and certain indirect manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty payable as a percentage of payments received from sublicensees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfRoyaltyPayableOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty payable, as a percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfRoyaltyPayableOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RegulatoryMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RegulatoryMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties payable period after first commercial sale of product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SalesMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SalesMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_ResearchAndDevelopmentSupportMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_ResearchAndDevelopmentSupportMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_PaionAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_PaionAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_CommercialSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_CommercialSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_GeorgeWashingtonUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_GeorgeWashingtonUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_HarvardUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_HarvardUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_ParatekPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_ParatekPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280511963568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 20, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 291,049<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 201,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,559<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity and long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,013<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">483,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,231,497<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">926,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,968<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,231,497<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">926,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract', window );"><strong>Income statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,339<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">391,866<span></span>
</td>
<td class="nump">$ 336,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,373)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,626)<span></span>
</td>
<td class="num">(348)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,687<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76,439<span></span>
</td>
<td class="nump">60,431<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,262<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">368,837<span></span>
</td>
<td class="nump">293,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract', window );"><strong>Income statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,645<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">391,866<span></span>
</td>
<td class="nump">326,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_CollaborativeArrangementsMember', window );">Revenue from collaborative arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract', window );"><strong>Income statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember', window );">Theravance Respiratory Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>CONSOLIDATED ENTITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_OwnershipInterestInConsolidatedEntities', window );">Ownership interest in LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement', window );">Proceeds from sale of economic interest under Equity Purchase Agreement</a></td>
<td class="nump">$ 277,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ContingentSalesBasedMilestonePayment', window );">Contingent sales based milestone payment</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CashDistributionReceived', window );">Cash distribution</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Total carrying value of investments</a></td>
<td class="nump">$ 39,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">50,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Receivables from collaborative arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">42,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity and long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">37,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">130,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">LLC members' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">130,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">130,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract', window );"><strong>Income statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">126,688<span></span>
</td>
<td class="nump">83,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,956<span></span>
</td>
<td class="nump">2,612<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,697<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">122,732<span></span>
</td>
<td class="nump">80,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RealizedLoss', window );">Realized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,386)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Changes in fair values of other equity and long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,884)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,541)<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,438<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">121,191<span></span>
</td>
<td class="nump">81,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember', window );">Theravance Respiratory Company, LLC | Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract', window );"><strong>Income statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,029<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">126,688<span></span>
</td>
<td class="nump">73,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember', window );">Theravance Respiratory Company, LLC | Revenue from collaborative arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract', window );"><strong>Income statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember', window );">ISP Fund LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">195,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract', window );"><strong>Income statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Changes in fair values of other equity and long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CashDistributionReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CashDistributionReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ContingentSalesBasedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent sales based milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ContingentSalesBasedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_OwnershipInterestInConsolidatedEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ownership interest in consolidated entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_OwnershipInterestInConsolidatedEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of economic interest under Equity Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Realized loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of ownership interest in limited liability company (LLC), attributable to the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125520817&amp;loc=d3e70258-108054<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70434-108055<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=125520817&amp;loc=d3e70229-108054<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_CollaborativeArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_CollaborativeArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_TheravanceRespiratoryCompanyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518131152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund LP (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>CONSOLIDATED ENTITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,231,497<span></span>
</td>
<td class="nump">$ 926,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember', window );">ISP Fund LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>CONSOLIDATED ENTITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedPartnersCumulativeCashDistributions', window );">Distribution from partnership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedPartnersContributedCapital', window );">Capital contribution</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfEconomicInterestInPartnership', window );">Economic interest of the Partnership (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInvestmentExpense', window );">Investment-related expenses, net of investment-related income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Investment Income, Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on other equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PartnershipAgreementLockUpPeriod', window );">Lock-up period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Investment Income, Interest and Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Realized gain on equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,600<span></span>
</td>
<td class="nump">$ 195,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PartnershipAgreementLockUpPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time in which contributors to an investment fund have waived the right of redemption, as defined in the partnership agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PartnershipAgreementLockUpPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfEconomicInterestInPartnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of economic interest held in Partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfEconomicInterestInPartnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInvestmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the generation of investment income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInvestmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of capital contributed by the limited partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersCumulativeCashDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate cumulative cash distributions made to the limited partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersCumulativeCashDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280517760400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Director</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 549,704,000<span></span>
</td>
<td class="nump">$ 433,484,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,341,000)<span></span>
</td>
<td class="num">$ (102,983,000)<span></span>
</td>
<td class="num">$ (69,412,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers', window );">Number of investee's board members which may be designated by the Company | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Remeasurement loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment towards convertible promissory note</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Measurement period adjustments for change in value of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice', window );">Measurement period adjustments for change in estimated purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Measurement period adjustments for change in value of noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Measurement period adjustments for change in value of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment', window );">Business Acquisitions of Change in Fair Value of Investment</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc | Consolidated Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc | Securities purchase agreement | Convertable promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 18,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,672,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc | Common stock | Innoviva Strategic Opportunities, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction', window );">Number of warrants purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,672,897<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc | Warrants | Innoviva Strategic Opportunities, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc | Common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc | Warrants acquired in second quarter of 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc | Warrants acquired in third quarter of 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc | Warrants acquired in second quarter of 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisitions of change in fair value of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in estimated purchase price during measurement period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of the investee's board members which the Company has the right to designate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_CommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_CommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_WarrantsAcquiredInSecondQuarterOf2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_WarrantsAcquiredInSecondQuarterOf2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_WarrantsAcquiredInThirdQuarterOf2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_WarrantsAcquiredInThirdQuarterOf2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_WarrantsAcquiredInSecondQuarterOf2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_WarrantsAcquiredInSecondQuarterOf2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280523765904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 22, 2022</div></th>
<th class="th"><div>Feb. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 26,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember', window );">La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Short-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">$ 151,000<span></span>
</td>
<td class="nump">151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">'Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total assets acquired, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">'Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses', window );">Accrued personnel-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total assets acquired, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued personnel-related expenses due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed other accrued liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280522699408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla Pharmaceutical Company (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 22, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Change in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (280)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember', window );">La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration paid</a></td>
<td class="nump">$ 206,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Acquisition share price</a></td>
<td class="nump">$ 6.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Measurement period adjustments for change in value of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Change in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Measurement period adjustments for change in value of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities', window );">Measurement Period Adjustments Increase Decrease In Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquisitionCosts', window );">Acquisition-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncreaseDecreaseInDeferredTaxLiabilities', window );">Measurement period adjustments increase decrease in deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncreaseDecreaseInDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deferred tax liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncreaseDecreaseInDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Measurement period adjustments increase decrease In liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126954596&amp;loc=d3e511914-122862<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(3)(ii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126954596&amp;loc=d3e511914-122862<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518467568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma Information (Details) - Entasis Therapeutics Holdings Inc - La Jolla Pharmaceutical Company - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Revenue</a></td>
<td class="nump">$ 357,880<span></span>
</td>
<td class="nump">$ 435,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net income</a></td>
<td class="nump">204,987<span></span>
</td>
<td class="nump">281,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Innoviva stockholders</a></td>
<td class="nump">$ 214,390<span></span>
</td>
<td class="nump">$ 197,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280524031824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Armata (Details) - Armata<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 09, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Tranche </div>
<div>Director</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementNumberOfTranches', window );">Number of tranches | Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_VotingAgreementMaximumVotingRightsPercent', window );">Percentage of maximum voting rights</a></td>
<td class="nump">49.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee', window );">Number of Investee's Board members currently representing the Company | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfBoardMembersOfInvestee', window );">Number of the Investee's Board members | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee', window );">Special terms on re-designating board member to board of investee</a></td>
<td class="text">In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least 12.5% of the outstanding shares of Armata&#8217;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#8217;s board of directors, and for so long as the Company and ISO hold at least 8%, but less than 12.5%, of the outstanding shares of Armata&#8217;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#8217;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Consolidated Investees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.40%<span></span>
</td>
<td class="nump">59.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Two Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Armata outstanding shares percentage</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.2<span></span>
</td>
<td class="nump">$ 146.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Warrants purchased in 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction', window );">Number of warrants purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Warrants purchased in 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Warrants Purchased in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,710,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.1<span></span>
</td>
<td class="nump">$ 88.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | One Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Armata outstanding shares percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | One Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Armata outstanding shares percentage</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember', window );">Innoviva Strategic Opportunities, LLC | Common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember', window );">Innoviva Strategic Opportunities, LLC | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement', window );">Number of warrants to be purchased under the securities purchase agreement | shares</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,153,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember', window );">Innoviva Strategic Opportunities, LLC | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,212,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement', window );">Number of warrants to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,153,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfBoardMembersOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of Board members of the Investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfBoardMembersOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of the Company's Board members currently serving on the Investee's Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of tranches in which the Company agreed to purchase common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of shares to be purchased under the terms of a securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of warrants to be purchased under the terms of a securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Terms on amended and restated investor rights agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_VotingAgreementMaximumVotingRightsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of maximum voting rights under voting agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_VotingAgreementMaximumVotingRightsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=inva_TwoDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=inva_TwoDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_CommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_CommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=inva_OneDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=inva_OneDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280523789184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Summarized Financial Data (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract', window );"><strong>Income Statement Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract', window );"><strong>Income Statement Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (32,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract', window );"><strong>Income Statement Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">$ (26,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,323)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (24,529)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (125,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518011968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in InCarda (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 15, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Director </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember', window );">InCarda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee', window );">Number of Investee's Board members currently representing the Company | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfBoardMembersOfInvestee', window );">Number of the Investee's Board members | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss from fair value changes in equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaConvertibleNoteMember', window );">InCarda Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt instrument principal amount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaConvertibleNoteMember', window );">InCarda Convertible Note | Qualified Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross Proceeds from sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesCPreferredStockAndWarrantsMember', window );">Series C preferred stock and warrants | InCarda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_Incarda2020WarrantsMember', window );">Incarda 2020 Warrants [Member] | InCarda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants', window );">Maximum number of additional shares into which warrants may be converted under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,117,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ExtendedExpirationDate', window );">Extended expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_ConvertibleNoteAndWarrantsMember', window );">Convertible note and warrants | InCarda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember', window );">Common stock | InCarda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="nump">4,093,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesA1PreferredStockMember', window );">Series A1 preferred stock | InCarda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="nump">37,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD1PreferredStockMember', window );">Series D 1 Preferred Stock | InCarda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="nump">8,771,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD2PreferredStockMember', window );">Series D 2 Preferred Stock | InCarda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="nump">3,369,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD1WarrantMember', window );">Series D1 Warrant | InCarda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="nump">2,490,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock | InCarda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,469,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued | shares</a></td>
<td class="nump">5,117,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentTransactionCost', window );">Transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="nump">15,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesCWarrantsAndSeriesDWarrantsMember', window );">Series C Warrants and Series D Warrants | InCarda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock | InCarda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Payments to acquire equity securities</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD1AndD2PreferredStockAndCommonStockMember', window );">Series D 1 And D 2 Preferred Stock And Common Stock | InCarda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Backsolve Valuation | InCarda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ExpectedHoldingPeriod', window );">Expected Holding Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DividendYield', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfEstimatedVolatility', window );">Estimated volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument transaction cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DividendYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend yield.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DividendYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ExpectedHoldingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected holding period of equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ExpectedHoldingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ExtendedExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ExtendedExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfBoardMembersOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of Board members of the Investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfBoardMembersOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of the Company's Board members currently serving on the Investee's Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfEstimatedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of estimated volatility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfEstimatedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk free interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of additional common stock shares into which the warrants may be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI https://asc.fasb.org/extlink&amp;oid=126903467&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NameOfEventAxis=inva_QualifiedFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NameOfEventAxis=inva_QualifiedFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesCPreferredStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesCPreferredStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_Incarda2020WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_Incarda2020WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ConvertibleNoteAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ConvertibleNoteAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesA1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesA1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesD1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesD2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD1WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesD1WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesCWarrantsAndSeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesCWarrantsAndSeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD1AndD2PreferredStockAndCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesD1AndD2PreferredStockAndCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=inva_OptionPricingModelBacksolveValuationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=inva_OptionPricingModelBacksolveValuationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280528634720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in ImaginAb (Details) - ImaginAb<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Director</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs to acquire equity securities</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.70%<span></span>
</td>
<td class="nump">14.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee', window );">Number of Investee's Board members currently representing the Company | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfBoardMembersOfInvestee', window );">Number of the Investee's Board members | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="nump">4,051,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_OneOfImaginabsCommonStockholderMember', window );">One of ImaginAb's Common Stockholders | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="nump">4,097,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfBoardMembersOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of Board members of the Investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfBoardMembersOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of the Company's Board members currently serving on the Investee's Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of shares to be purchased under the terms of a securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ImaginabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ImaginabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_OneOfImaginabsCommonStockholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_OneOfImaginabsCommonStockholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280524437216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Convertible Promissory Note in Gate Neurosciences (Details) - Gate Neurosciences Member - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 24, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCommonStockIssuedDescription', window );">Number of common stock issued description</a></td>
<td class="text">The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#8220;Capped Conversion Price&#8221;) and the qualified event price (the &#8220;Qualified Event Price&#8221;). The Capped Conversion Price is calculated as $50.0 million divided by the number of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Gate are at least $35.0 million, and (iii) the stated or implied equity valuation of Gate is at least $80.0 million. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain from fair value changes in equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss from fair value changes in equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementMember', window );">Convertible Promissory Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument, Principal Payment</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCommonStockIssuedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issued description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCommonStockIssuedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_GateNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_GateNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280522704848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Nanolive (Details) - Nanolive<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 18, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 18, 2022 </div>
<div>CHF (SFr) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Director</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Transaction costs to acquire equity securities | $</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee', window );">Number of Investee's Board members currently representing the Company | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfBoardMembersOfInvestee', window );">Number of the Investee's Board members | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair value of equity securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,750,000<span></span>
</td>
<td class="nump">18,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.8<span></span>
</td>
<td class="nump">SFr 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfBoardMembersOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of Board members of the Investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfBoardMembersOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of the Company's Board members currently serving on the Investee's Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of shares to be purchased under the terms of a securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_NanoliveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_NanoliveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280523811952">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 263,469<span></span>
</td>
<td class="nump">$ 145,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">263,469<span></span>
</td>
<td class="nump">145,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Credit loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">263,469<span></span>
</td>
<td class="nump">145,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 263,469<span></span>
</td>
<td class="nump">$ 145,132<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds are included in cash and cash equivalents on the consolidated balance sheets.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280524069696">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ContingentValueRightsLiability', window );">Contingent value rights liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 595<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_IspFundLpMember', window );">ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PartnershipAgreementLockUpPeriod', window );">Lock-up period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">36 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">36 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedPartnersContributedCapital', window );">Contributed to partnership for investing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity investment | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">295,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">192,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=inva_PrivatePlacementPositionsAndConvertibleNotesMember', window );">Private Placement Positions And Convertible Notes | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">639,488<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">606,792<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">263,469<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">145,132<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Equity investments and Money market funds | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">320,560<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">195,745<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">560,546<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">489,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">265,982<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">263,469<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">145,132<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investments and Money market funds | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">193,677<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs, Level 2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,059<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">99,509<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs, Level 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70,883<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,579<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investments and Money market funds | ISP Fund LP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54,578<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,068<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ContingentValueRightsLiability', window );">Contingent value rights liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">595<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">506,259<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | Debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleSubordinatedDebtFairValueDisclosures', window );">2023 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">96,089<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">261,769<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleSeniorDebtFairValueDisclosures', window );">2025 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">197,807<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">234,498<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">211,768<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">505,664<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">496,267<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | Significant Other Observable Inputs, Level 2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">211,768<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">505,664<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">505,664<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | Significant Other Observable Inputs, Level 2 | Debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleSubordinatedDebtFairValueDisclosures', window );">2023 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">96,089<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">261,769<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleSeniorDebtFairValueDisclosures', window );">2025 Notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">197,807<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">234,498<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">496,267<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | Significant Unobservable Inputs, Level 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ContingentValueRightsLiability', window );">Contingent value rights liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">595<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">595<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Equity investment | Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,095<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">88,101<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Equity investment | Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,059<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">58,595<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,095<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">88,101<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,059<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">58,595<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">62,794<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis | Recurring basis | Equity investment | Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">62,794<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis | Recurring basis | Equity investment | Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">40,914<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">40,914<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember', window );">InCarda | Recurring basis | Equity investment | Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">605<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">411<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember', window );">InCarda | Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investment | Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">605<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">411<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_GateNeuroscienceMember', window );">Gate Neurosciences Member | Recurring basis | Convertible debt investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_GateNeuroscienceMember', window );">Gate Neurosciences Member | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">295.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in equity investments, which included private placement positions and convertible notes of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in money market funds. Our total capital contribution of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million is subject to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lock-up period from the date of such capital contributions.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million equity investments and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million money market funds, are subject to a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-month lock-up period from our initial contribution date, December 11, 2020.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ContingentValueRightsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ContingentValueRightsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConvertibleSeniorDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of long-term notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Senior debt has the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConvertibleSeniorDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConvertibleSubordinatedDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of subordinated debt obligations which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConvertibleSubordinatedDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PartnershipAgreementLockUpPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time in which contributors to an investment fund have waived the right of redemption, as defined in the partnership agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PartnershipAgreementLockUpPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of capital contributed by the limited partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_IspFundLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_IspFundLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=inva_PrivatePlacementPositionsAndConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=inva_PrivatePlacementPositionsAndConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=inva_EquityInvestmentsAndMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=inva_EquityInvestmentsAndMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_GateNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_GateNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280519286064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITALIZED FEES PAID - Schedule of Capitalized Fees Paid (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Gross carrying value</a></td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(122,393)<span></span>
</td>
<td class="num">(108,570)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Net carrying value</a></td>
<td class="nump">$ 97,607<span></span>
</td>
<td class="nump">111,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidWeightedAverageUsefulLife', window );">Weighted average remaining amortization period</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidFutureAmortizationAbstract', window );"><strong>Capitalized Fees paid, Future amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths', window );">Estimated amortization for the year 2023</a></td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo', window );">Estimated amortization for the year 2024</a></td>
<td class="nump">13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree', window );">Estimated amortization for the year 2025</a></td>
<td class="nump">13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour', window );">Estimated amortization for the year 2026</a></td>
<td class="nump">13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive', window );">Estimated amortization for the year 2027</a></td>
<td class="nump">13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive', window );">Estimated amortization after 2027</a></td>
<td class="nump">28,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization expense</a></td>
<td class="nump">13,823<span></span>
</td>
<td class="nump">13,823<span></span>
</td>
<td class="nump">$ 13,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Gross carrying value</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Gross carrying value</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Gross carrying value</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidFutureAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized fees paid future amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidFutureAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized fees paid weighted average useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280523897888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 26,713<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">5,581<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development | Collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember', window );">La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Future amortization expense, 2023</a></td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Future amortization expense, 2024</a></td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Future amortization expense, 2025</a></td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Future amortization expense, 2026</a></td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Future amortization expense, thereafter</a></td>
<td class="nump">68,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis | Collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">35,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">$ 72,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280512432864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsMarketedProductsGross', window );">Marketed products, gross carrying amount</a></td>
<td class="nump">$ 151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentGross', window );">In-process research and development, gross carrying amount</a></td>
<td class="nump">72,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsCollaborationAgreementGross', window );">Collaboration agreement, gross carrying amount</a></td>
<td class="nump">35,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total gross carrying amount</a></td>
<td class="nump">258,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsMarketedProductsAccumulatedAmortization', window );">Marketed products, Accumulated amortization</a></td>
<td class="num">(5,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(5,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsMarketedProductsNet', window );">Marketed products, net carrying amount</a></td>
<td class="nump">145,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentNet', window );">In-process research and development, net carrying amount</a></td>
<td class="nump">72,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsCollaborationAgreementNet', window );">Collaboration agreement, net carrying amount</a></td>
<td class="nump">35,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net carrying amount</a></td>
<td class="nump">$ 252,919<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Marketed products, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Marketed products, Useful Life</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsCollaborationAgreementGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets collaboration agreement gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsCollaborationAgreementGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsCollaborationAgreementNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets collaboration agreement net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsCollaborationAgreementNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsInProcessResearchAndDevelopmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount of In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsInProcessResearchAndDevelopmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsMarketedProductsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amortization amount of Marketed Products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsMarketedProductsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsMarketedProductsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of Marketed products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsMarketedProductsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsMarketedProductsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount of Marketed Products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsMarketedProductsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280528603968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Inventory, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 5,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">25,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">25,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 55,897<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280527379184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">$ 70,918<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaPharmaceuticalCompanyMember', window );">La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FairValueAdjustmentsOfInventoryFromAcquistion', window );">Fair Value Adjustments Of Inventory From Acquistion</a></td>
<td class="nump">49,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold', window );">Amortization of fair value adjustments of Cost of products sold</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of fair value adjustments of cost of products sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_FairValueAdjustmentsOfInventoryFromAcquistion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of net fair value adjustment of inventory resulting from the acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_FairValueAdjustmentsOfInventoryFromAcquistion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280517727696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule Of Other Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedContractManufacturingLiability', window );">Accrued contract manufacturing expenses</a></td>
<td class="nump">$ 8,382<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedClinicalLiability', window );">Accrued clinical expenses</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedResearchLiability', window );">Accrued research expenses</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedProfessionalServices', window );">Accrued professional services</a></td>
<td class="nump">3,977<span></span>
</td>
<td class="nump">894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredRoyaltyObligationCurrent', window );">Current portion of deferred royalty obligation</a></td>
<td class="nump">2,639<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedLicenseFeesAndRoyalties', window );">Accrued license fees and royalties</a></td>
<td class="nump">943<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other</a></td>
<td class="nump">2,909<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total other accrued liabilities</a></td>
<td class="nump">$ 21,207<span></span>
</td>
<td class="nump">$ 1,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedClinicalLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedClinicalLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedContractManufacturingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued contract manufacturing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedContractManufacturingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedLicenseFeesAndRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued license fees and royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedLicenseFeesAndRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Professional Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedResearchLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedResearchLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredRoyaltyObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of deferred royalty obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredRoyaltyObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280519306496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS -Schedule of Other Long-term Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredRoyaltyObligationNonCurrent', window );">Long-term portion of deferred royalty obligation</a></td>
<td class="nump">$ 67,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">2,376<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ContingentValueRightsLiability', window );">Contingent value rights liability</a></td>
<td class="nump">595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 70,918<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ContingentValueRightsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ContingentValueRightsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredRoyaltyObligationNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term portion of deferred royalty obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredRoyaltyObligationNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518116368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - 2012 Plan and ESPP (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Item </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inva_EquityIncentivePlan2012Member', window );">2012 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for issuance</a></td>
<td class="nump">3,838,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price as a percentage of fair market value of stock</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod', window );">Total duration of consecutive and overlapping offering periods</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods', window );">Number of offering periods | Item</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Duration of purchase period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum contributions as a percentage of employee's eligible compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares an employee may purchase during any purchase period</a></td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation', window );">Maximum value of shares an employee may purchase in a calendar year | $</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for issuance</a></td>
<td class="nump">160,995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the consecutive and overlapping offering period for the offering of share-based payment awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute of employee's eligible compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of purchase periods having duration of six months each.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the duration of each purchase period within each consecutive and overlapping purchase period for offering of share-based payment awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inva_EquityIncentivePlan2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inva_EquityIncentivePlan2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280527241088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Director Compensation Program (Details) - RSUs - Non-employee director<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>Installment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue', window );">One time grant of shares, value</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue', window );">Pro rata shares grant, value</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments', window );">Number of annual installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue', window );">Annual grant of shares, value</a></td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The additional value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of shares granted annually to independent directors upon re-election the to Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of annual installments that RSUs granted to newly appointed independent directors will vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280523817888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 7,347<span></span>
</td>
<td class="nump">$ 2,017<span></span>
</td>
<td class="nump">$ 1,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">8,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,057<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 3,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Amortization Period (Years)</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,053<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
<td class="nump">1,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 4,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Amortization Period (Years)</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Amortization Period (Years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,305<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,042<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518976544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Compensation Awards (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of outstanding options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">492,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Released RSUs/RSAs (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(295,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">948,000<span></span>
</td>
<td class="nump">766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price of Outstanding Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 20.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">14.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">17.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Released RSUs/RSAs (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">28.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">15.56<span></span>
</td>
<td class="nump">$ 20.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at the end of the period (in dollars per shares)</a></td>
<td class="nump">$ 15.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable option</a></td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term of options exercisable</a></td>
<td class="text">8 years 3 days<span></span>
</td>
<td class="text">4 years 5 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total estimated fair value of options vested</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of outstanding RSUs and PSUs/RSAs and PSAs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="nump">676,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released RSUs and RSAs (in shares)</a></td>
<td class="num">(233,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited (in shares)</a></td>
<td class="num">(41,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">518,000<span></span>
</td>
<td class="nump">116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">518,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Fair Value per Share at Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 12.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">11.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released RSUs and RSAs (in dollars per share)</a></td>
<td class="nump">9.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">8.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">12.16<span></span>
</td>
<td class="nump">$ 12.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare', window );">Vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 12.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of outstanding RSUs and PSUs/RSAs and PSAs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released RSUs and RSAs (in shares)</a></td>
<td class="num">(14,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Fair Value per Share at Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 13.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">16.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released RSUs and RSAs (in dollars per share)</a></td>
<td class="nump">13.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">14.97<span></span>
</td>
<td class="nump">$ 13.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare', window );">Vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee exercised the right during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Fair Value per Share of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280526568768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Valuation Assumptions (Details) - Stock options - Weighted-average - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 14 days<span></span>
</td>
<td class="text">6 years 1 month 9 days<span></span>
</td>
<td class="text">6 years 1 month 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">38.60%<span></span>
</td>
<td class="nump">44.90%<span></span>
</td>
<td class="nump">46.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average estimated fair value of shares granted (in dollars per share)</a></td>
<td class="nump">$ 6.43<span></span>
</td>
<td class="nump">$ 5.84<span></span>
</td>
<td class="nump">$ 6.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280524352128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - Common Stock [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 24, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount of shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock repurchased and retired during period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">647,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CommonStockAcquiredAverageCostPerShare', window );">Shares repurchased average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock repurchased and retired during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount of shares repurchased</a></td>
<td class="nump">$ 1,522,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CommonStockAcquiredAverageCostPerShare', window );">Shares repurchased average price per share</a></td>
<td class="nump">$ 12.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock repurchased and retired during period, value</a></td>
<td class="nump">$ 19,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CommonStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Acquired Average Cost Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CommonStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518052192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Schedule of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 18, 2022</div></th>
<th class="th"><div>Mar. 07, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 549,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 433,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt discount and issuance costs</a></td>
<td class="num">(9,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,831)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total debt, net</a></td>
<td class="nump">540,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Less: Current portion of long-term debt, net</a></td>
<td class="nump">96,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, net</a></td>
<td class="nump">$ 444,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_HealthCareRoyaltyPartnersMember', window );">HealthCare Royalty Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyAgreementMaximumPotentialPayoutPercent', window );">Maximum potential royalty payout</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent', window );">Increase in maximum potential payout percent</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo', window );">Maximum aggregate royalty payments</a></td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne', window );">Required payment for breach of agreement, payment one</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PaymentsForRoyaltyAgreement', window );">Payment for royalty agreement</a></td>
<td class="nump">12,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Convertible subordinated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Total debt</a></td>
<td class="nump">96,204<span></span>
</td>
<td class="nump">$ 96,200<span></span>
</td>
<td class="nump">$ 96,200<span></span>
</td>
<td class="nump">240,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt discount and issuance costs</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
<td class="num">(620)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes | Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Total debt</a></td>
<td class="nump">192,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt discount and issuance costs</a></td>
<td class="num">(1,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,211)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember', window );">2028 Notes | Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Total debt</a></td>
<td class="nump">261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt discount and issuance costs</a></td>
<td class="num">(7,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_RoyaltyFinancingAgreementMember', window );">Royalty Financing Agreement | Loans Payable [Member] | HealthCare Royalty Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest expense</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredRoyaltyObligationAndAccruedInterest', window );">Deferred royalty obligation and accrued interest</a></td>
<td class="nump">70,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyPayments', window );">Royalty Payments</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_InterestRateOfDeferredRoyaltyObligation', window );">Percentage of interest rate</a></td>
<td class="nump">7.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_RoyaltyFinancingAgreementMember', window );">Royalty Financing Agreement | Loans Payable [Member] | HealthCare Royalty Partners | Other Long Term Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyObligationPayable', window );">Royalty Obligation Payable</a></td>
<td class="nump">$ 67,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_RoyaltyFinancingAgreementMember', window );">Royalty Financing Agreement | Loans Payable [Member] | HealthCare Royalty Partners | Other Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent', window );">Short term accrued interest</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredRoyaltyObligationAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred royalty obligation and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredRoyaltyObligationAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_InterestRateOfDeferredRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate of deferred royalty obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_InterestRateOfDeferredRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PaymentsForRoyaltyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Royalty Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PaymentsForRoyaltyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty agreement increase in maximum potential payout percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyAgreementMaximumPotentialPayoutPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty agreement, maximum potential payout, percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyAgreementMaximumPotentialPayoutPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty agreement required payment for breach of agreement payment one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty agreement required payment for breach of agreement payment two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyObligationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty obligation payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyObligationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7,8)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_HealthCareRoyaltyPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_HealthCareRoyaltyPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_RoyaltyFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_RoyaltyFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=inva_OtherAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=inva_OtherAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280517531536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Convertible Subordinated Notes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 18, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 07, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2014 </div>
<div>$ / shares </div>
<div>$ / Item</div>
</th>
<th class="th">
<div>Jul. 31, 2014 </div>
<div>$ / shares </div>
<div>$ / Item </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2013 </div>
<div>USD ($) </div>
<div>Item </div>
<div>$ / shares </div>
<div>$ / Item </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Payment for repurchase of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,131,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,359,000<span></span>
</td>
<td class="nump">4,152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,662,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,704,000<span></span>
</td>
<td class="nump">433,484,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,331,000)<span></span>
</td>
<td class="num">(38,831,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Privately-negotiated capped call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCapPrice', window );">Cap price for the underlying number of shares (in dollars per share) | $ / Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.04<span></span>
</td>
<td class="nump">27.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Convertible subordinated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from issuance of notes payable, net of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConversionRate', window );">Conversion rate | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.5818<span></span>
</td>
<td class="nump">35.9903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price of convertible notes into common stock (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Portion of debt retired, face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Portion of debt retired, carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Payment for repurchase of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentRepurchasePercentage', window );">Percentage of notes repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Principal</a></td>
<td class="nump">$ 96,200,000<span></span>
</td>
<td class="nump">96,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,204,000<span></span>
</td>
<td class="nump">240,984,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="num">(620,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Net Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,193,000<span></span>
</td>
<td class="nump">240,364,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,617,000<span></span>
</td>
<td class="nump">5,121,000<span></span>
</td>
<td class="nump">5,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,000<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
<td class="nump">567,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,919,000<span></span>
</td>
<td class="nump">$ 5,701,000<span></span>
</td>
<td class="nump">$ 5,688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Convertible subordinated notes | Privately-negotiated capped call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCostOfHedge', window );">Payments for capped call options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfDerivativeInstrumentsPurchased', window );">Number of derivative instruments purchased | Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CappedCallStrikePrice', window );">Capped call strike price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.77<span></span>
</td>
<td class="nump">$ 19.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1', window );">Strike price for the underlying number of shares (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.79<span></span>
</td>
<td class="nump">$ 19.77<span></span>
</td>
<td class="nump">$ 27.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCapPrice', window );">Cap price for the underlying number of shares (in dollars per share) | $ / Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Convertible subordinated notes | Stock prices below $27.79 per share | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument', window );">Net shares settlement payable to the entity | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Convertible subordinated notes | Stock prices above $38.00 per share | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument', window );">Net shares settlement payable to the entity | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,779,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Old Rate [Member] | Convertible subordinated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | New Rate [Member] | Convertible subordinated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=inva_InnovivaCommonStockMember', window );">Innoviva's Common Stock | 2023 Notes | Convertible subordinated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notes converted into common stock, Amount</a></td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CappedCallStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capped call strike price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CappedCallStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentRepurchasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of debt Instrument, repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentRepurchasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfDerivativeInstrumentsPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of derivative instruments purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfDerivativeInstrumentsPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares payable to the entity on settlement of derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCapPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCapPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCostOfHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The premium (cost) of a hedge, expensed during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCostOfHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityStrikePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=inva_PrivatelyNegotiatedCappedCallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=inva_PrivatelyNegotiatedCappedCallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_CallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_CallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_PutOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_PutOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=inva_InnovivaCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=inva_InnovivaCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280513906208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Convertible Senior Notes (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 07, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 07, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>$ / Item</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 18, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th">
<div>Aug. 01, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2014 </div>
<div>$ / Item</div>
</th>
<th class="th">
<div>Jan. 31, 2013 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>$ / Item</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Payment for repurchase of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,131<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleDebtInstrumentLiabilityComponentAbstract', window );"><strong>Liability component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,704<span></span>
</td>
<td class="nump">433,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,331)<span></span>
</td>
<td class="num">(38,831)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Privately-negotiated capped call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCapPrice', window );">Cap price for the underlying number of shares (in dollars per share) | $ / Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage', window );">Common stock price to current conversion price ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtConversionConvertedInstrumentAverageTradePricePercentage', window );">Average trading price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Total issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Liability issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Equity issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes | ASU 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCovenantTerms', window );">Debt instrument, covenant terms description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount', window );">Ratio of repurchase price to the principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleDebtInstrumentLiabilityComponentAbstract', window );"><strong>Liability component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,500<span></span>
</td>
<td class="nump">192,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,917)<span></span>
</td>
<td class="num">(38,211)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,583<span></span>
</td>
<td class="nump">154,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Equity component, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowingsAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,813<span></span>
</td>
<td class="nump">4,813<span></span>
</td>
<td class="nump">4,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">692<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="nump">601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,898<span></span>
</td>
<td class="nump">7,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,505<span></span>
</td>
<td class="nump">13,368<span></span>
</td>
<td class="nump">12,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2025 Notes | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PortionOfDebtInstrumentFaceAmountExercised', window );">Portion of debt instrument face amount, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2025 Notes | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2025 Notes | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate for shares of common stock per $1,000 principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.9240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 15,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentConvertibleConversionPremium', window );">Conversion premium (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 15,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage', window );">Common stock price to current conversion price ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtConversionConvertedInstrumentAverageTradePricePercentage', window );">Average trading price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount', window );">Ratio of repurchase price to the principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleDebtInstrumentLiabilityComponentAbstract', window );"><strong>Liability component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowingsAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2028 Notes | Privately-negotiated capped call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCapPrice', window );">Cap price for the underlying number of shares (in dollars per share) | $ / Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.9850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes', window );">Purchases of capped calls in connection with convertible senior notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2028 Notes | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PortionOfDebtInstrumentFaceAmountExercised', window );">Portion of debt instrument face amount, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2028 Notes | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2028 Notes | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate for shares of common stock per $1,000 principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.1432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember', window );">Convertible subordinated notes | 2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt Instrument, Repurchased Face Amount</a></td>
<td class="nump">$ 144,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Payment for repurchase of debt instrument</a></td>
<td class="nump">165,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConvertibleDebtInstrumentLiabilityComponentAbstract', window );"><strong>Liability component</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Principal</a></td>
<td class="nump">96,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,204<span></span>
</td>
<td class="nump">240,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(620)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowingsAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,617<span></span>
</td>
<td class="nump">5,121<span></span>
</td>
<td class="nump">5,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,919<span></span>
</td>
<td class="nump">$ 5,701<span></span>
</td>
<td class="nump">$ 5,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember', window );">Convertible subordinated notes | 2023 Notes | Privately-negotiated capped call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCapPrice', window );">Cap price for the underlying number of shares (in dollars per share) | $ / Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConvertibleDebtInstrumentLiabilityComponentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConvertibleDebtInstrumentLiabilityComponentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of common stock price as a percentage of conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtConversionConvertedInstrumentAverageTradePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average trading price per $1,000 of Notes with respect to product of the closing common stock price and the conversion rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtConversionConvertedInstrumentAverageTradePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentConvertibleConversionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage above the last reported sale price of the Company's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentConvertibleConversionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Ratio of repurchase price to the principal amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PortionOfDebtInstrumentFaceAmountExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of debt instrument face amount, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PortionOfDebtInstrumentFaceAmountExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of capped calls In connection with convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCapPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCapPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCovenantTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the conditions for borrowing under the credit facility including the nature of any restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCovenantTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=inva_PrivatelyNegotiatedCappedCallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=inva_PrivatelyNegotiatedCappedCallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280527412352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Debt Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term debt maturities for years ending December 31:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 96,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">192,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 549,704<span></span>
</td>
<td class="nump">$ 433,484<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280528537872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - ft&#178;<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, Weighted average remaining lease term</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate', window );">Operating lease, weighted average incremental borrowing rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=inva_BurlingameCaliforniaMember', window );">Burlingame, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable square feet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=inva_WalthamMassachusettsMember', window );">Waltham Massachusetts Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Lease space</a></td>
<td class="nump">20,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Weighted Average Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=inva_BurlingameCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=inva_BurlingameCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=inva_WalthamMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=inva_WalthamMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280521928368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Components of Least Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Straight line operating lease costs</a></td>
<td class="nump">$ 1,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 1,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280527203296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Cash Flow Information Related to Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities:</a></td>
<td class="nump">$ 790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">3,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RightOfUseAssetsObtainedThroughAcquistions', window );">Right-of-use assets obtained through acquisitions</a></td>
<td class="nump">$ 1,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RightOfUseAssetsObtainedThroughAcquistions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Use Assets Obtained Through Acquistions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RightOfUseAssetsObtainedThroughAcquistions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518548720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Operating Lease Information Presented in Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Leases, Operating [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 3,265<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Liabilities, Current<span></span>
</td>
<td class="text">Liabilities, Current<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities included within Other accrued liabilities</a></td>
<td class="nump">$ 1,316<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">$ 2,376<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 3,692<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280526558480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 3,692<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280528579360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Income tax expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 40,822<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">41,286<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">26,026<span></span>
</td>
<td class="nump">70,893<span></span>
</td>
<td class="nump">60,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(625)<span></span>
</td>
<td class="nump">5,539<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">25,401<span></span>
</td>
<td class="nump">76,432<span></span>
</td>
<td class="nump">60,420<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit), net</a></td>
<td class="nump">$ 66,687<span></span>
</td>
<td class="nump">$ 76,439<span></span>
</td>
<td class="nump">$ 60,431<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280526376016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Differences between the expected U.S. federal statutory income tax to income tax expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected tax at federal statutory rate</a></td>
<td class="nump">$ 58,928<span></span>
</td>
<td class="nump">$ 93,507<span></span>
</td>
<td class="nump">$ 74,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="num">(1,414)<span></span>
</td>
<td class="nump">848<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Federal and state research credits</a></td>
<td class="num">(2,453)<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense', window );">Noncontrolling Interest</a></td>
<td class="num">(7,468)<span></span>
</td>
<td class="nump">21,626<span></span>
</td>
<td class="nump">14,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary', window );">Impact of consolidation and deconsolidation of subsidiaries</a></td>
<td class="num">(8,897)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(125)<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">13,180<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit), net</a></td>
<td class="nump">$ 66,687<span></span>
</td>
<td class="nump">$ 76,439<span></span>
</td>
<td class="nump">$ 60,431<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518205392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 149,646<span></span>
</td>
<td class="nump">$ 64,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">21,230<span></span>
</td>
<td class="nump">53,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet', window );">Unrealized loss on investment, net</a></td>
<td class="nump">6,032<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredTaxAssetsDeferredRoyaltyObligationNet', window );">Deferred royalty obligation, net</a></td>
<td class="nump">17,404<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">8,527<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets before valuation allowance</a></td>
<td class="nump">202,839<span></span>
</td>
<td class="nump">119,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(144,808)<span></span>
</td>
<td class="num">(64,744)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">58,031<span></span>
</td>
<td class="nump">54,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredTaxLiabilitiesDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(50,587)<span></span>
</td>
<td class="num">(9,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Unrealized Gain on Investment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,794)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment', window );">Inventory fair value adjustment</a></td>
<td class="num">(12,410)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(805)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,327<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Net deferred tax (liabilities)</a></td>
<td class="num">$ (5,771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredTaxAssetsDeferredRoyaltyObligationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets deferred royalty obligation, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredTaxAssetsDeferredRoyaltyObligationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets unrealized losses on investment, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredTaxLiabilitiesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation and amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredTaxLiabilitiesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities inventory fair value adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280523918688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional Tax Disclosures (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Uncertain Tax Positions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">16,324<span></span>
</td>
<td class="nump">14,872<span></span>
</td>
<td class="nump">$ 15,185<span></span>
</td>
<td class="nump">$ 15,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Net decrease in tax portions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (313)<span></span>
</td>
<td class="num">$ (157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Net increase in tax portions</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis Therapeutics Holdings Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FederalNetOperatingLossesEstimatedUtilizationAmount', window );">Federal net operating losses estimated utilization amount</a></td>
<td class="nump">157,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember', window );">La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FederalNetOperatingLossesEstimatedUtilizationAmount', window );">Federal net operating losses estimated utilization amount</a></td>
<td class="nump">254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">411,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">955,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 33,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_FederalNetOperatingLossesEstimatedUtilizationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal net operating losses estimated utilization amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_FederalNetOperatingLossesEstimatedUtilizationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140280518288816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS - Additional Information (Details) - Subsequent Event - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Armata | Secured Convertible Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility in aggregate amount</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Note Amendment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">New principal amount convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Note Amendment Agreement | New Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">New principal amount convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_SecuredConvertibleCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_SecuredConvertibleCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_NoteAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_NoteAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanRestructuringModificationAxis=inva_NewPrincipalAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanRestructuringModificationAxis=inva_NewPrincipalAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>inva-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:inva="http://www.inva.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="inva-20221231.xsd" xlink:type="simple"/>
    <context id="C_fd54577e-ca59-4227-b618-f18cb6ef69e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-07</instant>
        </period>
    </context>
    <context id="C_12567e61-7617-4c87-b922-068faca8ecd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e262e47d-f2f5-4208-90c1-3bcda7144a65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3f8a395a-d382-4590-8d7a-2cc22d27ec5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c728d113-afc3-4116-a5d3-755dcf10b52b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_aceba262-3c48-4f1a-bb24-393e5d13eb1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dbcbd115-0d6a-4e3b-8ad7-7e5315f18708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_de6c7395-9939-4c9f-99ac-cc5059cad3dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f1759049-001a-42bc-8f15-3224ecf2b407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0e7db92f-80b2-4ff0-a803-9c8f7437c5ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_aea68a38-c031-44ae-8b1c-3569bc07a0e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_80058a16-9c51-485f-8884-e6849191bd21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e61918a2-0f31-4d42-984d-dedda7b852ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3476905e-b09a-418b-a03e-4f699aa88fc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_acc278fb-4048-4edf-b4c0-fffa88f0aada">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XeravaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5d3e731d-77ad-41c9-8fb2-80c5c772794f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-07</instant>
        </period>
    </context>
    <context id="C_5ba64f62-a97d-4706-a41e-89bb10ec307f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4722bfe5-dfa7-4d44-bbd1-d47edc793461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d36b2a4f-1056-4575-a198-9dd2e9d0fa87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_bb7f1b9c-c794-42e0-872f-0ba49fe65cad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_494cf265-665e-4bbf-b3fc-fe7700a6a612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8f698f68-0c0f-4134-b100-4f1a9c7c7c0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3eb9313e-795c-4ac2-b142-a5922e05f973">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_bf93a6aa-8431-42fa-b295-0929da337285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c5fa27cc-5d17-4a15-b456-34db9e1c8687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ResearchAndDevelopmentSupportMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ed938f8f-9dc7-47dc-b811-6331bcb70bcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_11135088-2eb4-4727-a68e-256cf6c9a775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fb4a498e-2f50-4c71-a55e-558ce1139356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5c9aad10-5990-4d65-89ff-a00df760aa5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_c0c14dc4-3f99-40d8-a419-fb1d3a855ff6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-01-31</endDate>
        </period>
    </context>
    <context id="C_39cf12a7-a194-4f3f-a151-0889b4253c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1f716eb1-7bc2-436b-be0b-e1913992c7a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_24fc258b-a785-47f6-b359-705130868321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_dba05bba-de09-4343-af7e-9fb38e51a065">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5312202a-22d7-4d9a-824b-4d80ac1dd701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_4fdff83b-7c27-43e0-9faa-0d7971a875c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-01-31</endDate>
        </period>
    </context>
    <context id="C_1e690336-d9c4-4186-8f97-2aa319621487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">inva:NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="C_94397c13-ded5-4700-8d54-52976b909049">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0d5aeb89-6a39-4e78-aae5-e1088841d223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_71a8eb9a-e948-4bab-961c-28016a550572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="C_b21c6819-077d-4af6-bc82-465ef43a2339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_592136c4-250e-4250-b700-73aee7f30946">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7bb172e8-abbc-4585-873a-e59b32f846e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsAcquiredInThirdQuarterOf2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_392be0e2-bd01-417a-94b2-2ef2c1b381d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a88168cf-1d99-4dfc-90ff-08a54f07f704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e6adac0f-99fa-4f60-8e56-74a08935e56a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f935b07f-6611-49a5-95c9-c3a28c0fd4ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_82199548-5f77-4397-8b16-459c147af958">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_37b32554-8570-46f1-ad40-8f1d76b0a567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-07</instant>
        </period>
    </context>
    <context id="C_2075bc58-bfcf-44dd-85f6-c2f80538247e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_93e0e07a-b332-46ca-be2f-706ee21b9d8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_8d4db9d3-f0ac-411c-b4be-66a68e66086e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f7e84609-a139-4ee7-8f30-bd52dd4de851">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="C_c144de1c-726a-4b34-8527-25bd42031613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_93969c86-aa8a-4cdb-96b4-ca743740fab3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_3014405b-7e86-4ca8-9b06-d944fd32e11a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_936c37a5-d79d-48ab-8b0a-483fe51759c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_8a92f3b2-2579-4b68-b675-6468f004fa64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_529cdd05-9d97-48df-bfe5-ae228fa9889c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_225556d0-78ae-4d3f-a563-0e5f56e17bdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-02-24</endDate>
        </period>
    </context>
    <context id="C_a1a5f0dc-847a-45a8-ad9c-42c8df5a3705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1AndD2PreferredStockAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_41da565b-a64a-4074-a703-94289af0897b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-01</startDate>
            <endDate>2014-07-31</endDate>
        </period>
    </context>
    <context id="C_4367a010-1302-41f0-9af4-c6068dec7a67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ba934ce3-7b7f-485e-9ba2-cec7f54bb480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsAcquiredInThirdQuarterOf2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_5ade68fe-6e7d-408e-8079-b75ae0d3ebb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_611351f3-6fef-4e71-8874-413587b99402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8200e2df-4805-452f-bcfe-d016a4e29503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b6fe683b-fcbf-4fcd-a6b7-3a89c78e4ee9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-20</instant>
        </period>
    </context>
    <context id="C_2e87648d-cc31-4ce1-9ec1-efcc2c23941b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cd064fce-df3e-4265-92e6-caa1f8eccd27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_470cc2e5-a00e-4451-811a-42f58ffbce14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-20</startDate>
            <endDate>2022-07-20</endDate>
        </period>
    </context>
    <context id="C_9ce8be5c-e87f-4f02-aa59-8b21ebff6e2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4440fd71-0092-4f2b-a8d0-66d0304e4b87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-07-31</instant>
        </period>
    </context>
    <context id="C_b7c08163-5751-4218-b1ca-b2546c9f4635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_71ef9fc1-7268-4619-8fc8-2922d4e683a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:StrategicAllianceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_76ed3040-752a-4fbc-b4b9-e70787083404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:OneOfImaginabsCommonStockholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="C_8021ae84-5f41-4763-9cbd-85aedc0bb507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_62138785-e6ec-474a-9927-12031239b970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a386f2f5-a2d5-44d9-be1d-92de778d3a08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2abf6f42-38e2-40d9-a0d2-9871c5194249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-30</instant>
        </period>
    </context>
    <context id="C_8020a62f-296d-4e43-981f-bbe959befede">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_33ced285-7a79-4d44-9fd4-1c555534d19d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_d570bc58-8501-4a6e-9371-fe8bdd84afc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_ea59fe25-23ca-4e88-abc7-36f9a00934f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_50fc44f2-33ae-4838-8017-374904e41b9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b379ab38-d0be-476e-a799-edfb4d18808f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ConvertibleNoteAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-09</startDate>
            <endDate>2022-03-09</endDate>
        </period>
    </context>
    <context id="C_cee61bd9-edd6-431b-94c0-5db6bc13f016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_9d42290f-ab32-4e25-95da-79728346288a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_70bef282-aa1e-40ca-bbc9-61204a5b14c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-30</instant>
        </period>
    </context>
    <context id="C_938323ae-b1cf-434a-be7f-895d09c3f4f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_834647f0-edd8-451a-9b07-12ae7db8308b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_940c56ba-ea2f-4556-9041-85af949e6f93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_86d0f3a8-8fec-4fc2-be60-22b8b5cff09c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b3aac9f2-453c-4c3b-bd1b-f1503e5f3a1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_a5a2a364-b173-4ae1-ab6f-e2302488dee0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fc1deebf-6f63-4335-bca2-8ee328f41791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4cba0f99-f007-421e-b754-c13fe2c48144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9c4ddbeb-ee5a-4ac2-80c1-fb1faed19718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b203b0f4-9fcb-40af-9c5b-8e2482e2f95a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_375a042d-32ca-4692-acf8-8877c36d21ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_db24b4c5-31a5-4774-89a4-c8ee79bc160f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_eddd93e6-6ae6-44b1-8b18-2af265b00535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_31d13e09-7b0b-45f3-8c0c-c5750ed2e05f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="C_49c795a8-613b-4bce-862e-f82adaa95de1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="C_be6598b9-e8cb-47df-9144-93cf81d26295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cbe9c478-819e-42cc-915c-04157a313403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-24</startDate>
            <endDate>2021-11-24</endDate>
        </period>
    </context>
    <context id="C_15fd9d26-7d1b-4c32-bc1c-d97f9e0dd0c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_87e97c41-b41b-4af2-ab13-cf95548ea435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5be2f762-e576-4a23-bf25-e027f2186039">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e26b8922-044d-455a-825e-2cbd6970866c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-31</startDate>
            <endDate>2014-07-31</endDate>
        </period>
    </context>
    <context id="C_5713e251-00d3-4344-8351-32137ba92c7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_429f62d7-eb47-4068-90e0-c5530e1e1a8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1c0f3b4a-32d1-4930-9562-67d67a9ae07c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9600166d-2800-4110-aac1-2f841a170cbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_892e4f08-128a-4e39-b8ba-c31860bb66fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8a0c9ff2-8643-499c-bef2-5ff0feb5293d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_44d06045-6a65-4a7d-ad2c-0c393e7cddf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_64c565f8-b8c8-4b5e-8680-bd30e909b71f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_e0f2d71d-8e5b-4880-912e-cb4bc6a346e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c906192d-d614-4f00-bca0-46d8da21845f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:Incarda2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_c88e8766-779e-489b-97e4-b86fcdc4511b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_33e742dc-e3d7-4460-84e9-9ec66d586b4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:OneDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="C_238e19e1-e3b1-4349-834a-98123138313f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_eeedca61-ff8b-43cf-9322-e4e591891f4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-01-31</instant>
        </period>
    </context>
    <context id="C_9f672909-6502-4136-b275-680e838ad815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a2b80c7a-b827-400e-b441-ce92d2d12b34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e1aa07de-fcc2-48ae-85fd-403ac523f2e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3df3cdfa-bdca-4ba3-afb8-18a6a9c0e333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-01</instant>
        </period>
    </context>
    <context id="C_50f48cec-18c8-457e-b20c-0910ae62e850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_d4c99a87-e213-4345-a8ee-cea346b72126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a428dc65-c5ce-4719-a4dc-1d99f661076d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d061c9e4-9a0b-4b25-b83f-bf29e8dbc3c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3b24b3e3-6e06-4dcd-8419-f71edb3c36c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_760e546c-c33b-4240-91c4-bc5ba9131a71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-01-31</endDate>
        </period>
    </context>
    <context id="C_4d3c3fb3-98ab-4ad6-a151-b473b325e723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1f7d116a-6a4c-4c15-ba57-35c3c1ecdd1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:NanoliveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="C_f52e619c-c936-46d8-b929-f6e8db146294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5d0145a4-6b73-42eb-8fa3-e5ad7079aeb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8df9d62f-9d01-41f9-9bda-746317ef7f2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_98afe62c-821a-4537-b552-da050d3c5568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8a492117-f656-4dab-adc6-be5db6e4dc3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_67669f2c-13f6-4732-9377-f8c04349b09d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_c9fa8159-64b4-4582-868c-ef082d816dac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f25f9085-e7bd-462a-8c86-23de80c89333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4e529e8a-034a-4095-b62a-b22926e66498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_432870a0-b84a-44de-a37b-e2b21c245d8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ad8f45f5-b03e-455b-875b-da3585e6e901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dd16336a-4a72-4552-8d5c-b8332029c781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_85dfe886-0475-4835-8057-5fdac892ef0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_39efe5a8-fdf1-4e75-a1c6-ce190c067d56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_55981a3b-c27e-47a6-bec2-2df69c4457cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5c8ba09c-4a2f-49c9-b6ed-a569b29e1d50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5e575930-339e-44e7-8b69-11dba2c9c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_9367326d-93f1-4347-bc8c-ea4df5b4b7d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-09</instant>
        </period>
    </context>
    <context id="C_6b106910-d499-49e8-b2c4-ca13347b8e1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1aa9bc6a-6c60-4a2b-9e33-2d8d6bc2de04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GeorgeWashingtonUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2496c994-d13e-4a41-b18c-1c9ff1040e5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6e288046-0f09-4c78-b427-4c133f35ca3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_37ba5274-8715-4011-ab28-b8eda0d172d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5440a9c2-207c-4fb3-b81e-e1b717693af2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1e9dfcc6-abf8-428e-99c1-2f4e7d75a1e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2889d5e4-431b-4019-8db7-26884c76cb7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0bc981e7-59dd-45eb-91b4-c1399903b025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:StrategicAllianceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_75ae1480-904e-4b6a-9936-f2f684cc1cce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_931f2e1a-1b03-4282-9cfd-4d87cffcdb25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-01</startDate>
            <endDate>2014-07-31</endDate>
        </period>
    </context>
    <context id="C_be87ba60-82c5-4092-a52b-166288166d4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4225ffae-2b85-4646-9d44-6752e738321b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a97f4d78-4d9f-4a85-ba1d-e3c8a7909bfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesCWarrantsAndSeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a7b3b46b-f87a-4221-a2f4-8bb306339707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4cc2b7aa-5de5-44f3-bfb9-3a6bc72ba7cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_97660a37-a4d7-4e93-aa09-8f8b998393d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-08-22</endDate>
        </period>
    </context>
    <context id="C_922cb55e-d579-4403-bdee-2933b4cbd111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:NanoliveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-18</startDate>
            <endDate>2022-02-18</endDate>
        </period>
    </context>
    <context id="C_0c973e72-2f06-4c3d-9d8c-a65f18682660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="C_7b234623-662e-464a-ac46-f26ea16b01cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_04636ba8-4bff-4dfa-bb5d-8f341cc9b324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4b4d9d60-6153-4fc7-8983-cb3d99a8f061">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_b9cae3f5-7d7b-44a5-96e4-e89f716538d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4f4721dc-8199-4105-9ec9-a169e1f0086c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c518252b-f9c2-461f-b418-d8ec329b7c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">inva:OtherAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_30ae7ed9-ac4b-45ec-bc1f-029433db9949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NoteAmendmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LoanRestructuringModificationAxis">inva:NewPrincipalAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="C_3b80a067-6f7f-440f-919a-9b96d0afd716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7cb7feed-1acc-460a-b96e-c4eeb94c9ae0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_439a2891-953d-43ed-8e7a-3e4c09d85e29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">inva:OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="C_28a088e4-0dee-445b-90da-54cb1133ddc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_a0e9d271-5df5-456e-9adc-2159553bd716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e21d4ed9-45f2-4010-8231-c9ee66700c0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-24</instant>
        </period>
    </context>
    <context id="C_9efe7ef9-0fdb-45f7-9960-db3353139806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_afbd1fdf-91b2-49f5-a71e-24558788a9c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_66c13dac-92c4-4ae1-b13e-27c3b81b27cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b372f4b9-70bb-4a82-8853-c638fa566549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesA1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_f2fd0a10-b4dd-4ad0-a2ee-0219d554486f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_faceb50e-f20b-4852-8586-ecbbd210fdd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="C_e03c9a47-30dc-46ba-ba0f-c21cd67ac704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d6464796-f61e-480a-9439-0d5437aeff80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ef07e831-a84d-46db-aeb8-00314c87ec4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="inva:NameOfEventAxis">inva:QualifiedFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-09</startDate>
            <endDate>2022-03-09</endDate>
        </period>
    </context>
    <context id="C_a01857da-29eb-401d-8a40-ba6e666521ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5977bcd8-fc31-490c-827a-9db6ad3d5078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-13</startDate>
            <endDate>2022-07-13</endDate>
        </period>
    </context>
    <context id="C_2137129a-9873-421f-b2c8-dd60cf04b4e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:SarissaCapitalManagementLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6a9f3a87-35e9-4510-9ef5-42186f58a55d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_09f7a472-62b7-4efe-90de-d979015c8cfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_faf804e2-dcb7-4016-8d35-d20f9d798b45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="C_c2438911-cddb-444f-87c4-9270c2e0d009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="C_a7908317-48f4-4013-9edd-7fd23e773791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_2bb91c3f-a494-494f-95f3-8e82d7a8ba80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4b3a5f9b-38bc-43b9-a48b-838362ad8efb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b35cf83c-d2ac-4656-ba86-ef13b30bffd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_077c554a-e6a5-43dd-991a-36356231105e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dd7cfa80-9759-4df0-9de9-4910b0bcbdbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ResearchAndDevelopmentSupportMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3251587b-f79c-4e54-ba80-2c3e2d36881d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_29f0ba10-c2ca-4f06-b767-8af5d73dfda3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ab967707-220b-4a3c-b5c1-3b1d1f192c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_507fe221-0e42-48ef-9715-fb7f62c2affb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="C_53339bec-ba31-4b54-aa6a-0f92f4e9a13e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5b484229-9ff6-4262-be39-4c53a0370b53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e5766cee-a03e-4c21-8d34-5eef3d851a41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_06e9721c-182a-4413-aa61-bad3afc7b434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_16264887-a1ec-4e23-98dd-1206cc8034cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6ef35e49-a54c-4f19-af9c-bb154b983308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_35170e33-91df-4d33-a732-d1197ad1bca9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_b5fa8ada-d91d-4d2c-8821-dc19094a35f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3ec4a281-c777-436a-bc57-5fae20c64ea6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b4c52322-2f44-4631-88a7-a410b93eca72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0420bbef-96b0-4a85-a0f8-18bc3bd3a1fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0690f27e-7810-4f26-b005-086fd5e63db8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:WalthamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_df021323-12d6-4b65-922a-6ba6dda7e339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a12f3c2b-1e4a-41a5-98c5-e299cd3ff20e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-07</startDate>
            <endDate>2017-08-07</endDate>
        </period>
    </context>
    <context id="C_335d8004-849d-4d3c-98bc-66869944d3b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d412530e-32f1-46d9-9ba9-881230cd54e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b4cfe9be-7f2a-4e82-81ce-72548c7e28d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dc5624db-df9d-4192-9bd1-604ef2b78e37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9f0ef079-42c1-4987-9230-951829c1a9cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_95e0527f-161f-4b7c-9dae-e5bbe64ee040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_148b7599-6dc0-4526-80ae-e58d4cb847c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b00c2afd-3ef2-4717-a264-dd840bff9783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c4982d06-6abd-4b3b-a27d-5ce207408578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:Incarda2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f25bc928-3562-4b6b-b70a-81d5cabd17d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_5fa7258b-a8a4-4978-9f93-639f24732e53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:PrivatePlacementPositionsAndConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6c19dc5a-41dc-4631-b9f8-3af4b5d09eaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9355643f-3d44-439f-a87f-deec9514dc9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">inva:OptionPricingModelBacksolveValuationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a9729f5e-1b98-42eb-9368-262a78500403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-15</instant>
        </period>
    </context>
    <context id="C_b335fc75-9e6c-4232-9459-e0730898b34c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsAcquiredInSecondQuarterOf2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bf38e94a-771f-41f7-b87c-9a8cf1a2bfaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9bd4526f-35d6-4207-93b9-c8a7c2cbe092">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2ae54ce1-89e0-4a29-9584-2ca3a58b8d7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2989da91-3f0d-4f40-9d12-9977d248744f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_32a14238-9913-4ca5-a7cb-512e18bd93f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7a637d38-c05d-4d65-9849-9fabc00c0938">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9bfb09dd-8121-4c62-a617-c890849a7575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d59a34b7-1a2d-4e81-b069-63e808ef44cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3542ed0a-f698-456b-b13d-df3808be4d52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ca10358b-8c3c-4daf-beb4-bf93df5c5577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-01-31</endDate>
        </period>
    </context>
    <context id="C_d577f45e-f619-4e15-880c-f1fd5f863799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b353aac4-69f8-4721-bb91-b64e5c3524b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2fa03dd5-7a6f-44af-9267-849f7de0b04b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_8dd6f727-6b68-40d1-9cf3-bc4664dc52cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_5ba508af-5e54-40ad-899c-3cb351c9a5ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e4693a06-73d0-43e9-970e-27d36a30e4b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_50f6e318-ebf2-4aff-955a-5ec178352190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_77c4d3bf-3c11-40c8-aa43-61402306a12b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_99cd87c6-e3ec-4551-aa1e-6daadd1c00f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_df1e5c6b-3532-43eb-bfbb-32de7d69dfa7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1816159f-f867-4167-b36c-2cc22460814e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b36371f8-68e7-4572-9b2d-995236afdd29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-18</instant>
        </period>
    </context>
    <context id="C_192456a0-bad3-4bac-8b5f-fc4b793611f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:OneOfImaginabsCommonStockholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="C_4b40705b-aebd-47f7-baf6-3520cd3218b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0aeb2ace-977a-42ee-96fb-3b9b90a42f4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2bc5e510-4f44-48df-99c8-e241a16a04b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:SoftwareAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f30142e1-26a2-4c83-99ca-64d73afa243d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c0cc6f7b-c585-47f1-8084-1c731c93f71e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6a053a42-fce9-401c-8cfb-e85edab1757f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_974a2f30-5728-48a5-ab31-4e0b26a6014c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cd8c3695-a759-4ca6-9be7-64a5775cc175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_01ddf3ce-393e-4a0e-9c61-5439a63de921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_353f3f99-bbf5-4207-bc66-407db6f33a5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_87d07c35-75b2-4cc6-9d24-9604a851da8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e0e7a33a-815b-42a2-be04-e2cbe14d7628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e02457d0-db2e-4c20-9634-fdad76ee8508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NoteAmendmentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="C_07d0dcab-49d7-4bf5-b5eb-1625e2fe2a1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_93c757ad-d7f6-4687-bcce-bed6a5cfc531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0a4c2cad-c447-47db-88d7-dca325de6712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b8336f2e-614a-4763-8c0e-216cd28cb786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2023-02-14</instant>
        </period>
    </context>
    <context id="C_ffc2073e-976b-4b32-9c37-71e4c30ee0f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:Incarda2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_afaf4531-656e-4b03-aaf3-eae9277b1b15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_3a796252-a67b-414a-b751-63b9b85b975a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b56a4e8a-6960-4138-a57e-8ccc853dd6b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6063f5cf-dd80-437b-b1b3-9141091e7037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-09</instant>
        </period>
    </context>
    <context id="C_f9f855c6-99ff-45d5-bdf0-1bbca9152b56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8c2a82e7-af19-4a3f-9713-a56397f35d56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_873e7b0b-00b1-48d4-b5e4-b4a6e7d0eff2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EquityIncentivePlan2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_331a70dd-7cba-4846-8cf2-0dcd886d6087">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_c9ec2c09-fd7a-47dc-bc8d-518a4c5588a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_66038b3d-4a2d-4124-9988-d7ed75e02d5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_12bcde56-3f0c-4b2f-8eca-3b4cd31cef94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:NanoliveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_00652450-632d-460a-ac6b-98ad2aecada7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a7955fc6-6a0b-47e2-b852-f7b1e5cc5350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e8422a9e-f163-4920-b53e-2d0b99405fc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7f74dd91-9ab3-47f8-86b1-ab0b359a7b86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1a6e7bd4-d8ef-4aaa-8381-bf457ccf3981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_546bf034-6546-4012-bb5a-e1fa071bebc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bce10091-26f4-4aa8-ad2d-b5ecfe6c2aa9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3209a07a-0aa1-4b9b-907d-d83100cde8c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:TwoDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="C_508ec2d0-8cb9-4e9c-9ae3-821ebe4d8f78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_716be5cd-91a6-46f4-a203-c3c353f3575d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_5cd517a3-e6ab-4830-97d8-59d7687a4f18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dda65400-d844-4684-b486-4ce48278b7bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-24</startDate>
            <endDate>2021-11-24</endDate>
        </period>
    </context>
    <context id="C_dadd5411-7bb4-4843-b9b2-3fddc474ba05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:CommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2ec07c39-1f00-4f12-9dfe-a75a6a1075ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20d483d2-f9e7-4620-9d3b-694ecd5af926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b5917fe5-11ac-449e-b814-c92fd58e4ce4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_49055080-48eb-4604-9031-96d7f9cda5c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b8bfe4f9-1bc3-43e2-b056-965fbab72a8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:TrelegyElliptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e6a0ce61-2e09-425f-a9c6-2a0984724e44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_443136d7-7ad0-44e7-a11c-023a948f7f76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="C_92728848-49b6-4fe1-8f74-6dcb6ee6a998">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_94003f87-2752-45fd-9a31-20cecedf555d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_3da5364e-c3cc-4073-9770-65a8da75a030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a09a0970-3cec-406a-9c07-37e23fc89e0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_61f224cf-c012-4c9e-a814-7844fb193f6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_c69e13b2-db45-4b02-9138-80f02fcf96a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2dcd6e7e-1bb4-4f65-ae76-a45c841c8639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9e7a9b82-3d75-4c07-8fd4-3439f3f270c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b78012d3-6ecc-432d-b96a-e66ef1252516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-10</startDate>
            <endDate>2023-01-10</endDate>
        </period>
    </context>
    <context id="C_de713b03-f9a9-4480-b3f1-0fc2adfaf825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8f59c417-5760-4636-8972-e9f5a4490a93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1c21adc5-4d90-4234-8636-2bd75a4b4f4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9aeccb9a-f0c1-46ac-b1b4-641f1442275d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_91dd5dfc-a8fa-4797-a5f1-1cbcfbb0101d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0741d536-3cd1-4bb3-a3d8-4a8b9e768e1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_bfd9e7de-9f9b-458b-8962-ee3a5d4c660f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_eee47a4c-1fd8-4bc9-916a-4c43bdc117fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-17</startDate>
            <endDate>2022-02-17</endDate>
        </period>
    </context>
    <context id="C_1331927b-9f86-4b7d-81d5-27a5846306f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d1735a85-987d-4b96-a5cd-b22f73816924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_975e5da7-351c-4671-96f0-b5f31daa46d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ae9baafd-ad15-49ea-bd45-fcc80a92f494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4d7d202f-bfb9-44a0-8281-04c234b04110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b3fdbdd6-df91-4856-b880-a7ace484739f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_96b9f402-f543-4b27-a705-44de9fb1db9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_283916fc-d81b-4ecf-99aa-3b90c5c75493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:StrategicAllianceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c85a10d8-967e-4263-82f9-7532cc5b50dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-20</instant>
        </period>
    </context>
    <context id="C_1503c149-1764-496d-a943-a3df60f05cd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8b1298b5-e265-402c-a375-7a6c3874e7ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_9d895e55-890d-4019-93ff-8bf714b8997b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsAcquiredInSecondQuarterOf2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ec493f0e-c275-474e-89f4-31047349c878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_09f49082-679c-4f54-a8ef-7379e98314ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_32dbf528-70de-47c3-9e65-d8c113adb297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_875d8b01-4f11-410a-9178-6e2dadcb8eea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_547286c7-fffc-4b6d-aa24-854799abba90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="C_d895b864-cb0d-4144-94d3-dd388365edb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_4e7f2983-a46f-475a-ac66-4031d4994ae7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5afc9e88-7462-4e21-81dd-9bb66b6d8fd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_e5ee6d05-e981-4946-800e-de9d31604888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_ef336b9b-40a1-496c-9596-1c6f52048c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:NanoliveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_5344bb21-de35-4c37-a9d5-00a950034cac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b62fd465-f5dd-40eb-aa36-8c18ef36ea86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9005816e-b3a5-4468-8183-9e0fc2383e1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_90bb4c16-e20f-46dc-b959-d3bb3d63c67d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d984fd86-fecd-403b-b06f-fd6cf9bdd507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:BurlingameCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_e611e3bf-95e5-47ba-b2ae-1c43a06561de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_bb6b6c9e-02d0-4be8-b0ad-089e8436ed15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsAcquiredInSecondQuarterOf2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_f8534932-ac9d-4cc5-9b1b-d50687f54e10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_77fb24cf-b9f6-407a-ba9c-858247b06623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_421fbd90-baa7-4fc2-a696-1d4532ffc1a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:Incarda2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1c748875-71fe-4003-b725-ef74b25e3855">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="C_86b3b196-2603-41a6-85b5-4466e0d2b8da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3eed0352-afa7-4942-b39b-760e5fbff0cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f39c54bb-13a8-4982-a1a5-05cf42acdcd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-30</startDate>
            <endDate>2022-03-30</endDate>
        </period>
    </context>
    <context id="C_6a2877be-4f3b-4a25-870f-05069f62cb38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_973bdb10-2dc0-4260-8de9-4c602b8d6d62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ac5e1f2a-cef7-4391-8f23-5ab0d707cb92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-07-31</instant>
        </period>
    </context>
    <context id="C_47e6ee25-6bf5-41cf-80de-9652c932b3be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesCPreferredStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_676e4e88-33ae-4484-8dfc-e0acec87e7a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e64b6004-f679-415f-b389-067903b29e9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d8114345-dec6-4194-93e9-3a1b415dbb83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsAcquiredInSecondQuarterOf2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_ce65868a-35fd-4e2c-8c9d-86e62db676f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_eec2ed38-0112-4b50-a764-67406d54c678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2f726f21-debb-4664-8555-842fbb037578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f6111456-3ab3-4369-86bb-70377a24aea5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5825419d-fd73-4fa4-a6ed-aa1e87d36fa0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_02211f41-81dd-4ee9-8d76-5d38e227447b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3f8b66a1-3a27-4782-83da-ba9f7e42a440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bc3e2576-1b0b-4887-9679-84a1bff0d7ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_2276852d-99f8-449f-9f8f-9a1d7ddf7c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20021136-8c2b-48e8-bb1e-b92302a7d43e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_16a2d28f-c3aa-4dc0-a79e-e3f051ba1c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5d2ad42a-8c00-45ec-8588-2ffd6e64e9db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-01-31</instant>
        </period>
    </context>
    <context id="C_9ff0d1ff-97a5-44b9-b6c1-09183a2ca1b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="C_14af044e-180c-4ba7-afe8-2099db903530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_74da3b8a-5055-48ca-bb11-71f8c49ad956">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ccb9cff0-df82-484b-91d7-3221007e9ea4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_435ca12f-523f-4739-86cf-686a945e5797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_80443d0e-d8f2-4471-a9e1-605e05202133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_79aa90dd-9d5c-4099-932c-8e69511d4d22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_89b41b07-63fa-44a6-be15-5461c1916d4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-10</instant>
        </period>
    </context>
    <context id="C_a82881ba-2b0c-4f06-bda8-ddec8bb16fb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c321cb39-f5e8-42ab-b6ee-7480dacfaf27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dc90f4aa-923b-4d08-8914-8e2e4b24dcfd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_006d6f8d-3460-4b4e-a5bd-62c377110a66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_77f70987-1a99-49d7-a124-ec8a7e4706b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b3984c86-3600-4ad8-878a-2b917b585a43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_38a0f685-2b21-4d8e-aa54-1e3d3d0df2e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:OneDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="C_412716b4-7218-40f6-adc0-a9a7b2226300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_3f794c11-9aa6-4337-8539-a68ea7a89d87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-24</instant>
        </period>
    </context>
    <context id="C_7b619186-bedd-4f77-a50f-71d5615f05fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fa2052dc-83db-4d14-bb22-476be0ffb9e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d7e11212-8609-4fda-a248-41d5348f3383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6a6afb3d-ff23-4bc0-870f-2ba1de52231b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6cb7b433-593e-4c62-95c5-c68106abd3d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e25220e7-99ed-4348-b545-ac306b1dcf61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-09</instant>
        </period>
    </context>
    <context id="C_69d1b8aa-4af1-4156-8bdb-c7f20d548e88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-15</endDate>
        </period>
    </context>
    <context id="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a8932c51-4ee5-4ba0-82b7-47753c1c9a9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:CommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_83077a73-bb79-4182-b3f3-f8a33937add7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="C_46102164-0773-400f-906c-f458fc8d0c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_b92b149a-66d4-4743-8737-7ac6c96eb78c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_13412d83-cfbd-464c-9c34-a973a9caf860">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_32d6e1d8-d581-4a23-a3d6-067540daf4c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="C_d25498d0-9e4d-4ee3-9937-2ee1a353b204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_13f5a4a8-8af1-45cd-bfa0-3c008efc367c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="C_16124fa1-bc15-44d0-adf6-79a805b582fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3016f145-17f8-4f1a-82c7-f26a7aa8c466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="C_c844f75a-7bd8-4650-befd-f25662e94508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c50e19a1-f680-4297-ba13-d0cc4e167f05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">inva:InnovivaCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-17</startDate>
            <endDate>2022-04-18</endDate>
        </period>
    </context>
    <context id="C_a5469324-8168-4017-8117-1393b1043fb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_a50f2f58-78df-4b27-976a-27d61652adb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dcd3daed-e03d-43b3-995a-2376fd31c571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_836c70a9-4623-4b63-8ab6-169221b585c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8af701ba-469b-4d82-804b-8716aa0537d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-22</instant>
        </period>
    </context>
    <context id="C_9d320509-4249-4817-85c1-0897de8b2875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_40d9b41f-8564-4e43-91f2-98018ace4541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_776c1f34-bbdc-44d5-80e8-a6cccdaa9570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5dd1e719-80fe-4711-a19b-c407c3e1587a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="C_0d234c0c-f63c-4792-acb9-96224e1a9014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="C_161e223f-b687-4431-bc47-286346549fa0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:GateNeuroscienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d2c072bc-c407-4f39-8c36-301e061f1ca8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ParatekPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_86245344-c6d4-4840-98eb-541f5a63c983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9d306884-7dee-45a2-9203-d77e41d65ae4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5874bedc-4e02-4a10-b901-1e4be59451b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:TheravanceRespiratoryCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cccb0641-aa44-4b1c-a0d0-fd6d4158c2b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CollaborativeArrangementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:StrategicAllianceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fe02af8a-5018-4690-9673-9a7063d85b4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ce4ecb89-132b-48b5-b413-d18d79b1b130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="U_Director">
        <measure>inva:Director</measure>
    </unit>
    <unit id="U_UsdItem">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>inva:Item</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Item">
        <measure>inva:Item</measure>
    </unit>
    <unit id="U_Customer">
        <measure>inva:Customer</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_CHF">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="U_Tranche">
        <measure>inva:Tranche</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Installment">
        <measure>inva:Installment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_c9380da1-1d8c-4aed-8026-f9776db8418d">0001080014</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      id="F_2e85503a-2fc3-4106-aa45-a099021141e5"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_79aa90dd-9d5c-4099-932c-8e69511d4d22"
      id="F_d6ac2f39-dcb6-4aaf-82a3-69ebb7891582">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      id="F_41a23557-411b-40b9-88d7-b7d2076397f5">http://fasb.org/us-gaap/2022#LiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_f52e619c-c936-46d8-b929-f6e8db146294"
      id="F_cf0494fe-35c5-4e21-a54e-9b2134b96a37">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      id="F_890207b9-615b-4ab9-910d-0ca859f06d2a">http://fasb.org/us-gaap/2022#LiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_b5fa8ada-d91d-4d2c-8821-dc19094a35f7"
      id="F_bd486c7a-19c1-4a3e-8db9-a057cc3e8d34">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_e6a0ce61-2e09-425f-a9c6-2a0984724e44"
      id="F_490b67c1-915e-4461-9105-5bfc1a0f9c4a">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      id="F_49451cf0-b5b9-4245-8fca-d0d88b0b3246">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_1ff8c176-e5d5-4586-9991-756042d36424">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_6c19dc5a-41dc-4631-b9f8-3af4b5d09eaa"
      id="F_53358c08-6ab6-4a25-9b5c-5457a5063101">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      id="F_8a7a89c9-1023-44e8-a6a6-bd7e14049025"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:AmendmentFlag
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_55538cac-7c93-47fb-820f-c1af2a09b9f9">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      id="F_547a2096-ca1f-487c-b0b5-45f04c844618">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_b35cf83c-d2ac-4656-ba86-ef13b30bffd3"
      id="F_464685a2-4b4f-4d9b-b1f5-911c9d18b2b2">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_d984fd86-fecd-403b-b06f-fd6cf9bdd507"
      id="F_73893738-ee85-428b-aa7d-acd3031222eb">P36M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_fa641eff-3195-4693-8182-1d9e0f743f4c">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_48b0a504-5b75-4f2b-826e-46f825b25523">2022</dei:DocumentFiscalYearFocus>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_a0e9d271-5df5-456e-9adc-2159553bd716"
      id="F_9f0bad49-93fa-4614-803a-31125d7d8918">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-5"
      id="F_2214fc13-a135-4176-9e10-3d32422ab21f"
      unitRef="U_USD">13800000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive>
    <dei:DocumentType
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_dcddda3d-1ad3-4635-9cff-16a0d0d34511">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_340059d9-bc11-4383-ab1d-9898d7f40844">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_046e47cd-e27e-4b1b-96bc-bfdfbd84974d">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_4e63a6f6-ab62-4d4d-b214-66a5780910e9">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_40461f0e-70ff-48de-8736-3795d61e23c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_08c5ead1-75c3-4543-9d98-6ede24d1d4ac">000-30319</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_a6468257-5059-4262-b3df-375311a0c278">INNOVIVA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_bfc1595a-5821-4ae0-abb9-c8228f30d383">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_bbddd764-b195-4e08-b44c-3e872fa3a957">94-3265960</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_28c78492-1cdd-4539-b492-c6ee303e546d">1350 Old Bayshore Highway, Suite 400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_a67fe044-03c0-4a42-86d7-1efe0e6ce50b">Burlingame</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_5e9e63e0-2b33-44a3-afab-9c26cebfda2b">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_f9449fcd-1fe2-493a-9e41-fa0f33a50716">94010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_655df631-b48c-4b0e-b279-aff0a1be2c4e">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_f8c32672-5e0f-44f4-986b-a350667b9f17">238-9600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_6b36d678-bafa-49bf-9b5f-1cfbd0bb7273">Common Stock $0.01 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_1d2ce033-9201-4a4b-aa09-dd01bd5ba181">INVA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_9e15b5c2-7961-4ff9-94b3-6e05096283a2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_89242ff0-8be2-47a5-9a02-2ead34fec8f8">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_0d59e38f-127e-4840-9502-686c097066f0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_1b67b0a6-b90a-4179-bebd-b03c7576d308">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_2e59e8d4-7b10-4a15-a7fd-be0cbbb0e4ad">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_8c6d7867-e52c-4fb2-9001-1c632f8b8a42">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_306588a6-164a-4173-b477-27fc575cbf64">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_0c6c0d60-cb1b-4ff5-8f6e-64f13980671f">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_b90c5fa5-0f3c-42c2-89ff-9ced8b297006">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_e3903336-673e-49d7-9b6e-54b03680829b">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_d570bc58-8501-4a6e-9371-fe8bdd84afc4"
      decimals="-3"
      id="F_fd2f195a-9d3e-43e4-aa4e-62380e34a6df"
      unitRef="U_USD">923930805000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_b8336f2e-614a-4763-8c0e-216cd28cb786"
      decimals="INF"
      id="F_57d3d938-e448-47b4-b50a-ec9fa84eedc0"
      unitRef="U_shares">68126089</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_9452a3f5-7ab5-4913-9a5e-a8e5cbe3e193">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:5.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Specified portions of the registrant&#x2019;s definitive Proxy Statement to be issued in conjunction with the registrant&#x2019;s 2023 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant&#x2019;s fiscal year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, are incorporated by reference into Part III of this Annual Report. Except as expressly incorporated by reference, the registrant&#x2019;s Proxy Statement shall not be deemed to be a part of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_fe76dd6b-16e2-42e9-96e3-beb61a94c643">34</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_ffa14a0b-0669-4633-9f48-2ed1fe12cd71"
      unitRef="U_USD">291049000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_4f62bfc4-4c71-41dd-a448-e171166ed977"
      unitRef="U_USD">201525000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_9c7d6402-aeab-4103-8c8a-19e50bc4f90f"
      unitRef="U_USD">9401000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_44718965-473a-4b18-80ee-4290cac3bb05"
      unitRef="U_USD">0</us-gaap:AccountsReceivableNet>
    <us-gaap:ReceivablesLongTermContractsOrPrograms
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_a6bdb46e-bbd5-4c5a-a640-8df9dcc97773"
      unitRef="U_USD">54672000</us-gaap:ReceivablesLongTermContractsOrPrograms>
    <us-gaap:ReceivablesLongTermContractsOrPrograms
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_4f7108ed-212e-4815-ad51-5d2d0f914143"
      unitRef="U_USD">110711000</us-gaap:ReceivablesLongTermContractsOrPrograms>
    <us-gaap:InventoryNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_dacccc88-963c-4e95-94ae-e3a86194d7d8"
      unitRef="U_USD">55897000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_36adbd41-5a9d-415d-ab1e-8469998b1ec7"
      unitRef="U_USD">0</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_294d068e-2869-4653-a545-35d0c0c4c9ba"
      unitRef="U_USD">29559000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_a4166ca6-74de-4e72-8a5c-020978004e6d"
      unitRef="U_USD">1367000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_57561e5a-7f91-4180-b08a-f19364a825b9"
      unitRef="U_USD">2933000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_a8480d30-facc-46c9-bc77-955e12b7615e"
      unitRef="U_USD">70000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_16447c94-1cd2-4c24-bd57-25a3fc62fed0"
      unitRef="U_USD">443511000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_9021a528-96c0-43e3-b72a-30e62d7b67ee"
      unitRef="U_USD">313673000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_a2e638a4-da6c-4005-b87f-5955c20f4f99"
      unitRef="U_USD">170000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_b3b3848a-6d6b-40b5-80b8-ef5c3b29989e"
      unitRef="U_USD">12000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermInvestments
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_5a9ea10d-3ad6-4811-b682-968dc083406d"
      unitRef="U_USD">403013000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_4d77dc1f-5ad2-4233-952e-7fd6eca381d9"
      unitRef="U_USD">483845000</us-gaap:LongTermInvestments>
    <us-gaap:CapitalizedContractCostNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_7de93ead-579d-4e74-aef8-366e379c570e"
      unitRef="U_USD">97607000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_a0820892-d7b3-4bd2-aca5-ac191e499c97"
      unitRef="U_USD">111430000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_29ef1b62-c024-4e06-8a8e-04f7e6a25bd4"
      unitRef="U_USD">3265000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_86aa114a-7079-44e7-890c-0c82f9f6fea6"
      unitRef="U_USD">97000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_4a119989-a786-4e82-a004-390fecf27a09"
      unitRef="U_USD">26713000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_105853ef-8b1e-48ee-82d1-16d0e79b52d5"
      unitRef="U_USD">0</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_40c3f70b-5856-4220-b6dd-ea295f13a5d4"
      unitRef="U_USD">252919000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_02865d50-ae0a-4511-bc15-e8d3c06c5c81"
      unitRef="U_USD">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_9d185ecb-af69-4722-8471-72b3acbd998e"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_2b65cfd2-b3d8-4b7f-be48-057d05a17fcc"
      unitRef="U_USD">17327000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_1eacd42d-ae7a-4a9b-9d72-9e800043edbb"
      unitRef="U_USD">4299000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_6e510278-5c25-4ba8-877d-9db379200e1f"
      unitRef="U_USD">11000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_7887beb7-4756-4cde-aa97-992d5a6ae3d9"
      unitRef="U_USD">1231497000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_4b114434-a73f-4fda-aa27-8be2f3be6e14"
      unitRef="U_USD">926395000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_94987e30-8f5c-4ed5-88f6-610a1f1d1ff1"
      unitRef="U_USD">2939000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_005ee45a-7f84-4f0b-b582-c9a58331b906"
      unitRef="U_USD">27000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_15af0585-55d4-427a-91a3-fc56ef0de204"
      unitRef="U_USD">8022000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_75a4b244-1f08-40b7-bfae-f32684111dbf"
      unitRef="U_USD">619000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_33f0f984-40fe-4ced-8ecf-3349565835b6"
      unitRef="U_USD">4359000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_4fad14d9-a375-4377-86ff-2eb3157fcf18"
      unitRef="U_USD">4152000</us-gaap:InterestPayableCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_89d837f9-c748-4443-b45a-0ff20cf7b565"
      unitRef="U_USD">2094000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_a0ed24ad-e6e7-43c8-aa88-df7baab2991a"
      unitRef="U_USD">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_dfdb2276-a4ef-48f0-9df6-728b040d785a"
      unitRef="U_USD">96193000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_a293c13d-aa72-476f-b983-37f90db5e3ca"
      unitRef="U_USD">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_00ff1ae2-e0e3-499d-b588-970be21625c7"
      unitRef="U_USD">154000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_a44dcb18-7146-469c-af20-5f5ba1be3887"
      unitRef="U_USD">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_c2dad4e6-3be7-4ba7-95cd-87d4b6c5e864"
      unitRef="U_USD">21207000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_209d9899-cce9-4bc4-84ae-01c93eef1c3f"
      unitRef="U_USD">1009000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_7c89c053-42cd-4b2c-994c-fc7536184b42"
      unitRef="U_USD">134968000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_46760854-151b-4636-b68c-13d221f2a85d"
      unitRef="U_USD">5807000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_caf82ec1-e73c-4786-acaa-a9fee009883c"
      unitRef="U_USD">444180000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_64b278ca-cc00-4aec-b629-7c399fcd1454"
      unitRef="U_USD">394653000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_53cb5430-853e-4343-873b-780bd97eaa5e"
      unitRef="U_USD">70918000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_3865028c-3ce2-485c-81ec-71f3d2aa6b35"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_85f8e1d9-e743-4979-88c9-d1a3449fc97f"
      unitRef="U_USD">5771000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_c00681c1-15cf-48ee-a9df-2dfa14854e72"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <inva:IncomeTaxPayableNonCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_c69696be-17ef-4121-8f1d-cf8e5697306a"
      unitRef="U_USD">9872000</inva:IncomeTaxPayableNonCurrent>
    <inva:IncomeTaxPayableNonCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_f66f77df-2a3c-44ba-a47c-240ba6cec5c1"
      unitRef="U_USD">0</inva:IncomeTaxPayableNonCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="2"
      id="F_9aca373a-c4aa-44bd-a3c9-f9cb9e5e904f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="2"
      id="F_0463b34b-6a5b-4139-93a7-68752c17668f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_d3fcf65b-2171-4012-b6e5-2895dace5ee5"
      unitRef="U_shares">230000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_762d3acd-739c-4c44-84ac-da15b415adf4"
      unitRef="U_shares">230000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_b3c210cd-6fde-4d4a-a872-9ae62aadb282"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_82c05776-f3e0-4bb4-a41c-30e26225a8c2"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_c127a8a0-2705-4f3d-b57a-3e9cfb0f2981"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_3bd87928-62ac-4f63-a208-07abb69b69ba"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_ac94ca89-9b2d-453f-960c-290dfb9def53"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_f5bed797-68f4-4476-8f7b-cc1d75a589f2"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="2"
      id="F_4591183a-bc67-4d4a-86f8-c13e652332aa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="2"
      id="F_1cfbb424-c6e2-4ecb-8223-34be53e9a89b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_016a920b-3002-4847-9397-2c10982961b1"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_c145f654-bc24-4ad7-abb5-41a8b2f60e62"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_22dcb022-b361-40a2-b62e-f3b70ec1f56d"
      unitRef="U_shares">69188000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_3224ac6a-66ff-4c20-98e2-b548def73510"
      unitRef="U_shares">69188000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_a42ee816-3f28-4419-bfaf-9b0f55fd564f"
      unitRef="U_shares">69566000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_f17f600b-1931-4d7a-b5a5-6e39c16b8e3d"
      unitRef="U_shares">69566000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_f9609fd5-29c1-4447-aef8-e7b7bc8a13e3"
      unitRef="U_USD">692000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_bd4942f7-ac04-40a3-a9d7-b99c33968d52"
      unitRef="U_USD">696000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_081a2878-669f-4067-8ac1-9cd43a081b57"
      unitRef="U_shares">32005000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_26d4ca81-482d-464c-8718-126ecaba4946"
      unitRef="U_shares">32005000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_52c10d5f-41b1-4fbe-8a3b-56c72dae4b34"
      unitRef="U_USD">393829000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_b27496a5-0732-4ae3-ac14-af0f94abc9e3"
      unitRef="U_USD">393829000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_5a093c52-f021-4392-88dd-073489b97971"
      unitRef="U_USD">1163836000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_c9b07481-a8fe-4dd2-8cf9-25f350945e35"
      unitRef="U_USD">1264024000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_4175af08-1b81-4e3a-8996-7c115d6d59d2"
      unitRef="U_USD">-204911000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_031d486d-1237-49f0-92d8-14014dbc76da"
      unitRef="U_USD">-456148000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_5c967300-846f-43e4-b846-49747ea3129a"
      unitRef="U_USD">565788000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_77e0e694-c916-4b93-be7c-669692bd11fc"
      unitRef="U_USD">414743000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_5350fb77-5710-4ef5-8fe5-85690545377f"
      unitRef="U_USD">0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_a4f9cd8c-4fec-4312-81cc-400270d0ed48"
      unitRef="U_USD">111192000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_ffa144c5-d0d2-4301-a0b2-8df881f1ab96"
      unitRef="U_USD">565788000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_1b41bfd2-2fcf-4856-8f12-239c9c5cde34"
      unitRef="U_USD">525935000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_c241c7ee-22e3-4f19-bdc8-0a4ebdb82482"
      unitRef="U_USD">1231497000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_335284a6-b264-41fc-95b6-c7e0e3ad927a"
      unitRef="U_USD">926395000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_a01857da-29eb-401d-8a40-ba6e666521ec"
      decimals="-3"
      id="F_4f35d57f-fa4a-4eb6-85fc-deb011d40201"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_66c13dac-92c4-4ae1-b13e-27c3b81b27cd"
      decimals="-3"
      id="F_25a64ae1-c1ee-4881-be58-782816e8b64a"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_a09a0970-3cec-406a-9c07-37e23fc89e0c"
      decimals="-3"
      id="F_42b05438-b74c-4ac9-a07e-e1570dddc88b"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a01857da-29eb-401d-8a40-ba6e666521ec"
      decimals="-3"
      id="F_9980bf7e-a8aa-45aa-bcd6-a4d531eabdab"
      unitRef="U_USD">311645000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_66c13dac-92c4-4ae1-b13e-27c3b81b27cd"
      decimals="-3"
      id="F_7602cb24-d20b-4b32-bd79-3255f12ad808"
      unitRef="U_USD">391866000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a09a0970-3cec-406a-9c07-37e23fc89e0c"
      decimals="-3"
      id="F_03796f25-b984-40bc-8662-5f8056a6401d"
      unitRef="U_USD">326794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b4cfe9be-7f2a-4e82-81ce-72548c7e28d9"
      decimals="-3"
      id="F_9cbfc654-518f-49c7-9007-f7e14c4736e9"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ec493f0e-c275-474e-89f4-31047349c878"
      decimals="-3"
      id="F_87104c64-1ac3-4394-a214-1025f57fbf67"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3eed0352-afa7-4942-b39b-760e5fbff0cd"
      decimals="-3"
      id="F_15759648-29db-40d9-bcfc-ecacfda24c86"
      unitRef="U_USD">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9f672909-6502-4136-b275-680e838ad815"
      decimals="-3"
      id="F_c6a58764-1f64-448c-895a-d33433581c1f"
      unitRef="U_USD">19694000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_974a2f30-5728-48a5-ab31-4e0b26a6014c"
      decimals="-3"
      id="F_e4266e63-255d-40aa-b20a-a232ae083f35"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_85dfe886-0475-4835-8057-5fdac892ef0d"
      decimals="-3"
      id="F_441d7088-708b-4893-b543-bd3968b51688"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_5036a2dc-279e-43ec-b568-371855e6b283"
      unitRef="U_USD">331339000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_27cae3db-a7c3-41a5-a4c8-4e66d42e29fc"
      unitRef="U_USD">391866000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_8a65b3bd-8cb0-46f6-ada3-e0e8fc092029"
      unitRef="U_USD">336794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_9f672909-6502-4136-b275-680e838ad815"
      decimals="-3"
      id="F_5251dbab-4b84-4a27-97f0-270f17558c5c"
      unitRef="U_USD">13793000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_974a2f30-5728-48a5-ab31-4e0b26a6014c"
      decimals="-3"
      id="F_7eefe72b-f719-4476-963b-34b9b597c379"
      unitRef="U_USD">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_85dfe886-0475-4835-8057-5fdac892ef0d"
      decimals="-3"
      id="F_1433eba2-6924-484f-a5df-5f5bbb23c8a3"
      unitRef="U_USD">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_820df8e3-984a-42b7-abd0-549d4f3f80d7"
      unitRef="U_USD">63538000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_8328a8bd-3484-4921-9260-8e11001a824e"
      unitRef="U_USD">16187000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_865f3927-4420-4a01-b0fe-dd5cab2ae08a"
      unitRef="U_USD">13883000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_d0dcec15-614b-4e08-87fc-3855f4c77a20"
      unitRef="U_USD">41432000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_654d32de-973b-47e2-bbbf-3a7c2af06238"
      unitRef="U_USD">576000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_b17b220a-b1aa-49f1-81fe-6a301720a367"
      unitRef="U_USD">1788000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_579a6601-281d-4e90-bad4-4e994bc81bca"
      unitRef="U_USD">5581000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_a3e1c127-a32d-475b-8d3f-0fef030e9df9"
      unitRef="U_USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_b5c967bb-d7a6-4fb3-83cf-8a742b86d36d"
      unitRef="U_USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_676eff52-1be4-4509-b4d4-c9694f3b9b91"
      unitRef="U_USD">266696000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_50152f8c-4f16-4091-82e5-a1af54b38e1f"
      unitRef="U_USD">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_95b4f24c-7df3-4c42-8408-a35f2e4d6c9e"
      unitRef="U_USD">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_8c2c4353-0f84-401c-812f-53c90faa7977"
      unitRef="U_USD">-20662000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_6781e19d-f333-41da-9266-438d1225c92c"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_25e0dd87-b7aa-4645-a21b-837176e310b3"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_031b0fda-79cb-48a6-b472-ae942b6fc2da"
      unitRef="U_USD">-161749000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_3ebf0179-f8ea-4092-bfcd-de334760a1cd"
      unitRef="U_USD">84392000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_dfbf60fa-0697-4b3e-8bf5-d2f18b3426fa"
      unitRef="U_USD">49511000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <inva:GainLossOnOtherInvestments
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_4bd08421-5fde-4aed-803a-0da52d3251a1"
      unitRef="U_USD">8462000</inva:GainLossOnOtherInvestments>
    <inva:GainLossOnOtherInvestments
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_1cc63ac4-5edc-4cb9-8592-8d11a7eafae2"
      unitRef="U_USD">6638000</inva:GainLossOnOtherInvestments>
    <inva:GainLossOnOtherInvestments
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_eab60972-0044-4393-9adc-819e62a9047d"
      unitRef="U_USD">766000</inva:GainLossOnOtherInvestments>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_51e06bc7-fece-44c5-9559-357593fe6582"
      unitRef="U_USD">6369000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_da185db2-26b2-4dcf-92b0-af3a7fe3ea11"
      unitRef="U_USD">1839000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_33a64ff8-f274-4ae2-9fa7-fc0d6c6a59d9"
      unitRef="U_USD">1524000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_4f8a65ad-6c96-4d62-87c7-dde5c1875ecf"
      unitRef="U_USD">15789000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_df5f8a4f-65c5-413a-afdc-6d4bfa3149bf"
      unitRef="U_USD">19070000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_71a172d6-0a2f-465e-a4f2-3fb09568e4f3"
      unitRef="U_USD">18331000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_234460ef-5d7b-416a-a5f1-79dd6674f9be"
      unitRef="U_USD">-3373000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_c2f23237-c365-4496-a019-9264bbe6f903"
      unitRef="U_USD">-3626000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_2dd6390a-8c0b-46e9-85a5-710959855c7f"
      unitRef="U_USD">-348000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_c76b7667-109c-4698-bbaa-44c3d2ba0fe2"
      unitRef="U_USD">44390000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_d332ec06-0cba-4db8-95a4-22e7c0b7319d"
      unitRef="U_USD">-53410000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_51952bb4-9ff1-43a7-a470-d6bd8008d258"
      unitRef="U_USD">-17451000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_40ae883a-bfa7-4139-ac72-a7bd885619e9"
      unitRef="U_USD">286949000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_3cd46bfc-b19a-4c5d-847f-544a1fbe9209"
      unitRef="U_USD">445276000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_c7efd31e-05eb-4d51-8d10-9d3d156d1435"
      unitRef="U_USD">354245000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_747951dc-41dd-4a3e-b98c-0666a77faf55"
      unitRef="U_USD">66687000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_3eee3aa7-3648-4d27-b162-96b585d22705"
      unitRef="U_USD">76439000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_90f8a101-636c-4f52-9ada-422edcffdf5c"
      unitRef="U_USD">60431000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_3a915d56-b38e-4b88-8ce9-2ec3b0c18e4a"
      unitRef="U_USD">220262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_c3afd013-f484-4eb2-955e-e90e1cd085fd"
      unitRef="U_USD">368837000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_36171a20-778a-4057-8f76-b6ff824fcc78"
      unitRef="U_USD">293814000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_ac3fc47d-eff8-4e8b-b29c-f0c2f7e6b559"
      unitRef="U_USD">6341000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_d1cfdf4f-fe09-4509-a514-18178e9a5f80"
      unitRef="U_USD">102983000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_b0ecfa99-09b1-4c7a-89bc-beb06b30ef17"
      unitRef="U_USD">69412000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_6783e8dd-b3ce-4953-b20c-33ac6d55f622"
      unitRef="U_USD">213921000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_28d32350-ea3b-4ef0-bac0-13c7b987bd71"
      unitRef="U_USD">265854000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_c639770f-481e-478c-a0a6-9cadc1fa6f05"
      unitRef="U_USD">224402000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="2"
      id="F_06ccc68d-cc7d-4f28-b626-c9ff2f6a14f2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="2"
      id="F_614f9468-2428-4994-b67a-cb110eefed8a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="2"
      id="F_98c9549d-807b-44ce-af72-b5ef72b2de2d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="2"
      id="F_c1e9d898-11ea-4049-8342-f7844aaf77f9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="2"
      id="F_93640f12-509e-4a10-9165-cbefe7fb5ea6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="2"
      id="F_69de7118-fbe8-409e-b7e1-38d74adc949d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_1046bd7f-c22e-4a13-bdd5-a44e68398038"
      unitRef="U_shares">69644000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_6929fba5-5517-4bfa-a7c3-671349ae1d78"
      unitRef="U_shares">82062000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_b59dcaf3-a846-4970-a07e-841966e55e78"
      unitRef="U_shares">101320000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_7ab04d96-b731-4dd0-8eec-b140576cfa6e"
      unitRef="U_shares">95248000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_4b91e611-8f67-4cd2-b99f-954f110f82c8"
      unitRef="U_shares">94310000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_f02d1dce-9907-41a4-81ba-ca3ed24bf26c"
      unitRef="U_shares">113554000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_91f65247-1cb6-4fb6-8dd9-1391565dbcbb"
      unitRef="U_USD">220262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_2ef95e5d-eb4d-4775-bb4a-97d25c79e859"
      unitRef="U_USD">368837000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_dbb99212-8593-4fbc-b42f-85abf2571a62"
      unitRef="U_USD">293814000</us-gaap:ProfitLoss>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_6eb3dffd-ce64-4e27-8562-afde457d03e1"
      unitRef="U_USD">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_45643bf2-5976-42f5-9ad2-b2f0eccc4393"
      unitRef="U_USD">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_c787becb-00b5-4480-ac22-fa85f9c467b0"
      unitRef="U_USD">27000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_d45b7954-994f-4cf8-80ac-b437f86ab28c"
      unitRef="U_USD">220262000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_ff88aa90-9410-413e-867d-1a1e037512c7"
      unitRef="U_USD">368837000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_6462eb3a-827c-4403-b765-af7e1296f0fd"
      unitRef="U_USD">293787000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_65a661a7-f84d-4f4c-aed6-750ab4f7b630"
      unitRef="U_USD">6341000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_5724582f-2c94-4765-97ab-a8753b61efe8"
      unitRef="U_USD">102983000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_f26ec341-76ad-4b25-97e6-9005950bb1b3"
      unitRef="U_USD">69412000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_d186e011-0019-4683-9c12-47977f6c4911"
      unitRef="U_USD">213921000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_45597322-c4dc-4794-8502-d8429af54696"
      unitRef="U_USD">265854000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_857389ed-2588-4013-8b76-2ef2138201f6"
      unitRef="U_USD">224375000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_331a70dd-7cba-4846-8cf2-0dcd886d6087"
      decimals="-3"
      id="F_d135a057-7149-4241-b104-c2575e8d893a"
      unitRef="U_shares">101288000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_331a70dd-7cba-4846-8cf2-0dcd886d6087"
      decimals="-3"
      id="F_39ff3a63-80fc-46ee-b5a1-16ef09b022f4"
      unitRef="U_USD">1013000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_35170e33-91df-4d33-a732-d1197ad1bca9"
      decimals="-3"
      id="F_ec15830a-a611-4a49-9c37-2ff00df13691"
      unitRef="U_USD">1258859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b00c2afd-3ef2-4717-a264-dd840bff9783"
      decimals="-3"
      id="F_dbc899f5-6112-4b52-a7ce-38afcc85441b"
      unitRef="U_USD">27000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_716be5cd-91a6-46f4-a203-c3c353f3575d"
      decimals="-3"
      id="F_09fbd640-845e-4736-b8de-755df17eb9fe"
      unitRef="U_USD">-946404000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_94003f87-2752-45fd-9a31-20cecedf555d"
      decimals="-3"
      id="F_89242625-25cc-4a21-878c-26106f41ae5c"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_ea59fe25-23ca-4e88-abc7-36f9a00934f8"
      decimals="-3"
      id="F_f5dbb237-e847-4a94-92a1-b42b5590cbcc"
      unitRef="U_USD">28621000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_5afc9e88-7462-4e21-81dd-9bb66b6d8fd1"
      decimals="-3"
      id="F_de9f48ad-d123-469e-aad3-ea8e74c6ca8b"
      unitRef="U_USD">342116000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_8200e2df-4805-452f-bcfe-d016a4e29503"
      decimals="-3"
      id="F_2c0789d4-42fd-4c48-b420-eeccea30fb40"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_1816159f-f867-4167-b36c-2cc22460814e"
      decimals="-3"
      id="F_794b2c2c-9f8f-4775-86b9-191906fae0a2"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_16264887-a1ec-4e23-98dd-1206cc8034cf"
      decimals="-3"
      id="F_a9519bb7-bb81-435f-b517-fce6af221a63"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_de6c7395-9939-4c9f-99ac-cc5059cad3dc"
      decimals="-3"
      id="F_390f6e29-d22c-47fa-bb5e-b5292e672582"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_1a6e7bd4-d8ef-4aaa-8381-bf457ccf3981"
      decimals="-3"
      id="F_0eea3a5c-a1e5-4c1a-8cad-cb635d48ce24"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_2fa03dd5-7a6f-44af-9267-849f7de0b04b"
      decimals="-3"
      id="F_e1ca30a9-9cda-4c74-a454-45f6e3484fa0"
      unitRef="U_USD">30474000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_87e94ff7-853b-4e04-b311-221b0852b207"
      unitRef="U_USD">30474000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_8200e2df-4805-452f-bcfe-d016a4e29503"
      decimals="-3"
      id="F_6ea60851-0d58-4c2d-9a5a-67783aed8949"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_1816159f-f867-4167-b36c-2cc22460814e"
      decimals="-3"
      id="F_1f99b414-62bb-4412-84e2-77199071231f"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_16264887-a1ec-4e23-98dd-1206cc8034cf"
      decimals="-3"
      id="F_e2b8adae-3f5a-4240-8123-43b605d9b4f1"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_de6c7395-9939-4c9f-99ac-cc5059cad3dc"
      decimals="-3"
      id="F_92ba6226-615d-4113-b426-a9c939fc097c"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_1a6e7bd4-d8ef-4aaa-8381-bf457ccf3981"
      decimals="-3"
      id="F_c3e9e69b-541e-4959-9714-d0ce90385415"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_2fa03dd5-7a6f-44af-9267-849f7de0b04b"
      decimals="-3"
      id="F_fd5574ef-b326-4a41-9988-0968c45b1e84"
      unitRef="U_USD">366000</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_2d29a30b-6457-462d-8c2e-5eb784bd97bd"
      unitRef="U_USD">366000</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8"
      decimals="-3"
      id="F_b91562a1-3223-4390-aa93-e29bdeb62804"
      unitRef="U_shares">104000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8"
      decimals="-3"
      id="F_e790b98e-c29a-4531-9d8d-ec6aec832a7e"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_07d0dcab-49d7-4bf5-b5eb-1625e2fe2a1f"
      decimals="-3"
      id="F_9ce25205-8c54-49dc-86b9-4c39c1b757b8"
      unitRef="U_USD">343000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_24fc258b-a785-47f6-b359-705130868321"
      decimals="-3"
      id="F_0810c464-a1cf-43cb-b98e-fd2348dbd6bb"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_bfd9e7de-9f9b-458b-8962-ee3a5d4c660f"
      decimals="-3"
      id="F_7bac8121-b2ca-4592-9221-209110cc51e0"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_be6598b9-e8cb-47df-9144-93cf81d26295"
      decimals="-3"
      id="F_87a442b2-a1ed-45ed-bdcc-51911916ef2b"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_892e4f08-128a-4e39-b8ba-c31860bb66fe"
      decimals="-3"
      id="F_32c97ded-6560-48e3-a292-06d368617557"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_234f9bd3-ed25-4dfe-904d-618c5af2e477"
      unitRef="U_USD">344000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8200e2df-4805-452f-bcfe-d016a4e29503"
      decimals="-3"
      id="F_c60b7905-3761-40fa-ab77-3e0d40cfb4c7"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1816159f-f867-4167-b36c-2cc22460814e"
      decimals="-3"
      id="F_4b959a93-110d-4418-b1d7-b7e6b95852da"
      unitRef="U_USD">1698000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_16264887-a1ec-4e23-98dd-1206cc8034cf"
      decimals="-3"
      id="F_93338fc9-3499-40a7-a5f2-51ec9100c66b"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_de6c7395-9939-4c9f-99ac-cc5059cad3dc"
      decimals="-3"
      id="F_bea60194-c3aa-48ce-a459-86f7c0677f2e"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1a6e7bd4-d8ef-4aaa-8381-bf457ccf3981"
      decimals="-3"
      id="F_7e252729-2551-4262-a05d-0a90f9d69863"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2fa03dd5-7a6f-44af-9267-849f7de0b04b"
      decimals="-3"
      id="F_76b0cc3c-414a-4b6e-b37e-f1b43d736974"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_bf404eac-4a0b-4658-9f44-e9340692ca59"
      unitRef="U_USD">1698000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_8200e2df-4805-452f-bcfe-d016a4e29503"
      decimals="-3"
      id="F_ddb4f7b4-7efa-447c-b6b4-be4abbf052ad"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_1816159f-f867-4167-b36c-2cc22460814e"
      decimals="-3"
      id="F_e3163c86-7e90-4090-8050-3d5dca221bbe"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_16264887-a1ec-4e23-98dd-1206cc8034cf"
      decimals="-3"
      id="F_861bb67d-72bc-47f7-9df8-0c92e0273bc2"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_de6c7395-9939-4c9f-99ac-cc5059cad3dc"
      decimals="-3"
      id="F_7e4db440-5375-4187-b10b-fc3ddf312fc2"
      unitRef="U_USD">224402000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_1a6e7bd4-d8ef-4aaa-8381-bf457ccf3981"
      decimals="-3"
      id="F_b3476b7c-a16d-46d4-8978-ad354219a85f"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_2fa03dd5-7a6f-44af-9267-849f7de0b04b"
      decimals="-3"
      id="F_51f53d00-4bf9-4a7d-911a-4cf0e9cbeb44"
      unitRef="U_USD">69412000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_71097c77-f612-4f95-bb3b-5cecba18ccdb"
      unitRef="U_USD">293814000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_8200e2df-4805-452f-bcfe-d016a4e29503"
      decimals="-3"
      id="F_d42f0e0c-f5c2-455e-9ce3-90159092a672"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_1816159f-f867-4167-b36c-2cc22460814e"
      decimals="-3"
      id="F_25ff77e2-d6ee-4819-adf8-33463d7a3821"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_16264887-a1ec-4e23-98dd-1206cc8034cf"
      decimals="-3"
      id="F_bca3f635-2d02-4be2-b125-77183dd59a80"
      unitRef="U_USD">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_de6c7395-9939-4c9f-99ac-cc5059cad3dc"
      decimals="-3"
      id="F_063aaf7f-04c6-4a2c-9956-eeac8aaaea6c"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_1a6e7bd4-d8ef-4aaa-8381-bf457ccf3981"
      decimals="-3"
      id="F_dfaad911-7b70-4737-b231-8d5ea659c70a"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_2fa03dd5-7a6f-44af-9267-849f7de0b04b"
      decimals="-3"
      id="F_55f9246c-6036-40e5-aa15-217b8a35a1f7"
      unitRef="U_USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_45e675fb-a8f2-4970-b1c8-01b342634fbe"
      unitRef="U_USD">-27000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_16a2d28f-c3aa-4dc0-a79e-e3f051ba1c79"
      decimals="-3"
      id="F_b09186ca-86c0-48cc-9a96-3ff2a09f7701"
      unitRef="U_shares">101392000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_16a2d28f-c3aa-4dc0-a79e-e3f051ba1c79"
      decimals="-3"
      id="F_734364a5-0dc8-4b55-ac62-c5655b9db49f"
      unitRef="U_USD">1014000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_ed938f8f-9dc7-47dc-b811-6331bcb70bcd"
      decimals="-3"
      id="F_dd8bc3f1-29d9-454c-94a7-1eb79536e444"
      unitRef="U_USD">1260900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_99cd87c6-e3ec-4551-aa1e-6daadd1c00f9"
      decimals="-3"
      id="F_e692bbdb-f746-4b9c-ab01-88674a3ba2a3"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_9c4ddbeb-ee5a-4ac2-80c1-fb1faed19718"
      decimals="-3"
      id="F_a84c37ce-f72e-431a-899c-7f382b3dd768"
      unitRef="U_USD">-722002000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_86d0f3a8-8fec-4fc2-be60-22b8b5cff09c"
      decimals="-3"
      id="F_55261dca-5e9f-4dd1-ac57-04d3165c2b4f"
      unitRef="U_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_86d0f3a8-8fec-4fc2-be60-22b8b5cff09c"
      decimals="-3"
      id="F_f8b61098-2312-4aa0-856d-8f764d24cc63"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b3fdbdd6-df91-4856-b880-a7ace484739f"
      decimals="-3"
      id="F_af1fb753-435a-4e42-9f4d-72d55c1e45fc"
      unitRef="U_USD">67925000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f1759049-001a-42bc-8f15-3224ecf2b407"
      decimals="-3"
      id="F_55982c15-2cd0-463f-a7a4-5358d831f072"
      unitRef="U_USD">607837000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8"
      decimals="-3"
      id="F_074dae46-2263-4a60-b644-be851451480e"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_07d0dcab-49d7-4bf5-b5eb-1625e2fe2a1f"
      decimals="-3"
      id="F_96694fe0-4b9f-4650-ac82-6460b1394979"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_24fc258b-a785-47f6-b359-705130868321"
      decimals="-3"
      id="F_295688cd-569c-450f-b551-b9711e560b78"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_bfd9e7de-9f9b-458b-8962-ee3a5d4c660f"
      decimals="-3"
      id="F_51225bb9-cc37-4d5b-9fed-06590a7cd896"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_be6598b9-e8cb-47df-9144-93cf81d26295"
      decimals="-3"
      id="F_b0570ad6-ec1f-4521-a6b0-43661cc73583"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_892e4f08-128a-4e39-b8ba-c31860bb66fe"
      decimals="-3"
      id="F_fff7ce37-b4b6-4cb4-bf41-415c7a763f0d"
      unitRef="U_USD">59457000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_062f2899-9cc4-42c6-b3ef-03859af3481a"
      unitRef="U_USD">59457000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8"
      decimals="-3"
      id="F_47204fd6-3974-4edd-a7d2-7e14709a26c6"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_07d0dcab-49d7-4bf5-b5eb-1625e2fe2a1f"
      decimals="-3"
      id="F_74f51307-2171-4820-a2d2-854999295255"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_24fc258b-a785-47f6-b359-705130868321"
      decimals="-3"
      id="F_bdea1402-c62c-4f9b-8674-3fcc54842c02"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_bfd9e7de-9f9b-458b-8962-ee3a5d4c660f"
      decimals="-3"
      id="F_c4217ce7-3666-4e9f-b33e-6a7fc568b98a"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_be6598b9-e8cb-47df-9144-93cf81d26295"
      decimals="-3"
      id="F_16bbff58-b184-47a7-9517-25a1794647dc"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_892e4f08-128a-4e39-b8ba-c31860bb66fe"
      decimals="-3"
      id="F_3d8ca537-114b-4eeb-bf84-a0f0a99c9899"
      unitRef="U_USD">-259000</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_9b846cbe-0cff-46df-9b5b-c9bfb5d818a9"
      unitRef="U_USD">-259000</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_8200e2df-4805-452f-bcfe-d016a4e29503"
      decimals="-3"
      id="F_f0274f4f-206f-42db-a49c-2d66f66860d0"
      unitRef="U_shares">179000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_8200e2df-4805-452f-bcfe-d016a4e29503"
      decimals="-3"
      id="F_63ab6646-5897-49e0-9f41-8f949593de59"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_1816159f-f867-4167-b36c-2cc22460814e"
      decimals="-3"
      id="F_01dd7805-0300-457c-9311-56013624f62b"
      unitRef="U_USD">1107000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_16264887-a1ec-4e23-98dd-1206cc8034cf"
      decimals="-3"
      id="F_66e90dc2-1137-4276-bac7-fec694e8986a"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_de6c7395-9939-4c9f-99ac-cc5059cad3dc"
      decimals="-3"
      id="F_632a7d85-250e-4897-9298-0328ad72dfe8"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_1a6e7bd4-d8ef-4aaa-8381-bf457ccf3981"
      decimals="-3"
      id="F_a1caa619-e69f-41b0-b718-680597fd86a9"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_2fa03dd5-7a6f-44af-9267-849f7de0b04b"
      decimals="-3"
      id="F_3e67aeee-3000-44a8-8bcd-77970b92a211"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_693a86ef-3cce-439e-97d3-e2b8fa0ea0f5"
      unitRef="U_USD">1109000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8"
      decimals="-3"
      id="F_a32b3f27-40a6-4981-b698-77a8edfa436b"
      unitRef="U_shares">-32005000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8"
      decimals="-3"
      id="F_7d14a4ae-ec68-48b5-8454-674a6cf69d9f"
      unitRef="U_USD">320000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_07d0dcab-49d7-4bf5-b5eb-1625e2fe2a1f"
      decimals="-3"
      id="F_68625d0c-089c-46c4-b0e1-3e80802315ba"
      unitRef="U_USD">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_24fc258b-a785-47f6-b359-705130868321"
      decimals="-3"
      id="F_017bf663-6a9b-424e-98fb-68d1d4d62f2d"
      unitRef="U_USD">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_bfd9e7de-9f9b-458b-8962-ee3a5d4c660f"
      decimals="-3"
      id="F_0f34d022-838c-4b87-a369-c7c2cba19953"
      unitRef="U_USD">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="C_be6598b9-e8cb-47df-9144-93cf81d26295"
      decimals="-3"
      id="F_67dd2d7c-3ed8-4783-b9d7-01cf65881dd6"
      unitRef="U_shares">32005000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_be6598b9-e8cb-47df-9144-93cf81d26295"
      decimals="-3"
      id="F_6c7d5a9a-1101-43bf-a4ca-759196e694b5"
      unitRef="U_USD">393829000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_892e4f08-128a-4e39-b8ba-c31860bb66fe"
      decimals="-3"
      id="F_79c26418-7235-45c3-ab90-e048190a2422"
      unitRef="U_USD">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_b9113422-96fa-42ac-a1d7-0b17725aa06e"
      unitRef="U_USD">394149000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8"
      decimals="-3"
      id="F_89038a7f-af3d-4cd6-b98c-93997d9f7bbf"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_07d0dcab-49d7-4bf5-b5eb-1625e2fe2a1f"
      decimals="-3"
      id="F_85e0b262-ee0b-4e77-88f2-5ed6116c5e47"
      unitRef="U_USD">2017000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_24fc258b-a785-47f6-b359-705130868321"
      decimals="-3"
      id="F_22adb6ea-6714-4474-b786-a294441139f5"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_bfd9e7de-9f9b-458b-8962-ee3a5d4c660f"
      decimals="-3"
      id="F_169450f5-a23a-423d-a5c2-a43e5a12294d"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_be6598b9-e8cb-47df-9144-93cf81d26295"
      decimals="-3"
      id="F_fc1bc3d9-fae0-4493-a723-21c1e5be1c6c"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_892e4f08-128a-4e39-b8ba-c31860bb66fe"
      decimals="-3"
      id="F_d1f8f7a2-2930-48ff-b5e6-a38adab3a47d"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_6fd51007-aec5-4502-b6fd-b3ed5afc5e97"
      unitRef="U_USD">2017000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_1503c149-1764-496d-a943-a3df60f05cd8"
      decimals="-3"
      id="F_64ec2bef-c05b-4e23-83b5-85d9bb8b2d1d"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_07d0dcab-49d7-4bf5-b5eb-1625e2fe2a1f"
      decimals="-3"
      id="F_67b275a9-b4d0-4cc9-b85b-ed4a8d3a92d1"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_24fc258b-a785-47f6-b359-705130868321"
      decimals="-3"
      id="F_d9365f71-018d-4432-8b5d-4585b0b93e98"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_bfd9e7de-9f9b-458b-8962-ee3a5d4c660f"
      decimals="-3"
      id="F_9c3bedd8-08d2-4650-8af5-83d757230731"
      unitRef="U_USD">265854000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_be6598b9-e8cb-47df-9144-93cf81d26295"
      decimals="-3"
      id="F_62a80325-3910-4071-a32d-8a85f26a4265"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_892e4f08-128a-4e39-b8ba-c31860bb66fe"
      decimals="-3"
      id="F_3b089bf3-7a84-46ba-b61d-7dea13e6e1d0"
      unitRef="U_USD">102983000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_9484962a-7599-47b5-8b79-76710c7a7b84"
      unitRef="U_USD">368837000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_6a053a42-fce9-401c-8cfb-e85edab1757f"
      decimals="-3"
      id="F_6b47c910-9f7d-4868-9ca8-6a4ec3a2e9be"
      unitRef="U_shares">69566000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_6a053a42-fce9-401c-8cfb-e85edab1757f"
      decimals="-3"
      id="F_b1c2e370-2793-40b9-983e-d5467b15a2b6"
      unitRef="U_USD">696000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f9f855c6-99ff-45d5-bdf0-1bbca9152b56"
      decimals="-3"
      id="F_7732f461-8b97-451d-a8cd-b2358fedaf60"
      unitRef="U_USD">1264024000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_d4c99a87-e213-4345-a8ee-cea346b72126"
      decimals="-3"
      id="F_cdbf81d8-7d85-4d7e-ab1b-d6add5ee168e"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_ad8f45f5-b03e-455b-875b-da3585e6e901"
      decimals="-3"
      id="F_a45ebc92-95b9-4554-adc8-0d81ead0d104"
      unitRef="U_USD">-456148000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e6adac0f-99fa-4f60-8e56-74a08935e56a"
      decimals="-3"
      id="F_a5010f12-20ff-4f99-a423-5b7310b9a3fa"
      unitRef="U_shares">32005000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e6adac0f-99fa-4f60-8e56-74a08935e56a"
      decimals="-3"
      id="F_7119a221-55ca-4c7d-bfef-98da55da8cb8"
      unitRef="U_USD">-393829000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0aeb2ace-977a-42ee-96fb-3b9b90a42f4c"
      decimals="-3"
      id="F_ccabf4d8-f943-4108-9e6a-2dd0e896d1c4"
      unitRef="U_USD">111192000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_709f5edb-ff4a-491c-8728-6b05da9e9f17"
      unitRef="U_USD">525935000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_8a92f3b2-2579-4b68-b675-6468f004fa64"
      decimals="-3"
      id="F_090f059f-8e2f-4d99-b6e7-955ef9ac1298"
      unitRef="U_USD">65467000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_afbd1fdf-91b2-49f5-a71e-24558788a9c5"
      decimals="-3"
      id="F_f6d82fb6-d296-43eb-a437-2129ac16c4c8"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a428dc65-c5ce-4719-a4dc-1d99f661076d"
      decimals="-3"
      id="F_f3eb2ca7-9108-4303-a5f1-431127bf5dba"
      unitRef="U_USD">37238000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_592136c4-250e-4250-b700-73aee7f30946"
      decimals="-3"
      id="F_66e34e3a-a086-4826-90a6-764dd33d1db0"
      unitRef="U_USD">28229000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67"
      decimals="-3"
      id="F_8d5a09d7-b334-4740-9f22-55da19ee0c93"
      unitRef="U_USD">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8"
      decimals="-3"
      id="F_5ef049d9-eb85-411a-9bff-4f832f0433fa"
      unitRef="U_USD">69811000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_eca78dff-8079-4497-aee9-32c90680ced1"
      unitRef="U_USD">69811000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis
      contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8"
      decimals="-3"
      id="F_e2e524c5-a478-409c-b4f4-aea8a6240801"
      unitRef="U_USD">38471000</inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis>
    <inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_b5e3d9ea-65b1-41f1-b767-60e1614885fa"
      unitRef="U_USD">38471000</inva:RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67"
      decimals="-3"
      id="F_531fe12b-4e0d-41d1-85a5-6aa9a9acf638"
      unitRef="U_USD">0</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8"
      decimals="-3"
      id="F_8261dae6-d09d-4b99-9987-6774c4cddbcd"
      unitRef="U_USD">-2000</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_523f068a-5cf6-4ffc-85bd-b0347b864357"
      unitRef="U_USD">-2000</inva:ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
      contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869"
      decimals="-3"
      id="F_37e8433c-e0f3-410c-8f2f-fb7e27c5a9bd"
      unitRef="U_USD">0</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
      contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1"
      decimals="-3"
      id="F_a295b0e3-6566-41a3-a303-f3e8a3c17a58"
      unitRef="U_USD">0</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
      contextRef="C_50f6e318-ebf2-4aff-955a-5ec178352190"
      decimals="-3"
      id="F_77ed4aea-b006-4462-92c6-355d3314c434"
      unitRef="U_USD">0</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
      contextRef="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230"
      decimals="-3"
      id="F_447d8bd6-d77c-46bb-9c52-1ac7d501422f"
      unitRef="U_USD">78000</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
      contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67"
      decimals="-3"
      id="F_3ee7a65b-4f9a-486c-83ce-52de6510e0c9"
      unitRef="U_USD">0</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
      contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8"
      decimals="-3"
      id="F_18c54641-b490-48ce-9450-69c0f81dbf7e"
      unitRef="U_USD">-61304000</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc>
    <inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_e12e12c4-a6e7-4e60-a4cb-92f4ee5a2d83"
      unitRef="U_USD">-61226000</inva:DerecognitionOfNoncontrollingInterestsUponSaleOfTrc>
    <inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
      contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869"
      decimals="-3"
      id="F_ebc667bf-8e7d-4fad-a2ce-dfbaf70efa42"
      unitRef="U_USD">0</inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest>
    <inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
      contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1"
      decimals="-3"
      id="F_7596c80a-b3e6-4a9f-81c0-29013766ab6f"
      unitRef="U_USD">-14153000</inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest>
    <inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
      contextRef="C_50f6e318-ebf2-4aff-955a-5ec178352190"
      decimals="-3"
      id="F_3e0eaa13-1996-4be3-a14b-626735000f76"
      unitRef="U_USD">0</inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest>
    <inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
      contextRef="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230"
      decimals="-3"
      id="F_87c3720c-e39c-4571-acb9-f1d4f7263c50"
      unitRef="U_USD">0</inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest>
    <inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
      contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67"
      decimals="-3"
      id="F_062ab92d-31b9-4d59-b501-0e795808c3a0"
      unitRef="U_USD">0</inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest>
    <inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
      contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8"
      decimals="-3"
      id="F_b2d1fe2f-f3fb-4a92-b2ac-0eb97083618a"
      unitRef="U_USD">-28009000</inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest>
    <inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_a51a9378-3f6d-4ca5-b4c8-38a3cdc5275b"
      unitRef="U_USD">-42162000</inva:DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869"
      decimals="-3"
      id="F_d1e4bd7c-3ede-490f-9b21-c111719b6dab"
      unitRef="U_shares">269000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869"
      decimals="-3"
      id="F_d2c665eb-055b-4c93-9b8b-b8b315fd0c35"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1"
      decimals="-3"
      id="F_5ac4338b-fb4f-4b49-9cff-dceb0aa02ff8"
      unitRef="U_USD">286000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_50f6e318-ebf2-4aff-955a-5ec178352190"
      decimals="-3"
      id="F_77d46774-4880-47ea-96f6-13c224bf296b"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230"
      decimals="-3"
      id="F_3428f95d-d1d9-49e2-a349-793df9e2859b"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67"
      decimals="-3"
      id="F_0fe30b62-d595-4e41-a8ac-bb6855d59900"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8"
      decimals="-3"
      id="F_ee421b02-8dc0-4df5-9b34-bbd0932d887a"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_c5768f2b-7b28-4214-b955-578bc581d5be"
      unitRef="U_USD">288000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869"
      decimals="-3"
      id="F_f3a0716a-da6e-488b-b408-1ca03ffe01f1"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1"
      decimals="-3"
      id="F_35856006-1f60-4bee-8c3e-d7b45fadf902"
      unitRef="U_USD">-16585000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_50f6e318-ebf2-4aff-955a-5ec178352190"
      decimals="-3"
      id="F_b21506f0-fd25-4ef3-9eed-e9317d1e455d"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230"
      decimals="-3"
      id="F_284a9a2e-4607-4f00-a952-70b14f002a3e"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67"
      decimals="-3"
      id="F_717ca7ff-6a2e-483d-89db-8f514c0f9187"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8"
      decimals="-3"
      id="F_3228f643-490e-4643-9ec6-7cdc60f76606"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="INF"
      id="F_6fb20df2-c713-4500-9b49-ed994413ed6c"
      unitRef="U_USD">16585000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869"
      decimals="-3"
      id="F_c49e3994-643b-4c4c-b3a1-70e23bdae5c5"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1"
      decimals="-3"
      id="F_7182e84d-e0fe-4191-9884-648eba00026b"
      unitRef="U_USD">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="C_50f6e318-ebf2-4aff-955a-5ec178352190"
      decimals="-3"
      id="F_2c201d21-96be-4e28-95fe-c297cf00f8ef"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230"
      decimals="-3"
      id="F_9b5deffc-d12f-4612-a7ee-4869a4527c21"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67"
      decimals="-3"
      id="F_9069a23f-b1ff-48a7-a55f-a287d76583ff"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8"
      decimals="-3"
      id="F_ca2f3510-d2f8-429c-a786-5de8d93cfb77"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_c0bfa283-6f3d-4c5e-90cf-fbc5fe5cd033"
      unitRef="U_USD">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869"
      decimals="-3"
      id="F_4a4e7138-4ffd-4b11-b16e-5dadbc6014a3"
      unitRef="U_shares">-647000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869"
      decimals="-3"
      id="F_fb255e8c-3043-4fa3-83a2-df33a8f6eae4"
      unitRef="U_USD">6000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1"
      decimals="-3"
      id="F_da9cdb22-18bd-4f3c-8f60-702413495264"
      unitRef="U_USD">-8497000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_3728cf0a-470b-4865-8b4d-fed48964c4b3"
      unitRef="U_USD">8503000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869"
      decimals="-3"
      id="F_777799a1-f60a-4d86-8c50-f8dfc7b14b12"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1"
      decimals="-3"
      id="F_35887c31-5a6c-4a38-a4d1-9a75938eeb17"
      unitRef="U_USD">4225000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_50f6e318-ebf2-4aff-955a-5ec178352190"
      decimals="-3"
      id="F_c6773e86-23e9-4520-93b6-f5e48cbc3ff4"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230"
      decimals="-3"
      id="F_29e2fbf0-e0fd-4410-9b17-598ac81071b9"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67"
      decimals="-3"
      id="F_69c33f92-52ec-4c11-87a5-c2f7faf93f34"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8"
      decimals="-3"
      id="F_ed08fa3f-3c13-4758-b3c5-4846eb7f728b"
      unitRef="U_USD">3122000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_42207b40-3496-42cb-bc6f-b15eca37be28"
      unitRef="U_USD">7347000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869"
      decimals="-3"
      id="F_6a599d39-070b-4980-9f66-efdc265f45f8"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_f2bb0db9-964b-416c-bbaa-f838658b7cd1"
      decimals="-3"
      id="F_a4b3e3fe-4ebe-4e06-9951-3945147ee6f9"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_50f6e318-ebf2-4aff-955a-5ec178352190"
      decimals="-3"
      id="F_1ab98ffc-45ac-4866-90d8-4e6731382092"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_8b3e6c14-e656-40c8-ac78-cfba6f82d230"
      decimals="-3"
      id="F_17eac5cb-28be-480f-b048-e3717533180a"
      unitRef="U_USD">213921000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_4367a010-1302-41f0-9af4-c6068dec7a67"
      decimals="-3"
      id="F_8dc5a6e3-4b68-450c-ad59-5fa0711c9953"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_a50f2f58-78df-4b27-976a-27d61652adb8"
      decimals="-3"
      id="F_cc4daa1f-29a0-4d94-a1d3-16d812f581f3"
      unitRef="U_USD">6341000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_16d5a7bf-1df9-44cb-a7ca-beb4ea3ecd75"
      unitRef="U_USD">220262000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_148b7599-6dc0-4526-80ae-e58d4cb847c3"
      decimals="-3"
      id="F_f68a0c39-bc26-4fdc-aee4-d9148ade2085"
      unitRef="U_shares">69188000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_148b7599-6dc0-4526-80ae-e58d4cb847c3"
      decimals="-3"
      id="F_9d34019d-285b-426b-be51-cac46e3192ed"
      unitRef="U_USD">692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c69e13b2-db45-4b02-9138-80f02fcf96a4"
      decimals="-3"
      id="F_19222542-cf87-4448-b247-4f801b85d97e"
      unitRef="U_USD">1163836000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a7b3b46b-f87a-4221-a2f4-8bb306339707"
      decimals="-3"
      id="F_e65c7bb6-a34a-4f88-b4e4-9430ac6e5e7e"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_9aeccb9a-f0c1-46ac-b1b4-641f1442275d"
      decimals="-3"
      id="F_22cba2b9-a561-4b36-b628-3fb16c44209f"
      unitRef="U_USD">-204911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2989da91-3f0d-4f40-9d12-9977d248744f"
      decimals="-3"
      id="F_424107a3-6244-4337-b79b-8f03ce04e9e4"
      unitRef="U_shares">32005000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_2989da91-3f0d-4f40-9d12-9977d248744f"
      decimals="-3"
      id="F_7d456a8e-e401-4ba7-b62c-d349a066a359"
      unitRef="U_USD">-393829000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_ce4ecb89-132b-48b5-b413-d18d79b1b130"
      decimals="-3"
      id="F_cbc390e9-97d1-4281-8830-66249b149aba"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_a689e531-ea01-4dae-9546-a32d9c19a050"
      unitRef="U_USD">565788000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_91af4684-e08f-4dfb-a349-085e9a2baf28"
      unitRef="U_USD">220262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_df2cb629-0381-445b-a47e-75b80cf5b06d"
      unitRef="U_USD">368837000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_25709006-2088-4641-8008-d9b083a32037"
      unitRef="U_USD">293814000</us-gaap:ProfitLoss>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_56441984-a37d-441a-aa28-932b3a1117d6"
      unitRef="U_USD">25006000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_568cbc87-37d1-47a1-91ea-ac268af753e7"
      unitRef="U_USD">76432000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_00ef2583-e567-495c-878e-c56656ee6c3f"
      unitRef="U_USD">60420000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_1af5812d-7484-4e1f-84b7-e217ab8e64b6"
      unitRef="U_USD">13931000</inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment>
    <inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_0c5b066d-8a96-4d26-b07d-a44feca83b1d"
      unitRef="U_USD">13832000</inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment>
    <inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_154614c4-dc3b-46a9-9471-1eaad482e758"
      unitRef="U_USD">13840000</inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_e84ac999-30a3-409d-9f14-3fb584d8c546"
      unitRef="U_USD">5581000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_012deacb-0901-4cd3-a61a-67a27aaa9093"
      unitRef="U_USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_85450aa7-49fa-4a71-ac8d-bd18ae938e03"
      unitRef="U_USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <inva:FairValueAdjustmentsIncludedInCostOfProductSales
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_9bd0448a-4f04-432e-996b-1a31cb6f9d0c"
      unitRef="U_USD">10023000</inva:FairValueAdjustmentsIncludedInCostOfProductSales>
    <inva:FairValueAdjustmentsIncludedInCostOfProductSales
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_bacec573-7467-4da5-b7d9-2c19a5f167b0"
      unitRef="U_USD">0</inva:FairValueAdjustmentsIncludedInCostOfProductSales>
    <inva:FairValueAdjustmentsIncludedInCostOfProductSales
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_fbee73ec-3778-44f9-b31c-eb971052d6ec"
      unitRef="U_USD">0</inva:FairValueAdjustmentsIncludedInCostOfProductSales>
    <us-gaap:ShareBasedCompensation
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_796b39ca-a5e9-4593-aff3-e3419eeed3a2"
      unitRef="U_USD">7347000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_d6cbf670-6442-4657-8363-a6f407363a2b"
      unitRef="U_USD">2017000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_b690842e-3b7d-429d-bf01-413368feca3f"
      unitRef="U_USD">1698000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_e2cd0426-4163-4c75-95ff-a8ad46ecd48b"
      unitRef="U_USD">2055000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_9958f727-033d-4883-a08a-22afe367ba84"
      unitRef="U_USD">9136000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_1a813590-99d5-4950-be64-c3a4471d1ff6"
      unitRef="U_USD">8397000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_f3ed547b-169d-48b7-8c50-cf8215b1eb75"
      unitRef="U_USD">-161749000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_fd7721d1-9f28-40f8-9b4c-393dcfe732d9"
      unitRef="U_USD">84392000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_d180a1de-b778-42ed-b636-119bad335961"
      unitRef="U_USD">49511000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <inva:UnrealizedOtherGainLossOnInvestments
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_3e2edf85-fdc0-4ef5-93f8-39f86581c418"
      unitRef="U_USD">8462000</inva:UnrealizedOtherGainLossOnInvestments>
    <inva:UnrealizedOtherGainLossOnInvestments
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_ca0d45ca-2f8e-4834-b05a-a6786eb9b91e"
      unitRef="U_USD">4917000</inva:UnrealizedOtherGainLossOnInvestments>
    <inva:UnrealizedOtherGainLossOnInvestments
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_644dc88a-ab97-47e0-b355-82665d2e7c3f"
      unitRef="U_USD">766000</inva:UnrealizedOtherGainLossOnInvestments>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_ec834e49-4221-4f58-bcd0-4fffaebd3b25"
      unitRef="U_USD">-20662000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_1dd57470-0dee-4b5e-90a7-a3e79cc5c1df"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_91ac264b-bb7e-4053-a835-ca8d2dacf60c"
      unitRef="U_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_59b0ccfe-ec12-4e24-a0db-36316e35db81"
      unitRef="U_USD">266696000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_94e77ae1-2061-4cd7-a45e-9d1f81faf303"
      unitRef="U_USD">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_5f8516eb-ad7f-4252-95ad-db5adf093927"
      unitRef="U_USD">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_97b7924c-1885-49bf-9d16-443443303a91"
      unitRef="U_USD">0</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_5b8416f5-1e9f-435d-8809-5e14eae9d35b"
      unitRef="U_USD">0</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_85eafdf7-c120-4680-897b-2e96095450ed"
      unitRef="U_USD">343000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:IncreaseDecreaseInDeferredLeasingFees
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_40d489d6-3809-4bef-9910-97e64d71980f"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInDeferredLeasingFees>
    <us-gaap:IncreaseDecreaseInDeferredLeasingFees
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_bb4c6e75-61dc-40c6-8066-c31038b10472"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInDeferredLeasingFees>
    <us-gaap:IncreaseDecreaseInDeferredLeasingFees
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_a8517535-7b7f-490a-910e-3be78066543c"
      unitRef="U_USD">135000</us-gaap:IncreaseDecreaseInDeferredLeasingFees>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_96fcbc28-faba-47a5-b924-242e5bf25241"
      unitRef="U_USD">-3402000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_6533a778-303f-44bd-b4f5-d78ae825659c"
      unitRef="U_USD">259000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_a3fc6565-8340-4ece-a6e9-174281f263d9"
      unitRef="U_USD">-21000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_5fbe12d0-9621-4a34-8616-9c9f72ac50d0"
      unitRef="U_USD">3525000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_8d9fdd48-a339-4b63-9f8d-55e8c0125272"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_8944717b-2f6e-4716-949f-f082aa6527cf"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_9c88aca4-3732-41ad-aa43-6675913e6793"
      unitRef="U_USD">-13319000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_5df3d89e-e5cf-4264-86b9-bd757784b860"
      unitRef="U_USD">16780000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_a6c50541-fb7b-4f36-ae2a-29be309576b4"
      unitRef="U_USD">14504000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_e7f4c456-d718-4641-a9e6-45bbb5e58af0"
      unitRef="U_USD">-280000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_95c629ae-1154-4d87-9153-442b79a58aa7"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_2d9f3691-7d3f-4935-87bb-af4a0c320cd1"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_db341937-696f-4a3d-b90d-a76b0ecfbe7e"
      unitRef="U_USD">21350000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_a8c5bbc5-c4c8-473d-829e-6c79e0a26a0f"
      unitRef="U_USD">-203000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_fb8190e8-7f0b-4149-b220-62e5d9b2b7e3"
      unitRef="U_USD">678000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_00107acd-53f8-4752-9b07-a4a1b6fcb5c6"
      unitRef="U_USD">3341000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_036384e0-3d52-4fcd-984d-efdf65f25ec2"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_36f56be1-8944-47bc-95ab-0ffb4e8c221d"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_77033039-abec-4f2e-b4e0-4a618a1d69d7"
      unitRef="U_USD">92000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_b1330a2a-485e-4ad2-b0b8-1c1bbc558b98"
      unitRef="U_USD">-39000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_6fa56fc0-7281-4276-bba1-d4e3cd359112"
      unitRef="U_USD">56000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_b8fd0ef3-4b25-473c-acee-67054c4ed203"
      unitRef="U_USD">11913000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_20b0e5f4-1d37-4b60-9963-08ff5f510186"
      unitRef="U_USD">-257000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_ce7d37d6-9a99-435c-843d-98f43623e72a"
      unitRef="U_USD">804000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_39db0b8e-c510-40e5-9bf0-f4f506a20093"
      unitRef="U_USD">207000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_d0af0891-05b7-4b90-98f6-0db00cd22c19"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_9f877bfa-b609-4203-ba14-8f2784e54138"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_2338b206-adb5-4981-8a21-a26e35deb47a"
      unitRef="U_USD">-755000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_53e3def4-f144-48e4-828c-df34ea8ccc17"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_1cb0a8fa-5d11-412b-be2a-2d61325006eb"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_1b48086e-9913-4f12-90c8-d9dad8b6244b"
      unitRef="U_USD">10026000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_999ef877-19be-4d58-b375-47d4b5c977a5"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_f809645e-cec7-435a-ae6f-636833c27ac4"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_2238ff01-2247-40b8-948d-7b681b73f8ba"
      unitRef="U_USD">201726000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_6e0d695c-de15-44c6-b3f4-15e71b5b5d22"
      unitRef="U_USD">363813000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_edf6b218-9a2d-41f1-a2f1-7c7bbd1ecd2c"
      unitRef="U_USD">313113000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_2b4d9b3d-2f80-4ed4-9153-38c2aff37d81"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_04b899a4-6061-49a3-8788-cbdc9cd961cf"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_68944a78-3b60-400f-b621-7571e45cf3ba"
      unitRef="U_USD">86000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_e2f2b9e4-b7c9-4975-8bd7-5ed0d22c3e52"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_b4a16f3f-895f-411e-90c3-f5188e6afd08"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_d7f493a0-47bf-4ccc-8ecd-238e3849c653"
      unitRef="U_USD">12943000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_f6b64c3f-6fc5-4bb0-bb76-e703211b16ae"
      unitRef="U_USD">58725000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_27cfb315-aadc-492c-a105-731197bf1f02"
      unitRef="U_USD">66278000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_28eaacc8-1f59-47c5-b8aa-55d88870555c"
      unitRef="U_USD">87981000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <inva:PurchasesOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_c3884e75-f989-40ec-8784-d2a3a53478d7"
      unitRef="U_USD">60910000</inva:PurchasesOfEquityInvestmentsManagedByIspFundLp>
    <inva:PurchasesOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_d7fd8acb-e607-458c-bd4a-8512c2f73cf8"
      unitRef="U_USD">190970000</inva:PurchasesOfEquityInvestmentsManagedByIspFundLp>
    <inva:PurchasesOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_e7755f4c-189b-4f95-9394-7af386df074d"
      unitRef="U_USD">14877000</inva:PurchasesOfEquityInvestmentsManagedByIspFundLp>
    <inva:PurchasesOfTradingSecurityManagedByIspFundLp
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_f3964fbc-7e7d-4df8-a7f5-20251450af11"
      unitRef="U_USD">50000000</inva:PurchasesOfTradingSecurityManagedByIspFundLp>
    <inva:PurchasesOfTradingSecurityManagedByIspFundLp
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_cd94d96b-a4f6-4462-a458-907c9e97a126"
      unitRef="U_USD">0</inva:PurchasesOfTradingSecurityManagedByIspFundLp>
    <inva:PurchasesOfTradingSecurityManagedByIspFundLp
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_64a3f51d-8bb4-4202-8991-7131ee7849c0"
      unitRef="U_USD">0</inva:PurchasesOfTradingSecurityManagedByIspFundLp>
    <inva:SaleOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_bcd7aa48-f359-4ba8-9eef-e927c96238ca"
      unitRef="U_USD">24281000</inva:SaleOfEquityInvestmentsManagedByIspFundLp>
    <inva:SaleOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_06db4836-64da-40de-ab79-7053104cedb7"
      unitRef="U_USD">21440000</inva:SaleOfEquityInvestmentsManagedByIspFundLp>
    <inva:SaleOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_3745ba12-4a46-411e-a51d-5dd752defe8c"
      unitRef="U_USD">0</inva:SaleOfEquityInvestmentsManagedByIspFundLp>
    <inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_9125cc66-931b-4078-8fd8-3809f1553886"
      unitRef="U_USD">23371000</inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp>
    <inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_389feae9-188e-42b7-bef2-d2a12fd9e190"
      unitRef="U_USD">-279530000</inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp>
    <inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_546de689-eaca-4d09-9a84-ebf675d3fd7e"
      unitRef="U_USD">285123000</inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_e999159b-2eb4-4cae-8aa3-ac0894dd25d5"
      unitRef="U_USD">67000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_38b80993-a0c3-4cc7-8e1e-0be1cecec1c5"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_4e85557a-350e-46d1-8c03-a198a8cb24e5"
      unitRef="U_USD">13000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <inva:NetProceedsFromSaleOfVariableInterestEntityEquity
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_3d378007-a40d-4389-b259-94b1e62e05b7"
      unitRef="U_USD">248191000</inva:NetProceedsFromSaleOfVariableInterestEntityEquity>
    <inva:NetProceedsFromSaleOfVariableInterestEntityEquity
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_37778c14-4397-4921-8490-216efeeac7dc"
      unitRef="U_USD">0</inva:NetProceedsFromSaleOfVariableInterestEntityEquity>
    <inva:NetProceedsFromSaleOfVariableInterestEntityEquity
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_610e2219-7cc9-4a16-a2c0-1215aef4ccc1"
      unitRef="U_USD">0</inva:NetProceedsFromSaleOfVariableInterestEntityEquity>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_1584bb63-b19d-4d12-83ae-7fb094012ef8"
      unitRef="U_USD">23070000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_ee284282-5f31-417c-9b6f-9ac19e39870b"
      unitRef="U_USD">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_3e2a9d40-f079-4520-b84b-0f7c10e63bd8"
      unitRef="U_USD">0</us-gaap:CashAcquiredFromAcquisition>
    <inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_d7471a9f-54bc-45f8-ab5d-d41b3e8091e2"
      unitRef="U_USD">159103000</inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired>
    <inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_ecdd0e53-20d8-4a61-ac41-d39232bd3669"
      unitRef="U_USD">0</inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired>
    <inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_3be5f737-c367-44bd-90aa-3038589f63a1"
      unitRef="U_USD">0</inva:CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_4fc91531-5f0e-45f4-8c23-51109ad96045"
      unitRef="U_USD">-56634000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_7c8dbaa7-22a9-4b3d-9130-7db013b11ee6"
      unitRef="U_USD">43722000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_09b53f0e-47b0-40fa-8df1-8fc27f75d31f"
      unitRef="U_USD">-314937000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_4e92123b-654d-4ff4-b78e-e80d05a87943"
      unitRef="U_USD">69811000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_013cdd14-5121-4f4d-ac8d-860be00cc0fd"
      unitRef="U_USD">59457000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_899db423-39da-4ff3-be5e-c8d435f83466"
      unitRef="U_USD">30474000</us-gaap:PaymentsToMinorityShareholders>
    <inva:PurchaseOfEntasisNoncontrollingInterest
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_8c5527c6-07e2-49ae-9409-5c573e379d66"
      unitRef="U_USD">43910000</inva:PurchaseOfEntasisNoncontrollingInterest>
    <inva:PurchaseOfEntasisNoncontrollingInterest
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_c785063c-3f43-4667-9cd3-e51f2e6f1583"
      unitRef="U_USD">0</inva:PurchaseOfEntasisNoncontrollingInterest>
    <inva:PurchaseOfEntasisNoncontrollingInterest
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_27d118fa-240e-46ee-880b-15a01fb0ffbf"
      unitRef="U_USD">0</inva:PurchaseOfEntasisNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_4235e96b-14bf-460d-b1e9-d83bde91013f"
      unitRef="U_USD">8503000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_4dfa4ca9-8d8c-4ddb-b44a-0fb9354524bf"
      unitRef="U_USD">394149000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_f7d9d33b-4f0b-4c6b-a35f-a998e8326e81"
      unitRef="U_USD">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_5db59ffb-176a-4e2d-998a-aad93d1911df"
      unitRef="U_USD">82000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_091750fa-56ee-42c7-83cb-2d4d49611d45"
      unitRef="U_USD">60000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_2fada53b-38b4-44ed-9bcf-2ac8f688a0eb"
      unitRef="U_USD">92000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_8109a26e-db9b-40b7-8a52-994752be034c"
      unitRef="U_USD">370000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_58242b74-a7c2-4ebd-89ef-e7d7f2f80c0e"
      unitRef="U_USD">1169000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_eee6ad8f-bb3f-4cd8-a82f-b8bd99a498a2"
      unitRef="U_USD">436000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <inva:NetProceedsFromIssuanceOfVariableInterestEntityEquity
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_675ecd08-909a-4ad8-9dc3-6848ac29bd85"
      unitRef="U_USD">0</inva:NetProceedsFromIssuanceOfVariableInterestEntityEquity>
    <inva:NetProceedsFromIssuanceOfVariableInterestEntityEquity
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_936fe78f-d79c-46e9-820c-cea40e739657"
      unitRef="U_USD">0</inva:NetProceedsFromIssuanceOfVariableInterestEntityEquity>
    <inva:NetProceedsFromIssuanceOfVariableInterestEntityEquity
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_f1c400ba-0318-4bdf-905b-93f315c62d1c"
      unitRef="U_USD">345000</inva:NetProceedsFromIssuanceOfVariableInterestEntityEquity>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_6ddf8638-1437-4ec9-a180-aa963c1c74b5"
      unitRef="U_USD">165131000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_230682b6-142c-4db3-956b-f8c16d816ed4"
      unitRef="U_USD">0</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_02da083f-dc6a-44d9-9694-dd2704261336"
      unitRef="U_USD">0</us-gaap:RepaymentsOfUnsecuredDebt>
    <inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_992416e6-1a5f-4bdc-9cf0-e07d3039460a"
      unitRef="U_USD">21037000</inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes>
    <inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_7d3b11f7-ff65-45a7-8e9a-8814f7e18faa"
      unitRef="U_USD">0</inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes>
    <inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_fd4b1d8b-56fd-430c-bbcb-8bec5b1ca2fd"
      unitRef="U_USD">0</inva:PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_af24e247-30b5-4399-b0cb-f3c2f046769d"
      unitRef="U_USD">252536000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_b07f017c-0501-4205-861c-abafff2e62e8"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_07308d06-a996-4602-af20-975a5b4d1ac7"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_86de4f7c-b528-4940-900a-44406e577eaa"
      unitRef="U_USD">-55568000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_933d2be9-a133-49a0-9060-21bd253d56fd"
      unitRef="U_USD">-452497000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_dbd7515e-d759-475b-8abb-0f6895b7ca57"
      unitRef="U_USD">-29785000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_16e84fb5-47be-4925-8d90-488ca2a579da"
      unitRef="U_USD">89524000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_f542074c-64c4-4bd5-abf8-7175fd4edf96"
      unitRef="U_USD">-44962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_e7d09422-fa25-4b0d-a42b-fb9c34f2dade"
      unitRef="U_USD">-31609000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_6dad4e6a-f0d9-4f66-8f29-51615e4a9d16"
      unitRef="U_USD">201525000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_f1759049-001a-42bc-8f15-3224ecf2b407"
      decimals="-3"
      id="F_3284f99e-1678-4ada-9f01-2ccb187f4ee8"
      unitRef="U_USD">246487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_5afc9e88-7462-4e21-81dd-9bb66b6d8fd1"
      decimals="-3"
      id="F_a467ee7d-5ab8-4159-a71f-a4d4faa4cd4f"
      unitRef="U_USD">278096000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_9783d2d1-d713-4bb9-ae50-c7bdb1d49f79"
      unitRef="U_USD">291049000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_d5900507-1b4d-4a45-a286-7c22e6bc9af8"
      unitRef="U_USD">201525000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_f1759049-001a-42bc-8f15-3224ecf2b407"
      decimals="-3"
      id="F_98a168e5-71a4-4239-a25f-0356e00b9041"
      unitRef="U_USD">246487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_896840db-6f26-4b9d-a7bb-fbe14169b45d"
      unitRef="U_USD">11736000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_11c20919-2cab-4bd5-b281-d97216be538b"
      unitRef="U_USD">9933000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_16300703-62b7-483b-a73a-904b1e24d0c3"
      unitRef="U_USD">9933000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_32ee0e8c-b51b-4753-a91e-1ea305d99a31"
      unitRef="U_USD">53855000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_4b00da6b-9ea7-413d-a700-5e174185fb8e"
      unitRef="U_USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_53b928ca-fe7c-487c-8a19-c52ce3493488"
      unitRef="U_USD">0</us-gaap:IncomeTaxesPaidNet>
    <inva:NonCashActivity
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_64478ebf-a799-4b7d-aff8-9b6ddf61c9fc"
      unitRef="U_USD">-28228000</inva:NonCashActivity>
    <inva:NonCashActivity
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_f6707fd3-9ac7-4d6b-9592-7c3d7c29e5d9"
      unitRef="U_USD">0</inva:NonCashActivity>
    <inva:NonCashActivity
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_fbf869cc-6494-47b0-830c-1990ba4ef7ed"
      unitRef="U_USD">0</inva:NonCashActivity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_16c4f3e2-77f0-4fcd-b81a-0746dad96288">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.  DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Description of Operations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Innoviva, Inc. (referred to as &#x201c;Innoviva&#x201d;, the &#x201c;Company&#x201d;, or &#x201c;we&#x201d; and other similar pronouns) is a company with a portfolio of royalties and innovative healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#x201c;GSK&#x201d;), including RELVAR&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(fluticasone furoate/vilanterol, &#x201c;FF/VI&#x201d;) and ANORO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(umeclidinium bromide/vilanterol, &#x201c;UMEC/VI&#x201d;), and up until July 2022, TRELEGY&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(the combination FF/UMEC/VI). We sold our &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% ownership interest in Theravance Respiratory Company, LLC (&#x201c;TRC&#x201d;) on July 20, 2022, and are no longer entitled to receive royalties on sales of TRELEGY&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; products. Under the Long-Acting Beta2 Agonist (&#x201c;LABA&#x201d;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as follows: &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% on the first $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion of annual global net sales and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% for all annual global net sales above $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion; and royalties from the sales of ANORO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which tier upward at a range from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We expanded our portfolio of royalties and innovative healthcare assets through the acquisition of Entasis Therapeutics Holdings Inc. (&#x201c;Entasis&#x201d;) on July 11, 2022 and the acquisition of La Jolla Pharmaceutical Company (&#x201c;La Jolla&#x201d;) on August 22, 2022. Our commercial and marketed products include GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Our development pipeline includes medicines for the treatment of bacterial infections, such as our lead asset sulbactam-durlobactam (&#x201c;SUL-DUR&#x201d;). As such, we have a wholly owned robust infectious disease and hospital operating platform, as well as other assets in these areas, such as a large equity stake in Armata Pharmaceuticals, a leader in bacteriophage development with potential use across a range of infectious and other serious diseases.  We also have economic interests in other healthcare companies.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#x201c;VIE&#x201d;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Presentation Reclassification&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certain amounts in prepaid expenses and other current assets, other assets and changes in fair values of equity and long-term investments, net, reported in the Company's prior year financial statements have been reclassified to conform to the current year presentation. These reclassifications had no net effect on the net income or net cash flows as previously reported.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Factors Affecting Comparability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors below and as discussed in Note 5, &#x201c;Consolidated Entities and Acquisitions&#x201d;.&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Adoption of Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06 effective January 1, 2022;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining noncontrolling interest in Entasis on July 11, 2022;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sale of our &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% ownership interest in TRC on July 20, 2022; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Acquisition of La Jolla on August 22, 2022.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Management&#x2019;s Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and of Significant Suppliers and Partners&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#x201c;API&#x201d;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK&#x2019;s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Our royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts&#x2019; or investors&#x2019; expectations, due to a number of important factors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We also started recognizing revenue from product sales as a result of our acquisition of La Jolla Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Three&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of our customers each account for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, respectively, of our net product sales from the time of our acquisition of La Jolla through &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. These same customers account for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, respectively, of our receivables from net product sales, which are included in &#x201c;Accounts receivables, net&#x201d; on our consolidated balance sheet as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We operate in a single segment, which is to provide capital return to stockholders by maximizing the potential value of our portfolio of royalties and innovative healthcare assets. Our Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Innoviva at the consolidated level using information about our revenues, operating results and other key financial data as needed. Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net sales of GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Refer to Note 3, &#x201c;Revenue Recognition&#x201d;, for more information on our revenues for the periods presented. Our long-term assets are located within the United States.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Variable Interest Entities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The primary beneficiary of a variable interest entity (&#x201c;VIE&#x2019;) is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#x2019;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#x2019;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Business Combination&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When we acquire an entity in a business combination, we recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establish the acquisition date as the fair value measurement point. We recognize and measure goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. Acquisition-related expenses and related restructuring costs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, we typically use the income method. This method starts with a forecast of all of the expected future net cash flows for each asset. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Some of the more significant estimates and assumptions inherent in the income method or other methods include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows and the assessment of the asset&#x2019;s life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory, or economic barriers to entry. Determining the useful life of an intangible asset also requires judgment as different types of intangible assets will have different useful lives and certain assets may even be considered to have indefinite useful lives.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We invest in short-term investments and marketable securities, primarily corporate notes, government securities, government agencies, and government commercial papers. We limit the amount of credit exposure with any one issuer, industry or geographic area for investments other than instruments backed by the U.S. federal government. We classify our marketable securities as available-for-sale securities and report them at fair value in cash equivalents or short-term marketable securities on the consolidated balance sheets with related unrealized gains and losses included as a component of stockholders&#x2019; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. Realized gains and losses, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and dividend income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We regularly review all of our investments for other-than-temporary declines in estimated fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in estimated fair value of an investment is below the amortized cost basis and the decline is other-than-temporary, we reduce the carrying value of the security and record a loss for the amount of such decline to other expense, net.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inventory is stated at the lower of cost or estimated net realizable value on a first in, first out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, which consisted of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements, were not material as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.167%;"/&gt;
          &lt;td style="width:1.667%;"/&gt;
          &lt;td style="width:49.167%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shorter of remaining lease terms or useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment, furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Software and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity and Long-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 825, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of other equity and long-term investments, net, on the consolidated statements of income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If we conclude that we do not have an ability to exercise significant influence over an investee, we may elect to account for the equity investment without a readily determinable fair value using the measurement alternative under ASC Topic 312, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Investments - Equity Securities&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. This measurement alternative allows us to measure the equity investment at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We also invest in ISP Fund LP, which investments consist of money market funds, trading and equity securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered in December 2020, we became a limited partner of this partnership, and our contributions are subject to a 36-month lock-up period which restriction prevents us to have control and access to the contributions and related investments. These investments are classified as long-term investments on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Unobservable inputs and little, if any, market activity for the assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Capitalized Fees Paid&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#x201c;Capitalized Fees&#x201d;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#x2019;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#x2019;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#x2019;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#x2019;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We apply the guidance on principal versus agent considerations under ASC Topic 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includ&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(37,37,37,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;es being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Royalty Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We recognize the royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on its methodology and assumptions to estimate rebates and returns, which it monitors and adjusts regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Our partner may make significant adjustments to its sales based on actual results recorded, which could cause our royalty revenue to fluctuate. We conduct periodic royalty audits to evaluate the information provided by our partner. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Product Sales&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#x2019; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#x201c;GPO&#x201d;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state&#x2019;s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research expenses based on the progress of the studies and progress of research manufacturing activities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Interest Expense on Deferred Royalty Obligation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#x201c;Debt&#x201d;, for more information.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Stock&#x2011;Based Compensation Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#x201c;ESPP&#x201d;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#x201c;simplified&#x201d; method as described in Staff Accounting Bulletin No. 107, &#x201c;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;,&#x201d; for the expected option term. We use our historical volatility to estimate expected stock price volatility.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units (&#x201c;RSUs&#x201d;) and restricted stock awards (&#x201c;RSAs&#x201d;) are measured based on the fair market values of the underlying stock on the dates of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#x2019;s best estimate as to whether it is probable that the shares awarded are expected to vest.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#x201c;more likely than not&#x201d; standard.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Income&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive income is comprised of net income and other comprehensive income (loss). Other comprehensive income (loss) consists of changes in unrealized and realized gains and losses on our marketable securities and the related tax impact of these changes.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Related Parties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Transactions with GSK were considered related party transactions up until May 2021, when we completed the share repurchase agreement with GSK to buy back all of its shares of common stock in Innoviva. GSK is no longer considered a related party after the completion of the share repurchase. Transactions with GSK are described in Note 3, &#x201c;Revenue Recognition and Collaborative Arrangements.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sarissa Capital ow&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ned &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of o&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ur outstanding common stock as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Transactions with Sarissa Capital are described in Note 5, &#x201c;Consolidated Entities and Acquisitions&#x201d;. Sarissa Capital is considered to be a related party because two of its principals are members of our board of directors.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting Pronouncements Adopted by the Company&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt-Debt with Conversion and Other Options (Subtopic&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;470-20) and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which is intended to simplify the accounting for convertible instruments by removing certain separation models in Subtopic 470-20 for&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;convertible instruments. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new standard also requires the if-converted method to be used to calculate diluted earnings per share (&#x201c;EPS&#x201d;) for convertible instruments. Effective January 1, 2022, we adopted the new standard using the modified retrospective approach and assessed the effect of this adoption on the accounting for our outstanding convertible notes. The effect of the adoption on our 2025 Notes (as defined below) resulted in a decrease to the opening balance of accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, a reduction to additional paid-in capital of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, an increase to the balance of the notes by an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and an increase to deferred tax assets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The dilutive EPS of our 2025 Notes will be computed under the if-converted method going forward. There was no financial impact from the implementation of the standard for our 2023 Notes (as defined below). Refer to Note 12, &#x201c;Debt&#x201d;, for more information.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Business Combinations&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (Topic 805), &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting for Contract Assets and Contract Liabilities&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;recognized and measured by the acquirer on the acquisition date in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. During the third quarter of 2022, we elected to early adopt ASU 2021-08 effective July 1, 2022. The adoption did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_b6fe683b-fcbf-4fcd-a6b7-3a89c78e4ee9"
      decimals="2"
      id="F_6ed14cb7-6d0d-4b30-862a-6c71a30c1a7e"
      unitRef="U_pure">0.15</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne
      contextRef="C_8a492117-f656-4dab-adc6-be5db6e4dc3e"
      decimals="2"
      id="F_526d11ac-967d-47bb-82a3-49d5297346f8"
      unitRef="U_pure">0.15</inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne>
    <inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
      contextRef="C_8a492117-f656-4dab-adc6-be5db6e4dc3e"
      decimals="-8"
      id="F_4f3bc4d1-f286-40dc-ad93-a57fa5bcff22"
      unitRef="U_USD">3000000000.0</inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate>
    <inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo
      contextRef="C_8a492117-f656-4dab-adc6-be5db6e4dc3e"
      decimals="2"
      id="F_0545c4bc-f7f7-42e1-a57e-030a577287db"
      unitRef="U_pure">0.05</inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo>
    <inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
      contextRef="C_8a492117-f656-4dab-adc6-be5db6e4dc3e"
      decimals="-8"
      id="F_62a003e8-d773-4993-8661-13c316567b23"
      unitRef="U_USD">3000000000.0</inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_0a4c2cad-c447-47db-88d7-dca325de6712"
      decimals="3"
      id="F_d89e7e26-6b76-4df2-bcf1-f60c89cd0613"
      unitRef="U_pure">0.065</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_94397c13-ded5-4700-8d54-52976b909049"
      decimals="2"
      id="F_0f466c54-e0f0-4e4b-9650-6f92b09c87db"
      unitRef="U_pure">0.10</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_2c35a896-dda7-4130-a367-73f18fab4782">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#x201c;VIE&#x201d;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <inva:PresentationReclassificationPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_19ad1374-46d0-430a-94b2-2f839739da16">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Presentation Reclassification&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certain amounts in prepaid expenses and other current assets, other assets and changes in fair values of equity and long-term investments, net, reported in the Company's prior year financial statements have been reclassified to conform to the current year presentation. These reclassifications had no net effect on the net income or net cash flows as previously reported.&lt;/span&gt;&lt;/p&gt;</inva:PresentationReclassificationPolicyTextBlock>
    <inva:FactorsAffectingComparabilityPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_15b5e9c9-f288-44f4-8fe2-8f9fd0d52042">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Factors Affecting Comparability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our historical financial condition and results of operations for the periods presented may not be comparable, either between periods or going forward due to the factors below and as discussed in Note 5, &#x201c;Consolidated Entities and Acquisitions&#x201d;.&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Adoption of Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06 effective January 1, 2022;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounting consolidation of Entasis on February 17, 2022 and purchase of remaining noncontrolling interest in Entasis on July 11, 2022;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sale of our &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% ownership interest in TRC on July 20, 2022; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Acquisition of La Jolla on August 22, 2022.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</inva:FactorsAffectingComparabilityPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_b6fe683b-fcbf-4fcd-a6b7-3a89c78e4ee9"
      decimals="2"
      id="F_c784dc3c-3d14-49a4-96ac-25a5e3c233c8"
      unitRef="U_pure">0.15</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:UseOfEstimates
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_15dec71d-daf9-4495-8d8e-a2d5cbc5fd4a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Management&#x2019;s Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_9ab80c57-bd3a-4f2a-8f49-9aa2d9889a51">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and of Significant Suppliers and Partners&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#x201c;API&#x201d;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Currently, we derive most of our revenues from GSK and our near-term success depends in large part on GSK&#x2019;s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Our royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our, analysts&#x2019; or investors&#x2019; expectations, due to a number of important factors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We also started recognizing revenue from product sales as a result of our acquisition of La Jolla Hospitals and other healthcare organizations generally purchase our products through a network of specialty distributors. These specialty distributors, which are located in the U.S., are considered our customers for accounting purposes. We do not believe that loss of one of these distributors would significantly impact our ability to distribute our products, as we expect that sales volume would be absorbed by new or remaining distributors. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Three&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of our customers each account for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, respectively, of our net product sales from the time of our acquisition of La Jolla through &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. These same customers account for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, respectively, of our receivables from net product sales, which are included in &#x201c;Accounts receivables, net&#x201d; on our consolidated balance sheet as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <inva:NumberOfCustomers
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="0"
      id="F_3e54de09-0cf2-4f9e-9047-64c623b58040"
      unitRef="U_Customer">3</inva:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_6a6afb3d-ff23-4bc0-870f-2ba1de52231b"
      decimals="2"
      id="F_53f43a84-b5b8-4dda-804d-0c9b536f5f94"
      unitRef="U_pure">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_ae9baafd-ad15-49ea-bd45-fcc80a92f494"
      decimals="2"
      id="F_670d57a3-a193-4fa1-95c8-99a75c9cc9a8"
      unitRef="U_pure">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_f2fd0a10-b4dd-4ad0-a2ee-0219d554486f"
      decimals="2"
      id="F_8d311ec9-3924-4ead-939c-7a3516db2b40"
      unitRef="U_pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_6b106910-d499-49e8-b2c4-ca13347b8e1f"
      decimals="2"
      id="F_f12de711-173b-4015-8fa2-d9da6538dcd2"
      unitRef="U_pure">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_1e9dfcc6-abf8-428e-99c1-2f4e7d75a1e1"
      decimals="2"
      id="F_5ed26ca6-429d-4b86-a679-9b92de900ccc"
      unitRef="U_pure">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_bce10091-26f4-4aa8-ad2d-b5ecfe6c2aa9"
      decimals="2"
      id="F_081b8803-6ee4-43c4-b6b5-ffda4910a63a"
      unitRef="U_pure">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_e1eadf82-3759-45fa-a9ea-f698b737b0fb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We operate in a single segment, which is to provide capital return to stockholders by maximizing the potential value of our portfolio of royalties and innovative healthcare assets. Our Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is our Chief Executive Officer. The CODM allocates resources and evaluates the performance of Innoviva at the consolidated level using information about our revenues, operating results and other key financial data as needed. Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net sales of GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Refer to Note 3, &#x201c;Revenue Recognition&#x201d;, for more information on our revenues for the periods presented. Our long-term assets are located within the United States.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_7547f908-2f70-462f-88c3-373fd8749bd7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Variable Interest Entities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The primary beneficiary of a variable interest entity (&#x201c;VIE&#x2019;) is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#x2019;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#x2019;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_a9766b5f-140d-4913-bf0f-50e3d692caf3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Business Combination&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When we acquire an entity in a business combination, we recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establish the acquisition date as the fair value measurement point. We recognize and measure goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired. Acquisition-related expenses and related restructuring costs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, we typically use the income method. This method starts with a forecast of all of the expected future net cash flows for each asset. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Some of the more significant estimates and assumptions inherent in the income method or other methods include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows and the assessment of the asset&#x2019;s life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory, or economic barriers to entry. Determining the useful life of an intangible asset also requires judgment as different types of intangible assets will have different useful lives and certain assets may even be considered to have indefinite useful lives.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_1e1ff176-ab15-452c-8bff-bf77ed899ce3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_249bbf36-5b28-40c4-837c-6b6e6d10a01e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We invest in short-term investments and marketable securities, primarily corporate notes, government securities, government agencies, and government commercial papers. We limit the amount of credit exposure with any one issuer, industry or geographic area for investments other than instruments backed by the U.S. federal government. We classify our marketable securities as available-for-sale securities and report them at fair value in cash equivalents or short-term marketable securities on the consolidated balance sheets with related unrealized gains and losses included as a component of stockholders&#x2019; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. Realized gains and losses, if any, on available-for-sale securities are included in interest income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest and dividend income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We regularly review all of our investments for other-than-temporary declines in estimated fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in estimated fair value of an investment is below the amortized cost basis and the decline is other-than-temporary, we reduce the carrying value of the security and record a loss for the amount of such decline to other expense, net.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_7f059b8e-336a-4d02-a982-0279a0c1cb08">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_f57111ee-2094-4e21-af16-9fa5d7075471">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inventory is stated at the lower of cost or estimated net realizable value on a first in, first out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_0bdad1d7-6fe5-4dae-90cf-0460f754d2aa">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, which consisted of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements, were not material as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.167%;"/&gt;
          &lt;td style="width:1.667%;"/&gt;
          &lt;td style="width:49.167%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shorter of remaining lease terms or useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment, furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Software and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_7eb15296-0743-490e-86c2-e60fb0623f92">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Property and equipment are depreciated using the straight-line method as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.167%;"/&gt;
          &lt;td style="width:1.667%;"/&gt;
          &lt;td style="width:49.167%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shorter of remaining lease terms or useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment, furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Software and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_5c8ba09c-4a2f-49c9-b6ed-a569b29e1d50"
      id="F_0b6b6aaf-70c2-4383-808c-7399fe383de9">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_fc1deebf-6f63-4335-bca2-8ee328f41791"
      id="F_07f1b0fb-e1e0-43e6-9f67-6af2936715aa">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_2bc5e510-4f44-48df-99c8-e241a16a04b5"
      id="F_e2bbcbf3-c5e8-46a9-9714-0abb58e1c566">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_45274200-24f9-44a0-9309-9186f734383d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity and Long-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 825, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of other equity and long-term investments, net, on the consolidated statements of income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If we conclude that we do not have an ability to exercise significant influence over an investee, we may elect to account for the equity investment without a readily determinable fair value using the measurement alternative under ASC Topic 312, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Investments - Equity Securities&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. This measurement alternative allows us to measure the equity investment at its cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We also invest in ISP Fund LP, which investments consist of money market funds, trading and equity securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered in December 2020, we became a limited partner of this partnership, and our contributions are subject to a 36-month lock-up period which restriction prevents us to have control and access to the contributions and related investments. These investments are classified as long-term investments on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_db9b95ca-d9b3-43f3-a3c9-46f5ab65ae55">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;Unobservable inputs and little, if any, market activity for the assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <inva:CapitalizedFeesPaidPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_4f8f1c07-3db1-4524-af43-bc8387fe4ba7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Capitalized Fees Paid&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#x201c;Capitalized Fees&#x201d;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#x2019;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#x2019;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.&lt;/span&gt;&lt;/p&gt;</inva:CapitalizedFeesPaidPolicyTextBlock>
    <inva:CapitalizedFeePaidEstimatedUsefulLife
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      id="F_df28e1da-7046-494b-8daa-8110a7c35c5f">P15Y</inva:CapitalizedFeePaidEstimatedUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_44487e95-078a-480b-8134-1d5d33d312cb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#x2019;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#x2019;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_698f3f11-75a0-46dc-8917-89edcda5d2f9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_264ac7b4-c762-475b-bdc8-60d29b091099">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We apply the guidance on principal versus agent considerations under ASC Topic 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includ&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(37,37,37,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;es being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Royalty Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We recognize the royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on its methodology and assumptions to estimate rebates and returns, which it monitors and adjusts regularly in light of contractual and legal obligations, historical trends, past experience and projected market conditions. Our partner may make significant adjustments to its sales based on actual results recorded, which could cause our royalty revenue to fluctuate. We conduct periodic royalty audits to evaluate the information provided by our partner. Royalties are recognized net of amortization of capitalized fees associated with any approval and launch milestone payments made to GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Product Sales&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#x2019; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#x201c;GPO&#x201d;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state&#x2019;s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_9e341e8f-8ad3-4d31-bbc4-fb0d4f5fca39">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research expenses based on the progress of the studies and progress of research manufacturing activities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InterestExpensePolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_24b6d4ab-8175-4809-b675-d52045776ded">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Interest Expense on Deferred Royalty Obligation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#x201c;Debt&#x201d;, for more information.&lt;/span&gt;&lt;/p&gt;</us-gaap:InterestExpensePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_621e7bf5-e821-4e87-8ea9-4be0b6641036">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Stock&#x2011;Based Compensation Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#x201c;ESPP&#x201d;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#x201c;simplified&#x201d; method as described in Staff Accounting Bulletin No. 107, &#x201c;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;,&#x201d; for the expected option term. We use our historical volatility to estimate expected stock price volatility.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units (&#x201c;RSUs&#x201d;) and restricted stock awards (&#x201c;RSAs&#x201d;) are measured based on the fair market values of the underlying stock on the dates of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#x2019;s best estimate as to whether it is probable that the shares awarded are expected to vest.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_9b4e31d6-e872-4930-a026-0516fb39be0f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#x201c;more likely than not&#x201d; standard.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_252a611e-89b6-4b53-8f9f-a40b1fbb11b8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Income&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive income is comprised of net income and other comprehensive income (loss). Other comprehensive income (loss) consists of changes in unrealized and realized gains and losses on our marketable securities and the related tax impact of these changes.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <inva:RelatedPartyTransactionsPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_52ae26fc-df54-4878-a163-18c3218417c3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Related Parties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Transactions with GSK were considered related party transactions up until May 2021, when we completed the share repurchase agreement with GSK to buy back all of its shares of common stock in Innoviva. GSK is no longer considered a related party after the completion of the share repurchase. Transactions with GSK are described in Note 3, &#x201c;Revenue Recognition and Collaborative Arrangements.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sarissa Capital ow&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ned &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of o&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ur outstanding common stock as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Transactions with Sarissa Capital are described in Note 5, &#x201c;Consolidated Entities and Acquisitions&#x201d;. Sarissa Capital is considered to be a related party because two of its principals are members of our board of directors.&lt;/span&gt;&lt;/p&gt;</inva:RelatedPartyTransactionsPolicyTextBlock>
    <inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty
      contextRef="C_2137129a-9873-421f-b2c8-dd60cf04b4e3"
      decimals="3"
      id="F_598bd2e7-3635-43f9-b91e-f6c0d4b8692b"
      unitRef="U_pure">0.096</inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_62ce5c6f-f397-4d62-95c2-0c53881f9997">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting Pronouncements Adopted by the Company&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt-Debt with Conversion and Other Options (Subtopic&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;470-20) and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which is intended to simplify the accounting for convertible instruments by removing certain separation models in Subtopic 470-20 for&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;convertible instruments. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, as long as no other features require bifurcation and recognition as derivatives. The new standard also requires the if-converted method to be used to calculate diluted earnings per share (&#x201c;EPS&#x201d;) for convertible instruments. Effective January 1, 2022, we adopted the new standard using the modified retrospective approach and assessed the effect of this adoption on the accounting for our outstanding convertible notes. The effect of the adoption on our 2025 Notes (as defined below) resulted in a decrease to the opening balance of accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, a reduction to additional paid-in capital of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, an increase to the balance of the notes by an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and an increase to deferred tax assets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The dilutive EPS of our 2025 Notes will be computed under the if-converted method going forward. There was no financial impact from the implementation of the standard for our 2023 Notes (as defined below). Refer to Note 12, &#x201c;Debt&#x201d;, for more information.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Business Combinations&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (Topic 805), &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting for Contract Assets and Contract Liabilities&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;recognized and measured by the acquirer on the acquisition date in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. During the third quarter of 2022, we elected to early adopt ASU 2021-08 effective July 1, 2022. The adoption did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <inva:DecreaseToAccumulatedDeficit
      contextRef="C_353f3f99-bbf5-4207-bc66-407db6f33a5a"
      decimals="-5"
      id="F_7c169904-c9ff-4ade-9537-82a66594c213"
      unitRef="U_USD">37200000</inva:DecreaseToAccumulatedDeficit>
    <inva:ReductionToAdditionalPaidInCapital
      contextRef="C_353f3f99-bbf5-4207-bc66-407db6f33a5a"
      decimals="-5"
      id="F_10e2e822-9c25-4662-9e2d-fdc636592681"
      unitRef="U_USD">65400000</inva:ReductionToAdditionalPaidInCapital>
    <inva:IncreaseToConvertibleNotes
      contextRef="C_f935b07f-6611-49a5-95c9-c3a28c0fd4ed"
      decimals="-5"
      id="F_78c632e5-ae8a-4996-b39f-4d6d48ffeab7"
      unitRef="U_USD">35600000</inva:IncreaseToConvertibleNotes>
    <inva:IncreaseInDeferredTaxAssets
      contextRef="C_353f3f99-bbf5-4207-bc66-407db6f33a5a"
      decimals="-5"
      id="F_d31a04dc-0159-4bd8-abda-c02768bf6632"
      unitRef="U_USD">7400000</inva:IncreaseInDeferredTaxAssets>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_28cc57e4-1056-413a-a77a-ab0dc1859dea">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.  NET INCOME PER SHARE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock outstanding. Diluted net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock and dilutive potential common stock equivalents then outstanding. Dilutive potential common stock equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method, as well as common stock issuable upon assumed conversion of our convertible subordinated notes due 2023 (the &#x201c;2023 Notes&#x201d;), our convertible senior notes due 2025 (the &#x201c;2025 Notes&#x201d;), and our convertible senior notes due 2028 (the &#x201c;2028 Notes&#x201d;) using the if-converted method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2025 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. Our current intent is to settle the principal amount of th&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;e 2025 Notes in cash upon conversion. The impact of the assumed conversion premium to diluted net income per share was historically computed using the treasury stock method until the adoption of ASU 2020-06. As the average market price per share of our common stock as reported on The Nasdaq Global Select Market was lower than the initial conversion price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.26&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, there was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; dilutive effect of the assumed conversion premium for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021 and 2020 respectively. The dilutive EPS of the notes was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.31&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per sh&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;are using the if-converted method for the year ended December 31, 2022 as a result of the adoption of ASU 2020-06.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table shows the computation of basic and diluted net income per share for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.638%;"/&gt;
        &lt;td style="width:1.409%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.979000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.578%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.409%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.979%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands except per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income attributable to Innoviva stockholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;213,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;265,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;224,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Add: interest expense on 2023 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Add: interest expense on 2025 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Add: interest expense on 2028 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income attributable to Innoviva stockholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;270,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;229,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average shares used to compute basic net income&lt;br/&gt;&#160;&#160;&#160;per share attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;101,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dilutive effect of 2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dilutive effect of 2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dilutive effect of 2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dilutive effect of options and awards granted under equity&lt;br/&gt;&#160;&#160;&#160;incentive plan and employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average shares used to compute diluted net income&lt;br/&gt;&#160;&#160;&#160;per share attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income per share attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Anti&#x2011;dilutive Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#x2011;dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.353%;"/&gt;
        &lt;td style="width:1.844%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.583%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.027%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.583%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.027%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.583%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding options and awards granted under equity incentive&lt;br/&gt;&#160;&#160;&#160;plan and employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding stock warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_e1aa07de-fcc2-48ae-85fd-403ac523f2e3"
      decimals="2"
      id="F_6468508e-54c8-427e-92b2-014b07860df1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.26</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <inva:IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod
      contextRef="C_6e288046-0f09-4c78-b427-4c133f35ca3f"
      decimals="0"
      id="F_dd86681d-c7ad-495d-afef-80cc055b4fae"
      unitRef="U_shares">0</inva:IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod>
    <inva:IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod
      contextRef="C_a7955fc6-6a0b-47e2-b852-f7b1e5cc5350"
      decimals="0"
      id="F_fc14c802-bdc4-4430-894e-629fbbdf3e08"
      unitRef="U_shares">0</inva:IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod>
    <inva:DilutiveEpsOfNotes
      contextRef="C_02211f41-81dd-4ee9-8d76-5d38e227447b"
      decimals="2"
      id="F_e4d6dc2c-a6a3-404c-b348-d0a88aaa506a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.31</inva:DilutiveEpsOfNotes>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_82fc6415-fa69-45ce-8934-9bb33d8384ce">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table shows the computation of basic and diluted net income per share for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.638%;"/&gt;
        &lt;td style="width:1.409%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.979000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.578%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.409%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.979%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands except per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income attributable to Innoviva stockholders, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;213,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;265,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;224,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Add: interest expense on 2023 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Add: interest expense on 2025 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Add: interest expense on 2028 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income attributable to Innoviva stockholders, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;270,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;229,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average shares used to compute basic net income&lt;br/&gt;&#160;&#160;&#160;per share attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;101,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dilutive effect of 2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dilutive effect of 2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dilutive effect of 2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dilutive effect of options and awards granted under equity&lt;br/&gt;&#160;&#160;&#160;incentive plan and employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average shares used to compute diluted net income&lt;br/&gt;&#160;&#160;&#160;per share attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income per share attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_1f0f2f0e-6536-4c36-acee-ffe2fea5ad4e"
      unitRef="U_USD">213921000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_293d67e7-866a-4bf4-9dad-31251d4db4cc"
      unitRef="U_USD">265854000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_edc3a7c9-5a15-434b-837a-ae6f9ad3caea"
      unitRef="U_USD">224402000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_32dbf528-70de-47c3-9e65-d8c113adb297"
      decimals="-3"
      id="F_c515da19-a106-4021-bb51-bcc0dd373d89"
      unitRef="U_USD">2439000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_eec2ed38-0112-4b50-a764-67406d54c678"
      decimals="-3"
      id="F_f2add44a-f09f-4b69-9843-0f6918293daf"
      unitRef="U_USD">4736000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_ccb9cff0-df82-484b-91d7-3221007e9ea4"
      decimals="-3"
      id="F_fe0fa733-4242-4bcc-88a2-0863e7e42c9c"
      unitRef="U_USD">4717000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_98afe62c-821a-4537-b552-da050d3c5568"
      decimals="-3"
      id="F_9f81a349-7ae9-4995-96da-df42a1196aa9"
      unitRef="U_USD">4583000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_d6464796-f61e-480a-9439-0d5437aeff80"
      decimals="-3"
      id="F_8970328f-5bbe-4deb-9423-becc90d7c216"
      unitRef="U_USD">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_dc5624db-df9d-4192-9bd1-604ef2b78e37"
      decimals="-3"
      id="F_c155445c-8da3-4b2f-983c-446654478bde"
      unitRef="U_USD">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_04636ba8-4bff-4dfa-bb5d-8f341cc9b324"
      decimals="-3"
      id="F_5551f2a1-b107-4bf2-ad1b-11b0e11f68b4"
      unitRef="U_USD">4626000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_20d483d2-f9e7-4620-9d3b-694ecd5af926"
      decimals="-3"
      id="F_3e9bfc86-6f96-43e5-bea9-1d85166bfebf"
      unitRef="U_USD">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_2ae54ce1-89e0-4a29-9584-2ca3a58b8d7e"
      decimals="-3"
      id="F_ad15c002-b8cf-429f-b1a5-1b960b074077"
      unitRef="U_USD">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_47d18be6-5b76-4f04-8996-4bcb43bd141d"
      unitRef="U_USD">225569000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_e04b31e4-be5d-4bf8-84c4-c35476a9cb00"
      unitRef="U_USD">270590000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_7208605e-1b29-49e3-89dc-e0dc146271af"
      unitRef="U_USD">229119000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_7259e344-594d-4228-a36c-0c6dd8f10809"
      unitRef="U_shares">69644000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_4081e4cb-69ce-482b-8272-90cfe7292c46"
      unitRef="U_shares">82062000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_6b57dfa1-4994-4b2c-98c7-04fa56445016"
      unitRef="U_shares">101320000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_32dbf528-70de-47c3-9e65-d8c113adb297"
      decimals="-3"
      id="F_35ca1678-5afc-47a4-896b-473c10dd9ca8"
      unitRef="U_shares">6188000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_eec2ed38-0112-4b50-a764-67406d54c678"
      decimals="-3"
      id="F_d903ba24-bbc5-4ef3-9b64-3e50343c89e8"
      unitRef="U_shares">12189000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_ccb9cff0-df82-484b-91d7-3221007e9ea4"
      decimals="-3"
      id="F_18e2efa4-379d-4805-b26e-9c0c4fb12a25"
      unitRef="U_shares">12189000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_98afe62c-821a-4537-b552-da050d3c5568"
      decimals="-3"
      id="F_b0705277-4f79-42af-ad36-b751dd9a3b91"
      unitRef="U_shares">11150000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_d6464796-f61e-480a-9439-0d5437aeff80"
      decimals="-3"
      id="F_7557b637-11ee-4faf-b096-911be9ba08f0"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_dc5624db-df9d-4192-9bd1-604ef2b78e37"
      decimals="-3"
      id="F_7a5237cb-2ca9-4d17-821d-1dcd0660a0a5"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_04636ba8-4bff-4dfa-bb5d-8f341cc9b324"
      decimals="-3"
      id="F_a88d0c7b-d9b1-4617-8bd8-c0587abfbf48"
      unitRef="U_shares">8158000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_20d483d2-f9e7-4620-9d3b-694ecd5af926"
      decimals="-3"
      id="F_f2061daa-ba5c-46a6-a923-16e0bf248ab6"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_2ae54ce1-89e0-4a29-9584-2ca3a58b8d7e"
      decimals="-3"
      id="F_ea186b27-ddd1-4bdf-a90d-b140ac56770e"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_837bb571-cd01-49aa-8a1f-83207a178441"
      unitRef="U_shares">108000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_b7456a17-36b9-4441-ae8e-86c84e18b949"
      unitRef="U_shares">59000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_7df44bf9-21f9-4c9d-a6bb-4ad61e04603e"
      unitRef="U_shares">45000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_4600c968-ebe6-43d6-b659-78af520bbfcd"
      unitRef="U_shares">95248000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_627827e4-6fb8-4571-b7e5-ba041e3f8e47"
      unitRef="U_shares">94310000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_513fd7bb-4cd5-4ee1-bcf2-196e9121b44a"
      unitRef="U_shares">113554000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="2"
      id="F_a83256e9-2116-46d8-a72b-f2b022dd4f62"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="2"
      id="F_65451f49-ff66-48d0-af2f-09d98cecf058"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="2"
      id="F_9fd97b3e-6905-444f-ac1e-debe996a7684"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="2"
      id="F_751f5869-19f1-4dfc-a703-0b382de6303f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="2"
      id="F_3f8ab089-41b6-443a-bb41-f3da872b0394"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="2"
      id="F_a5695f9e-1e59-41d9-b635-5ec650d67a6a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_ea7cfcbd-f243-4286-9c82-18039febd081">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#x2011;dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.353%;"/&gt;
        &lt;td style="width:1.844%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.583%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.027%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.583%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.027%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.583%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding options and awards granted under equity incentive&lt;br/&gt;&#160;&#160;&#160;plan and employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding stock warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9600166d-2800-4110-aac1-2f841a170cbb"
      decimals="-3"
      id="F_878e9ddd-9c73-439a-8fd9-8591d59cf97f"
      unitRef="U_shares">648000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8020a62f-296d-4e43-981f-bbe959befede"
      decimals="-3"
      id="F_e0214525-9ff5-4476-9d20-f23cfec61233"
      unitRef="U_shares">979000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_53339bec-ba31-4b54-aa6a-0f92f4e9a13e"
      decimals="-3"
      id="F_d719594d-5575-4ba0-a36e-65a2d97dbe0a"
      unitRef="U_shares">1193000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_429f62d7-eb47-4068-90e0-c5530e1e1a8d"
      decimals="-3"
      id="F_28f2d66e-5468-45a6-bcdc-a9f3b8960d7d"
      unitRef="U_shares">282000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_86245344-c6d4-4840-98eb-541f5a63c983"
      decimals="-3"
      id="F_03a3c635-befc-4bfc-bb57-0b9c214d6371"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1c0f3b4a-32d1-4930-9562-67d67a9ae07c"
      decimals="-3"
      id="F_80992e77-766a-41d1-8b17-48f95ae0f111"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_f6fcfd77-0084-4642-ba40-187d4c786ff6"
      unitRef="U_shares">930000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_a5e91d19-bc37-4651-8234-e059515c40cb"
      unitRef="U_shares">979000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_079bf5bc-1c6f-417b-8341-eea323d7d954"
      unitRef="U_shares">1193000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_0a2f1dad-14f8-4ef7-8943-459837d27584">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.  REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Revenue from Collaboration Arrangement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 13, 2022, Innoviva&#x2019;s wholly owned subsidiary, Innoviva TRC Holdings, LLC (&#x201c;ITH&#x201d;) entered into an equity purchase agreement (&#x201c;TRC Equity Purchase Agreement&#x201d;) with Royalty Pharma Investments 2019 ICAV (&#x201c;Royalty Pharma&#x201d;) to sell our ownership interest in TRC. As a result of the sale of our ownership interest in TRC, which was consummated on July 20, 2022, we are no longer entitled to receive &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of royalty payments made by GSK stemming from sales of TRELEGY&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. We retained our royalty rights with respect to RELVAR&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net revenue recognized under our GSK Agreements was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.213%;"/&gt;
        &lt;td style="width:1.013%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.063%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.063%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.64%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Royalties - RELVAR/BREO&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;215,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;234,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;221,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Royalties - ANORO&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Royalties - TRELEGY&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;325,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;405,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;340,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: amortization of capitalized&lt;br/&gt;&#160;&#160;&#160;fees paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Royalty revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;311,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;391,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;326,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Strategic alliance - MABA program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total net royalty revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;311,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;391,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;336,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;LABA Collaboration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of the launch and approval of RELVAR&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in the U.S., Japan and Europe, we paid milestone fees to GSK totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;220.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the year ended December 31, 2014. The milestone fees paid to GSK were recognized as capitalized fees paid, which are being amortized over their estimated useful lives commencing upon the commercial launch of the product. The amortization is recorded as a reduction to the royalties from GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We are entitled to receive annual royalties from GSK on sales of RELVAR&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as follows: &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% on the first $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion of annual global net sales and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% for all annual global net sales above $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion. Sales of single&#x2011;agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the LABA Collaboration, such as ANORO&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, royalties are upward tiering and range from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We are also entitled to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of royalty payments made by GSK under its agreements originally entered into with us, and since assigned to TRC in connection with the Spin-Off, including TRELEGY&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which royalties are upward tiering and range from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2004 Strategic Alliance&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2020, we recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in revenue from a termination fee paid in connection with the termination of the Bifunctional Muscarinic Antagonist-Beta2 Agonist (&#x201c;MABA&#x201d;) program under the Strategic Alliance Agreement with GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Product Sales&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net product sales we recognized from the date of acquisition of La Jolla, which occurred on August 22, 2022, to December 31, 2022 were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, consisting of net sales of GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. We derived approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of our net product sales for the same period from customers located in the U.S. and the rest of the world, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <inva:PercentageOfRoyaltyPaymentsNotEntitledToReceive
      contextRef="C_5977bcd8-fc31-490c-827a-9db6ad3d5078"
      decimals="2"
      id="F_061e66bc-ca95-4f8b-afa2-7cfd800d04c6"
      unitRef="U_pure">0.15</inva:PercentageOfRoyaltyPaymentsNotEntitledToReceive>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_691656d3-8dac-44fb-ae47-ca110be44dca">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net revenue recognized under our GSK Agreements was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.213%;"/&gt;
        &lt;td style="width:1.013%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.063%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.063%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.004%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.64%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Royalties - RELVAR/BREO&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;215,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;234,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;221,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Royalties - ANORO&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,405&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,935&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Royalties - TRELEGY&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;325,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;405,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;340,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: amortization of capitalized&lt;br/&gt;&#160;&#160;&#160;fees paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Royalty revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;311,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;391,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;326,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Strategic alliance - MABA program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total net royalty revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;311,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;391,866&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;336,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_5cd517a3-e6ab-4830-97d8-59d7687a4f18"
      decimals="-3"
      id="F_e8ba4813-708c-4569-8cfa-77e6f85723f9"
      unitRef="U_USD">215034000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_676e4e88-33ae-4484-8dfc-e0acec87e7a1"
      decimals="-3"
      id="F_a35fa89d-3e65-45de-a021-7e6fa75c15be"
      unitRef="U_USD">234066000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_238e19e1-e3b1-4349-834a-98123138313f"
      decimals="-3"
      id="F_6922d983-bb98-4a62-82ca-a5660d061caa"
      unitRef="U_USD">221536000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_12567e61-7617-4c87-b922-068faca8ecd2"
      decimals="-3"
      id="F_2c975d32-d607-43a9-bfac-62e69b0d3f5d"
      unitRef="U_USD">38405000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_6ef35e49-a54c-4f19-af9c-bb154b983308"
      decimals="-3"
      id="F_3b598aa7-095f-4039-94db-b70b96c493bd"
      unitRef="U_USD">44935000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_375a042d-32ca-4692-acf8-8877c36d21ae"
      decimals="-3"
      id="F_47e9c144-3a3d-4623-8bf4-0ceedefb8d02"
      unitRef="U_USD">45992000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_fb4a498e-2f50-4c71-a55e-558ce1139356"
      decimals="-3"
      id="F_070ab747-3ff0-43ab-ab7c-2df737234964"
      unitRef="U_USD">72029000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_3b24b3e3-6e06-4dcd-8419-f71edb3c36c3"
      decimals="-3"
      id="F_59e862ea-7c9a-402d-aa79-4489e0bc0b8c"
      unitRef="U_USD">126688000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_75ae1480-904e-4b6a-9936-f2f684cc1cce"
      decimals="-3"
      id="F_3cbdb43d-63a2-4f8b-8be2-bb65e768510f"
      unitRef="U_USD">73089000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_dcd3daed-e03d-43b3-995a-2376fd31c571"
      decimals="-3"
      id="F_65a9ef7e-0be1-49b3-9dfb-6c776a325191"
      unitRef="U_USD">325468000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_5825419d-fd73-4fa4-a6ed-aa1e87d36fa0"
      decimals="-3"
      id="F_81d8de7b-2bc6-4d0d-8ec2-88fc52067b83"
      unitRef="U_USD">405689000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_e03c9a47-30dc-46ba-ba0f-c21cd67ac704"
      decimals="-3"
      id="F_0ca11364-81fb-41a1-8e83-766550eb1c3b"
      unitRef="U_USD">340617000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_dcd3daed-e03d-43b3-995a-2376fd31c571"
      decimals="-3"
      id="F_3ee5ee7e-d639-4078-b76b-37eda6a8ac51"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_5825419d-fd73-4fa4-a6ed-aa1e87d36fa0"
      decimals="-3"
      id="F_18f3ed8a-13eb-4df5-b719-81aabb8faea8"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_e03c9a47-30dc-46ba-ba0f-c21cd67ac704"
      decimals="-3"
      id="F_6b0fcda8-2e5a-413a-a275-30809059de6c"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_dcd3daed-e03d-43b3-995a-2376fd31c571"
      decimals="-3"
      id="F_d9dfb7c4-7c76-4fcd-85e7-ddeec492577a"
      unitRef="U_USD">311645000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5825419d-fd73-4fa4-a6ed-aa1e87d36fa0"
      decimals="-3"
      id="F_d0401d0f-3571-499a-b71c-172a055eaded"
      unitRef="U_USD">391866000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e03c9a47-30dc-46ba-ba0f-c21cd67ac704"
      decimals="-3"
      id="F_73592a36-58e8-4e35-b859-db07c16070a4"
      unitRef="U_USD">326794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <inva:StrategicAllianceMabaProgram
      contextRef="C_283916fc-d81b-4ecf-99aa-3b90c5c75493"
      decimals="-3"
      id="F_7002e176-c98d-4ae5-99f8-9c8911ea0b91"
      unitRef="U_USD">0</inva:StrategicAllianceMabaProgram>
    <inva:StrategicAllianceMabaProgram
      contextRef="C_cccb0641-aa44-4b1c-a0d0-fd6d4158c2b4"
      decimals="-3"
      id="F_f249b3e1-9c0b-4382-8d4e-5a40caefee28"
      unitRef="U_USD">0</inva:StrategicAllianceMabaProgram>
    <inva:StrategicAllianceMabaProgram
      contextRef="C_0bc981e7-59dd-45eb-91b4-c1399903b025"
      decimals="-3"
      id="F_39b485ea-26e0-4dec-8489-6a2483d0fff8"
      unitRef="U_USD">10000000</inva:StrategicAllianceMabaProgram>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b62fd465-f5dd-40eb-aa36-8c18ef36ea86"
      decimals="-3"
      id="F_9ca5a9af-4236-4b36-9dc7-76086b307684"
      unitRef="U_USD">311645000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2ec07c39-1f00-4f12-9dfe-a75a6a1075ea"
      decimals="-3"
      id="F_fe2a09db-8b2c-49a1-ad4b-45a2181bbcff"
      unitRef="U_USD">391866000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_936c37a5-d79d-48ab-8b0a-483fe51759c2"
      decimals="-3"
      id="F_7b975180-d246-42e7-9c6c-75dd6b1a8fc0"
      unitRef="U_USD">336794000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_507fe221-0e42-48ef-9715-fb7f62c2affb"
      decimals="-5"
      id="F_794b0d0a-f86e-441f-8dc4-65d21304dff8"
      unitRef="U_USD">220000000.0</us-gaap:CapitalizedContractCostGross>
    <inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne
      contextRef="C_1331927b-9f86-4b7d-81d5-27a5846306f8"
      decimals="2"
      id="F_2427a668-a5a3-4a23-a1a6-8f7aeaf66462"
      unitRef="U_pure">0.15</inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne>
    <inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
      contextRef="C_1331927b-9f86-4b7d-81d5-27a5846306f8"
      decimals="-8"
      id="F_adbe931c-16ea-40df-8810-bf165bbdb1d9"
      unitRef="U_USD">3000000000.0</inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate>
    <inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo
      contextRef="C_1331927b-9f86-4b7d-81d5-27a5846306f8"
      decimals="2"
      id="F_45265d5c-91cf-4174-898b-52b2ecacf29b"
      unitRef="U_pure">0.05</inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo>
    <inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
      contextRef="C_1331927b-9f86-4b7d-81d5-27a5846306f8"
      decimals="-8"
      id="F_edf78583-1411-481f-b8d1-9b5bc65248bc"
      unitRef="U_USD">3000000000.0</inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_d59a34b7-1a2d-4e81-b069-63e808ef44cb"
      decimals="3"
      id="F_06f36741-2d42-43b5-a485-9d036b513bb1"
      unitRef="U_pure">0.065</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_e61918a2-0f31-4d42-984d-dedda7b852ed"
      decimals="2"
      id="F_47544d1a-06c0-4a9b-b968-8e5d6a288a93"
      unitRef="U_pure">0.10</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <inva:PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements
      contextRef="C_77fb24cf-b9f6-407a-ba9c-858247b06623"
      decimals="2"
      id="F_a259b091-94b5-467d-ac0a-c8680b5a53af"
      unitRef="U_pure">0.15</inva:PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_cd8c3695-a759-4ca6-9be7-64a5775cc175"
      decimals="3"
      id="F_7f197308-02e9-4b20-96b8-246df3eb12bb"
      unitRef="U_pure">0.065</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_b8bfe4f9-1bc3-43e2-b056-965fbab72a8a"
      decimals="2"
      id="F_e7f32927-c0d3-4858-85ef-37198d4018de"
      unitRef="U_pure">0.10</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <us-gaap:GainLossOnContractTermination
      contextRef="C_71ef9fc1-7268-4619-8fc8-2922d4e683a5"
      decimals="-5"
      id="F_43b87ea2-d22b-4c1f-8665-2f80c7e2aeed"
      unitRef="U_USD">10000000.0</us-gaap:GainLossOnContractTermination>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_dd16336a-4a72-4552-8d5c-b8332029c781"
      decimals="-5"
      id="F_5d05a0aa-08ec-46b7-9421-bef97aac5dad"
      unitRef="U_USD">19700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4d7d202f-bfb9-44a0-8281-04c234b04110"
      decimals="-5"
      id="F_57b667ef-59f4-45af-ae2e-c292264664cf"
      unitRef="U_USD">14200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_acc278fb-4048-4edf-b4c0-fffa88f0aada"
      decimals="-5"
      id="F_f6755624-d76d-4fd3-90aa-f1a66ac639f4"
      unitRef="U_USD">5500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_3014405b-7e86-4ca8-9b06-d944fd32e11a"
      decimals="2"
      id="F_26ecb390-3303-4e29-bfec-a3dab2a36813"
      unitRef="U_pure">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_dc90f4aa-923b-4d08-8914-8e2e4b24dcfd"
      decimals="2"
      id="F_b2a35dce-cdbe-4e41-8e26-63577fbfbae4"
      unitRef="U_pure">0.04</us-gaap:ConcentrationRiskPercentage1>
    <inva:LicenseAndCollaborationArrangementsDisclosureTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_25a30460-f138-406a-88bf-bf2563ccfc5c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.  LICENSE AND COLLABORATION ARRANGEMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Out-License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Zai Lab&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Entasis entered into a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. (&#x201c;Zai Lab&#x201d;), pursuant to which Zai Lab licensed exclusive rights to durlobactam and SUL-DUR, in the Asia-Pacific region (&#x201c;the Zai Agreement&#x201d;). Under the terms of the Zai Agreement, Zai Lab will fund most of the registrational clinical trial costs in China for SUL-DUR, with the exception of Phase 3 patient drug supply of licensed products. Zai Lab will conduct development activities and plan and obtain regulatory approval in a specified number of countries in the Asia-Pacific region beyond China after receipt of regulatory approval of a licensed product in China. Zai Lab is also solely responsible for commercializing licensed products in the Asia-Pacific region and will commercialize licensed products for which it has obtained regulatory approval. We are obligated to supply Zai Lab with the licensed products for clinical development and, if the licensed product is approved, for commercial use for a certain period unless Zai Lab notifies otherwise. Zai Lab may take over manufacturing responsibilities for its own commercialization activities within a specified time period following the effective date of the Zai Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We ar&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;e eligible to receive up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;91.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in research and development support payments and development, regulatory and sales milestone payments related to SUL-DUR, imipenem and other combinations with the licensed products. Zai Lab will pay us a tiered royalty equal to from a high-single digit to low-double digit percentage based on annual net sales of licensed products in the territory, subject to specified reductions for the market entry of competing products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; revenue was recognized under the Zai Agreement from the acquisition date of Entasis. Payments received for research support and reimbursable clinical trial costs are recorded as a reduction to research and development expense during the period in which the qualifying expenses are incurred. Such amounts recorded from the date of acquisition of Entasis to December 31, 2022 are not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;GARDP&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Entasis entered into a collaboration agreement with the Global Antibiotic Research and Development Partnership (&#x201c;GARDP&#x201d;) for the development, manufacture and commercialization of the product candidate zoliflodacin in certain countries (&#x201c;the GARDP Collaboration Agreement&#x201d;). Under the terms of the GARDP Collaboration Agreement, GARDP will use commercially reasonable endeavors to perform and fully fund the Phase 3 registrational trial, including the manufacture and supply of the product candidate containing zoliflodacin, in uncomplicated gonorrhea. We recorded reimbursements from GARDP under this agreement as reduction to research and development expense. Relevant amounts from the date of acquisition of Entasis to December 31, 2022 are not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition, under the GARDP Collaboration Agreement, GARDP was granted a worldwide, fully paid, exclusive and royalty-free license, with the right to sublicense, to use our zoliflodacin technology in connection with GARDP&#x2019;s development, manufacture and commercialization of zoliflodacin in low-income and specified middle-income countries. We retained commercial rights in all other countries worldwide, including the major markets in North America, Europe and Asia-Pacific. We also retained the right to use and grant licenses to our zoliflodacin technology to perform our obligations under the GARDP Collaboration Agreement and for any purpose other than gonorrhea or community-acquired indications. If we believe that the results of the Phase 3 registrational trial of zoliflodacin would be supportive of an application for marketing approval, we are obligated to use our best efforts to file an application for marketing approval with the FDA within six months of the completion of the trial and to use commercially reasonable endeavors to file an application for marketing approval with the European Medicines Agency (&#x201c;EMA&#x201d;). Each party is responsible for using commercially reasonable efforts to obtain marketing authorizations for the product candidate in their respective territories.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;PAION AG&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the PAION AG (&#x201c;PAION&#x201d;) License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in the European Economic Area, the United Kingdom and Switzerland (collectively, the &#x201c;PAION Territory&#x201d;). We are entitled to receive potential commercial milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and double-digit tiered royalty payments. Royalties payable in a given jurisdiction under the PAION License will be subject to reduction on account of generic competition and after patent expiration in that jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA&#xae; and XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in the PAION Territory. We have not recognized any revenue from PAION related to commercial milestones from the date of acquisition of La Jolla to December 31, 2022. Royalty revenue recognized under this agreement from the date of acquisition of La Jolla to December 31, 2022 was not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;La Jolla also entered into the PAION commercial supply agreement (the &#x201c;PAION Supply Agreement&#x201d;) whereby La Jolla will supply PAION a minimum quantity of GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; through July 13, 2024. The PAION supply agreement will automatically renew until the earlier of July 13, 2027, or until a new supply agreement is executed. During the initial term of the supply agreement, we will be reimbursed for direct and certain indirect manufacturing costs at cost. Amounts recognized under this agreement from the date of acquisition of La Jolla to December 31, 2022 were not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Everest Medicines Limited&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the Everest Medicines Limited (&#x201c;Everest&#x201d;) License, La Jolla granted Everest an exclusive license to develop and commercialize XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the treatment of complicated intra-abdominal infections (&#x201c;cIAI&#x201d;) and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the &#x201c;Everest Territory&#x201d;). We are eligible to receive an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million regulatory milestone payment and up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in sales milestone payments. We are also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (i) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (iii) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years after the first commercial sale of a product in such jurisdiction in the Everest Territory. We have not recognized any revenue from Everest related to regulatory and sales milestones from the date of acquisition of La Jolla to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022. Royalty revenue recognized under this agreement from the date of acquisition of La Jolla to December 31, 2022 was not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A new drug application (&#x201c;NDA&#x201d;) was submitted with the China National Medical Products Administration (&#x201c;NMPA&#x201d;) for XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the treatment of cIAI in patients in China in 2021. XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was approved in Singapore by the Health Science Authority in 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;La Jolla also entered into the Everest commercial supply agreement (the &#x201c;Everest Supply Agreement&#x201d;) whereby La Jolla will supply Everest a minimum quantity of XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; through December 31, 2023 and will transfer to Everest certain XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-related manufacturing know-how. We will be reimbursed for direct and certain indirect manufacturing costs at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of cost through December 31, 2023. We initially recognized a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million partial prepayment for XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as deferred revenue, of which, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was recognized as revenue for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;In-License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;George Washington University&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the George Washington University (&#x201c;GW&#x201d;) License, GW exclusively licensed to La Jolla certain intellectual property rights relating to GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Under the GW License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. We are obligated to pay a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% royalty on net sales of GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. From the date of acquisition of La Jolla to December 31, 2022, the amounts recognized under this agreement were not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Harvard University&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the Harvard University (&#x201c;Harvard&#x201d;) License, Harvard exclusively licensed to La Jolla certain intellectual property rights relating to tetracycline-based products, including XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. For each product covered by the Harvard License, we are obligated to make certain payments for the following: (i) up to approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million upon the achievement of certain clinical development and regulatory milestones; (ii) a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% royalty on direct U.S. net sales of XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, starting at a minimum royalty rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, with step-ups to a maximum royalty of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% based on the achievement of annual net product sales thresholds; and (iv) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. From the date of acquisition of La Jolla to December 31, 2022, amounts recognized under this agreement were not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Paratek Pharmaceuticals, Inc.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the Paratek Pharmaceuticals, Inc. (&#x201c;Paratek&#x201d;) License, Paratek non-exclusively licensed to La Jolla certain intellectual property rights relating to XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, including non-exclusive rights to certain issued patents and patent applications covering XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. We are obligated to pay Paratek a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% royalty based on direct U.S. net sales of XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Our obligation to pay royalties with respect to the licensed product is retroactive to the date of the first commercial sale of XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and shall continue until there are no longer any valid claims of the Paratek patents, which will expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;October 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. From the date of acquisition of La Jolla to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, amounts recognized under this agreement were not material.&lt;/span&gt;&lt;/p&gt;</inva:LicenseAndCollaborationArrangementsDisclosureTextBlock>
    <inva:FuturePotentialMilestonePayment
      contextRef="C_dd7cfa80-9759-4df0-9de9-4910b0bcbdbb"
      decimals="-5"
      id="F_f5f62d7b-8231-4704-838f-947082fd47bc"
      unitRef="U_USD">91000000.0</inva:FuturePotentialMilestonePayment>
    <us-gaap:Revenues
      contextRef="C_c5fa27cc-5d17-4a15-b456-34db9e1c8687"
      decimals="-6"
      id="F_f65fa3a2-f242-4090-aa44-c9bfa3bcbb26"
      unitRef="U_USD">0</us-gaap:Revenues>
    <inva:FuturePotentialMilestonePayment
      contextRef="C_39cf12a7-a194-4f3f-a151-0889b4253c28"
      decimals="-5"
      id="F_1e361813-8eb7-4038-9d80-2c705934e5ea"
      unitRef="U_USD">109500000</inva:FuturePotentialMilestonePayment>
    <inva:RegulatoryMilestonePaymentsReceivable
      contextRef="C_80058a16-9c51-485f-8884-e6849191bd21"
      decimals="-5"
      id="F_2925b995-12ad-442b-842f-97ba7cc1519a"
      unitRef="U_USD">8000000.0</inva:RegulatoryMilestonePaymentsReceivable>
    <inva:SalesMilestonePaymentsReceivable
      contextRef="C_80058a16-9c51-485f-8884-e6849191bd21"
      decimals="-5"
      id="F_a403aa57-c5cf-426e-a668-d2eaf696004b"
      unitRef="U_USD">20000000.0</inva:SalesMilestonePaymentsReceivable>
    <inva:RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct
      contextRef="C_d7e11212-8609-4fda-a248-41d5348f3383"
      id="F_e3085b5b-18cc-413f-8e70-6a97671804de">P10Y</inva:RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct>
    <inva:PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts
      contextRef="C_a8932c51-4ee5-4ba0-82b7-47753c1c9a9a"
      decimals="2"
      id="F_d82a7dd8-d4f3-460c-bb0b-15d9baafef84"
      unitRef="U_pure">1.10</inva:PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts>
    <us-gaap:DeferredRevenue
      contextRef="C_dadd5411-7bb4-4843-b9b2-3fddc474ba05"
      decimals="-5"
      id="F_d990b634-3cd0-4b81-81e8-9bd95d328cd6"
      unitRef="U_USD">2800000</us-gaap:DeferredRevenue>
    <us-gaap:Revenues
      contextRef="C_a8932c51-4ee5-4ba0-82b7-47753c1c9a9a"
      decimals="-5"
      id="F_b97d1007-24fb-48c1-9ab0-e15ad6ce3480"
      unitRef="U_USD">800000</us-gaap:Revenues>
    <inva:PercentageOfRoyaltyPayableOnNetSales
      contextRef="C_1aa9bc6a-6c60-4a2b-9e33-2d8d6bc2de04"
      decimals="2"
      id="F_b616c0d5-6fe9-467f-ba8c-8dfc3f476717"
      unitRef="U_pure">0.06</inva:PercentageOfRoyaltyPayableOnNetSales>
    <inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees
      contextRef="C_1aa9bc6a-6c60-4a2b-9e33-2d8d6bc2de04"
      decimals="2"
      id="F_7743f961-065b-495c-99ba-1773d75e2682"
      unitRef="U_pure">0.15</inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees>
    <inva:ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable
      contextRef="C_6a2877be-4f3b-4a25-870f-05069f62cb38"
      decimals="-5"
      id="F_f7d54ed1-738e-4c0b-8ec4-034dfa1c1776"
      unitRef="U_USD">15100000</inva:ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable>
    <inva:PercentageOfRoyaltyPayableOnNetSales
      contextRef="C_6a2877be-4f3b-4a25-870f-05069f62cb38"
      decimals="2"
      id="F_739aeea5-05e6-4734-abdb-78aefdb20aa0"
      unitRef="U_pure">0.05</inva:PercentageOfRoyaltyPayableOnNetSales>
    <inva:PercentageOfMinimumRoyaltyRate
      contextRef="C_6a2877be-4f3b-4a25-870f-05069f62cb38"
      decimals="3"
      id="F_be5bb615-f034-42e6-95b7-0b19b33c5acc"
      unitRef="U_pure">0.045</inva:PercentageOfMinimumRoyaltyRate>
    <inva:PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds
      contextRef="C_6a2877be-4f3b-4a25-870f-05069f62cb38"
      decimals="3"
      id="F_91f861e8-e406-4630-9cc7-abad22dea84a"
      unitRef="U_pure">0.075</inva:PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds>
    <inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees
      contextRef="C_6a2877be-4f3b-4a25-870f-05069f62cb38"
      decimals="2"
      id="F_87a78243-8e85-4092-86e6-9072ff276cd1"
      unitRef="U_pure">0.20</inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees>
    <inva:PercentageOfRoyaltyPayableOnNetSales
      contextRef="C_d2c072bc-c407-4f39-8c36-301e061f1ca8"
      decimals="4"
      id="F_d3231d1e-24f1-472b-927c-76665cc04fd5"
      unitRef="U_pure">0.0225</inva:PercentageOfRoyaltyPayableOnNetSales>
    <inva:ClaimExpirationDate
      contextRef="C_d2c072bc-c407-4f39-8c36-301e061f1ca8"
      id="F_6cfe3c77-3030-4421-98d5-699d2ab0b12a">2023-10</inva:ClaimExpirationDate>
    <inva:ConsolidatedEntitiesAndAcquisitionsTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_dac67ad3-1249-49c3-8da4-1aa59afeda19">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5. CONSOLIDATED ENTITIES AND ACQUISITIONS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Consolidated Entities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Theravance Respiratory Company, LLC&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Up until July 20, 2022, we consolidated TRC under the VIE model as we determined that TRC was a VIE and we were the primary beneficiary of the entity because we had the power to direct the economically significant activities of TRC and the obligation to absorb losses of, or the right to receive benefits from, TRC. We held &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% ownership interest of TRC. The primary source of revenue for TRC is the royalties generated from the net sales of TRELEGY&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; by GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As discussed in Note 3, &#x201c;Revenue Recognition&#x201d;, on July 13, 2022, ITH entered into the TRC Equity Purchase Agreement to sell our ownership interest in TRC. Upon the closing of the transaction on July 20, 2022, we received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;277.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in cash from Royalty Pharma. We are also entitled to receive up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in contingent sales-based milestone payments in the future. In connection with the closing of the transaction, we also received our portion of TRC&#x2019;s remaining cash balance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million from Royalty Pharma rather than through a cash distribution from TRC.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to the closing of the transaction and as part of the agreement, TRC distributed its ownership interests and investments in InCarda Therapeutics, Inc., ImaginAb, Inc., Gate Neurosciences, Inc. and Nanolive SA, which had a total carrying value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to ITH. We accounted for the transaction similar to an upstream sale between a parent and a VIE under ASC 810-10. As such,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ITH &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;recorded the transferred investments at their respective carrying values and no gain or loss was recognized in the consolidated statement of income.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The summarized financial information for TRC as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021 and for the relevant periods through the sale date in 2022 are presented as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance sheet&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.325%;"/&gt;
        &lt;td style="width:1.794%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.881%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Receivables from collaborative arrangements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity and long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liabilities and LLC Members&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;LLC members&#x2019; equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total liabilities and LLC members&#x2019; equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income statements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.112%;"/&gt;
        &lt;td style="width:0.995%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.276%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.45%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.276%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.45%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.443000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Royalty revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue from collaborative arrangements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total net revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;122,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Realized loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in fair values of other equity and&lt;br/&gt;&#160;&#160;&#160;long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;121,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;ISP Fund LP&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2020, Innoviva Strategic Partners LLC, our wholly owned subsidiary (&#x201c;Strategic Partners&#x201d;), contributed $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to ISP Fund LP (the "Partnership") for investing in &#x201c;long&#x201d; positions in the healthcare, pharmaceutical and biotechnology sectors and became a limited partner. The general partner of the Partnership ("General Partner") is an affiliate of Sarissa Capital.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Partnership Agreement provides for Sarissa Capital to receive management fees from the Partnership, payable quarterly in advance, measured based on the Net Asset Value of Strategic Partners' capital account in the Partnership. In addition, the General Partner is entitled to an annual performance fee based on the Net Profits of the Partnership during the annual measurement period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Partnership Agreement includes a lock-up period of thirty-six months after which Strategic Partners is entitled to make withdrawals from the Partnership as of such lock-up expiration date and each anniversary thereafter, subject to certain limitations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2021, Strategic Partners received a distribution of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million from the Partnership to provide funding to Innoviva for a strategic repurchase of the Company's shares held by GSK. On March 30, 2022, Strategic Partners made an additional capital contribution of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to the Partnership pursuant to the letter agreement entered into between Strategic Partners, the Partnership and Sarissa Capital Fund GP LP on May 20, 2021. The capital contribution is subject to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; lock up period from the contribution date&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We consolidate ISP Fund LP under the VIE model as we have determined that ISP Fund LP is a VIE and we are the primary beneficiary of the entity via our related party relationships with Sarissa Capital entities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, we continued to hold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the economic interest of Partnership. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, total assets of the Partnership were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;320.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;195.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, of which the majority was attributable to equity, debt and long-term investments. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, total liabilities of the Partnership w&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ere $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; mill&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ion and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The Partnership's assets can only be used to settle its own obligations. During the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, the Partnership incurred&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;million in net investment-related expenses, generated $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million interest income, recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net realized gains and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net unrealized losses as changes in fair values of other equity and long-term investments, net, on the consolidated statements of income. During the year ended December 31, 2021, the Partnership incurred&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net investment-related expense, generated $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million interest and dividend income, and recorded net $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million realized gains and net $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million unrealized losses as changes in fair values of other equity and long-term investments, net, on the consolidated statements of income. We account for the long-term investments held by ISP Fund LP as equity investments measured at fair value and an investment in convertible notes as trading security.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Acquisitions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Entasis Therapeutics Holdings Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We started investing in Entasis in 2020 as part of our capital allocation strategy of deploying cash generated from royalty income and investing in different life sciences companies. Entasis is an advanced, late clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products. During the second quarter of 2020, we purchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock as well as warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional shares of common stock of Entasis for approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in cash. During the third quarter of 2020, we purchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,672,897&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Entasis common stock as well as warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,672,897&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional shares of its common stock for approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in cash. Effective in June 2020, after certain conditions were met with respect to the sales of Entasis equity shares, Innoviva had the right to designate &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; members to Entasis&#x2019; board of directors. During the second quarter of 2021, Innoviva&#x2019;s wholly owned subsidiary, Innoviva Strategic Opportunities, LLC (&#x201c;ISO&#x201d;) entered into a securities purchase agreement with Entasis to acquire &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Entasis common stock and warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional shares of Entasis common stock for approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of Entasis&#x2019; common stock was measured based on its closing market price at each balance sheet date. The warrants had an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.675&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for those warrants acquired in the second and third quarter of 2020, respectively. The warrants acquired in the second quarter of 2021 had an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. All of the warrants were exercisable immediately within &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; from the issuance date of the warrants and included a cashless exercise option. We used the Black-Scholes-Merton pricing model to estimate the fair value of these warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 17, 2022, ISO entered into a securities purchase agreement with Entasis pursuant to which ISO purchased a convertible promissory note for a total purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The note bore an annual interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.59&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and was due to mature and become payable on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 18, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; unless it was converted at a conversion price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.48&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; before the maturity date. With this financing, we determined that we had both (i) the power to direct the economically significant activities of Entasis and (ii) the obligation to absorb the losses, or the right to receive the benefits, that could potentially be significant to Entasis and therefore, we were the primary beneficiary of Entasis. Accordingly, we consolidated Entasis&#x2019; financial position and results of operations effective on February 17, 2022. Our equity ownership interest remained at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% as of February 17, 2022, and the fair values of our holdings of Entasis common stock and warrants were remeasured and estimated at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The remeasurement resulted in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million loss in the first quarter of 2022 which was included in changes in fair values of equity method investments, net, on the consolidated statements of income for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We completed our acquisition of Entasis&#x2019; remaining noncontrolling interest on July 11, 2022. We remeasured our holdings in Entasis as of that date and recognized a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million loss, which was included in changes in fair values of equity method investments, net, on the consolidated statement of income for the year ended December 31, 2022. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; payments were made toward the convertible promissory note through the date of acquisition of Entasis. In connection with the acquisition, all of the Entasis warrants were replaced with Innoviva warrants (the &#x201c;Replacement Warrants&#x201d;) of equivalent value and bearing the same terms. The Replacement Warrants are classified as equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We recognized the difference between the acquisition price and the carrying value of the acquired noncontrolling interest on July 11, 2022 in our additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair values assigned to assets acquired and liabilities assumed as of February 17, 2022 were based on management&#x2019;s best estimates and assumptions. After the acquisition in July 2022, we adjusted the preliminary estimates of fair value of assets acquired and liabilities assumed based on new and additional information related to product sales forecast provided by Entasis and deferred tax liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2022, we recorded measurement period adjustments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million decrease in goodwill, primarily related to a decrease in estimated purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, an increase in noncontrolling interests of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and an increase in intangible assets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The cumulative impact of the measurement period adjustments included in the consolidated net income for the year ended December 31, 2022 was not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has completed a preliminary valuation and expects to finalize it as soon as practical, but no later than one year from the acquisition date. The purchase accounting for this transaction is not yet finalized.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table represents the adjusted fair values of the assets acquired and liabilities assumed by us in the transaction:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.325%;"/&gt;
        &lt;td style="width:1.794%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.881%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;February 17, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;107,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;149,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued personnel-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total liabilities assumed&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets acquired, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The goodwill arising from the acquisition of Entasis is primarily attributable to Entasis&#x2019; assembled workforce and the value associated with growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Refer to Note 8, &#x201c;Goodwill and Intangible Assets&#x201d;, for more discussion on the intangible assets recognized as part of this acquisition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our consolidated net income for the year ended December 31, 2022 included the net loss attributable to noncontrolling interest since the consolidation date until the date of acquisition &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;La Jolla Pharmaceutical Company&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 22, 2022, ISO acquired La Jolla for a total consideration of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;206.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. ISO acquired La Jolla at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.23&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. La Jolla is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla brings to Innoviva an established product portfolio, including GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (eravacycline) for the treatment of cIAIs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair values assigned to assets acquired and liabilities assumed are based on management&#x2019;s best estimates and assumptions as of August 22, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2022, we recorded measurement period adjustments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million increase in goodwill, primarily related to a decrease in inventory and intangible assets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, and an increase in deferred tax liabilities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, partially offset by a decrease in other long-term liabilities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The cumulative impact of the measurement period adjustments included in the consolidated net income for the year ended December 31, 2022 was not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We have completed a preliminary valuation and expect to finalize it as soon as practicable, but no later than one year from the acquisition date. The purchase accounting for this transaction is not yet finalized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We incurred approximate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ly $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in acquisition-related costs in connection with this acquisition and such amount is included in selling, general and administrative exp&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;enses for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the adjusted allocation of the fair values assigned to the assets acquired and liabilities assumed as of the date of the acquisition:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.325%;"/&gt;
        &lt;td style="width:1.794%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.881%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 22, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;290,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total liabilities assumed&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets acquired, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;206,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The goodwill arising from the acquisition of La Jolla is primarily attributable to La Jolla&#x2019;s assembled workforce and the value associated with leveraging the workforce to develop and commercialize new drug products in the future and growing our business more efficiently. The goodwill from this acquisition is not expected to be deductible for tax purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Refer to Note 8, &#x201c;Goodwill and Intangible Assets&#x201d;, for more discussion on the intangible assets recognized as part of this acquisition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Pro Forma Financial Information&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents certain unaudited pro-forma financial information for the years ended December 31, 2022 and 2021 as if the consolidation of Entasis and La Jolla occurred on January 1, 2021. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2021, or of results that may occur in the future. The unaudited pro forma financial information combines the historical results of the Entasis and La Jolla with the Company&#x2019;s consolidated historical results and includes certain adjustments including, but not limited to, fair value adjustments to equity investments in Entasis&#x2019; common stock and warrants, fair value adjustments to inventory, amortization of intangible assets, and interest expense on deferred royalty obligations and acquisition-related costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.399%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.6%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;357,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;435,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;204,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;281,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;214,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;197,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</inva:ConsolidatedEntitiesAndAcquisitionsTextBlock>
    <inva:OwnershipInterestInConsolidatedEntities
      contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69"
      decimals="2"
      id="F_79d79c14-7513-4b46-9976-041eb445f3bf"
      unitRef="U_pure">0.15</inva:OwnershipInterestInConsolidatedEntities>
    <inva:ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement
      contextRef="C_c85a10d8-967e-4263-82f9-7532cc5b50dc"
      decimals="-5"
      id="F_38e3bf72-b173-44ec-b7e4-270c72facd23"
      unitRef="U_USD">277500000</inva:ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement>
    <inva:ContingentSalesBasedMilestonePayment
      contextRef="C_470cc2e5-a00e-4451-811a-42f58ffbce14"
      decimals="-5"
      id="F_350540ee-47da-4b77-9b59-356bbdb774bf"
      unitRef="U_USD">50000000.0</inva:ContingentSalesBasedMilestonePayment>
    <inva:CashDistributionReceived
      contextRef="C_470cc2e5-a00e-4451-811a-42f58ffbce14"
      decimals="-5"
      id="F_2e0b7989-bd7d-4fb0-9e80-07eea2d46d7e"
      unitRef="U_USD">4400000</inva:CashDistributionReceived>
    <us-gaap:EquityMethodInvestments
      contextRef="C_c85a10d8-967e-4263-82f9-7532cc5b50dc"
      decimals="-5"
      id="F_94b48be6-594e-4da3-8ef7-7c50670980eb"
      unitRef="U_USD">39400000</us-gaap:EquityMethodInvestments>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69"
      id="F_6c765c10-3de1-4c9a-acaa-81478337378c">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The summarized financial information for TRC as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021 and for the relevant periods through the sale date in 2022 are presented as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance sheet&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.325%;"/&gt;
        &lt;td style="width:1.794%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.881%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Receivables from collaborative arrangements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity and long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liabilities and LLC Members&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;LLC members&#x2019; equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total liabilities and LLC members&#x2019; equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income statements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.112%;"/&gt;
        &lt;td style="width:0.995%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.276%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.45%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.276%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.45%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.443000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Royalty revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue from collaborative arrangements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total net revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;71,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;122,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Realized loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in fair values of other equity and&lt;br/&gt;&#160;&#160;&#160;long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;121,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0"
      decimals="-3"
      id="F_678dbc81-a047-451a-a58f-f90654fc5b94"
      unitRef="U_USD">50713000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0"
      decimals="-3"
      id="F_697ee9d6-e8f9-4fb3-b1f0-fba0edc9372f"
      unitRef="U_USD">42492000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0"
      decimals="-3"
      id="F_bda9dace-f602-4ca5-9627-5e36c8982319"
      unitRef="U_USD">71000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0"
      decimals="-3"
      id="F_d8909cdf-477a-4799-bc9d-2ef6c5b4ffc3"
      unitRef="U_USD">37695000</us-gaap:LongTermInvestments>
    <us-gaap:Assets
      contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0"
      decimals="-3"
      id="F_d066799f-8e42-4bd6-a7fc-4d09531366e4"
      unitRef="U_USD">130971000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0"
      decimals="-3"
      id="F_3815119d-fa06-4153-81c1-17c5214eb943"
      unitRef="U_USD">252000</us-gaap:LiabilitiesCurrent>
    <us-gaap:MembersEquity
      contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0"
      decimals="-3"
      id="F_458f20b6-d7e5-4e2a-9437-e28ec00628c3"
      unitRef="U_USD">130719000</us-gaap:MembersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_5874bedc-4e02-4a10-b901-1e4be59451b0"
      decimals="-3"
      id="F_a5f5e607-2998-40f3-9249-5f9fd863e7dd"
      unitRef="U_USD">130971000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_776c1f34-bbdc-44d5-80e8-a6cccdaa9570"
      decimals="-3"
      id="F_86dc67a7-1dc7-4bb6-ae4c-31c620a7a8c0"
      unitRef="U_USD">72029000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_55981a3b-c27e-47a6-bec2-2df69c4457cd"
      decimals="-3"
      id="F_98a0fa34-bfcb-411a-92b3-5062e6f9910c"
      unitRef="U_USD">126688000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3542ed0a-f698-456b-b13d-df3808be4d52"
      decimals="-3"
      id="F_3742c219-905a-48fe-86c8-33365a383f87"
      unitRef="U_USD">73089000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f6111456-3ab3-4369-86bb-70377a24aea5"
      decimals="-3"
      id="F_e86b34eb-a400-4de8-a6d1-bda0467868f1"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_77f70987-1a99-49d7-a124-ec8a7e4706b5"
      decimals="-3"
      id="F_a38f3c97-fdb8-4f00-9091-1923e15698c0"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4b3a5f9b-38bc-43b9-a48b-838362ad8efb"
      decimals="-3"
      id="F_6fa7d1f1-4912-4c20-acc4-de592d5a64a9"
      unitRef="U_USD">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69"
      decimals="-3"
      id="F_acb2f52d-086e-48bc-98c6-39e21bc6a54e"
      unitRef="U_USD">72029000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0"
      decimals="-3"
      id="F_c820748f-06d6-4a57-9482-76de9ecd3733"
      unitRef="U_USD">126688000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38"
      decimals="-3"
      id="F_e86bf1c5-e873-417a-9942-d251b15b5e2b"
      unitRef="U_USD">83089000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingExpenses
      contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69"
      decimals="-3"
      id="F_521f41f8-3102-4803-8dd3-d66c56b3ac30"
      unitRef="U_USD">332000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0"
      decimals="-3"
      id="F_2ec83a3a-1181-43ef-a15b-50e557b6f143"
      unitRef="U_USD">3956000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38"
      decimals="-3"
      id="F_b2b49101-c1b2-4d2d-9475-041a7955e7a0"
      unitRef="U_USD">2612000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69"
      decimals="-3"
      id="F_6c392004-41b0-4c06-b69e-3c3989f1da72"
      unitRef="U_USD">71697000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0"
      decimals="-3"
      id="F_ef4a669e-84af-4e93-a59a-e7e80f5e6640"
      unitRef="U_USD">122732000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38"
      decimals="-3"
      id="F_db40794b-d0e9-45b2-abba-fb3f524dd8e5"
      unitRef="U_USD">80477000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69"
      decimals="-3"
      id="F_8d9bf4a0-4bf1-43e0-b158-8e543323249a"
      unitRef="U_USD">10000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0"
      decimals="-3"
      id="F_cc45e58a-7c37-4347-8239-30a4a8625107"
      unitRef="U_USD">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38"
      decimals="-3"
      id="F_3732e541-5006-4acc-b367-cfa92115e2e6"
      unitRef="U_USD">38000</us-gaap:OtherNonoperatingIncomeExpense>
    <inva:RealizedLoss
      contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69"
      decimals="-3"
      id="F_a60f2bef-ef0a-446d-8d7c-bfb962574365"
      unitRef="U_USD">-39386000</inva:RealizedLoss>
    <inva:RealizedLoss
      contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0"
      decimals="-3"
      id="F_6f303a35-1dc7-49a1-9257-893ab105849c"
      unitRef="U_USD">0</inva:RealizedLoss>
    <inva:RealizedLoss
      contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38"
      decimals="-3"
      id="F_1059cbcf-ca20-4b0b-a329-ba17c65e0449"
      unitRef="U_USD">0</inva:RealizedLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69"
      decimals="-3"
      id="F_1fa0aea7-9d32-43e0-8b99-2f28dfa45057"
      unitRef="U_USD">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0"
      decimals="-3"
      id="F_c3d08855-136a-44d2-b946-f3beb0c817da"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38"
      decimals="-3"
      id="F_a406f92c-df9a-4bf7-8897-c35e9a2d9ab1"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:GainLossOnInvestments
      contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69"
      decimals="-3"
      id="F_58a6e17d-816a-4800-b40a-497386e20e19"
      unitRef="U_USD">-8884000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0"
      decimals="-3"
      id="F_35369e73-be35-4e15-ab61-f7bf7cf72b44"
      unitRef="U_USD">-1541000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38"
      decimals="-3"
      id="F_dabee276-d1fc-4f0d-8c23-4a092d8b1429"
      unitRef="U_USD">1147000</us-gaap:GainLossOnInvestments>
    <us-gaap:ProfitLoss
      contextRef="C_78ff815a-1619-48b9-baf1-0f3abaf5cd69"
      decimals="-3"
      id="F_498794db-f6ff-4500-b278-62cc95d92aa2"
      unitRef="U_USD">23438000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_58a6fc45-3a96-4a07-987b-2354bc51fbf0"
      decimals="-3"
      id="F_8af723af-c819-4e74-b7bd-591d01c78f98"
      unitRef="U_USD">121191000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_01454fb2-c5af-4c5f-b7f4-f2acef729d38"
      decimals="-3"
      id="F_167587f4-80f0-46d2-ba33-7d91029e053c"
      unitRef="U_USD">81662000</us-gaap:ProfitLoss>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="C_3da5364e-c3cc-4073-9770-65a8da75a030"
      decimals="-5"
      id="F_393a18ff-87e4-4f59-b623-31230e0f60b5"
      unitRef="U_USD">300000000.0</us-gaap:LimitedPartnersContributedCapital>
    <us-gaap:LimitedPartnersCumulativeCashDistributions
      contextRef="C_93e0e07a-b332-46ca-be2f-706ee21b9d8b"
      decimals="-5"
      id="F_9587a82d-8a9b-4f28-abf5-2db84eff985a"
      unitRef="U_USD">110000000.0</us-gaap:LimitedPartnersCumulativeCashDistributions>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="C_2abf6f42-38e2-40d9-a0d2-9871c5194249"
      decimals="-5"
      id="F_f3731579-0b9e-4445-9c04-31d4b95ad0c6"
      unitRef="U_USD">110000000.0</us-gaap:LimitedPartnersContributedCapital>
    <inva:PartnershipAgreementLockUpPeriod
      contextRef="C_f39c54bb-13a8-4982-a1a5-05cf42acdcd2"
      id="F_2f0236ed-aaae-4f1b-b812-a8d8ba596d9b">P36M</inva:PartnershipAgreementLockUpPeriod>
    <inva:PercentageOfEconomicInterestInPartnership
      contextRef="C_006d6f8d-3460-4b4e-a5bd-62c377110a66"
      decimals="2"
      id="F_edc755d6-03a7-48f7-9911-a49de6dbaa82"
      unitRef="U_pure">1</inva:PercentageOfEconomicInterestInPartnership>
    <us-gaap:Assets
      contextRef="C_9d306884-7dee-45a2-9203-d77e41d65ae4"
      decimals="-5"
      id="F_f53fa3a7-d305-4fa5-bf82-9fd8f3ef3879"
      unitRef="U_USD">320600000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_f25f9085-e7bd-462a-8c86-23de80c89333"
      decimals="-5"
      id="F_ec1f9a51-68cc-4403-a005-2054d31a8dc8"
      unitRef="U_USD">195800000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="C_9d306884-7dee-45a2-9203-d77e41d65ae4"
      decimals="-5"
      id="F_d70129dc-2555-497a-be31-803b7e21c9c2"
      unitRef="U_USD">1600000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_f25f9085-e7bd-462a-8c86-23de80c89333"
      decimals="-5"
      id="F_b09271f4-06cd-44f3-8bfc-da84d7f5c7d8"
      unitRef="U_USD">200000</us-gaap:Liabilities>
    <us-gaap:InvestmentIncomeInvestmentExpense
      contextRef="C_006d6f8d-3460-4b4e-a5bd-62c377110a66"
      decimals="-5"
      id="F_8cbe553c-396c-443e-83a8-dc204a7a7c1f"
      unitRef="U_USD">5200000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_006d6f8d-3460-4b4e-a5bd-62c377110a66"
      decimals="-5"
      id="F_0a70cd8e-cc04-4783-a5b8-73f49a93b282"
      unitRef="U_USD">2000000.0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:GainLossOnInvestments
      contextRef="C_006d6f8d-3460-4b4e-a5bd-62c377110a66"
      decimals="-5"
      id="F_b5833325-776b-445a-89d5-adbaf326cb82"
      unitRef="U_USD">6800000</us-gaap:GainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_006d6f8d-3460-4b4e-a5bd-62c377110a66"
      decimals="-5"
      id="F_d00f0c00-9161-40f1-acd4-fa3c63e6d7c5"
      unitRef="U_USD">9900000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:InvestmentIncomeInvestmentExpense
      contextRef="C_3251587b-f79c-4e54-ba80-2c3e2d36881d"
      decimals="-5"
      id="F_e29e5f78-ed25-46c6-a8c1-139c8e6566db"
      unitRef="U_USD">3600000</us-gaap:InvestmentIncomeInvestmentExpense>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="C_3251587b-f79c-4e54-ba80-2c3e2d36881d"
      decimals="-5"
      id="F_61b844cf-2bb1-4caa-9e7c-63ebcc7f6891"
      unitRef="U_USD">1800000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:GainLossOnInvestments
      contextRef="C_3251587b-f79c-4e54-ba80-2c3e2d36881d"
      decimals="-5"
      id="F_316076a8-3da1-48f1-9427-b4a635e92e6f"
      unitRef="U_USD">10500000</us-gaap:GainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_3251587b-f79c-4e54-ba80-2c3e2d36881d"
      decimals="-5"
      id="F_5febf443-ad25-4595-9e43-197e2a75c13e"
      unitRef="U_USD">2400000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_64c565f8-b8c8-4b5e-8680-bd30e909b71f"
      decimals="INF"
      id="F_1aa76c99-e8a8-4ebf-857c-0fcce1ad52ab"
      unitRef="U_shares">14000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction
      contextRef="C_d36b2a4f-1056-4575-a198-9dd2e9d0fa87"
      decimals="INF"
      id="F_b1ea64cf-cfd5-40bb-81ed-aeaddb09a5ce"
      unitRef="U_shares">14000000</inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="C_33ced285-7a79-4d44-9fd4-1c555534d19d"
      decimals="-5"
      id="F_1d488521-d6a6-4dcf-a19a-59a1c1c78e94"
      unitRef="U_USD">35000000.0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_412716b4-7218-40f6-adc0-a9a7b2226300"
      decimals="INF"
      id="F_82821955-e836-42fe-b6b4-843d39069a52"
      unitRef="U_shares">4672897</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction
      contextRef="C_6a9f3a87-35e9-4510-9ef5-42186f58a55d"
      decimals="INF"
      id="F_fa30c432-d5a2-4eb5-9c67-a448956adb10"
      unitRef="U_shares">4672897</inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="C_bb7f1b9c-c794-42e0-872f-0ba49fe65cad"
      decimals="-5"
      id="F_e2a2bdf6-b8c3-4612-b72a-b9d5f6067b0e"
      unitRef="U_USD">12500000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <inva:SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers
      contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223"
      decimals="INF"
      id="F_322d7a72-0791-40da-9039-ad40f9ca5a61"
      unitRef="U_Director">2</inva:SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_91dd5dfc-a8fa-4797-a5f1-1cbcfbb0101d"
      decimals="INF"
      id="F_8650c5b9-b879-4956-b4b4-65189c57ea82"
      unitRef="U_shares">10000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_5713e251-00d3-4344-8351-32137ba92c7f"
      decimals="INF"
      id="F_eeb014e1-7a8a-497f-a2f2-e463ab259aa6"
      unitRef="U_shares">10000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="C_46102164-0773-400f-906c-f458fc8d0c96"
      decimals="-5"
      id="F_b31b2756-cd20-45d5-9608-d75098d0e6d5"
      unitRef="U_USD">20000000.0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_d8114345-dec6-4194-93e9-3a1b415dbb83"
      decimals="2"
      id="F_44460c84-9a40-4933-95d8-de9a0a501474"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_ba934ce3-7b7f-485e-9ba2-cec7f54bb480"
      decimals="3"
      id="F_0e013fda-1d27-4c4a-ae72-b4c616f72df9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.675</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_bb6b6c9e-02d0-4be8-b0ad-089e8436ed15"
      decimals="2"
      id="F_cf25b911-c264-427c-bb7a-a153af00b081"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_9d895e55-890d-4019-93ff-8bf714b8997b"
      id="F_3e8976d9-c095-4f5f-b06f-79eea450f9f5">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_7bb172e8-abbc-4585-873a-e59b32f846e6"
      id="F_5c7b9d47-577c-442c-8ac5-7da0ec91f57e">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_b335fc75-9e6c-4232-9459-e0730898b34c"
      id="F_70aa63f0-4e3f-4a37-a71e-c4f69411f5f4">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_71a8eb9a-e948-4bab-961c-28016a550572"
      decimals="-5"
      id="F_cc792e20-88c5-4540-b4fe-8b66b4755c15"
      unitRef="U_USD">15000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_71a8eb9a-e948-4bab-961c-28016a550572"
      decimals="4"
      id="F_f1d4e95e-3573-4c3a-9240-cc2e003d8790"
      unitRef="U_pure">0.0059</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_eee47a4c-1fd8-4bc9-916a-4c43bdc117fd"
      id="F_281316dc-d99b-4982-a1d9-732dcc1f26b6">2022-08-18</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_71a8eb9a-e948-4bab-961c-28016a550572"
      decimals="2"
      id="F_a0c23186-119c-4203-b7ac-86bf051747f4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.48</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_31d13e09-7b0b-45f3-8c0c-c5750ed2e05f"
      decimals="3"
      id="F_9971abdf-4717-4848-9229-e727719915af"
      unitRef="U_pure">0.599</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_32d6e1d8-d581-4a23-a3d6-067540daf4c9"
      decimals="-5"
      id="F_909e5bf9-582c-4a04-8780-b336fefc535c"
      unitRef="U_USD">64500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_faf804e2-dcb7-4016-8d35-d20f9d798b45"
      decimals="-5"
      id="F_40326ac4-aa2e-451e-bc6c-655ee11c65f2"
      unitRef="U_USD">31400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223"
      decimals="-5"
      id="F_368e9bc5-00c3-467b-8b6e-c9b27ff1592d"
      unitRef="U_USD">7800000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <inva:BusinessAcquisitionsOfChangeInFairValueOfInvestment
      contextRef="C_c2438911-cddb-444f-87c4-9270c2e0d009"
      decimals="-5"
      id="F_f36a9872-338b-441e-af8c-f9d950abd8cd"
      unitRef="U_USD">1400000</inva:BusinessAcquisitionsOfChangeInFairValueOfInvestment>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="C_c2438911-cddb-444f-87c4-9270c2e0d009"
      decimals="INF"
      id="F_3d24e3e3-85ab-4b03-b27d-5a91148b0eb9"
      unitRef="U_USD">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223"
      decimals="-5"
      id="F_06a5a051-e079-450a-93f3-d18ec00e4beb"
      unitRef="U_USD">-4700000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <inva:MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice
      contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223"
      decimals="-5"
      id="F_94c06862-0038-40a3-b326-92247d4162f1"
      unitRef="U_USD">-1400000</inva:MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223"
      decimals="-5"
      id="F_58f60120-2d36-4fda-95db-7e2dbac2936f"
      unitRef="U_USD">1700000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223"
      decimals="-5"
      id="F_9adedabd-6b4b-4a70-b94a-96264dfb9573"
      unitRef="U_USD">2500000</us-gaap:IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223"
      id="F_064aa016-ed12-4baf-8063-93fdd24adc37">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table represents the adjusted fair values of the assets acquired and liabilities assumed by us in the transaction:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.325%;"/&gt;
        &lt;td style="width:1.794%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.881%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;February 17, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;107,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;149,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued personnel-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,058&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total liabilities assumed&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets acquired, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_44939635-2168-4449-bc96-02f14b8f192a"
      unitRef="U_USD">23070000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_1a5b095a-5fce-48ce-8d66-5b969b1b1d1c"
      unitRef="U_USD">5554000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_7c822daf-f1e8-4b58-a0d9-3be61e05ca08"
      unitRef="U_USD">1959000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_f852d7d9-276f-4d55-bd04-e1812d4bff2b"
      unitRef="U_USD">185000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_178447ed-df0f-4de3-8816-c5986589afa0"
      unitRef="U_USD">959000</inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:Goodwill
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_129308f1-ccf8-4e36-b410-2606c0187e19"
      unitRef="U_USD">10260000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_6e31b833-dc4f-4291-aeef-6b259a48bd8f"
      unitRef="U_USD">107500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_c01b9e84-48dd-486d-ab83-082a892fc7c0"
      unitRef="U_USD">302000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_abfdb16c-2f3c-46fd-ad1e-e94b282dd30f"
      unitRef="U_USD">149789000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_12ab55d4-4d41-4421-a363-5ad80e0a2028"
      unitRef="U_USD">1583000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_acd5080c-c2e0-4ac6-9d6d-c0d20f48130e"
      unitRef="U_USD">1058000</inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses>
    <inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_52f67d9e-0655-4afa-8c3a-c03508887031"
      unitRef="U_USD">5096000</inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_b92fbe1e-3621-4a44-9e42-42824ff101f0"
      unitRef="U_USD">7336000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_f8f87624-29a4-480f-9788-e13088b826ae"
      unitRef="U_USD">15073000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="C_0c973e72-2f06-4c3d-9d8c-a65f18682660"
      decimals="-3"
      id="F_20e85d73-5f8f-4768-8508-8b55b2c49b52"
      unitRef="U_USD">134716000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_0d5aeb89-6a39-4e78-aae5-e1088841d223"
      decimals="-5"
      id="F_e44c6bd4-cf8e-4363-8a79-e2d736142398"
      unitRef="U_USD">-13600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_97660a37-a4d7-4e93-aa09-8f8b998393d8"
      decimals="-5"
      id="F_552aba39-b057-4e58-82f9-1b170ecd94b0"
      unitRef="U_USD">206600000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="2"
      id="F_abf068f2-552c-4525-a62d-3bd83417712f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.23</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:GoodwillPeriodIncreaseDecrease
      contextRef="C_6cb7b433-593e-4c62-95c5-c68106abd3d7"
      decimals="-5"
      id="F_d4ea727e-c688-4941-906b-76e7f5ac1bc2"
      unitRef="U_USD">3700000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_6cb7b433-593e-4c62-95c5-c68106abd3d7"
      decimals="-5"
      id="F_92dce771-c259-4612-95e3-37b2a02f6252"
      unitRef="U_USD">-7700000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="C_6cb7b433-593e-4c62-95c5-c68106abd3d7"
      decimals="-5"
      id="F_279247c0-5e05-42dc-ad44-ffad8bdc0ecc"
      unitRef="U_USD">-1500000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <inva:IncreaseDecreaseInDeferredTaxLiabilities
      contextRef="C_6cb7b433-593e-4c62-95c5-c68106abd3d7"
      decimals="-5"
      id="F_03eae049-e466-4d2e-91b1-fb08af516064"
      unitRef="U_USD">2600000</inva:IncreaseDecreaseInDeferredTaxLiabilities>
    <inva:MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities
      contextRef="C_6cb7b433-593e-4c62-95c5-c68106abd3d7"
      decimals="-5"
      id="F_2bebc147-7536-4961-a81e-4f1d5689d5a2"
      unitRef="U_USD">-8300000</inva:MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities>
    <us-gaap:AcquisitionCosts
      contextRef="C_6cb7b433-593e-4c62-95c5-c68106abd3d7"
      decimals="-5"
      id="F_124adacc-590d-4b31-bbef-ba7428ed563d"
      unitRef="U_USD">5300000</us-gaap:AcquisitionCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="C_6cb7b433-593e-4c62-95c5-c68106abd3d7"
      id="F_553aa9c8-1f29-410d-993b-64e2566c55c0">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the adjusted allocation of the fair values assigned to the assets acquired and liabilities assumed as of the date of the acquisition:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.325%;"/&gt;
        &lt;td style="width:1.794%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.881%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 22, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;907&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets acquired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;290,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other long-term liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total liabilities assumed&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83,973&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets acquired, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;206,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_fa5b7012-9353-41bc-8b2e-6e4614f01d52"
      unitRef="U_USD">47415000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_c01bf1e3-a386-41a6-a38a-e178574d1703"
      unitRef="U_USD">471000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_eafb9551-7f35-4e6d-a36b-0b0823506088"
      unitRef="U_USD">5876000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_b49d9acb-5bf5-486f-90df-bc75d66f7bdc"
      unitRef="U_USD">66200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_37c7c808-db92-47f1-81b4-ec69c760c1ac"
      unitRef="U_USD">1261000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_7ff1a0ce-58da-426b-8360-c3f2a560cd63"
      unitRef="U_USD">907000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_9eb0eb24-95ce-480d-af81-7524c2100da3"
      unitRef="U_USD">13000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_411036e1-f1fe-49bc-979c-01a3be2f445f"
      unitRef="U_USD">226000</inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:Goodwill
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_d07bb7c4-8d86-4df3-9f00-2c021c131a81"
      unitRef="U_USD">16453000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_8b5314b6-56f3-4302-9082-6403a64b26b1"
      unitRef="U_USD">151000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_4d675b27-9911-4549-b74f-9a5c5560d4eb"
      unitRef="U_USD">710000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_058933e0-ba86-4159-bea0-d7f76c6267c4"
      unitRef="U_USD">290532000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_b11e0415-54be-4e54-bd23-c5d7c9832026"
      unitRef="U_USD">1237000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_934aa8ea-264b-48d9-b4e5-4d4c107c52ee"
      unitRef="U_USD">2849000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_bee6eea6-aba4-4946-a0a7-d114864fcab8"
      unitRef="U_USD">11362000</inva:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_af5e06da-ce54-4d46-a34f-871d2d5d379d"
      unitRef="U_USD">65944000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_80d10efd-93d3-4be9-8cfc-079e7ccba806"
      unitRef="U_USD">2581000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_4404724d-f4da-4842-a37f-0dff625a69cf"
      unitRef="U_USD">83973000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="C_8af701ba-469b-4d82-804b-8716aa0537d9"
      decimals="-3"
      id="F_f4b0a68b-26d2-45cb-a45e-e16ada701f04"
      unitRef="U_USD">206559000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_7dd9bbf9-90bf-45b4-9718-1943527ef9fc">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents certain unaudited pro-forma financial information for the years ended December 31, 2022 and 2021 as if the consolidation of Entasis and La Jolla occurred on January 1, 2021. The unaudited pro forma financial information is presented for informational purposes only, and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place on January 1, 2021, or of results that may occur in the future. The unaudited pro forma financial information combines the historical results of the Entasis and La Jolla with the Company&#x2019;s consolidated historical results and includes certain adjustments including, but not limited to, fair value adjustments to equity investments in Entasis&#x2019; common stock and warrants, fair value adjustments to inventory, amortization of intangible assets, and interest expense on deferred royalty obligations and acquisition-related costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.399%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.6%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;357,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;435,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;204,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;281,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income attributable to Innoviva stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;214,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;197,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="C_15fd9d26-7d1b-4c32-bc1c-d97f9e0dd0c8"
      decimals="-3"
      id="F_29964cdf-1188-43df-b447-ecaebafc9c74"
      unitRef="U_USD">357880000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="C_4f4721dc-8199-4105-9ec9-a169e1f0086c"
      decimals="-3"
      id="F_967e0cd9-e9c4-4149-9ae7-d5f2153a6799"
      unitRef="U_USD">435398000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="C_15fd9d26-7d1b-4c32-bc1c-d97f9e0dd0c8"
      decimals="-3"
      id="F_1c82b98c-249c-446b-a7da-9992136addce"
      unitRef="U_USD">204987000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="C_4f4721dc-8199-4105-9ec9-a169e1f0086c"
      decimals="-3"
      id="F_464d6224-b4b3-4c59-bd39-9b8d45abfcd8"
      unitRef="U_USD">281719000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_15fd9d26-7d1b-4c32-bc1c-d97f9e0dd0c8"
      decimals="-3"
      id="F_38938b3a-3687-4cb3-9b68-0add4f004755"
      unitRef="U_USD">214390000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4f4721dc-8199-4105-9ec9-a169e1f0086c"
      decimals="-3"
      id="F_b30245c3-d491-400f-8108-0f662321500f"
      unitRef="U_USD">197535000</us-gaap:NetIncomeLoss>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_3dea71c6-c9ec-4f72-970d-2583ab2a09e5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6. EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Method Investment in Armata&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the first quarter of 2020, Innoviva acquired &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,710,800&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock as well as warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,710,800&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional shares of common stock of Armata Pharmaceuticals, Inc. (&#x201c;Armata&#x201d;) for approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in cash. Armata is a clinical stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the first quarter of 2021, ISO entered into a securities purchase agreement with Armata to acquire &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,153,847&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Armata common stock and warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,153,847&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional shares of Armata common stock for approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Armata also entered into a voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the total number of shares of Armata&#x2019;s common stock for voting on the matters related to election or removal of Armata&#x2019;s board members. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#x2019;s product candidates for marketing and commercial distribution. During the fourth quarter of 2021, ISO also purchased an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,212,122&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Armata common stock for approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 9, 2022, ISO entered into a securities purchase agreement with Armata to acquire &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Armata common stock and warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional shares of common stock with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The investment closed in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; tranches on February 9, 2022 and March 31, 2022. The investment is intended to aid Armata in advancing its clinical pipeline and strengthening its bacteriophage platform. On February 9, 2022, Armata also entered a second amended and restated voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the total number of shares of Armata&#x2019;s common stock for voting on the matters related to election or removal of Armata&#x2019;s board members or amend the bylaws of Armata to reduce the maximum number of directors or set the number of directors who may serve on the board of Armata. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#x2019;s product candidates for marketing and commercial distribution. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the outstanding shares of Armata&#x2019;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#x2019;s board of directors, and for so long as the Company and ISO hold at least &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, but less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, of the outstanding shares of Armata&#x2019;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#x2019;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; As of December 31, 2022,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;eight&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;members of Armata&#x2019;s board of directors are also members of the board of directors of Innoviva. As of December 31, 2022 and 2021, we owned approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% an&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;d &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, respectively, of Armata&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The investments in Armata provide Innoviva and ISO the ability to have significant influence, but not control over Armata&#x2019;s operations. Armata&#x2019;s business and affairs are managed under the direction of its board of directors, which Innoviva and ISO do not control. Based on our evaluation, we determined that Armata is a VIE, but Innoviva and ISO are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We account for both Armata&#x2019;s common stock and warrants under the equity method using the fair value option. The fair value of Armata&#x2019;s common stock is measured based on its closing market price. The warrants purchased in 2020, 2021 and 2022 have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.87&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, respectively. All warrants are exercisable immediately within &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; from the issuance date of the warrants and include a cashless exercise option. We use the Black-Scholes-Merton pricing model to estimate the fair value of these warrants with the following input assumptions: Armata&#x2019;s closing market price on the valuation date, the risk-free interest rate computed based on the U.S. Treasury yield, the remaining contractual term as the expected term, and the expected stock price volatility calculated based on the historical volatility of the common stock of Armata and its peer companies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of Dece&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;mber 31, 2022, the fair values of our holdings of Armata common stock and warrants were estimated at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. As of December 31, 2021, the fair values of our holdings of Armata common stock and warrants were estimated at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The total fair value of both financial instruments in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;146.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was recorded as equity and long-term investments on the consolidated balance sheets as of December 31, 2022 and 2021, respectively. We recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;152.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million unrealized losses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million unrealized gains as changes in fair values of equity method investments, net, on the consolidated statements of income for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag regardless of the date of our investments as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Balance Sheet Information&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.94%;"/&gt;
        &lt;td style="width:2.262%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.57%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.262%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.968%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Noncurrent assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Statement Information&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.034%;"/&gt;
        &lt;td style="width:1.11%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.577%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.11%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.394%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.09%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.683%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Twelve Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Nine Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Method Investment in Entasis&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to the consolidation of Entasis&#x2019; financial position and results of operations in February 2022, we accounted for Entasis as an equity method investment. Refer to Note 5, &#x201c;Consolidated Entities and Acquisitions&#x201d;, for more information.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The summarized financial information, including the portion we did not own, is presented for Entasis on a one quarter lag regardless of the date of our investments as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Balance Sheet Information&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.276%;"/&gt;
        &lt;td style="width:1.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.929%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Noncurrent assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Statement Information&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.668%;"/&gt;
        &lt;td style="width:2.249%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.917%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.249%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.917%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Twelve Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Six Months&lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Investment in InCarda&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the third quarter of 2020, TRC purchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,469,432&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Series C preferred stock and a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,117,358&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional shares of Series C preferred stock of InCarda Therapeutics, Inc. (&#x201c;InCarda&#x201d;) (the &#x201c;InCarda 2020 Warrant&#x201d;) for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which included $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of transaction costs. InCarda is a privately held biopharmaceutical company focused on developing inhaled therapies for cardiovascular diseases. The investment is intended to fund the ongoing clinical development of InRhythmTM (flecainide for inhalation), InCarda&#x2019;s lead program, for the treatment of a recent-onset episode of paroxysmal atrial fibrillation. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#x2019;s ownership interests and investments in InCarda. ITH has the right to designate one member to InCarda&#x2019;s board of directors. As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of InCarda&#x2019;s &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;eight&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; board members was designated by ITH. The InCarda 2020 Warrant is exercisable immediately with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7328&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. In September 2021, TRC and InCarda entered into an amendment to extend the expiration date of the InCarda 2020 Warrant from October 6, 2021 to March 31, 2022. On March 9, 2022, TRC and InCarda entered into an amendment to further extend the expiration date of the InCarda 2020 Warrant from March 31, 2022 to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The InCarda 2020 Warrant is recorded at fair value and subject to remeasurement at each balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 9, 2022, TRC entered into a Note and Warrant Purchase Agreement (the &#x201c;InCarda Agreement&#x201d;) with InCarda to acquire a convertible promissory note (the &#x201c;InCarda Convertible Note&#x201d;) and warrants (the &#x201c;InCarda 2022 Warrant&#x201d;) for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The InCarda Convertible Note bears an annual interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and will convert into Series D preferred stock upon a qualified financing, non-qualified financing, or maturity conversion. A qualified financing is defined as the first issuance or series of related issuances by InCarda of its equity securities following March 9, 2022 from which InCarda receives immediately available gross proceeds of at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million (excluding the aggregate amount of any notes converted into equity securities pursuant to the conversion of notes or any other debt securities converted into equity securities) (the &#x201c;Qualified Financing Amount&#x201d;). A non-qualified financing is defined as the first issuance or series of related issuances by InCarda of its equity securities following March 9, 2022 from which InCarda receives immediately available gross proceeds of less than the Qualified Financing Amount. The InCarda 2022 Warrant entitles TRC to purchase a number of shares of equity securities equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the principal amount of the InCarda Convertible Note divided by the number of shares issued in InCarda&#x2019;s next equity financing, which is defined as the earliest to occur of specific financing events, including capital raises through public offerings. The InCarda 2022 Warrant expires on March 9, 2027. The InCarda Convertible Note and InCarda 2022 Warrant are measured at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On June 15, 2022, the principal amount and the accrued interest of the InCarda Convertible Note were converted into equity securities. In addition, TRC participated in InCarda&#x2019;s Series D preferred stock financing by investing $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. In connection with the new round of financing, InCarda recapitalized its equity structure resulting in TRC owning &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,093,886&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of InCarda&#x2019;s common&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;stock, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,350&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its Series A-1 preferred stock, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,469,432&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its Series C preferred stock, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,771,780&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its Series D-1 preferred stock, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,369,802&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its Series D-2 preferred stock, a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,117,358&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its Series C preferred stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.73&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,490,033&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its Series D-1 preferred stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, we held &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of InCarda equity ownership, respectively. Our investment in InCarda does not provide us with the ability to control or have significant influence over InCarda&#x2019;s operations. Based on our evaluation, we determined that InCarda is a VIE, but we are not the primary beneficiary of the VIE.  We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We account for our investments in InCarda under the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer. Due to InCarda&#x2019;s equity recapitalization in the second quarter of 2022, TRC reassessed the value of its investments in InCarda using the Option Pricing Model Backsolve valuation methodology. Key assumptions used in the valuation model include an expected holding period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, a risk free interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, a dividend yield of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and an estimated volatility of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;122.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. The estimated volatility is calculated based on the historical volatility of a selected peer group of public companies comparable to InCarda. We recognized an impairment charge of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as a result of the valuation. There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; impairment or other change to the value of our investments in InCarda as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, we recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in fair value of InCarda&#x2019;s Series C preferred stock and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in fair value of Series C warrants and Series D warrants (the &#x201c;InCarda Preferred Stock Warrants&#x201d;). As of December 31, 2022, we recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for InCarda&#x2019;s Series D-1 preferred stock, Series D-2 preferred stock, and common stock using the measurement alternative. As of December 31, 2021, we recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in fair value of the InCarda 2020 Warrant. As of December 31, 2021, we recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the investment in InCarda&#x2019;s Series C preferred stock using the measurement alternative. We recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million unrealized loss as changes in fair values of other equity and long-term investments, net, on the consolidated statements of income for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Investment in ImaginAb&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 18, 2021, TRC entered into a securities purchase agreement with ImaginAb, Inc. (&#x201c;ImaginAb&#x201d;) to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,051,724&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of ImaginAb Series C preferred stock for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. On the same day, TRC also entered into a securities purchase agreement with one of ImaginAb&#x2019;s common stockholders to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,097,157&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of ImaginAb common stock for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. ImaginAb is a privately held biotechnology company focused on clinically managing cancer and autoimmune diseases via molecular imaging. $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was incurred for investment due diligence costs and execution and recorded as part of the equity and long-term investment on the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#x2019;s ownership interests and investments in ImaginAb. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of ImaginAb&#x2019;s &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;six&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; board members is designated by ITH, and ITH held&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ImaginAb&#x2019;s equity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ownership. As of December 31, 2021, TRC held &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of ImaginAb equity ownership.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Our investment in ImaginAb does not provide us with the ability to control or have significant influence over ImaginAb&#x2019;s operations. Based on our evaluation, we determined that ImaginAb is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Because ImaginAb&#x2019;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in ImaginAb&#x2019;s Series C preferred stock and common stock using the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer. As of  December 31, 2022 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and 2021, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was recorded as equity and long-term investments on the consolidated balance sheets and there was no change to the fair value of our investment in ImaginAb.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Convertible Promissory Note in Gate Neurosciences&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On November 24, 2021, TRC entered into a Convertible Promissory Note Purchase Agreement with Gate Neurosciences, Inc. (&#x201c;Gate&#x201d;) to acquire a convertible promissory note (the &#x201c;Convertible Note&#x201d;) with a principal amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Gate is a privately held biopharmaceutical company focused on developing the next generation of targeted nervous system therapies, leveraging precision medicine approaches to develop breakthrough drugs for psychiatric and neurologic diseases. The investment is intended to fund its ongoing development and research. The Convertible Note bears an annual interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% and will convert into common stock shares upon a qualified event or into shares of shadow preferred stock (&#x201c;Shadow Preferred&#x201d;) upon a qualified financing. A qualifying event can be a qualified initial price offering, a qualified merger, or a merger with a special-purpose acquisition company (&#x201c;SPAC&#x201d;). Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#x201c;Capped Conversion Price&#x201d;) and the qualified event price (the &#x201c;Qualified Event Price&#x201d;). The Capped Conversion Price is calculated as $50.0 million divided by the number of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Gate are at least $35.0 million, and (iii) the stated or implied equity valuation of Gate is at least $80.0 million. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"/&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH its debt investment in Gate. We have accounted for the Gate Convertible Note as a trading security, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of equity value of Gate, risk-free rate, expected stock price, volatility of its peer companies, and the time until a financing is raised. As of December 31, 2022 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021, the fair value of the Gate Convertible Note was estimated at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, and recorded as equity and long-term investments on the consolidated balance sheets. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of unrealized gain and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of unrealized loss as changes in fair values of other equity and long-term investments, net, on the consolidated statements of income for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Investment in Nanolive&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 18, 2022, TRC entered into an investment and shareholders agreement with Nanolive SA (&#x201c;Nanolive&#x201d;) to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,750,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Nanolive Series C preferred stock for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million (equivalent to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million CHF). Nanolive SA is a Swiss privately held life sciences company focused on developing breakthrough imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was incurred for investment due diligence costs and execution and recorded as part of the equity and long-term investment on the consolidated balance sheets. On July 20, 2022, under the terms of the TRC Equity Purchase Agreement, TRC transferred to ITH all of TRC&#x2019;s ownership interests and investments in Nanolive. ITH has the right to designate one member to Nanolive&#x2019;s board. ITH also has the right to designate another member, who will be mutually acceptable to ITH and another majority common stockholder, to Nanolive&#x2019;s board. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of Innoviva designees is serving on Nanolive&#x2019;s &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;seven&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-member board. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, we held &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of Nanolive equity ownership.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our investment in Nanolive does not provide us with the ability to control or have significant influence over Nanolive&#x2019;s operations. Based on our evaluation, we determined that Nanolive is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Because Nanolive&#x2019;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in Nanolive&#x2019;s Series C preferred stock using the measurement alternative. As of  December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was recorded as equity and long-term investments on the consolidated balance sheets and there was no change to the fair value of our investment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Available-for-Sale Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.883%;"/&gt;
        &lt;td style="width:1.553%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.133999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.133999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.133999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.475%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds are included in cash and cash equivalents on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.883%;"/&gt;
        &lt;td style="width:1.553%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.133999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.133999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.133999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.475%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds are included in cash and cash equivalents on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, all investments were money market funds, and there was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; credit loss recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our available-for-sale securities, equity and long-term investments are measured at fair value on a recurring basis and our debt is carried at amortized cost basis. The estimated fair values were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.189%;"/&gt;
        &lt;td style="width:1.418%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.956999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.408%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.956999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.408%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.956999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.408%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.299%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Fair Value Measurements as of December 31, 2022 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Price&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Types of Instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments held by ISP Fund LP &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;265,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;320,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - Armata Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - Armata Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - InCarda Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Convertible debt investment - Gate Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;560,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;639,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;197,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;197,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;211,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;211,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Total fair value of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;505,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;505,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contingent value rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total liabilities at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;505,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;506,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The investments held by ISP Fund LP, consisted of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;295.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in equity investments, which included private placement positions and convertible notes of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in money market funds. Our total capital contribution of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million is subject to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; lock-up period from the date of such capital contributions.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.931%;"/&gt;
        &lt;td style="width:1.418%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.032%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.032%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.032%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.334999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Fair Value Measurements as of December 31, 2021 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in Active&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Markets for&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Types of Instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments held by ISP Fund LP &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;193,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;195,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - Armata Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - Armata Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - Entasis Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - Entasis Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - InCarda Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Convertible debt investment - Gate Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;489,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;606,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;261,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;261,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;234,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;234,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total fair value of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;496,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;496,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The investments held by ISP Fund LP, consisted of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;192.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million equity investments and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million money market funds, are subject to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-month lock-up period from our initial contribution date, December 11, 2020.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair values of our equity investments in Armata&#x2019;s and Entasis&#x2019;s common stock and public traded investments held by ISP Fund LP are based on the quoted prices in active markets and are classified as Level 1 financial instruments. The fair values of the warrants of Armata and Entasis classified within Level 2 are based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;InCarda&#x2019;s equity securities, Gate's convertible note, private placement positions and convertible notes held by ISP Fund LP, and contingent value rights are classified as Level 3 financial instruments as these securities are not publicly traded and the assumptions used in the valuation model for valuing these securities are based on significant unobservable and observable inputs including those of publicly traded peer companies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair values of our 2023 Notes, 2025 Notes and 2028 Notes are based on recent trading prices of the respective instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_28a088e4-0dee-445b-90da-54cb1133ddc8"
      decimals="INF"
      id="F_43e49a4e-ceca-4e8b-97e1-2024defaa014"
      unitRef="U_shares">8710800</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction
      contextRef="C_b92b149a-66d4-4743-8737-7ac6c96eb78c"
      decimals="0"
      id="F_f9050dec-5a4d-4f2c-bbdd-57f78bf8981b"
      unitRef="U_shares">8710800</inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_4e529e8a-034a-4095-b62a-b22926e66498"
      decimals="-5"
      id="F_015e1c6f-a9b2-400f-a315-a62e4c68b091"
      unitRef="U_USD">25000000.0</inva:SecuritiesPurchaseAgreementAmount>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement
      contextRef="C_4b40705b-aebd-47f7-baf6-3520cd3218b6"
      decimals="INF"
      id="F_09901c6b-5b33-4510-8a3f-018e0d3acada"
      unitRef="U_shares">6153847</inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement
      contextRef="C_a7908317-48f4-4013-9edd-7fd23e773791"
      decimals="INF"
      id="F_dfa784d2-ad91-46af-8b5e-0b961b97012a"
      unitRef="U_shares">6153847</inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_8dd6f727-6b68-40d1-9cf3-bc4664dc52cd"
      decimals="-5"
      id="F_cff8af51-8390-4570-aa33-a181f9eb1c01"
      unitRef="U_USD">20000000.0</inva:SecuritiesPurchaseAgreementAmount>
    <inva:VotingAgreementMaximumVotingRightsPercent
      contextRef="C_b9cae3f5-7d7b-44a5-96e4-e89f716538d3"
      decimals="3"
      id="F_4f3e13b4-7542-40fe-82d8-29a556f4b83a"
      unitRef="U_pure">0.495</inva:VotingAgreementMaximumVotingRightsPercent>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_44d06045-6a65-4a7d-ad2c-0c393e7cddf9"
      decimals="INF"
      id="F_ad060c5f-a293-4f77-9a01-0473549ac433"
      unitRef="U_shares">1212122</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_44d06045-6a65-4a7d-ad2c-0c393e7cddf9"
      decimals="-5"
      id="F_08385c89-c39e-4552-9bc7-7b23b0f94021"
      unitRef="U_USD">4000000.0</inva:SecuritiesPurchaseAgreementAmount>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement
      contextRef="C_9367326d-93f1-4347-bc8c-ea4df5b4b7d8"
      decimals="INF"
      id="F_ccacf2b7-1584-40ea-9025-f5eaa71ae265"
      unitRef="U_shares">9000000</inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement
      contextRef="C_6063f5cf-dd80-437b-b1b3-9141091e7037"
      decimals="INF"
      id="F_de84b9e6-069b-4874-b1d7-74c2814ae937"
      unitRef="U_shares">4500000</inva:SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_6063f5cf-dd80-437b-b1b3-9141091e7037"
      decimals="INF"
      id="F_80ad6058-101d-474c-a30e-faee8845bbec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_13f5a4a8-8af1-45cd-bfa0-3c008efc367c"
      decimals="-5"
      id="F_22b6b57d-e93b-4837-bfcd-608d875ea43c"
      unitRef="U_USD">45000000.0</inva:SecuritiesPurchaseAgreementAmount>
    <inva:SecuritiesPurchaseAgreementNumberOfTranches
      contextRef="C_b9cae3f5-7d7b-44a5-96e4-e89f716538d3"
      decimals="0"
      id="F_20642b11-37b0-4ef4-9300-31c7c7076e90"
      unitRef="U_Tranche">2</inva:SecuritiesPurchaseAgreementNumberOfTranches>
    <inva:VotingAgreementMaximumVotingRightsPercent
      contextRef="C_83077a73-bb79-4182-b3f3-f8a33937add7"
      decimals="3"
      id="F_42013e46-26cb-4f7c-82fc-1e4f67f329ee"
      unitRef="U_pure">0.495</inva:VotingAgreementMaximumVotingRightsPercent>
    <inva:SpecialTermReDesignatingBoardMemberToBoardOfInvestee
      contextRef="C_83077a73-bb79-4182-b3f3-f8a33937add7"
      id="F_088cc42b-a01a-4d03-afaf-19cf730b18d4">In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least 12.5% of the outstanding shares of Armata&#x2019;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#x2019;s board of directors, and for so long as the Company and ISO hold at least 8%, but less than 12.5%, of the outstanding shares of Armata&#x2019;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#x2019;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.</inva:SpecialTermReDesignatingBoardMemberToBoardOfInvestee>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_3209a07a-0aa1-4b9b-907d-d83100cde8c5"
      decimals="3"
      id="F_c0a169ed-f880-427c-86f9-36dda472222c"
      unitRef="U_pure">0.125</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_38a0f685-2b21-4d8e-aa54-1e3d3d0df2e0"
      decimals="2"
      id="F_c9412816-0c60-4e54-a6db-20daffde43e1"
      unitRef="U_pure">0.08</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_33e742dc-e3d7-4460-84e9-9ec66d586b4d"
      decimals="3"
      id="F_93d11913-5351-4253-bd74-e02bd2ca66b9"
      unitRef="U_pure">0.125</us-gaap:VariableInterestEntityOwnershipPercentage>
    <inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee
      contextRef="C_8f59c417-5760-4636-8972-e9f5a4490a93"
      decimals="0"
      id="F_f60822ae-95ae-4ed2-bc3e-8274d225eb42"
      unitRef="U_Director">3</inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee>
    <inva:NumberOfBoardMembersOfInvestee
      contextRef="C_8f59c417-5760-4636-8972-e9f5a4490a93"
      decimals="0"
      id="F_98f3e485-3764-444d-8791-e84b442b7e3d"
      unitRef="U_Director">8</inva:NumberOfBoardMembersOfInvestee>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_9ce8be5c-e87f-4f02-aa59-8b21ebff6e2b"
      decimals="3"
      id="F_77e968a5-fba8-409a-9e64-2740923566d4"
      unitRef="U_pure">0.694</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_01ddf3ce-393e-4a0e-9c61-5439a63de921"
      decimals="3"
      id="F_0adcf9ba-9c3d-457e-90b5-f86f2bdfe451"
      unitRef="U_pure">0.593</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_61f224cf-c012-4c9e-a814-7844fb193f6f"
      decimals="2"
      id="F_400fc6c9-b9ff-482e-bed3-2ea67c179b99"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.87</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_a5469324-8168-4017-8117-1393b1043fb1"
      decimals="2"
      id="F_2159838f-4c73-4b0c-ac53-f108170994f6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e25220e7-99ed-4348-b545-ac306b1dcf61"
      decimals="2"
      id="F_f3d90b53-855d-4730-858c-3260f617f71d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_61f224cf-c012-4c9e-a814-7844fb193f6f"
      id="F_3f423f1b-a312-4755-9970-5fe48df7cd75">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_a5469324-8168-4017-8117-1393b1043fb1"
      id="F_e3b43238-9001-496d-8c1c-e9b4c03bbaeb">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_e25220e7-99ed-4348-b545-ac306b1dcf61"
      id="F_71bd0d3b-d96a-476a-85e8-0adc01f65bc1">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_432870a0-b84a-44de-a37b-e2b21c245d8d"
      decimals="-5"
      id="F_cf46feb4-ddac-4195-95a8-3e66986810f5"
      unitRef="U_USD">31100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_d061c9e4-9a0b-4b25-b83f-bf29e8dbc3c7"
      decimals="-5"
      id="F_6e6f2504-1179-4b8e-92e8-f51979d5d679"
      unitRef="U_USD">8100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_e0f2d71d-8e5b-4880-912e-cb4bc6a346e6"
      decimals="-5"
      id="F_7a6b8260-f22c-4936-9291-f1fb44b10204"
      unitRef="U_USD">88100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_49055080-48eb-4604-9031-96d7f9cda5c1"
      decimals="-5"
      id="F_1fea3d0a-e556-4bee-98b1-f4b1fb4cf9f8"
      unitRef="U_USD">58600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_836c70a9-4623-4b63-8ab6-169221b585c7"
      decimals="-5"
      id="F_165ea258-89e7-485b-b213-84bca9481e54"
      unitRef="U_USD">39200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_9005816e-b3a5-4468-8183-9e0fc2383e1e"
      decimals="-5"
      id="F_4c4267e8-d1dc-4240-9092-bec874c9a3b5"
      unitRef="U_USD">146700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_b9cae3f5-7d7b-44a5-96e4-e89f716538d3"
      decimals="-5"
      id="F_0348a340-a7c3-4288-970c-bf9eb0a72198"
      unitRef="U_USD">152500000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_5d0145a4-6b73-42eb-8fa3-e5ad7079aeb2"
      decimals="-5"
      id="F_3bb2297f-df4f-41bb-85cd-473b38e62858"
      unitRef="U_USD">78700000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="C_b9cae3f5-7d7b-44a5-96e4-e89f716538d3"
      id="F_53ce1297-acb9-4393-8876-90517656db97">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag regardless of the date of our investments as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Balance Sheet Information&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.94%;"/&gt;
        &lt;td style="width:2.262%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.57%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.262%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.968%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Noncurrent assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Statement Information&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.034%;"/&gt;
        &lt;td style="width:1.11%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.577%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.11%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.394%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.09%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.683%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Twelve Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Nine Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:AssetsCurrent
      contextRef="C_8b1298b5-e265-402c-a375-7a6c3874e7ba"
      decimals="-3"
      id="F_07071560-1606-4dd1-adb4-67a6e5a36124"
      unitRef="U_USD">33245000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_f25bc928-3562-4b6b-b70a-81d5cabd17d6"
      decimals="-3"
      id="F_e6acfe50-64f1-4e57-bb32-6ae5aeb55e81"
      unitRef="U_USD">14178000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_8b1298b5-e265-402c-a375-7a6c3874e7ba"
      decimals="-3"
      id="F_71c13276-d3af-43d5-a549-10d3fd97a0aa"
      unitRef="U_USD">59636000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_f25bc928-3562-4b6b-b70a-81d5cabd17d6"
      decimals="-3"
      id="F_ac5655a4-a23d-4394-9ad1-fd81f43969a4"
      unitRef="U_USD">28493000</us-gaap:AssetsNoncurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_8b1298b5-e265-402c-a375-7a6c3874e7ba"
      decimals="-3"
      id="F_864e5133-2b4e-46ba-a719-dbd914d68c1e"
      unitRef="U_USD">7004000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_f25bc928-3562-4b6b-b70a-81d5cabd17d6"
      decimals="-3"
      id="F_5e0478ba-214f-4e76-8871-2a1451c9cdc8"
      unitRef="U_USD">5254000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_8b1298b5-e265-402c-a375-7a6c3874e7ba"
      decimals="-3"
      id="F_48ad43fe-f637-4991-9f9b-1857140810a9"
      unitRef="U_USD">40300000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_f25bc928-3562-4b6b-b70a-81d5cabd17d6"
      decimals="-3"
      id="F_82f4ce67-e6f5-40cb-8fb5-eefbbaee443e"
      unitRef="U_USD">13662000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_66038b3d-4a2d-4124-9988-d7ed75e02d5d"
      decimals="-3"
      id="F_ddf6f8d1-5703-4860-a2e7-f9925a79850d"
      unitRef="U_USD">5446000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_93c757ad-d7f6-4687-bcce-bed6a5cfc531"
      decimals="-3"
      id="F_73c11393-881d-4377-a936-70cea7d58e04"
      unitRef="U_USD">3989000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5c9aad10-5990-4d65-89ff-a00df760aa5e"
      decimals="-3"
      id="F_4711ea9e-1900-4618-b4b1-8c950eb734ea"
      unitRef="U_USD">319000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_66038b3d-4a2d-4124-9988-d7ed75e02d5d"
      decimals="-3"
      id="F_4e1688c7-dd7e-4945-aa6d-512a6c13dc94"
      unitRef="U_USD">-32666000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_93c757ad-d7f6-4687-bcce-bed6a5cfc531"
      decimals="-3"
      id="F_23407890-c061-4d7b-bd84-b19929bd99ea"
      unitRef="U_USD">-24227000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_5c9aad10-5990-4d65-89ff-a00df760aa5e"
      decimals="-3"
      id="F_91f35849-ca3b-4182-892f-86b574667a4e"
      unitRef="U_USD">-15134000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="C_66038b3d-4a2d-4124-9988-d7ed75e02d5d"
      decimals="-3"
      id="F_80b83271-bdf9-4a5b-9bf1-972ac3e5672c"
      unitRef="U_USD">-32650000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_93c757ad-d7f6-4687-bcce-bed6a5cfc531"
      decimals="-3"
      id="F_82ab42cf-6f5c-4f9e-92b3-fb1baeae10da"
      unitRef="U_USD">-23732000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_5c9aad10-5990-4d65-89ff-a00df760aa5e"
      decimals="-3"
      id="F_144f934e-66ad-4f39-8973-bca18c3476f5"
      unitRef="U_USD">-15557000</us-gaap:ProfitLoss>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="C_9bd4526f-35d6-4207-93b9-c8a7c2cbe092"
      id="F_1dc72967-6188-4df3-bc30-89a78c5f7704">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The summarized financial information, including the portion we did not own, is presented for Entasis on a one quarter lag regardless of the date of our investments as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Balance Sheet Information&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.276%;"/&gt;
        &lt;td style="width:1.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.929%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Noncurrent assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Statement Information&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.668%;"/&gt;
        &lt;td style="width:2.249%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.917%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.249%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.917%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Twelve Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Six Months&lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:AssetsCurrent
      contextRef="C_afaf4531-656e-4b03-aaf3-eae9277b1b15"
      decimals="-3"
      id="F_f75e2b54-61d3-4f92-9b85-b46fbc7726a6"
      unitRef="U_USD">49746000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_afaf4531-656e-4b03-aaf3-eae9277b1b15"
      decimals="-3"
      id="F_b86c7cf7-6fcb-4dcc-a053-9f21f4bf5a81"
      unitRef="U_USD">1020000</us-gaap:AssetsNoncurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_afaf4531-656e-4b03-aaf3-eae9277b1b15"
      decimals="-3"
      id="F_8d05145d-9bef-4905-b4ab-eaec956ab172"
      unitRef="U_USD">9348000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_afaf4531-656e-4b03-aaf3-eae9277b1b15"
      decimals="-3"
      id="F_8bacc1aa-016d-4b0c-905d-430b841bdcac"
      unitRef="U_USD">183000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_d895b864-cb0d-4144-94d3-dd388365edb0"
      decimals="-3"
      id="F_c640ee16-10ca-4cfb-95d2-c1a1f1229a7a"
      unitRef="U_USD">-52323000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_bc3e2576-1b0b-4887-9679-84a1bff0d7ca"
      decimals="-3"
      id="F_3d0de308-1c14-4a4e-a6ec-17a0931afa2e"
      unitRef="U_USD">-26080000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="C_d895b864-cb0d-4144-94d3-dd388365edb0"
      decimals="-3"
      id="F_d1c675d7-d90d-478f-9f35-7ea6fc40e6e9"
      unitRef="U_USD">-125413000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_bc3e2576-1b0b-4887-9679-84a1bff0d7ca"
      decimals="-3"
      id="F_e6e14458-ff77-4bcc-835c-b5ea4e5688b0"
      unitRef="U_USD">-24529000</us-gaap:ProfitLoss>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_50f48cec-18c8-457e-b20c-0910ae62e850"
      decimals="INF"
      id="F_a7a41008-fae1-4dc3-b7e3-c007470a10f5"
      unitRef="U_shares">20469432</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inva:SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants
      contextRef="C_c906192d-d614-4f00-bca0-46d8da21845f"
      decimals="INF"
      id="F_57df645f-ed80-4eea-9c22-bbb06e8c86c2"
      unitRef="U_shares">5117358</inva:SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_47e6ee25-6bf5-41cf-80de-9652c932b3be"
      decimals="-5"
      id="F_4b185559-378b-4d9d-9a4d-d1e91b0464ff"
      unitRef="U_USD">15800000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:DebtInstrumentTransactionCost
      contextRef="C_50f48cec-18c8-457e-b20c-0910ae62e850"
      decimals="-5"
      id="F_db3f97c3-4ed2-4af1-bea1-d5f8f3f7405f"
      unitRef="U_USD">800000</inva:DebtInstrumentTransactionCost>
    <inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee
      contextRef="C_96b9f402-f543-4b27-a705-44de9fb1db9f"
      decimals="0"
      id="F_2b1b2f82-0aa2-4b32-966c-afc341d8100b"
      unitRef="U_Director">1</inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee>
    <inva:NumberOfBoardMembersOfInvestee
      contextRef="C_96b9f402-f543-4b27-a705-44de9fb1db9f"
      decimals="INF"
      id="F_0cb2891d-b91d-4aeb-8e7e-09598de13c88"
      unitRef="U_Director">8</inva:NumberOfBoardMembersOfInvestee>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c4982d06-6abd-4b3b-a27d-5ce207408578"
      decimals="4"
      id="F_3434e41c-8dfa-41d4-bc66-5a6b17ca079d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.7328</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <inva:ExtendedExpirationDate
      contextRef="C_421fbd90-baa7-4fc2-a696-1d4532ffc1a0"
      id="F_5b0d2763-86d6-47a0-a20f-3093a73cfd12">2023-03-31</inva:ExtendedExpirationDate>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_b379ab38-d0be-476e-a799-edfb4d18808f"
      decimals="-5"
      id="F_fd0b77b7-f98d-4e67-a00e-303f0027d3db"
      unitRef="U_USD">700000</inva:SecuritiesPurchaseAgreementAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_70bef282-aa1e-40ca-bbc9-61204a5b14c2"
      decimals="2"
      id="F_2753f756-be27-4a82-aa6c-0af3cdb2e918"
      unitRef="U_pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_ef07e831-a84d-46db-aeb8-00314c87ec4b"
      decimals="-5"
      id="F_9217ee48-e27a-49a1-b03c-dc95030dbcd5"
      unitRef="U_USD">10000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="C_f30142e1-26a2-4c83-99ca-64d73afa243d"
      decimals="2"
      id="F_ff843e11-b6c0-4329-8e7b-28603022b9f0"
      unitRef="U_pure">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="C_67669f2c-13f6-4732-9377-f8c04349b09d"
      decimals="-5"
      id="F_0442d879-587c-4f48-b27f-980fb8dac6a1"
      unitRef="U_USD">2300000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_5312202a-22d7-4d9a-824b-4d80ac1dd701"
      decimals="INF"
      id="F_e9351429-99fa-43b7-b0df-54395cc5d56a"
      unitRef="U_shares">4093886</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_b372f4b9-70bb-4a82-8853-c638fa566549"
      decimals="INF"
      id="F_020a8fe8-8daa-49d6-880e-82f77a6d482c"
      unitRef="U_shares">37350</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_50f48cec-18c8-457e-b20c-0910ae62e850"
      decimals="INF"
      id="F_2c4670b0-a0a5-4f8c-9dfe-3cb7610fccd1"
      unitRef="U_shares">20469432</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_3eb9313e-795c-4ac2-b142-a5922e05f973"
      decimals="INF"
      id="F_6dc41cc3-e6d1-4202-8c16-213e9191b012"
      unitRef="U_shares">8771780</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_b3984c86-3600-4ad8-878a-2b917b585a43"
      decimals="INF"
      id="F_68d23bae-78c3-449a-92a4-21de5b71d879"
      unitRef="U_shares">3369802</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_69d1b8aa-4af1-4156-8bdb-c7f20d548e88"
      decimals="INF"
      id="F_e6f3eafa-157f-42fe-a387-47daabe573c0"
      unitRef="U_shares">5117358</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_49c795a8-613b-4bce-862e-f82adaa95de1"
      decimals="2"
      id="F_cc1207f7-1bcb-40de-82d9-047cc92d970a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_ce65868a-35fd-4e2c-8c9d-86e62db676f1"
      decimals="INF"
      id="F_ddd8d548-9598-4d94-9e09-1f6ae09af7e6"
      unitRef="U_shares">2490033</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_a9729f5e-1b98-42eb-9368-262a78500403"
      decimals="2"
      id="F_5ef6272d-7e8b-4123-a4dd-2fa436f8bf26"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_96b9f402-f543-4b27-a705-44de9fb1db9f"
      decimals="3"
      id="F_26b12285-4667-42c7-9141-e36151e787ad"
      unitRef="U_pure">0.090</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_b7c08163-5751-4218-b1ca-b2546c9f4635"
      decimals="3"
      id="F_01e184a7-6421-4561-aa9f-71eb64760b4e"
      unitRef="U_pure">0.130</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <inva:ExpectedHoldingPeriod
      contextRef="C_9355643f-3d44-439f-a87f-deec9514dc9b"
      id="F_73ce9899-6991-4d32-abba-faa9a31e0e76">P2Y</inva:ExpectedHoldingPeriod>
    <inva:RiskFreeInterestRate
      contextRef="C_9355643f-3d44-439f-a87f-deec9514dc9b"
      decimals="3"
      id="F_66026895-52f7-4014-86c6-d1a913d49a55"
      unitRef="U_pure">0.032</inva:RiskFreeInterestRate>
    <inva:DividendYield
      contextRef="C_9355643f-3d44-439f-a87f-deec9514dc9b"
      decimals="3"
      id="F_d965e774-17b7-4ff4-b26f-5586134811ef"
      unitRef="U_pure">0.000</inva:DividendYield>
    <inva:PercentageOfEstimatedVolatility
      contextRef="C_9355643f-3d44-439f-a87f-deec9514dc9b"
      decimals="3"
      id="F_e69f8f7b-55a5-4ec9-a339-165b7ef23bc8"
      unitRef="U_pure">1.220</inva:PercentageOfEstimatedVolatility>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="C_16124fa1-bc15-44d0-adf6-79a805b582fd"
      decimals="-5"
      id="F_7ff68512-aa4b-459e-86d4-3048a824bf00"
      unitRef="U_USD">9000000.0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="C_4d3c3fb3-98ab-4ad6-a151-b473b325e723"
      decimals="INF"
      id="F_df7fa1cc-080f-47f9-83f1-e60a2f67c5d4"
      unitRef="U_USD">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_2276852d-99f8-449f-9f8f-9a1d7ddf7c39"
      decimals="-5"
      id="F_5ba2e99c-ef4d-4270-978f-2d9f898637e5"
      unitRef="U_USD">6800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_a97f4d78-4d9f-4a85-ba1d-e3c8a7909bfa"
      decimals="-5"
      id="F_d70f279f-dd3f-492f-9eb2-5b214b714cb4"
      unitRef="U_USD">600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_a1a5f0dc-847a-45a8-ad9c-42c8df5a3705"
      decimals="-5"
      id="F_e4b7e853-c939-494f-a6cf-22f1fd954ff8"
      unitRef="U_USD">3200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_ffc2073e-976b-4b32-9c37-71e4c30ee0f5"
      decimals="-5"
      id="F_6c599604-d2fb-43b9-87c2-a511bbe96f24"
      unitRef="U_USD">400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_7f74dd91-9ab3-47f8-86b1-ab0b359a7b86"
      decimals="-5"
      id="F_bb62feb7-b84d-4c46-8b75-07eda916a532"
      unitRef="U_USD">15800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_bf93a6aa-8431-42fa-b295-0929da337285"
      decimals="-5"
      id="F_e1bb7370-25d4-4367-9377-d1c4b599af6e"
      unitRef="U_USD">8700000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_4e7f2983-a46f-475a-ac66-4031d4994ae7"
      decimals="-5"
      id="F_573b1615-f9dd-4c1d-af37-a518b5b16048"
      unitRef="U_USD">700000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement
      contextRef="C_faceb50e-f20b-4852-8586-ecbbd210fdd7"
      decimals="INF"
      id="F_48fe7db8-14cd-47e7-9ca9-8fb82577da28"
      unitRef="U_shares">4051724</inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_9ff0d1ff-97a5-44b9-b6c1-09183a2ca1b7"
      decimals="-5"
      id="F_40619b15-9387-4198-88a5-267ebf724318"
      unitRef="U_USD">4700000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement
      contextRef="C_192456a0-bad3-4bac-8b5f-fc4b793611f8"
      decimals="INF"
      id="F_d3ff04d2-7864-4f78-8973-8355ceb992cf"
      unitRef="U_shares">4097157</inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_76ed3040-752a-4fbc-b4b9-e70787083404"
      decimals="-5"
      id="F_87f64a22-4355-4fb4-84f0-ea00b5c8e050"
      unitRef="U_USD">1300000</inva:SecuritiesPurchaseAgreementAmount>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_547286c7-fffc-4b6d-aa24-854799abba90"
      decimals="-5"
      id="F_9f07286d-7391-4943-b9dd-e5edb3ba2025"
      unitRef="U_USD">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee
      contextRef="C_77c4d3bf-3c11-40c8-aa43-61402306a12b"
      decimals="INF"
      id="F_81b851b1-2d6b-43f8-80fb-e6b5b9780e76"
      unitRef="U_Director">1</inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee>
    <inva:NumberOfBoardMembersOfInvestee
      contextRef="C_77c4d3bf-3c11-40c8-aa43-61402306a12b"
      decimals="INF"
      id="F_95187cdc-4ca0-46c9-9460-b2853c2ad2d5"
      unitRef="U_Director">6</inva:NumberOfBoardMembersOfInvestee>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_77c4d3bf-3c11-40c8-aa43-61402306a12b"
      decimals="3"
      id="F_226ede22-f669-407d-9ac4-182d8ffc5562"
      unitRef="U_pure">0.127</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_aea68a38-c031-44ae-8b1c-3569bc07a0e7"
      decimals="3"
      id="F_3d730c8a-77c5-4479-a262-8e4a5d5495dc"
      unitRef="U_pure">0.145</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_77c4d3bf-3c11-40c8-aa43-61402306a12b"
      decimals="-5"
      id="F_389d7a80-c479-4a36-8a4c-e00d59a4bf71"
      unitRef="U_USD">6400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_aea68a38-c031-44ae-8b1c-3569bc07a0e7"
      decimals="-5"
      id="F_8cdb30df-b1e8-424d-bfcc-af0d333c7d68"
      unitRef="U_USD">6400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="C_cbe9c478-819e-42cc-915c-04157a313403"
      decimals="-5"
      id="F_92699d57-e7f9-4607-be19-335f2e4d2e1d"
      unitRef="U_USD">15000000.0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_3f794c11-9aa6-4337-8539-a68ea7a89d87"
      decimals="2"
      id="F_63c776e6-174b-4ed6-b365-f8ef750c8215"
      unitRef="U_pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <inva:NumberOfCommonStockIssuedDescription
      contextRef="C_dda65400-d844-4684-b486-4ce48278b7bc"
      id="F_d8baf4dd-1955-4861-b555-487cda45583b">The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#x201c;Capped Conversion Price&#x201d;) and the qualified event price (the &#x201c;Qualified Event Price&#x201d;). The Capped Conversion Price is calculated as $50.0 million divided by the number of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Gate are at least $35.0 million, and (iii) the stated or implied equity valuation of Gate is at least $80.0 million. </inva:NumberOfCommonStockIssuedDescription>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_b56a4e8a-6960-4138-a57e-8ccc853dd6b5"
      decimals="-5"
      id="F_727b65dc-ec85-45b6-ae19-44b11f6f20cd"
      unitRef="U_USD">15700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_2e87648d-cc31-4ce1-9ec1-efcc2c23941b"
      decimals="-5"
      id="F_14bf974b-0443-453b-ab96-b0a5b0e1ce65"
      unitRef="U_USD">15100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_2dcd6e7e-1bb4-4f65-ae76-a45c841c8639"
      decimals="-5"
      id="F_143def3b-ed9a-4266-aa7f-ad3ee7f6a6de"
      unitRef="U_USD">600000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_df1e5c6b-3532-43eb-bfbb-32de7d69dfa7"
      decimals="-5"
      id="F_8815c27b-336b-4739-ab70-58a98b2be3d7"
      unitRef="U_USD">800000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement
      contextRef="C_1f7d116a-6a4c-4c15-ba57-35c3c1ecdd1e"
      decimals="INF"
      id="F_feda7d5b-be5f-4fcf-9314-431961f9f5f0"
      unitRef="U_shares">18750000</inva:SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_922cb55e-d579-4403-bdee-2933b4cbd111"
      decimals="-5"
      id="F_e53feeb6-978b-44d6-969a-a3dfd6a89d3a"
      unitRef="U_USD">9800000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_922cb55e-d579-4403-bdee-2933b4cbd111"
      decimals="-5"
      id="F_3f8f8607-d59d-423e-b41b-3f2faa056e09"
      unitRef="U_CHF">9000000.0</inva:SecuritiesPurchaseAgreementAmount>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_ef336b9b-40a1-496c-9596-1c6f52048c42"
      decimals="-5"
      id="F_6e9f9669-5374-4bd3-8f4b-3a35f9c8d430"
      unitRef="U_USD">700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee
      contextRef="C_12bcde56-3f0c-4b2f-8eca-3b4cd31cef94"
      decimals="INF"
      id="F_bb8a9431-4a3e-4772-809e-4109663b2ada"
      unitRef="U_Director">1</inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee>
    <inva:NumberOfBoardMembersOfInvestee
      contextRef="C_12bcde56-3f0c-4b2f-8eca-3b4cd31cef94"
      decimals="INF"
      id="F_3d65441d-68d0-4e5b-9262-4d0d4914d19c"
      unitRef="U_Director">7</inva:NumberOfBoardMembersOfInvestee>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_12bcde56-3f0c-4b2f-8eca-3b4cd31cef94"
      decimals="3"
      id="F_e8e39009-fc06-4703-b3e0-46bb6db74faa"
      unitRef="U_pure">0.155</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_12bcde56-3f0c-4b2f-8eca-3b4cd31cef94"
      decimals="-5"
      id="F_cf45a054-eeaf-43ee-aeb8-411a994bd6b6"
      unitRef="U_USD">10600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_0ba9bb7a-8587-4d58-93ec-131fc0f9783d">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.883%;"/&gt;
        &lt;td style="width:1.553%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.133999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.133999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.133999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.475%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds are included in cash and cash equivalents on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.883%;"/&gt;
        &lt;td style="width:1.553%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.133999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.133999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.133999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.563%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.475%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds are included in cash and cash equivalents on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_74da3b8a-5055-48ca-bb11-71f8c49ad956"
      decimals="-3"
      id="F_e2769ce1-6e57-4189-82bf-0320009c398c"
      unitRef="U_USD">263469000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_74da3b8a-5055-48ca-bb11-71f8c49ad956"
      decimals="-3"
      id="F_46f2d473-be14-45e0-bd3f-88d1ffb40cc2"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_74da3b8a-5055-48ca-bb11-71f8c49ad956"
      decimals="-3"
      id="F_d4974520-3462-491d-ba7f-e59c61419650"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_74da3b8a-5055-48ca-bb11-71f8c49ad956"
      decimals="-3"
      id="F_065f3d03-454a-409c-b707-3411450de866"
      unitRef="U_USD">263469000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_9bb718fb-be1a-42cc-a54e-205bd04d6a50"
      unitRef="U_USD">263469000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_fe1df1fa-cf95-4078-8ed6-4395ca751a13"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_f4416c5a-e099-4365-803b-2ed7effe0376"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_492a832d-1bc7-4bff-a929-c66b3e1f86a3"
      unitRef="U_USD">263469000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e4693a06-73d0-43e9-970e-27d36a30e4b0"
      decimals="-3"
      id="F_5bf8e1c8-f663-4fd3-a775-9c0173609862"
      unitRef="U_USD">145132000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e4693a06-73d0-43e9-970e-27d36a30e4b0"
      decimals="-3"
      id="F_13064dda-8ed2-4197-9462-3233b6e646b6"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e4693a06-73d0-43e9-970e-27d36a30e4b0"
      decimals="-3"
      id="F_92d64aad-a8aa-4799-a07a-ce78039e04c4"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e4693a06-73d0-43e9-970e-27d36a30e4b0"
      decimals="-3"
      id="F_afe13dec-76d8-453c-8941-b3e094fe42de"
      unitRef="U_USD">145132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_6a98f893-de05-443e-b0e7-67fb1e05261b"
      unitRef="U_USD">145132000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_5d8391d5-9da7-4a3c-a82a-e95e039a6b72"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_dd4142a3-18b9-4e1e-9980-a2b18a60f884"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_48babb9d-a7dd-411c-b6e9-fd4bb26c21cf"
      unitRef="U_USD">145132000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_5d0d6ec5-55bb-4294-97d1-b1a2383b8576"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_73ac4d6c-e3c5-45e0-b22b-6147027893f5">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our available-for-sale securities, equity and long-term investments are measured at fair value on a recurring basis and our debt is carried at amortized cost basis. The estimated fair values were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.189%;"/&gt;
        &lt;td style="width:1.418%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.956999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.408%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.956999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.408%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.956999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.408%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.299%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Fair Value Measurements as of December 31, 2022 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Price&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Types of Instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;263,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments held by ISP Fund LP &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;265,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;320,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - Armata Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - Armata Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - InCarda Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Convertible debt investment - Gate Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;560,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;639,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;197,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;197,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;211,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;211,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Total fair value of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;505,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;505,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contingent value rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total liabilities at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;505,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;506,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The investments held by ISP Fund LP, consisted of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;295.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in equity investments, which included private placement positions and convertible notes of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in money market funds. Our total capital contribution of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million is subject to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; lock-up period from the date of such capital contributions.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.931%;"/&gt;
        &lt;td style="width:1.418%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.032%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.032%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.032%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.334999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Fair Value Measurements as of December 31, 2021 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in Active&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Markets for&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Types of Instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,132&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments held by ISP Fund LP &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;193,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;195,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - Armata Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - Armata Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - Entasis Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - Entasis Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity investment - InCarda Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Convertible debt investment - Gate Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;489,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99,509&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;606,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;261,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;261,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;234,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;234,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total fair value of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;496,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;496,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The investments held by ISP Fund LP, consisted of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;192.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million equity investments and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million money market funds, are subject to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-month lock-up period from our initial contribution date, December 11, 2020.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9d320509-4249-4817-85c1-0897de8b2875"
      decimals="-3"
      id="F_4d5cc6ee-8fcb-44cd-8811-594451d2ee11"
      unitRef="U_USD">263469000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2bb91c3f-a494-494f-95f3-8e82d7a8ba80"
      decimals="-3"
      id="F_77e9e049-a6c9-4a81-92f2-c084dc804806"
      unitRef="U_USD">263469000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_39efe5a8-fdf1-4e75-a1c6-ce190c067d56"
      decimals="-3"
      id="F_3fdd078f-51c8-441a-bc63-74e8c5af4fba"
      unitRef="U_USD">265982000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ab967707-220b-4a3c-b5c1-3b1d1f192c17"
      decimals="-3"
      id="F_e20c2f4f-cc35-4c06-b838-d820cfd05871"
      unitRef="U_USD">54578000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fa2052dc-83db-4d14-bb22-476be0ffb9e9"
      decimals="-3"
      id="F_e1fa47be-e26f-49c6-9689-9c7c455a418b"
      unitRef="U_USD">320560000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7b234623-662e-464a-ac46-f26ea16b01cc"
      decimals="-3"
      id="F_22ec90f9-d52e-4741-95dc-4feb3f616906"
      unitRef="U_USD">31095000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d25498d0-9e4d-4ee3-9937-2ee1a353b204"
      decimals="-3"
      id="F_204fb3cf-2c72-4ad8-ac66-4534ee5d6872"
      unitRef="U_USD">31095000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1c21adc5-4d90-4234-8636-2bd75a4b4f4d"
      decimals="-3"
      id="F_121aa3a7-4b00-4ae4-a16f-e8ffd24b9e46"
      unitRef="U_USD">8059000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_87e97c41-b41b-4af2-ab13-cf95548ea435"
      decimals="-3"
      id="F_76ee2cd6-7e7b-4c54-94cc-46df34651442"
      unitRef="U_USD">8059000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e5766cee-a03e-4c21-8d34-5eef3d851a41"
      decimals="-3"
      id="F_431cd787-08e1-43ca-80c9-aabd9f56bce0"
      unitRef="U_USD">605000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3476905e-b09a-418b-a03e-4f699aa88fc9"
      decimals="-3"
      id="F_214b7042-2276-4150-b0a3-23dfdb220ef3"
      unitRef="U_USD">605000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_161e223f-b687-4431-bc47-286346549fa0"
      decimals="-3"
      id="F_cac7423b-0de7-44c9-9b38-4e1fb378de6e"
      unitRef="U_USD">15700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a82881ba-2b0c-4f06-bda8-ddec8bb16fb8"
      decimals="-3"
      id="F_7abf01d1-5996-41a3-a1dd-cb473046791f"
      unitRef="U_USD">15700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_508ec2d0-8cb9-4e9c-9ae3-821ebe4d8f78"
      decimals="-3"
      id="F_9a4ed7f8-5279-4514-920e-e9ae6f4b8c8c"
      unitRef="U_USD">560546000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_06e9721c-182a-4413-aa61-bad3afc7b434"
      decimals="-3"
      id="F_b113b590-cb54-42c9-aea7-8ca765428b51"
      unitRef="U_USD">8059000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8a0c9ff2-8643-499c-bef2-5ff0feb5293d"
      decimals="-3"
      id="F_6a3d50aa-993b-44ae-a18a-938fc0338e41"
      unitRef="U_USD">70883000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7b619186-bedd-4f77-a50f-71d5615f05fa"
      decimals="-3"
      id="F_c5fa989b-4b72-4a04-8ac1-350be86ad815"
      unitRef="U_USD">639488000</us-gaap:AssetsFairValueDisclosure>
    <inva:ConvertibleSubordinatedDebtFairValueDisclosures
      contextRef="C_4cba0f99-f007-421e-b754-c13fe2c48144"
      decimals="-3"
      id="F_203204be-b7ba-4a5d-bdc1-a93b06f3da62"
      unitRef="U_USD">96089000</inva:ConvertibleSubordinatedDebtFairValueDisclosures>
    <inva:ConvertibleSubordinatedDebtFairValueDisclosures
      contextRef="C_940c56ba-ea2f-4556-9041-85af949e6f93"
      decimals="-3"
      id="F_781ae318-bd45-44c1-af0f-c59a02bd7c2e"
      unitRef="U_USD">96089000</inva:ConvertibleSubordinatedDebtFairValueDisclosures>
    <inva:ConvertibleSeniorDebtFairValueDisclosures
      contextRef="C_4cba0f99-f007-421e-b754-c13fe2c48144"
      decimals="-3"
      id="F_3bc7be0b-5e3f-44b9-8ab6-4211a47af4c1"
      unitRef="U_USD">197807000</inva:ConvertibleSeniorDebtFairValueDisclosures>
    <inva:ConvertibleSeniorDebtFairValueDisclosures
      contextRef="C_940c56ba-ea2f-4556-9041-85af949e6f93"
      decimals="-3"
      id="F_9f276a7d-bcf1-4453-89bb-9f801470c42e"
      unitRef="U_USD">197807000</inva:ConvertibleSeniorDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_3ec4a281-c777-436a-bc57-5fae20c64ea6"
      decimals="-3"
      id="F_1f406ff4-67cb-4b15-9e50-bc202277f2b9"
      unitRef="U_USD">211768000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_940c56ba-ea2f-4556-9041-85af949e6f93"
      decimals="-3"
      id="F_38ee33f8-feae-494f-89e1-1dfaaa2b179a"
      unitRef="U_USD">211768000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_3ec4a281-c777-436a-bc57-5fae20c64ea6"
      decimals="-3"
      id="F_a9fb27bd-4fe3-49bd-83a4-fde6373388a3"
      unitRef="U_USD">505664000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_940c56ba-ea2f-4556-9041-85af949e6f93"
      decimals="-3"
      id="F_1c8096bc-10f2-4164-bc02-036cbdbc3006"
      unitRef="U_USD">505664000</us-gaap:DebtInstrumentFairValue>
    <inva:ContingentValueRightsLiability
      contextRef="C_e64b6004-f679-415f-b389-067903b29e9e"
      decimals="-3"
      id="F_89b700a2-bdb7-4a64-9f4c-28d703bd8b1b"
      unitRef="U_USD">595000</inva:ContingentValueRightsLiability>
    <inva:ContingentValueRightsLiability
      contextRef="C_9f0ef079-42c1-4987-9230-951829c1a9cd"
      decimals="-3"
      id="F_f8d7a183-d574-408c-bb5f-93c79c2e6b88"
      unitRef="U_USD">595000</inva:ContingentValueRightsLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_3ec4a281-c777-436a-bc57-5fae20c64ea6"
      decimals="-3"
      id="F_7984e985-a20b-43a1-beec-88e48f6f8c16"
      unitRef="U_USD">505664000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_e64b6004-f679-415f-b389-067903b29e9e"
      decimals="-3"
      id="F_58ec3c13-2192-4787-b529-4ef4dd331606"
      unitRef="U_USD">595000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_9f0ef079-42c1-4987-9230-951829c1a9cd"
      decimals="-3"
      id="F_c3b366a5-07e7-405d-bf1e-92a7748f0c92"
      unitRef="U_USD">506259000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_29f0ba10-c2ca-4f06-b767-8af5d73dfda3"
      decimals="-5"
      id="F_ce09d3af-850b-4264-9b21-979339aa380f"
      unitRef="U_USD">295400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5fa7258b-a8a4-4978-9f93-639f24732e53"
      decimals="-5"
      id="F_b78e1020-4be4-4f12-81e1-756968848aba"
      unitRef="U_USD">54600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_973bdb10-2dc0-4260-8de9-4c602b8d6d62"
      decimals="-5"
      id="F_233c0ba3-bce8-4c65-a156-e9de984ddb53"
      unitRef="U_USD">25100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="C_62138785-e6ec-474a-9927-12031239b970"
      decimals="-5"
      id="F_5450b349-0fd3-4ebd-8e41-2c94f8c389fd"
      unitRef="U_USD">300000000.0</us-gaap:LimitedPartnersContributedCapital>
    <inva:PartnershipAgreementLockUpPeriod
      contextRef="C_3b80a067-6f7f-440f-919a-9b96d0afd716"
      id="F_4c7b0dce-8bc6-41c4-9c1e-97e630443d43">P36M</inva:PartnershipAgreementLockUpPeriod>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b5917fe5-11ac-449e-b814-c92fd58e4ce4"
      decimals="-3"
      id="F_2397cd13-a109-41b8-9532-d5ae2fc701ac"
      unitRef="U_USD">145132000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d412530e-32f1-46d9-9ba9-881230cd54e2"
      decimals="-3"
      id="F_6cca47e1-7a5a-496a-876d-90e17aea1597"
      unitRef="U_USD">145132000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a88168cf-1d99-4dfc-90ff-08a54f07f704"
      decimals="-3"
      id="F_5206e769-270f-4857-aebd-f5a635bf2283"
      unitRef="U_USD">193677000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5344bb21-de35-4c37-a9d5-00a950034cac"
      decimals="-3"
      id="F_148f5b6e-664c-4651-a517-7669a8556d7c"
      unitRef="U_USD">2068000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2f726f21-debb-4664-8555-842fbb037578"
      decimals="-3"
      id="F_dbecb97d-2479-4c89-ac9e-9028c435f74c"
      unitRef="U_USD">195745000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_13412d83-cfbd-464c-9c34-a973a9caf860"
      decimals="-3"
      id="F_b046544a-9c6e-438b-a15d-bb603ff3e627"
      unitRef="U_USD">88101000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3f8b66a1-3a27-4782-83da-ba9f7e42a440"
      decimals="-3"
      id="F_a6d057a3-ec47-4db8-9f93-499ae140e3fd"
      unitRef="U_USD">88101000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_529cdd05-9d97-48df-bfe5-ae228fa9889c"
      decimals="-3"
      id="F_2476efb6-894a-45f9-ba70-12d15ce119de"
      unitRef="U_USD">58595000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c844f75a-7bd8-4650-befd-f25662e94508"
      decimals="-3"
      id="F_4f5d76c9-70c6-448a-acdd-dec5dc8c63ac"
      unitRef="U_USD">58595000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2075bc58-bfcf-44dd-85f6-c2f80538247e"
      decimals="-3"
      id="F_e087bb63-3f62-422d-913c-1b251935f6a3"
      unitRef="U_USD">62794000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_00652450-632d-460a-ac6b-98ad2aecada7"
      decimals="-3"
      id="F_69aaf0ae-f1e2-41f1-949a-25eff939507d"
      unitRef="U_USD">62794000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a5a2a364-b173-4ae1-ab6f-e2302488dee0"
      decimals="-3"
      id="F_021a7c50-ccb1-4162-ba64-acd7df113414"
      unitRef="U_USD">40914000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_be87ba60-82c5-4092-a52b-166288166d4b"
      decimals="-3"
      id="F_dbbc1134-2099-4962-9ffe-920fe1b8f7e7"
      unitRef="U_USD">40914000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c321cb39-f5e8-42ab-b6ee-7480dacfaf27"
      decimals="-3"
      id="F_cf120614-cc7d-4f35-824c-324b56d24e6b"
      unitRef="U_USD">411000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_95e0527f-161f-4b7c-9dae-e5bbe64ee040"
      decimals="-3"
      id="F_af613946-a1ae-4d45-8ccc-298df70219ba"
      unitRef="U_USD">411000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_494cf265-665e-4bbf-b3fc-fe7700a6a612"
      decimals="-3"
      id="F_e1228d44-2ec2-456f-a547-dd55cb97074f"
      unitRef="U_USD">15100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_611351f3-6fef-4e71-8874-413587b99402"
      decimals="-3"
      id="F_49e7e86d-f89a-4981-8773-c8de7d845eb0"
      unitRef="U_USD">15100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_df021323-12d6-4b65-922a-6ba6dda7e339"
      decimals="-3"
      id="F_79727c17-b74f-466d-b1c1-8b673a06e1b6"
      unitRef="U_USD">489704000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3a796252-a67b-414a-b751-63b9b85b975a"
      decimals="-3"
      id="F_59b0938c-fd22-48b8-9a3b-4e19aac11025"
      unitRef="U_USD">99509000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_435ca12f-523f-4739-86cf-686a945e5797"
      decimals="-3"
      id="F_0f433f27-8f6c-4e4d-994f-474963cb3d8e"
      unitRef="U_USD">17579000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8df9d62f-9d01-41f9-9bda-746317ef7f2a"
      decimals="-3"
      id="F_a64e4501-41de-45eb-bbbb-8f39d6e79e7a"
      unitRef="U_USD">606792000</us-gaap:AssetsFairValueDisclosure>
    <inva:ConvertibleSubordinatedDebtFairValueDisclosures
      contextRef="C_0e7db92f-80b2-4ff0-a803-9c8f7437c5ee"
      decimals="-3"
      id="F_d621ef6c-49c1-448d-81e4-002cb132f9d2"
      unitRef="U_USD">261769000</inva:ConvertibleSubordinatedDebtFairValueDisclosures>
    <inva:ConvertibleSubordinatedDebtFairValueDisclosures
      contextRef="C_c9ec2c09-fd7a-47dc-bc8d-518a4c5588a5"
      decimals="-3"
      id="F_b9b577cc-a842-4a6f-b1e3-d6c2d9530e38"
      unitRef="U_USD">261769000</inva:ConvertibleSubordinatedDebtFairValueDisclosures>
    <inva:ConvertibleSeniorDebtFairValueDisclosures
      contextRef="C_0e7db92f-80b2-4ff0-a803-9c8f7437c5ee"
      decimals="-3"
      id="F_30860e19-99c5-41ef-8120-15aa95a02e45"
      unitRef="U_USD">234498000</inva:ConvertibleSeniorDebtFairValueDisclosures>
    <inva:ConvertibleSeniorDebtFairValueDisclosures
      contextRef="C_c9ec2c09-fd7a-47dc-bc8d-518a4c5588a5"
      decimals="-3"
      id="F_31348f56-d12e-43f1-9094-4e31c3545aea"
      unitRef="U_USD">234498000</inva:ConvertibleSeniorDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_0e7db92f-80b2-4ff0-a803-9c8f7437c5ee"
      decimals="-3"
      id="F_9d9ade93-c009-4f4b-99e8-55197fc3ecb2"
      unitRef="U_USD">496267000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_c9ec2c09-fd7a-47dc-bc8d-518a4c5588a5"
      decimals="-3"
      id="F_461533e0-78ac-4dac-a2eb-35635cd8035d"
      unitRef="U_USD">496267000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d1735a85-987d-4b96-a5cd-b22f73816924"
      decimals="-5"
      id="F_8e0d8d2a-9596-4e29-aa5b-8ed6be4c8007"
      unitRef="U_USD">192200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9d42290f-ab32-4e25-95da-79728346288a"
      decimals="-5"
      id="F_8bd39d35-d497-4566-90a8-3399d8308e84"
      unitRef="U_USD">3500000</us-gaap:AssetsFairValueDisclosure>
    <inva:PartnershipAgreementLockUpPeriod
      contextRef="C_5ba64f62-a97d-4706-a41e-89bb10ec307f"
      id="F_44f2c8d4-a5eb-477e-894b-b22ca325e761">P36M</inva:PartnershipAgreementLockUpPeriod>
    <inva:CapitalizedFeesPaidDisclosureTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_b7122a24-60a8-4dc4-bbd4-09272ed49cca">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7. CAPITALIZED FEES PAID&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.362%;"/&gt;
        &lt;td style="width:1.739%;"/&gt;
        &lt;td style="width:16.039%;"/&gt;
        &lt;td style="width:1.739%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.093%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.739%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.287%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2013-2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Europe&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2013-2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Japan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2013-2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;122,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;These milestone fees are amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization recorded as a reduction in revenue from collaborative arrangements. As of December 31, 2022, the weighted average remaining amortization period was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; y&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ears.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additional information regarding these milestone fees is included in Note 3, &#x201c;Revenue Recognition&#x201d;. Amortization for each of the years ended December 31, 2022, 2021 and 2020 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The remaining estimated amortization is &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_2214fc13-a135-4176-9e10-3d32422ab21f;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;each&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the years from 2023 to 2027 and&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thereafter.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</inva:CapitalizedFeesPaidDisclosureTextBlock>
    <us-gaap:CapitalizedContractCostTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_c56d195d-d835-4e53-8225-95c95a88ebc4">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.362%;"/&gt;
        &lt;td style="width:1.739%;"/&gt;
        &lt;td style="width:16.039%;"/&gt;
        &lt;td style="width:1.739%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.093%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.739%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.287%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2013-2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Europe&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2013-2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Japan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2013-2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;122,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CapitalizedContractCostTableTextBlock>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_938323ae-b1cf-434a-be7f-895d09c3f4f5"
      decimals="-3"
      id="F_6604d889-4f5f-4644-8752-309fb21bb025"
      unitRef="U_USD">120000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_1f716eb1-7bc2-436b-be0b-e1913992c7a5"
      decimals="-3"
      id="F_558d85c5-bd4b-4ed8-b825-cb60ab327224"
      unitRef="U_USD">120000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_b21c6819-077d-4af6-bc82-465ef43a2339"
      decimals="-3"
      id="F_e589715f-9c81-4370-9c29-7aa80260f7d0"
      unitRef="U_USD">60000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_8c2a82e7-af19-4a3f-9713-a56397f35d56"
      decimals="-3"
      id="F_952206ae-031f-4e9e-93ef-5ce633c242e3"
      unitRef="U_USD">60000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_dba05bba-de09-4343-af7e-9fb38e51a065"
      decimals="-3"
      id="F_dbd72872-06de-4984-adbd-0b46d6850f58"
      unitRef="U_USD">40000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_5be2f762-e576-4a23-bf25-e027f2186039"
      decimals="-3"
      id="F_6cf882bb-b58b-43b9-95c9-32230753f458"
      unitRef="U_USD">40000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_fc4dc889-029c-4d57-b63d-1df049bfe1d3"
      unitRef="U_USD">220000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_e94b28b3-a4d3-405e-b238-e74d64fa70c2"
      unitRef="U_USD">220000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostAccumulatedAmortization
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_84dfc54d-fb31-49ec-a414-ab329f2056bc"
      unitRef="U_USD">122393000</us-gaap:CapitalizedContractCostAccumulatedAmortization>
    <us-gaap:CapitalizedContractCostAccumulatedAmortization
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_05c0043a-5adc-4eea-a1cd-bb624e624b28"
      unitRef="U_USD">108570000</us-gaap:CapitalizedContractCostAccumulatedAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_f1cc2000-3f4e-46f8-b25a-dece1e66be0b"
      unitRef="U_USD">97607000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_d301af9e-306f-475c-a1b7-f0cadc9279e6"
      unitRef="U_USD">111430000</us-gaap:CapitalizedContractCostNet>
    <inva:CapitalizedFeesPaidWeightedAverageUsefulLife
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_ec3b9466-a735-49ef-9af6-b7146df8cda0">P7Y1M6D</inva:CapitalizedFeesPaidWeightedAverageUsefulLife>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_a01857da-29eb-401d-8a40-ba6e666521ec"
      decimals="-5"
      id="F_a989f5fc-ff5e-4ed0-8833-bdcdf63c1949"
      unitRef="U_USD">13800000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_66c13dac-92c4-4ae1-b13e-27c3b81b27cd"
      decimals="-5"
      id="F_1a28b372-ca71-40f0-8c29-2c0532e20585"
      unitRef="U_USD">13800000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_a09a0970-3cec-406a-9c07-37e23fc89e0c"
      decimals="-5"
      id="F_7af1ad96-c496-47d9-8282-155b00c03cba"
      unitRef="U_USD">13800000</us-gaap:CapitalizedContractCostAmortization>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-5"
      id="F_2101ce1d-84da-416e-b5bc-f53e18f0b6d4"
      unitRef="U_USD">13800000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-5"
      id="F_8e5d93b8-381f-43ce-a705-ba6a997c1559"
      unitRef="U_USD">13800000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-5"
      id="F_ab6c1d2c-3b37-429c-ab4e-6959d9c92893"
      unitRef="U_USD">13800000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-5"
      id="F_8d4a15aa-6128-4011-9ea5-c22568978304"
      unitRef="U_USD">13800000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-5"
      id="F_7ddcc080-9cb9-4697-9168-a444f4d68367"
      unitRef="U_USD">28600000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_eb54fa93-b53e-4bf1-b9f9-0f2594fe6abd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8. GOODWILL AND INTANGIBLE ASSETS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill and intangible assets acquired are recognized at fair value as of the acquisition date. The carrying amount of goodwill as of December 31, 2022 was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. We have not recognized any impairment losses related to goodwill and intangible assets during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets with definite lives are amortized over their estimated useful lives. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying basis and accumulated amortization of recognized intangible assets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.438%;"/&gt;
        &lt;td style="width:1.112%;"/&gt;
        &lt;td style="width:11.146%;"/&gt;
        &lt;td style="width:1.102%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.333%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.102%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.333%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.102%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.333%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net Carrying&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketed products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;258,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;252,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets recognized as a result of the acquisition of Entasis amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;107.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which consisted of Entasis&#x2019; in-process research and development related to its antibacterial therapeutic product candidates and a collaboration agreement amounting to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The useful lives of these intangible assets will be determined upon commercialization of the underlying product candidates; thus, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; amortization expense of determinable assets was recognized during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets recognized as a result of the acquisition of La Jolla amounting to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million pertain to product rights and developed technologies on La Jolla&#x2019;s currently marketed products. These are intangible assets with determinable lives and are amortized over their estimated useful lives. We recognized amortization expense of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Future amortization expense is expected to be $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for each of the years from 2023 to 2027 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million thereafter.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-5"
      id="F_6b3f99b7-3eba-4c03-94a0-9a15b20c6424"
      unitRef="U_USD">26700000</us-gaap:Goodwill>
    <inva:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_b5fd36e6-a4fa-49cf-b9b2-03d3a5b95426">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying basis and accumulated amortization of recognized intangible assets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 were as follows:&lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.438%;"/&gt;
        &lt;td style="width:1.112%;"/&gt;
        &lt;td style="width:11.146%;"/&gt;
        &lt;td style="width:1.102%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.333%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.102%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.333%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.102%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.333%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accumulated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net Carrying&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Marketed products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;151,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,419&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;258,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;252,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</inva:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_2496c994-d13e-4a41-b18c-1c9ff1040e5d"
      id="F_c931f3a6-a8b4-470a-946b-2e07b61d9cce">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_5b484229-9ff6-4262-be39-4c53a0370b53"
      id="F_4a17b80f-e258-479f-b82e-e0b6dfabc0b2">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <inva:IntangibleAssetsMarketedProductsGross
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_61988858-a0ef-4f3f-a1ff-dd0695b8eaba"
      unitRef="U_USD">151000000</inva:IntangibleAssetsMarketedProductsGross>
    <inva:IntangibleAssetsMarketedProductsAccumulatedAmortization
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_c7158887-a25f-4683-be31-b853faac7f8d"
      unitRef="U_USD">-5581000</inva:IntangibleAssetsMarketedProductsAccumulatedAmortization>
    <inva:IntangibleAssetsMarketedProductsNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_5d3e5060-bb60-4dde-a0f5-aa59ea67bf2e"
      unitRef="U_USD">145419000</inva:IntangibleAssetsMarketedProductsNet>
    <inva:IntangibleAssetsInProcessResearchAndDevelopmentGross
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_5b83375e-a47e-4538-919e-3e04d63bad6b"
      unitRef="U_USD">72100000</inva:IntangibleAssetsInProcessResearchAndDevelopmentGross>
    <inva:IntangibleAssetsInProcessResearchAndDevelopmentNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_f5c19a98-9bde-4a68-b8c0-0d2df92c1996"
      unitRef="U_USD">72100000</inva:IntangibleAssetsInProcessResearchAndDevelopmentNet>
    <inva:IntangibleAssetsCollaborationAgreementGross
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_053b18b2-163d-40c5-b851-dc1fc5a33efb"
      unitRef="U_USD">35400000</inva:IntangibleAssetsCollaborationAgreementGross>
    <inva:IntangibleAssetsCollaborationAgreementNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_82798bbe-3cfa-4933-b27f-d9a2baa9e0f1"
      unitRef="U_USD">35400000</inva:IntangibleAssetsCollaborationAgreementNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_4faf0de0-e069-44e7-b88a-177f12d8f36b"
      unitRef="U_USD">258500000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_0f560df3-bdc7-4eb2-aceb-d3d3cad1289b"
      unitRef="U_USD">-5581000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_3c0c89df-2753-42cd-9eee-61ea26cfda25"
      unitRef="U_USD">252919000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_834647f0-edd8-451a-9b07-12ae7db8308b"
      decimals="-5"
      id="F_18346be1-01cc-4163-8a0f-962efd0e0ec1"
      unitRef="U_USD">107500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_5ade68fe-6e7d-408e-8079-b75ae0d3ebb4"
      decimals="-5"
      id="F_be9ba9ba-022b-4669-9384-b6c8f17558e6"
      unitRef="U_USD">72100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_11135088-2eb4-4727-a68e-256cf6c9a775"
      decimals="-5"
      id="F_0cb59c89-94ff-488e-a6a9-cfa2438933cd"
      unitRef="U_USD">35400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_392be0e2-bd01-417a-94b2-2ef2c1b381d8"
      decimals="-3"
      id="F_c93dbb12-3f52-439c-a312-c40ff735a54b"
      unitRef="U_USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_86b3b196-2603-41a6-85b5-4466e0d2b8da"
      decimals="-5"
      id="F_ac0f84e0-fb23-4ce8-988a-c4ef60be8671"
      unitRef="U_USD">151000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-5"
      id="F_a4d0db88-aa6e-4d9f-b129-7edfab50070f"
      unitRef="U_USD">5600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_86b3b196-2603-41a6-85b5-4466e0d2b8da"
      decimals="-5"
      id="F_6aef5c70-cd94-40b8-acb1-06d08ef96309"
      unitRef="U_USD">15400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_86b3b196-2603-41a6-85b5-4466e0d2b8da"
      decimals="-5"
      id="F_a3a9cc15-39e1-4f68-b8ce-9bbd09914f1f"
      unitRef="U_USD">15400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_86b3b196-2603-41a6-85b5-4466e0d2b8da"
      decimals="-5"
      id="F_150822f3-7c01-4268-83fd-a7cf22c82ee9"
      unitRef="U_USD">15400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_86b3b196-2603-41a6-85b5-4466e0d2b8da"
      decimals="-5"
      id="F_74ea6f0d-4ea0-4d01-bdef-522590488f60"
      unitRef="U_USD">15400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_86b3b196-2603-41a6-85b5-4466e0d2b8da"
      decimals="-5"
      id="F_30c4d4a2-05c0-4a48-a5ad-1febb3f2560d"
      unitRef="U_USD">68200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_17fc2d15-41e5-4d62-9579-046c9b725eea">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9. BALANCE SHEET COMPONENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inventory consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.252%;"/&gt;
        &lt;td style="width:1.784%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.964%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Work-in-process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, total inventory included net fair value adjustments resulting from the acquisition of La Jolla of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which will be recognized as cost of products sold when sales occur in future periods. The fair value adjustments recorded as part of cost of products sold amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; inventory as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Other Accrued Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other accrued liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.399%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.6%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued contract manufacturing expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued research expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current portion of deferred royalty obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued license fees and royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Other Long-Term Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other long-term liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.252%;"/&gt;
        &lt;td style="width:1.784%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.964%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term portion of deferred royalty obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contingent value rights liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; other long-term liabilities as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_f792c48e-206b-4b6e-bce7-57a2651a5484">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inventory consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.252%;"/&gt;
        &lt;td style="width:1.784%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.964%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Work-in-process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_5d0d3edc-e7c3-48c4-ab05-2f4154a637c2"
      unitRef="U_USD">5757000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_23608efc-5ab7-4567-a077-acd9d485410c"
      unitRef="U_USD">25052000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_db6a066d-019f-42bb-9b00-b13e102c1126"
      unitRef="U_USD">25088000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_86219660-003b-4238-b37d-7a177801125f"
      unitRef="U_USD">55897000</us-gaap:InventoryNet>
    <inva:FairValueAdjustmentsOfInventoryFromAcquistion
      contextRef="C_c728d113-afc3-4116-a5d3-755dcf10b52b"
      decimals="-5"
      id="F_df630fc8-9b03-4105-9214-3064c4f66863"
      unitRef="U_USD">49500000</inva:FairValueAdjustmentsOfInventoryFromAcquistion>
    <inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold
      contextRef="C_8f698f68-0c0f-4134-b100-4f1a9c7c7c0a"
      decimals="-5"
      id="F_79246c9e-9ba7-4fea-b450-e181070a2dfc"
      unitRef="U_USD">10000000.0</inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold>
    <us-gaap:InventoryGross
      contextRef="C_a2b80c7a-b827-400e-b441-ce92d2d12b34"
      decimals="-3"
      id="F_a145c373-5074-413a-9f10-a5e1b7af1e93"
      unitRef="U_USD">0</us-gaap:InventoryGross>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_06a90728-adcc-409a-bbe0-84b591e0297e">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other accrued liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.399%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.6%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.502%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued contract manufacturing expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued research expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current portion of deferred royalty obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued license fees and royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <inva:AccruedContractManufacturingLiability
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_aae9a5ae-e79a-403f-8c33-b13fb3d46cb3"
      unitRef="U_USD">8382000</inva:AccruedContractManufacturingLiability>
    <inva:AccruedContractManufacturingLiability
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_b2197405-4d23-46ec-ada3-8072f36b03bb"
      unitRef="U_USD">0</inva:AccruedContractManufacturingLiability>
    <inva:AccruedClinicalLiability
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_2f6c7c69-95fc-456e-9054-002c2d48861d"
      unitRef="U_USD">692000</inva:AccruedClinicalLiability>
    <inva:AccruedClinicalLiability
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_5cff4dcc-bd08-4fef-bf96-d700266a5e0a"
      unitRef="U_USD">0</inva:AccruedClinicalLiability>
    <inva:AccruedResearchLiability
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_8d4e0b3b-029a-4ab4-ace9-7ae67e542483"
      unitRef="U_USD">349000</inva:AccruedResearchLiability>
    <inva:AccruedResearchLiability
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_da785943-018f-4e55-b87e-e0d3f0634960"
      unitRef="U_USD">0</inva:AccruedResearchLiability>
    <inva:AccruedProfessionalServices
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_ba1d0f71-379f-4927-bd69-2af01d178f3a"
      unitRef="U_USD">3977000</inva:AccruedProfessionalServices>
    <inva:AccruedProfessionalServices
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_d91b86f3-ab50-449e-9843-d222ac199043"
      unitRef="U_USD">894000</inva:AccruedProfessionalServices>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_44529633-d0c9-413b-8ec9-ae7dbd25a69d"
      unitRef="U_USD">1316000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_089892d9-0b75-4222-a792-145e818a1e0e"
      unitRef="U_USD">106000</us-gaap:OperatingLeaseLiabilityCurrent>
    <inva:DeferredRoyaltyObligationCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_953cf1b8-4219-43b8-a1fc-8c349b42f0ac"
      unitRef="U_USD">2639000</inva:DeferredRoyaltyObligationCurrent>
    <inva:DeferredRoyaltyObligationCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_58a2f01f-99b7-4c55-9d37-1bbed5ce9cdc"
      unitRef="U_USD">0</inva:DeferredRoyaltyObligationCurrent>
    <inva:AccruedLicenseFeesAndRoyalties
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_4a8a0269-34a2-47c7-b0f4-f5b2e9177764"
      unitRef="U_USD">943000</inva:AccruedLicenseFeesAndRoyalties>
    <inva:AccruedLicenseFeesAndRoyalties
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_9d5a8d9c-43b9-4ebf-9bf4-50c07f52f23c"
      unitRef="U_USD">0</inva:AccruedLicenseFeesAndRoyalties>
    <us-gaap:OtherLiabilities
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_5d08b7d8-2529-4780-8799-5916da345a6a"
      unitRef="U_USD">2909000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_e636e940-5a84-4042-8285-0a8ed2a991b4"
      unitRef="U_USD">9000</us-gaap:OtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_a535bbf1-ca4d-487e-8bf9-d1ab1d96f354"
      unitRef="U_USD">21207000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_27f5de2f-a6c6-488d-9870-235c5c74b782"
      unitRef="U_USD">1009000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_d04afe4d-4ffa-431b-994c-aa4c75bc5724">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other long-term liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.252%;"/&gt;
        &lt;td style="width:1.784%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.964%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term portion of deferred royalty obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contingent value rights liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <inva:DeferredRoyaltyObligationNonCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_bf80d1e5-e684-4dd5-aa02-24609b9aa9bc"
      unitRef="U_USD">67947000</inva:DeferredRoyaltyObligationNonCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_c0ccf2a9-606c-4ac7-aa80-cfea3521ec09"
      unitRef="U_USD">2376000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <inva:ContingentValueRightsLiability
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_c18a2840-5649-4c90-a80b-581a359675ec"
      unitRef="U_USD">595000</inva:ContingentValueRightsLiability>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_61b99f55-990b-407e-a9c1-9c4d0dc96d1c"
      unitRef="U_USD">70918000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_991e407d-890b-4d13-9d3b-89a052dff9e2"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_a8cdf0de-28ab-463c-82dc-99cff2a503bc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10. STOCK&#x2011;BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2012, we adopted the 2012 Equity Incentive Plan (the &#x201c;2012 Plan&#x201d;). The 2012 Plan provides for the grant of incentive stock options, nonstatutory stock options, RSAs, RSUs and Stock Appreciation Rights to employees, non-employee directors and consultants. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, total shares remaining available for issuance under the 2012 Plan were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,838,270&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the 2004 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), our employees may purchase common stock through payroll deductions at a price equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The ESPP provides for consecutive and overlapping offering periods of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in duration, with each offering period composed of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; consecutive &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; purchase periods. The purchase periods end on either May 15 or November 15. ESPP contributions are limited to a maximum of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of an employee&#x2019;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. An employee may not purchase shares with a value greater than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in any calendar year.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, total shares remaining available for issuance under the ESPP were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;160,995&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Director Compensation Program&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our non-employee directors receive compensation for services provided as a director. Each member of our board of directors who is not an employee receives both cash and equity compensation for services as a director, member of a committee of the board of directors, lead independent director and chairman, as applicable. In October 2017, both the cash and equity components of the compensation program were amended, effective immediately (the &#x201c;October 2017 Amendments&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Each of our independent directors receives periodic automatic grants of equity awards under a program implemented under the 2012 Plan. These grants are non&#x2011;discretionary. Only our independent directors or affiliates of such directors are eligible to receive automatic grants under the 2012 Plan. Under the program, each individual who first became a non-employee director will, on the date such individual joins the board of directors, automatically be granted a one&#x2011;time grant of RSUs covering a number of shares of our common stock calculated as $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share (the &#x201c;Initial RSUs&#x201d;), plus a one&#x2011;time grant of RSUs covering a number of shares of our common stock calculated as $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, which would be pro-rated for the number of whole months remaining until the anniversary of the prior year&#x2019;s stockholders&#x2019; meeting, rounded down to the nearest whole share (the &#x201c;Pro Rata RSUs&#x201d;). The Initial RSUs vest in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; equal annual installments, while Pro Rata RSUs vest in a single installment at the sooner of the next annual stockholder meeting or the one-year grant anniversary, in each case subject to the non-employee director&#x2019;s continuous service through the applicable vesting date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Annually, upon his or her re&#x2011;election to the board of directors at the Annual Meeting of Stockholders, each non-employee director is automatically granted an RSU covering a number of shares of our common stock calculated as $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; prior to the October 2017 Amendments) divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share. These RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the non-employee director&#x2019;s continuous service through the applicable vesting date. Following the amendment to our non-employee director compensation program, both the annual RSUs and Initial RSUs described above remained unchanged with the exception that the number of shares of our common stock subject to each award has been reduced.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;These RSUs will vest in full upon the director&#x2019;s death, the occurrence of a change in control or, with respect to awards made after the October 2017 Amendments, the director&#x2019;s disability before the director&#x2019;s service terminates. Director RSUs carry dividend equivalent rights to be credited with an amount equal to all cash dividends paid on the underlying shares of common stock while unvested. Dividend equivalents are subject to the same terms and conditions, including vesting, as the RSUs to which they attach and are paid in cash upon vesting.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock&#x2011;Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock&#x2011;based compensation expense is included in the consolidated statements of income as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.423%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.707%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock&#x2011;based compensation expense included in the consolidated statements of income by award type is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.52%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.540000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.540000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.940000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.185%;"/&gt;
        &lt;td style="width:1.808%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.413999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.351%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.243%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized Compensation Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Amortization Period (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total unrecognized compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Compensation Awards&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:31.657%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.326%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.311%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.977%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.34%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.311%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.977%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.34%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.778%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands, except per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of outstanding options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Exercise Price of Outstanding Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of outstanding RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Fair Value per Share at Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of outstanding RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Fair Value per Share at Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Released RSUs and RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest &lt;br/&gt;&#160;&#160;&#160;as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the aggregate intrinsic value of options outstanding and options exercisable was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t material&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2021, the aggregate intrinsic value of the options outstanding was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and the aggregate intrinsic value of options exercisable was immaterial. As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;290&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; options were exercisable. The weighted average remaining contractual term of options outstanding was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.01&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.43&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The total intrinsic value of the options exercised was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t material as of December 31, 2022. The total intrinsic value of the options exercised was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2021 and 2020, respectively. The total estimated fair value of options vested was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2021. The total estimated fair value of options vested was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t material for the year ended December 31, 2022 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The total estimated fair value of RSUs vested was $2.3 million, $1.1 million and $1.3 million for the year December 31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The total estimated fair value of RSAs vested was not material for the year ended December 31, 2022, 2021, and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Valuation Assumptions&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted-average assumptions used in calculating the estimated value of our stock options on the date of grant as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.741%;"/&gt;
        &lt;td style="width:1.474%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.955%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.464%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.955%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.464%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.946%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.04&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.11&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.11&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average estimated fair value of stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_873e7b0b-00b1-48d4-b5e4-b4a6e7d0eff2"
      decimals="INF"
      id="F_ec742614-b930-4f11-a12b-7139b0b67a61"
      unitRef="U_shares">3838270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_20021136-8c2b-48e8-bb1e-b92302a7d43e"
      decimals="2"
      id="F_5ec66399-dad0-4987-9d48-790e20929695"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod
      contextRef="C_20021136-8c2b-48e8-bb1e-b92302a7d43e"
      id="F_e43e282a-a227-43c2-b89e-505346090ac1">P24M</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods
      contextRef="C_20021136-8c2b-48e8-bb1e-b92302a7d43e"
      decimals="0"
      id="F_ddba829a-d82c-4abf-9df7-c39e4815b66d"
      unitRef="U_Item">4</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="C_20021136-8c2b-48e8-bb1e-b92302a7d43e"
      id="F_d767746c-ce7c-43aa-bdae-fea8cc4686cf">P6M</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_bf38e94a-771f-41f7-b87c-9a8cf1a2bfaf"
      decimals="2"
      id="F_378a2305-3584-4802-aaf0-503beefda9b7"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="C_20021136-8c2b-48e8-bb1e-b92302a7d43e"
      decimals="INF"
      id="F_58ebf8bd-46b3-4db7-a73f-2936ff83e3bb"
      unitRef="U_shares">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation
      contextRef="C_20021136-8c2b-48e8-bb1e-b92302a7d43e"
      decimals="-3"
      id="F_20518f19-f5dd-49a2-908b-13924c1e9a82"
      unitRef="U_USD">25000000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_bf38e94a-771f-41f7-b87c-9a8cf1a2bfaf"
      decimals="INF"
      id="F_11144eef-7aab-40dd-a122-6209963216c1"
      unitRef="U_shares">160995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue
      contextRef="C_37ba5274-8715-4011-ab28-b8eda0d172d2"
      decimals="0"
      id="F_331e5604-1e24-4a4b-8793-fb87a34f75fc"
      unitRef="U_USD">125000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue
      contextRef="C_1c748875-71fe-4003-b725-ef74b25e3855"
      decimals="0"
      id="F_691da6f2-1636-4f92-98be-e7e3999b3619"
      unitRef="U_USD">250000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue
      contextRef="C_37ba5274-8715-4011-ab28-b8eda0d172d2"
      decimals="0"
      id="F_c4576346-5ddf-406d-83c3-9824d2ba4a30"
      unitRef="U_USD">225000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue
      contextRef="C_1c748875-71fe-4003-b725-ef74b25e3855"
      decimals="0"
      id="F_6eebda48-760a-49ab-a587-a509b13fcd81"
      unitRef="U_USD">250000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments
      contextRef="C_e5ee6d05-e981-4946-800e-de9d31604888"
      decimals="INF"
      id="F_57f9955a-12c7-4ac1-9ae6-41bdd33cee44"
      unitRef="U_Installment">2</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue
      contextRef="C_5dd1e719-80fe-4711-a19b-c407c3e1587a"
      decimals="0"
      id="F_72072464-7686-46b5-9355-bca19119bd3a"
      unitRef="U_USD">225000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue
      contextRef="C_0d234c0c-f63c-4792-acb9-96224e1a9014"
      decimals="0"
      id="F_bfe8c6e7-1660-4250-8e07-333bd6458a1f"
      unitRef="U_USD">250000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_9cbae0d8-5799-4d8d-b7c8-bfd0a0591baa">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock&#x2011;based compensation expense is included in the consolidated statements of income as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.423%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.707%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_077c554a-e6a5-43dd-991a-36356231105e"
      decimals="-3"
      id="F_4649a00a-1865-467e-a560-23073d4cb515"
      unitRef="U_USD">5305000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4722bfe5-dfa7-4d44-bbd1-d47edc793461"
      decimals="-3"
      id="F_f01c12b3-c2eb-4b94-bf30-4090af9eb211"
      unitRef="U_USD">2017000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0741d536-3cd1-4bb3-a3d8-4a8b9e768e1c"
      decimals="-3"
      id="F_5559fcd6-7d94-4716-b14c-2db780bab5f5"
      unitRef="U_USD">1698000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7a637d38-c05d-4d65-9849-9fabc00c0938"
      decimals="-3"
      id="F_c25efe31-c10a-4088-a28b-58b372797ec5"
      unitRef="U_USD">2042000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_546bf034-6546-4012-bb5a-e1fa071bebc2"
      decimals="-3"
      id="F_de588f10-bdac-44b3-a183-f544ac4edb44"
      unitRef="U_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c9fa8159-64b4-4582-868c-ef082d816dac"
      decimals="-3"
      id="F_e5947bcc-a2e0-463c-b9b0-0202620beb23"
      unitRef="U_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_1b592c3f-0b1a-49d8-9a33-2da2656512c6"
      unitRef="U_USD">7347000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_e36f4462-e8c1-40fc-9ee3-8dc298124fd7"
      unitRef="U_USD">2017000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_2fc9a9e1-1d6f-495e-9b73-07726308026f"
      unitRef="U_USD">1698000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_8cd36799-2367-4fba-b382-abd9d10ad1c6">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock&#x2011;based compensation expense included in the consolidated statements of income by award type is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.52%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.540000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.540000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.940000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee"
      decimals="-3"
      id="F_7bc2fc86-974b-40b8-83fa-a21ae6275382"
      unitRef="U_USD">3057000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a386f2f5-a2d5-44d9-be1d-92de778d3a08"
      decimals="-3"
      id="F_9bd04c91-c1d2-443a-aa33-de04933a5878"
      unitRef="U_USD">490000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8d4db9d3-f0ac-411c-b4be-66a68e66086e"
      decimals="-3"
      id="F_6182905a-5a1a-409c-b0cc-38a0f271c8e2"
      unitRef="U_USD">242000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575"
      decimals="-3"
      id="F_ce3fb0a3-4bee-441d-9385-fd5f6414d4a2"
      unitRef="U_USD">4053000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b353aac4-69f8-4721-bb91-b64e5c3524b9"
      decimals="-3"
      id="F_687805a4-80b8-4fe8-b8af-881a43bf05be"
      unitRef="U_USD">1280000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c0cc6f7b-c585-47f1-8084-1c731c93f71e"
      decimals="-3"
      id="F_92013cd1-6598-4d40-b966-811c9e3f8753"
      unitRef="U_USD">1149000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f"
      decimals="-3"
      id="F_f54add1c-caa2-4d13-8fbf-c94cfd7a1611"
      unitRef="U_USD">194000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_eddd93e6-6ae6-44b1-8b18-2af265b00535"
      decimals="-3"
      id="F_6f28e779-943c-4acc-802b-3e88d2a00958"
      unitRef="U_USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dbcbd115-0d6a-4e3b-8ad7-7e5315f18708"
      decimals="-3"
      id="F_cc103f01-b904-495c-95d3-8dea6c5cd254"
      unitRef="U_USD">273000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20021136-8c2b-48e8-bb1e-b92302a7d43e"
      decimals="-3"
      id="F_e10de987-656b-44c5-9b69-2533afe7e9d1"
      unitRef="U_USD">43000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0420bbef-96b0-4a85-a0f8-18bc3bd3a1fd"
      decimals="-3"
      id="F_1f42bbbb-a169-4970-bde7-fb18c5d94257"
      unitRef="U_USD">47000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5ba508af-5e54-40ad-899c-3cb351c9a5ec"
      decimals="-3"
      id="F_7151a92b-a8c2-4374-b26a-97dbcfafe110"
      unitRef="U_USD">34000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_76970b92-868e-41a4-8a7d-cfd579837946"
      unitRef="U_USD">7347000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_211f7c5f-f3bd-41a5-abdd-03461f5a4e6a"
      unitRef="U_USD">2017000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_39af200b-318c-44c8-a1a9-6320e6a04e01"
      unitRef="U_USD">1698000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_eff20a45-0a63-4668-a488-55db9d845256">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.185%;"/&gt;
        &lt;td style="width:1.808%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.413999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.351%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.243%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized Compensation Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Amortization Period (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total unrecognized compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8"
      decimals="-3"
      id="F_946c0b43-0008-4023-b5df-ade6089681c4"
      unitRef="U_USD">3550000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee"
      id="F_318a6c4d-050f-4ed5-a9d5-a8946a2821a3">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_4225ffae-2b85-4646-9d44-6752e738321b"
      decimals="-3"
      id="F_8301d511-513f-44a4-83da-55d31e5596d3"
      unitRef="U_USD">4776000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575"
      id="F_d01dff65-34ae-4c50-a1b0-76baee3fdf77">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_d577f45e-f619-4e15-880c-f1fd5f863799"
      decimals="-3"
      id="F_86ec0c93-573a-4a14-8818-eebcce378eee"
      unitRef="U_USD">388000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f"
      id="F_3f4abe74-8863-4efd-9786-75a3274efd81">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_4604dfdd-f070-4a1e-9c09-977d5ae797c2"
      unitRef="U_USD">8714000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_a73e9064-ffeb-4daf-a049-63fe56df5220">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:31.657%;"/&gt;
        &lt;td style="width:0.963%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.326%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.311%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.977%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.34%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.311%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.977%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.34%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.778%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands, except per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of outstanding options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Exercise Price of Outstanding Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of outstanding RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Fair Value per Share at Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of outstanding RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Fair Value per Share at Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Released RSUs and RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest &lt;br/&gt;&#160;&#160;&#160;as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_e262e47d-f2f5-4208-90c1-3bcda7144a65"
      decimals="-3"
      id="F_bdf48bcf-f028-4ab2-85b2-df15c8c21a6a"
      unitRef="U_shares">766000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e262e47d-f2f5-4208-90c1-3bcda7144a65"
      decimals="2"
      id="F_b3d95162-1362-44a9-b51b-b1d6d8b87b00"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_c88e8766-779e-489b-97e4-b86fcdc4511b"
      decimals="-3"
      id="F_04dc9ca5-943b-4cdc-b6f9-a0f78946d864"
      unitRef="U_shares">116000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_c88e8766-779e-489b-97e4-b86fcdc4511b"
      decimals="2"
      id="F_a70950df-5622-449c-a7c2-aa1b082be897"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_90bb4c16-e20f-46dc-b959-d3bb3d63c67d"
      decimals="-3"
      id="F_d7fe5322-574d-417e-86db-7b9d4387ee43"
      unitRef="U_shares">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_90bb4c16-e20f-46dc-b959-d3bb3d63c67d"
      decimals="2"
      id="F_622f237f-5acb-4488-9a58-910ddb540ec3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee"
      decimals="-3"
      id="F_b0fec715-334e-4500-8308-f8c69b7ae413"
      unitRef="U_shares">492000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee"
      decimals="2"
      id="F_5eafe8d4-a666-48bf-820f-e0fcf76d175b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575"
      decimals="-3"
      id="F_2dcc6f7f-c8d9-49bc-8ff6-aa22f7c8ab84"
      unitRef="U_shares">676000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575"
      decimals="2"
      id="F_e3c2e039-bf41-45f9-a0f7-784e3742621e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f"
      decimals="-3"
      id="F_d498894f-4508-4b5a-a1a9-abe32a49c349"
      unitRef="U_shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f"
      decimals="2"
      id="F_21789102-40fb-46f9-9098-1906e28174d7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee"
      decimals="-3"
      id="F_4bcc4acf-3a82-4cff-8e47-73bde58ddbdb"
      unitRef="U_shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee"
      decimals="2"
      id="F_cd52c68b-b86a-4924-ac13-0df6a0cacff9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575"
      decimals="-3"
      id="F_41d0b51f-e028-4e6d-93cb-0baa9e6e35a1"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575"
      decimals="0"
      id="F_9457fa90-a6f2-49f9-b063-54e9984b3b26"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f"
      decimals="-3"
      id="F_a9fcd736-a84c-400f-9921-a7c35e8da0de"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f"
      decimals="0"
      id="F_a52844a3-b2d1-40fc-808d-e84c563352cd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee"
      decimals="-3"
      id="F_389e9f63-934a-4a05-8de6-3a94332eb534"
      unitRef="U_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee"
      decimals="0"
      id="F_3fd52f31-16ff-4156-a37b-d55ded3e832f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575"
      decimals="-3"
      id="F_9476876b-7b8c-4e33-8078-a5c39c64faa3"
      unitRef="U_shares">233000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575"
      decimals="2"
      id="F_c84636d9-71ec-4b83-8de6-3a78ae6edb18"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f"
      decimals="-3"
      id="F_d8c58806-256a-493f-a667-23100565d30a"
      unitRef="U_shares">14000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f"
      decimals="2"
      id="F_b0770733-217f-4b7c-93d6-cc666297dd2f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee"
      decimals="-3"
      id="F_a2e996ec-d7a1-44c4-90c1-2422db0e88cb"
      unitRef="U_shares">295000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee"
      decimals="2"
      id="F_90ef06c2-6425-4314-84b8-b7bcf4601d4d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">28.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575"
      decimals="-3"
      id="F_e18800df-c518-4014-a383-e86ffcb5683e"
      unitRef="U_shares">41000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_9bfb09dd-8121-4c62-a617-c890849a7575"
      decimals="2"
      id="F_13e0a6c6-5a57-47b0-81d1-9a0a5f03dbe2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f"
      decimals="-3"
      id="F_e1cb379a-6b8d-4d2f-8295-00fd46af4ca5"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0edcd973-5c5e-4541-b6cf-73bd83857d7f"
      decimals="0"
      id="F_dead00fd-fc88-431c-b25d-e19d4bb69ced"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8"
      decimals="-3"
      id="F_595ed31a-5767-4de2-ae4d-9bfb87f30253"
      unitRef="U_shares">948000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8"
      decimals="2"
      id="F_f7e1982c-2823-4dfb-b447-84951234103d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_4225ffae-2b85-4646-9d44-6752e738321b"
      decimals="-3"
      id="F_a49fcb0d-0e4f-47bb-bdfe-8254f2bdaa59"
      unitRef="U_shares">518000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_4225ffae-2b85-4646-9d44-6752e738321b"
      decimals="2"
      id="F_7c81efb0-565b-4585-842f-ae1a887a758d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_d577f45e-f619-4e15-880c-f1fd5f863799"
      decimals="-3"
      id="F_a3ea0384-651f-49ee-ab95-c7c6b528b73f"
      unitRef="U_shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_d577f45e-f619-4e15-880c-f1fd5f863799"
      decimals="2"
      id="F_eeacd384-0572-411a-bf55-81c376b55633"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8"
      decimals="-3"
      id="F_7f6aeebc-6eb4-42a3-bc31-11b35d508848"
      unitRef="U_shares">948000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8"
      decimals="2"
      id="F_a4d2d2a8-e0c3-475f-8dcf-92cab65f353d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_4225ffae-2b85-4646-9d44-6752e738321b"
      decimals="-3"
      id="F_c973c6d6-f07c-4426-86e6-d7aed35123cb"
      unitRef="U_shares">518000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare
      contextRef="C_4225ffae-2b85-4646-9d44-6752e738321b"
      decimals="2"
      id="F_14f86c3f-6d77-47f5-a2c6-b020529c6a0b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.16</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_d577f45e-f619-4e15-880c-f1fd5f863799"
      decimals="0"
      id="F_d0c7ff1f-797d-406e-8dd8-466a49bce388"
      unitRef="U_shares">0</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare
      contextRef="C_d577f45e-f619-4e15-880c-f1fd5f863799"
      decimals="0"
      id="F_1641c701-f7e9-4e01-af07-f560127a7257"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8"
      decimals="-3"
      id="F_8979d928-ffed-4faa-9d74-51267e05f260"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8"
      decimals="-3"
      id="F_cb353724-9097-4f41-89b1-e22ac6c2610e"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_e262e47d-f2f5-4208-90c1-3bcda7144a65"
      decimals="-5"
      id="F_1376941e-0c37-49b7-8459-265e504ab4c7"
      unitRef="U_USD">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_567e6ab9-d35b-49eb-9cc8-a3b2a57e27d8"
      decimals="INF"
      id="F_49e3d95c-e59c-46a5-983c-18ad7c9236b2"
      unitRef="U_shares">290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee"
      id="F_1b0ab645-3982-473a-ac2e-0def378dab7a">P8Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_a386f2f5-a2d5-44d9-be1d-92de778d3a08"
      id="F_c54b0988-0d30-4685-b481-c80596fdb978">P4Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee"
      decimals="-6"
      id="F_f5fc643c-7065-4d6b-9e71-1f0fc1798486"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_a386f2f5-a2d5-44d9-be1d-92de778d3a08"
      decimals="-5"
      id="F_4900f038-359e-4230-9523-73f5e7e53f92"
      unitRef="U_USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_8d4db9d3-f0ac-411c-b4be-66a68e66086e"
      decimals="-5"
      id="F_453f35fc-4553-408b-aeb8-bae66036085a"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_a386f2f5-a2d5-44d9-be1d-92de778d3a08"
      decimals="-5"
      id="F_b1a97aa1-d31b-4cad-8b38-d40eb0f7c143"
      unitRef="U_USD">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee"
      decimals="-6"
      id="F_095604a5-b5eb-4caa-9a06-e36e77e03609"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_8d4db9d3-f0ac-411c-b4be-66a68e66086e"
      decimals="-6"
      id="F_ff391fa3-17ed-49a4-8c4b-a7eb7de384fc"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_ee7e738b-3b4f-48c9-ba8f-5c03822e27c8">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted-average assumptions used in calculating the estimated value of our stock options on the date of grant as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.741%;"/&gt;
        &lt;td style="width:1.474%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.955%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.464%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.955%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.464%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.946%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.04&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.11&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.11&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average estimated fair value of stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_5440a9c2-207c-4fb3-b81e-e1b717693af2"
      decimals="3"
      id="F_8eb013fc-50eb-4f2a-a755-f0bacb8d1d84"
      unitRef="U_pure">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_fe02af8a-5018-4690-9673-9a7063d85b4a"
      decimals="3"
      id="F_ccb3cc83-d2c4-4f4c-8bd0-d942ca15ff8a"
      unitRef="U_pure">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_7cb7feed-1acc-460a-b96e-c4eeb94c9ae0"
      decimals="3"
      id="F_8293e117-50d8-40ec-9aa4-12d56edb7e8e"
      unitRef="U_pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5440a9c2-207c-4fb3-b81e-e1b717693af2"
      id="F_f78aab1e-f250-4ab7-b1e9-fd10c84efb6e">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_fe02af8a-5018-4690-9673-9a7063d85b4a"
      id="F_dd527153-dd9d-42b5-950a-4700e8395806">P6Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_7cb7feed-1acc-460a-b96e-c4eeb94c9ae0"
      id="F_2cbf4a81-4f52-40ab-a30f-79cf957b6c7e">P6Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_5440a9c2-207c-4fb3-b81e-e1b717693af2"
      decimals="3"
      id="F_db860bfe-c610-4e68-98a5-75b4817d868c"
      unitRef="U_pure">0.386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_fe02af8a-5018-4690-9673-9a7063d85b4a"
      decimals="3"
      id="F_a2bfe5cb-c4df-4e48-b9f7-a42a48fe361e"
      unitRef="U_pure">0.449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_7cb7feed-1acc-460a-b96e-c4eeb94c9ae0"
      decimals="3"
      id="F_e115f6d3-a4f1-4264-8115-e79706e3638b"
      unitRef="U_pure">0.469</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_5440a9c2-207c-4fb3-b81e-e1b717693af2"
      decimals="3"
      id="F_1b119ad9-3c14-4718-9251-a193a1c2d3d1"
      unitRef="U_pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_fe02af8a-5018-4690-9673-9a7063d85b4a"
      decimals="3"
      id="F_b98df59d-40eb-4464-9583-c5e91148c9f2"
      unitRef="U_pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_7cb7feed-1acc-460a-b96e-c4eeb94c9ae0"
      decimals="3"
      id="F_a3d3446c-5f71-4028-ab2b-0877f30b1751"
      unitRef="U_pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_5440a9c2-207c-4fb3-b81e-e1b717693af2"
      decimals="2"
      id="F_af3e8eb7-3c07-4799-b2c9-862a81c1166d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_fe02af8a-5018-4690-9673-9a7063d85b4a"
      decimals="2"
      id="F_412797d0-c967-434a-9cab-6967a87fa784"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_7cb7feed-1acc-460a-b96e-c4eeb94c9ae0"
      decimals="2"
      id="F_dc3d4823-5438-47db-9028-7b261314dd23"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_08628a03-3017-46a4-83b0-b9cbd307f886">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On October 31, 2022, our board of directors authorized a new share repurchase program under which we may repurchase up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of our outstanding shares of common stock. The timing and amount of any share repurchases under the share repurchase program will be determined by our management in its discretion based on ongoing assessments of the capital needs of the business, the market price of our common stock, prevailing stock prices, general market conditions and other considerations. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. This program has no termination date, may be suspended or discontinued at any time at our discretion, and does not obligate us to acquire any amount of common stock. As of December 31, 2022, we have repurchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;647,394&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares in the open market at an average price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.13&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for a total amount of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Subsequent to December 31, 2022 and through February 24, 2023, we have repurchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,522,947&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares in the open market at an average price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.63&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for a total amount of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. All the repurchased shares were retired.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="C_f7e84609-a139-4ee7-8f30-bd52dd4de851"
      decimals="-5"
      id="F_65e8bc03-dc37-4620-a97b-48d97984b0b0"
      unitRef="U_USD">100000000.0</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869"
      decimals="INF"
      id="F_cb34957d-c976-4c10-8eec-e389793f3f09"
      unitRef="U_shares">647394</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <inva:CommonStockAcquiredAverageCostPerShare
      contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869"
      decimals="2"
      id="F_30c17bbc-3710-4db6-bb20-e7a354023082"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.13</inva:CommonStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_cd10ec09-e489-4d3d-9dac-cc21b2f64869"
      decimals="-5"
      id="F_10a38b78-8a1e-49ee-b52f-0e2ba5ba25c9"
      unitRef="U_USD">8500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="C_e21d4ed9-45f2-4010-8231-c9ee66700c0c"
      decimals="INF"
      id="F_6e228388-db4d-420f-984e-725b998979e9"
      unitRef="U_USD">1522947</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <inva:CommonStockAcquiredAverageCostPerShare
      contextRef="C_225556d0-78ae-4d3f-a563-0e5f56e17bdb"
      decimals="2"
      id="F_bf810c75-b80a-4aed-92da-c4f067665682"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.63</inva:CommonStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_225556d0-78ae-4d3f-a563-0e5f56e17bdb"
      decimals="-5"
      id="F_641bbc49-4e91-4c70-b45a-c577a66da8fa"
      unitRef="U_USD">19200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_6e2fe99c-f329-4e4f-a9ef-e5058e2fc961">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12. DEBT&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our debt consists of:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.265%;"/&gt;
        &lt;td style="width:1.498%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.772%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.498%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.966000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;240,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;549,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;433,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;540,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;394,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Less: Current portion of long-term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total long-term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;444,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;394,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Convertible Subordinated Notes Due 2023&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2013, we completed an underwritten public offering of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;287.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million aggregate principal amount of unsecured convertible subordinated notes, with maturity date of January 15, 2023. The financing raised proceeds, net of issuance costs, of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;281.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, less $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; privately &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;negotiated capped call option transactions in connection&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;with &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the issuance of the notes. The 2023 Notes bear interest at the rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.125&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% per year that is payable semi-annually in arrears in cash on January 15 and July 15 of each year, beginning on July 15, 2013.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2023 Notes were convertible, at the option of the holder, into shares of our common stock at an initial conversion rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35.9903&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares per $1,000 principal amount of the 2023 Notes, subject to adjustment in certain circumstances, which represents an initial conversion price of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.79&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the offering of the 2023 Notes, we entered into two privately negotiated capped call option transactions with a single counterparty. The capped call option transaction is an integrated instrument consisting of a call option on our common stock purchased by us with a strike price equal to the initial conversion price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.79&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for the underlying number of shares and a cap price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, both of which are subject to adjustments consistent with the 2023 Notes. The cap component is economically equivalent to a call option sold by us for the underlying number of shares with an initial strike price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. As an integrated instrument, the settlement of the capped call coincides with the due date of the convertible debt. Upon settlement, we would receive from our hedge counterparty a number of shares of our common shares that would range from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, if the stock price was below $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.79&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, to a maximum of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,779,659&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, if the stock price is above $38.00 per share. However, if the market price of our common stock, as measured under the terms of the capped call transactions, exceeds $38.00 per share, there is no incremental anti-dilutive benefit from the capped call.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of the partial conversion by certain holders of the 2023 Notes in July 2014, and dividends declared and paid in 2014 and 2015, the conversion rate with respect to our 2023 Notes was adjusted in total to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.5818&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock per $1,000 principal amount of the 2023 Notes, which represents a conversion price of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.77&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. As a result of the conversion rate adjustments, the capped call strike price and cap price were also adjusted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.77&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.04&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31, 2016, we retired a portion of our 2023 Notes with a face value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and carrying value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million by way of purchase in the open market.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 7, 2022, we used $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;165.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million from the sale of the 2028 Notes to repurchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the 2023 Notes with a face value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;144.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The carrying value of the repurchased 2023 Notes was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;144.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Accrued interest was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and unamortized debt issuance costs were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million on the date of repurchase. We recognized a loss on the extinguishment of the 2023 Notes of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in other expense, net, in the consolidated statement of operations. The repurchase reduced the outstanding principal balance to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and unamortized debt issuance costs to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The annual effective interest rate of the 2023 Notes changed from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.36&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.37&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On April 18, 2022, certain 2023 Notes holders converted their notes of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; thousand into Innoviva&#x2019;s common stock. The outstanding principal balance was reduced slightly to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our outstanding 2023 Notes balances consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.265%;"/&gt;
        &lt;td style="width:1.498%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.772%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.498%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.966000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;240,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;240,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2023 Notes for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.52%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.540000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.540000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.940000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2023 Notes were fully paid upon their maturity date in January 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Convertible Senior Notes Due 2025&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On August 7, 2017, we completed a private placement of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;192.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million aggregate principal amount of our 2025 Notes. The proceeds include the 2025 Notes sold pursuant to the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million over-allotment option granted by us to the initial purchasers, which option was exercised in full. The 2025 Notes were sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The 2025 Notes are senior unsecured obligations and bear interest at a rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% per year, payable semi-annually in arrears on February 15 and August 15 of each year, beginning on February 15, 2018.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2025 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate for the 2025 Notes is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57.9240&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock per $1,000 principal amount of the 2025 Notes (which is equivalent to an initial conversion price of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.26&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share), representing a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% conversion premium over the last reported sale price of the Company&#x2019;s common stock on August 1, 2017, which was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.28&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. The conversion rate is subject to customary anti-dilution adjustments in certain circumstances. The 2025 Notes will mature on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 15, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, unless repurchased or converted in accordance with their terms prior to such date. Prior to February 15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods. From, and including, February 15, 2025, until the close of business on the second scheduled trading day immediately preceding the maturity date, the 2025 Notes will be convertible at any time.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Holders of the 2025 Notes may convert all or a portion of their 2025 Notes prior to the close of business on February 15, 2025 only under the following circumstances:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;after September 30, 2017, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the current conversion price of the 2025 Notes;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the product of our closing common stock price and the conversion rate of the 2025 Notes on such day; and,&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental changes (as defined in the indenture governing the 2025 Notes) or a transaction resulting in our common stock converting into other securities or property or assets. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On or after February 15, 2025, holders of the 2025 Notes may convert their 2025 Notes at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2025 Notes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the event of default or a fundamental change (as defined above), holders of the 2025 Notes may require us to repurchase all or a portion of their 2025 Notes at price equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the principal amount of the 2025 Notes, plus any accrued and unpaid interest.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective January 1, 2022, we adopted ASU 2020-06 using a modified retrospective method, under which financial results reported in prior periods were not adjusted. The adoption of ASU 2020-06 had a material impact on the 2025 notes. Refer to Note 1, &#x201c;Description of Operations and Summary of Significant Accounting Policies&#x201d;, for further information.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to the adoption of ASU 2020-06, we separately accounted for the liability and equity components of the 2025 Notes by allocating the proceeds between the liability component and the embedded conversion option (&#x201c;equity component&#x201d;) due to our ability to settle the conversion obligation of the 2025 Notes in cash, common stock or a combination of cash and common stock, at our option. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature using the income approach. The allocation was performed in a manner that reflected our non-convertible debt borrowing rate for similar debt. The equity component of the 2025 Notes of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was recognized as a debt discount and represents the difference between the proceeds from the issuance of the 2025 Notes and the fair value of the liability of the 2025 Notes on the date of issuance. The excess of the principal amount of the liability component over its carrying amount (&#x201c;debt discount&#x201d;) was amortized to interest expense using the effective interest method over the term of the 2025 Notes. The equity component was not remeasured as long as it continued to meet the conditions for equity classification. Additionally, we separated the total issuance costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million incurred into liability and equity components in proportion to the allocation of the initial proceeds, resulting in liability issuance costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and equity issuance costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Issuance costs attributable to the liability&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;component &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;were amortized on a straight-line basis, which approximated the effective interest rate method, to interest expense over the term of the 2025 Notes. The issuance costs attributable to the equity component were netted against the equity component in additional paid-in capital. The annual effective interest rate of the liability component of the 2025 Notes was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.87&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon adoption of ASU 2020-06 on January 1, 2022, we combined the liability and equity components of the 2025 Notes assuming that the instrument was accounted for as a single liability from inception to the date of adoption. We similarly combined the liability and equity components of the issuance costs. The issuance costs are presented as a deduction from the outstanding principal balance of the 2025 Notes and are amortized on a straight-line basis over the term of the 2025 Notes under the effective interest rate method. As of January 1, 2022, the annual effective interest rate on the 2025 Notes was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.88&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our outstanding 2025 Notes balances consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.265%;"/&gt;
        &lt;td style="width:1.498%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.772%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.498%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.966000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liability component&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt discount and issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;190,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;154,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity component, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.423%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.707%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Convertible Senior Notes Due 2028&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2022, we completed a private placement of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;261.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million aggregate principal amount of our 2028 Notes, which will mature on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 15, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The proceeds include the 2028 Notes sold pursuant to the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million over-allotment option granted by us to the initial purchasers, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was exercised. The 2028 Notes were sold in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The net proceeds from the sale of the $261.0 million aggregate principal amount of 2028 Notes were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;252.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million after deducting the initial purchasers&#x2019; discounts and commissions and our estimated offering expenses. We used approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the net proceeds from the offering to fund the cost of entering into the capped call transactions described below. In addition, we used $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;165.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the remaining net proceeds to repurchase $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;144.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million aggregate principal amount of the 2023 Notes in separate and individually negotiated transactions with certain holders of the 2023 Notes, which closed concurrently with the issuance of the 2028 Notes. We expect to use the remaining net proceeds for general corporate purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2028 Notes bear interest at an annual rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.125&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% that is payable semi-annually in arrears in cash on March 15 and September 15 of each year, beginning on September 15, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2028 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38.1432&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares per $1,000 principal amount of the 2028 Notes, subject to customary anti-dilution adjustment in certain circumstances, which represented an initial conversion price of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.22&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to September 15, 2027, the 2028 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods, and will be convertible on or after September 15, 2027, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2028 Notes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Holders of the 2028 Notes may convert all or a portion of their 2028 Notes prior to the close of business on September 15, 2027, only under the following circumstances:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;after March 31, 2022, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the current conversion price of the 2028 Notes;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the product of our closing common stock price and the conversion rate of the 2028 Notes on such day; and,&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental changes (as defined in the indenture governing the 2028 Notes) or a transaction resulting in our common stock converting into other securities or property or assets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On or after September 15, 2027, holders of the 2028 Notes may convert their 2028 Notes at any time until the close of the business on the second day immediately preceding the maturity date of the 2028 Notes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2028 Notes will be redeemable, in whole or in part, at our option at any time, and from time to time, on or after March 20, 2025, and on or before the 75th scheduled trading day immediately before the maturity date but only if the last reported sale price per share of our common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the 2028 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, calling any 2028 Note for redemption will constitute a make-whole fundamental change (as defined in the indenture governing the 2028 Notes) with respect to that 2028 Note, in which case the conversion rate applicable to the conversion of that 2028 Note will be increased in certain circumstances if it is converted after it is called for redemption.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If we undergo a fundamental change, subject to certain conditions, holders may require us to purchase for cash all or any portion of their 2028 Notes. The fundamental change purchase price will be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the principal amount of the 2028 Notes to be purchased plus any accrued and unpaid interest to, but excluding, the fundamental change purchase date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions. The cap price of the capped call transaction is initially $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33.9850&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and is subject to certain adjustments under the terms of the capped call transactions. The capped call transactions cover, subject to customary adjustments, the number of shares of common stock initially underlying the 2028 Notes. The capped call transactions are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the aggregate principal amount of converted 2028 Notes, as the case may be, with such reduction or offset subject to a cap.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The annual effective interest rate on the 2028 Notes is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.70&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our outstanding 2028 Notes balance consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.252%;"/&gt;
        &lt;td style="width:1.784%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.964%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liability component&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt discount and issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;253,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2028 Notes from the issuance through &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.287%;"/&gt;
        &lt;td style="width:1.802%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.911%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Date of Issuance through&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Debt Maturities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate scheduled maturities of our long-term debt as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.325%;"/&gt;
        &lt;td style="width:1.794%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.881%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;549,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Deferred Royalty Obligation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As part of our acquisition of La Jolla, we recorded the fair value of its deferred royalty obligation in connection with La Jolla&#x2019;s royalty financing agreement (&#x201c;La Jolla Royalty Agreement&#x201d;) with HealthCare Royalty Partners (&#x201c;HCR&#x201d;). Under the terms of the La Jolla Royalty Agreement, HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; until either January 1, 2031 or when the maximum aggregate royalty payments have been made, whichever occurs first. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. The current maximum royalty rate is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. Starting January 1, 2024, the maximum royalty rate may increase by an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%, if an agreed-upon, cumulative net product sales threshold has not been met. The La Jolla Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From the date of our acquisition of La Jolla through December 31, 2022, we recognized interest expense of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million on the deferred royalty obligation. The carrying value of the deferred royalty obligation and accrued interest as of December 31, 2022 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;million of which &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;was classified as part of other long-term liabilities on the consolidated balance sheet and the remaining $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was classified as other accrued liabilities on the consolidated balance sheet. From the date of acquisition of La Jolla through December 31, 2022, we made royalty payments to HCR of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The deferred royalty obligation was valued using Level 3 inputs, and its carrying value as of December 31, 2022 approximates fair value. The fair value of the deferred royalty obligation was calculated as the discounted deferred royalty obligations based on risk-adjusted revenue projections for GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The annual effective interest rate of the deferred royalty obligation was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the La Jolla Royalty Agreement, if we are unable to meet certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, HCR would have the right to terminate the La Jolla Royalty Agreement and demand payment of either $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million or $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million (depending on which obligation we have failed to meet) less aggregate royalties already paid to HCR. As of December 31, 2022, inclusive of the aggregate royalties paid to HCR by La Jolla under the La Jolla Royalty Agreement prior to our acquisition, La Jolla paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;aggregate royalties to HCR. In the event that we fail to pay such amount if and when due in a timely manner, HCR would have the right to foreclose on the GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-related assets. HCR has no recourse against any asset other than GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certain contract provisions within the La Jolla Royalty Agreement that could result in an acceleration of amounts due under the La Jolla Royalty Agreement are recognized as embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. We determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, we determined that the fair value of the embedded derivatives is not material and, therefore, not recognized as of December 31, 2022. We estimate the fair value of the embedded derivatives for each reporting period until either the features lapse or the La Jolla Royalty Agreement is terminated, whichever occurs first. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss on the consolidated statements of income.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_b9846e37-eccc-4bea-86c1-fbfa149ae0a4">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our debt consists of:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.265%;"/&gt;
        &lt;td style="width:1.498%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.772%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.498%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.966000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;240,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;549,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;433,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;540,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;394,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Less: Current portion of long-term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total long-term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;444,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;394,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_db24b4c5-31a5-4774-89a4-c8ee79bc160f"
      decimals="-3"
      id="F_817a431e-6c56-4ec9-a1d5-fd7aa2b49d26"
      unitRef="U_USD">96204000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_e0e7a33a-815b-42a2-be04-e2cbe14d7628"
      decimals="-3"
      id="F_7f50c3e9-1391-447c-ab78-10e91d53b568"
      unitRef="U_USD">240984000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_975e5da7-351c-4671-96f0-b5f31daa46d0"
      decimals="-3"
      id="F_d65e4a32-3307-4c62-bf86-7295c16341d0"
      unitRef="U_USD">192500000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_3f8a395a-d382-4590-8d7a-2cc22d27ec5d"
      decimals="-3"
      id="F_6beb6149-2112-4519-8a06-a00fed755d85"
      unitRef="U_USD">192500000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_87d07c35-75b2-4cc6-9d24-9604a851da8f"
      decimals="-3"
      id="F_452848d6-b6e3-470d-9f22-2a9e21960155"
      unitRef="U_USD">261000000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_4cc2b7aa-5de5-44f3-bfb9-3a6bc72ba7cc"
      decimals="-3"
      id="F_0b6b637f-86be-44a6-a527-1ebbd52acc95"
      unitRef="U_USD">0</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_bdadef31-edc0-4f19-9270-e9ca6daf3f7b"
      unitRef="U_USD">549704000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_16ecf6dc-f429-4f90-873a-5c7cdfd464a5"
      unitRef="U_USD">433484000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_2be14dd0-2cf5-4a4e-8c03-cf3b9ede8f38"
      unitRef="U_USD">9331000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_a7ec226a-f039-4fba-8dee-47fa7110d3e4"
      unitRef="U_USD">38831000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_87529182-981c-4648-a437-1075130c6c01"
      unitRef="U_USD">540373000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_56949bdf-aa88-4f3c-8aec-09ce005fc275"
      unitRef="U_USD">394653000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_17c44fd4-82ba-44b1-aaf0-24d43640cb46"
      unitRef="U_USD">96193000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_f575a754-f475-423c-b982-7054e41dee2a"
      unitRef="U_USD">0</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_a637dd0a-6101-445d-ae1c-fe864a45277f"
      unitRef="U_USD">444180000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_f78c0932-6d5d-49fa-af71-7301137e5f6e"
      unitRef="U_USD">394653000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_5d2ad42a-8c00-45ec-8588-2ffd6e64e9db"
      decimals="-5"
      id="F_f623463c-3e35-4b23-b779-38a054a483c3"
      unitRef="U_USD">287500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="C_4fdff83b-7c27-43e0-9faa-0d7971a875c1"
      decimals="-5"
      id="F_dc57ab98-7faa-4975-b0f0-505f084f8d4d"
      unitRef="U_USD">281200000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DerivativeCostOfHedge
      contextRef="C_c0c14dc4-3f99-40d8-a419-fb1d3a855ff6"
      decimals="-5"
      id="F_70dd6b55-9185-4a0e-94d6-f9cae0edb4e6"
      unitRef="U_USD">36800000</us-gaap:DerivativeCostOfHedge>
    <inva:NumberOfDerivativeInstrumentsPurchased
      contextRef="C_eeedca61-ff8b-43cf-9322-e4e591891f4a"
      decimals="0"
      id="F_87ffbbfb-f25f-490e-ae4d-112697ded482"
      unitRef="U_Item">2</inva:NumberOfDerivativeInstrumentsPurchased>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_5d2ad42a-8c00-45ec-8588-2ffd6e64e9db"
      decimals="5"
      id="F_19d164d8-7749-42e3-8fe6-b38ee77e7ada"
      unitRef="U_pure">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <inva:ConversionRate
      contextRef="C_4fdff83b-7c27-43e0-9faa-0d7971a875c1"
      decimals="4"
      id="F_86c2ae96-eb8c-44f7-b18a-ac3c96f47b4c"
      unitRef="U_shares">35.9903</inva:ConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_5d2ad42a-8c00-45ec-8588-2ffd6e64e9db"
      decimals="2"
      id="F_067ec2d1-b0d8-429e-b4fb-f3748d765b92"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.79</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="C_c0c14dc4-3f99-40d8-a419-fb1d3a855ff6"
      decimals="2"
      id="F_c6429131-ce48-4043-91c1-85d7570349b2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.79</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:DerivativeCapPrice
      contextRef="C_eeedca61-ff8b-43cf-9322-e4e591891f4a"
      decimals="2"
      id="F_b5d620bd-7f37-4efe-ade0-3796d76522c6"
      unitRef="U_UsdItem">38.00</us-gaap:DerivativeCapPrice>
    <us-gaap:DerivativeCapPrice
      contextRef="C_eeedca61-ff8b-43cf-9322-e4e591891f4a"
      decimals="2"
      id="F_18b61989-066f-46c9-a5ad-30f401c94985"
      unitRef="U_UsdItem">38.00</us-gaap:DerivativeCapPrice>
    <inva:NumberOfSharesReceivableOnSettlementOfDerivativeInstrument
      contextRef="C_ca10358b-8c3c-4daf-beb4-bf93df5c5577"
      decimals="0"
      id="F_9497ea9d-48c3-4c2a-8c8e-d16fecc6d0a9"
      unitRef="U_shares">0</inva:NumberOfSharesReceivableOnSettlementOfDerivativeInstrument>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="C_e26b8922-044d-455a-825e-2cbd6970866c"
      decimals="2"
      id="F_15a1bf2b-4649-4b29-a4ae-1143e84e258e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.79</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <inva:NumberOfSharesReceivableOnSettlementOfDerivativeInstrument
      contextRef="C_760e546c-c33b-4240-91c4-bc5ba9131a71"
      decimals="INF"
      id="F_1a11e067-5409-4134-a23f-a03c9d5734ce"
      unitRef="U_shares">2779659</inva:NumberOfSharesReceivableOnSettlementOfDerivativeInstrument>
    <inva:ConversionRate
      contextRef="C_41da565b-a64a-4074-a703-94289af0897b"
      decimals="4"
      id="F_880d9e98-7aad-45b3-ac18-9ddbbafe80bc"
      unitRef="U_shares">50.5818</inva:ConversionRate>
    <inva:CappedCallStrikePrice
      contextRef="C_ac5e1f2a-cef7-4391-8f23-5ab0d707cb92"
      decimals="2"
      id="F_c4a28574-923b-41be-af9d-eaebd7946421"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.77</inva:CappedCallStrikePrice>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="C_931f2e1a-1b03-4282-9cfd-4d87cffcdb25"
      decimals="2"
      id="F_5bfac29c-8db3-4c25-b3e4-34d5f469e9df"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.77</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:DerivativeCapPrice
      contextRef="C_4440fd71-0092-4f2b-a8d0-66d0304e4b87"
      decimals="2"
      id="F_79493d95-3846-41e0-bcb4-8f451a0014b4"
      unitRef="U_UsdItem">27.04</us-gaap:DerivativeCapPrice>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="C_b203b0f4-9fcb-40af-9c5b-8e2482e2f95a"
      decimals="-5"
      id="F_bce73673-bbbf-4bdf-a4d9-b5bbbbfe5be1"
      unitRef="U_USD">14100000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="C_b203b0f4-9fcb-40af-9c5b-8e2482e2f95a"
      decimals="-5"
      id="F_e0b33235-e240-4eea-b423-176c1097a3f9"
      unitRef="U_USD">13900000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_3016f145-17f8-4f1a-82c7-f26a7aa8c466"
      decimals="-5"
      id="F_702264ac-efd5-4e88-90c6-4444d0ccb9a4"
      unitRef="U_USD">165600000</us-gaap:RepaymentsOfUnsecuredDebt>
    <inva:DebtInstrumentRepurchasePercentage
      contextRef="C_3016f145-17f8-4f1a-82c7-f26a7aa8c466"
      decimals="2"
      id="F_3d635f24-d3f0-4f67-93a5-ce61dc79c35e"
      unitRef="U_pure">0.60</inva:DebtInstrumentRepurchasePercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="C_443136d7-7ad0-44e7-a11c-023a948f7f76"
      decimals="-5"
      id="F_609f1c51-fe72-4318-8cfd-768db6304387"
      unitRef="U_USD">144800000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="C_443136d7-7ad0-44e7-a11c-023a948f7f76"
      decimals="-5"
      id="F_930375a0-bee4-40cd-92db-6773a83db301"
      unitRef="U_USD">144500000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:InterestPayableCurrent
      contextRef="C_443136d7-7ad0-44e7-a11c-023a948f7f76"
      decimals="-5"
      id="F_c677aa60-83d2-456b-8e1b-57b9d47dfd36"
      unitRef="U_USD">400000</us-gaap:InterestPayableCurrent>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="C_443136d7-7ad0-44e7-a11c-023a948f7f76"
      decimals="-5"
      id="F_a6b70a24-a112-4818-ada4-c38617706193"
      unitRef="U_USD">300000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_3016f145-17f8-4f1a-82c7-f26a7aa8c466"
      decimals="-5"
      id="F_2423bacd-6653-4932-a4ac-40da6161a0d3"
      unitRef="U_USD">20700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_443136d7-7ad0-44e7-a11c-023a948f7f76"
      decimals="-5"
      id="F_59a8c04d-f092-4cca-ac15-692a256b62c8"
      unitRef="U_USD">96200000</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_443136d7-7ad0-44e7-a11c-023a948f7f76"
      decimals="-5"
      id="F_b1512bbf-e6b5-41a1-899e-2db6d651ec64"
      unitRef="U_USD">200000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_439a2891-953d-43ed-8e7a-3e4c09d85e29"
      decimals="4"
      id="F_e0c073cf-ed92-49fd-9e25-24071c9d5125"
      unitRef="U_pure">0.0236</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_1e690336-d9c4-4186-8f97-2aa319621487"
      decimals="4"
      id="F_cf31a30d-374e-4cc5-afa4-21e3f0960fc2"
      unitRef="U_pure">0.0237</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="C_c50e19a1-f680-4297-ba13-d0cc4e167f05"
      decimals="-2"
      id="F_5b9557e4-a881-4c5b-8ce5-6f91f62cda41"
      unitRef="U_USD">3000.0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_b36371f8-68e7-4572-9b2d-995236afdd29"
      decimals="-5"
      id="F_ef763c5d-0522-4859-b274-c0f6dee071ad"
      unitRef="U_USD">96200000</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="C_32dbf528-70de-47c3-9e65-d8c113adb297"
      id="F_b3d82245-e41a-45fa-bee3-af0cc23f9c76">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our outstanding 2023 Notes balances consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.265%;"/&gt;
        &lt;td style="width:1.498%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.772%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.498%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.966000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;240,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;240,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_db24b4c5-31a5-4774-89a4-c8ee79bc160f"
      decimals="-3"
      id="F_e587b9df-2624-4d07-a295-5d31b5b2bcca"
      unitRef="U_USD">96204000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_e0e7a33a-815b-42a2-be04-e2cbe14d7628"
      decimals="-3"
      id="F_f0dcc63a-06fd-40ab-b341-8c2f883b0b2b"
      unitRef="U_USD">240984000</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_db24b4c5-31a5-4774-89a4-c8ee79bc160f"
      decimals="-3"
      id="F_b75d8460-5980-4bc8-8d82-c8d07e750b3f"
      unitRef="U_USD">11000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_e0e7a33a-815b-42a2-be04-e2cbe14d7628"
      decimals="-3"
      id="F_35f480b8-0d5b-4b41-b0e5-2b0312c0848e"
      unitRef="U_USD">620000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_db24b4c5-31a5-4774-89a4-c8ee79bc160f"
      decimals="-3"
      id="F_5f06fdcc-7813-4b55-aaf2-725a0d1d79ec"
      unitRef="U_USD">96193000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="C_e0e7a33a-815b-42a2-be04-e2cbe14d7628"
      decimals="-3"
      id="F_95a4cd47-ef3d-41ca-b08c-b8fb869c3640"
      unitRef="U_USD">240364000</us-gaap:LongTermDebtCurrent>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="C_32dbf528-70de-47c3-9e65-d8c113adb297"
      id="F_a35bc66d-f68e-4ae6-9ddd-b503d276cf26">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2023 Notes for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.52%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.540000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.540000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.940000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_2889d5e4-431b-4019-8db7-26884c76cb7f"
      decimals="-3"
      id="F_fea69e71-260a-48f9-b097-b6f902a32596"
      unitRef="U_USD">2617000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_82199548-5f77-4397-8b16-459c147af958"
      decimals="-3"
      id="F_6dec873e-d2a3-465f-820d-41c762d79ac6"
      unitRef="U_USD">5121000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_e8422a9e-f163-4920-b53e-2d0b99405fc9"
      decimals="-3"
      id="F_f086c5ad-3c90-4804-9684-1283233ff441"
      unitRef="U_USD">5121000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_2889d5e4-431b-4019-8db7-26884c76cb7f"
      decimals="-3"
      id="F_8874eb00-061d-46c3-be5e-76e158010e1b"
      unitRef="U_USD">302000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_82199548-5f77-4397-8b16-459c147af958"
      decimals="-3"
      id="F_89a55a64-7ae5-4e64-945d-13a14d10291d"
      unitRef="U_USD">580000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_e8422a9e-f163-4920-b53e-2d0b99405fc9"
      decimals="-3"
      id="F_b57407c4-e772-48db-8e50-c28ed1ba94bd"
      unitRef="U_USD">567000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="C_2889d5e4-431b-4019-8db7-26884c76cb7f"
      decimals="-3"
      id="F_25db4e6b-ffd3-43d6-a9bf-0c4a6c9fc7bf"
      unitRef="U_USD">2919000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_82199548-5f77-4397-8b16-459c147af958"
      decimals="-3"
      id="F_e44c4548-f737-4768-b788-cf0964482d25"
      unitRef="U_USD">5701000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_e8422a9e-f163-4920-b53e-2d0b99405fc9"
      decimals="-3"
      id="F_f171181f-7579-4f9a-bade-c0c5af11fc81"
      unitRef="U_USD">5688000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_fd54577e-ca59-4227-b618-f18cb6ef69e3"
      decimals="-5"
      id="F_039805a8-b080-4759-8e0b-19accc340a62"
      unitRef="U_USD">192500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_5d3e731d-77ad-41c9-8fb2-80c5c772794f"
      decimals="-5"
      id="F_58ea36fe-6e40-44ee-a466-8f968b38aea5"
      unitRef="U_USD">17500000</us-gaap:DebtInstrumentFaceAmount>
    <inva:PortionOfDebtInstrumentFaceAmountExercised
      contextRef="C_5d3e731d-77ad-41c9-8fb2-80c5c772794f"
      decimals="-5"
      id="F_88c11449-00f2-4f3a-8c30-d20dd5a6f5e8"
      unitRef="U_USD">17500000</inva:PortionOfDebtInstrumentFaceAmountExercised>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_fd54577e-ca59-4227-b618-f18cb6ef69e3"
      decimals="3"
      id="F_b58940b0-ecc9-4be7-a3ec-5b068031dca1"
      unitRef="U_pure">0.025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="C_a12f3c2b-1e4a-41a5-98c5-e299cd3ff20e"
      decimals="4"
      id="F_c892ca6f-a3d7-4dfe-9301-c3aec6b29f97"
      unitRef="U_pure">57.9240</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_37b32554-8570-46f1-ad40-8f1d76b0a567"
      decimals="2"
      id="F_47146212-034f-4ed3-a990-5da68566c3a7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.26</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <inva:DebtInstrumentConvertibleConversionPremium
      contextRef="C_37b32554-8570-46f1-ad40-8f1d76b0a567"
      decimals="3"
      id="F_86260ba6-05de-48ae-9ec0-054b7abf6900"
      unitRef="U_pure">0.300</inva:DebtInstrumentConvertibleConversionPremium>
    <us-gaap:SharePrice
      contextRef="C_3df3cdfa-bdca-4ba3-afb8-18a6a9c0e333"
      decimals="2"
      id="F_1fa5bdf8-c0b3-4421-985a-91b79525b8c4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.28</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_a12f3c2b-1e4a-41a5-98c5-e299cd3ff20e"
      id="F_fd7a86ce-dec1-496c-bab5-54d8620d5778">2025-08-15</us-gaap:DebtInstrumentMaturityDate>
    <inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage
      contextRef="C_98afe62c-821a-4537-b552-da050d3c5568"
      decimals="2"
      id="F_6dd1f508-9bb4-4750-a1c7-d59da0ca422a"
      unitRef="U_pure">1.30</inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage>
    <inva:DebtConversionConvertedInstrumentAverageTradePricePercentage
      contextRef="C_98afe62c-821a-4537-b552-da050d3c5568"
      decimals="2"
      id="F_94259da0-fbc2-45b6-abfe-8d57fef07352"
      unitRef="U_pure">0.98</inva:DebtConversionConvertedInstrumentAverageTradePricePercentage>
    <inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount
      contextRef="C_02211f41-81dd-4ee9-8d76-5d38e227447b"
      decimals="2"
      id="F_2d2ad514-16fa-4887-807b-fa30d401f0eb"
      unitRef="U_pure">1</inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="C_f935b07f-6611-49a5-95c9-c3a28c0fd4ed"
      decimals="-5"
      id="F_d09cb842-6fba-447b-bd8b-c192a919b736"
      unitRef="U_USD">67300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="C_98afe62c-821a-4537-b552-da050d3c5568"
      decimals="-5"
      id="F_224a86e7-8ac3-4e66-a027-50de89eaef6d"
      unitRef="U_USD">5400000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_98afe62c-821a-4537-b552-da050d3c5568"
      decimals="-5"
      id="F_eb5eccc8-a24d-46a9-87d5-6f655d466a7b"
      unitRef="U_USD">3500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_98afe62c-821a-4537-b552-da050d3c5568"
      decimals="-5"
      id="F_25ee2968-54b7-4e4c-8ea3-da3348ba57b6"
      unitRef="U_USD">1900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_92728848-49b6-4fe1-8f74-6dcb6ee6a998"
      decimals="4"
      id="F_38db790d-a4eb-4121-acb0-b385cd053fc8"
      unitRef="U_pure">0.0887</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_9efe7ef9-0fdb-45f7-9960-db3353139806"
      decimals="4"
      id="F_102c180d-e4ff-4fac-bb4a-2140040073ac"
      unitRef="U_pure">0.0288</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="C_98afe62c-821a-4537-b552-da050d3c5568"
      id="F_913a944c-bbd3-42a0-9849-590b9376ddb6">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our outstanding 2025 Notes balances consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.265%;"/&gt;
        &lt;td style="width:1.498%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.772%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.498%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.966000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liability component&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt discount and issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;190,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;154,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity component, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_975e5da7-351c-4671-96f0-b5f31daa46d0"
      decimals="-3"
      id="F_b2c5afbf-c959-47d4-ae7f-1a3de6841109"
      unitRef="U_USD">192500000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_3f8a395a-d382-4590-8d7a-2cc22d27ec5d"
      decimals="-3"
      id="F_af532fb0-98d6-4165-83da-fc544583a920"
      unitRef="U_USD">192500000</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_975e5da7-351c-4671-96f0-b5f31daa46d0"
      decimals="-3"
      id="F_9c31ba29-378c-4fe6-8598-ed59edc57e1e"
      unitRef="U_USD">1917000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_3f8a395a-d382-4590-8d7a-2cc22d27ec5d"
      decimals="-3"
      id="F_84568c4d-13a8-43eb-9ffe-d24473098caa"
      unitRef="U_USD">38211000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="C_975e5da7-351c-4671-96f0-b5f31daa46d0"
      decimals="-3"
      id="F_4730745a-f535-4720-92a7-1909954faf66"
      unitRef="U_USD">190583000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_3f8a395a-d382-4590-8d7a-2cc22d27ec5d"
      decimals="-3"
      id="F_2dee919a-732b-4afb-ae31-3599183ca4b6"
      unitRef="U_USD">154289000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="C_975e5da7-351c-4671-96f0-b5f31daa46d0"
      decimals="-3"
      id="F_459419f9-0dfa-4b5f-acbe-de57b2caa8bc"
      unitRef="U_USD">0</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="C_3f8a395a-d382-4590-8d7a-2cc22d27ec5d"
      decimals="-3"
      id="F_9b24f8f0-d533-403c-b290-aef9593d35a3"
      unitRef="U_USD">65361000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="C_98afe62c-821a-4537-b552-da050d3c5568"
      id="F_4918c993-18c0-4298-a044-3351f7aa0db0">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.423%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.923%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.707%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,505&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_02211f41-81dd-4ee9-8d76-5d38e227447b"
      decimals="-3"
      id="F_caccbdc8-45f1-43d1-a10d-3c4394f2f7db"
      unitRef="U_USD">4813000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_6e288046-0f09-4c78-b427-4c133f35ca3f"
      decimals="-3"
      id="F_140b7c01-c796-4e3e-8e8b-9c22032ac413"
      unitRef="U_USD">4813000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_a7955fc6-6a0b-47e2-b852-f7b1e5cc5350"
      decimals="-3"
      id="F_99f74fff-84ed-4934-acb1-733c9aef9b1c"
      unitRef="U_USD">4813000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_02211f41-81dd-4ee9-8d76-5d38e227447b"
      decimals="-3"
      id="F_6530f324-1121-42dc-8e0a-e8050a82aaa8"
      unitRef="U_USD">692000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_6e288046-0f09-4c78-b427-4c133f35ca3f"
      decimals="-3"
      id="F_8fe37491-86d1-4187-a433-f52746eb74ba"
      unitRef="U_USD">657000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_a7955fc6-6a0b-47e2-b852-f7b1e5cc5350"
      decimals="-3"
      id="F_5355d21a-0dbc-4d9d-b8e1-8ae47d8bcc2c"
      unitRef="U_USD">601000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_02211f41-81dd-4ee9-8d76-5d38e227447b"
      decimals="-3"
      id="F_333cf855-73f5-4a84-903d-53039bfedd99"
      unitRef="U_USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_6e288046-0f09-4c78-b427-4c133f35ca3f"
      decimals="-3"
      id="F_36b0e0ce-670d-4c7c-8336-9db022ea5cf2"
      unitRef="U_USD">7898000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_a7955fc6-6a0b-47e2-b852-f7b1e5cc5350"
      decimals="-3"
      id="F_8840988c-b18d-4e9e-9775-1c424a654422"
      unitRef="U_USD">7230000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="C_02211f41-81dd-4ee9-8d76-5d38e227447b"
      decimals="-3"
      id="F_2a1c5b7d-2325-4dfa-b1f1-cac9ba501a5a"
      unitRef="U_USD">5505000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_6e288046-0f09-4c78-b427-4c133f35ca3f"
      decimals="-3"
      id="F_ac0bc2ff-7aee-4558-be78-8b5e2baa1502"
      unitRef="U_USD">13368000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_a7955fc6-6a0b-47e2-b852-f7b1e5cc5350"
      decimals="-3"
      id="F_04d0861e-20d1-4da8-b07b-8875242b29aa"
      unitRef="U_USD">12644000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_b3aac9f2-453c-4c3b-bd1b-f1503e5f3a1f"
      decimals="-5"
      id="F_adde91c8-ecf1-4bfc-963f-dd89973da5d3"
      unitRef="U_USD">261000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_93969c86-aa8a-4cdb-96b4-ca743740fab3"
      id="F_3c267b42-5c22-46dc-a2b6-7bed26d0274e">2028-03-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_8021ae84-5f41-4763-9cbd-85aedc0bb507"
      decimals="-5"
      id="F_221090af-75c2-4937-82de-3a8be69fed71"
      unitRef="U_USD">45000000.0</us-gaap:DebtInstrumentFaceAmount>
    <inva:PortionOfDebtInstrumentFaceAmountExercised
      contextRef="C_8021ae84-5f41-4763-9cbd-85aedc0bb507"
      decimals="-5"
      id="F_69eb58e4-4ffa-424f-800f-81015f7e8d27"
      unitRef="U_USD">36000000.0</inva:PortionOfDebtInstrumentFaceAmountExercised>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_93969c86-aa8a-4cdb-96b4-ca743740fab3"
      decimals="-5"
      id="F_cfe05e7e-b12c-464a-a2e9-bad597b3aaaf"
      unitRef="U_USD">252600000</us-gaap:ProceedsFromConvertibleDebt>
    <inva:PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes
      contextRef="C_cee61bd9-edd6-431b-94c0-5db6bc13f016"
      decimals="-5"
      id="F_59994af2-4d5f-4fa8-a9d6-38f941f0b4b7"
      unitRef="U_USD">21000000.0</inva:PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_e611e3bf-95e5-47ba-b2ae-1c43a06561de"
      decimals="-5"
      id="F_7fc85249-33e8-4f42-8249-c7f40806f97b"
      unitRef="U_USD">165600000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="C_875d8b01-4f11-410a-9178-6e2dadcb8eea"
      decimals="-5"
      id="F_755c5cbb-84a2-4640-a5f7-d40ffe3eb34e"
      unitRef="U_USD">144800000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_4b4d9d60-6153-4fc7-8983-cb3d99a8f061"
      decimals="5"
      id="F_5f897408-e1ab-4e4a-9fb1-4788ea9c95e9"
      unitRef="U_pure">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="C_c144de1c-726a-4b34-8527-25bd42031613"
      decimals="4"
      id="F_347f56b3-f9bd-432e-8658-e3e4509f84f5"
      unitRef="U_pure">38.1432</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_f8534932-ac9d-4cc5-9b1b-d50687f54e10"
      decimals="2"
      id="F_59eacaf1-6522-49ee-a8a0-a0e8b4fb0471"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.22</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage
      contextRef="C_93969c86-aa8a-4cdb-96b4-ca743740fab3"
      decimals="2"
      id="F_876ffcf0-69ed-4436-b0bf-8a564ff94041"
      unitRef="U_pure">1.30</inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage>
    <inva:DebtConversionConvertedInstrumentAverageTradePricePercentage
      contextRef="C_93969c86-aa8a-4cdb-96b4-ca743740fab3"
      decimals="2"
      id="F_ce5c5742-bf6a-4498-bd15-d841d9cf6208"
      unitRef="U_pure">0.98</inva:DebtConversionConvertedInstrumentAverageTradePricePercentage>
    <inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount
      contextRef="C_93969c86-aa8a-4cdb-96b4-ca743740fab3"
      decimals="2"
      id="F_b0129f43-dd96-4ea1-a816-ac6acbe0ba42"
      unitRef="U_pure">1</inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount>
    <us-gaap:LineOfCreditFacilityCovenantTerms
      contextRef="C_04636ba8-4bff-4dfa-bb5d-8f341cc9b324"
      id="F_6e3ef555-d570-4bcc-b532-d4f895aa96e4">The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.</us-gaap:LineOfCreditFacilityCovenantTerms>
    <us-gaap:DerivativeCapPrice
      contextRef="C_5e575930-339e-44e7-8b69-11dba2c9c328"
      decimals="4"
      id="F_8d730f76-289f-4e69-b588-77e4043a2e90"
      unitRef="U_UsdItem">33.9850</us-gaap:DerivativeCapPrice>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_87d07c35-75b2-4cc6-9d24-9604a851da8f"
      decimals="4"
      id="F_e8cf0d26-2d2f-4c6a-ba65-dcbae9158832"
      unitRef="U_pure">0.0270</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="C_04636ba8-4bff-4dfa-bb5d-8f341cc9b324"
      id="F_5ac92b16-9940-4e84-bc39-064947a69f70">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our outstanding 2028 Notes balance consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.252%;"/&gt;
        &lt;td style="width:1.784%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.964%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Liability component&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Debt discount and issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;253,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_87d07c35-75b2-4cc6-9d24-9604a851da8f"
      decimals="-3"
      id="F_89800a86-3354-461f-bb64-a7b54e83ed79"
      unitRef="U_USD">261000000</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_87d07c35-75b2-4cc6-9d24-9604a851da8f"
      decimals="-3"
      id="F_fb738130-d4ae-4da5-b617-956910fad83d"
      unitRef="U_USD">7403000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="C_87d07c35-75b2-4cc6-9d24-9604a851da8f"
      decimals="-3"
      id="F_db244b89-1a71-448b-a740-c6826926448a"
      unitRef="U_USD">253597000</us-gaap:LongTermDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="C_04636ba8-4bff-4dfa-bb5d-8f341cc9b324"
      id="F_e2e95117-0bb8-445e-807a-c253b57fb967">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2028 Notes from the issuance through &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.287%;"/&gt;
        &lt;td style="width:1.802%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.911%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Date of Issuance through&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_40d9b41f-8564-4e43-91f2-98018ace4541"
      decimals="-3"
      id="F_8e1a6ccf-1931-4741-b790-0aa92ad8f8a1"
      unitRef="U_USD">4514000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_40d9b41f-8564-4e43-91f2-98018ace4541"
      decimals="-3"
      id="F_8928097a-1627-49c6-b17d-d5d8c956065f"
      unitRef="U_USD">1061000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="C_40d9b41f-8564-4e43-91f2-98018ace4541"
      decimals="-3"
      id="F_031c9087-45f0-4f35-9767-ea73f52ac582"
      unitRef="U_USD">5575000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_40925803-ff90-455c-abea-74ad6749d9a8">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate scheduled maturities of our long-term debt as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.325%;"/&gt;
        &lt;td style="width:1.794%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.881%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;549,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_664ee05f-18c0-4393-8920-047219279888"
      unitRef="U_USD">96204000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_ca195a91-0e15-49d3-8815-dd04d32ec468"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_966c9395-5811-43bf-911a-1e6f1ad0f4bd"
      unitRef="U_USD">192500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_2c78d32e-f27d-4fa4-a93b-25e27ba451a5"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_2cfd61b0-740e-4b9c-9737-a02358917549"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_260d037c-ef70-41f7-ab9c-ccdc3358ffb7"
      unitRef="U_USD">261000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_d427985f-c4ae-4960-a019-393bc5c0b40a"
      unitRef="U_USD">549704000</us-gaap:DebtInstrumentCarryingAmount>
    <inva:RoyaltyAgreementMaximumPotentialPayoutPercent
      contextRef="C_b4c52322-2f44-4631-88a7-a410b93eca72"
      decimals="2"
      id="F_497cacbc-7596-4f07-8c0c-357940c4bf2a"
      unitRef="U_pure">0.14</inva:RoyaltyAgreementMaximumPotentialPayoutPercent>
    <inva:RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent
      contextRef="C_b4c52322-2f44-4631-88a7-a410b93eca72"
      decimals="2"
      id="F_a8062c63-5fe0-45f6-b164-5e3a740f5886"
      unitRef="U_pure">0.04</inva:RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent>
    <inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo
      contextRef="C_b4c52322-2f44-4631-88a7-a410b93eca72"
      decimals="-5"
      id="F_cb56fb18-759c-415d-8b21-71c6c6b9393b"
      unitRef="U_USD">225000000.0</inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo>
    <us-gaap:InterestExpenseBorrowings
      contextRef="C_9e7a9b82-3d75-4c07-8fd4-3439f3f270c1"
      decimals="-5"
      id="F_1b90ea8f-0ad5-4c4c-af64-40f62e9ae05f"
      unitRef="U_USD">1800000</us-gaap:InterestExpenseBorrowings>
    <inva:DeferredRoyaltyObligationAndAccruedInterest
      contextRef="C_09f7a472-62b7-4efe-90de-d979015c8cfa"
      decimals="-5"
      id="F_a6596785-bf33-4b78-87bc-229843a7f166"
      unitRef="U_USD">70600000</inva:DeferredRoyaltyObligationAndAccruedInterest>
    <inva:RoyaltyObligationPayable
      contextRef="C_32a14238-9913-4ca5-a7cb-512e18bd93f7"
      decimals="-5"
      id="F_7eecf986-dab8-440a-84dc-b1829532dfea"
      unitRef="U_USD">67900000</inva:RoyaltyObligationPayable>
    <us-gaap:InterestAndDividendsPayableCurrentAndNoncurrent
      contextRef="C_c518252b-f9c2-461f-b418-d8ec329b7c60"
      decimals="-5"
      id="F_7655205f-8636-4768-8abd-1466bb9c03cc"
      unitRef="U_USD">2700000</us-gaap:InterestAndDividendsPayableCurrentAndNoncurrent>
    <inva:RoyaltyPayments
      contextRef="C_9e7a9b82-3d75-4c07-8fd4-3439f3f270c1"
      decimals="-5"
      id="F_b722b3af-e60b-4fe4-a434-173c9cc77c30"
      unitRef="U_USD">1000000.0</inva:RoyaltyPayments>
    <inva:InterestRateOfDeferredRoyaltyObligation
      contextRef="C_9e7a9b82-3d75-4c07-8fd4-3439f3f270c1"
      decimals="4"
      id="F_52200d81-4d2e-407d-80ba-889ccb4955e0"
      unitRef="U_pure">0.0734</inva:InterestRateOfDeferredRoyaltyObligation>
    <inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne
      contextRef="C_b4c52322-2f44-4631-88a7-a410b93eca72"
      decimals="-5"
      id="F_03345e08-5bde-411c-b6a9-d3bfa7fe40e7"
      unitRef="U_USD">125000000.0</inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne>
    <inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo
      contextRef="C_b4c52322-2f44-4631-88a7-a410b93eca72"
      decimals="-5"
      id="F_00da8744-c77e-4df8-a2e4-e4c390bce5fc"
      unitRef="U_USD">225000000.0</inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo>
    <inva:PaymentsForRoyaltyAgreement
      contextRef="C_b4c52322-2f44-4631-88a7-a410b93eca72"
      decimals="-5"
      id="F_22879cba-e6ad-4b12-b7e0-527472b0d89e"
      unitRef="U_USD">12700000</inva:PaymentsForRoyaltyAgreement>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_25c374b8-c2bd-4d89-b388-0beb97eb7949">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Operating Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We have operating leases for our corporate headquarters, office spaces and laboratory facilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our operating leases include a facility lease consisting of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,062&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of office and laboratory space in Waltham, Massachusetts. Effective April 2022, we exercised our renewal option for to extend the lease term for three additional years through December 2025.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In 2019, we entered into an operating lease for our headquarters in Burlingame, California for approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,111&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; rentable square feet. The lease commenced in November 2019 with a term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_73893738-ee85-428b-aa7d-acd3031222eb;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;thirty-six&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; calendar months, which was subsequently amended to expire in December 2023.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease costs are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.28%;"/&gt;
        &lt;td style="width:1.798%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Straight line operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Supplemental cash flow information related to leases are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.28%;"/&gt;
        &lt;td style="width:1.798%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of &lt;br/&gt;&#160;&#160;&#160;operating lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets obtained in exchange &lt;br/&gt;&#160;&#160;&#160;for operating lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets obtained through acquisitions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, our operating leases have a weighted-average remaining lease term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years and the weighted-average incremental borrowing rate used to determine the operating lease right-of-use assets and lease liabilities was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We have not presented the comparative information above for the years ended December 31, 2021 and 2020 as our operating lease during those years was not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes our operating leases as presented on the consolidated balance sheets:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.424%;"/&gt;
        &lt;td style="width:2.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.587%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.985%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_41a23557-411b-40b9-88d7-b7d2076397f5;"&gt;&lt;span style="-sec-ix-hidden:F_890207b9-615b-4ab9-910d-0ca859f06d2a;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current portion of lease liabilities included within&lt;br/&gt;   Other accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_49451cf0-b5b9-4245-8fca-d0d88b0b3246;"&gt;&lt;span style="-sec-ix-hidden:F_547a2096-ca1f-487c-b0b5-45f04c844618;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term portion of lease liabilities included within&lt;br/&gt;   Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future minimum lease payments on our operating leases as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.291%;"/&gt;
        &lt;td style="width:1.798%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.911999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, the Company is involved in legal proceedings in the ordinary course of its business. We are not currently a party to any material legal proceedings except as discussed below.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 15, 2022, La Jolla received a paragraph IV notice of certification (the &#x201c;Notice Letter&#x201d;) from Gland Pharma Limited (&#x201c;Gland&#x201d;) advising that Gland had submitted an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in the U.S. prior to the expiration of U.S. Patent Nos.: 9,220,745; 9,572,856; 9,867,863; 10,028,995; 10,335,451; 10,493,124; 10,500,247; 10,548,943; 11,096,983; and 11,219,662 (the &#x201c;GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Patents&#x201d;), which are listed in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#x201c;Orange Book&#x201d;). The Notice Letter alleges that the GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Gland&#x2019;s ANDA.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 29, 2022, La Jolla filed a complaint for patent infringement of the GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland&#x2019;s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; is a new chemical entity and La Jolla filed a complaint for patent infringement within 45 days of receipt of the Notice Letter, the FDA cannot approve Gland&#x2019;s ANDA any earlier than 7.5 years from the approval of the GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed. We intend to vigorously enforce our intellectual property rights relating to GIAPREZA&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Given the early stage of this matter, we cannot reasonably estimate a potential future loss or a range of potential future losses, if any, and have not recorded a contingent liability accrual as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Indemnifications and Other Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the ordinary course of business, we may provide indemnifications of varying scope and terms to vendors, directors, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by us, our negligence or willful misconduct, violations of law, or intellectual property infringement claims made by&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;third &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;parties. In addition, we have entered into indemnification agreements with directors and certain officers and employees that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers, or employees. No material demands have been made upon us to provide indemnification under such agreements, and thus, there are no claims that we are aware of that could have a material effect on our consolidated financial statements. We also maintain director and officer insurance, which may cover certain liabilities arising from our obligation to indemnify our directors. To date, we have not incurred any material costs and, as of December 31, 2022, we have not accrued any liabilities in the consolidated financial statements as a result of these provisions.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_0690f27e-7810-4f26-b005-086fd5e63db8"
      decimals="INF"
      id="F_b2ef93ba-d06f-4aee-b113-16f38495c678"
      unitRef="U_sqft">20062</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:NetRentableArea
      contextRef="C_d984fd86-fecd-403b-b06f-fd6cf9bdd507"
      decimals="INF"
      id="F_74082a87-9899-49ff-ab3d-d0338802d091"
      unitRef="U_sqft">2111</us-gaap:NetRentableArea>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_b84f73f6-0a4b-471f-b5da-3f606e29b5ad">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease costs are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.28%;"/&gt;
        &lt;td style="width:1.798%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Straight line operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_23507953-6a78-4b45-ab82-e0ce8bf3475a"
      unitRef="U_USD">1585000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeaseCost
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_6372f6c7-11c8-419d-ab97-74cb59e97076"
      unitRef="U_USD">155000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_a6a2c002-74bf-4ecf-a2ae-cc4022d4f767"
      unitRef="U_USD">1740000</us-gaap:LeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_38c23dc4-0e00-4264-a463-563f1815a572">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Supplemental cash flow information related to leases are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.28%;"/&gt;
        &lt;td style="width:1.798%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of &lt;br/&gt;&#160;&#160;&#160;operating lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets obtained in exchange &lt;br/&gt;&#160;&#160;&#160;for operating lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets obtained through acquisitions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_77638ba9-9e9d-4fbd-a46c-0f19dbf4ca3d"
      unitRef="U_USD">790000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_679b2bed-011c-4431-ba1a-7456c032669b"
      unitRef="U_USD">3323000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <inva:RightOfUseAssetsObtainedThroughAcquistions
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_55bd4a85-bffd-478d-bb64-4f51ae1738a3"
      unitRef="U_USD">1185000</inva:RightOfUseAssetsObtainedThroughAcquistions>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      id="F_8acb6566-3679-4cba-9828-d4c05244cbe2">P2Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <inva:OperatingLeaseWeightedAverageIncrementalBorrowingRate
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="3"
      id="F_1a87d0eb-a058-46b6-a1bf-07b6a1dddcbb"
      unitRef="U_pure">0.075</inva:OperatingLeaseWeightedAverageIncrementalBorrowingRate>
    <inva:ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_f1d6fb62-0771-4b72-85f8-2b4ea968a25b">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes our operating leases as presented on the consolidated balance sheets:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.424%;"/&gt;
        &lt;td style="width:2.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.587%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.985%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_41a23557-411b-40b9-88d7-b7d2076397f5;"&gt;&lt;span style="-sec-ix-hidden:F_890207b9-615b-4ab9-910d-0ca859f06d2a;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current portion of lease liabilities included within&lt;br/&gt;   Other accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_49451cf0-b5b9-4245-8fca-d0d88b0b3246;"&gt;&lt;span style="-sec-ix-hidden:F_547a2096-ca1f-487c-b0b5-45f04c844618;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Long-term portion of lease liabilities included within&lt;br/&gt;   Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</inva:ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_2e4f1a71-fe5e-48c2-a3b1-81bd8bfe7c44"
      unitRef="U_USD">3265000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_f4aaf262-9ae3-4735-9777-05a3bd7ac418"
      unitRef="U_USD">97000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_c025b267-97e6-48c3-9a1f-6ec01c8e2943"
      unitRef="U_USD">1316000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_1f6041f6-a90c-4426-bca8-c2e0bc4a448a"
      unitRef="U_USD">106000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_adaac0e9-02c4-4dce-88b2-91ad67204c0a"
      unitRef="U_USD">2376000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_ddf06473-dc57-4cf3-908e-75aa76157524"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_6297c0fc-afd0-4e36-bb37-a229fc7d5a4b"
      unitRef="U_USD">3692000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_13c2b03d-608b-4092-87df-dea1d9b2f430"
      unitRef="U_USD">106000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_02c7ec2d-4e38-47b5-805b-dedeb9b628e8">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future minimum lease payments on our operating leases as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.291%;"/&gt;
        &lt;td style="width:1.798%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.911999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_308b26a5-e66b-4cbc-8983-58568edd4797"
      unitRef="U_USD">1542000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_0d4842ee-a46b-4642-91b8-81a4a641459e"
      unitRef="U_USD">1269000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_05b45038-53bb-4663-b4f9-67b916c408dc"
      unitRef="U_USD">1289000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_8d8fa7c7-1cb9-42fa-b920-6b9579682fd1"
      unitRef="U_USD">4100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_7536593e-718b-43bf-8bbe-95f4bcb3dd35"
      unitRef="U_USD">408000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_f3451ccf-8373-47b0-8191-f423166e0e6e"
      unitRef="U_USD">3692000</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_08660d2e-ba2b-4c22-b229-b61a22d99641">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14. INCOME TAXES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax expense consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.419%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.712%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.508%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.907%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The impacts of the differences between the expected U.S. federal statutory income tax to our income tax expense are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.315%;"/&gt;
        &lt;td style="width:1.472%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.686%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.481%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.686%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.481%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.88%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected tax at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal and state research credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Noncontrolling interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Impact of consolidation and deconsolidation of subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax expense (benefit), net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant components of our deferred tax assets and deferred tax liabilities are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.313%;"/&gt;
        &lt;td style="width:1.998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.748%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.942%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;149,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized loss on investment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred royalty obligation, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;202,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;144,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized gain on investment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inventory fair value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We record deferred tax assets if the realization of such assets is more likely than not to occur. Significant management judgment is required in determining whether a valuation allowance against the deferred tax assets is required. We have considered all available evidence, both positive and negative, such as our historical operating results and predictability of future taxable income, in making such determination. We are also required to exercise significant management&#x2019;s judgment in forecasting future taxable income. Specifically, we evaluate the following criteria when considering a valuation allowance:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the history of tax net operating losses in recent years;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;predictability of operating results;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;profitability for a sustained period of time; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:10.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;level of profitability on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, we had federal net operating loss carryforwards of approximately &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;411.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which will expire beginning 2032. As of December 31, 2022, we also had state net operating loss carryforwards of approximately &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;955.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which will expire beginning 2029 and state research tax credits of approximately &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which do not expire.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Utilization of net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We conducted an Internal Revenue Code of 1986, as amended, Section 382 (&#x201c;Section 382&#x201d;) analysis of the Company through December 31, 2022 to determine whether an ownership change had occurred since inception. The Section 382 study concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. However, notwithstanding the applicable annual limitations, no portion of our net operating loss or credit carryforwards is expected to expire before becoming available to reduce federal and state income tax liabilities as a result of those identified ownership changes. If we undergo another ownership change, the utilization of the pre-ownership change net operating loss carryforwards or pre-ownership change tax attributes, such as research tax credits, to offset the post-ownership change income may be subject to an annual limitation, pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. Similar rules may apply under state tax laws.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of the acquisition of Entasis, we conducted a study of Entasis&#x2019; ownership changes and estimated that we will be able to utilize $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;157.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of its federal net operating losses, which are subject to annual limitations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of the acquisition of La Jolla, we also performed a preliminary analysis of its ownership changes and estimated that we will be able to utilize $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;254.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of its federal net operating losses, which are subject to annual limitations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December 31, 2022 and 2021, we had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; accrued interest or penalties due to the Company's net operating losses available to offset any tax adjustments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.35%;"/&gt;
        &lt;td style="width:2.339%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.312%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net decrease in tax portions for 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net decrease in tax portions for 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net increase in tax portions for 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We are subject to taxation in the U.S. and various state jurisdictions. The tax years 2004 through 2013, 2015 and forward remain open to examination by the federal and most state tax authorities due to net operating loss and overall credit carryforward positions.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_19f04e85-c295-4714-935a-a1e406de3abc">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax expense consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.419%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.712%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.508%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.484%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.907%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,893&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_872534a2-4204-4f48-ae44-2c98d1294c24"
      unitRef="U_USD">40822000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_5622c6fe-34af-4f97-871b-058b0a4b63f0"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_74756052-9d71-4d02-a9ab-8ace37bb9a18"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_11c603d8-5f1f-4d82-8b84-bcc7bdc421f2"
      unitRef="U_USD">464000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_0971f155-d5e7-49ae-a873-8c6afb523e4e"
      unitRef="U_USD">7000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_eaac7d6f-e7df-4e36-9eec-86e2d8bf2cee"
      unitRef="U_USD">11000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_6a8b18b7-fec2-49ee-90a8-63ca03e95def"
      unitRef="U_USD">41286000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_daa7abaa-2640-46fe-9e21-ce7444172f10"
      unitRef="U_USD">7000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_a08785ca-d1ef-4b7f-aa38-23796efb8153"
      unitRef="U_USD">11000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_cc80d519-ca0b-4488-bfb9-e2f2457c02a7"
      unitRef="U_USD">26026000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_6fab8bdc-0809-4ae8-a4a9-7698d1a8f54c"
      unitRef="U_USD">70893000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_f29da669-da99-4706-a882-ebe26d9bcbe1"
      unitRef="U_USD">60408000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_9a9df4ce-5242-4f2c-ac27-bce540efa539"
      unitRef="U_USD">-625000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_e42a5cfc-da05-403d-82e4-43933f446bc6"
      unitRef="U_USD">5539000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_1c5724e7-b73d-491c-acc1-bc6be1b35ef3"
      unitRef="U_USD">12000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_5c215345-a310-45fb-98d0-27daf2233693"
      unitRef="U_USD">25401000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_9e597e83-0164-4646-a544-70a2fef6a112"
      unitRef="U_USD">76432000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_5fae3c2e-8845-4c0b-ae5b-d32fc88d5280"
      unitRef="U_USD">60420000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_4bca5a9a-75af-4f69-8f6d-21cbac6b4f5b"
      unitRef="U_USD">66687000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_91e43204-2a44-4176-9eec-05acc8794a3d"
      unitRef="U_USD">76439000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_5f289664-5a40-43bb-bbe1-6c1d39dc5384"
      unitRef="U_USD">60431000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_b61824fc-7f9a-4aac-9439-f45471d547a4">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The impacts of the differences between the expected U.S. federal statutory income tax to our income tax expense are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.315%;"/&gt;
        &lt;td style="width:1.472%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.686%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.481%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.686%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.481%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.88%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected tax at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,414&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal and state research credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Noncontrolling interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Impact of consolidation and deconsolidation of subsidiaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,180&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax expense (benefit), net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_de12ec8b-5d80-4670-a4d2-dc199a742dd0"
      unitRef="U_USD">58928000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_2b2ff811-ca04-44e1-9a96-05156592d177"
      unitRef="U_USD">93507000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_2a138b55-44e7-4300-89db-4097b13d53fa"
      unitRef="U_USD">74392000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_51c87171-2a14-4e28-9da1-53a3dbb0efea"
      unitRef="U_USD">-1414000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_ad0aab0f-df50-4039-89d9-d81154e0eded"
      unitRef="U_USD">848000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_2fa7fc89-2229-4665-870e-6842283b4a4d"
      unitRef="U_USD">-26000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_1d26665d-c6fb-4860-9d9e-73eeae3b5b64"
      unitRef="U_USD">-2453000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_6c7d729d-7fa3-4674-b6fc-ea6d273ef115"
      unitRef="U_USD">1260000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_ea3eb281-c35d-4964-85b5-b216299f9654"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_98b73de4-52ff-4bf8-b51f-e77262840535"
      unitRef="U_USD">7468000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_d55feb52-1d10-4545-90b7-f9bedf814198"
      unitRef="U_USD">-21626000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_feffe534-c59d-49ee-a92c-fcc61ae5bb8f"
      unitRef="U_USD">-14577000</us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense>
    <us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_1ffe4eaa-86da-4095-8007-0b4d51890f40"
      unitRef="U_USD">-8897000</us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_cbd2c7b4-609c-488c-b925-ef68e5fdb10a"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_bba10584-1e03-4b1e-b4f0-463a23589f6e"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_9f737e14-1c47-4795-a32c-7256fa25c268"
      unitRef="U_USD">-125000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_74a62a5a-7a34-4025-9fed-70f7fc4f2e87"
      unitRef="U_USD">1129000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_e0b69f7b-b7a7-4665-8406-e45209db429b"
      unitRef="U_USD">839000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_3cf344d5-1318-482c-9af0-d29c3ece6867"
      unitRef="U_USD">13180000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_11bfe002-3ad0-46df-b831-c63af76b185b"
      unitRef="U_USD">1321000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_15240979-71fc-49ae-950f-06de94851bd7"
      unitRef="U_USD">-197000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_64faac50-416f-419a-9952-9dade7d5203a"
      unitRef="U_USD">66687000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_2c129660-9b0a-44c0-9d6d-7a432132b81d"
      unitRef="U_USD">76439000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_78cf5198-9594-4b60-bd2f-afa4b0af3863"
      unitRef="U_USD">60431000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_b5f9e8e4-b440-4b47-984c-e1b6a752559f">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant components of our deferred tax assets and deferred tax liabilities are as follows:&lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.313%;"/&gt;
        &lt;td style="width:1.998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.748%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.942%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;149,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized loss on investment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred royalty obligation, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;202,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;144,808&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized gain on investment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,794&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inventory fair value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_31e4f802-f542-480b-b201-be6bf705dce0"
      unitRef="U_USD">149646000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_9ee0f1e0-377e-4149-9f7a-a4b3a91ec8ef"
      unitRef="U_USD">64813000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_9327f2a8-2108-4048-a149-45505f77caf3"
      unitRef="U_USD">21230000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_d45822a5-0740-4e04-b50b-65467d83c117"
      unitRef="U_USD">53467000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_890df4e1-3c00-42c8-8252-36bc80c5eda6"
      unitRef="U_USD">6032000</inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet>
    <inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_a22635f3-0b28-4bfc-8ce4-e9100f7467df"
      unitRef="U_USD">0</inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet>
    <inva:DeferredTaxAssetsDeferredRoyaltyObligationNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_10a53fa7-f254-4a69-af96-7ed61f4fb695"
      unitRef="U_USD">17404000</inva:DeferredTaxAssetsDeferredRoyaltyObligationNet>
    <inva:DeferredTaxAssetsDeferredRoyaltyObligationNet
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_1725233e-e6f3-4e7b-b1ca-0de47770fe9b"
      unitRef="U_USD">0</inva:DeferredTaxAssetsDeferredRoyaltyObligationNet>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_67bef30a-b827-401e-96f1-b4b53f214a11"
      unitRef="U_USD">8527000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_1f8b091b-bd60-4c06-a4f6-3c3f0cf98219"
      unitRef="U_USD">743000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_f529bdf7-00b2-40a4-aeff-cc5d700e5149"
      unitRef="U_USD">202839000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_ffa4a1b0-d671-4978-b0ab-9878649b5bb6"
      unitRef="U_USD">119023000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_78502548-52aa-44a2-b99c-0e88a2fbd002"
      unitRef="U_USD">144808000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_cfddbe9d-652f-46c6-9a92-1fadfb458368"
      unitRef="U_USD">64744000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_670ec869-62d0-49ca-bced-8077d737d593"
      unitRef="U_USD">58031000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_e6a3b0cc-b8ba-4a34-930a-b8bd14f5de0d"
      unitRef="U_USD">54279000</us-gaap:DeferredTaxAssetsNet>
    <inva:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_1bf8e9ae-c643-43c5-b726-5e5c7e1cb2ec"
      unitRef="U_USD">-50587000</inva:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <inva:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_64b22032-0ba0-4718-ac9f-c718db7bfae5"
      unitRef="U_USD">-9158000</inva:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_41638774-27fb-46f6-bffe-3e3863bf40f7"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_cfcfe8f7-94dd-499d-8f9a-db82c4b228c1"
      unitRef="U_USD">27794000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_5243b21d-5c2b-4ea4-b904-a1417ae980ed"
      unitRef="U_USD">-12410000</inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment>
    <inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_377c6998-7c75-46d2-b21c-20f652feaee8"
      unitRef="U_USD">0</inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_7899bef4-65d5-48e7-8570-b17cf3963a60"
      unitRef="U_USD">-805000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_c0a65248-a5bb-4cc4-9589-a8270d7b0014"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_0e5babe8-03b7-4dc5-87d8-c30163b8814a"
      unitRef="U_USD">5771000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_8c109e71-031e-4715-a6e8-ceffe444df07"
      unitRef="U_USD">17327000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_aceba262-3c48-4f1a-bb24-393e5d13eb1c"
      decimals="-5"
      id="F_f83798e6-3340-47b5-88d5-d51af6434174"
      unitRef="U_USD">411500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_de713b03-f9a9-4480-b3f1-0fc2adfaf825"
      decimals="-5"
      id="F_75b1dcc5-a838-4454-9568-0ed1e3a012b4"
      unitRef="U_USD">955300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_50fc44f2-33ae-4838-8017-374904e41b9f"
      decimals="-5"
      id="F_d529a67f-fb79-46ff-a339-93e51edd1eaf"
      unitRef="U_USD">33300000</us-gaap:TaxCreditCarryforwardAmount>
    <inva:FederalNetOperatingLossesEstimatedUtilizationAmount
      contextRef="C_09f49082-679c-4f54-a8ef-7379e98314ed"
      decimals="-5"
      id="F_c74e5d9d-6f86-4c01-be59-7761f2817f96"
      unitRef="U_USD">157400000</inva:FederalNetOperatingLossesEstimatedUtilizationAmount>
    <inva:FederalNetOperatingLossesEstimatedUtilizationAmount
      contextRef="C_86b3b196-2603-41a6-85b5-4466e0d2b8da"
      decimals="-5"
      id="F_e0555218-3a2e-4571-810f-54833162f2d1"
      unitRef="U_USD">254000000.0</inva:FederalNetOperatingLossesEstimatedUtilizationAmount>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_3c759c7b-c3d6-49f6-9bb8-798a6b5a881a"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_aeaaf3bc-cf0d-4978-a8c2-aa7b4299de22"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_e993c943-7fd1-477a-89cb-229df1e01390">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.35%;"/&gt;
        &lt;td style="width:2.339%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.312%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net decrease in tax portions for 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net decrease in tax portions for 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net increase in tax portions for 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_5afc9e88-7462-4e21-81dd-9bb66b6d8fd1"
      decimals="-3"
      id="F_efce97a6-f30d-4a7e-8c61-f653879e99ca"
      unitRef="U_USD">15342000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_80443d0e-d8f2-4471-a9e1-605e05202133"
      decimals="-3"
      id="F_ac44931c-941d-44a1-90a7-a47cc9a9f353"
      unitRef="U_USD">157000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_f1759049-001a-42bc-8f15-3224ecf2b407"
      decimals="-3"
      id="F_9c872719-bdea-429e-994b-4d8d855dcb43"
      unitRef="U_USD">15185000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_c4ea8566-a9ad-4bd7-ad71-c9e113e3e976"
      decimals="-3"
      id="F_b4a67b94-61dd-433b-b23d-58079aed6eb5"
      unitRef="U_USD">313000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_14af044e-180c-4ba7-afe8-2099db903530"
      decimals="-3"
      id="F_7c0b5218-8c38-4c51-b38b-7b2e0a7d306a"
      unitRef="U_USD">14872000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      decimals="-3"
      id="F_abf0561a-54dc-42b1-b1b6-10d477af1313"
      unitRef="U_USD">1452000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_335d8004-849d-4d3c-98bc-66869944d3b5"
      decimals="-3"
      id="F_37712227-4159-4e2b-970e-2a0780f8cd42"
      unitRef="U_USD">16324000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_d2e91346-9256-4775-b561-939650f5def7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15. SUBSEQUENT EVENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 10, 2023, we entered into a Secured Convertible Credit Agreement (the &#x201c;Credit Agreement&#x201d;) with Armata, under which we extended a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; term loan facility in an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million at an interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% per annum. Pursuant to the Credit Agreement, the balance on the loan, including all accrued and unpaid interest thereon, will convert into shares of Armata's common stock upon the occurrence of a qualified financing, as defined in the Credit Agreement. Any portion of the balance on the loan, including all accrued and unpaid interest thereon, may also be converted into shares of Armata's common stock at our option once a registration statement covering the resale of such securities has been declared effective by the SEC. The loan is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 2, 2023, ITH entered into a Note Amendment Agreement (the "Note Amendment Agreement") with Gate to amend the Convertible Promissory Note Purchase Agreement entered into in November 2021 between TRC and Gate to acquire the Gate Convertible Note (refer to Note 6, &#x201c;Equity and Long-Term Investments and Fair Value Measurements&#x201d;). Pursuant to the Note Amendment Agreement, the principal amount of the Gate Convertible Note was increased from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which represents the original principal and accrued interests as of the amendment date. All other material terms of the Gate Convertible Note were unchanged.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentTerm
      contextRef="C_b78012d3-6ecc-432d-b96a-e66ef1252516"
      id="F_96e24b41-a007-42d6-957d-b9158392012a">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_89b41b07-63fa-44a6-be15-5461c1916d4a"
      decimals="-5"
      id="F_d484fa2f-2308-4de9-a825-a7d78a516d88"
      unitRef="U_USD">30000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_89b41b07-63fa-44a6-be15-5461c1916d4a"
      decimals="3"
      id="F_bfd579e4-8fd0-4549-9b25-ab23a7e7f5a0"
      unitRef="U_pure">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_e02457d0-db2e-4c20-9634-fdad76ee8508"
      decimals="-5"
      id="F_c1554ace-bf2c-42e2-9c20-a2d1526962a1"
      unitRef="U_USD">15000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_30ae7ed9-ac4b-45ec-bc1f-029433db9949"
      decimals="-5"
      id="F_32a112d4-a51b-469e-bc20-952abd7834e7"
      unitRef="U_USD">21500000</us-gaap:DebtInstrumentFaceAmount>
    <dei:AuditorName
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_d6a63689-607e-4ca5-96c5-1a5b2355d526">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_cd064fce-df3e-4265-92e6-caa1f8eccd27"
      id="F_81b80a36-695a-46b3-b02a-24cacc866f4f">San Jose, California</dei:AuditorLocation>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_521f41f8-3102-4803-8dd3-d66c56b3ac30"
          xlink:label="F_521f41f8-3102-4803-8dd3-d66c56b3ac30"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_8d9bf4a0-4bf1-43e0-b158-8e543323249a"
          xlink:label="F_8d9bf4a0-4bf1-43e0-b158-8e543323249a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_58a6e17d-816a-4800-b40a-497386e20e19"
          xlink:label="F_58a6e17d-816a-4800-b40a-497386e20e19"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_1fa0aea7-9d32-43e0-8b99-2f28dfa45057"
          xlink:label="F_1fa0aea7-9d32-43e0-8b99-2f28dfa45057"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6c392004-41b0-4c06-b69e-3c3989f1da72"
          xlink:label="F_6c392004-41b0-4c06-b69e-3c3989f1da72"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_acb2f52d-086e-48bc-98c6-39e21bc6a54e"
          xlink:label="F_acb2f52d-086e-48bc-98c6-39e21bc6a54e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_498794db-f6ff-4500-b278-62cc95d92aa2"
          xlink:label="F_498794db-f6ff-4500-b278-62cc95d92aa2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_86dc67a7-1dc7-4bb6-ae4c-31c620a7a8c0"
          xlink:label="F_86dc67a7-1dc7-4bb6-ae4c-31c620a7a8c0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e86b34eb-a400-4de8-a6d1-bda0467868f1"
          xlink:label="F_e86b34eb-a400-4de8-a6d1-bda0467868f1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_a60f2bef-ef0a-446d-8d7c-bfb962574365"
          xlink:label="F_a60f2bef-ef0a-446d-8d7c-bfb962574365"
          xlink:type="locator"/>
        <link:footnote id="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71" xlink:label="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1)</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   The year ended December 31, 2022 represents the period from January 1, 2022 to July 20, 2022, the date of the sale of our ownership interest in TRC.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_521f41f8-3102-4803-8dd3-d66c56b3ac30"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8d9bf4a0-4bf1-43e0-b158-8e543323249a"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_58a6e17d-816a-4800-b40a-497386e20e19"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_1fa0aea7-9d32-43e0-8b99-2f28dfa45057"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6c392004-41b0-4c06-b69e-3c3989f1da72"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_acb2f52d-086e-48bc-98c6-39e21bc6a54e"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_498794db-f6ff-4500-b278-62cc95d92aa2"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_86dc67a7-1dc7-4bb6-ae4c-31c620a7a8c0"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e86b34eb-a400-4de8-a6d1-bda0467868f1"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a60f2bef-ef0a-446d-8d7c-bfb962574365"
          xlink:to="FNT_e66ad88b-f785-4158-ae1c-5740243b0d71"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_065f3d03-454a-409c-b707-3411450de866"
          xlink:label="F_065f3d03-454a-409c-b707-3411450de866"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e2769ce1-6e57-4189-82bf-0320009c398c"
          xlink:label="F_e2769ce1-6e57-4189-82bf-0320009c398c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5bf8e1c8-f663-4fd3-a775-9c0173609862"
          xlink:label="F_5bf8e1c8-f663-4fd3-a775-9c0173609862"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_92d64aad-a8aa-4799-a07a-ce78039e04c4"
          xlink:label="F_92d64aad-a8aa-4799-a07a-ce78039e04c4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_46f2d473-be14-45e0-bd3f-88d1ffb40cc2"
          xlink:label="F_46f2d473-be14-45e0-bd3f-88d1ffb40cc2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d4974520-3462-491d-ba7f-e59c61419650"
          xlink:label="F_d4974520-3462-491d-ba7f-e59c61419650"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_afe13dec-76d8-453c-8941-b3e094fe42de"
          xlink:label="F_afe13dec-76d8-453c-8941-b3e094fe42de"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_13064dda-8ed2-4197-9462-3233b6e646b6"
          xlink:label="F_13064dda-8ed2-4197-9462-3233b6e646b6"
          xlink:type="locator"/>
        <link:footnote id="FNT_30a29ac4-a358-403f-922e-b22439018a34" xlink:label="FNT_30a29ac4-a358-403f-922e-b22439018a34" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds are included in cash and cash equivalents on the consolidated balance sheets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_065f3d03-454a-409c-b707-3411450de866"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e2769ce1-6e57-4189-82bf-0320009c398c"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5bf8e1c8-f663-4fd3-a775-9c0173609862"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_92d64aad-a8aa-4799-a07a-ce78039e04c4"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_46f2d473-be14-45e0-bd3f-88d1ffb40cc2"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d4974520-3462-491d-ba7f-e59c61419650"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_afe13dec-76d8-453c-8941-b3e094fe42de"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_13064dda-8ed2-4197-9462-3233b6e646b6"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_e20c2f4f-cc35-4c06-b838-d820cfd05871"
          xlink:label="F_e20c2f4f-cc35-4c06-b838-d820cfd05871"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3fdd078f-51c8-441a-bc63-74e8c5af4fba"
          xlink:label="F_3fdd078f-51c8-441a-bc63-74e8c5af4fba"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e1fa47be-e26f-49c6-9689-9c7c455a418b"
          xlink:label="F_e1fa47be-e26f-49c6-9689-9c7c455a418b"
          xlink:type="locator"/>
        <link:footnote id="FNT_575e1359-ac7d-4d28-a8d2-44d2392097f1" xlink:label="FNT_575e1359-ac7d-4d28-a8d2-44d2392097f1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</xhtml:span><xhtml:span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">295.4</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in equity investments, which included private placement positions and convertible notes of $</xhtml:span><xhtml:span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54.6</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</xhtml:span><xhtml:span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.1</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in money market funds. Our total capital contribution of $</xhtml:span><xhtml:span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300.0</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million is subject to a </xhtml:span><xhtml:span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36-month</xhtml:span></xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lock-up period from the date of such capital contributions.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e20c2f4f-cc35-4c06-b838-d820cfd05871"
          xlink:to="FNT_575e1359-ac7d-4d28-a8d2-44d2392097f1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3fdd078f-51c8-441a-bc63-74e8c5af4fba"
          xlink:to="FNT_575e1359-ac7d-4d28-a8d2-44d2392097f1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e1fa47be-e26f-49c6-9689-9c7c455a418b"
          xlink:to="FNT_575e1359-ac7d-4d28-a8d2-44d2392097f1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_dbecb97d-2479-4c89-ac9e-9028c435f74c"
          xlink:label="F_dbecb97d-2479-4c89-ac9e-9028c435f74c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5206e769-270f-4857-aebd-f5a635bf2283"
          xlink:label="F_5206e769-270f-4857-aebd-f5a635bf2283"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_148f5b6e-664c-4651-a517-7669a8556d7c"
          xlink:label="F_148f5b6e-664c-4651-a517-7669a8556d7c"
          xlink:type="locator"/>
        <link:footnote id="FNT_4def478b-9e06-438e-961a-d2a1b65d4c32" xlink:label="FNT_4def478b-9e06-438e-961a-d2a1b65d4c32" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investments held by ISP Fund LP, consisted of $</xhtml:span><xhtml:span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192.2</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million equity investments and $</xhtml:span><xhtml:span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.5</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million money market funds, are subject to a </xhtml:span><xhtml:span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</xhtml:span></xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-month lock-up period from our initial contribution date, December 11, 2020.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_dbecb97d-2479-4c89-ac9e-9028c435f74c"
          xlink:to="FNT_4def478b-9e06-438e-961a-d2a1b65d4c32"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5206e769-270f-4857-aebd-f5a635bf2283"
          xlink:to="FNT_4def478b-9e06-438e-961a-d2a1b65d4c32"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_148f5b6e-664c-4651-a517-7669a8556d7c"
          xlink:to="FNT_4def478b-9e06-438e-961a-d2a1b65d4c32"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>115
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )B%7%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "8A5Q6O6S(5>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)OITV+2.CFLN))07!!\1:2V=U@\X=DI-VWMZV[740?P&-F?OGF
M&YA.1Z%#PN<4(B:RF&]&U_LL=-RP(U$4 %D?T:E<3@D_-?<A.473,QT@*OVA
M#@B\JF[!(2FC2,$,+.)*9+(S6NB$BD(ZXXU>\?$S]0O,:, >'7K*4)<U,#E/
MC*>Q[^ *F&&$R>7O IJ5N%3_Q"X=8.?DF.V:&H:A')HE-^U0P]O3X\NR;F%]
M)N4U3K^R%72*N&&7R:_-]G[WP"2O>%-4O.!W.UZ+MA6\?9]=?_A=A5TP=F__
ML?%%4';PZR[D%U!+ P04    " "8A5Q6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M )B%7%:NX1O/Q0@  "LT   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9MM<^*V&H;_BH;N[+0S2? +D&0WR0PQT-)F"2=DT]EV^D'8(KAK6QQ)#N'?
MGT<VV'B/+/",^)+P]MR6+TOV?<ORS9JR[WQ)B$#O<93PV]92B-6G=IO[2Q)C
M?D%7)(%O%I3%6,!;]MKF*T9PD!7%4=NQK%X[QF'2NKO)/INRNQN:BBA,R)0A
MGL8Q9IM[$M'U;<MN[3YX"E^70G[0OKM9X5<R(^+K:LK@7;M0"<*8)#RD"6)D
M<=OJVY\&'4L69+]X"<F:[[U&<E?FE'Z7;\;!;<N2+2(1\864P/#OC7@DBJ02
MM.._6]%6L4U9N/]ZIS[*=AYV9HXY\6CT9QB(Y6WKJH4"LL!I))[H^C>RW:&N
MU/-IQ+._:)W_MGO90G[*!8VWQ="".$SR__A]"V*OX,JJ*7"V!<X/!7:GIL#=
M%KC'%G2V!9V,3+XK&8<!%OCNAM$U8O+7H"9?9#"S:MC],)''?288?!M"G;@;
M4#^%PR@03@(T3$0H-FB<Y/U)'I=S]'4V0#]_^ 5]0&&"GI<TY?!3?M,6L'6I
MT?:W6[K/M^34;,EVT!>:B"6'S00DJ JTH=E%VYU=V^\=K>* ^!?(M<^08SF.
MHD&>OGQ$YA?([F3EKJ)\H"__/4U@ZY9JZY6]<8LCX69Z;HV>1]\(0W_WYUPP
M& W_J CG"AVU@CQ%?.(K[)/;%IP#.&%OI'7W\2>[9WU6T3$I-C D5B'7*<AU
M=.IWVV[[1%Y#R0XZ\P3'1,5/KS.>3!Y?QB_],S2>>!<J9-KZIL@,B560=0MD
M7>VN%L/^>;-2DM*7V];Y'RH^VJJF? R)5?CT"CZ]X_CTDR3%$?2M%65"!4JO
M(UBJPNMIJYJ",B16 759@+H\#M24L)#*2TB X$*D[%,'E'9G\]K3N;:^*31#
M8A5H5P6TJR-''YRM>)A=:.M[F%YK@2.N[&+:LJ:T#(E5:%T7M*ZU>S@C?LH
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M-@04MOXR7LKN-W@>;(,%R!JI>#4,U@BJHN[_TF]#(O8&0.(8@(8!Z-@!>!B
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MHG]=WM\HONW>.#]RI7C576X8U;A; _W]FFMI--RT+[''?UI8_1]02P,$%
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MNNM-LU+E&W -4-\7C,F7CIZ@*PBS_P!02P,$%     @ F(5<5N LD43H#@
M%:L  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6S=G>USVM@9Q?\5C=MI
M-S/K-;H2 K:.9Q) [R]IG+33V>D'!62C!A KB3CY[RL);"S=AWLA>]S9[7[8
M@-$]OWLEG8<KZ4A</V3YYV*1)*7R=;5<%Z\O%F6Y^?GJJI@MDE5<_)1MDG7U
MR5V6K^*R>IO?7Q6;/(GG3:/5\HKU>L;5*D[7%S?7S=_>Y3?7V;9<INOD7:X4
MV]4JSK^]39;9P^L+]>+Q#^_3^T59_^'JYGH3WR>W2?EQ\RZOWET]J<S35;(N
MTFRMY,G=ZXLWZL^1WC1HEOA'FCP4SUXK]5 ^9=GG^HTS?WW1JWN4+)-964O$
MU3]?DG&R7-9*53]^W8M>/#'KAL]?/ZJ;S>"KP7R*BV2<+?^9SLO%ZXOAA3)/
M[N+MLGR?/=C)?D#]6F^6+8OF_\K#?MG>A3+;%F6VVC>N>K!*U[M_XZ_[%?&L
M@:H?:<#V#5BG0;]_I(&V;Z!U"=J1!OJ^@=YI8 R/-.CO&_0[#=C@2 -CW\#H
M-#BZE@;[!H-. ]TXTF"X;S \E3#:-QAUQW!TP_4>MUROTV1P;$NH3QN;V]I'
MFSQN;K6[O0='._:XP=7N%F?']BGU<9.KW6T^&!UK\KC1=SO\U6Z/;^PRB<OX
MYCK/'I2\7K[2JU\TGFO:5RY)UW5YN"WSZM.T:E?>C*/P-O*=R9L/TXER^Z'Z
M)YB&'VZ5R*S>16//COS)]/WM7Y7IWS\Z'_ZE7"H?;R?*#W]^I12+.$\*)5TK
M'Q;9MHC7\^+ZJJRZ5 M?S?;XMSL\.X+_D)7QDF@V%C<;;U?;95P7%B6YNZLJ
MC;))\C2;*]F=$L^SS:[RS/]3K<&JE)7**EE]2G*",Y%PLM6J4JJVP^PST7IZ
M>FL%UF53#'TSGZ>U5KQ4WL7I_-)9*^-XD]*KV?I>+=QP;$D79K,=*9DK4;E(
M<J5:J]47X:+^AJK@SGJ6K1+E!S\KBE>$O .4QPW:/;U7D^0NG:4E(>*=+8(;
M@"^Q=353*;;Y-^7VB'."<]KCNAV*L6%6;>YUF6?+ZI/[:N.7257BJ'4??9<0
M9"!7585_*O/LJ<RSID/ZD0Z]C9?Q>I8H<5GM"[.?%$W]46$]=415[)U2OU&J
M9Y=?;C2=J:K1Z_6NK[X\+])"9CVQ_;G8Q+/D]47EJ"+)OR07-W_Y4R7T-ZH2
M\UBUIVH<=(J$F@24]8?#_HCC6DBNS7/9@$,Z2*3+(R]'NJ'W=([K(;D^S^W@
M B0N)-;LT& J-\@(1&W947NRHW:2'7^H9D^[>=2KDZPI5#US38V18I.=F-%V
M+QL..^9%,DVDF(44LY%B#E+,18IY2#$?*18@Q4*D6 02:Y4=_:GLZ(VZ=J3L
M5+/9>F)5U9VJTC2O7M7';\TD:Y$MYTE>5 =ZOV[3\AM5?71D]4&*39!B4Z28
MB12SD&(V4LQ!BKE(,0\IYB/% J18B!2+0&*M&M5_JE%]X=1HDA9EGG[:UH="
MA5)FRKI]+)7NCZ7(DTU];A9RJ?7T 3_%'0L[<6[YZ<NFN%,DSN1'V3U60>)L
M*<Y!XEPISD/B?"DN0.+"D_?0"(1MF=!X,J$A-.%N#K"[=E._R.Z.V;">/\1*
M]4F1+=-Y<[+I2YRG\:=E<E@F69='IA0&MSHT@SC1(.SMN6[EF5VW(G&F%&<A
M<;84YR!QKA3G(7&^%!<@<>%INV<$8K:L.GBRZD!LU:])/DNK.7WET=V5AMUI
MQ.)')5[/E;0HMLVIANKCV?/K$=MU6A;-(KOW\4.<SZM&ZZ2LE\V3S3:?+>*]
M\.Y:3_5M7,1E6MQ]4\KXJ_*0EHOZL*&J!Y2W!_PI ;7'GU@;"\=WKKD'_.D?
M_A0BDFB2P^1/YEE(J,U#NRY'XEPISD/B?"DN0.)"*2X"X5H&'SX9?/@',/CS
M4Y64V85C./?< %)L,N3].1AU"@(2:"+%+*28C11SD&(N4LQ#BOE(L0 I%B+%
M(I!8J\*-GBK<2%CAFO./EW7(:UZ7L$VRKHM0MJ;JS(AWLS$:\I,*(?'<$C*2
M'M\C<>:)8[204)N'=F<42)PKQ7E(G"_%!4A<*,5%(%S+;VKOR7!U2D[@N#"I
M#]SK: L9V>IQW6<C;:@2I]'$G'-]1H"[1H,"33G0@@)M.="! EUJ6S)=[_%'
M11X4[,M'&D"!(0$T1KK*#S1"<=OF>Y:X5(7FV^7,9JV<F<",*G_&D,B*C,70
MLYW(4SDG(H&F'&A!@?:)Z]6!4EWY,#THT)<# R@PE ,C%+#MOT,43OV>+!SK
MD>YC?%'I#88:94!H&DXEXW#\-_ 4BC6)\:K,:,[:<=-/*-DFR)P5H7DX G@Y
M8-77!?75"$W$$=N6\R0T$T?MQ8,1ZQ-?C2^1BE,/L3CUM^;BCM@4&HR#JDU4
M,AJGC5C7R-!L'%3-@JK94#4'JN9"U3RHFD_L25S=@ ;?H&H12JU=6P[9-_5%
MPV\J-/T&59M U:90-1.J9D'5;*B: U5SH6H>5,V'J@50M1"J%J'4VC7KD(53
M7S ,IQ)9H_Y([U/'+M XG"K/PT&!)C%2[F %&HF3 QTHT)4#/2C0EV_#  H,
M3]];(Q2X;<I#-D[]G83C5#Y^=,F(6]/&X@Z?;5]Y0 X*-.5 "PJTY4 '"G3E
M0 \*].7   H,3]U7(Q2V;=Y#6D[]H\;E5#Z&I.G4)3=H7D[E W/\O9)3*-,D
M1\K?Z6M!J39!Y4P/#<W)@1X4Z,N! 108RH$1"MBV^R$[I_X_A.?$@SC[W (T
M/J<2^;F>WJT/T  =5,V"JME0-0>JYD+5/*B:#U4+H&HA5"U"J;4KWB%+IXK#
M=.];I6DF?H#16Y5/*EUJ(UW5J:,,:*9.Y4-UEQKC+S-.H5B3&# W[8#FZN1
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M\R2O%Z@^O\NR\O'-5:7_D.6?&\;-?P%02P,$%     @ F(5<5DDMN_SO"P
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M%D^0'T^Z@#J=YB$7(688DW&B!\B<5C@;1I"%$>2'D7ZH[]CSY#AWR6',O@M
M,\/C>0 0T0D\1)9!T D&R7/9Z!Q.SP&UJ"I>SB0OF>*V9[7304?*;"\^FAQ
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M9@5PB"!GZP62180X/L^&(FRA"/NAZ-"<[0BM#Z8[A#WM>7*Y%T.K-1C/'>?
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MSF7(%$NW2+"PR*D=LA;<8<WU8',OU09A:&89 DOIVCH IMCS31CO^Q0H_6+
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M)AHTSAPHDY09K_>E\1>>@S8XMI36ZJ22? +- G(HK#'WR H@K5XB&=07VK*
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MLL$9N*;)V99+HK*T7/C7M)WKHL1VUIK!KN3 /E>*IJ1ULT,-8(YIEPMT4J%
M1;%8%_I_)"Y#VJ)PRV>R-FU&7DV^D1/^!W_095?:O6^K',\Z/Y #.I]N4MBE
M-[)24$L;<GQ(+M]QG?&?[(]"3E&WB16<?7:0Y 4>JA#2Y-S%7%2B+?(-382K
MU+<L&';#P9J#Y^)I<2JY[C0PF\%1,N.9T$Y9 ,<V![3U,]RXP;:U=O,.;'&0
M..B;KL&>PHJ%"^AJR?']9+F>*QCB]);YW2AH^=ID/U@>6W3VL E)8TY,\-2V
M\G!?)(GB3!:HL5W6EI+.Y=P%V.4,7UI.[0ZZ:MG[4N\8S<(7RIV>_$4NC5]-
M/OGMEN(N&XU3$>TYA=IL+);AD?"]\]L"$MC)'883NX!4IR=WO[B5>:V7;UD8
M1-X($?%J$'M)W*>KL._U_?#D*LM.;1- F0V2P@\(#930ZP;L67%(?_Z\S+?0
MZT<CUO>&T8!^@^%!H'@_4-^+D\@VV2 \6XX'P9)#8 .LF9=@OR[<,BE(IMB+
M!R.Z&OI>//+MLY$7!*.3&ZAD2=V6HO/]Y8&A;=4--7GJWZYIM3'9R+;!R!OT
M^RP)/7\0LL /O CC?O.ZOM<!80,O2!(6A#B,VF&/Q;)5!X$7Q/XK:78;M0JS
M!&V28VQ<26I; ^VAXE'QRO9HK -ECRYF@=XE+,:TB8^6:T=YCF(O["=LU/>B
MP$?'(B^.^YM!_L6SX\EU6R91UQ_:(;0%T@V#DYMU(G2CH1T2-_@AN\+MA43Q
M1V>KWC@!W%BQK:,KVPUI[TEN3ET=^^CR2)?1MKJC91UL5%-(.4I'=D(M T-M
MF;_F>&2#>M6*OJS/JD<''(G221:%&5#(AIBM7C"*MK"<) A" "Q,PE<9]U4:
MW"9'D;]&8+N^W'H;G];8-A_M'PAT9L6#@/O*7CU=_4=QY3[-U]/='QRX:S\*
M=+" &9KZW6'<8<K]:>!NC*SMA_I4&OSLMY<Y<'2=)N#[F<02:F]H@=4_-Y?_
M E!+ P04    " "8A5Q6-8OO7:,'  !+$@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6RM6.M/XT@2_\Y?4<JRJQG)D_B1A(27%)C<#',,H,"PMW>Z
M#QV[D[36[O9VM\FP?_U5==LF@<#-ZDY"I&W7^_&KLH_72O]N5IQ;^%[DTIQT
M5M:6A[V>25>\8*:K2B[QR4+I@EF\U,N>*35GF6,J\EX<AL->P83LG!Z[>S?Z
M]%A5-A>2WV@P55$P_7C&<[4^Z42=YL9,+%>6;O1.CTNVY+?<?BMO-%[U6BF9
M*+@T0DG0?''2F42'9WVB=P3W@J_-QAG(D[E2O]/%17;2"<D@GO/4D@2&/P_\
MG.<Y"4(S_JAE=EJ5Q+AY;J3_S?F.OLR9X><J_U5D=G72&74@XPM6Y7:FUI]Y
M[<^ Y*4J-^X_K#UM_Z #:66L*FIFM* 0TO^R[W4<-AA&X2L,<<T0.[N](F?E
M1V;9Z;%6:]!$C=+HX%QUW&B<D)246ZOQJ4 ^>SJ;WD^OODUA-CV__G1U<7=Q
M?77<LRB8'O?26LB9%Q*_(B2*X:N2=F5@*C.>;0OHH46M67%CUEG\IL2//.U"
M$@40AW'\AKRD=3-Q\I+7W.0/7%8<%EH5<(ZV:BP'#+5=P;D+,M?PK\G<N/O_
MWA4!+[^_6SZUSJ$I6<I/.M@;ANL'WCG]Y:=H&!Z]87V_M;[_EO0?3=*;0G:;
MF'1AAW"X0C1X%K(\9W.EF6NEB=9,+CGVIH5K"5^J_!&BQ"<K@ LIU8-X8+_\
M-(JC@R,#ZQ5R/X):2YYA]\^-R 0"P!,EW,W.X;/*,R&7)H#+RW-X1]QQ>'1Q
M]]F=HJ/W@.JX1A%"6@5, O^C$O81RDJG*VQ,8$O-O5$--\F=>JJ;AFK24+5R
M71G,U"/+B6[%L-G1M =N+)$9="L:P\7YY+Z5NTW<"D*S$&]R4)5VWFJS$B69
MBV8;BP=RM L3 PP!S2!P@%J 77$P+.=T?I,SP$B*= 5K9B!5TN&HQ7BH.@5Q
MV*1@C<'0'*2"7&&B-(5.V!QIT43-4XY("-$ ?B:=NG:F9(_>WX)E'.:/\.GV
M[V L+Q!VEKX,R$Q#/'>SZ>7TTV^ )7[0/X+IY>7%S=VDN>S"KQS56)P)9![Z
MU.C0!)+&1QP]*Q&;R224=C^9->R]L]GT^A713&8PN;J>O?:\ZVI7U[6+KJJE
M%'^B%14BDW:VD%MM$1@73?Q;8(VJM3G<^XTS[7$,$(5X,4<V1**]=Q<24Z4J
M@R:8]R[0]"^B?^&>KPB!T?E0>^.]V(<X&@1ATJ=3T@_"X9!.<10,DN$6E_<J
M&07]< #]?C!.\&<0C,?Q%ED3^7?1>SB(@S >0Q0/@^%H! =)$([&>W?*LKR.
M./$D\2#H#T> <I%L#$D_#(;1P=XE-^806*&T%7_ZQL;,IJP4R.]B]HZZ>A0G
M\'[W<:_I@R;>210%P_X DG$4C-#3!"T[&/?W$(>P4I<B!9;G@LF4HR=?)V<3
M*+5::E:  XOXJ/V-PB ,P]H722E]IFJ_5;;?JL-3XA2ZZ-QA7SU2,OF+9/KL
M:>Z D(J >K#D6JC,%_H7)BN$*&A(L4:?M1AQ9.C47^K@+ER2T\_0]"4<Y*R2
MV.A4[*S$$#U@$/#1_Z]-A'1ZOG5ONP$Z6R*:$LNTTKCN.?PHF<APX<!^MTKB
M%.!821@%:AY+22%,H$(.NR&1Y>1)5FFZ;=\,?-3ONM0\D^WTU0K6&+/-WB6\
MVRC+EKX!1,*Z.2?5=343ZCR@1K1$H!G&"H^4E>&+*H<<X8\@M$ $2(FM*I4/
MB+NG4X'QKG-09P23D%6I]:9O]8PPSE2=>4,IE41)C] =XGUJ15=;Z*$#2+)Z
M%RXSB;67[^ BH&\1^"_4PA.XU9CO?5T(C86)/8,9G-<91,&U^F6NYG7K>9U4
M'\2-+P+4Q:_3S3'TVV*[<-N8;3#<.:<N#\='N/7CL'8M4?!,8"IJ/9B&N9 ^
MOD]/UJK*,TQT_9@J06F?G4J7RG@-=D49J=$B97E:Y4Y0%W"-!X7DNLFF>9+D
M)A+SMKAXD]B7S1K@_D(%9][LKF C>93EJEPSC3D6W/4'>>@6**]IV*6P8@%$
M(?S<5@;+C=HJCQ\:UW[*";S+GB:<PJF+T:0=;&N%<CY7N'"109@81&5FC%A*
MKY"6)\0)W#1D_0KE&"@PMZ60'ZX7BP )TKRBO>V_K 1-J_X/@<'WS#X\39))
M,TD^_@CJ$'"OMT!E'\5N8)>0[6AQRAE@I(JF"!%R/$*]$I!-VAHQSL0" 83N
M8'M\K4S*T$RR6UJV5%(8^^$,5Z08=Q%WU2Z7-!?;E;*9CSZQ+O8O(]!N,]X@
M!S"T!MWX,J^[C^[4A5^WZG9 VK)OQAI+<74VHG'JDL$7ZH4FE2I-*ZW]_CFI
MEO@:!308Z_&H=@Q<A^L8]W'WH(E[X#99=)]2B$J>< 0O/EU,;F;3?VY-M7],
M9Y/[]@X!  KL=^,VD42T#P.LG59%O6DBN.:/KL$PEGA1#]?O;CA@<XR'6&[$
MWO>=1J-<O@A:@SF&%=L[0UJ_2!I<NE,W;C:FK)/KA@%M W6)K)7.L^?F[7I?
M[&V\X*.&I?N,0>A52>O?]=N[[9>2B?] \$3N/[-\91K! &WD"V0-NP>#CM_*
MFPNK2O>Y8*XLNN..*XX0HXD GR^4LLT%*6B_'YW^!U!+ P04    " "8A5Q6
M52++5U,/  #I,@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6S56VMS
M&S>R_2LH)3?E5%'4PW:<C1]5M"4[VI5EE63'6WOK?@!G0!+Q<# !9D0QO_Z>
M;CQF2 YIQO9NW?O%%H= H]%]NOLT,'RV,/:3FRE5B_MY4;KG![.ZKGXY.G+9
M3,VE&YI*E?AF8NQ<UOAHIT>NLDKF/&E>')T>'_]T-)>Z/'CQC)]=VQ?/3%,7
MNE375KAF/I=V^5(59O'\X.0@/KC1TUE-#XY>/*OD5-VJ^D-U;?'I*$G)]5R5
M3IM26#5Y?C Z^>7E(QK/ W[3:N$Z?PO:R=B83_3A(G]^<$P*J4)E-4F0^.].
MO5)%08*@QA]!YD%:DB9V_X[27_/>L9>Q=.J5*3[JO)X]/_CY0.1J(INBOC&+
M7U78SV.2EYG"\;]B$<8>'XBL<;69A\G08*Y+_[^\#W;89\)IF'#*>ON%6,LS
M6<L7SZQ9"$NC(8W^X*WR;"BG2W+*;6WQK<:\^L7EQ:OSJ]MS,;HZ$Z_>75Z.
M7KZ[&;V_>'<E1C<WHZLWYV_/K][?/CNJL1;-.,J"W)=>[ND6N2>GXJTIZYD3
MYV6N\E4!1U R:7H:-7UYNE/BF<J&XN')0)P>GY[ND/<P[?PARWNX1=X[.Y6E
M_E,2. ;BE2F=*70N/5;*7%Q;Y519^P=F(E[K4I:9EH6XQ4,%8-9._/=H[&H+
M:/U/GXF\ H_Z%:!P^\55,E//#RI:R]ZI@Q<_?'?RT_'3'=M[E+;W:)?TKW#L
M;KF/AF(_T>)=4Q]>Z@P!K,1H:E4PV;^D%I=R#%S4TFDG\%!9E0M=UD9(4809
MY * NY!C8X-3H@R$2#U+<A[<SF0YG4G](YPX'(C+.A^*!S]\]_/IZ?'3,(@_
MG3S]<2"JQKI&0@866\QTULH)"^="W6=%XY KA*60=C0T;VQAQO"SG+-FMQ\N
M#\\^W R@M:AGV)_3\O!:9GJB840U)7VC#O0]+9)L$+49B@^(#<L"8(.Y(YAM
MC!XD#1>Z*,2DP?)SX^HXF%8C#)*- ,X,#M,9_J@M837#2$=:OIH!OP)9O-6=
MS4@BL&-519Q?SY#DQ$-102(9.[?-%#F[JHHE?9W,5%F3-QDJPJI^F2GI,3+C
M'3)^Q?[BU*LASK'QJD+Z$#/C&F6#=M 4LC9V*60%L7?0&X^E<)4BBV*QLIF/
M82FLGYFFQ-:4VV7ZL5I"C;!G.8%Q\4VF=,56ZUL/C^7&WI+=VCT"L+)P1B!9
M*!@$<5LA<^AQH=BVF9G/E:4LH?_4Y7336KNT)I,$&[925(\,6LF#5]<"[@J&
MQ)">K0W%1T2351A4Z"DR5TZ #@YM71>@T+]8 M6*5\L<^)_T3F,[L0(*@U8M
M(QKGC25%IBPCH%)6FUPT9:%<FR%*4Y/WL3TL81?:J=8/<[D4M?R$7=W!N7-9
M-A.@K+%D].0477C0T6(:6S&+<L6VLB4&?B"980UY-2A(U&^"?&06M 1'S62B
MF%,(5 W5&[O!]@*#87M&"6S/4,2TIJ)/% M33)@&(=^+OYT,CU'KBX*TX_AP
M2EIXFP#2]0 YT=@:H;KTN75MP& %#_C.21B81"L0BU*U$ZTJ(C+:U#;7H'[*
M)SQV 1EOC' @L[D=F%E+"5@%/H=586/*]-8L95$OA?JCH3QEQ,0:K")F2+>'
M#N:%F7*8BY,T#'Z8FV:<GL$7&=7EJ6(Z!M4H<DH258+$^BWV):H8>L@&5I-)
M!C#@^'?XD ,B>1PJ-IG?(@&'IH"O?H)L+&N7/@G-*U43$*+P 11UO"[R)ODF
M(V"2DKVJD$E)>'* 67CK W\6XZ1-P)5YKD-N#_6H!'Z< X6F"9_+%>N;'HHK
M0N"=*ALE%I)<GYDIB)"B^(OE: 7%WC_T6&9_--JQ.@GTH8X/Q74+)L:WWV$"
M;P0K;=TJ/1^C$DMR:V_%HH1%FEF01R$)/,DM/H2VA(2ZKY@^Y#X5D-(A>&$(
MGS/I&2%/3Y8T),SP2^HR:RQ6&HK;AJ3/J=JX5I-DB;C[KD5:8Y"*X*N*BU;D
MK+P <AK0!&]HRLQO1C=GU]N8T$[V0SJ\(4I2B%%9(]4A5V;BIFN6LXY9K@&H
M4EDWTU7B);QXY"()ZBOIH\VKD9"M)\^0]6+:SS!*LVW^!)N>%"9'B>,D%E-]
M6[^[_,@;XM7*CO?G2SMG#\+7G(JH]+2;X (N'6*+<*@@7-X9R]X#:*CC]8':
MT$@F7K1:)$AKQ(O12X00[#&/V%LW8,NC^JT&]D16HNE= S+/;$I*.XAPSM13
M4QIK9TIRC4D C9$5R#;CU>\_!C=5YH0ECO^_$%=#0*Q0=T2@8VQ\XY"X*%/&
M&W02TGXNQG:F%LI1SJ#C@")'-ZT&P8.5U" C+;WG3.1KT>$$HF+V[#!CSKB>
M+XW3M_A(.#*-745YK;)9:0HS73+@35F&HP<6E\+MY,E3]P5AMAY05!@U02(@
M*]6ON<[S0L7O4KP%G 2BV*%CH:H0[T&$Q$(?H[1CQ75H_VYLJ(P\^PK9?29&
M$ N(#L1Y8TWE=>N274^)B$(G758,W83>C_T8/<+HV67O3L32L$!UN8;OB:%4
MDF6YI"ZQ,N1B-D:-!K.--Q'(;%-JX(;![I-V3I%)2P+$$[$ /0'I@YMI?AU:
M-=<4=4I;NQ+)AL<7IBERB(QUE !,P582SR["TKP![Q)R4VP!!J3-1@L0,3P&
M&20R"Z%LYPGHX7YRVSAY?3:*Y-GI>_2G?/03]LEI2W7+A=\B63SHL5=._A+%
M/ HQZ:V"?P W!Y>K,ENF\G/^=M06F'.)W$?L:TD=S'IWUQ YW:YK:\+0V'84
M:^J9L2&:6UZY60 \7=/,FZK07D3NQD%\/>*#EC?BNG.2P6B*7\2-\8-4WR]C
M]KJ4XN\4 BE3^HDP49L9XR',!K]\<S&ZOCG_UTC\\-W)DT=/V87_/+\9_9:>
M!+Z9['Z./&CFX"8CF&K WWU Y&#=?\ PN0GG*7#8G\H6]/<#(CY^Z\72S^CN
M2+R/5+9U6^AP$<:Z+CRZ8Y-5&:+CGEBFE-?3 0&9OA_[7IP<_VWX.#5@7 FY
M 3D,3<EJ%Q,EH#3R$TJ:>,:0X%YR"C5*\3L(J0,$&;5M3O);BL=DS%$XQE-?
MTI9G;E4Y,9.R #$EVMB*I&-+?]H1FA!4;1T2'?L%>:BKQW +B!)6_,>D5?^9
M!\V;-%R\UHX'^@O9WAA:<W?$/@=FR+J?2Q]M2/;C^"^K *3-Y)TG+9W.B8I&
M;*J8$/F)G;:Z#WV?)T\I6/O84T1<NW1/+[="][YJ.:97JV0MC>>"OM*_M-;K
M[#S0WU:A!QO1?>N';)!_-&\0/EZV:S(L@\20P^B&1,^;.?5WE N6^^&MGEG3
M3&?B[PU$G3SD[3X:BO=I"QMZ\]I(Z@:VH-Z585>J!<Q>Z\(?#TF+\L]GEEVY
M3P9$(/PP*6C*AG!J!>]5UM34AYZUC2SVQHF,>I]82=<G<ZF/ 9N: <]L<H1,
M%@(S=&/$6OCAZ@E:Z,%K_F,(3M>VP?]&>*F-9N#\#L_ 3MKB?:GG7#S6$]?V
MD:G.^Q%[%,0H:UM)#%EN(\.I-5C%Y%@C(]5LH'!T%'LX!(J5AW*,*JA+/O2>
MJ'#R%+7.+D872>7V(*[#-@43#5UR[>33ZH%X+_5"HG_ZU<"9_\ _ _%69K(9
MB%L#)H)'7(QOX6L),JE\E7TK"[D$52_%:P7OAILQ^B:6:NC_?B9UP4>_],6-
MJK@QHF\NRIQRF@Y5_M:P56#'[J#?M*K+<(FR+L!S8EWHJF(/;B<"T4,[J$#/
M>:LLNX=IWXN?.\>LG8/2#7+ RFX[K#T]7CVLW7;$FC2+J7*#J:SP"AV+0P)C
M]^0S'>NA"13=TU%'+(%5X*-YE*5T1;5A,SZLC,>$G8,'>/Y.9DLZEE-=4D/*
M1V+#_#I05-J#(MZ\0G&VKMIF2*J-CJ>;+*.N;?*+>*!_#-^Y^K VA\Q@V-1M
M@QO(3=NWNF;?U9]B :S0X460W-)T/J],0(C!3W7D+ZX"05@(*YT<BR4J@0N\
MC+F2MJY>J8KPE[^ ZMP[[;_:_J0D3NW0DMT7!/_O"<J(*RQ?87:[QIA=K\Y&
M+;_ 9/!N% TR36H@_1WB56S.N;[@_^L8.*.<.$=LWUO);Z]'*V>K^Y0&Y'KR
M<KAY[5S;X@]L\&2X)H54CK=L-";E<P&>1.)_5;#^3-QFD)<I,?)=J(<S!!Y_
MEL%%Q.S+X>+X+V-Q*=?U\KA^SK:.@H?M-2I\4KH)@<RT&PG$9U7888R(51KT
MJ32+PYE9<(1].U)U@J3P7YX+4/K;MA%>-7 ^YI=M8%/=&?Z<R@Y?%\$UE56Q
M9&U"3M*A(ZS!-<:'XX"4X$N1 20>=R2N70SQIY!( G(IJ_'Q3-X7]Q=EWZL?
M;Y2Q4R4^2@=43Y%@Z"@ CG'DX75&MW-PNL/XN,GGWGQL:1OLEJ[$(#>AKG55
MK9AC-&P^@Q)+V<I7%@8%DV^ST42LGX;VO322%G&N264KO +A2U@G)SE_8TCR
MUM?JWGM@<VFCVP[U]NB& X4=K/+70;SHY%( P_2HTO<R 5WP2O$30!T/1>"M
ME<O8OA[LY#%%0=F]A([WAE0%VA-W.O:B7JP]U8V+MERIMYJH>U@Y=RG$>HA%
M][:VW_:OOZ8D>=8J]^R?>CJ@7Z6]DS;?%2@]0V)XA*\V8R3.^?:!4BMZ'\ZS
MQT-_0=_>D;<QLYJ;_IW1Q$2J?3.A#:5H@_]D/'V1=8!!)%VFV.G F':'R;'.
M[[.5.;TND]ZXB4&73O#BNRV>@X=VA\C%O28X8NO?(V2')ZE&-)4IPUL!,[KG
M2#0FWO1N>6FHM]=R@9E+\7@UC812^F%X.UQ-*:LV>AKXMA3^!9+^L]I6GKH_
M_)S(@7 U%58ZON]RDBC,AGSP: B5PYVAJU5UV%2,"4GOZ:[,P. G-+A]<:7'
M?)UW6:*WO8+(8LK-3)$[GS\?Z+L?D63^#R;1+T7YUV7:K\BRUY*<^8ENY.Q<
M9JKA0STH>U%F/8?D.T>GZQ<_:C/WQNFE*0^_??[=GEA7UOL&B77=?=N80=RO
M!&<][49WBH(]8WPHWJW<[6X">/U88MNKB18 -3+<KID5S.WLT-<8-67UF?0O
MO<+^8,?I<,.J\&Z#*$PY5?Y:^0Y5 6U"(77[[DJT3C#[(+RDQ-U&""_XYEU6
M&T([-SA?&2GB:T*E[\WTH\[/#V"Q*?_(POEW"/PO$=+3]#N.D?_Y0CO<_PCD
MK;13#9 5:H*IQ\,GCP\\4N.'VE3\8X:QJ6LSYS]G2D)U&H#O)\;4\0,MD'[=
M\N)_ 5!+ P04    " "8A5Q6ZY?Z0I46   *1@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6SM7%ESVTB2?M>OJ-!X=NP(B ; NWU$R++:K5FWK97<
M[9U]*P)%$FT08*, R=I?OWE4%8H@2,OA/2/VH=LD44=6GE]F)?3ROJR^Z+52
MM?BZR0O]ZG1=U]N?GC_7R5IMI!Z46U7 DV59;60-7ZO5<[VME$QITB9_'H?A
MY/E&9L7IZY?TVW7U^F79U'E6J.M*Z&:SD=7#&Y67]Z].HU/[PTVV6M?XP_/7
M+[=RI6Y5_=OVNH)OS]TJ:;91A<[*0E1J^>KT//KIS0C'TX#?,W6OO<\"3[(H
MRR_XY2I]=1HB02I728TK2/CG3EVH/,>%@(P_S9JG;DN<Z'^VJ_],9X>S+*16
M%V7^.4OK]:O3V:E(U5(V>7U3WO^BS'G&N%Y2YIK^+^YY['!^*I)&U^7&3 8*
M-EG!_\JOA@_>A%EX8$)L)L1$-V]$5+Z5M7S]LBKO186C837\0$>EV4!<5J!0
M;NL*GF8PKWY]\?'#[<?W5V_//UV^%9<?/EU]NKJ\%><?WHKSBW_Y[>H6OL.(
ME\]KV MG/$_,NF]XW?C NE$L?BV+>JW%99&J='>!YT"DHS2VE+Z)CZ[X5B4#
M,8P"$8=Q?&2]H3OYD-8;'CIY6>@RSU)9JQ2(K+,Z4[KOH+S,J'\9-)J?]%8F
MZM4I6(56U9TZ??U/?XDFX8LC1(X<D:-CJ_^ >(ZNVT_U>" >MY_HY9WXM%:5
MO)-%HL2-TMNLDG59/<#@S586#X%X__Y"_+85#8S/Q=^;_ %$R>(,Q+T2B;_H
MIYL+&)BJ2M1K)7Z_NA2;,E6YD!J'IJI6%5@##*S7LJ;1]_!(TDA9I#CH7E6*
M9F^K#!V.6*A"+;,DP\_EDAXII!V?)++1.$6L9<J3RGO<O!1I5H$'X=% 8KG)
M$ID#[3I;%1DL)XN:?0LS 19&:I &G%(N\FPER0'!6G*ARVHA\E)K&AJ(D@]8
MH?/ $;"7 C=E:*VU6%;E)L E!^(S4*?R5$1C\5=1WA>JTNML*[("F*%T;;8>
MH!S<F7795" />%2I.U4T2H C)PHSS3N7#S(GRE>P947,QSWI80%10<O<'NOR
M_>6[?PA0[NGHA;A\__[J^M.Y_;IX$.]N_WD@SC5P3(/GTK!05H@/9:W$,(!A
MLS@.7]P8*FZ E\ _9 P]B5X +PK6BFAHM>+JTR\H(C@>K@7L0:*0^,L_&Y3;
M-1QN#3Y9G*\JI2!6$ _!Y^<"SMW'(Z"(>/3;%B4"JR4@C*Q8686H*UEHR1'#
MTK.CI49 J7@BXNET, :GG.<X&E9.I%XS\VZ(JT#@6D+H(-%)T$:9ZY)U+D?5
M;<7=;/';$S$.!^'.BN!#@3H\&,GA#"-0BB/@,&4!<I8/>&R-@Y'^95,WE1J(
M*YI;F-AWG]7K;YR6#D?TN1,B"[=EQ;P@W4)11=,7&L9@P,>5Z,P+F9/9PZ@G
M8C08N2/T,$. CJW)KB627)7-:@V&2^N YM15MFAJ-Y>$=5UE)=GB-P2&1@=>
M8"NKVCZ65C'(AMH-4*& :_L:HFF5K+B#SXZS5\6%K%+)'FZK@+Y$@W86R0#^
MOY&KK#A?V._OP(3$!]54I4XR!5PQ(VG=#[( %P<"OST'AJ^S9$T.1\+A:ID#
M$ZKJ 0]W)_/&L',X;_D9(!/ *%BADJ0$7XKV:KR(SPN=P1Q)7 ,^-ULXMY(;
MTB)P+O6]4L O9!7J%C&.?"?[W//;"S&+PK,H)(/63;)F8P3=**M4I>UV2U6Q
M=;8,D^0MLPI&ZZTBV-4Y&3.Y*,4*M A]('I$\N 5^X5_9^=!\O;#@J[A'[)S
MX$U6).5&L;]C4$GSEED!RI@!.[."42MIDW%[DGP9@ FU6<!)#:"(B"#+QPI
MXQWZ]:T"S4NU4U-\2!Q$:I! = MDV11%21BPP;+, >SJG\0;8Q>$STZ>7N&)
MRD;#7OK9/@TGY^ T:WUR@:: ])!-*'!UP#3B+#J(8!H-3V[(1N4"73/9">#
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M]A#L'$RC#(,!_:S+] <R)Y<M'2L)#+C\M=GFJC;M#++-9'KB;]O54)0%%=,
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MS:TI'IY3$M;E5>8:NTQ3ETS_ %1@F+VM%%ZN%$A)NS30MXNZ'GLV1WZA[IG
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M[^V7NMS27_M8E'5=;NCC6DD@%P? \V4)'MM\P0W<GW]Y_1]02P,$%     @
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MMO+FDSEZLZ4W74TLD#3A:!'K:B +WG@\Q=%>,)NZ<)K#IF-O OX/)IQX\WF
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M@A./VL.@?D9O^OY=. @^'.'>:[CWCJ'_KSP=1XK;< @,KN0S2JOT>F>5*.I
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M)8V*J)T G6=*V>V',] ,G]-_ 5!+ P04    " "8A5Q6OE>B [$,  #C)0
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M8WCB#LOU36E6_#>>F2E+D_'E4N&T7] "_#XWIJQOB$'SOZX7_P902P,$%
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M)B#U*0J% U"' !8((,"153LP)U4-1]^+%#>$]1;6T8ST<3(0GW92;& I' 4
MJ3C3L,=!E8F4J6;ZP+HF\R+\4WR I[YD<(3,[PF-T6!LT8A$#JQ">LX'2X=;
M50(%5+(#6RNJNQ(QO.7EA=R654;P)[ Q_<AS41Z(P:#>A8[)V&N1%8A[86P_
MH5D!#@Y"  U_)S(P>H$RK&6L8 <0 *E!+"MZ5!GBC <CT(L_B@-HUST^6.W@
MB4R+0WP?$YWE/KN."R!A#C #(#$(8JP8IECO1%D$%":I_Z'.Z3-L+^-D1_M&
M ,8V*PJ2@,(^$I$ =2"^ U!#9D<6:D,;@^ZNS$'.(L2M%'H7 W[X50DV!,1Q
M#P^"PTD^XV(0RJS(@-JYV9?=L"'"9#98K883NP?2XC';@3YYK!K 1BB)OP)G
MD--Q^BLXN3TJ*I('P(_Q9Z:2>J\K9!5*Z2X#HBA)UK< L] /'!S-G.T(W6*P
M6!&0!.\ ];%/.D*-:\,,&BM)(E*FWE=+)IT6"PWGY,BS&G<]Q*JZ9ZZ>7H^"
M1MA7<JOHO*P QU83!8T+,!C$C3WP7YO-5LU2L;X7M0>M4MEG:<@I_P9RC)PB
M]3E!] Z9!82,M(J,6WZ/8!4U>25XW$@.2C\">@@WFBP'*$EV(]"$$@"#KU@0
M<.]>$=*6 D@,QU7/14=@,KYE05*GA815Y3Y+2%\!7V!JCE_AW@T::E ?0ZI+
M<&-R>E%MT+4/T8&X.<[=B,[3LJIR2=PV0AK*2U*B\J7V;/PZ!1]D[3H]'G@$
M=&X#\<L!47/[DJC?E36@JB"*@)A9;%2Y)^G9R73;E%F@4 ?OED7A/Y*5--O&
MQ=9L^G>I2@'VB&$S4DGTN8O1#D/.T!6LB#D#47"VK_=DDZ/%8@4>>65.Z]T1
M-6== CJ/.V3_KKR3MV08>1GD)Y_!I3E.M34'S*L6>QEK<K(D [0.0P;=QYC0
M D1"?B&_V0&$6*P(TJ($UB>*.(*VM*BRZS3+:\QA@"Z%W&05D[!U%,L0L$Y#
M7F)!05:U]!;$V%I;]@JZ:_70))/? 9\SC4A7T^P6Y OB2!">)(\5A2\0"L09
MRBH]2'^ #[,H$#CO/4@R ;R#45^D;>C)@+*LT23]\$3%]F<V',R6H^4IM_5
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M);@JNY4R+R0]95^VR#Z=I!F@'I_8RUP\&Z45NW:F-0A_P5DB_)E1U EVI6;
M]CAR:70ZS=B,HA39;2&3U61#60-O4GX(:QP-R\<\,T7,9F&/9&L6=!: _!AI
MF9+R.?-(_J:TKM<:8Z]$ABZN/N7&@1I!EC^E#[I)6(GS4/0].O)]) A*F@_$
M%0>55',QD/8:)NJG.?G 0[']%F,Y_!IG[+"0D[D"6U"A2(^)#*F_]>1] G>1
M,&7G\>G*&[E_< XH:-L82W;]#Z)]<^)#A=AK<A"'#(3F(9V07D7M6 34@^5@
M21T1&BXX%I"$@U!!),4>RE#\X3X<]*;>LXZ;\D,P(D/VH1$HD'TUTSC^,+*7
MH"[R$ J_-7(6(>JL&;.?WW\5X$W&]PN#HCP7C;WW!YCW-1J@I[L__=8^OD@;
MSDEP4#HXK1_4*@_G"RW3JPLDL.@3L_%@N:3&6[=IY4*Z_[ZFU8]=\6\TLNR8
MK/O$G:P3 ZZNK16M1@L[Y3K&)M>1YM9H-8QF2^QNC6;3:+Q</7K7DBP[K6HF
M6C&ZF$63^>@?T0:S-/Y?U :;1LO1I/WSHC;8?#4&4BW$?'BD;>;X:$F[B):K
M)?P_G@P?T#B;@63,J)P,;%GBAW$TGT[/=KR6F(GS6$1H*L]UN\;ST6#XL&[7
MLCDATZH[,PBFNK$4IWMB=@[C2$]L.@M@^XT],3<?2//$PT8\[=ICKJAN ?N=
MVF(%C9>U@_-PB.7Q0QC71J@S 3L;!T,S7*@R/L1E3&V*FAZ)$WOMTD10')?U
M4S,*B,(QDIN@->*NR4/2Y$X'I! [.X[=2Q6W*= 7ZTTF:M:$.0WENH(=?7-D
M[@X0QO+%&F4)!PNILF7CHN,31F[&!Z\XT9QG"&2S7M6:&3K#-*,BP;"=C>E-
M+X.&[;BK&0P8=Z>)SP[R64VFVB'ESJ80#CL?G8WW,D5,1(YR4ZO6\A1)T!EL
M)>32U/:S%6&@T:'405?+RFNWX5O86* ]<O\UD_;66G&)RK4L3C> P^?8>77
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M<:50 >*'$DNY4L*TSS-Z[@1(0IC*BL38TN 5UH$H?E;2>F5=),Q\KA,E&)H
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M!=C'/*.K*H)YE,U&@.<9LWS1^NA"845Y%O4^Y-=HC&=P$6X+*(T IQOA$]<
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M7$ 5]?FN;&8B6K0=@WX!=)B;"*G5?#G?@4$\6#1W"J(T&'NQ=.XT9$6]+[>
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M0@%,;_.=>FV-C+!+@%RS71\3^SC5JN_<=2>#)50.F\A\[MH"E!A1'N4L$\8
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M$!JQQ<)C7(JZAU!>YJ+F!)O0;3P+KD,[MW2'2P^\@^VBM9OB?!\S7AQ'5#+
M4%2*P1NE/>)-]0HU>N^>C+,=\CST^ZZ,KB7)?X5>!.Y1"P2^+ / DC4#F_TM
M^[_B/0(*S;JLMI>"P#+J-B2JLD?1*/5L1@7X;/;?/+@@T:G4YFH.>-D&.NRV
MSDUJ3HVT7S,B^C1T_[0H>&#?E#0D;-;FV"*3[>EC^]36ZWZZV6 SISZ%D=A
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MOL=!2OT PAFG!.VP 4#2GYA5Y"M\ 'Y?E4 U\@$7P)>.T_9>_!=02P,$%
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M*<24-O'![MI1GEGLL2B%+/+"P"=BH1?'T7:07TOJH'#WSKHR"0?^R"W,%<B
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MNB!UH>[YYA?:.!1J?1DOI/F+-G9N'(Q15DO%RT88$)2LLO_)YV8A.@*)\XJ
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M(*A= IWG2MGGP#7H_I.F_P)02P,$%     @ F(5<5I@1)\S4 P  PPD  !D
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MLE [ YI?*F6?.FZ!YMTV^1=02P,$%     @ F(5<5IAS^(GY!0  N1   !D
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M-]V:EPJE33#[:R'T,;#=T[U]T5]02P,$%     @ F(5<5D/@@[]  P  L T
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M0)4B+XYTBPO)DOR0<\FD9''^<4MP0'@&4-^OF>J;\B)[0'6P/OL/4$L#!!0
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M#UE6/K^I.GC,\F^KW1[\#U!+ P04    " "8A5Q6Y+5N"JH%  !@&0  &0
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M18* \F>#)B@,$Y*,XW<.[11M)H[EXQW=2SLO._,..9K0\%\<B-6H<]L! 5K
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MA,HZ+ZA@T[Y<)RVNOF]TM@$6L\L0*<P"2YW:K!P0[5TF=R)>$OG56+WN/C7
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M#GW#VFN*".KR>D]?3F;9\E_M87,^-"R%TAB4%J!HNHB4@>N9GRKP_SIO@EK
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M!PN>%F\0VQ^2)']9* 1V3\M/_P-02P,$%     @ F(5<5BU) %KU#   DI
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M/Q_G>?GZHJK@.5??ELT^_S]02P,$%     @ F(5<5EO]>65Y!   ;Q4  !D
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MG\?S._0X_O(P0XO9>/EP-\OK+M#L>QJ(9S2/M\"%7 X"!3&:1V03Q.,5^NB
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M"M#Z0E(5S0?60'$'UO\/4$L#!!0    ( )B%7%88D'0S, 0  -T3   9
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;*V8:V_B.!2&_XJ5K78[T@RY<&T7
MD"@),Y6F; =H5_O1A -83>*,[<!4FA^_=I)F @T1:)P/$,<^3X[?<^);?T_9
M"]\""/0C#"(^,+9"Q+>FR?TMA)@W: R1K%E3%F(ABVQC\I@!7J5&86 ZEM4Q
M0TPB8]A/GSVR89\F(B 1/#+$DS#$[/4. KH?&+;Q]F!&-ENA'IC#?HPW, ?Q
M%#\R63(+RHJ$$'%"(\1@/3!&]JUGIP9IBV<">UZZ1ZHK2TI?5.%^-3 LY1$$
MX N%P/)O!V,( D62?GS/H4;Q3F58OG^C3]+.R\XL,8<Q#?XE*[$=&#T#K6"-
MDT#,Z/X+Y!UJ*YY/ Y[^HGW>UC*0GW!!P]Q8>A"2*/O'/W(A2@:.<\+ R0V<
M8X.;$P;-W*!Y9-"T3QBT<H/6N0;MW"#MNIGU/17.Q0(/^XSN$5.M)4W=I.JG
MUE(O$JE$F0LF:XFT$T/OV]/]XC\TFKKHZS_3SY\6WNP!W4^?O?GBP9LNYFG-
M9'0_0\^CKT\>>O!&\Z>9E]5]0M[WA(A7=!_M@ N9/P*1"$UQ1 ,9?G3M@L D
MX!]DR^+A?,)4HP<2!#)3^$=T52[V32%[I7PS_;P'=UD/G!,]F,"R@9S>1^18
MCH.>YBZZOOI0@1F?@;&/,(AO,8,JI]Q+:.,O$W0M^UW#\^IY+O@-U+2/O',)
MD]\;98<\4Z9 D0=.D0=.^H+FJ3PX#F15(#)$JQJAAK1;'F,?!H8<LSBP'1C#
M/_^P.];?5>'0"7-UPCQ-L(,X-(LX-.OHPP7#$<?9(.I3+C@25(ZF,CH,$&1!
MXN GC @"'/U$5U6!RM[12]^AIHK=T&IT^^:NK'^M'Y?JKQ/F:8(=Z-\J]&_5
MZC]-PB4P1-?YIP#P%T=W%+,5"D%5<3DJ,R8_D.!53I2I!Y$@T0:)+: Q#6,<
MO<JP5'^:671J/;CT,]()<W7"O S6*26A7:3@06S:16S:9\9&:7TR/O7BU[[B
M4O%UPER=,*_]3OQNM?B=0OQ.K?CY!$%^S?1T'TFYMR1&,3!?/I$+RRK%:[F7
M*JX3YNJ$>1G,M@\&7;O=KI:]6\C>K95]@@E#.QPDH/+^[ F@%GJIYCIAKDZ8
MUWTWS]E6HU.M>*]0O%>K^!R8$G:,I -KD$/]"LE5N/]2)7,MZ5*9=<)<G3!/
M$^P@'#=%.&Y^?V%ZHS,..F&N3IBG"780!]OZM5.TSIQ^LUV,6IDN <4)\[=R
MJ[Y"2;22]6IN+@U0;]4(;QA .G'\/+T-NJOWX=)0YK2#-4BOV[;D=;@:=L]N
MZ>GR\# *I?VZ71N%44@3-?FNZT6NU+:6?+&V]KO!]Z;1L\J7?2QR?A;1*ML<
MRZO)R4Q>LW0RH@Z^'C#;D(BC -82+S=%<IW$LK.DK"!HG!Z6+*D0-$QOMX!E
M7JL&LGY-J7@KJ/.7XD1O^#]02P,$%     @ F(5<5C8PJ(3# P  C@X  !D
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MA7&GXYABD-4QUUAQT&S?RXAE36T$"4V4#O16BLI&6-94F9*-* @E"-[JZ-#
M')>%76_5T]FN9SN[O%5B#X6Q1_=6C7<+$@E &/*L!I?=^UJ/$2"B$J^H-]2E
M42D)RYHJ4U(2!?$$P:69YJH.M3S6X8>+/?7XW?[#V#JZ=3OT?+<33+S<9YW^
M ;66A"T*PY;>?7Y=9U4;"1B?\2I\?E9/XY#KNN,4==CF:BYZ53P3S;SQJ3?D
M(W_F";&-S8F$64WSC0%M5$(;#8;V(516P[*FRI2L1N&XUNO[4*@C.+,$A7=O
M"WHZ-PA]RS7?%AR)80Z,8;A^O?]. 5>G]_3(& $O1Q*@8P_T<@>5\;"LJ3(E
MXSEP8.RU7OYACWWS'>"\R:4BDQ<&M-,W8.M#6Z<U,PBC(7H/.NPI JY5;P\;
M(R;G2#AUW*$="94LL:RI,B59.G#@[M6WB\;^WJ<(0SKH*<*1T.C .(7N[(@/
M(7#5>[O*&,$]1_*FXP_M$:B<B&5-E2DYT8&#>Z^_M<#V-?QOVA 50AMKZJ.*
MPWQ_1V^3>.G >*GWMKOX*8T?15]*2_*I7/"<?'JHZE>M#")7Z6HM>Y=IU<PY
M7&!OX6.$$%W)KN[0:547E3*QK*DR)66Z(T^KNOJT:F!YW7N&(548>E9H=F)7
MTJ,+TQWLQ%_2;)<#.T8MJ%%%+&MJTTAT=(?.N+JH=(=E39796D<V\HRKJ\^D
M^E80.%T/-DRX^IZ_RX,EMKDPM@WW8%S @:O9VRG&"#^ZDB3=H9.T+BK'85E3
M94J.<T>>I'5-D[2>WYGENMA3C1U!5H-Q:K&.[<M]ML$0JRM9T(59[29+\_US
MO;"1WMXQ1OS0E8#GPG.]/985NZCDAF5-78,KR<V#HXZ#EA9[^D2NOK88+GBH
M,,EJ'AP1W+/LUD,-"V)94[5*L/,."0LF4G&?8<W3@WN>Q:A&I7 =AFJ4A.;!
MP3U]3!*WZ0O^4!HUH4(;EC55N80V#P[)]1B:/-08'98U57=K?P ,>]2BSF;5
MG%&J'E@+F15H7FN*T]D^VX&BGJ0F#XZ_B=IY0.U,<Z9^8/G=ZNGIJ..Z8;"C
M>I)V/!@%1/4"H'H&VK!%JW17[,"%#/4 R2'>(3$I.7Q5VZ_FN[J\'OKQ+(\Q
MMRM)3^>&C+(=(2)/$H0'AXB, ]1KHT1PF;T[]!BLP21K,#A*U&,@8ZAA(RQK
MJFZ)(@P.&\%]D1F6VIOZ(ES(4!&2,=@AC'%87V0FI##T1;C(H9(D4C XZ+-O
M9Q8J1&!94[5*B&"'1'X&(B+3PSGFZSD&,# )# P&AE>/P !1PD7W=H91-B2V
M=B3"$9\^ S'N_L0Q0D!,0A';"T4 43(=BDQ$:4@&$263M,-@VH&)DIFFM@Q$
M:4@'$263?,,.66%UX T %5N88<D5@&R^!!(?#G[L'3#ZSHG Y?75C65-;1V)
M+3X<0>DQ2OBHT10L:ZIN23H^3#J#0F*^ 7FTD!A<\%!ADG?\5_&.C\H[6-94
MK9)W_!%YQS?PCGXQQX =7\*.#\/.677>3"3&JP.V$XCOSK/E,DM)46:S;T;)
MJ'R#94UM&\DW_M 9+1\59["LJ3);!RZ,/*/EZRCCV);NZ7JR(+ M>\?M5P*/
M#P-/3Q?^+<KS:-<-"'4N"LN:VBZ2M/RA^PY]5*["LJ:>LR'I*QAYWV&@3T,9
M5M,84GE!>SA7JR_Q*("C.H#W8J_$/&#\ABO;US.PK*E-*PDL&+J5,4!==(1E
M394I>2P8>2MCH&]1-(W?AF3 ^!U(Q@I@Q@)Z0,^H2]_A'JY8;S<8@^0"27+!
MT%V. 2J485E394HH"T;>Y1CH<V6FX5Y/!0WW$K8"&+:F:?E_'-U15YIC65-;
MLG7 UM =B0$JQ6%94V5*B@M&WI$(V^_=&GH0C5$_W+%M,904%\(4)_L%SH,H
M7%SOT\;&"*&%DA'#H=L20U1>P[*FRI2\%HZ[+?$<MM^[-?18'.3JDM="F-?Z
MNCI$,'!1O16/$6P+)0B&\ HEP,U100W+FBI3@EHX\J9!V'[OUM"7-KE6:.]R
M<PEJ(0QJD)N/S/5PS7HWT!CAN5 28SATXV"(BG-8UE29$N?"<3<.GL/V>[>&
M87T7T"M:YZ;".'>5GD?Y'"=:"1?56_$X1ZJVSU0=?J@J\JFJHQRK:K7.5;7&
M/EC5TI=[,:L;L3&E<NT= 1O;HJWZPZ0&>?%KME+M<?@]U>KO!Z.<SVJU#FBU
M!I_0:N$>T8IEKB.U=4BK=<A,ZJM<7I].-;F\G@IP^=81K19,;;]4![3>\'6>
M%;.8I[/Z)0W+!X$NID[0/K&U6MW2\G&S-MSC6K',=5JK=6"K-?C$5@OWR%8L
M<QVIK4-;K;%/;;7TB5';\_5C6XWI[)W'#UNM$UDM&+[Z.7>/$;YW/\ ]^!7+
M7*=A6T>_6H//?K5P#W_%,M<Y*KZ%;_!A]!B'Q6\*\/;U V.ZW?V@/N^^\U4+
M=?8<(O^[_0>Y7W!EO_>")W/R\+V]O?L-F66IZ!Z5S.R1_$1HZ!V[9!DG2?5*
MJ#@E7-LW_H:\+.+90GPU2]9SD7'5G .^VIX#OMJ> U[M,9^U>E-:GP->%^6Y
MQ^Q'26_JA*)X[]ANE[[4MJ<?DT_KG)3U59M%J[C^]\=;*ZI<M6W'LHXM::@@
MQ?KA/WQ65B^UB(C#WM9OS"")\M8.\IAG2R*>Z\F\DB,,%6NATU2*J,:0UK5#
M>DRWU=*;MFD%Y]C;)M);0+15SKN""* H6U=O[A 7I-M4E<PWY(+/-H.FO7E/
MD75LZEJ3UNNGECQ_JE\45@A[Z[3<O YF^^WV;60?ZE=P=;X_K]Y29OJ>OKLP
MI9_2=Y>F[T47L-]-JVYB_(U6O]7Y)K*ZFU>I74?Y4RQ\,^&/HNK6<;5>*]^\
MG&SSH<Q6]<NT'K*RS);UGPL>S7E>)1"_/V;"BYL/50';=\2=_@]02P,$%
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MC<\1V\SQQ0C2&.!X)H1^Z9@W2?,&3?X'4$L#!!0    ( )B%7%8/QFT6TP(
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MXYP43-WRU056>MHF7\29M%]85;&> U$A%4\KL&:0TJS\DX?*APU H_4*P*\
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M<4>#1?E E!W%<UMC9USIBFV;B7Y349@ /3_G7#UV3-FN7^GP#U!+ P04
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M =<!ZO^*,;EOZ &J!Z'_#U!+ P04    " "8A5Q69B%2?T0%  !R(P  &0
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M\##;7#+JL3@-D)^_<"YV.^D)RF4VHW\!4$L#!!0    ( )B%7%;;*IHI^0@
M "])   9    >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;+6<;W/:N!;&OXJ&
MN[/3SFP RY:!;I(9@K/W[MQIDPEM][6#!7AJ;*YMDO;;7_E/$$+B8)/COFC
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MZG,CFHJFZ2A>U6_\$U>Z8JB;:UT$HC &>G[)N7KMF 6ZLC+Y 5!+ P04
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MB%6JD"XR*,JR%4LG'$U$IJPE9]U&=Z=O9P/?QWO:.GO25%M(&+7TW^_W=P[
MT+:[U;9[Y(!\CU)N'97=6L.=P/-[_IYRSG::*@<)H_4#\ =!M^/;E>MME>L=
M,2I'*RFY'H/+?&CJ^8R^+,8BG9\I+A.WK+U:KP9=/-A7U=F'IJI"PFB]_YY=
MT/Y6T/X10_%(]?KU2A,$N._MR>=LL:E\D##:;S0H!UL-!TX-/W(6J\6(28[N
MQ:O^_(KNF%0IE]::Z(0UO>)#PD)(& 6"&1G!7C5Q]DZ:;I5A0.J#TD)0&H6B
MF0G8<2[8>5+<LI<H626Z1BM=JB-=9&1Y;BS9J_;$UN24;LC;K6_G>'\JYFZY
ML>J0- I%,U4GE>K$J?JG="*Y=N:Y%TQJ&5@KCY9<3O0OU@P06P9JDV%W+QIG
M ))&H6AF!BJ;AYU69CONV7PN^9PIOCON$RV[W9K[M4LK(1W/V[^TNAMO+#RH
MQ8.BF<)7)@^[7=X]_[Z*I/8II<YH)B0:Z[-ALL@GB$RG@^>_O]_N(%)NS450
MFR5@:RY +2$HC4+1S%Q4WA&[S>/=3@HVPW^; *OF=:.%2:\N.:A3!*51*)HI
M>64IL=M3$H_XZ'==ZC/T+QJ)](EK;S2..<I68R&G4:I+T12E^0[6!$":OQ$H
M+02E42B:F:?*P.+>:1-32)\X J6%H#0*13,34!E>?(SC/70W$-<MXJ!+ZA.@
MNA7.=]NK5^%QNU%+HR3P!H=NX>'*F&*W,X6YB5<V8MP%P_OW\-P]:3SB!C7A
MSBRZ63JFY;6K1BKO2)S6*"^E'7LIY6FDKV@'BZB;V_0<!J6%H#0*13,S5)E+
M@D\JH@32RXU :2$HC4+1S 14/I.X?::[B);!QFQND$^A]VJ&NY'& H/:R!\?
M@RE=91")VR#"U.2R$;,F#W!O7V%0OPA*H[9#\/L$'UA<(943)&XGJ.MW_[3Z
M#>G!1J"T$)1&H6AFABI_2#JGU6](1S8"I86@- I%,Q-0N45R[ JD-0WUQ3O2
MQ?4[(.Y&&@L,:O-*VNX,\E#IKKP;.6;U\7^7[OHBWEDO\/87(=U]:2PNJ(6#
MHIEYJ"P<<5NXS2K;ARC54D?I'%UO;B[IBO]9L#1#=^R5Y37_KUN>C+G\6V]H
MN$[G[D3C8@2Z*@I*HU T,YV52R6#TZX&H"NEH+00E$:A:.:3:97A]=V&]U.J
MN.8JQ%^6/,VL=\5+A#$?[M>N".Z&&C^!!NI9H6BFR)5G]=T+HB&?<9FO3VQN
MB(MQ',W9^H%<?>%@DXE<Z<U1F0QK$G M"3VO6\\"J'$%I5$HFIF%RKCZ;N-:
M%?[#BW$E8G?J8)G\N!MJ+#*H>86BF2+O/.KJMKAWZP5F-B^>6-X,:"29LI>6
M-0UC<]&YYP?>SK_]&X[N/C36'_9IUY^Q%.I7!MC_P5(H^/Q(;_VB%ESJ8$U[
MS)\4^QRQ<11'*K)[:7<7&S_8#.JE06D4BF8FN_+2_FE>V@?UTJ"T$)1&H6AF
M BHO[;N]].9<^5)=S\N3RYJ6NB_M]@;UJPNHM0:E42B:J7?EPGVW"_^)U>VZ
MG(/]J+:!KM6"TD)0&H6BF:FNC+[?/ZVV@5IS4%H(2J-0-#,!E37WW0O(#PLA
M%2J>##_*G]27;2U/\;C;;*PWJ!.'HJWU;N^\^I=P.2_>N<Q0<;=P_1;@]M?M
M>YW7Q=N,[6KW]4NAMTS.(UW98C[3H=YY3XLLU^]9KK\HL2Q>)!P+I412?%QP
M-N4RWT%OGPFA-E_R!K9ONP[_ U!+ P04    " "8A5Q6GU &^R8.  !$LP
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MAV_.];<G^=L!UZO?G!XV4M_HI3T$JMFUIAP%#*W1P5$ VJJ+:AZJ^:@F4"U
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MB6,Y3H]\]GZY_5)N8N@NN=,E=VH_]PV_7[Q<G2D0!3YU#%\\A\=W@SP"%9)
MF;)RA:N30+$ @>4G?;F;0EY_(?T>3F1%$Y@:^*))$!LPXH\?[,#ZTK<*_\GL
MQ9JXW9JX0^XQ+JW;%[!1^;5*[PN;. P<RXO,S2[YH/>1Y%Y'[ATB]_K(&U6P
M0VZ]HA[T/9+:[ZC]0]1^'[6_1VV'CF^]1A\T/Q(]Z-"#0^A!'WIP<,$'?8^D
M'G74HT/4HS[JT4'J0=\CJ<<=]7B0^C8#/*&7N%GUL8_WV)W MO;^+(,EC@P0
M=@'"X0!<T;R//=S;6'PO'.WM+/O3/-?UQL_3&BISYQS4WR"75*Q8*4D.2Q1:
MYR-T$,VYWG04K^JC<<$5'K1U,\-/(1!Z HXO.5=/'7W:=A]7\3]02P,$%
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M@\"3E509-1BJM:MS!30IBS+N^IX7N!EEPHG"<N]!1:$L#&<"'A311991]7L
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M*CN-RLXI] C7U-Y+8@\(MK*BAHDUX58]B5'\P9]4@79+4-O6FZC5O>F&[N:
ME&XCI7M2RC-5C"[Q)KW#7:$$;[B/4 <-=7"2>B$-Y>_Q!O][ONYX_Q"[>YV6
M@5J7\T0C:"%,U73-;C.R^E6G_DVOYMV4JC43&F6ML-2[ND9J5<V0*C R+_MV
M*0U.@7*9XM@%91/P?"6EV066H!GDT1]02P,$%     @ F(5<5OA54,?W @
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MCQG>QT#9 /R^EM(\#.R17]_PXN]02P,$%     @ F(5<5LN8_O/M @  !@D
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MMF=]JZO ?TKVJAZMJAZMINR^*FNKSF"A:N<JO8UL?+OMJOG;[((WICX2W*W
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ML=-I'M)FXN;:5QG61E.0?)(<I__^)$&H#0J3A[[82'S[:;]=:;5,#US\E 6
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M<7Y0'6&/N/V!5A6CLJ+N"[L)#(=Q&(_<W:DL,RP.4Q@T42]XPX8W[.6]4S.
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MP+X_D]*\7N0/J,[Z3/X#4$L#!!0    ( )B%7%;L9[].8@,  -4-   9
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M\( A05#>!_?N1][F/N4U_X@8_0%02P,$%     @ F(5<5I>*NQS     $P(
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M>@_CYZ$.MYZO-5[_.ZD>+^?6V^6ORZ^=DWO\BG.XKQB>_P)02P,$%     @
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M:6_:X3D_6_X\<?,+4$L! A0#%     @ F(5<5@=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "8A5Q6
MO6S(5>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " "8A5Q6F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( )B%7%:NX1O/Q0@
M "LT   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " "8A5Q6C,)67X0'  # (   &               @($(
M$0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ F(5<5J"M
M?X$9 P  K H  !@              ("!PA@  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( )B%7%8FC8=.S <  .<F   8
M  " @1$<  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "8
MA5Q6Z)1U>GX"  "?!@  &               @($3)   >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ F(5<5A"XQ*]* P  ' H  !@
M         ("!QR8  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( )B%7%;@+)%$Z X  !6K   8              " @4<J  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "8A5Q622V[_.\+   K/
M&               @(%E.0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ F(5<5LS[Q7'J*P   8@  !@              ("!BD4  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( )B%7%84._<?7 8
M ,41   9              " @:IQ  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ F(5<5C6+[UVC!P  2Q(  !D              ("!
M/7@  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "8A5Q6
M52++5U,/  #I,@  &0              @($7@   >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( )B%7%;KE_I"E18   I&   9
M      " @:&/  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ F(5<5FZ[B B4'   /&T  !D              ("!;:8  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "8A5Q62&&="18$  #Z"
M&0              @($XPP  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( )B%7%8$8WG*" 4  #4,   9              " @87'  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ F(5<5M*9VOIS
M!   B H  !D              ("!Q,P  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " "8A5Q6OE>B [$,  #C)0  &0
M@(%NT0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( )B%
M7%8EP=D!?P0  "X*   9              " @5;>  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ F(5<5M&2U!*X&0  L%L  !D
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M=#(T+GAM;%!+ 0(4 Q0    ( )B%7%:.,];^% ,  '@&   9
M  " @;)% 0!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
MF(5<5B7KRY]N!   70L  !D              ("!_4@! 'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " "8A5Q6YR/@RJH#  !M!P  &0
M            @(&B30$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( )B%7%9K7R5[N@@  /L9   9              " @8-1 0!X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ F(5<5L:<>(:2"
M+1T  !D              ("!=%H! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " "8A5Q6/5^&JP,#  !=!@  &0              @($]
M8P$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( )B%7%8E
ML([F)0,  )\&   9              " @7=F 0!X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ F(5<5I@1)\S4 P  PPD  !D
M     ("!TVD! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )B%7%8914L$/0<  #$Q   9              "
M@?2$ 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ F(5<
M5G.ED03L @  T D  !D              ("!:(P! 'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " "8A5Q64LR53E4"   '!0  &0
M        @(&+CP$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( )B%7%9#X(._0 ,  + -   9              " @1>2 0!X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ F(5<5GD''@*)!0  9!\
M !D              ("!CI4! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " "8A5Q6KYT3D"4#  !G#0  &0              @(%.FP$
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( )B%7%9B(>EM
M?P4  ,PD   9              " @:J> 0!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ F(5<5IA8.R0$"P  X8,  !D
M ("!8*0! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " "8
MA5Q6Y+5N"JH%  !@&0  &0              @(&;KP$ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( )B%7%8:"/TAQ H  *A5   9
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M970U,"YX;6Q02P$"% ,4    " "8A5Q6)PR)V@4#  !K!P  &0
M    @(%*WP$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M )B%7%:)JWC-7 P  #R#   9              " @8;B 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ F(5<5DCOR<_,!@  .3\  !D
M             ("!&>\! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " "8A5Q6+4D 6O4,  "2D   &0              @($<]@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( )B%7%9;_7EE>00
M &\5   9              " @4@# @!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ F(5<5G[R-#5)!0  #Q,  !D              ("!
M^ <" 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " "8A5Q6
M&)!T,S $  #=$P  &0              @(%X#0( >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( )B%7%8V,*B$PP,  (X.   9
M      " @=\1 @!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ F(5<5E%*]4D>#0  +VX  !D              ("!V14" 'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " "8A5Q6.5!YE_L$   4(
M&0              @($N(P( >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+
M 0(4 Q0    ( )B%7%8!XZZD@04  (XK   9              " @6 H @!X
M;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ F(5<5O\8_V\:
M!   F1,  !D              ("!&"X" 'AL+W=O<FMS:&5E=',O<VAE970V
M,BYX;6Q02P$"% ,4    " "8A5Q6P<&1!YX"  !F!P  &0
M@(%I,@( >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( )B%
M7%8RME("+@,  "\*   9              " @3XU @!X;"]W;W)K<VAE971S
M+W-H965T-C0N>&UL4$L! A0#%     @ F(5<5O1;"^AI P  CPH  !D
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M=#8Y+GAM;%!+ 0(4 Q0    ( )B%7%;;*IHI^0@  "])   9
M  " @15, @!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @
MF(5<5HXK-'-. P  8@H  !D              ("!154" 'AL+W=O<FMS:&5E
M=',O<VAE970W,2YX;6Q02P$"% ,4    " "8A5Q6^TRZPU@#   N#@  &0
M            @('*6 ( >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4
M Q0    ( )B%7%;0FZS^E0<  /DZ   9              " @5E< @!X;"]W
M;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ F(5<5I]0!OLF#@
M1+,  !D              ("!)60" 'AL+W=O<FMS:&5E=',O<VAE970W-"YX
M;6Q02P$"% ,4    " "8A5Q6B;N7F%D:  !EF0$ &0              @(&"
M<@( >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( )B%7%;$
M4*R!M (  &@)   9              " @1*- @!X;"]W;W)K<VAE971S+W-H
M965T-S8N>&UL4$L! A0#%     @ F(5<5F*U&1^  P  ; T  !D
M     ("!_8\" 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )B%7%9?^U233 ,  !X,   9              "
M@3Z@ @!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ F(5<
M5O?=U*?I P  I0P  !D              ("!P:," 'AL+W=O<FMS:&5E=',O
M<VAE970X,RYX;6Q02P$"% ,4    " "8A5Q6OFN9?!4$   3#P  &0
M        @('AIP( >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0
M   ( )B%7%:7-I!V0@4  /<C   9              " @2VL @!X;"]W;W)K
M<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ F(5<5NQGOTYB P  U0T
M !D              ("!IK$" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q0
M2P$"% ,4    " "8A5Q6A^L\3W8#  "5&   #0              @ $_M0(
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( )B%7%:7BKL<P    !,"   +
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4!08     7@!> ,D9  !3Q0(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>449</ContextCount>
  <ElementCount>594</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>142</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100070 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100080 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100090 - Statement - CONSOLIDATED STATEMENTS OF INCOME (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100100 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100110 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100120 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100130 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100140 - Disclosure - NET INCOME PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShare</Role>
      <ShortName>NET INCOME PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100150 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognition1</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100160 - Disclosure - LICENSE AND COLLABORATION ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangements</Role>
      <ShortName>LICENSE AND COLLABORATION ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100170 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions1</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100180 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100190 - Disclosure - CAPITALIZED FEES PAID</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaid1</Role>
      <ShortName>CAPITALIZED FEES PAID</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100200 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100210 - Disclosure - BALANCE SHEET COMPONENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>BALANCE SHEET COMPONENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100220 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100230 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100240 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureDebt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100250 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100260 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100270 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100280 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100290 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100300 - Disclosure - NET INCOME PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareTables</Role>
      <ShortName>NET INCOME PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100310 - Disclosure - REVENUE RECOGNITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionTables</Role>
      <ShortName>REVENUE RECOGNITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognition1</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100320 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions1</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100330 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100340 - Disclosure - CAPITALIZED FEES PAID (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidTables</Role>
      <ShortName>CAPITALIZED FEES PAID (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaid1</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100350 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100360 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>BALANCE SHEET COMPONENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100370 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100380 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureDebt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100390 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100400 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100410 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails</Role>
      <ShortName>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100420 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100430 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails</Role>
      <ShortName>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100440 - Disclosure - NET INCOME PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails</Role>
      <ShortName>NET INCOME PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100450 - Disclosure - NET INCOME PER SHARE - Basic and Diluted EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails</Role>
      <ShortName>NET INCOME PER SHARE - Basic and Diluted EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100460 - Disclosure - NET INCOME PER SHARE - Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails</Role>
      <ShortName>NET INCOME PER SHARE - Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100470 - Disclosure - REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails</Role>
      <ShortName>REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100480 - Disclosure - REVENUE RECOGNITION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails</Role>
      <ShortName>REVENUE RECOGNITION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100490 - Disclosure - LICENSE AND COLLABORATION ARRANGEMENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails</Role>
      <ShortName>LICENSE AND COLLABORATION ARRANGEMENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100500 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100510 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund LP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund LP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100520 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100530 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100540 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla Pharmaceutical Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla Pharmaceutical Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100550 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails</Role>
      <ShortName>CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100560 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Armata (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Armata (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100570 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Summarized Financial Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Summarized Financial Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100580 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in InCarda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in InCarda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100590 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in ImaginAb (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in ImaginAb (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100600 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Convertible Promissory Note in Gate Neurosciences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Convertible Promissory Note in Gate Neurosciences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100610 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Nanolive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Nanolive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100620 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100630 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet</Role>
      <ShortName>EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100640 - Disclosure - CAPITALIZED FEES PAID - Schedule of Capitalized Fees Paid (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails</Role>
      <ShortName>CAPITALIZED FEES PAID - Schedule of Capitalized Fees Paid (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100650 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100660 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100670 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Inventory, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100680 - Disclosure - BALANCE SHEET COMPONENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100690 - Disclosure - BALANCE SHEET COMPONENTS - Schedule Of Other Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule Of Other Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100700 - Disclosure - BALANCE SHEET COMPONENTS -Schedule of Other Long-term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS -Schedule of Other Long-term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100710 - Disclosure - STOCK-BASED COMPENSATION - 2012 Plan and ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - 2012 Plan and ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100720 - Disclosure - STOCK-BASED COMPENSATION - Director Compensation Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Director Compensation Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100730 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100740 - Disclosure - STOCK-BASED COMPENSATION - Compensation Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Compensation Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100750 - Disclosure - STOCK-BASED COMPENSATION - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100760 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100770 - Disclosure - DEBT - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails</Role>
      <ShortName>DEBT - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100780 - Disclosure - DEBT - Convertible Subordinated Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails</Role>
      <ShortName>DEBT - Convertible Subordinated Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100790 - Disclosure - DEBT - Convertible Senior Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails</Role>
      <ShortName>DEBT - Convertible Senior Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>100800 - Disclosure - DEBT - Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails</Role>
      <ShortName>DEBT - Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>100810 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>100820 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Components of Least Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Components of Least Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>100830 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Cash Flow Information Related to Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Cash Flow Information Related to Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>100840 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Operating Lease Information Presented in Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Operating Lease Information Presented in Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>100850 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>100860 - Disclosure - INCOME TAXES - Income tax expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails</Role>
      <ShortName>INCOME TAXES - Income tax expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>100870 - Disclosure - INCOME TAXES - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>100880 - Disclosure - INCOME TAXES - Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails</Role>
      <ShortName>INCOME TAXES - Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>100890 - Disclosure - INCOME TAXES - Additional Tax Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails</Role>
      <ShortName>INCOME TAXES - Additional Tax Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="inva-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>100900 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>SUBSEQUENT EVENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive, us-gaap:LesseeOperatingLeaseTermOfContract -  inva-20221231.htm 8</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 3 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:AccountingStandardsUpdateExtensibleList -  inva-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="inva-20221231.htm">inva-20221231.htm</File>
    <File>inva-20221231.xsd</File>
    <File>inva-20221231_cal.xml</File>
    <File>inva-20221231_def.xml</File>
    <File>inva-20221231_lab.xml</File>
    <File>inva-20221231_pre.xml</File>
    <File>inva-ex21_1.htm</File>
    <File>inva-ex23_1.htm</File>
    <File>inva-ex23_2.htm</File>
    <File>inva-ex31_1.htm</File>
    <File>inva-ex31_2.htm</File>
    <File>inva-ex32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img11029722_0.jpg</File>
    <File>img11029722_1.jpg</File>
    <File>img11029722_10.jpg</File>
    <File>img11029722_11.jpg</File>
    <File>img11029722_12.jpg</File>
    <File>img11029722_13.jpg</File>
    <File>img11029722_14.jpg</File>
    <File>img11029722_2.jpg</File>
    <File>img11029722_3.jpg</File>
    <File>img11029722_4.jpg</File>
    <File>img11029722_5.jpg</File>
    <File>img11029722_6.jpg</File>
    <File>img11029722_7.jpg</File>
    <File>img11029722_8.jpg</File>
    <File>img11029722_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1248">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>121
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "inva-20221231.htm": {
   "axisCustom": 1,
   "axisStandard": 39,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1248,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 449,
   "dts": {
    "calculationLink": {
     "local": [
      "inva-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "inva-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "inva-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "inva-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "inva-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "inva-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 970,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 14,
    "http://www.inva.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 20
   },
   "keyCustom": 155,
   "keyStandard": 439,
   "memberCustom": 82,
   "memberStandard": 52,
   "nsprefix": "inva",
   "nsuri": "http://www.inva.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - NET INCOME PER SHARE",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShare",
     "shortName": "NET INCOME PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - REVENUE RECOGNITION",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognition1",
     "shortName": "REVENUE RECOGNITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inva:LicenseAndCollaborationArrangementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - LICENSE AND COLLABORATION ARRANGEMENTS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangements",
     "shortName": "LICENSE AND COLLABORATION ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inva:LicenseAndCollaborationArrangementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions1",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inva:CapitalizedFeesPaidDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - CAPITALIZED FEES PAID",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaid1",
     "shortName": "CAPITALIZED FEES PAID",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inva:CapitalizedFeesPaidDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - GOODWILL AND INTANGIBLE ASSETS",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - BALANCE SHEET COMPONENTS",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponents",
     "shortName": "BALANCE SHEET COMPONENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - STOCK-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - STOCKHOLDERS' EQUITY",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - DEBT",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureDebt",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "24",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - NET INCOME PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareTables",
     "shortName": "NET INCOME PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - REVENUE RECOGNITION (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionTables",
     "shortName": "REVENUE RECOGNITION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "inva:CapitalizedFeesPaidDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - CAPITALIZED FEES PAID (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidTables",
     "shortName": "CAPITALIZED FEES PAID (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "inva:CapitalizedFeesPaidDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inva:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inva:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - BALANCE SHEET COMPONENTS (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables",
     "shortName": "BALANCE SHEET COMPONENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - DEBT (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inva:NumberOfCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Customer",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Operations (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
     "shortName": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Description of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inva:NumberOfCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Customer",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_5c8ba09c-4a2f-49c9-b6ed-a569b29e1d50",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "shortName": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_5c8ba09c-4a2f-49c9-b6ed-a569b29e1d50",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "inva:RelatedPartyTransactionsPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_2137129a-9873-421f-b2c8-dd60cf04b4e3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails",
     "shortName": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "inva:RelatedPartyTransactionsPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_2137129a-9873-421f-b2c8-dd60cf04b4e3",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_6e288046-0f09-4c78-b427-4c133f35ca3f",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inva:IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - NET INCOME PER SHARE (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails",
     "shortName": "NET INCOME PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_6e288046-0f09-4c78-b427-4c133f35ca3f",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inva:IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - NET INCOME PER SHARE - Basic and Diluted EPS (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
     "shortName": "NET INCOME PER SHARE - Basic and Diluted EPS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - NET INCOME PER SHARE - Anti-Dilutive Securities (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails",
     "shortName": "NET INCOME PER SHARE - Anti-Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
     "shortName": "REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_dcd3daed-e03d-43b3-995a-2376fd31c571",
      "decimals": "-3",
      "lang": null,
      "name": "inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - REVENUE RECOGNITION (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
     "shortName": "REVENUE RECOGNITION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_dd16336a-4a72-4552-8d5c-b8332029c781",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "inva:LicenseAndCollaborationArrangementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_c5fa27cc-5d17-4a15-b456-34db9e1c8687",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - LICENSE AND COLLABORATION ARRANGEMENTS - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails",
     "shortName": "LICENSE AND COLLABORATION ARRANGEMENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "inva:LicenseAndCollaborationArrangementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_c5fa27cc-5d17-4a15-b456-34db9e1c8687",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS - Theravance Respiratory Company, LLC (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_78ff815a-1619-48b9-baf1-0f3abaf5cd69",
      "decimals": "2",
      "lang": null,
      "name": "inva:OwnershipInterestInConsolidatedEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund LP (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund LP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_93e0e07a-b332-46ca-be2f-706ee21b9d8b",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LimitedPartnersCumulativeCashDistributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_64c565f8-b8c8-4b5e-8680-bd30e909b71f",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "div",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_8af701ba-469b-4d82-804b-8716aa0537d9",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_a01857da-29eb-401d-8a40-ba6e666521ec",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100090 - Statement - CONSOLIDATED STATEMENTS OF INCOME (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInInventories",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla Pharmaceutical Company (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla Pharmaceutical Company (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_97660a37-a4d7-4e93-aa09-8f8b998393d8",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "div",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_15fd9d26-7d1b-4c32-bc1c-d97f9e0dd0c8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma Information (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
     "shortName": "CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "div",
       "inva:ConsolidatedEntitiesAndAcquisitionsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_15fd9d26-7d1b-4c32-bc1c-d97f9e0dd0c8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_b9cae3f5-7d7b-44a5-96e4-e89f716538d3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inva:SecuritiesPurchaseAgreementNumberOfTranches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Tranche",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Armata (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Armata (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_b9cae3f5-7d7b-44a5-96e4-e89f716538d3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inva:SecuritiesPurchaseAgreementNumberOfTranches",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Tranche",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Summarized Financial Data (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Summarized Financial Data (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_8b1298b5-e265-402c-a375-7a6c3874e7ba",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_96b9f402-f543-4b27-a705-44de9fb1db9f",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Director",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in InCarda (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in InCarda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_96b9f402-f543-4b27-a705-44de9fb1db9f",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Director",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_547286c7-fffc-4b6d-aa24-854799abba90",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in ImaginAb (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in ImaginAb (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_547286c7-fffc-4b6d-aa24-854799abba90",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_dda65400-d844-4684-b486-4ce48278b7bc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inva:NumberOfCommonStockIssuedDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Convertible Promissory Note in Gate Neurosciences (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Convertible Promissory Note in Gate Neurosciences (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_dda65400-d844-4684-b486-4ce48278b7bc",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "inva:NumberOfCommonStockIssuedDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_ef336b9b-40a1-496c-9596-1c6f52048c42",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Nanolive (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Equity Investment in Nanolive (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_ef336b9b-40a1-496c-9596-1c6f52048c42",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Available-for-Sale Securities (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Available-for-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "inva:ContingentValueRightsLiability",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
     "shortName": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_3b80a067-6f7f-440f-919a-9b96d0afd716",
      "decimals": null,
      "lang": "en-US",
      "name": "inva:PartnershipAgreementLockUpPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100100 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CapitalizedContractCostTableTextBlock",
       "div",
       "inva:CapitalizedFeesPaidDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalizedContractCostGross",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - CAPITALIZED FEES PAID - Schedule of Capitalized Fees Paid (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
     "shortName": "CAPITALIZED FEES PAID - Schedule of Capitalized Fees Paid (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CapitalizedContractCostTableTextBlock",
       "div",
       "inva:CapitalizedFeesPaidDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CapitalizedContractCostAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_392be0e2-bd01-417a-94b2-2ef2c1b381d8",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "inva:IntangibleAssetsMarketedProductsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "inva:IntangibleAssetsMarketedProductsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory, net (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Inventory, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - BALANCE SHEET COMPONENTS - Additional Information (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
     "shortName": "BALANCE SHEET COMPONENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_a2b80c7a-b827-400e-b441-ce92d2d12b34",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InventoryGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "inva:AccruedContractManufacturingLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - BALANCE SHEET COMPONENTS - Schedule Of Other Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule Of Other Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "inva:AccruedContractManufacturingLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "inva:DeferredRoyaltyObligationNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - BALANCE SHEET COMPONENTS -Schedule of Other Long-term Liabilities (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails",
     "shortName": "BALANCE SHEET COMPONENTS -Schedule of Other Long-term Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "inva:DeferredRoyaltyObligationNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_873e7b0b-00b1-48d4-b5e4-b4a6e7d0eff2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - STOCK-BASED COMPENSATION - 2012 Plan and ESPP (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails",
     "shortName": "STOCK-BASED COMPENSATION - 2012 Plan and ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_873e7b0b-00b1-48d4-b5e4-b4a6e7d0eff2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_37ba5274-8715-4011-ab28-b8eda0d172d2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - STOCK-BASED COMPENSATION - Director Compensation Program (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails",
     "shortName": "STOCK-BASED COMPENSATION - Director Compensation Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_37ba5274-8715-4011-ab28-b8eda0d172d2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_5afc9e88-7462-4e21-81dd-9bb66b6d8fd1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100110 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_5afc9e88-7462-4e21-81dd-9bb66b6d8fd1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_e262e47d-f2f5-4208-90c1-3bcda7144a65",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - STOCK-BASED COMPENSATION - Compensation Awards (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Compensation Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_e452d3c0-ba12-4464-8a7d-d44d57ce15ee",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_5440a9c2-207c-4fb3-b81e-e1b717693af2",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - STOCK-BASED COMPENSATION - Valuation Assumptions (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_5440a9c2-207c-4fb3-b81e-e1b717693af2",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_f7e84609-a139-4ee7-8f30-bd52dd4de851",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_f7e84609-a139-4ee7-8f30-bd52dd4de851",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100770 - Disclosure - DEBT - Schedule of Debt (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
     "shortName": "DEBT - Schedule of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfUnsecuredDebt",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100780 - Disclosure - DEBT - Convertible Subordinated Notes (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
     "shortName": "DEBT - Convertible Subordinated Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_4fdff83b-7c27-43e0-9faa-0d7971a875c1",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromDebtNetOfIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfUnsecuredDebt",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100790 - Disclosure - DEBT - Convertible Senior Notes (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
     "shortName": "DEBT - Convertible Senior Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_98afe62c-821a-4537-b552-da050d3c5568",
      "decimals": "2",
      "lang": null,
      "name": "inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100800 - Disclosure - DEBT - Debt Maturities (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails",
     "shortName": "DEBT - Debt Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100810 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100820 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Components of Least Cost (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Components of Least Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100830 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Cash Flow Information Related to Lease (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Supplemental Cash Flow Information Related to Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100120 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100840 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Operating Lease Information Presented in Balance Sheet (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Operating Lease Information Presented in Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100850 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100860 - Disclosure - INCOME TAXES - Income tax expense (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
     "shortName": "INCOME TAXES - Income tax expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100870 - Disclosure - INCOME TAXES - Reconciliation (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails",
     "shortName": "INCOME TAXES - Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100880 - Disclosure - INCOME TAXES - Deferred Taxes (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails",
     "shortName": "INCOME TAXES - Deferred Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100890 - Disclosure - INCOME TAXES - Additional Tax Disclosures (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails",
     "shortName": "INCOME TAXES - Additional Tax Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_335d8004-849d-4d3c-98bc-66869944d3b5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_89b41b07-63fa-44a6-be15-5461c1916d4a",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100900 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "SUBSEQUENT EVENTS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_89b41b07-63fa-44a6-be15-5461c1916d4a",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies",
     "shortName": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "inva-20221231.htm",
      "contextRef": "C_cd064fce-df3e-4265-92e6-caa1f8eccd27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 142,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r885",
      "r886",
      "r887"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r885",
      "r886",
      "r887"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r885",
      "r886",
      "r887"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r885",
      "r886",
      "r887"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r888"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r883"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r890"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r885",
      "r886",
      "r887"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r884"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "inva_AccruedClinicalLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Liability",
        "label": "Accrued Clinical Liability",
        "terseLabel": "Accrued clinical expenses"
       }
      }
     },
     "localname": "AccruedClinicalLiability",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_AccruedContractManufacturingLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued contract manufacturing liability.",
        "label": "Accrued Contract Manufacturing Liability",
        "terseLabel": "Accrued contract manufacturing expenses"
       }
      }
     },
     "localname": "AccruedContractManufacturingLiability",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_AccruedLicenseFeesAndRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued license fees and royalties",
        "label": "Accrued License Fees and Royalties",
        "terseLabel": "Accrued license fees and royalties"
       }
      }
     },
     "localname": "AccruedLicenseFeesAndRoyalties",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_AccruedProfessionalServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Professional Services",
        "label": "Accrued Professional Services",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalServices",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_AccruedResearchLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research Liability",
        "label": "Accrued Research Liability",
        "terseLabel": "Accrued research expenses"
       }
      }
     },
     "localname": "AccruedResearchLiability",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital share based compensation requisite service period recognition shares.",
        "label": "Adjustments To Additional Paid In Capital Share based Compensation Requisite Service Period Recognition Shares",
        "terseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of capitalized fees and depreciation of property and equipment.",
        "label": "Amortization of Capitalized Fees and Depreciation of Property and Equipment",
        "terseLabel": "Amortization of capitalized fees and depreciation of property and equipment"
       }
      }
     },
     "localname": "AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of fair value adjustments of cost of products sold.",
        "label": "Amortization of Fair Value Adjustments of Cost of Products Sold",
        "terseLabel": "Amortization of fair value adjustments of Cost of products sold"
       }
      }
     },
     "localname": "AmortizationOfFairValueAdjustmentsOfCostOfProductsSold",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_ArmataPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections.",
        "label": "Armata Pharmaceuticals Inc [Member]",
        "terseLabel": "Armata"
       }
      }
     },
     "localname": "ArmataPharmaceuticalsIncMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_BalanceSheetDisclosuresOfVariableInterestEntityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Balance Sheet Disclosures of Variable Interest Entity [Abstract]",
        "terseLabel": "Balance sheets"
       }
      }
     },
     "localname": "BalanceSheetDisclosuresOfVariableInterestEntityAbstract",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_BurlingameCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Burlingame, California.",
        "label": "Burlingame California [Member]",
        "terseLabel": "Burlingame, California"
       }
      }
     },
     "localname": "BurlingameCaliforniaMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_BusinessAcquisitionsOfChangeInFairValueOfInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisitions of change in fair value of investment.",
        "label": "Business Acquisitions of Change in Fair Value of Investment"
       }
      }
     },
     "localname": "BusinessAcquisitionsOfChangeInFairValueOfInvestment",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued personnel-related expenses due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Personnel- Related Expenses",
        "terseLabel": "Accrued personnel-related expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedPersonnelRelatedExpenses",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed operating lease right-of-use assets.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Operating Lease Right-of-Use Assets",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed other accrued liabilities",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Accrued Liabilities",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAccruedLiabilities",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_CapitalizedFeePaidEstimatedUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized fee paid estimated useful life.",
        "label": "Capitalized Fee Paid Estimated Useful Life",
        "terseLabel": "Capitalized fees paid, estimated useful life"
       }
      }
     },
     "localname": "CapitalizedFeePaidEstimatedUsefulLife",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inva_CapitalizedFeesPaidDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about capitalized fees paid.",
        "label": "Capitalized Fees Paid Disclosure [Text Block]",
        "terseLabel": "CAPITALIZED FEES PAID"
       }
      }
     },
     "localname": "CapitalizedFeesPaidDisclosureTextBlock",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaid1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inva_CapitalizedFeesPaidFutureAmortizationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized fees paid future amortization.",
        "label": "Capitalized Fees Paid Future Amortization [Abstract]",
        "terseLabel": "Capitalized Fees paid, Future amortization"
       }
      }
     },
     "localname": "CapitalizedFeesPaidFutureAmortizationAbstract",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_CapitalizedFeesPaidPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized fees paid.",
        "label": "Capitalized Fees Paid [Policy Text Block]",
        "terseLabel": "Capitalized Fees Paid"
       }
      }
     },
     "localname": "CapitalizedFeesPaidPolicyTextBlock",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated amortization for assets expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization After Year Five",
        "terseLabel": "Estimated amortization after 2027"
       }
      }
     },
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationAfterYearFive",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization Next Twelve Months",
        "terseLabel": "Estimated amortization for the year 2023"
       }
      }
     },
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization Year Five",
        "terseLabel": "Estimated amortization for the year 2027"
       }
      }
     },
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization Year Four",
        "terseLabel": "Estimated amortization for the year 2026"
       }
      }
     },
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization Year Two",
        "terseLabel": "Estimated amortization for the year 2024"
       }
      }
     },
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization YearThree",
        "terseLabel": "Estimated amortization for the year 2025"
       }
      }
     },
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for capitalized fees paid to a related party.",
        "label": "Capitalized Fees Paid To A Related Party [Policy Text Block]",
        "terseLabel": "Capitalized Fees Paid"
       }
      }
     },
     "localname": "CapitalizedFeesPaidToRelatedPartyPolicyTextBlock",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inva_CapitalizedFeesPaidWeightedAverageUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized fees paid weighted average useful life.",
        "label": "Capitalized Fees Paid Weighted Average Useful Life",
        "terseLabel": "Weighted average remaining amortization period"
       }
      }
     },
     "localname": "CapitalizedFeesPaidWeightedAverageUsefulLife",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inva_CappedCallStrikePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capped call strike price.",
        "label": "Capped Call Strike Price",
        "terseLabel": "Capped call strike price"
       }
      }
     },
     "localname": "CappedCallStrikePrice",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "inva_CashDistributionReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash distribution received.",
        "label": "Cash Distribution Received",
        "terseLabel": "Cash distribution"
       }
      }
     },
     "localname": "CashDistributionReceived",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_CashDividendForfeited": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash dividend forfeited.",
        "label": "Cash Dividend Forfeited",
        "terseLabel": "Cash dividend forfeited"
       }
      }
     },
     "localname": "CashDividendForfeited",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for the acquisition of La Jolla Pharmaceutical Company, net of cash acquired.",
        "label": "Cash Paid for the Acquisition of La Jolla Pharmaceutical Company, Net of Cash Acquired",
        "negatedLabel": "Cash paid for the acquisition of La Jolla, net of cash acquired"
       }
      }
     },
     "localname": "CashPaidForTheAcquisitionOfLaJollaPharmaceuticalCompanyNetOfCashAcquired",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes to noncontrolling interest from a consolidated variable interest entity.",
        "label": "Changes to noncontrolling interest from a consolidated variable interest entity",
        "terseLabel": "Equity activity of noncontrolling interest in a consolidated variable interest entity"
       }
      }
     },
     "localname": "ChangesToNoncontrollingInterestFromAConsolidatedVariableInterestEntity",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_ClaimExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Claim expiration date.",
        "label": "Claim Expiration Date"
       }
      }
     },
     "localname": "ClaimExpirationDate",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical development and regulatory milestones amount payable.",
        "label": "Clinical Development And Regulatory Milestones Amount Payable",
        "terseLabel": "Clinical development and regulatory milestones amount payable"
       }
      }
     },
     "localname": "ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty rate for combination products.",
        "label": "Collaborative Arrangement Annual Royalties as Percentage of Net Sales for Combination Products",
        "terseLabel": "Royalty rate for combination products (as a percent)"
       }
      }
     },
     "localname": "CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.",
        "label": "Collaborative Arrangement, Royalty Rate Defined, Level One",
        "terseLabel": "Royalty rate for first level of annual global net sales (as a percent)"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltyRateDefinedLevelOne",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.",
        "label": "Collaborative Arrangement, Royalty Rate Defined, Level Two",
        "terseLabel": "Royalty rate for sales above first level of annual global net sales (as a percent)"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltyRateDefinedLevelTwo",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.",
        "label": "Collaborative Arrangement, Specified Sales Level for Determining Royalty Rate",
        "terseLabel": "Annual global sales level used to determine royalty rate"
       }
      }
     },
     "localname": "CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_CollaborativeArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to collaborative arrangements.",
        "label": "Collaborative Arrangements [Member]",
        "terseLabel": "Revenue from collaborative arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementsMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_CommercialSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial supply agreement.",
        "label": "Commercial Supply Agreement [Member]",
        "terseLabel": "Commercial Supply Agreement"
       }
      }
     },
     "localname": "CommercialSupplyAgreementMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_CommonStockAcquiredAverageCostPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Acquired Average Cost Per Share",
        "label": "Common Stock Acquired Average Cost Per Share",
        "terseLabel": "Shares repurchased average price per share"
       }
      }
     },
     "localname": "CommonStockAcquiredAverageCostPerShare",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "inva_CommonStockAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common stock and warrants.",
        "label": "Common Stock And Warrants [Member]",
        "terseLabel": "Common stock and warrants"
       }
      }
     },
     "localname": "CommonStockAndWarrantsMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated entities and acquisitions disclosure abstract.",
        "label": "Consolidated Entities and Acquisitions Disclosure Abstract"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract",
     "nsuri": "http://www.inva.com/20221231",
     "xbrltype": "stringItemType"
    },
    "inva_ConsolidatedEntitiesAndAcquisitionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated entities and acquisitions.",
        "label": "Consolidated Entities and Acquisitions [Line Items]",
        "terseLabel": "Consolidated Entities and Acquisitions [Line Items]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAndAcquisitionsLineItems",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_ConsolidatedEntitiesAndAcquisitionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated entities and acquisitions text block.",
        "label": "Consolidated Entities and Acquisitions [Text Block]",
        "terseLabel": "CONSOLIDATED ENTITIES AND ACQUISITIONS"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAndAcquisitionsTextBlock",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inva_ConsolidatedEntitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDisclosureAbstract",
     "nsuri": "http://www.inva.com/20221231",
     "xbrltype": "stringItemType"
    },
    "inva_ConsolidatedInvesteesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated investees.",
        "label": "Consolidated Investees [Member]",
        "terseLabel": "Consolidated Investees"
       }
      }
     },
     "localname": "ConsolidatedInvesteesMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_ContingentSalesBasedMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent sales based milestone payment.",
        "label": "Contingent Sales Based Milestone Payment",
        "terseLabel": "Contingent sales based milestone payment"
       }
      }
     },
     "localname": "ContingentSalesBasedMilestonePayment",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_ContingentValueRightsLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet1": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights liability",
        "label": "Contingent value rights liability",
        "terseLabel": "Contingent value rights liability"
       }
      }
     },
     "localname": "ContingentValueRightsLiability",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_ConversionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion rate",
        "label": "Conversion rate"
       }
      }
     },
     "localname": "ConversionRate",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_ConvertibleDebtInstrumentLiabilityComponentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Convertible Debt Instrument, Liability Component [Abstract]",
        "terseLabel": "Liability component"
       }
      }
     },
     "localname": "ConvertibleDebtInstrumentLiabilityComponentAbstract",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_ConvertibleNoteAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible note and warrants.",
        "label": "Convertible Note and Warrants [Member]",
        "terseLabel": "In Carda Convertible Note",
        "verboseLabel": "Convertible note and warrants"
       }
      }
     },
     "localname": "ConvertibleNoteAndWarrantsMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_ConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible promissory note member.",
        "label": "Convertible Promissory Note [Member]",
        "terseLabel": "Convertable promissory note"
       }
      }
     },
     "localname": "ConvertiblePromissoryNoteMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_ConvertiblePromissoryNotePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible promissory note purchase agreement [Member]",
        "label": "Convertible Promissory Note Purchase Agreement [Member]",
        "terseLabel": "Convertible Promissory Note Purchase Agreement"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotePurchaseAgreementMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_ConvertibleSeniorDebtFairValueDisclosures": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentFairValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of long-term notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Senior debt has the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.",
        "label": "Convertible Senior Debt, Fair Value Disclosures",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorDebtFairValueDisclosures",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_ConvertibleSubordinatedDebtFairValueDisclosures": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet": {
       "order": 0.0,
       "parentTag": "us-gaap_DebtInstrumentFairValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of subordinated debt obligations which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Subordinated Debt, Fair Value Disclosures",
        "terseLabel": "2023 Notes"
       }
      }
     },
     "localname": "ConvertibleSubordinatedDebtFairValueDisclosures",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer one.",
        "label": "Customer One [Member]",
        "terseLabel": "Customer One"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer three.",
        "label": "Customer Three [Member]",
        "terseLabel": "Customer Three"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer two.",
        "label": "Customer Two [Member]",
        "terseLabel": "Customer Two"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of common stock price as a percentage of conversion price.",
        "label": "Debt Conversion, Common Stock Price to Conversion Price Ratio, Percentage",
        "terseLabel": "Common stock price to current conversion price ratio"
       }
      }
     },
     "localname": "DebtConversionCommonStockPriceToConversionPriceRatioPercentage",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_DebtConversionConvertedInstrumentAdjustedSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The adjusted number of shares per $1,000 principal amount issued in exchange for the original debt being converted.",
        "label": "Debt Conversion, Converted Instrument, Adjusted Shares Issued",
        "terseLabel": "Adjusted conversion, shares per $1,000 principal amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAdjustedSharesIssued",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_DebtConversionConvertedInstrumentAverageTradePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average trading price per $1,000 of Notes with respect to product of the closing common stock price and the conversion rate",
        "label": "Debt Conversion, Converted Instrument, Average Trade Price Percentage",
        "terseLabel": "Average trading price percentage"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAverageTradePricePercentage",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_DebtConversionConvertedInstrumentSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The initial number of shares per $1,000 principal amount issued in exchange for the original debt being converted.",
        "label": "Debt Conversion Converted Instrument Shares Issued",
        "terseLabel": "Initial conversion, shares per $1,000 principal amount | shares"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_DebtInstrumentConvertibleConversionPremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage above the last reported sale price of the Company's common stock.",
        "label": "Debt Instrument, Convertible, Conversion Premium",
        "terseLabel": "Conversion premium (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPremium",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_DebtInstrumentPrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Principal Amount",
        "label": "Debt Instrument Principal Amount",
        "terseLabel": "Total debt",
        "verboseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentPrincipalAmount",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Ratio of repurchase price to the principal amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Ratio of repurchase price to the principal amount",
        "terseLabel": "Ratio of repurchase price to the principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_DebtInstrumentRepurchasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of debt Instrument, repurchased.",
        "label": "Debt Instrument, Repurchase Percentage",
        "terseLabel": "Percentage of notes repurchased"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePercentage",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_DebtInstrumentTransactionCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument transaction cost",
        "label": "Debt Instrument Transaction Cost",
        "terseLabel": "Transaction cost"
       }
      }
     },
     "localname": "DebtInstrumentTransactionCost",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_DecreaseToAccumulatedDeficit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease to accumulated deficit.",
        "label": "Decrease to Accumulated Deficit",
        "terseLabel": "Decrease to accumulated deficit"
       }
      }
     },
     "localname": "DecreaseToAccumulatedDeficit",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_DeferredRoyaltyObligationAndAccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred royalty obligation and accrued interest.",
        "label": "Deferred Royalty Obligation and Accrued Interest",
        "terseLabel": "Deferred royalty obligation and accrued interest"
       }
      }
     },
     "localname": "DeferredRoyaltyObligationAndAccruedInterest",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_DeferredRoyaltyObligationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of deferred royalty obligation.",
        "label": "Deferred Royalty Obligation, Current",
        "terseLabel": "Current portion of deferred royalty obligation"
       }
      }
     },
     "localname": "DeferredRoyaltyObligationCurrent",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_DeferredRoyaltyObligationNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term portion of deferred royalty obligation.",
        "label": "Deferred Royalty Obligation, Non Current",
        "terseLabel": "Long-term portion of deferred royalty obligation"
       }
      }
     },
     "localname": "DeferredRoyaltyObligationNonCurrent",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_DeferredTaxAssetsDeferredRoyaltyObligationNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets deferred royalty obligation, net",
        "label": "Deferred Tax Assets Deferred Royalty Obligation, Net",
        "terseLabel": "Deferred royalty obligation, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredRoyaltyObligationNet",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets unrealized losses on investment, net",
        "label": "Deferred Tax Assets Unrealized Losses On Investment, Net",
        "terseLabel": "Unrealized loss on investment, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrealizedLossesOnInvestmentNet",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_DeferredTaxLiabilitiesDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities depreciation and amortization",
        "label": "Deferred Tax Liabilities Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities inventory fair value adjustment",
        "label": "Deferred Tax Liabilities Inventory Fair Value Adjustment",
        "terseLabel": "Inventory fair value adjustment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInventoryFairValueAdjustment",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_DemandLettersSentByStockholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of demand letters that were sent to the Company by purported stockholders.",
        "label": "Demand Letters Sent By Stockholders",
        "terseLabel": "Demand letters sent by stockholders"
       }
      }
     },
     "localname": "DemandLettersSentByStockholders",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derecognition of non controlling interests upon acquisition of entasis minority interest.",
        "label": "Derecognition Of Non Controlling Interests Upon Acquisition Of Entasis Minority Interest",
        "terseLabel": "Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest"
       }
      }
     },
     "localname": "DerecognitionOfNonControllingInterestsUponAcquisitionOfEntasisMinorityInterest",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest.",
        "label": "Derecognition Of NonControlling Interests Upon Acquisition Of Entasis Noncontrolling Interest",
        "terseLabel": "Derecognition of noncontrolling interests upon acquisition of Entasis noncontrolling interest"
       }
      }
     },
     "localname": "DerecognitionOfNoncontrollingInterestsUponAcquisitionOfEntasisNoncontrollingInterest",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_DerecognitionOfNoncontrollingInterestsUponSaleOfTrc": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derecognition of noncontrolling interestsupon sale of TRC.",
        "label": "Derecognition of Noncontrolling Interests Upon Sale of TRC",
        "terseLabel": "Derecognition of noncontrolling interests upon sale of TRC"
       }
      }
     },
     "localname": "DerecognitionOfNoncontrollingInterestsUponSaleOfTrc",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_DilutiveEpsOfNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to convertible notes.",
        "label": "Dilutive EPS of Notes",
        "terseLabel": "Dilutive EPS of note"
       }
      }
     },
     "localname": "DilutiveEpsOfNotes",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "inva_DividendYield": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend yield.",
        "label": "Dividend Yield"
       }
      }
     },
     "localname": "DividendYield",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Company's Employee Stock Purchase Plan (the \"ESPP\").",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_EntasisLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entasis Lease [Member]",
        "label": "Entasis Lease [Member]",
        "terseLabel": "Entasis Lease"
       }
      }
     },
     "localname": "EntasisLeaseMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_EntasisTherapeuticsHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Entasis Therapeutics Holdings Inc.",
        "label": "Entasis Therapeutics Holdings Inc [Member]",
        "terseLabel": "Entasis",
        "verboseLabel": "Entasis Therapeutics Holdings Inc"
       }
      }
     },
     "localname": "EntasisTherapeuticsHoldingsIncMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_EquityIncentivePlan2012Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2012 Equity Incentive Plan as approved by shareowners.",
        "label": "Equity Incentive Plan2012 [Member]",
        "terseLabel": "2012 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlan2012Member",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_EquityIncentivePlansAndESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to options, Equity Incentive Plans and Employee Stock Purchase Plans.",
        "label": "Equity Incentive Plans And E S P P [Member]",
        "terseLabel": "Equity incentive plans and ESPP"
       }
      }
     },
     "localname": "EquityIncentivePlansAndESPPMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_EquityInvestmentsAndMoneyMarketFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to equity investments and money market funds.",
        "label": "Equity Investments And Money Market Funds [Member]",
        "terseLabel": "Equity investments and Money market funds"
       }
      }
     },
     "localname": "EquityInvestmentsAndMoneyMarketFundsMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_EverestMedicinesLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Everest Medicines Limited [Member]",
        "label": "Everest Medicines Limited [Member]",
        "terseLabel": "Everest Medicines Limited"
       }
      }
     },
     "localname": "EverestMedicinesLimitedMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_ExpectedHoldingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected holding period of equity method investment.",
        "label": "Expected Holding Period",
        "terseLabel": "Expected holding period"
       }
      }
     },
     "localname": "ExpectedHoldingPeriod",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inva_ExtendedExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended expiration date.",
        "label": "Extended Expiration Date",
        "terseLabel": "Extended expiration date"
       }
      }
     },
     "localname": "ExtendedExpirationDate",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "inva_FactorsAffectingComparabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Factors affecting comparability.",
        "label": "Factors Affecting Comparability Policy [Text Block]",
        "terseLabel": "Factors Affecting Comparability"
       }
      }
     },
     "localname": "FactorsAffectingComparabilityPolicyTextBlock",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inva_FairValueAdjustmentsIncludedInCostOfProductSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value adjustments included in cost of product sales.",
        "label": "Fair Value Adjustments Included In Cost Of Product Sales",
        "terseLabel": "Fair value adjustments included in cost of product sales"
       }
      }
     },
     "localname": "FairValueAdjustmentsIncludedInCostOfProductSales",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_FairValueAdjustmentsOfInventoryFromAcquistion": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of net fair value adjustment of inventory resulting from the acquisition.",
        "label": "Fair Value Adjustments Of Inventory From Acquistion",
        "terseLabel": "Net fair value adjustment of inventory"
       }
      }
     },
     "localname": "FairValueAdjustmentsOfInventoryFromAcquistion",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_FairValueOfNonControllingInterestInSubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of noncontrolling interest in a consolidated variable interest entity.",
        "label": "Fair Value of Non-controlling Interest in Subsidiary",
        "terseLabel": "Fair value of noncontrolling interests in a consolidated variable interest entity"
       }
      }
     },
     "localname": "FairValueOfNonControllingInterestInSubsidiary",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_FederalNetOperatingLossesEstimatedUtilizationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal net operating losses estimated utilization amount.",
        "label": "Federal Net Operating Losses Estimated Utilization Amount",
        "terseLabel": "Federal net operating losses estimated utilization amount"
       }
      }
     },
     "localname": "FederalNetOperatingLossesEstimatedUtilizationAmount",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_FuturePotentialMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future potential milestone payment receivable.",
        "label": "Future Potential Milestone Payment",
        "terseLabel": "Future potential milestone payment receivable"
       }
      }
     },
     "localname": "FuturePotentialMilestonePayment",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_GSKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents GSK, with whom the entity has agreements and arrangements, such as those for developing and commercializing different products.",
        "label": "G S K [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GSKMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_GainLossOnOtherInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain loss on other investments.",
        "label": "Gain (Loss) on Other Investments",
        "negatedLabel": "Changes in fair value of other equity and long-term investments, net",
        "terseLabel": "Changes in fair value of other equity and long-term investments, net"
       }
      }
     },
     "localname": "GainLossOnOtherInvestments",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_GateNeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gate Neuroscience [Member]",
        "label": "Gate Neuroscience [Member]",
        "terseLabel": "Gate Neurosciences Member"
       }
      }
     },
     "localname": "GateNeuroscienceMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_GeorgeWashingtonUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "George Washington University.",
        "label": "George Washington University [Member]",
        "terseLabel": "George Washington University"
       }
      }
     },
     "localname": "GeorgeWashingtonUniversityMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_GiaprezaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GIAPREZA.",
        "label": "GIAPREZA [Member]",
        "terseLabel": "GIAPREZA"
       }
      }
     },
     "localname": "GiaprezaMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer before amortization of capitalized fees.",
        "label": "Gross Revenue from Contract with Customer, Excluding Assessed Tax, Before Amortization Of Capitalized Fees",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_HarvardUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvard University.",
        "label": "Harvard University [Member]",
        "terseLabel": "Harvard University"
       }
      }
     },
     "localname": "HarvardUniversityMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_HealthCareRoyaltyPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health care royalty partners member.",
        "label": "Health Care Royalty Partners [Member]",
        "terseLabel": "HealthCare Royalty Partners"
       }
      }
     },
     "localname": "HealthCareRoyaltyPartnersMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_ImaginabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to ImaginAb.",
        "label": "Imaginab [Member]",
        "terseLabel": "ImaginAb"
       }
      }
     },
     "localname": "ImaginabMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_InCardaConvertibleNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In Carda Convertible note.",
        "label": "In Carda Convertible Note [Member]",
        "terseLabel": "InCarda Convertible Note"
       }
      }
     },
     "localname": "InCardaConvertibleNoteMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_Incarda2020WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "InCarda 2020 Warrants [Member]",
        "label": "InCarda 2020 Warrants [Member]",
        "terseLabel": "Incarda 2020 Warrants [Member]"
       }
      }
     },
     "localname": "Incarda2020WarrantsMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_IncardaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to InCarda.",
        "label": "Incarda [Member]",
        "terseLabel": "InCarda"
       }
      }
     },
     "localname": "IncardaMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_IncomeStatementDisclosuresOfVariableInterestEntityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Income Statement Disclosures of Variable Interest Entity [Abstract]",
        "terseLabel": "Income statements"
       }
      }
     },
     "localname": "IncomeStatementDisclosuresOfVariableInterestEntityAbstract",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_IncomeTaxPayableNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax payable non current.",
        "label": "Income Tax Payable Non Current",
        "terseLabel": "Income tax payable, long-term"
       }
      }
     },
     "localname": "IncomeTaxPayableNonCurrent",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of income taxes.",
        "label": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_IncreaseDecreaseInDeferredTaxLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deferred tax liabilities.",
        "label": "Increase (Decrease) in Deferred Tax Liabilities",
        "terseLabel": "Measurement period adjustments increase decrease in deferred tax liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredTaxLiabilities",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_IncreaseInDeferredTaxAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in deferred tax assets.",
        "label": "Increase in Deferred Tax Assets",
        "terseLabel": "Increase in Deferred Tax Assets"
       }
      }
     },
     "localname": "IncreaseInDeferredTaxAssets",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_IncreaseToConvertibleNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase to convertible notes.",
        "label": "Increase To Convertible Notes",
        "terseLabel": "Increase in convertible notes"
       }
      }
     },
     "localname": "IncreaseToConvertibleNotes",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Conversion Of Debt Securities, Treasury Stock Method",
        "terseLabel": "Dilutive effect of the assumed conversion premium"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecuritiesTreasuryStockMethod",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_InnovivaCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innoviva's Common Stock Member",
        "label": "Innoviva Common Stock Member",
        "terseLabel": "Innoviva's Common Stock"
       }
      }
     },
     "localname": "InnovivaCommonStockMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_InnovivaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innoviva [Member]",
        "label": "Innoviva [Member]",
        "terseLabel": "Innoviva [Member]"
       }
      }
     },
     "localname": "InnovivaMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Innoviva Strategic Opportunities, LLC.",
        "label": "Innoviva Strategic Opportunities Limited Liability Corporation [Member]",
        "terseLabel": "Innoviva Strategic Opportunities, LLC"
       }
      }
     },
     "localname": "InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_IntangibleAssetsCollaborationAgreementGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets collaboration agreement gross.",
        "label": "Intangible Assets Collaboration Agreement Gross",
        "terseLabel": "Collaboration agreement, gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsCollaborationAgreementGross",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_IntangibleAssetsCollaborationAgreementNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets collaboration agreement net.",
        "label": "Intangible Assets Collaboration Agreement Net",
        "terseLabel": "Collaboration agreement, net carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsCollaborationAgreementNet",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_IntangibleAssetsInProcessResearchAndDevelopmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of In-process research and development.",
        "label": "Intangible Assets In-process Research and Development, Gross",
        "terseLabel": "In-process research and development, gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsInProcessResearchAndDevelopmentGross",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_IntangibleAssetsInProcessResearchAndDevelopmentNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount of In-process research and development.",
        "label": "Intangible Assets In-process Research and Development, Net",
        "terseLabel": "In-process research and development, net carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsInProcessResearchAndDevelopmentNet",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_IntangibleAssetsMarketedProductsAccumulatedAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amortization amount of Marketed Products.",
        "label": "Intangible Assets Marketed Products, Accumulated Amortization",
        "terseLabel": "Marketed products, Accumulated amortization"
       }
      }
     },
     "localname": "IntangibleAssetsMarketedProductsAccumulatedAmortization",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_IntangibleAssetsMarketedProductsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of Marketed products.",
        "label": "Intangible Assets Marketed Products, Gross",
        "terseLabel": "Marketed products, gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsMarketedProductsGross",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_IntangibleAssetsMarketedProductsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount of Marketed Products.",
        "label": "Intangible Assets Marketed Products, Net",
        "terseLabel": "Marketed products, net carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsMarketedProductsNet",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_InterestRateOfDeferredRoyaltyObligation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate of deferred royalty obligation.",
        "label": "Interest Rate of Deferred Royalty Obligation",
        "terseLabel": "Percentage of interest rate"
       }
      }
     },
     "localname": "InterestRateOfDeferredRoyaltyObligation",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_IspFundLpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to ISP Fund LP, an investment managed by Sarissa Capital.",
        "label": "Isp Fund Lp [Member]",
        "terseLabel": "ISP Fund LP"
       }
      }
     },
     "localname": "IspFundLpMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_LaJollaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "La Jolla [Member]",
        "label": "La Jolla [Member]",
        "terseLabel": "La Jolla [Member]"
       }
      }
     },
     "localname": "LaJollaMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_LaJollaPharmaceuticalCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "La jolla pharmaceutical company member.",
        "label": "La Jolla Pharmaceutical Company [Member]",
        "terseLabel": "La Jolla Pharmaceutical Company"
       }
      }
     },
     "localname": "LaJollaPharmaceuticalCompanyMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_LabaCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the collaboration with GSK to develop and commercialize once-daily LABA products and combination products RELVAR.",
        "label": "Laba Collaboration [Member]",
        "terseLabel": "Long-Acting Beta2 Agonist (LABA) Collaboration"
       }
      }
     },
     "localname": "LabaCollaborationMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_LaboratoryEquipmentFurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment, furniture and fixtures.",
        "label": "Laboratory Equipment, Furniture And Fixtures [Member]",
        "terseLabel": "Laboratory equipment furniture and fixtures"
       }
      }
     },
     "localname": "LaboratoryEquipmentFurnitureAndFixturesMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_LicenseAndCollaborationArrangementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration arrangements disclosure.",
        "label": "License and Collaboration Arrangements Disclosure [Text Block]",
        "terseLabel": "LICENSE AND COLLABORATION ARRANGEMENTS"
       }
      }
     },
     "localname": "LicenseAndCollaborationArrangementsDisclosureTextBlock",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inva_LongActingBeta2AgonistAnoroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Long-Acting Beta2 Agonist, ANORO, which is being developed and commercialized by entering into a strategic alliance with GSK",
        "label": "Long Acting Beta2 Agonist Anoro [Member]",
        "terseLabel": "ANORO"
       }
      }
     },
     "localname": "LongActingBeta2AgonistAnoroMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_LongActingBeta2AgonistRelvarBreoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Long-Acting Beta2 Agonist, RELVAR/BREO, which is being developed and commercialized by entering into a strategic alliance with GSK",
        "label": "Long Acting Beta2 Agonist Relvar Breo [Member]",
        "terseLabel": "RELVAR/BREO"
       }
      }
     },
     "localname": "LongActingBeta2AgonistRelvarBreoMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in estimated purchase price during measurement period.",
        "label": "Measurement Period Adjustments, Increase Decrease In estimated Purchase Price",
        "terseLabel": "Measurement period adjustments for change in estimated purchase price"
       }
      }
     },
     "localname": "MeasurementPeriodAdjustmentsIncreaseDecreaseInEstimatedPurchasePrice",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement period adjustments increase decrease In liabilities",
        "label": "Measurement Period Adjustments Increase Decrease In liabilities",
        "terseLabel": "Measurement Period Adjustments Increase Decrease In Liabilities"
       }
      }
     },
     "localname": "MeasurementPeriodAdjustmentsIncreaseDecreaseInLiabilities",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minority interest decrease from distributions to noncontrolling interest holders shares.",
        "label": "Minority Interest Decrease From Distributions To Noncontrolling Interest Holders Shares",
        "terseLabel": "Distributions to noncontrolling interest (in shares)"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersShares",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_NameOfEventAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name Of Event [Axis]",
        "label": "Name Of Event [Axis]"
       }
      }
     },
     "localname": "NameOfEventAxis",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_NameOfEventDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name Of Event [Domain]",
        "label": "Name Of Event [Domain]"
       }
      }
     },
     "localname": "NameOfEventDomain",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_NanoliveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nanolive [Member]",
        "label": "Nanolive [Member]",
        "terseLabel": "Nanolive"
       }
      }
     },
     "localname": "NanoliveMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net income loss including portion attributable to noncontrolling interest shares.",
        "label": "Net Income Loss Including Portion Attributable to Noncontrolling Interest Shares",
        "terseLabel": "Net income (in shares)"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestShares",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_NetIncomeLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Net Income (Loss) Per Share [Abstract]",
        "terseLabel": "Net income per share attributable to Innoviva stockholders"
       }
      }
     },
     "localname": "NetIncomeLossPerShareAbstract",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_NetOperatingLossEstimatingDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Estimating Date",
        "label": "Net Operating Loss Estimating Date",
        "terseLabel": "Net operating loss estimating date"
       }
      }
     },
     "localname": "NetOperatingLossEstimatingDate",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "inva_NetProceedsFromIssuanceOfVariableInterestEntityEquity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of variable interest entity's equity.",
        "label": "Net Proceeds From Issuance Of Variable Interest Entity Equity",
        "terseLabel": "Net proceeds from the issuance of variable interest entity's equity"
       }
      }
     },
     "localname": "NetProceedsFromIssuanceOfVariableInterestEntityEquity",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_NetProceedsFromSaleOfVariableInterestEntityEquity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Proceeds from sale of variable interest entity equity.",
        "label": "Net Proceeds from Sale of Variable Interest Entity Equity",
        "terseLabel": "Proceeds from sale of ownership interest in TRC, net"
       }
      }
     },
     "localname": "NetProceedsFromSaleOfVariableInterestEntityEquity",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements not yet adopted.",
        "label": "New Accounting Pronouncements Not Yet Adopted, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards or Updates Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New debt instrument interest rate after repurchase of notes member.",
        "label": "New Debt Instrument Interest Rate After Repurchase Of Notes [Member]",
        "terseLabel": "New Rate [Member]"
       }
      }
     },
     "localname": "NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_NewPrincipalAmountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New principal amount.",
        "label": "New Principal Amount [Member]",
        "terseLabel": "New Principal Amount"
       }
      }
     },
     "localname": "NewPrincipalAmountMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_NonCashActivity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash activity.",
        "label": "Non Cash Activity",
        "terseLabel": "Adoption of ASU 2020-06"
       }
      }
     },
     "localname": "NonCashActivity",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling interest increase decrease from subsidiary equity shares issuance.",
        "label": "Noncontrolling Interest Increase Decrease From Subsidiary Equity Shares Issuance",
        "terseLabel": "Equity activity of noncontrolling interest from a consolidated variable interest entity (in shares)"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseDecreaseFromSubsidiaryEquitySharesIssuance",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_NoteAmendmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note amendment agreement member.",
        "label": "Note Amendment Agreement [Member]",
        "terseLabel": "Note Amendment Agreement"
       }
      }
     },
     "localname": "NoteAmendmentAgreementMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_NumberOfBoardMembersOfInvestee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of Board members of the Investee.",
        "label": "Number of Board Members of the Investee",
        "terseLabel": "Number of the Investee's Board members"
       }
      }
     },
     "localname": "NumberOfBoardMembersOfInvestee",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inva_NumberOfCommonStockIssuedDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock issued description.",
        "label": "Number Of Common Stock Issued Description",
        "terseLabel": "Number of common stock issued description"
       }
      }
     },
     "localname": "NumberOfCommonStockIssuedDescription",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of the Company's Board members currently serving on the Investee's Board.",
        "label": "Number of the Company's Board Members Currently Serving on the Board of Investee",
        "terseLabel": "Number of Investee's Board members currently representing the Company"
       }
      }
     },
     "localname": "NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inva_NumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of customers.",
        "label": "Number Of Customers",
        "terseLabel": "Number of customers"
       }
      }
     },
     "localname": "NumberOfCustomers",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inva_NumberOfDerivativeInstrumentsPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of derivative instruments purchased.",
        "label": "Number of Derivative Instruments Purchased",
        "terseLabel": "Number of derivative instruments purchased"
       }
      }
     },
     "localname": "NumberOfDerivativeInstrumentsPurchased",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares payable to the entity on settlement of derivative instruments.",
        "label": "Number of Shares Receivable on Settlement of Derivative Instrument",
        "terseLabel": "Net shares settlement payable to the entity"
       }
      }
     },
     "localname": "NumberOfSharesReceivableOnSettlementOfDerivativeInstrument",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Old debt instrument interest rate before repurchase of notes member.",
        "label": "Old Debt Instrument Interest Rate Before Repurchase Of Notes [Member]",
        "terseLabel": "Old Rate [Member]"
       }
      }
     },
     "localname": "OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_OneDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Director.",
        "label": "One Director [Member]",
        "terseLabel": "One Director"
       }
      }
     },
     "localname": "OneDirectorMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_OneOfImaginabsCommonStockholderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to one of ImaginAb's common stockholders.",
        "label": "One Of Imaginabs Common Stockholder [Member]",
        "terseLabel": "One of ImaginAb's Common Stockholders"
       }
      }
     },
     "localname": "OneOfImaginabsCommonStockholderMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_OperatingLeaseWeightedAverageIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Weighted Average Incremental Borrowing Rate",
        "label": "Operating Lease Weighted Average Incremental Borrowing Rate",
        "terseLabel": "Operating lease, weighted average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageIncrementalBorrowingRate",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_OperatingLossCarryforwardsIndefinitePeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforwards which can be carry forward indefinitely.",
        "label": "Operating Loss Carryforwards, Indefinite Period",
        "terseLabel": "Net operating loss carryforwards, indefinite period"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsIndefinitePeriod",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_OptionPricingModelBacksolveValuationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Pricing Model Backsolve valuation.",
        "label": "Option Pricing Model Backsolve Valuation [Member]",
        "terseLabel": "Backsolve Valuation"
       }
      }
     },
     "localname": "OptionPricingModelBacksolveValuationMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_OtherAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Accrued Liabilities [Member]",
        "label": "Other Accrued Liabilities [Member]",
        "terseLabel": "Other Accrued Liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other comprehensive income loss net of tax portion attributable to parent shares.",
        "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Shares",
        "terseLabel": "Other comprehensive income (in shares)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentShares",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_OutstandingStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock warrant member",
        "label": "Outstanding Stock Warrant [Member]",
        "terseLabel": "Outstanding Stock Warrant"
       }
      }
     },
     "localname": "OutstandingStockWarrantMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_OwnershipInterestInConsolidatedEntities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest in consolidated entities.",
        "label": "Ownership Interest in Consolidated Entities",
        "terseLabel": "Ownership interest in LLC"
       }
      }
     },
     "localname": "OwnershipInterestInConsolidatedEntities",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_PaionAgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PAION AG [Member]",
        "label": "PAION AG [Member]",
        "terseLabel": "PAION AG"
       }
      }
     },
     "localname": "PaionAgMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_ParatekPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paratek Pharmaceuticals, Inc.",
        "label": "Paratek Pharmaceuticals, Inc [Member]",
        "terseLabel": "Paratek Pharmaceuticals, Inc"
       }
      }
     },
     "localname": "ParatekPharmaceuticalsIncMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_PartnershipAgreementLockUpPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time in which contributors to an investment fund have waived the right of redemption, as defined in the partnership agreement.",
        "label": "Partnership Agreement, Lock-Up Period",
        "terseLabel": "Lock-up period"
       }
      }
     },
     "localname": "PartnershipAgreementLockUpPeriod",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "durationItemType"
    },
    "inva_PaymentOfManagementAndIncentiveFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of management and Incentive fee",
        "label": "Payment of Management and Incentive fee",
        "terseLabel": "Payment for management and annual performance incentive fees"
       }
      }
     },
     "localname": "PaymentOfManagementAndIncentiveFee",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_PaymentsForRoyaltyAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Royalty Agreement",
        "label": "Payments For Royalty Agreement",
        "terseLabel": "Payment for royalty agreement"
       }
      }
     },
     "localname": "PaymentsForRoyaltyAgreement",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_Percent2.50ConvertibleDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2.50% convertible senior notes due 2025.",
        "label": "Percent2.50 Convertible Debt [Member]",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "localname": "Percent2.50ConvertibleDebtMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_PercentageOfEconomicInterestInPartnership": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of economic interest held in Partnership.",
        "label": "Percentage of Economic Interest In Partnership",
        "terseLabel": "Economic interest of the Partnership (in percent)"
       }
      }
     },
     "localname": "PercentageOfEconomicInterestInPartnership",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of economic interest in any future payments made under the agreements.",
        "label": "Percentage of Economic Interest on Future Payments Under Agreements",
        "terseLabel": "Percentage of economic interest in any future payments made under the agreements"
       }
      }
     },
     "localname": "PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_PercentageOfEstimatedVolatility": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of estimated volatility.",
        "label": "Percentage of Estimated Volatility",
        "terseLabel": "Estimated volatility"
       }
      }
     },
     "localname": "PercentageOfEstimatedVolatility",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of maximum royalty based on achievement of annual net product sales thresholds.",
        "label": "Percentage Of Maximum Royalty Based On Achievement Of Annual Net Product Sales Thresholds",
        "terseLabel": "Percentage of maximum royalty based on achievement of annual net product sales thresholds"
       }
      }
     },
     "localname": "PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_PercentageOfMinimumRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of minimum royalty rate.",
        "label": "Percentage Of Minimum Royalty Rate",
        "terseLabel": "Percentage of minimum royalty rate"
       }
      }
     },
     "localname": "PercentageOfMinimumRoyaltyRate",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reimbursed for direct and certain indirect manufacturing costs.",
        "label": "Percentage Of Reimbursed For Direct And Certain Indirect Manufacturing Costs",
        "terseLabel": "Percentage of reimbursed for direct and certain indirect manufacturing costs"
       }
      }
     },
     "localname": "PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty payable as a percentage of payments received from sublicensees.",
        "label": "Percentage Of Royalty On Payments Received From Sublicensees",
        "terseLabel": "Percentage of royalty on payments received from sublicensees"
       }
      }
     },
     "localname": "PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_PercentageOfRoyaltyPayableOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty payable, as a percentage of net sales.",
        "label": "Percentage Of Royalty Payable On Net Sales",
        "terseLabel": "Percentage of royalty payable on net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPayableOnNetSales",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payments the company is not entitled to receive.",
        "label": "Percentage of royalty payments not entitled to receive"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsNotEntitledToReceive",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_PortionOfDebtInstrumentFaceAmountExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of debt instrument face amount, exercised.",
        "label": "Portion of Debt Instrument Face Amount, Exercised",
        "terseLabel": "Portion of debt instrument face amount, Exercised"
       }
      }
     },
     "localname": "PortionOfDebtInstrumentFaceAmountExercised",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_PreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrants.",
        "label": "Preferred Stock Warrants Member",
        "terseLabel": "Preferred Stock Warrants"
       }
      }
     },
     "localname": "PreferredStockWarrantsMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_PresentationReclassificationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Presentation reclassification.",
        "label": "Presentation Reclassification [Policy Text Block]",
        "terseLabel": "Presentation Reclassification"
       }
      }
     },
     "localname": "PresentationReclassificationPolicyTextBlock",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inva_PriorPeriodImmaterialCorrectionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting prior period immaterial correction.",
        "label": "Prior Period Immaterial Correction [Policy Text Block]",
        "terseLabel": "Prior Period Immaterial Correction"
       }
      }
     },
     "localname": "PriorPeriodImmaterialCorrectionPolicyTextBlock",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inva_PrivatePlacementPositionsAndConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement Positions And Convertible Notes.",
        "label": "Private Placement Positions And Convertible Notes [Member]",
        "terseLabel": "Private Placement Positions And Convertible Notes"
       }
      }
     },
     "localname": "PrivatePlacementPositionsAndConvertibleNotesMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_PrivatelyNegotiatedCappedCallOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the capped call option entered in connection with the offering of convertible debt.",
        "label": "Privately Negotiated Capped Call Option [Member]",
        "terseLabel": "Privately-negotiated capped call option"
       }
      }
     },
     "localname": "PrivatelyNegotiatedCappedCallOptionMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of economic interest under Equity Purchase Agreement.",
        "label": "Proceeds from sale of economic interest under Equity Purchase Agreement",
        "terseLabel": "Proceeds from sale of economic interest under Equity Purchase Agreement"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEconomicInterestUnderEquityPurchaseAgreement",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment Useful Life [Table Text Block]",
        "terseLabel": "Schedule of property, equipment and leasehold improvements useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase and sale of other investments managed by ISP FUND LP",
        "label": "Purchase and sale of other investments managed by ISP FUND LP",
        "negatedLabel": "Purchase and sales of other investments managed by ISP Fund LP, net",
        "terseLabel": "Purchase and sales of other investments managed by ISP Fund LP, net"
       }
      }
     },
     "localname": "PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_PurchaseOfEntasisNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of entasis noncontrolling interest.",
        "label": "Purchase Of Entasis noncontrolling Interest",
        "negatedLabel": "Purchase of Entasis noncontrolling interest"
       }
      }
     },
     "localname": "PurchaseOfEntasisNoncontrollingInterest",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases of capped call options associated with convertible senior notes.",
        "label": "Purchases of Capped Call Options Associated with Convertible Senior Notes",
        "negatedLabel": "Purchases of capped call options associated with convertible senior notes due 2028"
       }
      }
     },
     "localname": "PurchasesOfCappedCallOptionsAssociatedWithConvertibleSeniorNotes",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases of capped calls In connection with convertible senior notes.",
        "label": "Purchases Of Capped Calls In Connection With Convertible Senior Notes",
        "terseLabel": "Purchases of capped calls in connection with convertible senior notes due 2028"
       }
      }
     },
     "localname": "PurchasesOfCappedCallsInConnectionWithConvertibleSeniorNotes",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_PurchasesOfEquityInvestmentsManagedByIspFundLp": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases of Equity Investments Managed by Isp Fund Lp",
        "label": "Purchases of Equity Investments Managed by Isp Fund Lp",
        "negatedLabel": "Purchases of equity investments managed by ISP Fund LP"
       }
      }
     },
     "localname": "PurchasesOfEquityInvestmentsManagedByIspFundLp",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_PurchasesOfTradingSecurityManagedByIspFundLp": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases of trading security managed by Isp fund Lp.",
        "label": "Purchases of Trading Security Managed by Isp Fund Lp",
        "negatedLabel": "Purchases of trading security managed by ISP Fund LP"
       }
      }
     },
     "localname": "PurchasesOfTradingSecurityManagedByIspFundLp",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_QualifiedFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qualified Financing [Member]",
        "label": "Qualified Financing [Member]",
        "terseLabel": "Qualified Financing"
       }
      }
     },
     "localname": "QualifiedFinancingMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_RealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Realized loss",
        "label": "Realized Loss",
        "terseLabel": "Realized loss"
       }
      }
     },
     "localname": "RealizedLoss",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognition Of Noncontrolling Interest Upon Initial Consolidation Of Entasis",
        "label": "Recognition of noncontrolling interest upon initial consolidation of Entasis"
       }
      }
     },
     "localname": "RecognitionOfNoncontrollingInterestUponInitialConsolidationOfEntasis",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_ReductionToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction to additional paid in capital",
        "label": "Reduction to Additional Paid in Capital",
        "terseLabel": "Reduction to Additional Paid in Capital"
       }
      }
     },
     "localname": "ReductionToAdditionalPaidInCapital",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_ReductionToResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction to Research and Development Expense",
        "label": "Reduction to Research and Development Expense",
        "terseLabel": "Reduction to research and development expense"
       }
      }
     },
     "localname": "ReductionToResearchAndDevelopmentExpense",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_RegulatoryMilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payments receivable.",
        "label": "Regulatory Milestone Payments Receivable",
        "terseLabel": "Additional regulatory milestone payments receivable"
       }
      }
     },
     "localname": "RegulatoryMilestonePaymentsReceivable",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock in the reporting entity owned by related parties.",
        "label": "Related Party Transaction, Common Stock Ownership Percentage By Related Party",
        "terseLabel": "Percentage of common stock owned by a related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_RelatedPartyTransactionsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the entity's accounting policies for transactions entered with related parties.",
        "label": "Related Party Transactions [Policy Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsPolicyTextBlock",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inva_ResearchAndDevelopmentSupportMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Support [Member]",
        "label": "Research and Development Support [Member]",
        "terseLabel": "Research and Development Support"
       }
      }
     },
     "localname": "ResearchAndDevelopmentSupportMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_RightOfUseAssetsObtainedThroughAcquistions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Use Assets Obtained Through Acquistions",
        "label": "Right of Use Assets Obtained Through Acquistions",
        "terseLabel": "Right-of-use assets obtained through acquisitions"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedThroughAcquistions",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_RiskFreeInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk free interest rate.",
        "label": "Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "RiskFreeInterestRate",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties payable period after first commercial sale of product.",
        "label": "Royalties Payable Period After First Commercial Sale Of Product",
        "terseLabel": "Royalties payable period after first commercial sale of product"
       }
      }
     },
     "localname": "RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty agreement increase in maximum potential payout percent.",
        "label": "Royalty Agreement Increase In Maximum Potential Payout Percent",
        "terseLabel": "Increase in maximum potential payout percent"
       }
      }
     },
     "localname": "RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_RoyaltyAgreementMaximumPotentialPayoutPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty agreement, maximum potential payout, percent.",
        "label": "Royalty Agreement Maximum Potential Payout Percent",
        "terseLabel": "Maximum potential royalty payout"
       }
      }
     },
     "localname": "RoyaltyAgreementMaximumPotentialPayoutPercent",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty agreement required payment for breach of agreement payment one.",
        "label": "Royalty Agreement Required Payment For Breach Of Agreement Payment One",
        "terseLabel": "Required payment for breach of agreement, payment one"
       }
      }
     },
     "localname": "RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty agreement required payment for breach of agreement payment two.",
        "label": "Royalty Agreement Required Payment For Breach Of Agreement Payment Two",
        "terseLabel": "Maximum aggregate royalty payments"
       }
      }
     },
     "localname": "RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_RoyaltyFinancingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty financing agreement member.",
        "label": "Royalty Financing Agreement [Member]",
        "terseLabel": "Royalty Financing Agreement"
       }
      }
     },
     "localname": "RoyaltyFinancingAgreementMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_RoyaltyObligationPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty obligation payable.",
        "label": "Royalty Obligation Payable",
        "terseLabel": "Royalty Obligation Payable"
       }
      }
     },
     "localname": "RoyaltyObligationPayable",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_RoyaltyPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Payments",
        "label": "Royalty Payments",
        "terseLabel": "Royalty Payments"
       }
      }
     },
     "localname": "RoyaltyPayments",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_SaleOfEquityInvestmentsManagedByIspFundLp": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of equity investments managed by ISP FUND LP",
        "label": "Sale of equity investments managed by ISP FUND LP",
        "terseLabel": "Sales of equity investments managed by ISP Fund LP"
       }
      }
     },
     "localname": "SaleOfEquityInvestmentsManagedByIspFundLp",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Warrants, Number of Warrants Issued in Transaction",
        "terseLabel": "Number of warrants purchased under the securities purchase agreement",
        "verboseLabel": "Maximum number of additional shares into which warrants may be converted under the securities purchase agreement"
       }
      }
     },
     "localname": "SaleOfWarrantsNumberOfWarrantsIssuedInTransaction",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_SalesMilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone payments receivable.",
        "label": "Sales Milestone Payments Receivable",
        "terseLabel": "Sales milestone payments receivable"
       }
      }
     },
     "localname": "SalesMilestonePaymentsReceivable",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_SarissaCapitalManagementLpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Sarissa Capital.",
        "label": "Sarissa Capital Management Lp [Member]",
        "terseLabel": "Sarissa Capital"
       }
      }
     },
     "localname": "SarissaCapitalManagementLpMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Balance sheet Information Related To Operating Lease Table Text Block",
        "label": "Schedule Of Balance sheet Information Related To Operating Lease Table Text Block",
        "terseLabel": "Schedule of Operating Lease Information Presented In Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of consolidated entities and business acquisitions by acquisition.",
        "label": "Schedule of Consolidated Entities and Business Acquisitions by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of finite and indefinite lived intangible assets.",
        "label": "Schedule Of Finite and Indefinite Lived Intangible Assets[Table Text Block]",
        "terseLabel": "Summary of Accumulated Amortization of Recognized Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "inva_SecuredConvertibleCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured convertible credit agreement.",
        "label": "Secured Convertible Credit Agreement [Member]",
        "terseLabel": "Secured Convertible Credit Agreement"
       }
      }
     },
     "localname": "SecuredConvertibleCreditAgreementMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_SecuritiesPurchaseAgreementAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.",
        "label": "Securities Purchase Agreement, Amount",
        "terseLabel": "Amount of securities purchase agreement",
        "verboseLabel": "Payments for acquire variable interest"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementAmount",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities purchase agreement member.",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities purchase agreement"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_SecuritiesPurchaseAgreementNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of tranches in which the Company agreed to purchase common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.",
        "label": "Securities Purchase Agreement, Number of Tranches",
        "terseLabel": "Number of tranches",
        "verboseLabel": "Number of tranches"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementNumberOfTranches",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inva_SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of the investee's board members which the Company has the right to designate.",
        "label": "Securities Purchase Agreement Rights To Designate Investee Board Members Number Of Board Members",
        "terseLabel": "Number of investee's board members which may be designated by the Company"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementRightsToDesignateInvesteeBoardMembersNumberOfBoardMembers",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inva_SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of shares to be purchased under the terms of a securities purchase agreement.",
        "label": "Securities Purchase Agreement, Total Number of Shares To Be Purchased Under the Agreement",
        "terseLabel": "Securities to be purchased",
        "verboseLabel": "Number of shares to be purchased under the securities purchase agreement"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementTotalNumberOfSharesToBePurchasedUnderAgreement",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of warrants to be purchased under the terms of a securities purchase agreement.",
        "label": "Securities Purchase Agreement, Total Number of Warrants To Be Purchased Under Agreement",
        "terseLabel": "Number of warrants to be purchased under the securities purchase agreement"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementTotalNumberOfWarrantsToBePurchasedUnderAgreement",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of additional common stock shares into which the warrants may be converted.",
        "label": "Securities Purchase Agreement, Warrants, Number of Securities Called by Warrants",
        "terseLabel": "Maximum number of additional shares into which warrants may be converted under the securities purchase agreement",
        "verboseLabel": "Maximum number of additional shares into which warrants may be converted under the securities purchase agreement"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementWarrantsNumberOfSecuritiesCalledByWarrants",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_SeniorUnsecuredConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which takes priority over other debt securities and can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Senior Unsecured Convertible Notes [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "SeniorUnsecuredConvertibleNotesMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_SeriesA1PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A1 preferred stock member.",
        "label": "Series A1 preferred stock [Member]",
        "terseLabel": "Series A1 preferred stock"
       }
      }
     },
     "localname": "SeriesA1PreferredStockMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_SeriesCPreferredStockAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to series C preferred stock and warrants.",
        "label": "Series C Preferred Stock And Warrants [Member]",
        "terseLabel": "Series C preferred stock and warrants"
       }
      }
     },
     "localname": "SeriesCPreferredStockAndWarrantsMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_SeriesCWarrantsAndSeriesDWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C warrants and Series D warrants.",
        "label": "Series C warrants and Series D warrants [Member]",
        "terseLabel": "Series C Warrants and Series D Warrants"
       }
      }
     },
     "localname": "SeriesCWarrantsAndSeriesDWarrantsMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_SeriesD1AndD2PreferredStockAndCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D 1 and D 2 preferred stock and common stock.",
        "label": "Series D 1 And D 2 Preferred Stock And Common Stock Member",
        "terseLabel": "Series D 1 And D 2 Preferred Stock And Common Stock"
       }
      }
     },
     "localname": "SeriesD1AndD2PreferredStockAndCommonStockMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_SeriesD1PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D 1 preferred stock member.",
        "label": "Series D 1 Preferred Stock [Member]",
        "terseLabel": "Series D 1 Preferred Stock"
       }
      }
     },
     "localname": "SeriesD1PreferredStockMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_SeriesD1WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D1 Warrant [Member]",
        "label": "Series D1 Warrant [Member]",
        "terseLabel": "Series D1 Warrant"
       }
      }
     },
     "localname": "SeriesD1WarrantMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_SeriesD2PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D 2 preferred stock member.",
        "label": "Series D 2 Preferred Stock [Member]",
        "terseLabel": "Series D 2 Preferred Stock"
       }
      }
     },
     "localname": "SeriesD2PreferredStockMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_SeriesD2WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D2 Warrant.",
        "label": "Series D2 Warrant [Member]",
        "terseLabel": "Series D2 Warrant"
       }
      }
     },
     "localname": "SeriesD2WarrantMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Additional Equity Grant Value",
        "terseLabel": "Pro rata shares grant, value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of shares granted annually to independent directors upon re-election the to Board.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Annual Equity Grant, Value",
        "terseLabel": "Annual grant of shares, value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the consecutive and overlapping offering period for the offering of share-based payment awards.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Consecutive and Overlapping Offering Period",
        "terseLabel": "Total duration of consecutive and overlapping offering periods"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee exercised the right during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Initial Equity Grant Value",
        "terseLabel": "One time grant of shares, value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the employee may contribute of employee's eligible compensation.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award Maximum Amount As A Contribution Of Eligible Compensation",
        "terseLabel": "Maximum value of shares an employee may purchase in a calendar year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Fair Value per Share of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest Outstanding, Weighted-Average Fair Value per Share",
        "terseLabel": "Vested and expected to vest at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of annual installments that RSUs granted to newly appointed independent directors will vest.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award number of annual installments",
        "terseLabel": "Number of annual installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of purchase periods having duration of six months each.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Number of Purchase Periods",
        "terseLabel": "Number of offering periods"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the duration of each purchase period within each consecutive and overlapping purchase period for offering of share-based payment awards.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Purchase Period",
        "terseLabel": "Duration of purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to share repurchase agreement with Glaxo Group Limited.",
        "label": "Share Repurchase Agreement With Glaxo Group Limited [Member]",
        "terseLabel": "Share repurchase agreement with GSK"
       }
      }
     },
     "localname": "ShareRepurchaseAgreementWithGlaxoGroupLimitedMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_SoftwareAndComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Software and computer equipment",
        "label": "Software And Computer Equipment [Member]",
        "terseLabel": "Software and computer equipment"
       }
      }
     },
     "localname": "SoftwareAndComputerEquipmentMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Special Terms on amended and restated investor rights agreement.",
        "label": "Special Term Re Designating Board Member To Board Of Investee",
        "terseLabel": "Special terms on re-designating board member to board of investee"
       }
      }
     },
     "localname": "SpecialTermReDesignatingBoardMemberToBoardOfInvestee",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_StateNetOperatingLossesEstimatedUtilizationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State net operating losses estimated utilization amount.",
        "label": "State Net Operating Losses Estimated Utilization Amount",
        "terseLabel": "State net operating losses estimated utilization amount"
       }
      }
     },
     "localname": "StateNetOperatingLossesEstimatedUtilizationAmount",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_StrategicAllianceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the strategic alliance with GSK for initiating three new full discovery programs and giving GSK option to license exclusive development and commercialization rights of products.",
        "label": "Strategic Alliance Agreement [Member]",
        "terseLabel": "Strategic alliance - MABA program"
       }
      }
     },
     "localname": "StrategicAllianceAgreementMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_StrategicAllianceMabaProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "strategic alliance - MABA program",
        "label": "strategic alliance - MABA program",
        "terseLabel": "Strategic alliance - MABA program"
       }
      }
     },
     "localname": "StrategicAllianceMabaProgram",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "terseLabel": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to various accounting policies of the entity.",
        "label": "Summary of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "inva_TheravanceRespiratoryCompanyLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the variable interest entity, Theravance Respiratory Company, LLC (\"TRC\").",
        "label": "Theravance Respiratory Company Llc [Member]",
        "terseLabel": "Theravance Respiratory Company, LLC"
       }
      }
     },
     "localname": "TheravanceRespiratoryCompanyLlcMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_TrelegyElliptaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Trelegy Ellipta.",
        "label": "Trelegy Ellipta [Member]",
        "terseLabel": "TRELEGY"
       }
      }
     },
     "localname": "TrelegyElliptaMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_TwoDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Directors.",
        "label": "Two Directors [Member]",
        "terseLabel": "Two Directors"
       }
      }
     },
     "localname": "TwoDirectorsMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_TwoThousandTwentyEightNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty eight notes.",
        "label": "Two Thousand Twenty Eight Notes [Member]",
        "terseLabel": "2028 Notes"
       }
      }
     },
     "localname": "TwoThousandTwentyEightNotesMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_TwoThousandTwentyFiveNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty five notes.",
        "label": "Two Thousand Twenty Five Notes [Member]",
        "terseLabel": "2025 Notes",
        "verboseLabel": "Two Thousand Twenty Five Notes [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyFiveNotesMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_TwoThousandTwentyThreeNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty three notes.",
        "label": "Two Thousand Twenty Three Notes [Member]",
        "terseLabel": "2023 Notes"
       }
      }
     },
     "localname": "TwoThousandTwentyThreeNotesMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_UnrealizedOtherGainLossOnInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized other gain loss on investments",
        "label": "Unrealized Other Gain Loss on Investments",
        "negatedLabel": "Changes in fair values of other equity and long-term investments, net"
       }
      }
     },
     "localname": "UnrealizedOtherGainLossOnInvestments",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions, Net",
        "terseLabel": "Net decrease in tax portions for 2021"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreaseResultingFromCurrentPeriodTaxPositionsNet",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions, Net",
        "terseLabel": "Net decrease in tax portions for 2020"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreaseResultingFromPriorPeriodTaxPositionsNet",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits increase resulting from current period tax positions Net",
        "label": "Unrecognized Tax Benefits Increase Resulting From Current Period Tax Positions Net",
        "terseLabel": "Net increase in tax portions for 2022"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseResultingFromCurrentPeriodTaxPositionsNet",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "inva_VotingAgreementMaximumVotingRightsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of maximum voting rights under voting agreement.",
        "label": "Voting Agreement, Maximum Voting Rights, Percent",
        "terseLabel": "Percentage of maximum voting rights"
       }
      }
     },
     "localname": "VotingAgreementMaximumVotingRightsPercent",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "inva_WalthamMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Waltham Massachusetts Member",
        "label": "Waltham Massachusetts Member"
       }
      }
     },
     "localname": "WalthamMassachusettsMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_WarrantsAcquiredInSecondQuarterOf2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants acquired in the second quarter of 2020.",
        "label": "Warrants Acquired In Second Quarter Of2020 [Member]",
        "terseLabel": "Warrants acquired in second quarter of 2020"
       }
      }
     },
     "localname": "WarrantsAcquiredInSecondQuarterOf2020Member",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_WarrantsAcquiredInSecondQuarterOf2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to warrants acquired in the second quarter of 2021",
        "label": "Warrants Acquired In Second Quarter Of2021 [Member]",
        "terseLabel": "Warrants acquired in second quarter of 2021"
       }
      }
     },
     "localname": "WarrantsAcquiredInSecondQuarterOf2021Member",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_WarrantsAcquiredInThirdQuarterOf2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants acquired in the third quarter of 2020.",
        "label": "Warrants Acquired In Third Quarter Of2020 [Member]",
        "terseLabel": "Warrants acquired in third quarter of 2020"
       }
      }
     },
     "localname": "WarrantsAcquiredInThirdQuarterOf2020Member",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_WarrantsPurchasedIn2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants purchased in 2020.",
        "label": "Warrants Purchased In2020 [Member]",
        "terseLabel": "Warrants purchased in 2020"
       }
      }
     },
     "localname": "WarrantsPurchasedIn2020Member",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_WarrantsPurchasedIn2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants purchased in 2021.",
        "label": "Warrants Purchased In2021 [Member]",
        "terseLabel": "Warrants purchased in 2021"
       }
      }
     },
     "localname": "WarrantsPurchasedIn2021Member",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_WarrantsPurchasedIn2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants purchased in 2022 member.",
        "label": "Warrants Purchased In 2022 [Member]",
        "terseLabel": "Warrants Purchased in 2022"
       }
      }
     },
     "localname": "WarrantsPurchasedIn2022Member",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_XeravaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XERAVA.",
        "label": "XERAVA [Member]",
        "terseLabel": "XERAVA"
       }
      }
     },
     "localname": "XeravaMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "inva_ZaiLabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab.",
        "label": "Zai Lab [Member]",
        "terseLabel": "Zai Lab"
       }
      }
     },
     "localname": "ZaiLabMember",
     "nsuri": "http://www.inva.com/20221231",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r322",
      "r630",
      "r631",
      "r634",
      "r635",
      "r705",
      "r827",
      "r934",
      "r937",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r322",
      "r630",
      "r631",
      "r634",
      "r635",
      "r705",
      "r827",
      "r934",
      "r937",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r320",
      "r321",
      "r476",
      "r507",
      "r837",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r270",
      "r326",
      "r333",
      "r339",
      "r419",
      "r582",
      "r583",
      "r584",
      "r611",
      "r612",
      "r641",
      "r644",
      "r646",
      "r647",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect period of adoption adjustment member"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r270",
      "r326",
      "r333",
      "r339",
      "r419",
      "r582",
      "r583",
      "r584",
      "r611",
      "r612",
      "r641",
      "r644",
      "r646",
      "r647",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r270",
      "r326",
      "r333",
      "r339",
      "r419",
      "r582",
      "r583",
      "r584",
      "r611",
      "r612",
      "r641",
      "r644",
      "r646",
      "r647",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Non-employee director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r400",
      "r858",
      "r943",
      "r1004"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461",
      "r542",
      "r742",
      "r777",
      "r828",
      "r829",
      "r855",
      "r868",
      "r877",
      "r939",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461",
      "r542",
      "r742",
      "r777",
      "r828",
      "r829",
      "r855",
      "r868",
      "r877",
      "r939",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r400",
      "r858",
      "r943",
      "r1004"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r397",
      "r744",
      "r856",
      "r875",
      "r931",
      "r932",
      "r943",
      "r1003"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r397",
      "r744",
      "r856",
      "r875",
      "r931",
      "r932",
      "r943",
      "r1003"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461",
      "r534",
      "r542",
      "r573",
      "r574",
      "r575",
      "r715",
      "r742",
      "r777",
      "r828",
      "r829",
      "r855",
      "r868",
      "r877",
      "r930",
      "r939",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r458",
      "r459",
      "r460",
      "r461",
      "r534",
      "r542",
      "r573",
      "r574",
      "r575",
      "r715",
      "r742",
      "r777",
      "r828",
      "r829",
      "r855",
      "r868",
      "r877",
      "r930",
      "r939",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r320",
      "r321",
      "r476",
      "r507",
      "r838",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r398",
      "r399",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r857",
      "r876",
      "r943"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r398",
      "r399",
      "r812",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r857",
      "r876",
      "r943"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r918",
      "r992"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r828",
      "r829",
      "r996",
      "r998",
      "r1001"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted-average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "ASU 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r327",
      "r328",
      "r329",
      "r404",
      "r405",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r582",
      "r583",
      "r584",
      "r611",
      "r612",
      "r625",
      "r626",
      "r627",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r676",
      "r677",
      "r681",
      "r682",
      "r683",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r915"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r21",
      "r874"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r770",
      "r813"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r6",
      "r231",
      "r252"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total other accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r36",
      "r37",
      "r184",
      "r702",
      "r780",
      "r781",
      "r901",
      "r902",
      "r903",
      "r912",
      "r913",
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquisitionCosts": {
     "auth_ref": [
      "r226",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.",
        "label": "Acquisition Costs, Period Cost",
        "terseLabel": "Acquisition-related costs"
       }
      }
     },
     "localname": "AcquisitionCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r582",
      "r583",
      "r584",
      "r912",
      "r913",
      "r914",
      "r984"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r327",
      "r328",
      "r329",
      "r330",
      "r339",
      "r404",
      "r405",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r582",
      "r583",
      "r584",
      "r609",
      "r610",
      "r611",
      "r612",
      "r625",
      "r626",
      "r627",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r676",
      "r677",
      "r681",
      "r682",
      "r683",
      "r684",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r746",
      "r747",
      "r748",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "auth_ref": [
      "r126",
      "r132",
      "r608"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.",
        "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature",
        "terseLabel": "Conversion of convertible subordinated notes due 2023"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Capped call options associated with convertible senior notes due 2028"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r155",
      "r156",
      "r544"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r50",
      "r65",
      "r220",
      "r495"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r43",
      "r495",
      "r679",
      "r906"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r495",
      "r679",
      "r853",
      "r854",
      "r906"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs",
        "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r65",
      "r99",
      "r104"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of acquired intangible assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-Dilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Lease space"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r229",
      "r251",
      "r282",
      "r317",
      "r381",
      "r391",
      "r395",
      "r415",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r630",
      "r634",
      "r660",
      "r874",
      "r935",
      "r936",
      "r994"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r274",
      "r290",
      "r317",
      "r415",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r630",
      "r634",
      "r660",
      "r874",
      "r935",
      "r936",
      "r994"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets measured at estimated fair value",
        "totalLabel": "Assets, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r317",
      "r415",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r630",
      "r634",
      "r660",
      "r935",
      "r936",
      "r994"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "terseLabel": "Noncurrent assets",
        "totalLabel": "Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r407",
      "r427"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r88",
      "r406",
      "r427",
      "r763"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Debt Securities, Available-for-sale, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Information"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r624",
      "r866",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r624",
      "r866",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r981",
      "r982"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Acquisition share price"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r622",
      "r623"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net income",
        "verboseLabel": "Business acquisition, net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r622",
      "r623"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r173",
      "r174",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total consideration paid",
        "totalLabel": "Total consideration paid"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "'Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r170",
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r170",
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total assets acquired, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets",
        "terseLabel": "Other assets",
        "totalLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r170",
      "r171"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CallOptionMember": {
     "auth_ref": [
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option.",
        "label": "Call Option [Member]",
        "terseLabel": "Stock prices below $27.79 per share"
       }
      }
     },
     "localname": "CallOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedContractCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost [Abstract]"
       }
      }
     },
     "localname": "CapitalizedContractCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostAccumulatedAmortization": {
     "auth_ref": [
      "r925"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CapitalizedContractCostNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "CapitalizedContractCostAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "negatedLabel": "Less: amortization of capitalized fees paid",
        "terseLabel": "Amortization of capitalized fees paid",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r925"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CapitalizedContractCostNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Gross",
        "terseLabel": "Milestone fees paid",
        "verboseLabel": "Gross carrying value"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Capitalized Contract Cost [Line Items]",
        "terseLabel": "Capitalized Fees paid"
       }
      }
     },
     "localname": "CapitalizedContractCostLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Net",
        "terseLabel": "Capitalized fees paid, net",
        "totalLabel": "Net carrying value"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostTable": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Table]"
       }
      }
     },
     "localname": "CapitalizedContractCostTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostTableTextBlock": {
     "auth_ref": [
      "r926"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Table Text Block]",
        "terseLabel": "Schedule of Capitalized Fees Paid"
       }
      }
     },
     "localname": "CapitalizedContractCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash acquired through the consolidation of Entasis"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r67",
      "r277",
      "r830"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Cash balance"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r62",
      "r67",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Total cash, cash equivalents and restricted cash at end of period shown in the consolidated statements of cash flows",
        "totalLabel": "Total cash, cash equivalents and restricted cash at end of period shown in the condensed consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r62",
      "r218"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants",
        "verboseLabel": "Exercise price of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r32",
      "r238",
      "r258"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r456",
      "r457",
      "r815",
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r912",
      "r913",
      "r984"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r12",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r12",
      "r874"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock: $0.01 par value, 200,000 shares authorized, 69,188 and 69,566 issued and outstanding as of December 31, 2022 and December 31, 2021 respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of deferred tax assets and deferred tax liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r38",
      "r294",
      "r296",
      "r305",
      "r766",
      "r773"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Innoviva stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r179",
      "r180",
      "r197",
      "r294",
      "r296",
      "r304",
      "r765",
      "r772"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income attributable to noncontrolling interests",
        "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r178",
      "r197",
      "r294",
      "r296",
      "r303",
      "r764",
      "r771"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r79",
      "r80",
      "r215",
      "r216",
      "r400",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r79",
      "r80",
      "r215",
      "r216",
      "r400",
      "r790",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r79",
      "r80",
      "r215",
      "r216",
      "r400",
      "r814",
      "r1005"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r247",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and of Significant Suppliers and Partners"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r79",
      "r80",
      "r215",
      "r216",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration Risk, Percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r79",
      "r80",
      "r215",
      "r216",
      "r400",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r181",
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r186",
      "r188",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "terseLabel": "Convertible subordinated notes due 2023, net of issuance costs"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentFairValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "2028 Notes"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r116",
      "r473",
      "r474",
      "r485",
      "r486",
      "r487",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible debt investment"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Summary of Liability and Equity Components of Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleSubordinatedDebtMember": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt that places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Subordinated Debt [Member]",
        "terseLabel": "Convertible subordinated notes"
       }
      }
     },
     "localname": "ConvertibleSubordinatedDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r45",
      "r744"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 10.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold (inclusive of amortization of inventory fair value adjustments and excluding amortization of acquired intangible assets)",
        "totalLabel": "Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total expenses",
        "verboseLabel": "Operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r909",
      "r978",
      "r980"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r166",
      "r605",
      "r616",
      "r909"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r909",
      "r978",
      "r980"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "negatedLabel": "State",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r77",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r70",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Notes converted into common stock, Amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r70",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Less: Current portion of long-term debt, net",
        "totalLabel": "Debt, Current, Total"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r123",
      "r315",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r489",
      "r496",
      "r497",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r230",
      "r233",
      "r249",
      "r322",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r680",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r907"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r7",
      "r233",
      "r249",
      "r500"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LongTermDebtCurrent",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Total debt",
        "totalLabel": "Total",
        "verboseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Equity component, net"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r120",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (dollars per share)",
        "verboseLabel": "Conversion price of convertible notes into common stock (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r29",
      "r127",
      "r128",
      "r130",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Conversion rate for shares of common stock per $1,000 principal"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r221",
      "r223",
      "r473",
      "r680",
      "r851",
      "r852"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Loan amount",
        "verboseLabel": "New principal amount convertible note"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r487",
      "r659",
      "r851",
      "r852"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "totalLabel": "Total fair value of debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "auth_ref": [
      "r907"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period.",
        "label": "Debt Instrument, Increase (Decrease), Net",
        "terseLabel": "New principal amount convertible note",
        "totalLabel": "New principal amount"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r28",
      "r221",
      "r503",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r28",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt Instrument, annual interest rate",
        "verboseLabel": "Debt Instrument, annual interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r291",
      "r850",
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt instrument maturity date",
        "verboseLabel": "Debt instrument maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r30",
      "r322",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r680",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r907"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Debt Instrument, Principal Payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Debt instrument principal amount percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Portion of debt retired, carrying value"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Debt Instrument, Repurchased Face Amount",
        "verboseLabel": "Portion of debt retired, face value"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r30",
      "r127",
      "r129",
      "r130",
      "r131",
      "r220",
      "r221",
      "r223",
      "r246",
      "r322",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r498",
      "r680",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r907"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r220",
      "r223",
      "r940"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "totalLabel": "Debt Instrument, Unamortized Discount, Total",
        "verboseLabel": "Unamortized Debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r222",
      "r485",
      "r501",
      "r851",
      "r852"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtCurrent",
       "weight": -1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: Unamortized debt discount and issuance costs",
        "negatedTerseLabel": "Debt discount and issuance costs, net",
        "terseLabel": "Debt discount and issuance costs, net",
        "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "terseLabel": "Total debt, net",
        "totalLabel": "Total debt, net"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates.",
        "label": "Debt [Member]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r408",
      "r427",
      "r430",
      "r431"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance",
        "totalLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Total",
        "verboseLabel": "Credit loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r919"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of amortized cost and estimated fair values for available-for-sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "negatedLabel": "Net gain on sale of TRC",
        "negatedTerseLabel": "Gain on sale of Theravance Respiratory Company, LLC (\"TRC\")",
        "terseLabel": "Net gain on sale of TRC"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r909",
      "r979",
      "r980"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedLabel": "Federal",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r972"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "negatedTotalLabel": "Total",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net",
        "totalLabel": "Deferred Income Tax Assets, Net, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r65",
      "r166",
      "r606",
      "r615",
      "r616",
      "r909"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes",
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r9",
      "r10",
      "r232",
      "r248",
      "r600"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Net deferred tax (liabilities)",
        "totalLabel": "Net deferred tax (liabilities)"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net",
        "totalLabel": "Net deferred tax (liabilities)"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r894"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Deferred Revenue, Total"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r893"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Deferred Revenue, Current, Total"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r909",
      "r979",
      "r980"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "negatedLabel": "State",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r601"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r976"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r976"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r164",
      "r977"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r164",
      "r977"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r162",
      "r164",
      "r977"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Liabilities, Investments",
        "negatedLabel": "Unrealized Gain on Investment, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r164",
      "r977"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCapPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract.",
        "label": "Derivative, Cap Price",
        "terseLabel": "Cap price for the underlying number of shares (in dollars per share)"
       }
      }
     },
     "localname": "DerivativeCapPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "us-gaap_DerivativeCostOfHedge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The premium (cost) of a hedge, expensed during the period.",
        "label": "Derivative, Cost of Hedge",
        "terseLabel": "Payments for capped call options"
       }
      }
     },
     "localname": "DerivativeCostOfHedge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Revenue Recognition and Collaborative Arrangements"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r531",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r943"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of net revenue from collaborative arrangements"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r547",
      "r578",
      "r579",
      "r581",
      "r586",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r286",
      "r464",
      "r465",
      "r466",
      "r470",
      "r471",
      "r472",
      "r704",
      "r832",
      "r910"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Receivables from collaboration arrangements",
        "totalLabel": "Due from Related Parties, Current, Total",
        "verboseLabel": "Receivables from collaborative arrangements"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r306",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r340",
      "r343",
      "r356",
      "r357",
      "r358",
      "r362",
      "r647",
      "r648",
      "r767",
      "r774",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net income per share attributable to Innoviva stockholders",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "verboseLabel": "Basic net income per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r306",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r343",
      "r356",
      "r357",
      "r358",
      "r362",
      "r647",
      "r648",
      "r767",
      "r774",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net income per share attributable to Innoviva stockholders",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Diluted net income per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "verboseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareDilutedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "NET INCOME PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued personnel-related expenses",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-Average Amortization Period (Years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r126",
      "r270",
      "r298",
      "r299",
      "r300",
      "r323",
      "r324",
      "r325",
      "r328",
      "r336",
      "r338",
      "r365",
      "r419",
      "r521",
      "r582",
      "r583",
      "r584",
      "r611",
      "r612",
      "r646",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r702",
      "r780",
      "r781",
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.",
        "label": "Equity Method Investment, Other than Temporary Impairment",
        "terseLabel": "Impairment of equity investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment ownership percentage",
        "verboseLabel": "Equity investment ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r93",
      "r382",
      "r892"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Total carrying value of investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r61",
      "r95",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity and Long-Term Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r283",
      "r658",
      "r833"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity and long-term investments at fair value",
        "verboseLabel": "Fair value of equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r775",
      "r923"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "terseLabel": "Remeasurement loss",
        "totalLabel": "Equity Securities, FV-NI, Realized Gain (Loss), Total"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGain": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain",
        "terseLabel": "Unrealized gain from fair value changes in equity investments",
        "verboseLabel": "Unrealized gain"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "negatedLabel": "Unrealized loss from fair value changes in equity investments",
        "terseLabel": "Unrealized loss from fair value changes in equity investments",
        "verboseLabel": "Unrealized loss"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r91",
      "r250",
      "r878",
      "r879",
      "r880"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity investment"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements",
        "verboseLabel": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r650",
      "r651",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of available-for-sale securities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Equity Investment"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r205",
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r487",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r651",
      "r712",
      "r713",
      "r714",
      "r851",
      "r852",
      "r863",
      "r864",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r650",
      "r651",
      "r652",
      "r653",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r487",
      "r535",
      "r540",
      "r651",
      "r712",
      "r863",
      "r864",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Price in Active Markets for Identical Assets, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r487",
      "r535",
      "r540",
      "r651",
      "r713",
      "r851",
      "r852",
      "r863",
      "r864",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r487",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r651",
      "r714",
      "r851",
      "r852",
      "r863",
      "r864",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs, Level 3",
        "verboseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r487",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r712",
      "r713",
      "r714",
      "r851",
      "r852",
      "r863",
      "r864",
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Nonrecurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r655",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r409",
      "r410",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r432",
      "r498",
      "r518",
      "r636",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r848",
      "r920",
      "r921",
      "r922",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Marketed products, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r280",
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Future amortization expense, thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Future amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Future amortization expense, 2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Future amortization expense, 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Future amortization expense, 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Future amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r453",
      "r745",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r100",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)",
        "terseLabel": "Measurement period adjustments for change in value of intangible assets",
        "totalLabel": "Finite-Lived Intangible Assets, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnContractTermination": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.",
        "label": "Gain (Loss) on Contract Termination",
        "terseLabel": "Revenue recognized upon termination of contract"
       }
      }
     },
     "localname": "GainLossOnContractTermination",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r49",
      "r87",
      "r891"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "order": 4.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedLabel": "Changes in fair values of equity and long-term investments, net",
        "terseLabel": "Realized gain on equity investments",
        "totalLabel": "Gain (Loss) on Investments, Total",
        "verboseLabel": "Changes in fair values of other equity and long-term investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r65",
      "r121",
      "r122"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt",
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralPartnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Party to a partnership business who has unlimited liability.",
        "label": "General Partner [Member]",
        "terseLabel": "General Partner"
       }
      }
     },
     "localname": "GeneralPartnerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r78",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r279",
      "r438",
      "r762",
      "r849",
      "r874",
      "r927",
      "r928"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "GOODWILL AND INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "auth_ref": [
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Period Increase (Decrease)",
        "terseLabel": "Measurement period adjustments for change in value of goodwill",
        "totalLabel": "Goodwill, Period Increase (Decrease), Total",
        "verboseLabel": "Decrease in goodwill"
       }
      }
     },
     "localname": "GoodwillPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r40",
      "r228",
      "r240",
      "r262",
      "r381",
      "r390",
      "r394",
      "r396",
      "r768",
      "r847"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 0.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r41",
      "r65",
      "r93",
      "r239",
      "r260",
      "r379"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 0.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Changes in fair values of equity method investments, net",
        "terseLabel": "Changes in fair values of equity method investments, net"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Related Disclosures [Abstract]",
        "terseLabel": "Income Statement Information"
       }
      }
     },
     "localname": "IncomeStatementRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r318",
      "r594",
      "r598",
      "r604",
      "r613",
      "r617",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r974"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties",
        "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r319",
      "r337",
      "r338",
      "r380",
      "r592",
      "r614",
      "r618",
      "r776"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax expense, net",
        "negatedTotalLabel": "Total income tax expense, net",
        "terseLabel": "Income tax expense, net",
        "totalLabel": "Income tax expense (benefit), net",
        "verboseLabel": "Income tax expense, net"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "verboseLabel": "Differences between the expected U.S. federal statutory income tax to income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r297",
      "r588",
      "r589",
      "r598",
      "r599",
      "r603",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r973"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary": {
     "auth_ref": [
      "r973"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Amount",
        "negatedLabel": "Impact of consolidation and deconsolidation of subsidiaries",
        "terseLabel": "Impact of consolidation and deconsolidation of subsidiaries"
       }
      }
     },
     "localname": "IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r593"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Expected tax at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationMinorityInterestIncomeExpense": {
     "auth_ref": [
      "r973"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount",
        "negatedTerseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "IncomeTaxReconciliationMinorityInterestIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r973"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r973"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income tax, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r973"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Federal and state research credits",
        "terseLabel": "Federal and state research credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes",
        "totalLabel": "Income Taxes Paid, Net, Total"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued personnel-related expenses and other accrued liabilities",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "terseLabel": "Income tax expense recognized"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLeasingFees": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the book value of deferred leasing fees. Amortization of these fees over the terms of the leases reduces deferred leasing fees. Originating new leases increases the balance of deferred leasing fees.",
        "label": "Increase (Decrease) in Deferred Leasing Fees",
        "negatedLabel": "Amortization of lease guarantee"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLeasingFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r840"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due from Related Parties, Current",
        "negatedLabel": "Receivables from collaborative arrangements",
        "totalLabel": "Increase (Decrease) in Due from Related Parties, Current, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 34.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "terseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "terseLabel": "Measurement period adjustments for change in value of Inventory",
        "totalLabel": "Increase (Decrease) in Inventories, Total",
        "verboseLabel": "Change in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r352",
      "r353",
      "r358"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Dilutive effect",
        "totalLabel": "Incremental Common Shares Attributable to Conversion of Debt Securities, Total"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r358",
      "r546"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan",
        "totalLabel": "Incremental Common Shares Attributable to Share-based Payment Arrangements, Total"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets, Period Increase (Decrease)",
        "terseLabel": "Measurement period adjustments for change in value of intangible assets",
        "totalLabel": "Indefinite-Lived Intangible Assets, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total gross carrying amount",
        "totalLabel": "Total gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r98",
      "r102"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Intangible Assets Abstract"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestAndDividendIncomeOperating": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.",
        "label": "Interest and Dividend Income, Operating",
        "negatedLabel": "Interest and dividend income",
        "terseLabel": "Interest and dividend income",
        "totalLabel": "Interest and Dividend Income, Operating, Total"
       }
      }
     },
     "localname": "InterestAndDividendIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r236",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity).",
        "label": "Interest and Dividends Payable",
        "terseLabel": "Short term accrued interest",
        "totalLabel": "Interest and Dividends Payable, Total"
       }
      }
     },
     "localname": "InterestAndDividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r222",
      "r244",
      "r301",
      "r378",
      "r678"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseBorrowings": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of interest expense on all borrowings.",
        "label": "Interest Expense, Borrowings",
        "terseLabel": "Interest expense",
        "totalLabel": "Interest Expense, Borrowings, Total"
       }
      }
     },
     "localname": "InterestExpenseBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Borrowings [Abstract]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseBorrowingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r50",
      "r493",
      "r504",
      "r853",
      "r854"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "totalLabel": "Total interest and amortization expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt [Abstract]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r52",
      "r494",
      "r853",
      "r854"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpensePolicyTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.",
        "label": "Interest Expense, Policy [Policy Text Block]",
        "terseLabel": "Interest Expense on Deferred Royalty Obligation"
       }
      }
     },
     "localname": "InterestExpensePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Components of Interest Expense"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestOnConvertibleDebtNetOfTax": {
     "auth_ref": [
      "r342",
      "r349",
      "r358"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.",
        "label": "Interest on Convertible Debt, Net of Tax",
        "terseLabel": "Add: interest expense on Notes, net of tax effect"
       }
      }
     },
     "localname": "InterestOnConvertibleDebtNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r309",
      "r313",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "verboseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r96",
      "r834"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r898"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory, Gross, Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r288",
      "r831",
      "r874"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r276",
      "r287",
      "r364",
      "r433",
      "r434",
      "r435",
      "r743",
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r96",
      "r836"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r96",
      "r835"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r48",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Investment Income, Interest"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Interest and Dividend",
        "totalLabel": "Investment Income, Interest and Dividend, Total"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInvestmentExpense": {
     "auth_ref": [
      "r51",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses related to the generation of investment income.",
        "label": "Investment Income, Investment Expense",
        "terseLabel": "Investment-related expenses, net of investment-related income"
       }
      }
     },
     "localname": "InvestmentIncomeInvestmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Amortization of discount on short-term investments",
        "totalLabel": "Investment Income, Net, Amortization of Discount and Premium, Total"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r989"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r989"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r695",
      "r873"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r990"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesOperatingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Operating [Abstract]"
       }
      }
     },
     "localname": "LeasesOperatingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Operating Lease"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r991"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r696"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r696"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r696"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r696"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r696"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r988"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r25",
      "r317",
      "r415",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r631",
      "r634",
      "r635",
      "r660",
      "r846",
      "r935",
      "r994",
      "r995"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Liabilities, Total",
        "verboseLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r17",
      "r235",
      "r256",
      "r874",
      "r908",
      "r924",
      "r986"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and Stockholders Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r27",
      "r275",
      "r317",
      "r415",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r631",
      "r634",
      "r635",
      "r660",
      "r874",
      "r935",
      "r994",
      "r995"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r205"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities measured at estimated fair value",
        "totalLabel": "Total liabilities at estimated fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r7",
      "r8",
      "r317",
      "r415",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r631",
      "r634",
      "r635",
      "r660",
      "r935",
      "r994",
      "r995"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Noncurrent liabilities",
        "totalLabel": "Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LimitedPartnersContributedCapital": {
     "auth_ref": [
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of capital contributed by the limited partners.",
        "label": "Limited Partners' Contributed Capital",
        "terseLabel": "Contributed to partnership for investing",
        "verboseLabel": "Capital contribution"
       }
      }
     },
     "localname": "LimitedPartnersContributedCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LimitedPartnersCumulativeCashDistributions": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cumulative cash distributions made to the limited partners.",
        "label": "Limited Partners' Cumulative Cash Distributions",
        "terseLabel": "Distribution from partnership"
       }
      }
     },
     "localname": "LimitedPartnersCumulativeCashDistributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCovenantTerms": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the conditions for borrowing under the credit facility including the nature of any restrictions.",
        "label": "Line of Credit Facility, Covenant Terms",
        "terseLabel": "Debt instrument, covenant terms description"
       }
      }
     },
     "localname": "LineOfCreditFacilityCovenantTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Term loan facility in aggregate amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoanRestructuringModificationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by concessions made to the terms of loan contracts.",
        "label": "Loan Restructuring Modification [Axis]"
       }
      }
     },
     "localname": "LoanRestructuringModificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoanRestructuringModificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concessions made to the terms of loan contracts, including but not limited to, interest rate reductions, maturity extensions, principal forgiveness, and payment deferral.",
        "label": "Loan Restructuring Modification [Domain]"
       }
      }
     },
     "localname": "LoanRestructuringModificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loans Payable [Member]"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r7",
      "r233",
      "r253",
      "r486",
      "r502",
      "r851",
      "r852"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Long-term debt maturities for years ending December 31:"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r114",
      "r322",
      "r941"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r114",
      "r322",
      "r491"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r114",
      "r322",
      "r491"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r114",
      "r322",
      "r491"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r114",
      "r322",
      "r491"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r114",
      "r322",
      "r491"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of discount and issuance costs",
        "totalLabel": "Total long-term debt, net",
        "verboseLabel": "Total long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Equity and long-term investments",
        "totalLabel": "Long-term Investments, Total"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r30",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAllegations": {
     "auth_ref": [
      "r111",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Presents an assertion of a fact by a plaintiff in a pleading or complaint, which the plaintiff claims it will prove upon presentation of evidence at the proceeding.",
        "label": "Loss Contingency, Allegations",
        "terseLabel": "Complaints filed by stockholders"
       }
      }
     },
     "localname": "LossContingencyAllegations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Investments in Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MembersEquity": {
     "auth_ref": [
      "r132",
      "r366",
      "r367",
      "r368",
      "r369"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of ownership interest in limited liability company (LLC), attributable to the parent entity.",
        "label": "Members' Equity",
        "totalLabel": "Members' Equity, Total",
        "verboseLabel": "LLC members' equity"
       }
      }
     },
     "localname": "MembersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r35",
      "r234",
      "r255",
      "r317",
      "r415",
      "r462",
      "r465",
      "r466",
      "r467",
      "r471",
      "r472",
      "r660"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance",
        "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance",
        "terseLabel": "Noncontrolling interests",
        "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distributions to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "terseLabel": "Measurement period adjustments for change in value of noncontrolling interests",
        "totalLabel": "Noncontrolling Interest, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r945"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r62",
      "r63",
      "r66"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r42",
      "r66",
      "r241",
      "r261",
      "r273",
      "r292",
      "r295",
      "r300",
      "r317",
      "r327",
      "r331",
      "r332",
      "r333",
      "r334",
      "r337",
      "r338",
      "r354",
      "r381",
      "r390",
      "r394",
      "r396",
      "r415",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r648",
      "r660",
      "r847",
      "r935"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss)",
        "verboseLabel": "Net income attributable to Innoviva stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r182",
      "r196",
      "r292",
      "r295",
      "r337",
      "r338",
      "r903"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to noncontrolling interests",
        "terseLabel": "Net loss attributable to noncontrolling interests",
        "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r340",
      "r341",
      "r355",
      "r358",
      "r381",
      "r390",
      "r394",
      "r396",
      "r847"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to Innoviva stockholders",
        "totalLabel": "Net income attributable to Innoviva stockholders",
        "verboseLabel": "Net income attributable to Innoviva stockholders, basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r342",
      "r348",
      "r349",
      "r350",
      "r351",
      "r355",
      "r358"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Innoviva stockholders, diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Rentable square feet"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Pronouncements Adopted by the Company"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of the world"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-cash Investing and Financing Activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r176",
      "r521",
      "r912",
      "r913",
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Operating expenses",
        "totalLabel": "Total expenses",
        "verboseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r381",
      "r390",
      "r394",
      "r396",
      "r847"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating expenses",
        "totalLabel": "Income from operations",
        "verboseLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r987"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Straight line operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liabilities included within Other accrued liabilities",
        "verboseLabel": "Current portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r686"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r688",
      "r692"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities:"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r685"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseInformationPresentedInBalanceSheetDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r694",
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": {
     "auth_ref": [
      "r124",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.",
        "label": "Option Indexed to Issuer's Equity, Strike Price",
        "terseLabel": "Strike price for the underlying number of shares (in dollars per share)"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityStrikePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r125",
      "r201",
      "r202",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r73",
      "r84",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "verboseLabel": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r289",
      "r874"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r178",
      "r179",
      "r183",
      "r293",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Other",
        "totalLabel": "Other Liabilities, Total"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r26",
      "r874"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "totalLabel": "Other Liabilities, Current, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Total other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items",
        "totalLabel": "Other Noncash Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities",
        "verboseLabel": "Other Long Term Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Long-term Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expense, net",
        "terseLabel": "Other expense, net",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "verboseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.",
        "label": "Payment of Financing and Stock Issuance Costs",
        "terseLabel": "Total issuance costs",
        "totalLabel": "Payment of Financing and Stock Issuance Costs, Total"
       }
      }
     },
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Liability issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Transaction costs to acquire equity securities",
        "verboseLabel": "Equity issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r308"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Repurchase of shares to satisfy tax withholding"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r310",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "terseLabel": "Payments to acquire equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "auth_ref": [
      "r904"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.",
        "label": "Payments to Acquire Long-Term Investments",
        "negatedTerseLabel": "Purchases of equity and long term investments",
        "verboseLabel": "Initial contribution"
       }
      }
     },
     "localname": "PaymentsToAcquireLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedLabel": "Distributions to noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r11",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r11",
      "r874"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r899"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible notes, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from issuance of notes payable, net of debt issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuances of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r905"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of convertible senior notes due 2028, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Gross Proceeds from sale of equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of marketable securities",
        "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r273",
      "r292",
      "r295",
      "r311",
      "r317",
      "r327",
      "r337",
      "r338",
      "r381",
      "r390",
      "r394",
      "r396",
      "r415",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r629",
      "r632",
      "r633",
      "r648",
      "r660",
      "r768",
      "r847",
      "r871",
      "r872",
      "r903",
      "r935"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, equipment and leasehold improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r109",
      "r257",
      "r769",
      "r874"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, Plant and Equipment, Net, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r816",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PutOptionMember": {
     "auth_ref": [
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option.",
        "label": "Put Option [Member]",
        "terseLabel": "Stock prices above $38.00 per share"
       }
      }
     },
     "localname": "PutOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesLongTermContractsOrPrograms": {
     "auth_ref": [
      "r897"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date.",
        "label": "Receivables, Long-Term Contracts or Programs",
        "terseLabel": "Receivables from collaboration arrangements"
       }
      }
     },
     "localname": "ReceivablesLongTermContractsOrPrograms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r37",
      "r39",
      "r299",
      "r669",
      "r673",
      "r674",
      "r901"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedLabel": "Reclassifications to net income"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Uncertain Tax Positions"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r541",
      "r703",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r541",
      "r703",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r993"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "terseLabel": "Payment towards convertible promissory note"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfUnsecuredDebt": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.",
        "label": "Repayments of Unsecured Debt",
        "negatedLabel": "Payment for repurchase of convertible subordinated notes due 2023",
        "terseLabel": "Payment for repurchase of debt instrument"
       }
      }
     },
     "localname": "RepaymentsOfUnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r157",
      "r264",
      "r1002"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "RSAs"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r14",
      "r132",
      "r254",
      "r784",
      "r789",
      "r874"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r270",
      "r323",
      "r324",
      "r325",
      "r328",
      "r336",
      "r338",
      "r419",
      "r582",
      "r583",
      "r584",
      "r611",
      "r612",
      "r646",
      "r780",
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r375",
      "r376",
      "r389",
      "r392",
      "r393",
      "r397",
      "r398",
      "r400",
      "r530",
      "r531",
      "r744"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "totalLabel": "Net revenue",
        "verboseLabel": "Total net revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "verboseLabel": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognition1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r843",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r302",
      "r317",
      "r375",
      "r376",
      "r389",
      "r392",
      "r393",
      "r397",
      "r398",
      "r400",
      "r415",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r660",
      "r768",
      "r935"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Revenues, Total"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r693",
      "r873"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets obtained in exchange for operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r944"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenue",
        "verboseLabel": "Royalty revenue from a related party"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares purchased under the securities purchase agreement",
        "verboseLabel": "Number of shares to be purchased under the securities purchase agreement"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r400",
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Net Product Sales"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of anti-dilutive securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Available-for-Sale Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r168",
      "r169",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsLaJollaPharmaceuticalCompanyDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsProFormaInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r983"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense included in the consolidated statements of operations by award type"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "verboseLabel": "Schedule of components of the income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r30",
      "r127",
      "r129",
      "r130",
      "r131",
      "r220",
      "r221",
      "r223",
      "r246",
      "r851",
      "r853",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and deferred tax liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r916"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of computation of basic and diluted net income per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "auth_ref": [
      "r74",
      "r76",
      "r343",
      "r347",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of differences between expected U.S. federal statutory income tax to income tax expense"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r100",
      "r103",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r849"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r18",
      "r19",
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, net"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Aggregate Scheduled Maturities of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r146",
      "r147",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of equity award activity and related information"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r543",
      "r545",
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Summary of weighted-average assumptions used to calculate estimated value of stock options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity.",
        "label": "Schedule of Subsidiary or Equity Method Investee [Table]"
       }
      }
     },
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "verboseLabel": "Schedule of unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r870",
      "r975"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Summary of changes in unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r187",
      "r189",
      "r192",
      "r193",
      "r194",
      "r630",
      "r631",
      "r634",
      "r635",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r187",
      "r189",
      "r192",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "terseLabel": "Schedule of Balance Sheets and Income Statements of VIE"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome": {
       "order": 9.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "totalLabel": "Selling, General and Administrative Expense, Total"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r895",
      "r896",
      "r942"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C preferred stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "auth_ref": [
      "r895",
      "r896",
      "r942"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D preferred stock.",
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Preferred Stock"
       }
      }
     },
     "localname": "SeriesDPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Fair Value per Share at Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Released RSUs and RSAs (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r567"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total estimated fair value of equity instruments vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released RSUs and RSAs (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Valuation Assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum contributions as a percentage of employee's eligible compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum number of shares an employee may purchase during any purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r141",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Number of outstanding RSUs and PSUs/RSAs and PSAs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares remaining available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable option"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r567"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average estimated fair value of shares granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of outstanding options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price of Outstanding Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at the end of the period (in dollars per shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r551",
      "r570",
      "r571",
      "r572",
      "r573",
      "r576",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Fair Value of Stock-Based Compensation Awards"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term of options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term of options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r567"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total estimated fair value of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Released RSUs/RSAs (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released RSUs/RSAs (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price as a percentage of fair market value of stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensation2012PlanAndEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r33",
      "r126",
      "r270",
      "r298",
      "r299",
      "r300",
      "r323",
      "r324",
      "r325",
      "r328",
      "r336",
      "r338",
      "r365",
      "r419",
      "r521",
      "r582",
      "r583",
      "r584",
      "r611",
      "r612",
      "r646",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r702",
      "r780",
      "r781",
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r365",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncomeParenthetical",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r11",
      "r12",
      "r126",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "totalLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total",
        "verboseLabel": "Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r11",
      "r12",
      "r126",
      "r132",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockBasedCompensationCompensationAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r11",
      "r12",
      "r132",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "totalLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total",
        "verboseLabel": "Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount of shares repurchased"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r11",
      "r12",
      "r126",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Stock repurchased and retired during period, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r11",
      "r12",
      "r126",
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "terseLabel": "Stock repurchased and retired during period, value"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r12",
      "r15",
      "r16",
      "r85",
      "r874",
      "r908",
      "r924",
      "r986"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance",
        "periodStartLabel": "Stockholders' Equity Attributable to Parent, Beginning Balance",
        "terseLabel": "LLC members' equity",
        "totalLabel": "Total Innoviva stockholders' equity",
        "verboseLabel": "LLC members' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r176",
      "r177",
      "r195",
      "r270",
      "r271",
      "r299",
      "r323",
      "r324",
      "r325",
      "r328",
      "r336",
      "r419",
      "r521",
      "r582",
      "r583",
      "r584",
      "r611",
      "r612",
      "r646",
      "r669",
      "r670",
      "r674",
      "r702",
      "r781",
      "r782",
      "r908",
      "r924",
      "r986"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r316",
      "r506",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r519",
      "r521",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r675",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r675",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r675",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r675",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureStockholdersEquityDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r706",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary or Equity Method Investee [Line Items]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r900"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "BALANCE SHEET COMPONENTS"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Receivables from Net Product Sales"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r409",
      "r410",
      "r498",
      "r518",
      "r636",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r920",
      "r921",
      "r922",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInGateNeurosciencesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r34",
      "r136",
      "r139"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedLabel": "Treasury stock: at cost, 32,005 shares as of December 31, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r12",
      "r126",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of treasury stock"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r12",
      "r126",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Repurchase of common stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r12",
      "r126",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "verboseLabel": "Retirement of treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r126",
      "r132",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Repurchase of common stock",
        "terseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r327",
      "r328",
      "r329",
      "r330",
      "r339",
      "r404",
      "r405",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r582",
      "r583",
      "r584",
      "r609",
      "r610",
      "r611",
      "r612",
      "r625",
      "r626",
      "r627",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r676",
      "r677",
      "r681",
      "r682",
      "r683",
      "r684",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r746",
      "r747",
      "r748",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r983"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureLicenseAndCollaborationArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborativeArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Changes in fair values of other equity and long-term investments, net",
        "totalLabel": "Unrealized Gain (Loss) on Investments, Total",
        "verboseLabel": "Unrealized loss on other equity investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r587",
      "r595"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "negatedLabel": "Gross decrease in tax portions from current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r596"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Net decrease in tax portions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Net increase in tax portions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r597"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits would affect the effective income tax rate if recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalTaxDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r370",
      "r371",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Management's Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "CONSOLIDATED ENTITIES"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Armata outstanding shares percentage"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r187",
      "r630",
      "r631",
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsIspFundLpDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTheravanceRespiratoryCompanyLlcDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r691",
      "r873"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r985"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrants",
        "verboseLabel": "Term of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsEntasisTherapeuticsHoldingsIncDetails",
      "http://www.inva.com/20221231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r342",
      "r358"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used to compute diluted net income per share",
        "totalLabel": "Weighted-average shares used to compute diluted net income per share attributable to Innoviva stockholders"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares used to compute Innoviva basic and diluted net income per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r340",
      "r358"
     ],
     "calculation": {
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used to compute basic net income per share",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted-average shares used to compute basic net income per share attributable to Innoviva stockholders"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inva.com/20221231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1000": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1001": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1002": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1003": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1004": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1005": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1006": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1007": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1008": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1009": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1010": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1011": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1012": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4875-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=28365394&loc=d3e23770-108382",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.1-5)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.7,8)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70258-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e34017-109320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r881": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r882": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r883": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r884": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r885": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r886": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r887": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r888": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r889": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=126903467&loc=d3e32787-111569",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r993": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r994": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r995": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r996": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r997": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r998": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r999": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>122
<FILENAME>0000950170-23-005168-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-005168-xbrl.zip
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M= RM$I1L?&R$*EM]-M>E"D$X1@:6:, 1;@D: ,7\<D)NB'.8@Y([1@,,H]
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MN5/5#!N*Z04O&/4?Z[)GUD *B4Y5"+SIZ\=M,YLG[9AZYY_2\:P &XVWY9?
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M0=\%'J6J_D;9/TM0_G2*MV0?M"K9?  ]HJK5TYR6#$I(\'9I;O_'5#77-AJ
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M(;&&OG<"">\M1! @#>GEMJ:MK>M@\=CHLL'%VKZX&8*D@$!]X528\ U  Z[
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MQ5T4C9Q=O/5DHUJ(IN6KS>N#TYPD]E2-R+L!8[>Q>.J!T9-Y\'F\&AAO7;@
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M+]>5*[.Q$MG!D.G=3OLN=?4_*2WH?RBE*,\17D8+LL.-]X/::[>X-.PQ%1,
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M20!L#!( ^Q;(P8-? 9LG!  G$$H (.0)@,$\J/S ?\9MP_]'"U1X#;[G9$,
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MI;,2^*L\@<+_M_TVC<2<=EO?&6]T]E]FO&BF$S'V?,"=[MFG6)%7::YILNL
M"K8]$ZS2%G-6#8] L-\3.B>PT$:[4%KT65D;2"?>=6LIUD0=(M>C*@W8M+,Q
MU6O^F;K"Y\H1&W901^FXU/$XE/J@4N)=LJ,F5M-PG 8F=L4"P3F/ ;=6/Q9,
MF[V7JG[U@^@?C<LIMV,/;<$)FH!_/MOA]>[VH;CR>Z>OMTSW;\FS$X&J7GCV
M61EV#$>.CNQ0!:%9S4&Q7[*0 U\.KOO_"#@W&91Z>J"FHO%BI2 'P#Z/$<U
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M N'^6M$7YTM""BP6>]>L-:$L#\]K7))$Z#P6A96'+V+_><M!T2'5:P$F59C
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MZJ/2=\JZ!;,PC9/PFD3].(N9+_E0*6T0F<;.K6R&,+%VWDA6LF/G@+)<>.^
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MKJ[(5_XI!BL0N0 '3&0@$L0\C_&^ZB#S26DY!S95=)#3+NT7K/X3%Q1\5=D
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MRK\D@?^^./Y_N/ZY8%L?%^_@%)P/:NR:BO>.SIL]M0F47,^B4>)9Y@KY;VQ
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MD>3467PO(O"-7_XIXF@*' -=\>.PY?"9*,3!,,S'$^WW'7/]Q\],7T\J*;A
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M0W7<HGOS+;3V.N2N3?*YO-EFFDI*5B-?F!@!_D.D0W9FLLLRY@[_RY: X9=
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MS-9'1:U[1!E2R>?Q1]D&UVJ)06HB.2]RG3(MKM@?%/6T%95> B\M71$#W!F
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MQ4P:V;"6B]KD#K;/AB57H_9>Q:@=U.\\GP ^NV\96OP3NF11/SR&H?UC4F3
M@K5Z:3LV4.C+M@@E':/PVMGXEZ 2WUEOR#:!O_&-:Y]?T[@$LO)].OY-PN6B
MBM@[YRL9ZJS;0UK/@HW>0\($T"R@\Y7XT8DQ??1#J OGSP9U!C$!M27E4#UB
M@.B/0<_QLX+H<_7Z_ND76XFQA)G5- K\FU[J;Z3$)7;^ &;[-+WU"TJ4YW8A
M23?H\V=6VO)[<S]V-@PN 5O$Z>UR^)\'%A>D=UVFKCS2#A,7E OS_1$<[&V9
M"#M"9?]+@FH65=.4-E[%C!W?1(C!2E)3?_L )>IFP2?X"?$YWM1BA_#W9FGL
M)6!10G@EMIV_?4&Z!0AF28A#ZUU9( [LI),_0<1$2YOSPJC&RUGXW\%G;*+9
MDP[)\*3FTXN02',63(@8Y?7'LGL<5).F-(GOUHG.Y_7Z7+;81-)1U^4T(?KE
M4;MC9UT\ ^"L([(9=_-;2Z*3FR0U:00Q;9#X;2@8U;E8<[7+*B#KS'E@5(>L
MT2#V;_F,FQN(8WJ+"\9;MC@2;-!7J(R,.=O8KOEZ"QD"*EF22G%-_X%/S1R)
M;<*[:9:ABSS(\J,1R/;MIK.[3X!U/#F\^\9@T\[2)?"$#ZF$A&#YE+$/LQ<.
MSQ_#]W#)ZPQ$F)-P/PFR:+RX9NZLVK,IC?/(V]-C":P?BP[[Q3(GD:4[3B_+
M_B;@,83-,9!SV-W[FO42$%P5#9W??R,!G^C8V_<YBPN\#XF<WW_:0#!.<VUS
M^W-)^"]Y@H>-@Y:/-N#T3<N?8-'XALR&D7]M(U[\K_G$[MP57:%O*W),86F&
MC^HB?_C",CH?W654GU[7VM7.ZBKU@<=;[#_9@VRAN"^H]+@G48]<PB6R/$3J
M0M(_<#W6$TL#CL)5$E@Y'_)>836THEV'+I\*333/5PI)5UNID,A],[F"9F*M
M3FQ22J3%&HSK[2-CN!1]C^-HE5J6Y/+S:P7_%*;$G]+,)P/^4DCXKY\$/3R1
MUW1&A$1 ; 9.V:H09_L6%U0&@VE3J8-2#+HI4",E;C2]A7Q W\A=;*]>2$+M
MX44;.@'>&0C^B$P!RQ",YY7VV8J+Q?.)GGEV/E5L^Q6Y,L.=L>_N[];A8@3
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M@7IZ?0%T3W!"1"PMTRK-N$5T-BXR2Y;,+W<RKZ*X2$?CNR(%%V<$"G(-IH!
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MF\"C'M"">0X=5!@V47"6A1/,-\#*P1_?H+/5C;W);&31%='I49[OG+B%?;%
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M-,A41#H1[8MHT!F5$V*A"(I-VRXK_=A4F3FR)(:4MF>+S+#4,XWMF;R8'PA
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MM,+O<][.Y;S/Z2^W&"0+IO'254CO-+D_6E724+WZ/1Q6=#FCP8\R$>:LQ*+
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M19:#^525Y"PRF\WY,!QQP%#^"*M+("@MR(4_Z]#4LAKEG%2//I;Z-7&S^&<
M7[ &(2AHQHCV=G?H+V-CK8&5C:_F>+P*3'/,D52KHBJ>J^)LY/ME\),$?^G$
MPPA"=-2@\O,8\9$)5?A+B%[>4<16R85F+1[.C;XEGW"S/O,S\F82K3D!C5ZX
M :97@'X,)T_[=!T)S_9SQ#I9(^C0CD!J0HW^8;$QM+5^8N'420,OC!=SG\Y^
MY2]]BHHE)'?8&19ZX*+#L[U,@?5&=!OKJ)\Q,+S9_^_5] J4#L^);6@U$0Q9
MII81P$G<JZ=2N4ZODMAP%)3DD,$6Y5$2WF)C!_WZ-0CI>E8,YFOJ^0D:$U#&
M\<]=Q!GP(NJJ$BDAD;!S,/_ V(@^^/&FIV:="2^>#2+#JB[N>';XR21VO]EI
M3!ZZ;/)+9OWY8-)^M/_^5]>,4Z)!\=_-=[$-G<U4WT:J9>B&'=RR*RC'O#SS
MO6:^A?YHM"+G?/.K"1(!H,/. 1L[P8I?,&HCRBC?\7KCMV<>*W[:_5AUN4D\
M/_RI^O5-#S6;O-Q>*96JL"GSKI]Q68W/R)2/9)SXURNSUW^A=LA5OCP\!P9A
ME;=W3>KZ8=I7_IH5()KVEQC\VZ%M=KW05QK.RT$QT&'H8;7/,1!%&_\T@NFC
MUE?%^$ 7^4)ZHGZX'!I.&*_1 W$#7V<M5.WYW51TQ0>_]I+_3#M>0T(>8&!M
MI5HHE7'A;QS?E>X>)M(%I <TW[FO),XN!)IH+BLLNY?=$-;I2NJJ^.R)<D#H
M"D%>GCT_C*O_5FDM# -1.'(?:^FO[<LGK@<HJJ..QV,),4U5K3MY#BP)89X*
M==_W2)YF#0CG3JK_OGBPZ0226(NB.O7-C,RS&6SN>UI1X^=GS?E"^NR223;%
MVCD0ZXV8A7YOMCC+D#L'@H,+V9S/DO[:Y)E5B KD34T3CV=NQFB30 V A&:C
MLT\!A#^*MNDV%KJ+6.CEWY0T1]*7E'(K;[>X500JC?B#+S:^F.AB1ML\\7SH
MSKQ?*91&QAL)#X\IOGES.9'8L_=,%["C?="^6A?6_:TM!-*U1(_>EJ2ISAF4
MTB>AUWK<9F@]P)!4?]5KL,!!HA0%8L V+.>'^[I:YC=_6+*'B-:EIH9?8U@A
M_LD:^RD@8.Q0Y,!W(CIOX<FMAM'7O[G);ZP&& 7]N5E:XEPB?TN!-J"*DXUH
M(_8)L"=X45.V>@[\6_7I"UA5*"ZLWNKL+:'=%%1,.MF<_WV=ST3JXA3KR'S$
M3S7$P8MW1+\X:,9PEFC4XPJ,=G#+C#2TB&S_DX0UDJL"_G.5=76IGBU@\,FZ
MM.JIO*WD1/3M#Y_6UYY]^P:[5P89_E6_%GCU$MOAX$;:'\' "-9%?$@)$:D1
M,8C0>,8?:L)SIP:LJD?O9K_?LXB88XA=)K,FZ8%<PHDV#QDXTFUY]#NZ"YMH
MYS4&T81Y6YG]S #(C:PFFGB60;C$+#K$3R%"+E)(V^!/_Y?Z-'_("[3 A^5<
ML>9;Z/S#;\/3!("C'NB]36AKO,BQ!+LW>2U'TCE S>]6;Z.$'GND2>)P#E3%
M7]\U;G#%6F&*$*]@QVF(G=%SP$ZWKO_CAA@CS#9+M2(9A7_35/\0;T&X@2/6
M?O&#ZS)YM&YG,V?,<]/*R%2>5(^SO.ZYQ^R3 1E.0*<O5!:@(@H@H.ZW10W$
M4OXM JP56N&Q:<TYA1VT=_.UPTE#BX.9+Z:KV5HZP.2=J%B*V0VJ+?:NQS4C
MM8^37*-.V>)\P\LSX0]18 8<R[B \(?GJO';N2Z#-@]XF>M8EQ-)70-&.<_L
M-C<CEJ<IZZ)T[RL)6ZSDAC%=E,4CQJ$VE,7IHD$*:'3(GGK2K4R$\!U(&+T%
M'OI![W^?.&JGUNMU,DZWJ_KXK=9^!5YZ-#BDO0GP=YT#U@CJ#TKM.FDK#WZG
MJZ6\S@4=6V!)LW(NX?I];MT@>E<,R#%Q'F6#XB%,-K5^8MB47,I#F\515(P*
MI9O>1PTN6+X\J&-R,HE-!]V6Q<>$&C2.(+,EA&=L-(RZ#&Y6,+,Y_=CLCR$]
MK]D %<9]&CI-SDUS#!E?PU_%+A5C(;W"8#KK?6-*$5K%CN.''=FF_'?84 $_
MS^PVWA1[Y_^TY;M^\GUZ50E0IZL[(ZA]]]V=FZ]@/$KH'[$NN!N9\*ASH#Z'
M9Y]A$PP2@=':F5R+(8B("9AY2[(N/^,[\P[O8S\M%ZD_98&#JJ,'YP!V[TMU
M#0K\+?AY;*MV/8#9C<D""4JKF=N7K:.%CPYYS=-(F6W,!A2'9XMX8A8S<1RL
M;2T<[B JZWCKZ:YWTZ%32BE4S9XI-PL7N8@+Q#<R)6F:[#8^Y[A^VM"M#/]=
MU2?QBRW\UE^3CP!\XS/,:Q+U]/EL.FR[A5JO:W_1(D>H2+RW+?[4V5^F8??"
MJ&[G'T9U2;M/(L)HZ?EX6S7N P?YG50:@3?#N<@3:&6SR8<O#O[S"<5^P*S9
MW4D84)V]JD0\#5Y-@O47;UV)Y@P1LU*.-V[>Y_-7G\@E"&S*PSCTAO5!%MWC
M+$]13U*:[KL7E@O@L'+?_-[_*#11 )Q:R.'R\S>Q=@4J_-?K*OO?Y1[=B2[
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M=>(*>6F(N!=?U:L3I,V>BLCNT<4\>Z\18GOJPORG\AR %1.ZX HP@STJ6MA
M@+)3U)OJJI+^4*"L N6C=,TS+%RC HYUTZP7KN(<EQU!-A 0NGQZ92SA]JG#
M1ZY?\F)?P5+@>/DDUEANM,P9R5];=EWM".-7G) ,DLP7+P67MB#=&B-(#=/3
MPZ4W9(^S[,Q<?(&=/W^R0?<Q(*1Z.(3^2PI,<G2.B3Q=.EEW)-6<A/OK+!&G
MBPKSIE_U!H(4SV6,1:K7CU2G3AAK]3XJJ2/*#\,DD+N+DQ[-2OUJTM'+R60,
M>:$;/59<3!5"'D@-;T#3LR(B1I&L5[,L/H#JJ%H6>4DVMF9ZA$]9(V>*2#T.
M,545W]8_YW#CY9O-QG#V*,=("+\]#[)B5G]*]*G'T'=S2B:\1(;[SDX&\'!R
M"B(Z7YW2'JW'Q>#]0R.01EQ(0&DY>Y+_5&Q#\]&2O:[.G=/3]$$N9_PR)Q<X
MLG95EJUQG@A;O$C14N/69+[3QS@H+%H+$F1_MCX+H,J?9F(9.M66O>%F&/,G
M$VNUAMX%C97Z7(^29O/HXS.['9QG9+:V(XZ?=XN*UB-VJ-E$G;AIV14'Y,/N
MBXDE_W#^K0*-!GQU_]T])07N,[9[T!(ZI%HP/VOPY.2M<V7;#47^KP-"$EVR
MN.+OVS@?E.!UK(\"&A:RVI2 ([ WAP:A+%'U#V%D\BZ%](4\T@<G)^I_&UEW
M$%;]+-]'6^T_=S.>V&__KOC^9N=1L.:Z9%;1B0:9%1(*>.VW^XE&H'0;A#;4
MJ3(]4]X84\;OK3Z[++$FCK.9EVC&?ER&LBQX(9!79_5L/!H8=YSQ*Y 7=%W/
M!Y\/0[E,IO3?K(4+.U(;4'ZPTJJM" ^_8OF:D:M0>W/!/QM$D;+H&!MU>PU/
M5\C=!'QHL4W/Q$FPJQP6XEEPBAA( .I]XXWEU-\"YLFH[;?&D&/[51[*D)6*
MQ("QJ*M*+1^-X3[H6]\@VG.K U)(6R3T:'X: Z+U2D-V++"\_K/#^31.S>>5
M[H!&Z3=1 :?+^!W UQMV;Q:G."Y]#Y-BU-30/":P;5_V>]E0L$HL><';W.B:
M?_;.3A?_YI-CR$C7I-993MD]05.5G96)WV)=*+Z?5EQ<=3UL&F0G6-AR>2>K
M>8F)K4J!OMJ^X8S:P_:H7.<:85+4W#?.HQ)^07HL(3%'HD;_%*>GE@90WRNI
M2#5/N^F'LSB09J.-400YPW3=F!@6855-52:ZH0Z!1*(;J'LQ3W!O20XD</V
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MVJRK/:T4@>H-ST8;N& [F.2(F!R,@^N.RVC<I?9"*V=Q\%S\[0O'N)C75_R
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MAG5\$Z0ONP=ND+_9^6!O"/_F\(6Y"Y-Y-+51VC*1;TIX^ZI**N?[V)H B;0
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M+^R[B2+^0'4)-[^5296WM58\;:%4AQY]X73[S;7CWPB4P[K)Z=[Q)P+TBZ-
MU+CA4)E45FA^")6?./2"N!!Q^&12^3D!&$.6T^$.^!:#IK/;#IF9Q(U/:OB:
M[/0/$.N*'R^!QLZ%#9C!9&^ _-^NO17\,]:7@$%M3.&B@F@3#^<8#587/)ZT
MA/BGS&&/N=0_Q0V'<33ZL+<FW&1$EF\T03\.ECE'&DCK0Q;YH\7S%\ S<,M^
M&GM/4I45F:ZT&![%Y:/.;9H9YCWS'S_M/7TD/[GD;=)F,22OFVLRH<%'"H&[
MMJ"5G=N&FA=9]74>1*25=^[DJAK>O8\E+7YR\4UX?@'YF_HK:DTW5NI$-W:A
M7]7;N15K@TGIW-M)B:(I;#_[T%9F]>4[_LR:?AO!+F[G@0@UA)(Q^EY+W+/=
MJG0M0%QQ19 !^>>0J2YG=#^_OMF)E&M=PMCB.V;"UW 8VVJ'V"#HIK4SY^#V
MWM]CCZ]-PVD^DQK]<0N:#;ZFV&Y8-03N1U3$I.G!\S7J]/5X)U['JC^M'! C
M\!'#>KA9;/:B#OUND)M;CI+UW-ANA%O&0*,KMHD0T5L], ]F-(8]9Z^_2;XO
MRA;!=U>;VI](>O"<=W+4<WAZW82.ND_^S;31S$_QLA+]9ZH@WG2@.9/J4R6$
M'#ZX.!AY:_SP6>*2SK)0=W0/:_MCST?@.7E*^-K78C5TR@[HZ]:-#KMB4\GW
MKE@8Q!-[[43A*8:$<K7!Y[9E]3N^T(>)_$1)0\$%5&_4]<PI"![0TL@Y6J'M
M&- [S2JDIOWU>@'7G0&R4MZ\I3>=;KMNZ0*@^82)AX9JY-%$!D_CU?.*DQO_
MPHMNSO.K1HCU:H>I@&OS9N9^=T92U^N8HDO5=EVU!..; L^_;YB+_0_C)?TJ
M@K:1&Q[54IL4\RLJLQ#WM-7*V_PV&RF856W!"4%C_NEO^YY+X/IH%^)0@!"X
M @E()<:7*E!>Y0?V>ZO!64YAKG_PKKK'_2O6)*3-7%(2H\/_[R[07O$KQQ#?
M0O-WA1^]>R*T7!.E!SM.BML#HU3P'D<2WIQ="U<E:Y :'OD:G_;$?\F-,_(A
M7X+\W[SQ#]T$CBJM/<BSZ'FX8E'UWU$9+<-+VL.%=HSWIC?KB+420\J6V&[S
MNA: F5NZ03F";HM[X1GM"(K#TU=WG>X>V A*8>A =B>G6LMGJW6]P.GN0O,E
MP)(5;N<*?Y=9UCDH4WSP[BS0_#.*:FH>(UXHJ4!V?#T*/2*!.WD\'#8P%T0'
M"KPWYRW7)/(U+Y.LUK'<V,XSN4A%_E[6:\.OW$I+^\5<F.)6!#4\!%6@R%N>
MVFQTS7'N;6+)&YYIUL#<\WHW\U%"ZFO'/4,G?UV"DDHFY<A?=SL.7^'PI7]"
MZBI*M):ZDY=)*8;T>B>"8UW,<_^BL^B;()XH%=_Q@53>5:GX)K8MORI6D=L(
M*Z916N7PV>XMZ<[DFHU%LME<@MO[7:I<B(9A/X3&[S8*0>JGG=+I(Y%691#C
M<MR>*OT[6!+B;P6*%X4JW/-9#92MAKR:(S'M%)9HT,PAD^^,OOG#"7M%$X21
MZ(&?+%:D7QW*PMR**!P4*+>VHY^T"K]^A;PH-X_7DWW UU#5[ESKSV>K<YLP
M808$BGI64&3,"O1\,K*1%YN"ZFC"\02PH7'#TUJ]-D8]20M@'K<7=X25Y,\H
M"4SY!XX>\^XDJIYA[5G*0$-IQO;._?.1HB']S^,U7.G809^U>@=T1CL'%S:?
M*N+N:@D#L:F7!6\!V]7CT,7;^#VV20=T6PNXN9%&1]'+6"0W?M!]HS>,B^+[
M'P \R=_@^0$P3,%I866LEWS?__SSO#"TN$*P7-@RC2BHCBU8UHEYJ71G\V^I
M<>(2H,2+VMWG>Q=:+CK-WYO^..>!P#%),'C(8/!= )&9=KYP_I*CIC/LC>>O
M2+7X7L1&5DQP0$AQH6\''3"F&D-/\^!;(/VS%T3K@NF8P;>.?LY(AQB652C?
MQPCN#*<ENJCATH5@Y>-;M;("H-4HD;<P.ISB@8GM=%F+XVVYZ4E=VX0ZJV*P
M]%[T9#U<4+41?0F$5.P(/JMC3"GAN98S:W3_E5!T%2_Y4H;6PK= >9%.&&!5
M/0XS0/OC#)Z(G399?2R[ZYBV*J6K=3!D&:<K^RKW;8 ,S;%EX>_20""I\HH,
M+N#(GT(5@.\%-E([F$A%%=;KH<S\8##3L!D6N5ZCLJ33+#\.$,=][.2/+<\G
M]CZ4WRUH[_1X.-P5&!QB>$*D.#M^)@#J4:3$24S*7T/\G+7?-RZ;>QC!5)7P
M<?G&8]?O$PU.D0*@CGKOOW/%A_T"#G_]JM24>HCAP/K%TBNQYJ<;6^8-/XW4
M?VXPUKK_[J.?I0*5'1&-_>!92*TBA*K-IFN*?%@M.\/6>:X;)O>[C9Q,;LSO
ML/K5X'04%"GAET#'Y%#/D@CUNU]Q:>*K7C!KO7?,1X-K,)5A)>9IA@@+9#_#
MI.:HQ7ZAT'M[D2>^B5#7QYJ*1\MX"2P4147MIQ_6GNQF=)U(J*XDT8"2Q%?E
M#=TEX!7K,&V;25QO,HB$A OAQ:6B6!Q .9\WA$OXG,4<0$%5SN;^_^V*T27&
M0 \$^T:JE>S#Y'R^@H%=8;8B%4"Z63%IPUV7E"JXPC2#$BNB.2+"(EE=&:C.
M'9Y8L]7"Y3-Q]%=\60CC0'B O#-JQO^I5FK+"].'0>_:"PJ8Y-(6;R^10TR.
M4P6(!6VC)4L?:O!1W^;Y\[+>&37Y-V(L=/PZRTF2"&[^%0&Z'F%L=,]+IOEI
M)U- Y8ZX+HG!,)/CR_!X+:XGZB4=WK"=:X44$.2ACWW5GH3@AP>0/]"TC/-U
M_C7S<IB4G[;I0G@3RUV<D"TOPP2?X]2OM%L!WE:XZI,_"K:@X0"2=9WO.(FJ
MZ@2-E">?=L,5'J#SSP0@Z#N'O:$#(]>O"]S=L:29F>DL?1CR[6<TT2E9ZO]]
MO9Y/B_]J9.0CSBXR+H&'$OZW81(;&?L>SI< K/P26 _]C[99=UC[C/8*G(3X
M!E/D'6F7BI@(#%$V-1(X_8/CP$8A!7] W]8_X)@:>-#U9DC,QTEE?PTCGHL$
MM\,8YYK]S%!7M(T&7'A7/:$GNA9N>P18$?XM4+1>"CD'::VE*(K+Z2B;O]()
MG??<_>V;Z'T);!DFX;3_&A(C_&S!9)1@U\IT&O/N!05DI8-$T$)?'3K D!,C
MUSJ)OX]6'8C+J;_FOJ^V:?/RI^<OC6[2.C(!T%NLSN*.=@L'=<JC<=XJWPCA
M><2LC#69_C/R>)E3Z)H99T2]6 Z\ZD&&QOA+4=.^8.;'+)+LS-"7D+.N$-._
M?7EH_6@Q:^\JK_&CDZN+6=^PL(;^^A"GQNF.MT%GXK@(,?;'R[CVZ>.^9URH
M54RNX&Z>]"!*L?+0GXZH'\[?PF(8Y [;OI PGG_ @D)!F\1\,I3D*!>>OQ]Z
M/M/FY2A4V:Y]EY8[5F/62C0A^.KAS>QO@8I>&,9F"@>=\7Y")/(0WZ]BB)6Y
M99L3II#4I1=["MZ:R*=ZFT'GIW%CIIWE(/LCC^O<)I6B0FNP,N0)X;DQ=$0#
M<)Z6"7-2]*R/PH>R1U*?K%.5B!)5 A^#E9L!'\JC-:F,:SAE2.=;S$L=RXM4
MD>^U7+WSK\9!/$[S]3Z3%<-*5WN+LHV(LUX$2]^LIS7%\J$H1+H$B[ W=P>F
MKWR DKMI=+\(6 >>D"%40O;V/NB2>.*]IKZ=:T1#2[R#1;5VNZ0'I?LU_R=E
M&/X?&$0'-I%-RQL$'K-UW$=@!%TPS<G_?MWK/R"7H9@7!M1FH"@<U7K"N.)A
M9TQCL?\\YK=H9@E3#XG7GA*[!'TO]CL*\JZ>6R0AW]ZVR@B\/7P[\9%OT F"
MS>!5"":N)8"K05M:XM:OFO@@%K-.2W+HBP4O2 S@58GDK/CR&VV"=;%(UVA3
M:'D1J_:&I]/E"/+%MP'.OT/ Y!QXEDL@8.U458DC&SVA>0OKB-S@\_22U%OY
MN)RNX/"C"(J,P[T7H;P$)A,-)BI1%#QMOQ .$Q*LO@)0LE'%ZYRJ[$;G9,#(
MM_I.1%SZE5"$D'"QS?.EW['CP1<!KSE':C.N8R^!-L5[=U,E<]X_SJ\IG'OD
M2K15&=A]PDQ'-#*LJC\F(2ATJU-[3FV7U=0HU-PX[4Y<^]"5GX+]3@'R<,IK
MT^)-M6DBF [[<^BHM,0$W+DS@ /C+G(KXD>;NZXU:H57>5,OD,MWB8ZH096^
M$QN'R@W!B;A/I)R5-4RS*324,1LCYKO(_"-( ^7N" X<9L3@2<>=GBR<:YE*
MN;V3>O/A^7E)-V<$<<,U=MX8JYBDX?^F&M22277[XJM-*E68P2JSN>ATM);6
M?6967NFE=<B=(2R]>#E.J,PNVYL)>N_*G_<Q:Q-E?XL(I_R23<>T483Y[M%&
M^YJ.RD/0]C.ZX\46%97:$>6\A=%?U@)EWV_+9%*9?JOO"5# 4L]Y0U[77TOS
M[AS_Y8]H.#/,W/ I#*W,[4#DF'5X. CT:M-:<3I;[HSI7ND5*!"A@7>US=.^
MLYHXTA#2)L^R$>*YH''MVHH$YK[5-P1 X,PY?VP:]9=.0L=V\-X7@K5#?CK?
ML-]^SZW7?F!,N-WF;4,>=I$M+8@-4F+Y/^47#&E15%'FY.B5F6FSS3ZA$<G)
MT''R;*HW&J?*')_Z5;[YO42KU7G^BM]<L/DR,&9:_5LYKIPS!<TO3C2OIVH!
MC^I4Y$"G"=ZJ^JEL;V3-(V/'N1Z5#'FN2[I#O[*%.6_NEVQ3V"_FK)?,=3X8
MW#";"$$Y,G8PO-I3'<NLCWC,VB=M!=FYW0)K)P,FOD6NWL5SPVUT,:\;&7\U
MB>0_W(UA3%QT4M(&VBUYP$WVP,9Z$4][!D,])]*WJKQ^+/K$5@,N1-W=[7_M
M///<1L*F]1*@)2#B\XPR.Y^/YS:\IH]#I5Y ZM)9T;<"93=;)G%VR,'K4!+9
M^7R*M/+@X?Q0OE"7=*+F0@7HT_+ABKXOVKIIRG:O0S6MN+[\5 C5/",[=5OR
MBJJ ,&Z=64^\\S^NMJB\WSW_M*NRBC9:-F0D4#$_\EDZ7?(M*M8\:XNAD&[Q
MLP,%_B6I0*$*!U;ORHNR#F<6V8M8MV Z8FFM0X;QN^_59<L?*S8+X4=>M72E
M5'EN>VST Z;?:F) *,90>>W<A06[Z<3/#@#%[_<\#WE(;ER["V;C["WAPBXM
M^L88BV/WBA2]:+)6I]Y:O0\:A'71$:V/Z0U935XO\GN!?ASB.E&^B4*Y2[M7
MJ B/[K:MX,12@=V\8MD1O#2<\>D7"T>"Q;]^,=?:77-X5Q0\%B\X]"U9!J5I
MD6 5TVSM+D-.]>#JI@ H MMQ-]Y/8-(J4CVF]2&(Y\7!'=#@2 WG5"?*&R>8
M?SJJ>6MF.&;[L:+REAFL$W'*FWIRGH!87RZ"'+_^6]<S)H2W\4M@Z I@'S!4
MW@]NRW<C+V9V5./C8XJ.261S.>1,LO4C2S7&,TR)C]1'\W\DWM;L/-@R_J^Z
M2P^!<_34E=\_9ZC!O&^1I>B;[OMY\=.=5]:XTYI,W;%MY7A+B7V'OM46PN1'
MC[I>41'R3'*24DEC=^F^DV)07%_&ZTDO0IB-_=?A6WWFNX\!^K74XLY+ &3G
MY>AXD2TT\Z--(HMOB&UI[PU5,7,F97['OKSBM<GLB"E>'5EDTMCB#YI?5Q5B
MX$W;,UYN"B?A3QPBK)392 1KN-B:Y">_S<.7VAKO8Q$HJ6$/IK4$\;H07G(R
MC8Q:IY_>7=5+\_6CQ[:70'Q<>-/6!\[^==!ZY%](="<G^\>?]6-1F+WAF^GI
M3M']W\AG ?X7^8.YV*-%#1N:[)U90N)0X*ET_(X_:[D0 (T*RIE,N@]2;O3G
MV9\D3)L(7A%5U.A9OR<C8=J6+C14;VI[(LOQG7Z:FUCU>7Z.C],3(O:S6!=S
M94PQBNK=T=Y5Z#>[U,SJ,8L&'<Q57EU))XH#>C+O0W&B'5GAFAQXE(Z.BF:=
M=K[ZRV\/2<ACOX-3AXI!6!6,2*LB(YK-Q*D\_R(5X\3KQCF5'7!M<>59W$1#
M1ML\[XB\?@["=KTJ>'/4.^XW39E?6UX;X!L[1I2OZNK9=,-/T!O5A6YGB9+\
M659/*L+=>AKQI:^.J;OE&%7;"P@4^7:82PW),])7I*[,* D;)U.7BB7/1%\,
MN43'#50>SJE-&HXZ5K(R^\V8?IPPRK!C_1 =$M*-LR4>IZ<?'V](*D@Q?-IU
MI5[+1-/ZQ<_O8^]'ZC</EIJ"A)RB!?W=WA"U)+*^NGV:1HLEI"=LF_BO2X#,
M8XH[:2F>5TGT/ICT&3AA6Z/HZ;%;3?I22VWN%_'$UTW<7J72'":'_;9^JIC'
M$:BFX.FCU8@\5:\;!=RMRZ*<,M+6TCP8^J1_" @"OJKTW;,X'?27C$@$DK5Z
M+-HG);7DM2V;@&<GZ;9E6JR/FYD'0*?O>[[E* :M;FKXJ.+@R*I]-R;M3EZ/
MO-M("4YPJ8D*/C1'08G999ET3F5AU/E:'G) E+:(?T8T\C^+1O[9H+8X6W"U
M*1JR__P0<B($.73X-]T>;W G9RC+7FQEC.R)1G(W7T--I&IU0OR:IS+3TRZ)
M31:^#ZFO@G*-'O6.S)AT7"_S']%7XK6IH@^(! 2;Y7W1M'IC.&VW'UA[5(]0
MT6P?7\5NMZ5;GV-K_+-T7TOI8L2W0)GB,#QK-3HNJ**?<M-VI?J7H:B\]TS-
M7%I0>ILGA*P96X,^U\7@$W);<LQ,E=WLY!2%C9.8C=]XZ_/+@*H*??@(L,H*
M0JS(;=I>JHP2DA68W/UF/BO J<3SX^M%NI]>WN]<4XQ0^OBB*+,3$Y5C"^*+
M/ZLJX*((QIHA]T!4B@-2M6/&GI4KG=?C=+]_B\M5S)I8BRJ0$'K:*EN4D:5)
MYW4BN4,.%:37JPOI)@D)=MF+G":0\HS%D]8=E>8JV>2O!9KV)RE72UJ%9G^U
M#YCR!HV]^UL0G?CKSAC.2 38(X,.V^R02O++Y70H,TWGMMH!8V ;&>*MR(KY
MG"J@/VJP(UZG.L8BV6"D^UP<X=Y3X<0S(Y/_3$^)PQGS%/FE*XZA=>_QV)-!
MO5)RG@/E/XOQWM8K&CQYI-57<?286GJ&^ULCITPSJP2HL0;*?7HP.72H"X['
MR6#ORDODYX;+J_BDAOZL@2\]*GNXANV3$I[S;FZ165Z,,R=0J].#3DXB#UN/
MM?%Z5N\;:OO>/YSV/V95O5Y;MN@DVNCFB6VP2X: Y7U1$8LP%GBD>TEXR(K"
MS'/-2X"(+0^R<P-:6OPU+Y.*.F.Q<B>E_8+?<)BA=>%!6?(T5"C+68QFR5-M
MWBC^L5N/Q,XAX768+="*NP==M3N70+AJ6JW"^6R]^:/"U>]RNVJ<(B3^_C7T
M,9!62 0'?74ZU;6MLI[<[BF]*\@J2_S^#4;%Q=0ST4@ +7(51S+&-Y%B@"D\
M] (@'R=Z>+0.I"[$W6;^V"A^:T #/^F5 ') [LFP$H<0QN:_<?%SQZ?:J1U"
MR<-<SHH&!N3L/=)D\#:JB8:<R+]LK9S UCKQU%&/1M+GA'GJ""\7L/(LS^")
M*-':*KT7,B-4I)Y[T4&!]0F<99,_X6-K1\JJ:ULBV-+,@XX(:E#AKZ+66!:3
M9%5=E<@G-,3PA!0AN[\7LD!^M$!L7_MEHECH/5^[(-O+>37+^*F>WEC!2=M,
M2B@*&KKG9[JHHZ(ZFDY?F]:I^[O#<"7!:#G0%S1='D"#%7N*EGI;Y#ZGOS./
M<IBLYE!)ULVF4>(-&NQ&R.[E99*EYGQV++ S]''<=/Y5&_$M 3%E$:NPM6:#
MY5_:([??'T0ZFCUZ[7D7;<;JS2PJ[3**[MF :>DIL8D0P! Y/*K-1&(-QSO]
M&0:;F_6N'QCUMK1ENCN'3WLC2(L:;#66=Q-G*4IRH6C\01[P-*OY[2>QA$19
MFO=_UG*9BO4)=-%W2)'%[RE+[!?'O*T#Y:QI*&N2;%3M]@-*>O629C H=GQ7
MD0N-_X+RO[&D.<YUX&C#Q,4FFM!MK1 ND:L*^&U 6JA8L:;/? ?!6]W=< /C
MU/DGLLBP.0OLP?H=&%9947SK^C(,^V['PHDU(%.IJRF9TF'=7@ 4BK5&'S5R
M;AB^T<G[/)/?\["L6N=G%OD+JT2?=.B**?X.NO,+ZA*@FK4]2Z4EK\\OIF"-
MC<X=0X3OF3[3!?=#T#D!/'!#O22<6+Z@&L[[5]6KN2^^SD^#L%:3VLBX8)8D
M?$GJ8#N%?B6S[K+):;\PSIUR9^8BX?2XV(7@\6%(KS8*AY8 B?%*TY,R22]J
M33I!I^4J44%*R4!2A@:?2 &@((YNPVTK@';\,/]5C$U]>?+5WV_?D?<J]0"8
M]R8$KTSV8\%Z%6"O>7POT+3M/&Q9B?*^;OD*M\:%\ M0JT5$*+(V8)R#)"@8
M'\,--MV85<3H8<FJEHE$VU3V6P*9E& D9X@$! 376M,9-Y_;O=7@&[0L8TVF
M1T>LP88+.R@Z^U=13@*=T<ZBWFDL;^@B$6*7L[OYYH:!*'V2%=G]*N;33N_M
MOX3[/T)[5UPCI6VZQ*<]I%O.YF]%A_!XN@^7P*]ZJ_-@JHGZTH#K.$TT;H2"
M5E\I Z[PY;S9Z#PD%C'@L/%3 +2*P#Z!T?@IB[*[&86]D!'R\N7=%IL$@3/:
M#0O]I+'&%FCL\^=\RRFU[WJO+G]*>?DS).W.\E(:8:HHDQ8(AIC1GD$QCZUJ
M3@V-RI47])")_OHILKCO9FD/< RN?(7C0;_*772^]GRC-G^FH7VR^(U\V-VO
M6C<#-4$9\7@/P@VNN"Q0![#;(:C%NU&U;H[^I ']GE&)GS:OXOD4,Q**.@FQ
MK742Z=R!N.8=#_<U5JNT_/)K\AW=^8<W  0Z4%#5FA&IR'\Q&(Y[?+."?RU6
MN^H#9Y;#?D9[Y!E+)-"-;@SA#)47RUTO?7R0G68.2UVZ,N#Z6,[5QS 5IX.]
MB[\]_ME\2/AKQ5@:E2*SZP]!RE@FJWQ+]A*7/VN*;00+/V4,"A"WIZ$0/FG7
M<;:,*12<7T[JDL\3]G&'C(W*JY[+S?/E? *'%>UD)]'C9UR\>-3,(IBF,ZGI
MR#&36S 5PNMY&W9DO"V#K]I*F-U!L?H_8<+E:@9=$[7AX77GX2\=?'S?/)_P
MG)-,/W%LC@2[[(S>Y&J(9D6ZU!T/1H\_;]GNQ%D$4H+9\]>U!#*)\^TE+75'
MA;<_]5X/-[_9;$, 3/C*5X0O]'-PD3'.O2==1PXV*F06.H(VA[+>.Y2.+=1&
M&Z*L>[T-%84J$V]Z&XXY&06H"J[7"H Z<?1H\*.AO6]C'ELM/Y\_5%%W*MUY
M9^3U>O\2R#PB;4C\:X*5@V_Q7&.-XBJH[E>E+/8+)G/4(R7O7UM(D3MV!JC$
M^D8>IPIDDG9GH]S9C36*6;"JZ'P86BIR3T+!Q($A6/M6E;*SH!B#<$SZ,Y>W
MD(_%-H1$BH:P^5%.6&,>39^\%;$([[]?O6^B<KV%6X:/R7, ^MJPD9!>5-$S
M+0&*H_70BU+4CKWQU]BI;[%S>RPOM2WSSC/)?=8D.-L7@@=17XPK=X@W674T
MFP^0*7<22]:1H5J_[L^ V6/=ML5UP8,)<,8EM:_4(WM^#R>.I:='&G8UG[OU
M!J_EJESHB+7#RAM0)G;Q<)_=:6,]V$X5HZNX]9^$F)]$1$J#[ &5AQ($:!7E
M\+?<]<//-JPCOO^E^'AC92UWML6M/ZU.3#/1N#"V$_H=\;^E8F0QX3N-*(IJ
MHNH^%3Q.<]K-)>*SY#8V4/K.ZH-;DC^6^-=E^ICWR('*I:[AY>'E"EAIQ-LH
M%^Y'>U/1+SAW,T8:#"*!/O3$9\DXI!FG=K65W?;VUZJ$[[P_K)2RHI>B(\<(
M25YP#3JMKF+K$<,#BV9_W^IHQ5/.?;<I@ARQEWHF7",284['<1^M</PQG&5'
M/<,6:F>8B5,SQ%]18@F@GE /]^/,VISJ,S/YWK.-;8MK":)?;?K'HK9NP,#9
MX8%M;4;H[H3J>^@';6H/'GM%+Y%?3+1QQS\1TRKXAV9B^%8' G_+RJ04:\L
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M@<B@MYR+I6WW<%9+1\5/T(9M<518!D99*Q&^Y:A?ICT#&TP^Y"\$CD&C,AV
M>ZU'M,FK%+O<EHQ;$W2A\G][L@I<7#'^N[[6AK#=H^SWR-H(X H6[7G5?V4
M/&?88J#8$L1I0+^K3S&7W7"1-9'R)NOX@%OS9H)K06[>S4#Y\L6]=G^>)^AW
MR5%YL!:''QN8JY*/D20)Q5>?I5/U!:J;*VP58M3;XZYC'_=J%GM(6Z>!RD;F
MVA-K#IOE_1]?\9ZO.9?:2#%\HO-MZZF16M?->;C?"NS%3%#7Y*WLH28;=I:!
ME5L3E;XQJL_6NB-%N*E*Y2)XUE4!#P[A2N<(!&E6=>DOJ^JZ7]I]<*/=%YLJ
MKSFR I_Y._3B27#*)>BQDW2.B:(KA96SK4:WWK^-?>[X8OFP^WK/HF5ZY6%,
M=G;#NS3)Y)(L271FK/20A;Y2,V"8]K_]9/FU?4?T]&M> A9U&:M'1PK>7W);
M9N2@$2)+-/D# Y.N9OX?6N\Q'R34*8AV50(^UG#U'9%+@&OO;^G>^&\;S+I)
M&@PK\C<G]<YK[L]ZB=U3=65E#SD]%XE(;BA< 4S_+8DL<U84YA>59LZ_V$Z<
M-RJ/%2V@PO>;[R'[Z>7ED/T0]=A7G^XB"5S[GBD[9OH'O*^E%A8K+I:]&32N
MC^M^%8Y$^=$D;+7(@ N!IVBO*'?32X!XPVOGIW%GPO3#\D^WGNVG"9"S\L<J
MY^-%DF7PG%LC'3=[6#>\R&/#N(,BPKE.Z)<%S\7:A8,0]#)5 UI1U&SG-@$0
MM@#Z'5I;@WVL 92J()&OW)B5"\=P]>FK@.I,*O!_JN<DK5T"E $,,SCYFJ9T
MH2>FDW4/'W!P,^EF93Q-KURG(P#''69DS>+D:WE-<JN9YP^$<JPY/55YBZ"U
MZ9!9B4T$92/O!H<(^J(D^4R@$O[R66U54FNY-%MMR#C47-:&M([]J7;I1,74
MX8[6A-QGS<G7"1JB5_%A0[&J\,[2<\F-*D:J6W'%4!MF&>I9I5N@/_?NN!R1
M!BK0=C915T# ZRF,8C#3/O^5C'(3WJ!T]9WF]9I-?\@=3'$@!WO=>#W,&]57
M:4F1YZ&I<0D8RV?X<JH*99R\<S>1VI[),9WEK>VL<_%FXOKHB*0.V39*ECY[
M,5FVX:,?&Y73DFOWJW3&1*G.,O)^,^?8>;H.X'(),%\"RXD."[NJ?SM15%\"
M4^5X53,;?)/AWZK:IJ(P>ME<"%UY_$ZB;29[.D_T6^@=_1!**O-G!M"V)D 9
M?:Y56QJ*UQYUDTH=P+SM EX T&S ->._V-H\J;IT"9"T+2U0YKR7V$ZV$&;P
M2*(F!/L6DMC?]EW!\OR,P7XBI!$4,W-W'^]:NY-I6J:'9 /PJAU69,W2>,7>
MC39FR?UV(1MK3I>QQ*P+91X\R#Q_D3-\&A)U>%W3!#\MI*N6[V&_?\6%BXD7
M-*ZY3+,56SEA;V*=7)JKD[LI.3P[_;C.*E(YO@WG?VX8[0 I=TIQ>;-O>[;3
M\<$JD;OZ[2-PR8MG2UNIP+&9BL&H^\='TS$7A5DOK"K;>T..)$R5,+<24%&W
MG<5-Q^JK(BU!W9'-8."&#$C^WK)+/WP\;'O8J4S0GN-6\D,\;U7%503I7422
MS\E;'%\V7$25Q2".+8HHOG>'9]>.+? Z[=8[4""8C@BY4!'Z3MYG/JGX&ZVC
M1-,4>R#2S/BCS2;3);!PJ^$ILBONL)@>:] S?48WEAGQLBY8D[C: V  TI\=
M@1?8E8MR38?%]VCL:#=\"LMF31[?6Y^U' H9H_D3B2%XUU0.N%8H%YNJ4=CW
M)H4A6$T/C[8&$SAO#<82E9.4NYX2P#&<$Z4W[OS=P8;ZRP9QR9TIGOP7\73^
MT*\KB%=QIU>Q4?@:9=Q\ ZBEB51> <F;Z.DM<L0?\_W\>2\0]8;KXVA\+O@'
M[_EX1ACD^@Z> YJG3?E#:*/^V1,.ZL_$R0H1@_.9E/A(@4Q*%YPW,L]/SPW9
M]^4)J^-CBD^1B+G0V:^!!O*TH6PV$KGY<QOW; _Z\OOM:QW4'A:^Z5LI2QA:
M"\GX/]A[[[ FMVU=_$,$E!91Z25($90F3:4&1)J(%!60JH 4J=)+( @"T@4$
M%94."@*1+BWT)B(=I),$Z26A!@C)#?OLYYZU7/MWGGWO/K^][M['/P8/D!#>
M.;\YQQQCS#'><6N[&;<Y,QR%#M#>MBB?,'IT*\,Z^1(G7T.#\/O/ /V)15/M
M^I5OF9;.4'UC;A^&T0?/]E]>/3QJD<9+HXT-UBPK>_Q>G;-9G!M[$DF&OQ%X
M=QG&Y60^CWPX&WGR0*%%XBW]> 416!D:Q*DTR@H$2XV4]LT\E'@^H"/DG* O
MRP3IO>_F,SO\+>.!0_[BB&S RC4'DU=C%ZP@+=GW(X$-\.ANB[$W_MSM14ES
M9<8?Y>.?(]6I[[$<8[']\&W]2YU?EV[)8(9]@8O(6J:A8,_Q)X.7EDY2?=B"
MGQJ$V+S1=![=6C^MY>+<'<\Q'&Q >C:>/;-"@_B3,^,NQW#V4OX.>:+U?@.:
MPI',[ASD0;*T9&W: '0199^#$6A?+-?Z\+VI^ED=&H=Z_N,9GC5\T'"  5?:
MW+_(>T?[4?,*O[?OG"<UI>0W':KOFT93\CB73-Q^OSB4;6J?X9G+.7*_V!H-
M O\.)$P&+E5VF,)CTN B?VO#.%CBT^A3+[#^+*BCEXH!&X4ZRR4[M(H:..>R
M4BA5K>KZ13EIFE6Q>7:&RT?@>P#S;P-:0N]&"#0+QN]#A<OH)&SZ9\K3>B2$
M+0U?1Z[R=_*2C+&A:,/'R,-S4B"0_?YUM[).VV-*)!]C7$TR$M@K17N]\T7V
M1/8M8R[<K=DH*IQM/Z;1E ?6O:N#/V'8&\B*182BWIWFO/6%0$'[.IF57Q=3
MZ?D@57Q_F^/.E! F.1XMPKK5;7X,:^OA=JZY97KJ]G=">)T/2?&4RKXI&,=E
M%U8)1 A7RL9.A .$%\!Z#/BLQZ2*^F=,:C!VN@QWY:4XM*_M@\JJOB+V2[".
M$A5<6V>TAG!]TH30!#[0%LKH#Z3U\5;#M.7DC$L5^GXPD:ZMCDZ7B@0]Y 1Z
M'HQ42<,QZPVZ>$C?6AG.96IWE9G+USOZO*+NYP:!_B Y^BQ*A$ZJ%TX56X&Z
M&Q$3K5\J[(#WVH@.@DQVX/41G^#O(/:J V'%F1*V!S<;4*967!HNB1 ,#PYO
M=TPLR._Z&!&(E79ALJ!;=68)5YA_]39^RVQZMQ>>+?04!T'VX-0('/9]'6^<
M7:C&!7I,/[.KSSQ1'V1;6_B'&X+^H?^DQ8W?)]C_M93U+P(_A5M$3S/XF!CV
M%W@H*(VJ"]-)%3PK,%UK %^Z2D[UOO"^<5R<=\6EJ?&NQ_RUV(+B3RF]S@:L
M5,?G,Q:5P.IZ%A)76G4BIB@',T-:F=I\QM,N;DS>]ML=Y2%+7-^TZD<$85Y&
M"LM;(;N<;'4F>%Y>Q-9/Q;1/W=XZ5*:J YSZ_E9!@.F5UH\P!E/<:9]:\9TL
MJ(TVJB_RB]6\JZG["*><30F!^AZNI*?9NPN55DGI\'9<9#/YN>CTFW6.)ZG3
M%L; UI@0N%61MPSS,@PNW;4PES U*#K[]%A+Z7&63O*/U#T8L5C2I(#M)9?8
M NJZJQO%0_MG!&4:9%@$HAF4.%7=F<"GH))YN'QTL\'8$]DR>FP9B*;HGN3G
M8VKTE_PWHZ,C%Y?GIF.8;N/$4&$O4:M2CE=4;=%!#Y\%-1PP"J69I@#[-R(_
MYCXZ]6CL;FJ6HSO%X 4IV\-D(&[>X,-_/"&$-U8L#JIGCYV4<@BP]-GJRS-1
MWGE(4VKE.'&B76;"=[D[@.%O!XX8-Q$U6-MV+B$LQ7#,3(RLAF686AST4@3_
M??HKDI?&@M#C7.4Q,%MLLT:%TZTE)[OK(5^=7MI?[EO2,\+B=*D&I0PCH7RX
M=F^4F;:\ NH<*R)>LZ)&E6;NN<3=H)G+9-S1Y-%6"@%%0=1"+00!_,.Z?NED
MS,C3/OY!O:?NIBN;U!H^&WU^3(MOYU/%4^;"PP-E3<<.:Y>8E[Y>.:$X]0Q'
M!+RY0>^/^@'T6<C[,*-O5>7ZA,I#T$'W:!$JIMW@ER(U6^P- ,-;:S1OD78
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M\Z9]FNUA,A%0&;S?'SA<S)K[)$'<B;5-A2'D\S$?@61XSD+Z\;MW=/,!W4L
M!YG6?\N:^CL+VZ"C!YI$H&,H"S:2"%NPJ5MO@FV<7X#M@"I)V]+!_.3O7HT1
M0^O$%$CY"\G!J!N%+^\LGG5C]XW]<1?@HI<Y%J3 C)Y@<H.*5B?,"+QC;#G_
M/;[#;88#UJ!E(+8R41I'M?3U /'-A:2L4]]4B*[ T.5H@AAVN XM8M /8I*O
M,+CTV<K)P=&PB^KC<2^*-YP20UL]S29I-%TS71KR I#75L 8$O="9O8UE8U
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M%A=]*@FW-&$KXK9$H.SC4C6PL<Z(]\+TA+N<+RZ+#3!88Q)$T0H_:OX@ZD<
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M6*FT%NT2(K PMKL$[+7O/._-J!CVB'$[2[T;7WOFN7CR34:!:5KU/E5_L>:
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M;>&91C[N:A7]'AW7+R<OEC-7;?/M\FUH6^%OE%])HX.JGHZ.M^)[101<G8G
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M>I'2@.LI%YVV*N!;E('A;:@<D(H?-;N7+,,SA@S"O_&"4!?GX,]@SK\6?'G
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MQBA]EBP.!::Q2Q4J,=%VN16YQL^7X1AVS?\C+0..#:F^0@1F'E\F D*Z0D1
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M-IO;'?+ZY(,CQMU>E6"Z!MJML1Z/7*VG2:NJ!ZGFSJ&LI$]KHX,&Z!-B1X]
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MHN'=W^O[_^\G>/0OXE:>_QJ ]6\J9A;&D0U,&/L.LQ:GU#+C:RO6]%<8VTD
M33;NNM0=APR06#6&:,%[89+1^'BODMO6BS_M#-L4-U2GW:',.-9 !ZOI0[8:
MO"RBKO!Z*\/<(<LGIO<@.O8-_5;0T9'?R;F64\J0A8.\A6N,!T6*MPI$0MB%
M"E'$L9\!<D2%-31<1Z5\++Q!*OLB[)55Y%(8R<1-WI\!?!AJOSL#+H>M>=)!
M8<NZ_/0$(F3ZPO@E'O M<@*_8;[BV$A9QBI&9 Q+?P[>[>:3QP-+WX4KJ%GM
M-/CDD('*GO47J9X42S8V2&W'&5#RLW*'((A^K^D4.!9KB HWU0-AHK0JG0&B
M6^W4[B7W.C_$!I+OG?S4XXGW\;]M172NW?M,/3SCUZ>5 P00_=W^R;(/@]P9
M.W#BRS'MHM4R=]9GESJ%E$Z\SI)UG8VLKA]9W&XIV8+6SC"?O)._F71-H.*C
MUSV&A,X/D+?IRM"VA XO'+VZ.TM+,:BPSZ^5Y&;_"56)'O95(0S<LL3R-D#V
MGM=WD(3CM?1ED;K5)VSAR][@W4B@_*L?!=JH,;LW?X9#2<PT_*.;O1!/6MI"
M$$+$)N.V<L:CNJM+_KX+Q\77@HK7?XFDZQSPQ!A9<,M^#8D@'T&HJ/IK6^F<
MWS4QZ4<=B;LR79HM'Z*R[^P]>/%+Z2T;'@B,! X+N)ZU/AKD'1/)N6+2 TI+
M%-JLZM>SFCA"UJ7AAI0YNCOB"FPJ[L.QAF87G[.KWB_.CGC8MG)_X6VM/<^F
MBU?ZJ;?JW*!\"17$CZ!<MTW_NH&&HZ6(6M>AW%A(L?.8_ -YJVS&RB01H5VZ
MW&=R;*WV;(6-T7A@7U-Z[X27,"*[+9ERWBA*/O7D&D6$OXIR?AMKD\(A-#AP
M%LS"6SW_3U>J<,IN3^9,P6V=Y1.":-:FF(EN@6_J9.QPAR@B+$!WK+:LZ,]E
M-E.TOVVQ/[+@G9?:DF_1I;HV<)F[B@_Q(/+$!SC51F*O+^[%D.L'LIZ4UY]P
M/@V34$>^N=#Q-X<*8;6K]9C]W,]I,B1Y9YJ?W.K3X)%=;@]?A*K#ELP0K7,4
M8]+.^LK#+L][Z?EX;B]P>C7SX!B)6-XV\,",6Q(_>,8\HQ #^N,SN@4K#._P
M*6.*U.!3)$UHY1%_-?>+]9T?$#12N%>9%L;;BB0K+-A2%D@T7W1=?Z!SE<P1
M["ZRS+E@D^-W;EV_"@%@8F-\>("Q(9)>35O3GN,)Z#59H'( AH0'&OF(XB5O
MXJ\G1+C=%;Y3RC/MML;]&YMXX&A%%A?HO+H7I !9=-%9V9D\=CS>V8AI92W^
MBKT?(QCF^=@@Q?EV('?.TPP0T44J'EA^.OX7]LN?W6UPN?C$;X#T=^(->%UJ
M1#(AUW_ =)@,^'6?:\"[CK[!)V[!#Y\G'P8DX0$>9_#921P>N,-T$+YS%0_P
MC7W$ T\(U&[PI_'@F1XVZ#M\:PYR0:I/WBUC)3R\HRS9C_1_S1'UR:1X]5-/
MZ+T&M45N63KE1Y6-J/$2>*LZ#((+JEF[P/PIJ32> GLVU7,7<_SJPI6">\#I
MRK3$C!H;[46+9$C'92&//:@.'F@17&P\8SDLQA+'885(UJ!1\"M8A:4=VI;I
M!S]'>&O+JR7<:B*E.2CCFYA>W^Z;FRV8P%'VBW:VN-!GW[XAH K9CK  #4=N
MX('%*ZCY"ZHS8QR1.HXICY1NJBG>O)WS9D:+.GNH(7<@[3NB_<9V<U@13JG'
M1=XMS#Q*;E9S,_M/ML/1?;I[SFY<]76:C+>$[L>0,3VF!LB?0L7\'N"!) )/
MJJP5OR"6/TL/5(PZCJR(A(:/)?T$R7#=D9&Y#60%*X?'=1DAFKR>80RM69?Y
M#T*/.;IQMJ/@*0Z<YG?X,5W4GT3,:A0+3M,2<>%':/&75& 5XNAV2N( /D*+
MXX++U^&4!.N]A_GBZLD/I-<:R_)O#92Q=/X2LR4]3V;%J=7B@3?[(HU4BLI=
M+R]5S+=)DIQ% MOKF1_75%=/K9R\$3,SDJ?Z).M_?76 1%:@+;&^*5.OYJDK
MF=UKDD:UU"BP!9N_3FV0]M@TP8OZ2?@Z/8$BOKA#4UCW^AC-K]_VA4&*U5#_
M)L 5"G/;$75A&SJDJL_JU<R.DUL.SH<?FYTXH?# U".<Z@X(US"/!U0R:(<7
M9D,+W[?L<.UD:*2OL#M^5)>X;2VA%P" 0Z&8+RY<XZU@>G7>X()G^]31^XTW
M+U1RE1D(KKXPX487OH@+FORUMKC3:PV$.?'#;_[L,F$ENOBX3 !UN8A39O/7
M)#,1DMC0Y[C!^7T]*3QP3ME)6-JSO^M-?L(I8;5Q%Y7[*36@J6O,[Q?;2P,U
MHAY&]"G0)(KC>E78X<2-R^\<&X_&X!>LHQM,*W@ *.:MQCPEI5BH+Q\9["+7
MUYR#J#&MUZ3GV&<YOF>/_?(BY3AEW4J3$T5^I!2XZT"R"@\$[S\N@F_]<KN@
M$5Z'L\.[HI#@<S(+/+#^K?ASH_TJ"*V\&'[/YA;X9,IX4)GP?@DL;9!CZFK"
MG-%1X0:?$W[ILO_C=,$:#Z\5P]#BV,B:Q@MO@NDSV%'PR1S</?D_O4"88U^D
M?<??)GQ%]>5'2O3:WR09V98B6H"40K'1\FM_OB:&0S6,>QM+;2,5]0KOZ_6-
M.37YDK/AK!L2,T ?(8Z@4^ZR_G,R<5Q,8D/<$'R9Q@8/6*$)K\G;\.+B*V39
M9QBRS=IX)J-U!M'$ _'2<1>^A'[,B 1.X<C".F,X]TK%9]E6T?8TUZ]'#_]D
MSIYE4EPMKXR=F^./9'W'JQ9"^<?I_5'\7OD:O+L%/CW['A?$Y:^GPJUZKFJN
M*MZZI3E)_HDVXQ,'9Z!!,_A>Y[*PWH)"J=^-$NJ7#-XMYS3+>$#"*6Z'AD >
MQR#G%*J$9]=;8*@(IT7]N(9K>&"@%_ 17=DI^NPH,+OSVVALD&9(6_*-(?<R
M2CBH ;.T('R=77K4MMINX2)]<B* -!"TX-S3 -DZB\$#T3MU$DD?MJ_&RNX?
MA'I#(9(^"W3D.<KE6\I@C-)"+VV+D.V0Z!%58%9O59W>S5HO!=V[<4\@\@!:
M+QI!+P7FOI,5PZM0GMC[;<Z5[W+KFXU@>*W5!6I,+6DQ)YPM5N-'!!RX";EC
M!3F_Z^##'>6<492<O3'&\.N [5)AS?V^C&N29=2QY5OSU/#ECS O7%UBH*+-
M,0%-$PK4"';_JVG^Y!F$<5#_#3[^%7H&%"/@CE)/D2Y,Z/U/,L!Y^&V<=3T>
M:$T4F6,=LKOWSE?.5*_DC@I3G2,>X!5_"]]F\R",^-0ZR#'AA_B^/U6:T/!U
M':O%);U3>K][!(3N05PPCBX2B)4>-LP3#YR=$'#FKA.P 7>XT-*&DV^D^MPR
MK*V;PT"\#?3(IT5 "\(9&(ZO][[YB?_X?.7Y^)Y 6^^F%Q,4ZVE\5.1U'#^\
MC&A)U3F[?MT%9N-'&S0><O@K"!.YKGQIBVX33OV\,.% &<&?<B#F#;YE!]'Y
M_F<+)@EZ'>M6QD[>CJB<)&$L;:=!\94%)G=A;?K'I8_L_'+0KY=PA#D?':(]
M')&\='/CESI?P%+MOOU?VSP&;C>K*B+MSG_RN&.BQW_!245$W7#"@E,9FF_H
MM:7N=-RMXJ,Y8D,V%$9*A_%'*&\*&1PR[<\W04]O_"1T*![H=2#9]#F-.HZI
MB!3G<CS(O.1==G1  8:%O[A\TD&^(+PQ=9KUSRE P)GL@]=)6J5>MY\%71:L
MOG&CJ!JIP]%J%+QF.E*XG6E]]Z/YI:Y-)I_*A1L=_[0N[J_4>8&9E:4YE)[M
M/BZ3_)T?^<(F6*E-K>'-$NEYD@IWNR=ZKREE^=38Z[W<'DT!-1Z8]W5N4U1%
M.H.N^#F6CI<%2=R1WOD(O7VW8GFBNDGPO/PP)JX50KHQ\%T?8Z/S(HNM*O!!
MYR:4?[P_'?)S^' O=F#*,66L8FQPUC2(ILSI;>'^E?UB8*T0\+>$BCC,[WL\
MA$^XKIW6^^O]TRG@KZ?*V"\O+OOKX-%OW.HBXE<@^'],/?AO8>Y_*-7?2BO]
M[Y?#\O]N?LR_YD*-_XM@]1]*_[=<J/]$L?KPO[HQ_]/'WZJR%6QHG1;_\;0*
MX&<7"#QP7QKPO_Y?K:#]OUJ=_%^SH:!_5ZS^1^Y81V&.'Q1E_%::HY!M]XA&
MQO?C-=4H%@W##VG>]B(YZ2_(1\8'_A0J+49S+ EL?M*0HLI]UC&$WF!P(Q_9
M)07]^H9ZW^Q&#XNR8I^/74G@M6?0I"[U3IJQR;"^/%5/;K$42&YP:,<(C*C&
M,-'?S0QD>OR$:%UXS=^MN?$*]@K21?LQJK"W?31F]O=[#A<39:];<C#S H_H
MP(#,ALC,0&57"$. A/Q%@I_2*T);8 [[;N @UHOKZ=R8>T@\P(X)]8SCU%:J
M+[WI^&"?1#$#3IQ['E(IU_D4JF6@0M],:E2!-F]F[Z368)"Z$_C'N1B@1(F_
MA9)Y%L 9-)'02VDI23O7)ODG11ZN"63UD]JGV?-ED#4$$1[L&8>$=HB*,977
MHNK>,]@XI+K<</GM__+-=4BHO27&'(EHM]2:+9]V%!')O TM5U]6IU#2B-LK
M6:J"&$!U!E58YYA0H^_?^-UVS)RP;2?&#LG.)?2+=,X@4(6I0AG$59!_IJ\K
M+^ $)KV<Z#R_2_!:LA()5 TE&%C>3^? HLR+:M]2_>Y8^?0ASSE5T<#+F,EJ
M16X*"$+'>RDN^L0H+JLB#LZY7<L.>U5IJK&NNR 3=Q+(W5'3.%F*4[6TQS4:
M$_QGIIUW1$@(A3*=U3I[(B:I[6V$3V1 CV-\AP1,;-F]EJUIC:W?*KWY^X;1
MV6J$?[:EZ[XX#\RB6)_5AF_&LV!$G[QGS(H;DXR*@E9_4ANV'7&Q8WT61I;.
M-G E^%>C1 *&/JF;J5ZTO[TXTB!&S%_1@?U!FH76$QA)3L.^*2XJT'=\X)4^
M>3_B,I:\" 9%]AY8;%1&?)ON=*<V3NPL%[!LND[^I8NP^ :],J5/Z# ,(O6)
M]&0DVF^?#Z[S1K5V/'+BYOA16U/Y$$D5!:/>1"6=V.I+@$AN[THH.8\VL&PU
MTI5?6)^MM;]F,-DH .CN'Z>KV<[<)FKPZ/!%UJL1W,_SI?XW?O>*,:VZ-4.O
M?&LGF)ON]Y/:!?](Z*.5?]%2OZ0;L3BTPYOPNN9N9.M *%N!E#YYO)\Y1E4V
MRE6M/J/,L>#&I51RE\P%VC>R*DWN_:0V";&P'@@GUA;5IFGGG3$+%;EG73^'
MX*\^O%BV=3U;3CW3(CP5J>.\!(^^7%$Y;#^(] BWJSR_1GX^Q+6$(_:P.L@T
MMYQTD/?,ONB<<GM2'JD0<7)E52.?1$9/D/]*KQ5A +["!"WT,SA!.!\]*AUT
M$_SA'*7.<IG;IB6?3*"&FDG)>;U&* ,D@UG,W/0Y"60>URI)W5]TLXEOI]QU
MR;@I"'Y; "4KB[EW'^/N:)<WV>OX\EIR]".Q,:"D0]6+,)UIT-#F1YBEYF([
MV\=.S/N%[3]>3Q4UT3U.GWP(YS2.P'@88\H7HDB^3,#@^@ZRMV+XA],-V 03
MH\ENI?LD]-?[:ZL"3S&WCZH5^7(TD;=B++-$7U+FQVO*=5D1=<@;_S[3LG!&
ME*E_LA%^ *E<3M,(YVE)3!%4_L3"=$C>#KEB ;-IJO1BOBX\/TOO[+*2)V 9
M=%JU$7B9&U/DM?"^=155$3S5ETVD ]4WV*]JO0/2;V@[@@3NJ' 7_N4OR/NI
MH.PCI,&QU_,FURN3)J3;LZ+>Q-U:-"1AF"6C3"\_M"2 ?H*?'^JX!$E#KJ'#
MIUO5 ',U_6IRQ5W?."3(JE85>(F@>75>+[S8%V$#=ST^,;@3P1O_]%V*(*D_
MC1EZ-+DO:T'I=5\?<^JJ,]M#N>&"DD>!2EM?,O\XW7#47/GBN0O\W.9!3<G!
M'$C(0DV_8>"T2?DC^+./5V2=@@NRD1JZ_EZG0B'W^/N'[IC.&Q-[P42$:4^R
MHLTEB/1JB7FV\:I>>=?7FY9KH=(YRCMPO9,DI-^/.[-&SN\66AC9OM.(%8@1
M2_K2=CYU+:I;\&*B_[?Y("(H70DT2(#V_GD*[)5"C ?R6[927YRW\[>ODNW4
M!U<I6W];5KF>$M<7M\N4SL/NF9551'<K'E]I9Z?]WLL!0!B<S2(!5&.@,O-X
M&8V>V2?C(==MFQ36%$EW-ITV!EU)J^7UGWQ\T07$%$>,FX1WC6J\!#M8#(_^
M-J(H^]3+TS6[C849Q3:Z*+C;E6'+3>8Q8^LS7N G/AYPU?FL_:@_<IN_9-@(
MX(G848SNKGI)XK<6?=+N$T-P14XZ$128<"@Z[+/GU_43KQ^B@1'I%#V7GO*E
M<;Y:#/7M^'RE-7M*E7?G52A3^!=*22.'#-!G91Z89%MJ7"?CR/:A>?<V.W*P
MO47] RH_*,(UY)*>V9E8I!!);X.<0TUZ_<*E\J'OS^JJS">6;]VM_>1 ?;D3
M>6.\N9!/?U"9T\S4Z;6'F45$M@UC3WF@B'N"Y04CT1*4/8#%25FX.@0Z\$X;
M3FWUX+@]^",=@^&[=%GJA&!OUDY=[T(%I& 'C7*?J !66&FTA>=^5=7P,PGZ
M8?Y@Q@N-L]6_UB8+M'TK&.R4JH&6*1.3YG):7;0Y9P0T!EK+8S6LR&C)1A?L
MTYWG<>")6<=&T*&P\ 0WU8?G@[81'6RT\F"?#<+T%<6,HW#G'3ZBG^<26-\;
M#$^B+S]I>/Z<;$&R8^$Q/>;<.-4AX!JF/=-1'^/3<V]$IB53CO_3@V<.[W]0
MJ\W0?GP>2Z =0B3IHRZ>PO/AQA5).9_R^[]V,[ZM.EUUT."QB36Y$.Y1!C#F
M5@/22DXN4,W:DE@3:Y/>-CM9.DVY7M]L1J)/2!K:GK8:IM6XW"^^YE\G)C9S
M<I_N4I#Z"Z^1HP3;XD*GL)4-'+&^6Q[[$<^7#NYWIY,FO/3 <+Z6/J(AV/;5
MG *F%TG!WC%\K[;,4=DH=5X7]O9X[I3J:&'<$H58P.+8"%3R37B;"V=J$2B!
MN )-I&3ZZ4M 5G104G<_=^<?!R2G&4$&2[J/29)>S<N<,S,7K>NR2U7*U^0#
MN/% J#\+X9H%"'>= )(&WBYOV9?PU7*NI2+ 7)'^/>7TQ,)2#JEQHX$*TZN)
M.2ZQH>N,!5^%OH.L&9\U^*$[6_68,.:=#+#2YD$=CRLS'.^8E_Q^*#"8:L$9
MTM(#42_\<3$$,_I#N?ULT9SJVC]1G1."\(3=]NCX=]L!CN9.B/&AZMK^-PW7
M![#.7^0J:D;-3*]6U]5%4*DELFD^,3EH A+=TY*@C_Y\$]K()HS8>-S 2Z<A
MA\JH'+A3/V0J&EX[,?U6H<8C :HZ2+CF_=?LCNKS^]X5$F6MYP&:;6]?4E^_
M;NVQ4>(.5?%[A);N#%.D\G*W3JR_&&2NF#-+-)P ?XK] "3L1:X%7/93=J-R
M$/V^J<\X>G0)+!PM17=$M:WW"$,[0K0Y\C]4-> _!@G\Y13_AQK9(T2'V?_X
MWL6I'A<@Y( '0&NEE8T5M=7I&Z:CHBW8?%H);?J1PS/VI<;%KWZR!"?#Q7B?
MP%\CBQ[];6/"IS&L 0Q37FNI46K#L0_SIYH+6<X6CJ18!R;"ME*!93SPSS<H
M?HQ:K75#NH%,G642NCE9W/<>OZ/IZ6:56\K]WH@QPE'B@2]0+3S09(<'*->?
M;^^4G<L5BNPL55:$ONYDU&)Z[ ,($?O<^.1TY@2-(AMQ83X\K)04BB?\P2.U
M6N42D]4^KE\WI+^A-GB,<^= ,)YW;9A_)-[BGB>QGIN4Q]VEZ_S/V4Q\@N4'
M2-\9:L\^TAN^_PQW-C;^6TY/V4ZG<UHP5?Q(!Z)5=F[UQ=_%T25><3K"2&HM
MAQ\9*#KX6*K>36MLT;&L4&OH3+ICM>*C[33"@AO"7J>AK\E#U'TMD#FR&=&!
MNU*1U@R)*(.MD.:I-40S$3B7+#C&V71^<E-FR]W&Z]((S9 &/VT.FE/_4J10
M?M)FJG_AC-%[EN,?,[UQ8FS7#+W6.*_?EB)RC2SVA=M_FY;NO9AA_B%N:A_/
M&]>69L@EV\X-'A/<E^KUT*G[A)B=GN6KY$+1.I"8_154_B7/V4<W.G_J6YZ=
M=>&)SFA+.^(;\@:79-L4;1G.ZGVAX\E/&P7178,)T M:5<!I\ ^-,ID*C_*[
M_?67]8CTCL28P=CMHD$H[E10VEEG7"KFR:VA(VV.A4;?[<K+8LJUFAE4AP:&
MXIXZ$!WZ3^=;YM";BXJGR;+@Y^D.Q+-,-.VSY=FE,S,SJC0U-+TBL01S)<*8
M/CU%SM,ZO>>=UAL_K,WK;HJDJIJ-&R!)^E,AX<]XM7)!?^I,Q$BV=),AKO4^
M,A!EI 7=X@$KQ+G'DU?W.P$#:'A[,15,YG59;77B[D7 46$&;9<_:R+QQ>7^
M\A=9Q\G#BE@PK>7;QCHQQLJ5N"T3R&5E^FE,9C^.P>W*::F9ULZQK_7* XQB
M;:6%O5SS&NGAUH[]XGP(354(CMZ%[PEK5YG._,F8Y-D &?Q-@##,N.-187;,
M]/3\S5]3ED6=;B>Z6I4#G.?&+E:J>7X40YEHF8^%L)<;97B@U$I5L>(GP[JA
MQ:T)G[RE+UUGQD4#1*I&#2/?7]5ZN.=:34^IR'>[W^C(0O-3]E2@BT/=!.G,
M8>\U4JU?O]&>Z+EUS+:&RJ"9$MJ4^&.\//M\QZDHC0K9XTH=MK;@R\G'_B]@
M^3[AD75*7V>I+-4MAT7%(&O)[5-\H%Q!WD#I]=S"W2>UE9H[WV(=+.SX8T*$
M0=9RTM"'8Z]ZV8ED\G*G3-HZ*4\D19X@5$RB!RY-W0C[6+@A/^)R+3EO<I[W
M8LE%OKMRJRS-\ P0RG_/7O39T9.IL/?BNRP#'BB(U$RV/.T$TE+-+W1;M2K.
M=;/\7>P!N0-7 9-QB!&/_J5\85EM-%E,81CNU^AWMXKH'Q55II07*HI&(34=
MT;O-!FJF'Q:(5&@S2T3K;!:C>DH<79"BUYR#7[_-JH_Y@% A6JU8)TG&A"P)
MH,1#H28RSW:P(V%RE=N7/BDFA00%^AJ"P_[$=BX^=91]KY=S$>EL^N9YL,YF
M4W0P+7DC>,E2\&W9+(OAX+,*-*G1D..,%,+!);=*D6N2]6RU &.LB5I-R):R
M8HWL%4F_^WOLIW=D_\#*SY=P=F F,[*]%AT7]NH4&]5/[VBTO^:HZ<9G1#YS
MI1UP,="?FC.'FA>V?_XM2U<YF\A"F[.NSB0-,!KI?D$B0!L2'\JY/'3*WM%1
M>\SRRB[K.JV$Y3S-;U[;&!\;CS\\$%TQ93EXJ KHHZT:TIE1%5\*NTET*Q+<
MZ,FFZY8!R>G$VT60Q?#V1VC*7=R0BY!)CS/[K^QK!TPC:=RMI)S^'CN6N!Q'
M&_@WBZE- U71=PD)$MHGE">]3S'W[J("$KAZ, \Y 'X>W>-2[Z]+&:))<=G
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MS;<AF F^TYNL]K.O8Z^3L&/QO"L5W)\(F.OC*5A<W7&1V;B<9?8G]5K\@DW
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M .O _.[-\W/RO1YK _TY702O^?4=;BQ]I,6KRM[)'JI*9*C2!+S. +WW>[J
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M7A.D"(*(HH @$%!I(D51D1H1D"8@TD(-H!3I'46:TD6(]-Z;B/3>";V34$*
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M/T/A.5M=$U/R)4(4!6(,TLKC/H>P*O<(WVF"_M$&%8]TII(].]8&?DQ]RLK
MC\I9;ZT3]13$@L((1K;?K71>B%:-\]-=%S!_V3BY3*'%9G+4"RHYO2^G&^#=
MGY#@8#E^(>E-4S\9>?O(LFA7WR(!7A(>R8Z0NQB-B'""S)'1_"?SY[NB6\_>
MF3C,<#=R73IY:TD)GAWV3U^= =^N7C]W64HWRBV!E>?,QB%/KET%6YO<]X3V
M?/VV 73I<*K<;X'%C:CS",==^3'F3_.]%".KZX;,$<UB(?(,5J*R<GGM.&FN
MU$DC*DW$Y.-V$"1ERD&_T//\L+/!!14=K'R)Q 5O&Q>#IU;)Z6'8G81WX@XK
MU*!:X(WW7TXPY)  *_#A):>>8QH4,3BZROZ#\=_"P-UDJ><>+A7QY# P-EGD
M+Q0LKLJU"%XU[#GE]..]3BY.3,@PH.^)]MEZ"EF33&.\_$0SQ#)$YZ<X]&JW
M[((5^X%@@=3+\-$>]WV-4X:#DLXP%>UDGI+R>SNJ[3ZPW V0(UP:[SA[C,A&
MEP7.B5*3@ V9Y>WR;1>:JWI)5^FDE0&*J';*;'V#5'\H<XURWYB->Z'' Y.
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MP<4EQ.)9I9M$G(* P>#L\GHTPA_OB(W9( %C,Q-2O+UTR%]Z9:99,LN0T59
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M4.OIT)O;1O(&)YI;G.HO HSU#  /CU2[K +=3B2+1)=*.Y*)L0G'<+.LK-)
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M=6G_S+Y; S^30ZPF<=3.PX/TH>_WU$,^H_(7ZW9ZQO(9%'KX<+-.AOORJ7$
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M:#.9YY_ZPMZ-/'QQF<>O[ET;B*IB[4X/I-1&'SOB7R,+PF55FU,R@.+YITG
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MFK6""[%]D^T 1'=/C7U<2"S.LUK-LQP9?Q/>P3U5$WD+]8P^4PV:;$C^*A*
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M4'E$S##HQ3<VX&;$.CG>YF?=4,OK./E</"]T5W --1MC,&?(<I>]GK"OMBI
M]PU]-S56S=L'0+$&?N#+9HQYN%/1S]3)(\0YRH-@Y\H7J'BKQ-5Q!> YWCS6
M,1+NLL'8KY8'J/XDSWY9\:;AS?&].45+_'4R>_2,L7KUXS%31=J 3YF5R"M
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MG*T?!M(N5,ELKP"R4P+5J5'N,&;CE O%HI#%U1B3FKKDZ]BY/UMS:8D?A:%
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MD'4,E@Q==4E4V1W:H:G\Y)=]6(2/IO.9[J"@!O S5!+#9KXHI2AEH5M/DU
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MM'OTBDM*AHU%XW8Q1=\5H.TG2O>2B$87=Q.!^3,]C+G5Y$C0R@1#VKPL0Z]
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MSH.OERXTO/N>G:%"QKN;!U@$F6[9\'J1P/95/.I"G#53Q,B#)X^*POM6L)V
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MFGMOR_2'G.OB!4>Y9QD)9\ KEF;<=Z 7]V)A8P>$@YWPZ=14IRR7F+X>7XX
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MNMR.]V72D&)D^\&,:%.**ES>XB#;I!64)\5$0ZGF.7GR&\+! _J(M'N$C23
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MIJ6YJLZRU=-M?=@<C+@"6X1BEA*,.SZLZ]O?J'UX4AR7Z+1*!^9*'[I8'=/
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MT,]-H?CK/H!?N4:V/\#8ZR.+_5T=ZR-6]]XI3 CE<'<=>$>/_1I[J*5S[%9
M<$?SPT >K^V,EN4FW_%4^W.PFLM?]*:[Q#>D3:GY;(<DB#F=SP#CM&.VX\A'
M3;ABK.[NWPW-WT+%6V9V14,S["\\>HEDU4G<B 9?KXC?9\#[<A2L[22X$NNE
M5; FJ=!U,PDNMA13<*Z/JXW=-A0886_/@&.N2MC)14EB=$S3%^3G__Q+^H4R
M'\WT5E0L[;QE]?T&'9/N'SV?^KX&@J$+^I6O/,9WT4\P$O7>5OQ*SA3O1Y1O
M'*A0J?%@T^F<%P?;ZF&AU9+5(M9Z<"V72*Z5*&YE2JD6/MXTO]^KC*CF\J/P
MRN8K>6%ZAK^%'()KJT5\,XX^SOZU;Y7;JT3<W6P2MJ[&"[?+ZYYHUB6-K[%=
M27CHV$?SG0YL?RF=#A5Q_$49UXGZ['/';'&+PWC=[U9MDH)]CI9(UF-"AN))
M-ZNT/7"P.6#1#F.MB+PCWO\-KO=!I<FVP*% 5,RLH \42.E82WHBRXQ+\(M^
MMV=QK1;#XIG1!=,/>6,67FFV@8+B1AU[UL:XOCIO5 !/)=W=#IGTYDP>E;YH
M95<7B!Y^2A./N)S2D'#X?B)G5([ZXA?R8(ANS:5;LAU!SN!!B\448$^+ 3?=
M"6/VT3H-6#Q(X13_4^36TZF4+M<KPEF/3E]XYW6(%]Z<S^JTC2ZQ84YFEJ)(
M&K1U"EI+HE$[0J\9P<I70C)&&Z[AT5W0B8*^:>.8AVJ/_*%%+"?8-=-&!2Z^
M[WX#4QP_:D=<"T^LZI!3#QZE/;GPU8\/6PQ^[W<-FQPD/J"E/IY]?S43./P5
MOQ/66^/;XFDJ&A<P/=7X+@*X70)!'18B,@FBOX4KI@OL[.,R+HFITJ3WI2\<
M+J1@O<&1<W=J,7YIBP,WO MWZ&<U;_2Z]#<I/_![]OC UCQ)GG*5[(""<8&T
MD>UTVD&ZC8RGMKIRA))%I>OV7,EDP'&E-?92TMVP1YM$?A^=V!9]I^=_NCF[
MREURLM2EU?2DYEK>O7L'[ 2M]5!FZ\"E_GB\0/-%VUW5_](ANH;]*=>#3MG5
ML&N7)E=EP&Y]N)N/3>M !+,=-"+#E[_HCBY+=W;DZMR-;3#[2&@-\8+HQ(WX
M0S]E%EC)%.=69QM9)]WW3*K6N61F^W(!']-=RKB,H">8H<M1Z$7X1:L1!T-=
M=:%X[I_NB(KY&\*VJ:>=@#<MXUZYCR2N]UW(-ISQ44)4'/BPHC7$5R(Z:R_?
M!XQ5ZC1EQ5;XL6"_[FE2/Q9<EI2RLILY'9^#[L:KO-.BY)D!K>(Q8%:?AUC]
MS]A.%W[Y9YFC3-LCPN5A'P)+2I/($P=EI[^>\H\U\3S'Y9ZTH82IC#^)BSA&
MJ;D^&%Y8NC!#IP8+]BE&&GGD0L+2WOS^:X$53@/V:+YW_[R;"O\IM:KK#QW/
M;+BJACD#NI;&;8V.].+L]%U$F>O#0UK:W126L*G\<ZM T2!]?!/S[TEU\N>/
M%3F;E(Q<DU'P8T97!'[W"XE1BI%X3YO6A;54^8F=(G'UG>L1U'!IS<+OI79]
MTC/%W>+K7J&;T^F-Y=&21F,9:0X]]CZUS-#%9T_X$TZ_-"^]^]V\"3D#*AF:
M8AN;*D;M>.L;:R.FYJ[7+B>V?8]]9PE:3@-PH2]P-M@[/K((46K)!J;DI)-J
MU23N2P:C^=+;4LC"PJ5]%5PR=G%[O^9ST5)3C'Z"_856IB%CO+DPZW:+P3B)
M:<-E/9 HH>)%9$RRNG/AG%"H%:_?FTP)[;SX['S3S[P'!_(V@@?@\UJ;19K!
M,.U6[J>8AR(O3$Y31():R,N27\T<0K_=!JV].)$ZH)7YV_>ZC3\LE6]ZPN8"
M'4QF+XV,P/(# PN;?JYIY#WY4)-#;9B<NKY BH^/PXW$H4/#4>P(P @9GH(^
M>2XW?+WFY<A+6;O>%;G7#84+JE$^RB@P^SI32E.IN[?#:>H>U5_?5F-U%G(O
MQ^Z\8L#WDBD9Q@+%%]&@@R[8=/WVK*38:$3=)XOAMCY-#8]UH$PJ_P_<MQP?
MU:9Q@6S,FPUE<\'# ;8G<6FB3DO;&ZV0.&2J')D5ZLL\O9CIE<^98X20FTG/
ME):7+)+0);=!6];\O4T<:Y!K H3'HQYUITLC'31RU=]X9Y:B7@H_(?Q&A!%%
ML)-8)PPR2&Q-LN@.;[+ZE;>RS5,.<<Q56GXH?_F0B./))G:">:V2NW!$CGJ7
M6NB)T<MVZ!>5X>,Q*"4N X6DP4W!:#Q^>>8&YS+M?ODJ5K7MM^$ \53GD>8+
MBMLFV_?U?%* D7S\6\Z9+YSW=XG.S3IF7:.PC\OE\2 +?ZU*KTH?+$J+U2-F
MXC"X>H1[W!X]BJ@H6CBYV[S=)Q7KR#^TXD18!:UZW49^MFL26">RX[Z@6%U-
M5 Z/G@3:Y*>7"G\4X @;<],6F1B=R %\Q95]Y@\140AZNU^E#J[0+Z_X!AS(
M#6[]-M'23.<DD46DV5,?<:QL%Q3 6AQ*1B[7U54RW#7N]EI>"KM*+.58^M$Z
MJ$NU%E-!MG]P+:)OE9/E_H\>[B5ZC?.SBUOLJ*M6BZ>2"B&/Y3=S/?UANP,R
MH$U#DI@!D';().B]GW.\N-]<\5&&*G9%S%Q%2I#Q![#+P!$\V.LRSGNQ*]9:
MSWST@=#; V&^@<$:<G!;_5WE9P^ITBET_"E?F;[ HDU_NX O_IFQ8MZ;U+R)
M[]I5.#%$)JVPX@..M2D+AN'2JEB;SCF>$9=8&MR#2]NN"=;-=DWF%/WHOUU^
MST#UU<Y=,E]/G=L1+ TB;V[5.Y58BZI2[=W:%>=+[M=)?7ZI52>U)>!XB'*T
MPB#1AP.7YH2V\8X6-I@\15H&*MX%,CWV O]P7"2/0L<H>_G.CC%).)O,/OHQ
MW1+-6R;=H@SB36OSOY799#?NQ^\QV$V\(2,<@$H9F0R_M S<<H5T;7M$^8I$
M'8BM$2$^%J4!R-=8QN6.[R"6U[^7+&S=VJ_0R8LJ0-1T3"DQ_6AHGE ]<PCA
M59! F:>(29VG??P*&2\'G19K"_?!KW?RZ^I,MZ=47^:GEU_]<QEP9=P+[HYI
M<,?J=3JOF=+6V$D^"14HB5VFYW+D4F65ALW">]#BUHB+/A:8LM.F[@[=]6#H
MVQ#9B:^I*TN? ._]I2'*H<H%KONX<%2Q*#IB5=^K4#E7<#8;;D%_G<+$3. 2
M?ZI[M33>(,,C%\9N Z>MZ'5ADH!>3Q3\6Q=%3V^<:ZY8G\L2 \[Q&?A_"[/_
M3WQL_F<;RB/E<*,H:D[FQ<[3QADKL:F(TZ0YINWN;V< AL-^L&3>:/_^OTHW
M\KA:M!):F.WQ^*[]J*VS@U50.^!G<08$T!]3I-.!R0,='652CH0G^SLD).IR
M\]('.*S<O9@L;Q'O2( ^D1:$!AC'7&F/ R\*2"*HA(L/J'Z+"[X3KXE1X6BY
M]A;BU-M[:&L0\,+8VI01>^/QE^)*09F5C/62Z$!P-3G]C#;E;.+NRC\ZZ/A7
MFZD]0B8Z3=E*QXMZZ&>Z6!.D19I5E+;IE'W6_FF_"?R5X\14=W!)C_P=$TLN
M,[S^J67.)^?)0D8-F1;+*Q,(070P&K92DDBZ&9(([3#(( Z< ;LWUA&'5QU.
M&3F];P+ZHULI@YJ5E6YT0VUQ29P]@,4^,LY/] SH?3'1/!]Y!CS,\0V%<_WK
MW% U$M',3 Q_!/2-[H/99CQ\A?>G!4U-;@;9V=AM?B(/6?0VY\ :ZO-;2>1<
M7G<>9"Q4DSM^K<B3OZW :TX4/XAMV3GF35$]V2,]I!7D==S)(M4^C+&]^'D;
M3\7OIQ4!JM0RISNY"XKX[72P)X8R5$YZ<8?F12PMO7C.2+CFI&PJ>JBT96V4
MA64EIG)X=E;)[(W\;/O[0*JIYRQGP.7\7M@')-7I5X+^KV0B8VVR+.54,8@K
M2"I.%?6L=+NK'AS3=(/8@7.5SW:(C'ZB:%VS4;XCC7]I1PJ--N5/?/#L8)2<
MA?C/* 9?W:/ K38'6T KG1R<CBRKV)@'KZ5HEGQQ*/A#[6VI2Z[GF.:J &I.
M1T8WB"_2NG<>Z4U;ZE_<-KRBSKW'<"_]*YUQ ,Y @W1)&BC(*?7\\;EQ=O=M
MT!=L3!Q=,)K60+,JCK<J9+$A-#H(Q'J<$$?L93Q MD.NG %MFI@C]2;W6<<X
MWU2?@[VKR[RGCNQ8Y$<?C07AJQ[0N4L'L_>FE&6O13>L+E'X_X*J2!%L?B-(
M4H3>TV *&7H3D?2&V1%TNMQ6@__P] QHT01<$!5:H4WSB^SR[WA_UMF>\/(0
M/=4#\/>T?DY\(P[BSX!#>.RT9AR6K@#TD-)!!.H*^^!T!EQ YO@H9W6BP+3K
M,@__7/*TQYJ?-_F%$.C BW"&M2-W/S:L8.6?!\E>KB.U2EVL[(FPI-N@.805
MIW?O2,6W"Y+')3=M"OR)Z]'?P:4"\T<#>J=?&F!GP'4$?5]JDK;D$DFCE?E5
M_IUG).@P1_KX>B)L^#Z_8>!EZCX-YB#:&A+%]\^ =@08T2:R0,NCZ3(I]5Y3
MBB=-A/B6<NVKWS6R'%3Q.Q@MSD!OW+Q+4'!*F3(+>B\+^YH2#>?PT'@"9\"M
M:%8T?WMH(*FXG9/80D$VLY0PXX^X:KI\HH*+W&R"C#; KJ(T)A_OD9T!<J/I
M,'UN4K#X.^3$%V!7/=JHP_<%[\UVVK?R.LA(M?":@[^%("X#)Y1ZC4/B)K=V
M-&O&-FD;Q\"@ %(>!% V-_KHW#>V])K.?$0Q$-U+S6O!XR5)#LD?<$-@LINN
MGP%#C6= 0M490'A7V\R 4S+%!/]DPF\%5"2Y"+/LZ2JT<'!IQ^&T*2>)'..O
ML>"0_2U3#MOZ:G5'V/NX/B(E#Z8P>5RB[EO4N,$X=L;H9PYOA'+?CR-&]!E0
MC@QKFEZTV;IH\+/.9\Y<X0P8O'/?$1K%3L0S;ETC0U>G <5V.U,;[5RWQRHT
M!^(C:+[X!M 4'R?HKL'(Q#K&=$\Z4I8/&V]PO/_(,MP\=_PY]B__A&7Z164:
MMW^5N3O9@A\JDSVE P"7:_C_Y9-(1V%+Z_/$9A(.#=/"'QD,>%D0OIV_]MXD
M;0/7\T%KC\X[O%5Z]2H6T$$:RN<6JX))L$@):KYYRSR=M!U/6\0'\8-BG]#"
M\"8V']OXU8XY31*?G=)1.#G<Y5CPWGS=K ,W,IPW6G>[ G_^.&'Z2:!:MM*'
M/B\VH%29\5)]%7/@SQGEP\P013IL0[J48'7)?87!1L"G'NMGY:..+78QX_%T
M:JR,,I27W.+C.OY ?'9 F_B5S3>Z,;'HM:RWQ_CM#R[/=/QAU^$"/MH6F*/N
M<'%I):J1O^,'5!R)VN_16'U(L*\!S?",(@>FQB-;>W5C.("57)O"[L7CJO&*
MR('[6^XO9A\,]<A_,N.9;_09P-#MVDFBWM<YF57]G3(T\;9_P,+A1<C;$]^?
MR\E_827S9CS+[42P^+55MH.R3@+\/@%4]D4/]PV:^W2SJBK)PM:I]M<0-,\9
MTC)$6>3C10)W \\S $["H-77I<T6)C>ZA"E-K3?LFQU2MQ8\8_GZM;-O[[/R
MGA O5/G)(WKY&\X 9!AB7X2$,A9IQ[?*$'\>P$\I;H-&75^H5=)R'?YR!=-@
MY)[D9=!D0U;@0@2R$0%7A[!?$^,;DG^*4M>!F> /<M;LG!@6]#QEI:\>C.#=
M3UPD/MOCVT2?&S]HDS:XIVEXB;L WJ])'SMU*_E$Y9+=1R%Q?FF,U'%8=.S?
M=P@V?&Z3X3^./+J0'<C[?%O0Y&HWQFW<S,VRKV9J.US7NWHZ;B[4'S=C3B<[
M,2Z^F]=>N&$"0Z/[W664V.=,.HI6@'J'RZ+;:M?(#N"* :8\)^I6]WH7&WD,
MJ4]P0@.EW*ZJ*O9^P3 ]TUG3FR?JUJ7*B]]XU&=/CK<'NH9/QQXT$.^#>X8H
MGV.>'"#]KEFQ_REO>?,^8977%GRR%(&=CT'L&IRW=,[-GP$/Q#<1% (I_8LJ
ML8V/&N9L.^@GLVTA)RN,Z'_VWEF"UF6.G?5(N/%-ZX1&D9#4E(5,%H<=2X^1
MXM(!Z;4$K38SK=^WX@*/N[+$W*PJ2S'LD3H.9( 9&_C[_?)Z;- D-';P_&-#
ME7Z+2C?.Z($BS)@?W#'1X('JTU1M\3K-5OC\9O0O%:7;'T>8#*9YLEXO9+ZC
MKBMEER)^>Y(W6@O+\F?)U_&8)$;69.P[&%@EA'8O)'7STDT2-&42>-QFHM!2
MZ9>G0G+,<HS$Y[(\*7+*?-<L/MR([9A@=\=^:6$R#\%>4&NON/?HF/  ?8"\
MAI6?R\)JH65P;MY5@5WLO7;<VE(Q4D<.CK*E5%K0]G2DU2B1Q@.L%7#UA-[>
M1/7^3-_VP+:*TS&9 A<%EJ=CRB <RC>](7-M@)>&^Z)*5(90'B<593KCP:S/
M9ZS-PU$Y&/;!7+=Z><3('V70L0Z=)),TK*^I_+\?7*$*%\0UA#5;U3PG:M<U
M!C'XBEQ"%MP&_6V>4GV:!+^V)J./7IJ>_'QX.+>M>'K%SW5R%<(&A:R:0GZ,
M%"\UJ&V]5/-_H1<5T+LQLT04;_<;/A0&1[M,;S77U?R@#UKOV4H;3FH,;2=2
M8X0J%[=D=4/;O1[&S4QG!P27[:JQ;DU(7R/K]<A"PP+$=RZOU^G$8P=^%\5Q
M>^M%+S\9G2A_260<\!LP>%=2BGR^=*SEP)'M1E.DNFMFVDVB$O.M\'W^-3B.
MIGG1*$4U9%\3-$#L&;'=?%RS1]MP-Q@[RNN:#@:=9N_,$E0SUZ9_]=BQ^7[>
MWC: '=,U#K9ZR<E0!NY'2S!.7:_4)+B^N]^-?:WI(;S%\]8,&Y+@71&<TMX_
M^%I7A>\,4&+<IPQVO5T9>\F*[;UFK9 @#R)CZCXT?4F;W/3>R&9E+-5Z4O+A
MFMS%R6D;NJCO:J]6%5D'//C^V7J3N$/D;ZH<;> K-#%]\D$AJ>RBNQ3K706(
MKAK@?JL!=&A_!L3UZY-R&4$<>W3>='L[G4X+Y4Y($*9'3"1,I/@-0';IL,RG
MKD''\E[PCIWC6Z8W2(##AQ0[38$M<:*$\1N4NU[ .O'?H<APOKPDSHPY""GN
M6@VO'G3#R'4G+.?K7O.BB2?I [(7,*[FI<0YQ$0'#,_R'5$^2$AX#MN\+DP,
M_$BVOOE]5>?\+3^Y.3V<G\"K/-HD$\GO4\1_<P:PP#TS)DF2F(A_P8W%?X$;
M]V8\^4>R ]*JQ>X(GX0>&_Q,*X\E?)17(K;J(E;_%*[U!ECR N:)W."VIE>G
M7S\;H&YB^"@J:H$CJ*TJ7IMR3'PO;4N0Q(B^@8B-RR22D-04A?QZ!E@Y'-.L
M0@YVA(GO*\@VYFGEY%\M#I)9:4^J@(Q?Y/S<I=]3Y\E_K34JQ=5B8&)(O$H*
MI*02*9"^S<1(H^0.KX*A!M'OUJV@RF]%"=^YHIZI@[ W_%F+<6E*F"5K?%>A
MU9N:-_I6P%NN_C'BA5K9V.AY\-:TY?B4WGQ_Y<< W%:G1W<[XG)U9S.+=1TR
M'&F1(G6A5TIE:D0TGE&1R$BF]:2%+.)(#4J/HYN5X O94CN(FQW\^],2U$:D
MFU'BZUJ\^;FSJ&NUNPOZ@ 7)67<9S]])%!XA7,T2*BCTG%/Z^2,_6%+D]:6U
MN$FM9;@L@2^$'Q%[B^H*KTB_1UCAT&T#@!2NY'$7>>$."=CKWYNO&JKF.%1O
M]]#(0)!\>^E@R3,@) 1C0-C]C<!P(G!UZPW,6'8E[%)R>#9UCHU"B*+3%>.0
M7R*!B#JK9LQW DGR/!B(/=U%=%6)"5]>-66]&LVL45VV=WB<>[/5QX(5.@G[
M!EC-S+1:V-T<&,.VDILY]_,'/^/*3J5P2FYFD:-X_;,,%T'Y1JJ#OO<V[,%W
M98^C+CMO/:QJ1XT<*PWQV4?15G*G?8,4A699+[0?92ZXV"LU&J/4@C?)=IJQ
M"M6NT98<=.9_$WN2'@R:AGP#/*J[FEE6N>[_WJ]OI'-+ZPE ?4YA>@"US3_V
M']2#/\:93,&I5LND^\7?TVC51MNL:,5"68=]Q+^O#EM.N3"IBS&(15[I0K&\
M3,'SM2%V;ZTB#L'5)#IDHP"1(GA$O\657M/\AK2Y\-6+P6:M6%BC;-BEWU?R
M2;6&MX;+)0Y+*1 ^=>G@5M-;W.8&I#/?W#GXA>4EJ+\(,F]+:&NG^'I]Q>=;
MU9]!W;P6=]<]R=F Y:;;:U<V8+3BJS>-/]F9_A6-4>J2C$+,2Q$T/=TWAWVF
M&Y1?_G)#78KS!?\B";!56*)77L>L+B?/8E6SDZC=GL!2M9;N+FTDOM(3OCEL
M/H_5@9=]:ZX)9N>XNI<$P8-7%%C/@(IO)\UA^R:RGI.T65KE\K-]*Z0U,5&+
M$U8-5<"8QN6VU3^4*&B.*5$Q) JH(RE.LVU_^MT;<7#[4&[HZ;GY2*WCG+ T
M^6-*<IA*%P5YM,.K;W9F.^S+JJB.<40 D5UL)DFEBYRZ(\19/O]I6;M7PXGJ
M-/)4/-)(\G_4:TD4O=-]O,[]_8%-8>\(%<.XPJ\5T$TUT+HZ0+<TX>\W,+\K
M;3U_""81QG %KN 3A?6RM3. CJ+BR=-Y4U70PH$"Z^!Z8.9IFIBA@ ^ 3]?:
MCU99[)=>U[FD#%%0@G2,(2J>?4R&@+>$M!D$D<-ID\\YG8\3(=$O<&3?VWTQ
M4[*,/@.OG'CMO[6\%0(/;</BTL%ZR*0FZ)I5%D$M2*?\IZ[I],WV^]CP9Q%+
MWHM/3VW6C8[=T<3TNN:.2)/[_:(:5C:<]3=V?29>3ZLN]"I -*R80W6&BQS"
M6FNK8VS!AQ\A&W!!#[!:Z7B3K+I-OD+Y=/'66-,+W_]*C/C73>X.GLBJEI;V
MP-Y6QW#$G#P%K\'%?(1(%"3@"[%)&)$P1#GFNINW16'%6-TQ*"%^>4)"1..6
M;-5ST6-NY/>-Y<$I?N(C<>1I$ FHA^.U*4?JH'%FZ6L24V^_V/\P>I';,XSX
M?,!7(#_@"=_BM+F62CZZ'1$KPZG\[ 5'L.4\#_9N<Z(WHR?DO!#"^W>"V.:$
M6*V]#3)8,-Z2;(L69\_6_16T]E>$6+D"KZ@FA+B \>>3HA\8[8/]FW<?D33
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ME/1Z2QXPL![XFJ&180M1YA4P(^NF)<OMCW0DB.W2XQ3T;:0GM@#]#0JT.RU
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MCJ$RTTFHD'C3;OK^V:A;=QD[2\2J8.$YIY\^.LL_2KNTMNYF++3RE>D'[@O
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M$[<N;M#Z#1X$6C:VY@M66JL"0S,XY?Y,L7#4.U2SW=?A.([KS_3WXN!_W%G
M<WNN4^K:;.F)$K+"DC\K)*E(UUWX2K.7Y?V>UIZM-VM&^X".F34F:H&V9)Z'
MCWN-]G"0<S,!G( BODI$%TC _'DNUPU*BM/R7B0'_=R00*N0_L@=[I!_ZU!H
MP$;I#Y49 AO^4Z"G(1W_X>'A.O/(A5JH,M8?8(#V!DH.8A]O.Y[SQH'MJYW[
M'1Q>V337V4AG2?: F.&4Y 6^!II%V#!5]$S<M/OG!\22(H$C-;S^U.Z6FP0E
MO%@P=>I7##2*/]31G6?WXW[W0(NOC0)>M4YF>86U,I)'NO/)'1E52MAT2(;2
M6?[Y_/.[]<Z1BIE<)<&@L9\CFG3\9PUC>V=M8+F&P^U,KCDGR),@LR"281,%
M9K1J0N?M,#6*-SQWEVZJZ)BY8C3:S&BUPA@K=W*?&7ZW=S2;LK-0_<4!<5<
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M)E6B:6S)=,V6RJ'M O">_IP=]\"_H ]R&(91['+,1(]_J 3OE"8%7@!!5C>
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M$Y/ &^7U_50=/A(1?*0#,?G&LQUY)"_\WLM%2^6?1"X8ST,#4X?:1$^3WET
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M1$'B!/*.ETC[I"8L'W8X/) 'Z[YI_Y$\^RH8$O,:RN+G[HKZ?&5.=93+SNF
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MAA:)O6/G1Q6238V;V=E06:T;<K5LK&L7 #$"=0%,G0]> ->O. Y(G*6;?KP
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M?U_[C]ZN5%Q=,&H):[@V:VP1;5%V4F#C$'X*2>'4ZEI\N0A2KG<.(0'O[$C
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MI+=6R>;JE%NISVTB =1X)52!A,SX\X)R"T,U:L="&\;KW#M?*P&PN2TQN"N
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M;?,-VKB:8F'ZZ=85P_?B-Q[L-7%1@QX IU<:C(<;EU;(<%,T,[COBTO_^VL
ME_Z_SX2Q9%RZ,7B/!+P<_4M\X"94&O^4!,2O?B$!U8YG*:*!RA_^[>=S_G_3
M_KTKB/R_NOV##.79AH$E&2P%#,D/?@HAACD!N,?_V8M!_][+;/^K=0AC?*[7
M5";-+O EL>EEQU7UU,0%7=BY4.A&9&X,:EPS&FE$L\%;SC+;DDE B-L\ L=\
M@,!30]&(SWC);$<DA&M:*[WG#W((MZV=U]#71>OWW]C[SK"FNFW=A501B/1.
ME"(H(H+22Q"EB8"@]!(5D"8@(#T0BO0F(*"(!*2)E #2I7=$>@F]!6E2$FJ
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M6<CW0Z_!!BFA*/>>GL+!9TB1S_.(##L+KN&Q5K72T+X);0]5682>SG6_/BW
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ML^8<W1E5+AWP?3[DOK//C(5$O-)2:TF=.0/"MC5!5Y[H6+^EV7@#<G^F-C)
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MBG?_Q.,?4OQ]JZT#:F)4_LN>AOX&$\G.2F#CTC+1Z$O2B6]G:$%U43WI%&=
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M5\'A! [B*D,V^>2^BZA=Z=DMJH>-'+T%%4N>LJ'ZYZ@@2]5JA-,Y0M#^OCD
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M%KWW.5MR:,,A)9RK67R>4GJ5ZD+_YT,FDCWWEW-L[E1[9T!(ZI0<,*Q:<HF
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M/5M,C!8IX4KLX:E1P(H3E@%]XVAA0#*\Q+]M.BXU7UAK2(VN,A?FKHP\O"G
MJ5'Q1>^LBR0D]32S %7Z@!<H\=N_BG;6K??#A7"@37UOH9A?6K:LL9.,3,]%
M8(!>)RT>SNVT75VX $[IQ" 8!MRX.H;^>=RF5VCQ]+5&^,7>F7_9K)(8USM[
M[:,WQ&^?-+JHR%3H*4^L.AZM^G3XA3.FY 3N4*WN9<O4M>": >JKX,VFA&.I
MM(@O@,$B7+2P4 ?&WHQ#*\F!+X"[^1$70,@&')V^@?-UZ5YI!9OT\S8C_ (O
M2H_I#TIS#"9XBMJ"1#N-_Y-:U$_:CT(N3]"S_U  &/_C_/RO=,Z7)_&V\R>\
MN&CUW!>"C3'ZXRC^KWS._U,[Z?]7/'QKC:+81Z671 ?P<ZH_"A7_D?WA_SQ6
M<(*U 3IX[[#A!3"QFX9]'=N4A/AG+N>_UW#>_3'D[WQV7^/*YJ_2E3$;?D8K
M,>V]VP63)19PYM.FIL=(D][%"V"*55EZ,E2WKF*]-F"C^1U=-JA8$0"(@(TK
ML+1=IAS[[G8]F8WJIZ./=P6B^UMA?;7MO@N%W04*E;N5RQ= A?6WJPM\+#8I
MA <.))M,$-';N2O!&Y*@;]I$W2V($VYFYW//+%RL+>ZCOTOV2:L0=M2O=O>A
MGE=Q%>34_CI75@<A.,P7\:=WPHZ[[3Z.-/&_'F[0<"9$G>V>P-.9<=EH^Q0W
M(AP#L<S]64@UU58>0B09+VVY]TC]=*S^C,7Q4=M2UQYWZM22*&MD^_7D:&9C
MOAIQ,EP@9DMC/*/RI6L9C0,?3(P&URM:9ZYH.BIZ&QX ;W20N&^>9#6MW9P%
M\H5>Y4Y#F@1-YKN0<(X$[ 'I47-,\X&:Y_R9]P4P'+G=J<!T"P7N1NQ*N0V^
M*RY>>^&AVTR,/?7$;$\WB:E8HU41O -D9*Z[8K:GVL2WSB3A/>^*X9,X'++_
MZ(=+WG=^RDB&5;[!8W]N5IR0^2T(=$XX4>7!)(9WL!9\V8HF=!XN> $DI_QF
M\T<LOH[$I8[VNJ[.MS7(ZRI'\B+=2DB2"-F7F@JS00F!H UF[\C FYV.12T\
MU<%<-=22LUZ/A1F]F:2[_7U=S4T! "#'&R0]T5IXVB'LKX]OJ$->]4N5T3+F
M>VO+;RGB T0Q+\'Z_I3&_6#*F#*5J*\]9N//B04!\MI3__FL2M^XMOKCT28&
M=.#B3#V9,U?2!?!PL@#;;^9^]L!!1_!MSJ9%Z]LUOY#&MK IT)(!5J61;)$[
MYPM:?Q$=%6\TTQ^*G?YZ >R,XBUF_>DP/[NQSIB/['4UD]H->T:0,N$%\. $
M_H_,MR.^E<7F=A/CKX[7JQ.Y3[\DG-L1K(+#%6X,E@9RSL"2NA@^B- ;1Z[8
MF6E.4+9GW,[L')B@VS='U@>RPP?;+T_JP1BG!IZ%JH@<*%:R9KCAGC5;FWQN
MQ9V>;P7?]<R(2-8O]1,;S["T%T 0?,,D%(OMO0 ZM8G#,$XHH; &_1)[W[@(
M9_HM"[).C[:KG%*$M#]^,VW-RBND'$J$(CI![:9"YF/Y!\NF@GSOWJH)7 #\
MK9;!O27[:%TL'C%6N0>ROY.%>>HINC'EV14^Q9^:\%X\^^Q.M<FG$UC74&R&
MKS8QV05 -M$".:3%&3H>UP6P!-5OGZ>3XUQZ_UR>[\$H5^+!4YO[?MZ:TRI:
M7);9/,A/YLB\)MSL&B^ I&HPQJWB$!QN!D)V?4K/C,M][=>A]S1Y1N,F'J,4
M>8='-N6]/VI_W*$7@(54\Z%)\L#/X_933T1(;$T\0>'L=RZWAS/Q42YT <3N
M6X&AH#_?=9B@K[B2-Y-S1$GKY(6OZ=P(37Q9I:+J1"*&M_GC]0T1F7 50I'/
M/9R#$WTRW%_0D*/(D*ZQ*B7V3X[+!!5NJW>QCZX$6)C?[A0+Y#S/6\Z<.4F
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M$<.GC=*/S$WM?_2YTN?%+J&R=X8M242&MZ#O<IQS0;3=CS(=#<3L<VGP T\
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M39Q^6A;_*97\"3T;I30MWJN%77V="3G. @??R@]3YB9=9FI/F>X>N+;3J*B
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M)D<LC],$52\56,^:['2"#KF]" YMN+= P:,W6G&2UU ;DZYJG*:MYL6&U[)
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M\>25..-)>C#0'_[B9_(PK[:?YAW7OG\RI9*\(:M,<T918[F9",=39$X%LV-
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M7)L(=HC01']?*)YG@JG<R>=(Q':9*TC5]^59)(/-7OHNLVWW8\'^=K5(Z^1
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MZ2AO7S,<N-X?W^S#> $P$%)I21%/-?YH,D0',$]AAP4(.:TT"LV[:#U(:5Z
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MZSB"X[/Q.V7ZS>O4BRED^(V4ZO(!T(VZ/X\(P7B>+:=1"O.=4&)6*'"W7&_
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MU#35Z;%1I[%+E7)L6-90\(+;3"ZU1C#BM:X0ZA[!>PW<)@-2_7K/2D7H1Q?
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M+P'S(2V?4JWL!([]Y $18R;L2($Z)T VPV&"#FEK0_P$<.A'5+M"KFQ5'S(
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M]>ID1 )C$VXBFE&O(!-*GS!2UO#I9N2R7,VB6?,)\"!XQ'O_R)-JDV,'TCG
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M4YFZHFW*,<OY_-57'7Z-JG;NC0@07A]\]<C8S,R'F1N[&9H6J)B 8WVW DS
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M31O>A1]KZQ-^3%,=R1G94J,#/%,KI*0N#[XS'@.W"G#JP!^=S-"UU8F_"#)
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MLZO.;(&<(?A&.&Z#V%0P247A47'@@-F@$!Q<ROU'L#]84R4TS=O#\9+"+!M
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M>4XX[,')]&.\@+W;QQ]MDAZT!"KKS?].*S7KDMW*;-A<'N%"S;Z7Y2!=22(
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M!;-E%[U_8O41"_#8E@7X463! MR<PL[+A&'_YW0G.48;% \M:9)+/"!]<SW
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MLQ6..?&SV!&DSKD@'!G<_HS6O]H_EMUL.]081#Y "\2;9*F65XIIJDC561:
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M'W<T).VID2@Y/OZ^?X@M_PJ/.J4[;GU>4#'WZ/R,RLU$%J!F( 12P#P\Z'3
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MKY .UNOA92 N 1$!^SL@4;.3GE4<E9]6T YM35=M+$A,!$_P>.I4_B!RYC-
M<L=506V 3&"C8.(W-9C^:+K67'C)K9)SDM:01NHN1;=I!\J0S];8W@!J5WK,
MB,SK9OA/>*#CSIH;*1FN?F(M?IF]6__"9C+^*A-Q6H+&:&&@*81%F,*3/7/&
MF;:71627MV1G^09@:_?M/";[[=SN"T4I!,@Q_N<'7VFO6]NE58,5VM&-?=JA
M4%*3KEK<#:!GF0T=8N^4>_N.DMV]ZX+)Y&QO??WWTC&)"]Z*;2.ZN""$T'\J
M#0-1)(5F(*]K:BC1DLG.&9-"*%>U"_C"<<R5.$OODZ>P<B]?J!1;\NE6K_;W
M:T9<*444+FI8K8J?4V3>PFA1OG*IG";L:#,F_%U/L&@P'^5?K!OZ7GPPY)",
M*UXLW;ICAZM<["QQR-MG<'CP<Y.UB/ ]>A;T?=F)_4*OJI!-%17T,0(:=LVX
MS6>)\&-;48D*$-0(<2YV/_I.,)(0^31C,7.K'5Q9">)[48,)1WF4&=MZOK>
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MV%+'L!:6C;$FCP[BT[94SE\3HHV:SG]>&%2#:3&;[4(#(]K=V>PY7<N2TS>
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M4-<F6F)B;#R_:R#TT/A\XGQ2MO:^J$W"M#!GDOGEI3[F4ABOM[YV3?-W5'4
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M)25H=V&B8&HSSX/O[\(TISYA"*BAR\0)J]@N.@]N=(T^ 4(7.].-JU_TF8_
M,J,#;[=*$+S=%B/V!J=0)L3*!D(Q]2!WQ5AM1D.-KG+THUF+>4M3L<^5R;"F
M%F5)?L]]EC5B'W$GJF?^>ZK]?._UKSP^Z^G2IR*9/&9N-U1$L1S=V.UI97QZ
MXINL>2?QW/4#.XWR?O*F5Y?T#XWP-X]9"P=9X4Q Y(GZZLCJ I-L WUK.G/2
M@ R8SJQH?$;PH?S\8_KD642OP/9$0XHQ@2>M #;Z@&B0@)LT&_F1.BY8]8+B
M8 ?__F[(8=S=@D"I,.XWVJK<$/OLSY9'56VIXNB-;6)*<X"('$?V<A ?(9_P
M]7!(4V!OVD-3.('RD[ CNR6K(:!PTW<<%9JZ?1!00_3#/ZG)<9J&ANU_+,2.
MWDS1_[2@:^O.IJ\P([RPV_4G*&K1 _KPX0B?G9RMNU$68[4K=N <E#^XK#NU
M4Q=Z@A([&P6#T6(DO1\P:MWJR7K13*=D'40A4*8_7.SF]J(JSM9U,XDA]-ND
MHMTYR%AZOL'DP'L23NZS^'RXD6MJP<S!7+KP"N>IDI\BST/.+S/]3T>D[<5(
M?Q+G&_3<^"U_/EJ[J\U9,IB_"> 2S#@,J<L4K:_@TU455_<RXW<]Y&ZHB*BJ
M;9]Q9FXNV'TU1;14,YRB>UZR7K1-JC/D>,Z2@=EEEJ5CNL1\^JF4@[BJL\'Z
MF*5UZ\ET*MJRCX(T#**W\!)4BR\XCK<]7$5, WTZ74:.HLQ,RVQ]N?:.?9]B
M_5L_'VDTUV:AR,\$S&!E[1QV/U6D<%"*5=8[:\E>C'.JT>.E"1.[_"]JW6BH
M\,7JN;#8=HZ.;#P]$LRV57\IWU&-<426^\D(;GY^/+N1->5Z*-+0S_;>>LVG
M @GJ4)5CD_%NT0Y=T=*2@4=?P;O 8;'\18.@K!^^,/6LM]#9G*X@NV]WRBF5
M!5N5+FA[;>W=M=+X0*-/$3%Z8L&'8T?N;2@V#)8/Z"=JM 4P#U<8J 20A3P>
MR:T>_1OAO)I3[3"B&55\#A*37F2DG!/Z7AR)/VRR$/<%3VUC*]I\ X=<W?A'
MT<4RI6M=D7;/$V\%LUCM3A9O^QYBD(BK[P>1OCGH0L'L @#9YEN;Y3V]5.>Y
M/-?+0<87=<?H6L35ECQR_M0MEBEO4-N5Q4T\G^K*@6MN7VO:,UR_C1XQ)Y_P
M9!?;L(3TS -RL=8-.5!-[F_YVOMS@E=#VODI+W% Q=Z%?.L=LJMJO GW&FKD
MAR, ;K7(;&?PBU%/[OMG2\?G(-W421O_B/NN2:^?]BW"VT!:3YQ7]<$PP5:<
M5JB;#*VY<Y>KP.LDP=$MZWF8P,/9A(=K[PJ+1O,.9/M@^HO^%U7NI3WNFT5;
M(S\Q!V/C=C A'\#7:-;8%ALKW?- \RF47$Q=;5^M?XYWEZ\IX"9@8YQV(-#0
M6#VRE359KU\T P1O#;^T_ZK:3GHGDD3N90@6U^=RE5U;8!!S%SPM.F.RRB[?
M,6_]L=8KT-+6(?S[0Y,=.?77]_QV#<VO;5]A/VNW)E.B'H-;)T*]GMY[Q;QC
MH@K;-M^9N[P!ER7:J(]+J$!.-,7,K38ZUG%TH;+5%CYL_1P-Q<M/U&PYGVAW
ML:'A@&SN[,S9* 0LD5U1'3R_;C#2=X.>4^31Y?R!#CX:2HVHH-2###Y2M=<E
MF+4O_2YIE9KQ)[44Z 691VRNK%JOQ:QB+-4ILE"B'#6%;JT\K"PSLRS.^,D:
MAA.,[MB\[V69#]J[&6MC.1D,=Z7?F,''?JRUCRJ/=FDO=MX!0AZ.E???M?B]
MS_97\[3G\]AF/)O+-+ X.1K-I\QJ)]:9WWV,$#%=@@51]?ULC:.[1!*994/_
M!I9;K"\1;X3!F0@.:].R RB_/+AV#9%B^E6'Y6J<9>$._SM7"L%Q/D6%RR43
MC:UGQ,TG\^K\C'12\6,C7KEL.SG!IX-?_D>*&&*R//B?**&9X_\+B@C5.9M,
MYP$<<8BIR396%,OV]Y%ZD<HUO$&\;K?C^^=9=^]G)L=)$S*+M5?TX%/_<2.!
MT-.21NYS4 N"8#R DV1R.&/&$ ;R7^)TQ37:V,X&F&;D#"2D)^1F'RHN<SN)
M(FJ&_GFC*2.]M! (N7H.>EUD<^ SIJ+UTW&>G5C>R%"2H,_@%+?*-&4M]C88
MWBU.?<-$I"&,+23&>1M#V9UC"6@]2-&([1G.*@DJM)E^YEH3Y6-#&1\ZT[R$
M484X;].0I(!H^PPG:W:@%0LAAUL1C8-.OWA-,-GH$EG*>_]V,Q=F!)-A@Y6_
M1H%\R2#J:CP.NX!WDS7'B%LE9P'MW>D)J'B5Q-Y'HU]^42']/M]A0AV2OSL0
MX3Q*1/UH%5F\'^8J#&FB9$NB/=!,5[8R;-H,7GD=K/ZA_O$W*I<3D^]G?0@*
M3\D@"#UZK\BCS16'ON[,T3Y?]W/M_G4*0RO+.XXJ>9U4*.%%;W[B5Y-B@WN7
MX> 378OU,Y73PL)Z;F?<-]W[)2F/M30<12]KE'S^]CTJ,>*DI9$?^%YSVE@>
M>T)Q^\)S^J;CX_P!H<W2[TO&U]HE'(;SQD>\'$6598;CST$TV3BF<Y LU)IG
MH?[?A,.% >191$?#A=/^T2UGU]0OBT7W[2,FQ=:+M"]X/_,YZ(AI&0+8@ADN
MW&DZB5'\EXAYCQKO.>A'"3K@'8(X?7PW0O637P#O68T]='<' ER&G#TX&CQC
MUVJ#[!G+;@_H_R.C?C<V'+%2Z+SP%47R:HSZ$6O+LQ".*#:;))%BSR[I7UQ>
MS>,<%&9 I#]EB?8[!]WZEP;Z)[C&.4C3QIKTYQ\)]#U;9C_A Y+&Z;L!S/(?
M!.$:@O1Q%_7O1H[]]X9>_!^>'E7,Q1'+,O31$9A$AKH8&KY\ 40F#GPLRG&X
M+/0O.?C_WE;H0P.MTECW-L@%!F<!6N<@4.X%K"C%<]#_#M91][\IU/][<__?
MP##XG\*PF_AORO;_SEATIG#FE%85#KR>?/%3"-\Y*/#9.>B/_M=ST/^!US_V
M_E^  6#^1_R.F/[KJWG^SZ[V+^_\GZ'T+W2<5WJ$#PPV >3QWV^(P:[_ZTA"
M_/GWT"__KT'_+X@FAS\9;&3.$.GW>Y7.0:B+.&^ZR(0=H0'$OP_4_YL!]?\8
MD/\%^/__C472Q__O4/P?TG+GOP+Q2P5F"MFF]"0R#QH;X;O1,3*O&\0I$^+5
M)AZ[GSZ^!?GE'2XKR0"G",,_;ZP>$XHUJ/YH6QO7A07=9R[YLR^;@=<_8B2I
M_S-C.O:4>7SP'-2L*GV![[%4[-&UV7,0_P_19$>)3FO;+SB/&/8VHP[9V_>+
M9%*C7HTX>9L+-,3R_:?[2AZU_N>S<M97$36&_YI_0_0-$0T"]HEJ[B&0JW -
MO+*_K*S/^\\C!K;\85(2JRS:LY=N8LM&ZM9V4-.HYM2%-LE :PG"-E(L)K,(
MJL$X,_V113[I"]M.&QU(*-&TUX;9UA'#4>^:">PVF\O'P&_D.)A#H]*U9>J*
MY)\YYQ<MFT:UB":)7'E$YLU[DT>4%3*MW#'/3V@LPV.HX)"2B0!NQP3]TK7U
MYW?6E#[=D3++K0R_K?>]P)6NJ5(T'\A?M')O2U<%./,<#R154Y">^1(59DE#
M_JF")0Y)O[3%O+^^?(>@<^XGB6)1$1BJ &8GR%492?).'!OO#:]4<.2-YV'*
M"IO+/MSF:W*GB["^Z+B@D!>^DY"&?&,MLZ* 89Z;DRK>BX-T< 7"P!<</U$K
MC/[CYC[MJ]--OF!>8;UB%M/T[R\\JO$Y3K8 'H^Z 62V<T O6@X*1]]]](>_
M%N+FAP;CYK\MH52MO<X.+'2XFH[#EC^QYFA"YV)Z :$75Q4(#P\8QVZ28T\<
M&)V"/E'6GYCW/!?T?K$S=T=AJ?[P^>FWUP3W-GJNN5GX[6H@)=?Y.-%IVO,L
M!=V(DBW0SO1O:+-[37&%G5'8)MA?N#YN/&;=]/2GI*PX&!NZ' 2_B,^KW)TQ
M@K7ENJ(SJ#+5*(+D0"D#U70,E^+&C:A1N"81_32Q%<-<STLD;Y%C/>,=(LE+
ME$^P<GQ ORPPO5NZI/BKE'?VVJ\.+0-+^HAR50\L3]&)LND*S]61PHK/[OLZ
MKPF-27EU]QI=Q':R3)@2X"U7E3]OBG]]X6$%"5=C V9PGLOM$$ZG  YWNH6U
M=/K$EFEZ9%9]A/,7Z<:'R?;&4AGV+S(TWMS5R>Z_62HCLQ##(U QKL8!<#;S
M4(U*2LAB*#6*6B0K=&Y5C0X_</Y;%]>W\K.)O#<QZK" >#9.>1_PQG^#M@=P
MRED+$\+0/*'>/QQ-P ZZO=V5:9Y5<4$[U9[\OWH6_SP'TP?<@*$T@&;"H'G#
MR#2MM!;@?8KT5TR^>[-A[L;6+TY^4O0N?4I,12]L]\"5*-DF#L&'EB<;$_4*
M8(VM;>9D\_WADA/S<\P%Y:ZU=WZ_[VXE\QA!R71FK*:#@0;<Z8W.=!;"9!OZ
MZFH %Y2Y3CU[8:4VOBY&.=MJ:?I-3YU5BK+9NZQ\EF:8W\$/(!HGB:S%Q!8U
MLCNBL>*,.UO4N-JRR-[/17]?)UN8]KRL_/D'R<=_AUL$&@:A>I6&\_Y0(0 P
M-])&ZE;?\%CG6/AH6^\@2$Y]H##B;>RZT'Z3G#+'>5"-<@W%>%%_IC!0@CV2
M1$N[WXC.=S;WC_T(-HA0MC#]6Y?TVCD\=EN>5[+\IFLKMV)^G5N?L995$0S?
MQE&UZ?Y]#4%?WJO/B'"%JT4L71F7-)^8$.98[!)XE_$YX0Z(7%'5^?L8Q&G3
M7AO0P"$8K6!WK^,NJA$L3)+>28G&N_V[C]705=XT\!W;-R9OUB?)*M3 )/;Q
M>G(BOO4P^6#[+=8*W,1ZQJ7WN"NPH<TC3,1$N:S<;4 J1MK2K89@TF%22]]V
M BO7X)^>O,#>L@0JQ[MLIL4OJ!-F$4A61;FDL.)TNDZM@6XD&I<'W(7SEA G
M0\HMH QKSYR">]8?CQ<+LEX7^/7J;:@9]\[3, J)NZ)?RDY_-O(Z06GV%\(/
M%NAD?%3 V).Z/%E!5]OD'8?-I=LRE<2-#F;0FS^OE[E,LDF/"$^JT %#8"JX
MYLM7DQP28<=?QHKKVWGNI<[R^U $3[FI/?4G6OM@41_4[OPZC3SCA7'X\V82
MC?-/:\7VSD%J*ET2@EX?W.=^N1E3)DBE._FO;*C2X=L6N"J^:72:RX>H<0->
MHVWF?Y>B>3#>;POF9;._A69]WJE*,NS0&KQ&R=;_'D)U)@8.GZC=S"G*D43"
M];$S^%RG8_=I8P=<BL-KV%\\W"WK[E?R,9M;]<H=J+*&/SPJ0RHOO1>%@!![
M3ZP_Y.&X3)J56:&[BUL1SHCQX8.\A Q0 =G<\^M6[A<E::JJ)5V8X%;S$@_Y
M<&R/E#G5-=3MVGM;,#L_JUW":_JG-JV_,Y5<OB>ZG$PIM7SYO2A?%5!"##AI
M;N0C8#[ Q3/:<>[L0%R_P+>*]L&I3?%-+*A792=0VXB?ADY'=D#KY#']U=5&
MU1 <ZT>>$!SDRN_V_#FS56^H8R6F\G-2L(4C&YFW&D,!2(/'.0K(.!%<\:4K
M68RV;^:A0%H.R5"Y;:!5!-SS^^WYAV89EOQ\HKX?A:_WU%WF_5F!V1AHA!#T
MV_SO0I!R*!JHQ2BV=-0-7>&#WK^:%6'TA;9SVUH&V?>@)9-U/37E]N[E^)$U
M3/F--LR5-13]*R*T-5KHR2]B>I5]ULRLV3J]]&^?964WYN]M=8J<3T:,D$Y[
M4'+X\QJB#X!:6OTUC6@!%UFM/MU(2MO4I:$6]NXZTA&/HHD1;5:3@8WB)&I^
MPFG+B"9!R- B/'$I+C5TU^FZI<#?H5VY2,_'5<EO-G0W^41 ZU:?E&ZTH9$!
M@D!=SDKZ52B3&6S4&&4TLI\]]C)XOF^0K*W[712\+\.2%%1ES^69D[4U9,8,
MER:FG;':1ZI==EX@(']?W*.?X:"TSBD'3+(DK!B'0LJ=RUS:I=\BS()$QYU_
M(*:]=&.G\ ^(^V%(FC/!<?>,X9L$4IG2][%4?!?,C%@M<K?.K>/-I6U+5/-%
M+S!_EQ#3<*+0G^>P26'-0%@J>5FH+<$'L4M_K<ZX*"5>YWA2%[@=494!IR"R
M(#<5!<8J2RX,*"P9DU"Q>;D;)8=6$:7N+%,.-.1Y\E M@,[IU?*8EY8%'A7-
M(SM,4D=/.33>()RFIV7\%)O.C?(,&[TU)O!ZUGCPK_)PP*H7'A+]%H_[ANZ0
M9#GKL[Y;$N8J-VHR)FOO9_9Z\%/O2Y':,CJV*\]"5B/Z:P$MG+\\+J5-7-\8
M,'M)A!A.;,,W*=N.*S:N#+0LO'@>;)K=^Y!/$5)WWZ)8709^"^#$0V@ [P/_
M4<]HMI8SIC%/]&9EC$-E,S-!C\M0F+:G)OX-)9]*T*,=[O@QS1,=H-6:L%6'
M1]$ UP:? V\S9RT?3'JLV8D_.6;C*AR=42\O'C***+@C=JF(V^,@;-)3/WR>
M@X"^2" ZQW0!9!L/!_2Z^5IJZ(F%!HV=5<VGRT)N\[T#.,I'Q"*F ]M:P.^[
M4SI3VN)/X&!3PMY*NNTZD&JAI[8TKR6&<D(.FD3E*9O>XIZ!K5L/8Z&A2IC0
M,S5 WZAR6'QO@=HQ@.*LS?U7G_G\_/+FI38JKJ.H#/76ZT,>1CZ1&GUJ2O W
M1$0DQ@[\,2_U 0\KT3NLPG3/WTW457U:YAG_:QU7D< ^KKM1<G34)N-J+-7C
M:2VU[^=Y@SMZC5B;BS-&EQQ=AX)(=(N,<HM?#P4;78BY32AV(+$)4_XPQ3'[
M)Q3(M*@:D]%,?D]VH##!-PD1?'2',U!QO=V?%SL3B6*"R<VNI<I.!+WU='I9
M/2J1':/S:C&'^F&[?M[-O5OEP=YCR? R8B8>$:TF$-!W!B&JQ2^FO0=\_'.M
M+$S71/.OYW>SXCGFCCB]PGO)WM9Y#>E7^!JE=- S5$R&J9 O@NE-@<@VN73.
MT7UQPUW3!F<+3F';T <B9NKV"8\905R7$JV="P$^/&7H.<ANSF\Q.7)1>__H
M9EGU2/DV4V>^.DO%>&39'4'!6YHHQ]M5G-XOMEAFS0')3O#5LUN:>#WZEDV\
M,K=W*X=U;)'#04J\Q;R9E5D;H[P&']6?^^PAM%,4K^U*+7L>%U$Z+51D @CL
M5D.>4R.;GG*'N6 =/5*RW&<[L"QBZ95*3?^ 0I6(MWL'K$/:*BR$:-%NKA?[
M458RG(=SI!Q-[ZADXQ0/)+;6HF8*W0S4Q1EH*(+O7=%B4^2:1&D0,+A; *+S
M3**:L!22!TOKX&BOF#L,\=32#;=X% 81=Z4IVJ$.KGD!\'E=\9N4QL9.1>RV
MF4]&;^YA*.?@8()\N(J\6M+;[[-.SEY5)B-WI&:I;+RTQZ6Z*87B@XSZ><VX
MQU&;O'AN^=8 ,'$PHOZRS0^X\D1NE?;6]W&:Z>@/)C043):MY1*M-=Z778JQ
MZ?LUN&B#,XZSD<;K">S2/T@:P?YR.PM>-C<.2GQ^/6D,_2$1?;HAF0V;1&+L
M9U ;5I2MM2E-G&:>SHXOD :3DJ1GRJNT7"[REEJ,3UZ+O:VQ$;[SA)YE'<4B
M-M.Q4%[5PDTVQ*I/7;3\L4*0*_R5%*>?YX&=%[_O!\%45S>.]ZKTN)3H"GH0
MH%?!S==:%2 R+E =,3*C7Z&LH<.WN<"'/WPK:?Q.@:Q^NVFAG+7$G^@V@ST'
M191?M!PYV?ZY@WEF<[!G9O)$=&(P\4EA1AP^SI>+H^;$"*Y&%&ISO[0RD7H9
M=3!7D5[AC"B$O;<Z_;S.JJW_Q86?_U)BQ:\V\LIJ>BK2;2(E248H&&Z12Q(?
M;>2!*;7JCA6^+B]/^#W[T3;*-6'Q@5>21^A3:KPC?Z#C(\,E:M[WF.G.SDD,
MU1\@']):= M,]KO_EA.-+/+D;81BWUT]"ML[SZ\/APM]]4)K$6]TZ#,Y@1D%
M"/:M@S2.QZ=GWW*;?SI53<^=F,U8\#=]?FGULV_T#F=)%$A==FD"<@5N#]Y@
MP8&1T9EW@8ZMD6.%]ZTJ9EX)>STA 9LAPAZ3Y#E^)H;S-XBY+9!(\Y0H%46L
MHHIC%BQ-9_2"D*B-[' Z%W#.F%:*QLJ$.GQ[0J\<Q-Z<OY34TE5P<F,MQ7<
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M /0<]'(5LZ>.'J(V-2JZ*70220JUMS@=0)XV'&6@N$F/3Y&NO,!M'(06+DM
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MG,_C6E>;VUS@XJ]]&>8"N9'*Y1$$]YER+\'>'/!YD:KB^Q.&-K<2^)/\I_7
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M<K\HOFQ9+B([V/ZI]@?*#O,IVCL)0J\^7#!P37Y&O5)I)7_X2OG7\I3',X<
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MT&LMQDD'[?^P@/^H=7Y5%TB2:*;/5A[TX:34P^O9$C34@LFD:MDB][6T33
MQM \NGC2J,,][VX.Y=*K'U=F^%Z'IKJ:+O3H"FJZ:O4SU]!<"G4 ?;Y*!U1R
M;'&'I%3:]QMFUJP,9\=.R=-E2RR=0X-?AR.V\M\NP(Q:!@[F>C%G[\_5&VR\
M%)S/#2RW7W^RH>KOF5E@TI,4?':*/7JX]<%/LS!.!<=@@M@2MX9D&9:%J?,P
MQ[*F$C)_(5'O=<B QG?]I^^:%2]=Z7IWZTF%@?@C7[ XL:L[[]S):SCV#LEK
MLO*R1.L$B1<&PJG; Q6-WS4HVFJ]/<P\6YQ:6A_*ULGV_1",3^T$145(-8S-
M6! "D?&G *SD5.%CAN(4LF(&6GU W%3(:W.WGBZA*..CQG2$*LSQ%!#3YX4=
MH% 2;C(6^&/?;;3NNZ75^-;#^MLS"P[;X;'S;N>O"44<VJ>$1R_"NS,(P5A0
MG):5N)%7<#B5W0#TM[6WLVO*(YH#UE+1WM:E+G#M0D*$$.D&P:>;7T?"DRS=
M/-$Z4]Y&6Q>F%[9=\REJW)[30>S&O4ME3&F?EZ<@QVHP[3:B'=ZT2P<XP>$T
MR2O5BHZY<].*Z_/HY\A#C'U4^'L1':]W08[*E&Y4OAMTP-IT"A@QL0;B3>5_
MJTV< JHKAW93&DD>IX +X'CXEHC_*: PIQJTF ?>]2D_!3C9(59$W$X!\GP%
M!^"]6SA*@[TO?R+IEO:OO3D/AOW7_RN_/_Y?!]/]=KG^TES/]0&WN1[@G[C.
M,4H7YK7_9P.%OG4+#"Z^G,3V+V9M_&OC&+'(8<^E0?@\RGC7X.'T+05CO1!J
M+B\A#_>B5T%4JB/&>KS7> AJW:> ?_RM\SOR.4H:WD_^;ZWP6Y.LLL-9$?)^
MPBD R0,2#WL+'4H]!;@%$I\>7R<:X$3VMV-ZDPO7@S6\OL6$>*R%5]SB]T=D
MN,\JGET3W=\:OR_*75C<% .,A,FSQ0S%%N$G4X%Q; XBCR_PNKWM.[0+.OD9
M>A>"8"/)XQ*%9.3<ND+UD6[.IP#1S*D#!5,>-)5!9M6[RP#J2 VV6_.%3[_S
M3Z(8\"LQ>>4>7MB3R_-CED$9YE$RTI.:DTZQ'B^9#0VE))X.*G6BJ/%#3YWS
M0"Q$?R/\D3V[J\/E7AFGBR)J-.8MHOM->F=6]%V;L Y<W8.NF-[4THW>;Z:J
M,]N3_0HQ1]XF[=LZ2XT\P%B2$':'WG8(DN]NZQT'T<S*%%'\IAF0UNSM<HU:
M.%@%J4?UI?&J P@K_S2@_GXMWBKN<>=L\6YBN.39SEFIV9< ='B8FOF0"J0;
MR$J2PLWI+YA-:<D7;FK$5)]A&M0UC0TIZ/C,^/-=2LA26P"WF7"9P"[1QR"W
MFQTRZJ$J7W6=(U;$J')L6T'?_Z6-[R=YJ95O,D/D2S"!K!X@6[TV=?M1"F)1
M:. 863]GQ)I!,YFU!0UL?E8BSM9KM';.W[% #X#+J=E;ZT!_#Z)T+V"NRZ1
MW+;/S8E]!4HWXV3MD2<RDF4R5EEIS OK2F=2<#WXG1Q6%9WO$<$SYC16YZ Z
M9C!6T)_RK9,FEEL\_59A))W1T)UW$QO2W \+*Y)$A"ATB(%=K738%#2-#0B7
MMVJ5]?;9JK@0&Y+(:0=+*$@Q$E_>-57.Z>O:88)&VYB [^&_)9=MC/0M5Y[\
M1# W4EVQ\GG]Q8Y?/)S%9^2ZI3XCD;Z+8\;#<@#;=M[K5[;6G(9$3;Q<QBD@
ME)V/0U2CY-(V.K8N3#MTQS[Z5DV<;8M>PM+=E.^\J^Y30N;+U/Y43R.-J*E'
MZ]SS95-NDR3P:@BMM0Y'$36N;XW^@R>OZ'Y+6KQ*RW4UCC)B#MF<;SZP!*.2
M\I-G";_AM]R/NR91ZD1_"A5 +"A-Z((%@;5<^Q30Y176<R@J.N<KICXB_TI,
M=3L]PKJ8N;\7\#AT-<K.S/UHRAB/RL!N)AZ_53+Z.'99A2%B)%CE[<<;4XK!
M(0+Z]FO$7"GQ296^3A_J.7M/-2ZH?->8:=F#!<.C>[15U1VU8EX#V$AOHV5J
M1P?\<9]@5ERK">'H=]T@O!?X?5XQ97[*:*0/4\6K6A<MP^S]I8#J8?<9>@L'
M>#19V5-'AL!2DN6+1_:1A1+\9NI-(,8),H97&'Y_=WFHE,2JD<-P-W&TSPIG
M&HOB()1^1W3K< ^3KA\8DEX+68P5?'(W6V(L'M\69GU5_AX:U&<[XCKJ4]<2
MKFN4KL"<J61;D;F5F'0^J6J4CHX[R1>L[6G;V*U_@M01E6P+AI1 ;_V4\Y93
MTAU;"1&\F3#+X1\P*]/B36O&?$Y@ Y),;%-!)(#<V81!\<KRSVV_/<>VR9LV
M1,G3SMG;=7&XI'N4>J6?\Z\?=_);N+B40/NM,@QH2,S WLD.Q#=VS]/A)]^6
M$&T7K,>JMLQE93.ESZ>[VS#'2K?W_WZJOIFP%D%''CJ2[U@X0[0P;ANK"[?K
ML:5-G4Z-GS*Y^2EP?AFPI=5C)MZKY&A ".MQ%(QK!]&B/[8:5YG@4^^WNB-9
MT\*U<NI_19B[<U>? @P#6=FR:V45HGLH]/C(VG:Y#8L0#,^ZAQHG2;C@&+Q@
M(-'ZBQEWZ^NMI[XF+()VN'_G)E0@5$>E)6XI9F+R1MRP;X5,)Y'UB2:2O5.6
M:$9Y^8(&O;QE^3E.H^2A5/][/BA1HL5=@KC.A19\;W(PCO_6ZWI(LHY4RXTB
MQIO%P4\T_.U^F3WV)U\B!F--18R\R1)X5#*.KV'VG)=MITQFO"H#QL%(A/X.
M6VAC.=3XQM0OA<*-',G<,O<-[LN(8#?AA@V^GSA)6NAV'T^Y'O5')9@F-IRO
MX\A]C 0J6C_BS1,IY@WU^FC7U9IG]Q"@&$:X1P+A3P&=\USC5?LL;%T:.HGP
MD%, 4,TV\)F9L:J15-BEJ-DWNY#0!-HO2=LR7:$Z,8%PWQ(/5=O'A[N_I_QL
M9MZ9^$H=+E^B.SA\/-[<FU@*331&F$Q4R 6::"QZY7S;Y<F\J.\?:TDC&HTL
MMJ=4:MM>UHP_9SRB74E>S<:VB=UIK7DV8VMO:ZW'G4G@-$I1O4_+GOGPW@-_
MB_5Y%CPYU>?]S/0/6Z]B5+&823@SKV^A0TOXZDO:$^R#.\%N5RM#I9G$F+I0
M5/B^9P''Y2Q,E#M%HG,@Q07>(XH+!B!^G8<?(F=]ASQKG+#:;$;X8W=+C<L(
MMX*7T&_9M!4>GN:U3;>O>6'\/_>IE.M1/?(/E>^2IX,&+=W)-<;'QI2@$#*#
MKI.ACQ54:E%J=2[WN.6>IBN\8=Q%1*(_IJ3B2PTFMDG&K'%+,INI[/:0!K4L
MP8>UUMFJ[.\?#=#14GT6RT>&%D:%B)7$Q9&'P;4'Z./K$%O>K#+HA]X^;&7Q
M-JH(7BB99WNT"VV$#_1NT3QH=Q;V"T'Z8#X4W*.]=H5'_XHFHZVT8$*B%[VI
M:8GZD?GFCAXWMS-QC'SSSQ"7:8VU4X">R@-XAQ9Z><&*W-D(^J*Q\+_<QH\@
MM3K&3< '_WG["LSUN '_'NON?WGBZ67SE7_E@2<F, +\]P>>RE/_^P-/#PH3
M9/KY_]N1K+H7N$'+IP#EU&-J)#DA]-@5)4E$G *D?K^#3XO ?UE,WE=U+/W'
MO5L!?_9N!?Y?C2SF\1W_)8PHAB*>D>E5D5A$8IX H0HA,-)JAV-JF;:\>G]Z
MYG/:LY<<AR(V:JS/>.A'VZJRI(Z&=:UF?Q<MRF^MX9B M# ]_%J/Q^IXKNW4
M4DNBV5@]711D!EJ0HE[L%A-=Q"'X\^[U;T;?(,,P@6,%(AOE]OI<=G];4#LP
M4$A[WJAU:N?R0X&[I0K]YRTZ?FK+3(0^3*#EERC2&NB=IY_81Z8"F4CF$.]T
M]V:6ADK1 H57]Y<\%N_%7\JSDV4[YWL/9E%!<L&C$[6NG\3EKSM>'?9)5RIZ
M'LA?=S"Z//.<\TF78J\=JT"$=]%HFW?6Z--=R4K_56VQ SC!K6,Z@@NB(]#P
MD9!7CF4!F8WMLUP.B_G(!_3*^I8)"?:M%WDD6]XB<#L >9,HOYC*X1$A2UA(
M;C5W@A1XYLDV-:8%& L]?=(PTL7;HW@K7S9#U>\6H5U '6G5_JMH:OZI?D[B
M)W-CH^M.>MQF5PH3I '_DT7];]U@4T[VL >?1% 2^MU7P@)1YA'!E@C&RHZI
MITB3;O[\.7?FV5W399F//C/4BTT4^<G'9T31PR:^%)($(8O)DC @/KC71'+!
MF(",D]/2*YT96--CF59/)B2W1YU51ZJ= F)9B+2G@)M=AJ< 5,DI +?YHYKX
M5<O]QJO[<D*8OE7.5(55('[J%$ '^E'D 7R))NG]S0R-(UWQ:9<_DA0T.#FD
M')#/X&^V ]"^XR!KT;36((NB3L D?HI@3WX70>$I@1O^5YMG XCO0 /0/UY[
M  ]G%T@.?S?_\Y%$!T7!IP 6.-Z9G*":]MOX%-!M_C?;ZCV\BXYTAG)DIW?P
M!7\X(8!BPZC^P0[WI\> (\.40^ D"BD[4H^D,08K\J< #H._V8X%IP!F 3P]
M^7ELVBD@?/ 4T/-GVI40GND?/]G_"O2(H-H:H83WWX:6P=25\&(B_?]-L!
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MA. '2?>K2&KXE9W(2ACD?3\6@JC9X,M2ND!><>V0C@>_4'HCG/(L!-XMG[+
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M\T-4$?\J-;F5KPH*OKN'KE5)UO%27,D/_QBBV.L<7IGZJJ&F8PN20[0@C'7
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M&33NH'KTX1BG<<B.CL!F,TPC+K-3O20=-WM3\/KPFCCS6G3"[XQ.E$#S)$H
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MQ_Y=\[+#N"GGEI&?3B9RBU&&<RYI+RX;IUPQ;)?20<-?#SA+9@S =P[SV=Z
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M)38Y-9BK=(5?HO7?R=4BP:HW]?76[Q68"FCF_.H\AHWE[&5JIE#54?1$@WT
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M+V?+T?!EZ-FL%NU[UPSD*0EN--B=)',.Y:=E#$-2@&<S$MZ<ZV%AH2)M$]8
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M%NA [ -BG?X)QO3+.)X7ZJ/II]R GF2'IRR=@[AC<)9C<;.RR6<1*Z[Y<Y>
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M?!#&/T8U^DA>2K=E+_>71M^*=?H6E_O$VYX'ZR274BVY'IM+1$7 E"CI. ;
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M.?>TP7)+L&5/GCXPC(I3-2P-&&^;Z5>(I):>C#*WS&L7UCHS=R-4PSY?;ZM
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M4F>M$G'=A^9A(@@^F_F$C'.V#9D>PE=]10Y<G_O&]ARI]5R[>#Z1:[$.O<0
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M%*5.E^D$&R0MW9F">?*Q;_7WT$!)W<V;J>;CZ9_'1Q#7P[JE9K "KM)$%%6
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M534E?^^@=T*?:M6IBS\8 #$R",%$EEPTDR(A"/HQ)CD.RI/6DX,,B:3@8>8
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MT'^\ -QZ;J/_?W:7P$?1I&MO,(#MB1VN4?IH/WSN[Y&B&$UY$?_>RDJ\6</
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MB>"3ON\YJEWHFQY6IX"M&S=4_(]O;LP)#+O;IA86"N#E(O+5/MT88DOA?'C
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M-3=RC7N?B%C4IW!Z_\Z%3KOW!5<8R:Z^$%T D.(6Y.?+K.R("=X?YP UV0>
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M[C@6ZYTWF-[<?=W\QZ^<Y@Y;LCVQD<4DIOFM$+8JT/3C>\&[?<7A.Y%-AZ+
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M>Z!)G8-\IIV;I'F1QX#_>^K[0(XBD4 D3391&F<-Q^C2,U$FY$P75=S5[",
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M(=G]5_3Q:578*97K208ND)6BUZ\;-F)#/AUOZEC/$KK Q"E8P&9W 9";TPJ
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MY-X2L?)0EV9?'$_1I1&.*,-_;.GR&JI@H&LYBB@<B:X+!A=R]9'4",:$F9!
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M%W_6SCK":2S"RSDNEG.<RH")2@4D7M'IA;04>ZG5;4^]_2F8,O8?4$L#!!0
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MX-\NG!NX>#?Q"0AOW2:ZOJ'Z#G #!Q?W!A[NS9MX>->_^E[_#N"1WZ1@$5+
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M5IIMYR<PT8C,)/IR,^%[)>XJ 7?#1^EP:X#X="5](J-UG@29]*&\6IYP9L[
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MTQ'QRMJ&VJ7K$-B[40Y&EK\_+L7MF@<%#+[!_!KG?.KMX?S\]9@@"1Q/\(Q
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M)E>O;Q*'M9Q<Y^ YDW_MD@;_@^YM;CT6B)9LV4Z!<:O*HPX#KUK11<VM@UA
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ML!\+STOS8#U2H$R,54G+K&.N[JC\"A/9;RP@K.)#=K&GW3)O@:$Y[Z@UK3P
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MW^$MH5$ YS4Y;IJOW?$VZ0P)D9$^Z%8[6 ^M?G!\TJ3 GG>3=V\QY'6;.)#
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MARPO%A/BG;J-*;Q>Z:3I3K>UGP8,1V8ITR4RG>%(7&WS9K.[L]O+1WG#<;
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M,WOD3 ;/CH:N__X9>].)3Z*W7<8HO(-SL:K9O-&?P,T7RM"MX+$NR0]?V<6
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MU3--BV<MJ0H'O%;" <WJ>%-_-F=T<F&]#GTE&2/'JN7==.K!VH[=:UB!0W%
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MF5M*PHL[&-<:*_F4:8)ADB"U3I]<1?:1+;L#[!W@4/?GKA30=TG+>15/1?3
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M!9XL'%##BO4%/:C.: -?$F8EA:8AR24\=<P^L[L*LO.3$K\*8'JE/X/A4W'
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M#RW#AL<4>9E\F;3% 25IUJ[C(2?.L=1WXC]=H SB>6],E?4$LI,_TNI#/H*
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M%QU9&O^RWD,[O>8#&G).#M2-?>=B=X.92[WT_1CW4J7.@-O#SIN"Y9'URW'
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M.*'NP! \*BPHX/4H.2>SET>^<9>%W3O6PS/RG>GO2PZS-<4)#18M%Z-(=?A
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MRL,'LQF[SXMI^CYBSM8P[ ]AZQ2#1S7@(M_G3=KU2P+[!^+HAB)IE!HL^\=
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M<Q;@++DU3"5SR-_0' JGYXQ'F&9;);&U>:AK0-C[(3:G\_*'[\CCP'.NI3N
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M^;(B15$I_^1\I[ ;OP%Y1%B^J@()C_28I7:$G[^9>]\![?RRE?CZ2*L0<[K
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MV7:D7-DL;QZ50#4RM(5J#_\KN$"#7<RI(ES5<Z-$8*W_XT+V+X/3/9VQE;8
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MGF,H^WACVL7.Q)LG#X[LDC4" MA?YQ"JW@^3NQ-[M)"@W[M$C!RM0%C3[$K
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M2[M-XHX@8FQ[S9I@SH"4Y<L6']1+VQ6#1B0G+ UEG-H>1*$?NI+091RIYEF
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MA!>;0P^.G&_ (>Y\UZVX%K")TW^8#[:8D &BDCUAQ;\ED8#Q,_\%4$L#!!0
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MEGA-2G\W/JNR\PJ/I"Z2P<IMA(R15PI^ _5;M3\T^\\4>_-_I-E_*?8/O6#
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MKABU_67GO 2$/OP-5Y\22/\;<]'4;4^E!-A,O:R 03N;[D=+BSRO^SER%+:
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M\FM9><!>R[BFFLGWJH_JM"**#"-8TH,H'DH^U3B9&LFO% A[#\DJ'@X<O@7
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M,+)7/WTC&,9!_#$*,%2':4UQ<GY4$VONQE75.)33?B1\ &"(FI=E0OSR-\!
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MM4S7 +X]$,S%!XMO[M#BW-7X)JB*@/QLL^%Y;.>'2#A4ET=R*N4\M5&(B<=
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MEJD0MW-=B"NF4,XT$L-+ *JK<:P+<#_4$QJJ_-6G>_HKDN-75C@55-,4;#E
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M)$[%; J*.D@IP5IWX]'T9S3%&.GV4]W61S53!^XXT,UYZ@JUY1/+-X$ZU-N
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M=XQAD3<4WEFR"/^79!=6B7VY>_$J9\+#-%U<0&N[YJ/$ABQ1PG2S.U$7;Z(
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ML^7O8N85W<P)6)I*%<C?H)&NE'&KISN&EY&"-L'4]S0[:/I(N5R*.DMB )*
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MU96K-^RX411.0K)(E;(+;:269&Y1Y]K8V-.WS/@D76\TDQ27@2H7Z-'5.[V
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M?(3&O)UEPSHO6 I3'+F[,?,5T\F[VERP$65;B4KF$\$[T/\Q-,7_<:4W<7*
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MUBO6 ,G^ON0G600U=_W*UD9%U\I^@T^%-Q_H LQC V]JK*+D=[51*K328VM
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M1WT>S]>%+70.L=HBM<[D*=. 4Z@,T\UL'>)_^*!_?]7#WV[(!_Z@BLR5&?'
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M11ILUO,4ACSQ4%\P?&N7_C69D>"@G,J?A6C9N__Z)EQR"HDR2*UR\T4QZ,7
M,)8S8N(:+)!4II<:0=E:[GFC./:-V3L5H%*+=D^.'5&E1M^FI(@RQ.D=\J<S
MF<F]O.?CIBO02/;TPAN?#ZH8C?U"IN^F11DB1C_L<#_+2FW_,4(LG,-1J^-M
M67'?DL/D6L64@(5 Q23OP0^C/HS(2*C?=N_]G >8T0(SMZ@^LRU3-@M:WE%M
MSKZNQN\_)*)FTH"/S$4+072HNGF_Y*G3%U#9U/0'V>8/Z?.*%0Z(QS1UB[%W
MJ\T<I6F%T^G43ICDXP]_BWFN2D&K]T0:^#D!5F791 _HYI@WC[?5'+]F'3M^
MYM@8J+8&\KDE;;)P*/1D.?X"V;B!$'%O6HH)TB^PUG9*L_ W^P&E:XYR[.G%
M27<2QMM7&4AL5&/Y4#OBY3'N7H6.#9FDOH*5&"9:CMR/H@H$PP$E)5C)$4D_
MD(]>("'[<NT&W/V=W9ND=)V:.K/S,!BP_9?<(LB?<XMB 8&J<:B^/*Q3]B<]
MP4_825R%M5_-PY2.IAJ7@#C+CN>+>$#O0C^[CRV<P>.K;W'?#?8G4(6IWLB@
MN\6;,J8640UE=ZK+YGN2%$?GR/WR$W2YC0D4'9)U>0^M;+M)D35HDFRD>R*M
MQLHH&;GM#G&JO?CANO^BZ3?#A;DYSN//J/+YAKE7XNY&F*#23 TD9<^JY[?=
M0D1PMEASU@A)GM&8T0B!57H7I:*M^8PPV&9V461'W]W'WN/GNUOM#WE*5IU(
M*>&]Q97UGPU?T_G!V414<+3WJH/5JO+I[N2MV8GN>LP('3HK>$+]WE,$R[2'
M"+=-B+2M"* UX85//11]!5R+-G.<Q.792WQ=F9=%2<BA6; C^<-,+HSY-"L"
MUK#:*0U[YDLVK6*7YI2F@_(J9?&$JV&%1O_IXJMTT<PMN,B_9?+452I/&Q.N
M5B_,'BFY^IBJ !HQU8+K[4#(MM5$7447B&Z U4MY,N\9(W2^'D3&[5)"Q1\E
MWM]1#.;86;R*)G-%/)VP-&QD7-3M/$-8/IO;;V:N)#1$WX[UYHH*<-N2OU6!
MY- *5N9U]4;E;3KS$PJ_3VJ@"#GEX7 AG)"T5A;AT:__V*"?5O^Q@*9$CIM!
M/10""/YR]@L&V8\<_9C(=I@PF>7V&ACIKP7QX*["1M]?@2WYPM]NN2<,J'(&
M(D78S)O1QC_@3),Y&A.SBSQ@D?7LDSB]2*+(3@>:[6\O N-COZ-R(J5$I/>"
M#:TF4\RGG&.>^.<V,**U69/5;UX)O*0U;!AMDEOJ9W!H.BE2[B/BO6#9RY":
MD!QEMD;0E+C2?R--.34.!<$Q4N446[G:2*9<J#-\#-]24M5B8J(:7F]/.@VG
MS)<DV,I_7UC H23@ E2">SD)QW#<KA\W9P<-E=Z"*WI3V1-8G*R6&8VNL9](
MC8ZJ<OH78@E1RHFE%F[23;?3_=UO#E D^"KL/%VB^!&2NN']SYP<BC05<9G?
MEL63SJ8S-KBN.J :7MF-24)H%UU-1S+4W5Z.<ON:>F&2F!GLQ%\$3!>-JC(O
MTJ)F_0S5ZL:O^S_'IBKL.?$$51J8SW'T\TX-_7[_;*<7,BT6.$QDPG* &#$?
MYLR51=!4[VYJ:;C;ORQA_KKZXRJ5Q%*E._B+"O433*"]CZM'F5M3EL3 ^NKC
M1CKF[\>DD<PD8TU-_ 0"+GFA9#^QUBN9B33:SB()F'$I-H'?ZD]%KF4\3A7T
M>A7J9[\4N\'_GEH*-=SNAY4!4RS-F9IF[K75WFW9& ]>FY9]TV;\@.H*E6R5
M;N$_<XOEVKB^;\**(HZ;]=WLB9-$R@KG8W4<XT!#\>"L / PP\J)#0O&9#8A
MLK(,=2D"4%BF[XP-LV6#-]Z$BS+'O,OEC0<15@33EKE*SRYF@^U?PAWKNISD
MF#ZH<2(0Q]WF03>B=V5JW,YQ94AJ^9F=9>C9N$>M_K2+,4L(R3<O%\*FAH2G
M]Q*8W&[N$E8"&X(!X6/3.VFH+HZ"@]%'X ,#8O'@K0! @&TOIU"$FRV,I!#P
M*X<Q1J MNVUNC"*GZRS91"0>]Q3EWKO.OU=I_+ KCI^MXR!>O>'A-Z%6%'&&
M?4%] Q$3+/(8#\R1MN8\\G&-VV4+V2!O<)I_XKT]I.:!2M>L:T13%)^JU97M
M[[)D. GQ/MIY+,(6SW!FK*549MH>0O8)I9PI55%PFO[)4,)0:3%7#N:?=>JL
M] (@'"$#-GX7AD+AF,\@?_O\VZ^/RJJ=RS;Y<7J25QR2' 0KV+@=M]3!2>%*
M$M:[7K:T".:--GK)QG*?)"^>F#BMJ>F[M$2K<F2JS[/9) F^^3%UB/&MP8L\
M*P9*_&"S@5$3Z["%)\D/^8$.>]RUB5*&'XGI<G)R1VL7>8TYE%@65-&KNK6I
MV@&A=W52";F':VV-;]\J/8[VNG8>N[OQCU.?_K-14Z';_SIFR?V/VR3^@U33
MW]7!6/9O*7L7ON^I.3'9*R556#U?'Y^5P$363I%2R^]S[=X\EK<[07<*HV2N
M4^%T"*\T&48BV*:"N)R\,S<MUMM%<I,9D^T%PHW$A+D3!Q^PTQC:FXWZ@2P3
M5WUCCS,5OJ^&>]SJ%EEQ;=!N955'FAVFSI.MM$+E34[#[-&4)\UE6[.3"1\R
M*$9[02"0L^])9*836. )L406P>]+M@JY(_]0"38^Z+).^898R38J[0+)$CYX
MF[._U]2AOQ&YMS"O8&"6S,*^39R9LO HW^3J^'KDO1374U>_),99/L'R9MU+
M-]%YZ_)OR79;ZC&=74\L(B<W]_X.XFE,MX*NVI>[^-*+'@M?#K2'5&HC%4GK
MIX+4REU]A/S9C.MW/693@.Q(-1]R)^JK+X)E4!FV-]#CS%6@?T0/R%CWWDE5
M,#T8'TRXUM203"UF0+9G)*[4X]Z'=5Y1X<!\P@.&]6.+AI2NLY1OQRRMU +(
MW9A"'IK1A^$!X<Z@7E_;^R=-^OECH>+8.TVQ&+ >:[M&&;E9R,S: 2*D?=V>
MH\&ISO52/!9<_N]L'\'=!*KGX\7_6PR#J$H.E=A=XK/_N@D/1!QS\&_ZGGO%
M/'FKMZ[MR\3B*,LLE)2T;Y,P#CO;[Q9=V&*MST7F4'RWLO&+[CSOS>%HMFRQ
M?5;G;?8C1H^@^796XGU@'X00LNY'RZ^V-VF]2:^QV.S!(0\"$P5%?3UHJTAN
MR_;O/I94@6H;H52BI3(3.-)-T?2[Q!GYL]]X_44-S+-"Z?F-S(X(.>N&S/K@
M;)@!ND6-(#R UN]+]Q5R%>IY#@>)I;RPHHOH_7CE<QOA1@ \9P7R"BX<_5MK
MLRU%W)R2GJ'E2[U7T* (P9XOC'.1LD>*#T@:7'$B4RO3M;M"9B/=-3;EY>EI
M-3%/K>.R*[YP)RI5=[MARKI&,4X] F1L<<T9R;-3\S04GQK4CO:"(S7S,*5S
M72DEX\N-L 7PNI4A81<-'O F 5*.D)\AL6_ZJ6.5N=P,DXIFMBD:B+P?\?[V
MNG?.\Y<+X4<\\"IMP##2]/%$N<CS$7ZXRJ4">QZ1 C?\;;+,^GG/R19R<?%\
MT7\7Y1@K9PP3#6 D+ SZM5HLG-G#Q>B[R?0HN$P]BG_A&:\/W(?BFD9#&E'5
M?99=YZFGL6PB]]OO*%*<',Y;SK0XW"=^^5R0Y!VQ9\K28JARZ/CQKHJ)*V,/
M;G8WWR[AQ]=*#:KWH0'3\(4@LZF4;AAGNGN>Q?S,MJ_I@YF%UM'X5PT/K#->
MPAN?/3D0LS%&=7:9G,*.&C8+;,S<M_-Z"UW1V;?<O5/?KGRXLYV !T3[CHC6
MF]O8E(I>(7B"A,(\]F##.GJCBB.S>H+J5<]I]>@?G;X+J2781(A.[[5(%&0;
M*?@TU]8K.R()8QAI3[-)O/*S?*_4/P/=G!!Y^CE<,XTTR0&JJ2B>]$9[PI0!
MLNK. >Y0%FB&LKT^FE,POTFWH(XZ&[3GW34%CF\XLZ>8(JZ[IEO<[>0B_[[D
MZ4N<?>5^8[O)=RH5JK<$T_^ES:#_!^6/PG#J#]$=>L#O?R7#52K<0T=E%VV^
MG!JKA3]SK:LO8AFRN:3_H1X>^+!TVHL';$+EY86R_ER5B#&4;#OWP -!D.,-
MPOR"ITV?E_Y8]9<&Q"^5OY*7X6Y@(KF5ZPDLJH+^A95^L=#'U_R"'.K'W&8K
M!L3^0_98/HP:&/7A_(0\V'C?6U>X(C=VT<EN0!YTZ"@GRS;@G'A_6V5%<0P/
M;#;\0N.!Z7P<W=!=7"9DB>M7 +"Q40G^P_N?/GQ/!8W]^=^@_[>@FX7ZX"44
MW!5R-(?#X('M43Q NIZ.!_3;]A-QK8 WF^&*7L2QU#"DP[\0#XR#+E;Q0)4V
M]C;,]I<T'D"HG!\1C'@HIUH^&MNMBR/=J7IJF>F:[MZS&L4UOFW.]?<-/_L^
M$\=FYC%2#>6[UOR]^LMFLK_B8_G%&'<DY9V?AJT:(H4=SY((4WE]EJ%J#!E_
M@OUCJR-$LURO5D;L.VR6%C^N<.+6/KCTB$4.JUE:&LP[?<8#_X9_)7T\B,<M
M&9$G*K7:1.&.,8E]5EX%4(QB_&D%D?7GOLK _[<(^=^@_S^"_N&&(..[?V#V
M+6C=*J7"@[&]BCS7H!DZ@+[74Y4+/_,_ %!+ P04    " "8A5Q6\L2;S]UD
M  #0@@  $@   &EM9S$Q,#(Y-S(R7S$S+FIP9\R\"513]]8V?AQ1$9'9@I(Z
M("HBK3)4AJ0.B(H842',J0,R":DR2\)Q! $Q=0 J5%)!0 @0&4)D2BJ#5!"B
M3!$0 F$>0A*0#"0Y^0ZM;6_O>]OO_M_OO>_Z!U@K)+^SS][/?O:S]XXL%>\5
M_<#:HX>.' (6+5H$? -_ 8H>X "P9/'BA6_XL13^7K9BV;*E2Y>M4E):OF+U
MJM6KE5<I*ZNL45^KLD9MC;+R6NVU:AJ:6EI:JU5UUFEKKE/7U-)<,+)H"7S-
MTF4KERU;J:FBK*+Y__FA^ E06P&,+GZT9-$F8+':HB5JBQ1U  ( %BU;],L#
M^/18M!CV<;G2BI6KE.$#U+7 XD5+EBQ>NF3!:_A= OP^L%1MF?K&+_<MUW \
MH[3IDN;N:_>>K-B\O^BEULEW_"U[SEZ^OG*5MLZZSW0-MAINV[[#U,S<XJN]
ME@<.VAZR.WSDZ*G33LX8%U>W<^>]+_CX^OD'AX2&A4=$7KEQ\U9,[.VX^/L/
M'B8EIWS_*#4C\VE6=LZSW+SBDE)J&>U%>45-;5W]JX:?7S>VMK5W=++>=W4/
M< :'AD=&Q\8G!#.S'^>$(K%D?B&N1<"21;\]_F5<:G!<BY<N7;)4:2&N18O#
M%PZH+5VV\<OEZOL<E<Y<TMBT^]H*S?WWGA2]7+EYSTF^UMG+[U9I;S$=,! L
MA/9+9/]>8-?_6Y']'M@?<74#JY<L@I.W1 U  ?.H01XWBD.\J0 TYA J?MW'
M4T*]_>_M;@HI3I9D8"!M!>!?)58 +_=5?6LY9HE MBH 06A#=#=IYEOZ1B9V
M!TL!'#2(./--W:5KV$)O"7)QV9H?ANW[+MGU=V5'?O_N54?6T?SR<UL)1Q2
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MR5;F!9ZJTTVO'@;]_%-24[Y+.ROU8)H\9$S! P1,OC#$QZ\\?BOPA5O5#"Z
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M5+ 0F 9)8%)^T:$ 1B4,WD.*KEA+<'V4PR7%CY:W;6[#'F %E=XZ[#V+7P"
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MO^HM-Q59Q4$L_^[A[_QUJVL($KP"D)R/@YJ=Q+<&2 BHX<I%+RL^CRBS'50
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M>E^'HBZ6&S1ZIM<Y./IK&:-5SS-CSY:9]:D,+Y 1*(P$TDRL/6QZT!Y)!UU
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MOU\RD7.'."6-*=@!?S?L+&DTQ1 _I_AY]FSJL'4_8=6%GG2P90G*AN>4U)N
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MUG6U(E'!+Z'FG,*0-["TC66B0_G()[TJ[EEM32<;EC^=(X U.73R5(_S78D
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MZ#'83-XT]L0\R5A@7EZ5K-K@"M8C681^(WQIID55BR*FCB%OA TAMFVEO#I
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M5T75H=YG$J>01;:=C5Q1>6#$2:BD0'[XE\($$WP2=IOOC&=J%/_#*Y6)V&]
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MQ-9FXZ0RJT'V3+26]_PY,=M'AXJK=2- &R-+J>%R(%W<*6B%E[<X#+FG'CJ
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MWP"7.,4HEHIP]PR*"H5N96,P^7U5>94:R1=G(INZ/F;XT>S>D"!6MD"O-CG
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M9Q5=<$"$P-D2H/H(LAD!7>]_ U!+ P04    " "8A5Q6/+2>YJ1D @"CJP,
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M::]&%E##MP><[/B983G_N,.U1W,6^"SP6>"SP&>!SP*?!3X+?!;X+/!9X+/
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MKR:BMKSNFL?QV-,IZ\Q/%57+J$%6R, )[#@O=AL2L;FGP9X1XJTO]=Y+@>4
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M0 'QK$K@DK[\MX?)DN(1/NY&2#0'"%[B61$!2DJ6F/"3SXHQ!2>J6NS#/A.
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M;CJY_O$7(T\B 9"J2_2:L%@;?>HU"0>__TS28F:&Y9-@6&SNV1](\,)(%'K
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M&XU>I1EY>LI\&>EMF:WP$K6V!RT2.R1:V_+O-JK%YG^R>-?(S.&4BRVCNHG
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M/)U."@<B]DI]_"5?4NS-B$_SUR8O+KBZMW:.A_//& EQI7==9>YI"9$[MPC
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M9L??R/9)TV"?:HGJ*]Z]<Y40355)AS,(62<P9_N"QQ%&[?[)8G$X2S^7QKM
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M21E_ 6,PX/-=V\K!PZVBN+N^$LFVZ@EOJMI2FZOCJU'B7?TUE9X8@Z=WA.@
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MRK0@9!!! JZT!9& 5382\.6LS5MGV 4(1.ZM%X'J !*P.=R'U61V*( M5I(
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MX$RH?=)G85W: ?8^@=)XPD;J7_% O-R;3HT/MW>E=_26<V?#P:J3:U?*OI$
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MVE$_&!9ZNXQ*&:\?SY]?[F2J*V"XS9/-!*\KGZ42%;7D?^0!P;$*O[J\S4<
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M->N#I!(;+\Z+\YP*#1IFI_><%ZX-$7T2*X"V,#VT_FSHYIIE1886II79$6N
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M UAE/XK:%(=TFKRY79W"Z,JSWZQ],:E0*R_+<X*X:<?L00!4")-CCYDST:"
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M/HP98H->=4 F1(JMQ58*<0A#=I70G")7ZB7IJ&4=0XHP\_S'O=&A,RDGOPD
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MTV/F1-7+624SP1./B]E^^.?SZDN^Q,][]6<&TO*P\N2<BO277W(#J2@-51\
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M17E5Z3=)RYM?.T"^U-=C80\3),<^Q2U%*-;,^1-92?DO@&]GX#M'FS: +@2
MMPZ.8X++4VUQFB..LQASR75W6<@UJSY$"Y)V<T75 !WOJH'WLZ8G &XL73GA
M A._PK%1X$R[H]O-<>KHH;.(*0B%&7TR3\81<X*U_?B>MUJXP)),2I3=!A29
M"]=+:6\DJ_F^F-*FS1HFU,IB\%X">#KF]@@!79S 23WU"\IO=XZ=$6#(3]GS
MWYA7NB0&Y:$B=1QGH\_%OBNP.2+G-]%/4YO*8OE+/\$8@F^&<6^0GG[? :^P
M1U6.M4=NBQ4.2[(?NT[?5+$I,FQ ?&%[NS&?AF'RRS>GLT$(9/-U6ILTO<M:
M3N*.4AH5AZ:X'VR;B XZ?3T\S8!S3;D$;=M,GS1!;._'O?#>:YK'FSU=8J0[
MX#)MXI5W+N-V8PT+DB$M>-AU/H[P\::VG.-Z\97E@B3>3= A[\S_XOY8D\2^
MWHV,CEV&P.ZMK]VM-X'O..K1.;"Y4;!1(;?K;2HNX3(/P=S3[2L;^^=@CDO(
MQ#\_1G@(TM-G#16KRTBAC9#&#X?.-G5NXIXN$!,U#\)*=-QB?.V>KLSSA6S[
MX%@FC.;Y1U6,HM^D:WUV<ITQT5*48$H=*0BO=(]:VU*+X?726GN>N_'31$.Y
M\)KR:XD-*3?!7Q4^&5MP"I\5T #Y%5(=06_J5VK./1WJ*,WB>0S\$K3^Z^(4
M",-JD+##*OP2,H1+UF!Q2"ROUL7MM),7"8].V6Z(45T D3FK^A'ZCR74FSL_
M0<DLQT1?%888R*FPF*XQL#;B0[!_<;SX[4H"P!DO[<AVHH60HM1(=_Q'G,8>
M+X 6B%NV?M59>YVCL_E";!@6S[OAI7H*[$0I25TA<CDJ*CG%8;WWPQ:]V($V
M;_K1>LZ"GNRMWS1KBFK^+YA/3,2:K^@- ]VF.).G3"-:;>&']:FP:%%<T5$W
M<#_;'6CC?\BRD?((*_GA(/JW%3\-NB?ZAR-0E'.+-"=W \I^9MG>2#XFREA0
M&9K!I%9FF 3NXCGWP2&5#-)7)Y/IWZ2B)R)KSHOQEN>U0NM$"K- 77/WK.C*
M[-9<<]1=.TN>/=F'38A2QN9-#8X5^'77"R6T=%8CPT!.=^ONHV!7VY.8H88K
M"W\>)($ZWJ?8Y+9PU_L3/P=I#JLK(&F#)G,L'P7'%^N)[!.57P)3UAQ5<G.V
MS(>D[)F>'&!"HQKGD-:K$PL+^%W2FOUC8"S\=I&F,HQO-C1>U4Q=MT1#V'+[
M0D]@LMB63>:S?B'RF"EGJKZGK5%,.+\R)%'D91#Q_N.S>2)1DE98D?U4-MRK
M<)8^:-LOJNFGHQK3-^>\"@-2"^%CO%XD:ZJ06\I/2![>)_Z FV8J-F@XNP+J
M(59+Z\5^/[D<A9;Z)D'+2$PU)X4^Z9Z6O_L4E^YT%F]_^^IWOW:,LZ26'>3;
MA7ST4!T+>#'H)N+9C.]Z5A\?I_B,0JD*_V7=M?;N=&Q:VI>B8HOK$]&:@&<:
M^OF-<VMU.K;^C4R(C@LW,Y;ZLI3+&*J:[$WU> 5$F#G96^\C)BU8'K]SH_^-
MZ!9?$579KD0G.R?Z4WJ9_JI!OB!1-SKK?'*<_D>V(]'Q;P  X \C("N]X7D[
MV-A!3CFZS.4_DP+]G]C@'E[6.=H-?3,]E/)C"6>D*F\?A@/^1WCFJ_>S@Z7V
MQ@'PUX&A/??O^'WX>(FG_#)'TI?*RJIM#Z8$AR-9_"D"<53L/MR_A%_E+/IL
M;NK@JT9Y[6%=#XMH</^.?2^2-45% :XX+,ZDV6Y!K\HIUFJOQI"?4X)DV]8&
M_FL-*;YK*WR.<'T"X"=I*P%PM,UVB;<]R-NO!Z;/:V=R6C!SI[X/9_$'/'B0
M3 "$?KDQX BCVSK7'S7W'@,0 -$.#+_%$G(O+>N'16TSMQ*,PB%EBM ?1M\@
MY8YX-:0% 4"*X6 <UGI=_]/!E\8.ZX(#L:^LA"R%9831,BK>*VDFVGP+?(NA
MI=0(-!=G&W/\_&AJI8(%K]ESQ$8 Z*#;7>+!;8S"IU8NW59KHC8@/K.#72S>
M\1IJ2"%4<RW$.&!LR$\M<H5\Q_Q?A W)PWST+9<@]V8T=;L<S,C#^T)W'G?!
M)F 0]^-\#ACMCYP@_Y?'EJ:6<A5Y(AFM?UB_76,]"-P1Y5@TG]L2N< &?T4>
M@>DQSCLR.R(H3Y:WTS^X]G4=%.$@XO!W45)O>N)G.8W<8Y'/I]B;I:B(QT8?
MJ9?ISG26MM+,]'IH5-L%-S8B1JQ6ZFI_@RF-6)/QK:,HF&M0FR#3X\8CXVZ=
M[/?<9GLPE3T+R$/7:"B9OEVMB-# 7CH!, EK.LP5!:7J;I\NT93]AO-T@^^
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MV2Y/FI;!N">-CPF 5*N4TRD"(,2#G^JH QGMZM$ZQSR,F99/^[3QO:53OEB
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MZW!I5C?:'&MIR;9Z^-Q]4$=?@6*SF^81[ID-JZKTUY&]T8O6MG.M-_8:PP2
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M4KC97-*N9$6Z,X%)1#M_;+\<_8E8_R#N89<;;,Q$8@97,E>[ZB8TP)':OH=
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M*'V!B/:I?@?( +0>VM3)6TQ5E3LD^003L)1Z:U]16BV\1 MOD(9;K3UZY+V
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M^ERBU6%('JHK6U]QBPK#X''3&];<? :@QE.COVA]"V?2GWI2,QDMQTL/=28
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MT<2'9R,RM@3/G52[.>RN%!PDE5Z-'A@1ADO&-S@NYHEWQDKHO0ERT.-0\28
M@GQ,2?>\1. S;M%R"A=F;(>448*KF1&9$N?^F$$2@67@'6O:%:00;57ZZI;+
M-M.,KEZ2>Z(4^V\H#AK VFIT1FE. , 1!,"@:AW.!/\BC@ XWF7%^UE_PR@0
M $_"%HXQ!, YZ=MKEW>JFZT3"IC5DQN:G1,.H/'($R\%^B)6WFXVWSD2\WY
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MP[P"\#0Y 2!9!DUMA?T[>2%=QX3CI)N0;GWE-X3][;!AV96"GR^EJ&POI B
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ML$^;;ERJ+,E+ -+T^$]*<PN^K0^Z,2)P\G//$^KO_*P2>*>EE(+9_U3U"0#
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ML<C36-PS!8@=E834 QDMM0X81"J MX-5>9[4295QQD]#J&E(2 Y*Q"Y '03
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M6UG(W^A.#N_?IV;/KOQ?^?^A<C.WP'8/BX"C> %.S4494KL"$7>ZLKP]90)
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MGWRZ7<U3Y'4HFLP,B:@9DTS@5&I*D0TV:%J)]_-"M)H)GU5E]6V-H\#T23A
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M+$PG<*)74<,HPYSVYX[\9\HRCW2Y/F!+"I<6VM47.$TN%:8<U4G8!?-W#P@
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M/^L9^(KH86?*#VY2<U<!O(VIB IP I(( BLM=:T<=R:].1@)6@.AAY?&;SL
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M_T%#^IK9Y$\]-_=VX.JLZ*]2R>;08WT38E6Q5WUF/8VV#"^*--P;MDY4B=J
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MEY$,A<?P13^EX4+?V[6;?T3',VK^<+Z7S :&QG!D92 ,OT)/1OUIA;-H9DR
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M[;@Z*X8&SH9P\(7["YV991IO>C A(0QI3\RN<\NW_6T,^<6HS)6@^=[7)I\
MQXB^0)OT5,?YCD?ROE-_XZFIA_A-<@'GX9PC@+FAB/$?>NM>4W:BDAL$<8$Q
M1_Q;7RVE%T.5Q> .SK>&$0E.<6S#+N8HQO>0%Y",0AR:^7,&/X>0A.L>*^M
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M"HP7T>GKP"QS5/U@<O.SI^Z?R@'QOZ\<^.]O&?_?;.N#'^5 JN"WCJEM[Z@
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M7EN;>?D:DJS9P=]>QB0L5^M%3QE+L(M):"-U7QMQLH>(5+@Q@2PJ!L6B^ZB
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M/C7;AO&U\^W>_2PH/UF!((+AKZJPJYFPZM(WZ/$!L_KZMD*XG%@IT\Y#.Z?
M51,5=E:YXO6LN%5Q8C=]999ZQOL/T;>P)2MD&O)8J9M?GP()_> #E>&(%#KI
MO(.PZ;T>[I;7(A35R?%+\4[K"L/WS&X.D! ]]IO[F$8A3$J: ,K*\I#WU)V<
M7+A4.3$5DZ67>^ I$3D7=7<T:YDD"K:MOHBFFB(\>#Q="2NA2+)L0_2O7KD%
M68@SJ?$5O!*=FEU>_2%=.G69=D.*M,6-+0Z79@:)> *$3W.MVKM=J5+6I7;-
M%Q>2TH4MXMO$T?2\+#G@T[N12CW1'C78:P5%:YEHH*%EE37>*PU.?</OW\S1
M/'AD.!$7+\RAE?/3H9,%PZ/B!:(/B,]$()2.S5%7DK],?;.7F99F?HRD*DJ\
M!\IJ&CI8,VV&LA O=/<Y)C:EJUD-D3X%F&IBI<'U8RK288^[T#)6QL:TAFT&
M#!:SEC!92T:'>FK"XLV9#NO!Z]HF-U!,7ZLDEX4I9QCB4MWYG_QBU_]!+.2[
M'ST!# KO0;P<05B> A/B.=W")-#/9C6EB(TDB3VSDGW"DQV3,6(LQ6/ND6,?
MS!'G.>4YY3GE.>4YY3GE.>4YY3GE.>4YY3GE/Y/RJC^=%S=-W>X*['^FTN,"
MV1I3;O3=TA+_EWXE3?K"C11]AHG[&>G_^L*L<YSC1S@OVCO'7Q/_5T5[YSC'
MGQ?G'\><XR^*\X]CSO%7Q+F??8Z_)L[]['/\17'N9Y_C+XIS/_L<?T6<^]GG
M^&OBW,\^QU\4YW[V.?ZB^)_QLS/Y!X>AGXH("\R/8=^3MXIWQPIGJ \3"!2;
MW'A[S JS3OA[3N+E]>]5B[N)0]<(L%:Z^B=P#N)E^CFSA" "@Y%RWF,NLV^Y
MIX4I?!GR(+L^FQD[CIQ^NM]!>VGOFX0G+0S6 O>.'(X&[<O%8Z(])E+>7K8G
MSHOV)?$5L@FN"0*T/O[K=<0YSO$3_L=LQ8.(W&$/8QZFE&P+EQNLV;&7=]9&
M.+$Z5N();(/4IW+7HF4@J. 9.K!M28:.3B))0)(I^;Y7I9K9U)CYPEIQB>JU
MI\UT^E.2#'%).-2Q50NG@%= UO<.DHBD*8U$5X91R?=(#BK[H#3H:T[C84C9
M-.*6ANE1?_R>:TX<I-,<]DV2CPPM*\6[R'H/.V%PM\-!ID;5=H(0DH@5R/9>
MN@0_O(EM%<H?65_>]#FC@W\YFL*XQ?^*@%2%X\Z2QLY_/!SVZ3MTJ=:75B4&
MXB/_!8S0RS/1G (/@#2BFCBV!T]?:_#B('8S,,I)IP"4"*-S8A().Q,@Z9D+
M.6_2 <AO%8$/#Y!;I\"*_)P)=!L%GCL%!K+ZY"Z"&>5/@7C?4X %4T3],W>5
MV#^-YZ7LX!YJP[$K<,8=6I=,M$R'O=!\>#:6X32T$^&^EZ9.*>0MEG1;'V)A
M&MI^"N1(O$L_!3H;$)&G@'J>O#"Q2XX$QHT677/4YZB.1*,ESG@S=XFQ)/ZY
M''(5$_1UCPQEOK'C8H/;BAX$G@);Q"6G@ /:"/@3"_^'/)<T+5P?%HA_3I6;
MG"7<S*C\AP#4SN+MW<'CB;[^92#I9Y:DGT6ADIYP!?+S4P3_SMKOY/]/X>C4
M[Y,G"T1-7MTY&Y6B+L]V YU:%_8RZ$#IL*9/"K.$4=*1.5L;=$?Q"\)7_]5R
M_J_Q*-)CNKSOAJ8]NI4+G )7NC/W)U!S++U'71?A@W(17'9Q@JPM+3_1_>,]
M];_HQ0C=.05LG_7]LY?"?Y$CDF-"N(7<5N#;I9^&].%G?O%$3/'(R2FPF?5G
M[?HOU[U/-<]=0B$>K)A)O4/E%'F=PZO0X_@I8= O6D+^XA5K?W2_=_CWMM)_
M?L-*R_<N(/_U/.R3SBM>+\(3ABVM00?/QG^>CYR=NPJG0(U*^I^AES_BP>;7
M6<-]84QN>]MIDG S)<CNLIZ*VDS]U4 DIDBU^FS-WW>+'X@U/G,A0A'E]R[4
M_'E'\A]X$J,V$O3Q^:D6L &$EXD2E>B)6<GQ*?"_=Y*-;81-W>9(72##P4+.
M*?YC::7'8QY%G +KIT"0]K_6A/R7.+QYJB/4:-5Z[_VT5LZ6_N>S";:2MU^3
MD8#]9]=:,K\TD<I>[!:[UQ'EB'> G/M$Y[500V'"=/"4PC^8,XXLT(X,?:<
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MQ'\["<6^-P!_V5?)9V.:^E58ZH.]U4H+<#1==>6^ ES!Z+V@]3V#YUV>+9S
MT8^6-V,\BB6 R45H3OA3JV-Z)R:U!UPYOI +FK11+9= KNL/WNDI&KLCPZWA
M@?/P>RU# DWP";M %\CNQR^LV73B6G9ACLC.,2-?$6/IF2W+9K@2EQ!#C;@"
MK!KEPNIKKG'F.$VJLSHS]EC>?A_(MJ,X>DQ)OO*CV?PJC$Z^,(S](\W#K\T
M5E\T8$?R11NM6.@_+?(\94Q[N$'2.<2>I<\2?C1=#B.$YTFC'CX<8'\7=4G[
M\B4J5]2HLS\P\L.UDK$<G1*'3&MU=F7UQST*;V7XA%V6"\;<;"QORV/V<XIX
M:OEY5A^9RG8VN>5 '^6?%5:I-ZL5:+3C>47?G*'-C'_$[ZEB](..-Z# _IRG
MP-7AY$B#Y&A%WP1DI,T)J HPZ]:\6-)(85NEX:HG6=$K>C+H4D*=K$OIRJ$U
M>J/1Y@(,Q^^A+ ]M8LOS97Q ZH>"MG:C137P<VTM17 K+*M'D;&*QH>ON,LZ
M3Q*V?=[)\XOHF3CQU.B=ZTECP$IA,(*NZ5^H:5\2IIHC]J]]RQ[R+-!#H.='
M$Z[.!$KT8:U7PXA?J"GS$R(GFG5$HA= ;30"#K8J#%-Y8./JVQ]6PVC5=':N
M/?E^U948%;[F;IK]HX0*WDB[*^2;1D69\KT[6M_6NJX <?[;4=4,8]<&E=TH
MRC\\5406YNOB[K8H@!:T#'U<%%/AT4.M!O>O)YS,7K=<.G"@GG;G3O^1<LV.
MOP;W;JYWLJJHTFL=H31NEQSW1)L&0V]8K%'=[4-SV)D9W*Y[(HV--&O#=GOA
M+D3MGY:R7*S>X:$])%M0=]*L!'ECSV7] P.8K67:J*[\VM'8-/UI*WWKH:3F
M&_"XWI"A/S#\,525WUOA2FB(R*2_^H]U?_9CE'88AC;\T;'(K730.*FR>84(
M9D] >>S'VDF!XZ+"5V% /WPX?P=,O*1-N]T4SV?H]:EEQI3HN_L.%%,I=ZGC
MA_9124A%L;B[L'47KXD1AS'B2RL?+^ <)IR ]U;9+2C[N^FPK<, ^X9?*<UF
MRUB_CY[Z'YA(56IZE%O4%#Q\[=46C*9-Y%H[T;(SEEHUU4%0BNE@EGZWE*'U
M E'V&Q*;1=R-W02"IA^:$D8DZE:#%J-PI2E]L'3[VU- -?\:"6$B0TTO)]:0
MO.8IX.WR/!7^D>=FRG19H,%DY ;6LI"8[8^Z1LO^,>+EE03],$L@X>+'4KQ3
M((!<*&?)8WA@>IGK%6?;(\_ULI4C%9TD4V7^O;B2XNL;OC'7Q,DHNH*;W#E_
M^*8RRX.3C).'SG0!>[T%:3L;1MB!JUX"9?/$M)9B2(L^_Y7C @[2NN;$"=CA
M?\!H^MZ"*:FLY)V!M]C5X+3;KS-^I ;^>54LC#$HAP#=S92B[#"-PBU-J2)Y
M#7-B/:L3B05A\O*OY6_XA;Y&/[O,M0D;HRW&@F)RK<;+-G#A(CME8)7^B37^
M_N:OZ\T.[^+J)_HPV,%5U%$9PZ;D+BH#['ZZ(982<LX> D0J][ [T-8Y4Q.D
MQM0,?I)^[T5M@@]FMN_!3K:U@X,+[I2S&CP/D7C$2-C$#]U;\-HP([%AA7&#
MM59:P$A:5/:&#WGG7MZ;*7_QKWN&+0BMI/7X=N27+I#6[ZDAM3A:TW>; ZD#
MNA]>F]WMJ+(IW-G?R3;3:2ZW#YJ&%SJG#]V6,RCM),I?Q-UI5ASAZL]B_/BW
MYXNTW''G9?$I7_!913-<Q7<V-;;T"JKKN)/$<6._;)D-.:?*"J^1[('0F#K%
MF#(UW,(-K6-Z2[7F->I(6PJ-M5?W<7=A$PS7;D]U.6!NIPSV;\X3AJ,9>::>
MWJS9#.JPH;0Z25S7<<1^1TJJN=O$AS;"%OW)I-5<TW'U:8ON65UX98/ETZPK
M@=#S7V'\YO(<OSIQYA0@'#%>3E/PEZ=O3YBCO2@YMH-5P[;,V)W^.Q-FUA;A
M2_XR:QHOB"[C=<2CB"V!JT\E0(NN0FZ5<A=A_AV6@O=OO:MIX9%D&#D9I30<
MX45;J>^-W]TL=*(39Q)O$F"[V>_>DN@QL_YV)=YDK+3$>WU<VMDW3%6?0HM2
MGS6/'Q7I@1;Z"-<^!>0_?[IC>^5:5,R;AY.&.$<W!MS9*BEF @CQ%Q75*:0K
M_))+'8N;+O4I$&.%N58Q=J-YIJMX&F]N"87:1CQT#&EC;8_S"<;-$&2R,#6;
M"N)4?_B"NS@H@ ;,-LP.JS8-W9SEWM<A+C)=HW]FC!(M4 ET0=X>"8%>@TVZ
M&F%W_U:?9RZK;"XY&72@#[=R9MA9J61!(NM&%_H=FX.8$PL/O!*DLYAMW\\\
MO$PF?Q?&L.A2X)J5O!D?^*I2\15&_?"6U39]!;<DU7OJF4,WM?Y^6S.H1N$Q
M=Y))>&.,N_65>#D)VLT$ L7F:IIN9D&PL\7-1$,;P43!].EW6I]+;6IGL.\6
M[-3XE6M'):FJ!5 L10SC3H7)95YZY&[5N=VH@I+PVL''4]M<JZK*BZ0:F]Q.
M#A-_GO\DJ#(&<%!)T::@D&'6L__4K$=I^%59_A-+*C0%X)'JS]ZMXF=<(1-L
MH5L*]<!=QETU6;/4P6.B\Y&L*;^"^CXZ&FY&@;"UBI^%3G*-_XXM?@[_W) /
MUY"\E7<Y=ER$TLI[)$Q$,*X>Z*\BU"Q 78J.+%8P@!'X;(B/]2'5@2G;*MEV
MV8/$7$C9'1$!=/%GF;I,>S(A]M*%E15Y]"/4I2 KQ\2BJEF>N\.+THPCGZQ]
M<5MP*/6/#(L<R >]=A#7B,W$6PU"+]T4>Y$-2I607S4-Z-G1 L,.LFT/F!3N
MF:V6/ Z6W@B9#-\VC&%#IU]8U;G)F60= (EWQB& 1[VE%I($';ZL:$D)/O,\
M8[5YY-K:K$FI14B^HA_%PWQJ]_U<B.+$1LS3-L@$B'96=K*J"0I*>]&TJ2-:
M'@RJ!6U.N5(T8$M<L!=@_EM];UU-A^J(]"[Z((#GJ]707JU&? ID/I($41V"
MD#!U8)'K/KV/=$4$\+05KP"K[Y,B<J!TP@NJ9X$O0Z<A,Q5;W=.\ 5Y?& 'G
MFI9ZP',3@N%T:G="16DS6G2=_2?M="Z81/!_C<Y[L]'3,<<7!N*5DUJKQ7&H
MI93#0=PHS(%(KK[TH"GO;ZQK!+VU+XS7T;3J+,V!8AU$K"@$STCT>S)GZ=5O
M+"\3L+O6?H&478J=VL#5KCV+DLS@_FB=Y2?<#:#[UW8I"=S<L<('<PS'[Z0U
M9=TPWH_K^I"3=A*)#76'G44$EWY/H9<1^EF/BDU^B/\\RR@9<)\J)![U!6W<
M#3\%GEK<U#2RN?]&'*.@R>&21S.9L;/@[CP(<S2^>!)3',GF1_/N"3_U9-<E
M!Z^!!KB.[$TLR%==!>Y]WL//&S$+XY4SC4=.2QC.8)TK3=W+K,*#*O<O<:="
MO^]32;@$\RW(0G$.\D1*(\ $*U8I;W)"[@KF]9G10F9R[+1O;A:Z47L;I\;F
M[E*$ET_/'95\ZN3%("* NYMYOB]0S#XD6T"89P&\>9-WY8 :]VA@S'&_?JA!
MFQ;UU#[I)J,M#ESP MF1&[BGZM)OO:T' GXS1<41TXJ^TX]670$RKJ\'*LW<
MU P1&G:B9K9OWOJ-T/?V@77DA4GCB0R0F.LL^**(4X"FGL_8VDUQ^Q[?'H!Y
M/(C@RJGJR-*0N6JM4;[&5N"1[/3B<Z78U KT^I*9@?V5F'5_)3"GV3(T/?<!
M(>A@C.D4*(#YWI%AH7!@O#XB!&J/BRW!$J;<K5H=)T%1)V8:$;4S>UYLJV6=
M*-.@#8W7B^$I78ASC?ZV3G%\SWPMWH6#QM9"3NRYEI&3><"D]!K7-;QG12$5
M;',?C 7\=K]!G^1L#GX[!=Y0MW=\XY&:6SBNZ-SM .P*?^/VJ4'H!N]LKOM!
MDAZ^U'K_+)#2_(7E)2-L]<IYLMOA,S)MR[QM&EX%!'#\(A@UNF;:-&=SPN]A
MI4QJ0);RR)U)F<M03K.E=2%"ITX4PO,YZH&8#<Z$05\"N#S&@:P%/]AIAS8%
M,('[=SZI[#87_^1K1OMH=:U?J&^/:QZ".VA1R6%E<"FA@#D@(TS7D(\HMD'?
MR280^0C?0F2R\\;REIC%M-DKZ;3'7]X_?_&T=%= 8M[:I+,1E^GVIJ8\CN17
MQ:;BY4H]()#0K"R!8,L_+\W/^X,),\<"KN+7ULZ.U_$#V;\7O4 84.5&)5DI
M2P/(=!.DYVQSV(T:WMD8>Q)1T0,OP?*Z)<CM7ME8F]L7N&^_O>YT@2(TKLF=
MT84KC+L?+<SL<0J8G"1$X;FN501;K57D3:UI.?A6<J4=1#2,C(OCN(,?V($%
M#4=&ALM8R!9O#8MG"FHDZ,/ //+W6IZ/Y8\2];E!4LLMKL)+8"BNZ$J"_+'T
MD[7//%_3^IR03L"<"WW6Q('.F5/Z1EKS14L#'M]V:*<PX3[,0K2YM\?TF]M]
MW-1P,>\ASRR*^-',D[6TLRDT@FRJ(O^=^"$7I'3@8W<WB0GI71C%Q>T)>55+
M%HD4KI*H<?N>0!#9F,,/EU8R??'XX_=-"3FVSJ7HKP?F>T&36;""-U?Q+M?M
M;G-\<T4AZXGC;J"RJ>\:9S.O5;>GBQ,<4+RS6[2*EYT<9''$WZ^'7N-:2[:&
M)6B5=))"+8^<B8;V*>5 TC-@')&\!HM7CT:6N]&M=] ?G]KB;RP:5U]$/3LJ
MM#'F3[^?I>928#[9DC #E>_"@*ILRY7S]'+4F,:\ZF1NV-7.P9((FDJ-E>]7
M<VE 8KW91L*=%!/,LOG05PAS[_V>!4^HK"SI79VK*'_WPH/^X?J8%P#3)&R,
MB'+A,2UD<Q_+B\%:YB[&VOLIV\"(]..OQ)B-OYM:,NB9H2.;E>##SFB90J@O
MO>*B8IP&>1OZ9CV0Y)8A@@K*]%USJ_1<VR7&JGIAI@,KX=: M.CI,.H>VNL%
MNI$L8)@VWPP+#:+IJLF^WOCBTIHS0TDTFKZSJ_T^,YJZQ'&22O4 H?UPV(:-
M>Y"7[AY#^BE@V&?/M=0]*L)56AIL-'Y)JTY,]QE2<Z<1,(#K-,C!/XA+#T7J
MNZ]&/SQIID(03!=G?:NF^$CET% P= JTL.4";Y#E;B]IP:_!KTD6"W\;GJA!
M;J/PX[UWFJHJZ;:+>2,W_A:0^EKXD>\F23BFP\VF>NEH"8MJ:T\!HTW74K($
M/.H'$;R8^W#$L3"V[IU#GI/NVP\Y=K]UMJ@D:&K4.YCO[1/1?6KA+N=M>;[.
M^!Y%@#28Z<2KMS)X$,4V/_S4F7K9E2,0_$@HB[&.F@MN@/F"8J0P>X0]E_R9
MTC'N-3(O<6-W&2LRT[BD!G_W;?_.QZW%WE*U208!5^2.Q9?C([.@5?*@0)Z(
MSFJR$'Z>_.Q3@+A5/^Y6G\SQO1(C4JKFC.9VI,L,2?AFS_WI39FT.-RKZ]V>
M)W6C;F70(,"N[S>:3+/9W\7 8FK OX?"H:HO#5Q>C-QAH#P!9KM ,&V'S -7
M00T42+&X6DUAN*?Q.@/E\P_S5X4<60X5EDX!H@VF7=752NGDXIC/KJU/"KSV
M;U<X![];=!47 QS=//-T#L!*U%2H&S=>P(ZX!@VHRC ;&,^=/)@R0>);CV3]
M:_ [!6B1J6,6HJ4@0W@<J@6R<Z;IZZL<QY!^7$A AMLS4T-H^6)'P/V5. "\
M&B^;E (X=9#X31D,G*UAES&G9Z89,2WYF5AS]Q?3P NC [\3I*L0YAX<J7))
M]!3B\^T*M'R>?W?Q'>XR:V6,@R"6PIF]\E3K S_I6^WP3BYK, L!4X9ZMD":
MW/F<H9>DIV-YE 9XI,PRJQ,91S;HX:#U>%EKCA&2K@.>)H4Q65LJ."F7D6RC
M,>^VU=E,*T(?#=IIQ@=64MSRG;REG"R26<=!7!]TL)B-"%T3IC(@F>..XT<1
M#R VD?2>);ZBAQ ;K*W7_>\1<*>=#>T/:<UV!+$65#OM7#U-. 4/)CGTPOV!
MS[_1P^QJ>AZWHE6>!7,]7&W&$IX-UW9P0-$J5$0;;F(\F<8"080"X@N02A98
M<Q%@AV$LC1BLBT[N2N+T^%ZW1D9+2X;FB*^KW(-=-.%G#DB%>XHXWI+WOA@V
M3]3Z*C"&X,12I1H*6:AS>UB(D@F0NDYJ_O%+] 6;$B%<H=I<;W>^B<OPXM[&
MFQ211-H-H/A+3LY()8Q2MTKL046=@[K=/IH.0WZ7HM3/<5*D/G@5A+":6.F/
MM@CDFB#54=,PZL*[-S5"?U*?;G<*V#J#96N$+R<02OPVG$K,7KGI1!#%=+*R
MYL<+N"Z8MX%LA&^M!!\$7-T?5HY-%0X6F]NQDEQF)W%<6?I&.*6JX"(UV,.6
M'H]?L$1W"F0;N(D[;31!GVSLF+WHU>J9ZGLX]#Z9BB(SM ]L)4SMD+FD[E-?
MI;K"?\^XT%$5+\!::DB(L"3)?M'UA%!\X%71&K? "AE/TR@)U)&B/'2H?XE6
MZB,\10P^2G(6JG[9Q5&)-!G6.@7J<U17U%F-;1W?7UX;VHSZ]R:^",GZSPAR
M9:^XW1WX\$SIF-K#7\__EIRZS<GJ,?5,\.B6Z>??V0=8J%2<'H%=U9"HYBZM
M_.!KUK4UOM"EPF:!8E HZ+N-;%"GC.#N!4?(!*=(Y%+D"DR[LQQ8B,1M-SHU
M5>0,QPLQ7U7V>S#[(#A0@)K;7:**9_JE%WZ3M]W[:Q*N^FWC+ZYRW!6NA7P'
MC5RJ>#\KI:=&J]LRR?Z)#X?:NT!0/1%].\OS%("$@5NE$O#X20[[.2GPYJ&"
MF[0UQT,+NQU&*J D>'1[/0+?MKTBJ5P\*(*4&-W#JM?;Y137_WGRD.LXBVRC
M:$")AYFNI.1R85V<STHS*%Z[$*N[^S=1@=4X'6IP[V7227BR:G5*QBE :73Y
MV0SO3)AKA5,72":SU>YFJ".]/QGSP"W6]/4#WA/3F$U"'T7)KIF*,O=3P'C,
MDZ[S 7KY\I3CK%7K?F8<%0H=65[:O=LAN#3XS8I:1*ZY(&34P]GI;#CS[H*#
MC4XNVA2H7+_<H00/@2ATUCL1+T%W6:&^^(:750]*60)(=0B&I&.(:YZ"#[!/
M 2\C>$5C1PJ_,?]3A/% KIOJC'P\"[3!]00T#5_&&NA^QBEIA\MIJEJD-N \
M!QMO20+B5UZ_CCO(VOG5*&_??O;Y&C ;/NQ^L\P"W)@Q>J _;&PE11=Y@TYA
ME>P.1TQ\JB5A/E=0NHM855E5-"&^4<\RF[ 5W3'9VY,+>SL,>2EF<(DF>PR#
M% U<IC@1]VO(C9C@*)WF]#5A\G)MS[0E?G[CD)&F+K.&#V_!G/M,*]'3: $3
M0384]['XFU #9U#L=2>B%G2UE392D[J V^5Y%Z6=J83BH32&$VM<7O-NSG20
MA,:@HNAF4NYB#%<_"BL4$ *]@,:+:/7,WKLJ\LI:N,D(R^AW]MH2S5*,MW6T
M)6D]2$:_(D)V&5(<9VNN<WV7SUNMY%Y+N0^MLK,)72FUA&K*76H.*'2>N :/
M%^N=]1=-8EY*LSM.\=%;:@). ?B@=+I1M%M*,B2*J_#%4&J?DIQ@-2_CHICH
MU,0UM8/P)QHK3_,$]/VJ=\P6$4U%Z=@>!\\%-[\O1S/5WW3E7TP'?:+S $UG
M(\@W3#LKF01O0CA1@;UM^8_"+E/%3&)%T&&*3,4&[9 D\!"MI875:G 1/5FR
MK#EL!Q-[-.TNX/0O_-RX#''K(-J5S"R;LT6L*<=I1#<PT(N*![QT<"0'DM?T
M+DJ4R3[8D'&NT.&1*BD,R7_^SI#O(FP^;7,O6R"(<9HY"KP7Z%2@W0(Q9GJ[
MCK[P#L"00MYUG<V5@7$ZY:+8B[EII">SH"2]C#-'F/FC.Y]&A8S$5-PGBVS1
MT44> IS\&[%QS5U'/&[>50Q/^]:X@B",*V2//TGRTJ8+U5+Y9JPS3564A(U/
MTT>0$6<E7?4&%3D*'>F@N5#7<\/OC*GIS*9\*-80 FAL^C8EM-]BK11UPIWK
M0N (A7[FJ=@HBY3Q?"RO(&M9H4.&S70T;8K)@*6FCJE*0;NS4^WXA0DZB#M!
M\R"E)<ADZ7?V74N1U^">JGU<\YL+WH_HOYJ6+Z]A5D6[+%TE7CC.I.B-C<%7
M:G-9+ QE-&#@%:MOW>N69&Z52'6@R[,V2;,?+0,I>=6ZY]?/1(>A5Z+DCT^=
M:/DI8==^"EPP2:K'T+PXL@'OF.:V"4D<0Y)*>BJJL!MN0FA[([9:CZSHS/:3
M+!Y!<P2TNUY5BJ4*O5O6IU80.?N?O##YD_8[(/&KV>RX?#@J<:-H_KZ'17RY
M@GPYU?$6EF[P@GJC'=)ET*N=W6PJJ )*-LC!;K(=%+QN.?(\5@/R:)]OE=6)
MVKM*]%&O00^GJ?/]#?J*"+9MF?NM=#'[:TO"Q"Y<4](P_&;&[#P[5[ZO^PHG
M"QNO%SDZ%7=SCGYM(,1U,]5\@:MASBJQ5#H-&*Z*4@AU*5*V)\':8UJ67!G\
M&N)#:3?O+G1A\VLQSZ7O#K*T>N0+9*\LH?S; 3"?.\>U-S\^YHX>CG@K60^B
MV\R9(,4>!3<H2$PC;\"Y,0(6Q&)[[60$-Y=9+X-%7\<GUN9)?*XLJ2GT7QY0
MBKBL8LT?AYM P% [SA:;B_2I?$2.KW CGRX<R?.3S[/H?*9M.Q5ZUW:U^)WQ
M4IAP%I7<5W:I)[=5J3DVO4I\5RMW#$KZ=#4;+>$X!/;Y._MKAX-D229Q]U&Q
ME?P/1DF9UCZ<L,@%5;^4@U/X*#:;5\%<W(WK-V?47^O  AIZFI/S^8)XS&GV
M1F)L)N+K*F)OB15TV0ZMOM(;N;XE-1=;D2_4H1W$+9Y1]L$(V\8.,A_[Z^0*
ME9Y22;?MAR#QQ?@')*W86=3NA-:6]R[LVF@+%M;4;*8TQL7B23_L)"_(DZMX
MS; #]K*1EYC9N*$>I#Z,P>>^?&G%^=5DP1[4=G<7FI!1"*6:,#YZW^VB1?A]
MW>9-^0-BL,S0#.BX'KD@C(]B>+W0"^G,@>L6\A3[)DX'(K*OL)42:MI18:J<
MP+CPZI&&/=7;S_ON@*L]H0=;QPB6A9[!F(.%>D/IMP=Y8K&OUB?-MID?^722
M414X!Y\"V@E4*OXN'&;300_5.V[[JXZX<-S[UK1/5;N3^V)D:CX#WBTZ37@-
MYJ!W^2)3Z A^<!1#VK)K([1>$>[9.)R26^9,.V1<7+\O]TCR1C5KPT+FPN"B
M0/3.%2 8]T6Q!^_M(#U_KBN^25C"BQ>E?FVJ-?<#*J5/ =SY6#(/, 0SA\XR
M0E2.IPWIN]&I,'(C4>2\B,)(%8FRIAFC;-X]("CY%(B)!B90XD$V.?#P>E11
M351J+6V[9?-%:^ !J1.E'BI73ZV[B-#G*'_0EJ;'V)I24^.ZI$B<STAW!0+B
M60?AES&Q236Q/$$J(VD2*1Z_L?LBZ'T6=M+FAW%&< <_5A&_J*:J?\V92)CL
MB+K,8!J?B^55<EL<%>%X4$4&=9'?=.=%?+=EJB=-:]E%O,)X][Z1$D0UTR#E
M-2.J#*PV%W1\GG6GBAK8-ZJWCH2/YO*'+CK;'NUBB'J+DKB:2G(UVYA9B'$*
M0)>O&-+2YF/4^&9C .7NRDNH92(3;9J^E'[SZ5H_?;IDP\'PSD6AK,+?*/;2
M#6(X4H&\$D*UN6-T%)-5K19/H:NC#?_&MS#B(0/8<]77> 67S&A9SZ@6WFW,
M2?+XCG1QE[Z_*J)X." S>?!ZZOE)(OVL4TKF-J>N^;# K.XUH>89K4AO%T6]
M:6="R-"AS5V<+K;#D%- ?M$(VSN_NL^-? 5;MD]ZU$CEZE,.K-BXF:ZCO&FA
M$_'+T^4>?).A^O[_EN-:?U"<E:*VHNY2S--]^7:(VP/G,QEJJ^ O^+K<R-:$
MZ\G:]D&Z.(S*6GU+4'KY35*@X!-^=R?SFKN?J=\WBWI<ML"[>+*M>T](<E5R
M'QK_I&,SS4OC,<?$\BVP:?_Z89Q; D&%R@@:E**]^>V=8[+1RL63G<A(V7DU
MJI';JKM*G;RGP,I XV]#,NIW"X/E$[Z"2ME:QN.D$0+2C-S?N59. 0HG L+$
MI</M9V ME(.'>>\Q'%]:QKXY)F9F<0@'_')EV)V^UPT<JU>W+Y-99V;GN)X2
M1?]\^_8W5M=G(;"94$4XK#'223GQ;.)V^GTF^:I/=XL ;C5T8T+H0\V3]<(.
MV5[53\%[3081ET$X=J"NX.;A@DJU*0$8L3%&\[W_.JN+WY<Y6.*NHC#511OM
M!YX-)4V,^,0C(\-?DV'VG3[(/JR==7:W6%.O'BX=DI40'B^:*!OL]^M<Q*Z-
M=RCU+%=Z/?LP+ZM>?AL=5A,Q?QFF=QV'7=*Z\W5@^(HPL:!0@OJ!C51PTR"3
M9[D417:P4[CZKXM]2+2/MO#YFYS;(T:NXNK;K%YT7.4X&&EBXTY)TZI/,9X-
MM:"@Y'2W"A.F.W%RN@*L"FJ0S&)N]"5^\DHM#;ON']#G6:^WV6%-7E/?>J?;
M]GB,^#W7AWN*<%$DG_LL4OR;6]6]7D&SK .$HA9#T[40BA.M2?G>OAEO':N6
MC7_/!>KK7BF(\1 2 ZRU\5#);C2^0Q-8EW)P&T)#2[XV*X#TE@40S-6E+-1P
M>2IP@Y-^NV'Z,))KPKZ6AFK[>TW\D\2IE8GK\.GUMG7'Z&:9?-UOFP8R#9[H
M[2$;8?+A=:]IEAO+:WH.#[F=<,PI]EDB8^S(]H\VA58^%15YM_4P:L ;+!M>
M$X%T^9_U_;J^(6 ZGDAT*I9L0Q_&K@S19#/<*%LZ<.#$*M),"RK,ZC RVI.K
MTR_B:=E_"O4"A%P_P994\5-<Q"K=3?24@R\/66C0V*]1>;.50'4:!GR\*AWI
M^_?W6'QICJG3TUY\9NX/K<)=;=X2JK@"=* 8O#=<&#+BKQ\8F;VQL3&Y](S%
M32 O?:W/V=Z- D4?Z5?8;6<RHJ]Y.9%A/JA*J#EQ0X-.7W<G[R'J92B#!Y<D
M6BI1AI)(\IB^4,^]84N8JN_(?EG(74AL_Y69^ZW:8=))P_'2 "C>"OEX!776
M=,;MK;4/W .L,0E\RZXUBA.O_3_411S-9V5 _;@<YXK]GWTWTTWVPG6Z"9Z-
MJV)E_+W8<1:M-6W:P3\_*-Z=>&/E5DP3X1VNA7EHZ$HS3O3"^AKDCI$D%U%Z
M8WJF2\\73P<JC$(2[<FX$7;")M)[W;9#5*5OEU.\IKS,+.S2V'%N$G644)67
M\D%\BICCE&$U+J17OVUQ)K='F':I!>IE= !KXM:^5WQ;(M29]&OQ*D))J'DK
MH](HL9(LZRR"@JP:7=CS@MM18<,J]2*CQZAJQA]P',V7!5E,I<:FCU.,0>9E
MV&=C\OVLHW;Q0CUW>/>RCQ&W@F[4\G,%!9[%7,Q,_;JOQ>UG)SD(9P4&85-4
MM/(]A:T42M41\WMSZ"62#]9-L.<GSDYR%V$$\)N]HE7\7AU]Y<$?X3>^LI64
M8#/$6(7)V-G^NKI"!2][97B\) ^6 '^>Y+,Z@=IW.KEV"MA:NL5RQ.PT&6%G
M#4Q6E'5MZ'ZRC%1XU'KC1N!U(6<E,*Z1]-0I0*"ASOF<6<VE/?":5,CNK%TS
MK*ZT/5:Z:?Q*E+F=A(R*#!W(8,%BQOW9B35C3;==!1-"1GJ%C$=\E#V.C*+\
MTZH1=@ JI6 1P[V)J3#GYNSU-;^"*M6_>O(D'^R>)UQ6[+$U+NW\_N^9WB,5
M(M3CM=Y"'\S:D<U2;5+#.'UE/]>-J?BKL?L6[\K*%;>^5'T10F:L==ET7:"(
M][*DGX$EF_*H6_.HUD4V?[K]NGF0JQ=N43>,\&;2%I#KD6%A[V081VQ2]R.D
M\ETYI(H+PN:E([TN1"5#.1#Q<[^I@](O:,9AX<R^SMOWF6T1F(T&7&T@O-UV
M^ C)DOQ\7:+<D%'\(8B.S8:G)])D05$>91&4$KWPN!0IW9-D'2H8PYGL,'GC
M!%*:OE:I-4UXV43J^71+X%X!)?VH+B6AG#"%3SJ49RN!4+RHR./;3\M]@/>%
MG*^[)9"++5HL@SU=G9@VDMLN/8+@HJ4$X.9QS7"P^@Z>LZ_YVDSISU4;&YK,
M.0_M:TAM6Y/M@J&K\\94P0 @_0UQ!5C9#;H%&WP5E)IH7M#<#Q,772;4TWR"
MOO?,WD]0Q+[XJINIY?N'0M]6$3.%.1DF<4(##>1/MU47[:TOA:VQYS$2B$,3
MUOKV2!8+L6#2/:L[9A !"M+'<N*\5*WK4NLFOZDV/K-&'=6ODS1->(""!L@S
M4*3>%VQ4+MG#:AK3XGIEI*)_@R1/[4O2O#8G0\]3 .GV%JO+5)NB;$#0-$5;
M-N/N.^,;'+>A6X,,9%2UAXB-<"WZM1ARK[<#D6Q^MZ.N\,=-#N)-;5"-C2SK
M/49I0@VJ0":C)%>RG<W7.E]2JB1T@; WJU**BP<X_4CS\RL?<(SP@79%#P=%
MIJ&X2VYW?5T+V".OL$826:ZLK0L%6;M1]V?O@(G@ UM[\I1XUFEC'VS? PX,
M7(AZZ(C;W<%;#9$%[8:I361F3"2?Z!2;-/H<.FUZ7PM?^^["6!P\S9&^/,@S
MT$V94J85L",8!WF?>T)T)T@O2(E(6$F)%"!P5TS_=5U+- KAE]R54%*4[[E&
MGK+B:-]MAUT,FX>V)!!$E G=J'>0@S>K#>S22U&KX+V<7" Z$: T [_>S<:+
MY9D6"Q25DU%@S !]W<OP1.JF"$-]IC0P1*BJ&M_:PK) ]>70!1>0^\&R"C1]
M66CQ LR7_*EZVAL+LA"R'+G1QV.#%@S;9%G:>-6N$K7#!@V!:NAX)K_E)]?+
MSJ)Z$TPISUG 2OK-S(#T%' GGQ2$3K?KX*-Y>[]0NZ)S'M2^JE(]#&K=P[C>
MP^[5L.\MH<AO<GI9!B:$R\X+*6LY-'!(.&1^)KJFK>?E;-9Y"%:/KQW6_FR&
M_RTI5UN:?FR)P*SU\#F5MP#X^2+CKV5RAL1RM;AO=L4&:E]?T;Y<I*"\<3!X
M>QIZ;7E0?7)SPOO=Q469_5LL^\\5D7GI"Z#T9JX 1QZD((W8;G^;R0!VE/!A
M,=(-FZ5/WZD+I#AI05#CLW,M4MZKC\%Z'[^4C8'!J-,-JF *FC;[."2= @_&
M&;&QL$Y?K;P)AAMB#FE1N27UU;3Y*.88YNPA;VUZKY^V5URK")UJ#U(3#M@Z
M4QH,#[M 1MEDHM@AXB*9Y,,F"D:#]Y.E*!V^EOHE+_(MH)JL-C3CJJ;;PXJK
MP9M;AT>5J'0'V9 +EQQW,4I]<&?I>/%NFH*RRK!U?9S* LHM64FR!>QQ]WL'
MBG4A<.O^V(DU\L!3@*NQW5IU]TOG*XRKC.VSW^CJV/9L>'B3NM=7"'F< !5S
M_QY%R0JC\YF@",9@O D$X4W1]DE9\!?S[4\9%]J>D3"56"^$1O?U% YQNC*/
MUWU_U'CE(J6=4.L^ P,J3Y":#@7SV @#7Y?8.X&(UXTV>TAT?^+;,W=E[%ZU
MR"EBO)?W<%Y-]YT#;1X"4U,$6,)>E8.:\/3,N3660]A"55Z7>L:C'470IMVF
M'BB]AP@BP8>S:V2ZL&+$T:Z.XH =(?ER\^/-U<Y+L7C8#FYE9 L?XV$PG13
M5INYQ\[5O&>\7K8B>'A Y0[JF\/J#G52KH2;P,LB3E?J]D>]>OGY ?I2??&5
M"Q4W1J/+KKZ\IQ=8(2G_:,,FXA5!VGC\KX-8&9B\IU0O,\NZU+4O7B-4L 3J
M693PS95W*!T?YDJ1;"/W55?V<67G]'8]P0N\ZP2X:-,X+T&;Z2%HD5D1[DZ%
MROPPT&!.Y4=S7607&O% AK:9/"X@(PC<=.U0UFUNONN2P(U@W'TJ@?T$PL=A
MI"FO$\*XC**>L!.%2#S5ZRDE].F.96APH^WR!-^Y_"8D@^]+*QE:?**MZJ(J
M^]_J*26<MK.8'@T^.8B=-LUJC:" K\E_1_9 OV[WN N1ES$YU-\:IT7A7, L
MB7M>\+F)"B.7$O ^!<"R( 53#K%X-52\[^V!P,]#1A'!,I5/+ V%MI>%G.VI
M.IPN NSWDCR(O8E59\2NI/\4J0)IO_ZF0QD4X/*DFKQG0#^@LR(670'_*4ZE
M\CD@V&UK3W619$48Y680QN]CFKS@IX#A1?OP PPG5H7%5$64V^UQT\CE, V)
M*TR1';%II(+VM/.G0'4-$Y3$F.A,55<5AF)#([3O(+R^M,4O[=S-%Z2?*1I@
M)GB76;\GI'99ZPV)&NXR<!:FYG9XSSUP(O('YB 4XT4;'MGU8>J7C*0@[JBC
M:] K8P.KLWVV3(_:[N!\'FDE-TR=3KZ*X5J X*&$XKVKP1U6U@YMYK.J-(K;
MDO9ILWRS@S*3*_C6&@%!#IIE[PPJY6@+OEVG^R;".'1$:!,' \BH\3:I&JZ+
MIL/?W(H>?554]/)J/B#5VDPE1>,FY.3$]9O2X!9X5D/)WM&[ZM<)CPM,2O!*
M*W2S[R_;-,$9XL;+B+$&!QDFX_%'%S]-:"V;Y&1J?>N@2_0TL&DB3.2#^G8^
M6<B[<^ UE8+I,EW<E;P5]5&^!KN&%$2]HN7@5:FF-QW 00<N+PMT.QH+?G*,
ME-\0)H42[_2[$N"_N%VPWJ34$% [+ L5KP4C<^RC70=';$<T/K$MU(7IG4P2
M[F:#??4@.'W_'W'OW=74&OW[!D&BM C26T104$ Z(@0"(DV$(""]*$5Z[X$0
MBM*+@(#2D=Y[[])4I$CO)?2>4 .$<-F_>\ZXXV[W_?..\P+62,:SYIKS^YG/
M+#U"!]? ]B-<)\ZS>3.-]H]PR0.IL1(#7>F*GBPI(S7G_Y6 +\'<E6V9:!9-
M./<QT475Z_JTM-/2FXL-@KO3OZ<O@6^5!D4C$)S3;N'I25:3Z_;PPO0U[[$%
MDDVZ::FH^Z,..4U-\;\KZ>PZ;F\5PARVDV;_]LZ5/BI6WLBEH@L5,7\W8;F[
MO!'K^8.V$=$]#0AE@XEFY9(Y*U;Z6 D;;]$9%_CES)"C=^"02U2&ENWT8(3/
M7>=8&SDW%8$98LUUAS_EMZ1Z Z?]),K(+?]L2(&K*UZ0WL^P"L$_NG46O7Y.
M8! <4A+W IN<L96PO1HI@_L:@&8()5'"L2 ?[PF7Z WJC2RW5GQ6(L5;_U/"
M:1#<)24"(ZW?JEL&GPXC/P(\XML]E[]/#]2@>,6W7[UC]%(ABG/H"&%>25NY
MT^6D5(8-N.AJS/)TZ.3[R&QD_.CLM;>?PN'^D+;3.VO;Z@MOK32EWP(?!']<
MH^GHT$T^$-:WKS/)9&HJKSD6W,(.3T?O_DVF-/V_M=RK# :6V#Z2-K&VDR4=
MYN=A@B.;^RX%,:ZI_ +ZCDKD#T'JTAP7)SM"_=<N4&3(P4?6(4]WIO+RLV&1
M8>D.55K6! ,$P9T==2NS3I$]4HM:+<S/D9K,E&;MQ$A@ L);D)N,VHCX!#UO
MZGH],L$>Q-K2#7^EW@MY)/RD4GZ+P5!5EG H4)K5>TG?*=-'>?S(4T9?*?-N
M3V#&JB+A9DOPDE&X$=+%B3RQ>[T^[4T8S4BXXIXC-<$58#P_HW7,Q[NT]T'$
MR*0EK7K0X:=XKTED6BI@>Y":X.:Z7PVO=L_TAT3!+Z[>H;16C$_7#%Q?P0/3
MVHQ?'MGHZ_#8F=34A)H$/)@.R0*0)/V?G.JXBK-"654SZ7O;2?%):+8@G\P)
MI+C^[/7-(,!3$XQJIV"/5_] ##.QGWH&;>CVS&9F8F$HV:>KF@X0Z'*_X.@V
MNT$L"B6PIFQ;604 <MR$<IN.@%]NNZH\[^M-HWSG=2-=B']6'OJQU^UH1^$Z
MC&E-\,_K*[C8/>XC*V1@494AKC=FP>HF2CW\$QKXND;*MM68]2V+_A;0^'52
M;VWSN!2#-?' R3,^X4<&7U9D3ETV-^8+X2?'I8':V,B,*X#);]L\FZ*"K$?,
M-T2!3O1GE0)A@ 5T:VTK&_JR-K.:)XKD5]:W^D4\RQ6 ,2_74YX)=L=PVZ..
M#^'-'4?ZLOY HYQPHA8A^2S7$RA7/X3C)J.S5O<RS'65U!!K/U\$]33"_WXK
MI4S=YP,%WB4R2W;$L,=;9@LNCA20[*-!^V>#1M(L-H2:Z-RVQ4EH[5&_M7[5
M[3G'B&QS[UA2ELZ)D;*A&[L?45A35%J.@Z^[3.$=S*M>0HX57X;9-KVCW#>N
M9FYDQ?PR#$3:;(C<*1\Y],>2:7_R3C9/L^U5J+S&5@,]+O+=1IIH,WJL]X0N
M_'Z\'@^/A[3]KQ/.B\Y9EVWI.]N-/@L@'QF*INP"?%\#\@EJEI4.LKPY&OU<
M8+CEON-TT&?4\,KWB3OX+5<&[GK'=E^1=L_!K@3?!Y7AG=.4%XBQT1#E^ZGY
M!(,:>.E^.'&JU0FYX/!OT2M U?<8^^/I#(NC#+(V,D^CD4ZM5S$5:7L:C:C5
MWGXV?.!TW5^M@V6BK<G:F+TVCSRKNG[3+)W:G^]?K6EM3D8<B3'T$%\KX:$R
M._R$J9,MDT/R786F$7:&4N!25&YMA2'6'NWU='Q$Z+' 12?6[Y3(8L-&8'E<
MBM&&ME+9][21MV\GSA'*5]87%T08$U5?&M@C!4K43.#U?A[W:\R$P%\V6HSB
M"W2^=WUH"&B8OSG>6!)1JUU>7/Z2_Q?RRY'4\;HOV+N,$#N(IYSYJF<HB-NK
M<=_IS4,I3BN4DEMN@*F*UV 5VXN3QMT'38)W(A2V\B8Q^YJE92:8P:CJF)PB
MR:C/>-<).46B/2 A1@TX>JX&-$7943G<L8*^#<,KBW@0:\D-'.VUK0^76NF]
M20O/ZS8UO1-%WXOJ;>!L$''_]Q=>M##?F:=C8#0KRA8@Q)[^5DB:EOL+-C!/
MI<!3]$3"44^QMK\:>4<C[MP,3_-SVC+IM(M^0:MUC&-DQS"DIDY:YZU'C\+Z
MZ'(=C<OWZ822I4'J*\!WWI(!^_M?/?1^=Z6K\\/$Q-B!F=0$?[!,!H%ZZ.ZR
MA':8'6.GL-?JRPC"HWL65X Q+1_84C+TKE6D@_B'5!E^5:! '98557\%N./I
MH8[.+<5SH(?7"/O[OT7XB:=)E"'M9UVG1Z0>8.$G7?TNCK9K<GV=]V.1BQR@
MY+,+M9O&P8W]^U\]EDJTH;8C]<_AGX'T@SYF;\\I]<6O !_INO1R/M<EQK)(
MS5*-2[\S\^U*'SDS?5@.8:[<;A4:\]$LA] *YL408P(?BD;@E<]2W,MD,HA[
M&>48>QD?W_<K+.0'L/CE_56, UT&48'(+5&6653SJO-OFA52Z@H(RZ\ !//U
M4S[/EM=K\!/BL^FVO5]/A..#@(;U%PTGF]*,X+LF]=7)+R8RGV^^<THT[E8\
M)RN%4AKV).?/6$_[/!UWOGWOJ\>CHQ.IY1R7UKL3[S#IP0^#U8)$OT)=W"B9
M117(HZ;6-V1*7V>-X>FWHCD43QN)]F.A]8@K0./\)=,9P-7W&=IOK&2@*#>0
MMLSV:9%"QV<^L2N ISLT>$2A0XK-@<H3+O&UXB3_2[>46!_@66_]O4L730ML
M\E+7".,6=W"L78.^ T\P[X8WJ-1*BFF33L\^D+<?19_;^F7@/CN3-K/3#"3]
MEQ]?]Q(]4[?&=MTIG]=#A2F3&%]]I]WMW<V)N'[7OQ-73,N&2+6 M<'.<[:>
M B0.@8(9VP>GM8.M 3M%_6ZD%4O(<$ZUEE]3UHZWNO*^.6;%[:A9##'F%7B"
MC=&7R39:C$>G3S^!1,T[B/PGB.*:""N8HW\UZKM68J,7OTRO:DE$:39&?'G/
MTENQN'S]!;Z]]2XF@-PK,=Q5MYFE4 &52N3EN#_C9B^USCERD3=2T2/Y-=LS
MZS5:<FBH684L5H\/YSV;U__Q!'^ S\JK,<8$1[CV:[] @!5<\HT6=B.I.*!<
M',[.XIAA/PEOB:XQUR_VNP;?#+ZS, 'B?^!-*B%"2V(0*8N&)/>6T5+ZKZ4K
MS)]@,A.$$Q,'17B6$6-%]/''#Q\8V#YP?_*<&UW&/*S>^#LB-A\:M([A]%%6
M.(DL0R8);B@6UVBP4I?'?+S,P-"QJTLW;=^$1JV1J\Z\CKT"J'C<AMB21&<R
MB V^OXXR:J17 % 9<6"I=1I]FY1A1\I/4@&4;/06O\*R4:2;S<W=XH0) 8[R
M'TV&S&;7&BRLF9<NG(?7+?*Q,;>:SKBRE\S,&M^\&LQT$%AWD)GA(Z?#O.G+
MI5#5]F''ZJO4=9CWI B>=81CI*EYL^JQ;LM<)2\B'P87M([-^BX-0$5^_-P#
MK6XPGB0[%6U,T(I.E%EP9(!$M#D95GS9HVJ^>X:K!_:*GWS-VF@?)&^>=^L>
M4J>A:[U],CB*:A'U$W*5I.CK/+?6U57XR-R4WL+N88*P>?GOT_G*4_!/-H_V
MGVS>#I!CXDNG50E.L3[MK.:V\!P#<TZS]6V^J)4;@@@E24]J@EG/*ECR&W1I
ME@7@H=7]7P1C(6Q^.*?HG@I?)IM/UE*,89UL]CL*B1QF!]J0IR-UHUJLD1Y%
MGNS=[N>T1>X3>G9+7505T$><@(BC]0"A!1&';B/JMA$14Q22;-5>,S%M2F'A
M^)['H!M.09A@TF::/#&DNK>RY57@;V=0"Q,\^K#?F95HU*$Z\OWV=\8B>V]'
MH[%+[5)@!9!])$:[VC@TZ<%EJ=MMWP[7P'4E@L<P1#:2O=]B0SV=UN<%DE+O
M.V9S7.V+:4P/9/Q>].67]';X$% 9Y4"63E63HF'<1_Y9G2YM#GB^K^IMBMG6
M=Q\?TIU1L+.CZB:SIJ&4!]#\U7-NBDTW#N^$,T]_"&/I_4F-7' 90@HB_#/(
MPY:D'DT9J"Q=V&P[ZN]HWU @K$P3PC+[NL4*@UAM:+.T$5:[]LQ>,;K%)?2$
MY>V+3I-XR>T,-"ST 88E<CZYJ*MMFK8A:HG!:>W1CU4$/ #:XR=.3JI;.U$=
M(D*J==,,+&[Q4'0O;U8+&@EA X7RD T][BWXWA#TNF<'>5LJ+2T84ZI^;<AC
MOLS;5-9)ST4&0@5^#YFE!@Z=FU;Y A>RHU$60>FJ%QH&/V()XFQ-I-XC)*%Z
M *0?1$ZJ(>OGS1/?!1/4HW R6I;0T\7 HZ*G:93!ZIB76^>1?;,=) 0.[[</
MY.<&V\HF)K6T.XM(LRY+R@R?O\6/I?>'L4\Y]T)EFZ)SO2=<_J.=^I?G0I>V
MGEQ)35!"T['RZ<$BP,)RD?;\ # X4>-"9PQJEK.R=E-&WH%)%0;^%@A8$-B2
M-O'"*4B-$MAT>Y O#8:<:[6(5^GTT<7N0(/SH9_>(L[*Y*->)'$D<&I'C@I6
MI@0!,XGK^XD/%E"@0+/:L3L,0V<:-/2/%WTJ^:[I<3LJ?G#S?* $O79D)3[J
MX)8M(/4"$]T(G1K<RLMS<"3%/T6O-,K]P+P/O A/=E]P#!%[-U=Q!<BD6%R?
MD(0X]R[S$56]^ ZNFQ$\W_&58<6^T_'EP.R%0X/S:D?R+NSF=E3('+^)RKR+
M^*30IGK<L-A_W^[N]UIW;8@J@1?=14ZH&$XH#-"/-O;_AIY%VC0_DLI=9NKE
MICI_@M3 (KP9_VK["\"H%A5N2]V'D6P(7:;&0_KZXCFH6;\R1]W:'/TDMN8G
M,7T((Y\'D>->C%<G'Y9;"WF5O^PE".71]&4+.8]X0Z[1.7WJ%R/2 M6./:!^
M=_+9[3$_S"GN$XPUBWW;4+4A<PI[T:F5>%+,UB00RKL*_>Z=Y6T1;2)T#-C.
M"7OV_Q0SRNS(>;EGVCSM=*"6S=>E$W]PN)-TWZ5J%"']4^,8K ^GB[;XDXOO
MQMBJ=[J ?CUYN3<K8=]K?!KD<CX",2_5]^S<26,>@LT\C#6/58I7_3%*.'OI
M!0V& S:;[9:F<!J9G786$*<^YCY!H;B:H%M;4@VXQ^M!S2+F2ZG"^OKDAU)D
M(S&'B@M#<)+Q #8'!^K'2I09:C ?,LW/?Y5HO^$UZ3\FI\7_$IT^I3UXD7W"
MDPU:-T*RC>'9K>NL+'Q/&&F*OHR-< XX&-P02FM. <AI?SQ&!C->EK3L;L];
M)MK5>5O<\B1:C*N. AE0G@-L</QCR^*:263+OUHJ8JX [G.ZRE3(^XK0C^[B
MI7$6)58'.@LO.#[VHO(J@!4T/SP[.T[5C<M"FB%KO.KL#<M&D%F*K 5FRJ'H
ML6E@5XOH 9A=%SIU^@?S\%B"/JI^#U1Q:4D(_>XR[ZG0'>NIBI=]D--C5O7I
M:$]>DJ"#".GI/9X7WDS*%]HL:PY_,LYD%B(KAI?,B#LX67=_MKFO6S['%^G+
M-F5L]:=AQ+6F;[9RV=M9FN&TE_6KR"8U@=[W[Q/*%6$# S1AMX)HM'$'B*W^
M?V=]++;AS8RTT4[YLV;9W)\R#GY[ A J7D?BVI$X;5L1EZ+49QQ,N[NQ"A%V
M.XZMK7D/_<2AH>*VT]&!N0<$%K4Q%H_%XQF !T3IWZLA;*4SVWC6VK2'K*Z6
M[&F0@RAB*/NHUE-_G#("X>21L1U^!;C+#<'U1_S(6%P?C7JV1VYJHT><MQCY
M[O@*0,$6V]%07\/ IN"H<(H .>0 W%EYT"5Y8<(CU/ZF31%WB;#_<^-^[?$Z
M6YSWUDA+2#5F^8[&IQ(@E1;T4O7L#$?W\RJO959?,J@:YGA217 HO:%;M2/=
M<0DER5FTY!SSD2W"%BQ:\NY#W>PCGID3F5T!EK,P@SD X%*SAY% TYC#NE(Q
M1^* OE-*%:OC7#G4V'K_S7.N-P N>@ %(.>O]@^7GC1V),7&TNYG)80S_DVE
M*51@/PJ+-U,#*ABY86[F_L$I9WJ&]UGQ9C@\D99P2?\=L!"O@0Q.N]]0C1].
M[J*Z MA0KMVJG 26SITM7A)#4VVQ"F]8!=#'>S&E+S@:ZJ0TEX)(*?IWV@.Q
M$4- <QNWF\?9VEK#U]23&3.*EBEE[TVC>6^,53SRZ2B8]CV1!;.:1%T!]D&C
M3ILZY09;5P R-T([UVCOC-\K/=MCL+HL>%1PC6M28A>"0%CW84W#A4I7B):$
MXP=1E+BH B$N8H@X/?C8'./PX<-NR&K2TX"W67NM_$YGZYAB8V*<9+1TRH(U
MC*5_*Y9M)C8F^G7:^E'1]5L[LDFE^U[ ,DV=A-)*S;(O^ 0 +I" E@T-_VLP
MQS*+@T;RFQIT3\"\X?'P?I*CTRKG1-USI>T1%IOT,0BX#*LZN@VW;Q 9+?<Y
MO:494>82H/AN"S3N]T3!$\*',3K<73<OS0_L^QH%X*3GG+E7AB*'OR;X7 20
M60R<;[A=O-/*CA6<7QJ5=?SUROX9_R^Q=WO9T7TT@=^P/1??M=EE,)KJMM$A
M]I_MSR20S:W+,2.L?F08UL2G?C4_?!2^E?(\0"2*=NY%G)P ZS)Q-]WF.8>C
MPWTXWE5^I1XH@/!< 5Q/&7KS1?JQ(]U:C/B$1N*@!8?F5E?"/HT/!(%NDE@<
ML5*WAYY<Z(BP#3?517_S;4H'=0#1$+'Q!QRGS5(X5>&+B<J(04<%'@0P ^\V
M]-?,(2.G@MDM_%,,RWQT]GPR[^.NW?KZ5VORFU$":3+M/YCO;DJSA@K[NE(I
MQ#:-EBK8AAV6!<']1LS;T-WH@[)WJ=G2O?MH0H(SBUFP]4!][;@OH[56W7.\
M\BZKQ]3C<G;628[%90[*">8)I670;1:O>^/5NB_TLE^R/M6H&S#*2NL=P@,G
M"4M:*VI'BW.JFC^:![P.DM_' ^>;%Q0NM/U\K),X*JL;Y;\MU+_'TT((CP<(
M3CI*6 A1*A7@MQC&FJA,RLF]'\\%6+.PL$U<85H!DBZJV31;;_/Q\+15I=<$
MG;ZB4:$C=#\%I(X@MB2TZ)DGJ\>HC*?RM@Q+L_'$[@^X,SL+C&)&YALEP0J5
M0]63.[8F4U1NG/O/]KI.'Y;]>VK0&[OGY^1"L/J6!KOR]H^SI^U'IQFD(H/8
M&=5K:>J;96-/^DI-/!_/6\P$CN*."IKID1*+/%:L8<_1O8N/)%'\64_8<>8%
MU<"2C* =0FITW!J:^5!4>B?W]!B^K-03B@WZ/@-.KOD)M[)NUYZW!?&6C 7,
M3LF7*[-ZM=-KG=^!0L:O7;R$.4I%H.3)$)!!X!6P_UJ;;DE,,*$<2+?$B4M]
M5);\9BKU4&/RSB ._SF8TTS^R>AP*Z?ETP0C\Z,24\>L]= _7^[B?Q+&G#$"
M"M!7 (V6BK9F=$*ABY-Y@G_H5HJC9 .1-]@Z41/KVM@;^6"LM%1S\^"CA;\S
MRU=-\K:]% M);^]15KI#B/)RT0*U'&%G7B]=#*%8QZ=%,KPNKKWL>0:Q'+7C
M\T_?PYDM,]]0O^5B 5#_52W:C=%J36,:>M_VF-4@9$GV3\K18!T1GJ:+TP\G
M5ZI'KJ$^D1.L]MDKE !X.TV:@[)N \AZ1)"%>4X:8OKG.%^M<?-4(M4W1Q&:
MM(PIG5 >+:E!B))N*Q%V"NZQ9IP"9UU+H1UZ_0,5%%E+97<R$@Y&J9TX'RH>
M5J]/ )E/?YR/<Y1O+9"Y*:3-&1UVGH(.'WK!RK+<!V5Q?N(P9D])MR+3 JO%
M[J(9\A\;CN:$*0@$:.FH:1%)"0W!2549F.XZ/HV7(GYZ1\S6._!LK;"MJXR\
M-,&!:C/IE9-=>2@I'.[[K%L6/:/<6#7\I(:T_K?ZM3KJHQ6H\69V'X MA0&*
MEAR"_EB>9R<V1E3,T6=#S:0IQEA2_?%\]H$+$1Y'?U$VV[+#'6.=FK3P++*M
M1O_O_-N,KH/+@Y+E*@"WX[7&N0D<.YCFWEAI!^W3H9"(U#B_O ,VI1.1:QG>
MGG;OSTZR3M7$>OTHF['@"R9_6V=')8G6#R[GVG)YDGE=#D0?6]_H^[V4N+?V
M2$$>K";3VT!-,,7-G6_.]CDB@$*&9BU-8.@]NC4CC6=(.MST"I#S'-CWL\?I
M<F0HVE%.)@<;K8$FG_P#D:6.LUK&2^ZQKUM?P,OJ7NOY\F)*XY 9?;E6@LD7
M?<<'65$<$(N&']L;XFM^XDP;(SU2)&XUGU[PE5PSV_,Z()!UF;C 4ZC#T?/]
MS&!*\?GG\.#/SG>0;BXS"RW66&/E.'ET?U"Z +%.UAG:)8BC NPO5O(?V=0R
M*0Q%9I%G<M>PI\6+!M&$D^WDOAQ.Z*LH1,7L>GFQG8+B1"O+3XH2BX*?"--F
MWBY[DBB$/,RH?_2N-!V.TA,"1<T9=]:M]\5Z_?XDP<I\Z'_\6 ;\\L@[W-.^
M9*6N/O1!D-SCC66VX$R:']CDS@2\\)\2$15Q&1ITI'EM<NXJY*.).,(;W%,E
M# YY_TLV&UOZC-?AG01YARK3Y:(XV*GC)(/D(0.>"=L*?C15S2)W$F^:?NW=
MP]:?[7$78 8_VD->FUNPE'0Y]A'-5#UTJD;#/5ALDC'O\QR6BRZAG></[6G>
M'^8UD+CW9)@6G'!BVM=:Q,C(U(BU@W%0\Z5^ =N=D7DET'Q,"PSK7O+7)+,H
MKZS: *4UQQCYG+EH:<!/D;50SC ?),<$''%HI?=20-'Q=\E#B=3F=-_.C'UI
MEO406[-1G$2^[G,GGB'!O"93?X/!3EY[[A(B*RKPDY.NRFJ[#BZ=E.7)%'#&
M<:$OPT1-R=VNK$Y6CL\#Y@RU#>]Y8'F_O=XZ*D ">X<=Z#U53WB5?)27FGOS
MY3U42"C,3@D;>E\O;(\2EHV[ZO-ZJ\3VG/-BZAYW[K.[FTM&.K&2-K>BUT,M
MKETJYU=:L@1G7Z;Z$W9.EA 1[Q?8U&S#F9VQT)'].R9R9B81WLL,[!M(O:Q<
M51]3#".+_2].0R&5\%]WQ9?[;44%L+6^@;66-ZX H<TWYN]C7C &SA6[^ZHI
M#5EX32N=>;OLC\PW,4E(>),JEMB9Z&2$NG_C6B1)^S^Z'HLP"!MY<BDIW (?
M4.#.&_QJ,OA+]NVU:MR HA_/J'##)D0,N;LPOW9,_,Z4QQ3?.CI-1J0?<&NK
M502KC^SQE-*Y:O2\#JY@\:WI]GG6FM2C(OM]HA\?\XY=V'B7#;(\PP'&T@ \
MQM:O *"L"V!(\^M<OCN=SHPB+$$&2-ZV>/A-KWL8+O1@!$3-U+^4[\E[S=J0
M&QY2, /W]3P-:=9$!"*'*;\Z>=-NVJ9&@C>'H+E=4F;Y<#NLS'S)D%2UZ>)-
M;J(#]>**F$&\U-0F5HOO6H1(MHS83!]>9NFFKYTUW"&<=!\06\Z3,8S_2ZO1
MK)]''D\$X3EEG%P<=W.W*D):30]Z% "@5Z*@/_WPFRY2$D-M=3X"XB\:&NLN
M<6+,L4!V# /80(TXFY$EOK7%I;BG^,F>B4XVQ\I;T^M/&+CR>'>LT7!:Q>[>
MKY>13" 3?AO2#O']DRM D-T>RZE!]\77PPG/?6P$N*?Q,6#)EUJQ?^E9EBF^
M$#.$$"W FXW/]2\$0V0*^S)FL^D2U3B__/CY*36*J8*!H6/_N$P0O=90T/O.
M8VF7@DX\?G6Y(3DC",+%*1D-3%M0YQYIYEVR@9%-TB]+V<TV#SIV)D*'O-5N
MSO%)#U>K+4R-\\\D7OS.XE'(A8F5_,7?7!D@*%IE=SP>):G?R1@QR!/.;J#_
MD]VL'I*&Z""_ B"T#;,LW?7(J\=/N/J8JX2[A"R(EB/.';ECL.$6HJEN>9ZE
M/Y%(\WM*%3A%&,/)2L$5 -X4SO3#C92>CW?&52@C!E1!33" DZ_53R=<B!7\
M8QL#RR03.K^KE\943^4)4T[3)KRDN+_3&W7'+*E@N>R,RLWX? 5ZQ&; FNA2
MB!U4+D?OI;=.O*KQISI?!WL3[D6C]Q?" +NHX._SHG<-2'7XR*CHD]0_ZK/G
M_>97/"J989$:?%5+.R[Z1__[LRG&18O1\W1X],OAXB-#*6XF^@^./5!:R9^2
M/XO^ZGTF2$1)W#Z&4BQ,3?_"P'A>R/]R5-J..&=^>\&X#F'QH@N'T#R)*W"P
M>@M^7\_0:8J%343WJ[@?KYW*XN_LA\881,>IC/MJX[=^P#C1)J _D0#XS<@4
M/<3'EL^ D(Q(TU?'[?3K\_71(8KW)B!\OLU*+!O/$?*KT"&\V\($ 4;U3<"@
MPM?#2HFA_FAI(6F6W)P"/2M1JOGYWQ4R]'T"^SM EUT=--;[^_21VM:?S83A
MXN7?VK>TW1'2/;#QAF0FIOV0I"3KI&^2K8&$X"J]=6+3+60!#NAB%,UL16W#
M;)D?=J,POQW@?L./BBLKZ$$8A\ZRS$<Y>@"< /8OG\,=A8VQ\_&!TF::"H<^
M3!>?%7RTZ#\;A16#OIHP?95$OW<OED$3XOQ(06.6,H"+,#EHH+-'S5+\0H*X
MYN&;2"_#67N-(W/F"VV8D<>B53;Z--0->GM.PI;B?34O3O8*4%H/]2][\8_5
M=2&GKGD9IV0*IE1B'-!T_?EXX4)MPC3?&FZ>7:Z[,/L\TG/>P$EI\ O,%NZ^
M/MZ\KHDADF+$II8:*S.]W#6+Z6:\ C!_>"'-6;Z(?].PA"2=F]L"HV.QB:=)
M$>G"M#M2.D![";#,S/80H2_H%M9W&FW8F:V7W;YR)^71,6$&[J;=?\PO<V3E
M;FY$KT<)ESBMQ51/3>Q4L3DD0(TW%M!W#:W^\!@;J[C8,-7X?;_E\+G@V8 D
M'.\&#*N6PP"#[8L=(<--2YS5@3%X\',;[J7YZNF\H/'QQ1B/M[Z#C^L,0(VP
MI=ZQ:RG5=>,6^[UCFG8?05BE:%O>$Y\FFV%J7YLK0&78_G;/3K.,=[9-ZX,1
MX:+WZ1JMHRSW[ID]9#E8R#_9@KT$'$7*J@V)D.M")! K!G/BB7?$[0D));V9
MS<Y'SRV"CNP8M1)A(YD!&AV.@I-'1"MA ^C$#UEH')^+\Q7 :LQ>RB8\Z-DS
M2#S1R>G^F6GNWX4?S5> YRV-0ZWWK>$/+CM_4F3TH*96GOW< J[<.L\HDRX%
MHU03A383IE<3M Y??5)D4) 0%#IC!N=:$N8.'TGPWE_#>\N]/:WR&MY[=M;2
M4JF$4WF#B:R<\Y30BNQY/@-)#R/O/*;Q>#%F,GYD8R@/;A(G9K\H&8IN#WB4
MQG8%B+%X<P4H>]9V1"C-,'_C2_\B@G?R**),*JP+^5)ZG@Z3VCU*S.2]R3/)
MWO"*,N5R?$\0)#O=?"H]*F*'[*R5NOLG/B.2IO]X:J-P6*#]I.,\+57(J"!S
MP]T(/*+^ZQ>$:W7V<I.IZ>ZV]%VK1M7T;/TOPA>*)<N<'/<7*TXE8<O:_^Z%
M+,G7EUQ+=;%C[B>+[?I1F=GQ7)Z YCH +^((X&XL%%> 3KW"."<SHWG-]ZM9
MM@%"$X$Q1]UNYZJ)#EE6CE8GR<TA,J3U*RFQ2M#04KIN$A_.Y28099?HU+PO
M:H?BZP9L-?!8PRBBF$'V$1'E)P4X8+&5N^>N[,C^9]^3:8Q[NK1FW'GAA).+
MAX.%U8.YWWW4E*7K,5$ FAX?[>NSDH1N;T+CM RX\WV46B)^<%2C5XLHQ$4Z
M08=8A"5A7J 2NB[<;GEL!!;@] C:S/4Z% AT%X@[+@V:GV=2I"+U5*=7>Z<N
M0E(HZ?=M>II4PG*WY)M.9N3S;USM-W+^,@P*B]YQ.FT\50.M\X\XZ1<7IF+S
M=+'0)[X9;R3H;?'W/&V4FAMCNA)&N'\510B5D67#*0>7#1-?!QHY+2U@LWWO
M&6V #B:WP*W5/Q=9'8%X2!N:4IHUVN!FM2D,V^]<@4ZL]9Y2>+6(U+Q^[-(K
M,?0X!"*)D2*77Q&23_(ZTW3NV@?XNA)L,"84Y&TZR;N1?LE02I%O?7?1=1UA
M(6\HET 4X1VNPMXR7,^N -H'ZY?SZ3DN4N A/A^5@KQ0GY?I?/H2[*>OO:DD
M)9N.13:$ :[T?RF"#NP)ZN+%V)'#G0Z>2!L'SCC(/5R]?1[K,KM4G^&JVGAU
M?4T)X[9J\L<TP<R*U+Q\J']'QBV.8===;8V1FMFJ/@<&?O&Z7[\Z Q268_3&
M.G&B8P\0XNO/6W[-6\72G]09?L4'LV^&[7$1^J%?F SVS'-7J;(?QK<?G7VY
M NR,#6\UE@:YD2)(U?G[11;FZESG):LV=XV\7%"WCT"LGB&Z,R+=ES,<HC^(
MY7<H%/>/2CN_2U':/5K0&LN^4*UQ.51B9S[SPE/N;R$)>M7([:#?IUGC74["
M>05OY>Y@?X)?'>&XC?Y#  YV[PX&^SY2(I\=EHPJ#U\5JB/I](,2QD3+TTSH
M;KAK,;:<Y-W@KV^965NME#(X.AKP.B?IQ(9^$RU9JJWWA\WPP-+O\AF FH&+
M0L<W:B#<)64A$ D;1,Q:_!0_2S8S>+!L* S05*Q7LA>.L%[FYFW*6\MM*/MX
M*-QZV_\VZE&VS-$ LL1MI'3;2WOLUB5W-TZ@Q'I"_(:GZ?/0A .OU-6&C?L1
MRRDG^X.K/Q<)A]?2.XTX1TM=0[/J6AJJ#>K-!N8=W>LJVL5$<G(MD]Y',CU,
M-:>I=VA6<UY0]Q+1Z#1BK$0/)/&6!)VE$UO].,MVV)"\:??7/!]",UD.5?\I
MTD=,B?FG-!V>-\Z]]5LTOC>F!"F'ZS(L/U$UO'W6]L4!2^-QO)X&"3 D-1J!
MZ%L6^]3=F7M\!: ZP?4HK$JS)(1^T]U@=*RHH&"C&#Q,28E+:YV3"FA8"!/M
M@P;DQ 3SJS"''W,ZX/L-$<T80WTY)]+@,$V*"(D 07(78\HKP,KST2O ;B(^
M\B5@>F1OY()X^  E]T+T)WM3"D T0$DDYF;Z1Q\;4FMN\YOC4V1VCYY'*!Y#
M[G: 4YUJ006>)].]BG6'O,+<7"916_:'XOD_P$/N6]XD1Q>DI(9/>K@EQ+2X
M[M._,3[\>9H!U)W2VSSIL[-P8+Y3]B)2FD;R7RESG7F>D5(1!])K)?1C4Z+W
M\[13?93[)84 =KR?FJ##,F !!?1;JFQ->I$V-?; #"JZN@$;0QJ<:WN&5'S[
MQO7FM1]0FGN _9HW)5 V\KXJ3_48F-]I/4=F@=LEX=<1EC';I'>9(L:)#FQ;
M:_X9A&+30<KABJI'W91Y[P_-&<_F-$L$[/FNG+#6=&#7U0*5,./^^09[=SKN
M5MDQ<);=2%0:=FAV*<AM*9,W'6%_5EDA20]/?[V_L"G-HH&%=29ZD'I.JR0W
M^2S%2VD-^E"0VWWCN58_-)ION>@!:H W)!D ,8#[?W@X=A1_6U7U2$T3@UE/
MJB.KHO_W<C$&]J-S@9*>\A'(:]KHHO+W!_0&,Y_F;G=TX*1Q<M9&4YWY.H,6
MCDV97TG$3N[7.P1[N%C5P1,_\B6?GJC3!4.[/AQ&V\LBV_,)A[C]_IC2(NF.
M?[#31WF_%H5.2^ER'O*>32"-WI39+* C<2JC?%K$]4GZ#\*X>CW8G-+MN0A;
MQVM2&7N4$= WL?<==.3+&QW(TP05<CU_YNIBE:7+F^G<I]\TNP3&VS5,(Z0A
MH.\5D$=+RC&>/K(HVL-CJU8S^4W ;F_90>GXWUW^AY?.Y]N=2"J>FMM[+-7]
M\@+V'=%]E/3,\+=+;;37<=Z[IY'N'WBQMXMQ<:(_S%A.W9ZYYI](@'&T;&5T
M%]6V=2G?@P_/>SWZ_!3$CA=!W\OZJ%1(N^_]$H]_MP726X< 2Z\ ]E@38'SH
M-3]UG6TI;B IHWM%1M2 0'1V-9S\LHHYQ"&%\ I 8(PNV>Y; -GH56%]=]\V
M-4:2!3V-=H09/'U_:=,OK.*M7B.>&_Q->K]@P?B9KL2+U-OG%R=EBNB\C[S-
M(N\7GJ8CGSZEXQV+-@ YK(_[\5GYL@X+J_?GZ<@2\G>X,9A("GIU6_W'\'NO
M*\ '!WM7)/W6/-/HPU@-GJ"U:5VF!X<_<1- _ V;TF%A"5[R)^H_&;10[JF=
MHHZ]S"![[L_8Z+Q^6QX(S*2^<23;F#]J,TUH!P26%YG:K$-O)=G5'#?\UNAA
M053-;(FK$7-&EVAM=XC'EJ\)4Q4</6Z_ D3JH2/6C(DWU7_,\:I1(:A-SU\O
MT\PM[AH@1XK2AYNW%9K'FG6S=#Q-E<GMS(FDC>=B1LUP63B)"X E8=,+=%VD
MWE)W2\NV/C3A@/KQ_.2[  4C;$D+5*5RN.1CR\=B+8R%A*F!V7FZQFO+<\F$
MC[F]IJ:T/^(*H%Z#[IP-(KY_F0'7-JWSEKC(:HJ0L& _Z7W%O)M*S-HT2_*L
MW&BY]: :A@=A:T,A'.S[7.2?<6&[O1<B&V[KC!,X=3"EG5O\F>NEFI<V!%W2
M \,'+)R.7?-.:K&[J)K><P%J@6)K2;_V4G"/0#@4[*FA%O%N+7EG1\&I00$_
M*K(PD>[SLCYLY#6Z?[375FV>@:4BA8L+=I!!L79^/J%2%;MWX!HT+Y#@O@'M
MW=15]W3HA/<]_#;MEM.;1!3PQ@ X^,_Z5F>MVKH%*A&1MC9=WF8)^RM ?=T
MV8H'=/3DG\9NSV]1M]2Y8M2%U0K#^*DI_$@ ]X/$[E_+&_9(8AI*:1+)OS/%
M#:"0\8EA3TLC'1B'L\ZO.K+\ZW^+[ S$,FYO5LK'O< H9L:,%CW:D-GB(DP-
M8I'H-6(><7CR)BQ8Z23+U#:\\]$QB\)PX\O#])N*>$;,^YPEY2 IY8JT/\G8
M>GQ1=+<*7 3@2"7/@Q?^KF:ZF_ @>0$0?9G+730ATL(M5R-;^#N<>G?U@_E<
MFZ2OT:)'Z=T>^'=+\%W7N9<ZTR_"8=#[QR8^0\ U.6NL0Z='8VDV1 7UKG&W
MW,Z.WJ><ST2A+&-W]'"($ X&8MU)*SQH8ZPK S^YKQ!NT67@BIS_(^[[8U+'
M%H*OC0T;V!]_=$!>C5E?58-C]IZ=Y[@Y?)LTV*Z=WB,UE+T=]E3K[&7*X7D:
MHO]I5Y(P_,3?(Z^>:>555R_6P#GO\%)(QYA")+AUB$FU\5KGE*R(UQFV=9Z]
M+<,1^TD\7I1BEN<Y1E);;7:YG_K=.^F+7OG6=([9\)'UR,3F=9W [:H,K/4^
MKO4Y$C__-!B'M3^''V6 Y$=K>(GW-<,[I_T#4&MN//=BGOK[QZ3+1L1< ;8*
M7!?(-AHA:][DXK?,H0=#9.7G=U-\:;[^?U2]3VC\7:#AA4]&N&7@7K4-[Y>R
M*MMIGX[OLPTPE;.FDN!)C?P-C+LB[RN74$GJC7![YT)3(EK<5RP.VAW:AX!R
M>9;N>H;X3"_KX@=MGY1$EV/2X'!G)9PUE%J?=^&CFXZ!HYT9^Q9US+D_#(TO
M8VW*U+,66&306'^->R+V[FPM=QRZ<AMY!3 Z0&X\]./'L[P<\:13Y7'65$SW
M<R<\*HA(H\<@YL;BNAT0(C$D.QJYR$;\5V!FF3AZ+Z_(&L]:@\X-B;Q+M>OE
M[GGK8S3@9!DCR3V*@RY=\%%8A5N\3SM0]#V*W$)VU@!T1EP1$@H?.O-TN^TC
M^VR-]+?@Z3VE__*"-#2_>9VLA+FY7PRSWXL1+V!G8$7E?/.#;'>H2^+CBK 2
M6C'CJ,EF+ZVS"%M%#E8LY\$[PYZ87+FL3=I&5Z(ON\NWZR/L)0=1SC;!F!2'
MI3+:S=;'_D@G]EM\-Z*R6'QSD&]H-IQ^Q+V([>F(&14LWY#9L"0,P'X.F-[N
MG/Z&X6W9,)SO"KH"3"'U]DJ?L%77Q:)0;\+H1ZN:F&\2MC@NT(+?^^>UG3I\
MO@(L1VJF[K<^V'K/%5';REB+_'K^/Y3C!EE4 ^J=\P7A5*CUOE;6-.G*KZ8\
M(3U9B;@[0B]286?C8&Z?<%+>2\;%7\#XD1!-K:>G/ZDG9V-#U4VD7$.I - <
M_7O^W;]R0O^_+HP 2BS#J*!!P@)N1$J\ORM#OFEOQM[^21C7?BFGO.1 /87-
M4KW;_L+CMC^$Z"#X/'!R#$EIZ0%O"X% !0N3F9Y-6QW,!@"X>WWEH8SK$(TE
MFW[@:RE.=+M HWDI[R='!6>@FV0O2M)/\G[S?B__SZ4K .5F&D^-1HV!C'NA
MU,$5X'B"':VWB>-%)4.IK;Y[WHI:XN?T2U.[ JAY,S:56)7;Z,G-?Q4 J+!*
M7DM34E\B"W0&:7D_2Q?EX%U@E!Q%A/@=>9GB_&:^[&X4@UMW7?].X+[ KX*>
MIP23,0O7'&]PS<=VZMHC]J[<LR5K7]DBBMRFXG!1"B,TLW\?AX%Q.,[=1Z!X
M2I>W<" JS:YC\/>=6.(%7Z'!XW[W^%\*2U^?X"R*K1E3*%5,G:P3T(^>_5JT
M)W(CHKGTS* (5AVU<].G+[/-U7W[V5P'R;Z!*!SSTAS:,B9S2Z_6#WW2#'6^
M HC?_07>Z*S84-C<A+MGV11.=GN;"_8193WN/ /+[DHSTZ9> :B1705'A_$C
M-4ZM8#EG5>!Z/$X.+NET?73"IH58UWF]E7FKG?>1GP[]3_UP5<=ZD^C6ZL8K
M0'")0P>KZ9,I321I%!/.]X/:S4@)V1'7@CV+BNHH!GMCG^(6)7S@I)/>OYT1
MN^ WNO<DA8)*$ +E-R+ZVJU_]DO8[2IA#AS6"-)'A&=#P%O3$V'-[]PDL.:H
MBI%[)N%._!U?HO,YT81;UMPP1ILTAM$X& ;18&F\9]B3E5?&S'\I9X U+.QQ
M#:U^%ASO;<X>Q^3X,FZ0M?<>GF;2AE$RH2E/R11QQS,]$^P%>J\Q.42X5[(K
MTG)?AY2GMLZ)9C[X7@'S':3>LA3S@HKYP\PEF[7N[@\1?RRPG]*<=F-!.))"
MSY=;I]]]'R%O;PDR\+[OF_H%]V!G]5O$3 6WJ"Q_,4-? 4*%!VGU"B:99=WI
ML,$._<Y0 FF6R_[JIPG#,P;RE;*//[O:1X!>JVTV&B9$FR2XW^'AYV13>":5
MG:9T/HI68?E-.7@-1__+P K^"EXW@JJ*]"WA*CU9KK!XDG7+K2XTX/1A_8M$
MU,,F6Q&;1R4[=K,. :.[9'V3!WG/3MDW]9%4Q0_;T+9K *6Z& MSEE$S\ ]F
M/$W>$J_U@@%Z-:>+[.FW6ZNO#J*(;^&S)H> DDMMX)?GP2=/0^WPW?F$-6;L
MU@T[MW9@ID,76KU1U7R[^V0P:JOD+U $L%3A-38BNO31/!\ZOBSTZ."6SOXW
MXUE85/I.^AMHGEX_%H$B;7D^OJXX1DBNH&H78;PO>+0^&L /&_83;J:\UL@.
M6)-Y#]O9SHNO9^N._W,_4.-FR-JI7Z-O)S]E$6H@IJ[8P8JJMP%AL_ /^DU\
M521T"%#+'_\QS>MX>(-FXP@PN:R8I;,L]T*-YHT\@+"<>NM?RJ;"Y\WU#WU_
MMG01*6.J^\" P[(WH&O18M(923)=:M/#R#+?G/2FFDUO6F(T88.V8U)H9*)@
M>5,:^ %B;(<*Y[E3OM %11 C,:O'X+ZSHYIU/!_ZXV^Z-G2LIVVU^ <%GPIY
MZ#C\DR1" 5EFV/9?HWW6""(QC#TV3T=P&B9MFZ)4CW\IN XRG/QDQ]\T+$U'
M4.3EZ2_HIW1#3.1.?FP@-EIKZD9YUBOJ";+21.4-#F26H25.8(K]AR/VQV 2
M8_[#G6P^T(4B3.QDY2F.Q$\\M%D@Q\#37Z3![G3^VT>BE%(%^=[\XY+_F$E-
MH=#3*N1 TA+A./.@*Z["@JSK'1U#;\,@<+KN"&'29SABVEJ1Z ,;!3<'-\9,
MAO4THH].\5(JJGM<*R/?RODS3"@,0XEHS@4NN3^/'O4K+ V4NB'N"9_S_"8Z
M65FWJ,!'8L&.((TRL=;_05^#IUFW<[<);5O#SAB@I^,@W*T)IZQM6KV]9);C
MB":4;\;EBN1H5)>6=N21  I$-MM!3^X"W'_7R^D<W71M4UUJ0"7=DT;69(M"
M@RVMDYB<U<'S*7EG9*<D9KP21UZ&=/!\?]L,,:'FN^9SS",.[GI[Z6+XX#\N
MNB;@5X"09HU"@RG/U]]J*VOL8HWZ(B3@%""P3!KN?=.I(:9R)2) 4$([!2?0
M8BAJI]SYU$_!FZ93,>,* ";0 >4.^09/^]V/[D[C1$<>N>,?UUV\20DF=;G#
M '[.#QI:G,CLE$RKR UE<ZVO;HB(B))]M!B]J9QO==*8$U'K45X\I,C_:^$W
M' P_3&78PQ$N4P^5/K!RC92ILM_%\7@"MU,(L8R NO_[JD $>GNVBIKB??5[
M/-L58,( W#Z1J<2HS*1P/TC^IJ[BCWLGI2"42,2XLQ7^487Q4?)M&O/>_Y<I
MY>3IS\_\CRGA%& E +D<RW/?4&N[ZFWS@/O=/Q@XXK9@#\O^?43Z:JUU(\)G
M^_;I9G?8/*0Z1^:+)Z#+X;>/^8BWM,87JW,(/[+HVQ"S'Q#[/=/9]_% Y2>K
M#^<$JI1SG%%*/564=-9</Z*1"EV>F2%_93G/6W?!.R"MGYJIN9Z[XQ1]$@P>
MJ/4%VVB=UWVT,XGT2^NGO6TZR$X(N+P%'ARNAJ@L)?/=M<J=7GW^JH%_ -C/
MA'R]Q44PS_DGKHN5I;%\^;?;'"GKP#.-2ZD/X]#.5*L:*$6X1(#<6II/*$WC
M+M@UO9WR&J(+P:!C[QGOIC:2K:[+TMXO.BFK0-M3Y@#)Z!JMT394%#:>^)N4
MRE-MIH>2\3]7\-[Z&&&"^2T]\[0RTP?QN!LV'CV:L<]8;K%_LK:QL>39S:JM
M#34)^F<D%H#D/W:##4S4O/DC+-&B-(+\E!RPSO0EA2"]@"9P<9!9!J4363.<
MTYKMEQ#A6 EZ,[CU>#VRVGO.H_,*\+9BIE%I67"UXH#P)U@5M*0KQ8=6F.Z"
MEW[$1Q;J^6G*NY]EPA'T[I+GC( ]FU!L7/9/IZS.8CV?NB2S /.WSZ9BTG_X
M(0DUL$(]5F4]M@Y^@=J!]Q4G[0X%1OTGSZ/&QE]6O(PDR]0U4\]AP@8[A0&R
M,K;^V"2QY&;10GW\*J.7WG6"VM<R1GWXLK<:6TKSO!S69O7)B^(.R@?DEQ:(
MX@P2 [*1Y-@B#71.IT#HE\'W_;.FT,)EC(91^-\4X8Q_BM'':JO6)=RBL@E=
MF2YB$R-Y9MJ["&7<XOXZ+LQ= NO1X]W^)I7Z/E8H0/[%!Z?>R\,S1L 0^C3$
MMEDIEW<U^6W4@Y#T)-$CZ-!IB?4A^(ZG[T4'/!,##B:XX-0O>OVK\'3YHNT<
M-)+GM+1_9\HS[I5^GV@'LS(E5-AN YFY+\V,#-/$:O2*LCX(X:]NDI);9!$W
MA7X";L5O%/ZS(TF&@<BC./VN)08;*-TT$K4@D.BJ '7K?8R$#B7U8%V*6[.6
M]LMG5XRL^E<42R8L+[+Q+Y#MEH09AB 5%?-CM^H(XT9;(8]>6*Y3#QQ5_1]3
M(L54C+O$UVI*89E8307PE&=C2QS3Z[9&05#]!LS M?^]$HJ/WE-T$Q1B8B@+
M<^](NR=VSD^8_IYY-.UV$R,XPJV%&+N3A'+AX)EU6$D?4V3?L/EC;_>VI39V
M>NU! @.=359$ -<-\J?J5>.NV'V>'-V251:$I Q+=(UC&C/G=R-H*QKW@3?R
M"K!?(C3$Z@CE*1N3T]#9DV+RK.0:5HB3&36FM_>I&CED8#X%JS[UY=@4',R6
M+9Y:=7#]253XZW\;DS1+C<4FG#7YV]DUB8S'=*RWGHFNQV%/3C8>";/H\;J\
MJ!XUZ7DHK:N +E\*7G31$_Z+$)@/%>R(XGXOW8]4;F(- _P463?5PD1'L.J7
M@9KUW+\RT82N]6Q6+.RE;TB8H9H<[DPIYV-=7E<%7KJ.[X5(JHJ!HU^NM=)O
MWS'$VKEV'AA.)FA'H%\F<(A"F7U9CPA2<['+VD-N(L.X=W95'K--;PBC-:+H
MO:,4<CP82S[6MF3.ZC9Q=[C1THRNP(M F1VY-HTTB2&N$Y4MT8^]%,!PT6/B
M^C:BA05+UGOI'>=9^R2DTTI;XHO>E'$[,M0$'DNU>4\G[7%0[_CF$8Y'U>F+
M/_$*4'^:J?DI_2U1YVG#KLJ.Q[NN]JCF*T!WV#P-IC459:D9KA^W8OCQ_&W<
MM=_I.,^!"U8V K7^F0P)H92FV>'A=>WC*MY9TK%#T6O^DV\N$O[7IZ,UZF Z
MXCI3-"6O/O\P/@CN)Q16I9/&5]XR!N%%F.=]?"J83U(\X_STACRB79@@='$A
MY XV['UE:Y2$_DX<58&$F;%,VJ(OPC>UQA'/AB;2GI9,MNJ2*9S\'DI=Z'Z6
M+-W..1%%SA<(>7\>$2PW[G_M)1X=1K;:0^/@49=R  -L8&:J1:>@$DEZS52Z
M%%6+JA0:UZ;V^#3PN ,%(I\Q$GKOQJIY#4=_X'@?<$\=*5>["?&R'PA^& G"
M/P*%),+9?1I]<R$S#G+VCM"C![B; '?QWB#7%CAJ&/$<)+*K4TFVR"_YQ8,9
M=)@T#GC\40W #)!0_WLI)/,5(,+GQ3S#4.3.:YZJY@"NF'/[9\_$UNF)$[^W
M/J["R*>O=8?L90%@!)#,8]:,$Q%@:+5RBX7.$*.(5F5-@Y#!:KDGH(REE\A7
M9!!;]+TNZ4GF%> V-$B(^4_L*>T/L7>S_K.LRQAJ@HVQ]33)ND39B6M5/OWP
MU1.VAM>XER[1O^T-+KFST65AQ;C7>6<5)A+Y[7?;85P(A7S)2,NM<U?&GGBW
MW,'(JA[MT8*=!?\.'->-L98N;?<_!M)+J'C"+(H/E)^L4QI9OTI5T);P9MLA
MJ':45#W!JE]/MPW*.NU4WUEX+&TOA_>+/L^$N0YN!Z:WA^W]7:%4RMDE]6"L
MM*9J:8%,/A(>WHA:;>>^=;0>M9P&7V8HG6Z>4&PR!OFHCQ7O#W2/SO@(UCU7
MFLTZYCZF)J#IJ5B.!OZJ8VP/UQCY23#/S]^&OD=@W&72M'O7H )#G))82[4O
MV_EH*::%WEW$5W'8,NW1:Z.G_TQ/Y)>4H5EMS/F\0(Y3H"C*L[=CQ. :%@?<
M/6;.S I.V+<(W,'8K-:'U0:ER25D9:?_7%Y0245Q_]F.Q>Q%B>R3U'27#3I9
MW^QOXE,7B 6.NAS?J/9A+P7=\;0?/_KTGK O!2Y^C,-"(P$&%7^$YT0/MO:&
MA\5*GR2[#HA7X ,ABQXE)/^2IP'21'%^XDF/23<8M[ZOS>G;*-^]Y_!<AB&#
M@L30I0O/UUH/(VW6@MLU45\8+!R,!><!#PBWO+JUZS")(1#>_)S$\)+?M0>.
MB4[Y@Z.F0:RSC#7H)@W%8OMJTIB5!;U7_:MU1!&+^'M1OM^:#+5?5HU7G_$X
M?*.2O8?3/+EW<M^/>=NB>/-5<JRW1'[(;!Y;?+ URI=UKC_'FC'QP[Z!5VTL
MPSU.[*?CWC4F/)%U7I ]GP\#:@$K5Y8M.&G(,AZ;UG74F^LHP]I64@:>Z?NV
M=6X1;CNZ5_=)SAEP\<LEXE)^%2<'\!CII/E-)2/($Z.8P\*4=8-?IG#:*,XT
M2Y<W+=V^7/JVA+P2QRG' 6R\6&^VV\N*_#<%*\,G<?Z]6S_^7D]&4*E8\>+@
MV??[":8;-QW3:+%QQ#4%/TV1)'J0,GS8U%*P.<<5@*Y-=F1[W&9\0CN).-/&
MO&Y72!K36[]H%N%6:K2_M-MR!0@\NJ"B)5<=)JA\=WEX*)CB9MAU*7XI+9'4
M@8D*@L@L%27+J=E3>Y6#%8P"_[G^<&F]@T'\PSZ1V$_"U^QCIOX#.0Z_@4"
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M_$DM[_C9>\4G$VQ\_WK_OOEEX=EY!T-R=!'H"DEUIT3JDL7Z 6^,G>"?P!*
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M_U:[ S!5Y__O]%RHW^R9N'WQ*6_PC[&0QD:KA(A8-KZ+:GSW<5\'LQ+7;S"
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MC,'R11ZU8WISBG9X!U&/=4>MQ5[SR<K__<KFOX<<C.0O! \27[YV]Y "R-+
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M77);5>+[5$V.Z]FS&U'ST;5:WE-)#=<W8S4!U13J3):Q<@-]5 ^ M;AOLCX
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MKQ[;"Q6&*8Y%(/":S8/%J6J=E"2#5T&K_S6"*X:FX,?V>2-1,L4WZ^8ND*J
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M#M*D?(9FS"0&<*TC<I00OV*S!66R+ HXW9/[K6'9[-E7VD/_(55BNA;9&?/
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M'+3O&HV&F-V"9%O.5NX B1R89:6*:SQ1<WD1A(OUCK6V!UO=.J4X2Y@(ZCM
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M-B5G=?YI,=XE$ZM&]!V JP] SEQ!ON7/72ZQ',LJ0_-)Z2P4VR[MA]@BHQ1
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M$S2*(\6?$G(U:T0QQW>?@0<F6CQ3#+PO@CX8I%0):#]JTJ&K+-K\VS2V!AS
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MHNNB-4:RA+O$<?0+IB4OW:B*Z;LOSZ0>I>EJ;?Y3_^ HVE.'S)&/U@S..2'
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M"G^8BJ:1<#P&%AWXUW*1)B-+N*38W;+XZX-INF%O/:077RCVA!TPP1)R($@
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M]ZO.@.FD;0A&@PF 0PU/NLX GE.IOQW=527_$]&Z@"_@"_@"OH OX OX KZ
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ML\X[-"![Z\J!$;@!R/"3@H+"G<_/#KH,E]=?(#G]7"@@ZAR>9_]MQ_M ;$#
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M#ZVFKM1KE8.!4\0V5:\S?I/H9O;\[7-7NF2V,:$MU9PBN!)DTK4,@OUVF#W
M-;L'XD<-H@49EPO4L+Q 6B,%@6JQ,_G4F7()M3895J,W.10KV?X8<IN*QU+N
MFU,^E >1B6/LK<[R )&E.GQ,F^U?3[P;<RQ2,9[]$"EP)+_K(/Q2HM,8 P6$
MDPFCG+2@LG+J_AVW&)2<9QD"?8TJ>U,L!G'4SM)NL.JEI32QI@0:#CV\!W('
MLP@8)V>SK@()'<I0E3VNZE%"WOSL\K F[LGNUFB_SJ ,>ZR*^(^,SV](Z%&A
MCONH#L(AAI(SL04JB!=?,K(;8&PGSPZ;#,S:7@^(Q2;\FHAS&7ZL':),^S5Q
MQB*F BR,U*%.$=SR%WME,WX98!B\O5)PJ<A^_\GH"+GNW\ OSS;29O%ZE)1V
M]#.8Q,:N13M6F(&F'NUNVPG?;!STUE$1W BPE^62.:,@E! NJ\D6HW'/7&$9
M#ABA=!E(:D=8-G7M63'J.$*NI2K,:DAQHP'A[.B5^/9]CE2K82?D[AG<5G7G
M[#L\& #3GNS^MA%BT>C,3@F(HYYONOT]^#6[9<-PHD6:>;P']S.QR(F[>L4]
M^N83_GJ2(N3IZ"EYH(,EO[X21+^NK@X3\A$?NHTJAG&KHH?@UWP_.3AJG>7T
MYZYK:'L$[< \UJI:::#@P;'.QUDZ(!K.E/IVW\%QV7)I+(UXIZAU_<3$KY3S
MG3&A >'L()>I.N4X& BBQKBX&[] 097@[(&1V9#Y,I^";BTUFP\?HI7V9]@?
MY_HMR@C]ZIV_=7T(98L6L9N%U,Y#*E%3GC%8C.N@8F_-"-(N?ZEY_HKEU'&>
M]U/3;%GG^ ]-#[[0XXP'6^T6$SS6 )M B/3G^@N4\98ID:H1=5,)R:\EO@_%
MBA)TJEU?H6Z)RO.L;\X%YC.@[PF[R02O$BZ2^>M9'Q<G((CL(QH\+@%UJ/,J
MW"CZ<DCQ:]>T2MS0L; ^_T4GBS9X*,MZD>S4X0XR7Q.=YWRK:G=6?L0F[J"G
MD*E[57+_AV^NS^YI%.' P057M8>PAYE'D<;4K54V<#LT1O1N&BEHX[7*!I8/
M86M1YT!\OQUQSO&*5JS:4V2U\V-R)2C$,,SSR:IY#JQ6LTWQ/_*.+1F>%@GY
M#%B/<)GL@T+Y0VT@]=I]5_3E>D7Z!'9)"9H=Z_/U6-I[H W:!'Z"DJ+R9M1M
M?JQO.&^"*5WN?G:D95N5104>C_3"/D0TOX*(,AL?*8>6;(J%#XW;#,S6#XT9
MGC,-TNWTR'-)3^]<>;31D0L*F8 B:N1"(6OP-_F&A4EC?GH=4\0AVUYH&;J=
M!^X\^) 8#N6W2*)JDWXH89$]VSZ&GT!2]6;K7<M5<AE^YERV$O03P/I/5^5%
M01"I3.+U89\-(GAI($WW-$=]W<.IQ[+7%LX$?>,S^\0YZL.:MU)O7?GR<49\
MSB5ZVX$IJ4@ZUL$X_7/S>L#HXQZH;203R)XEQ"/]*7 3JEPSC+-7J:[49*[)
M9_9;[Y/!JPEY7I'Q#H<- V(37^A)]KC:W)5U@5.M] Z;-'*-S$NY+:=N<S$/
M3<-GO11P<<FHLU1V -N:C%=RAU=J[)<=B+35%M@=$@=I@3@4/NI<(^/"P6(H
M.:0I58CE3F(?\P"YEEK&E"!E.CR9.7NP-7D)\OE>?V-@9]O+6YV-[%]NLF\$
M!GR5*8#\UN;J"&JL8A=W14D4S<.>H Z/Z&A3N-KYD4K *P_R+M3R_%'@Q(^K
M2;E.2N<=98_VF:JN^!KJR0B?P <"FQ18,[:<V*+-<[>E0[1R;57'M3(XN,['
MTRMFUYYFY-0OYC/1V.+W%=28R3=@\YO"S9D \1_&[\C@"YUK,$WF9]' R#<
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MC>:'D-5\QM/O-6#(JS!^9A]-E+,%-\Y2)TT$SH=I#?=)KDQQNB_.Z\"/)=&
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M"V;T@R_ZOI+Q4O.9EA,18;3>EK"U5E+F7QS46N3$;V\ZX$/[%I )308X9$=
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MI2DIE2#H*Z/ARW2)]O7Q1_B2/U&, MB]I  C_)\)Z7C(-*-X-XBN@@)HQ%"
M->;Q0$/T349-CGLTMF)'>C#^9N+[@M7TEA!_H?>8;69;N.-:FH=(#P.M-,.#
MQYE']SUM9XPK/^!NC'V7=/ZQUO[$^=%Z5[,T:L_M/<X.]A!/']7DOP 1<LYF
M]N[+YB">XV^4Y2J+_Z"O(E\[\[IHOD-#+,+(LS,H")>(Z0K!)[<2A"[@CC=]
MN?:OY%5:'Q3]GI%C.O (%X<>F0_."TB[40"'['A/DL67X?*:;'IH>J 5\?/
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ML +[%S.%<ARD8^9*<3496A>Y:5KCNK0TMM;J!%:4._W<L&L4X*(OWE%(FR!
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MOO)62Z=G-N$]Y\.^^O;+"GXR3J-.OH[K[LE8G>&(_-E^946G=ZS5XA--%RD
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MLGCGKJ;OQ]9<+^VJ+[4X_LPH'S.M.\-VRN:W^K>/[#^SQK']^P9^<*QI$3'
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M>A[+O0 YX]1P$A&GRE(TLX8_?6[#I+(I%7/S1L]1EU&S&[7((X\$-6GC5BC
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M;0635DP#(.*&"M,(%:K+0+5:;6Y6 7Z5<"_3E]G$7'N\24H.JY9!DVSQ!<6
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MA[9YT7K79%N+SCQ%/+W0?/9QL\2!\B48OQ)P@W:VTPZN0CF_]CUM&MM'AO
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MV?11W#Y$G,]>W'/!V>+E>X&10P-AMEPCUQWZM8D2AIKP9HIV%^00 SK$.$R
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MR<]N+BS=Z%W9\GA"T].QURJIT3Y/>L6MCIM,\WG,<C,EC0=?Q#Z"_F&F:AR
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M^R]N-![=6@[0EU_#4C!5VAT-S,E0Y<!QL$T[N@"W&M%7K@0+.N?8"'V@7HG
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M13VZNHBNJ L@HE?;A]LSR\9*WD4PG>50-K)]S5#_(U4Z>3Y85^W0TO],=?@
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MDPWO.+#%J3BV(OC'(R_YZ&SJA=^/3SU@? )YNB#0C5@P!8H]*<O;'G5 Y$?
M[W9-!D[(^^.O$5Z[+^%=;H-@*?GU>7RM7^_OMX52Z3L0(5IW@U"BCANI!.;8
MF+YA1O&+5$!J^N6_/TK-B[#-LTVV\,%>],)_LP _FGMZ !KSPXU*:@'^1"5^
MI-VPCD462WVRNS8TY>KSJ3/&(83O*Y%*LM;@)E(PZDZY"D-')V6&Q!I%XUW&
MBE6QD"?UC@YV#T]EAWE\^@GO6M4;MS&5#OP\:WPQ:NK590'Q(U#5\H](&)!)
M$2+65!-Z(\<+0@C[+!,MXYXQ)S'#FZ.-;W4[LWD>VQX7.*6<0M4@:9+,;NPG
MKCWL\\UF=CL \:JZ2Q&N5_JHMH^&$2K"\TSF?:1'^J;!6;(2;S .><$X%M#H
M>[H=R?3X*3@Z2XKBG+EGR%)&F%#B*DA] 4HMMU=IEX!I:O(Y>;"H;6GF<#.0
MT:M*%*O#6 I'43++[H2B)AF2^_W>*]EMUL^2J[NQXR+O[</KE9Y/#'J9OV9K
M?I"4OH)4)BKQ(A(V2-X VH:,;1O3@9#4S$KN._"<-HN]-3B;]+-^G^B1I@@)
MP(?'*6J4=(''] ;PLV5MX$@GW XW=\A6K,1]78.56,Q628'_E<<9GT-JDUY<
M5[Z-Y44[%9=)NF)4!E:0:)_WMHC:=DL@PRIT3UDF 3$P+1O^,N:!5;]@N$.]
M&&91>(FA%ZD,C%)0R[,[.$AT>O5HY-8ZU\05:)@TIEKTU,R5DNJR4I&Y4]K/
M>N:8(A[<V;I[+K(U>YRN_IX!QMX#QY#^A&R)%J*")(TH86_<YR%/&EB;-71N
M2?HV9331.W6"VI0%'T!:[JD"&42;-G>?%CT-("Z])LE7H'QP]"IY4S30;:/E
M7!=_R)6$BA.N??Z/C[Q0O@&@M[TI1Y#69,]$*I1R9ADWCHTH*5U971DT>?[M
M:YN7L/&$^(.7R(_)[1D:S2 +UE[LD2TL+\*, &L5&"GH0]Z0+*=<)G;P^>=^
M2,7OC';8OO=>>-S>]\KKFYS 0DF )U51*2Y+BYP8ASD#Z,$X%FF\Y/VIS0!T
MQ):<YNGZX=E*/].\Y)\F3)Q21GL@(_:01LW2E+8#4,6#<0ELQ.8?'4^OH#R$
M7X<Y<4JQ?_-'/W':0V354?\ I)5:=Q\L(J;?4K"476&=4T,[UZ>C25&R)F.#
M=2S]=.<+"8V!PJ>31&=3O%-K%3;TDY-QI6)B"0,7]45XJ.Y . 5-](@EK$=J
M9442IOBLR:IIL4;O/BVN^^NPN$T)JEXZQ?(5))ZEEM*INIA="6Z7\"2.MJD-
M44WA+NY$3O5;V'ZE U!E&[O_P^HZA-WM-MY;L+ON>6]=1(KUA "Q D";6.6H
M/*@D*J:A(P<GF+F+7U8S8.)3*2)>^_E6;=*IQL>&QD:529S=B:PV/R5A96ZM
MO>]I,1)7@9.2';7A5$X$O0V?B=OI0.1P&_P_-R[_'W PR([KT@U2P13& ?J#
MW+]^QW59YPXUPY!%(]9\^OGOWZH 2_J?(4CA#(M/@NO[8 [NJT="^N[_*[]1
M_^+A%J60P]^[ ?_]7/6_W8#Y_^Y 'XS]#U!+ P04    " "8A5Q6O?IF'(+Y
M   _$@$ $0   &EM9S$Q,#(Y-S(R7S0N:G!G[+MW4)/MVB\:1$!$0*1+B0J*
MBH HO45%0$1%0$!I41!I(DUZ2!2D2(N @-2 =! 0Z2V1KM*D0R@I])Y0 VDG
MKG>M[]OOVGN^;Y\S<V;.F=E/GG_N/,]]U=]U7;\[,Z&/T[& DW=U]74!3$Q,
M@ ^,#X ^"= &,!\Y\N=F7$<9-\LQ%I:C1UF.L[&Q'CMQ_,0)CN,<')Q<ITYR
M<O%P<7"<%#C)P\O'S\]_@EM02(!/Z!0?/]\?(4S,C#U'6=A96-CY.#DX^?YO
M7_3O )YC3++,5YF9S@&.\# Q\S#1VP%  (")A>D?%^"?%],1AHVL;,?8CW,P
M7J@^"3C"Q,Q\Y"CS'ZL93X,8SP%'>5A.G96_R<IK](SMG ??M;=QV<<D;E6T
M\!L/$"2OVWH&LQ\7$!02/GW^@M3%2Y<5%)645535M&_KZ.K=T;]K\LC4S/SQ
M$PN[Y_8O'!R=G+U>>_OX^OD'A+P+#0N/>!\9G_ Q,2GY4TKJYYS<O/R"PJ+B
M;Y55U36U=?4-K6WM'9U=/W[^&AP:'AD=&Y] X_"S<_,+BTO+*\2M[9W=O7W2
MP>$?OY@ S$S_NOZ7?O$P_#IR]"CS4;8_?C$=\?WS L]1EK/RK*=N&K$]\^ ]
M=^WM,;Y;<=D5+>P2UXT)_+:> \<%)!5PYXE_7/N'9_][C@7_/_+L/QS[3[_0
M@!/,3(SD,?, 0 "J/+$KJA3"@1,S;!?L*7(JN/7BTP^?Z.=<,#5"/^F5VQ%7
M(/':T%AL&*Z2#L@:<R%;<9,Z,1':A;0>3=B,!27<U+KI(C#42&I%BJ*L_!:T
M=*D AM6&$15@;5Y^O+3@5%_:464Z@!><G*:7E>.XP\=T&$X'</9B#0^/.V%(
M)S&4^T#"U,Q1AO#\##K@+2<=T#XVOS"P=!&MR0* 9M,!?Y>C]S<MB@?^50''
ME> W;P +8?\N9N#?]$!M7,6#8W)^/V1; ?X?6_^/K?__M36&_-J/\U'2R&NL
M.J+J+VL;];+RK2YN@:,]T&] 9A0CLBV)^[NR64VF[.C.)A=F>K)T.J]ZN.=^
MN\R^M7L!O/0YK*U%ZSBP<7::)[PPR9!V :4&PGX>IP-",[!B61<VCSU)J+)3
MV7"9U^)6 28&(=G.YKUON[P=4*F]STT39R>8T\)[!6DT%!W HPUKN:EUO):M
M*U6.2H4Q)/%2%'$9AIVGYS.C<A[?+W).CC]6NNZ:_#I>=2DK('!L) E!N >.
MJ S*Y"@7]),R&)6*5EOR-5_?Z["])G&9E0/H+"^LQ<SA.)99GB6M! W^AZ6Q
M()S& &QSE0X@\B$(!+G@')K#/PW@!7^DB5 _0,^X@$7Q),-"2TN2;\>I+LF*
MFCQ$99-SWG[)!<]C.V7@-@1S-1W #W$"AYWVLC0LIU:LV<Q*_= U"8/LGO'^
M+"Q[Q.)RJ@4=((N/K[+7PA21 3!L%H+%D-+_3\?>T@$LS*3+H 7(/RU1/) A
MZT%[:%+43Q3M@F6M"_5?A\$/:Y4%QM2<[#BP'TRNL/7(]X\VZ[6 " \P0J0Q
MW,S;V0O$KA %,6FK:LL2TY&RW-#?0)RJT(5O_C;6I^]6EN3XL)9*^^HM=5$T
M>+%%=$#*M@X=@"IGP,.8 2U&(.B WP>?Z0#,&!V E]["S#JL6<_"WJ[BR+UW
MM^^.[HAY+E_!CE;Y0R8=YWU:2WC[D7K/;)*+8"U7(6Z?(\(*B"(X6K)"I)@M
M$AE_X3(LZBALM]C&.K$$Y+P[]./5Y<N+&!2!8!B,VM%R1.T?T &D2! .BV )
M@+7Z_Z?6;KSOFL-L_SLZX&33>=Q]6^MK;J2[9795@[LEJL)K&>.S"YI^1\59
M L+RZ("CK<3,*/^]^WIX<-NJR =W@C6XR5,..7A=N]MSY%CW),1\\[?UHT $
M]"_WXN D0P4P^9 .H.@HT\19""8:I,U_A6!L?@I6T5<IU>D/%>$6):DXRR^C
MT [F+K/43!.5<6 9'>"\OHL@7: #HJM0'*L6\^5P"'>9=NYD]4@O,B5@J^[&
MM1O?L8<O"LC*,OD)&=9CGP8;YQV6?"D:'-AR*O<_TPPG^0FV@ ^!"D9T@.MS
MAL,N6\E[KM0$RA.RD?7* .G%MN'@^DZ'6>JJZ16)\[%'GQ:"Y%=M[&;AK"L@
M[J9G)207,YW[>@9U+OY[08,W5^H7V68:<N*P]BH#,6#_5V'Q\3#?'FH^'1#^
M!L)WF8TBU?"7VD04-@O$P@TB9#(BO_>G(D]5:0KLMUM,AR7F3XHTDI='9XX)
MEC2*,MD<%-#:Q>6&H5K*K1<UM+- [W.&Z("J5[+,/UR?63'/SW'./.V7$"HN
MBG]:]-/KT=+\EJX36BM\&?,'4W_Y28/1SC'\E/J'GV RY4^XH7HKX$K?R"HP
M/ XB.2S>U]5N8AWUJ 'A7F.O\25K]OR=LL!9O=9>;:QA>X9YBQIU/K&OH& -
MHUGD=JE6]N;1:-IK;<GOPR3GG7I(C<,:_#^54?^N[!^YA8I0BZ>;FK]U;7NT
M<=4OVV00@'L!1/BZ,!Z71;H[>.9696^1#:M #4[WCB]ST1J+ZMSC.T->WC[F
M4FO;P'+P?V)T]S\P"EOZ5UWRDXAY%!ZB8012;@JB-" C,:JAQSEDH89&?.0'
M*:2\?,965&Y"ZB6S4&Z2I+$BFX+3*S9 HGA" 2H9BC[?=F=4[PQ0@6=$GYEY
MM"+)\.V[HDY3J*+GY_I\W#A5@9&X8 @_VU]Y^J,]]=^U'Z (&!K[$/$Z7BKX
M=?\IF).CN.A]8\U#GXS2GH%IZ^CG? "[!5%XJ?]F6_^$70>CA38%X?M9+)N3
M$O'E7)/Z'K+)A?*GK%_^O"2@5L&L00RY]<MS_U*'*70I9U.G>PY:\:=4D'_K
M!)?^IP@$R31._I3T[!SH%U'PU#NS].N.2I>[7L"K@27I2JI-ZX/+1H7JP"8H
MD%J*%">UW1SU7N=M5_/)RUT6T<WV/1'S;=)W>CIQ<]U4@EJI=5JWV+S=PL<2
MM#50 2<OH%10SSWH *%NXOCBQD^'J@"/8?,S64I";QYO/=X%69"N#%SA]#VV
M I]2$7Q#L#)]5Q19;M31,DY]0 >$#9#<Z !M\30Z &9)![QGE$&; T4)@R#=
MV=DD'_Z9>A:NXB%;C,D+3/1#6?J.4^5H9V;,IO,L]%;<*$K);6Z'0E5_O<FV
MUT=R[KF.UU2FT6K_C($,,!OMU KBM(;5C/A V<M2V='I#4CWPN4T\T)LX%C)
M3_()4IE.QA4-(UR0[0:?U)J/>=JBK3K+[N'8/>='\4U&6WXT%MP5U$E"W9?
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MPP.GL#7YL*Y.+_;I]9AB5=& P5AP],*C])<?-[T'5VUPP( ^:UG4#P;SBD0
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M$]7WX@8U;A)&04=(P-9R[/JQGLHI933SCPTN7+!J9Y!+5B6UA#%N.'EO@2-
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MP7&'-LD5?(GH+W1:B[G\P1/ 7%&>EDLT*^&<GDJR**4A3@PUM1Z3S3BR81O
M'+W]<,8ORFSXK+R-\_[^!_$**VOU(@I[R=ZR7E*_F]R65B><95;<010RSV60
M/[N)R4?PEV_5QNV!OR.BT/WM_6' 4UDH TL9Y?M#@R(<EBJM72<O^O+L=@5L
M<T\D=XD+D+P)^YVU-I>&=L6,9W:/4#/[IK\.[#Q;>%NMK_F^3!K;U=D-#H7R
M$I/BM%*T<F2;C[?'ZUTN;@L]\YRGWZ*: -I[$XZ#OO_BY])N<89H^,[[(70@
M?_,8#C7QJFVW]^*(^?U-NU_MA,[KW 97"\+;0 ZJ+1VZ=V7R7JR1,<W-C$%0
M3A$C]"*3"9MXWU:1)U\^#RL>PY^V7@O3G0)F/I[S:MDK]]EZ?1$JYX<Q&O#V
M""(^N ]\?G@B&MHKPM+''+ ]5&MQ &),RFI)=#M-L(9@$P5\1P'A)F[O!036
M)7C%]ND]U)NUKEY<S\ E-@U#]/,I*I9 H+/ S.W#,323[DL[G[XZJH>%;I6)
MEN4U'/)<Y\,V\MUKF?%WUU4E%]+MC&J+OXV./0=6I'NM(,^0$G"]#V22&D(_
M8E[6)) DC=O?(@(. O!3+1X>P@!_SP;BT.;I0[T]CU$4CI< [."...SY%3]E
MF68IY038+K#U+%9;3#THRG4Z$2_.H>K57]3K\0@R$!QDXK JJJQ;L-?WS(RV
MN($G>Q6NNK5PSJY<_!PY;ZB]J_"E5@T>BMHR:9*B YZI@'8N4V,(--@WUV8E
MF 7%DV2F#'E(B-Q7RP7 ,*9D8-976D=5"XU[Q66DE2*U)16]YQ\K[&UTT6^Q
M90^J08@MR@)WB4RLG#PP_I(>S'YT<:N<$_BU_PW9*=6?#JB1H0,ZS =O>^._
M*<)YE]5$N\5HI7;/I,O,U$MRWW\*>--N[MJ_J%6C(4@3<O@.V^$8H@,VNV'$
M1["V$R1NVML &/7 C7:Y^1M(W"\HY:%?\IUK%4PWD!%)B_G*9AT9%$$R&KTB
M_4&$<^Z'*/-R'*4X3DY[$45ZAF"B W[+&=(!J#\&&-$!)ZYC08<LRW3 _CR*
M5'QXTPOA;))JA;9RZ,40VK28Z8 L&P9]A5HRCI(Y?S?%= >N\'R@MS3<;F'S
MOQ>L)^E;O'>86#WW;'WC<]W]#M]6W)A$X8_LNSB[1;?_?OMM^TIT6K_&7O$-
M".[?'X)P81 V.N!&,XA&J:4#^,%ZK.IPS>*[1ZNU7.F ,&$"D'IDAPX@;V$H
MIL!_=ZH\MQZ?E4F;F<%?E*R+5,WK3Q91.4%:??/ $&><YS%^,/1?QA\9^T0;
M6S3%C8O\X!"I6OWU\4'M?_U^:)I)320N.W#\;(9)K^.,S@E>D%^9G_@.67W)
MF^-1YHQ?V5FHV1TK-9XU/=985Z8ER.9_Z^V=D*T!1(!J PL\#?5OS_0H5_O?
MT %+@@5T ":)#L"7+ ,#[)0?! [T?I6$S/[W@93U/]^0ZAE;X!O@>_ZUEMO_
M1C2]!K.4[XQQ'TO4&!&6#Q.I6(V\:^[*%[==_N^F%/Z[L*#3@Z+E*BUM=M7^
M7-FS""%2FPTQ'X'UKYI/N&E2(+<7?*H4\DO$BV? Z+$8JF,PS8?W]]R_6_P_
M.5P,8R75XD/AD90GV R[C@!0I'>@IJPZ23%*[(IEWL?<]#:%9Q&J7:*+]4>:
MX3A4='(7].20=T;F[3$>6Q<O.N#*G$FXR8ZB15AX)!WPMU3"_QVTYH,&0V5.
M(\IB< 9G_.\3<?=BW>.#\O\:+1\_1X7^OR[M#H;1E6HRT#;IYJB-?R0QSS'K
M"@0S:SBQB,LL#;*G ]C[0U[3 :>=E4:[.:OG?S^_^EWE<7+FC3)OV NY";(;
MB+7J*?0+K#00U!X*G'S(.,E>N4F][UDZVMR@\2OZT7/:/LU!8P&_%LM-$P[?
M@](!GY5SH*XT!5C;55H_:D=W!]:+ZFQLD/YLU8M)H6Y2?II*NB,(/:#*?2I/
ML\BV&S'G;_L4IP=N+9KM8V;H@)Y$8]]A' CW">: .90( "U@9O4HU[G7J'3
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M4]]#-FFHV[5AA9<W.::F%F@!"&>D@ [881^"$23H@'(]!KCI@"5>!L2P>G2
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MBH!*E181 1$Q DJ'J( T(=(#!"(B(#44 0$% 6E2(M)KI L(2 T])/2>2-M
M$FX\SSGG.>\=W_O>;]QQ__C^N&.0,?;.G&O-N>::OUE&UMX4?-^/FOOZV[/
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M@'$>(ED6R[W^R]-\&%O>GS)Q_&ML>\_ITLZS\96".GDZQ7:#E0;2<7A5CM,
MV$7%_^ >TIP\U+^WH%,-8ULJ[CD9+LL;PV%=];PA/+) I^1SE&G#?1?>8]L,
MV!E#P(^ #E(1JLRZG=*EPU-:/OFC(NBH:6IA5.]5?T===,@41SWY>%JUJZ>3
M/,;VY.LQ\LPEXFVWSIMM)W<R]>?18EKE$N-:"G$3>T$[FD.RAZ"CF%8V)I,:
MO1N[VN3C0Y28J4ZN[MKXBQWQ45V5_=6'H-'*Z:E4LO9T0Z5/?G?>DOZ*T.7J
M88^/1AV4@@BW;Q_C[[0(9H0H1:MC\I .!RJ4JT#4%\U\1$ZS+@Y#T!#PYGDI
MV*C3P]XO ^!,[0@0CI%1#5O&7*?C[_3?QDTI7LO[].0X0\[QQQ/O<G:]**S4
MST;C$N,+AZ!C0$1K&H\S1R/VM(HF0;EVY0#%;&XA5U'D<:?2-S%GF=NI\LEU
MT9;O!DS']1R1I_M?J+"0<YO,X&_@MK5]GAAZ?6#OE"HUYADW8W]9QD6,U>3K
MC*"2\8@2-! I\VE)^/Y N82?GJHWQ[=6]E/K(A7:R-EAA=<!)Y"*@)/DQ!1G
MQ8 LK]0'E6X[%PV=H)AS<8@.%>:;Z1)OK9)NQ%&A:92G_!8!DT(GN$^T+>.;
M*[7U6?J>7:UEP/4EA$UC7YM!0I!P8B\7'E%[ #/&B6CJ6$U<**]0?TLP3+O5
MT;%AB?\;91X>NGDS!M?C[2":'O14#Z4R&=+S.#7H\R'HER=D8U(8!N=8$J#^
MKR'JP41'?O1_@T^&\>9]+:LH>A,> =Y?Q?;4NP9L^]!2,QUBE[E[A;Z5WOW&
M:-)D[;I53+$12&]+49FX_V[.0_CR3+U/;PMFC.4[GFF;19>#:[F2SW]H\+G]
ML*#:_"P7T['$<'D&LMSB3]_'?M5\BK/MM]Y0$7E)-=6UHF[:1GU$)>FU;I)Y
M2[P&=P)QR9-!MNF8G[_H]L!/,7[=$R_9_:%<ZZ2?I5K1N5>:+S8\IG<DB)]=
MI*"6EM(2>KF5:ZAF0COCPC_'U4BY"RP1UY0/X(]P-.GF:3;O-8532VH,I*ET
M>-&$C^OE*[L7N&8-@"X/9HXBRZ&D%.C&1:5E_Y\]/"*D*_P%/XHDYU*,3W+:
MVWC1E@/C4%?VCF =-GB1]P _DC:4U!BD3C9N"12V7.XZ$>L!7%!,-)D)X.U1
M-%JRRIJ. (<+\0RJV!+P?'A4$XQ0M<K6ED1LC^9W"N/-@M\X^10-<E9L/M*C
M=R7\%[PCP6]M;B\M=QKV-@ ,)! 6MS?8'/67:^[$J>AXGGJ2'4,(/2_$YG%1
M?:4?JQC ? AJ^D6"K09]0=XB+:!#T$X95I83YHB7)AJJ]8-.BA.B"8&>5Q7\
M!UK]J+WM<$Y[&(_:&4??C_T:I TB8TPB\<?MSZ:.+UZK'_36:7"\LXL<DD](
M^I3E#="8!H]_;Z\7^Y"5OXM)\L2CQZC85DQX2FLV(970V_R1M6@J7>"NWE0^
M^AKF?< 3+F:28J]9+TEPH_U@@P-0(-["99'%<5+"20;TT/KI]51GIT$ HEC1
M"X%S:!;2D2VC8,' DT-0$  VY>493IV/]MO'_<26B;5@3B-0;0.F,*3Z0,,I
MX$8[U+QW+7+<TE'I8_,IE?=%GSO&JF>#.Q1;??"O#D&.<,X5, --$<I8ZEJT
M3&,\,09_"R_#?IVP_!QNJ3+N]NGRN7:&#X-XK0-'<Z.2G4/0^]J2-%\<9$;Z
M+4T 0$FAP6_E[F[AAC:XFUKN%B*7QM<_?5<4PX?O62T0DUHP]!H?Y-$;-B5,
M3B8;U1/-E96=E9M#FLZ]*')9-[T#K]=^W^A]5%VMO)N")'&T]+(M8YG6*>9D
M!MI9?EZ*ONU.EVGAA0JGFUW2I\Y]GZK^L;?7:A!=Y"7CIB/JGYT-K&@-J^A\
M6>1.DA;-S_XB-ZAW[&T>O_++N=N54((85X4H3'] ;E,MG9S;UDT.FHE&.PLV
MU,,)_FIC"UK](J,O&JP9)X2L X.B%R*-@Q$K.UEDL:94?V7S0U#P$$=TG3;G
M#HX/$[15?U$B2NK<O'_1D?K@DU%)*MPOXG)2AD8$U]RWE']:!*9![WGJEU3S
MZ#=>X4B(M2!',O(>Q0SX'K-LR4P,USRI*<D)>F?0=^M__P*<+7D)Y(-IT:3W
M\G,5,_%S=M[WW2W2H*[=GMC3AZ!9F7_U.%9S3+XZ)L2/>R'K:N]<()/9F36T
M.XZB,TM:,]0QL\NP'W)G76EKO&KORH1"YR8U*<%>09>B0?,EAFTI(FE7DYI6
M\NY,70@9L=+-16_'-IG;>VUU;!=)WIYRJI='G*]RT@T3MC']=;3OS GV(],Q
M/HU;F,2 DQ39,L#ZP!:1UL2F=6!95T.JL;1R]'W7FE/]KN=&R]G@+69%P0*)
M@W%^IR[W955CX])?6[5%V@^KHOO;AD73_,+X6?C$NZ[O/X8Q [FZ9&SH"\\U
MYC4YP8M[*N-.>8TL5V8C7_FTJ6..4[-%:H!N9R)':(I*?VNF@SQ;'B)=/RCR
M.&_(K].4^P&[)<6X';TPR4.0'0<H\X()#OH[DPT'?_]=&A<N;+"V:"=>)-AK
MT( -TBVIKJN-=5YSCOV<XL#.Q:6E(UIM"9T1"_* '3='5!R81X\W[ZKKU7>U
M',Q/_A)!3+7L'['R/'BXPJ-4D4O:($R6H3D#)(:YE7=F&<O0\PA:-8L)JJSL
MFGTZ9P,'?DG-JJC8?O=&*@=C2W#TI_=7>CZ3^441SYL&E9*B)_7OR:?HEJP)
M'0$*"/!P;IP[PMK(\HYI5?2\6!@AD5M8&.G" -)VNVXI.3>KY%^X:VS0[NQ\
ME/=2RG/FO*PX'56)!8X0;V.SA34?HK\WK )^W G')Z*?&[S^/<XO[W'[_IUX
ML?4YX4_,.H++N+4!HD04"R$@$"[ HS \%H)UX!I**'D<MZXZO>>C@IR\AL@U
M\'IC!U\FG&MP$/6%O$'90T-I2N0S]DH*;U76K#3MPL>(P^;6UZQR9"[2 P-)
M8*C>:28TL$YYQE[E0KX3V0P(>:[)W28F7K@W)G1+_H+B8HMQ+#!N-%36>Q8I
M/Q@@"9@W9]VQO'?.P[R>>]ZSOK_X;8N$_,:[R"?7K!2+SQ*Y(_*6?E.>D$3&
MM'*]B3#>93)LR3C,L?>%9%=!(5J17WCD2\NZ<%Y&[Z.U?EAP>"2/C/$RUG"E
M"-;J:Q64[R#/L^L$]RO0G355+RN]#XB]4F)EZ"!FD16B9.&,[=:BE<B*TW@+
MR:*ZZ,\%]R8Y8ZY5[V(^7@VX@7J.^#WPV)]!GUQ1*AF9:":4GJO#=[?BX1,+
MRXWXN0L31^O)_?4!RYNWJ1D-)Y?/C!;(A9387FR+DQJ5=#DE=&XG%CQ050"?
M,.,MV"SMBY[[(?&+&"]V4#Z+_89!2S><1Y[M*]XV=O#4Y8G72]->GN>^'J(V
M*RVWDI!-";-H]@;?4P#?,Q/'QE )"N#UOJI#D%=BN/0L7UC5OOZ_;SXJA.JB
MFB0P0A]R?9NM;M2#IMW-T_X<2M&U.@2],@)CAAM0I\FEBR\E?\L]G4#%:PNE
M%UWBZO&M:94\/C.PG86&#L>%JZ,N(+:H]O3[SYFOL#&N-#UYA\R*X/GD_G/6
MQ]-TP(YY G$ZBY>'YB#E#]"%*X>@4GS4JL?QY&W>%W=_9QRKZSS'K=GN_VE0
M=])+(GO5 6&W$P*XSX#/2 5]1J1(?-0;C9-#V(1?-O5].V=[8H':[VX5UJ[6
MK.I$. 2A\9QU;*@#<4"JM\DX<=.QQKDU8GQD])5+6;OVP_D[8%F3V3.NPPTC
MOXI3'_5[U+Z^MGFGT)NM5L>*7A7QC=,L]79N/C7?+8DP3]['199!V5?XM!+R
M8)_Y$C'"FM:.-S9DCL1_9V(0[.5J!B)V/@+6!-@91R7V;.)-1DQ.QYR5^=B(
MA86/]"NO4JTW=DS#U=*OE%*1]X%NLG3;[FR9KR410.F&Q:"R6H+<OZH5[LWN
M%,,)QB$T><JU4O)4.7L@ 6$]6!ZVK1MA:>"CMSUH'3@GBZI]^(B5<6.X-->A
MP_W%$(WD[OJFL,+K )WMX?^LMX5/M3C_J;">K<?KNY8)L<E0C?)7PF2N5D37
MS.XK&GCEF_T8K<#;+E^K0%A#*-5=D7F2??8VQ&P$L"0+/P JIYW%6LT4$47E
MG%/65:"ZJY\+,H1_!?678.TYP@V1(H &D>/4:*G\YZ_4] >1L\DN(LK"X, 7
M-,ZY']DV75%[/BDB)&C[1BC^=*%G02\[$*V\XLQENLTK=/G"P35FD_6IK \,
M[698T@IQ(8@FV>PN_68[>.AXZ97.*,Z8N]6\3#:OSIQ89Y1HD6X .2J!5]T+
M$+YMPSH4ZR_:0B5%=S<.5L;3K]LFN]T4 =TN<K\&+&\8 )%ILJ3ZM*P<C4/0
MB4ELR-6LP:MI8Z:8T2"[KAA&S[ 'IJ$@9F21;M(^+:W-8JW8SX$:8)YNO*AV
MI5]%WS6_.=M*<F4IB;%_]=.3DD[0)8W3(=/1R7E;Z;SV*3NE7Y:X%9;D\[._
MFG<9\%I=W5(4CEU7Q# #NN25YI3CV%"* IRP]F"@&<?3[U Q)97XR,]\A4(#
MKEHO\*>_9)UP-:(W%5U+:KQ($\"6S #5.F/I*$%8,ZS\>*Q.=!I2H]X^'":A
M([7/I_4EKL;<T?]D-';F#WZ$G2T[<X4!_\UN3E6;T2]),76^ 66N2_O]^G>]
M?[.K0LRLZ)][XBQ[3'1FZ3^ XSQ.B4A1@Y07TG&;6("?JG?/W\$(]Z%FKUL?
M@BR3]G#%TE-?M&,C@%_#,T(?>QQY!^O8/QW]^48*:O:\*+NUP&%S]&>_B/M1
M%JUQ$W\V-S I;RO[A3_6<"G2_W-_X@]"]$(J[0?D!%*/E$3 O/60YAS7L,ZS
M6DG:+9&L[_Q9Q/JM5-C65^!TNQD9'PH^1I- "I&PX76\&1297YZ"=OJU#0?@
MEIQ!R6'HE>GX!I,1GY:\9[4:[N'[:?!@)6@2NG+9[U8[Q5\ O=G_#GFIW^8&
M@W_^J9%C+''RL<;#LZU;:O8DW&HWF;\1>X(>!XWDATN1ZL!+W%%_L;6W%P<)
MB5HW+OX,>'3UFKJJQ"B2PXYLW,:W$.:Y<6X<$RSK5\!=,H 42M*W+'-SOI ;
MYW%..>P<0^[-XM&&4TMG!,K7/_LL[62AL]E($?<DRO".?CI[H6/HGZH<Y??K
M-U:J*-BB=838FP 08D"'&EZG32+ZR_=#N*8D1T*ZI7"=\!N67<E*1S4MZ!%:
MJ#N'UE;QT-&P-0<1VKCOF4#-_O[R-LS\C01?+,Y=:DIIOKZQX8S#?76G-;V2
M%3='9720K^2@J')JZDI>C8_[3T'?V9=:XM\H6%"$$YD"%0,ND41G'E'?N2"5
MB:EQ:>?)K9&XFJ%95T+=049MQL+<<6VUA*AI+!L%-8#\<U@P"%I*&N03Z6OV
MG@$P&1^L1EL"9KVJIJ)7RMTF6/EVU4FA.E;'U[.C:F_QB($,^0E2T84L5LOJ
MH4=H_:@K/ ]5SK;C&9%/"?@QI\= ?#9%M;]!<DFI(@%N)UB1X0^'RR?(:F^T
M+[RN"LBU9PI?*),>/001)^GU*-W)PY#:MKDZQ8A]95./]VL8GBZ]O$?C):KR
M+Q6$./1A>N!@,X-2L?%ME=]>J7$R*\## "X'/UV6-9V^MV)4D>GHP0:Q.2?&
M6'3/0C+E%C7-4SH,_.T0%%IW6N3KDI5X7^&J75F*]N;%\)T)B>//U'XG6IQ1
MYB-0_ GX:#R?%$UP= 7,489G&0&\3<H'/9URA@E5!_!$+3/0AT_'N)O=U%O]
MV;$GRW)>1&D83C"RN^B)4:[H77J/REVVK>$YT)GU?;QI91"W?"\JXUQ#Z&O$
MP(X#&1VIHG>@_LS)_TISV[YE>5IL'N\N<BE.XPNEL[YTP\I[!OT:RTMQ/H",
M(^5_!9Q%>!,FAHD]>O?V<8;E]MOPTIJ/X<)'DKQ87)"T\AT>RA5!D5C:Q_PU
MVL98M,S*7?R)K80]O9WLR,0QERCQI0+!<J5).9$(:)E._(M,$?8O"';.Y\7D
M%8O3@.YG2@]\6R6O;:,LA:FI_M+;5EKNCXGK'@^TBZ2RE*?$B55HX)$9C'((
M6D8!G'].B6IF'X)Z:;F'H$"M]X)83E<+;<H526D::AM"899%-67V'X(6#D&&
MAZ#O6;?^?_K_Q_10 OO_Q=Y[1C75=>W"45142D"DEZ@T:2("THF-+B*]$Z5(
MB8!("Q (B/02$0&E104$A(#T'CI(1SH!0@?I"35 ""?>3[F?=WSEO..,\_WX
MQC@_,L;.7G.NMJ]KKCG77GNMA& R*O<4,*/[F?84$)Y27X[68%<VZN\:C+=
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MY3.O:@P6@MZH^(1%WT%5/+]F"SIKN7SM&8.J7*$0T74V37B"? D][Y_\4O1
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M]L\9X1RNY7Z_?IXFZH>4)DC7GYQQ+M)VO6+.#";PE:W@,%"\VH9A)ER=2 H
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M\QY$8\NE\Z"$&(#O_4 ZRVUV?UR)Z-XH!]-/W'_\+/QO/X<.3?JNZ(&K6AF
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M #A442KHVK^PP>N^P;8C\24K_V"-WG_+U:A?'*E:_Q-C?Y.T@.;R#\9J53(
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M-43S_I3Q]9ZJ='>0%.6&>;72Z\./L( :MSR"O;GID*8&U_J7@NLY>)49N>*
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MT:3OM;4E?=!IW-JA8K@->2%&4SUP.JI2C:9"Y,@TG+ACVVWU;CO>_HY3V.A
M8T+PF\>GTN<#FW"<^@-*2<=Y^#A3(2F!-:MXTAI8@";R7>FM2&BNSQ',D*<0
M(E!S$SY;MJ[].)2_ASYN,SP2O@]V2YRX.3)SN[9F<%U*;_S&)8-(H;4.=0/=
MU]*3#$ SGWGR4RT@P0LY1\TD[%855KKZ-4JY3OJ-2;TZV?CRED!(XVU%'/M
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M21;9,6-:2_:?#7@RT<764>-T->Q.@@E+8S"()G%%CV7_TF X:EMV]%>>N,A
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M4**X?WD.$X'@?$BU*G ?'82:$'%\;DE5!W/DZ%/N6,"NSPMV-R !(.IKC:C
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M:RWX;[+9[ 0SX+^>=BG-%D>H*)?Z1CSZUIHX[%)>WF?['&D21U&V98 &Q]:
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M6;3%5TZE#E-/ZAIFO'GT9K:F1UW]CS46%CL0'"W<*$9B[%DYM6DK9=SXMIK
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M4;L/=?;UB!(>\R!=GRE6<%5F<R?K].%BR<F8]M0$L>:YE!=XHW+S)G$T^\)
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MA3<D&IE-A Z4EDKX>PI2+P0*Z7QW+&1[5!/418A:GW+"!V#@L9+R6RS$U/8
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MJB%R<3K"U4@WNE!1G%DHWO%:XY+620ZR3-$$[Q6[.Q=-%B;,Q2)5I[PV$'1
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MGEF.DX^A0BLJ+I&-5_ 07H,A7YOH/YIE1DK?(#.F'MY]($NO]54$>J,R2@2
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M9TF> G*L-4D,UANBV4Q29%833MA@&9!,*P'$OX4TD"-<3P%X:7!5[@LE%-%
MS>X4<+L*1N2J@GTSP&X=L>=1@%5'^7 L@*)3,,*$@),+%(4__WCHSYE1_\>)
MC?[>KO+_&<+^_XG_^Q,CX26V]F"6SJPKE7:T7%.^,GDQ-17S\4P?+7/_?F;?
M7654W\Q?3T4NA#Z)"*\A4_. UD/HR>$;IX 7G75'8C_W/;=F78"*;P9ACLN@
M7: 7B5;NGS7Y@2&]2MB/MHSN9<V*7:DCYM_]_ZHM+>=-HA8=^G[Y G\><9[0
M39T"J!+^I>JS:[H^MR.]$\A/MZ\1<0K0VJ>(R5'O7^JV)VS!BJ0?RHV)X<?
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M$E:WY&6HJ*[44BL0)GMCLP5-[\8H'ODZ))7"=#B;WWG_,SA)0$ID:$B_H>2
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M-S)J!!2OWW(CA+Y_U-6,CZ*DC0@?; JRJWQS*)LJD4[1-0M0',<P%<IWR0?
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M$)QYY$72)=-8.L-NE@U%_"BJ@I9;I-UV-J6\!^^&]WP0.@%T+P)J-D(.FTI
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M'N8>1AMV+SM^V2](G_XX#V:PKN/P"ZR8ZK3BPI.QNT=WJRU.LQ)TQ2_.W]%
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MVO6+&HAK@KB[K/;^CY1'=M(GWGN-1C1"J(LQ^K\)TB,6S"0SK$9"#TNMCWP
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M_'2:GAA*.P$DH=ND4_O.PXQF0O3T6<KH=]NG*Y/VH247\B"KSZU-5LL"XVB
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M*!RU=@5?F8YZTN;,-"1^I3?? C^?TOACKT1QR^AR+?';)CCP(OO0^0.3PP^
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MBG<-*H(CN5':>]8U\P'&QLOF61![I%U:](#V/D7%OQRSG,FWY *[TT>P)OW
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M?I<>9, N77:0I8L)_.M^N;\8'O!?&!Z$YK?GZ<B:L/A#_Y\B\0#$3I$AK9P
M6A,K"=4C>6NLD]2)]:*2\Y_'+&8NELIZ#PEQ?AP7SKO6WW)EA :E.4J$)[@H
MD-)PD,46<P)C3=6"$^7FC&I!5<:G\J6EJ)?YG-Q-7=EG#A8V>.*GVZ#?_EX-
M+OG_SK+_&EM;(%\"8Q3\W;_HO:_:'!1NFULS^F=7G$CY(RX7(,G_#W/O&=7D
MMJX-1Y&B"%BHTE1 % 2D=T*1+EVI DJ'4*1W0I%>(B"@]-XA=) 6.B)-NM1
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M'P(:3!V7A=J9\H [R1%L@Z*>%P"W8?3M@RFDY]*\:#<<K\S'>6E>IF,&%UH
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M,&R^N1R_;2RQB6-&=\-W*(KU,%XJ,B\-R,($[[TX]2T.C-T$5(*LWSU+7/E
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M"X_]V- ]06B=H^+Q0QI7HIZ$)3AO)[3(P((\0%M.B\B\,S/><9A)^ !ZJ2Y
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M>YMD;;C1>7_17YX^K(3OYJ^O1&9?S9@QQ:GV'YE<,NCT):.B=<8G?@XCN2\
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M-[PFTHLHFY:!=S#;AF-B6N;+PBXI=KQJC:;WV%29ZBHI@:Z39FP#J\IOCPD
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M1A+>S-V"STK*-IM#V0>ZPQ2JO(+S-%EM;)0R[EMD.9N^.+?D??_Q8U3,]@S
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M'U&AQ@,I7RF_63'9Y.UY/$@II0OFZW5E72Q9F8O^LIH5Y!/W"H@39?3!W],
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MOY0$B)ILCA-Z5:(T79P@%F"S'D3W6D"VV'^I#>?OV 95CFWEY)AKJI. WZK
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M"N#;R>D4C[RL"JN'BN%'HLJEGSU)S50=.H<BA+)W[2Z^XZ^H>2.ZWONYJES
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M@<6QG2?Z;2/E&2JW1BK03#VY&K[LDW')%ZL>=A,J(R:+GW('K_7)H<>:&JQ
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M$7=XM=-HP)D0P*2&79*VWLQ G211AQ!FAYW2UR@?@ A,GRF+7*\10-MO3=J
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M SWT#(?M25 4XN#6BU+Y3"$ZVF1=M8?ENCXV(;M6HN]1]WZ_A_"O-I:Z\V3
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M6??6KJAZ?=-HK.TXS.VS0;\'K?#Q2NB#(!X,2N90E=!I1HC&1]KTU]&MSC!
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MLB6= .\0450D'PV@8]&,B8#(T1N5D;'T*&;]]8#W3[>HDT1*TK[]27K0CM
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MPVLFX5&L6#>N[U\>L*.^>;B_"R)ZSL7OR2>@5(PO?=7V!M<,=&,3IRYCD,#
MC%#%;KLS!$RTHH2MG\*VX3U?0W4+;RYKF1D?Q?66O>RK8LAXLL/!^4!9'"):
MC"C9JE94"(<^KDP_L6+U.FW(97Q.YR#D#F3/:\?F$;$=E-4Q#?T.Q.VB-WCN
MN648N,4W/]K\L12L/(60FW#,5HJ2(Y%F<4)7NO6%#X^?(/D,_=C+M"$CB+$'
M'=!:Q;@*Y%D[%Q4L)T5?OCZML*?86J]&1Z(C5E_ 9^YE.\ G65^J&1B#JE7L
MQ I ;E81$"\?$NUR>5 OW?UZT]KW[]2M=6+23I:*>D[P,]6;1WRD?)="1M
MD?8$,%T._@91.V4FZ)2X43#J!]M&91<YI,RI8)-,'@Q8A7=C/R">M[I+Q?C)
M-9-B2EW4[@^]'U,2N6LH5+IZ;?HZ*!H<F.5[VB=IZGFSS^( !R9,AN)$Y(NE
M 9Q,6+'+ 5C6UNLSQ_V$/$]:LQZW',-].B7AS5C]66%V ?!A5OC^WABV&Y%@
MY=F!C49>2,&_Z>K$<K2:*=VCB]X/<,R!U:6G>1-+]0OKS65E[NW,I1W QST'
MZF0I3">08R?$6K9</9<!+:<F?,%6]76<V)K#V?M6U[R-\=^_.-A1>Y& 41#G
MC F+048#"1Q7Y[D&ORE/DE15']L2<M_C.W>Y8W]0]*NMY8J5+6ZTMD7H8Y[1
MEU:?-R(,ONPP3)MER1.X^,@J''[F4^241*1&C[1KB6G*RG/S6W[P%[%GWSVP
MD_]5. K<!SW@&Z#&(EP0O 0H)7<.=1BW\*N.E!&P;G&@L!<:D4C'#A[P]=6Q
M%>,BA)7?_3 /NB8__[?3R/]8G7M?_1\5N#<6-[YMG\[U;?]CK)6QSL4+&:-S
M)V0,WJST%*/V\,EOCVJ56$_8N.QZV1>8/)!0:&#U@LEUWXYBS\5-8B:5->Z3
M=SM4[$]2@&5D)_-&9-W(CIY1&WJI9N]4[:/X,B0'0P?SZ*/;GTF#G%]-ONM2
M3[K!)EJ,1CR5V<TV</.Y?J4HM.\H795?3Y[Y(NJ4:L+T/+DMB'4PR\*R/!#:
M+;B[ED0D!%K@5%]JRB@%" 8UV?/6WOMP[*?_VX:JN2H?V'KL_F1G;@WSLU9]
M>C;^,8<]^>.*T0A(5BE 3;D[$YP4X'8.*MA;FY5LJ*(KG5/72]$^C*#R4VX1
MYZMGV!U-3O; 7;\FV]8EPF=U5DM*. 9S8L'"&&!UFD)&IDP^F@9P<V>U&48Y
M;D3\>O4D)T4=!SOY9<;-1_KE=A*0Y&8 F8XVR"[0.^*Y()SC6MP!Y5@. QU6
M^P8JTQ-\LNHT)AK"R+UK'@A%/ZU5%?QX,^+.T+,+O;_]N'C]5'C[@OB2(?@[
M,VXG[;D2\#ACI5'^8L8R.7%@8#2N7Z&]_<=!$(QQ?3I@(6,%Y$?01=O_IGF:
M[-G#UTT#F! MHB@=CTM= L!.WK#Q*YKF;4&7F0]ZQN$C*2YQZ<!L8!UGU\81
M\M8,9]<7"PLB&TE4DO#Q^](42Z*0R^.[C75O06MM6K<YEC^S]-QRPVI*06Y^
M$!4[S &[N 7=Q>J,WG;6E'@-^7C9R;P%6NO-$A:A':I.:)F&AE-_(VM35/.6
M7BR8I.+=2@O&KMF:*"4?;F[R,,UZ;5<^5/RNBMN&'MU1C(AD-S9AQMIFCGA*
MKC]N>/7IPT.^R4V%N:_GP[:"AV\7.TX"+VI:F$3[!)J0/,A+Q*D -_<0O"9<
M)>4],LQYC5'IMS7IH1MP&N!)#_SV80Q5!@(B@-=.ND\C&-R&E^V$Z :0YX)J
M3ACZB-:XGU2X^O12V_6LQ(*98637*-01Q;B< R2'Y/VPGH(ZD'F=UWWC@+6<
M,@4WC[ITC\PGQ6?-@/8S1LD1!/6/N5S*)FRN@H6OQ]72(G>.CFZOP"53AV^_
MOH^++?T1Q2A.<2:9SQOCF]4G9(P#A!-#41]3\CI6;',<K7;^&F8OQ1?LO]M3
MS>2)?=1V(G3Q[LXN',)S0,\9/FLCKT"_B2H>GIA"[E2"1@YQT$APTK=ZW>Y<
M+M3LH2_L   \Y),,T0Y$=2+VP+;BU':ZP-"F:V8[/_>\1=CP%FSZ/GBE'WR%
MGJ'8]/3'V7.&89&,]C%8(>0)\H,/'(4.\!N%89N-SSZ<WV7CAD$L?HA+2W@#
M%B::VGQP#5$@TQFZ-"TV'19O(W)&04:*[#TA$WMQ41\C)[PO[SWG%K@-4S)K
MVG.:X>2QA_B9L$ ,1W')+$K9/NBPD]$W.>[@XWM]O5;F<]HZ>%;M+A,#NDUB
M@-S(\ZYA(KD6U<V$R!;1[,(?BO'RM=F*^HDJG^,R]9]9)RE^27,4SN)XBZC"
MD-S(3IQ1#H.G/JJ4YO=4B 2YW_CP3)%\2%T[J&F?47]Z(=9$,.P+F!4I%O@I
ML+PSAW6DSC;D0EKSZT_E%V#K0=7E3&G"H3L> )&S5]KB6W)8_8K(4?B%M2R(
M/)S<TAD&')PAW(F$!Q4%^E@F3_"VJ <\\95PG^J9O^D!\ FWR6F !Z;@C=,.
MM *WS,DQ>"#S"IBCC@6N) (T'$5^<7(1:=Z(*0XOF'=4]][KG79Z=Z""Q:$B
M*R@AX(0'PP_BNBY]5\B4>E_1D?#AU5V-]&\ \0_A-CWQ*$=4)/"W5EM@+$AW
M^@OX-H;/\:"4+5;JFW?D[;LL"N#)N],.[[J.(;NV-1VC.G/$R7,'UR"\0WX;
M_(%1'?YV4F3?C)S"8F?!N'N9Y<F;60J7=>[G[9[]67O?RX9]H\<D1@5U#/A1
M,*RES*T:T=D$$??$:X_>G=C?[+C=W*F8>4;D[=I6#"A4=@D;@_WP \@+=F$_
MU445JQK>,6&T)#\TX@V]J)ND<+0C53<!_^W88$O:/$>!MYI%04,[- I.Z H3
M!;*X8 D1"''];Y.,'C_GF;\>[BV$K4UM"X3(((L_[9-*B4XX[.H*<7[ I@TY
MY+Y=6]<X"-G@O5[AIO8@Z+8A&^9\U2M&M *AE?=(?:LR%(]X20.(4G_K88YO
M-<)W$0/"/>I$[$W&$1-XEO6']5NWT, C8I:W(?D@ORO*VSFP Q6*TA"%L2)0
MW(006J I-"ZL7_)=(CFMY4GD,7W#O807QRY2&+H\P!^A)U1C6B\A5&)S)^T$
MZMQ$Q%;Z7REGR>59G5>]_^+BQ?8,YM7'8[DG*$>)3MU8 9-I^QC>+6R_<D(0
M?JQR!RHPH9 6ZOI(1A*.?'MPTZP;(.ZBX+^]5\8ILJRIV$; K"GBR6'B@6B3
M9@(XUG_1_VYP0=+$1[;PI[X#_1'^SUZN\4L+9QR ]0_?4GG)T)Z>;G]1EA$X
MQ$!!=,XC+>Q3L6?;N6O6?;H: ><8<US7!MH5HW:#P7&UZ1!55I<I^>8#CP;F
M7-7])]^_DM0WBT&41F[NDKY\30C9(11OST@=$V4:DB:BHBF&#V84CR)KRCK@
M4T&$PRH(]=&%:3GQ*WNW )>FD.A*,W!$&'=45[-BS(A.C-^:D(G:G8B-=*E%
M>;V>U\?6"AR:F XP%EIUEQOAU^A9PZCLG[8<VO"MP)D 2A9?.PUPP$(#K-U;
MR>>DF+3N5PK2 &'0G?5B:F82:8?;U!*8_@^UI__\CK7:L#_6GJ8!_GGQZ87J
MP;#O&5&)2M!G2.E1"E_%!!EZH-GM!K]&B5+-,7O&J_ZPX(F_Q%SO-,<YNLSR
M%'(+.W[XVH\&.+6X>Q%=H95WE6@_$X*6B!-,;UINOW)%0PU31&[Y&&R12%$L
M)0?8UO+MJQ0R-+36*?3.=^M)!L@P^8H<7[*TP+*"Y,OL]/U""B1G^O+KGTOX
M?%[C3I5X\<"YSWV9X8?.NMJP5]IUQCX:P'%/V9Z#HDM.FI9%G'(3E1W:?C2\
M48'PFT34V=[853DHC/X<)/N&C?MP$$W$;6,G^O".#7A65GGU=CN!C)%[Q&.E
MN&RIH)T@O']3S5[K=\R#R9-V+=Z=X?%>N7EA A!Q JRC36KF)L$?)@IS\@)/
M.'5^N+G9^RPO1U\@O>H80!KP],(=WX$7FL>'%6HS,S6.798:KE.'N_:V[IFD
M!#V] ,J7\[YWJN.3R+/"/E4AFP +D)O683G%8@;.AYL-XR,DPL QD.N%RU;(
M/,\R5RXM%\^C\1M,*ZP1<K;I++9H0.C,*(9U9@!F)T,N)T"I7*$J^)F/#2IV
M@+'6ZT$<L" Q.0M.\'>X#D'K\LG/[210[+9GO'UU5UJ\+_3H4AAKRW"K<E&@
MHW5#G/%8Q5SKB^M/^]<-Y>(4L?[N+23AS6+^RAG<QNH(#GB4HJC)UE9'_9&X
MI1NG/>8QZQ2#R+NVUG "VV([W/0Q"5,95+'GVELW&+8TER-XB%#.I '"S0-S
M^M DGQ_L3L:$U*0'I3:](J-I'W1B1["S84L"<6IKO>=TC(V"<SLXX^PDB*0F
MXJD;1/^8PD6KXG $OJI14&/DI[:LDJ9#E2-@^F1[NT;TL5+(P\-T7_OHJ:-$
MG:0\953D3JB_$+^"XFQ,I5BZ^],S7#K6&TQ"D*[.9PQ;3\]!OR-(T+1IE3@\
M=]/HDQT172N4==/DS;H0-[UK.N()XI8"N>\D:JHE4I)=WY?)G FI!Z7A<M>J
M\=#8'*FQVI]"[54@/EZ++6>N-ZT=.5BO1-E>*\DXKK73_+;U.9S*Q>"U1L2T
MR2ER=P^ZVLXYF".BZ(?-0PLNJ-M/)+;:][)>E,)3^W?=;A.M0 *P'<4)L0_%
MPSB=90O=5+MUDN]5.CI;A'CX",O-7]XT-AX360Y5G8:^\*4!6 -AZ+M(_AK8
M=2+[:$,&/%$@>=[%J^VK_NDY!GX0#]/#7'F=!KYFR$$1]7O.Q;%65O8OJ.?;
M.'PIQ.@QCIS??.!>E/VTP6#*9JAV2 +M)L/^9BTIZ[GM$QJ@-BW.%RS("7"S
M$QYBALUC?%=8#:U9TS.&0X2BK2P]WF2RW33D;M\68,VI6Q($KLY-RW->KQK>
MIJ?">G)/_/1V,GU32?/^AI]08Y\>!;&*M%(*D@8,"E4[@I3M)P2Q^)QRC;@$
M1?U0<<.ZAGJO<WN)AGV@^*?]#.?*WC$TYFQ[?_'HR?^V 'ZR9MB]+]V>R[5L
MQSJ^5GM\U5VB$36J!ZT__OP6US?$\7YCUI3VI?%&Q(0!MK,Y,FIZR1<FZK8?
MUA1:H.N.&V -=#3G62^N.*]S8(1>X'P2DXU[9MHK71<JCA]@<=%4)W3GXWX&
M?_%C!YI%K>[Z]_>_N+?)(F#&_PLX;!0[%;^GX1JZC R-1B$FN(51A.^D=E5-
MNK)0N0\;:];IS0+3T:R<8J1K,8LOT_ 5X$2Y/=$^/(R=;(#_N#=#U")RQ+A[
MCZNR/TDS4_K\H=,V6&?M5: X<UZ%/=G54P Q"5(&A_LJDU-!#T'B1[."7^?K
M;PDR/)5T,=C+O/;H/EM*_(E=^1 <(I)BA/LIK36FA*U?4KM-PJCX;QJ=WIQM
M./VQ*_R8>Z'NE/3E!648'OPLC('H!XN&*T,Y.D+XHI69QNJ.;!D@)/&G;Z3S
MGW=^>[;;X9S:Z&<>Q<!J'X7BC$ PZ?UXW09/H"%:$!:Y?<#NO=%E,<4S/CZU
MM/""Q1VW=:-^X'F;]>D'D;I7%F+10U!7E#!Y\C;!(P4'.T'V<#?L5$NM<WXT
MJCAO&'BFZK5B9A,CKUSZY1X;AWA,V3*X1AK-;MZ>81]>3,AN))#2O3W=Y=_G
M.,\F3K\0-+_8F)3^P=N0*[!W^B[L9=B10-9V<^=?6FC()=E99W$):;.9Y$[*
M"L)I>7.L!GSBGQ$H[C4O%YD9W!J(@M;JQOEM)/+9'2-&1?HBCK:O/55:<>M5
M/&7:>G(3)A"('#CW0?;*\8,7KT(L!L=I "*1[V!F#Y-)#B$%D8-P]J*],T:7
MT"[,,1(NV1ZS33EW(@KQ.HG2KPJ>H,7/OIM.&L04_&V3SZK+0':*.R/D/]WJ
M0Z?3 &VCU&;Q"G+*GXZ-V/$0:JC&Y3/00X@BG3/]*H5U>S9UER"ZU%T3:MLP
M#3#B=8*X,?%UJ[O9LQW!8T>6OELSZ %76BDO_VGP=!XO&SCM+^O>4%#1KK 9
M=C6 P^V;FWIGCLA(ZP/<FLGUL;74+8-1>$%M2X/C8ZZ/RW<PLB\NL@@PB;IE
M[5G*%L$4B)P)=0@V:L]P8//G("D,78:P;]H9'O0<:-7H;-W+;?4V3 Y.^N*%
MK>'I;LB#W,1 @'[X-K>N_4=(_J'6:PV".]B)A?KFIOB8.X] T=@3G[,!2RMV
M0S3 "<3'[AF#-]MO4@[HP7QB6$8J"6?-IZW[/%_.M.,.HQS+;AF*39,U4'KZ
M2V4><[C2<5^]C3E+#\O'R1;>Y77']@3>GHO',7]69] 2_C!/]\L.#3"!Z>8-
M[IHC94X?<G@R79_1 W$W- 2_CBD)S2N\G6I^7,C?>U+'IUW"07F4.@:L[=IM
MUS!'JRE$Y4VN!(\WD-+-UWI]"3W< (_/UKH2A=^J&%DC.GYH>ULMK%Y7C-94
MMR5/K71F.#ACK-;J6TFYW^,;/@VNR9S0JQ0[8:LE/Y<F?KH:$4A.)T [: !^
M^"J.&!:OK.4D:^0N%\ U^87U/'HM55J7(<HT2YAM^]V7$)U"ATYEV*2XV5!M
MB&%?[O'0Q(5.46#=*.12\912]9> $HW!NHS/-L\3$C^WES#E_8R%X\&3U^\,
MAJD;3M^#G&Y.32M:5LG0@?LY\<RFB069LO;Q?HN7Y7:\>CSYZJS,:5]$*(JL
MBV.WLC_>]C7"TTOQY1R?H(RC]Y,?9VT0X//MP!#QTZ)Z7YQ<<QD@+!44K? >
M"SN@!1%D(A3WK=(Q0=*77R=9TDLX'C#](:6GZIUWPAT23.C#83'RM$H*@ER_
M\5%3.*I=#1@[B6Y(NX4UWITRL&4-\GCA<)^UZ=XL#1 2;U%%X2._"2'Z?&S.
MC;[[=7C$.-1J<T0[0\J%=WU80/#LNKV&Z@?49W6..MUN()-[)9*+W-).90\W
M'K+HW+0U]-]_Z6.K(]$$1J5Y4-*D7UVJ%?W8C&4@'^MI!W)NFQQ;6OQ2O*3F
M&^P;M&<[=$O&)_XW$W.LM(:S<-!&Z6;/<]#C<H@XT2D1Y%!&N8IIA4ZCV)=4
MKW<%%_YXN=0@.)3KJS+QZ!$>+'^O^T#_EA[SH$<8FNZU'7"LJ!2Y(H,&B%NE
MZ):)7!O>'QXQ:;YD;3FI#Y 7:00%>36=3+Z0>C/'*!B#1GVWQZ5]_.EM:_X1
MR:L6NJ)#0*6'^/B<U#U=OUB8E")1LN#AAB ,H%'LY$M6F+K04WH-(YX[2_FY
MIJD W9S%S%.)L4>($0!1?>Y3_$;6YG.H**PH)6@:R[>R5/+->F7J^*BF[(_
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MO-@,CMHNEQ>>6*("4:'F1B_42Y]%SO6E>@?,;=HF8CYO#9=]:<E:^&)?HY@
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MRG CA[Y$@WD&FXBJ8]*,"EB 8D@X('$2=CMEWX+K0*8<SQ]U;7RXKB\1<V)
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M;9#PB=8#1\A"5_G.Q]1Y<D]\;U6+6/GFDO9,5QP4D-+=,1,=\6G"IT5T)Y/
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M.TX \AMF-2.8HM'LUWIPTU" ;>^HRMH 8$%Y;NIR V$@01D&M$=%4)6M5.-
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M+M)5?]&J-SPJU]T-HO !+HPI^K@UH8XSF@@)9N_Q;2\TL9G0YEF^]N92N#O
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MND;8SO>O"4LIS?H<OO0#*M13^>HF2,CX7C;8'!EP^6N%Q'"<#ZZ?81@%FKX
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M%$[?II\B4I\@)'_80+Q=G_K3RG=Y'NF=G;2]@$D&%%6?> E1T!M-SMX6L+T
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MY/9B,J"OI/)1EA[-Z= ?=58V^88G)JQ9BO8_]%5V]K+XZP_;#+47?%JE=@%
M>&M/T I-5)R/'-<&4!]:SI]&!J+^881C6$>_Z@+@58G.[FB+0+ANVP9NOGJ7
MG6?PZ/+:)^D/P-WR6I]CC1FT+H7)A5,6SXA#F-IG-U<46KRJ6\\6;X]_S9"K
ML%C!H#U?\OI? 11#HYME^EE#\$3I%G'3]PA7?1J?*+&FMND69>'?%6U/3/5
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M$-59PCL*QU!=MV\''$MQP.:DQ10[RTH;]_GLG#LJ"T/%7(=YB*IA/>KO/?\
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M?$8"7K\1O(_*:Q.O,A@L9\>\D5"CV;0;\GYN0$:AQ2SMJF+81_3E9Q?M$FB
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M$FG JV\'._&<I$BZ(;)M.]K1 'X\1<S6?Y!Z$;M]LW_+\_C?'S;Q=\DS)YY
MI-]U01K0-$Y@J: ;CY8!*/ H%+P9#\= 7A._@D;9BR,H/9H0'7AJ =$HF3ZU
MSN_WWN2:B?9=$5S1NMWO2F=->O%C6C%\HPO^$ID1EPXKH#H:464IQL6Z*@)
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M1OPH0@,\ I"SFDHCP9IEJX.!"O!N:_K\/ @&J#3$YA8-:,EMI&8I16^39U7
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M:VPN[-GYJLPAZ]ASD)*K,S>);TERC1G:?&4NT,$E9R[<<%YDAWM,BT)^"Z-
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M=Z&A51-?U&Z3.0:]9R8P5[; ]MK>86=N@W);_L[@LNDKK2<*JZ5)NE"4(7[
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M*1L;4<86I9,^W1X^8O\/;]\9U=36M1L$!:7W7A00E&:A2(V*-)$F E*CTD%
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MO]1@]=?O!V>ID3=9ZN][7W-<M_) !?8]P>?8&A7\93I]O9*_F=_?YCX*^],
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M#CX^"KPP,JF&#1:GQ!=VH[;4P*FDMM^X#$_]NW;H\G\+'SP^?_,A]8"V&(>
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MH-V)">V#9NN*'WRLNWD!TU9NJ:W95,M' "9IB+<;.EB:D=/JC8YO]'I(9@7
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MOR%V.'7L]*P[J9]*=L#)]M!);V(_]F?\<9&+;&D3X,/3OW?TFKJ5E3KO@H\
M05G CRCTW2/ KR4@I40:-.Z2QO^<F. OS2KXETUWJMS)4@!V[8M\5G8RP.9_
MN%7%__)L@/4_SMI<_SJ9NH'HJ=(2 FU'K.C\<NHU7H/C=J._]Q1W1Q_W%!M\
M1-ZVV,^*VE?F?Y1&]G=AOPDJ)1&^H!U#E#SD_3N@L.Y =H6CYSN/%3//$>#T
M,='#Q]%23U+M[U8GQ?%W7G78:[__G6'5;OF'C!K*ERAV[@+S =9O$WS>AG <
M___&AMT8@CJP"QEUY;N?4L)@=9_NM)NEULBLS&4IC])YEIL;R(XZ7DL^=+S$
MB%,.8Y8*(ZX0X_%<[;(3B(DDJ8-NX%:Y7/C-W&E*)F(A"YSF&O?6M=CN];TE
MEY/W*!>H,KOEIL%+Z&8$=B 62M?<G#)-8LJFKUQ!/?S6Y=ID_#*D NL4S^[H
MV2LZJ7_JVWC1X'5!";#_KBT^*QM;RJK7T#0XT#Y#W97:K%C9%*^C7RB[_?-S
M#9S;.K9$]//3'J[$=[E.O7([2L&SKW8+C:XS#W GGF9Z8JY]>$$*>UF=AS7S
M'><6N]0?$;BP_&@_0-C.2P+OO]MT^+PQ&(?H3CL"1$O)/LOT;PM,GA]_L6(J
M;G=I\U&GJ-'V^:OCA?G0>@(6TQW1S LB^ UWU!?N&A/"?OK,J.D\3&@7[:/+
M<Q.Z6Y[2VK5U1?.D6#ST/-BRE2<JJ@K!Y$)[Z@U&8K!PV4^"ME]N9%J7J2A6
M?Y12<M[-:"1VQXO85F!M-G7#6K4+ILIR(=Y4RS1N^U./_(?]<#W$!&-<-C/0
MGA;$Y0IEQY>2=5*$@^6B"],DP6O7,5;3L$6V!I>@<Y=Q%B&.)$@<G 4CT8M(
M; F]NO$@4>9-/WO3X=8D:)K++B$D1$M2&242;Z+-OGOO8RK#CPP>VNRT'V;?
MX#CAW=MI*S1Y^*5GLA$?7]Y*Y2G(#G)\S)4!&-9U*<K IPB9(591N#L&3TD<
M7V5V^HT[>&8*X \?[Z4JN$$B6-CN?B9J];0,\ >9F>UWAJVU+2TL"&0/(8V@
M'-#6;$H5_[D@05ZPO^&(B@XZ_:,-6#H_Y8[2F[-(_W(K)I/(H:N=@;!6T*3'
M'#RV4;@ 7-D::!^)>+-R9LC21E9Z>K=<\Z0];W*XQ D:*B;7,QFZD;%[YR:L
MB%DXQM9-#J).4SP]IV9]BMACN6%-4Y&E8EM0*:ABLRU3O35-$^[\Y+-IU^39
M*\PA\[[ TD#_]G3!J+398HRJ<'MBN[\O^EEKH8MGIWLO?W57"\D4\\8\[(.8
M\[4!N29<%&8\%'K)62EY+U0N6JY$ZLJ^GM**MJT/\Y=7WS[:4SUG4J<KI@YS
MG?>6' N 7_1<T-:"('V"+SB];;ST6YFJ[*Q]8Z)5QI6+H3\D8:7W_RA@%;F7
MY5:&Z10HV\;15MI>,[QB,"]^PL4U[I/6'3Q(OI#(!IKCR_51DT%^A(L$)( ]
MC%\P,#!PNT6KQ'<U#;3,J@Q"1<%:^GB9J V[AL%JFL\UPWH>H@U7(B62^&++
M&L/;*:X+9L"J'-<F,9L4X '+T=(?TW%F[7O^=ZVU@EPB/C^<*#<'<'.);,\V
M"F@XY3G-&_/%/C'J&@)2@BK<,(>GMCN3"(:@5GDD?>(*J_.,G:Z?US-AAI8/
M0HY#=0@V""T.^%QEN(@0^,DQ:5.[G,I[X[ZW3=[E;^^&M'Z<U\)TWN'G,OSL
MY+V55_=V;<K2^NK6S=C#<^/ A\@HI<C-RBD]6[(7$0..RWW6.P)0[>/"+VWM
M\-]CW-] $C5\)-VD:]7V4Y]QTXTN%B#7402QEI?5>TFP5C6B))>MT>BI8$<0
MZ5R5+#GPDVGCJ)#0WO,'^++JO=BGT!IW9@>R;]&4=&?^)/N,5B!0PK^]^?08
MT>2)T'#5S\4!<S^TV8H>-,X)5"$3)GNU7O4BAV+O+#EM4OH1S(F&1KQ]&^UV
MSL3F%!M @MLV=3)FRSSU.=L"-1V2;G-6'Q5V!+C:#72 1=9'1:RMI<Q=NB]\
MNH$?MO]M?)CV1;<<?6DCA^=:S EQ;&ALAKR^Q*? FH%%HD8 YMVG)K, G1J2
M.[;H;:PFA<FF5'];%T77)/L10#BM7 ,@IWEAY"\?'WDB**#&,@7Q(FAA#*AL
MK.5B5SY<[ 3'<I<N:9F?3>7?[8F>V*!@1Y$-HBPA""W8B8P69&X\70:QJ,,U
M6CB&SB=N=:':O0Q$TO(/;CZT+&[L-&)Y=_5#G#]D8/Q$$R=FJ=W-$A/?-#<C
M[U@-HIQ Q5E:U+YX-1 L*6HQ1/]QZM$V$/Q3Y:?+)2_78ZN>3-0XN$(8,,5W
ME>>W!N3"VAK&B(Z.V*"&29&7+@G]%!'];S4Y'YHFSM DU-PLMRX,!]T[+B_=
MXY!?'!L2C^DUBBW_5;T6A3X@OY5;1P!;E #9,;'MP&-F.8<7\ ))1>K44VMK
M7:OIIK%R\+/ &.WK7E?CP8A!F>@C 'NC# ZN6S%"-"^&V2[7^G^8$)U/T,;E
M#=5,=#Q_=\O%@#>;-O&*LYH0Q!#7W4X/U&_$GR^0/#>">#O\_L6C@/RZNI?H
M<_'7VJ]>WN4"L#R10)Y\7ASZOL1XAH*X8V,Q4&C5U/2-9<I*TZ]1@<9H9)\I
MH*AD-VCW*:'\0,Y9[4HC+K5CPDVZ4<N#SMO ':+H&WQ.2^C;<QLN*SHX9#RV
M&_=L5YF0A(:Q@].U+/N!6KC^BIF5<9V'19.TX(D$+I'R8E@]^+HGR$TWIJ@7
MND7/L+1HS;XGG8MSW%5/%*U3D\.[ISZ:]O3W+G!AFB[RJ.\724DW,=B+Z0QB
M@^%TD1%QN>20HC!:[K5L)?54"MZ7Z[,>P\SL@X<"\NM+:LGCI/('ZY4'84L+
M78SY9X5\,4@]$CVI39!"[0I87X:5H&"!Q&M&B0Q9E@Y_ZQ7<9$*/%-]Z&*\4
M_Y2Y%:%-D#D0(9["UX0?-J%5SW=;?(A=<17+6CFMFX>KTS%*><#%U+*[Q\?S
MJ9#EX:.FB9JVI?G-" @MAI$/))H5D3NSXEUK</YJ%:-?UTEH-JD31E$]$*7&
M,_RX^@8IP=[U=1AE-3<^F;I9U?6[QXGO,(;TSK2]<!_YT!T$?7Z#BT5P4^4Y
MBYB11J&:F:<5S]>I$I0P]:!((+L*-9[U+EX^:6[]$<J$G(MO[OJ5L#'7ISO_
M_.G5<DI0@K[O1;*P"L_/QP/7LAX*.N0ZS:*]FR-NMX4L75O,R\M'9/[&%&[B
M$Q&!_6Q %_MJG\5[?_1/4-M<\WF(#P[8.J/>+F]S:9Q5([LC-==@B#AAYYOE
M=>^DY+N;7JM]#[S'0I2G/N'E$^4.J8V&+=19;"QUW:WHUF?SO0D.11!U0@QZ
M,T*-=E3%'%.JX1-'>>>YKG_ N:O1(Q^,MG(D=21/ <32*M$@3F<;1=Q8$H:?
M975]2JWX<:I?ZEENE9X,>TLZ"F[^Z%-IJ)NY%S1O&\VX0,T@9H?9C;:X9_?J
MHHR&W*5E.V#?5DR_V\5JK.E0+JAU-8['SYR$CLQHT<][L+W(ZWU^Y1*58%LC
MJE.PLK =Q56>9(CK#]<';]M&V4)=8W>$XY=%8)H+:C*W,Z\-??Y ['=:X*C>
M=CX"O/ZIJ@&-6T%]R&YOZ'*HK:VOY%ZF[WL #2@+]""(+3VUN6D[(J<AD.T$
M6JE&CE_P51L3D+1C(;P<?V_V?1(GQ;[WBARC0PDFEIGJQ@\4%]&PMV.=\#7A
MN1)38TE_3FMDD#+S_B-XV1"[ <<5&LA%CR$@SF# X$:\@<MJHR"NW0:?/*3E
M_%#),N5GF=W-=]2UI=!8<E!G@C.(Z@ERNSC!OM*EVKVMB- <@@I\K[_])GY2
M?S;<S7N W]<I%[,-XK1VN9N?@E[W=7<&]LIL.V80*7$F&Z'NYS^:WJ@"7(YO
M:^KWCG>A>10[>O,M%64\]>UD>U-#+:'Q%)CB;7TOKY2U8#:C&V=-$.O]H^]?
M4(:U"Q:5R/[]_.9?+VV4S]"P%5J'Y$.Q< 2H2HV L&,V0TF7/A#"5?R@;!PR
MJJ/;"3P#?;R)X %'34"9HAAE$X2<4%/MC2&@XF"L-9ZSX_#V\7?72MXL^]7P
M:!0@''?-:K_.QUDH3^2*+&PP7@$:7N=GD%C.CD.=. *@@UP$V,K'JVM 5,O^
M[48CC0K\-6;F+Q@>Z.3-=&BW7-8K].S2;LDC9.).R?! -' &<"*P%-8FBF6D
MUYFO_B'_UFY$=O<(8&E[Q=WJS4JAHGI/#F,F29  Q]1$'1A !XMQJZWUU+%N
M(,OAJ2T]1ZM@U3>P\KAWL>5J<YH!V/S'T$F><?@.?**P2T& K+LOT#,!<A+,
M'O;Y+J5!="\.WYUX/R3K7)7RC::UA7O 95V.<=(1HYF$-^Z&7L91=^7A[ 1D
M&B*WMO72V_SVH\UBS[)@=$2IN:@_K)I!3 YD"9L8_V-.0S OAKIS%*]2G]F?
MWUE62!WYH%Q>EZI$6"R5[U52@.$5[2[EK]1)T"%!%K7+J_72Z3AD-XD3YQ$"
M4<2?4<\Y K0]%"B4+W%S%0ZY)<4=J5JI?4780=F?H?HK:6I6]*L:-Y&7X(&+
MW3;Y6#74J 6SST7-O,K[F.SS[#K<9ZV\Y"K'O?BKH4< *8/\X-/XVCD2'-^'
MUJ^;RWQ295J?C$QE_^;\6LK1BJM0'[IUC4YQ33.@S !]!%C;*_H.9),UX"?D
M=LE@#ETU<550[BI4X3,3XT7JK.^APM MZR(:?OFL@!S&LX=Q:E)@/:@"Q(S@
MC=;36K?A:JP3D,)]3QQS!4DKMI7.T_+UQ-4HAGUH:6%A#*S#C7?5 "O*2@]N
M@'5-U/0CT(BKW8%LP-D/C:;.9Y_[T?HD"O%_SMI9!S&33LO$-4L2%?&'\553
M M7HTV4<UC68AT7F P*3;E8;UCESE]R?:'I:+74/3()T"3^Q'C2N>_4=^W<L
ME(.SC2LBF<^MRJOY&!\FWKWO!I)G<VMAW8OBSF'D'I=ST]JU/ R1H[^[;TO=
M(</M\3$+<E7;U\UHJ[]%\HXX\0%K]/5.;V2E8P<\"GCF". \P !6;N'YG#K+
MBO>(*/5YW5$?W/^V^[WS]YO S;?7[WQ-_?(ML<<[7F+5(!IT2JO#(U:0H5$/
M]E[6PBS<W5V.IDJCAJ[6#,X<>\%"#R7SDKO'NE"T\D4LG.QX!06[&6F_CSU9
ME4(W>=P:D_)MDC&/_Z:_6]GV\R ]]>(G<^UOUUP .^QN;9E&;9TOYQ="6[M+
M=?[^!3='<"@,HUN4=02P3X!A"ZI<"O+=/20WI&H?L]X:W.CR3-!THD0+3B"[
ML@5^;$ZFMNS.LA(\T5(>[>6MERJ1(RI&4N^W$%,BO>"(AC7%GA;;X=DFK=W4
ML68AZVZ<H&;U>%FSP&JS./[B<OWD5_=;F&M3G_Q3KLU\I6XU2/Z$NWX-4T14
M/$PDR1)%<0Z9:. 9Z."399+@L$GBT!CHQ)3^8(FRXLDIM_X^ ;U ]T*<C W^
M'NA,&=$$ZUFV.GMZ+-T\VPBNH_NPN#S2Z6: ]L%#"@>^.)1_H2P%!D4+9=29
MVYS.[;B$A#<Z(C*56\?\@W::[NGM9FY_SK(B:*!X#N<:'\:HC"= [A)FBL!:
M+4K(N!\&\5!Y?"K\1\D10-X'MY$L =:X9P5P>VTA*&6[U:,N]JK;7^4'HJ)1
M \>P:DI8%NN0 ++U/K0M^NYX?5R6L]R<8__;U0I9[PUZVA-+";QJH_/U46NB
M&#WCN9F!MB!XG%(.(8CMO)2,?M2M6ITW)_3P4AWH6JMS"LJ:_1/<*H94]07'
M5%V@:O\8%2G.#A S6+G5SX9IR%=G#0)\DO#9O2!ECI+O?>E"&5/JE)K;.T;V
M)8'SA_EJ0@09M-12N+3ONJX1WAK1X:Q" [$L6'ZT:932RJ3O+EQS(ZI^ZY48
M9:*";UG; 7K@F>_F-*BSO<U&N0[G@"@ ,VJ&K^?>B=\=6[ZS=S9%-X#++BZG
MF.[,_ [5>+[. >]W1ERRBM@1X#1#F<JM^B6BJ&U7;-_AF\,JD&>3,*_!'J31
M;>+RYG4!1YQZ=]:E<D(C1#$?V0EB(@)'JESK-G9DHO<EO^KF@VY1WGI4[S3L
M=5N!/BI77+A,XDL5O1DF$G[ 25#'K@]THMA<U,2KXS]MZ)US/D?JJZMVK8[(
M29-*S_/3%/EDZ1=HR[[C$0H]14 8X%_.BN/'.Z5TNZ;2G(>64^2?W"]X73@M
M\I3SY717A\Z%EI\3N&L TUO9%4_U#LY-$&D%Q!(TG!U/%N[.E?/"4Y4^\_:B
M0C,_=FUVA:@X8CF[K,VZ!*L4XHB"GJ40@Z\0&;2$JS)8F&";J^LIUSD_&( 0
M_;S*NVYR\D1W"&^B2V0IWA:S%PVE)XI5-HVJW)B#L[D(LF)Q;\:JZ<4G9E8L
M'L;.=_I*O8]ENYJC*1'7,"SW@S,>Z&@=N(JQ/P+ H0*0FQ\)P1@IBR^\_/:6
MNL_N5HUP,-VZ(GOERGHR)1.70 :32PGT4[%8E!K?LC<!93ZZV2B!(1!M?4M<
M!9<5>#+;WK=B@9>8WEQ]PL;TYGKKZG4!HS=@UJYQ5%7J<S5ZP3@U)0&62MQA
M8?008:;-UU.E0D7M[LQ/F*2PPV%H@!@WP'L-61X57WT$B!8\L59&-"J2+R]=
MWL_*S=,KU@ZUJ[=TK3L;KP6P#;AE]6)D?J\,KD50JO=8/XF W.6IU)4NS9GZ
MKJ4K/R?YB#O+0.'S3*\ROM:#:\6ENP7XE)SOME2"W>1,QTSU[AX8'^BVSB>X
MNPL\2O=7F$'5*BYQ8T)4S_WKMU/_P\6@BT%$$J]BC@!1S6<'&QWY6, 6&UUV
M(\U?6XT>G-%5]$!/[X7["?$0U'=IQS@Q9ETTG-U3&[EE* )04QA=[RI?\&WV
M^Z9$EZ\<]:'=6JBPU(B00-[X!*J*LU5'3=6)QS%2FJCE^99@CA#.MOI0&7[%
M9:Q'/?AEW\< HTJ*!D *)9\IK$MF<JP/<Z_YS&@5OS98L#.+OCX^F/-^997Y
MK4NA-;IF\(L"G 8O"S2O=0+ *OM['9G4NZN$+B@?P>P6_D[B]T"A)CU7<S>5
MFU0&'PHF\E 9&?-TC^I!4[I6A&>EI,XC (\((0X=S-DV[KG,(I47*/]^*JR/
M>[HN,TUDZD9+%[U/\Y7#UY!@7WQ)1S8S\30^ $+KCZ'E5>:=OJ!R^51>GF6Q
MR<6AV_)+(G,,AWKW1Y&.L!@!90((BSP)WL/R026K\.<S=VF#HB%2)T.')S*J
M7L6#9N<?/'CQW) ZEFA(&,5GDT,-*HA"+KBD%4J'0X43#6P]T#]5K*;>[\<U
MI]0RT6!3%E&]ZI$]W+V&'798A/F!7J_M@2RILYF7 "I<315P+V'/#L\9K;GZ
M2<CS64G"B\C'DA(2@!SL18GO*!:BV&"C/2[>(RJ0")L*5/V26']OHZ_J(_-3
M%HK)4,/V+!J$+,'_0'HEBQ>OT,YOVZFFDMX5ASL":#8,_9A8&NZ0$AEF"EN8
M_ORX_OI;Z0RLWXV5]R%;0'(X=<R*=G 77-("/3%B 3M)*+E=.R9;E/4I2"/<
ML";F05T$A].P*$8[_^>->3E_*.7(VA' ,7M*%\L8M:.3TMUF<VX8B7ZXO"[L
M%J\H#)(P-MJLLWVY3\V^(LBK1@-_EE8;XMLGY4Q4Q#">6HTIF5PY[;:4"K<5
MV?V<GSJ?K'W7NX5?@G$WX_#5&LR9%\BHN;\S$.GNTQ!CZEJB354:8*OTN+[R
MB7;;IX]+&0_X>!X$<(9 G+UQ"KL*^,VN0Y=3!IS@(4L$&XU##TQ^/KIJ%>+;
MIC4/R2T L<\?8P$Z/  0?D(O[A&J'7HN_:X'RW>MMEFIQ&"UE0FU(LMU^3TI
MD<%S#;)#!@)>^MS@59 +\3Z!UPU_UR!J#%X4I]R>Q3[V8,QNT+:&+G7=_:GE
M+<LG$]$'H%Q')W;;W0C"5>KN@8C U*?2<O*#T@MIO W\%ER-O9+2;U[8Q=M;
MMXO>_M&SXD0Y''5#UZ1JPMWMQ^I]A#3'QL:U%PX?[Q/+)4(H+UEEYF1DV&%5
M7?K_SMF#+UQ?QW4!GPNH$13F,'U\^X6[^U.WV]7TAIR[M$7VWQ=%X1 5J_V-
MP;@D$BLYTJ$GVDT55ZC1?6S*?#Q&C]E<YUADH77GE5]2;!W0%Z><1\8AF1G7
M+Q\H$56_+M)9' ':I^ Q1"-WZ _89,H7.&L(^#PAAZR^68Y#=:5 K#R",X)T
MDG@ERAC?%9,CTSX-8EI)%624K6T<=3?/N,%V=M"JE279SY&V]V(=^X_LIS#;
M)IDVGM0NV@;KP  M>.G&X_4'B1./!X4R/FUK,<UL1Z8Y)!S.7A?XD8WKJ?P>
M*-.>#J<!KZRVD91P-M'U5#;GX 8ZZ!')%MXW'ZL=VJ7Q34\F347"KPNPET >
M$G+S2/W9G)BP@ZZT !SI30'\-*&A<^I.FE^^+]6VIH!B[;F?!6+?WL]!>MK/
M-8EU3X&>$SDQH$A!&A^/F%FQE&W,R9T=$@)3>MNIL+FJIKK:W#ZLY^?#1]M<
MSY]TGO*TCD<<7%A1$R488S9I"<\P:J48029"P>[8_A' IJD6=)&5ZD6%EH=3
M&0O7AU=3I1GE(DG6A5T#H3CB_5K<S&$*,@ -Y 3;?$<Y0<^6Q]@'F7.KU)E@
M8"G:>0;)"5@AWQS&T^,JY,T2JG:%$($;,^!SS9(<*B,)N@A(?MUQ<[!+NC?L
M+M4;K]W?8C*;5W^%Y4H>\WU.1PRLS2 ,QJ@FYP)DEQM@<>6\XDQMC=O!1R^;
MR:=ZL.GQ73YY2O&>=F'_-UVFCAWL$,0 =^X(T IB)$F#MSN;9>KP1X#X'9G3
MULOAAD%L%6%C_6?]F6X\?OJ4KMN;1>?126\@.?=SX'?M1)V!LB!BFT5= O?:
M#Z7[],;>$X7/9])I#6B/:3_*6H8&O(GK.7LF?"M$IQ/P9/828;24J$?HQ,L/
M;78 .:KHA=O2&IR4Y!#M>F=TTV%*XJ-Y61LF<<1Q1]B.&$!<<+;_,;(#] S&
M3%:S[CLC.VZN:&0,1">XQ+E9R--^5S<&'<;1T7;Z7O3,J'K!G%^J",/)(& ,
MT"&;>9*PW4$2([CBE;;1DWCCO/W%+)]7OKP!9>SRP044PA<B[X;>$'ZB?$,X
M=G"8O))TMZN&!!U/ZI@=713AND-C]L#HQ,R,2Z+535N_E$?MSGT<<\Q? 2<!
M8&@AWK4367ER:?WTVP%,L&7WE/]3R&5;C!0#C/5VY4R[7&O*5;;$=XC77#Z:
M@/A36H$+*F+XJQC&R)V!$ZL\TKGXPFZ>A=U<9\:8'T@6@JE3E;.;_5G'E&\!
M%Z4@%>K%=)JCK?W!>F70_GK@,[6S$/5QX@T_7SWAKBR!:MSZ[/,'$^=BA2](
M5VST2BWNT^??Z"T#M1T!*AF?_SC8I#4'/\."HE74YU!T5AK>A=^_3G3;>CYY
MQ!4A(XUU&Z?)Y;82?TP_F:/P;8O? H7AA)<!G>F]21P#L1 %VSEKF_4J6GH!
MIT%F;)5.=+87JX@Y@*8"T"=0D$=V C'-9\G;;FT';W,$P*C5ELP0#DR&?=:]
MV[VC4[699F]^IF*Z2,FK>3/A(.8Q'\X3=-T95ODMT ^.?Z9/^I:H07@6X.VW
M%9S ^"%@K(_"4(&TS>MOM_[%,_1>P>%K;!*ZL'7SM"!S#Q!M[:+D_C8UVY87
M0>KFUHM0(&U"O3-J+L^&J([%WN@YE1+R#]#SO[FXI>6W)#Y7PV/-O" ^@VK\
M3GXUX^YIC]/&HZ4+Q>1-\UZMOP"H]$J^J<>QG-]A7ZX(1G4U>Q*$A6O70P^T
M>=N@7TO1"U7;2H>I:U29R+6?!0;=LA3C.@?6$.ZJ$=D#;I*H$_,,2G_W:[?H
MU[OV.CSRICUM_"OMBUV>G?YJYPG%<P@JE&AJ- 24XZ2 X$IVVU'5IW7F/BUT
MR>R!=H_* 0\!W@IE'B3'GV'N1/OZX(O]&Q[2*D;^GE=OYB^D2*R&LI9WZ=S@
ML1UV0NCB"]N ?,1;@T3Z$B<8?3,#>.H;P:7U_$CS.4L]^1R1K5![4VV^ $B8
MXA?SCSF,YH2X W7G-&#[]*$K>F42HC\VM#+5AM+[*I,X+[G=PRS@]PR6S#)?
M>9GO8MJBB@P^'6/V%'H%;-8BR.X#HY, UP]M835'543EVL_IN7*EN 9@TQ>/
M *8Z#(747-TJWE#.\?S#!"@W 4F.E5@@O+CI5@[+]:$OP^BXAJ[]E]U>[^^>
M/O><4_*Z30NG2,A%CY 4/Y+2,9B85@LC^ RBX(L_X:HHY0,Z_7V_2N$2P:^S
MV9G)S7OQ2ZNWY,<62LH%[ARZ)MO=1,)P 5%M3$U*(41%M1 B/S2?%2"K:HI9
M9&3J?4CW/M'*ZZV(%WNF[</$RP/"JH7/2<K@ODY!%DG(:1S\SE</N8BO:+Q
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ML9WOO/W /8?X&UE/9?)]01]N)0'78+B& 6>N(X ]]'M?9M=9B>CM(P!@^KK
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M-LG:WKJ_7MT4%4.4@!9+FG8V-I1POVS*'SHE$M>;_# I*JZ\$[)4^#V;D21
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M0<]^-DJ@^1G;O5#R!\6R)32E4[89Q 4VQVR+12@K4:89-Q"G$HSU8.YU \9
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MFU]8_+FT3-S\M;6]LTO:V_^M%P/ R/"/X]_JQ4G7ZQ 3$R,3RV^]& [Y_;Z
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MI_=FB5 J<^$_->62_H>FN*Q.V/UY^:5/]R,3)1Z<.X-Z)+/?R-%")YPWUO9
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M5EHTOF(I]//0H%5E&#ZV9XIWUNGN%:>)PO!.U47881HP5^[/'4>?#_<[PFF
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M28X_R!-_02:72']=HX\M/(@_3RTD>O'(0Y)L'#C VP*5TDN+XN_=$1PVC\^
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M =<5:0; Z#X03"9T#FD6&GKAC/ATZB>G\X/?HT;/F*I$_Q2.V#*S+U+3LWW
MMZL(/,;T+W0]4E:Q.OP,.![8>>7Q!'C,[!I.>36\:Y*=#%?D%@FD-=!"H\WJ
MB*%9_J0VBRI:O^UGR-FR.]D^.?;:62'/CV%#W$DX9>^IG'B:!'._LIG!@=B4
M%4RQ \+5+(B]6[]0^7[U.M8:R-!B1IG6)05EM(A(?&,<YJ8_!BO7!E))PJU(
M+GE6%>,QX=&J/E>CA-SJL6V67W('W_!J=APZ@7>9>D)4'C3ST+*.$1.,Z1$I
M,4Z FFU?XNEZ>)/E%Z3*0_09_1V,[N+6-48^U#%>[_@R+RP/!5R.;)TEZ<8U
MLA0M&1'>\*DT2 ,Z\E/E%_V"SUT=_N5VS,'I&^O+?)^^P*[?BT^PI"XHJK#=
M%0EFE9Q=_?K9.3/QW?N&;D][_I%K!B:R(!O#B'G)YWN=3%SKZG( $PX"=E(7
M'-[Q)!JIM!$\,DHM7&3:BJ8<_"LL7P8D?V6=./C!4VH4B62&RY.2#!JK2(>H
MUNY@R*2GY\:ZS<KFNI4]O/+Z]/RI8RFALL_[&)0][JZ1(.?@O+6D<10.RS0)
MH!^2Q6+\B-<;59S]O,[>:X["?3-_TF!;N=%P6>]%0K>CP#5#9[@TT(>O4&SK
MK7/;MD1&V5P=76]4RUL:5^BO"7KBORHT5=ECR<%X;O'9UZE7\9@F9RK#L.\1
M2, %<4UO(1TZ*BE4D1RX(%5AV:G_Z/T=V[,5HDU&8I_++-N0E0-AE"L$![)Z
MMCN\YN6 EY^SO?QJM[V#W*^M@C#ZS<Z!E&3940*/''-+(>PM,NG-@?1N/Z"M
M5M0^B8Y"]8H3FVS.WS*YQ?[YY5NS)K.7@&=K4'HLTBD!V651D-J7F)JSW-96
M?];L]KW^_E;+A@(FP, ]P3*/06RX*2C\T?*S][&7)5 ?CD#_7DO=*;\P@IR_
MZ$Q+3&:_,.7[8UFFLK!$VMM4-TMW\F8MJ_2]1(OY[?3TIM4S2@8 G77TDM)'
M!.WM[>/$L\<BCD G9C"'3/+L?9#?W_3ST3):SD+NK]^'1EE6W6/DI@@'0+?Y
M1R%R_UIP?N&Q2@W/C%K(IAAZ#&F<AY(29I"#/O<H(__:"_'"^]^W/<W2$8,0
M@1($ Z",O><NL]IN02T*$'SS'H;H CN-EO-3*@ISZ"7Z)C3ECDV V:V2?B6N
M@#.19#EDJYK/$4AS1FOK]\E-;F2F]O+)<%QS\JP<62R<PHZ7/C7U.OT>K2J=
M)>^\><1\[+NW@GVM+X_H0YTU?K,\X( PFS&7?=[IYD8' CP$5V$,]\)+>G0]
M"$,2A1TW\V5O<O_4YJAEX^?P"5499/J0Q#9=0^GZ%WSHG]K!1",&T-6.X0AQ
M^(611M=2UTSU,$^_@&%$3Z7ZE/-$1DY-@ //ZU:N*?#E[B4&_V'J&)3Y DFD
M62Z]:U+5ALN@6X*Q2*3#+AEWO?[&INQ%'O"S,QH" Q3A]'^KTSFO;4^,:O\O
M=?G4FW5!&&'%N,12PL I6%AON[K "%%**K^I(B5(^G7$Q",_8]#2,]<^Y%/H
M)*8MFUM5%B<@WFYSE30//>MG*._'@F9;3CEM/\ORZ5.EXG?AJ[?7)93PH6H-
MU#,-Y?ML+O^E6D5: :/9][=JZR"QD"ID&R0LW=1_5HF<E8HK+FZI9PGN1@<1
M;LQ4:%[TH=RRGZUWI@K#;# M:%):+YY5 <)RF$V$3K'ZAF%ZU,#?^Z?]]\D:
M'(I190]"_?YEL=<P__E-^7^-:Z&GJ*-H9E4_G.=I6-Q-\FY2D=/^<4FO3U9M
MUVF=6_RI=+\+"MAGUX+,A ^4J#\$.8$^4HH5>3ROU&E?*KO A;,MH'[^D[EE
M#(_[]X$+]Q>400 8"[K'1"/9/Y$D ;I2_VTW)5(-8;$-FY"VEP+C[,CTC!GN
M"[,JC:^#Q2S7Z1VG_T%@+'+&5M6TL=IW\$*C).#.!3.K]05]'>]27\AP9SKG
M/#5_?9G?_?+7E.>IJF0- 21%N.;&P.YZ;M(GF@;9:>YB&' /$HLDRQ,@U6"B
M8R[UNSJ=S"'Z#LW[1XQ/9DIE%%66&*=<%>Z]J/F*WW9/<80NO06)$HML%)]3
ML2R/Q9ZF\+"A=\5#[CIO2U=I/]U-OW68K#?L5C>;,^<-Z[^N(=CWO\2DE6XB
MQ,7S!9K5[T" O4-0?<C7T&:'0\]M?5VA&T7^7-NUWO+M "AKZX">:92?"[G4
M9H+QBW-7:*6NL(A;QEB*JXY<>W1?85$TYGP'R.A_D7/?!7U:5>T]K$&'U+1>
M=$KPXKA]ICODKMNO&N83C*;WF+1/R=Q5QIR$N'J&)X3D3"!;.P81F#*](>?!
MP\*%=VE:/ 3PY=D"33<Z79X<M@/JF:G<@=W_>K0^3>QA/S-UYE]1X$J/+^Q*
MBL(RN$M>(F/B? =82@EGJRV7JQOS_:[F26BL>SVWN>YX8&94#MLB//'G+8\D
MJM+/69_K=#7BM&86?;Y19N<L*]ZYZ&OP]6I<0U;5L6W%78:N0R84^\$R#=9#
M$K'7%_,OB%L;)X!5FS&JL),@=P,9_&)#RITB*UA<OKQ[;H_%?ZNGQ2X+ZS69
M-A^%VUQ,3%U]5=8R'GH=^1]ZT?V3#UW]8T&M_\&)X#_YL'3R,CW+/X9?C5/.
M*>D_"6?H/\PQ\S[T&OK_7=&"_'6GF#'R](G/S*\AR9-;AUJF,=+KW <R0SW?
MOE8R=B\6M91;R>.#TO^]XK;>JIMYI[7\9M=N%73[9"7E#<6).AY'?>Z/3$$F
M.-ZW*12Z7I=W6,I]2+?V]_%QO! 4GC:#A]GS6(+YZ/UO80OINXVZ(&>%)X=\
MM(]BHJC/%1!-?!37#+)1K!R6 0BXA_&+Z:O.L&4Q\KJ:I_10,#8G.00DX-J#
M=CP")>YG=[%SP]:'D>Q6,!^#H?DJ0QF!FYP":Z]Z(EY\*4-83W/=H<O9]#&?
M9)ZZMZ6V>F 'WF<PIQI1Y3:(L#KPA +B"!1,<5U@52&(=63',..3S@),.J1Z
MF+A68]V7FFJ,(+)ZE=5#+R//5^4B7VJH!+MFYBI-XTF#TXC^9_#;I)]?Y&>+
M7.F<_17K+LP:76U_J5\5C]>Y$*KCG\E=&=)5M"[\,)HD5ZRZ;WL$ZDPBPF T
M*S[,IJI1Y;=VBPB0>,%KY(%H7_!Q9W7!H1)5E?FI:9>L*S5UXI]F&FU_6$H\
M<4_PJ:J3['MJ3AVV$26#6XCBYH.-?+O9_%C7#9RS[[A_<F?/IM))(R^13S(7
MK!P#;#3>DYI0K$8%$!2N'_*E9.L(1$=3.I0(0R]Q.?Y2!# #LUS .S(3S<NX
MJ\ @N$YX6\T WE*\N%3,E-0SP,$LF6KAY!!K;#3CWM+2LAR[@^6$Q1F1DJ+D
M#7T>OEG;]WCC+CKVO1"PU^Z^<012<]YL*5X1SJ-B8BH2KG[[O>F3H+O;+GX$
MNE8,Z:9!;GY&YNY*.N\$88:?*5:(*F3G!38>&$B*&=4Z)@[W79(@\T7^S$B^
M4)#J51=#SU5.VL,7QI6H7W7!LJN+M+U7*/7,9PT:>41:2E9Q=M=R2Q548G[B
M<&,1(B^(=W:1G:6!W"CXVYQ(-^U.W^+KV?>P!*@TK:#A;I8%#EIU\6+A<''<
M 9:Q5US]'6XJ17&WL]B%O_P=7_C/O&L,:3+L]"E0;8L['B5S[^:2Q^831& B
M!Z0*T&NW9R>W(;>Y11K"!S%_N[,I%-@#A@Y+F9?S)_9]/8Y "?#%@X>(83,(
M754PGQ'[CY9BX -Q."#,09HUX:]4^^"8L)?/S%/O/7F2''1RA7H%V&J?=(QK
M%)A#,Y:E"Z+Q9^OK%2>_&TFBJD[KE& ;;A9D9(0E:@@X6[#4"K8=EK*#R5<J
M%Y^W;1'':4ZC,;#[,$TE9!WQ%C-P#EQUKA1O]**9?70[1&H('H!/T*ZR-%0V
M'G!):1,N'5T\?CU2+B'[H])569M20O&[8".2344 [G5U X98:A&LYS'66)RN
M69O;TK,.^GCA[3D!KYOS:9@S/XY ;EI'((UBZ6YT9\J!A?0^PP35D"K?05$B
M+[PCJWRM%XOU?=?:]:#:\H5NY]*;&[ I 9Y',MD%OGXN9Y88DWY'/\O_B/Z'
MM/!.VFV$_(L87/K??+HU&?&)UF9/7GIROT[+:\ &%6=:A?[%;('$.%#].,(J
MMX_OV'QHVBWDP%I=&2E]%'/^27A*]]Y').HBC33<RP\WL82'.]*_3E@C,69'
MH,$$L_)WZM77K3X.4D=IS%&-WNM%)H G7])N*6"HOSS))?N7I5_Q_OE*WH$Q
M>)]QDN:JDE3Y;.V+WI><D"ZM0<[5A50Z+$%SS):)R;"*J7#&L[?T]WG@L8+B
M%4 &SBB2>KQJ&(*[-+ZV[J<XVJ@AXFI@X*3'^B(^\M6/MZ 374%U)&E\6@/!
M-8D7".Y44%!&QJKR?12-+)!*7AL/8!&Q\?5NYUNX7YD<]5)7CB<XO6(-/3FX
M/G68X9I5.XDE&!P6G1%!/K78Z9KQ))<?)VT0SW"A6QH\P;"T?F?\N+Q!G#7+
MW<&U^2S\+D3A%DK[SMMOJSQV$RQ8E"%)A8 ::)=^'I3=#N%:[LUAX6LR])#(
M-;:8%7<^?]PM._..M,AC#P&&8^MB[D:^U-'H,F2ENQ=&Q9)FJU&:K<;_.@+Y
MH3N;[R7MA@(%N8#B3: 0KT;?YD61'RN3G-ANT,D^L#2LK'U6875[_I=G?%A/
MSF/>?634X_N-8VYNMA2-PY$U5IGA.X/4L;C"7?<B]3>T)RN7")>]<8+,T71,
MX%7L=!Q#&<4$?0X3(RF&GR&R?K_<B=_</2MC[:;T58_ZB!R?-J!6_+UJ8)(/
MGQB'0S+"=<BFKW#VI(,.[O'JU0_+QH:'A84=WE,77LTDI5_OMN[YI#SO*Q?M
MP1*<;8%T:8<L\#G3J&WHL/A$M[+[QZ\#OW5XC%S3C@;#XO#CE:0#7+R@8-A6
M6]J]&=>@FIAD9SM]L>ZPR<OXBS5<#'&<\8*IHQ06H!C2D7UBUGHER#=(.GH[
MY#9!9[QJZ:>,"/?+SV8_IAU.7'R^UR5WMHZ_I"RH?#=?&$*6K"(TLP/#1R"7
M6Y %'M<C$+P&P$12C(%<?"WUDA.:M5G0TED:'US,+!]W:-#.(F[^P[SXA57^
M$]F&BAOSC^FMVI%5U74X;"26 ]QA(?K"1IVDW:Y@8O[HVT+GK_63+);1O?!N
MSHU%)6';'+.P]9#K-&(XI'>';*3]G4=_AX1#>>%OL$RDKDYW:)MR5#LK&._J
MK.^#DY3!FF<;#PG#B#]K4OE_V2GQO GZ(A."Y_,F"(BC =M/L*AV089A/RC7
MA.5R?1_%W7M7H4>C.F'*]WZU_HS0A\&N&_W/0#G..A;B[P9VJR#;K+3JO-ER
M=55W-Y]V@?I]07'M17!1=)K(-J6TG,[J.C@U"2MLXXV:*!-&,=AGC1O-6EKI
M,(LP:H7)/.L96WK =;XK-_>PB)N& ?D'AG^%M?FVB?C_&JG'OB4D0(QC-DJ_
MCA ?9)QE!,W[3&7N7+2!_+$#Z9-JXY,'3TJ48R_GS)V\4B=7!:HROJ_!HBUZ
M%F36"ZZ*+"T$C';S#[,:M?&NT27P*V<G42^;&IY5DU8XOK[_4:$J?(WCLOV*
M;M!^UF=5YSD(&T6'1!Q_CD_@'; >*HN\]*4Y6I^/D-O"?^9'HC;H&98;[<1*
MC[N3R9CM>9JL&$O1#&9-3,'-*/Q4'_.U)@UO(AZ]"E!1FCNV 96@/".;L',C
MQFV4]/.$-4F=V7,A"OH@=>NQUO27WM>I7V#(J_L-.,A:&ZE\SGVG8^-Y(WL!
M@-B?<P^NO9__QGGEO:Y$3^'@:59G*)R)Q%B4 S3<:B0UI8ZGXGL_-(\3GT[W
M!BN=/)60\A(K]+CL>M696-"O8'Q4JQJG#3EIK91TV^#$I4'?;Q\P.S<N@'0O
M5%3J#2J,?$O6/P^V21V>6IKE(C,1R24_@/>2JEIS&R?,!W#NEXCW)8F-RV"B
MXOU;SQHZQVY^A>>PI6Y0.0&>.2B]B\6EW%R8-_9NXY!O^9J:^J/9F^YK ;\B
MN::[PJ:3O8U*'P"H V6* K!6K=75S#[2>'M<Y##3LL A[4+01]^+U=GKBX*C
MQTA1'9Y\2VG4<X=EC>9SO=&T0O3X:D(!S&)V_3M79=,H]/2LT1D;/N8KI@ZK
M-<T^-A7DN!9U)A*U]$ &+@?X.!>BH[>/0!P3+FGIRD\[T["WJQ,29D;C,WKT
M%,(>X7[L"37G-=.FRZK5JJP8X4A*2X/+YUFWA=CFYQ^3S,T4N@U)JST>UDZ9
M./[V;68NJ6;7$W @F1B/[K#3 ])W2#^I^<AA#W?[2SH\_8/?]1\.J)C1%YX]
MMBF ;1= =EC4=()CJ3Q)N*3GOH;J^P3M41241U>]H&CFS37[%J/KQEP>-V\U
M*LP]TR^SQ($CB=+- H@N06;RDPKI%ZJ:7I^ M,U^ HMSH-_6M/F43/;KLJ<2
M%5E+-VZ4?Z%H'0A2N,F."1N-T&**TI ?^QDH([=BRJVN/HD& QE'6SM(G,?Z
MKSY/6-1N(."%'XBL=VP[M&_E113,'<I<QGT97N?*<$_E=G&#;Q@S\;!F!X%(
MT'CL:77.B>4C$+^J)<Y:1IC@R0A[N&V /6VN7=UG@=./Q'C7I$O$7+RI:6QR
MX8EO^54 3<(\&"$B'< 1%K_WF_K&W5C+^I7>GO:!8# J+Q[LU)-?D7<YM4:U
M)-9(9&\9ZK(, 34++"%/>30+_(!IW4&1'HYZ<G4F\$/K_KK>RTV]Y!8:P)G%
MI'JRX!.B#WG*KSQB']E6? 1B=*[)8AGIE-C.2,V0_"7FK:0R]J5OBW% +!/T
M*PE'S2YS@E0QQ:E?@*7CN=L.H>8DLQ=2I7[N*BWU5N-O[.P76J6>/'7J%;_U
MK&Y:[;K-NP,0Y<H(G/E ";"W3KF;H*J/C[:T'O44B0]<VY,8_N0A?.%J[;$@
M/S7]<M-!I&-VE" WX%D$,.F1(M]] '1-(N::1B3OO_*XCW%EYA=8TR.(5FY8
M=Z;DFR\I6V>]*YPJ*$AX>\73\SC2_\;8S4])CT$Y[&\A3KV62%[$$+9R(_S4
M=2-^BW=[,>7"L#;PU?'IDL!ORXNWHP;Q=0.A5-9AQ 7$,%JP^;*-\_C^V_J[
M>=P1VV)IHC"\I:6?;* ]./B[71W_G%WSVUH@!+=:+F .]%M+*:D:.3[9]VM^
M_WV*4.//1G[^KE8B)TNV0Y -",9AHW8#=K,$A_'#Q(V-=7F#C[BGZNZCQ'IS
M?9&W%8N):I?IMTQP4MD$?;0C^ARP949>;+56U"9K[U":1=YT3(I@,I/O;M;+
MEZR+,&3H< FQO+P&DE_KQ2GY9I]%=$.84&K>DC;L;!,#^#=$_5?O#5Y4AHI^
MG+ITGN[ITG1"N/SV$^P7:,M4=G17ES=%94B$;)X^H!RN^;87\_WZHBU\J\'#
MI]_5$5^S=D!:)43MVI*Q+VAIA*/ZKP4#W0;3F3,WOIW*YRBDO^I]8UD#?!FN
M ?06N()YFV_ 38;]#$*T= #+.9W![8,E,%SX8?W35[N?<9&F9T4"&"NHHG#F
MH>;SU/;L4\WGG/?5JFS$R9T5N<Z8@#B0(L0UV6G=X](LPDTLK:V<!0JM69LB
M?0,\H:1]0-8P[A:F[&+]Z-I%TT3Q#*$?0A*?=.A^.4><!TO?7MXY D4U"Y!U
MZG S]@^'"4VCC6K/]BRL-F6?CIO%=_;G\'-^?O7M!E$#?!TN7$]*K#G00PS9
M2).)G7_M=T5YS@V5HE&3:O7^B=4?#UY!U_,3A\_9[E5C^F;I2;-Q'Q'?)U/3
M(X0LU<1HV;)C::VJ]QG(Y$.7-[/&]3T%RSM>/^01H;"MW<? 0S*DT]1&@FSV
MW/>=9[M"+(?*P<<8;R:-N=,B7>YS!)2S,QA$!2\I(U^LT;3),FDQ"3->L9PY
M=WYB=\+HPN--Z;YN%>R&X\8]IA1$W[,D+L10=I58?*@NJGK,K5'L<>\12"*Y
MYT?@T"*UOL<(%7+=:B^,"J;YTDQ6KBNN3TI2BO4FU?WNLM!3=;_1OGKS1Q5B
M/J=EK5E!DF=?WZ,;TM?^OP[D81\*CT 7Q='[*]C^II)#\0YY'9:BF;# +4O2
M0M,I<'M_4-/)46,/*/2G05T(,C6HGA^GS9>.^?7W2QHMKV5PH<)#D;H8+AR6
MT7QD]R^ U+;QIO1RY$I 2/8%JM^Z93H&B[)W5C\SN"V M,#('9P@^H4XY[GK
M$,]OU%TO&Y5,>?Z\"_2@]L,ZB[;]0IP:XT$K+WM[ (F]@\AB"#@R[% F4=6Y
MA7*9B3'>6O+?%395KB9\?U1&"GRLXRHVAXSR*"2!U[ DZCISLKRBC4QSS5M;
MZ@"+BD7,L:5._<'#!YA!=:'#=]3SL(:.(Q#I]:K@R6$4*ZS^VUZRCNY?O7OF
M@]=TA<=>9ZX22,T)[+'@=J\?[9F$B;(L3YV PW=6M=&GYJ0(60SV:SO2?VU"
M8[//R1^!N( O&[B MBNXI/:A=O040K2^I8I$D1X!$;[7/K[[X^#)]5*MCS#%
M74U W-Z5'Z/(&U(<YZHW1)GJL]@W[5?&%;SJ-WHLF\6@BS>:X)P;B)=?/?2T
M('%%YA5#OV.X%8VMK)C2=%:Z.)[_>MB GO#$B>Z%NZF*><V]X8$KVOJ)$LLR
MG[[5/;L)$FCA\! )54XAQL*_" PED=)Q_4VEP*Q1+/2,0XT1M[7%&T.QMO%*
MY@N#$M,_\_I]1(A)[XY )Y-V)S-2=IW(QLE#D[VB^8I6<R'ORNQGF04JQFLH
M3 ?7X)<!*-Y)51L'99APJA\]L<PU+WOG>^S*_4[!FTK&NL)-_@AUDDTV&?QU
M?R/"3]WWT*[?X$HTSU7^Q]?VF(X'Q\++7WTPW%$UVOUR!A9.Y3(*+9?*&U)5
MP2<X7VS$T'WJ?6H;]3W&?=XVNL"?3VN'AU#J;4IEA$9"JQA1<[]KTP"J>$JG
M#5M3%M7PZ3QT13FX54&+FJRS<67/OM<3/V^& G2_;L*FYOK?X*"Q0:Q913Z>
MW#\\']=-R9DA#-P3<2>4K%<^'6I=$3'%MJ'#J4R H< PH-7F;\%3WS4I^D*V
M5TJ9\=7$V^<_' 7'I+)EF[J^PZWG!B+53U8>1L\!4=+1?GR0:&7&-V*O2@2,
M'V3?:8Z\63$A<K$Z@HGE9VJOI]KJ.H1IE3>Q8$Z Y?Z8Y,W5&EXK1<Z)R).=
M/J>?:F9E0$('7!8\T8[(2-[T!*8XCT;._ &\M-Q=STSA+3UEO:'('WW] 5QB
M:JL?1QO9<43[CDG=6$_?'V5PK?PN"07E<%FFYR)X;9#"2$.SYJ<75@%V*76T
MEN&*^D4G6@)&7%QIE@$>%K?A(6=6%%)<!"^Z&P^5NL\EKD J+=I.N^-%09<%
M)GH%Q5?[++\JT.IV525<@F6[,J)RSNC,,FZAYH#M?5Q((3>CHI8,X\VRYSXM
MYX5SN3  NI47G-0(\<H%HHR2'@Y[\ A:ZF>$5>B<RB<^ACUFMQG+^_AH<J7>
MO2]B.,-=2LA)-,[+>NCSQ?0+83+L'LY7@QH^>]H3:BVL!0=ND]G#?D+9G,PR
M?]:$PH4_*;.$VS_=JF@:3<IHZU;-^>B_0I>E61X,,.'[ A[5D3%1.T2S \1B
M:_.%$"E6Y_=Z^?5)/8G:6W2LS7;<5_U#V9AXRAKN 0$X=Y.O9$!YXU9E=NN0
MID!5D(G8>K)<Y]?&>:ZO;8X7MMZ.6V,B1G#(-@&3.X G#A!&)_*PO2OLNJR!
MD7G"+*CKEGQ^7219SV:1+C/ILF#( 0\>$DF]5!TU/^(.AY9HV]'A;M$1A 7S
M?-35MFRVK#Q;L)&[Z!-4WB7ULV&>56].0(:E@@>>K=DX(^>,9<&=#9*]JY1B
MO25:I_P^@3;\.-V,[OFH^?<*R<01".- M?OTFR!-M]-,/IG'/S_X2?63067G
MX%%&WRN+:%W0*K4>37WATF3T49%R1PJ]6OGW3^O6RS.#LQWXO'.=\F=T5K2=
M),^^^3BCX03O);_1J@'*#Q[ #+[N]Y?ZX$)4] =%,%6'!K??K&5&$$?NV,&$
MZCKG'V@(I"JYQ6^7T=\>RYZKCCO0@#&U*2Y"JZL5G#^L<LITT]JE]_#L2JN[
MC897N6=9O!EU7?8;\-RM:":*V>?J2C(RJ@0%2+[M9IK49&<1+! QYO%Y_O;,
MVX>&X+G"4 H$=ZBB-0*7+)QP5@ZA!)6B2J[>+)U&>ONK?%FONR%AR*18&>"V
M#*?'!4./PWS:L@0K'QXHO'+U=.:FIYI_O->&#1\H*D]7YUY2S+I\&(6XXGSN
M?B,F/7WV<BR757+?;L9=1J7NEGW,^'L=4U/6K2O?5+T>-7.2(N/FK"\9RFJ.
MY(ZXB=1E$G/BTTSDRFS,?L4H/179#[(+^\GJT4!+\T_)'BD$HQ],=\)O-]>D
M+;8'>63D.^^2]7CF&QP35%_FO>SIF0"WA6?N=_9S5XX0<7;P)?=Q!7N,=P[3
M#F,MJ_!N ."0 QMKM"Z$B>E7D?GN8, >B;*;/=@@[?CJ#ON53^R7FD[KHY[/
M#-3E"&4V#;RF,@!E>RW9GYO1^!#E#C\U[S'YXE^E9<)28O5;/Z5$;4J"G@2
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MX8[AV2_\7J&E;RRN\L/:5'P"MM)RK?W&;@D,:%T3B=&Z!O*XR>7X_\:9G:^
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M%@8)-MG2AO0&>%,'<WK%FGV8W/IEN<)"-&F# G(81K%-JW4VC( <<+W&T/!
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MAB\ENB$.P!;*&X&AU:X0TG[[!:_9AJ<7%NE]CJ+UG,AA*0\0/0K)HX#ZWU-
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M6 ,SD-DZ$2B>I9CJE0ZVDIG>>53WBL=RLHFH;M<<':$(SU"Q:1@%3+-6&X0
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M4S'F+,K.GB057Z. 3"5?7EBR#54S-&Q!W95ZK/3<^\2BS751.*+.\3]^:>U
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MC0Y;["M^XFTQ+M#BJGJ]E3*S77Z'U&VGJT;IVO$/N]O8:Y7( EYHVU)<1V,
MWA^;$X]:Y6ZX6(Z+C?-&3;DDF]R>NBK]K+V^!![RQ,OXZLT_H+-*Z SNFPTF
M3$P7PCV4CXL QTV[-EVC&8L81B\9;4H92U@*T1"=E_</]]<;YZ.8%3J6C!I2
M):!7,7U<J=KM?TYN/#J93J-VH]T;S \WGW>G ?QU1TG\7ZG8JLF9GL%-F$[F
ML-]<&.Z##[M=A\#J! 3^/*M_ZL4_<C[_#1BJ!NEX!PO$:S'$Q[;V&^(+W%3'
MJN*W-V)1KX@W P>@+"3#3)BG^2!)=+; 9<7AEZIFKEITLBFW3*'+29FN\ LW
MF7JCA4!%R83N87=Y\'AE^]!XQYBLF51#UF!PDE>85WR34-6#P-?U!V7\2PNI
M8NJH%V\H(.6PM992J$6_JZ=@(6&X8U"/(_$"F_ )7D/5UZ<9UNY_LN4J8@@E
M!38,[6V%UM!1,[E@Z)QTB'3V:U<M*=52JW%+.?^$S7'VQ?@/;XE9UQBBQU+A
M[(!#CC,%Q)O<H7X*%YB-!9]:MI#OS<Y>BOB2JM)K^0#)&]^V_DQ&ZQN'FS":
M!YT;R$L2K0;L9XDLS)A5_;QQI_:A;KV(3//SE9/W7MB!/VIEG1=/ /5Z;6&)
MXV<MN\1S93/ZU[2K,*ZAXWC?-F0$WU([R^O#F58T!_S*:)&ZY.JYAL\+F.7>
MHX^)22W6FK#QAV^9(-.3,E -P-<:>A+]FL124)2?[Y+,9Y'I;#(J+9H!LWWT
MKN?:@=''N/="!@PH/P>"(*$W8XZ6W&!,<FJDVL"5=SGG9#\%9$ ZWK\RKF^#
MY\[%16.R_,!1==QX,#8,A082S*^BY*K*K)@WRS9,,#?O,(FK)%U\J;@I?/)9
MO?!L>,A6 T]@'YES@.08]0WJ6'/?!?AY>SFA]L]V4//T?<Y;02^-:5'^UY=-
M5T^QG#,>8?Q NS*6+0]7@U4)=YD(GOH,.;MGM% _<;:S@RP)((K6H,Q/\#-O
MR_A[#;;:A"X-EZ-9 >_SUPV%0AGCZ=Y&Y;/F=/')].GA,?6RA*=#$_>*\9L%
MKCF/ ?_FP]RW.8T#9<0)GW)'U[J\7W_.*5[+5*ZE.^\WG[K?C"7^:J87@JQ@
M(1W%JMZX+2-\Y1OO &9YD\&^;%I+M;W"P;+!CLD;^IV@#]U+%9[:-9\W^4K;
M(+9F"S6 88&+/Y^*X3E8\L-?*,Z2TZ&;9S*6BL?C5YG]ZR&M9%!4"X8+F>ED
M,IID81]:8S%AV:G\5%CS##?Z"V?&/Q%&WNB3:U6J:\I[$R05"Y"[K60**/>O
M2MA_?_(8ORE0^+/  DIZLTX!K9500#(F"*Q0'064 ]X_@G3D#I=)?-QC?&9[
MENN1;<0[//+>2+='Z=@7D<WZXQ-5?Y=30/EO<"WJK871"\A%:]G?]T/ZA1#/
MK(V"B:3&>:AR -RNVB0G@#/C*-1[C>6(#,5G_N?MK<>#FPZ#%N#?IM;?J9G1
MPO'MY.L2:#/$UC8%%'-B*<ZS*?#<BB(&L2&-/R3/=:Q.]Q&L3F*F]!@EC=\4
M/R%;LH9C?C,PA%@[X+8>IQ',AP//PU@>XAC>EH][ZS\C/AATDQ.\7+2Q]];M
M!=ME.^N+=L0LW2 &-8GUS(RI"AK86T&&]"JR5\%7Z[SSJN?!NF.YN=;O>>2Y
M1P[ L^(M_:P U S0Q!J>L[QW 2<=5E2N4GVM]X0S=Z*<A^7_P]Y[1C75=6VC
MH0@"0J1WHE25)KT3$&DB3:67J"A50*0%"(0BO0D(J$@'D2[2:^@@O2,@A(3>
M$VJ$$ [W_32?<][W&^??^7/&R(^=D;WW7'/.:U[K6CM[K96;P=X7': BX*"\
MI!QR]LS!I&%M>PT]QRD_A";L&[K0+4SQIVATKNLQJ@H Z*WWSL.]:UE#7"U]
M?A D0]0:K=7N XN&LBZ90R,Z<:H>=0&HDG33QM3JASS&D.!5,0?Z+@U#:61+
MWDZNE03ETM$ NT1I $I+5H!<ZG(\1T)@QL$M<6NYT,HV9<HIF.!B//7&]%5/
M$)VJ/&1S^B#P*Z#.YG8<+WF*0H"+X+9;]OSMH6>/Y)T_JH!*Y:HL:E^EO/V\
M]G'B F!^A8]5<A=V=/;*85H&41D>X2+\3(8Z_]?/S3<]&=\ZW#D2,W&4Q#/'
M78_/OU0U#OI"0A>DJT9%8'8H:G(CMB^%.3\+TH5&M(&[+H^XW6Y'O)OS$?!F
M/-3(1DD4FUJ967<XNSMXTJM*BMYAA/Z\WJ?A>]W-%$(=P&R)E\98IZ*^5IM,
M"GMTV0N+B*RHWE&M^X#F!:4]1\EP96LRM.W_J/8'?C2YGWD<C)N_[)2!(9+^
M?JB]<!M,UW%D(2YJ2T?>N0L_OG@_H;65^2Y^L"Y.YK731USVF1STH*T!TJY$
MKH%++=[\9)R&5C 5OE&-F<_2Y;MWEUF@W]KK(%,BV#1IT']@5GCNC3F_;#?L
M:/@@C]#9  @<^<I#3B^@K]=\BR?EMLOKRY'>!]7+[-"N6]-/@*L]A<UWNW;U
M2FD^ZQ;[O AW>&GX7>85$^T9=L*D%X@-T<.E8Z5=K\,>85([25#S9+C+'DL&
M106FG->U]9+I]_?XR>51D/A58_*DO 5<X2J=C*09_T'VLF>Z5/18_<3A4B\B
MM@B2-,;)U;(1,+-\: @*'R"0J=N4I)TXL EZVC*>MJ-@9!;,[D4:24/#S/H#
M8#*8<4EDI1"8U!C,'1U+=O(DTQJKFQFA:)+50?0)6O6U0[BZX+V<9Y"Y.#:N
M!!(">7$!>+;@$W32@2C;4W+/?#Q\"<8&8U))N:$W=I8$GRS7Y"-%T/&S\3D5
MS%[,T9-Q.\S)VW*8NGOANJ_S,O6KJ6,+9O<(BP\)\U;!'*]]*?//F#H$8=16
MADO[SD?S?L93SLRDMK-^7^S3,@W$!6>4;^*EFG%!B_,6'3W&_OQ*C^B=E59*
M$JK:^='JC_2O]2?/3]AQ5WO KQ2$'_IQ"NH%SX[K5X0*EY8N?;S7Q7;+R' X
M*XNQK)H[IPK\K:SYV65X^B^ETS,KWXX+ #P5;R^U&N^N'#5":&\X"K_D-U'<
MZ+\I)@LVNJOVQ[_X1^4B%:,N-BVU;Y[-?K\-;G[D>^XT410ORLS'7R+,8*C:
MRG\K/R>0+LK\%M%?!_38$E<F:(<&1B3(O10:;E0UZI'FW^)Y=-C/8+C[M#A%
M\5H%R:;ZJT^X$P*E$I:NH[V%%F>7[<ATDGH\.QTCM)K1HQ?3[^;.6"CQ^U:(
M0DRBT*6@(QYV!)QZ=X-I%>4P>ZK^[EULA$S4^4TKGC.7_-??U.M[*1L_Q"1J
MM6X]W@B0':DN]?5GZC'[WCBYL_.\Y5,W:X@N8U/]?O[+3<::S_339"UJYY\\
M_,IGB]'>$0'<,(O8'"PP^,A!<EX4U=4.S\6]VKF6U%<0^<7S1J184$AMC5RI
MTW%(^.)4]=D]&,3H6Z;19).5S:(5L>Z#QYP96_;$J1_#N6_-K-GR9"9Q=@'\
M"7)[IA6X_OOU6*F3<.$C"[/J,T'H;IG'SQ4RZ/-W">S?/2D[.>BG&;$F[<#9
M+<MJW,QB/)4CG/6R*T_LZ#K0L9,J#Y<<M5..?LTMSG/36-F#M_#1<-BZVU0A
MSGIZB3R>(!(PIJR$<T8K,;>GI)Q.^!HU'Y<7^-=7DXT[UTA])VY[]K:"+^]W
MI' KBR31R5AZ'_#KH*:G&V=ZR33]@W<==*Q<VC2,#-<2]9]>@3EC@<>5V-@+
MP#82$][=(#G5<B6\6US(_"1:Q&-Z0A@F3RR]<8UG3[ OU.A#*$G2EG$U*!;$
MH PB#" 8\+IH,"W.J8?6X?@.@1Y;$\W C33VF>#FG2H:^/I#,"?AQ%0*X&^!
M@C,Z6$N."GF6DC^JF9)T6L?/69S)W7\W\#FVKR-87,%HT.9)]<AA8[,&85-0
MD$HKPR\Z+8R*P[ HQ>XY% #0%AAK8<(EG)DX!C!APU(Q<1UH<$@ S?PZ&W5L
M-P*M:Z>O';V@P^)::39+7.$,\OG!X[((&+8<ODZ8,*_M0OP<1B]\="_=4+Z)
MY2LK9@YQ5E3+RK90LMAQI5.3SP;S,":'W%AD7 I1 ;EN7 YJ%$6+K>VE4Y1O
MCKN4>6[Q3WA\?59O[+=E4-1M'PB6!VQZTR@_LY*GZT^"<&Q(;V41Q@E\=:/;
M.^7"+?1XJ:K1;>&"!AU[]8GE7AL?R[<Q/J^[4A0!DVL-H!V?I5CZ'@*1$R(&
M"6RY.0]-LZH>DP*&M[!^>W3J:*G<#169['_P7'8(0[16"@AX.VK6PCW%@]D+
M/Q(V#GCZK3IE5<]M/X<)G%7^]A5!+F!,&ES)E88],<*2AZ%&A9X1)M/:$QUN
M#!=M[('[]EZ7*'Y4K+4JBHX!F"9J90%'* 571:- S,I\6\@JS;?*G#"QAG&A
MYPV8KN[:TGG'&J2]#F/"E(+#55*)Z^T/;]QA61( 3&<"Y]B[,J\$,,$@:3T-
M7Y*71*]#13O?05UUIGBJV3QK<I4Z;W/_[BUI%V-:15:MO;)K!O@WJ\/(,7O'
MG5B:5*QWJ[QQ+K:@%<DL!'M6Q)_@G0-UTCL3.A7ZGLNR$J;;.4A91]FM N2)
MR5 .QX&Q=I:X(&S:TA/OOZ8AMI.CV.>LF/750]6H\D(&6NR26&5% J\MNJMP
M;:G#!,AW5+'NUC@=3+_Q2'Y5 Q;2J<\YKYYG-NS$X=:3H\9;T.=>&[325=<?
M/&?!\YGRYRC>^4QK$\*E",$$([LS&)H3D0^KI[Y@O8]9];?Y/GZF,MUI&K 4
MF]NOBE$VZ#P(4@$Y&D+HH(^/ZW#1[AA!U>K@N8=82%>Z7U<MX?JH"#[)V08J
MG.^99)C,@*_(N?F\R$>6N-&5 C>]!&S;B^.ZBK'K1#"M7P"N5T'8.SQ2/H5E
MYE%+^TOO7^T,4XH:X(U,O2'602S7\QI8Z$3?I2PY@J=GRN1O+)Y9QVXR5SA,
M.?N)=XN(Y/-J4K[ #W5RW%I&MRA"8B <! &HWY)F-$P4/4C>MD".B:OX^B6A
M$.(@Z"=U*&V(QX;V%74.E'ZT<'_Y#3#K5%*+6T*#(C-NG*<>HIP*.D2C#S<4
M#<MG=>V3?AMTV9;%4KRC9SU8L;S; ? =(9\23&S*<' ZZ$%/[P0ME5/ V_71
M"=@"5&WX;I7/ZAFP?0MJ,RDBFAL;H;72I"TC-$;32UEX@^ZN4]-Y%OQ5?S.H
M.X,90Y.P!*&&W9Z0HB;CA)MB!2+19P;?S.[]]JK!O*#@YZWD7 ;D3@4JC^6T
M/#N/@]L/ZBR192\AJ#9;[HPJ^KFC+*(A/%T+H)#>FHF=71ZA_!S2B&4-8PW
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MCCG:9J<THD^:^N4CNK,]P!O%?^]D? '(2+9Y= %X%SI][@D_OSKI^[O&/R:
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M+TA/*^KFS3JQ]42Y>!;/S6N@&?S2>_>OWNO56-GO=&0F?1ZBK9VI VWL4>;
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M*G]E!?(+O'-Y&L<"_/#"#6(/;U?WO "H<*KMQU]JDUP"G6#Y*9$CZ#T<;P2
M[:%!(9?ZLH5JDXL!?'6LHYN+8EQ1@3E<!$^%%KX_JT(PZUO0.&.%32TKHPYL
MZZC!QV#L'OY."F9GY4O(BQ8A7.1+M#-<=7275?(<I!L[I7VSYAH8>H:.>0>X
M$DT;=0;ZVQQ@\V]S?^U["!^A,L#G7@#07TE6X]E@7+CL16 LEPS6N^-2$:CU
MS&K&!@PK'K?PUYT)S1K],KS:U.4JW-3[ ?#@&D=<2ZWGWLP)&A0! V-"-*==
M#ZU<=&6Z1G'173+R_I^-F=IEC37#6&X:79GD%0L<3+GY1M>?\3+8G/\.]C\
M=.5? -IWC4&\!''@53# GI^[-&DV: @[M$Q87S]X$Y5?W3B^C<^O"7L3R$C'
M^XKR(.:@R^@[#H0-[P$S*],ZM=S P1<A1#B)=O/B!4O[#*Y&>CTSYYGGG^MB
M&8KJV6T,$W[P3D]G8A+F_^/Q_PW_7#IG+K@,?0I"'_+Z2LW[#G__@@O 2W/&
M3=L&SR# Z4?!7C0.B*U%RP0J"F.\NVL6V$<#V!TH[+B*RQQ,$I46:IU<*Q)G
MG*."R-!%O'P1-SA,QK@4,0OQ6 7M$!TL^*UKM94T>YWH4JWWSQRHI:+^?B_%
M;"L'%XT<XSB\7?,/3&0!A7 03#ED)$ 99H8]KG=V96!K<#@U"1^C(&GX:7'O
M#0><PB%]2$FP>^<"\ +,MIE9F2==^\C!"\XPW2.*O=KFBW3XEH*Q;.2K&LA=
MC>EL@ZZ[S4D=(?Z/Y1:!Y\;$=S4[H:D1$8INJ L .5X9LYM)Q6O-B3DTA/R"
M6'(0*=;JTGV8]+E3L9@8\%S=ASJU#3X+;@=3!MRZ/'<^/%1XSJ)E4HJER4HZ
M9]BSD+V>XN>-6TS,/]L4>YXSB (^F\QD_HTX\O^.O_F_XG]E<6^FWQ2#Z(H/
M$8^&,K=!:/"<TA])?I_E)1F^5Z=U%>4D=:M _JHO=0V_ %#B[5 0.I@?-GDR
M/2^##VN%);0%N01!OL_-1I0:(4'\:[\ZO>:MA_]/C+6?G[E=L)1)C&?&L0N\
M_3*VAHO&K)JY%HP?R5VMFEBNCPU=MGU)6LRY]NJ#DASC*,X.!>[*Y( ]3$4/
M=VI).@M88@BQ/L]00'('9ELTN]G:0VW%$Z$B5J2C*"4 I!<0\=\.:OX=?^)_
MQA_P.]%U!M'= -EF=,9$:T9-PIX5FN>WE(K54W'HN[FO063?*,/(WP'W3-2+
M"4,-J_78Z$Z9=>PZ@;4&YWT!N&H7+GHC5<*B7\Q57C<D>9:)@^,@ZB3SO_S[
M)],(_PM505*9,]Y+9:48FAZ447S'<+@UR_AAS_>P Y/Q<ADKIP1U>>87 S:]
M0LQ^J;;"?3$NY:ZX? P$S?Q66=XQD[:% P=I;Y&OG#Z,MA(U&(%INQT;5Z7,
MO0Z#OKRU9#O5P2_^FL9I??B_2OJ_N2Z+1FT1$HRW0($HAQ9D6D;W%#7A'B?B
M75D;H[-F,QH!*U4OGRA&?<;OOXSD;Q;_AOBO[L?POQ(9*&-?(OH_.?LO4]2S
M@E3_3Z[[%_)(O*+:_[OZ-?^K. #S.?^?FO_U7VM<!.."5](UC[FRZI6T_KI[
M&8G!6*[360IAK/K1F-C-:&*Y=6@9GMTPJ3[TKS=,\L^3F,])MR\ >U_^6N?H
M^_-++](SSP^1*.O,JLAP00G[4M'M#XAU ;L+@+\,SO"_3E?*4^\;EL(-HB ,
M4$3KV"Q4IE,854YG\:O#S\&S_NVC*N<DTCD?L5[Q$O)JGP8<,]JU"QEI?75:
M^<;Z)^:00S#YO'(!]9>DPFK\R4FH].WYZOMN(NZUB;XF8Y 9,?B(WC#AU!63
M>\8O>DHQ<P% ZA(8J=N:'YAH1G=@D.:-YP6[,&_8NTS@+.Z91ZS$J]:^RB;"
MB\X"3'H6]7P/8V$13M!H6EEAG8NO04LS# _.M>RQB]3\<#)-4[3]F)7HN279
MT1O!R3]=UCQ^"#FDK[P M*3A;S61%R[*#\9WEQ/CSCIK%QAJQV!P5+/#4EWE
M]VE/]Q>GO$5IYE*_6;1I9?V+XQ\,8FK;$!'@:P'4I?&AU8-W]GJ8Y9<S;D[=
M;'@K')9G]^9@AK@M1LL]</$%XZ'48?B?A@@_H@G!7O"3<7BHZ)L3:OV,)B &
MV6U]"U>1!]WK81.)1E%!@#]_F:]GL(V4J??Q3@,H=E\D&#&[&5$RB"Y9(*KU
M0XZ G '#!+%QR>0#3]/2%,(4(VB+-VCJ*2)NZEQP]D\7=<Y3V?X:I)@M^]7B
M'C4]<O!D*HB&1EMAX9VB8<I K$D'5;KXOL[;X-,ES<E)8Z1Q#;3%S^M=R,I=
M687 S;O^@I\PR#9_=S1S3+4H/4Q_Y-"?6=^9QI5F@T _ZA*#:7-6<*E/U$XP
M8(;=8@>T<CK--XEB3NYCK-][#-+YL5.#AU,6+31Y0VF7W^Q5<>Q<^9">"[ +
M%(3\D6.&\YZZ(V4U7/$9)4[A<7B[&%2AH]0EI6&GI"%GL-3R*V'8H-V0Q4[6
MM3&V3OFMR8A;635JQ[6C@3\Z:U9W<7W'7+#YGK-*=+1N"*U&PG5S@Y_+*4L+
MC9G_*XB9N9W+LG:'/^%U<F!>3N6T]C5>7/33PGNK'ST0;$B]FA-?W9)<8@F7
MA-V$)=+0E\\R)*R+%\$D/9A,E%<"RI^,]FLZO1[35*3"5<*H>/";M9SP)-YC
M]DJK"\#_DF3)Q;1GA0?J:ZVN]&J8'M6&6C].3;1N>606]DN>P.?\EEQ8B?<<
MZ^O7T>Q71RN"OG$E_X3Q858+,,<]:/(8F&V*K]%N?>&/<NN?L\-K'3:DKXM(
MQ1?)_2M<;'ODRNW^L/,26M!J+A,K235(;UY?B1C;NZ[IYCBF57PGC+HJ(?[]
M.W&%?1I5[N3%ZGL36/C/"X!:TS><!%?%5S5>YHQ;$WLPC5'M2;K51Z/^P)3K
M%X#6XMFM>TI,5W/OZS[X0<MPIVB72(4%<.TUH #^HNL"H*H /MM M!=)1(T8
M._\:S*E"_"]U=:<Y3RWY8[63#OG997TWBAXPVOR5_+]7_;DL<.6T_"ZN?$?D
MK''9_2*OPE>?N=+OO)2=.24V=IH(-_SSN<U4RWB.3"WIIG0?K'MQ=RFIYT'X
MF33HE,("OH1$0>3]/6SK#3/5[>&VE^,'54%7O-]E$@;#"<'&2-P)S@"B^/!T
M*8 ?=A.3V4TMW]W3-6LVZ?S*17GZ5;2;$+^<5_+"M5<%LOS-5/^YI^;Q*_ A
M7<T%H ?1'B2GOCZ<TL1^QHGS:X-7U>+Y3KWBG)MN.V3=2Q&:K=H?^)3S2T*"
MT4[H2:<&4=]:C4^9DS8&TA,+1A\W+NTXH6K#8#8E'Q<X*760C'EW-Y@@'1QW
M(WII?C$EW8P<?G F^#];#6%F,?^1(8A"4N+ZNR",30I+HBSK4VR\YN#PU9IH
MW6H$<\2GT,X+0//3GZS$+$M$%3_>*!AKU.?A[3"@3GT&QP#@)8GYH\JO:Z4R
MG<(CI+RK_.E>!YD]OM.&XB6I?@W=&O0G.4\#GI.6(K![E\3[[T:H[+";K_6-
M$@:X^$8(S.N/'4[GT]>Z='DZQZ #"[\$^9(G#^OI57R38W,52/Q(HK84&1<A
MG+B.):G,3M<(<^,D5%+.AKN#N71H/N2\CNQC<D&&6<W7Y5M&!K(]4GN(F6\7
M@)$'<Q< KK^ZH,IGE[A)KB4H$1C(A8 TYV5-// EUYF]+NE/#R0;TJ/:BN8Z
MHUAZG;]H1Q'-1V6#'MU)[1RFWD2R5,'#X/0M7/,.TVRKD:+'0YE.7WN-QTZI
M(N[U4\F2=G?: ./?!PLB:?YR4-B"<(IO,#8)A1%E0P4TX[5&^2K'J^J6$[5V
MEGQ8;1:Z?MYZM?.H9S?FUH_6K#>5=H'J&-<N.)LRKP4T$]T=GKMN+I*>:VT_
ME<$^5LW4Y!?D6:5W8'G+@-DQL*@IWGR5<#N@/>#:)#_& ),:GL$B=/3UQ62*
ML^,RT7.&<-K==_B9N4ON.CH:/GZE"._LF_"7N:3^/_(<33E2'<<O/74(IK.7
MET[(,M=9["V)LMQ\#$E0*K[1:5#"2W_C#AG$2T//J2T;9X$-1PV'P\PP)ZW'
M 5P3BC?+K*Q^.2QP3WB27!F*YYR3T&>?"^5WSD]S&2/GD3J"_V$H?OLG?)W/
M^0(0#P\E@947MN$TV\&88F7&#6M6S#SB^/TGFO<U7M=_:?&<W8_X8#4 -1B>
M^+RD/+D\G4D$T_Z"E\2D#X:8;B*O'R+H!**KI3)<^:D?86M]L#Z- 09%9SPV
MK?O3W"W)_ZD[P[_AM0._A%<62#A1T09E'%X($\(@XQ6?+3VVRT=NGJ8/1^P)
M"]L=9'V+?6[TA&[1U;EBY<.U%]A+@O@.#*^F)E\T3O4LNG=<2[C1W(1E>*=U
M=Y2J/J8HG$#\A""US74+PQ^YI$NWICF5?\EYNUZ_CP=VBV\97R-Q;N/A25;D
M>!HL:.;1RVAD8E"M3L*NH4*2U<,5Z+:C(F*E&,5@'/Z_!(?L\_IP3M6?V/R3
M5T"*6AY_S(@Y6FD(2*-$SMV=$(X\8+XC\[)^8[S4-^/.7R^.W!:D4F<P>'U%
MW4W1JV9?7W [2DIDVP\@KK_RB&T_<[:\>Q!S<NR&BRV_[^;FG/-+N(YP.'8S
M[JY2OWP4X "!\R%OY?*"UAI^)&$\N(%9*."6IB!W$JZ_)KM)4>Z,L\/J=""8
M\2 [-)S*2M\OUZHJDF&:*<F\_E:7A5A?T1(IEU;Y!V4J:,=Q&,X$$]_.13L.
MM]W2Z1=FUZFMC%K5!YEUCU]1D7DOQIEWQ*-HVY Y"^Q&TGKJ1T)(%:\LSC^!
M@CM/EVOE6VKJ+>I*2Q8#*6CKB UXD^\=7NN3Z%8'^*NNEHWXW)@2>(OWS()N
M::<]P1 *R4H+U-R%<ZTLZ$9_5XAI,\BH50>Q<KQ@P^V"&7$=J-W\,RV<PB-<
M-EJ?=GV!&?.9[9<U=YTI67;!@C;#F**8?/=UZHILH[G]7733YG17R\WS2U%K
MBWR;05.%K:EKV.ODKCV1SSMUF 2&.RLF?UK;3JG@7WT^?LUEB*5"( IPSO=+
MR>%:EMN0O]@@3/!,!@]K^8[[26"OQO;$*O/@*-?4&B9<JD%LZ^(SE@XF!L\B
MZ"7%PN/NS^\O!<M/"5QF.!+,< B?20\ XQ#=L]V%O&_FM5%(LM;1+J>O[&FI
M42,+RO.[6;VA1F8J]ZVU^0/!JK6/?**G%4TZ"<IC!(F (2YFS%[GN1V:D+LD
M_%S7NGO:&I/>54*1K\\YT,_>95N4O>2!W*_1\_H<--:@8(0+.C.!SO54KB-H
MC\K#K*]@RDI%@O(U477H,[U<'\IX9;0/K_'Y3Z^?/  [![DL8*FY2@&YI$^(
MU#Y3/1H8RS8=@2?"W,3;V.1!9ZW8_/VZ,B1'=T)DQW/K]F^>B6ME&SM8$$6R
MW),=<F+2CU6^??Y>$8)]W,$EA'UYTCE/U4&@UF?9\#YMST%V\>@YA^8-LP7V
M[3O?_':5-0M8(P-TZ_9A<.4X&)* W(::+*[U_!;""R]])(CI@Z-%RH3+I3(I
MD!8:GRC-ZZFE2NXD?&0<I2$-C=/ZT0WMO^22SO+9.0-L:I1'?.0IH@-,L2'?
MO!"-:@9W8#H:=G;2^A,W=^99&B2ST%+=#%P^6<!OWO&^^E)J-E+[0_GHX4@J
M;,@Q'.=4@@NF11N^]$,#6?6SZ&JF#2RZN2-?]P%3A<I[6U<<)PB*V.DHN/T%
M(,:8"SC!V_0=H_]6>'N[RLR4RB+V#>I%.N>/;BU5MC>O)51 >KLL/] )^4\V
M7XM]/O.=;@=7,D<W.:/U([@X0EO$MKP)8F^9L+4=B @FP9>\VI4GB0Z]"201
M*S>(6=^7/Q)<=YUC?]PT<@E&2(1\63I:6*>#N2'@(]]\,^'=9BTU]].>Z[;&
MK0G!V:U#+$L,1",PT?/< !#,;KIZ'M36@)W:D]28\1V=U7M7^,MD.7F$-^1&
M?$*\FO4[/N.-1"6G1<WQ7<1+X,PP"A&$7%)'AEI8B"U ='V<C\^?#Y$05Z4T
M6%7=_0R42A/73J^W.; C0I!=BOI^!%%M=W\J%AZIS(=C;LO@JIUR=FTR*V 7
MUA99%KE2:2L[DPOC$63@X+IT/R"2X23[I?%>R+KO]$I)9K5F3-4%@-H4>CR'
MCH]K4L4RY@5O;K4Z+?9'>+#:>$.DA\1'7C[(E>87>6,BN]J2AR7+7LJ<E5@*
MCVUB12'9'3.I\;2+;LY.7QW9KKG![3?-8T8I:BAXC6F[V,37J%*$54"/4XC?
M:;$'3;6HXO+1>Q$0D@"*#2X0%M%-#=3"4J_6'+M!2\RTW0M_;=CPL@C3<7,=
MN)!PO&(5X$77Q\_X+<V/P9RQX6$[A!NX8C1S8!6"HC;";D+1*3]-84[A;9J-
MT*M1#6M^%:W?;N]>ZU$#_,$R._2++!Z@ZTX\9HG^8-6IX7!/"N%M%S[[\HX<
MEGM%3#")KT)97X>MJ7UE/LEN#0;XXYFG%;5S\1+GGZO2!9[4C7G&1[:((;#6
MM5)QC 7?!Z:%2M\%:.I7%A; [F$1G7:X<?2Y:"><J7KO+==MPH0]GNJ9CPT;
M[O&3&E(?*DF"Q5ZBVKO%[]^& 9?I/R6O>P$T][1=1\R"9GRAD\97)A4C"%/"
MVG=_SVF<OPWTVIV/B?LPZ#!";*BC#N!CJ#+X?W5@$KD)V:=K[,$?N2P<[3A;
MWRZ\ /0^V",TU!Z4JUW!2F24WZL6YF/<_(P>,U0'B/[>L)R,[W2EV;16G( Q
M.Q1INJ&=Y2=%7;9M'CT4DVM/>>5,>@'PEELV!O:(1E_'W\0H;(KER9@?X?L+
M[&LD'E0(#RY_OF'[G#@GIE%,EK)@PB0$1C0B"0$0)MFJTZ"9^EBRZD+H(ZK2
MQR9Q! 'YN'R^#LG\JRYN)T;D-XV@)6M\3"7FYESU2_#9.91K!X(1B7.UPE(/
MR _&C;I?*4OR]N 6RG[/%,5O^4Z3M6R#P(OS H>K];Q!?H")'A,5IOUXZO',
M1>5FS$OOD-[?6D/0+FAL>%MF[%_/$_APT1T!8 PAW;W<B=[I]8:X ]F*RWON
M(C6A :-<=@.1ZQQT>KHFTRW\VF=J,':<H:TPO%($[U/:QE3@6/"FASKMHRNS
MTKC'357P N<F0_IV3__/0T@$I%J@ Q+ZZ:@F$FWEM3ILE#&F<%1=.[9;9JK*
M[Z7@8UCS:Q'C4X9L#5 <#>"'6H]W*G/5I^QI-PA]ZY>J2MGMT@/N+AL]ZU52
MAQ+R,?KH[W@G[%H,7G1IGK[]M=.W6?,9-9&$X]^P"(.=J$<K]VZ_Z5GY(4<>
MU5I[7BS5/QR"T?3F^O@,^_S$O![S_NX/61V^IJ":05^SWLZKX0/+1ZU[VKI(
M@Q7CD9-2$K1FN*(A>H\.:J,]R=,RK2BW'&L\RR=;+1XF5OC*6<BK1H4WQCUJ
M \Y!0YC<AV^7HRX+':]TGDT0@7IK3@M+6<U:!UX 7,Y>O?GQ=5Y2HGF@XYIW
MA9?0G'LMC]06J-HNVA5/?P;&M5\ 'B1D3ZS5ZBK/OI054^J,IKD O"('YUN^
MA/[2=;+);L;-+);*M-8J2S1-HZHQ74W[%IP:IC]Y$WG#Q"MB;.]9,K(3S<=)
MZ&"FES1#6D3Y3O#<#3US:Q4O+8KE2I=KZL-?]Z5$&9D CF7;RAG.\YJD'!81
MX1< LB8E5)KQ!$P[9\O8%86@\7F6.[$<++H@5'"#.Y1O(#Q4<7$,KS I->]Z
M7#OI&G!S77 QGMZ1BU':5R_UY1L1](1SRL-!L49+L@33Q=L&3^@T'#F0XEJP
M!J[/R&KR]B-L$.8'UA-Q_&G>_^V/99UC5;?Q'Y=C4\$ Z%RC'+I9)[-G' 3!
ME"=<$JPHV2:(FG EG@AJT>8$;/<#\R]93.<VF>V5H,WP,R_BR&_F)<4N/'MU
M,!XS/6G.>/0E/WLC]1-LQ]M&JN31W$,?4:81HY:\IY/=)E[/'?O6,J#%QY]Q
M+Q<S&751\W9=!K.;*;L5\Z2U*:;.G"V;P^(WX[C].4,]6N1QA:CXL-.7H83F
MPM]W-X$K,_EY0$_A'W-UO]TZ2X:(\9U!@7)22PB0(E497@&GL 0"PL0P0O)=
M!9&)IP>=S*DR;0617R +?0D(B9:Q!V6+#$%1T6JCKIZB%'@:[$F'CLU2K$3'
M+&_#&S-'9FT[I0$ZE02?[#P%8W7HM[;X>RJ*3]Q;0KZ/'!<CH[B8OV&N!4@G
MF8;B17FU)7W?WGE!)_C-B+*(BDE(99;,?;8*;X@NE6D+X&R:KDX+^SY6,J+C
M)A>9UG=/Y5=?UCNR-]!%8CU >:*D62IJ!Q&&5T#?3S(=;Z+Z&KTUKZ 1/^2L
MUFE2J3!KJM9(1!CZ[O/V,V!.&^6T$4^$.]#$_4 U.S*/BY;PUM:E:4QYZ!K?
M394>VSE??@1X\*YW4Y4TF/J)7<#;*B_#ODJ-1(U-;$.XIN7U/A]2KL603Y[0
MU&W_XOD%&#N;\&'WZEK[;.E).&P_X-#K@)9Y.=0$4^Y<^GS\GE^T.A]#)Z.3
MS@7@77J!_E'_W$+1GUMHI R/N,V+B@]E)WS]]TR6U9+_894,,"6-_6K4;0:.
M41PZZ@ 9!V<J)=#@6(_N?K-R^O2V_\MZ@W]G,9N5M7:GXT /9?3)YXRH+T$*
M?.Y>/9?5+"4:(1\?M..IM8;52W_Q*70UDTWL[KUM1AUIZ>5$9<O=-G(6J979
MVIUFC+?:A*B0*TSS:X>[G6"'+*$5\5+CGAJLG3/O!9=[U $D4!DT2@ 1IN4G
M<W$%^M-'@X];4T[,:THY\8_\$8]3#;T^\+,$JU 6A>1P8Z,.RV?]S"?PD$*H
MS"(AWD\IO2=6A$O7>G5^QAJI&4*V&#+Y,)QV[3QW2W5X:(4]=\3C4F>U7)]4
M9H:W=]5.1F+< G_%JN[DW[.AKN46;QP>N$K"JE2<B4LX,X3)X'305R7!#$ZI
M3.954Y&PFI13J\'Q",MW)0M/G*L^>[QBZ\%MY,Y8FN/%<,_R+33MOFRQS3<T
M?[8GYD]_CK!/ ' 2B76VG#5OR9CB!+ 6!.;P.+P;"@Y:7Z"/MZJIK*XR\PB"
MRZ02OV,\>5<1/* ]D_A&Z=:=1WZ\OB>!,/\<F!ZFM" "+^<IO!KO,92@JU22
M,O! 3*-/JZAC]9$<Q_%7O *6O:-%""L3T03.<W1#;BYPI<A*R?(87P T$]KN
MA%8$OZ91$>"DH8;A$=76C44PP7#=>BL)+5P]O'0>JLNX2CNCYN:BF>[?<$^,
M3J/O3'LEZNN@ZAG?NC4KS@];N40>)BGL,FX8)9;W8=?XB"_5X,-<2H9;F,),
M^L<TE]?ZLEF<NH\T)Q$1''89=Y6<(IIPTXOI8-1AAES#]&(-)J=W5"1?TJ50
M0O!]Y].R%_VWJ:HX?RYQUX-GM[I2"=?/,YH>*Z>L<FH:[$M^L(VM^= R+GYO
M"/B<\6?(EJ7FCF[6+!3<!K_J :2VX%3K_"00(631H<QIJJ96^,.9U5C[NXI6
M.]WV6G;;FB3C;=F:A"UE<MS9HGXDFW$M''7NOI.P_DYJ*-=5N.2;Y5QWD86?
M*C?%7179FS[=Y%)K!P$+"%+G9PX%6+UL4ITI[2;P5^[XPKM/ Z2&\%*33:I%
M 3]3&PHZ18$%04V&/BA(A?VL56G[0D>A1=?=1 ?=V258A!:7F6%HVZ 'G($W
M:0F^0Y0%$T_1J,.$ASG;8&4B;P@]L!Z ,!E_]RU;?/%R%Y UG&%L_.O$6?!Q
MB/G8]A&[IJB#-Z4^U??W?*QJM^]H:)*^UE#WZ8FZ #CLA2F38V$MK%-X(^J,
M<I(>SKYHGQ?!HYF[)>-%+&B!.-9P0^N<,9;)9<O;]X5:0DCBE\%W?L<?.X]4
M_;4(3F^+H+/>@L(:]EK#T<)76Q*)!];6H(G (C+?YR%F#_K5YO#^6(O+'O':
MJVT1F%HA^TO$FY0$"XL?[E+=S'[BFFR5XJ&_HXD"[VH75@,C%UC&84#7)0JI
MB)>8E;[VJ9.:Q3Z!@\^\JHRJMK:V@%NL6^M.:^"04[O8:OTP9"6R<P>HI<^T
M^0D<5N;17RJRBQ7.^VAG1"'^X )PJR>1A.3'XYX68.B7:%17^5N8 IIE&4N3
MCMG?,-@X%8^T,,(J;?W@E:YPN7&W)NY>5QQ B*+[EGBL9J[=M+(0UB5UT14X
M[_1I_L?WL=)[52?*%K*19L&[3[/>924DX7EX%RFGXE1Y'=?[UEO%O[]3(Q:_
M>EPFVM8B,AH@BP.;U3A+;P["9@ZM+-0G<RC<G*1_:3,449"O/%4E+20/L?3>
M#BJ';$&(/>9T];P;FC#GYWOAUFBUE&1G 3&>I%\[5\&4U&5E3<-VJW'V.<';
M(9_D<J( E5_*\0^=?>&ED#7K-FO5+Y<2]M\3<(H52^RZ:"<,U<DS>#QD+T5!
MJ?)U7-I2>=OO)AZ4E>:#<4_6(RJ%GB03NC0?GF#/M/YG+/-A+PQ\W3X=LV^4
M/:\1=:"TU.VF7?X)7(KJ)XQ,'V1N.[VZ $RO70!L5+BNG'\\>_I%H@S/1))U
M.=2W+;X ]#C5C1& 6V#,6"J8OCK]WM#JE"A51];&L32J0^WVAWYW447 VE,6
M7I1/N;K3N7_#^C$2QWH!^#EZO ,O.):J)9#!CR6)#KXTGPE DR X.^R!3F:G
MN7]M5 O?YIX/32[#&TFFXXJ(Q%D*(J+XW:4[<ZH@N6XG2 ^$J(4'5Z")@Z#3
M)3H)H%%E$=R=V[GT/2\EUE,3!H+EGMI'^T2%&MUMW27EL(GQRYR3FF^] #R?
MLR,@P&=LRC/E\!&VN0L R>47 )8*$HQ@KHX/1]"F=<'IA(X@[-!<K22=;Y65
MP3K^Y%K&&E:CG=Y: ]X<O3.O (+NG<A*J_@H\,MF,(K843^?BOK.T-#TXRJK
M;JIHYUB&;/T%]B72D GZL6;]G8:3<Z)2!$;B E"1?^;5? %0<7+%7[L ;-N3
MK/G+'$-QI5B!K@4&!&YF*9;$]*]Y8#P3)9*B5 [[<YI?%WHRN5>Q*\_?A M7
MW*T'9]@6GXGB+4:/0.Q0]]9,VD,X$":+_5+H5H1,BU76G/*8KK\ Q"=7)EL\
M0P:KR?:MQ24?CC9/QUNQ(;^ ETXNFY"UL#4XK5%S>'G:,*$[4)&]^P)0"8Z"
MR:"'R7$]B\,1AX/ 3F40YE)G)IKABBA<A?8.,83G%*PL6KQFROZM^)YR1DW]
M\QA;K&8@0: +"^J*1X.Y8/>K+)3T+2I"?M2.H^+)J/Q,(]&W?I(MK_P>$ER/
MKW6Z !R2U5P 6B]-)NW,_B<@64 R#',K(EI^+0XF6H2WQ!['EVQP <]WD_-Q
MUD-.4BWU,Q4NKCHR WWUW%*_Q=VC5M*.=7"%>7/0U%9E-EQ"_OH%X"I,O<C*
M44;]%2]AH29N58VOJT2";/^XPI;XGLPM%WF3B>=GUM:?I+Y= &HOS5\VYO?P
ML50-?.O@;_O$V/#M/2RY.F[F"Q2)"H]25,HSOP"T2Y"'NMS \L5,5YK-=MU,
ML/Y97+8F0!I)0\&Q)A69$]!M?2-^<2U>DEH'3=V#%PC@Q>I ,T!,L]DT21JC
M:2\3[F:_OTJP;YV5N2[+>-@S5[UM<\:&!!W]_@?J_?Z#^L4%$AP0J]D)8FD2
MPY*@3Z)@8E^MH8]FT7-:E9BX=.&& 5N#1!TWWA+3S\ CIWV[3[N7+)WYUC>S
M1S3T.TY";T+8HU?TB)W5DZ*L%G;\[A?O&+<S^:JKD*CB&W>KD[GJ"\ IB05\
MT>ZR=C7GJO?^_46%BP];O B)K]:/92/O H?.[H4=#M.9KK^!OO$#,9KVN]E/
ME=[]H&C+S<E'W4-.ZC8NU0\%'<M-[U6)QOG"._=85=&-Y9$_'"L=&_PK:E)^
MJ1.IM)@MWA%C9Z!/MO:1.JR=._K#M/;QH!\+H:MF*Q.'_QOX;4U 3/C2Y$(%
MJM\U L0D68NI#5^.4X]O]Q*?03IIB+T]>U76>2>C+ ' GEV4<?<\4UEH'4*O
MZ(8&OFU1&H$IY4,W4&GFT=;C+^KKO]7%\;W]9?;]VZ,NP.\7[*K$+:%G7HC_
ME)F#\OR?E?Z[L0OTW20*SX^DJBX/Y;HUSMS90E[1,*X#7:!P?3K!4W]G;) G
MUR?Z]FN+._!H5H#[QP)"'XC1&AS'UHU8.F>VP,([J8F16I43/%4ILYP*CO(_
M6%18(@*35KI-EX1_2!V)_AEGS7_D?NX?N1\ACW;(K!1*N>PL6T".HOZ., $4
MB%07Y:?#(I/?DWXW3H[_<<R5_1R ^SM='_^>;;]+6US$U3C5<OR#$:GXM]+3
M!KVB^6,KKK3:K@SH%V_[!IX;]^T<J,S'EPEN9=8Z_8)W?OJGG_JU3O/PBG^5
M&75OMJFAD7NU"HF TIT';801+/DYT<X_?LP]4^L$'9+_LSP#9;Z6@': U^$C
M7/^\$[A*4?4RFG[_(BW?J/__^O_3];K0C/S_K%VBY,GI]R9L=.=X+5%4'GBV
M6L=Y;_KAF7_WV48ROJ.."A;H/BZWVO@M<27I;O%(5TY52__EQ2/WX'BR"\#6
MZ+&5*"&8_@*P*',!L&[6MV^48&>M,DZ=\4"<7M6_  0BSWV5^_/A?Y\/7M*9
M%1DPE@,R0\D[P-=?+59B-8(*H&%CY ?/0Q[5F"6P+#(1-7"8).,@QR:8@K<$
M91"70P8'9B4L@2:5NCHLT^DYG8[3Q/N*.DN1D0?O)*:C3H';#2;GI *7GMD0
M)'.F=3BEJ&).SS^L_9Z0H7!EDE@-Q?%@'[=]QV7>QX#BJBSTKT*#=_W:SFL=
M%$_#$L?AI4P#I=5A.HS(D4\; 5R$80Q, 6L7LOJ],<Z5!O>XX_N&_"NZ71E1
M3\7L,I$7LG,'5Y;(Y6PWK%?^\AJ^QH6TO0S!F'_2I8++O*P>#/L%H%RS<29N
M^_>>*4X'*]H.O][T& T*:Q$>%?;8HZ]R1SH$"%1G>%36W_]I5RV6L908VZWN
MB!,X?H:Q#EE4  &A:=K?L//+WB9LH5/Y)3-YL6X^"F09!E=O$MV Y7YCW 6]
M'+L K!'^$?LQ_]0'&\>_&VP(2HC30[_T#UPDF+7CIQAD!R*.2Q1;'1:*.M-5
M/IWM%F::&AK@;7#JHL_OCY,N_V3ZHG"-8UKU3!M'?("V:T4R0>$/AX^K4G)6
M6X'HNM"W">5H$U>TX#1A\#+3PY=\B*.^5%=Y3 VF3S6R7U]=#QB =V<V)"<^
M6X4=E.)<7&=Y4!> #@@(IV81W;$@-.I6Z)#*_/ICEIFYZ!WT[*IB2$RX1L^-
M$&.\ ,:]:W:M\P6VIW/'6WNBFDI)Q%] =ZQ)CO3;S)RFM.*&=Q^L^WU0T B1
M-3(?Y][AR]GTSF'P^"IO\BZ7H----LDX;X5W-#)BO$F_/C4>._^!O(+YAM&@
M_<^72F&XRQM#/=R^@@O-'<1L+BJE.9HP26B74Y$_'W2NJWVO1S._]MG=>NYE
M]A:!8TI1.!_G?^@')W:8TAC;G=K@<T(;$G<L-Z0'07_7QF1,(B]#_,_<,O^5
MVYFJEDS73-#1UF4\LF4+<I["1@(H8::8/.6;F)-@F'=.#XK:91.]*5>]I;TK
MI22DIYT@_%/Z!P/= ]=NP<DF<LPI\"V"R@-Q%6?9_5CKVYE23.KRCL_KP57M
MH,^2,::!"I\.12L=8!> SO8 ^,9E>9=K"7MDCQ%>NV<(5YP[E#U9B-$<KH54
M-A^"*&'@O)].QDC,9P?YY8#;\O,30B/6CL'W]JNB:);875ZP+-^"/#0^"<0K
MR+3%4^/VNKG$)[;+/)7T]EVO.^X[;([.6A3=__JN [%Z@YLHI8TWT_%8U2Y?
ME/B?X)I4@G1DL&/),H7#OG085KPO]',JIN5UK@JS+)25O4&[>^O$3RQ#[.P6
M5-\04]O6R)YNRU0[I:CJXXFFJC.]/JHT$::N09Y-4:E\M"V5Y^Q1.47X@S#@
METJ]U970_.1%3JDMCW34V)E(Z@5 E>)?)?0G>Y3;-]ZM2/MC=5.;[0;(OTI>
MRD:O=MS$L/JVO\2W9*W'KS3T?.VDQ#^_.O0C-B]_1*U)N,<,.9J\U'8\1EOF
MIT@]F=HKY?S&XF(\O4,T^LUJQ_XR?V^ V0HG-,,VCBH^K9A+*$>-G"FG70#
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M_:FW\NI-OB R8/A+2(*_M._:]@7@W#<_'^K=T<"8:[[1Z'%FG+QV=W8F8GS
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M]%]I+?S).C%:HTS56 FN (8W"$#(X@3[D#)=*IB7135^Z6TFT?=IK,Y#NI+
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M#UTI=QBLRA=GRT:#>9*PLP$S3/C(;"6(<UXC7(CYMM;#Q)FKW6.<P+7WIIU
MN<=/Q6-Q!?;8CDW>?&+L_-TA[/!D,W-OQ@P,ZNN(:Y]XGZ!?4K6KM/.ZQ54D
MZJ((V&'HOG[_(3ADEJM.$E]IB8^/++!XY %EL2X(2K9_E3[]QP?:R!C9=FI
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MK)-$8+-"0@ATTV5+=&\%-.3&^NF%:?QM]0.:C\D92]<]#2/VP(*K7E38@J7
M;&^Z^9M*C'E(NW&SR=N5P<8$R^/:*N-7@6&8NY>FWJB^\+[1$$.T)G BA!S)
MUTM&I V_KBN(D1+5BS,U;U>IO?F.T 2<?XB1H[Q*NQ#A:L196?7KE:>99SHD
MW_&@\D".<7K"\D%IDRN-BR;?,TY3W71*HS#\[/C,CBWQOE>:KDA?"N?8OMAE
M:LL2,PY[0<F41I$+1S>+WA2\F(KK>J[&8CC\X<^S5C?!?QZU:N0TFG *X%4$
M'VV@?C[1LE^1WZK74D@@O1='K?]UP,E(I-;?7V4LI2Q/M)-RST1>S8DEC4G]
MG) \QWYFD>!)-DA6%:^!Q<UDC62E5.=-%<9EZ2(\)U65_,ED.S('3J_/[S65
M#^6>L=W!6T)>"X\@L;((?G?(1:"60!_\(C'P6-U_LCE_K<&*M-!)(\SG E!V
ML\B)0#F= JB(<JU<,XGN*&;(AQ5:=O.1,DOAWZ++QZ][G>]#W8>T.>- !!HA
M?%862&":]E!TQ/E'8[%Z>+7Z6 BU:XVVM;&?ZN*7V"C;9UZL&U44;W7PY 0"
MN#71NKTG-:#?@0!CMQJ5:(Z^4DNS6G3;8$=+.^U[QM7 W=+.S?&[]1E.*T>5
M;4 6)3#6.NB0YV[*9A%<*;YXNDTY+)0+MG"+C[J3]J>E"B>GF(5]JP3&7@-/
M%<7=#,$R<,(RS*.:Q=1QLRT**@W'_&^86![=_V;@>>1'Y^T9\-W!FA'$2NZ;
MH<57U5G2&-:$'2R)S-'BQK0-=C(;77^N,Q$Z7"WCOQTKK%G=)-;/HS@<@1PR
M1733ZS=&![7 ])<HS,H8-R.%[&:KZ%HWFU]W*.VJZKA![I<U$$^P)U189U04
M7#5[O8&C- 59TI*Q=N2F\:T'M!/*-'E>TY[OEE3G]2$R%]RC'R$(\8D*X$DM
M@-FW5MPN&,8 0T6UL\8K;0(_JS^JL8]XY[<>2:3!&1.KYU:"6Q_N%=BW\] 2
ME)>2(+F/OO*Z>KO(9K5JINX'R351G!6ZG<0[NFPPY$%;90+NB]DKS P*^ZM
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M+!H';#TQQ/D2G\KJTDU8._9/M+Q8]/3>N=2UNTRS$\I-%6M!SCFFM;28@C0
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M6K?K9+>843_LKBQK=\6<4W6&8E'U^D[(1>\TAH$\2YV9(^6#(8W7:9MB-,&
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MV:,GN4K$:G1R5+)3K@S!+QH3W:3F@3(?NU0M)ZS-U &,A-9_)-$2:3&G@%=
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M):,FOY_+LU1 :X07@<W<=WO,^6P.X3%ZOMTP"O:5037+M88O(VXO1W7@P(#
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M&JQRR FQ&DKIV/<',WK[,B8VU2HQL%TP*DB)[1ZG$EO&(VA/DJ6=",)1U:>
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M89B%7C-D;*-YM9E_51-.WU"58'[C;2%-P.NO#-8YDX*@&HK8)]ZG ':;QZ>
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M,].PT:$CTP;)!GCGT*K/(:W?*S[:V/;S1"\F:J*3+EZ4H)*^TNWE0C6I+:W
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M\36)SGDK])(_I4H?E=I/\V?SJK]GV)EJWOFG>5S^KI)F[875/*'^ W4Y'?Q
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MIM\-I-\'F+E9CI^\>.T0C]$#UE->O)=>Q&>P25S_6L]GW$.05'CX).@P.[^
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M[.12.SI>FZ:?'-E'O@+EH @C*&;DPB=G$(F'!@QF4D44IN(HO)U,-( 1N3]
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M,/EN3]7%C,8 _'"2QY;OLYJ.*CXIK9/E[N>%XB[OC9:=0[U$0I$",#"&!O#
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M9:P.G/N*-WR+!>JI)X@QL7D!*J$^G(X^EA\]RI33>Q5_HIH<6@Q9\S1D1K;
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M6B'-<[#NG2@BY'D5#Q0G6*6*JX3*&/\8*&WZ[N(0M'2ID]=-A&'N6,$-41;
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M(O) =N)]*+NB#JN#3ZX+;/3DF-WA1JV6N&S'(\'+^DZLVM%+-HQN <4Z"ST
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M3]LJ<YS[8+5<(\,1D]EQK5IF#3)<%P/-2ZVDZ0"'^(X>NO>A'QT(&\?13F#
M6].C&[1'['BJU*]=G.Y-*IW?2?V)F5CUAO'KB7P/UB8+Q1+=(&W1,UAAY[Y.
MA%.ARX-Q8[V>0RR$)#:N#I['^[M/^A>CS1B=KS+B?D\^N+"Y<F?G9NGP9IWM
MY:K*4ZXY@ZL1HXG&-UY;'CB+NQBL.OVW)?\)N#P*,G!ZBN%$ GDU4-NU6B!5
M3F<D0+<EYLRD:F_)S(\.7;D.;X;V9+#$SM!R2>L[L,JZ 5RYW,MKL&8OSKJA
MVO6;JM_[WI<T&W:M8]V?FM)$-"@H.O!ZSQH=8*V$_3I5\E>L\ZN1_HBN+:4-
MR=F)2@(VK()".]FG8S*K%#,"X\&I<BN71:G)EI6'#AO9Y3C>*)GOK Q9&<C0
M+(Z<G0Y778O%[M<Q(QBKO527&^]THUS5G;NE\/G^^^;NM9_?8Z!:<PQI#D,[
M]6SS*-(!4J#/'Z=2.(1_T1#VBX8E!@T)%W6+UH(ZJ:W(-<^!&\ZP,O1#%"]Q
MCJR3<8"<\Z3H2'VNBQ?K6-E24?WU03ZC0W*'A:\>2 P++ZB7 &4)G0CP D['
M>O:YCA<.3#>G==0/X=R+5FRT=23.,7L\?A=R:3G!%'"-WF6X,:R)8++G'W@9
ML$P'E@?_ ?TD^@_D\QG(3V[ ^M#/[+5OZBB3%+N;;4@K(S'!<E/(-3/2YU W
M?I,AF;((<9?KOD;R.= T/P."Z=:W(M^M>I$!E!%B5D&C5>ID!5DI@GH^XX)S
M)3="P)?GR1@Y\S7'3ZCZ-YG0?7*1_QS71M23B.6?=. LRS2-VQT/OL4Y1=*V
M)O"?E:1F4=HD;K/281TUI6@].5<IM3X=I5,3W]..YNN^-4"<*/XREW+^9[&H
M ,'T!^X,&1?I#95<I E7#>J8.*NN\-&!';.RL@^/V@.UB@^=*KF_$A_MD5G
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MKD+4#P)><<\HV\-K<3KR]9J,"*<#]B0<IAP3I]%:QEN\*%1]7JA"N-=Z4G[
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M#]=Q.+5"2.WK1CW7:3(83+!<EP249*$4FF2\),;-YOK<Z2!WC6Z0UV[);3H
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MYJW5EK\OK8$SIT/)T3:HB@:15]0-#_#-=*U^&M_U B?OV<-_?H4Y7CRD(:Y
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M&S!U"\+.ZOZLF<AE2_%BHF%#58*-5X"PSTMAP:YC(D*?<F]8O>MA(O7DCI*
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M3 ])TB\.FQ6:"2:E%9"T+),Z6]+; B_\5)V BNV\[ M/N5EVFO7L:X%A'!6
M0V!IU&QG5$SK #FQ"#K21<W2D6B1(=DJC9*PT\>2C>C2;C:+R"4>%QIGI@)T
M$1L/Z!6H ."Y7O#B,[(%%=!,3P4XF]*N*!Q>@?]UQ>$-P9&8.EC/3F!LGF+!
M1X5Z-)YU:Q0?D%>%6G\<NE,1K7_R2O42[#R;%(_._I ]/3%W>%7W# S:@F"E
M<*^ 6)P(*MVN.<O7E[G&(O+:OUR@&&A+*'Z^9CQQSLNHNA71DT5^%;J P&_@
MZ"DQ].T*Y-,(H@^BM:L2M"="!7"@\?I4P,^1T>R&I<>N00_5R;M4P->7( $J
MX#_<TD=;N'PO8A%)OO[GPB&.]_N2_Q9!Z"%KU]%N? <FF!Y^77?P!O1;9C05
M\(=07Z*:&:_*OT0P0R$U44_@AE@4"RSY.HF7(+]^&[]R6RTE<(_.LU*Y<^Z*
M#9OCO/F+7T(R"(J0_?\L'L> !ZR'WY?]EX#\C7@7\)81Y5^(_RT!]-](\/MG
M*/VO2/A_C:G_*.&_BZG_)17^9X+V?SLK_)\IP.^? HK?(YI-X#H!^9,7IADH
MDAVB,6E>O1H"OOO;Q"C5+*SX_5[?H[F1IW491(5>S-H!?=T@N\KLHR1^"G]G
MJWTC_^&>M<T,5 !V"8RIUU:E33R--?\]\1X4IT0%]-P"K^>8$E\A%DJR=OI0
MV<07X.<'J[/U@5E*B%88"4J)J6G+^C-@83#:$/W'T'=K>LR)"LC\B)B^A*RD
MA9O.?2J@,4&H/VH#W!"E$@3ZSX\'P)PU#D\H)DB B4= 9/M@56),D,D9W8SB
M[V 7X)B$T4$F7,[U_<I)[R+[:7NQTM0T=\E;SF)/ZWX]/2I\-U6D-K%$TO?1
MB@W]3GE^ED$W39]ZY;_T,:(E0R.R>EID!9)D306P>5,!=VB1T3Y2"K<B?:>E
MWBI[1KW^+7N##B&Y$3[(!Q=;]Y:+ZQQZO ^2;K&,]CT^K]-MCL^:Y4!PK&Y'
MYWY XW\T9$\%AUGW^4IQ=#FK]<[.&U3UO7@J\,@MN KX"Q$D<[43>:B14R!9
MG?2,_N#)X0(N@ST5F%F,6A$Q!A,N--I*M/E ,IH5S\*:1RK!B%O=;UT8:I1Y
M4>(]>RK7-4]^ZJ##37"7\3"-J,Z@Q^):*9(D=G^" U$&Q]@ZW#]Y"7];;3_Y
MU[=[ ,G.'ZN 4^>[[B3']_M^.+A#(?+Y:;>V3E<[A\*E"JH2$_ %6/$W]S>[
M'KO/](:8*QDIB #NS\J:-,UFIM! QCR+0>V)3[.A\1? I-KU^C/[%]SV"N(K
MW>G:0<!ZHYD U<6\-)/ZQD^Q6)DL.?^/IG-L=Y(]M2"H*PNQV_:FMDBC@;5M
MQI6>CS]M+^RP]XA@'!-.W$)^ *2[5=$305-?']M4(3-HSH#_":Z!?0""\-O=
M?Z$%29&OZ[8DOC!3;Q)B'<G!3Y4'%9-:%E;WZ".QKXX/C0K7&G]OD[WL*'1W
M<L< X&T)LYDE%F"+P3RN2S,)]UH[,WD3I>3A9WR#&)(P3O/<D0NZEB(SY,[X
MIU)!#S6I@#3/=:&H3%JV@)$\_R4Q=)^V !19!A$#_B,R;:X?O*_W>@LK;N7C
MJL.;0OKEX89!1!G!J3,?/ST0=AJ_'Y1Q3_Q6!H#)%^5-,(I[6,^+Z;9T&%I/
M[S$>D)M:7L;$M%S*$3TPF5TV*CU5==*=!L.E45I^Y^]J!6^9'9ZG/!-.4QR-
MGW+@H^4@=X($+0?14!!7UMD"KIQ;J\*"F6_"D$V9PGCK+&Q2UUNWVI3O2H:!
M^XPEU\^R]6J]_5:\$>C+Z8IP=4%@5"G?W1DM(;0D[DGKV&1H_:#1F,C&U8*P
M_6S@7G=&*$19U(.\2!Q%T+#(K"7D6!+RL_$X@2/=)SVK!16=UFE6:S=NKJ7_
M)=+WF.R3@)>RV8G*F<$KYH>D %_ H-MHU<@C$.6GP^P[^*7#[_P[*6?Q0PE5
M@^6+BA<4?,$: 5!OX0FY&[X/;A+K! CUI]R1;9496.N"F8QH#]DJ25G'(=E?
M25?R#HK5.F'[8?R86^;:8;U].%J1^X5"-$VR!P*I@$@"?N2 W?-/^R_^QPLK
M2^@JTT%3<> ^C4"Z_B(02&4V&;E^;SYF4X*L'A6)7LP@F_R9[&GQC3R\ /_K
M L3L(!^RNR)QL.6R?Q&].6R^O]B'DT2([(]Z&V4?/H^,K*59KYJ4TGF>C\:!
MLREY[T.F,_EK!\5?P)5(Z:'1NW9ZO#-':+)E%I%55^IC?B_!?67$$O'P-F7O
M:@X)^1:EQ6T)7-NT]*1,.1>%FM5T96\@R>H%-+Y>3(?3>*^9UE(?[J[6H*U.
MP_\ %D)AX#X,_0$JP"V#$DAKY8/Y=(?4R=O)E#W59MRCK,TY&E*,RKML=I$O
M_]-CM(J,>0F#WA//8J,"\'IH\N/&K/T;TW_H1BQ"_V;IG#$,>(%FL::P5-0F
MZ!RB-? 0^*@V-/FTPN%^5A3^\5;$EEF(&$U0*((T%]C9KI#0@]^QZX5KY2T&
MIL7#[<MB<C_VJ2SUL]V-II/M-SW#R"=O)%&$_;"5-99Q&=FJJSH(OY6_W'AJ
M",[W_&O)8MI:Q?<XX8.NBWUO*F3#(ZYKUG TE+%3X&@R0^JO-Z]_  ]%!E/X
MR/\T2/VA9B-8"(K\Y+=%@C"@,;#%8+T)Y@#4GGELA$Q'@[6P4^_:MDRA<^R&
MH8'$"XKE ][+"<W\O?$$VRG-@^PM1%1M3VRIZEV8K+9ZKMURS4Z?[OJ4N8PH
M5Q'/7&[P9QZ-7UY&52V(GC0J(/3H8XIWUZ%<%4VR&BD5O :@F2_M<&6Q1F0[
M2,P=*F#TR*$YZ)^"7=X8W20,)V 4.&$2MTF(]RO#&Q.+419UD5@M#-_:<_6+
M"'])RSI'EE<+L4V#:&A<2M7(=@,C9CV:;#*C<V(>&FS01O1_="GKLZBYJ-KJ
MU/TO$5=O.FKHO@BZ+4'>19!8M?MK.KQ"! \JZADQS+)+>PHMB.@QIR>I)NV5
MFL O*)&TQT>>'5+T#'N[ZV__@39H_IJE--$=6JI?$Q0C3!"/*EC><U^J'4#A
M9FMK7MW$S/HR%1".A?BVNX&$5!(4; @3_D@OEKB9.LDUWP27KR]S4IY])3HY
ME&!U2KR:)G)*A49.TIH ".68?0%T,Y.6H9AQAZD _1>TD"1/3V9',+Z4)IF6
MF9_]=MPJ66K_FH-;VA2_)QN,L<WA9&^]F=*X2WI'@2_3\PGC95N.5R+NPSAA
MD/Q:;NCK ;+S_E6'Q491@FX6!DT'"^M4$^)L(859]:_=39#-'1.<O?@L\LVP
M$L_[K26CZC\=Q=HM U6.I?'!%G[Z@!T2@R )0RCG:5'-O'((_;_7UQB+1\67
MD-TQ;V3:^%0W[9<T\RK]_2I.B, ]WB8"#7J$=U *!!N<'.(N%L+J*L2&ET?/
M_L)__5DZM53SJ)DS-\._4G$WG'?NQJ]W3(GTEG\#A7,]KR21$T%3/M.HU3,&
M0CI#$W^K&ER-"/69]+\^[-[( 3>,LAY,DEQ7.!&1EG+VV*7P5\!O;S-/T*LN
M!W;BE)G2/2/$\66AQ;#&S3:^&V._K*4T?YIX.K$<2S*9W[K3><<<ZT&:KT9C
MX*XC8Q)/5 6Y^+N=R*XJ!F85EUB_?7@QK;+A\>5&3 A^S9CN7UX2H@(VA8P1
MGA!F#V&X*NG5B, BXQ];Z?V[H1P6""+8>W"E_JUNRVN1\\%"4)*LIX)CVM%F
M)RTV?_JDC&]%PO$GOI95X"P1/<ZZ^]U_2]"US?#^S1<P&E\4_(,O!@[Y0O<O
MO@@&_\TTAU,<5HCF?U%.U/]GO*46TM$H^8F4O7^?;$:8K(FLU\]V49_BJZB,
MJ!H_4>TMZ\GV<3-%8DX"L(5J6'F)YZ]/UUKW0TR#&K8X!UFV>Z)+BGO>R+BD
M393 JGP*VW/SWGV.C\3EN&O&RD:JN_.[#EK<I^_)JJG@H0*<0 +G'IZNCA*A
M-&)0)X>KH%F1FN .9&C@%;3S(-RB^!8XXAG;J7&HLU.SGNYR"VTQ@HJ9VT1$
M.S"R5J)]G6[9@9W X6V:LRQT\XW<O.+YT>652 'D*T-'*/H(7!!K'CO%28I#
M%'Q5B-56ALIE9CT2.\,I<-H?=4E8^4YF1H+.L9!@TJQA!7Y]=7__ILL>7,:S
MX";<H+SRJ1C(3X7+.&?EB<RZ^9BR31]9Y_!OH^MMS!RV5T($ZTP:>W6MY>BD
MR[22V@#G%S@SL,"?ZA@J(*9>>?;@Q,;T-2XAC:$TVV'MC!$3OB6_TWT?Y@ ;
M Z%+M^=?[9\DJX;=**\?]M2^-2M9\L N6H761L.2UJ]5W+HQ=[M5!'>/@>?+
MV91G(#629[.#6BTI8E]\T5I((JNI42H,\V8TZUJPILR2R%CJ^#M%TY0?YTZN
MM/M-L??!#3SW[[N$<)(V9QG7>=SXX&Q0!-#S;/73UBMUC^HDE/39XB?;3G;<
M3"@Q7I99D;/$J$=5(6.F0(3M-EJMWF*0/3KA.GPUF3/F[NNB9QR+YE\^Z;S/
M:@<^=> AU8$CY7U'RY)HA9SMZ\#JM&#'Q[WFGII>K2BQFX^^P7260B>-?H14
MXBH_Y>7=I_/KJWYCR&7 7YU0N2SY\4B=R_C5=W'"__N&[.[.L'_]G=,J VN^
M"U@&;3=3 2DW0D1-1PGEO1:'W_WG_?[N7W_@V%.C#U^W9_Q5=S&$%2PK =(Z
M':,K0K")T'8L(*7N87O,^K"UO?EV@B)FD13N4Q)@A5>*9M^-KEL$M(=$[?N5
M^6/5GZ@@8Z>8&_'HZ%1LL-#V.]>D*6^.5XDW4LZU%OR(VZ;CC,?^NIZ"%*H@
M<*)CP=!U^I7(?BK O'J(#(2I[ ?;CHY-Q'#A;)U<,E+<(Q[K*-ZVB=>V.CS&
M*ZMROJA ;27&IY3]0N5X#_F*LU&,Y0%FX<SV$N0B^0K)'#,=YU>MN$*P[_2]
M>_[SQ\'*KIK*ALIG\8JQ]W?31)YJ\GWII95?T\=AWOH#/G$R_-E0IQ+QQGXS
MV$9W #S+#_J*7]PQ\]'$_5,1)SF_(\^0XGR!861+_";F#:W_(]L$X\=;AKG2
MTCKU^YS0]K;SLK)<WRV14KS:G93-AT*T.AG_V@Q%Z=@9'K,JR\[KR2<;V"VA
MJA)4^_M$DJV?]T9* .>JIQ6!DXO0+=OSN9%ZR[].^_O.9 5B?3S#A3CZX'2%
M)#F?Z1H8U")].:A89D?YI"W60/9M\F@=FX[&5IZT!^9[@'5AHSSI#,$;TU !
MUQN!0_-@_7ONZA;]VQTQ+1KA7VK4ZECAE08[S^[?B1T_J%3(KSAX#3<5N,YC
M381JG9S^% DMG$W&2[<C9JP:9H _.YLA+-J&+'4%1L5NMJ65S*Y.7F5NR9 ,
M!O.;.'(+/$^$+O&18OIBHQQ<NXI4CA]I<V"M]3KJ5IW X<WY)=8B,O8*XN-R
M LFJ4)4KXGL94O0@3Z6H:CT:1 \_COF<@Y^.SJVK'?1!L\X&N7K97LCNE]RL
M-GHNRL#:>)MNX@;D>.4D!+.#4YR=9H+ET+K?\*ZV]&$DM 05RP1V3ELMG!>M
M3#JN)7+J9LIX0E/69=P,">%.J,- (M^2$K(=7#//?K!R3N*/K*FKJ(_GF0H*
MZ(V\1IK@$>"\V^X)5R:I8Y#AFVXVM@+J-7QEN=\\?8-MB:;CX\\^CZ)4PI.*
MDR-XCB:%S5\'*8UNHL)<=,7)WJ3G!+[5@.I:S@$86,^R7S0*&*"TI_RMR0/4
M\@EGBZA.*-FD="%.'_.J._M3-$F:1DPRVDY-H+6G,$K*8A:0(KB8Q>3#ZQ-\
M5"K[8^H:=K>]K</&]<'C#;;.<@FDONE=/!5PN7Q0V]Q;-&TO/D1$>/KFL@W2
MVZ7X0[9QMF>JBI.$M(:J5YS)V\^_(%6<38WXA>;<_KR$,I2V:TYC9M^;\4&1
MS_<[[[Q]3:2?*H);D^R!K3!?<[:R.O_@MX@6XTR1 6V>U*+:!8<7JS6&65KA
M#ZRG'#MW8C3*5IJR*A2>4 1)L5VV_;@JT^)23?6X*U%60^+U-0.L';SNCH\O
MZB'3$B=L/+' 8ZX.DB/:.N^7+4R]O-[^V+%6Y#6.>'!?:E[3Q^_4U?Z0-1.!
M0>F@B=N=W;82;4!N.'<_W$RPJNQYT2*%;7"U,ZY,/AP]QE>= []N6I3]R.]L
M]JL+D?2/KGC%;H$2?JBL)T*.5)FZJDV:O9]V_>BG-&[J=JLUZ&ALDY_J,"EC
M!ABF?7=6@612I677V9AD&E!6>J\!MKJ>2??2 7MDX]O7T/@]I@7.-T4PHQL$
M%(XS%_:4T@'U!)(4S%\L]5\]I^#+6%YMPCXD$GVLQZRG\S*';?1:($IG;^==
M:.^1+SA#'S<]"T,.AC^._/CCR,:;D?_5D1_Q>Y+OZHOE.^LY+ RY[)_,4&3)
M5WMUV9>&T\MR[HJ7HJ;.?^BK;-"=,"UT8S_7\QS(2_?D9A('BQELN&%?>T5(
MDF1.D+ C(4N7*'P$5/S8CS773#V5 UYW)Q/94M-JNO>?['&9IJ]M"LG7:>$I
M0@AKMS6*WAY'G;ZUPF=68?MSPJ6VOEI<])ZIH_/Y\\WG?P&T+,D*^UHD\U9-
M4+2*:UF]/M9=QJ&&JV8X1&(X?]#1I0.F?V87^/VQ329]'I_?N:07>>][\>OQ
M-E0 9[T%%OW4VD&Y7QN,^4P?[R[$XQ-L@A(;G&1-OS4R9\%DRO- ^K')'>65
M1013_2U,ER<+68^4C5W)T)+C;LN4="E=4STV?6JL^>S8K<1P]P<7FIZ'HL]S
M#L(DB&YXFR?;YC@M!5RID65BORF_:3?4)GW/CD'0[Z,=[TE6ICOWF0C#M4&(
M" >N,,QK,#"W/Z<>_\+/P)S24^LH# LD=P]6!TR.:/<YC5KD#Q=$DO8-1RB"
ME$$($]D**Q< =\U?&8L8CLEU3;:-\^^%+W;%W!GU.C=Z5.O#CX',[1J"5EMZ
M5#NT%#JSWM)E7/K.G9@I35 Y=_QC7_:+D#V&\E"Y\2+/%\&3;34Z6@I'*=V9
MIT@(K&EPR'>H9C7*E=%N=!(Z5CD6=O/2=( [N>5B@,!][\3M;ZY40#FX]4#@
M=EE&*6G3-'$>LY8?V]GN?T[DVX+\G V=EXZYK<JJ!*_8?>1#?%;D*ER0UA:V
M[CUTYWJ3-];JY)$D\"%1]=1GW?JC(?F-=V@Y248A%E1.!2#O#F]'^YC +=Y#
MU0,CRWUFC#S5QUY9FS">/JJ0^NI8_*F]./W^,_BUA+OY=MW>VESGQ.J]'7X,
M?/_V%M!O/%'GU25D%F#3"H[<(!G9D])F$LPO47KQXI\#Y*ONJGP1^IFT'E<L
M(1C[299[/U%RH#PWIQR;Q5\6(K?LP$BZFT.JN(P??NX)BO/1P*%4[ W7\H;S
M3&[D/LOO%8X75BH7);8'(E:_RMKZA1$R95K*[6^2>FYF7)._9,'KGU-3DWKI
M),[>/)0*>&!^E PF,"=6W>4J+W1P+>Q;BBEU&YAJS2]F8G47"(_^M/OX/%U\
MW^SZ3V03@DW;)*C,K7JOM&H^ATV_J#-W.?E6<U%'O?2D$>_1:_1=/1ZT=695
MI,X;K1I ?>E7T3/*_JER3)M,1<(M.TJ5SDMS*9U5,%K5C8ZDR!/R4.V[CJ17
M93#YE<N$Q/PS%;WD3\_E-9)_U$WEY3+5Z5W7.U5 7Z:;CR8%Y#KT8)QC4)5?
MM-7V2V1I-4!-M<P'X<2;(S'7)'FL9VS.S*)^)C<A3M<;!)>ZJ>WE):SE\;46
ME2'?FSJQY,<UV17."IMV\FK/QM-P6618$4Y"Y*Y,5_JW@J+0'-QM"'PTK-^=
M:^5J8V-LN_R=NNKGQ&_P&FENN=//&32N![*V>S72U0YN)?@WF\U$EXSON\_A
MHYYZD"\(N<CYU$FFFQ9W&G^K^.HM3?XD,F>E([-LMWYL23V3(:OE6JMX6K;)
M/9^YJ"O/QBO5YOQ6$Z*D-G[=#TSO((";:2FRN%53*$*N83@-FLTS;O*I;RV]
M?[[I'4]SI-7<X_"B;?ITV;J3 WZ]FRO3W(@6_$&2MCNB]&=SP63UJQ+7'4++
M>+9=AKF:6I)2P*B#W(Q0:_HZY?B*3<A9DM2,X-6]2ZG$]0L?4UV!-HY'YY C
MJ-G;R';SR I7--T(!MEZH 0U#79-,PHJW%AQA(IPU7U^U2/;SKCQV/X7RK9O
M*P@,="'R685?X&=DA.'D9@6Y5/1BP8#C7/8)'+;^P7$O#EDTX6BLY+NN#T(1
M,\!=NJ]4@#UR@W-0[C'E"*V#U\[:GOA]B,BZ-8P3'7,V,J_ %-ZW:[.C%A08
M[;>Y_475DL*ZC]IC<0/M JF Z-):@N?8+/92'GYG9G(B1"#=N/XN5H;&78N7
MV(X]W5C6YZM=J#T3<)XR=T*B -$"]J8"]"<-:!*H  +'G^/N/\><L^"/"HG;
M==.G2,5-%)5AT6%MZ SSO6 1B\&R'V+U->"&JKJ'FU$141)%ETJ@B/$PP\8-
MWW'/(Z2/"YC7-5T%!<C9FNA1Y5?P;,DXQ.N[F[H0%?'IEB<Z5 !MR5E_+SGG
MWT:H3#"FH%X=7]-"!;#76[U'QU8EJ!L1QEW491 JRAD!@N^NV)X%&'Y</WYM
M;E?GL0P*KX#3!\8TBH[!)-HR3Q D6B<AEA\S+/K&VTZR=%]B>.0D?>\YN>;:
MMW;0,3H](1K?,!ST'-"K LE15$";Q;\/;7H6B#-]?-R$4S#N]B2XK%V.&Q5P
M.J(2\K,K:N,[Y19"8WQ]]L?)&K2>VYN:3B07&E=52#I3R7P=<K09X^+)M>1<
MS56^EC*Z+.OOJ?CFG7#],ZO$"6\]T*7_@:7_&G-N3I/5KX97@_#)64=)-11.
MX\_[4J3PX3Z$\P$5H-"S4=^C]65Z8[=.<3K/>Z\&QXZ%T%-&(*S:BODD1-LT
MJQPRJC(()Z/?QZ=P=A2DA6-_)>:;H/Y OD >)J@!V$O^-XC\:>_E/^W-!QGG
M;E&',&ZA>%QKK]:]GW9+SW'AHG!75W04JAK*TBI-M3OE']W%7KV4/"8P,T0%
M1"$J#Z)BM6^A8#;MF1S#C?RP-*/^Q#I59#23;-(2)K;J^^.6M?CW34^5G^G/
MQ@*V/4E&:XA%K4+$+S#E+/+WX/P?@WK^"P>5E9-^F_J-:4U""OWU)['\HUL'
M(AW^?N6,,D6B[A_*X\^G:OS2EDU\(A V82.!5R<6CC!E":JB8](O%;^%V;4$
M;G]!7FL,\DO\P7$S1=;JK%CF[0\/9R(W 1-F@&#30^^._"=G^_[I[$28.K$L
MSH[@%YH-RZ)UX;&-@DAV92/,/LWG!@Q/*7IY;49=S^.57AP/?PPPUVGF5&]>
M'XO152$UKE_IK:?#&E<&@Z\U]*^3C1X)V\D$%?LY*5(!)5/[U8E6QOQ-&F^!
M]K3*/62%$I8>1:$Y&GOX'7+( B6L]H^A3!,"BHKG0[> HJ?IY&7M;M4.^,H%
M;O3O7^H3V10?W'222&;Y_F2Z03) F*4@U%XA%.$6S-[&#D-?)9A'5:&B,D7P
M^9FJP>9&(R()<VIB)MR*VK)+TG.7W^0^FV!-UA.J^.^A'N:*J+ZOY-;(&>R/
M28NO%\- .!U:[^; ,JQBIU<W3<]]%WKH*F/"\.RQ>N$.Z@H>W*$#[K0=:1-4
M&VM9&X,<=Y,PJTMZ<*$&^*ND+J=9@N?.^>:W+#7_;6"_/:C5U@G ("+2R[)F
M>MC<:M"L):@U%7OQYGM)OQHJSK[,6CA55[,0XE=X_69L[ #Q%_)ZU4AIY7HX
M16-0VPSS2A!N]+:3^5.RL5Y=:WV^A4!&\KQ5PJMH04FZ1=0_887\)^#JD]M
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M=J2P '>_ZIWTBHB(M>-MT8*D_?<G+NQ)<F;5A=B=&]Q3V+>>IH2FHDD[A]M
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MO0@>I4J"SC);8D%MR&C-[^K^]"U3@I\\69;&'LH>\U=_]&3'\H,.)$C6Q1Q
MMV+3Q>H69$[,Y>DA.I6!9R T6)2B@]5&J "A0SGS"N&TU*,K3@HCOAM200C8
MMF(FU3SI$VQ;6[EJ+GA!:[<N"OG3,9\_]7.\);)I_>7#,X2"SG56N-&0"BK:
M=N&IRC2SF[=+.G-FK.--\<QC)TS6A@9?Z2?/_7RFML IA*O\;)M%RP)N=E1
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M<+O=%]4AFG'SD74[>6<VDN>5[Z[N3P<;<*C'*W##6A:WP/<K"_87?<T\-8L
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M1F#60O7[<YP"BW0^C[>[<O?U=XK;P*'Z9/$^9^SDI(A$F='FLXJAC<QHD9)
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MY5)<53\?-Z560?%;O('I8-.C,,O#E@[UCT&-%6FM4QE?CT$XEB *&@LAT_O
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ML=-_L&=)S#Q\B=C?*SUQ@!X9V^M<G&]""IW7?L+*)= SD.]/K(KTCD'0733
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M:)%FJ-/&<' 7O!,4M3H=_%+JB8W%C;T0B_JV(ZSDW[@N^P?7=;]&JUV/0<3
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M0"2NJ,]'!(7O$%I&RF#E-G] ID>F944[Z_X+12*,2OT&6CU3RO93RG#-_P!
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MA\3ZKB/HS[JA1!]CZKK8%N2D]/>J!S0O_!K3P*Y$-$&Y8 IUG[@7B/(F-I@
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MKB)+LS61D^B2@5O+8Z7@S;>958YO+&*Y;[=0)7>D. ),:0N1ANV(\=2.F3,
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M#MA_/D$%O#2B ICZABGPIU1 @Z9G8@5Z3-Q+*$DU1H("2LLE4WJI %@$!/N
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M[\_>O7KRPS0OCVFR> )/CA:+D^^?/OWUUU__5.IH,I^.EPN^U/Q/>7K\] G
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MP?X.R'W]T/OE%F2POB"H1O9IA"P0T# "QS:NU%DEJ;L <"^*?$?#7J+W*9<
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M["L6_"_([^U#[^7?:UM8L P$$UO\2&>6WY3!N>!B-/R+M/'&UMUA,2.5U8)
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M8G@]G;2UF$U7C"@7\WT?)&"(VEIG= 5=6H49*QM60+Y"(<K12E-R[*Y-^&I
M\WBY:@K]0/EH,F)']_J8YI4(L6)8L?9/"XV?8?X'6Y"/=/EW0Y3"=HA<MM 0
MMY_"CM&K6"V!3#& 490@:A= .84^6"&,Z,[&?LT(MA_D0(&LK0KV?2WNC>%N
M]XI<:&UK]A8BL1MLE%80C8U PFL18DC:=#=I8CWQN/!15IRU,^+U>D_\[.5?
MEKSO:/:F-BP[E/[IBR!W0T&NJ@-%@^!]B\W+ZB&%%J#'D*M$E2IVV]2WV[K>
M#>5*4FGQ7X8QMI6%*N%9LZ<(.:#/*B<2L;M2A#6<VFUOE@YLM$*R)I.$$*E5
MS#<6"QL,J(P:V3\.Q7=;$;9^KOG%Z/!H\7"3S<2;L>C<AC3Q.8UQ!G@C%F ?
MHUC/JVNIVT4\^)4QRV?R=M=5Y)ES\3#W7PRQ8)2@JRA@JFE4F'SV&+TOR@1O
M3+>6;4WW_L-LE?4\72WE689M7^R<5B@9F(;&/:O!9&RC[',"*Q7)D$K4_?:K
M/L-Q*U)_?T3T.Q2TJV1:"[XL9S,^]P75_0!9\L=A,@]GF(Q'IWWA/9"%;36W
MK04HF$9VA2D+D474W>6XOHJ)^?.LNB_.")@?I-&)J2812X$@E62UYA2@DY[A
M>Q2\M.BM[W8^T._@!5[$Q6R4%^<CHG^9C!;S=^]_>9#+5VQ$;9(']GQ+*_"5
MD(2+X#0%$:@:D[L+(F^<!^4VF=UHL@:9W=I2-R2+Y5J/TR6MRXY(':Q15 1"
M=2V,;%L&76KV;JIF<4_$/DZ7P88A)M*NB;0Z;EC<C4><40K=TOLAZ\R@!2LD
M2@92C;I4FZWUW0+W+X/7:_GU]TO6.(6!):][.[A_-;I^Q.;#$</D05OISH((
M+R>%/E'Y,'TYGR_9XSAS73_SFG$\WD;8@=W*=??'V:%#00COJ['$.K7U9I.T
M$(+(4&4MM@9&_+&['J&O0X#[XEXE;35B-N!:M8GQ#,C;&#5(SI#-VBJ3]GPE
MMH3%=S08HZ+0I5A@-[F",6QHHFJ#,4RLOI!(PG2'Q?>A/&<WL"&4XJI7'EQR
MO!E%D1!SU9"R<<Z4;%7'75M?3$E?ZVPXF)0UBVB'0)\/9Z[G5A74C:&<]R.G
M1RL"JR7;)BT9@05"C!ET9LLC<T1+W599=$2)M:O$GHL:A0.OBP"C*4+T@D#Y
MHAUJ029UUY.XJ9;_^R&V ?O@K*B.M Q J75<86UC;BWR!LO2!T9L,G:[*#UW
M7'40:O(^-PZ1RMI1RG.>(S0:G#1":>%0JN[0W%#%@\=XR#OVKA&&W?A-C; H
M^.R =.-YMU;R4DD"5Q!+D5F(VJW?U/,NO+9:8D#NFBK9FW4)V-M5S9 E2#7Q
MCZJ0+RZ6BMW%XP;:6#_Q^KVFY6PZSR.:Y$TKSMVXP3)()VVL4 ,[OT;R/TF[
M#"IGI8P309IN*Y"Z[FO=U7AMI[VL 5P@7D[K&P.-:B.8K6+@64M1W2K7G87/
M-QCDOJ_5%09D&$*/RZB,=2A6HWC ),P0DN5MGTWR43O)0M.;8&P7( WG'PW(
M9'A'/=:;";^8B^>;7[ONT71<:+9AQTSH@833)".\L F06C>^;UT"6!UC#B5R
MT4J&] VU6G<IB'L1M;LMG0,--6.I5+R $+W'U@W'GUQE")QBB@*-JOVV.W66
M*=A,7$>E;,FNJ.=;;VXHE?%.#D#*2)1L],SFR47_Z *]G4WY41>G+1*Z:+-6
M>9U698S/3F_3QD[KXE><T:I5O\UYI=GEP0\RIE,UOVM%$I1#=CUST&U9$9PI
M7F-%971W.9W!&D*?MX;06Y0,#W*5L\C959\@VV";[9<01&#8F[V6N=7IRVX=
MT*[2Z#L:[8?":K:![$A0!",D^Q69C2,%2P63]-;O>QO,MKCE!K2(T1M4K#_!
M>A78(K;VE]0&GI-(K$T=O\CN(,O=E9?GWS[(.%PVA,$Z!QBQ$9(5#UB\A!Q)
M2DV:HM^X"[0G;ZJ$K%UL#5VVC6I'!S&19UB UGN;L^RO!^*QB'ZP(OH/,QK3
MX>D+]E1.%AN@S.@ $@E92M7L<.K89MZC8(<S.PG6Z(A.%XJJ.Z[)'89#!L+<
MU^_^XI"]*6W05E==8X24JCWC=4C9M8D_OB17M4;;'0G:57[F@KYL_N-T]II^
M/<BYA3Q'DT/6 Q/^>$96]]LDZ_E1C.,FA9'X_)>3MGH-X JW+^GPX(OP65OP
M-C4O-[,Y*\I =**-090%0[< >F-#;M:^@SZ8)#8C&23((^]<"-(FWM.H()$P
M0(VG19KBG>HN9?.8R]N"LB>AC&6U 24IQ@>9_?GHM(%:V&5PQ*ZWZ%8P>+WG
M*ZK]Q8N/]#G>_UL';*'0N:W] ?]!64G*5KK\-0B&EFJ0[ 0+0LG("B*RSVB:
M^4^6$DBG+*E*"F6W]J/K H[=>+=19V\]%BB^,GQSH0$Y=@42%8<VUVSU-X3]
M[Q\3E6+]ROWK%-7W\M^0=7+F-<S&\)9D! XA\.;D;:J5+>2\[*[O^2IVO2I;
M;+PNIQ_8WY]C7A%$/SN]_LUC ..1!6#MDK2@M:L,5)QLHTN]TQ!R:X60+A<5
M<O*AA\CF;>M\[43W&2)0&9UYW6H'7&IS)A3$K#UX229K021J=\'*3MF:NYHS
M,2":QXK5L%4'9QVC^20T(%8-A!25]TDFV:6(=$;)N9EI$QI]9"#=:)9\&_O#
M&BQYRVO5BG^"3='W&U<;@M]<#;9]O[VQ:\DZ-!007'2"94<'0.N)K5_.P>I2
M7']E27O3.K&A62+"Z<I>5AO"UMHV?6,L2AJB-%)$25[T-\#UFVKEOC]<^+I1
MEO>5S!;FB8, R5B#M2TY$&L%8XN%5"K[MREEC-(JUC:]26:O89[-J/N0%09%
M'K V9A[4E4&_9#!GG8Z^:EZR[E9HI>XO5N<GFAXR5CMJVN'*$W^Q;!6J>[,(
M[&OY)!((D60K!38M&LK_&'3DBZ!:NPV]?(XT8;5A6%.WLW]<T24H(>\"9=V8
M4ZTE>E$*^)S8]0_&M>) 5HDEEQ!<<2)T9T[[+ X<<I1ICI159A>IEM;/X$N&
ME$,!*P.:;&T(V!TN7=NL#YE#W*-QZ@.J4.>$#DF7-E."_Y&M%B&& ,53\9:$
M*K;+LOL^,Q!R_0R$&BX#(57*A:QKPPDRF*0J!,H(.IE<M,Q4H^EQ#0=P/5_C
MA*7@X]ZXG$(XJXP5X'3;;DX@8.-;B &+0EZTTA_!PBX:$+\TV_1R]LA*/-XW
MC3O8-(0!1/)>H= M6JN]B["AC];6W*9X,^0WGA2D8!54GQIK2;;:=DOHM'Z!
MTH^LS08MFMM8V=[]T_4[X6H+1BF,!%4Z#2;RN9/5!*J(%*,1+&&/G!E]U]EU
M($6^>E-*E! QZ=;'&""X) &32-I&]&GS:>X=0:YM97HO7?/5$-?G;V=4:3;;
M!FWT@#9+MD!4*@9*H,H^%B($W0:!5&-]SE7'T%V!5X]SPSK8\M:X5(4VX/A3
MZWUE^)$L LF*PLM$*7<;;.Q^P-)NRB]3)BE$;)P#U;3=&8#=L-*"R+F2RPJQ
M.RRPJI?#OT]GSY?S!2_J['K8X^)W*^L[E(9F7-$BTF<9NW>C^3^>G3YC'^/H
M&&?_N*T*L-!YIT[S+VCT<<CA;9^YD<^@H/-7\)N#MU!;_@K_UDH+'V1AGU8B
MLIY#$(@23(H)HFC#2X/F/90+A=Q=''G';8H?1HN&M%Y.RNCCJ"PO\FP7@/F'
MT8SR8GKG.,4!Y.5Z7OJ.H.3U0^]E+D6@S$X5A)S:Z)+8QH"3AJ DM6%0H?IN
MVU:&J*4:;'#\OD1Z!HR2VH"N9F-!8W2M)=I###Z!TM:D;&5E(-:;['0_X6LW
M$,M+E\CF I%=(3 -9Z$2&K+.JRYFZ_O++WVE _2.%CB:\(KC;-*BO/N2&>95
ML=*C!G*MH2QH =&7 #86[X)'4V5W&GKCU!I?W<KQCL8?<?9L1@^SGZ,49']7
M",9YC6W/A59=$W@G9S)!^9!\ZI);:"_*6F_GCMD1-6OJY^N'WFM]L11K^'0^
MI<:F:#0PM&?IJ:5DXTU"T1VL7Z?/JP6B:-;BBN^7)R?CTW4[?=>T\[_+T?OB
MXSF99N$_GUP6O^X+\E*4&S\%6YDJ&L,FGSB62HU]"1U*X2UUUP%Q'YNPGZ!*
MB<+FNBBHL?&^NT8)4'0"%PVQ4<<:57?9A[XX/#I8Q&2C])4LZW+,8$PD2$$:
MR%'58@,U"]OK(O;E( \\P>J/O(6N/?,!\UDF"FM%ZY8)E%K]DH$HM(3HBJ\Q
M%[2YNWS6/G"W;Z,_9<AFMY JF<HP(67=Y@0I2,(Z%@-;$R:O,#PHF+"6C-TF
M-<!/#Y74X!M@922'(I-C-XM$!*-L!8S9@4(1@_'*D.G6.F]M;MEZJO?L(GS.
M%[527KQ=K0*+<IF>7"6AUSKRDCKP08J<,5IJMJ/@L4T1-:VY3,H,0FF,)E1?
M-T\*_$=%[K$R[;=.N= @_!#6-BJO0C !3$R.G7*2P-)@P)6<'+&FBK&[0.WF
M"E^[B95$(X2NP8/R5H&QM4!$QL**#4>F4JW=^]3&5FJ[-I/=T.R+:&>H99IR
M8\;5;:*/ &<QE!;.$GH?<X@OYR?-AWUULM%=,N!(46QE(Y%?O,YM *QP"#$+
M#]J3TC6'2*++!,*7AQ.\FY[BN.4/'F"AHZ"22^3]8K,EUFM&0G*Y@M>I!!VL
M+_T.^5AO1LN#A(].5J4,KU-NI:DF1P)L\40?C*E)1EU=M\OV9;JO"XZOM\M9
M/L)Y(VQO$K^%@K[MM9'>4+Z##;/++I+424%)QC:V,06Q,1,%486JN4:'>^_%
M[H!'9,B$&^M:1YX:M8MA;.\L('D':&P.1N;@=)<ER/N77]^-5H[D,:; IRN>
M=V!#/J$6 ]KH6'557O0:,/_=%/<_$4.?H^<XHW,4U$AB)W1G'>O:.__+P817
M4YS,W^+ID)7EO^NEGC_AN7V:'&Z0,+P#84T^,'8H&APUGZFUJ"<V$4#.497*
M*BN[BT!UD-W9-LO]G5+[_C?]O,_YQ]$FZ>YO2*]NTBO%.M)[Z]![E3*19ZS#
MV*E&C&!,$)!TY6U4L\)2L0;5;2G36;C] WXZ6++%G%WFIVZ H0/V^Z<LNW];
MSD;S,LH;'ZL\Y.";:F,VTH/UC1[3:0<A>@44JT5CHL"H>UN<7AV$ 9=%9B6Q
M9$8F)?*R*&T@M+51B>$*FF2JZ2Z&.1#\W'C.ORM"WF$*$+Y"GVV/MV7?RG&&
M3$$@ [44$2J[$:Q5,3<&6P/.R"J-4>JQNV)G2R-+L:5FP% ;[U[T@);1B,PI
MUY3XC<INE^;9<MYJE^<'F9=F/KK*TF^!X&B?688W2@]YNV35K#_JQ@TUZL8;
M62S# YU+ZP%.&E"7  9#BN1=(-E=+N>K*!#>TWC,<OP335BVQXRW#\KQJ'7Y
MS,[*4LZX$!XFI4VJA=>P$,0:$Q@;$B-TQPB=--IBLG.BV_Q!-[:D@[IR(C(>
M3099V]9,.4*4CDU0-CJ5+*6OCX;G#Q9:7H'6BUS48'U%=P9UKD5SWLZFQZ/Y
M?#H[;04SFP]%,BSRZTCQK4/OQ6FJM8S*)]9&K=LP^0*!;0\HCS88IX6KW=4\
M;;3"N,<ZX&^S(U9Z;3'81DE0&A&*8V"?"R2EJM=!NJBZRZG>D=%9MZAH%^[_
M_1RZ 7L>HK=D"WK05F;VM7WK>JF-/;)J61"-*]T5E#W2CV[!TT>*";$6P"(M
MF$@(J1@+-><@,*IJ^J/?_GINK_<XIOD[^DB3);VF>\.=]6C,?KW+A-SG01^Y
MP[;6V5!\X3-62+5Q01D4$%1H,8RLM$G"2-F=ZKP#^OPTPI,9_=<6UBN 4EM>
MKZ1K2:4X*#6VN3K600I! 'ILM!_&Z[COH8#7O,7YF6?35<#G94-&*]J&_2BJ
MCB[%:MC9JM;H-O'!\]H(-CZF4*Q)EM3? FV5?K@;<*""CM+5#"7(!(9RA1BQ
MS>:((MOLK>DO[[US/_8RPG_ N[/QI0W*WO(%K7[->?Y(U^YM"Q2-.S#+.5B4
MH@3V8SR!46U6MZH1O-4J9YNL*-V%\WNDV;O9]>=!#3*,6%JALS01I'>&W0K'
M#D8TJXQ+=:(*FTMW$;">QJEU$(H/2:H8D@52CHVS4)E7SUOPZ+(.WI!/W=$D
M]%OT--B8[UA"M&0MA"A*8W*/$'6M$%+UTJ00HT^]+4M/&9+UNG56=SAKS3KO
MB=]_^9<E[SF:O:EK].YT ]\H,SZK@B"K5K[/6Y:%IAH^NV OR,0<^F,Q[A3C
M[$8%"UZM*(("YV,&P_X28!O%X;6/%(.6AK[%;&@W&TRKDJI5 ;PHC$%]UA")
MC64)64J-):G8[4"\/C@G.G D@K<E)+ZRJ9+_D0(A2A_ D2I8<@K4'VOD(W/)
M%YE+!J*8-EX%ESW46MMDTN;#H#(0^(L8,26,709^AXA3'>,A"TO:O%75(,-Z
M5O7&H??*@3. 3H'=TIP:@I;&0#1%0RDZ!.TLE=3ENM[AV&S;I-ZJ^EM[=K <
M;G8P^Z"5?50-:%QE^VM7 VG;?"LMBXG1('5G?WN/)'< >RW6'"DPK#).@2$^
M=Y"E0$S).5;#H9:-MQU_E=49DOJ'+)$KP@(#?(8CT3C@FR0H%(N63I@0NG/:
MOH[ Y)?):#%_]_Z7(<+AOS.EJ'UU,:%HDW!#N@$7OFKMVF0J(]J,JN@R1!OY
M MFQC\'KGDUW(_JZ'X3^VV)0M1;<N'7HO;29-B8EUF&%="-1T!XP%@M"8+1"
M:).QTT3%]DKNAF@WU)NL_SM#6"M)OOIZ?C IC_3<P_$R.U6+<1:J+2VR38G]
MK=9JG65@Y>@(^QM+O,OQ#3OBA!'"!ND(DL96L^$"@[/0 E^-JD '39)Z6Z7U
M8O_7$GJ\L2\R 5NHGMM)2FK(XF*1DLF,A4@)=L-<R9 8ND#1*>GB=':^VS#U
MKCCW-K,2)0932W!0*3<5JA,DP:YQ+2[7F$JQHD^'^"+E_A--#V=X<M2VP+4=
M\FPY:Y5NC$*>XWA4I[/):*-%5,VADP,E;,E)23I5:&E;,#XA)(7$N-YH%,XZ
M6;I5F(_QY7N:W1O!Z'M5M2:77*/%%&TLK4D4>&=C 1$B!</@J,AN^8'NGW(?
M;-Q.MUG)6XWN]U$X-;#+&?7_S]Z[/[6-K G#OW]_15?.SKZD"A'=+^&=4T6
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MI8^*;1FF9[BAK7FF 18\(*5&1?)40+W0-$W7TGN'B(,HQG[^*?<OTS'$BKW
M9H:A!92ZFFU9GN8[5J!1U^?4HWX0^;US =WK7.XX+D$/&R=E"5H.!KC;/,J'
M>IF?2T[_H$_ST2X)0S/GD'A,TDKH&H'A8PP&*YQB#[1S1X\USX@<UW!BW8E[
M%XT9F@=IC?[>F)JZ8T8,"XC0@V386@A20K,]-^1Z'(<![UV6K2J_?AVX&7G<
M,$QXG.^"<+/CB&K4M$&G 59BV7YL6?UK*W,/;AZ"$ )D^<PCN!TTG4_). 'U
M>"/]-"YU:1Q:D19C[T4[!!U4]$XU0VI$W#%-R^AMJOB+.VH?Y!W?K\LJ'_/B
M27SC]YAOC:]X'6_Z3/_(BW8OW7>TWX')MID4PD(O! 5;<P*+8VM:4PL<YFC,
M]0W=I6%D1;W5M/L<27@!4'(3&)K./2T(.*B]()ZTT+$=C3)+=T,C8K$[T+Y6
M;?NQUE "@P6/KK\>HL?J+PN>F,?H+VX0&:&/Q6LT-K"KHJOY(6C9S(M-/7*P
M'K%W>4 #\S*_9$7,R_B9 <Z.'8>FQAP:@\S 5IU>;&NQ2;';M1E$?>U(W^,H
MU,OD1U,?TZ$= _O .%C<! JR&6)##\^QF,$"&O365?*](5WH(.4%DNMY/9FD
MT[6ZUI1Q)9.>+=WSJ&=I82@Z]OHX#B:VM-BGEA58'HWZISKV2N3W(5+C&KII
MN-A)'GN#Z6 ;![K+M-AV_)CYD<Z"WF6?]'-JZ')*P4-[DBR-&'U42D%@AH8=
M4,UU(QM8N&UIOF=YFD>9"W#DH>>SO@+S[Q@ ]W4<'C W^"%M8&WCC W+-LS(
MMS06AV!!NC;3 F;9&@T\BP:,QK[;N[CM4)IZK2$5>VWSEE6'L7X%+-:8CFV9
MD<N-R-<BQS=P6IBE42MR<8R"8^L1C6W6NV":2KVXRPED>&L)8IF.'8 NIP7<
M%AT_+2T _5PS.3>HY5BAJ?>N7\!0V+KBI+WBI&L,_1I6[%";^IHO7*<.B[0P
MIKIF,5WW><PLUQNH-MW!R34/PGJA?,N[NT4?95E^G5S3<XQ,\JN$G4PF>5'5
MF5A:XYWYE- P246)?3%YMJ'N+V#M&ZYAVC$UM) 9V" +1 *-8E?S NKK3NCX
M9O]JM50TH.=N0$LWW-BP'5!6L!-J;%#--YFGQ:9+/4I]9O>O@$FUX[MGRK'N
M/9 U=2]]#!8QW[9CSZ&:%X+Q8KN.KH4\C@"+'-<U>6 [>B]C2IN@HZK"ZR%:
M^LS1N1& ,(]='\=+!YX64L/2(ITQFQNN%^N]JT'<9+[[X'??T]=I06]]OD(/
M$T,6QD/9OKVFYIK4L=W ,FW--URL%#(\^ O^,:S "@W=MN*P=SE+/6B<]'>B
M)?=YCQ_+V!:B$(_J7>3HL1D[ON;Y4:S9H>EI@>=2S?0BUW =DT8][EWTL)YM
MQWF&>R[R- 6)<X39!")K8 /-@XA%5D1YI''=PJS$$)V/H.>9EN?&D64PQ^L=
MA;^*Z5,OE33B,D^G :CX(B/?M32?AJYFN(%I&ECWSGJ7-+*97K7>.%I]&GLZ
M]JH#50#KOW"4E&Z'FN\9+J6Z8WG10$-6SYN"OA@\ZK:R>513_<@R=0>+GTP;
M_O%10W.PJ;X?>!'W0]/W>FMF#"OHKLKVUL92;#W"CJPQH*IK:S:W0>DP8E,+
M?-WP@1)MQ^Z=TO'D@P:?P#@^3*Y&U>8..?0\EQFQA?7($<-XB0.2B?L:=1EC
M$:6!X_4R'VH=ZN4Z-)-7.6TWB@SN&0%@2LPUVS,,C1J@US!;]YC%#<?W>IM1
MOW=#B^BV/PZ 5Q4)JYHHUI<L 9%P_F4="'1'EQS\Z>DZY'2F#WF:H:])YNB1
M:=E,9UKL6L LO,#4* L#+7!-T^8&#0!8"O#] ?Q"LYI')8JX!C=QB$?H^AY(
M"0OCZ[:GF;YKV:YC!SV<K_TRO;9[U9=8-?[NF]8>F4SWS) )6:G9,8[$8196
M1QA<=XW88+1WCM][ZL%.*>8=?7V):J*7<.ZYINU8MJTQ48#BVSI87#S4P-J*
M'0IB,>A?MY29"(0G1$E:8_O3>7SZ\!M+ZXA''XM\C(IK78GL,. 7M,@P]?B4
M%^< 7*#2U0_H=OT#U@6T@1G+0IP^+.S^6$QXF>ZF063IKN_;FA=QT((="K:W
MJ5M:Y'G<-B+7H;QWRM#+=C5^&I8*UH8=<C1>N6YJ-@5M-PQPR@B'KYW =HRP
M=[I)'PW+)TKA8"S471LL1 I,TPX-IE$]TK4X OX)EB(SP]Y1R9/&QAY2VCU+
MY=U+TP118*VUW4_0(7N8'#P&AD%C,?D3>[BZ <ARU[.T@'JZ:T6^$_9OI-4]
MYNS"\/*3R0/2O!^$,DOMB__-T2G*HSVPG.C54W>->AGD8-SF+/0#S;#$5/O0
MT4(;<\\,/_*"T B-IY^)^[=-WGZE:*Q+[F-)@X#.E\O6@3*#P%A:A9*-M;^V
MSVE_;#_C@U8\]$L9'<&YS9XI_#:\>^%Q/>9"$M]Z;9G;IN&]_W)^\+V7WKH?
MOSS@63[&_+\5CQ4:&:SI>P]=N/_=XM*_O^$)/.K6"3:0@#]_\/C*/^/JUM/J
MJGB//_SHL]#@*.]8F_SQ!Y^X -D?.M\5#VM;YJU^8/OKCZ)?E@@W)-!N"9H!
M/  LZ0.4R$4I#+ >(>9# ?'W<7/_UX^W3[?9#/SV@V=[ :H,L.+5\&I^_%%P
MG1_<N<![3GL5>B(G3%/DJ7=@Z?R"[S\Z^?:^X*FPX<M1,B' V[^>Y>FB$,(;
M=O+BZIVIZ]8[D #\'5[WAM""%=^_N+GB74Q9I<5Y7F5YQ=^0*C_C<?GSFX_'
M%Y?<=6GD^Z$6>[Z#+=E\C7+0_!W/UDW;"O7(,]Z0N,C'S3V7OALQUZ.>9D3,
M S,A=.$.FX&H8*ZI8S]TII./EY2%9NR8D:;[+D>AS+3 9ZYF!=PT0N92Q^9P
MF1%3G7)X&F9V:+;%=<T/@T S8]./8FH[NN/!97X4A+%-<201EC_B92&NU>>.
M;5FF9=H!A<L<G[K<\"),X*7P4ATNLW7X*_ L6(:).>IXF6G$MA'[L&:T0WW=
MTOPH H7!=9GCAA;V*(3+N ]_VSS4J(U#42(1:XT,G%VIVZ[GNWYLX$Y=/39#
M'FL\QE?9+KP^\I@6QF'@FG"0ENO 92ZS H *6%9@Y6HVPR&8;L U"[[W@]B(
MJ&?"97;@>X$= 4#<.-9@_[ %T_-Q A,+G"@P*<49P>^6<*<7R&3IU PHLS5J
M.9@_;<5:8)H<-@"H%&"R@V4O(I/MQF9D8]<F;L#). C7"&[S_<B(8X =8W@H
MH,"Y=A11@'<$ #,"P!?;!?7$M*S0Y:[MABY<%@&<;<?4<7H57!88D192#P#C
M!,PUX#;70;@&9N3:E$8:%;T(/4 WJGM48]P#5 BX;C,;L22,?2 %'R#A6MAM
MV=*HYSE:P'3#LUP]\%U<&XVY846<:9Z+M4*.Q30_ "LZ!"0-[)C;9H2(KKM.
M;$6 :;9C4YS]# CBZ1XLU3  RH!<+FZ!FYX;,)R>S1T/VU@%V (MUG0+@  W
M :ZPOH+?\1PX"@=.DP$)VI$)].(CO.!/Q/W BY=X"5 D,V,[UABSG(8F?,O7
M(A]^B"/=\3VD, Y<PO9"KG'3!9H 8(+U!R<3,(_9CD/AF$*XS(JC2/?\6',0
M:K9M4 T8C:5Y-O>Q.: =A[2O9P?<);8]X,. ?CACPN>P1=A 9%(C=)W(9I:Y
M>'91"$9/  =MVMCPC/EX[L!/ MWTF6TYL6<SP>MTEP-.:2:VFK9]P"K*PT@3
M+G! <=/T+:0PVX\=("7-Q3X[MNL8&G4,#Y#:#:CO.&[DK<8[^4V9UP7CI?PX
MXC02]@>H#__\?PCYOQ-25E,\(301M"1#N^F]OJ/_M!N#V:"5R5_\O0&?)]7N
MF!972:95^>2]_$)<$=-QDD[?7X#]5))C?D/.\C'-VHO#O (EKKE>O(*FR57V
M/N5QM0N+IF14\/CG-_\ 2QL^EA.:M0L**?MZ5>1U%FDL3_/B?7$5TBU]6_S_
MV]VE[TS'V3;>[MZ,0/O3X#&,OY\47+LIZ$2N\T98V^^SO!C35"X%.$-3Q U"
M'XX%<(;?WG9WE__Y9YU7NTM[E5]NDQ)4S7@7]#3M)HFJT?LXJ31A>V6XU0L:
MIISD,=F77X'"A[L%4%#XWV01&%C+Q MQU-:D(L+#N3NA$88$Q+?&_$"[,&LO
M:8[=F&]@K8!LEC?[SIFM<06(NS"]&SQR?>L\\/_\A^'JN[-3GO0!W7_@+)Q-
M/0OL_LZ+Y=/X,6K7'T3K89Y&W;V8ZSS2+\='%X<'Y/QB[^+P7)WL&D_V_'#_
MR]G1Q='A.=D[/B"'_[W_Z][Q+X=D_^3SYZ/S\Z.3XQ<Y;JLWQ^VO\[3_34%9
MR*ZJ/-LF!SO[.\34'3OH,T*_$L;9'WQ;+WE_/#G[3-H3[>[DL2]\(ZR%+,^$
M&RYAPB?T$>L*P3RU(LV@8";:H%F#<0+VN^%B"#6R;,< TZ=QDI^A,KI_R2(P
M:F/&M2C&81>F"_>8W-48I098GHQ%IO>&9!2#$ACG/,A9W?8Q&#I\#%W[UPSA
M%P[TGTMT4 F5MMEG@[RHZ;RG=96W2B)N _C+>WU77*ZE=)K7%;SS&X]VY?L-
M71!/<P-#7^VDY.]+/A%)42U=%&+OXMEO\/VP@*)]^W52)K(UT_OV_N8BN"J:
M<0[Y.FO'-KR?$%_>5=$=%_GNCN-;"Q?!'\7R>T<2($#MQJ1:\<9[H'\#6];"
M@M.O[\6_&GZQ&OXBO9+1M&$&P%%6*9AWL:8%,\#?',UCK:)P"VNJR$G&WW80
M?26./!E8Y0&_("3_AJ6R5AC<$K@/(3^Y@H%0W[/I28^$T!WBU+)UW0FB %O#
MH;O?MS0:&I$6^($?>;&M^[:]+G&ZEV4U3<\X=N)[0V)TW50_OTF^(1O(4TZS
MJJA?0-ZN&>$#SW9W[Y>XS\N($,/[Q86&!MB]X^,O>Y_(V>'IR=D%.?UR=OYE
M[_B"7)P0,' OP(HEAD5.SHCA;$5OR<E'<O'K(>G8OC.[=V__ G\V LM^+%^$
M0\('_/S&?--K'GD+HUREH0C;*2](->(D3DHX:#+EM" <CC"ZQZ!:IP#0;9?;
M'HLT;GH<<U%#+7!#C*E&<1CY&.>+UB4 3D4FTZ%,0%N4 )CQ.X:7C"(ZQ7/@
MV<!A>\"93$6SC.UG!*?-78NZL0M2' .SD0WD;AJVYKK4\7P],'0>K N<'P7:
M_@] ZR-\4PX<8)B(=Y_8OE^:=]GW\!BU\QI\?J]+U"IG@, "S'M51FA/C5 ;
ME! CUKGFZ9B)Y4<<!UBYFN4%3H15UA;3U^;3+6@F&S:M,$2UDC-AC(8T3?,J
MS+\-'.V%.6HK<W3CS-&+L[WC\R-A=SZK23H,?OBZ])C>D>SZC[]W&3=*B7R%
M2F3KKZEF.@21Q5DB790L_%^5?P];X+\8/AU8$IN%J8$]S,6P?_ LC,U$3^Q$
MFY18]4@^)BDGQ_G.<SH2?>9P&AF:YS"1>V]I013XFLLC;MJ1$=F4/5:)E[7G
MN#EX=RA*S88,,%W7-4NWC.!A"1J]2E2ZEU5L1MK6#]O%:TUVHJ[M^J;C:8[N
M8"=>%T>M1S$8QHYE&%1GIN>OAZ;.^%52HERKL)/1T).>CHZ/3WX_^GUOFQP=
M[^\,D+J>XL2;6HFGRK8Y_$99)? *RR**&3X16I)RPAF6[T<DR4A2E82-: ';
M?KL9*6B.>-MW$]!N7?(=N\%T=LSA^!Z?RUAX&JTEC)GAX%P*QS=Q;C+7-1J&
M@<9\T_1C2X\LWUH/ASW*V'S,I"AH%_WCL']1Q&][(4N\8E+DU_B<#8B&IO2&
M8O>$[[+B8;/ _QL6Y-T_MP1L"9B*.=B*!?FC+I(R2I@P%_-87I1TD4%<6US1
M+/E+?'ZY?,57S ?"*(H\U]9"(W"P:YJOA3;6VG/?,V-J8<_O]?"!"_KMJ&EG
MPP2X-\*4"6S-@@,(7/TUD/C1SMG.^0YI&DL5\MM%J*+UO9*0E3==>=/;Q' %
MD=>4*CYL"6GZS//MP-0,%D78?2, "0D?F<NYI5O<L=U')PHVO26CJ,#92O(_
MGY*,&P.7CH;EZ.0DC<@'.BU'><')K_#.&SK=)N<UK(O8^DO+S:?<OI2/S^>*
MIJX7<]VV-=UB.AAUMJGY;N1I!H>ON<NXHX=K1=5]^/.DN,AOAFZG?:BQ;<85
M['*#T?$Y\W$='G 7FVB9H65IMDTMC<8TU )F AZ&<43-]:*BL#Y/BM,BOP8C
M<^CE-/M[&XR'Y&Z^.#S+:*O!/W3^3@I O61"4\*_<28ZX\/78!GQ\L5K,5^G
M\A8'MAW$+-*,F&._-HMJ ;<->+ >6Q9U=,]PU\J&3G/LS/B_R41X-X=-IX&M
M&R^MGCV+6P/ 11!>W_5;/#YUY79L>"WI&@-M)/)$IS$\))R'H/_S']],W0AV
M2U+QE$]&><9))KRDVP0D2UIC5S1"@?\#RXKX^Y7ZW-"XS-;S*:6NXT2QB_/*
M;)]I=JACXU O ,TTUJD1<I/9_+'2 $VB/8#0!O!_UWEI[O^4NWO[C-90[#/+
M=#U3<SBVR+1C6PM\-\0NMKKK>F$0&X^.LGS*0><[19ZQ$8$5T_*UP+W7/=3'
M))87%\@#32>Q[!W#O:^CD;'CWGN-Z>Q8MG7O@VS?N.<:R[OUH+XYY7^HB6FO
M++ZA<20QPA7-_$/*1F0_I67YH@D+=T*>B+=@*^'V?P 1.+V^(T3O(([0[$'Y
MD2+Q9R/Q@@H3ZWPZAM=LO:#73A'X*R'PQCVK:/RY8'[<9&H+*7[XC8UPG!TY
MR<B_1PE\([TQO.#1)J=D#+QQ@AM:;N1ZOA;2&&?OA+$6A$ZL&2P.(ST,/=-[
M=/9R,]-X:IBAT/P&[V?$,KD\(V(:)/D/E!CDE!9$S%'O8Z.$OC.^?O03[3TX
M!LYJC,AD7+<LG.>-A1)VJ%&J!UH4Z488.2$U_$?WW6[43JEU#I[/'!W_?E_V
MPJ 06/&3ON4D#'KHR-,2W\6(/V-<(^"&$SK,U+S !>88QX$6V*&EN5QW], U
M?8N:Z]+#6E5=U.G>*AOC\.NS58P]+0B/:1G1/S<Z[T*R'ZF)8K=Z7I%/G_;[
ME7TQE&#/[#2Z@1YKQ[*LGVY/5GM2'OI<_<6>%C<[C<+.#G\Y.K\X/#L\6-UE
MS-RZFO47V]N_V(Q\C..3X\-^M)SH7?.K.\^B(3=%7?<;!UF$A8*<A%/"1ASX
M_QBGE22Q:##5Z9Z0E(22&YZF,BG*V/V:Y3>P<4[+/,.&"F598UX4+4G$XR23
M/1;.ZA2+2AQT\.$#&^4A@87NL>HYVP+Y@6F;<8S#IC'SU*.@YE#=U$Q.(\N.
M.?/C-;4P^3<<TK_P<,Z;LSD21S-X5/D?7FZT$D2:F1F@Y1SG9+ECJ>*\BO.^
M&.?-\@J^^;-."F"K54YB;*M6B+[!)9G415GCA? #\%=1]&U8V,QA]DDT7FU8
ML."[0,LMA@NE_KFXL!XY ;?\6#/$E ??UK7  2[L^B[3 T]WW?C1'98E%_X]
M3^NLHH7HTE8\QU" )[9"\U?!?!6_5?SV6?GMS8B+]CA+3'?+>$M&H,LBIXT(
M3=,9N^WRX9 W%\ S%UGO LOM:+VS #>P8?P9>UV3"'[-KL2E<#",BYP7PR1B
M$$U)MN!Y,?ROK-F(8-EV!>MM&KY6(UHMK_V&EK>EA;BYV<-;4-.SB&R9<H\A
MYP#7.OP#=H#7BTOA)EQ%\QSL6%^*18A%TK(B@4XB.BV?4X<W0M<+=>IJ8:!3
MS3:\0 MY&&FA;C'/\=S(TM>DP^_710%;EJWY,114T>I9)LLH%5ZI\$JD# 3=
M?DRD(*L%+CM.J@KX,D^!VQ9YAE&X=$KX-2^FY @]VI2)0N4#6E'9/WE)XLR?
MT=7\NYZ6,WY5I[+[T[EV0;80]MXN,2US9^:+243SRPDVOWQJ^2,7/!,KO'S[
MG$+#Y&!R^)&M>:&!33@,1Z->#$*#ZRP,0YW;=$W]8CK00^ U,F3P6/YZA(:2
M&4IFO+#,6/:XIW FG%#&0%Y@C5<D."CZV;/;WZ+A00D0J';KIQTP0KCTS"=-
M!U B/?EL]_9ST#JXX\WRIFAWYMTWS% S6TMGP;S9VA?[P\GG[Q5!;5QUH+%C
M.O?5]'D[@6W?5QWH[3C^?=6!IK5CFN9#*__T'>]Y<[^;!*H')TSU ;.-S4M@
M4^>OSE^=OSK_OI8(_2B8UI\TMPI.3Y1PP=S(\UU/XX[)-#L.32W0=4,SF&N9
ML1_ZU'YT+NKA; Y3L0\JSE5>3%>DHHJ+A/+*FHLV("OUTVKU?*,M=4GDMR.%
MO>:UPYT;^[3 W+ME==[VO0RJ"F+(!;Y/G;N0M5F#MWT-_8/Z_-A?JOI%V.C#
MA_LY/#L53JTFC KB?@P[FCZC^]_27<?WJ:L9KBUBQI86VIZGF5[,',]A8>S:
MZU%#Q&X_U&62\;)\^7'N3RV*?W2@^X#U\.<1X:K>L&^25D%$0:0O)=)**5D3
M6 ]!1%VA+@++OJE&+Z"2Z,QE>N3J&@N-$*MT'<V/7:Z!SF%8@:^[GA&O1R5I
M]_J+V.J^W*E239;!W,--D.^I4(\OOMW,2*I*37A<:D*,605\-7_$CN</+%C!
M1#>1W@8V/E:N5#FI2RZN@B/C ):(X)6ES$1H,LDPPPS?E4[QY3<)O!K9<@9[
MR-&$O$Y*X3/(:,82FJ+K$^?6XL5E1;.(%E%)<%!M$BVEQLTSL[?HVU69"CLJ
M[4?15M]219O*@\9Y0@!_,2N'5A7'D<R(SX#:.,,<UD"O1(;^?%X!+4M>EOA=
MB^\\CKE(3<R:X3AX:X(Z90;$A LM\I3DH(1V:&SNN(&CYO.",ENWM\)Y>0,M
M0@J/U4Z^I7PJ4W\,AWS9.=_9WR&>Z9IP\5O<^7R;V- /B#1,02OJ4'*<%&.9
M4PHPFE"\"(A?U!9'8L6TCI*J6==S9I&&@<Z<F#J:'EL,]"]F:GX0QUK >.2'
M9N#I^J,'UQRQN-C#_>7%WAS,'U-Z]2I4-O<!WB3%E1577J_&4\YKLX#=+'*G
M%2J$V>%[P.CNU(JZC'W.3Y&DFUJJ_':=KY@H(_LFR-N:"JPX%859\!7+BX*W
M$]R%LE846).5([N\3O*Z3*<MMUSUUA]2=%X*C=:#)VNEO=M-B7MW:@,DON]3
M#BK_@DARL!TDGL_1OR76#D$)K6%6=H)Z$\M%40VH1^FT3*32DZ$?#;0@+:1H
M3J#!P;-2ZE-8^@(_B6K.V=N[)#K7KSKS!.'+.-2M7<:+LEM)4X )=(UT/5M(
M8^AT^8JLS#%M?<?0#S0#F,OFVB+G_"KGY,M1T\U]AB1@"&I*]/6,^E9U_RE'
M/$UG_M*M%9U^##-L _TK2P+>RLX3SZ>V<RO0 2-<S?50!0\B3PM"EVN.#23K
M^KIO!FL:>WN.AZ,\K!N3:]8I(59=*10;?BHTP_ZP].H*6"WRXK'LO7F-+>!;
M_GF="\\(.G^PLJOYR&3S>%1WJBD!WB.T%E'Z%:/A $];96-(K:>>Y-+$8&E>
MXM,F0+?\>_K.0J]Z^ .7+?NBDE_2'#@;6$C"2FFZA\(EO]49)Y:^34S=-#>$
M)V!E\W\\@?0:WE$TTO:CJ'<&:#=S%2,S-@*':D&$HM/BMD:IS377M'R=6S9U
MHUN1S<CQ]) YON8[HJ$[2.? \@PMYGX81;Y-8V;?%K>GPG7X,<UI]8;462*?
M]N7RR_G!&U(RBD"QWH""PA(XA?+G-YJU()7?9_4XRJOF]S?_#$QK.P!L]76G
ME6?MWC9$H.T T6+1/TU9VQP@RGG;6TSZ&"@<6,4+>$3C81:>6#!L6HNKPUPP
M7B.L)*$O@E$S 4-M1TE*)2F?!G]/,O*1AT5-P9(V;"%6K.W-($T4NT!<-_B/
MDBYW2A?'BZPHL'R-V[:OV5YH:Z&C4XVS(*:^S7G$;C4/#'VP_F(31)"!Z;^>
M:VD^T[EF&B[8<3X+/=]=T?Y)J#M"VSD? =\K3^I*!)E!65H0-Z7XM2MGCHX_
M?E?0N/ZV8;K;NA]LJ)PA\DP>KDW.CU9)C[NE1Y1</ZVK)+ =DUJQHWDT=#0[
M,"PMH [7J,\=%G*+&\&C9W@=Y*P6WMJCC.6@,(@ZD ]3>!JPOHSQ"WCTAQ2P
MX@WAH,1-$/1%S;^3]/C$J+ 9(_8.3O:_?#X\OC@G1\?[)V>G)V=[%X<'Y,/_
MD+/#CX=GA\?[W0[S_3KK%R4\I;,]L@!H F(O3C"8BGDD:$5\1RRTW6FN.3DM
M\F]3<MY&=YK.9VT>2(9LZ(\ZD\J!2!6[ZYFH)9*]+*MI2CYS+GPGL 0A>D9
M<F#;;),;,6DRP;#.1*:M=7M[HH$$!I-PBE,, <O&EV +5;<<Y?,7QPE:H63*
M:4%DRML!9WP<PBV6L4E.D6UA&"8=AHZ>J*)EZ9ACE.-@PXH<'1W->L\U(#EK
M$GD.OS$^J7!X (  M <1Q[[KD=MW'OHRVH JDJ8"@"$V/X(O6]!2,L$EK5P.
M>J\^PID10]?^M;.0B+OLZ0:IK#25N[2VIA.1W.E\@.Z$1JCLB>^-^8ZZA]9>
MTNR[TREBK2>Y..37^MZ(WQ\XX:?M:_%\V&:8:T WX_9;AWD:_>]X@F<QFI56
M3N@5EX5'FA!4[VEZ U)K]PUYUX=3HV14H WQ#Q#$CU)S<-KZ#PA!L10PQE&L
M@/+P7N2UIDG&GPQG+T1[-Q T^_*K>3--.D04WEAZ?C%3;[U'>G1\?/+[T>][
MVVCKO8Q#Q=C4LT6EO=4,VSR7?RWJCOW"9>':>2R'[<'!W\U#%?_<E'ZB'K[L
MNSU ??_>2YRE*P;<=")X-!M> [H&3^M>&U*+@_7#XV\Y/#<0(HMF>-=5\&+M
M*!X(JZ$% D[!*/S!WCR-P.HOGWP5<GU0G%(99W?2W][9!3GJ$5Q[VE6F)\2F
MV&(_8I)K]I!4' SXG9>FPAX <N:$A46/+XW+L&U>N-$.V;9%XY(?5K'BEVOP
MM5X VXJ7ORY>OJ>8^2UF3B^+I/QZ&5-6Y8\<?]U[CGX&.R4?Y4X55]]0KFY9
MBJV_+K;^0;'U6VP]O*RS@I=Y>LVCR[*B<7R)I: 8$]ML'O]EMFW,[XMC442P
M(IU",?Q-8?ANH!C^JV+XIN+WR_S>O)P4^037RC><OY_.]JD8NF+HBJ$/'-:"
MH5N*H2\S=.LRY5<T1;;..,<BAPWGZY]PNUB8TVY7L7?%WA5['SBL!7NW%7M?
M9N_V)9P8ORQIS*OI9924V&&K+C9=>?\,#R?G8M/D8+YIQ>H5JU>LOH>)32J+
M</A9A"J-4*41;@Q?'* ,%"JPHU3@9178N91=;"_CO+B<-^FX+"]ES]H-UX1E
M_UMLCHE-2L[N[GYV*%KW;L,EJ>APTFE)0S[CF*>B%$U_C[#I34%.ZX*-:"D;
MJ\E[<2I),[M$:=H;JFE[NI(HKTJBN$JB+$L4][)LQDE>SH8:74:THILM2O[?
M,PX77//H_U/<?5.YNZ&X^ZOB[I[B[LO<W0-[H1U@"D8"^LSKL@06>PG:[V9S
M^,\K)K<>S/8OM/^]SO"RC[.)?OMY%LGAR7@-R(DZE2,%3R9<KEY9!!LK,TPE
M,UZ7S%#E3;>%!KW\$V<H)C@C^9JCJ, OTN;S9HN-_^KL7 B _YKOO!M^)7MA
M7L]&,F&1E!(*&RH4?%7S^KJ$@J]DPK),\#O>H?E<X,VW(N9FP?E\&C**A?-Z
M,DG%9YR9=$ KJOC_IO)_1_'_5\7_ \7_E_E_<"D'39>7B? =H2N)7A6\D0,X
M)F2S!<&^W#[.1T'V?]#=OIR2LL<8[+:B^$6>M1_;\;)S03(W(I3$V%")85C*
M9'AE(D/YD6[+#'J)IU3DJ3 49%E6M/D)^_O-I@7?/YUM6G%[Q>T5MQ\ZL"6W
M5]US;G/[\%),*P<#04[H338]'?5$#&<_FF]7<?B-Y?">XO"OB\/O*PY_B\.S
M3M$M5A_0 IL.8"T" ":[_*,N-IOASSTW6'L@=X\CJW#WY+>Z2,HH87(2;S6B
M%>C^_!KN!!%1XNA;E3FD1(02$7TM)%1ENQM0MJOJ=E7=[L8PQ@%*0=E;6%>Z
M\ZW>PCKHS@477=0O^3?.:I%:F<=QPGCQ"A)I#MK=;Y/#=OODI-F^\)3OY\4$
MU\/)+SE %<.E*D*ZN>JRKZ3"ZY(*:BK4;:E@=&0!R\<3GI6OP'$^%P#[G3TK
M7J]XO>+U0P>VY/6JV_QM7F]>EK*ES/0RO\E ZQTE$S  +D$!KFBRX2R_Z:8S
M)2?MUK&B=E]NG7S@&0=+ +,CY>_"()A7\#:5N'?V\E&B0XD.)3J&#FPI.E1?
M^]NBPVJ%Q&6!3! #B<!!7X'7J!409]UM+TB#BX*"_2"#J]M-:K[T-)$C6!Y8
M%P [Y4A2$D))B.$#6TH(U1K_MH2P+R=%DK%D0M-+.JL\NHPY?P52XK3=>J<&
MBWR$K<M*75Y<)TSEWRL1H$1 /W,!5.K-\%-O?N\18'O*6GM";8HO;JYJK%KF
MWU:-G4O^;92$B6Q7LZJ/S69KQX?-[I?:$,SZV9!S-N)1G2H->8,U9#53ZI5)
M M7J_K8D<+%42>1B?KTLZS$\9+K9K/\CO)@8NFR ;.S^BYS+72M&KQC]G8P>
M]H5/^/F-^>8ULHI66=QLSM JA8H3;"HGL!\_W.B5<X(2OJ75YO<K.I_M4W&#
MC>4&UO>X ?R7ABD7?]YUU#_U+SSQI/[2@9W%TSJ/__YAK%A8;\,D3TR$YM*!
MCF82>$*ON&2:&HUAL^]I>D.GY>X;\JX/>#B3B%7.-EL47B ;%)G)\JMEB=@#
M8&P"4_C1PS#N9 HDB7Y^@]U5T*&?Y=527YH;^/,RS?.O\'GH<=9SN4MR#+M<
M[#^#NVQ]/)_D9COMZA\",6O'LJRGAMG _*OR?ESF^Z2"';"[N<8H*<E>EM4
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MQ.;K_U,2.,\;,$=;+[9X#)MU9(W K$WSB2@72;*D2J0/\JU<1 56,_K+X33
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M/M,I/LC;(4<5P6X>H R(FNE(A!_%0Q>"B$VU ]RZ-RF2%)0(W135N[_50*)
M)+:H42XG=:;E<=P6AG-:(/EA#7>'M.=KD8^@68TM@N$IKGA*P<-"*FRB74NS
M,'QDN[#%(@Q54/0L!45P_DUX:*JXS/K/=M[A:=8Y!VR*IK4+]E/.6=WT>VF4
M,EGV/FO20ZYI6F,RP3;V_\$.!DT\#<T0; _T+1DG?[7MIN:M?^1M^8QH[ZOE
MP2[)^:1J'R;*WA=[>]#Z"@E=5!\U?85H*I@FMO5&9QMN/<'FS*)UM"Q:FLH%
M-!D2XUD3DEG#BYD-1D6)/9Q)V^8?%H!V78T9LZ"&=DRGLHF?CI-R7@S5&6C!
MV^8("S8?H#"82X7L7<2S$38F:<ZM;9#4M$9O]B<8&1Y4PNJ4%MO-63(16UU:
M36LNXK-G5AT"5(@4.( 03;517C8G)RQ3J='4HH>2T,<GP+:QP8;B?L_&_<X:
MU#QM O6GK2OA+A T9X9'T[+#38;*DYX]-AU#"D*??,N'U+FOY=SE_0]I&74[
MAT1I NLN+YZK^JAD"X5X(?$/)<MW<WEF:3HH6Z7:?:OO(<Y#8;SMH1/1).V,
M15AMT8/LS=#%$X)@K(4 !O&;CN5XCU8J=7H5GAXLEJ'1LAJ-J;1ZV,+21[3L
MY"^!D.=\(0.J7=@VJ6Z$V[;-(0(X8P,>$,DX!$<,B$5ICN_ !DMXM?3@SO*X
ME] 55(\?X1FP2Q"[T_=QRK_=QMX_0&R#%M,"4UP%9 5*P:Y 44WT?'R/7?N$
MJ%J)T7.\Z"YB@U!\X5!G)YID>"2:.-COOG>9+7SGT+M':=M>8 2&[1BZ:P7>
M3\)3]PU=X3-?70<7%E<U^"-_\T^53C<D:*ETN@$!2Z4$# Q>6W>4RF\IJAL0
M%!75#0M>B2P/ %5^4B2@KX/-()SYW4@B6@G[-*,1E;V#E=(R) @KBAP6O.ZB
MR+RNRB3BJ\@2\TB$XT"3'H.ND=Y&YT53;W3#RUD*5/@JMLF\(<9< '>D;Y-%
MBZ&-$4W%P&6$:U[B+4FG6=C1_GGGIA5=<;KR??'QVS/C'TR]YE_E!%!.@-?B
M!% U) ,"EA*G X/7UEUMGI9D9D=.HO!$,4E%W8C6S-P>UR6C!<Y8 J%5T=MM
MH#[O=9Z]JOO4XEJZM;>R!:B4R+\?[=PA$%7G^4<B@ZTZSZO.\X\&1O?T>]IY
M7D5V?T#]NC7@A:2TSIK\R.Z@.>7X&!)<5;1F0,!2:O7 X*6:'PP-8HK"A@6O
M3@1FF_Q&<3=BBEY=Y!,Q$$\,]RPBT0QJ-G/O>QEH(F=M0I.(P.)X60GO+.=B
MJ*S,2\,L0S!U_\,T82]XE>BB&=5%FV4]Y13;*& -R %G,AW.$A6RABU3R)8>
M+5[7/%\TERK FKC*X+PP\ZQ-TQ8?9]>WS:C$+%4N+/$QNIWQ(NRLA2M)8!EE
ME8Q%<G9=\KA.22KFNXET.ID77D^:UJ"=BMI&MVLTO5MUZ*]&JW[2S&"LGN)5
MHA)1GZ1NGF; 4I.)G%A)*V67# J RBX9$+"4UC0P>&V)[#$U8&5XD%.4-BQX
M;34!M;=RVC(3*A]O8UE9+6P#S#1IFU.$10Z:=QXE*9:QDJBHK[ A-YH*\!'L
MF4[:2K?;-:>LG3XN*M;A/ARZ'8GY]&53<]^M8Q=*$1H/$9\WLA5%,TVQBTR=
M.3D]$"9+.>ME0<*Z:EK&56!-R'EX5:ZJ4UX<WU1BRDM$1J)KFA2*(0\#6N_.
M>0$V=\1A5XZU2PZ2\FM=*N@-!'J_?E2JST!@1;9*FHZYS)I%5:*;[HIYNZ#
MH',&YXUTE9JW\U9^<K*(2GSM"U"5?O$"='0^!=+ A'+%^(8!,+*%G6WR.>,+
ML0%@GF%NX_>9W1[V3OI?GG%&%=/K"T 5TWL)HRHI#NI<#O]B:<*^*N8W#, ]
M4.L3>>59GFEE'0(]5'4E,EJO@/<5"2.BI9KL'"W-Z^T%/GEQ.._"JQCD2P-=
M,<B7T HG29%<4\46AP$N\BNZXK$X5'D*AP(RE%Z*S(8%,Z$PCJFRE8<"L"VP
M@BM4"^OQHBW\(><C3*CD!3F"?],13\9*Y^L+Y)3.]P+$<E"#^J!DT4"@=<L-
M.,[!+I:&\/?=@)]Y,7=X*%[WTJ!4O.X%J.>BCO+B+\7L!@(N<HJCM50>S'
MMD5GG3?N#$))$YCSL$@47 <"UP\%YW]QY6D:$LRVKM(IRR?3 IO4+]/C<7Z-
MDUG*U:WMSFN<)26FZLQ^4*IC7V"K5,<7&4+!BKKDBOL- USD,$V32:54_:'
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M5:8DE%;,_0K.$TY20'Z=D2$U#;Z6($-ABSS]9 O";Q^NN:TQSP'R[%?UX'"
M/ ^0YT$J#$G);GCL)"Q.^H5>VX-\MM%$JX#.?6K=YRB'/.1P^VY.'O+ICCSD
MT[X\Y&'0//3PX= \=,A#WGA#[OC%V2][Y_\U,^ME3/[&FCQM.@!.*C^+7KQ]
M_NJ_:-:&UC79X\AK2?[(?_X_'X^FA\_V,G)!XA78%9Y%KT_._XO9(+E@TSUC
M9H8-&Q+'0\QLB)E]MXGCD[2:+1WU#MA;HLG;UX+!FYIHDN<UM\@RZ%<RA)^'
MJS2DD(<4\G#A;OJ%^SY2R"=Q%://TCS-3#0OBU7?C>HED_DS>8BA$.)&+,<M
M/)\@PP^[-,8)B28+)OY8^[PQ#1%7LI6&W%OM]2K1RKU*F\#YVB'Z4]\!Y^^G
M^;RVX/8G5R=XPXUFR;]U861?O3+1G3SW.WD>[!_:JQP^>OCLX >XJ6=N^\ZY
MPP-@F7>\X_UG!I/WCL8/'CQI8HMAM\E!VG[C-?I$Z)G>V!][=G]H!Y\/@B*8
M@\=#\'F@Y!C<A!O@)GP?(:ZA-F*X0$-@:PAL#1?N]E^X[R.P==KOS+O+]U,T
MBX'?->6/%\;2B8[6=3ZKD/7D+ZSC-!]U(@*T:V@C;Y5+N?W'Y69=Q,;2,VT:
M-W_\,<U_EU9_^MQE9J9IE=KN]ZME6:RFA96_A-_I'Z I-_2N%;TJ>*3_,>*#
M/4]G*7)2^NS@@Y JO8^UER;+=N>I;E!N_P9YFSKZT+'\HNMS\,VB?5\V-$0B
M7DC$7\?E!TZ71F_*19RG?[1-S*\;6OUVJ_V%1>2_2(JLUEFQH34GX48"(T4K
MUB2R?B-6?B,J$Z\B,EI(>2)$5Q4,#4%4UI20,KI'B-;]?#HY.W_Q[PD_03R'
M<31A_K$3,S.,/3DZ0*K\\!#"B<05/QU57.BVD."31P_)TRCF)*.8);[%W73X
M."(/1#CQ9TS5!)0+C<%6NZ.UPR6]'D.6C(V"]MP.M_&:,W%U*;QD)MJ8N(P8
MD==W81[N'T7+PJY1Y^2A8>_';\>DRLO9,@:?G[N"HNF?/'X0? ._*;@_\M+$
M6;7D&U0$<G;70]U5_N7//&I!'DT99]G&/R@JZA)W&VU:+-LF]0+8L]Q4ET7Y
M@6%I<I^K#;_A<EF0/"*9Q%5093JMX49QHV1K/NNSS.?&XB5!+Q>,H"]S<!./
M170MV:>AM,DOZ,'14-HTE#;=55?DCIHT7U@FS)Q1PZ&W>#:CT;/52SIK75A#
MRH:,Y:2(\J**IB9+S841X '49 9V4CJLVNFH8K744C^719V164TK!BQVG%>D
M#M,535<>$$_3#$2]9%3[K[75).EQ>HIA*YV_1*\6*_VBR.J5T3=,\2Q;E%/2
M<=,-/[LTJSC-,9>V\CRIC3/B2Y/%$E,$YVG)C9N2O8H6DO[TOW5:BKT_3[,L
MXOR>+%./F3]"HZ@/6;&(R*;'6JUB[=E$W\=\IK4EN6$'*_U+6^G%:DU^V^ U
M?X&EI2,](RN3'D0G.;JWYE8P]% Z\*59TR_72[+DS7W7;0VV9WP1IQDKM5A-
MXG0FYC-]DNXT6:9@,<9'J\T:CBT]3YBYN4DAT[SBN@+/U-QD<!W3E9U]X'?1
MTR]B6R!!9R5ZZ1SFW^C7^,JL^EJ F<\+MU]W+Y;'#YY]Y0E^,;/_WHN<],TI
MC.[<=<I;9[/[$KIMMMF=)FZCARB)[9X@:] 3DX_0F!XH(M\W_1M%9^R4'472
M_'+R[I<W;_>.1HUX;[4C] 5"4WHM#1FN8D/,O2P$20?1'R>D.^@[- RDK6@(
M[-X6P5WPTR"-%![76?N*=68\]D,#2&S_X.DS2WJ2OIVN$0]J)!_N6BQ79D7C
M:PWU+XR0EW;)A/F-FK?QJO.I&"^:E89=YD2,A],YE#=N=YWS<^DEMI[-Z"OS
M&AM%CG&^,,%8UR42%O2!42?.!I. DX =)7P)[4SZ/TM7='(3<?Q#E4NZF/1[
M/9^;\EN1E]]9G:#P"#E[QE?3Y;[.CAM8ID4%J<_&&P<DZK(T; M*F%7[,&"_
MFX- 7T9SS2#4LEV#B1,G[;!;'/<_19/?_L_QY-_1O1DM<_Q'FL"D8V[\"VZG
M&:]&S:O)7IQ,I[^EAF3$;'S_6?3ZQ?GYB]?1Z6^#SK@=IS"ZYR$$G7V%]/XW
M_7X61V>OCFEOS\Y/7T_^Y_3786MOR]:26&^@(C-23]P8.&]O]&O2$1^B_XQ7
MZV?1<3$>N:M\_N)X<O[\_/0-+<K#HV?-TT:M1^'1Y R:/MFPZ]'O_L_/D^/3
M5\-!NBT'J4H79K:!'6?:.WPVI]>5;E]_FSQ_0QK@A3LQ#3I)S+%I4?8?$WIP
M%2,V3S,S-32>/RO_?G'^?/(_7PVT/YR5OWM68#?0P/Z(<[$;R(@H_HQP^/>;
MM_]GT#&W9KO7I!3([TB! +IRO]NB@C62V++\\[QF/)%S3%'FPZE ,F7]0P*#
M^$NZ1VJ87XMS-(0FK^68G9L%*D@+=$_^2)Z*32_2:C-XI->[RCW!>;Y@>,SQ
MTJPXAO,B1Z $04R)I,R>_7K\PLK/R;/[4;RFVW31Y!(8#_#R9.+#2/C%*,*7
MMCZ+4@&\D.R!18H[C>LHUS\RS;Y'G$P,GFX2P 6BET5!U_2$O%RYK,>%71FZ
M\=%D5C7#?7ER//'#=?'6&6T<+?D%Y 1G5WAD]$R2/WTR"9^A*?  'T+T/!X_
M9 B&E8)H_#V)*Q?T(?^:%HT>%SY7GS&.WBK?#L)O(UV(8Q1-%!?,XQI'#_<8
MW@&T59$T,A&AIW!=$$((81B:JZ&79IQ!DC "T^RU1D*3_Y66GO-8N8QIPK%!
MA*_D-U$Z]UNTC"46A@5+B]J2L/4[&><;#3GD=&KX&3A@FD["$SCZ%3,@/5H5
MJ:DV;A,T5K8J,C.KD<LM(T3D),YF_8'@*<T<<(Q7&J^Q]52XI9"G\K"8<'ED
M^49^'I#?'-,CK;&N^-F8$8V;YCR93O$/#F#B N!811-927ZW/U 36KOF_&,-
MHX?[#^]-[]\[O,_K2B,C%:)J,,YE>1#WP6+)HLOO](0)R1(M",_K<HGH:'L?
MD\+(%J#;(#U@&:.!8929!6TH5\OA&:4AU01T'L<G,W_H$M3O^RP=#T / W Z
MEW0+2EP@]SZ>+=:*E&$SE0=ZW!GT(&<9MW?[?./DI)4[!3C-,UA;<_=D^N0Z
MKB362M],$VP5C2DO<A+BPG ,_4WW9,D)2_>N)6D<6<@53S*C*[:09\9*)8F/
M3OAHIQE]5._'@X>T!!LK2S0SZ;IRPVV/+(>I860I:I+\,60)G;&-^WC[#FV\
MI CCR0ML%;DW163FB+=%R!)G<C;C,DLYUO<3>=?WHZ-].OMYM0QDR%7C>X95
MNI?2%VE)R3"IHK(&#/NS5]3?)OCO%SA7\C7K974\M;RTF%_K'7*)CO;W>,"R
M*,Y@<LQP..U\C.,54N,\!P03[Z6\6O=%&M&E;QW%1I#2DO&Y-EF\YJQ65[#N
M.'!#I/J:[8(W.:G8:5G'9'X=/'20PE=Q](\BRV(YHRS[(Y0K+6ATR^CT-[T^
M'(QN7:M[V"=O/,B'7AD2*F4C17FO?\Z8U7P9T^RB5V*&-V*7_QK8'0GHYECJ
MTZF2KR[C))!8?T.HJR*%TK#&?,!K_,&CO]%*UO.8*R)&DNHIZ7-T&^*N\=""
M.K<0DVB\[-YC/J[3TDM'_ON97.A?"SO^*7HZ.CS<'SU^\/ 9_?CP\>'HR<-'
M^/')H\?T_T?/H@,Z.8=/1D^?/N2?CXX>CAX\/."?'SP]&AT</N"?'^[OCPX?
M/):?']#G'^"[!Z/]IX]&3Y\<B9=&_SX\>#IZ].BPO7-^&C(TNV53P9++!)NM
M,WUY$J3?)LYDX$TX<]A.3H,$D:#H!0D'6F>60R_HAUI!HJW!O"G9V7M>%!_\
M.!CL&;4.&+2@61C;X'"ZL^!1J]BDO<P-JE5G1M+P>?)C48J<$U!/Y,2I-V$#
MK[+W5,29MPG=T5"\3I1(C:PL5W"Z>;'H.([O%/QT$,!_2@"_CDNZ4H=/MZ0O
M+)N$M?-JG9'5(UK=Z_] V^NQVS[Q:BR)S.3 #(I,TUQ 7J@Y=3Z?DU@YB^*W
M%?-VGZ0"$R%_"P:",RK\KZ&I:;[_ '/+)DJ]0<]F:<\YQY1HT&R$ %97)K#J
M13#@P;_$U6RY]Z_XXPH2?5:-Z"+.8ERP1K):QH9?1C/GMO(4!.[]%Y;NDX9C
M2\HT'@89Z^Q@B*CKG2SL1F<(DE3*^SS)KI'CYXD'U'F&8%1KR74GZ*JYU'%C
M_<>6#IO ,N)TY;U9-?WH>N[9.JT^0PYB9E[^,=@1+9-RQOU=I(NB%-=0O\FA
M,WP@ Y=/+5$W\LAH4]AAL0HI%#2%F^%@RUVS*'GO0R<_<Y$%+_C$!U81GL55
MN<"3B\O VIJ<_MK80QR:: 5#<-K?QG.C=^R4SOV%6#"=X,OD[6D8?@E]<5*
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MTJ3Q9-')KQ,!  0-2.([S>_RJR%3"ZMZRV:X\["(J<GU#.UCPS&CF;9ZAQV
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MK]TFN=TCH+V<G"FDK.Q5\]"FILR+TQ9<P>?#!F?CIAR7X89^"Q[>IJ.A4O=
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MPT' D(.*GY?":<# 3=7#-JUJ1_'2=D'85BQ="U&L.9KN^7+["\Q>'+?SYQ@
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M//(F/0])0YPL9K:BM&&]B$\=WPO"H?Q)"8;>A]O#-IZBL^,F*ZSO<@'OZM*
M!/#SWG:PW_LRG:-[0T^0>L/LK=$DH^-:+Y:?$%YDE8EU)+2 ;,GX[@I7V&0Q
M&0NK==4YI@85)8(95'*:!A#/QZW!]W)".AA;$+OVP$-_L)M#O1UK+9U@[$2_
MNSGL07E>O_(4X<V2;D)G;YJ2WSN+3G/DKSDL_VMQZ:'>/T].?Y5_I+:E*%WI
M0MI\SZ'^.V4D..[_?7IRAGB(1^Z+$/$RA@\ AR+P264%C3VL2&UO#S/7[Z[B
MQ%Q1#2*'/M!('40''\,\=,WG$'(;NA LI)3%ZH*QJF93* 62:LW.!SC2"HN"
M;'J!BG"*!] .2#8F0263P VE$YK1>?. =^ Y^'*)0M_H#>JYB9Q&X=5F70OW
M(=>EQ5X+8EC4 WXQK_.% \*VMK>M?OH4=,@M$;)60=W.8J:CE:935[VXH:I8
MQ_35A2#I=9:,+-1?VUVNV/^\.)_\)F[[V_>O]D[>G_?GUL*VN.Z<C:-_%_2B
MK$A(&N:2PY0:H?9WFX.YE7T*<#R,]LLE#C?C[RT*NL[ETL2##_;%?; SG$NZ
M#:9<H6ZE*H(&)B<HQGK17-9!JUQS"2$WE<-UK=<*\ZW #K$8@=LX:"2CX1:6
MKGP3.W5=M=2O%74I(FDDI#CZJ_?CMV,(!.'\ZW$V LX+SO+B+'#BF*VSAH+W
M! J([-V9B8[INIHJ]4/<=8PF,[[?!T^?/. J$#+S,DW3.1-2/+!?4-2P]Z_X
M(ZAO)IXMCW0?Q]$@3:;%A?)/[_@P5 QB0[&;21F,A&<%4;,6B]YK++4R:=DS
MX[[H5)S+\/EZ>3%_:64:BRQ<M:Q G84'=W=QY*VJQ*"ROIV['T>_%)>@,!JU
MGAU.AMP&&+*2W5=7:!6GK&#<1/TJ.!T<:4]VVHX' TCQ>P4I/AA B@-(<0 I
M#G9(LZ:J!UV,9@N1X\T-7V#(6EQ]EBQ.5U8@"-P]@^$"3G&&. "X:U)[R'JS
MYIQ-6DG>+_A#IP-*U<6RC:,W>#VBP:KA@H[QBOEIO1^U,9W@:F#?.)W<C;2T
M/[6-]O<\#/+!=5JVDJ(R-,FRO7][]NX-W#T&U]59)9\,.1]& 9[+<PEO0?W4
M,-GL,-4XHNZMA''T+R-.'3]!0T6A&8$$?O @%V-G@U$M.K^OC<,X<EFT>0VT
MRBBZ-,(3L5YGF\]Z!Z?RM&(8.WD)7YL-4:Y*3[RU*H%J]P#N\J'6#,+/KN8X
M6'RABTB\8:UFM:='R1A(MHN=NJF=D\9T\.TOT,S$)PX5%*K?]Q5VK1Y2@W=T
M/:8?NY]AK(AC9Y:S-(U3\O+D>"+A!["0)":+-]U"J,*C^+S7Y/$M :;7H?7H
M>1JEL\Q.=&'V("&# %9>Y'MZ)I/N((-^.^]S=JO>(ESLR::E05"3W$:.0$?2
M, \U17["ML#5GTPWQE%O7V_%Z92>#SC:()?P@[,0A-0"Y.)&#[P/,"K?@D/T
MVI@<285^K8J4D9D:L!/II!%YSLP)!3F'&UO"-IZ%DI%?HV63,S.. B:=UFXK
M.568UN/HO11"MC"<Y!Q.\0\.'_FI!)O+0=D) P9X41_N/[PWO7_O\'X#BZLJ
M%WI3^218%M53?N"\P)DGIVEOOCJS[-\R_7R66A?E%[#7JY/ O8M;!]#IN:"@
MC..Y<SCQHJ-I6]/*;1$CT("A:C*57M:2W")AD"CV$.<US>=89K/R6JFY.?ZX
M"RS<1W*WYJ=^,:]C>PFY$M81AKAF5RXSR!%FB6A[D=NTZE'ND:;4=9H6\46<
M9AUJ@)$$L"]-&;(#,%J'X]M-M+*Y71+,-:MV)%-;)5C;Y$.[ J*C>"7J[3.:
M<^4M">!!CM^8H[X.L6SU-ON58/8=6OU4UUHD2[C$K'"ML[ TME.&&6JICM["
M=^+#5ZPP*S</2Z*)+M.IXF@X+ OKKX%83K@"E)/V'./N2 6/\U?) /Q1%>CV
MVOHV!NU1CZ.77IZ*X=6["#Y_ODN>MWG:0'$GF<">JY6[=GR5TLWIAS7=,/5(
MRR0$'G)Z^S)O%?ZW"OX="P 2MDJW5,SY:^&5QHI,E;^&^ZL+"YX3#[@G#6AI
M%\G E5WONS9,;A!#BLM-ES=C5P>1P7"Y9L.EG:&R'D+G0YB-\>+2A %GW-49
MOJXK\[EY.)%X]%$]Y6K^R&W=UKH!FK&KH,)4&H>MFZ2Y#8BH KLI>/QHQX47
M4'A1KI<L+/WOOSM2EB%3M3M3Y>F_AI34%P4Z/ =TX*Q5YB&FP/$RS1)27"RQ
MO,VX+8;:M92M:^Y=!Q%%0O'FHCB,@MD616FN"BL*07BL,/V1:!GAET +T3L6
M)2E_H_RV'@6A&MYN:4Z$9]P,T[R!)S/.Z;*$29Y[:(6/EKWT/L6_]"/*']&M
M3)/O^;:C09 JL"+9G##H4DL:N_- =5"!D8ZUM=762QL+3XV:-@"D:/BM%7+B
M5)-O9_S.<6Y>:O!('N;H],@AVAK6(/N^N.P+2UYXX5UET"  OT3'\B <$\J1
M,!31K1O03\^W*LI:>=Z@I$OI[Q1^J 6B2.(JF960/]-SR=9;6=?_V'?E=NEE
M9K;52+%4OHRC5X)^3BT[DQLIU/+1GSK_D(MK(X\.<4B.P1YU&';D<(QAOQMA
M2E,!V2KR"D<%9_F">]9HL8=;KCCP=I0\S$E2-_J)H-@:LQ)8AFJS%LK#&9F(
MBR:<UDW1-XU]H)!H1EMN>J=R61\G?I9789Y.3=(;(\>;YHBO7&.  /_=Q.WC
M[-,5A+[R4:A6RPM#+B\?&@_Z!M=:T$1/=6 QWYKS%C="4PQ%%R09M6 '2XU1
MK<E3+K4GR07#L!0(XN?6JJ-J#H&'34ND*VSW",@Z)%7S33>91ADV,7:MWI)B
M582AY#@Q/H2OC*^1]26&FFP*8?,,9A3:3ZWH6DL+1UV;AAI#(UZA0M2:ZW:V
MJ"]XZX*/,A@%QO/'V0_*&W0D/W6^QP=HQ($0D (J/CE6(E(2#_Q(5X-F'*Y7
MC2G_!([T[."-7X/(-!5#@#'I)#:XQHHT-X[KG(O-T6]*$)4\\J3];.NS-]/6
M^0[AZ23,)!#7%A2Y0S'.R.S2X$C)S6W@B.9ZI]:&_BUD(OAGFO]>ZQ=]#(H!
M4)I_-/E"BE2;CHURSILC(.;;$+6X9L7WNBA-H:&S32MOVZE-9ZHUK3XV3,,
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M-"NI=4O.-W?-YG:45SX='1!S/=I%7;E%I^5.O;/?WN)UK!"*_LT=#(5KSO_
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MAR1\K/,2YZCB:9"SEU&DQ$_[ZY/']S.2F%)]Q[\^9#0,+1M7;+K7' ;L*Q<
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M 4^6-6U(AW79^T.2[F0$H<332VOQ A#G?'[P3/ *6E="(+<98EW]:@6/1Y;
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M7DJCEC8-A.[A^!E34WT0]$AYUG%C\X(>V=,3&=C6]2!_]<O)T==HEL=[V3/
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M=XF8KS@%9, S?&:*)D6?]D-JOL[(LX@"!HZ2*JI>ZT5"$!:">""EV")9N*4
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MK&RG]6L8E !=DSBB?PRWB:E1!'BZ+,U4';N1L4N7N'([^BD)0J5'8QL0K/$
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MVW9&IS4^'D]',"U&#1[G6PUP;>[PO1>JX$>[E.'O]; LT!3,/34\./5 MTZ
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M<T]N@!_-%G;)+P93OO,Q).Z.HF<6[8?,HF@A(*DAM7HJ?TJH]G2=::B69BJ
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MD =U(] /\F0#[@<'7? IVBY*A:>7$"*M-6?4Q-L=5+!R'0.-85BN$!7)A.!
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M(@^^[)L?2U<XQ05_,L-LCD;A838%+N7>1V"-QD=[0C9#HSS5(- SV=KI*.B
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MC[9\"E,MT!0X4,>H09VL",O 6@&2K.?NY6%T8<[FQF^2[M=#/I:>(20XKTD
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MIC>(8F[-/6G!I\'1I9WS!^? =E/"[3*N1B0;"^7OT 9MOVY/OO)XI*'@0]R
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MX12,+66S;MTH4@W>2"R6=4E%#3D8^:"KLE7=S!1GJ[H=JQK[87QF?H#U-2_
MT(7 9U%!SQ=S68**;VHS.)R);^E5GHR00H(J(#,FY28M@Q53>I#EF(<!C&Y7
M;U;;;B.HD<A9@AP5%[09E<NXR28FI8(<$ KN/X[UH#D9U>RCR/%DCGYN@702
M]7-B0/@%E+\_;TLW8R-Y6[J);6E260LJLMK1B6[,('VN=JKM'I/]0#<,[GX_
MSO^,KZBN^0*//[*%1U>>+.@&V]1<S#*J;_ 'X*1HI[)0H\XE E)U=A%?S?O
MS2S*O ]<81]8<"Q88_>>132FZ6])[8Y!/U()AU34+=U36%=7,_+WL>\%0<1#
M>Z$>'\ON$?@G+$'IM>'),(N@I-@[SLJ&F+_[T$I)UB?X5+T2?\R]$KE7XA?6
M*Y%=@^P:_!I<@S(Y=.4 -P [BPUD-"YW8#)J/:6!O(!.>#)_X7,E.,CKT\J$
M'[.S_I''FNA:YL#_=I98MNHK6#6]4#GA=4A\:]N^G'Z6H1F"I7$GT(+ZGNM
MVL$H>WJI4Z!64\Y3[3'?D-4*IU0"CY-:N?CYG(7@6,"32J@1*^">^0**9^$Z
MEC!5<JO&E=+P'E%R4V8 3A:,@V_G&3P$;NFBV.OXNA%1CXOLPBB4_;K6ONW"
M4XQ(@!.H*-!2\8K;+@Y^&Q.L'L5.><NZ&?O)6]9-Y"J5:N[H (T,2#U@;VFK
M4=R;[#ZU4!<W*(*,DIRD;YW\YN6+)$QU9[]D][FZY4:& "SD,H0(D0Y"JG>/
M=AUC\X;]-;;?"-4D>3:2C>3++#];=_G^7!AA')%0?5@Z/7_[O%_<S.+-^\5-
M[!=D0<!_N]"<=WD_V,Y0JR$3F1B>L79IW9_26IZS&=[,FLAF>!-FN$XXNG>N
M>W7L8$>HQP4^!W+Y1_!B(?@ <X9TS7.;8@?J)]$IL&&*,#]X;F]WK"LP7@\!
M+P"C?_/-_WSU^:O?_IGLNN4_9^N\F:62K?.JULE@/C7/P.18F8ZC]MZUM3,B
M8$E>D.R)I;_B5U-N](0-IZR!@+?-:=S;R)ZL0**VPB7RK A_TD._4-C+^HNW
MM.JRH5_[& XPO,IMZB%8/G=AB3D)%B^AEYCU_0>3YG97F\H+\)H4S6@H.K/J
MXR>:YS=I0U[,V_J$B<]Z_K3<J4=U'L!1YD(IY@"JY3YV0'+3(,!7;M#KSUJD
M4$MRO381>T$3H4F-:E'T5&O-_OH.2$&N5G)0J%J7.QSWY5 /OL]NVGO]**1U
MH=>R0JLA*W#9%/0S*8(S<\-/96Z8$P9/^$CHVB-PP$PBLEQ/]&VKPT24SE)K
M24]1+"3^.)9*.?8X3TAHL:5_<U1AOHAUWWJE5*;RZ< S-%,N+0(9#O* AV-9
M"WG*DZM5.YM>3N?L9Y[<9^F>Y9W^@Q@HE.(.2+K.2S<Y8R4BDK Q[<5>SBD*
M,MJU%L_VR9D_+=@+,81?M-K-[N[+9F2VATC6X!N[Z=$&4'\UJL7VGGXAP02:
M^+!=IT^-7;TIH?BWMZ"^P(YAV38F&X,A[U\RX]9BD2=O3[]RHCO%"883,V,O
MR5YL>0<0!NC'V6*$Z(^;'<X@!&?%G9.\#T[*R7M??G#N-59=98.0K+DSI! (
MA&7-S^;VP@"Y*)0P0Z%?7@+AV%'Q J$AWX(PK99SPBS=?HB\\(^M<,^ B?%C
MCTQX.,QIQ%Z4.F4H)X-\MCUYVU,""BOJQ30'ELDD?2S-"XRM9R-*: J"FK>
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MS9EA-UYCMA90L0C*M9&S4G0(YW/(?S"S3G%#N_%H$3/_+B _Z?<U)V.L:%W
M?$T$DU@J^6[UW<BGTOSVJ-#3$MS3F&$O./$'>!MP0HW!-/:>CM,TSO#"PV[H
MI:6?)6G&AS?T<"OR0TX^F4M#N7FW)Q-TT,?Y:_= E^H9D4+[9.VI^2^I[NBV
M/+BE%[Q;?1&QMEO18UH:AZ"UF7A7(A>M0DBX32=GP0.0/C1L--V[6JTW*)(&
MZ>P%@XWZ,4%0V&-9 M:'_(YA>P[ 1WI?VB<F\"..]\.2P!4.Y3OG*3_ZL^FT
M$+: A[T3R%$GXY ^'G]9GK&03XO&S.)+,, ,#_Q0]A7 -AXER8),H5EK<;OB
MPIE\T='4I$B1^.9Z\60RS'IHN]5N+'%1YU*X-7H]F7K:ZZ#+G(B^E/+%^ ?R
M2D-S33P15P9'E.@\U'SV'_!NEH-V081RCL 3W;Z&6:4%6>;*=K"7BJW>_CP(
MS-1*-#64!\?,U(!E 8$IB+1\1O^<W0%FC[:+P)M[W/)46*^JAA7%-O)G<>@Z
MON02F] R#;M7%YG2 8FT8Z+AQWP#'&Q-=C!.W%O 9%#FNLQM=)$4?HFW5;Y'
MBYUS.?IL<;!>8; $0LQ/FSV1%_9$7O.RX!F=K,5EP<?>PLTE2D<42@L->[FZ
M+H6LN<1[P7KY[Z_^6M!_7G_U>;%Z\_K;__OJ_PN[_^???'['23;9]O%KW??U
MH/ 5IK_=?7=G%D@!Y>C4[<$O5#]QF!9^^6+#8T]4V$?R7W?BP\B1J.'1EC4*
M\,'X-+Y5<4B$+96F0\"K!U=Q=N*0A/S^%#F=C^(5TNX %XD]@0!L#<=BPB1
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M#.*J,;WY:41Y>3RA3%:8D=<G2X ?6<WFZ@:4FV>NL&=YH$5$.^F^8Q [B'V
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MD K/W)RW8'$9OW(EEL%PW'##*F\Z]!8#< 98AZGI]3%N$R!":G["]8F8CP]
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MUAL9.:P:#TV4;YNNE5QR>&';_Y(#%/HF]SPS*L4[8Q[Q"%4TQ"W)^N%9NKB
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M 7.$:-@.:,LTFT>P[,UDD\=&NAE[5NL3<@,M.:0W\I6(BU0+"<>"*4 DB;D
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M8Q#3UX>DV9?=Q9#Q5]4L.E/)K>V]N';9G(>3\J;<<QUX"-&:QF3^ >ALYI+
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M,]R-;C-(B7K*>!)V9::5TX:5>R5'EA+N$E,*;^^1_/.)\VV9N=+'H/'@,%'
MI0=^A%N;'V=.L*T%<F]/C]O2(N/VUE42'B"[=>*@_3(YL6 /)A37*^9W5'"
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M^7<E-U$2$SOEFAIHTP"JR9-"6SAE8R$DR/ F249A+H,:J5T130YDAI#J(2[
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MT=1GGAX>. DKC:E3)8+#Q\."+ B? %1HO]#<%VA,8:FH]2KTA!"WG.Y6[V!
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M@6$+"ELB=B<!)Q\([SP7>F/CUIMJJ\]JY2*MK-ASJT6T=8(8F[I=TP%PQR*
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M[CWS#0F^(<%+A958!%HJD$V "#:?XGC=E?_Q\.0L.#JZS0YO/.L/]G]Y,<.
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M%8,WX7M]#62N9^!;FK>ZD E/XI!!'D\MUCL?07!4%)7*/9>O/F0_L0,.B5G
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M1\937K_<^]&T\X(<3,=XX1LDVP\48C][9O(*ZO$QY8.0@FO/4X]-07ECS3M
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M:DWZX9ADW>#9]C9(1'">ID3?Y#XT+CW4?H;]S4[]-\2#4]PG),8LGV4Y&^G
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M9$D\2;(H!-,)33+",8&#VQ@G88&3+JAIO(Q'<8:5#JU!M/,,WBN_4&$P4C0
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M[0; ?!MQ A4OA3D9'/#!><SQ*;(X-+@<EJ7JYMIKEDSU,B0B1M+I28MPQI7
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M["@_9W<9/VA7;51WBST/+*M9AN,:EQEZ6BR3G'[:!67Q]$YU1>MQ^E.XUU.
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M^AA!#[D3[T%LN.]KO8?1"EN[O9V];RV9]2RUWBS5L2WWNJ0+I_ @-MSKDGL
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M7O.>\P8( Q[G[O(3N#W8,R+G&<09$Y]]KKCSGS5NK\ #JSWQYUCI<PV!:(%
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M(W?;G6G&'$URZ]#&5E6/2QKZ6L."2QIVNZ0AKZ:LN&]%0[/>@= L(FF>7:A
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M3BXE=ZTLQ(V7QO.YIFI93N9YL?"5'/A@@[^ C&YTE?5$+L[%/Z!? N-+"G[
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MDB4U]S5_!%S5\UT<ST+&D=#D*+4RH# *@Z/4CD5J38=&063IJDVY;.IVI-)
M9Z"BH)H@H#H+>UE>\W*IQ7DCPZ ;G#=RT-T=7PHVITE$V/6<927#R2'#3L6P
M*UAR@V,J-CR.W)R*&;X5:8['5,,3^Y78IDIMRU9-.])"+;1"/Z!]]'JT#'W6
M$/1)%GVNIJQHCGMH=YOM:;<2Q;9QLQ(D(AE-C@HL PJC,#@J\%@4F%JZXX34
M45TK8JK%7$/UJ!VJFJ'Y+I=9YD1]=(:\E@+KBNGT-AJ!/"1I+PE."AD>_XB
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M>>:-T$CR+L^Q)1]+ZS?VDZ.N(G9!@ . &FE^_:D&28LD2%W()E'=3(<#X@4
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MJ^5\7I]RT-U->;VA;5"$6H\/M8C!*18H%HC!+Y\H5ZSUWC%PR!D@KY1LM4G
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M^_?!&,Q-'#P.#G8Q"R68 AN[PV)<BF!UZ/:(21=Y,,H$>Y6#F4DL11^ZIQO
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M%.\R)X9R.T*H)A&J+8,3+>_?!V,P]^!I>7B\2GNO;U87,MGHE33 .5:ED'.
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M[Q;;=]FN*+16?B#X&C)\M65PXNS]^V ,YB;.'@EGJ\R"V&Z28P$P&P.V.[]
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M-8?;C$_Y9;6LE_/3<KUNK3I ]/ZH$*PM@Q.]$[TW%!Q$[V.C=Q.$4=Y!P,0
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MX%OPPHP6/1$\$7PW!)]R'$H0'-@\M,C)%J&>OB-D$W+6B-RXHROWK)+WP5E
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M6X4<,V?'$(81AM%6(<?,V3&$881AM%7(,7-V#&$881AM%7+,G!U#&'8O7J
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MJ$Q?"GBM VA,W#JI!?<W&F9.)VV"KS;@JRV#$V=/[X,>S$V<W0=G"X^BQ,(
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M0B:%T0"WD<)HP0ND,$AAS%YAS$\B_.[=(B"A="24A$@QB.@A:,-!16D@&N%
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M6<;(?+P/UC5LJ89>E,2ZK0'0765#4ABB?=QY=#K,<?_OPYS98?YK"F>K??V
M_SU,1\;Z>F&=ZQZO[RRMWO_0V79(E]R_/7P3_WF^.AN2+ML(/;:UEV<CZ+[5
M"X2G?<3;2=#=JZ#CH6C'10:KG *%O(!3T0(*;D-T:%2\5?!BM7X3OO\8TY^7
MQQ\0_6D%]$?K_,-'</Z\O+@$\_J-)^^@?!3!Q^722SZ6X". FC- M65P8N7I
M?="#N8F5^V!EEH8V#R:#"]Z RL) 9#9#4*I@"DY&?JL>$(VQLALO^$$ -6>
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M;7V[XU;X<+F4?+3:7 *F.0-36P8G-I[>!SV8>_9L/#\ZI=2)+Z1.5&&0G4=
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MZ7W0@[F)?/L@7V9R5$X:,"H'4"PCA&@]6*8E9RIACL<%P=\:DKAG\N5+I:@
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MW!9AOXA8/_YZJ&_<E,79 5?:2,UIR^>S4;N4M]:D*J:\-0KL?4EVFJHK%9H
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M0Y<@:AY!62VKZN(('(-D.GL?Y%%+SYN%/09@_V7 ]3'%FI9+I]OL =X6:/7
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M8]WTO]WJ[FLJ%JSA/M#A*Y@W;[Q%4\]AN=H?O:KUN&>-+N^V6E[!GXNZ69;
M#&O<_Z:^XS,L+:1A*IP/D,.-]JXT?'\E>0-F6]MJL,*\\U5CK[\;#8(OS:MY
MZP&+7E1 3'5S9V_Q%KQ9SC6^-SW[EQG_4'N_P%8NO%]AKFCP_="]T2\7_]F]
MTH\GB TY6RFT$]^]^O5O9^]VI>8\(EUL.(G:%1R3$;&DI]E>M=DL?O[$+_A8
MA/^7G]Z].G>;=1B;Y;WZ]5>0UF='OU_>D6S8#^5LA4O7UG/ME:NF!O7W+S?
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M?UOOA^,?,</'OI]\-KN?\$4--J*3! \Z7$/N^Y'.F<HRU'% ".1I&K @DE$
MI)V)<+OALI,$T]O>3A*8'*X-QPCJ1;U7Q 7O#VE;G9U]4/MUXL$,Y)4'9Z_Q
M5HM;WBB/+SWN$=,SI]$)I <$DLH+G>DP9:G(4+B4(0-[!"R5U)=Y@;4 P99
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MME(5;SJ]6X(LY\!3;N K LGI<Y@IW1 OZUG[WUZ_&A1;%"3&TW=+;)9FL6C
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M-)I\J%]D#KT_1:--TVI@2T\;;195>J9J?/D"OVQ^12-[.YG/X(I_QO"RO3I
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M,QIQ*RG2U%MDA90X8$F\W:C2HTQ'DAIE1^8(XHR;U&O;(J,)981I^'^Y6]B
MD@/!,C88-#9X@AC3M@*,.<:T[1C36E>@[Q\Z'KY"VRV4N-7AV0/CO+U9])WG
MB0SR.I!'O5$B,(J"Q H FS7(E=8C2:,T#@=6BG 7Y!$JI(J2("4)G..U0@ZP
M(L)2PZE61Q_H3H$\I@\X?K@_<)9B68H-4HIES9YY(O-$UNSW:G;FA-'6*H2-
M*!''S"##@T-.86>DYX:Y#<TN8\E$Y 99P3WB)8%/I?'(.2*X,YHQO%MI'YP?
M&)8U>Y9B.R;%LF;//)%Y(FOV>S4[5]%XPCEBE@7$)65(NY(C[&,,L70Z8'I7
MLS,E+.8T()9".%P:BJPO-=):*<]DH,3&W=+LXL 8FC7[D*58KOUY1G&9[4Z3
M2JN,^*'49O5_ A[]\]_YBX8 W$SJJNE%/HTCFT8Z/]RIAWQ->YYGEU^Q6]#V
M"<=>?WWGK+U6'M^>=[Z@%GR@/):A<C_/4F'K%%>(E25.X2V'X&^/:"@54Y1Q
M(S>&3I>.6VYT1+04<(Y7!%DA(A)"^T@(,TS(G8+*BAY@:@:;PO39Q?=9/&9H
MD:%%AA9#VIP,+9X;M! F:DFC1<H;BSBF 5FK3"J(,A$[CYWV&UXX1[ECD2$9
ML40\^( T)P:5BL3@F&?2LYV"%H3* ZEUQA99/F9LL</;D['%@#<G8XOGABV8
M=\%Q%I!DEB)>:H>TBQ0Y)T544@N"R[O80@D;"=<8&<PCXDY:9 R3J*2EU-Q[
MXOUN1?@4.\ ZNRWV2SSF4JT]#PE>3$ .%-,^,)@37/858N9TB1U8])WGB0P)
M^VI\84TL543818*X<0R94#HDO5+2,BJ((7<A8?"!!1L#BC@EBK%TCA$64:9D
M&1CQ0NU6IQYXS0,NM^INRF(LB[&LVC-/[-RB[SQ/9-7>J79-@@Y1.42=3U$A
M')".GB*M2R\HELIIMM&@5U/!B0FH#(HA7EJ.K(PI!$6B5H')TN*=4NT<BP.Y
M77=/%F-9C&75GGEBYQ9]YWDBJ_8^_]1;0ICD2!.PU3FQ!%2[9DA)*02.CGCF
M[JIV,-:]L2EG%0>/N'06.8M+Y"GQ02KK%>8[I=H9QP>2J*S:ARS&<JW6G@=F
MW@#;ORCL"K<7D[+P2W[_#S<M_M91R>J_2Y #Q8VMPG!2'H:O 7<+%>9TH0&C
MQYPN] "/[: 0_O&^\MB,EONTIQA%C"JB()E!'"N-G)(.,16#E59;+[XJQC6O
MT:6U-R]60&Z/E5]-ZMDJ$MY.=C0[T)3E#*;A@+!O2.*Y*#S#I0R7AK\Y&2X-
M%R9DN/087"*Z9#%HBPB+#O%0"H!+Q"!-K'5.ES9:_35QPPR7,ES*<&F(HCS#
MI0R7,ES*<"G#I<_)H':X],%J1*.PB!-FD:5*((8U-EB8$.5&P?[GQ&(S7,IP
MZ?O#I2<OL%O=FNYJVPOM=ON4]J._^&Z2PO<6@6UGSMMBVJ:%Y.2E?077.1-F
M!Q9]YWDB@\@.1(94=*<\1\HKB7B9.CB)J% (,7INJ%!J8RCNEX0HOR"=;SNY
M>H0<2)XGIF0)M6,2*FOMS!.9)[+6OE]K8XY)P"5BH&H1-\:F2)E'1%&+A8@V
MQ(U9:%\2*?MN6MN0 RVW.J4^2Z@LH;+6SCRQ<XN^\SR1M7:GM143AEHFD=!1
M(QZ90$X+@X+#R@-5*6PWAC=\2<#FNVEM*@^4X5EK#UE"Y;JX/8^4G /#S^)E
MY0L[&E5V[&.!BE^/?CHJ;J:3RZF]'DYRQ?!UUV[AN9R8-&#<EQ.3,C[\"#[$
MF$:B)/)&!\1M%,B84B/CM2$D6NPV6R)2S0R1I4=!$P>8TI=PCK6(.8.]\$IP
MLSZ!8Z$>CCKM\*MU]FVK&;X,!?XK3B?!UE>)1_ZDF/"7.8<G"[<,#'9X>S(P
M&/#F9&#PW(!!25-_Y$@ "6!0\DQ3I ./2%B.O8UEC'2C,,I[[[#D!%G+.>*.
M>&1QP*@,,G BM*>.9V"0@<%N";?A"ZT,##(P&";O9&"P=\" &<>UB!91&3'B
MH(J1YMH@:2G7+."R+#>  7;>:!(5$B8$Q$5TR!#'D2?,&(.9PU0\,3"X6_@#
M:XQQQ@9[)=]RW4Z.1KWLQV>-XZP;H94K>/8>4VXU9K\N?.DA3=(W3.9N%(>-
M*H==;OGOPV&_3]_AX3-J!J8=,#7>"FMLB3AE$G$'_S+!*Z0DUM(QK*3>2'5R
MDI:!2X%*D8 I!F!J4[:4]D3'DLEHM1Q,JM/ RXH^RE09M0Y$_ U?J&7TD=%'
M1A\[P*@9??3QLD@M-B$-F:<><6,)LH$[Q(6E1!/G?+DQ;IY&CY5G!I$28\1+
M0M,\THBL$E9:@I6(=C#H8^#E41E]#$:]9?0QZ.W)Z".CCXP^]@M]*&>4(!JC
M0+E$G$:%C)<>*1&"=,3JTN.[Z,,PZ9FR @5E N+:)NR"+7QB911$">/I8- '
M&W:95T8?7Q^Q@\\6UNOA9?GAY8T-B;KZ%R-/M%1WHZ]J$7[M#V^DT0O%#Z54
M/WQL:3\")^33+O>]JXG8(>=ZN:!-T)$=,L9^V.IZDJ?2W9\JAN^P:SV_ 36V
MNO9J>VO_(UETE-SQ""IPX\55+&ZCG181*"84KZ./URY."T8."HHI+:81GJR&
MX^MB!L?"NE:34)2@&8I_V/'<3F^+_M#9I/C'?'0+?[1?'#1G!#N+:7Q>^ER#
M1DB?)_-I,?DPCM/ZJKHIJ@0Z8CV##\7%NU>':U*DU02G<U [E8>_0_7^,=&Q
M5U3]M?O>GI\>\T739M<_//$P%7&^FHQ&%H1BTW?WH[)E'\7(4S':45U8X*1Z
M/IKUK#"R\[&_*NPX%/;F9CIY;T?IIW?';WX_>O>-Y<NWE)Z@N11_N2<"]&\_
MO3L^RYNU&YM5'+]Y<_+VXBCOUX[L5Y*-1Z=G[S*'[<J.90[;K?T"P)VPR&^'
MYX<' .?3VR2F.YY/)S?QH/@0FV'6!=P'X/ED'(MFP#7@_%_._Q/^DS#E^++X
M]_N6(_OL>I^=X0X';%&I942<DQ+IX#F2(E#", _W)-(+K,I(*4$X<HJXCB4R
MB@A4.E5*ZJDM2_>)LS1^F4[J^D'GG%QSSHE'G7.4PFH]Z)K;=5: "XS2IH7Y
M--'T[%&[F/##QG*^PQ@-LW3<\0%,6H#\?G(Y3EM2V'IU@/SR>."RJRH9 G"X
MB^G6W=QY.&@"DBT]206/4<]@%V;PY;R.Y7Q4C*KW< 4_N;Z.8Y].F]],6FYN
MOIOZ"@R*SLCH3 ZP,L+<S]I'7YMN7]7-HTY#^Z#)5DE'II_@==*Y;8IU!;=L
M3']XP\-L(6Z1_OX9&PJ /ZK9*#94!#L289-!(H_GL)>;.U# ]B2/2IT-QUW;
M[FPX[M!F95B[8_L%*JR<C$:3#_6+(F/31[ IY519*36RPC+$+67($BN1+I6-
MMI222WH7FQ+&B*'*(0. %G&G M(D" 17$II+AF7"LRM%GBMNY??Q:#JUX\L(
MH&76S5UZ!ZCF=2RK<0QOXOLX.AO'-;AZ,Y_&!5Y%=!6PTL=K/Q_.H=]Q O^A
MZ*!>64WK6;:_'J5Q&UPT+'6PE]$BC@/87YI@Y$HBA7/!D6">C,;/;X :RRJ&
M\X33&OK^>3)]'6=Q"F\!L'V%"1XTTLR:D:8?SZ#88Q/-=28:H-T.$U^.)JZK
M 6V!</)>9&YXA!NXH%($X9$AOD0<M#[21CLDJ*/16U]2X[ZUQ+_X,-F.Q-]C
M@0]OG9KN/DSX;@*F8M8$C]%^#*720C-$."&(:U(BIP-!Q@GGI:!<NXVIMED3
M#'![>TUP6)SW[H\:5G 4VV9@Y*6]A .+)JGA.H;*@ZAI=8.?7+MJW#J]EK]\
MF,Q'H7"Q^SFYYR;3UF4VG]Y,ZO86LZOD)NM:#<!^^/FHN=!A 1M93.#P:>]B
MJY=7^E#-K@K;/DOCN$F7W4RW@%>>)R]@G2->.T6)V36P4_MUL.)&3?[6^<T'
M.PT%_-UX_9.(:"1VRZI9FSZB34'S,:DX032D&!5S EFN!3(!,^D$8<YMM)0.
MPE@&2A012P/B41/DL#1(LJBQCB7GWGV2-CUJ8-"[?B^/ZK=QFHH70/"?E:=Q
MUN@%$,NOEO+^;2>:/Q5J/IZI+@_W&&S.)IGT'S6BE. \$(NP]!AQ:QQR1FJD
MHPC24JUMZHQ^9]J.)(9H2Q$N&8#/Q#-&\X!"#,$JIP5-<_6&0?H?\:OM+:[\
M(<<TGR"F"20U60ML9MGRF+N2"N.P :N4@T;E$@Q.Z[%%7DN-G;""V8T"<Z5*
M1[D'<]:48*1BE29Y&8_ V*5<@8:5='U2PZK(.(9K3:XK?])EX9^-?Y[/0#:\
MM;=)W-2_ >%/CRZGL9$^VY(A>ZP]P53LK<2;;@V+:QMBX6Z;J/T\+6A1P;=V
ML:K%9%J!2+"CT6W1U& "IU1CX)7&?)S7!PTT!2/7 S_5-0B)EI4NWKU*25QP
M^W%LJ:@Y(=F8YS?PA&=E>0 '=.5Z</CQF^-?_BM;*[M!2]FZW*W]ZG.YLHVY
MK=S)DAC%L$:81H.XHQ@9Z32B7(:214>HVXA6^* ]DT:D]BIPCK<2&1<5DMP*
MI83W1(FA .UL8V;2?RA8H4I&#57(X\ 0!R@'<"Z6B"EB=."8Z! WVAQJ5T9>
M&D2<AW-8I,AA ?0O1>FL4]1J.Q32SS;F@S9F+F3]\D)6BC$OEG-*^[[RV:[?
M(@F__I04^50$_F$M SX'IQ_U*3*G5;04!4H=P)94)B*E0+34V*M(;4S^P3MV
M/XFE*3U!BDJ-N"0&Z=(#/#*4!AZE9E;<+1/YQ5;C-Y.Z/AOW52(7302Z$>);
MJ1,ASZ%,!(SNKMM\"^-M,5LN8ZKN:(M!'K#-5X_MBC-^JLKYN#G,CHI?Y[#N
MP&1)@B6M.QE7]0S]%&>6%D?M7\6/;;#;OTP#F-O/X>5?^TG,G9>A<01L2,-B
MX<YI'^F3JCGV2"NYR2A\0YT$@*GHX%&;L)"UT199,JUNEW;1Y4*MJYU%TD7?
MB,3Z_YE7==4SWQM;_"/!X-YXGW@_GR;_&_Q\-+^< ZNE5B9=0Y/)/2U2FE*O
MK-T>TVXB8&&QM0CKZ$%3.84,IP0Y4&#*6B^"W=!N(1#)F+2(6T41%R*-)A0>
M.<T8K+OQ2I.G;%SV63K/'*I]UWD':7]J4#T)_ 'C+),/X8]?3H[>OCO^W]E5
MN2N;FMR0_^_QNZ/?\Y;MRI:EI,2L9AY5,\I)J6*)A"EYZLE=(AMI1#Y91))+
MR?U&\)0'%4"=E,B5SB#.+4:::H(P]Y1QASDA>#!JAA_2?5<SC63*9/YH$WJI
MA)"4HZ!D0+P,#)D$KDIBI;1>,J#^NV1NO:=*EPYQS#7B,0#!<X]16996ZQ).
M#T_:A/YSR%SL;^!C"::FL;Y)?H'W<71[6/P3[!,X\7WLVL']V71[&-WF(,FC
M]:LR>L<,1HQA!D1-#4AQ,# L"]91RZ0F&XEX#!/.L7!(Q531X:U&QF&)@N&)
MDV@D9(,1@/I3^*--U7]7U7\LXR%D.P$/\_#(A1VG^!]R4=['R#B1J@@><$IP
M$<B8$Z0CE4@RD5*[2F?CACP/WN"2@] WE(%0#U@C;0A/)T;N* ^^#-^>C!]N
MW;WS5-RUK1UON)OZ6J$:UGJM/Z[O]&1=C":^Z=VSTF^KX8JFLT[J?-LY@3],
MIJ-P1S7<MX!#7*%BU:MY;]O>_Z,HOM"U?,^3?F8O].5D@QTG1(+)RD*G);U:
M#$"^ 49NN]LC6\+KOK"C#_:V?OF7XF]?L?A;ZT-OBZMIDB__-IOXK]J(OIG_
M)VY%\R@A];=J!-^+)C0RJL;QR3;I(G6X3TS]JOUJZ?&WBVW[SINQNOK?=Q#.
M=UR,;R<5MA)R>FA)3TY/SWX_^?WHH#@Y76N?_CPD[I.N[>G9Q?%Y<7%6O#H[
M/3][<_+ZZ.+X=?'SR>G1Z:N3HS?%^05\\>OQZ<5Y\6/B]@H,YO#789#W,'D=
MH,"V+( %H.Z 1F\6"LLPEQB5A&G$L;1(:Y<\?%1(YGWIQ4:AOP]8\A(P>$HL
M19Q* <@Z2N2M):6.W@>JUG+GWE1 X74\&H>U0NZ5++KZ=57[T:0&,'T!-_H)
M4. ??RDBP.J;1 K3>7QD.,R^1'^?E#GY85&\.7EU?'I^7!R=O@8>??/FZ*>S
M=T<7)V>GQ=&[=T>GO[3,F=,;GBR]X6P^0QTS+!-+/I[CL$<+_LVS'/^WK8HW
MUNVD:9@37KYR-8_',UM7]7J=F"U&'0NV;4Y6--*RS*S-]NJ(I_CQ_ HTU96M
M_@IFRN%!\686#I=99=U1B\2R@]0+I9Y;N$HJ2VM29?HK=;<.14P1@3HUK6TF
M9S6MPL-\FIH5^9F];I[M_+<WZ/5O[PYZ9\A175GTUJ;F.+Z8QLOTQ(NG2 >D
MNRSDRN)Y#HO?%AEN*9VN[GTH:X<?+)[Q0S4:%27L<W$]63I<TOWJSB%F1X4?
MI9P[^#";IO;)'HZLTW.^NJK&MG'T+)Y^D<L'[QQO^F2BMU<6MH 5-W#%M.!A
M.K\LZOG-S>@V_;Q8J+Y/S.'Z\\$F-XZED-H#36Z:/4M^M/=56TT$3W\SZIJT
M3]S,-EF(EZD/S61ZNYPC U_;HNX;#A7C>9.O!/?W0.CP:K%^;/%=O(7'Z-ZY
M\2.TK8AOFE6[[WXIJ6KCW1;KMGQ'(-JF&+B>C%)H([FY4D9)LI73VBX;5U?_
M2CDF&ZOUV%.G)>G6<'F5>,\UTIU:\JUF!6Q7MY!PR#VOU@1F4A'7Q($(:7QX
M0-+=ABZWKB.%^V^V(*JU71T'X(#RWM.:=6H>(,)!ZRN3VG^WS< *'Z<-!70N
MQ_EX%.MZ\5#CR2SM?MTV)OI0U7&Y#]?VMIC9/V+;8!P$S[P$*FNSNA>;4HU:
MHDLW2\6JDP_CM;7M9,N2.M,RW*&\6;7B$FTZLO:)X[$L6P_GVGRP-=[-Q?A;
M+\;?$V<\D ]L32,W5OJDSV_27TDZ7@()779DE3,)'LTD$*6D03FD:>I*HC!'
MFND2&?BH:1FXVFR)%X+RI=48F:; ,I3P*:3R3$.PP\Z[X-:;^'3]!";I24!T
M_-H/3>@Z#&PE9<"0YU)T4$<[[0;'K2J4I),FT]FRY<"= P[6U%MJ)M $KY83
M+!8G3N.H5W1+K'9=W<1Q;!%<V^INI95>_8@*O(-PX"Z@PE*Y1-6 U[Y30OR?
MU-82;ME54US!PJ*VJ5\1@-<;U GZ W73=MOO;A;QR\+9NLW9[CIDKF6G/H@D
M -Q,J[0DJ?^>^V]028U^7RBPQ1R,99@/],4?<.T41[UM,=7U36QR8ON+'\"#
MULU] 0:FO?%)SZ:'O/=1TI*FBR\V8/*A77U0IU,XSDX7>CB-<>V@:@>PQR#\
MZCI-X803/@9][K[T80[+/YYF)4K++$4E31W.L,'(6LZ1-PZ^!T'GJ-QP(\(I
M5'F/1" *<4L$<EQ(Q'AP)I+4Q44]D&;UJ5-ZY)H@1'7T21BF0=9U'/_E_SZ=
M[*T<["NN/MAZM<)C6>JTAA^7E1^K%1\]W.RLZ,/B[5+N-3BB9<:%G.WE:M.V
M(5;7#JS@)KIWKZUHNZ$_#TS2>5!ZQS]O&N-]9?I0!YN!9UMK)7V7A&15WJ9#
MNC/:6U;CMF;EL#AONHA>)SMO9:;/QVI@>I?"O>4MZ09@310I(2V]ZK,J%?OF
MKKU?CMZ]?IL=>_M,#)_IV'O4F9>8^I>V&?@1H&M7@=GOBW>K<N;UBIQY"V"B
M'[N]<+(U)+>L(.V!SAIX7#H)>@_C74_ ^I"QPL-152-N_C4!F36:!.NK!L+V
M?HNE,VK-W=<\S7ISY,]Q_SUZ^D'W<P-%DR=E^1J-/\K6@*V2<$\E[?;]9-J(
M1)#$2>&V0&V>CFS\B.ENO;_OCA^Q40FKC;=:X+B^A$NWX/WKE@C#-JW!UY:P
M<9S.QPEV@AQID/KE!"AS>A5MXZY:2/U>774MQMJQ8<W[]QJS6NE!5C1*]3.4
MU2&0V2B^3Q[A7N%\8SV3A<MGY(B,%];#P0IB^C1V =*XG,)&)U#3)BG"+>)!
MQPWM&,.E[[^!2JU=ATJX5&^)K#C-&^NE=:6ZQ:_P9^+)E&6Y)C-FT5^-84DO
M;^^KIU^17N9E_052ZZY\2E9FE?BK8].%,7A=A3"*_6\+\=4Q7>=$7G'5=B9:
M\HF"N.FMYE[HK2SC73GQWY-I9V8V9Y\"_KPJCIH,!WO036=MIR.O.,);5W5R
MKR^>96VEYUULJ-G(?DL:5GQLP5?$7SJL<X,W!O$G$M'"OK7CV[Z??K<8LRM@
MJ87P*CI'=S*";E$C.5HM&)*82[<\+$[*5-WMXJB";4[GS_H<VOEHMM !CTGE
MC1U?-/_OD'ZBX&;"3/+!C[I;-R_0;DG3PZT+#S0M3C;" ST1NY39&TLXM8V$
ME=4H?MIUEXSR\^NCWK%>5W\6U\#/5XOW;'1 7-6^[2LVJ<633U=P7_)@+17"
M2;\NQB@<7<:QOUUJ\^-?CU;T];$%59*<&;?MN-'UV,\\^7H>?MKE(G9AKY5'
MF\^N)M..GY=NFDU]VGH_JNE*>O7"%9+8>%7=@ '=R+,0O]3$V:4$NB=/6:;K
M*6#%)V<M?^_,N9RRW*<L?^^=&$X.8TY6?IIDY6<@:(>=J9Q9?*U^Z2L!P+.S
M/#_=Q_GVJ$G/_26[.?>9'A[<_94\PL9:ZZAA:3@TWRP=DF]Z!T'?JFOAC&A/
MA=58.A_Z-,B-<&CN4+1;9)([%.W>EG4)!@O?0#];I#@"\^Z@K7T>5XES_Q-,
M]S#I,H(_5+-_@7F3/O^8HAU][7-[QII4*"[ZY(45UT*7HQE79LST26$W?=;1
MJF/NGJ07,'S:_+&<+_982@2)3!)-&-+1*<0QT\@$C1'U"@O#>!31;C3<,+XD
MU"IDB>&(EZR$3X(@K+5QG KFJ?[F^6($F_UO,M-&;IJ$*=0E4:UG7?7D?U@L
M>KVG[QI70)/*>PD\-"[^>SZMZE"UA+!T^[8,V9?^-#&UQHVZR*-:AI.:3.'&
M]YTX[3*.FVJ]+G5JUC]JFVS>)4W%/V^JSI?<B!4[6WN.P^)^'+$ "^V?BZ>Z
M/^4\G5<VY'8W._O^6$$&$3O&"1E$[-R6=2#BCKH_[+YH8@==:.AC,8YEU.!^
M4Z!=MTPC^T,C@ 2O[/LVCV E0S"%'M?:M;<GKF0ZWX<./Y[/L#!([TMHZ)7J
M\M;WY"RN96!\U>V:*'W.GW@JDENL?3_.<IFBM:3$%2KJLGN6F_OCIBUSWAZS
MF=U4?+B"R[O;Y8XW.*:[9N?U $(=5]?SZY05FBR?VPQ0=H^LLO+9O2V;7<$#
M7UX5_Y@#,Q+6B%]^6%PLQ, &[S?<:^<@(&VSY@U.&<-MP2"J1FU!I)V.JK9*
M=_6ZZB"EQ;2'V2*=LG'QE#'Z9_3S6<K_7IG- ]*A<7RD],@^/^3NR4T"2V\C
M+?(%VWR= !C+=[90E[*9<G&:+]=K1KO<]UGSX; X6DD_?T)U%W->^C>,V1R_
M;Z8#KZ3[O*FNDRLO!W'VF4 ^-8CS('FLI(.UAWQ*7*>_VD.1G<Y7L^&GB5F5
M[A05+7QP,S#;9XU2Z"HJ^]3V*K6K1=:%21J8E5I;E+$KR%P0EC\Y.EE2U;)"
M=25SM&A2!JMQ$V-HNE(<%!>V^F#'!\7?)Z#"_A/^=5#\:KV='Q3GD_GL"KYJ
M@A;GH.'L#7QNHQ&_VI&]K2M8]I\CZ#3;)E2G7_J0!KS!Q96M1DV+A_3#NWC3
M9#FG7T[&(5F651<-.9\TA NDOGK0[U6<C;MV*7<OT.:W5J/JYJ9ALT<")CT7
M/18RN:>.WHY7ZTQS/.2Q> @U5#AC!"+4!L0Y=4AS6B*CG%7>$T',1CQ$8RRT
M)1(9+TB:[%HBK35'46INB"$N4+(6#WFW*-R^&PJIWS5[EKQ=6XF*Z&=01+]2
M!K\1!VPX+O>1^'P^L!PS:X5"7O@R=4^,R$JI4:#1EM)(C/G&H.[/YH-F=MY3
MLP#%SX '4C7! ^T?%JJA]W-MA-378HA5[R5=0+;5K@R+E@.CR8=BM7-#G2*"
MS2,T79#L^';1#VQ#:S6-%/H6!BM%<:!\WUM_F^JPXVH ,SU\'\1LRA6Z?/_T
M#C$5(:R%,Q^\Z](T3T[BNCF]F0T(S_.B^+'Z:_=;/0/+ #71RD90+.N%ND#F
ML@RHGG_JW5_"#> .*S%0N/*RYJ$I4%^(L1XB)Q?@9]X%+@0W@CL]A71[H#MK
M9%@+)QPBVGO$"0.^CPHC:8V2BFC,-R>;!Q4)H80B+;%)$V\ $](TQX8$P;@N
M&=-L76?VY/"VI82W337]40HP_UQ-Z]FKA=60I,I9V<WGW&RM$.;3-.1X]RVV
M-%*],X#O-N??#^&6MJGN<@B:N'[:YS67O&TK'.QJB[I/YY9/CR[UIZ[$EQYO
MOO-YD:8]V; <,-MK#]%1XZUN&F"NUA4NK/;3URM3J]-6U'-W7<T2ORR*#-L>
ME*=] 6?C7(+_ONW1P%%(,;"^Q'/EVK^^/5IO:)#]0KM$.P_XA4Z.3I)T[IJK
MKG1FA0_ T>0P;_-N;7-B^[[3:=K$A:^M<+?-_O\]@CZX*LX];'B:6]_6^K8X
M%W8<9Y']#7,<>ECSR5D._0E?F.>P,"GOS73(K+Y+I+4(FM^%86S9N1G4^+@N
M$\J;+&FMBSSGW=ZEW4:]Y;.>)_#'>/(!74T^-);4]K(.LF?V$<]LT-2J$#0*
MO&2(2^R1<]@A(H)QUI:QU)NS@K5AM''*QB@0=\U([%3OH91@GGACC5WSMBSG
M2)Z5[Q;[^?-D^KK9N#0CI]W+DVXK?UW=R5=I([<S?Y*0O77>_M"&1I,C\B%1
MVO!5E_;3I!@M710Y?O$XEQB#G60<,1\P4+PF2).8)@,'(P*CVH>-5J_!AB X
M(4@YQQ'7G"%G'$6L#,%SE=A&W&WU^CJ"?@-0U;5\W4[$XE#O*\TO A9-$V3
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M):#)@(U@A$D9MY+.U_H4MX(R"<,'9L >Q8_R20::W\<)^0R!YA %43$T3\K
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M+-<.:::9I#;H6+JA1)0(K#[&&2+LE>3+_?QSH.IEW\]_'&>YN&BO(&6.V>_
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MGM@/L;BR[R-HCM2!O$I!_=F5G:V=FL)[S5E)Q,$)@$7:])LI*)/I+4C)--#
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M6KQ>YENO%"GNR>IM )#- %<U]O/I-(8]>>,LX1[O(.5=%()YQ(Q,AA6+2*<
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M64$QV:6QS9T_&Q<_1S>=IZ%&1/4],4_.S[XBVK8Z?*[MAIZNM\R M&OE?S=
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M"2XRDU6QDYV.H35FG"6D"FL9$->9Z??X]O7T\AWPT76>B# L#=)T^C("U5U
MW?NS3S-0;D1>G\NWH]!Z-DH0N9XF=I\CGZY+P@((M?4<$6>(\Z"VU]A21J1
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MM7ZCAY_U9?OVA^*7[]7Q\TXKI(NS293\OX&G\R1"T++\&E*DI;C80CU%-=[
M4_QD6(_\\QFL[C@C% ?=GZYR3O3W[+WZ*#QP]RX^P\;\^]^(P&^_?Q?:%]0'
M&^GV>]=^'AX='?]Y^.?^H#@\.MA $^5M4K3/NK%'QZ?O3XK3X^+@^.CD^,/A
MN_W3]^^*WPZ/]H\.#O<_%">G\(??WQ^=GA0_12&O1S/O?NX!8_=0Q']Y$ !D
M9^BKVA[')L!#'P%:C"GJJ_[>M]6I=4'XF( '>#G>9M( Q$SMBN=A^B9V:!E>
M%F0!WF).WTK8\5K@<J7!<A< 30<=*85P,:GDTRBUO,]^V0/)+$QH)2N*&)-Q
MTB/Q -FD14$Y56)MG+1K?IFEG,E4*^!<_ X/2%:6(T4K''-@',;J6L^57V<M
M )VV76T"?QP.DI=P./H-7(0_HX=P'*Z. S8TMV?G(S[)1QM\7S_L:]VP?.QV
M;V3$4>Z99TB6&J3)Q 0#6CE4:A Q+@WV9JT\[FLD<!$9^<./YZ7N('I7Z04Q
M[V!=V+ZB=='1[G8N6FS8O"^8=C%U['-L6307CCN3BJ=G\*J?SKJV^/.DRMM-
MY%YQF%J0C7S'%)^[+ 2_>OD@S@E8),<O#-_- [KQ$/;)==]?=CU:7O13_.JB
MR]$?W<5)EA<%&5=MC^;J 91%_/QJJ(H!&5]V9@+6*F):1-MEE=YVQR)6!=I8
M[U6'.IKB1<>T')?>,!1;P3O='(9N_H.-J2#3S]Z/;C+4H@/ _(S8SA.JKY5
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M>A?<%SXQ?:"GZ(8P7C4H<:YR[;5FR\&U'0=Y7>7#D_%=#K#U!VILU-7==.?
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MQ5GF;3,:^2&:^&&:5IZG(.P4;,SE4%NPZ1GU;9\&O>-$S+H22VR1I1XCKJT
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M4M@%9&Q5.B%"9=Q:6XZ7QG1+E;\1$"?$@&*<8W1]5F$Y1K?C*.[CQ(]UW96
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M<)<5V\Z$;7)Z39\TSE789JVEWN%HU%S4%[JKO3YKALY/GC+\-I_9]0<"[G*
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M.?YP^&[_]/V[XK?#H_VC@\/]#\7)*?RAZ^W_4Q3R>C3S[N<>,'8/1?R7!P%
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MC)96:>T(1J52\!TG2B15"$AC[$(EL-:E[XV%)]F^]]J^YY;9.WY&\Z%IVR*
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MB[ B6'M!O2S78A4G.HZQ/YDV]B]0R,9/X)<S/?'M8=O.O#L<G4[TJ.V6=@T
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M?7R#8A7A <]UH0K_K27#MRRNM_-]GGEG"5D=I=95K/_];-E)<@PN8M=, .D
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M;WQD)[_;L^:[5]6?OG;P]S8E;?5Y7I3*?RQF_D&"6'NI=Q1%^RA9<<WFMJW
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M!*MA+L.YOG@/)#E O?5QMK"3RK;ZHSJ.MBB-4-E%%9M%1O\B?TA9K52G1:]
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M@K2PR7 393(,_--!J;;1++1#<[KA:2:*J7CP0CLDS/2:%^ZU9B H3\ $Q"$
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M.Q9TW,G'8<);0A,2E)4CF4%:^H2DEM9P$84R3UP1@ZB#?%.@&$ Q@&(,6CQ
M,8!B ,48%\6P,M,*@4M+P!!1R>)!+O^7&0<S049EHMHI[J%#RK]EBF%">V(R
MR+A@D>*2$1632O2)HQ@2RP-E*'",D7$,J DRDIR=[OSRF$?U(K^!OW9"_!#=
MHC^)K/VW9'VCG%D8Y=?O7]%7(*I^BPK$ ^(!\8"B&[VH0#P@'A /*+K1BPK$
M ^(!\8"B&[VH0#Q]%0_T_!U)R/8Z\5-,65NH&3K[#A.A+[RZ/:SWCP94 ]2>
MT*JQA\O,@"TP6/W%!!BLT8 *TLY6:6=!4A+;I';C">)<!Z1)Y ACZAUA-)E
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MF>GO(>^)6291?TRD4LM5R+M?"V7?!0RZTCW=K"K:SMZDC;V 3E,<J1%@E&7
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M:" [/WSNROQ.S7A87N.:&2;^2T:?;A*^-P*R3\E@=YY^6UU/9UH]. /WOK/
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M$)9OW[_)!-,&(0-8"0Y,R "&"P2$(DD]<Y;CC3JR2$K'.3,0A$GG4.]!:VR
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M+RA6I$&QB6(3NV;V+=$I%"LC'/. .(K @N=@=/ZA$H,:H@@V&V59 ^/$4X?
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MV!&[9YFP\B4M74FKJ,,FZ/!ZFI?T:_ ?9V86ZG?QN-D(;%[G[8#3NKG9I:Y
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M+ZD HY@#AE $K1.[&^DH#\H;Y#>VU'9D^TSQ"10D*U1>J+SX!(I/H&B!-K0
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M"7^XT=QO<VBGY[W;5WO+&WVCG_]JP:_GW8&Q7FO;Q7K!7T\O<Y&=)SM<K,2
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M<>.+B_&H*SPYJ;Z<AVK:7*1+X,K*Y+-.EYG1U8:\M7-!F\*';I7%;_ 0E0U
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M3@U%-F". G4V$.YE3=4S6_+$O;K,5.VW*7^"N,R^@G(E+K.GN(SXX;C,"^5
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MK#;1^VOH66(3^W/#5HVR;[[NBY>7K/%AECN]%DX\\XI2+E  !QZH'$W*A3,
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M(GWU!Y#H\Q3^RW\"/H0WS%E8TP[ .F&I'A!=U0]WE-8>+VQX55V"X%P!PP_
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MVX_Q+1 G^+< )MOW(Q"L4<A/\U_-]'Q%S+IX9E:1^Y&VGR%,,S=%VXW54EP
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MJVLF;G;13A,$70)6\ _A&4+.E,)I;I% >*8.LI:XY4/BEF#A3"2H%JG*1X>
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M\QLNV_!Z,>,.OG*Y$&ZZ[$K^VK2-S0&NUXM/K%RXNN&O^Q*%3ZB@J5CIUE6
M\Z<YD8K?ZSI\GZO$B:X?>[O5_7>KO_V\H[/*5-W^HU]B&2@^27L-V_&P\8]<
M]JH.5KG=Z!Q5^Q2X7]XGR#J>M:#9VK6&T#ZM@MV@_N.76CX/&]Q1$+97$MYC
M2S,0*KV;$VM](N-2!K8<YPM1\\4:PO?*$^^"ZVK8%FU]!RS9?>>-_LCZ'39]
M#M4>9-2Q'%">1IC0'R,^G'_?]@X?H!_R>V,Z7)I7EXY'\.H/"/:^:#L7[)Z1
M]Z6G2#S>!N^9+EL5V$M1:I+$I.^D*N3I*WF>P,*MPYO5\Y[?;7]&;[5W;35-
M4NS@PT<B=DFT_L#:8OV>D1:C\>%0XA'B]8R2].?^2%#_#6')VBZJB[3"V*@:
M,28XXC6)R-J:(R.MX$&QX.7&BHJ'9&VW%)GOJB1?W?_#UO;_L#O&,><)$+<F
M:8LFVRO[]P;RK2/X OD.01$E;;#<+CHOF9NOBDH[$-M!VO_4'Z^N9Z)[6'#P
MH;38J43WG4<\:F7[_(+RB Q13]'A 2K57TIMX@Z4&ZUDBC",/#<!<6\$LC61
M2(M:$QR-5\SOOS;Q[_!FZI7]G^#?S<W=ITFX:&87IZ.\^O7]W.Z]36;O0]@/
M%)8#CMD^@?!SZO#'5P/T%V\](_??6O;QK-%6^I30FQ;H_0/#Y<.T<F8RR5T=
M7=="?Z)&/9/TPP+:>XU6K"MI>D*3EO;C6:K;[#74[K=V[E&$]OX4[C]:+RAW
MCG*]I9Q;I1$QDB#.E45&<HQ<K6BM:0VOF'V@W-_'H[,T)R!!V/U$;P4;""U[
M&[V]4UIZ#UM?/N +?Z?*_E[U3;RPB2_KZ?9XO(3RS5Z3LJ"N+*@[6/50%M25
M!74]/-@/94'=TRRHVQB'](RSL>\WZN&%3^OI>[X##5H0(A&V5H$')0)26!KD
MP$.Q0D:K:[F/GN_%U(+W(S>^"*<COWCAU^^78=2&E"X8CMO9))1V\">?!'*]
M1W#>F1RF;?)6T\BL<1JCN)P,$CKJI(5HX[-1RNO G\,\%VL^7W>EG;P;"YWF
MT"VJ&Z;G<#AGYUO'B!S@V6UTIMW='O]2G/FRBNM0&M^5O%<'NL+W:Y"_;^,[
M(<?:^%[Z'5\PP[&G;%/I,B\2<\#=X_.U(N]O8)#^R&'?*=X?R>R]N2MS7LJ<
MES+GY< M<)GS4N:\E#DO/;'I9<[+H0?)4@8DE;/,ML01^].ZT3,ZOW16Y@7K
MXWM&B>,MJ/SI9K^4,LE%RWL@IG8N(J(905QR@JS4&&%C-#5>167(S20?QUY;
M3B)2HN:(!\Z0)I$BK3!1\/.XX.2V)-\BIQ<L_#G?(W3:-0;EJIN]E%#R@2"\
MMUT_/=-J+U\-^20]. 7KO:RZ617J;O.7G=[H;>^/4]<S<A\6Y'O"ZO+2UMZS
M1.'QM+47!+@<>D05UM(@4E.)N'8ULD1ZY(573HL:UR+N P&N&H2/\;=F!(8
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M^Q[TDP_&>0S78KC,G5B$8Y+9+PSG_=P>++K'</W3D9LPG)9IQ$.4D5 APG/
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ME\ O"AP4\#(^M]3Z6-6_@$2*X:E>'#+[Z:'F-NF=P&?R<+H=)WN;D^T]%\4
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MYM&UWD*'T+=;[6VW"*VKRV "9P:3ROYW$$R&*CBL+N&];H+"3,6^JD97-A$
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M+1U"3,,;[[/1-;B/[W\(?G[SJA46#&M3=_5?DTJ\B!#S;0%/)(5]%&GPB97
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MR_C\T[=.TJPF9M32BYN7^,(C=R"*S];W8-%[[U-YO#?#>RFC/*(\0UH)P&Z
M]5 >,HK26+ P5GDBE>XP;[1A\E8W":-H@&GJ*X>\+G)XV;TQ=H42.[/HWACO
MBC&6C&6,,X9P2D)$S-:<7.$("9410J(,ZZC+#3G;-,:=)F:\&NJ_&G)LV;T=
M=H42.[/HW@[OBAUF(<UH(AB2D=)@4S.-&(LIPG&6ITIS&B5QATF0;=KA;K,?
M7@_U()FQ>2O-]Y/,<%'7!,ZD[WV>PLW&G;U!"JZ1RI/'D\=16.$:+;Q6\V+C
MR=,[\GBMYK6:%QM/GI[%(G:[LJZ' <\/2JNZ5M*=N+AC-'5('M]VL*JGBY<1
M3PM/"Z^O=H(NGA:>%IX67E_UA2Z>%D[0PK?Z]'&#;@:O^8"X.^JSTUWLCE%B
M9Q:]]Z%M7T\ZJR<5@H8RB7(D6,@1(90BKGF.%-:8))D(,<NZV&0Y#^[.E/4V
MZTIQ.@AQIYLMO4[JOTYR;-F]47:%$CNSZ-XH[XI13C7CE$N!0AKFB#!%$2,L
M1UEJAIDRJA,BNMAL^8I&.0L'-(^]4?8ZR>%E]T;9%4KLS*)[H[PK1EGC7+(T
MS9%D.1CE+ 132RE&BBN<RIP+KJ(N=EZ^HE%.PP$)J3?*+NND5VTIZ;,<SBJE
MEPXT\VE)=T!$IWO5?2-RI_/WN].(O(=*\]V<#SRB78-H<Y9+381""2: 3C46
MB F<(2Y40D*E61+G7>9^[G14?S&N;8!1X=/# !<GSO88Z7N'=;='E?_DC@5P
MC&X>*GFHY*&2#YJ]SLP6@EDBM$"2A0DB82P1Q8H@$N=QK E)N4B[S&1U"S$>
M0!;) ,"1QQ9>XWEHT!=:>&C@,'$\-/C>H$$DD@P3E2&> 2H@>62B#R)"@ BX
MBGB<*-U))]-7AP81]KA@I]1=OQJAKH$6;C9"[:$F:Z>ZR9<W*O%U5.Y %5^S
MT(-%]W54_=.6ZW%?(G"4Q"1!+(Y"1!+-44YEB' FF<8XCM-\!?=UL./H%<;Y
MXF1 0G='^GK5Y&VSM\WN4&)G%MW;YEVQS;E*\DS1&(512A!)28I80@C*0H:U
MTBF+(KR%C4>O8)NS=$#B3@,S7C7U7S4YMNS>-KM"B9U9=&^;=\4V)YJI6&"%
M* 7GF8B0(Z82CF2,M:!4)IBN3&#M8/_1*]AFLPT)A]XVNZR:>K4-Z9$4B#/;
MD%Q4/B\?!>=K9%X3+KQ9D]">5LRX1C^7:.9\_O^[)IZGA5>$.TP_EVCF%:'+
MQ/.T\(IPA^GG$LV\(G2U3'3+,9+(F2!)#P.X;9EH86O,@PG[&J@V:#H(2C5Q
M)_CO1=F5$/-=+8SWL%'#LIKRD7+;=KK=!. O[LC:TRGL4W(.:O3U*3G"!4M8
MSE"6,(V(3G-$=2H1C@2\8\J)3G@7I:Q;[0&8#E*:.9M\>U1NG$>H.V/!/)IP
MAQ8>37@TX='$;J&)/%(DQB%!F!&"2)2E*%=*H#!A0M L)RR6713?;K7-ORFS
M[;0OBD<3'DV\_;)[-.'1A$<3'DWT!TTD&M,\30E*& D1B3E'G)O27Q').)<B
MB2GIHEQXV_,)8G<WU'HT\?)$&7QFL%[_.R?RR?02KBS@;UE<;5BL>"^.XQ^_
M.Q  "](5W19*8[;<,YW!TXABH@7*=,X084R@'. \TB0!72#A'[:B,YX3SSP3
M0R6G(W6JC[16(-17:J%&OK")^J+@'J(8%<S(^[EAD'.XXR^C2OSQ0Z! DXP-
M2]13M4F>WHI%>F@^SH<J*"[A]I,FJ'0P@3]E 62I52G@:EQ-KI4J[?<FC2DF
M2@:_[9WM!;K=( *OSB;3257?+&<\)U503>LU.=" U?"_!M3^:%1=-_O+'+Y)
M-7YWLCY7CE8W+GBK-3?FF8KR8C]\;W]%(W9332=PQ:\*;)>]>A3:19N= $PW
M8N-&[3=JS&H0KZ4:A*4RA:NB*3C(W.1F?W[&AF*%]B9)M!='R8]FX389X=G3
M[)$,/^FX\"E'X;V4IMU=;H_0Z+MY.$J?>;5':EOHMY>V=%7'M&;DT$/ BKJ@
M/:A3T0)/B3>HS8S"URK.G)'E&1U4Y^OY1N2\C3!L&V'Q:B2WQ13_5[$Z.((U
MD\$')=0E5W401P-WY/6;*T!=YQ!W1-YYJ]EUQ?;KZ/2^J8!WQ\9]JJ8-*V7C
MPF :+_E^(X:W]=WS! XQ=D"\G[NUPW5V<$R\7U57>]IXU>M5[X.J-W) 6KWJ
M]:KW.Z>-5[W?G^H-'9!6KWI[O\'YU7(/OAI@$P<<S5/\)F7/)FN2_":#[$#M
MHIL4_X[KA!VCA*_^]2V =ZVF5ZH(*T$Y2B0-$4FS$#$B,9(BRG.6$2SE2@O@
M%^TWOEN(MZ'4]V"RU"K8VH@[Q7S=C%NF@QQ39RN!'=-].V-PO/%WAQ9]$@!O
M_+WQWS7CCSG6FD816.Z0($)4A'*6IRA,HB1-<BRC+.MT>[ SQC^/!TGH;HL2
MQW3?SA@<;_S=H<5Z 7"3$M[X?WMBRQM_QXT_BV+*D\38_0R1. P1S25'),PS
M'L4RB37K=#>O,\8_(X,X=W!PGYNZ[VT,SM:' ^T:6.BA7K)SP);V<]I>MF;#
MZ#Q#Q%N=X$ FV$V:]PL@?BLMO(?D4.%2;X([/=2#[^;T]3AU7=>92- L J0)
M@)4@HC!%N6012F(62\Y#I=4*3NTP0W5G6.7B&-4\'8DVP*OPZ4%(&@U(1+I$
MI+NL;-WVQAW:C>48W3Q<<842.[/HO8<KWLS/S#R3(6,\U&"RDQ"1,,Y-."I'
MDD910E0(+F&WK6J[-O,/6'=*.JTS\9JIQYK)FV973+.;E-B91>]]IJB'IM5'
M$A[,>&F6:4%SA#'.$4G3!-$L5"BE!&,:<\+("L3H,./U.I$$G+H'-=S4M#T-
M(SB\9<I-2-E#_37+@0>LE':;E IJU2A6BV$@:B6+2>- R8>;U.X7DO55@SU8
M]-X'F7JH 3V2?0C)1A*G %_A-5+-$:%IB'*9*Y3%2C$5\X2GG715WX!DX8O#
MU@Q]F9FECC'L@"2Q>_59;JK9GL)8#U0\4'&$$CNSZ+T'*M[ SPQ\*C*9X5RB
M3+/8;,LFB*=:(,52,-.QTE&4;#$;]A(#_V"5"TY#;]>]5G)XV;U9=H42.[/H
MWBSOBEE6+%8<4["I,3C?)$\)H@E/$,=1BO-<YVG2[03$[9CE_ZBZDJP9&EGX
MBL.(O/=&V66=Y/!F*#?)U$.%<P)R#G_4U6A4E!=!80R!:ES8^^0FB?N%TWS)
M7@\6W>.T_JG-]3@MISR+I2(HP5HCPC5%/(DT4EF&4TQ)F,2KX9/N\B._%O#6
MQ>3F>*;$V\-F&]V[V<(^(*FO*?8*RN5E]Q;:%4KLS*+WWD+WT,+Z2HP'^^<F
MB58\P2B248A(0@ UA#Q#.N=*:AJ1**=;3-1TA#2>5)01#5(7BXO=5+F[6Y7A
M04M_[6>?)&AG%MV#%@]:W (M6FFMDI@@D>0FC:440!$LD!8BC9A*.*=ZBVFL
M5P0M$1DD6:=]?G=9Y?84M/@=4;N?'CN^A%O;YH#PG1V^9E6)W2$EU=WOX*!F
MRIM"%JPNE-\JM1M8UY<5]&#1/=;U6-<MK!L!U"6*,413R4QSZP31,,Q0R(E,
M(IJ'FFQSP-71GU.+=(]871;E1?.I:AK5G.K?REN;I>39W%S== M_Z8#F?LK%
M;J-?#V,\C'&$$CNSZ+V',=[\S\R_X!*+C!.4AKE A%*!>(X3I'1*5:(EC\+5
M[L'=Y>>V9_Y]/;?76-YD.TD++P#N"8 WV;TQV9RS*$PH09$*8S"_D4*<:#.<
M.F8X3FBN4[7%[)0WV5YC^2U8WV..Z70R5+4[A2&.$;1?F&V7T_0[L^B]QVP]
M5'(^6_3@QC&=Q9F* 'L*DB&2Y0EB,18HPTFJ&4X$3E?+N;O+%ED+="#_/6TF
ME_"870^9PHFOA/K><T$>I/377O9)@G9FT7L/4KQQGQGWC+ 4LX2AC,4$D1"#
MH=9*HBS4F19$8T6S+>:"GF_<'VRI%^'<6W6ODQQ>=F^47:'$SBRZ-\J[8I15
MR%/PNCGB&<MF0YE(F")%$ASFDA.<\RUF>[9BE&GL3;+3&LGO&-K];,[AD)47
M*BC*X(J-IK/=0J-1=<U*H=PI3'",T/W":IWFN3D<K>K;U4K&D\#F^X.[C.T8
MQ7:&.(\(RE/)X[&?@\IX/?:+A8X)D0F*XH@B0K% .=,ADC@7L1(JI>EJ0*:[
M;$MK(8[+#TJKNE82#CAH&C5I?I\;C(.YO>@F5A,/(NKN_(-'!&P9A@)O>$7H
M$8-'#!XQ."PH'C'L'&*((JY5&&(4,VDJ@J5&G,81$FG,=);RB"8KT:(.4SBO
MCA@&,8X\8/!ZT .&OM#" P:'B?/= (8>&GQ?F/H@\$F T?,L1UFD!2(Y4RA/
M0HW"5*J<T"0"6+/%--E6@,^3:E8=[E_2=_S3TR+7K6_%6B;-[&J=8K 9J0Q)
MYM?O)S>\M:ILE54P85\#U78/#=YQ52HXZJ=!4"H_/6LW,'BG!1!WM3;>PT9M
MRVK*1\IM%.ZVNOZ+.[+V= J[#^0] )Y/1">:,9&$B$2IAG]RAO(\P2B73*I,
M IR-5QOYO"17..M'_4MK3SH)YZ7I(*7N=J-^5&Z<1[0[8\$\FG"'%AY->#3A
MT<1NH0DL(IRG:8AR'C)$B(!/,I4H8R3&48PYC62G><0MH(DL'1"'"\T]FG#&
M@GDTX0XM/)KP:,*CB=U"$QD5.HERBO(D)X , %=PB35BFA' %SJF:=QI<FX;
ML8D0T$2GM48>33B )I:39?"9P7IM7I8?OSMC#]RNOHK15#Y[5=8\X3<NRZUV
M[WDZ+L)T:6T7'#A<9&C'[$*U.@!4([SS/AM=LYOF_0_!SV_.E"P8UD:#_M>D
M$B\BQ5S?/9$8]E',!+/:EE'LPUU4/2I*M34RG1LE8(:D';9?W0Y(8ZU0>/4P
M5P]OM!*OIQ%X-9+;2\^?G)S^?OS[P2 X/CG<>_FZ]DG5;G5A3T[/C\Z"\]/@
M\/3D[/33\8>#\Z,/P<?CDX.3P^.#3\'9.7SQZ]')^5GPS@AY44Z5_,D!QG90
MQ']^% +$>W$<?Y\+ Y[ R?023A3PMRRN'%NA'F*D>0%E4"QJE^ B@#Q&2DR"
MR5"9LJ6VHDEK^*HQAGJB+L> #^J;0!;P;:U* 2=Q-;E6JK0G"5;7-T5Y$;!+
M6([V+&8+-.V$U%'!>#$J)@6<!CY@H(N2E:)@([@S7'EBSAQ/ZW'5J/8$<\WY
MI:8-/*XYZ_:1%P?O!=NHVEWXV3/FFP\&2'2NJ"*($Q*"FTTRE%,BD(IXRK($
M@%>^,K;Z.24 9V*HY'2D3O5*N>M!*3_=KJ5%4N=PLU]&E?CCAT"!WSTVLE%/
M9Q,*K.8]F#SUZ?\5]9_#ST!:"PT>?#F!)0#&+=6,(:MI'<@Y_QLN6N+0.]\O
MLRNK@1,-UYKZXF9_H:'N:Z=;Q05ZJEM&G!&2+<^H>"HQG=*7;VM1YE$(&X18
M,'@;US'/!$IH/WQO?T4C=E--)W#%KTJ^;Z\>A1:?S$X SA^Q<:/V&S5FX#JI
MI8+?I9K@JZ(I+"O=[,_/V% 9W-XD2??B"$CSP^9HU^QI]O*</NFX\"E'97L9
MZ?!R73]<3O S+_=(L39]::WV\P/REX64(_7D*"%U04)IKU-?GA+/IP2LN_GU
M?WY(?WA=JCQC3]Q\.=^(FF_FY'?*$Q^44)=<U4$<#=R1T6_>\N0Z6[@CYLY;
MRJXW+[^.'N^;W+\[-AY]-6W *VI<&/3@)?]U#3Q^+0/__$WO3M*S;X*.0XP=
M$._G[F5VG1T<$V\G"SJ_;T_**]KO1M%&[LBF5[3?8U?W;PQQ^?SIH_G3V_R1
M _VCW"3O6Q<0/-_R=DP7]TOI72.5)X\GC]=J7JMYL?'DZ2ETWV)/MS6*T?=T
MZZJV64V":JS,;HCR(AA53=,6-^JJOF:U? G:?Z-ZA>_4+K[BYD#'*.$W0_LQ
MG;NVQ3F.%-$TQ$@G!"-"0XXX#B/$5<IU%B92J/!^[74<)Y*&(4&4Y!(1&0N4
M4RY0FM(TSPE\P9/[M=<K%=>G<UOP"4S!X;(EZ&;" LD'*4F=W??LF&K;&7OB
M;;L[M.B3 'C;[FW[KMGV7*E01RI$<98I1, DHEQG##'"8Y9'2E"ULJ\J(DR'
MA"@4T5 @PEF&F%84X3#/)<_#.(G#M[;M*1G0*/:FW673OO6<K6_FWQ/=]$4U
MBM5B.-L.>*5&U?@2?K*97@%JHYAT%@GR [;<08N=CF1QC!([L^@>[/5/H6X
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MN9-P3'=6.(KR08@[#<EX)=2#"(LOR.EEA.7W3@,H/C/G#HKPF3F'(9[/S&V
M@CU4H>_F?. A[1I(F]$DQ FA*,&,(4(81CS/!0H5I0QK+L,0;R6PM+!L!W/#
MUM$,*S*@(?4I1W<PU"OR^$_NZ'S'Z.;!D0=''AQY<.3!T3> (Z&EY HP3II@
MC4@J4I2S'*-(,ZDY26B<TJW$^[8$CE(RR$BG6^0]-NH_-O+U7*YPPUMKP8WU
M7.YDRQP3^7[!:I^IZ<&B^W1Q_Q3GIBU\H1(TS5&*98A(+ACB0DE$PRR369S)
M)-_.>+&N6BHE=!#&D<\5>PWD\+)[$^P*)79FT;T)WA43K%(6\U (Q"EGB+"8
MH+S=5,]E1'0B52BW$L'IS 23 <Y\T;33&FCKY5J[9K)[J%X^+ =%1@7CQ:B8
M%.HED9'=IK%KL Q6WOSZ/S_@'SQ='**+IX6GA:>%UU=]H8NGA1.T\$-B/#*?
M(W.XJRAFNR1*&;#+"A;_/_8+=X)&7I1]S,*AF(6/FOKZO9V/_D9<4Y4SA41*
M8D1BD2">X10E*A&9B@3'2G0YZ>;3;5QHV2H=E/)@R28]/2[< *O"IX<#Q.$@
MH9UV6=UE9=O3$CT/5SQ<<802.[/H'JYXN.(67$D)QSB,,0HY"Q')(HJ8R#42
M\$GRC&NF5@;SO63^SUO E7P0)9WNSMQE7=M3M.+;E[C"#6^MYV[GN0<7K"@#
MH^H6 ]U?.L+9Q]K= 5^=[@-SC!([L^B]1[P>*<Z0(HG2F&8903C3')%4IXAK
MK5"L8IK&7)-09QWO+%@"B\<+%?[,GG3;'1#I=5'_=9%CR^Z-L2N4V)E%[[TQ
M[J$Q]>&GA[M="*VHSE!.) "$'% "U3E#DE,L3&B*BI6)@R_<*]$EJ+C?;CX;
M9+F[O2X<4ZL^TN2KP'JMVHWZ*"=5?1-H5M1V\) *F/SWM-4I[N25'!/\?B';
M70[V[\RB>V3KD:U;R#;!).8XDB@1F".B&$& 30EB$8DRIG(:JI5=P!W5@2WL
MTD<P2Z:MFSI8&*5N,ZL1'I H]*G5G0:\'J]XO.(()79FT7N/5[R=G]GY.,L$
M&&>*,I$EB*02(S#[ N%0FPZNBBGUHGZM6[?SKY<D\YJI!SL2?=53+YVQT\E0
MU>ZDDAR3SGXA.#^)P&&DYR<1^ C6]X%L,YKG7&F"TD0"LJ4J0S3)0L2C3.@X
M3V.6AMLK^+(&K=MH%0T39W.S?@Z!J[$MCXSZ:WP],G*8.-\-,O*(8E[M%;(T
MP80BEG".B! $Y0G-$:,X"V7&PS BVZOV^D9$T=/B\;X#B9T)I/EY1+WT"4_4
M9-TTHN#=4@->GRK=#3C9:4+BKN+%>]AH7EE-^4BY#2C==MW^XHZL/9W"[F/2
M'FIF'ZU["%N'*N&, S .8YXA(D6":"8I$G$8I3&G%(!TE]&ZXU)4E^HNPNYF
M^L0@R]R=__2H#G >8+NM[CVT\M#*0RL/K7H,K3PDF4$2*J(P5UD$D"12IK=8
M@E@*"$4HK14!>*'#E8X1G0S"6H(D7<W$BK)!C-UM>=I_6/+V<3_XS&"]-BQ+
MO!?'\8_?G]D'AC>_%^64S3A>%E>OMT;1MNSL6ZO,?X)@*@%BNS;:6.A@,C1'
MF$YF[9B!2@?-5 P71S3!956K8%3\H48W<#2L1EE-@DD55$),Z[W@#%:KT* K
MRDD C\4NE"D,#OX]E1?V URA5G]."W/KHH3' &,*3UN4%\'U4)ED2<#LIM;9
MF(/1J+IFI5 !,WW5FHE]PK4/?WOAO0#><\BNE%'S30$Z"@Z%*P7LBA4C(VZ!
MNH*OX;*# $@^#,95 XH;3C!C%4IUP<P?@_FK!]6T#H9%,ZEJHP2#:JQJ. (>
MN5;-= 0W-Z<!/64A)JT1N#$KIZ>3*2P6/*2]9V&=UX%Y[4OVASG=7G^^!/:%
M[:,S. G,0W6[4K"^ZJNJ1=$H6W2RNL)MBBA_WRPM=6ELBQ*LL<^Z]FF 8&.P
M-N9RH]'-(+@V2V-77]F5UI4A@#E=U,"Z=<$,F<K%PII?UM)K?UF>07C7I0QF
MDGO/#OSX7A;->,1N]O5(?5T58U-L7NB;.5?;HU S8?7DO955!,]YV>QSUJA1
M4:KUHGTK(,L/L4.R?F=1%RM:E&9)D%W8!^][7S\^L.C+2TE(ED=Y1)(H3.,\
M^_']+'>)\4*_+_'"W:?J_9+_\+]&8EH]8>7?:*=239;TQ:@"9=48R02Y-#)Z
MHUC=W-H^:^7:?[W,>)GY'F1FU6RNF%<O'VX0R\O'F\A'!5_,Q0, '>"M!E8.
MT#  0Q"5HI+6V,#%WQL@ZH7%"<IY87D#81FI*S4RTG!7:HQC$OPYA<52-;BM
MP)E%L[=.3GR X84$.&C,ZG\ <'O)P96/HT%@F,\ZED,F ZW :007>A46!X+5
M]0WHMVM62WL5-@8J?BTNP1<%HJW+P_=P@?[BZPD>"-YK&F<Y52F*8V(&@_ $
M42H3)).(Z93$),I6:G7A#3C#*4:Q(!01'3'$.28HSF.5R"A6/!+W@_>G<];[
M!)QWN,QX&^/VZ9VX??)@W)Y$T=[F73\]Y^  +C!:FCC:\]<!U30LQ#"XAK<*
MU-=Q4:N *]#5-B9IIM3L!0]I-1NH,ZH-C/%$><7F%=O:;8T)CZ00"6(T!B5%
M$K,)(:4H5#)2,0LCS%<4FU19%/,P1CIG.9Q#0\1C':%0"\RD9IKBE4*I+2NV
M/$GV8J_8>O$ZCRDVG-NT1:NV:M4H5L/1)F8I3$AFXE75]ZFJ9()SEF8::9[E
M9N2&1BR.<V3@5*0DZ"NF[ZNJ!'02(1HP6,P4(D;'T3#*4)R1/"2*1#S7]U75
M.?MZ:!EM64T=7,(*;BZ>^!9=%<=>5?7D=>:J2E8VF]PJJ[WE#*)WS%\ZH&Q2
M+"?UU\!48PQNM?\]U'K);L!X!,V4_UL)F^\W44@.QJ.<%.#/L[*<PG]&Q64Q
M:6\BI\J6!5R7JFZ&Q3@00U9>J*5#&A.E,7EX&? ;FVT^-J5U)5SGB[I2)5S@
ML))M3KZ!LT:LGEDK>UYC+@'8_/Z=VX=M4P<FTV:YZ=DOSI7)H0=-=:D"$WL=
MC6YK(JRN:MI* ZY4&4SM(BOI6;?CHA7X0T[%Q)1QE!NX!*@2Y30=F'H-L#.P
MS'(0G*G6LL44!^_:$@GQ?NG+]BOY_B>X+AO=-(4%/885#ZM+6#7#EK!8%\-5
MY\\P][QT0]W6KI2K'&^<0UL=8RHYFL(4LYA_QFV]QSG<;/DQF\E4WI@7%J.I
M$8W)D $;3S:7WIC?EY]8%G*N16%9E:V=6?-4<FJ+-\R9$]56B+3)A+W@[]4U
MK&P],)>Y+B9#(^5R?C @PE$A; G)BM WYI1@;$:JMM)F"F?62!P(TEIA@W<T
M3VT);4M>9J#5BB!7HKJT]2:+*IZ)*9$!QE"+N.(MHFWK6ZQ@+VVBM-PQ5PZ6
MU%4#QQJ9+'0!M[V_3J!ACK7Q\T%B5'T!>@\6Q5#Z_H$#NSK3NVK6?&5$9F7U
M'P\3U.M/M!5/DTE=\"F0[;9$:1V 'U@%K'6C6@X95\UD]8JSA5JCX<M5"@^"
M\;1NIJ;V"(Z8\6UC&=<L?4SC^6L_64I-S5BKW.OI2+7:VS#93;OD,W):.K+K
MYHYJ!7"GOEHYV5Q6^K"2?4+FY9'RR=MZ\)ZKV0CG2VO;EJ?^=;C8E#YF%ZJM
M%49,PQOOL]$UNVG>_Q#\_-S%[ZQTE07#VC@+_S6IQ(L(,>^&\$12V$>1IJ#2
M"L>^95B;2ML6D<ZMW@,I.FR_:A8D8P^@C=>CA$-%Q&^T$J^G#W@UDEM;S^.3
MD]/?CW\_& 3')X>/X]F=4K1;7=B3T_.CL^#\-#@\/3D[_73\X>#\Z$/P\?CD
MX.3P^.!3<'8.7_QZ=')^%KPS0EZ [90_.<#8#HKXSX\" .]G?5/N_BXT!H0O
M_IP6IC2^A;-'Y<243MB\UY)+-O-9;@^8%Z.OHFF+$HV[82+*,^<&+F9CU( ^
MYZA^YD@'/E+[8&>KC*A$YA*EFJ:(B#!"7"4YRK(TTIA&F<[3^Y':,-<D#RE&
M:98+1'1"$*-*HRS.<I73.")F0LQ2%_B/K6=UHB9W<DNJ.9I3<2FTU&'X-DJR
MO<U3#7LN:O/XK9$9DVG97!9C?+PV.&IVA=SQSNX[WS[J]+K:\!,+_E&-1NRV
M#  H9SC:ZD1X9D.;DM4W=X)+-K'FU>(6U:(*DR3!$44QPPJ1)(L0C4*-$D+C
M.$JQQG)EO"M-><RC/$4X#6-$(I8BFO $$9*F*I284\F<4(LX(7N;9U_U7.:V
MJQ:7%\?)M_?ZN\/5/)W6P;@:%>+&A)5MI%A4%Z51GX5Q)$';&JW[LPFT*M#/
M-CH,.IO-@L]+\6.013C!;MM:^M9$JLM&;:P.LSH=/D2+XE>OM1\::22R)!<9
M1R*6 &9SG:*<<XJRG+*4)XS2:*65U'/Z-BQ:2!U]9?-=MY_G#'!0RN,9<QP(
M44\-%GY&'P?4*&$4MVFGT*ARTRLSQ9B.N4!"AV8.>48!BPN,&,LXP? *"N,N
MNF>]R2N7U1HKM:-FB[4+=ZM8[BB5629\*4?WW\WZ?:%W,ENSQ(U-0IJDSV+*
MUA. ?N?1H+<S$YT$X]KSS4/N RP H["Y3J(4JC:;JP*0E^!SU<+]9GG%ES;0
MO/2Y%IKA9'H)7X@Y@LWS6.0D1IF6$2)9QA#-!4<8YU)'*HSB?&4(AI!A2K10
M2.H84"].$Y1CE2+!6*2I$D+B[+YB.!-#):<C=:I_*Q?FT72T^465"M:E^0+^
MS<<V)6DS#^=POU]&E?CC!_!6!!L;M@/.W]35Y:W:E_10AQQ8?%(*\!GN9(]O
M*S:MB]CFX3D;F1X+BV*%234QN>]9/0I\.5TBI]4>?$;0MK=$,^OKT.S[N/*:
MN/*\-8_MS+/@J;;9D7DF(,%^^-[^BD;LIII.X(I?E7S?7CT*[:+-3A F1#!N
MU'ZCQ@S4O5IJZ+W4\]O4,[6[U?;G9VSH_-W>)$OWXL1L[]O8 :H]#H,(YD\X
M+C*/_/A1^5X<X6=>[I%VY]32] 5C Y_?#^ZRD'*D.I_-07NK[.X97=JEN+T[
M+DW9S;0!A?:BIN:O._KC^;W,7H<-'E&9G9+P"8TZ@5#FU__Y 3P8)X5XS7*^
M$37?++'=*4^T,4X'Q/EI?+ JSJXSA#L"OO6Y)2\FOF-M)GOHC_RVV8-8%^Z,
M\A=(OF^AO6LMM'=&#%]1XEQHC#VCFV]W[:!&WI#LUD+E&4N1CDT.@64*49%&
M2*=)3$U)3RY6TB8)TR)7E**,I!@1A4V"7$J3;TE3GDJJ38+\;JAP0X"PFS;7
MR2 FV+TVUVYJL;<Q'5O ?!T#?L?(U$,-TTZA$[#Z9D]4:6'?;#-78SO/X1"'
M#GAX'N>Y,M1X2X'3G=:DSH5"UH7$'(5]/52J?H#<0_"5"4+R.!(H)Q' 5\(B
ME(>FC(=D0N0LUW$2K]1JAH3$,E0(@"K 5Y)%B.4J0FF8J# Q%5=Q_$3X^F%F
M[9HOMM"W*"\^UM7EY[JHZL]V,S0<NZ@!Z CK=CK/Y375N//37-SV[S>FNGPX
M=?>A]3>&4U\$LWTXU1TDYP,1/5AT'PWMGT)=#R=S03.<13GB4C%$<*Y0GA..
MB*22)HD4G*S 21UE21Z2'(5A9,[A E$=)2C&F"BA,2?A2N'DEJ.A$=W</=@K
M(0>4D(^&[CYD>THT-'(@R.-AFBO1T*<5$OIHJ--UGCX:ZJ.A;P5?.6%IQG."
M4I..)W',$<>Q1 D-LYPIF2JSN>_>OA^B&$W2%+&<P3E<9HC)+$(B5U$4JUCE
M6>IL-#2.-K=H=ER-^VBHCX;VE<YOK?V^-1KZ$ICMHZ'N(#D?B.C!HOMH:/\4
MZH:A0R+DMA$2%6;HD$@BQ&/*4<:Q"EDFXS#MI*7&5J.A9$ S7QOJM!+RT=#=
MAVPF&EJ4#T=#L3M!'L<(WB^8YJ.A#L,Y'PWUL.^1FDJNPR2-&$J(%":A#; O
MXBF*0FE:">DHCE:2X,_I'K0!]AV7KUY3.2!)IQ#1QQ'?7!/Z,.#N8\IO#0.^
M!%_Z,* [$*8;#WRM>L5[V.A764U-ZRZG$:;;^1D7=J-_,X4]2'50RV]H]YME
M$<8X0R1*<K,'G:,\"Q7"+,QHJ*F0I)/>MUN-3::#&&^>4>&\9O30\U'H"9]-
MF\=%Z^)9GU;X6Q97OF7F[0+Z_J\O'G)[;Y(! .*V$ZR)M@Y5\-O>V9YM GO%
MP(N>-D$[&//?T[IH9-$.XFS'R1HH?:-8W0!H#LEBA"T.H]CV:DKL96:C1H-:
M79IVQ]58E>W0U46/\/E8YN7AJI=5,PEN1W*RZ618U<5RG^L-$Y:K*W.-T;K!
MKV8P:;$ZPF:MR(%<NL5K;]ZJ]A7Z44NL\B@F*<IQDII^U GB21JA/,[3)-2)
M5#KKI!_UE#?JSRF\Z]&5:73^C>VF.U>\/>]ZOG'2:[(7G/WVR]G1__GMZ.0\
M./K=3!OTRKR[!3XM@W^P<FI&/T6A#5W$=@B(]4G:.0%5P,SXY*GY\[ J+8(S
MP.RP58\'%[52IME_\,YHX/GH\ON_WLXO-W.Z@P,#5=E@-CBYG8]C;OMU8B<M
MPRVW47Z[06GDJ<*$DPBQ, 28CR6HCR0#0)M'"8US>&Z\4GW  ?M'6,8H!06!
M2(S-X2E#*DV5C@ 6)]%*,>L'Q2?'90.*P:S(N:HO5P=3R&E].XNCY\Q5E0H9
MZ[X0V/MF<I7"/7S+ "3E$M #O(1FPC9&-T#(S"2_ .Z_, "D;7AO(H5^(-I#
MOK8DE&B&-<)Q2,%O5CEB%">(93*C#$1*4KK29",'T>4@N&FLF6G,D2*NH@0E
M)(U$E,,YA-V7Q$]%J4YUJZ,^SHCV*_M:7$XO?ZGJNKH&0'C(3 /]R4TGP]#B
M\#N8A<;,#)C;T3)FA(!A><_Q#VVDT#+)<D40U3)$)"$YRKGA>(YCEJE,)VQE
M@,IS./ZN[9G/4?H")#HS+I+\K&H3B&07Z@Z_C\'L+Q@>X66.?SCB1'>7WW\T
MTS/M^+[+O>#SM&ZFK)PLYB;=PSV#=C9*.P8EJ%H'V1B+@2E2&DWME!3C;<XG
M,QD/=%J.6;$TI G.J54%I]@QFZ(%82TV:X;@C-L<5 NI_KN!WR\O*[/ X(X$
MT_'LGI4 "%<K^Q0:\-6?4P"RNH [:G"B2S,J9&"R6> A@7*4<U_^_OOL!0?E
MS;R>:C'ZI:/7NV0W[7A2KN9O.<>@C[TGZ)YJ6H,[WSZ7>1HS%/6B )9O0P0V
M%&"!JC >OGDP\[!P56!N<^%F"B"T,4BWC1(,836X4J7A^1$S\%=IK8"5K]0\
MWG!V=-@&,JSY+YKV=#@2?F_ 19P 9Q3P^C=V#>;#69M&399>Q:Z)R27*ZM),
M5A7SH =P<VE&^L'#LI&]7B$+5L.SO<D W1X$&=Q:BQ[J-O '/RI>6X<0S_W!
MX_._WW<(3RJP[0<@3=)*U(H3&)/WFPZQ/\[<P+_9Z!Q<T!PVFSMWZV%^KJO+
MHFDJ>!9[,="U8FBJ.F]O=^>Q0&6=@&C;1+S9BP/2.[DV GS^Y=#*U.)V9CQR
MK>P-[7?+=[6W>E<K#5>!8^V?Z6#AV![!J9,;>[E/57F!C!L7',/ILY%W]I>/
MK*B#W]EHJH)?%6M )=C?%D[PJMW8M%JM_1B#NA+%>#$Z:ZY*UC_\-6L6%;"@
M2& 5O=OQ\'CZ*$D(/!+B&ILZ-(51+G"(&)91@M,\Q6QE#K,*,4DRP&R2F]G-
MYO \C0G2DLDL58HF(7T8A('CH3H=0[^[D&OA8H"T>%9^,%L-K!IA21!XRQR1
M- >FMKR98,;!B8Z)6@F QR%3F9+@:PO3@2A1 LZ)- IQ3N)8\CPG^:NR,H[V
M-K<5VA%6GD\%KQ4\16,MAX7I=0$P Q3]DLH'@W)_;NN\\,SBR875D& . * ;
MJ&DP]2UV-"&JYA&C =<%VH&!+2^4[.<H\F_+PSV:A%GSI,X.S-KR,D=Q>"^7
M-UP4NH[9A6J+/Q#3\+K[;'3-;IKW/P0_OV#Q7YX!FR^^U8P@9N"S-O^J]+_,
M$XR5?8Q_M1ZB@9#_BOJ>+/MR]/FU=.16W^/TRWEP^C$X/OEP]/D(_CDY#[X<
M_>WX[/SHR]&'X/-OOWPZ/@P.#@]/?SLY/S[Y6_#Q^,NO]YBS1]4NT8:E.S"*
M>[%@K&S0,Q+NNYY\WK+6.V]]LS,381H"RZNZ=>_,E[]4IA[$U'Z#)RDF56WM
MZW%95E?%%0.GN12]-**.B4__M->X*-L0I&63CVUP%3#8V3S^V+B[VF]?(N30
M8O108?U3!4-V!2[!5!8F=&[= R&J2WBM&Q/QAD/MCBZ3\EF$[9NA4I-5[655
MW7+4>2FX=]A><A;+V[ )9C +L(_LW>[<>A&,MV>"IU-=JH&)Z,.J#579F!C[
M_-MF2?W^=Z!L_&U@'TZP9AAH,QY^8'=VF]N9@H.@+2)9\T!S[3U_J!)<'W@O
M,\B\C>R/;@(;^C-!11,I;+TR^YYZ(<JW3]\NP!ZLURS]8(6_??%UQP<S9R_0
MK*A'-P-;*0#^VL)3@Y_'\"3-_4O,"P_G3MR, )N7_O9-S=[&=IG-?]IZ1[,7
M?IYVN%W%)RXB/#,0T_CO)A)J [F&R<#[-RPV<UQ'L*X7JK2EE#?F=S6>W*:5
M?BLM?UJ=V*9"K,O&]MQ5!UXW[HAN- G&F8)LY0]XMY96$UI>-OQI,G<2 -XB
M:/)YRD>%6(C=P2V_GUZ!7C(O,(.$[^[P]D_!N\^'!Z>__#18%MO_;MI(C@GT
MF">LJY$M.UX2^-9AM>G332+.;7P?=(*H"ZL^ M6830 %*'0K:3T+F;7GF\?<
M+R; >V(C+8_GBW<X6[PVLT+>!^:7B]KJ]H\UNU375?U'\,X4E/_4L]78].Y%
MTTS;#/.,H4 +3Y3-8)^-C8VUJ>W3^H*5Q7]FJG[&Q.>U8O*:W;1G-8TMVC$5
M[V"Z6GX+6O-\FP.D\R2@^FI,5V-3^,&TO"T?J.X"WF=PN/>3O'5RWCIMU6D\
MM%%WH[*7#,OG.9!R=Z&=%-+OD3NWO*8'32"+1DRM_K=E%A,51//:A76.SF"I
M6&JQPV#9+5PX,+*RCL$2XY\MP-=O8V./[)@I%*:#W04T)IV*S#\M!&VS<PO[
M?&JS>:?CUIB_.YMR8$Y HR0+$0Y_LL=\@#M>,;/>K6?W=R6!,2^014@,/$I#
MMR-8X,E-"Y;R]_]_>U_;G3B29/W]^15Y:K9GJV8Q((E7>V?.H6Q<1;?+]H"[
M9V:_^"20&$T+B9:$;>;7/QF9$@@;7'89&PG=/3M=52"D5-R,R,B;\1*PBSOY
MF0YH6=ZU850/*N5/ATE(:&.8/#)<'OWJIZT\A3_UH(Q!N FP IL%<0CAQ!MJ
M5\@7TL]1^W>:]GPZ]3T^&*=X3YM&R>;2?K^I=_&9![;F=B)R.KVRA1N;;;-X
M-1;!!N:31P&7Q'#*9<SNZU2I53Y3;AOEL_A-%&M^H3:F*]?+F:QRO]5NE)::
MC?O/M:-8<":TYU4L4)%%&>V<337)DR S1[8_8<L@@25!I$@='9KCTSNI@%)%
M&??)CU]$&.A?1*SN(DD@\GTVD$\J?SY.94\$I#O\;GG^*%<7.5:N2F3,G&C1
MER.=.:M[_M[R]W1%^UY'^#RD !;OE.+5"L8AV\;A'RJK8S@;D+^_T+_G4[!J
M>K*KL1<DOXUT3U["0\HAGCI<3^FI\.F,0FN+>I)4/Z\?4@T)BHWV7*4]/ AF
MOGHT[WLS>8NQ4.[VQB,<4OB1KQFWQ;D-Z5)\26%QCZC0A/!]N?C*_Q_Y<B#:
MK,7O3DDR8C%8?8#B#<1P1NDNZ@0J($.G+*<=_!YL?&HLIO6[L2='5$C*Z^$0
M2*S:!@^U_2+QJZ$468]29A(7+UY'U^90.45D8%A(>3Y]\D/DQO#6'JH\)$J.
M]8>Q%ZTCV[65HLVFXP71/3>^5D*2@>;UEP.XY<Y,%_:(#T$?GT_-@B@C*9!:
M)EWX 07D4PK.1!U+3?A09?HL5R25(74G*)\I>/B(N&Q(=,+'DZ=UZP<O]:$O
M'%O<1I-WJ1)2I"2D0.4P+69J?^'')<X:8:_S:Z_?EI,DKV$@IVQ+3<EO/)1&
M)[WRQ63+MG- 692#>,II*SA14T[E><Y<^;F*61&.=T>; !Y_S>5:I%QURG,B
M8ZOS7,.#J:KA'-WK"4,<>0X\6'V2YS]TZU>^CEQY???!XA1.^]+R?A^-3U&4
MB5[&]0(4T&V3JYNZECR*9:S^9E)5W?VC^4DN<[>><QMY46IOH;-,I6_O.,*]
M40MO5*'+OA4%>BH%USCBGOU[-KR)%B E\\5+1>O56A H.56.UO7D8!V2NJ+Y
MYHP.$Q.+4;P)6^^#A/QWX=+*R:4[XCE"NQUW>O<E;UV@Q38QGFAA73\KU$0H
M1"NE.B:7$VS*==&!U=&LOP$MHV[2.7B,C1?E:-AA#"56V_P:P+==;9/1<8H]
M7^S8'R2<A@\33C7+;AW1@>&$SEETZ5"I?O+O)X*NC\ODD>_XFS287'/X4?[]
MXG&+.W63V:\!'=Q4M;+68O.T$LVW3MW3.S>@*-GP%)Y_>K;65953/Y"67QV:
MI5?^F(S9F(Q/N:U+.O=6I69*WT@LC?:03G43+*YTL:;JJ%8[BQ'GK&.TJ;0'
M2]XRXAB(!@F#1/:G)D4"5:A/WU;:Y6%DZT62PYJS"45WD\U6I5T64<1<E6=5
M*\&B$HNZVYQ]_*W3_D3>D+S&4W[8XRLNVOK<.4F7+001K+C.B;7BP:B+K,7D
ML^@'JY'I<_6^TVA!ZR\7M#AMUM:4F'3XPKEVHE6Y%B\<,^EXJZ^\.[V&#56"
M3N3I27<XDA?]1M>(79(_TH6VY2M$5PLY)F\BP8F8,1X5SZ'O:-3T^M(97R=(
M[=;W \_O!ZJRK CTAF(@U G]HG_$8M="-U2_DKZH0X5F:8)IKUYN/9($5;0"
MRQ_(N;(.]>6 \A58AWS=A4 -RW@@TK3EZ^[K@K!J I)6D5)8@I>H]VJ@%!E(
M6Z4@*BNG G!#KB--I"'Z@ZK)Q!^,N,Y(7&78Y29 [FOE"\BWCFM,31X?P$;D
MPF1Q>KFP-ATW3NDH+*SOTI;*W7T4#K-J5%7=AT"GG.B8L&@\9/(^+LGUZ 1S
ME3]W-R1;ZL5'!?3KHQ$*P)>BF[DV;=1UUHDO)IZZ@(XLXE$<T$!]?8PSI"([
M:HU:W.D[RX9:.+7I36"CZK)1^P8-T=(2N_&"J1BK>-'8L&9&E7X>+GDQ0M&=
M-E1T&PA?G6R%\ZD>IKA=DCS#E5U@=+\-C]+#C-;O8 7(!%8QBR17\*>2OU3Q
M=,*;_!@1/)ALR_BPE=5?/C^(OY)(A,3<Z)IIBEU3'SAR?:.  ,)$E:[X+\LL
M%VO+6I3RRO\REA\4XC-XE>,E1ST<*D^(YDEA4XK%FE?8^ 9V8D=N4X3\HU=2
M%.-_6?5ZL1F/"I'OV$'E?<'\AW2;26(ZA'*381H^XK'6:J'2,\4PKR=]H^-O
MS6 I/CP1@[3^D#A.%8U^]G)3&H?7)"UI;#Z7^Z25<V:UA5P]7G[TJKZG-AS+
MG*_$LJJ,KTT$]XU''ZOE,0X12H13Q1QC!( R<WI_I396!6:/B.8OJ,V57AE5
M$H]>49?+(JTRR4T?9V/Y1"FKFRA.0H$@05N\MXJ<<A-EZE3I=W5.(T82WC!9
M0)3>*NF5J"VT-Q(J?(D[@793E@97+0!+,,7]E.*6 Z'"(-QDH,/BN#T1<1'O
MN=>+_1'^\6).T1R;UW":L;3?HPF*0P08TW?C1K]Z=WHBK^5(_R'U6KI"469?
M%&JCKD@O+)BCV9BC&RND),.<8KO[8)5]G@N@5OM%R)<Z>/8<1U7O+U \F33P
MJA!><)A5/SO1,2F:'#0)#BO%JMGXZ>C1]!O:P=3A\\.1=&R24Z^FQOCO64"+
M?/PX=94T(G*E/U(3[$"^^R0XI!!IQW;%VNFX'+@<@U7_:>_FYXI,%P*U79+(
M@9+KD\]]J-)/R#PIRGK5-.J-6J5I6O5*W:S^I$S//6U"%\8G,1=6AY5YF:M-
M (6(1EJ\2!UT*?25R U/99 'L?>YQB][GL6(7;"D=[ETNY_P\M8<-KS?(<,.
M3Q@6]DAUD5P4U(1=@EW*B5V*MX.+M!O?D[9&?A ;I[7F*+']E'>3ID83X",5
MB)<@!G4_C,=<8=P*<\6I.7R9-C:+Y5H5VK@_VMAL-,UZHURMUJL5H]PD9?3R
MH(7M%15<,NV,DM 'H=I *)8M6>::QRT45A9[JH 34TK3N)_$\E)=#D?Q.?&.
M9.@-HD1WS8S=D \2A;FJ$N;Q<</J*5'BQ.:CMA Z0WY&6W#?IQP\===/10:M
M3LE,@U:_:^B4=OC7'88F5EEGZ<8_<3S0GS_FR]?KVP/=7 F;LE=K*VYR\K?J
MX.NXV@U/]OI2N;2%H1P"Y>TOG/V5]X@.1!;GX-$^8,TV('[QY4Y@6]X_+!,L
MTUY8IE/RTJ-X"LT6+.)@>!#8E'NL=7C-*=3BL"DJD[KV2*KPHEW%?V_B(S;'
MBD!Y4S2AH+R[VRP\/K]-)'B]^- A*J*\LET7R62=-5OY37J8HD.D-,*8^C)0
M$%H^CBM+08F=",>C_%[V9SZ9'K$K;S:0]N+L[#*]DDZC*#$]MR_3GAS]SQ[%
M-AU316;/=VV>F=/N%(>59G J/*K:G9EYD-YID$IQP8R^67<(>175U8CXM^4&
M/ Y@#6S:^M/YYW:B.)&SMH# L,R4YZP]J\?D$RTF=:YOUDM5=-N7N6K1V-P@
MO QU:-Q7J[VI0>-+FC.F#P@$.&?9/%Y\OQ36UOSR-WV1%'OE&315VVW-^)$3
M)\7O*(EYX/G2[U $]:>-/1N)_AX<K;#APXV=&XTM=6[4I:95/FRRB>,BMW=]
M+T<5)"?X8!P?9H5WGNI(N*@%&U7V6]^@T'A%ET<MI?6-'B.1[:[7X^L[9YC5
M:AI4(6MM7#:]QT;E6=][$_BE#+_'O5 !4<H@VN:J@+:UV$QD;3.Q;-WCK;;N
MP=8A15,@Y4UUEL$OV^FML[S?,UOL!#_88^?'>R['KKSJ&9+8[NQQOY[4GUK!
M)FR73EC32R?(<S.=1"D =--!-YV$4D3M=-!-!X[\;N,(OW1;YU?LZNM%]_SJ
MXCP90(C5&XJ14\7XQX:HFT0R?11\HW+8Z#-:.HG4@;G&K'PCD5)<[2FYLM)Y
M\M8%U[ZKE!]''NV)F!_&K#X, 4-4W:NCZJSM1M4=-(JU9NVGHRD?TFY#9P\V
MWFO"JT [2BJ\;EY'Q\O7MGLMMQW7<INS+.1P35O?K+._G:OV-]8L,G;\M77^
MI=UCG7/6.C]A)YU>ZTNWW?[6/K_JL7]TKK[&P78M^D!ZEHG8._K!:>>\=7[<
M:9W13X_/+GJ_=MO/432K:%D6UHOG8'7NN0+NR,[=D6?8#7X=EY-39F-)N.R'
MN6@5V?'%^57WXJRG=/^R>W'</I$*WTL5(!F7=91E'+%2)PN&3=<=H5*%Q(1=
M+N;6LTS#&YC;O74<5PAPOBR7[KF;NCD4F'R_B(L.9E.YY;07QRD+HERU-!G8
MTP6T1 XF*<ME*2GZ9C"VQ8B)>S&8J<8KWFAD#U3CCV'T78(KC;XL+$JW/"QS
MJ>O+$WVJZU#%\2GQ.)9$[K(BIN*:%],L;H^EFYN,5,T<_=:]]G%\\!2L_EJ7
MNTKPSJIR?129R!8-:O7 ])F9<-4@U'>VNRR#]>!<+1JOKFZ_O&7$0>MTB8@3
MMT,VLA6+O, H<1*V. 5K#10S;S2M"ON8_/23;CI&)Q]B6-!O0S6MJ0WN1*J$
MG(##N,&,?&ITS&@GARQG811#$C#54E<U)+ 71Y_1\5NB O_B'(\DH/^V 9<M
MBM&5;QK,= O>S6*D5*59?T+L]U*B*V*T59'"V63F+ H1KFMPK!^V[@@YH0I1
MLS8Z">!.0AVT$.+/E[Q]I F!:DPL91[0 6CBQ"2PI7G@/AO-W($Z'55'!8DJ
M*>HLAZHB*MA4C2C=W2=Q#+*0XE)MBNRS.IR.>NA(@2W-1D&IV+JW2"KU$V\3
M%7K4I:AY&'>5">A4AV)G"\_48=W/9F$<6-1&:NTIFR-NA;.CA@)[NK)_6U,.
MN*MTC [?5--<5X(>K?.Z(O'I8B[H*^7TPWJ__:KQ2=L3+(-7'*&# Y.-4$BE
M)MQVZ8!:_7LHK0$9#CL&<) $<*G,?@P@J6^\A$I3VY7&GAD6UY/".#*J'T>?
MXD4[:5B+RSGRW4=$!ZQ!= X\]1SI>XCUBP<UE)_&3;ZT;58O*-RX&I5>_N*5
M8.5<?BCD[QQE\'U=5$\M6RHPG4+AG;AX=2CM2L 'RZA8J@\4Q:,'L1^BNW$=
MJ5;T\=GJ6O.D>^"MW%)%W^AEFB3L"EJGB0"4[S2E4CO4%D W<H\\G[5Q VOB
M'-:$;:X]J([CLZ,S8E4I;QH=E5/U+G=H1R5%?3I2UB7"Y1MZKK,V!(C/)'K2
MP> K,GK0UVX8)Z(=J7]^M+XCN>4R)J5!G=R4,/SE<A>*02R@F1L/0;VR7/4T
M7@4ZDH^:VB=S"I80)JL ZNR4932$7H">2F/"GF;+-N[7K>]/7N'.%"C^9],6
M:],.AI[Y? N[B!2D9ETTZY8V?.EY9RR27?_^.9UY'KH2>F6I'-'G-[[RP4]]
M/A%WGO][QH2P,8I [2;4/F:QJ0I#'?W5H\5<&C$*[_1ON)LTJ'3Q%95NON/S
M9"3D1RDPBZ*NM)0^%=DZ[TT'?26V+(F()CV7E8\NG#@F+=BP$Z=>8@]G_.]B
MOG9NQ\[]8B^Z*"0=[3:2:U.T[NN5284C1>%/L0H)]];V/5='[GZ.U2:DIFL/
M=S")A6=U0_)"Y:1NE8E-R'I.!4O F[JY:^?P)MO[(L]V;;M3<9]HI?2"VX7L
MC+.?/<?A.F99SG$5FZBY*$H?#:5+I581VL+?JXA Z<7(6:'>YF&+UUKB8^7]
MS%0U546X)7-1UT>4:@)+LS+J32A+:$-:D*DCTP<14[!X#:E<K=G-+ @9\89*
M.(DWHZ]_GLD7,(S$EV.N,DVCQI)Q7.[C1?.A8)<5Z^-A]&>!3:B*8*/>,=UQ
M42&F3"&IZQKG]!GAY#<S>[CTUBG>=V6N<>4AJZK6CP8HIZIJ'N,I,ZZ6['63
MUU]LG]>\^^:]T1(\&L;2KX71>0.CD\R!2"1CK$_7*&RNB*A[A<99[B];<C9.
M]BO5S91:%@9A3)'&4VH9D?YB_]-.Q%CWY0O=@4C;XJPZLR=V&/MP&J?VPS4K
M/BV#1K^E&['57>'0D\.A=8ZXDD&X="V?P6Q'P?8O<$)MG0-PJW@4^7>5:J'O
M2_]4"1=!D;46MPKFTG)) ^5Z<<_GL7>GLPS('::F",.$3T\G1 ,)=4S&*))G
MR<@4U)M2XP5G1@S^0VI+]6CXMY[3BW5\=2B*1IH(Z;>?SGPZ:BLD=Q?16=O*
M#R;D=R1)N1&/Y4R_%Q&)%DA1#H1VKWQB H-EY8&H[<-*[SQUV[[^@7Q5LNZJ
M0 :AKPE%F_RK@)(I/HL!5^11[++0<R4$3D*GHW(6JX,/E.17G9[%")*"CF7Z
M4*3)6ZK=8I2<[^JJ^TK(49I-W)PZ.LF+2Z1H)JLOA!O19&(H)X@3>&HK]F\Q
M6&PKZ3!R=:BK3K64RFA&7.#B7) D'\P4XC$)2\D[,8\62UIY150#18Y[P3SW
MES)-%$8AAL6.SKB4OQI-JV7O;.5/VJOY7 NFV%LYN:4'JXKE-A6$V5(\$H(I
M$\&4E<R5*-P+7^)XJ3 X@=O1Y#^9^7%VWE,[ZH@W3NZ!$WLW97?C;309]GC+
MO4@1E_M57V\WX[H>$7\641PW?C(1,=J0/BCE$H=_T(2A/-5U/D>"4M,K#(V8
M_D4W7QY+Q:9ZTVTVN2X)GZL@]\NA<B34\JEB*[03,)#F(EYZ7(G&8@5)=*:@
M=G?R)?S5S$E*B^0^1?K0X1)% 7A3_2K+YE21)(C 9P%W$D%H>Y%M!MU]P7X@
MRL+FT7ZY+Z=M(?(FE^[2Q"-7-3X _-&9SSZN/SD_V'AD_NE95%U$)ZKAQH,D
M4DJY;.3'RWMHSSCRWN=2WWXGGC'T'O^@\+*7VB_5@<_W$I^OFG*?K[$[V:>Y
MT'0^-'47V2*U8G4ODD7V=;7?5!:;/MSKTMB;2K5C8J;!GB<J8V]U$X^IN&M9
M9-!&KJO'_?PMSN.*W%LIO&T6OA\3E[%0L!^/AV-Q0!Q;%Q&G8[\^94P:[Q88
M=WS1N]A0JSRN9AB'Q]/6>7-I\F4(V*O/\3&Y<S^Y:5K"O<2:_L9K.A4OC!;V
MPO-+8OYXN5E53?-3(3[]WVJ$XB)=.!Y8'",<A4#I!SWJ_5B(Z_CJV/V9^\>,
M2AC9ZK D4=77VU!:&%H*+7T;+6W1Z4 @/8"^7O.WE'!92$:^+R*95<DX5=!T
M&=3ZXNCF^+SR:BRDK,0LM <!^RJWRO+[0+O_^FR"@G"79Y(/@H0+*^>=['+,
MI9@'ZF[J];1VK[_1@V!D?:N[C<J;B+E^:9#U<TS8LKKL"V.M6\H.2ZE1.YQ%
M@58VM'7D=!2,^28 /4/V,'FY-7GOU,3A DT<H X94(>W;VCQ5&^*=<G]R5S^
M'Z(DHC7J@2OPZERJPC*#(%H\5YKZ;<FWV4ZWCA](S%VLT3_8P8/V17O==2-]
M]@"V,=.V<7UCC[3V]?@14TQ[FR7WO)%Z3K2C6-I8/3)MT'5A*_6.T9',"ZRV
M7@/B.-)E#'^B ,:=X+^K]4#<2\-&73JIF46TECQH5_&\7/%'X^LO,[E%-"3*
MRI"C>=1$1*6H/RK5IAIH)#,ZEH&K\5[.]@>S290\\427C#@Q(]CK+AFP?FG>
M*)U0T*@N4Z.VZ\D$PA%B!C [=\U<QB4L?\2GIGR'92V01!7(9]:!BAI:VWS9
MXV_31D=G37R_B):JFG8?O<!TYD\]G3+QPZ6U="+FCXOHS<JA%=;60RMLHR!:
MO'2'B?Q/)8$]J(^VN3;:ZJO^>*FT3672'LGR?:NF%=:434L,9[4NR[O44<."
MM6M99'#!2J1QZ_Z(C].X"R^PSY1>3.<T<4(^Z8A2J976B0&RK=,V=:'&F59C
M:AVX[LSHM<^3DK'OY>#=\YGJ8Z^:9)Q>#VN\9M4:S8-:N2X.*@->/6C6!M4#
M@U?[IE6M#JMF[8/2/RGIKAC]]</Q]6!8KE5& W$P'%GR-V9-_L84M8,!Y\:H
M(0:#H5G_P%P^D<,>"ONPI5NZG<L/LH_/QF)("RU8$?/?TJL<>6D3\RQAO)%Z
M-8Q^H\RMVD&M6>4'E5K?.NB737Y@2DT;#!JUVJ@RVI)ZG7D#M=AF7\6H'=_/
M'CGF:SKQK=>NU.?_I?B /8,SY%$$9&;F 3*VMYVQ74MYQO8SNI3UK]5ASW6B
M+TS6Z7W=G^QSD5U<?6UW6>?\]*+[K775N3A'+\*M"IIZ$:9W;<F+C_D,)1]<
M+XLF7B_(RVNI\7*>N-?_GOG[H?/'1=UX]+T2FMXVC9FZIU(9BE;W1-6<N.BV
M.U_.V<^_=CN]D\XQ&;0>N_K:NF*7W?9O5+.B<]Z[;.LO=E6\>']M79B(\D+%
MPZW[4O7,^5*Q\)6AI88IU[9M9]V07K:ZTHYT.BE=RHSR]>+L[GI15?@Z;O1'
MG7:SCH!:RN0MY5+6E<;\HMLKL/8_V\>_7G5^:[.+T]/.<;NK>^X>7W0O+[JM
MJS;[<O%;NTO-M]%O>_LQY&M[9JH4>CM@'2JEK"N\>_[4TQG6?76X3X=@ Z%S
MPW0];.]^GDAOBL/=B$5@+=>=<8=]$R*N_+!25T?',E/3S43<,S5;C:H2&V:9
M#:559,I$ZFAS=QC7JA])]T_>_,FL*7CRZ??D#2-A].@(4;C!_NS9#:.8L'3'
M%]\NV^<];-QAU&#4WLVH'32+9</\Z6C*A\01'-#0#QM%LU9_=UMG7D?I-O-K
M[\Z5\V5L3Z6G=SW0X7C[8?+,(DUXN:6_^A>[^,>Y].R^=BZI%J5T\JY:G7/V
MN7W>EBY?IW46?:\\OV^M\]:7]C?:]-,_N^TSZ06>L-[5Q?$O7R_.3MI=><G5
ME;P<)8[?K,3QNFRR1(97:QGW1T:Q$P0S%>^C&Z6WI<D-53&EQ2+.+AWN!KI%
M4"'*3H>11@>#%QU@OWK^P=?:NJ\U\ARITBJZ7D42+W*@HJ5L1<\?6A7*6HN4
M26C,DHZ_2K%3,8=1 /"&HFB'\(0V>T(:E7B.45"\K\8C$3LL'ZEO#QP^]V:A
MO-N]&![I.QME);#H!P,J^3$-Q&&@P^:%?)J\N;S[@LFD3LLZK>(POCJZ2%XU
M7,A#W;Q:+3:DSR5E50J'&ZXI%YOURG>N,6B(3U]1+E8;1C/Q?Z^_9;'6,+<R
ML*:5GL'4RI7R\O^,5]_2E*[V*GSR+_[#23/69DI77W\\6]:;1+-:+<3_(R,H
MIZBFT \UD4X?K#>-M\)7U6HBA=6*',_QA5I7IR%3M7O8JK65[[+)LL0ZK)2Z
MD=GEXL'JW=@J^4[ITL?2=-QX_CQAH];.H50 GWR<A"1U,^ [:\M6T7NTM*S"
M)D&B;_[ZP?R0*@@74W^-*'>$Y,X:2VQU/IS/E =&?=^73GE4DT17*IU-I0,G
M[H4_L'4*B?0PEH4&ILMDP-NH),"#2Z27&/JV*N$0T)9-NO9V&!<?>? 5OZ,*
M#1DU*FF?FBDR,^\*)(P]C#V,O:ZG0X\00YVR:QQQ"0^_$4OK/I76>).-3X<R
MPRK#*L,JPRKOD55>ZX+[8A(7][KEML/CVH]15KB]RI-OYEP_ZNK/JFI6\NZJ
MJ(>N."8%,INX["/_]"D=I@$V'C9^;VU\:ME3*!&4*"M*M%M'*>V:DC4'2'H>
MZ5"UM .;(N6#"4P#"C"!^V("^S"!,($P@3"!^36! YA F$"8P&VQ25%(ZK/I
MI'*]8%;*$BWS7=%"4/8FU-L;27T^I>!LG4@1IQ^Q*!7B!W5UO]'?;?3V6^+@
M>ME!82\$_GSG8;EZ[PH$G\S4'EA"HU"I50MULPRERJ52I4SD/Z!!-):#2K'6
M2&:P-*OR62_7K5JQ_G*8X^8-A[Z@=G^W8O,^S/C1?1C4+-MJAK7K+=:N:K%:
M@T+E4J%2)O(]7[=,K%OY5#.L6V\ L%60BEXP:U4H52Z5*F4BW^^U2P/_T5J[
M@L4<O_R3PL"_4QDCKHD55Y!Y([@>QFC7%T':\>7*$![6)0!4ENMU!&WM3;6,
M!#JT;S>*E'H?.GQ^.'+$_6/)_7L6A/9H'C] 7740A-P/C]3['E"AL."0VEL[
MMBO62G,YU*AHS>NT0771I&(MAU372'PL%VOUUZTR#VQ$,)O*5?:U9G QS -/
M3A;;/91"9>IUUT.W LP"%=LEL1XH<)X<T<-I_01PC_!8H442<V5U$'NP['?B
MMK/-2KW0+-=8,.;4WT\EG% 2RK/3P:M&O= P*NMOL"%7O-O[5?^XVVLE6H%*
M@4?_A:I"5;^OJF8N5/7$D[^A%J0A_YVJ\%$9+MW#^%GU%ZA1KY JK&LNZ%:]
MKO<@%Q@Z"!W\,1VT<J&#B^52NI1RPUR-5SO=/'?BN7%ADT42IT[8I$)Y[<G4
M\>9"Z$J6['+F#\9RUJL"AYOT#A7Q4E.#,U$$V(K+_5[KG9YT@<;V=(\:/5C%
M1:E?5<67FO=\[5SV5NKZ7G5;Y[V6[NQ34-_$S2%8Y_RD?=F6_T'O!Y1)SU0%
M7IC"EYG"RK7T&]V!/>7.=>2-JBYN0NR1.:P4V66W<W[<N6R=L=;Q\<6OYU>J
M^UF[K4UBK]W]K7/<WE5=<]@ZV#K8NE5AH(_=,B3%:J2]CYVY2?B)/G:W65],
M=!N[W]*ZE%>OQ?W8[MNA6KFO1[;+Y<(NU_6%T<PZ 'HUKU)#IZ^=SYTKO7B?
M=JA''?4RZ5W)C8WJ7]([_MH^^?7L>2OZNX&5>4OTD7]BC*UV'QAZ@QE-+KEZ
M^O$BRP-&.D\KJ%KGH_6Y*^0:+S]UV:D<)S/*<6'#7Y[520 =95ZP9A0I"N$T
MM@'2'XIL0+ K4>^KI%>U86%UEZZJ/B$+!F,QG#F::R0/LRMN[( XXE I#MV0
MVZXN\79)RM/I%+2#W"@PK2B#HW6 JMOW9M.IH_[-_3D[X2'7/QD>;5D)\^K%
MKK3SB-Y ]3'CL] [VEY_CY5H#'7O5W7\:%K%>K/VG9X1M:)9?G;/B+(*K7EN
MFNI"==\OP"D5$S(M86:0?R:* VX/IA^MAM!\M2OUO/WW=X!K[I_B;"R/NKO*
M%<_$*FLE22[YC7C;J@M;F!42KS0$ZW(V]L7HKQ_^),6G9B-QK]=][E"9XNM@
M+$08O&HZQ&5$GNF>JR$.Q8!(8(K!5>?N*NK@K=R\X\2+L\_ZQ5E/O?BFAG?*
MU99_,1:SC._.KB"-X@TF16-M[A\,R',-R'+72UV5Z5QG(G)D1A*[<FD_.NKU
MU5&5X(-QO/,/I>"$.D]2/3;IHZE\A#?<=+P$:[.OUJ8.:[,]:T.5EWPQ%FY@
MW^;7Z!PGI0 3!!/T'1/4@ G:G@D*$F$GN;5 R=@;?;C0/(I;P\,0P1!M,$1-
M&*(M^D(\&%^/'.\NOV;H6(J G9((8'5@=3;,G^;:&H6P.D]8'=<+17 =>M<K
MYF<1^+#?]N:<7IX"BE<,S[JP#)B,?349)DS&"TV&KV*.(DIX**9"#>7:5R%0
MPI?FP]AOLZ&#KB)2>"& * :,!, N9WW''K#6(@='&A5_PCY>'K<N/K/.";,J
MGV!2]M2D&)8!F_)#-N4)DS)5&I4'N_(:LV)6&K K^VM7K-=7*,MAL"_2#UXI
M57-3^@'KQ7'P2/G8LLQ;CI/(,E#U@?I"N,R;V*'*JQ4#/M,UP(CPXOU 9=BJ
MTB?NT-:5P'2Y$_DJ Y4E.U>Y"8N\7<]?W(5NL?@\D>1;D#^6*P^3_Y*CY4Z!
M\GN#L7?GQDS;NA2)0N)3Q2_0HX*5G(;E!8FG[2;Q=F^GT,<^Y7>UHS3"E7QM
ME8E2*QLT7Z1_,=-U4UAOYRE<^XK%LY/G Z&RX<,QY?2HW'6-'R.9W\M/>!@E
M**D28BR00N+A3.HH)0\OTH.T/XU,]BQ4[:A=T[RX-LK7OU\'LXG\_7P_<GMK
M179ZT?V6S$ICO5^_?6MU_P7SLF4BVQ7;4794:DCLMYH/1)JV2@T;9:^L2UQ
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M&C40>Z :L,*_?>IIS.LA Q7*!F7;[\2/U&,*)4L9(!E4,J/4**TXD  6F@9
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M9":8638M]M%V!\Z,,E!ME[7OQW;?#EDED6_.,V_7/J7%Q0")D0I#EWK?(<>
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M[,KG;L ']/@X'NYG[BIBSJ@KOLT"JX9]/A97))Q"V7:.")1MBYXL0,W OA*
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M!^+>-*YSD#]X9@<A-<+LS?J!/;2Y;XL X4#87@$1( )$@,B^()).1QV  !
M D R!$@&N85_@E7**?*F!58IS]8T!>)_R"I9>6"5CCTWH!PW;\0Z\F%3H<3.
MNN+&#J1E$4-V.>L[]H"U!@/YTJ%-Y=YM?P+F"7LX( )$@ @0V1=$TNG, Q
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MSBI88:6,!ONUV"L>%XF"4I26857+X)NP<P,B0 2( )%]022=+CP  2  !(
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M&X1V. NC0V3YK6<3I;MB70N,!\2EVCX+_9E05SK\;C1S6#QYXS@'VXW_-J+
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M1FB[<<!'\G4/N7/'Y\'1!U:25_YOJ>\-YW_[?_];&H<3YV__'U!+ P04
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MSY[&BS*14@VWJHO69#."LW9Z2==290J.FU<;IO*-N8OMLJ)+XR(^U"57=&R
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ML \W^&V_S<FK=$^^<3&EP<O':AF-TK *71<E+U4&<EM#/B4T2L.JDD_VI9I
M,$-1[%2/4PR;[N:31=X<T9/"*.2CBJK)!&?EOA(10X#;U)[K7VF\*[#=:E"J
M"3&;DJ?,.)72*0E/G$O98W]AI;LS_2"1(.1@;&7<C#6)U03*X-'Z, 3I[-Q,
M%$GQ.S5AO#KA_E?&%BMZHRJ$Y<;Q.+&-Y2N\.0PQ-4K!4J@&83< /IK[HJ6>
MG*X;\,2)T#KX\H1* OP-P^S)]HEP3O2-QZF;7?=442@**5BAZ?[M8R-[077'
M-O[J$>9B&DH,8<]B;%"DLZ!OFH.^Z1CHY<9DS01=7D)IR-%])R.['&4)48>
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MI&?4P5.P0%&^RBX7I(YL/>_8%6QS(<KJ<PP=I6G?J+%Z9UH%&#5GI%B]@7K
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M\]\8#/> CK)'W:5IS?KQ[:Y2 M_8V]9*&B\X_.ZG'.T0?%)5[)Z+3_DYFSQ
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M>X="NI^<_YS^W[U'T*__#U!+ P04    " "9A5Q66!%4M;UP  # U @ %0
M &EN=F$M,C R,C$R,S%?9&5F+GAM;.V]:9/C.)(H^/W]BMS:+^_9;E4>-5U]
MV/0\4UQ5T1,9BA<1636S7\H0)"2QDR)5(!D9ZE^_  ^)!TX2) ")9FU=F2D
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M:&0"7](C(7->!\I X]ME"@C"X3K%@U>(T@"+U0]8HPR2)$;[^SB%7!&!.\4
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M3:39TMH32*IFEN)D#H:QB G;YJ-W- +$@K(.ME/:Q*%$C@9[*-A+YHB/B0O
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M+4C"\!H*&CS3QQK8=&T+29%" H[_4O<+<6,F55<Q &B;E6/5^_K-"S-2:_'
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M)/T7-/%<Q-MM'#4J>M*?B<XX:Y@5[XJP)UBS_=Z\]G<LBX$L-!/^UWUX><?
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M"4;-[1)Z6*ZJJ\J5C[@3C=3@39*C0+U?A"%<YS(TN_LC<X+&>G];$/EWF*U
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MO(+O<BLL2\S4F CRK=4%C9TWQAP[$4F7Q\LDZN;O$VWJ$HOQ<1CX1(>_CM*
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MFQGO@C1Z.\I1I:6V#PG/D)! F^ZR+CWT? W+?R;_]X)EC?_X_P%02P,$%
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MW\'!].<;@D::Y.46W3/4>3M?@M)))Z7AH+N/.4M4F1>P0MGB+6T];II&3O:
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MXND1KO:YJ*JZ=H4SCJ!JK:;)G9_]0C">DN%>#:RZ-XJ40=.%BF&B"&G50H+
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M<?K6ET/<V<6%0:PLV%/3G7G;:.4">5(I?\9#')0J:#VK/K#S*0DXE5'N"TE
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MFD74_F<5=+#O6C,ZA(,ETA01Y+A2.[4$-:NP+Q47*4O9BY_P5[-*$V,V<Q
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M==8-ZV-L=JK%$ZXUKJCDXE9X)'D98YPK3=9D@S-O-,T,YZX+S=-FC+8Y+X,
M,JK,<&T>FE9_P\"N+I+6Z)ELR8GI><SZ^QFTL33OO2N0^]-U%(CE_)J$)&/7
MWDY=E7;#RRB*EB-J/^X;4?O1G6F#EK=$48S9*O2)%XUF+EP>8J^>;^4__Q"1
M#'%#MK3"4Y>W8UAG!VQAP<ZW*(YA=9LO[>##O!\-%TQ*C. =O(K.=[J_W]'
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MJ*])&)V,[@=9&([:F^L@ZDRPS:F)JA[(ND#_0)EMJ:F:12BU;4P+H[@(Z.+
M5G#,Z/S[7AM]>Z<O:+LYBZZM@%$5L?1*/L">[ZN10<P%A=1+8J&"\T@0!0@3
M=_,B6J.@K)IB,3#E.BU;7^;#B3G/-1,E/3!<8E!^6:V#BP<!"YV16^:,S(,L
MVO0EF7?U<)>-I4\CXW\^&D?\7@[S([#V,RG&;KW!]B%<XO%A5BU:\FF S [Z
M;P]FP;Y4CN"IO8SBLD!DZNY$[]YNYN0F8875:W#-)FZJ0[77;M&C '9V<?Z
MM: 2#GK'VOH=S94[).R(_C\$!81/@I\&-=/.<E=6AG)YY?6=_9:&KI#_62;
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M7&H"1!VH>9+<T<XX;IFL;75W_*P;MT-M]A9SCN[3Y*N!G?$(:I*H[O:69C:
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MKD4UU"FRV[0WK8BW'+(-]M@%TY;K*PGFPG%[.58F/."HZQ+=2/2*#.8L/S!
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M$HL1KG8U7HH-\8&.X>TZ8UATD:U=LUB1S'_%985;91.QHC/<)GP;!^./=C6
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ME*[3+'J)L& ]!LQP[/U L&/1@<_CC&ZH=WKAOW,#U#E)R#(R$)L5V,Y1-\N
MN,MX]!6CZ@%9"??Q/:=L\6JFE;[]G%P2]M^;9-=_.JZ&JG2@9A-X@HVRT^76
MKIBQ' -H@R.^\P1I[WM!_-=X7TSJNA=P-K#M63PM0KPRZ-LX3M\P:&_<]I/T
ML$@((W@:W#0?1 [[@_># .6H>)N=)&_J%3Z4P0E*8ZKH:Z/QIQ_J<&N_]_[E
MXP\?/V&X'!/@S[S/O_DH'G2_+%;P.O\#(X"25/R6/^4HYJ9ED8/<'EK%Z32P
M G&3>4J*?5!@V38JK(EOJ.S-;C9.84?NPD+T\30A\(,Q_BKLAS[NID)WF%7:
M^2*=A2$U_OCQ@Q^!WL"1::MRT_6"U,Q81+AFRRQ%CU7DPNB;B:[,!SHPQOS*
MD?]Y5D/8Y1YN+L[:(>LK5'O$5N3B$NI1U *AC/_/LV@U$'MEY9X/7#GKUR<K
M.("XE.\@O:3T"A"5ZQ= 8 2D!B/M<=HTLII2_U7.\6: .1C!+IBOR.&'/R"*
ML%G !4YT*HB%L3S$]>D+>I/A*(R=OP8Z83(^U!K-=S#FNEQSV,7' \J4Z].3
MUHRVEW%,QVR:JN7C68IWN)DO/4Y60K(^G@HWG?6QV[Z151C=@/G'_9CG0E'M
M1P7L6J2[)7"J=V:45_%2!'"3Y1(K?F-2%"M4P[PG#&Q8% <JX<+/1''F*,%%
MP[X;X)VYL-:;.-T2PI.HJN)-T.!;6D'5D,0&EGEV3'5MPJW)9;Z2R]PC=UET
MZSK8<8KL-'S1>N2KW)H$16^<"RR"]9PB7L<K489]VI @6D:@M?DQR6\QL/0Z
MS2X)IN+2<$M##\<L2;!V^$N</L-_<AS,BW$TK\R9S!7R,<D4SXF+Y9!>3V7H
MNH0M1_?H\!X=GXK;R@RF>)]<+$]W#3V_MG\P/9+M(>XG8_CQ<@NQ/NH^\OS-
M)H[DI8]_#BHFT:Y<<6GU><3Z/&OI?OK_V/O6YL:1*\N_DC$Q&UT=0?5VE=<S
M7G^C)*K,L4KD4%1[O/UA @*2$FP0H %0*LZOW[R/?  $52H""1%JQTRX2Q1U
M[SV)1#[NX]PNRF^L3(X^C7J@<NT*2/(&&+#ARW[2\@7,))EC3?U-L);'<055
MDVNL1 $B/5($>065](^'>ZGHW+UY'9A.>]4=/.U7+X(DD='Y3G^C76GYE^ K
MGI]MV#XPWAOCVH=.]K0$F638=;##7A8FX\$N/+;&4NQGLK^GD:RR&?US'(\=
M1W[]G*I4TU?7:!\)+7WD]-]U_H2, +('_<7W-$0-&3?KEV9<A1YC?_K!]#HX
M!7V5$EU@@D^QS)K[@4,Y]/A"W66S) 8.O>B7($=Z0=/7!8M*VKRDG#(-7"9/
MR ]RL)874@P"&!)CC7AB<^QWB&7D78V6W@E).=Q;#@T0UHO_%H>H]BIV/%2^
M7CZS).%:8)-F9NFM+,L$EZ_9ZE+FZF.X%=F$P;8MSWCU*8P:L0EVVFL "Y'7
M.=(?;GYUG,V)@#N4'. ]L<.@OF+U.AFC@Q^)U[:+UPFB3=,!QJJHC%5DQRHV
MIOFD<K+MXR LV$G$BE) G59Q&'!,+%WNZ:/92V@=,AH3(37M"D'<R&<$2R-0
M2^-%4#S.\^PICN!H>%= FO95G 9IJ$P9TR$E/H*OVWE$L "'2@VY(=6A9J7E
MZU.0U\?D#V1B\8$&H57 !>##'8']41A%8MP#6NN%=Q,<'/_B^6[?40\Q&SJ7
MV@6W0(ZHI3I94.R^N,G0@22CO\CXX5']=ZR.ZL&#_ PG^$MUH+@*XAP3)1;J
M\'%%K25;U3BSGC-6)$ !Y2=A0O\M,[8)M."?0_H*:@..'KDX7/<X3-S&*!/H
M'>G.0 X@0;WO2@5),*:1,*C4?9EQ"?T($9D :.[3_'5\7V#' X_L8+7.G.=9
MGF?/0"S52=]1;X0OG9N?U"PW/46MR &@J,8'#T/Q&_%3*[_;U&_*Y+FS5?,M
MC]Z?MG>93:7I'YQ6W3:'A^YT/Q0<A1_R4#@;KFE]"-J$5@<Y)EJAL/."3O.3
MP>-O\,#AP2I.5TGV?.2$\'A[N7W,\E*36+?,($19+BVW_WQ!;C/_D1VF'9#K
M<'/YC]H_?,J&)P=L]DYXU(7QM3>E3Q"5=ASDT. K0)#,,V(UT.>=-CTYM$_"
M"!=:NM?SE.5JNHH320Z=]L$6=342((_C*GU6"<YSN0GBZ'L)Y1IKZ%B6QR3@
MSG$T5V(-%(4YW#;6:VI<WOC\&EY]< Q<J<VYZ/*51V\#2NWEZC3?EG2YZZ(%
M$J9YYLA $=QG3U+\Z^_^\!/4Y?LGDV^)@Y^$DL)WW1XV$:Z[NGV4LN3&!I=Q
M$289<&0=/:?<)\(:!*H0#O_8T$ E37ATGPI'?B^OS-$^(UNW]%FF,@^2CA^W
ME8^-7UCR;V0@NG.%.</(YO4^Q4S)]U*&CVG\CVV[Q#.G@GRSR;. >7"-<-]Y
M:/^E!O$I:+_#_-=D,?YE?()&)JY]OB]1;0RMW9W(8%\Y =?J) !MR]/HPLT5
M=K/V[8O526.&Z^G%Y.9V(L8WE^)B=GT]/I\MQLOI[$:,%XOQS>?)E\G-\G;0
M<'FJL3)\CROJ*D41SL(E?O7?4Z&?$:C-87<D#N:D%\Z.Z-$IUNPF!)]6NSN;
MZQ5V'8"<4X<$=H5,XRP7:59R$]I//W_Z@^D$Y[OY6_<CD#2!GSK@0:B?1/!;
M^0"3YK/,'O)@\PA%I^VSV5UIGA/9.[,_Z=WT!;RQ[4\**.9T374N_G%1XK!^
M<;B1>^J$3%Z,6Z?[&84NNG1GN-)_T%%FGT=HVHB"^Z"R!;6?4=AA$[(\@#%%
MEL$G,7[(4O7TQ =US!C_6-V%3QN7/D,H:;7#@^>C:T?VOYP 6#T$Z,X&5".)
MC3_XJ+!>RQQ\Z_'_0.9D*,^B($YV IZF9:3EK^H&]?87B\GU+^.%SP#;]KZ(
MHSC(=U MR.]IFR!;0)VZR$WG*[AF"%L<IEW:_R^Y%^U<+7+Q=MW*T5&C\44*
M3]WK=D"8DF8XR/NJ18L/+-PC_V4S<\Z^(^>^[LC1%2IS</K.5D[[5F91:'7L
M-80!(%T$ZF6L=6Q%!N@U]@5G(FC(^@7UOX6QZL[C948:;<,HA-,H>*3[ _L)
M.(ZW45QF^746HMG'OD,D16@Q'B< %$XOU$Z2;N6-["!S@%->8%NAPO43MYU'
MG,6HPU :/L)+Z/'P //D6CX$"46G6^R"*$5G#?G>!/'UL57%T3B-%K($\O[+
M;:X.DL1%1@43[2-OMK$3T63FI$I$J$L0.Z"F3A\FZ,3%NZCA92V"U'!7"29F
M\X@74_J!SPT[EW;>7Q:6]"S%PZWZ"95Y[I31$2#SPF'% Q+>]='<U658P#X1
M?\GROT/N01;*HE"+WFRU4)>%_*G=*P=2S^+T;$-R!X6#GXR1/!(@F[(H4/I(
MW)#74&OPW<7HBRP?L\BR6,R>4S76C_'&DG%U4)>[1BW8083),C*MQSE8#A!K
ME7)AHAFYWAO,I(*/% BK822,#C'O 2=<T.4_MDK-!%ZDUI%K(TZ0O'[R?^@F
M *RJU%>HJ:W8L:Y[E@VN%Y8N#G45&QC"RCW5@<G-F30K7B_MX(^]D')1S^0K
MN,$*V)EKI4H+N::>L=BG6LW#;9! DO;'+BJ_1,!E0[G60NVG28T )BJ7?U!:
M*W_30]G=I=_4=#E6-U1U&<N%8[H V_WFB'_J/#/_4S^9^>T,3P[8W%-F?COC
M#V3F&Q"]1]X=)UOW ?B"(O"6"&= Z)(F8&YPW74 >FLE9GJI7-N:_DNG9]\X
MC5S?>"MJVY=: 0X58**Q.5UC'$UB#_3X'8"N+3(&?*G .]P0+S=_].@]R=*'
MLINR. PY]U459SL<W9>V"KQ>Q'&5Y>17NY$MB7N>][OUN=E,D,8T2) 5<HQ]
MD$/$9):9^[+2>+*A% <]1_[;;W75/;&R0? Z$E,+0K6<^+RU=8RDOA.\31_%
MKA]/4V>TEY!Y[Z*RU_Y-_>-"_1R7%^J$NUL1BT<!;M,@#Q];9;"Q#-RZ.'$%
MKV^PSX6H4X2NTL&B;CK%Z-YW\&]2)2JZ1D)KZW$V.^>9UCM#J9ZI<W#YX)Q<
M^GQ!6T)J6C]KYS#/G4$[1O3".GKM8O*RR^'Y&5EWP*63RT>UNB%1'MAPG7'4
M1]DRAX.L.DA7>C3, ^B@VRJN2HP_%>5Z!$ ]1H5F*QP--J':IF&9";+"6]#U
M[8:H=NV@H0HK0\4GAP2&BM/NX678\% %M8X6&QHJBL?[JL%YD[%RUX47!NI#
MG#)ZCTL>IZF YT0[,/\2EX\7VZ)4-N1'A[>K,;?%Y)?)S=U$+"87L\\W4R@Y
M&AZD1)\\*+$'?4): >71:A6>BXE,J_$,NPI1)N\B+OY.1P'X5[N^ HY8].+Q
M$0,$4X?9E;B-'])X%8?@>[W=8O>+G-*!U9M10IQQ$+B3!LB(<^2"'JGU/(G#
MG?B5_]O+XUWF6/.P0R>CIHW%')Z6+R,*T14()6MALO)>%IWND/'STP)U1B;)
M'.F<)X\YS]0'/4X?;J'E,IR][S9 ,3WY6L)JKO:*Z_CHOB56NC#B!<D7OUH-
M8I*JO9<FK\^<=65)Q+VY;'AX\C5,MI&,:+E=;[8E)X!/@ASB8L5<YE3FOFL6
MT,(#Z ITFQ'X;:4))!'!7$%:!Z'<8GE2H4X-[2-Q)'D09B>NQ:(F%0[%O@-R
MW<(Y7#$36U80R XJ.=@+*1N-V-'M]],(^.83ZL=Y5F ^_GV<E4 HD"79PPX/
M?$&Z$RNE&(+/2CK4YKB.#+4VHX>^D,E.'93S!PEQYWMUV !'Y>81A,+A,=B@
M[@([>8$06-%++4+MSS&HCL,S!2F&QO#070$:Z\'N[C'D6'6X7ECG-?VS@+T;
MQK55NH2517VX8 R8U[P6?426G7_]./H9"'>TUWF Z ]YFQT5^@<<%M3B,9X3
MIQ!JQ;/251 B:S<WXS%4I!?!1OVF)74[Q'F2+$C%BK5@CY"'AQQ9R+R'#WSB
MU/$LZ$YH3]M:RTCHYD9&D=":/"VNFKU9IPX6XS3ZDJ52(89BHJMM&A7MM[N]
M1$RZ/Z B7;:T E6#0YE4 #H:Q-@ )"4"M?C>+/TA/6;CE,W/?;WWW+WFP[ +
MDRK,@GR68UUVA*S<^LC:DDF0G:0%W4DV0<Y5>'#'BJ *5]V8#?>;Q^N6'[!)
M':>NAE,XU2Y,&ICE?*XYZSW>3IZ". '?W%660QT7;)#.)2-4\W2+A&B?\ZPH
M[E)U2(+2YNBSFICG4LU5\(ZW(K  N<(*%B#9HQ?D30"[IP\W2=D8<Z8$GX$Y
MZC-K@F@<G)&X1SO 8^[S)*8;UZA=$RLX6QTX@PT7W.KC-G8,3':PN.WUUNG[
M36^/U3Q@+6@$APVJ?/7HT0LV<4DS0WM4H2+JJ#RH1G;::UD4?ZRD..']P*H5
M*XF]D&*/SJ(N4;ZB['_XZ*I^RPH^[UTG/,!)S!)BGHN)'X#LD><$1%O!6!12
M7E/^4Q'F,::ZP_5C6LIUNW!6M9738# D=IF0T("*JC(=R>)7O)ZA<+\A'7V+
MASW6-,%Q&#;;/![@/!,W0($V* @V2F,2("GETVFD<]D+I2M$NC!T$B0NE:^C
MO),*Y_/Q]?CF8B)N_S29+,7%[,M\=N.'FK$/9/SX7!6BRE5<(9#M*W;JSM(.
MB].W:W6'Q>:VIHT=WF_9&U M6'>G=+_O92?5Z_4WLM<2=FCJ[(6<77V2/8M_
M_?3O/_W[_^V#G+TM$'.N2)+^Z-GKY;T=98K<WIW?3O[S3BUV G)&_"YY'2$P
MZ]M>A7)/2YDA='N2+IGL.(VP-7/SKY?J7T5 8:"VYZ:*"94B2RRK<7YVNN95
M_ZB?\U6M[E0WY;V$(+)DUI79MH0P6:1.L6V26$T/1UW)RSX!C/>5&88 E5(1
MD6Y,B>/,+[/F["7%3=,T>U(W<W(J,G'D<(?+78&_?W0&BSNISA!33+S7O-K1
MH6XCI-T?ZEG^$*1\^[2-VZDD;4Y^?<[M,(V7#)FIPURMONUDA]D<%LR=BEN<
M(ZL[Q>7D]F(QG2-]^>Q*S.83XC*_17KSV[LO7\:+O\)O;J>?;Z97TXNQVE/&
M%Q>SNYOE].:SF,^NIQ?3B<<-YM3'DZ>A:R:&CJVAE-#GF%KMNF6M=9G4X6_<
M]$ GBTF;W ?;^B4G!DTVQ6R%9^M6^?LZS6@ROX5!\%. UY'A2;/-GBX8'1G=
MT.&1"Q]AN.WR_P$2R'\T[G?B;1.!#D#0YE&ME/09251O0US*:P4]FBKCTP?0
M2O4Y7X*_9?E%$A3%3;!NUZ*$M)RA&F'UF$(@5"50EP!E/7!DFY*2A53C#;D*
M^.1P35!+%C!-)N8[;0G\(,7#5AX:VOZ5C+ !S3U5N T6+#_ER0KSLFQ9"922
M+ ![5>V(5EY<:5&U\WV,QGE*AL$WG<DJ"LV*JJ;]IY\_?6I_!]>"#=\J%)M"
MFX9/0T"2' 0Q)1"^DSPZ15-;C VJ3?W1B#7*][C GF\+=3,L"J2GHBZ?Q3S/
MKB"[Y$:6MEZGW7%2JR&.*M)#ZPSL-P.$5^?0I>5S@$"2V@,:NP](:1"H JOO
M>!G\ &H\A-FIW35?!L^S((_H[5)''DJNDM\=;V\X]: 3P<DE0$7\GJ'3&(X]
M6I^OPKAN4?(CO*EA^M*,:1"0*J^7P>7"^*&H/CJ/GDPFQ+4]5]U8BQO"\<+!
M6PGLF :M;D--TXQ2'<XQMCK\P4CVQ\% 'U6'I!K=\A\@H=FN[CUC94"$+'P/
MN41K.J!C5W*%$2R,Y ' 2%Y&X/N UB64VK:!D (#*3"0O)W.$)$3_E/[\#HN
MBBS?@2V=@'*#BQLC'B_TP\+5$"RU8M$KXWOJ=0QHOP*' A2UI^2GT<'%-H?2
M^RNUJ ;)7V603]+H4FTNQSX5$B=(G@"!0DD4(-(O;3DEO[<D0;."_/*?X32"
MI%TX6L]2#.,Y!07MLC,O'B$^"#4#U+/&-*O),%K(!0/@[4B \PW);YWR 4\<
M*EU!;GII?@N >8:"0+Z109DC!8 =L2>/H[8M(1XD,8%P"*)Q'HU'1T@3,;?-
MJ&_O 7&R\_VZ/+H'HOVG!]C31V[EP?50L#4NE;6'1"PDSAH2VI5EO\YJ$+ ;
MELL3!8T9-"ME)T1H9?X4AW'ZX 1S;7EN 7MST?RK]JUS;4#6$=M#!.@M\2=O
M ]TA Q]_K-;5=<;$/OX(A?]N\>  <"3?@- /07LW6)IYVALP^;V%3I0%15R@
MOZR#:FN2YJLNHR.+DP9CO5='M[:Z-F'ZLO[[6LIAF41O;?1P8QXDY,1%^\HF
M>K_X10M,YTLF33_??0E*.&4=W8=\KVTW7B^Q2?":1,-R!_DU.PF%JQ+S#\6E
M#'$BB]]]_.-0H"8.2H<IWO7U:!6]M),Z4%3HJ36B4V=X!?6?\[>H_^RFSN10
MR62O!2?H2*",*\BK)\=A>_+/ "6>N-F):['..K/B3MQZ-R__$ 3O[.BW3LJ^
M9F0![CQ,Y6V@F,7:#377LT1)>YBF:N;([Z<2=*$CP$KIP ]\87YOJ.D8<EL&
M><G8N>#P?0*=I-'[AND>RLS4)?7(N$<&---NEYFH&B&T%7W$=R@EZ496F .@
ME*3 K'@J!5C'VW4[OV"=_"%B^>"D+A[5[_:"",,$?S#Z1:J0>K[*HP"CH17J
M>@90.6C\[JK>9A"\;7H0J9U0-_HHRB$MD/YS':?R6,Y#DB=8TDC_0X!,,4M]
M>36<A")3&R,C- 9<3FG4E/EXOG-^PC-J%PE&CGZA#<#'V90<64"'2^=G/BM[
M\\"]S3#5G77.<(7N<$EWN.X;DGUQN)R?O267V+L,W,K@4D:LXIU< 'NZ]'E"
MTG#=,R#Z(5_W!*R>VM1$S>2MQX4M(L7S4V>=8QW!1/[GN8-LIT"2;V#P[77N
M%$R]^XH#BB(5SPR*(A;^CC[-I_TNLDY[/L!W"21Y$8/'B0:'L$N>&N,TW0;)
M0D*[G6/K25F4(%F"A/61R0T) &'VD))ST?;S!A?@34;Y]A$V[FZ9U5TC(W$.
M$UO'!'JISK#/.3(5F/[B8>9S4K[!@.A3:%.C=$OK@7XT4JK[I_?NG7VA$!<"
M";H4MT6NY<M%N'!\=,MPO69B\C,HKK)\D>V"1%VS=,YW*])B?K00_,E)KDTF
M/WTH205% 85A@F5Z+U3H$$9M-W\3.,W[WU[;W#Q; ^U1',5!ON,D,*0NT<W2
M.]XK34]=;8$ $X2U0=.L,8&*-N.=C=)>^4=EM&(]6K$>K4B/%F;.%7:T.%V.
MJ8EB-L=;4>$;#5=#UP$@OGJ"?R"71_/PX6 %53?"4Y#'N*>9;TGR2GEMG$4.
M%NA/)A_B<*SLA&'HL*K+R!8!"Q=GXLOX? PU'0]YX,%;Z@534H>CY?97YM4U
MI,,M%J#8M-A_<-B*\//MGW$7AR-+3(R\Y:.R0Z3R6:RV24(1 G7>W>E'3*ZQ
M!_5:J"_#WV?$)5AF(HE#;"4MH=D7]JAT.Q7!GT&K'9E#)J;V..= ;E50&Z,L
MVH9><^/=>DM=]NG4GW:1*E,IZ8PLW1$R;1>/8@4UKT[7"X]),I[0)@U F\MY
M^\B5P27?YE_-:9*VRA9&D4Y.EV"A/>1*6]K7V6JO87@7T[/28-IW2HD7--KY
M6R'(;6A[[G7VT5D>FQ_(9'<C'S)8/M4E.]ALX'^[HYPU2LY2HP4X^S?X'[5
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M?%B9W2?Q ZZT-[*;&Z^.5&5&\F#Q)35HSJW7?*8/?3,'[LTPX=8VY 8?AKH
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MPM8OCE9F-Q6F[9AX(IKJ!W>]XF8/OW[L!PM$:!7UM3Z^[C;V.6_)Q'WP;OT
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M8:OC": 1MV*N_L]WC]&ND1U3F)WITH(#XX%/5SL/,8_!L@G@-_JBE)RF2'T
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M\_B<W76BP5WW\D3T>J:A2Q04H[1,LI9(, T7LJ"D&C8\XZA79IJFV5/\Q"T
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M1LM*KD#!KG=^L,CXX9JN\8Z:D6B$VE]7@WG.';TQ,T]?1#K(E=%R.1U12QX
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M1M3U# ]:\@I4/:8C>$1:6_PKB/.:*E\$E-?!?P#+?_L%YSH0*,GW2]7*X&1
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MS@ A]%<TY N"WG.YQKI6)SXR!1J[$>?=SKTZA]QPUS+XRF5)A68U*=3;L$W
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MM*)J 2\S]Z<>KCQO-7+F;O32E7:BQI/*7)SO82^FJA&ZS**7VZZ32 #C!-J
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MS%C1!G6%0R;N/PD85-SX/)Q00@UF68*E?J U9T8)>%!1@EPS+V P!S$:LN;
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ME7SY[N\0L0S-GUE^2./L>9SB@-_@\N'#G"^S=UX/(]*GE3$MD5KJS)36DY,
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MCL47%L.[X2#%.MIG@##B$[CD&'GPTS\8%@40SI_,1F?<H0\YW_X-PPT&*D?
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M&Q&(DW>8\ M8]CE["]?+_1[NFD,LC;0=XLET].XF2?>)@'TX =J#Y%%?;F5
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MHNZ8<_$KM0H\GN&.QOGM65P$QDC4CCXC)AP+1LIM$@4LS01NJ<E!T+4ON>M
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M^N*?#U@2YXUSU/0"-!V&)&%6HD<95&GUX!..AHN_7XB#$8A/B?2JH(@2B%^
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M',@QO#6:3>:9K?'N0A[4V$\?)AR>[,;!BYYY6GC0WEF >X'U?:BI/\TJOH
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MY:.DZ#J-,WQ<1YYF\##_DA#R1"[YT]XK66$5.2HXVP,'M5'X67;&%_49B]C
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M#*B9GY;L\:2L^+4%5#%"EU&2"@SYHEY62C!3IR1E$9#K:_O<2VY5,Q6\%"A
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MG<DOJ2+U?$*,[,7T22C']IA8J \< SYB6^;1<^DQDOSIOC_ 1F2/L1NC7DC
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MU=PN,Y,$J?2<TH*$58ID>NK,;AX5N3X.G[G)XM!/29FVT+OQW\B?.&E#U08
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M%GV/TF,&_T5:Q) 0=X&7Z#["/X1I' 5!GNB9F_9 ?9QI.)$DCW%T$\4;I[$
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MQB5,[EP@@9ZO:VQTBX^>.(R/<;1%<;I_#)R\J">1>+:4U$OC?EM[SBD=TWW
MD\4CA*L[8H3,?:(>EE\21#W;8W_=8J)#!J4<?C[Q$R(P48]R4?)G<.( $Z-T
MG:^.@&CGDR<.X6C P8"KO,;K/[@N\2A,'IT]QWHT[AS @7Q56NJ?$!;\,SL@
MM^<P24D#4T*<Y1Z:212&*'A"06[C*>1XXZ*&Z/,G3I@5";PX;[4?1Z!&QH<G
M28*%IE@0 ANET3Y[XB1WE#=JOXVEM'(^?N*PCGM\(=$C&D._)U^Q[;0@>%^>
M,R^K/F<?G#ID7I>AI[[J^2@]YZL6/G#3(#+UF@R42H<_-M-3!<K2^ED1L,Z$
MZX!#4<PPS!KW )XMS"KK%/LTS.B/@W[#V0%X0BV;H-?<(8"G-9H,:?/])X G
MG)G,+I2V*> 9/FS"S7&\ )[50A;UT1TX3&3!.$'<N_X=P)-<V)4P!-XEP#-C
MV,2^ZW@"/7^&3;3;&.M5$J/4"6:,)1Q;H*?JF!;\'9<7Z/D^K EW0I\9Z,E"
M;!(^RZ4&>@(1>ZH,RST'>K:1:<B+72\>Z!E);.).)7"]RN@L/A[<@HQD,&D#
M/,WD&SR7ECFOQIQ78\ZK,>?5.':9A@\H86N^AXJ2DU5F?<R6/\@[>+*',)KS
MHG^2"RU9+4S04UZ[LDR>*$M0M3X6@SA9F?:HJQ!TLK",;D[+ZNF>[1O.[V-A
M$3?JB1"I"U,?1]LY5\L[*@@LZ3^8A<VKG>C+*&$&8W:::8.^BXA4H)-:WPEJ
M1[,[OR1.LSO_[,X_48L%1X@%2G,]I.+9&W]V*I_4 68H/C-:?8H8S._Q4IJ<
M"3?L287(J.+50VF<G:C[%LJ@O42=^]LV6P&>_9B/=":OG8_AA3S-Y[>JI,)M
MN"3_(?\VO[K-KVZG\NJ6Q&D-:ORW(\RD&C15V:-A*V@\Y^\&^I39@WXHS(7;
M=!J<I7-+GLBK*^VNDLMEQ^LYO['VA+Y5>4EY YK]+2Q.9@&<24Y#Y)V?7R1Q
MFI]?&*#)"4?]4JEHQ6I2=J(A5F^^.'%6QU+5T-V]^,_L5+;YO>CTPJ.F^>EN
M$DQ,]L5=ZSO4-&#3R<<8]4N!<;/1WXJU/N>=)M71*4LK,%V)S()ENZB%2P)J
MHG"%:7USK&)++-R'\K:UIZ:DZ'-L>(LW<>.DSHG9NP]K.Z*1, P-4EUL.-U6
M\[G87SB!$[KH>8U0^BF.LBW6*7B60JFN(UD':069[YT-W7HOT<&(5:KZ3L(V
M+O.:CP3E$RE+S;"L'G\;<S)4N-J_CC2ASW[H;[(-<TK-WP=.*D'N#ZMH]]Y#
M?C$G_(?C=/!??K]#*R?(!? ]9<MH+8Q/J?@6]>!U?K; \"KW2G(W/:-XY[N8
M5STL;_P0<S#?"6Y#S(RS_)9ZP=-(Z#]Q7P6U?D(C)]ILHO YC=RO>%Z_.3&>
M9<IE19SVX!\-!]/9KTZ<QQW?AE@FPGR\H/O[*'V,_8T3[R]0B):8,O ?J7O0
M?YR1]N:H2W3O4D+ K!N6<;4,&D[;(2G$T*89FO\<+.AA5:2C2&4'3O.,Y>E<
M&+]T<NTCZ2@S3'&OY[#:-NF8<ODQB]VUDZ#%*D;Y5U](H/U]1J!_6.9>N<E+
M=(&J=MX7K"G$A]:T_=0W^/PP+HCV:U]Y'%\A5FN-X6-AM/-WSC/6Q%*T\MV'
M[3:*TRS,0;KS-WYZS,2QOXQB_&NND+(YP] A1Z*?%Z)D/RQO0\_?^5[F!+_Y
MZ3I/'T6.[]K?OD0<D:[/"-HV[2'$:G2,7-R>O0W=1K: 99Q*>KNQ]!GGC:_/
M-'[7MG.5.'G@G;<A;O0C>Q?Y'?1=+0[9BNIC%:^O_GZ;)!GY<B[@.RXA;^H5
MHCR(MOF_?(LJ8N>(]I16AG?V@^K.?K#H2)=O7Z[X-"][\?;W&L(P]!]5H?^H
M_5!)BE35= Q);#+#6R"W<EI<);#99HR-66Q(WE1%N,M.%D"L&2NX0';;C0%F
M18'DU&,UEYJ#0*6[!8#I2OG#MQ#%1,)[1+%+GFA6K,<"^?[:-N37B"2[/Z!8
M2C+%O^;9[Y/RJ[3MD.^L;;[5-I=N;\E%Y,1>0:5)F5HWV.?VQ'#U$.:_$JFQ
M,(70UC!L0.WKJG]>;N*,'C;X2^ DR>$*>8AS$KA^PR3@)T7@[_%^*7]-6"FH
M^HUE[V8B9NQB%@]9FJ1.2)P-7U"\X5]6[&[6V->1Q][L[GTNIVHUG<B4OX0Q
M<@*2VO(3^_E!HN/DEL-Q 9?H.!GSOOQ]*-]?GX"R1<2"1H[@$[I"B;\*\W(P
M-2Z+16/QM=)K'-O>.S*N&HVX<BF_"'BNB?+.% >/=*Z+ TR$.CX2E2MPPU\!
M\-J;2E:U^I9S!+SU<UPN" 9=]P=X$)CTHZBQ%)ZOPIF%''0Q&N!C !@['0X)
M%2<378%PS[6*0VC%\SHL$2X\O=UZ#KQ-Y&("](3J]DXYX*G1&P1LU.24H]FF
M1)M\GY3ZU:M7_ &**\L=N)86:J#7#5#@!OCE'+"E.,><$UHTUJ8,*3PY1J3!
M-]V!X,:0&E5?!=Y-P(-,536(ED$-+LWI%WW5O=6 TIZ."Y/F.P<4+HM<\$,+
M6JT!T1."M@\7%":E 1A6KY,I]O/@'"<R_[Q.^<?6*8=:[UOUE LM#2;P@G?0
M];L5 Z=34RR X<0,/,5^G[N=8: P@=3YG??*6QTXW9D^Q10O>N!5'OJ<Y&'O
MS"8 /;\#WXVHF F5+F@.WA3@94Q,Z)\*P3(SNFH\02&H9XQ*,I"@'1A_5,+]
MEQEN-;A985$EGK_,>$KSW9Y16I61']J[N$FHQ;%A%:I0WT[,"0[M,+4*2?A/
M)6:1;$?/5;C"K:8Y/K+---I:#3'@D56(*:P AJ_NZK(E] I^K& VJIZ=2,[N
MYVRSP02*S_@!_ZLY9;?-_(Y%F6.RB\<"JN6.>0_A$^'0,5&60^\^P@RZ_.M%
M7CY()J_WX/%M5$RK\8O<]P=Y\CLMV=G"LHJM*+5PQNR;;>8,O? S]([,-#JW
MJP'&<3<@7>P)I4\%G'ZX*'IR$,V4F;!\?PN+*\N>W6!A%5-#/@WB97J9)2F>
M='S]Y@89,8&0$X#_1ZJ;,Y;99R1K%P\^IJ[$W5-K-I=I9@#ZL$5QKGD(:Y_2
M6EJ8<(V'\^4/2D,+TWV,HZ6?<F"M-;"+IO!0T=M.1C57S:0S7%V!%X[53VVI
MP]O2# "'^,VY,30=7)TJ0*,RH"01SSBKV6?.N6;QG&]C3OE@DKZ4M=4ZP^NE
M#0('=*@D4Y>*@4=?&K^0%8A[AEK]3C:TCR:V8E)OY\/O=#FC$'":'G1U4<U0
MX"FO_^5$LX(!CV ?1%]U,QSX &LM9$41?(Q&HYZ(VTFW5#RF2R?V9L>3N58\
ML^*(LR'1>5@Y2ZF^"(Q&VK[_?S(G\)?^P5,J7+'?J9AM1WK_EDOV7GL%%W30
M6*^:DU:^BR.ON17GDB#+F= +<M>A_Z^,#JBPN;Y:F?FU08(@"(E%'@HN'/<K
MAFR'#A_G%-&4[SW7=!=^0F/-L9@(I(^5("!?W5VRI]U;YO#'O_M86XG=]?X.
M[1"MCJIB9YO+J@LWW3ERB5!MC+D._%QM?2Z<JGFW+54M-R"/<.;-:&SS=-V&
MVRQ-<@[^$]<;E]?#A()!@9':1&.E^ES]Y=6=KS?0_5V2R%8L7K ;6R"B*_2:
M8O5@AZ4W3-/%GW(MH3J4=1;#JMJH.(A&V"\)DN4'?:PGWT<IXB'/:3^7-R[S
M1K1SYAZ;7CI!@+R+?=6"+CSK&%BGIES?:RGY7]AG+C(]Q2+3A L=64Y-&+J,
M$BJ0_ Z:%='%AZ8^*5(_&>WGBLI2:%\IHLUH#ZG.,Q^OCXIXT=O/Q==52)1W
M_7,:V@@<</:%^2Y:N!BOZK5*JF:T7%_M]"P+[D?KX)Y@_6VJA91[[_-ZZ(N'
M>MLB%RL>I;\+/KM^Y-'VGMY0M^FYE@>H)#9IV[.PJ[:Y/OG)UQLL/E8.1T].
M2KV/J.VLD=Z5,NG1>^@3/DGF8A1Z_^6C@$IRS0;:[Q),*.T[&?^32"KO-82V
MN1_OUH?E=9+Z&_(^^6M$BI*0DF:TN8JZ3$< 2=<H?ED[X0O:D,)L\?X6B\5^
MO&&'M/48R(:BUR^/'%T9[#66QNNB\'C!MX%?E,Z[8C _1LN)" OM#%/2HD.K
MX^26\XG]W"?1T9(U]6A1J%^5^6N4)]1&% :P$S_L(N0E)*B#&'/)X]M#7+Q+
M%1O"T@'$':WOUA/R,(>M7#E0_:;!_Q"Z_M8)"OL::8DVJ'W-:QO6MLMF[RAF
MKN\;O#@\OC_=P2&?[?$&--Q)WG7N@!'7H0T>Y<AZPAT+UBIXJ &E*I,.;;6R
M"G).8\ Q5O,SH]X%<JY<\(ZV+K>O*OY8Q$CA(=C'I9XACG")]QR0LUPW4BNV
MDPIK$CB[U9'3>V$!OWGXOGC-)#8LV>D,#K:*HS25-])\!H&2%L\K\5AQI*O&
MP2.C'HI9RZ,2>-BX4=V"XR0*'-:^DASK,C !U\08O$;)3=7%%R@Q]F)^//]B
MX"D.[)1%AHJFJ6+H6O&"QP-U^KH#IU"CLH_8#=]$6H]I60QLE5/6"NGYL8A6
M_72C>6< 'G].@ CPBO2J!YYNIS !$M!#+ @  DYN([R+LF*8YOKR9NO+PP=V
M4F6ZH<(] H=@Q=V5R!JM%0F1D 4%T*'B.0:E,B(>2V3_#!19<U6/I4(P3: [
M*2U_%!Y+-YW^9299:9*5#&@%CNPH;)9.K+\ A72LJO+@@31MC^*&,%=/H-!<
M88S)JXS(:R,X3L-Z-88;NCB O (8VF.],4*EA[L;@1$VG4K%XU>X0GTSU6_"
M;J81,((?;+KLEQ6A AKJZYYV0A7F;I@1U69(X::2J'"&^JQE N>>.2PJJ+6^
M#TS*>F5 +Z"GV*B@A&K 'LL,T$[]4>$ZFZ]UX?JI'@OR :HET)3?N6PRE I?
MK=8LL*Q5)1]+Y;4ZF[+Z4FZ?Q# 5ZD;M,J=;I6[CK/#.O,YEZJPM83)EZNA+
M.M7";!5E<VH0-%N,!-@3VK;]FB\)QT(QYK#IGHN=?%]]!=E"S%PKI)*:O68=
M!9BQ<FJQ276<R[ 9*,-V\DF%>QTLB!6^!$MN'W[&4JC-YB)D XJ0J1<1>8E2
M)VBF:WF)+E#5SON"):GXT)K&4/4-/E<D4TBR:[^:"IS2-)6O5YF]J%*425 (
MBQ2X7::38WK*12Z@UI>90"47(UF7N93#JS@Q)ZB=[%M[GY07+046:$ZH7CKQ
M,1NKG'H*%+LI>6A"PW;.'FHSW0)=LX6'D4B+K_!0X)#P0+*1:T)57Y_3K)Y2
MFM5IT+.]1!_PG=3UYO8"Z(UN,7'/3'V:\TH!=$HW&6I*-S\"3RIG/77*['YN
M,HY_1G?4Q#2SC[_>]"E0$_V,'H1NU(W_1-P<:RE.'_%N^$D2Q7N2[/0V_(2!
MOD=9'"6NC_!^)+/CX^SX",OQL4WB;!<]1LO9)V^*/GEC.J+,_G=#2]ARG)LH
M#:U/E\FXA,UG-\(!;H2:=['(]>*[I9WC$!(CM:?,SMHN)J98UK$7LJ\LY3%F
M7\>^U#2UFNEB[[;JWBOJYURAQ(W]_) *G-C8_4[=(\S>E-MAN](+:'6<W'**
MZ.X>R\D[3L8>,?OKZ?;78^E=0/VC[#]B R.WV=G,YC,737V#BQ);665C<F[T
M8RJ) 5M+ WY3B$P.M!)EDHHB<.1FWSOK]X0V7YW9E<Q8RB*HIW\N6&K=?8%O
M79I=QV;7,=OD*N4=,@-I)!GA[ UF)'>F4:>P$_%EZJ9LNW?"*/!W:/9<FCV7
M8'DN593-?OYMM9@]E:;HJ31G#YN(]Y(P>UB8X-/D$77Z.DSSVYB908S1=';_
MF;.(C4^ES)N*T_B,'('F/&)==#7G$9M3;9UHJJUI9FZ;EM?8[)<T64-W#[^D
MME8%_*UTSH4UNR=-[]P.>79FZVGG@-.<ZFGD9&1\HP"/*,_@^,Z..+8YHJQW
MP^QG,Z=LFK ;V.Q\,Z=LFOUNK ,[J:1",]QZDPK-;CDF,X[-M9>GF;2I"^6)
MN#HM=HX?D#MM&<6)$Z C6+.KDXU4 $?\#SMS$^4U;7F>3C(]9[^=*?KM?(Y"
MM/_LQ%]1>I.%7L)UV6$T/J-7]N%^4@<]LGU*CN>G<Z>T/:>4QK"PR/:T6NQA
M$\4I\?LE"MV%DS"W37F8Z2W5=;--%A![*18EDJ3I2GY!+CW,'=_ZK5]R[!,"
MA3B"FP*E.?8$0*E+.O4E2*Z;V7UR@L,B"*)O1*3&?[_$ JV?<M*I]!IJ,KJ#
MI".#E* %U_IO^K6>)=, ?:CO(;ZKO*D ),!>0E@=,W4!QPCMD3?L:= >J#?2
MTS_3B@0._+W/]'&7%?)GF,W W%(;M#X0_E+ '*(5^3!0H-FJ"/!'JL%(]M-\
M3#Q5G>P+ &4/.F\!97MOD1Z&> @73^3W&$L/N8QUA8ZZUOQ6,-H2%DF"\LV]
M\YU7/VALUT-XV"+<X#["'+N^8U*QTX/'/_< ZT6\<5+G<>W@_[HH2WW7"9+;
MT&4'7 MZ6*"V(QLA*L$EOHI7F&W^D9]L[HN%1,<)!.YPE\!H/!)9*U=IKU&X
M?%]MQ'Z;;(G)YV[+INYV$QN/0.LH3E_P]4C$!T*8G+<K>MLI3)K[+LIJ;9UY
M<*"F-)P?K>=':WTO0+DH0Y'D!+*?N-^4%J.Z",M)?0Y__+N/8JPYKO=W:(<"
MGC>!7&>;RZKK5]TY<GF#VAAS/@C1GOSJQ#[10ZILIOF,2&+CQ]C?./'^ H5H
MB1DP_B.7C:F/,R?1&6-_:VJI.F>7[#RY9?5:SJF:*3H&0 .FBCO]&85J"=6?
ML]<H]K (EY(<MJ\IS9A$4Y54AQCM-F@JD<S\591F=H6-VIUZ$Z-_92AT]W*2
M!K/G1,2,PZ24A8MVSSD1&DC'U\/6WX;;+$UR.?D#5^+A]9@(U2<'IBZW$EY7
M*^5E#_R=\'1!B5E:6VVW%3Y7N<E^C?6+;6YS3OX>!?C"6?%MU5+]],VRE9B7
M7/92Q@C5WL!K#4N(+"CTH[BOL,+O/!'N]U&9^WV<&/>KB['J#)#26]\[0.@Z
ML>=P7@$:#;1]%ROC.RPF/ :.FR_R,4K\/$X0'_4:@9*Z1AQ&T6,4"R3QFQ/'
M#J-N+[V-_2M.@IFH])P()_E)F9/\I)OP684PN\3-:&DI;(&+G E!!Y-5BAD>
M/M7YGCSYJS7>D])@L&=<;+P>&GE7/;M=>7*Y7(K3WGHEZP/5<_:6UEH?G$Z<
MEH'TA^?O.PS4EVU1#) *J:B/%4O@QB>UM\JI$6J,_=<,_].EL_539J5Y<3_;
MWG^]\X\.]WF"%UO1(TFIR#,)N&^_O%,3+Z<$<+!Z^2 =**SC#@04)2G'HD:
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MA*7:#UU1UO;(RP'0$%U;K*I\\@"*:E\;J/@  X\O5>%@/5ZG@*)GZQ 7[V5
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MXV$0@*PU4JB##=.!NOX#^<\K)NW_^Q]02P,$%     @ F85<5IUE<DD9!@
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M\?]@I6K+I6 )6H%"=FFQF%XA7)8MV4I79Q]^JSPQ.7CAMZJ3EI]02P,$%
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MV=B]A-'8^W3(/\)?N<RX2$GR9#[#(<W=!*-_LD,^L:>W"#&Y1Z!YOL 0^$*
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MY>6=@-,H;A+Z1TZCO('X!E!+ P04    " "9A5Q6Q+/Y "\(  "J1   #P
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MW"Q*I>LE.!@7B#.__G'X=C">]$G=^TF_^(;.&([N>\/(Z6S#'3%/;J9&E[E
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MO4GFK>>9TJ28HLA<E2GS"5-6K5+[LQ5PILJ2_DNL.OR>J%:NM*QX8N4#F42
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M9S$Q,#(Y-S(R7S N:G!G4$L! A0#%     @ F(5<5JUTAH>D60$ !8$! !$
M             ( !S'@$ &EM9S$Q,#(Y-S(R7S$N:G!G4$L! A0#%     @
MF(5<5MK@#WX$J   "<0  !(              ( !G](% &EM9S$Q,#(Y-S(R
M7S$P+FIP9U!+ 0(4 Q0    ( )B%7%:1]IM2#1P! +E^ 0 2
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M,CDW,C)?,BYJ<&=02P$"% ,4    " "8A5Q6+=A#_UBX   .S   $0
M        @ $%;@L :6UG,3$P,CDW,C)?,RYJ<&=02P$"% ,4    " "8A5Q6
MO?IF'(+Y   _$@$ $0              @ &,)@P :6UG,3$P,CDW,C)?-"YJ
M<&=02P$"% ,4    " "8A5Q6)FQ1O;61  #&J   $0              @ $]
M( T :6UG,3$P,CDW,C)?-2YJ<&=02P$"% ,4    " "8A5Q6K"QR'K=8 0#>
M@ $ $0              @ $AL@T :6UG,3$P,CDW,C)?-BYJ<&=02P$"% ,4
M    " "8A5Q6_==33!S*  "8ZP  $0              @ $'"P\ :6UG,3$P
M,CDW,C)?-RYJ<&=02P$"% ,4    " "8A5Q6 QV3SCB+ 0#RL@$ $0
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M,#(R,3(S,5]C86PN>&UL4$L! A0#%     @ F85<5E@15+6]<   P-0( !4
M             ( !*NL8 &EN=F$M,C R,C$R,S%?9&5F+GAM;%!+ 0(4 Q0
M   ( )F%7%82#M&>_E<! .6M#@ 5              "  1I<&0!I;G9A+3(P
M,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    " "9A5Q6ASGM3IN7  !T3PP %0
M            @ %+M!H :6YV82TR,#(R,3(S,5]P<F4N>&UL4$L! A0#%
M  @ F85<5IUE<DD9!@  /<4   \              ( !&4P; &EN=F$M97@R
M,5\Q+FAT;5!+ 0(4 Q0    ( )F%7%;W(-Z$[0(  ' 1   /
M  "  5]2&P!I;G9A+65X,C-?,2YH=&U02P$"% ,4    " "9A5Q6 =ZAG^<"
M  "($   #P              @ %Y51L :6YV82UE>#(S7S(N:'1M4$L! A0#
M%     @ F85<5L2S^0 O"   JD0   \              ( !C5@; &EN=F$M
M97@S,5\Q+FAT;5!+ 0(4 Q0    ( )F%7%;1];K)(0@  *A    /
M      "  >E@&P!I;G9A+65X,S%?,BYH=&U02P$"% ,4    " "9A5Q6E*:J
M;,4%  "]30  #0              @ $W:1L :6YV82UE>#,R+FAT;5!+!08
1    &P ; *P&   G;QL    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
